PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Haselkorn, JK; Mueller, BA; Rivara, FA				Haselkorn, JK; Mueller, BA; Rivara, FA			Characteristics of drivers and driving record after traumatic and nontraumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							EPILEPSY; DAMAGE; STROKE	Objective: To determine whether individuals with a traumatic brain injury (TBI) or stroke (cerebrovascular accident [CVA]) have an increased risk of subsequent motor vehicle crash or moving violation. Design: A retrospective study comparing the driving records of four cohorts hospitalized with TBI, CVA, isolated extremity fractures (FX), and appendicitis (APPY) with the records of four age-matched, gender-matched, and zip code-matched nonhospitalized cohorts. Setting: Eligible drivers in the state of Washington, 1991 to 1993. Participants/Methods: Four cohorts hospitalized in 1992 with TBI, CVA, FX, or APPY were identified from Washington state hospital discharge data. The state driver's license database identified patients with drivers' licenses. Each hospitalized cohort was compared with its own age-matched, gender-matched, and zip code-matched nonhospitalized cohort. Main Outcome Measures: Crashes and citations for moving violations 12 months after hospitalization adjusted for age, gender, and prior driving record. Results: The relative risks (RRs) of any subsequent crash or receipt of citation were not greater for those with either CVA or TBI than for nonhospitalized individuals, nor were the risks of experiencing two or more of these events in the 12 months after hospitalization significantly elevated. After adjustment for prior driving record, modest elevations were observed only for the risks of subsequent driving violation among those with TBI (RR = 1.3, 1.0-1.7) and among patients with FX (RR = 1.2, 1.1-1.4). Conclusions: The results do not support the hypothesis that individuals who have sustained a brain injury are at increased risk of motor vehicle crashes. Although patients with TBI were more likely to subsequently receive citations than nonhospitalized individuals, a similar increase was observed among patients without brain injury who had FX, suggesting an inability to completely control for driver characteristics that may be related to risk-taking behavior and that are also associated with an increased risk of driving violation. (C)1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Puget Sound Healthcare Syst, Dept Vet Affairs, Seattle, WA 98108 USA; Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA	Haselkorn, JK (corresponding author), Puget Sound Healthcare Syst, Dept Vet Affairs, PMR 117,1660 S Columbian Way, Seattle, WA 98108 USA.						Fox G K, 1992, Disabil Rehabil, V14, P140; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; Hansotia P, 1993, Clin Geriatr Med, V9, P323; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; KAWAI I, 1991, JPN J PSYCHIAT NEUR, V45, P311; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; Lings S, 1991, Int Disabil Stud, V13, P74; NOURI FM, 1993, BRIT MED J, V307, P482, DOI 10.1136/bmj.307.6902.482; *PRACT MAN INF COR, 1996, INT CLASS DIS; RETCHIN SM, 1993, CLIN GERIATR MED, V9, P276; SALINSKY MC, 1992, EPILEPSIA, V33, P469, DOI 10.1111/j.1528-1157.1992.tb01693.x; TAKEDA A, 1991, JPN J PSYCHIAT NEUR, V45, P319; YSANDER L, 1966, BRIT J IND MED, V23, P28	13	52	52	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	1998	79	7					738	742		10.1016/S0003-9993(98)90349-5			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	ZZ388	WOS:000074724400003	9685084				2021-06-18	
J	Xiong, Y; Peterson, PL; Verweij, BH; Vinas, FC; Muizelaar, JP; Lee, CP				Xiong, Y; Peterson, PL; Verweij, BH; Vinas, FC; Muizelaar, JP; Lee, CP			Mitochondrial dysfunction after experimental traumatic brain injury: Combined efficacy of SNX-111 and U-101033E	JOURNAL OF NEUROTRAUMA			English	Article						antioxidants, brain mitochondria; calcium channel blockers; oxidative phosphorylation; rats; traumatic brain injury	SEVERE HEAD-INJURY; LIPID-PEROXIDATION; FOREBRAIN MITOCHONDRIA; FOCAL ISCHEMIA; FREE-RADICALS; CALCIUM; DAMAGE; TRIAL; MULTICENTER; NEURONS	We recently demonstrated that posttraumatic administration of the N-type calcium channel blocker SNX-111 (S) and a novel blood-brain barrier penetrating antioxidant U-101033E (U), significantly alleviated mitochondrial dysfunction induced by traumatic brain injury (TBI) in rats. The present study was designed to determine whether a combination of S and U, which act on different biochemical mechanisms of secondary brain injury, would be more efficacious than either drug alone. Brain mitochondria from injured and uninjured hemispheres were isolated and examined at 12 h post TBI induced by a severe controlled cortical impact injury. S at 1.0 mg/kg significantly increased both State 3 and 4 rates and produced a slight increase in P/O ratio, and there was virtually no change in RCI, U at 1.0 mg/kg did not show any protection. However, the combined treatment of S at 1.0 mg/kg and U at 1.0 mg/kg eliminated the uncoupling effect of S, and restored not only State 3 rates and P/O ratios but also RCI to near sham values. These results provide further evidence that both reactive oxygen species and perturbation of cellular calcium homeostasis participate in the pathogenesis of TBI-induced mitochondrial dysfunction, and support the idea of using combined therapy with lower drug doses.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI 48201 USA	Lee, CP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.			Xiong, Ye/0000-0001-9770-6031			BERMAN RF, 1997, J NEUROTRAUM, V14, P800; BRAUGHLER JM, 1985, J NEUROCHEM, V45, P1288, DOI 10.1111/j.1471-4159.1985.tb05555.x; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; BUCHAN AM, 1994, J CEREBR BLOOD F MET, V14, P903, DOI 10.1038/jcbfm.1994.121; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CASTILHO RF, 1994, ARCH BIOCHEM BIOPHYS, V308, P158, DOI 10.1006/abbi.1994.1022; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; DYKENS JA, 1994, J NEUROCHEM, V63, P584; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall ED, 1996, ACT NEUR S, V66, P107; Hall ED, 1997, J PHARMACOL EXP THER, V281, P895; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HOVDA DA, 1994, ACTA NEUROCHIR, P521; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Lee C. P., 1993, V2, P41; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALIS CD, 1986, J BIOL CHEM, V261, P14201; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; PACKER L, 1996, FREE RADICALS BRAIN, pR29; PETERSON PL, 1997, J NEUROSURG, V36, P375; SCHUTZ H, 1973, ARCH NEUROL-CHICAGO, V29, P408, DOI 10.1001/archneur.1973.00490300070009; SCHUTZ H, 1973, ARCH NEUROL-CHICAGO, V29, P417, DOI 10.1001/archneur.1973.00490300079010; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SCIAMANNA MA, 1993, ARCH BIOCHEM BIOPHYS, V305, P215, DOI 10.1006/abbi.1993.1414; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Smith SL, 1996, EXP NEUROL, V141, P304, DOI 10.1006/exnr.1996.0165; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; ZHANG Y, 1990, J BIOL CHEM, V265, P16330; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V150, P459, DOI 10.1111/j.1748-1716.1994.tb09713.x	40	52	54	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	1998	15	7					531	544		10.1089/neu.1998.15.531			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZY374	WOS:000074614700007	9674556				2021-06-18	
J	LaPlaca, MC; Thibault, LE				LaPlaca, MC; Thibault, LE			Dynamic mechanical deformation of neurons triggers an acute calcium response and cell injury involving the N-methyl-D-aspartate glutamate receptor	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						glutamate; MK-801; neuronal injury; nifedipine; traumatic brain injury	TRAUMATIC BRAIN INJURY; SODIUM-CHANNEL BLOCKER; NERVOUS-SYSTEM; NTERA-2 CELLS; IN-VITRO; MODEL; CULTURES; RELEASE; INVITRO; RAT	A biomechanical in vitro model of traumatic brain injury was used to examine cellular response to physical insults and the underlying mechanisms that lead to cell dysfunction. A cell shearing injury device was used to deform human NTera-2 neurons at high loading rates during the investigation of mechanisms of cytosolic free calcium increases, which may be detrimental to a cell. Cytosolic free calcium rose immediately to almost three times baseline and was associated with lactate dehydrogenase release at 24 hr, indicating significant cell injury. Low loading rates did not elicit these responses. A major portion of the calcium increase and subsequent cell injury was dependent on the presence of extracellular free calcium. Blocking the N-methyl-D-aspartate glutamate receptor complex with dizocilipine maleate attenuated calcium increases by 45% in injured neurons and blocked a significant part (50%) of the lactate dehydrogenase release. In addition, pretreatment with nifedipine or riluzole also significantly reduced cytosolic free calcium but did not affect cell injury, whereas tetrodotoxin had no affect on either outcome parameter. These results suggest that the increased membrane permeability and immediate calcium influx associated with this model of mechanical injury trigger several cellular pathways, including N-methyl-D-aspartate receptor-mediated cell damage. (C) 1998 Wiley-Liss, Inc.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Allegheny Univ Hlth Sci, Div Bioengn, Dept Neurosurg, Philadelphia, PA 19102 USA	LaPlaca, MC (corresponding author), Univ Penn, Dept Neurosurg, 3320 Smith Walk,105C Hayden Hall, Philadelphia, PA 19104 USA.	laplacam@mail.med.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD026979] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD26979] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R491CCR304684] Funding Source: Medline		ADAMS JH, 1982, RECENT ADV NEUROPATH, P165; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BOND M, 1988, CELL CALCIUM, V9, P201, DOI 10.1016/0143-4160(88)90001-2; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHIU FC, 1994, J NEUROSCI RES, V38, P687, DOI 10.1002/jnr.490380611; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GROSS GW, 1983, J NEUROSCI, V3, P1979; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; MARTIN D, 1993, EUR J PHARMACOL, V250, P473, DOI 10.1016/0014-2999(93)90037-I; MATTSON MP, 1991, MECH AGEING DEV, V60, P171, DOI 10.1016/0047-6374(91)90129-N; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; Munir M, 1995, J NEUROSCI, V15, P7847; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; ROBINSON MB, 1993, J NEUROCHEM, V61, P2099, DOI 10.1111/j.1471-4159.1993.tb07447.x; RZIGALINSKI BA, 1996, J NEUROTRAUM, V13, P609; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; Shi RY, 1989, J NEUROTRAUM, V6, P261, DOI 10.1089/neu.1989.6.261; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SMITH DH, 1993, J NEUROSCI, V13, P5383; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; THIBAULT LE, 1992, INT C BIOM IMP IRCOB, P311; TYMIANSKI M, 1993, BRAIN RES, V607, P319, DOI 10.1016/0006-8993(93)91523-U; TYMIANSKI M, 1993, NEURON, V11, P221, DOI 10.1016/0896-6273(93)90180-Y; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	45	52	53	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	APR 15	1998	52	2					220	229		10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B			10	Neurosciences	Neurosciences & Neurology	ZJ002	WOS:000073169700010	9579412				2021-06-18	
J	Kreitner, KF; Botchen, K; Rude, J; Bittinger, F; Krummenauer, F; Thelen, M				Kreitner, KF; Botchen, K; Rude, J; Bittinger, F; Krummenauer, F; Thelen, M			Superior labrum and labral-bicipital complex: MR imaging with pathologic-anatomic and histologic correlation	AMERICAN JOURNAL OF ROENTGENOLOGY			English	Article							GLENOID LABRUM; BUFORD COMPLEX; BICEPS TENDON; SLAP INJURIES; SHOULDER; ARTHROGRAPHY; LESIONS; CADAVERS	OBJECTIVE. The purpose of this study was to analyze the anatomic relationship between the superior labrum, the superior glenoid rim, the superior glenohumeral ligament, and the long head of the biceps tendon. MATERIALS AND METHODS. Seventeen cadaveric shoulder specimens underwent axial, oblique coronal, and oblique sagittal MR imaging on a 1.5-T imager. Unenhanced proton density-and T2-weighted spin-echo images with and without fat suppression, and T1-weighted fat-suppressed spin-echo images after intraarticular injection of gadolinium, were obtained of each specimen. The shoulders were then frozen and sectioned into 4-mm-thick slices, either transversely or oblique coronally. After gross anatomic correlation, histologic analysis was performed on 32 sections. RESULTS. A sublabral recess was present in 12 (71%) of 17 shoulders. MR arthrography was significantly better at showing the sublabral recess than was unenhanced MR imaging. Histologically, the synovial recess in all cases was covered by synovial lining cells. Intralabral altered histologic patterns were found in 20 (63%) of 32 labral sections. In addition to signs of degeneration, five sections of two specimens showed proliferating fibroblasts and vessels, as well as fibrosis, suggesting trauma. The presence or absence of altered intralabral histologic patterns was better assessed with T1-weighted fat-suppressed arthrograms than with unenhanced MR images. We found a close association grossly and histologically between the superior labrum and the biceps tendon. CONCLUSION. The attachment of the superior glenoid labrum to the glenoid rim shows great variability. In MR imaging, an overlap appears to exist between physiologic recesses of the superior labrum and a type 2 superior labrum anterior-posterior lesion. T1-weighted fat-suppressed MR arthrograms provided the best view of the superior labrum and the labral-bicipital complex.	Johannes Gutenberg Univ Mainz, Dept Radiol, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Med Stat & Documentat, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Anat, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Pathol, D-55131 Mainz, Germany	Kreitner, KF (corresponding author), Johannes Gutenberg Univ Mainz, Dept Radiol, Langenbeckstr 1, D-55131 Mainz, Germany.						BURKHART S S, 1992, Arthroscopy, V8, P31, DOI 10.1016/0749-8063(92)90132-U; CARTLAND JP, 1992, AM J ROENTGENOL, V159, P787, DOI 10.2214/ajr.159.4.1529844; CHANDNANI VP, 1995, RADIOLOGY, V196, P27, DOI 10.1148/radiology.196.1.7784579; CHANDNANI VP, 1993, AM J ROENTGENOL, V161, P1229, DOI 10.2214/ajr.161.6.8249731; COOPER DE, 1992, J BONE JOINT SURG AM, V74A, P46, DOI 10.2106/00004623-199274010-00007; DePalma AF, 1949, AM ACAD ORTHOPEDIC S, V6, P225; DETRISAC DA, 1987, ARTHROSCOPIC SHOULDE, P71; ERICKSON SJ, 1993, RADIOLOGY, V188, P23, DOI 10.1148/radiology.188.1.7685531; FIELD LD, 1993, AM J SPORT MED, V21, P783, DOI 10.1177/036354659302100605; GRAUER JD, 1992, ARTHROSCOPY, V8, P488, DOI 10.1016/0749-8063(92)90013-2; Gusmer PB, 1996, RADIOLOGY, V200, P519, DOI 10.1148/radiology.200.2.8685350; HABERMEYER P, 1993, ARTHROSKOPIE, V6, P263; HODLER J, 1992, AM J ROENTGENOL, V159, P565, DOI 10.2214/ajr.159.3.1503027; HODLER J, 1992, INVEST RADIOL, V27, P323, DOI 10.1097/00004424-199204000-00015; LOREDO R, 1995, RADIOLOGY, V196, P33, DOI 10.1148/radiology.196.1.7784584; MASSENGILL AD, 1994, RADIOGRAPHICS, V14, P1211, DOI 10.1148/radiographics.14.6.7855336; MONU JUV, 1994, AM J ROENTGENOL, V163, P1425, DOI 10.2214/ajr.163.6.7992740; PALMER WE, 1994, RADIOLOGY, V190, P645, DOI 10.1148/radiology.190.3.8115604; RAMES RD, 1993, ORTHOP CLIN N AM, V24, P45; SMITH AM, 1993, SKELETAL RADIOL, V22, P507; Smith DK, 1996, RADIOLOGY, V201, P251, DOI 10.1148/radiology.201.1.8816553; SNYDER S J, 1990, Arthroscopy, V6, P274, DOI 10.1016/0749-8063(90)90056-J; Tirman PFJ, 1996, AM J ROENTGENOL, V166, P869, DOI 10.2214/ajr.166.4.8610565; Tuite MJ, 1996, RADIOLOGY, V199, P537, DOI 10.1148/radiology.199.2.8668808; WILLIAMS MM, 1994, ARTHROSCOPY, V10, P241, DOI 10.1016/S0749-8063(05)80105-7	25	52	56	0	1	AMER ROENTGEN RAY SOC	RESTON	1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA	0361-803X	1546-3141		AM J ROENTGENOL	Am. J. Roentgenol.	MAR	1998	170	3					599	605		10.2214/ajr.170.3.9490937			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	YY262	WOS:000072129500012	9490937				2021-06-18	
J	Janis, LS; Hoane, MR; Conde, D; Fulop, Z; Stein, DG				Janis, LS; Hoane, MR; Conde, D; Fulop, Z; Stein, DG			Acute ethanol administration reduces the cognitive deficits associated with traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						alcohol; Morris water maze; contusion; edema; trauma	FRONTAL CORTICAL CONTUSION; HEAD-INJURY; NEURONS; CORTEX; EXCITOTOXICITY; MICRODIALYSIS; MEMORY; EDEMA	The present study was designed to determine whether a low dose of acute ethanol administration could attenuate cognitive deficits associated with traumatic brain injury. Adult male rats received oral administration of ethanol or drinking water 2 h prior to surgery to produce a blood ethanol concentration of 100 mg% and then received bilateral contusion injuries of the medial prefrontal cortex, Seven days after surgery, the rats began 10 days of testing for acquisition of spatial localization in the Morris water maze where they were required to find a hidden platform to escape from the water, The results indicate that the rats given ethanol at the time of injury later spent significantly less time searching for the hidden platform than their water-treated counterparts, On a memory probe test given on the final day of testing, in which the platform was removed from the pool, rats given the ethanol spent more time in the area where the platform had been located indicating that they learned its location better than the lesion/water controls, In addition, acute ethanol treatment reduced some of the histopathology that typically occurs following severe contusion of the medial frontal cortex but did not attenuate post-traumatic formation of edema, These results indicate that acute ethanol intoxication can reduce the severity of cognitive impairments caused by contusive traumatic brain injury and support the contention that there is a dose-response relationship of acute ethanol intoxication in the setting of traumatic brain injury.	Emory Univ, Sch Med, Dept Neurol, Brain Res Lab, Atlanta, GA 30322 USA; Rutgers State Univ, Inst Anim Behav, Newark, NJ 07102 USA	Stein, DG (corresponding author), Emory Univ, Sch Med, Dept Neurol, Brain Res Lab, 575 Rollins Way, Atlanta, GA 30322 USA.		Stein, Donald/AAJ-5139-2020	Hoane, Michael/0000-0001-7779-2657			BONNICHSEN RK, 1951, SCAND J CLIN LAB INV, V3, P58, DOI 10.3109/00365515109060572; CHANDLER LJ, 1993, J NEUROCHEM, V60, P1578, DOI 10.1111/j.1471-4159.1993.tb03326.x; DEACON TW, 1983, J COMP NEUROL, V220, P168, DOI 10.1002/cne.902200205; DeCrescito V, 1974, Surg Forum, V25, P438; DIXON CE, 1991, J NEUROSCI METH, V15, P1; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; FERRARO TN, 1990, ALCOHOL, V7, P129, DOI 10.1016/0741-8329(90)90073-L; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; KARPIAK SE, 1984, J NEUROSCI RES, V12, P485, DOI 10.1002/jnr.490120231; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; KOLB B, 1984, BRAIN RES REV, V8, P65, DOI 10.1016/0165-0173(84)90018-3; LEONARD CM, 1969, BRAIN RES, V12, P321, DOI 10.1016/0006-8993(69)90003-1; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LUSTIG HS, 1992, NEUROSCI LETT, V135, P259, DOI 10.1016/0304-3940(92)90450-L; NURMI M, 1994, ALCOHOL, V11, P315, DOI 10.1016/0741-8329(94)90098-1; PACKARD MG, 1992, BEHAV NEUROSCI, V106, P439, DOI 10.1037/0735-7044.106.3.439; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PATRINI C, 1988, ALCOHOL ALCOHOLISM, V23, P455; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; STEWART PA, 1988, BRAIN RES, V443, P12, DOI 10.1016/0006-8993(88)91593-4; STRUBELT O, 1974, ARCH TOXICOL, V32, P83, DOI 10.1007/BF00316229; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAKADERA T, 1990, BRAIN RES, V537, P109, DOI 10.1016/0006-8993(90)90346-D; *US DEP TRANSP NAT, 1994, 1994 OCC PROT ID SAM; WIENER SI, 1993, J NEUROSCI, V13, P3802; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	41	52	53	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	1998	15	2					105	115		10.1089/neu.1998.15.105			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	YZ744	WOS:000072287300002	9512086				2021-06-18	
J	Tang, YP; Noda, Y; Hasegawa, T; Nabeshima, T				Tang, YP; Noda, Y; Hasegawa, T; Nabeshima, T			A concussive-like brain injury model in mice .1. Impairment in learning and memory	JOURNAL OF NEUROTRAUMA			English	Article						concussive-like brain injury (CLBI); learning and memory; mouse; traumatic brain injury (TBI); weight-drop impact	CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; CLOSED-HEAD-INJURY; LONG-TERM; RAT; DEFICITS; TRAUMA; MILD; PATHOPHYSIOLOGY; CLASSIFICATION	The modeling of human concussive brain injury (CBI) in the laboratory has been challenging. In the present study, we developed an experimental CBI model in mice using a novel weight-drop device. Various injury levels were examined by adjusting the height of the falling weight (diameter 10 mm, length 20 cm, weight 21 g). At a height of 50 cm, the impact resulted in a mortality rate of 46.7% with a skull fracture rate of 28.6%. At a height of 25 cm, however, the impact produced a concussive-like brain injury (CLBI) to the mice without skull fracture. A series of pathophysiological and neurobehavioral responses was evaluated at this injury level. The CLBI mice lost muscle tone and righting reflex response immediately following the trauma and recovered from the latter within a short duration of 1.6 +/- 0.32 min (mean +/- SE). Brain edema formation started at 12 h, reached a maximum at 24 h and recovered 48 h. Typically edema was found in the neocortex, hippocampus, and cerebellum, but not in the brain stem. Deficits in the feeding behaviors lasted for 2 days, accompanied by lower body weight persisting for 5 days. The body weight growth rate for 24 h returned to the control levels by the third day postinjury. Learning and memory were evaluated at the end of 1-3 weeks after the trauma using a water-finding task. At 1 week, exploratory behaviors were slightly inhibited while learning and memory were profoundly impaired. Interestingly, the learning and memory deficits lasted for 2 weeks while recovering to the control levels by 3 weeks. No motor disability was found in the CLBI mice during the 3-week evaluations. These results indicate that the weight-drop impact produced graded injury to the brain, and at the injury level of 25 cm it produced a CLBI in the mice in which the characteristics of transient loss of neurobehavioral responses, short duration of brain edema, and long-lasting learning and memory deficits are similar to those of human CBI.	NAGOYA UNIV,SCH MED,DEPT NEUROPHARMACOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,HOSP PHARM,SHOWA KU,NAGOYA,AICHI 466,JAPAN			Tang, Ya-Ping/A-1035-2011				AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; BECKMAN DL, 1969, P SOC EXP BIOL MED, V130, P5; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gennarelli T.A., 1985, CENTRAL NERVOUS SYST, P391; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LINDGREN S, 1966, BIOPHYSIK, V3, P74; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miyazaki S, 1989, INTRACRANIAL PRESSUR, P651; NABESHIMA T, 1994, EUR J PHARMACOL, V255, P57, DOI 10.1016/0014-2999(94)90082-5; NABESHIMA T, 1993, METHODS NEUROSCIENCE, V14, P217; NELSON SR, 1996, HEAD INJURY C P, P444; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARKINSON D, 1978, J NEUROSURG, V3, P76; REEVES TM, 1995, EXP BRAIN RES, V106, P248; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P211; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; RUTHERFORD WH, 1977, LANCET, V1, P1; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEASDALE G, 1976, BRIT J ANAESTH, V48, P761, DOI 10.1093/bja/48.8.761; VANDENBRINK WA, 1990, ACT NEUR S, V51, P261; WALKER AE, 1994, J NEUROSURG, V81, P493, DOI 10.3171/jns.1994.81.3.0493; WEST M, 1982, ELECTROEN CLIN NEURO, V53, P192, DOI 10.1016/0013-4694(82)90023-2; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YAMAMOTO M, 1987, N-S ARCH PHARMACOL, V336, P511; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	51	52	56	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	1997	14	11					851	862		10.1089/neu.1997.14.851			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	YK511	WOS:A1997YK51100004	9421456				2021-06-18	
J	Cherian, L; Goodman, JC; Robertson, CS				Cherian, L; Goodman, JC; Robertson, CS			Hyperglycemia increases brain injury caused by secondary ischemia after cortical impact injury in rats	CRITICAL CARE MEDICINE			English	Article						hyperglycemia; traumatic brain injury; cortical impact injury; cerebral ischemia; secondary insult; glucose	ENERGY PHOSPHATE-METABOLISM; TOTAL PARENTERAL-NUTRITION; SEVERE HEAD-INJURY; FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; VASOGENIC EDEMA; INSULTS; BIOCHEMISTRY; HYPOTENSION; ADENOSINE	Objective: To examine the effects of glucose infusion on the histologic brain damage caused by controlled cortical impact in jury alone and by cortical impact injury complicated by secondary ischemia. Design: Prospective, randomized study. Setting: University laboratory. Subjects: Male Long Evans rats. Interventions: Three experimental conditions were studied: a) 2.5-mm deformation impact (velocity 4 m/sec) injury followed by 40 mins of bilateral carotid occlusion; b) sham impact injury followed by 40 mins of bilateral carotid occlusion; and c) 2.5-mm deformation impact (velocity 4 m/sec) injury followed by sham carotid occlusion, For each experimental condition, animals were randomized to receive either glucose solution or saline solution before the induced injury and the sham impact injury, Contusion volume and neuron density in the CA1 and CA3 regions of the hippocampus were measured 2 wks after the injury. Measurements and Main Results: Parenteral administration of 2.2 g/kg glucose solution increased the blood glucose concentra- tion from 6.7 +/- 3.3 to 17.9 +/- 10.6 mmol/L before the impact injury, and to 12.3 +/- 5.6 mmol/L before carotid occlusion, Hyperglycemia had the greatest effect on the consequences of the impact injury complicated by secondary ischemia, increasing contusion volume from 1 to 30.6 mm(3) in the animals that received saline or glucose solution, respectively (p =.005), and reducing the density of normal appearing neurons in the CA1 area of the hippocampus from 201 to 144 cells/mm(2) in the animals that received saline solution and glucose solution, respectively (p =.038). The impact injury alone and bilateral carotid occlusion alone caused minimal neuronal loss in the hippocampus and minimal contusion or infarction at the impact site, Individually, these mild injuries were not adversely affected by infusion of glucose solution. Conclusion: Hyperglycemia increases brain damage when traumatic brain injury is complicated by secondary ischemia.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030	Cherian, L (corresponding author), BAYLOR COLL MED,DEPT NEUROSURG,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; COMBS DJ, 1989, J NEUROSURG, V70, P623, DOI 10.3171/jns.1989.70.4.0623; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; EISENBERG HM, 1983, INTRACRANIAL PRESSUR, V5, P549; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GISSELSSON L, 1992, J CEREBR BLOOD F MET, V12, P809, DOI 10.1038/jcbfm.1992.112; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HOFFMAN WE, 1990, ANESTHESIOLOGY, V32, P1045; HOFFMAN WE, 1988, ANESTHESIOLOGY REV, V15, P92; HSU SSF, 1991, AM J PHYSIOL, V261, pH398; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LUNDGREN J, 1991, J CEREBR BLOOD F MET, V11, P587, DOI 10.1038/jcbfm.1991.108; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; PHILLIS JW, 1990, BRAIN RES, V524, P336, DOI 10.1016/0006-8993(90)90712-K; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROSNER MJ, 1993, INTRACRANIAL PRESSUR, V8, P686; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; SHAPIRA Y, 1992, ANESTHESIOLOGY, V77, P79, DOI 10.1097/00000542-199207000-00012; SILBERMAN H, 1986, JPEN-PARENTER ENTER, V10, P151, DOI 10.1177/0148607186010002151; WATERS DC, 1986, J NEUROSURG, V64, P460, DOI 10.3171/jns.1986.64.3.0460; WELSH FA, 1987, J NEUROCHEM, V49, P846, DOI 10.1111/j.1471-4159.1987.tb00971.x; YOUNG B, 1987, J NEUROSURG, V67, P76, DOI 10.3171/jns.1987.67.1.0076; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	35	52	53	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0090-3493			CRIT CARE MED	Crit. Care Med.	AUG	1997	25	8					1378	1383		10.1097/00003246-199708000-00027			6	Critical Care Medicine	General & Internal Medicine	XQ994	WOS:A1997XQ99400027	9267953				2021-06-18	
J	Snow, P; Douglas, J; Ponsford, J				Snow, P; Douglas, J; Ponsford, J			Conversational assessment following traumatic brain injury: A comparison across two control groups	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; SOCIAL SKILL; VALIDATION; DISCOURSE; LISTENER; ABILITY	Although changes in discourse are frequently referred to in the traumatic brain injury (TBI) literature, they are difficult to objectify and measure. It is not always easy, therefore, for clinicians to differentiate between discourse behaviours which may have been present premorbidly, and those which are uniquely associated with TBI. The major aim of this study was to systematically examine and describe the nature of conversational impairment following severe TBI, with particular reference to the premorbid sociolinguistic characteristics of the TBI population. A second aim of the study was to examine the relationship between discourse impairment following TBI and severity of injury. Twenty-six TBI participants were compared with 26 non-brain-injured orthopaedic patients, and 26 university students, using Damico's Clinical Discourse Analysis (CDA). As predicted, global measures derived from the CDA did not differentiate the groups. The TBI group was, however, found to differ significantly from both control groups on a modified measure (CDA-M) which removes discourse errors that occurred with similar frequency across the three groups. Performance on this measure correlated significantly with severity of injury. Further, it was found that there were quantitative and qualitative differences between two severity subgroups in the TBI group with respect to their CDA-M profiles. While nearly all members of the TBI group made errors associated with information transfer, only the more severely injured TBI participants made errors in parameters which seem to be associated with more fundamental 'rules' of conversational interaction. The results are discussed in relation to the psychosocial implications of the findings, together with issues in sampling and measuring conversational discourse in the TBI population.	LA TROBE UNIV,MELBOURNE,VIC,AUSTRALIA; BETHSDA HOSP,MELBOURNE,FL			Douglas, Jacinta M/C-2380-2009	Snow, Pamela/0000-0002-2426-8349; Douglas, Jacinta/0000-0003-0940-6624			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BELLACK AS, 1983, BEHAV RES THER, V21, P29, DOI 10.1016/0005-7967(83)90123-7; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Burke WH, 1988, HEAD INJURY REHABILI; CAMPBELL TF, 1992, TOP LANG DISORD, V12, P42, DOI 10.1097/00011363-199202000-00006; COEHLO CA, 1994, DISCOURSE ANAL APPL, P95; COEHLO CA, 1991, J HEAD TRAUMA REHAB, V6, P92; COEHLO CA, 1995, BRAIN INJURY, V9, P471; CROSSON B, 1987, CLIN NEUROPSYCHOL, V1, P335, DOI DOI 10.1080/13854048708520069; Damico JS, 1985, COMMUNICATION SKILLS, P165; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Hartley L. L., 1995, COGNITIVE COMMUNICAT; HUDSON RA, 1980, SOCIOLINGUISTICS; JORDAN F, 1990, AUSTR J HUMAN COMMUN, V18, P69; KEARNS KJ, TREATMENT EFFICACY R, P79; KEPPELL G, 1991, DESIGN ANAL RES HDB; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; MALKMUS DD, 1989, TOP LANG DISORD, V9, P50, DOI 10.1097/00011363-198903000-00006; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; MILTON SB, 1981, P CLIN APH C, P114; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; PARSONS CL, 1989, AUSTR J HUMAN COMMUN, V17, P37; Patry R., 1990, DISCOURSE ABILITY BR, P3, DOI 10.1007/978-1-4612-3262-9_1; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1991, J CLIN EXPT NEUROPSY, V14, P822; POOLE ME, 1976, SOCIAL CLASS LANGUAG; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Rimel RW, 1990, REHABILITATION ADULT, P8; Ruff R, 1991, COGNITIVE REHABILITA, P23; SARNO MT, 1984, FUNCTIONAL ASSESSMEN, P210; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; SNOW P, 1995, TRAUMATIC BRAIN INJU, P137; Snow P, 1995, TRAUMATIC BRAIN INJU, P33; STUBBS M, 1983, DISCOURSE ANAL; Trudgill P., 1983, SOCIOLINGUISTICS INT; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILSON J, 1989, BOUNDARIES CONVERSAT	51	52	54	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUN	1997	11	6					409	429					21	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WZ726	WOS:A1997WZ72600003	9171927				2021-06-18	
J	King, NS; Crawford, S; Wenden, FJ; Moss, NEG; Wade, DT				King, NS; Crawford, S; Wenden, FJ; Moss, NEG; Wade, DT			Interventions and service need following mild and moderate head injury: The Oxford Head Injury Service	CLINICAL REHABILITATION			English	Article							QUESTIONNAIRE; CONCUSSION; SCALE	Objective: To describe the interventions given by the Oxford Head injury Service (OXHIS) to patients seen after head injury, predominantly mild or moderate, over the first six months after their injuries. Design: Descriptive data of the amounts of early intervention provided by OXHIS in relation to severity of head injury and the amount of service need identified at six month follow-up. Setting: OXHIS aimed to register all patients aged 16-65 with a head injury of any severity, resident in Oxfordshire. it contacted and provided interventions for a random half of those registered at 7-10 days post-injury as part of a randomized controlled trial to investigate the effectiveness of early follow-up, Al six months post-injury, independent assessment of all those registered was undertaken to evaluate outcome and identify continuing service needs. Subjects: The data come from the 579 patients (of the 1156 registered), randomized to receive the new service at 7-10 days post-injury. All but eight of these received some form of service, and 252 of the randomized patients were available for interview at six months post-injury to assess their continuing service need. Results: in the first five months after head injury: 240 patients received postal information alone and were not otherwise in contact with the service; 127 had telephone contact, advice and information; 93 were seen in person, assessed and given advice and information; 78 needed more help and support from the OXHIS team over the telephone; and 33 required further face-to-face contact either from OXHIS or other services. Extensive use was made of standardized leaflets but only accompanied by individualized assessment and advice. At six months 252 of the 579 patients were interviewed: 101 had no problems; 136 needed further reassurance; and 15 required further intervention. Patients with longer periods of post-traumatic amnesia (PTA) were more likely to receive a higher level of service, but the majority of patients who received the more extensive services were those with 'mild' and 'moderate' head injuries. Conclusions: Although the amount of service provided at 7-10 days post- injury increased with severity of head injury, most service was in fact given to patients with milder head injuries:which were much more common. The majority of patients seen at six months post-injury needed reassurance, advice or other services;and monitoring of patients for some time after their head injuries does seem warranted. A population of 560 000 people could receive service from three whole-time equivalent (WTE) staff using these assessment and management protocols.		King, NS (corresponding author), RIVERMEAD REHABIL CTR,OXFORD HEAD INJURY SERV,ABINGDON RD,OXFORD OX1 4XD,ENGLAND.			Wade, Derick/0000-0002-1188-8442			Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GRONWALL D, 1980, J CLIN NEUROPSYCHOL, V2, P147; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; KATZMAN R, 1983, AM J PSYCHIAT, V140, P737; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KING NS, 1997, IN PRESS BR J CLIN P; KING NS, 1997, IN PRESS J NEUROL NE; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moss NE, 1996, DISABIL REHABIL, V18, P169, DOI 10.3109/09638289609166296; MOSS NEG, 1994, CLIN REHABIL, V8, P149; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; SALKOVSKIS PM, COGNITIVE BEHAV THER; WADE DT, 1997, WADERESS; WADE DT, 1997, IN PRESS J NEUROL NE; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	20	52	52	0	1	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON, ENGLAND NW1 3BH	0269-2155			CLIN REHABIL	Clin. Rehabil.	FEB	1997	11	1					13	27		10.1177/026921559701100104			15	Rehabilitation	Rehabilitation	XA307	WOS:A1997XA30700003	9065356				2021-06-18	
J	Kapur, N; Scholey, K; Moore, E; Barker, S; Brice, J; Thompson, S; Shiel, A; Carn, R; Abbott, P; Fleming, J				Kapur, N; Scholey, K; Moore, E; Barker, S; Brice, J; Thompson, S; Shiel, A; Carn, R; Abbott, P; Fleming, J			Long-term retention deficits in two cases of disproportionate retrograde amnesia	JOURNAL OF COGNITIVE NEUROSCIENCE			English	Article							MEDIAL TEMPORAL-LOBE; CLOSED-HEAD-INJURY; AUTOBIOGRAPHICAL MEMORY; MAGNETIC-RESONANCE; EPISODIC MEMORY; FOLLOW-UP; HIPPOCAMPUS; CONSOLIDATION; IMPAIRMENT; KORSAKOFF	The status of very long-term retention, together with detailed brain imaging correlates, is presented in two patients with disproportionately dense retrograde amnesia. The first patient suffered a severe closed head injury and was left with dense autobiographical amnesia for events that she had experienced prior to her injury. She showed relatively mild, patchy memory impairment on standard anterograde memory tests. Postinjury autobiographical memory was relatively spaced. However, postinjury long-term knowledge acquisition was significantly impaired. The second patient also suffered a severe head injury and was left with marked retrograde amnesia for events that she had experienced prior to her injury. She also showed relatively mild, patchy impairment on standard antero grade memory tests. Using specially designed tests, this patient showed normal immediate learning and delayed recall using a range of materials, but displayed significantly faster rate of Forgetting over a period of 6 weeks than control subjects who were matched on initial delayed levels of retention. In both cases, there was major pathology in the region of the left temporal lobe, with lateral structures being more affected than medial structures. Our findings provide further evidence relating to the independence of certain anterograde and retrograde memory mechanisms,and support recent observations (De Renzi & Lucchelli, 1993) that link some instances of retrograde amnesia to impairment in very long-term retention. The possibility is raised that some forms of retrograde amnesia, such as the present cases, represent a type of ''disconnection syndrome,'' whereby visual-semantic and other associations are disconnected from verbal representations of such associations. Lesions to intrahemispheric fasciculi or similar association fibers, in combination with lesions to critical anterior or posterior cerebral structures, may play an important role in such a disconnection.	UNIV SOUTHAMPTON, SOUTHAMPTON, HANTS, ENGLAND	Kapur, N (corresponding author), SOUTHAMPTON GEN HOSP, WESSEX NEUROL CTR, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND.						AHERN GL, 1994, NEUROLOGY, V44, P1270, DOI 10.1212/WNL.44.7.1270; ALVAREZ P, 1994, P NATL ACAD SCI USA, V91, P7041, DOI 10.1073/pnas.91.15.7041; BARR ML, 1988, NERVOUS SYSTEM; BARR WB, 1990, NEUROPSYCHOLOGIA, V28, P243, DOI 10.1016/0028-3932(90)90018-J; Benton A. L., 1975, TEST FACIAL RECOGNIT; Damasio A. R., 1994, LARGE SCALE NEURONAL; DAMASIO AR, 1994, EXPLORING BRAIN FUNC; DELLASALA S, 1993, NEUROPSYCHOLOGIA, V31, P823; DENES G, 1990, CORTEX, V26, P269, DOI 10.1016/S0010-9452(13)80356-5; DERENZI E, 1987, CORTEX, V23, P575, DOI 10.1016/S0010-9452(87)80050-3; DERENZI E, 1993, CORTEX, V29, P449, DOI 10.1016/S0010-9452(13)80253-5; GABRIELI JDE, 1988, BRAIN COGNITION, V7, P157, DOI 10.1016/0278-2626(88)90027-9; Gardiner John M., 1993, P163; GOLDBERG E, 1981, SCIENCE, V213, P1392, DOI 10.1126/science.7268442; GROSSI D, 1988, CORTEX, V24, P457, DOI 10.1016/S0010-9452(88)80009-1; HODGES JR, 1993, BRAIN, V116, P921, DOI 10.1093/brain/116.4.921; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; KAPUR N, 1991, BRIT J PSYCHIAT, V159, P872, DOI 10.1192/bjp.159.6.872; KAPUR N, 1994, NEUROPSYCHOLOGIA, V32, P23, DOI 10.1016/0028-3932(94)90066-3; KAPUR N, 1989, CORTEX, V25, P387, DOI 10.1016/S0010-9452(89)80053-X; KAPUR N, 1993, CORTEX, V29, P217, DOI 10.1016/S0010-9452(13)80177-3; KAPUR N, 1992, BRAIN, V115, P73, DOI 10.1093/brain/115.1.73; KAPUR N, 1996, IN PRESS MEMORY; KAPUR N, 1996, CLASSIC CASE STUDIES; KOPELMAN MD, 1989, NEUROPSYCHOLOGIA, V27, P437, DOI 10.1016/0028-3932(89)90050-X; KOPELMAN MD, 1989, J CLIN EXP NEUROPSYC, V11, P724, DOI 10.1080/01688638908400928; KRITCHEVSKY M, 1993, NEUROLOGY, V43, P326, DOI 10.1212/WNL.43.2.326; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEZAK M, 1979, EUR M INT NEUR SOC N; MARKOWITSCH HJ, 1993, J NEUROL NEUROSUR PS, V56, P988, DOI 10.1136/jnnp.56.9.988; Martin R., 1991, NEUROPSYCHOLOGY, V5, P3, DOI DOI 10.1037/0894-4105.5.1.3; McKenna P.W.E., 1983, GRADED NAMING TEST; MILNER PM, 1989, NEUROPSYCHOLOGIA, V27, P23, DOI 10.1016/0028-3932(89)90087-0; MONTALDI D, 1989, DEV CLIN EXPT NEUROP; Nelson H., 1982, NATIONAL ADULT READI; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OCONNOR M, 1992, J CLIN EXP NEUROPSYC, V14, P159, DOI 10.1080/01688639208402821; SALMON DP, 1987, PSYCHOBIOLOGY, V15, P37; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; SQUIRE LR, 1989, J NEUROSCI, V9, P828; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SQUIRE LR, 1990, J NEUROSCI, V10, P3106; TULVING E, 1991, J EXP PSYCHOL LEARN, V17, P595, DOI 10.1037/0278-7393.17.4.595; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2012, DOI 10.1073/pnas.91.6.2012; Victor M, 1990, J Cogn Neurosci, V2, P246, DOI 10.1162/jocn.1990.2.3.246; WARRINGTON EK, 1988, BRAIN COGNITION, V7, P184, DOI 10.1016/0278-2626(88)90029-2; Warrington EK., 1984, RECOGNITION MEMORY T; WEBSTER MJ, 1994, CEREB CORTEX, V4, P470, DOI 10.1093/cercor/4.5.470; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILDER BJ, 1972, EXPT MODELS EPILEPSY, P85; WOOD FB, 1989, BRAIN COGNITION, V10, P76, DOI 10.1016/0278-2626(89)90076-6; YONEDA Y, 1992, EUR NEUROL, V32, P340, DOI 10.1159/000116857; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	54	52	53	0	3	MIT PRESS	CAMBRIDGE	ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA	0898-929X	1530-8898		J COGNITIVE NEUROSCI	J. Cogn. Neurosci.	SEP	1996	8	5					416	434		10.1162/jocn.1996.8.5.416			19	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	VG437	WOS:A1996VG43700004	23961945				2021-06-18	
J	Bernert, H; Turski, L				Bernert, H; Turski, L			Traumatic brain damage prevented by the non-N-methyl-D-aspartate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						brain injury; glutamate antagonists; therapeutic time-window	SPINAL-CORD INJURY; FUNCTIONAL DEFICITS; GLOBAL-ISCHEMIA; NMDA RECEPTORS; HIPPOCAMPUS; AMPA	The mechanisms of neuronal degeneration following traumatic head injury are not well understood and no adequate treatment is currently available for the prevention of traumatic brain damage in humans. Traumatic head injury leads to primary (at impact) and secondary (distant) damage to the brain. Mechanical percussion of the rat cortex mimics primary damage seen after traumatic head injury in humans; no animal model mimicking the secondary damage following traumatic head injury has yet been established. Rats subjected to percussion trauma of the cortex showed primary damage in the cortex and secondary damage in the hippocampus. Morphometric analysis demonstrated that both cortical and hippocampal damage was mitigated by pretreatment with either the N-methyl-D-aspartate (NMDA) antagonist 3-((+/-)-2-carboxypiperazin-4-yl)-propyl-1-phosphonate (CPP) or the non-NMDA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX). Neither treatment prevented primary damage in the cortex when therapy was started after trauma. Surprisingly, delayed treatment of rats with NBQX, but not with CPP, beginning between 1 and 7 hr after trauma prevented hippocampal damage. No protection was seen when therapy with NBQX was started 10 hr after trauma. These data indicate that both NMDA- and non-NMDA-dependent mechanisms contribute to the development of primary damage in the cortex, whereas non-NMDA mechanisms are involved in the evolution of secondary damage in the hippocampus in rats subjected to traumatic head injury. The wide therapeutic time-window documented for NBQX suggests that antagonism at non-NMDA receptors may offer a novel therapeutic approach for preventing deterioration of the brain after head injury.		Bernert, H (corresponding author), SCHERING AG,RES LABS,MULLERSTR 170-178,D-13342 BERLIN,GERMANY.						Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Bernert H., 1994, Society for Neuroscience Abstracts, V20, P845; CRUZORIVE LM, 1990, AM J PHYSIOL, V258, pL148; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1994, NEUROBIOLOGY CENTRAL, P227; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FINK ROBERT P., 1967, BRAIN RES, V4, P369, DOI 10.1016/0006-8993(67)90166-7; Gennarelli T A, 1984, Emerg Med Clin North Am, V2, P749; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GREENBERG J, 1993, HDB HEAD SPINE TRAUM; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; HU BR, 1995, J NEUROCHEM, V64, P277; Ikonomidou C, 1995, CURR OPIN NEUROL, V8, P487, DOI 10.1097/00019052-199512000-00017; LEHMANN J, 1987, J PHARMACOL EXP THER, V240, P737; LI H, 1993, J CEREBR BLOOD F MET, V13, P933, DOI 10.1038/jcbfm.1993.116; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MONAGHAN DT, 1991, EXCITATORY AMINO ACI, P1; MONYER H, 1991, Society for Neuroscience Abstracts, V17, P184; PAPAIOANNOU VE, 1993, LAB ANIM SCI, V43, P189; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PELLEGRINIGIAMPIETRO DE, 1992, P NATL ACAD SCI USA, V89, P10499, DOI 10.1073/pnas.89.21.10499; Povlishock John T., 1993, P185; SHEARDOWN MJ, 1993, EUR J PHARMACOL, V236, P347, DOI 10.1016/0014-2999(93)90470-3; TURSKI L, 1988, NEUROL NEUR, V46, P343; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q; WRATHALL JR, 1992, EUR J PHARMACOL, V218, P273, DOI 10.1016/0014-2999(92)90179-8; ZILLES K, 1987, CORTEX RAT	31	52	52	0	0	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	MAY 28	1996	93	11					5235	5240		10.1073/pnas.93.11.5235			6	Multidisciplinary Sciences	Science & Technology - Other Topics	UN253	WOS:A1996UN25300012	8643559	Bronze, Green Published			2021-06-18	
J	Noble, ER; Smoker, WRK				Noble, ER; Smoker, WRK			The forgotten condyle: The appearance, morphology, and classification of occipital condyle fractures	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article						occipital bone; skull, computed tomography; skull, fractures	INJURIES	PURPOSE: To evaluate the appearance, morphology, and treatment of occipital condyle fractures (OCF). METHODS: Cases were collected by a retrospective and prospective analysis of teaching files and case logs. patients' charts, when available, were reviewed for age, sex, mode of injury, physical examination, Glascow Coma Scale score, and associated injuries. Plain films and CT images were reviewed to determine OCF type and to assess for the presence of associated cervical spine and/or intracranial trauma. RESULTS: Fifteen patients with OCF, 13 occurring in a 43-month period, were identified. Ten patients were involved in motor vehicle accidents. Severity of closed head injury and associated clinical findings were variable. Three patients had associated cervical spine fracture. According to the Anderson and Montesano classification, two patients (13%) had type I OCF, eight patients (54%) had type II OCF, and five (33%) had type III OCF. Fourteen of the fractures were identified on screening trauma head. CT scans. Treatment varied according to the presence of associated injuries and stability of the cervical spine. CONCLUSIONS: Although OCFs are rare, they will be encountered by most radiologists who see a significant amount of trauma. Type II OCFs were the most common fracture type in our series. Type III fractures were the second most common and potentially unstable. CT should be initiated at the level of the C-l ring to screen for the presence of OCF in all patients who have suffered trauma.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT RADIOL,RICHMOND,VA 23298							ADAMS VI, 1992, J FORENSIC SCI, V37, P556; ANDERSON LD, 1974, J BONE JOINT SURG AM, VA 56, P1663, DOI 10.2106/00004623-197456080-00017; ANDERSON PA, 1988, SPINE, V13, P731, DOI 10.1097/00007632-198807000-00004; BELL C, 1817, MIDDLESEX HOSP J, V4, P469; BETTINI N, 1993, SKELETAL RADIOL, V22, P187; BOLENDER N, 1978, AM J ROENTGENOL, V131, P729, DOI 10.2214/ajr.131.4.729; BOZBOGA M, 1992, SPINE, V17, P1119, DOI 10.1097/00007632-199209000-00019; BRIDGMAN SA, 1992, SURG NEUROL, V38, P152, DOI 10.1016/0090-3019(92)90094-4; BUCHOLZ RW, 1979, J BONE JOINT SURG AM, V61, P248, DOI 10.2106/00004623-197961020-00014; BUCHOLZ RW, 1979, J TRAUMA, V19, P768, DOI 10.1097/00005373-197910000-00009; CLAYMAN DA, 1994, AM J NEURORADIOL, V15, P1309; DEEB ZL, 1988, CT-J COMPUT TOMOGR, V12, P261; DESAI SS, 1990, J TRAUMA, V30, P240, DOI 10.1097/00005373-199002000-00023; GOLDSTEIN SJ, 1982, SURG NEUROL, V17, P350, DOI 10.1016/0090-3019(82)90308-1; HARDINGSMITH J, 1981, J BONE JOINT SURG AM, V63, P1170, DOI 10.2106/00004623-198163070-00016; JONES DN, 1990, AM J NEURORADIOL, V11, P1181; Kissinger P., 1900, ZENTRALBL CHIR, V37, P933; LEVENTHAL MR, 1992, ORTHOPEDICS, V15, P944; MANN FA, 1994, AM J ROENTGENOL, V163, P193, DOI 10.2214/ajr.163.1.8010212; MARIANI PJ, 1990, ANN EMERG MED, V19, P1447, DOI 10.1016/S0196-0644(05)82618-6; MODY BS, 1992, INJURY, V23, P350, DOI 10.1016/0020-1383(92)90194-W; OLSSON R, 1994, ACTA RADIOL, V35, P90; ORBAY T, 1989, SURG NEUROL, V31, P402, DOI 10.1016/0090-3019(89)90076-1; RAILA FA, 1993, SKELETAL RADIOL, V22, P269; SHARMA BS, 1994, CLIN NEUROL NEUROSUR, V96, P197, DOI 10.1016/0303-8467(94)90063-9; SPENCER JA, 1984, NEUROSURGERY, V15, P101, DOI 10.1227/00006123-198407000-00019; STROOBANTS J, 1994, J TRAUMA, V36, P440, DOI 10.1097/00005373-199403000-00037; YOUNG WF, 1994, NEUROSURGERY, V34, P257, DOI 10.1227/00006123-199402000-00008	28	52	54	0	1	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	MAR	1996	17	3					507	513					7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	UB139	WOS:A1996UB13900018	8881246				2021-06-18	
J	NAWASHIRO, H; SHIMA, K; CHIGASAKI, H				NAWASHIRO, H; SHIMA, K; CHIGASAKI, H			SELECTIVE VULNERABILITY OF HIPPOCAMPAL CA3 NEURONS TO HYPOXIA AFTER MILD CONCUSSION IN THE RAT	NEUROLOGICAL RESEARCH			English	Article						CLOSED HEAD INJURY; HIPPOCAMPUS; HYPOXIA; SYNAPTOPHYSIN; MICROTUBULE-ASSOCIATED PROTEIN 2	KAINIC ACID; CEREBRAL-ISCHEMIA; BRAIN INJURY; FOREBRAIN ISCHEMIA; DAMAGE; SYNAPTOPHYSIN; MECHANISMS	Immunohistochemical staining for microtubule-associated protein 2 (MAP2) and synaptophysin was used to investigate the effect of hypoxia on hippocampal neurons after mild concussion in the rat. Male Sprague-Dawley rats were divided into four groups: Group 1 (n = 3) was subjected to a mild impact-acceleration closed head injury, group 2 (n = 3) was subjected to 30 min of moderate hypoxia, group 3 (n = 5) was subjected to head trauma followed by 30 min of moderate hypoxia, and group 4 (n = 3) comprised sham-operated controls. All rats were fixed by transcardial perfusion 24 h after insult. No damage was observed in CA1 or CA2 neurons in any of the rats. However, rats in group 3 showed selective damage of hippocampal CA3 neurons manifested by a pycnosis and a marked decrease in MAP2 immunoreactivity. Presynaptic terminals visualized by synaptophysin immunostaining showed no differences among groups. The loss of immunoreactivity for the post-synaptic somal and dendritic protein marker MAP2 from the CA3 subfield 24 h after combined insults indicates an increased vulnerability of pyramidal cells in this brain area.		NAWASHIRO, H (corresponding author), NATL DEF MED COLL, DEPT NEUROSURG, 3-2 NAMIKI, TOKOROZAWA, SAITAMA 359, JAPAN.						AKAI F, 1993, BRAIN RES, V603, P87, DOI 10.1016/0006-8993(93)91302-9; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COYLE JT, 1983, J NEUROCHEM, V41, P1; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; NADLER JV, 1980, BRAIN RES, V182, P1; NAWASHIRO H, 1994, ACTA NEUROCHIR, P440; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; SHIMA K, 1991, ADV EXPT NEUROTRAUMA, V3, P84; SLOVITER RS, 1981, NEUROPHARMACOLOGY, V20, P1003, DOI 10.1016/0028-3908(81)90088-5; TOMIMOTO H, 1992, ACTA NEUROPATHOL, V84, P394; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610	23	52	52	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	DEC	1995	17	6					455	460		10.1080/01616412.1995.11740363			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	TJ818	WOS:A1995TJ81800012	8622802				2021-06-18	
J	KELLY, DF				KELLY, DF			ALCOHOL AND HEAD-INJURY - AN ISSUE REVISITED	JOURNAL OF NEUROTRAUMA			English	Article						ALCOHOL; COAGULOPATHY; EXCITOTOXICITY; HEAD INJURY; N-METHYL-D-ASPARTATE RECEPTOR	ETHANOL WITHDRAWAL; BRAIN INJURY; CORTICAL-NEURONS; CEREBRAL-CORTEX; TRAUMA; INTOXICATION; FIBRINOLYSIS; HIPPOCAMPAL; INHIBITION; DRINKING	The pathophysiologic changes associated with acute and chronic alcohol exposure in the setting of traumatic brain injury are complex, Experimental data indicate that ethanol intoxication can exacerbate brain injury through several mechanisms including hemodynamic and respiratory depression, blood-brain barrier disruption, and derangements in hemostasis. Alcohol, however, is also a potent inhibitor of N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity, and thus is neuroprotective. In contrast to the effects of acute intoxication, chronic alcohol exposure appears to result in upregulation of NMDA receptor activity and downregulation of gamma-aminobutyric acid (GABA) receptor function. This imbalance, it is hypothesized, can result in a surge of exitotoxicity following alcohol withdrawal. Trauma-related excitotoxic cell damage may be significantly potentiated by this alcohol-induced receptor imbalance that is unmasked as withdrawal occurs. Clinical and epidemiologic investigations of alcohol and outcome after head injury have not consistently demonstrated a measurable effect from either acute or chronic alcohol use. Multiple factors including the timing of intoxication in relation to time of injury, the degree and chronicity of intoxication, as well as the influence of other secondary injury processes appear to determine the net effect of alcohol in a given individual. Further clinical and experimental investigations aimed at defining the impact of alcohol use on outcome after head injury are warranted.		KELLY, DF (corresponding author), UNIV CALIF LOS ANGELES,HLTH SCI CTR,DIV NEUROSURG,BOX 956901,LOS ANGELES,CA 90095, USA.						AGUAYO LG, 1990, EUR J PHARMACOL, V187, P127, DOI 10.1016/0014-2999(90)90349-B; ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; ALLAN AM, 1987, PHARMACOL BIOCHEM BE, V27, P665, DOI 10.1016/0091-3057(87)90192-4; BENGMARK S, 1980, THROMB HAEMOSTASIS, V43, P203; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; BUNEGIN L, 1986, CRIT CARE MED, V14, P387, DOI 10.1097/00003246-198604000-00151; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; CRONE KR, 1987, NEUROSURGERY, V21, P532, DOI 10.1227/00006123-198710000-00015; DECRESCITO V, 1974, SURG FORUM, V15, P438; DEYKIN D, 1982, NEW ENGL J MED, V306, P852, DOI 10.1056/NEJM198204083061406; DILDYMAYFIELD JE, 1991, J NEUROCHEM, V56, P1536, DOI 10.1111/j.1471-4159.1991.tb02048.x; ELMER O, 1984, HAEMOSTASIS, V14, P223; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; GERSHMAN H, 1991, Journal of Emergency Medicine, V9, P307, DOI 10.1016/0736-4679(91)90371-L; GONZALES RA, 1991, TRENDS PHARMACOL SCI, V12, P1, DOI 10.1016/0165-6147(91)90478-B; GRANT KA, 1990, EUR J PHARMACOL, V176, P289, DOI 10.1016/0014-2999(90)90022-X; GULYA K, 1991, BRAIN RES, V547, P129; HAUT MJ, 1974, AM J MED, V56, P2; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; INGLIS FM, 1990, ACT NEUR S, V51, P277; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KELLY DF, 1995, CRIT CARE MED, V23, pA245; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kraus JF, 1993, HEAD INJURY, P1; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; LESLIE SW, 1983, J PHARMACOL EXP THER, V225, P571; LINDENBA.J, 1969, NEW ENGL J MED, V281, P333, DOI 10.1056/NEJM196908142810701; LITTLE HJ, 1986, LIFE SCI, V39, P2059, DOI 10.1016/0024-3205(86)90356-5; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LOVINGER DM, 1993, ALCOHOL CLIN EXP RES, V17, P19, DOI 10.1111/j.1530-0277.1993.tb00720.x; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; McQueen J D, 1975, Surg Neurol, V4, P375; MODELL JG, 1990, NEW ENGL J MED, V323, P455, DOI 10.1056/NEJM199008163230706; MONTPIED P, 1991, MOL PHARMACOL, V39, P157; MORROW AL, 1988, J PHARMACOL EXP THER, V246, P158; NESTOROS JN, 1980, SCIENCE, V209, P708, DOI 10.1126/science.7394531; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; PERSSON LI, 1978, ACTA NEUROL SCAND, V57, P405; PIKAAR NA, 1987, METABOLISM, V36, P538, DOI 10.1016/0026-0495(87)90163-6; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSENGREN LE, 1979, ACTA NEUROL SCAND, V59, P119; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; RYBACK R, 1970, ARCH INTERN MED, V125, P475, DOI 10.1001/archinte.125.3.475; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; TAKADERA T, 1990, BRAIN RES, V537, P109, DOI 10.1016/0006-8993(90)90346-D; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; VANDERSANDE JJ, 1981, J NEUROSURG, V55, P718, DOI 10.3171/jns.1981.55.5.0718; WALKER DW, 1974, ELECTROEN CLIN NEURO, V36, P233, DOI 10.1016/0013-4694(74)90164-3; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; WHITTINGTON MA, 1991, BRIT J PHARMACOL, V103, P1677, DOI 10.1111/j.1476-5381.1991.tb09846.x; ZINC BJ, 1995, J NEUROSURGF, V82, P822; ZINC BJ, 1993, J NEUROTRAUM, V10, P275; 1994, 1994 OCCUPANT PROTEC	62	52	53	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					883	890		10.1089/neu.1995.12.883			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600012	8594215				2021-06-18	
J	SMITH, DH; MEANEY, DF; LENKINSKI, RE; ALSOP, DC; GROSSMAN, R; KIMURA, H; MCINTOSH, TK; GENNARELLI, TA				SMITH, DH; MEANEY, DF; LENKINSKI, RE; ALSOP, DC; GROSSMAN, R; KIMURA, H; MCINTOSH, TK; GENNARELLI, TA			NEW MAGNETIC-RESONANCE-IMAGING TECHNIQUES FOR THE EVALUATION OF TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, D.C.	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		DIFFUSION-WEIGHTED IMAGING; MAGNETIZATION TRANSFER IMAGING; TRAUMATIC BRAIN INJURY	DIFFUSE AXONAL INJURY; CLOSED HEAD-INJURY; CEREBRAL-ISCHEMIA; T2-WEIGHTED MRI; WEIGHTED MRI	Although current computerized tomography (CT) and magnetic resonance imaging (MRI) techniques have shown great utility in diagnosing various aspects traumatic brain injury, damage resulting from mild diffuse brain injury often goes undetected with these procedures. Newly developed MRI techniques, including magnetization transfer imaging (MTI) and diffusion-weighted imaging (DWI), have been proposed to have enhanced sensitivities for identifying damage induced by both diffuse and focal brain injury, Results from recent initial studies with experimental models of brain injury suggest that MTI may be useful for evaluating diffuse white matter damage, while DWI may demonstrate regions of focal contusion more acutely and with greater accuracy than conventional MRI procedures.	UNIV PENN, DEPT BIOENGN, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT RADIOL, PHILADELPHIA, PA 19104 USA; HAHNEMANN UNIV, DEPT NEUROSURG, PHILADELPHIA, PA 19102 USA	SMITH, DH (corresponding author), UNIV PENN, DIV NEUROSURG, 105 HAYDEN HALL, 240 S 33RD ST, PHILADELPHIA, PA 19104 USA.		Alsop, David C/J-5764-2013; smith, douglas/A-1321-2007; Lenkinski, Robert/F-9045-2014	Alsop, David C/0000-0002-8206-1995; Lenkinski, Robert/0000-0001-7371-5048; Meaney, David/0000-0002-0954-4122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALSOP DC, 1994, SOC MAGN RESON MED, V3, P1370; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; FORD JC, 1994, MAGNET RESON MED, V31, P488, DOI 10.1002/mrm.1910310504; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Graham D I, 1988, Prog Clin Biol Res, V264, P159; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HICKS RR, 1992, J NEUROTRAUM, V9, P388; KIMURA H, 1994, RADIOLOGY P, V193, P461; LENKINSKI RE, 1993, P SOC MAGN RES MED, V3, P1491; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LO EH, 1994, J CEREBR BLOOD F MET, V14, P597, DOI 10.1038/jcbfm.1994.74; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1993, AMD, V169, P169; MINEMATSU K, 1993, NEUROLOGY, V43, P397, DOI 10.1212/WNL.43.2.397; MINEMATSU K, 1992, NEUROLOGY, V42, P235, DOI 10.1212/WNL.42.1.235; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOSELEY ME, 1991, MAGNET RESON MED, V19, P321, DOI 10.1002/mrm.1910190222; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	30	52	55	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					573	577		10.1089/neu.1995.12.573			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000008	8683608				2021-06-18	
J	JOHNSTONE, B; HEXUM, CL; ASHKANAZI, G				JOHNSTONE, B; HEXUM, CL; ASHKANAZI, G			EXTENT OF COGNITIVE DECLINE IN TRAUMATIC BRAIN INJURY BASED ON ESTIMATES OF PREMORBID INTELLIGENCE	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; HALSTEAD-REITAN; WAIS-R; MEMORY; TOMOGRAPHY; CONCUSSION; MILD	Global cognitive impairment following traumatic brain injury (TBI) is common, with some abilities more significantly affected than others. However, due to difficulties in estimating premorbid intelligence, there has been no systematic evaluation of the extent of decline in different cognitive abilities following TBI. Recent studies indicate that the Wide Range Achievement Test-Revised (WRAT-R) Reading subtest is an accurate estimate of premorbid intelligence, suggesting that post-TBI cognitive test scores can be compared to the WRAT-R to estimate the extent of decline that occurs in specific cognitive abilities. The current study estimated the extent of deficit in intelligence, memory, attention, speed of processing, and cognitive flexibility for 97 outpatients with TBI. Extent of decline was calculated by subtracting WRAT-R z-scores from cognitive test z-scores to determine a z-difference score (Z(Diff)) for each cognitive ability. The results suggest that intelligence is least declined following TBI (WAIS-R 3-4-point decline; VIQ Z(Diff) = -0.23: FIQ Z(Diff) = -0.27), followed by attention (WMS-R 5-point decline; Z(Diff) = -0.31), memory (WMS-R 6-9-point decline; Verbal Memory Z(Diff) = -0.41; General Memory Z(Diff) = -0.51; Delay Memory Z(Diff) = -0.57), speed of processing (Trails A 15-16 second decline; Z(Diff) = -1.90) and cognitive flexibility (Trails B 35-52 second decline; Z(Diff) = -2.65). Implications for provision of feedback to individuals with TBI and their families are discussed.		JOHNSTONE, B (corresponding author), UNIV MISSOURI,SCH MED,RUSK REHABIL CTR 501,DEPT PHYS MED & REHABIL,1 HOSP DR,COLUMBIA,MO 65212, USA.			Johnstone, Brick/0000-0001-8845-9649			Acker MB, 1989, NEUROPSYCHOLOGY, V3, P123, DOI 10.1037//0894-4105.3.3.123; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BORNSTEIN RA, 1988, CLIN NEUROPSYCHOL, V2, P107, DOI DOI 10.1080/13854048808520093; Brooks D. N, 1990, REHABILITATION ADULT, P163; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Christensen H., 1991, PSYCHOL ASSESS J CON, V3, P147; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; FROMMAUCH D, 1983, J CLIN NEUROPSYCHOL, V5, P221, DOI 10.1080/01688638308401171; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Jastak J., 1984, WIDE RANGE ACHIEVEME; KANE RL, 1985, J CLIN EXP NEUROPSYC, V7, P211, DOI 10.1080/01688638508401254; KARPMAN T, 1986, J APPLIED REHABILITA, V17, P28; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; MOSS AR, 1991, BRIT J CLIN PSYCHOL, V30, P179, DOI 10.1111/j.2044-8260.1991.tb00934.x; NELSON HG, 1975, BRIT J SOC CLIN PSYC, V14, P257; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; Powell J B, 1991, Arch Clin Neuropsychol, V6, P241, DOI 10.1016/0887-6177(91)90001-P; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Reitan R, 1986, TRAIL MAKING TEST MA; ROLD GH, 1988, CLIN NEUROPSYCHOLOGI, V2, P116; ROTH DL, 1990, J CLIN EXP NEUROPSYC, V12, P834; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WIENS AN, 1993, CLIN NEUROPSYCHOL, V7, P70, DOI 10.1080/13854049308401889; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089	38	52	52	0	4	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1995	9	4					377	384		10.3109/02699059509005777			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QY080	WOS:A1995QY08000005	7640683				2021-06-18	
J	GREENSPAN, AI; MACKENZIE, EJ				GREENSPAN, AI; MACKENZIE, EJ			FUNCTIONAL OUTCOME AFTER PEDIATRIC HEAD-INJURY	PEDIATRICS			English	Article						TRAUMATIC HEAD INJURY; FUNCTIONAL LIMITATIONS; PHYSICAL HEALTH; BEHAVIOR PROBLEMS; SPECIAL EDUCATION	BRAIN INJURY; FOLLOW-UP; CHILDREN; SEVERITY; TRAUMA; SEQUELAE; SCORE	Objectives. To examine the consequences of head injury and the medical, economic, and sociodemographic factors affecting functional status 1 year after injury. Methods. A follow-up was conducted on 95 children (aged 5 to 15) 1 year after they were hospitalized for head injury. Parents were interviewed by phone concerning their child's preinjury and current health status, and the family's economic and social resources during the 1 year postinjury. Inpatient medical records were reviewed to obtain information regarding the characteristics of the injury. Results. We found that study children were more likely than children from the general population to have limitations in physical health, behavioral problems, and to be enrolled in a special education program. These findings were true for all levels of head injury severity, although children with severe head injuries (Abbreviated Injury Scale 5) were more likely to demonstrate these functional limitations than were children with less severe injuries (Abbreviated Injury Scale 2, 3, 4). After controlling for head injury severity, we found that the poorer outcomes were associated with poverty, preinjury chronic health problems, and lower extremity injuries. Conclusions. The large proportion of children who demonstrated functional limitations underscores the importance of evaluating all children hospitalized with head injuries for functional limitations and providing rehabilitation and social services when needed.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR HLTH SERV RES & DEV,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR INJURY PREVENT,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD							ADAY LA, 1984, ACCESS MED CARE; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BIJUR PE, 1990, PEDIATRICS, V86, P337; BULL JP, 1985, ACCIDENT ANAL PREV, V17, P387, DOI 10.1016/0001-4575(85)90093-4; CASEY R, 1986, PEDIATRICS, V78, P497; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; Dunham C M, 1989, Md Med J, V38, P227; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; EISEN M, 1980, R2313HEW RAND CORP P; FILEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194; FREEMAN HE, 1987, HLTH AFFAIRS     SPR, P6; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; MACKENZIE EJ, 1986, MED CARE, V24, P377, DOI 10.1097/00005650-198605000-00001; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; SIEGEL J, 1990, 3RD SCI ASS; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; ZILL N, 1985, BEHAVIOR PROBLEM SCA; ZILL N, 1985, BEHAVIOR PROBLEMS IN; 1985, ABBREVIATED INJURY S	28	52	52	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098	0031-4005			PEDIATRICS	Pediatrics	OCT	1994	94	4	1				425	432					8	Pediatrics	Pediatrics	PK840	WOS:A1994PK84000003	7936848				2021-06-18	
J	ARCIA, E; GUALTIERI, CT				ARCIA, E; GUALTIERI, CT			NEUROBEHAVIORAL PERFORMANCE OF ADULTS WITH CLOSED-HEAD INJURY, ADULTS WITH ATTENTION-DEFICIT, AND CONTROLS	BRAIN INJURY			English	Article							HYPERACTIVE-CHILDREN; EVALUATION SYSTEM; RECOVERY; DISORDER	The symptoms experienced by people with mild closed-head injury (mCHI) and by people with attention deficit disorder (ADD) are similar in many aspects. We examined the performance of 26 adults with mCHI, 23 adults with ADD, and 25 matched controls on four functional areas: (1) simple motor response, (2) response speed and attention, (3) complex perceptual-motor performance, and (4) memory and learning. Analyses of variance and multivariate analyses of variance were used to compare the performance of the three groups. Test results were also plotted to examine patterns of performance and similarities between the groups. Both groups with mCHI and ADD had significantly more difficulty than controls with sustained attention. However, whereas the group with mCHI was characterized by generalized slowness in their response times, the group with ADD was characterized by impulsivity or an inability to regulate their attention and responses.	N CAROLINA NEUROPSYCHIAT, CHAPEL HILL, NC 27516 USA	ARCIA, E (corresponding author), UNIV N CAROLINA, FRANK PORTER GRAHAM CHILD DEV CTR, 300 NAT BANK PLAZA, CHAPEL HILL, NC 27514 USA.						ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; ARCIA E, 1991, J SCHOOL PSYCHOL, V29, P337, DOI 10.1016/0022-4405(91)90021-I; ARCIA E, 1992, NEUROTOXICOL TERATOL, V14, P103, DOI 10.1016/0892-0362(92)90058-I; Bailey B. N., 1989, TXB HEAD INJURY, P308; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; CHELUNE GJ, 1986, CHILD PSYCHIAT HUM D, V16, P221, DOI 10.1007/BF00706479; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; EVANS RW, 1986, PSYCHOPHARMACOLOGY, V90, P211; GENTILINI M, 1989, MILD HEAD INJURY, P163; GRONWALL D, 1974, LANCET, V2, P605; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; HECHTMAN L, 1983, AM J ORTHOPSYCHIAT, V53, P532, DOI 10.1111/j.1939-0025.1983.tb03397.x; HOOISMA J, 1990, ADVANCES IN NEUROBEHAVIORAL TOXICOLOGY : APPLICATIONS IN ENVIRONMENTAL AND OCCUPATIONAL HEALTH, P245; KLEE SH, 1986, PSYCHIAT ANN, V16, P52, DOI 10.3928/0048-5713-19860101-12; LETZ R, 1990, ADVANCES IN NEUROBEHAVIORAL TOXICOLOGY : APPLICATIONS IN ENVIRONMENTAL AND OCCUPATIONAL HEALTH, P189; LETZ R, 1986, UNPUB NEUROBEHAVIORA; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LOU HC, 1984, ARCH NEUROL-CHICAGO, V41, P825, DOI 10.1001/archneur.1984.04050190031010; MATTES JA, 1980, COMPR PSYCHIAT, V21, P358, DOI 10.1016/0010-440X(80)90017-6; MENDELSON W, 1971, J NERV MENT DIS, V153, P127; RICHARDSON JTE, 1984, CORTEX, V20, P413, DOI 10.1016/S0010-9452(84)80009-X; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SERGEANT J, 1988, ATTENTION DEFICIT DI, P183; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Swanson JM, 1990, DEV ATTENTION RES TH, P383; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; WOODS D, 1986, PSYCHIAT ANN, V16, P23, DOI 10.3928/0048-5713-19860101-06; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001	31	52	53	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1994	8	5					395	404		10.3109/02699059409150991			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	NW122	WOS:A1994NW12200001	7951202				2021-06-18	
J	MITTENBERG, W; BURTON, DB				MITTENBERG, W; BURTON, DB			A SURVEY OF TREATMENTS FOR POST-CONCUSSION SYNDROME	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; SYMPTOMS; SEQUELAE	A survey of the members of the National Academy of Neuropsychology and the International Neuropsychological Society was conducted on current treatment approaches for post-concussion syndrome. The interventions that were found useful most frequently included education about the effects of head injury, reassurance that the symptoms are part of the normal recovery process, and support in coping with reactions to the symptoms. Graded resumption of activity, antidepressant medication, and cognitive restructuring were also regarded as useful. The relations.hips between type of treatment, factors contributing to the syndrome, ratings of treatment effectiveness, and duration of treatment were discussed.		MITTENBERG, W (corresponding author), NOVA UNIV,SCH PSYCHOL,FT LAUDERDALE,FL 33314, USA.						Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; BECK AT, 1979, COGNITIVE THERAPY DE; BECK AT, ANXIETY DISORDERS PH; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; CYTOWIC RE, 1987, NEUROPSYCHOLOGICAL S, P226; DIKMEN SS, MILD HEAD INJURY, P229; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GLISKY EL, 1986, J HEAD TRAUMA REHABI, V1, P81; GODFREY HPD, 1987, BRIT J CLIN PSYCHOL, V26, P83, DOI 10.1111/j.2044-8260.1987.tb00735.x; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; KERLINGER F, 1973, F BEHAV RES, P414; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 1989, MILD HEAD INJURY; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEVIN HS, 1990, J CLIN EXPT NEUROPSY, V12, P120; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; MEIER MJ, 1986, NEUROPSYCHOL REHABIL; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Philips HC, 1988, PSYCHOL MANAGEMENT C; Ruff R.M., 1989, MILD HEAD INJURY, P176; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1977, LANCET, V1, P1; SCHATZBERG AF, MANUAL CLIN PSYCHOPH; Uzzell B., 1986, CLIN NEUROPSYCHOLOGY; WRIGHTSON P, 1989, MILD HEAD INJURY, P245; 1978, MENTAL DISORDERS GLO	35	52	52	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1994	8	5					429	437		10.3109/02699059409150994			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	NW122	WOS:A1994NW12200004	7951205				2021-06-18	
J	VIGE, X; CARREAU, A; SCATTON, B; NOWICKI, JP				VIGE, X; CARREAU, A; SCATTON, B; NOWICKI, JP			ANTAGONISM BY NG-NITRO-L-ARGININE OF L-GLUTAMATE-INDUCED NEUROTOXICITY IN CULTURED NEONATAL RAT CORTICAL-NEURONS - PROLONGED APPLICATION ENHANCES NEUROPROTECTIVE EFFICACY	NEUROSCIENCE			English	Article							CEREBELLAR GRANULE CELLS; FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; OXIDE SYNTHASE; NMDA ANTAGONISTS; RECEPTOR AGONISTS; GYKI 52466; DEATH; RELEASE	The effects of N(G)-nitro-L-arginine on L-glutamate-induced neurotoxicity have been evaluated on primary cultures of neonatal rat cortical neurons. Treatment of cultures with increasing concentrations of L-glutamate during 5 min produced a delayed neuronal death, as measured by lactate dehydrogenase release in the medium 24 h later. Maximal toxicity was obtained with 500 mu M Of L-glutamate. Substantial nitric oxide synthase activity was detected in these cortical cultures. Nitric oxide synthase activity and cellular L-glutamate-induced cyclic guanosine 3',5'-monophosphate accumulation were totally inhibited by 100 mu M N(G)-nitro-L-arginine. Addition of N(G)-nitro-L-arginine (100 mu M) to the medium either 5 min prior to and during L-glutamate exposure (500 mu M, 5 min) or for 24 h after L-glutamate exposure decreased the amino acid-induced neurotoxicity by 23% (not significant) and 43%, respectively. When added 5 min before L-glutamate and just after L-glutamate removal and kept in contact with neurons for the following 24 h, N(G)-nitro-L-arginine (100 mu M) antagonized by 74% the L-glutamate-induced neurotoxicity. This effect was not reversed by a co-application Of L-arginine (1 mM). The neuroprotective effect of N(G)-nitro-L-arginine was concentration-dependent, a half-maximal inhibition of L-glutamate-induced neurotoxicity being observed with the addition (before and after L-glutamate) of 4 mu M of the drug. These results suggest that the neuroprotective effect of N(G)-nitro-L-arginine previously observed in vivo is exerted at the neuronal level. The increased neuroprotective efficacy of N(G)-nitro-L-arginine, with prolonged application indicates that a nitric oxide-dependent delayed neuronal death is taking place during the maturation phase that folloWS L-glutamate exposure.		VIGE, X (corresponding author), SYNTHELABO RECH,LERS,DEPT BIOL,31 AVE PAUL VAILLANT COUTURIER,F-92220 BAGNEUX,FRANCE.						ALHO H, 1988, DEV BRAIN RES, V39, P193, DOI 10.1016/0165-3806(88)90023-5; BERTOLINO M, 1988, NEUROSCI LETT, V84, P351, DOI 10.1016/0304-3940(88)90534-4; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUISSON A, 1992, BRIT J PHARMACOL, V106, P766, DOI 10.1111/j.1476-5381.1992.tb14410.x; CARREAU A, UNPUB DEVL BRAIN RES; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P369; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6338; DEMERLEPALLARDY C, 1991, BIOCHEM BIOPH RES CO, V181, P456, DOI 10.1016/S0006-291X(05)81441-X; DIEMER NH, 1992, ACTA NEUROL SCAND, V86, P45, DOI 10.1111/j.1600-0404.1992.tb08052.x; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GARTHWAITE G, 1986, NEUROSCI LETT, V66, P193, DOI 10.1016/0304-3940(86)90189-8; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HARTLEY DM, 1989, J PHARMACOL EXP THER, V250, P752; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; IZUMI Y, 1992, NEUROSCI LETT, V135, P227, DOI 10.1016/0304-3940(92)90442-A; KIEDROWSKI L, 1992, J NEUROCHEM, V58, P335, DOI 10.1111/j.1471-4159.1992.tb09315.x; LEPEILLET E, 1992, BRAIN RES, V571, P115; LEVI G, 1984, BRAIN RES, V290, P77, DOI 10.1016/0006-8993(84)90737-6; LUSTIG HS, 1992, BRAIN RES, V577, P343, DOI 10.1016/0006-8993(92)90295-K; MANEV H, 1989, MOL PHARMACOL, V36, P106; MARAGOS WF, 1987, TRENDS NEUROSCI, V10, P65, DOI 10.1016/0166-2236(87)90025-7; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; NOVELLI A, 1987, J NEUROSCI, V7, P40; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V183, P238, DOI 10.1016/0006-291X(92)91634-3; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PAUWELS PJ, 1992, NEUROSCI LETT, V143, P27, DOI 10.1016/0304-3940(92)90225-V; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SCATTON B, 1991, CEREBROVASC DIS, V1, P121, DOI 10.1159/000108829; SCHMIDT HHW, 1991, BIOCHEM BIOPH RES CO, V181, P1372, DOI 10.1016/0006-291X(91)92090-7; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SMITH SE, 1992, STROKE, V23, P861, DOI 10.1161/01.STR.23.6.861; TRIFLETTI RR, 1962, EUR J PHARMACOL, V218, P197; UEHARAKUNUGI Y, 1991, DEV BRAIN RES, V59, P157, DOI 10.1016/0165-3806(91)90095-Z; VIGE X, 1992, BRAIN RES, V591, P345, DOI 10.1016/0006-8993(92)91718-T; WOOD PL, 1990, J NEUROCHEM, V55, P346, DOI 10.1111/j.1471-4159.1990.tb08859.x; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210	45	52	52	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0306-4522			NEUROSCIENCE	Neuroscience	AUG	1993	55	4					893	901		10.1016/0306-4522(93)90306-Z			9	Neurosciences	Neurosciences & Neurology	LQ427	WOS:A1993LQ42700002	7694182				2021-06-18	
J	WARREN, M				WARREN, M			A HIERARCHICAL MODEL FOR EVALUATION AND TREATMENT OF VISUAL PERCEPTUAL DYSFUNCTION IN ADULT ACQUIRED BRAIN INJURY .1.	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						CEREBROVASCULAR DISORDERS; REHABILITATION; VISUAL PERCEPTION	SPATIAL CONTRAST SENSITIVITY; GUIDED EYE-MOVEMENTS; RESIDUAL VISION; UNILATERAL NEGLECT; CEREBRAL BLINDNESS; ISCHEMIC LESIONS; CORTICALLY BLIND; STROKE PATIENTS; DISCRIMINATION; INATTENTION	A developmental framework for evaluation and treatment of visual perceptual deficits in adults with acquired brain injury is presented The framework is based on a review of research conducted on post-cerebrovascular accident subjects and subjects with traumatic brain injuries. Visual perceptual skill is conceptualized as a hierarchy of skill levels that interact and subserve each other. Higher level skills evolve from integration of lower level skills and are subsequently affected by disruption of lower level skills. Oculomotor control, visual field, and acuity form the foundation skills, followed by visual attention, scanning, pattern recognition, memory, and visual cognition. Brain injury can affect the integrity and interaction of each skill level and affect daily living function. Application of this framework dictates a bottom-up approach to evaluation and treatment, emphasizing identification and remediation of deficits in lower level skills to allow normal integration of higher level skill.		WARREN, M (corresponding author), UNIV MISSOURI, EYE FDN KANSAS CITY, DEPT OPHTHALMOL, 2300 HOLMES, KANSAS CITY, MO 64108 USA.						ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; BELLEZA T, 1979, CORTEX, V15, P19, DOI 10.1016/S0010-9452(79)80003-9; BERGEN JR, 1983, NATURE, V303, P696, DOI 10.1038/303696a0; BISIACH E, 1979, BRAIN, V102, P609, DOI 10.1093/brain/102.3.609; BLYTHE IM, 1987, BRAIN, V110, P887, DOI 10.1093/brain/110.4.887; BODISWOL.I, 1972, SCIENCE, V178, P769, DOI 10.1126/science.178.4062.769; BODISWOLLNER I, 1976, BRAIN, V99, P695, DOI 10.1093/brain/99.4.695; BOSLEY TM, 1987, ANN NEUROL, V21, P444, DOI 10.1002/ana.410210505; BRUCE CJ, 1984, TRENDS NEUROSCI, V7, P436, DOI 10.1016/S0166-2236(84)80149-6; BULENS C, 1989, BRAIN, V112, P507, DOI 10.1093/brain/112.2.507; CAMPBELL FW, 1983, BEHAV BRAIN RES, V10, P87, DOI 10.1016/0166-4328(83)90154-7; CAMPION J, 1983, BEHAV BRAIN SCI, V6, P423, DOI 10.1017/S0140525X00016861; CAPLAN B, 1985, CORTEX, V21, P69, DOI 10.1016/S0010-9452(85)80016-2; CHEDRU F, 1973, Cortex, V9, P94; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; CORBETTA M, 1990, BRAIN, V113, P603, DOI 10.1093/brain/113.3.603; COTMAN CW, 1980, BEHAVIORAL NEUROSCIE; De Renzi E., 1982, DISORDERS SPACE EXPL; Delis D C, 1983, Int Rehabil Med, V5, P132; DEREFELDT G, 1979, ACTA OPHTHALMOL, V57, P679; DERENZI E, 1989, CORTEX, V25, P231, DOI 10.1016/S0010-9452(89)80039-5; DERENZI E, 1982, ARCH NEUROL-CHICAGO, V39, P482, DOI 10.1001/archneur.1982.00510200024004; DILLER L, 1970, Archives of Physical Medicine and Rehabilitation, V51, P358; FESTINGER L, 1971, CONTROL EYE MOVEMENT; GIANUTSOS R, 1983, ARCH PHYS MED REHAB, V64, P456; GIANUTSOS R, 1988, ARCH PHYS MED REHAB, V69, P573; Gianutsos R., 1987, NEUROPSYCHOL REHABIL, P202; GIANUTSOS R, 1989, J HEAD TRAUMA REHAB, V4, P17; GIBSON EJ, 1976, AM SCI, V235, P98; GOURAS P, 1985, PRINCIPLES NEURAL SC, P571; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; HEILMAN KM, 1979, ANN NEUROL, V5, P166, DOI 10.1002/ana.410050210; HESS RF, 1989, BRAIN, V112, P871, DOI 10.1093/brain/112.4.871; HIER DB, 1983, NEUROLOGY, V33, P334; HYVARINEN L, 1982, ACTA OPHTHALMOL    S, V157, P58; JOHNSON CA, 1983, ARCH OPHTHALMOL-CHIC, V101, P371; JULESZ B, 1981, NATURE, V290, P91, DOI 10.1038/290091a0; JULESZ B, 1985, PATTERN RECOGNITIO S, V111, P333; KANDEL E, 1985, PRINCIPLES NEURAL SC, P367; Kelly J. P., 1985, PRINCIPLES NEURAL SC, P356; LEIGH RJ, 1983, NEUROLOGY EYE MOVEME; LOCHER PJ, 1983, PERCEPT MOTOR SKILL, V57, P91, DOI 10.2466/pms.1983.57.1.91; MARSHALL JC, 1988, NATURE, V336, P766, DOI 10.1038/336766a0; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; MISHKIN M, 1987, SCI AM, V256, P80, DOI 10.1038/scientificamerican0687-80; MOORE JC, 1991, SEP PED THER INT GRO; MORROW MJ, 1990, NEUROLOGY, V40, P284, DOI 10.1212/WNL.40.2.284; NAGELLEIBY S, 1990, BRAIN, V113, P237, DOI 10.1093/brain/113.1.237; NEGER RE, 1989, J HEAD TRAUMA REHAB, V4, P27; NOTON D, 1971, SCIENCE, V171, P308, DOI 10.1126/science.171.3968.308; OWSLEY C, 1983, VISION RES, V23, P689, DOI 10.1016/0042-6989(83)90210-9; PADULA WV, 1988, BEHAVIORAL VISION AP; PALMER T, 1990, BRAIN COGNITION, V13, P46, DOI 10.1016/0278-2626(90)90039-Q; PERENIN MT, 1975, NEUROPSYCHOLOGIA, V13, P1, DOI 10.1016/0028-3932(75)90041-X; PIERROTDESEILLIGNY C, 1986, BRAIN, V109, P81, DOI 10.1093/brain/109.1.81; Pommerenke K, 1989, Restor Neurol Neurosci, V1, P47, DOI 10.3233/RNN-1989-1106; POPPEL E, 1973, NATURE, V243, P295, DOI 10.1038/243295a0; Posner M. I., 1987, NEUROPSYCHOL REHABIL, P182; PRING TR, 1981, CORTEX, V17, P227, DOI 10.1016/S0010-9452(81)80043-3; RAFAL RD, 1987, P NATL ACAD SCI USA, V84, P7349, DOI 10.1073/pnas.84.20.7349; RAPCSAK SZ, 1989, ARCH NEUROL-CHICAGO, V46, P178, DOI 10.1001/archneur.1989.00520380082018; RATCLIFF G, 1981, BRIT MED BULL, V37, P181, DOI 10.1093/oxfordjournals.bmb.a071698; RATCLIFF G, 1987, NEUROPSYCHOL REHABIL, P242; REGAN D, 1981, BRAIN, V104, P333, DOI 10.1093/brain/104.2.333; REUTERLORENZ PA, 1990, BRAIN COGNITION, V12, P240, DOI 10.1016/0278-2626(90)90018-J; ROSSI PW, 1990, NEUROLOGY, V40, P1597, DOI 10.1212/WNL.40.10.1597; SAGI D, 1985, SCIENCE, V228, P1217, DOI 10.1126/science.4001937; SCHEIBER F, 1988, TRANSPORTATION AGING, P325; SEKULER R, 1980, SCIENCE, V209, P1255, DOI 10.1126/science.7403884; SERGENT J, 1984, PSYCHOL BULL, V96, P99; SERGENT J, 1990, BRAIN COGNITION, V13, P98, DOI 10.1016/0278-2626(90)90043-N; SPIERS PA, 1990, NEUROLOGY, V40, P1600, DOI 10.1212/WNL.40.10.1600; STANWORTH A, 1974, BRIT J OPHTHALMOL, V58, P266, DOI 10.1136/bjo.58.3.266; TYLER HR, 1969, NEUROLOGY, V19, P105, DOI 10.1212/WNL.19.2.105; UZZELL BP, 1988, ARCH NEUROL-CHICAGO, V45, P420, DOI 10.1001/archneur.1988.00520280066017; WARREN M, 1990, AM J OCCUP THER, V44, P391, DOI 10.5014/ajot.44.5.391; WARREN M, 1981, AM J OCCUP THER, V35, P431, DOI 10.5014/ajot.35.7.431; WEINBERG J, 1982, Journal of Clinical Neuropsychology, V4, P59, DOI 10.1080/01688638208401117; WEINTRAUB S, 1988, J NEUROL NEUROSUR PS, V51, P1481, DOI 10.1136/jnnp.51.12.1481; WEISKRANTZ L, 1974, BRAIN, V97, P709, DOI 10.1093/brain/97.1.709; WEISKRANTZ L, 1987, BRAIN, V110, P77, DOI 10.1093/brain/110.1.77; Yarbus AL, 1967, EYE MOVEMENTS VISION, DOI [DOI 10.1007/978-1-4899-5379-7, 10.1007/978-1-4899-5379-7]; ZIHL J, 1986, J NEUROL NEUROSUR PS, V49, P965, DOI 10.1136/jnnp.49.8.965; ZIHL J, 1981, EXP BRAIN RES, V44, P159; ZIHL J, 1985, BRAIN, V108, P335, DOI 10.1093/brain/108.2.335; ZIHL J, 1980, NEUROPSYCHOLOGIA, V18, P71, DOI 10.1016/0028-3932(80)90085-8; ZIHL J, 1979, BRAIN, V102, P835, DOI 10.1093/brain/102.4.835; Zihl J, 1982, Hum Neurobiol, V1, P5; ZIHL J, 1979, J NEUROL NEUROSUR PS, V42, P312, DOI 10.1136/jnnp.42.4.312	91	52	53	0	11	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	JAN	1993	47	1					42	54		10.5014/ajot.47.1.42			13	Rehabilitation	Rehabilitation	KC858	WOS:A1993KC85800007	8418676				2021-06-18	
J	ELLIS, EF; DODSON, LY; POLICE, RJ				ELLIS, EF; DODSON, LY; POLICE, RJ			RESTORATION OF CEREBROVASCULAR RESPONSIVENESS TO HYPERVENTILATION BY THE OXYGEN RADICAL SCAVENGER NORMAL-ACETYLCYSTEINE FOLLOWING EXPERIMENTAL TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article						BRAIN INJURY; CYCLOOXYGENASE; FREE RADICAL; CATALASE; SUPEROXIDE DISMUTASE; CEREBROVASCULAR REACTIVITY; CAT; RABBIT	ENDOTHELIUM-DEPENDENT RELAXATION; CEREBRAL ARTERIOLAR DILATION; SUPEROXIDE-DISMUTASE; N-ACETYLCYSTEINE; ACUTE HYPERTENSION; CATS; MICROCIRCULATION; ABNORMALITIES; BRADYKININ; RECOVERY	Previous experiments have shown that, following experimental fluid-percussion brain injury, cyclo-oxygenase-dependent formation of oxygen radicals prevents arteriolar vasoconstriction in response to hyperventilation. The oxygen radical scavengers superoxide dismutase and catalase restore normal reactivity; however, they are not routinely available for clinical use. The present study tested whether n-acetylcysteine (Mucomyst), an agent currently available for acetaminophen toxicity, could be used as a radical scavenger to restore reactivity after brain injury. N-acetylcysteine (163 mg/kg) was given intraperitoneally prior to or 30 minutes after fluid-percussion brain injury (2.6 atm) in cats, and reactivity to hyperventilation was tested 1 hour after injury. The authors found either that pre- or postinjury administration led to normal reactivity. Additional experiments supported the hypothesis that n-acetylcysteine is an oxygen radical scavenger, since it reduced or prevented the free radical-dependent cerebral arteriolar dilation normally induced by the topical application of arachidonic acid or bradykinin. The mechanism by which n-acetylcysteine is effective in trauma may involve direct scavenging of radicals or stimulation of glutathione peroxidase activity. The results suggest that n-acetylcysteine may be useful for treatment of oxygen free radical-mediated brain injury.		ELLIS, EF (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,MCV STN BOX 613,RICHMOND,VA 23298, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [12587, 23432, 27214] Funding Source: Medline		AMRUTHESH SC, 1991, IN PRESS J NEUROCHEM; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BAEZ SILVIO, 1966, J APPL PHYSIOL, V21, P299; BERNARD GR, 1984, J CLIN INVEST, V73, P1772, DOI 10.1172/JCI111386; CERCHIARI EL, 1987, STROKE, V18, P869, DOI 10.1161/01.STR.18.5.869; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; ELLIS E F, 1989, Journal of Neurotrauma, V6, P31, DOI 10.1089/neu.1989.6.31; ELLIS EF, 1988, AM J PHYSIOL, V255, pH397; ELLIS EF, 1990, AM J PHYSIOL, V258, pH1780; ELLIS EF, 1990, AM J PHYSIOL, V259, pH1171, DOI 10.1152/ajpheart.1990.259.4.H1171; ELLIS EF, 1990, LIPID MEDIATORS ISCH, P129; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; HABERL RL, 1989, AM J PHYSIOL, V256, pH1255; HALLIWELL B, 1985, FREE RADICAL BIO MED, P67; HEISTAD DD, 1983, HDB PHYSL 2, V3, P137; KAMITANI T, 1985, CIRC RES, V57, P545, DOI 10.1161/01.RES.57.4.545; KONTOS HA, 1981, AM J PHYSIOL, V240, pH511; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; LIU TH, 1989, AM J PHYSIOL, V256, pH589; LUCHT WD, 1987, AM J MED SCI, V294, P161, DOI 10.1097/00000441-198709000-00006; MARMAROU A, 1989, INTRACRANIAL PRESSUR, V7, P688; ROSENBLUM WI, 1987, CIRC RES, V61, P601, DOI 10.1161/01.RES.61.4.601; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781; ZHANG XM, 1990, AM J PHYSIOL, V259, pH497; ZIMENT I, 1986, RESPIRATION, V50, P26	29	52	53	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	1991	75	5					774	779		10.3171/jns.1991.75.5.0774			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GM092	WOS:A1991GM09200015	1919701				2021-06-18	
J	WINER, JW; ROSENWASSER, RH; JIMENEZ, F				WINER, JW; ROSENWASSER, RH; JIMENEZ, F			ELECTROENCEPHALOGRAPHIC ACTIVITY AND SERUM AND CEREBROSPINAL-FLUID PENTOBARBITAL LEVELS IN DETERMINING THE THERAPEUTIC END-POINT DURING BARBITURATE COMA	NEUROSURGERY			English	Article						BARBITURATE; CEREBRAL PROTECTION; ELECTROENCEPHALOGRAPHY	EPILEPSY; PLASMA; BRAIN	Controversy exists regarding the optimal means for monitoring the patient receiving pentobarbital therapy during medical coma. Serum pentobarbital levels have been used traditionally to gauge cerebral penetration and efficacy of the drug. These peripheral levels have been assumed to reflect pentobarbital concentrations in the cerebrospinal fluid (CSF) and, therefore, the physiological effect on the central nervous system. To determine the relative accuracy of serum versus CSF pentobarbital levels, continuous electroencephalographic (EEG) monitoring in 10 consecutive patients was studied prospectively. Each patient received pentobarbital therapy for cerebral protection in the face of a traumatic injury. Simultaneous serum and CSF pentobarbital levels were obtained 1) before and after the initial barbiturate bolus, 2) every 12 hours during constant infusion therapy, and 3) before and after subsequent boluses necessary because of elevated intracranial pressure (ICP) (ICP > 15 mm Hg) or loss of burst suppression by continuous EEG monitoring (defined as greater than five bursts per minute). ICP and relevant clinical events were recorded hourly. Serum and CSF levels ranged from 33 to 74 mg/L and 4 to 54 mg/L, respectively. There was poor correlation between serum and CSF pentobarbital levels at any given time, although patients remained in burst suppression 73% of the time during their therapy. The EEG monitoring not only provided dynamic physiological monitoring, but it also permitted the lowest pentobarbital dose to maintain burst suppression for a specific patient's metabolism, reducing the likelihood of toxicity. In conclusion, CSF pentobarbital levels are of no greater accuracy than serum pentobarbital levels in predicting physiological effect. Constant EEG monitoring remains the best modality by showing the presence of burst suppression moment-to-moment and thus establishing the minimal necessary dose.	TEMPLE UNIV HOSP & MED SCH,DEPT NEUROSURG,PHILADELPHIA,PA 19140			ROSENWASSER, ROBERT H/L-2482-2014				BRENT DA, 1990, PEDIATRICS, V85, P1086; BROWNE TR, 1988, Q SCI ADV EPILEPSY M, V1, P3; FIRESTONE LL, 1990, CLIN ANESTHESIA PROC, P632; Hauptmann A., 1912, MUNCH MED WOCHENSCHR, V59, P1907; ISHII S, 1966, HEAD INJURY, P276; JENNETT B, 1981, MANAGEMENT HEAD INJU, P95; SHERWIN AL, 1988, EPILEPSY RES, V2, P281, DOI 10.1016/0920-1211(88)90035-6; SHERWIN AL, 1973, ARCH NEUROL-CHICAGO, V29, P73, DOI 10.1001/archneur.1973.00490260017001; SHERWIN AL, 1973, ARCH NEUROL-CHICAGO, V28, P178, DOI 10.1001/archneur.1973.00490210058007; SHERWIN AL, CLIN PHARM ANTIEPILE, P274; WOLLMAN H, 1980, GOODMAN GILMANS PHAR, P292	11	52	52	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	NOV	1991	29	5					739	742		10.1227/00006123-199111000-00016			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GL761	WOS:A1991GL76100016	1961405				2021-06-18	
J	WOOLF, PD; LEE, LA; HAMILL, RW; MCDONALD, JV				WOOLF, PD; LEE, LA; HAMILL, RW; MCDONALD, JV			THYROID TEST ABNORMALITIES IN TRAUMATIC BRAIN INJURY - CORRELATION WITH NEUROLOGIC IMPAIRMENT AND SYMPATHETIC NERVOUS-SYSTEM ACTIVATION	AMERICAN JOURNAL OF MEDICINE			English	Article										WOOLF, PD (corresponding author), UNIV ROCHESTER, MED CTR, DEPT MED, ENDOCRINE METAB UNIT, ROCHESTER, NY 14642 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA007066] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01 AA07066] Funding Source: Medline		AHREN B, 1985, ACTA ENDOCRINOL-COP, V108, P184, DOI 10.1530/acta.0.1080184; AHREN B, 1986, ENDOCR REV, V7, P149, DOI 10.1210/edrv-7-2-149; BACCI V, 1982, J CLIN ENDOCR METAB, V54, P1229, DOI 10.1210/jcem-54-6-1229; BECKER RA, 1980, ARCH SURG-CHICAGO, V115, P439; BRENT GA, 1986, J CLIN ENDOCR METAB, V63, P1; CHOPRA IJ, 1980, J CLIN ENDOCR METAB, V51, P135, DOI 10.1210/jcem-51-1-135; COLTON T, 1974, STATISTICS MED; COOPER DS, 1983, CLIN ENDOCRINOL, V18, P265, DOI 10.1111/j.1365-2265.1983.tb03211.x; CRYER PE, 1980, NEW ENGL J MED, V303, P436; DIEGUEZ C, 1984, ENDOCRINOLOGY, V114, P957, DOI 10.1210/endo-114-3-957; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; JENNETT B, 1975, LANCET, V1, P480; KAHANA L, 1983, CLIN ENDOCRINOL, V19, P131, DOI 10.1111/j.1365-2265.1983.tb00751.x; KAPTEIN EM, 1982, CLIN ENDOCRINOL, V16, P565, DOI 10.1111/j.1365-2265.1982.tb03173.x; KAPTEIN EM, 1982, J CLIN INVEST, V69, P526, DOI 10.1172/JCI110478; KRULICH L, 1982, ENDOCRINOLOGY, V110, P796, DOI 10.1210/endo-110-3-796; KRULICH L, 1982, NEUROENDOCRINOLOGY, V35, P139, DOI 10.1159/000123369; LEE LA, 1986, CLIN CHEM, V32, P797; LEEBAW WF, 1978, J CLIN ENDOCR METAB, V47, P480, DOI 10.1210/jcem-47-3-480; MANNISTO PT, 1981, ACTA ENDOCRINOL-COP, V97, P213, DOI 10.1530/acta.0.0970213; MURAKI T, 1982, ENDOCRINOLOGY, V110, P51, DOI 10.1210/endo-110-1-51; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; PITTMAN CS, 1979, METABOLISM, V28, P333, DOI 10.1016/0026-0495(79)90103-3; ROGOL AD, 1979, NEUROENDOCRINOLOGY, V29, P413, DOI 10.1159/000122952; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; SAVDIE E, 1978, CLIN NEPHROL, V9, P68; SHANNON N, 1984, CLIN CHEM, V30, P1770; SMITH PJ, 1984, ENDOCR REV, V5, P514, DOI 10.1210/edrv-5-4-514; TEASDALE G, 1974, LANCET, V2, P81; WARTOFSKY L, 1982, ENDOCR REV, V3, P164, DOI 10.1210/edrv-3-2-164; WEHMANN RE, 1985, NEW ENGL J MED, V312, P546, DOI 10.1056/NEJM198502283120904; WIERSINGA WM, 1981, CLIN ENDOCRINOL, V14, P367, DOI 10.1111/j.1365-2265.1981.tb00622.x; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; WOOLF PD, 1972, J CLIN ENDOCR METAB, V35, P616, DOI 10.1210/jcem-35-4-616; ZALOGA GP, 1985, ANN SURG, V201, P456, DOI 10.1097/00000658-198504000-00010	37	52	54	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9343	1555-7162		AM J MED	Am. J. Med.	FEB	1988	84	2					201	208		10.1016/0002-9343(88)90414-7			8	Medicine, General & Internal	General & Internal Medicine	M0068	WOS:A1988M006800003	3407649				2021-06-18	
J	SARAN, AS				SARAN, AS			DEPRESSION AFTER MINOR CLOSED HEAD-INJURY - ROLE OF DEXAMETHASONE SUPPRESSION TEST AND ANTIDEPRESSANTS	JOURNAL OF CLINICAL PSYCHIATRY			English	Article									CASE WESTERN RESERVE UNIV, SCH MED, DEPT PSYCHIAT, CLEVELAND, OH 44106 USA							American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; AMSTERDAM JD, 1982, AM J PSYCHIAT, V139, P287; BOISMARE F, 1977, PSYCHOPHARMACOLOGY, V55, P251, DOI 10.1007/BF00497856; BROWN WA, 1979, AM J PSYCHIAT, V136, P230; BROWN WA, 1981, PSYCHIAT RES, V4, P115, DOI 10.1016/0165-1781(81)90015-9; CARROLL BJ, 1981, ARCH GEN PSYCHIAT, V38, P15; DAVIDSON J, 1984, ARCH GEN PSYCHIAT, V41, P506; DAVIDSON JRT, 1982, ARCH GEN PSYCHIAT, V39, P527; FEIGHNER JP, 1972, ARCH GEN PSYCHIAT, V26, P57, DOI 10.1001/archpsyc.1972.01750190059011; GEORGOTAS A, 1981, J CLIN PSYCHOPHARM, V1, P27, DOI 10.1097/00004714-198101000-00006; GOLD MS, 1980, LANCET, V1, P1190; GROSSMAN R, 1975, 5TH P ANN M SOC NEUR, V76, P506; Guy, 1976, ECDEU ASSESSMENT MAN; HAMILTON M, 1980, J NEUROL NEUROSUR PS, V27, P56; JENNETT B, 1976, ARCH NEUROL-CHICAGO, V33, P595, DOI 10.1001/archneur.1976.00500090001001; KLEIN DF, 1980, DIAGNOSIS DRUG TREAT; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LIEBOWITZ MR, 1984, J CLIN PSYCHIAT, V45, P22; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAXSON CL, 1976, PEDIATRICS, V57, P893; QUITKIN F, 1979, ARCH GEN PSYCHIAT, V36, P749; RUTHERFORD WH, 1977, LANCET, V1, P1; SCHATZBERG AF, 1983, AM J PSYCHIAT, V140, P88; SCHLESSER MA, 1980, ARCH GEN PSYCHIAT, V37, P737; VANWOERKOM TCAM, 1977, LANCET, V1, P812; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	30	52	52	0	0	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 752870, MEMPHIS, TN 38175-2870 USA	0160-6689	1555-2101		J CLIN PSYCHIAT	J. Clin. Psychiatry		1985	46	8					335	338					4	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	APJ36	WOS:A1985APJ3600008	4019422				2021-06-18	
J	PAPANICOLAOU, AC; LEVIN, HS; EISENBERG, HM; MOORE, BD; GOETHE, KE; HIGH, WM				PAPANICOLAOU, AC; LEVIN, HS; EISENBERG, HM; MOORE, BD; GOETHE, KE; HIGH, WM			EVOKED-POTENTIAL CORRELATES OF POSTTRAUMATIC AMNESIA AFTER CLOSED HEAD-INJURY	NEUROSURGERY			English	Article										PAPANICOLAOU, AC (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS092314] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 9-2314, NS 07377] Funding Source: Medline		JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEVIN HS, NEUROPSYCHOLOGY MEMO; Moore BE, 1944, NEW ENGL J MED, V230, P445, DOI 10.1056/NEJM194404132301501; PRITCHARD WS, 1981, PSYCHOL BULL, V89, P506, DOI 10.1037/0033-2909.89.3.506; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SQUIRES KC, 1979, HUMAN EVOKED POTENTI, P383; TEASDALE G, 1974, LANCET, V2, P81	11	52	54	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery		1984	14	6					676	678		10.1227/00006123-198406000-00005			3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TB473	WOS:A1984TB47300005	6462402				2021-06-18	
J	Madsen, T; Erlangsen, A; Orlovska, S; Mofaddy, R; Nordentoft, M; Benros, ME				Madsen, Trine; Erlangsen, Annette; Orlovska, Sonja; Mofaddy, Ramy; Nordentoft, Merete; Benros, Michael E.			Association Between Traumatic Brain Injury and Risk of Suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POPULATION-BASED COHORT; MORTALITY; REGISTER; EPILEPSY; DEATH; INDIVIDUALS; PREVALENCE; CHILDREN; HEALTH	IMPORTANCE Traumatic brain injuries (TBIs) can have serious long-term consequences, including psychiatric disorders. However, few studies have assessed the association between TBI and risk of suicide. OBJECTIVE To examine the association between TBI and subsequent suicide. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study using nationwide registers covering 7 418 391 individuals (>= 10 years) living in Denmark (1980-2014) with 164 265 624 person-years' follow-up; 567 823 (7.6%) had a medical contact for TBI. Data were analyzed using Poisson regression adjusted for relevant covariates, including fractures not involving the skull, psychiatric diagnoses, and deliberate self-harm. EXPOSURE Medical contacts for TBI recorded in the National Patient Register (1977-2014) as mild TBI (concussion), skull fracture without documented TBI, and severe TBI (head injuries with evidence of structural brain injury). MAIN OUTCOMES AND MEASURES Suicide recorded in the Danish Cause of Death register until December 31, 2014. RESULTS Of 34 529 individuals who died by suicide (mean age, 52 years [SD, 18 years]; 32.7% women; absolute rate 21 per 100 000 person-years [95% CI, 20.8-21.2]), 3536 (10.2%) had medical contact: 2701 with mild TBI, 174 with skull fracture without documented TBI, and 661 with severe TBI. The absolute suicide rate was 41 per 100 000 person-years (95% CI, 39.2-41.9) among those with TBI vs 20 per 100 000 person-years (95% CI, 19.7-20.1) among those with no diagnosis of TBI. The adjusted incidence rate ratio (IRR) was 1.90 (95% CI, 1.83-1.97). Compared with those without TBI, severe TBI (absolute rate, 50.8 per 100 000 person-years; 95% CI, 46.9-54.6) was associated with an IRR of 2.38 (95% CI, 2.20-2.58), whereas mild TBI (absolute rate, 38.6 per 100 000 person-years; 95% CI, 37.1-40.0), and skull fracture without documented TBI (absolute rate, 42.4 per 100 000 person-years; 95% CI, 36.1-48.7) had an IRR of 1.81 (95% CI, 1.74-1.88) and an IRR of 2.01 (95% CI, 1.73-2.34), respectively. Suicide risk was associated with number of medical contacts for TBI compared with those with no TBI contacts: 1 TBI contact, absolute rate, 34.3 per 100 000 person-years (95% CI, 33.0-35.7; IRR, 1.75; 95% CI, 1.68-1.83); 2 TBI contacts, absolute rate, 59.8 per 100 000 person-years (95% CI, 55.1-64.6; IRR, 2.31; 95% CI, 2.13-2.51); and 3 or more TBI contacts, absolute rate, 90.6 per 100 000 person-years (95% CI, 82.3-98.9; IRR, 2.59; 95% CI, 2.35-2.85; all P < .001 for the IRR's). Compared with the general population, temporal proximity since the last medical contact for TBI was associated with risk of suicide (P <. 001), with an IRR of 3.67 (95% CI, 3.33-4.04) within the first 6 months and an incidence IRR of 1.76 (95% CI, 1.67-1.86) after 7 years. CONCLUSIONS AND RELEVANCE In this nationwide registry-based retrospective cohort study individuals with medical contact for TBI, compared with the general population without TBI, had increased suicide risk.	[Madsen, Trine; Erlangsen, Annette; Nordentoft, Merete] Mental Hlth Ctr Copenhagen, Danish Res Inst Suicide Prevent, Kildegardsvej 28, DK-2900 Hellerup, Capital Region, Denmark; [Madsen, Trine; Orlovska, Sonja; Mofaddy, Ramy; Nordentoft, Merete; Benros, Michael E.] Copenhagen Univ Hosp, Mental Hlth Ctr Copenhagen, Copenhagen, Denmark; [Erlangsen, Annette] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA; [Erlangsen, Annette; Nordentoft, Merete] iPSYCH Lundbeck Fdn Initiat Integrated Psychiat R, Aarhus, Denmark; [Erlangsen, Annette] Australian Natl Univ, Ctr Mental Hlth Res, Canberra, ACT, Australia	Madsen, T (corresponding author), Mental Hlth Ctr Copenhagen, Danish Res Inst Suicide Prevent, Kildegardsvej 28, DK-2900 Hellerup, Capital Region, Denmark.	trine.madsen@regionh.dk	Orlovska-Waast, Sonja/K-3057-2019; Benros, Michael Eriksen/N-5868-2016; Nordentoft, Merete/AAH-3253-2019; Erlangsen, Annette/A-7153-2017	Benros, Michael Eriksen/0000-0003-4939-9465; Erlangsen, Annette/0000-0003-3475-0558; Nordentoft, Merete/0000-0003-4895-7023	Mental Health Services Capital Region Denmark; Lundbeck FoundationLundbeckfonden	The study was partly funded by the Mental Health Services Capital Region Denmark and an unrestricted grant from the Lundbeck Foundation.	[Anonymous], 1991, INTEGRATED DATABASE; Bahraini NH, 2013, BRAIN IMPAIR, V14, P92, DOI 10.1017/BrImp.2013.11; Benham EC, 2017, AM J SURG, V214, P211, DOI 10.1016/j.amjsurg.2016.11.017; Bragatti JA, 2011, J NEUROL NEUROPHYSIO, pS2, DOI [10.4172/2155-9562, DOI 10.4172/2155-9562]; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Erlangsen A, 2015, SCAND J PUBLIC HEALT, V43, P333, DOI 10.1177/1403494815575193; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Fralick M, 2016, CAN MED ASSOC J, V188, P497, DOI 10.1503/cmaj.150790; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hawton K, 2009, LANCET, V373, P1372, DOI 10.1016/S0140-6736(09)60372-X; Helweg-Larsen K, 2011, SCAND J PUBLIC HEALT, V39, P26, DOI 10.1177/1403494811399958; Hills M., 2013, STAT MODELS EPIDEMIO; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kim SC, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13111063; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Mainio A, 2007, BRAIN INJURY, V21, P851, DOI 10.1080/02699050701504265; Mors O, 2011, SCAND J PUBLIC HEALT, V39, P54, DOI 10.1177/1403494810395825; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Richard YF, 2015, AM J EPIDEMIOL, V182, P177, DOI 10.1093/aje/kwv014; Sethi M, 2015, INJURY, V46, P2483, DOI 10.1016/j.injury.2015.07.030; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Simpson GK, 2007, MED J AUSTRALIA, V187, P229, DOI 10.5694/j.1326-5377.2007.tb01206.x; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tollefsen IM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009120; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wirrell EC, 2006, EPILEPSIA, V47, P1674, DOI 10.1111/j.1528-1167.2006.00639.x	34	51	51	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	2018	320	6					580	588		10.1001/jama.2018.10211			9	Medicine, General & Internal	General & Internal Medicine	GQ4KZ	WOS:000441642500012	30120477	Green Published, Bronze			2021-06-18	
J	Liu, W; Chen, YH; Meng, J; Wu, MF; Bi, FF; Chang, CC; Li, H; Zhang, LJ				Liu, Wei; Chen, Yuhua; Meng, Jiao; Wu, Minfei; Bi, Fangfang; Chang, Cuicui; Li, Hua; Zhang, Liangjun			Ablation of caspase-1 protects against TBI-induced pyroptosis in vitro and in vivo	JOURNAL OF NEUROINFLAMMATION			English	Article						TBI; Inflammation; Neuroinflammation; Pyroptosis; Caspase-1; Neuron damage	TRAUMATIC BRAIN-INJURY; INFLAMMASOME ACTIVATION; NLRP3 INFLAMMASOME; CELL-DEATH; INHIBITION; ISCHEMIA; PORE; NEUROPROTECTION; APOPTOSIS; STROKE	Background: Traumatic brain injury (TBI) is a critical public health and socioeconomic problem throughout the world. Inflammation-induced secondary injury is one of the vital pathogenic parameters of TBI. Molecular signaling cascades of pyroptosis, a specific type of cellular necrosis, are key drivers of TBI-induced inflammation. Methods: In this study, mice with genetically ablated caspase-1 (caspase-1(-/-)) were subjected to controlled cortical impact injury in vivo, and primary neuron deficient in caspase-1 through siRNA knockdown and pharmacologic inhibition was stimulated by mechanical scratch, equiaxial stretch, and LPS/ATP in vitro. We evaluated the effects of caspase-1 deficiency on neurological deficits, inflammatory factors, histopathology, cell apoptosis, and pyroptosis. Results: During the acute post-injury period (0-48 h) in vivo, motor deficits, anti-inflammatory cytokines (TGF-beta and IL-10), pro-inflammatory cytokines (IFN-gamma, IL-1 beta, and IL-18), and blood lactate dehydrogenase (LDH), as well as pyroptosis-related proteins (caspase-1, caspase-1 fragments, caspase-11 and GSDMD), were increased. Caspase-1 was activated in the cortex of TBI mice. Inflammatory activation was more profound in injured wild-type mice than in caspase-1(-/-) mice. In vitro, mechanical scratch, equiaxial stretch, and LPS/ATP-induced neuron pyroptosis, apoptosis, LDH release, and increased expression of inflammatory factors. The effects of mechanical and inflammatory stress were reduced through inhibition of caspase-1 activity through siRNA knockdown and pharmacologic inhibition. Conclusion: Collectively, these data demonstrate that pyroptosis is involved in neuroinflammation and neuronal injury after TBI, and ablation of caspase-1 inhibits TBI-induced pyroptosis. Our findings suggest that caspase-1 may be a potential target for TBI therapy.	[Liu, Wei; Chen, Yuhua; Meng, Jiao; Bi, Fangfang; Chang, Cuicui] Peihua Univ, Dept Med Sci, Res Ctr, Xian 710125, Shaanxi, Peoples R China; [Liu, Wei; Chen, Yuhua; Meng, Jiao; Bi, Fangfang; Chang, Cuicui; Li, Hua; Zhang, Liangjun] Shaanxi Fourth People Hosp, Res Ctr, Dept Med Sci, Xian 710043, Shaanxi, Peoples R China; [Wu, Minfei] Jilin Univ, Hosp 2, Dept Orthoped, Changchun 8974617, Jilin, Peoples R China	Liu, W; Chen, YH (corresponding author), Peihua Univ, Dept Med Sci, Res Ctr, Xian 710125, Shaanxi, Peoples R China.	vincelau@sina.com; chenyuhua.358@163.com			Shaanxi Fourth People Hospital [2017SY-006]	This work was supported by the Development Funding of Shaanxi Fourth People Hospital (2017SY-006).	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Albalawi F, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00227; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Barrington J, 2017, BRAIN PATHOL, V27, P205, DOI 10.1111/bpa.12476; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Chen QX, 2014, INNATE IMMUN-LONDON, V20, P290, DOI 10.1177/1753425913490575; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Dang BQ, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/1582182; de Zoete MR, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016287; Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590; DiPeso L, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.70; Dobrachinski F, 2017, J NEUROTRAUM, V34, P1318, DOI 10.1089/neu.2016.4563; Esterov D, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7080100; Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x; Gardner AJ, 2017, PHYS MED REH CLIN N, V28, P413, DOI 10.1016/j.pmr.2016.12.014; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Julien J, 2017, ANN PHYS REHABIL MED, V60, P347, DOI 10.1016/j.rehab.2017.03.009; Kaushal V, 2015, CELL DEATH DIFFER, V22, P1676, DOI 10.1038/cdd.2015.16; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; Kovacs SB, 2017, TRENDS CELL BIOL, V27, P673, DOI 10.1016/j.tcb.2017.05.005; Li R, 2017, BRAIN RES BULL, V130, P236, DOI 10.1016/j.brainresbull.2017.01.016; Lin QR, 2016, TOXICOL APPL PHARM, V292, P56, DOI 10.1016/j.taap.2015.12.027; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Liu ZJ, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12414; Mezzaroma E, 2011, P NATL ACAD SCI USA, V108, P19725, DOI 10.1073/pnas.1108586108; Mortezaee K, 2017, J CELL PHYSL; Okondo MC, 2017, NAT CHEM BIOL, V13, P46, DOI [10.1038/NCHEMBIO.2229, 10.1038/nchembio.2229]; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Rao W, 2015, BBA-MOL BASIS DIS, V1852, P2402, DOI 10.1016/j.bbadis.2015.08.014; Ray AM, 2000, BRAIN RES, V867, P62, DOI 10.1016/S0006-8993(00)02230-7; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Ross J, 2007, NEUROPHARMACOLOGY, V53, P638, DOI 10.1016/j.neuropharm.2007.07.015; Runyan DK, 2008, AM J PREV MED, V34, pS112, DOI 10.1016/j.amepre.2008.01.011; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Sharma D, 2016, J CELL BIOL, V213, P617, DOI 10.1083/jcb.201602089; Shradhanjali A, 2017, BIOCHEM BIOPH RES CO, V488, P590, DOI 10.1016/j.bbrc.2017.05.092; Sun M, 2017, BRAIN BEHAV IMMUN; Sun Q, 2016, J LEUKOCYTE BIOL, V100, P961, DOI 10.1189/jlb.3MR0516-224R; Thelin EP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00351; Van Horn JD, 2017, TRENDS NEUROSCI, V40, P39, DOI 10.1016/j.tins.2016.10.007; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep37098; Wellington M, 2014, EUKARYOT CELL, V13, P329, DOI 10.1128/EC.00336-13; Wu DD, 2016, SHOCK, V46, P329, DOI 10.1097/SHK.0000000000000595; Wu HY, 2016, CELL PHYSIOL BIOCHEM, V40, P1692, DOI 10.1159/000453218; Xu X, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0934-2; Yang DH, 2015, IMMUNITY, V43, P923, DOI 10.1016/j.immuni.2015.10.009; Ye YQ, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/5841814; Yu HS, 2016, J TISSUE ENG, V7, DOI [10.1177/2041731415618342, 10.1177/2041731416676337]; Yuan JY, 2016, CELL, V167, P1693, DOI 10.1016/j.cell.2016.11.047; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	58	51	58	2	16	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	FEB 19	2018	15								48	10.1186/s12974-018-1083-y			16	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	FX3LI	WOS:000425973100001	29458437	DOAJ Gold, Green Published			2021-06-18	
J	Leddy, JJ; Hinds, AL; Miecznikowski, J; Darling, S; Matuszak, J; Baker, JG; Picano, J; Willer, B				Leddy, John J.; Hinds, Andrea L.; Miecznikowski, Jeffrey; Darling, Scott; Matuszak, Jason; Baker, John G.; Picano, John; Willer, Barry			Safety and Prognostic Utility of Provocative Exercise Testing in Acutely Concussed Adolescents: A Randomized Trial	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						exercise; tolerance; treadmill test; sport; concussion; adolescent	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; NEUROCOGNITIVE PERFORMANCE; VOLUNTARY EXERCISE; UP-REGULATION; HIGH-SCHOOL; SYMPTOMS; RECOVERY; RELIABILITY	Objective: To evaluate (1) systematic assessment of exercise tolerance in adolescents shortly after sport-related concussion (SRC) and (2) the prognostic utility of such assessment. Design: Prospective randomized controlled trial. Setting: University and community sports medicine centers. Participants: Adolescents with SRC (1-9 days from injury). Sixty-five were randomized and 54 completed the study (mean age 15 years, 4 days after injury). Interventions: Buffalo Concussion Treadmill Test (BCTT, n = 27) or not (controls, n = 27) on visit day #1. Heart rate threshold (HRt) at symptom exacerbation represented level of exercise tolerance. Participants reported symptoms daily for 14 days and then had follow-up BCTT (n = 54). Recovery was defined as returning to normal level of symptoms and exercise tolerance, verified by independent physician examination. Main Outcome Measures: Days to recovery and typical (<= 21 days) versus prolonged recovery (>21 days). Mixed effects linear models and linear regression techniques examined symptom reports and time to recovery. Linear regression assessed the association of HRt with recovery time. Results: Days to recovery (P = 0.7060) and typical versus prolonged recovery (P = 50.1195) were not significantly different between groups. Symptom severity scores decreased in both groups over 14 days (P=0.0001), were similar (P=0.2984), and did not significantly increase the day after the BCTT (P = 0.1960). Lower HRt on visit day #1 was strongly associated with prolonged recovery time (P = 0.0032). Conclusions: Systematic evaluation of exercise tolerance using the BCTT within 1 week after SRC did not affect recovery. The degree of early exercise intolerance after SRC was important for prognosis. This has implications for school academic and team preparation.	[Leddy, John J.; Hinds, Andrea L.; Darling, Scott; Baker, John G.] SUNY Buffalo, UBMD Orthopaed & Sports Med, Buffalo, NY USA; [Miecznikowski, Jeffrey] SUNY Buffalo, Dept Biostat, Buffalo, NY USA; [Matuszak, Jason] SUNY Buffalo, Excelsior Orthoped, Buffalo, NY USA; [Matuszak, Jason] SUNY Buffalo, Dept Family Med, Buffalo, NY USA; [Baker, John G.] SUNY Buffalo, Nucl Med, Buffalo, NY USA; [Picano, John] SUNY Buffalo, Dept Internal Med, Buffalo, NY USA; [Willer, Barry] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Psychiat, Buffalo, NY USA	Leddy, JJ (corresponding author), UBMD Orthopaed & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	leddy@buffalo.edu			Ralph C. Wilson Foundation; Program for Understanding Childhood Concussion and Stroke; Robert Rich Family Foundation; Buffalo Sabres Foundation; National Football League Charities; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094444] Funding Source: NIH RePORTER	We gratefully acknowledge the assistance of Christopher Stawitz, ATC and Anthony Surace, ATC, for their tremendous efforts in diligently collecting much of the clinical data. We gratefully appreciate the support of The Ralph C. Wilson Foundation, Program for Understanding Childhood Concussion and Stroke, The Robert Rich Family Foundation, The Buffalo Sabres Foundation, and the National Football League Charities for their financial support.	[Anonymous], 2013, R LANG ENV STAT COMP; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Darling SR, 2014, CLIN J SPORT MED, V24, P128, DOI 10.1097/JSM.0000000000000026; Dematteo C, 2015, MED SCI SPORT EXER, V47, P2283, DOI 10.1249/MSS.0000000000000682; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guiney H, 2015, NEUROPSYCHOLOGY, V29, P1, DOI 10.1037/neu0000124; Kostyun RO, 2015, SPORTS HEALTH, V7, P52, DOI 10.1177/1941738114555075; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Matuszak JM, 2016, SPORTS HEALTH, V8, P260, DOI 10.1177/1941738116641394; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Sallis R, 2015, PHYSICIAN SPORTSMED, V43, P22, DOI 10.1080/00913847.2015.1001938; Sandel NK, 2013, APPL NEUROPSYCH-CHIL, V2, P64, DOI 10.1080/21622965.2012.670580; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966	31	51	52	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2018	28	1					13	20		10.1097/JSM.0000000000000431			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	GB0JM	WOS:000428732000004	29257777	Green Accepted			2021-06-18	
J	Tilahun, D; Hanlon, C; Fekadu, A; Tekola, B; Baheretibeb, Y; Hoekstra, RA				Tilahun, Dejene; Hanlon, Charlotte; Fekadu, Abebaw; Tekola, Bethlehem; Baheretibeb, Yonas; Hoekstra, Rosa A.			Stigma, explanatory models and unmet needs of caregivers of children with developmental disorders in a low-income African country: a cross-sectional facility-based survey	BMC HEALTH SERVICES RESEARCH			English	Article						Stigma; Developmental disorder; Autism Spectrum Disorder; Intellectual disability; Developing countries; Africa	FAMILY-MEMBERS; DISABILITIES; PARENTS; AUTISM; SCHIZOPHRENIA; INDIVIDUALS; CHALLENGES; ILLNESS; IMPACT	Background: Understanding the perspectives of caregivers of children with developmental disorders living in low-income countries is important to inform intervention programmes. The purpose of this study was to examine the stigma experiences, explanatory models, unmet needs, preferred interventions and coping mechanisms of caregivers of children with developmental disorders in Ethiopia. Methods: Participants comprised caregivers (n = 102) of children with developmental disorders attending two child mental health clinics in Addis Ababa. The majority (66.7 %; n = 68) had a diagnosis of intellectual disability (ID); 34 children (33.3 %) had autism spectrum disorder (ASD) as their primary diagnosis. All caregivers were administered a structured questionnaire via a face-to-face interview, which included an adaptation of the Family Interview Schedule, closed questions about socio-demographic characteristics, explanatory models of illness, type of interventions used or desired and coping strategies, and an open ended question regarding the family's unmet needs. Results: Most caregivers reported experience of stigma: 43.1 % worried about being treated differently, 45.1 % felt ashamed about their child's condition and 26.7 % made an effort to keep their child's condition secret. Stigma did not depend on the type of developmental disorder, the child's age or gender, or on the age or level of education of the caregiver (all p > 0.05). Reported stigma was significantly higher in caregivers who had sought traditional help (p < 0.01), provided supernatural explanations for their child's condition (p = .02) and in caregivers of Orthodox Christian faith (p = .03). Caregivers gave a mixture of biomedical explanations (e.g. head injury (30.4 %) or birth complications (25.5 %)) and supernatural explanations (e.g. spirit possession (40.2 %) or sinful act (27.5 %)) for their child's condition. The biggest reported unmet need was educational provision for their child (74.5 %), followed by treatment by a health professional (47.1 %), financial support (30.4 %) and expert help to support their child's development (27.5 %). Most caregivers reported that talking to health professionals (86.3 %) and family (85.3 %) helped them to cope. Many caregivers also used support from friends (76.5 %) and prayer (57.8 %) as coping mechanisms. Conclusions: This study highlights the stigma experienced by families caring for a child with a developmental disorder. Designing interventions appropriate for low-income settings that improve awareness about developmental disorders, decrease stigma, improve access to appropriate education and strengthen caregivers' support are needed.	[Tilahun, Dejene; Hanlon, Charlotte; Fekadu, Abebaw; Baheretibeb, Yonas] Univ Addis Ababa, Coll Hlth Sci, Sch Med, Dept Psychiat, Addis Ababa, Ethiopia; [Hanlon, Charlotte] Kings Coll London, Inst Psychiat Psychol & Neurosci, Hlth Serv & Populat Res Dept, Ctr Global Mental Hlth, London WC2R 2LS, England; [Fekadu, Abebaw] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, Ctr Affect Disorders, London WC2R 2LS, England; [Tekola, Bethlehem; Hoekstra, Rosa A.] Open Univ, Dept Life Hlth & Chem Sci, Milton Keynes MK7 6AA, Bucks, England; [Tilahun, Dejene] Jimma Univ, Coll Publ Hlth & Med Sci, Dept Hlth Educ & Behav Sci, Jimma, Ethiopia	Hanlon, C (corresponding author), Univ Addis Ababa, Coll Hlth Sci, Sch Med, Dept Psychiat, Addis Ababa, Ethiopia.; Hanlon, C (corresponding author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Hlth Serv & Populat Res Dept, Ctr Global Mental Hlth, London WC2R 2LS, England.	charlotte.hanlon@kcl.ac.uk		Hoekstra, Rosa/0000-0002-1333-9762; Gebru, Bethlehem/0000-0001-7641-1517; Fekadu, Abebaw/0000-0003-2219-0952	Autism Speaks [7770]	The study was funded by Autism Speaks (grant #7770 to Rosa Hoekstra). The funding body had no role in the design of the study, collection, analysis, or interpretation of data or in writing the manuscript.	Abera M, 2015, CHILD ADOL PSYCH MEN, V9, DOI 10.1186/s13034-015-0072-5; Altiere MJ, 2009, J INTELLECT DEV DIS, V34, P142, DOI 10.1080/13668250902845202; Ambikile Joel Semel, 2012, Child Adolesc Psychiatry Ment Health, V6, P16, DOI 10.1186/1753-2000-6-16; Bakare Muideen Owolabi, 2009, Ann Gen Psychiatry, V8, P6, DOI 10.1186/1744-859X-8-6; Brown HK, 2012, J APPL RES INTELLECT, V25, P497, DOI 10.1111/j.1468-3148.2012.00692.x; DePape AM, 2015, QUAL HEALTH RES, V25, P569, DOI 10.1177/1049732314552455; Divan G, 2012, AUTISM RES, V5, P190, DOI 10.1002/aur.1225; Douma JCH, 2006, J INTELL DISABIL RES, V50, P570, DOI 10.1111/j.1365-2788.2006.00825.x; Durban J. M., 2012, ASIAN J SOCIAL SCI H, V1, P177; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Gomes PTM, 2015, J PEDIAT-BRAZIL, V91, P111, DOI 10.1016/j.jped.2014.08.009; Gona JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132729; GRAY DE, 1993, SOCIOL HEALTH ILL, V15, P102, DOI 10.1111/1467-9566.ep11343802; Gray DE, 2002, SOCIOL HEALTH ILL, V24, P734, DOI 10.1111/1467-9566.00316; Green S, 2005, SOCIOL INQ, V75, P197, DOI 10.1111/j.1475-682X.2005.00119.x; Gureje O, 2005, BRIT J PSYCHIAT, V186, P436, DOI 10.1192/bjp.186.5.436; Gureje O, 2015, LANCET PSYCHIAT, V2, P168, DOI 10.1016/S2215-0366(15)00013-9; Heiman T, 2002, J DEV PHYS DISABIL, V14, P159, DOI 10.1023/A:1015219514621; Hoekstra RA, 2014, 13 INT M AUT RES ATL; Jegatheesan B, 2010, FOCUS AUTISM DEV DIS, V25, P98, DOI 10.1177/1088357610361344; Lauritsen JM, 2003, EPIDATA VERSION 3 1; Mackintosh V., 2005, J DEVELOPMENTAL DISA, V12, P41; Maulik PK, 2011, RES DEV DISABIL, V32, P419, DOI 10.1016/j.ridd.2010.12.018; mhGAP: Mental Health Gap Action Programme, 2008, SCAL CAR MENT NEUR S; Patel V, 2013, ARCH DIS CHILD, V98, P323, DOI 10.1136/archdischild-2012-302079; Ravindran N, 2013, FOCUS AUTISM DEV DIS, V28, P44, DOI 10.1177/1088357612458970; Sartorius N, 1996, SOC PSYCH PSYCH EPID, V31, P55, DOI 10.1007/BF00801901; Shibre T, 2001, SOC PSYCH PSYCH EPID, V36, P299, DOI 10.1007/s001270170048; Shibre T, 2003, SOC PSYCH PSYCH EPID, V38, P27, DOI 10.1007/s00127-003-0594-7; Shyu YIL, 2010, J AUTISM DEV DISORD, V40, P1323, DOI 10.1007/s10803-010-0991-1; Tekola B, 2014, 13 INT M AUT RES ATL; Wang PS, 2011, J AUTISM DEV DISORD, V41, P783, DOI 10.1007/s10803-010-1099-3	32	51	52	1	30	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1472-6963		BMC HEALTH SERV RES	BMC Health Serv. Res.	APR 27	2016	16								152	10.1186/s12913-016-1383-9			12	Health Care Sciences & Services	Health Care Sciences & Services	DK6KI	WOS:000375032000001	27117326	DOAJ Gold, Green Published			2021-06-18	
J	Howell, DR; Mannix, RC; Quinn, B; Taylor, JA; Tan, CO; Meehan, WP				Howell, David R.; Mannix, Rebekah C.; Quinn, Bridget; Taylor, J. Andrew; Tan, Can Ozan; Meehan, William P., III			Physical Activity Level and Symptom Duration Are Not Associated After Concussion	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						brain concussion; mild traumatic brain injury; physical activity; rehabilitation	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; HEAD-DOWN-TILT; HIGH-SCHOOL; POSTCONCUSSION SYNDROME; PROLONGED RECOVERY; PREDICTORS; EXERCISE; ADOLESCENTS; RETURN	Background: Physical rest after a concussion has been described as a key component in the management of the injury. Evidence supporting this recommendation, however, is limited. Purpose: To examine the association between physical activity and symptom duration in a cohort of patients after a concussion. Study Design: Cohort study; Level of evidence, 2. Methods: This study included 364 patients who were diagnosed with a concussion, were seen by a physician within 3 weeks of injury, and completed a questionnaire at the initial clinic visit. The questionnaire assessed the postconcussion symptom scale (PCSS) score, previous number of concussions, presence of the loss of consciousness or amnesia at the time of injury, and prior treatment for headaches. During each follow-up clinic visit, physical activity level was self-reported. A Cox proportional hazard model was constructed to determine the association between symptom duration, initial clinic visit responses, and self-reported physical activity level after the injury. Results: Study participants ranged in age from 8 to 27 years (mean age, 15.0 years) and had sustained a mean of 0.8 prior concussions; 222 patients (61%) were male. On initial examination, the mean PCSS score was 34.7. The mean symptom duration was 48.9 days after the injury. Among the variables included in the model, initial PCSS score and female sex were independently associated with symptom duration, while physical activity level after the injury was not. For participants aged between 13 and 18 years, however, higher levels of physical activity after the injury were associated with a shorter symptom duration. Conclusion: Results from this study indicate that physical activity after the injury may not be universally detrimental to the recovery of concussion symptoms.	[Howell, David R.; Mannix, Rebekah C.; Quinn, Bridget; Taylor, J. Andrew; Tan, Can Ozan; Meehan, William P., III] Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Sports Concuss Clin, Boston, MA USA; [Howell, David R.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA; [Howell, David R.; Mannix, Rebekah C.] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Mannix, Rebekah C.; Meehan, William P., III] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Mannix, Rebekah C.; Meehan, William P., III] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Taylor, J. Andrew; Tan, Can Ozan] Spaulding Hosp Cambridge, Cardiovasc Res Lab, Cambridge, MA USA; [Taylor, J. Andrew; Tan, Can Ozan] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Meehan, William P., III] Harvard Univ, Sch Med, Dept Orthopaed, Boston, MA USA	Howell, DR (corresponding author), Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA.	David.Howell2@childrens.harvard.edu	Tan, Can Ozan/E-2598-2016; Mannix, Rebekah/AAD-8702-2020	Tan, Can Ozan/0000-0001-9673-9907; Howell, David/0000-0002-2955-0191; Taylor, J Andrew/0000-0003-2802-4330	National Football League Players Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: W.P.M. receives publishing royalties from ABC-Clio and Wolters Kluwer. He is under contract with ABC-Clio for a future book entitled Concussions and with Springer International for a future book entitled Head and Neck Injuries in Young Athletes. His research is funded in part by a grant from the National Football League Players Association and by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament.	Bailey DM, 2013, CLIN SCI, V124, P177, DOI 10.1042/CS20120259; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Chan ST, 2009, BRAIN RES, V1291, P53, DOI 10.1016/j.brainres.2009.07.057; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gibson TB, 2015, JAMA PEDIATR, V169, P163, DOI 10.1001/jamapediatrics.2014.2320; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; KAWAI Y, 1993, J APPL PHYSIOL, V74, P3046; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Moser RS, 2015, BRAIN INJURY, V29, P58, DOI 10.3109/02699052.2014.964771; Ocon AJ, 2009, AM J PHYSIOL-HEART C, V297, pH2084, DOI 10.1152/ajpheart.00705.2009; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Simon L, 2015, DETECTING MULTICOLLI; Tan CO, 2014, NEUROLOGY, V83, P1665, DOI 10.1212/WNL.0000000000000944; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Tsushima WT, 2009, BRAIN INJURY, V23, P809, DOI 10.1080/02699050903200530; Zhang R, 1997, J APPL PHYSIOL, V83, P2139	40	51	52	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	APR	2016	44	4					1040	1046		10.1177/0363546515625045			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DI7FX	WOS:000373665800034	26838933	Green Accepted			2021-06-18	
J	Jourdan, C; Bayen, E; Pradat-Diehl, P; Ghout, I; Darnoux, E; Azerad, S; Vallat-Azouvi, C; Charanton, J; Aegerter, P; Ruet, A; Azouvi, P				Jourdan, C.; Bayen, E.; Pradat-Diehl, P.; Ghout, I.; Darnoux, E.; Azerad, S.; Vallat-Azouvi, C.; Charanton, J.; Aegerter, P.; Ruet, A.; Azouvi, P.			A comprehensive picture of 4-year outcome of severe brain injuries. Results from the PariS-TBI study	ANNALS OF PHYSICAL AND REHABILITATION MEDICINE			English	Article						Brain injuries; Craniocerebral trauma; Quality of life; International classification of functioning, disability and health	QUALITY-OF-LIFE; SEVERE HEAD-INJURY; FOLLOW-UP; PROGNOSTIC-FACTORS; DEPRESSION SCALE; HOSPITAL ANXIETY; PRACTICAL SCALE; COHORT; VALIDITY; MODERATE	Objectives: Survivors of severe traumatic brain injury have a great variety of impairments and participation restrictions. Detailed descriptions of their long-term outcome are critical. We aimed to assess brain injury outcome for subjects with traumatic brain injury in terms of the International classification of functioning, disability and health. Materials and methods: Four-year follow-up of an inception cohort of adults with severe traumatic brain injury by using face-to-face interviews with patients and proxies. Results: Among 245 survivors at 4 years, 147 were evaluated (80% male, mean age: 32.5 +/- 14.2 years at injury); 46 (32%) presented severe disability, 58 (40%) moderate disability, and 40 (28%) good recovery. Most frequent somatic problems were fatigue, headaches, other pain, and balance. One quarter of subjects had motor impairments. Rates of cognitive complaints ranged from 25 to 68%, the most frequent being memory, irritability, slowness and concentration. With the Hospital Anxiety and Depression Scale, 43% had anxiety and 25% depression. Overall, 79% were independent in daily living activities and 40 to 50% needed help for outdoor or organizational activities on the BICRO-39. Most had regular contacts with relatives or close friends but few contacts with colleagues or new acquaintances. Subjects spent little time in productive activities such as working, studying, looking after children or voluntary work. Quality of life on the QOLIBRI scale was associated with disability level (P < 0.0001). Conclusion: Management of late brain injury needs to focus on cognitive difficulties, particularly social skills, to enhance patient participation in life. (C) 2015 Elsevier Masson SAS. All rights reserved.	[Jourdan, C.; Vallat-Azouvi, C.; Ruet, A.; Azouvi, P.] Hop Raymond Poincare, AP HP, Dept Med Phys & Readaptat, 104 Blvd Raymond Poincare, F-92380 Garches, France; [Jourdan, C.; Azouvi, P.] Univ Versailles St Quentin, UFR Sci Sante Simone Veil, HANDIReSP EA 4047, 2 Ave Source de la Bievre, F-78180 Montigny Le Bretonneux, France; [Bayen, E.] Univ Paris 09, Lab Econ & Gest Org Sante LEDa LEGOS, F-75016 Paris, France; [Bayen, E.; Pradat-Diehl, P.; Vallat-Azouvi, C.] Univ Paris 06, F-75005 Paris, France; [Bayen, E.; Pradat-Diehl, P.] Hop Univ Pitie Salpetriere Charles Foix, AP HP, Serv Med Phys & Readaptat, F-75013 Paris, France; [Ghout, I.; Darnoux, E.; Azerad, S.; Aegerter, P.] Hop Ambroise Pare, AP HP, URC, F-92012 Boulogne, France; [Vallat-Azouvi, C.] Hop Raymond Poincare, Antenne UEROS UGECAM IDF SAMSAH92, F-92380 Garches, France; [Charanton, J.] CRFTC, F-75014 Paris, France; [Aegerter, P.] Univ Versailles St Quentin, UMR S 1168, UFR Sci Sante Simone Veil, 2 Ave Source de la Bievre, F-78180 Montigny Le Bretonneux, France	Jourdan, C (corresponding author), Hop Raymond Poincare, AP HP, Dept Med Phys & Readaptat, 104 Blvd Raymond Poincare, F-92380 Garches, France.	claire.jourdan@rpc.aphp.fr	RUET, Alexis/L-8726-2015	RUET, Alexis/0000-0002-5080-5734; AEGERTER, Philippe/0000-0002-9156-5028	French Ministry of Health (Programme hospitalier de recherche clinique) [AOM04084]; AP-HP (Departement de la recherche clinique et du developpement); Institut de recherche en sante publique (IRESP)	The authors thank all members of the CRFTC Steering Committee (Centre ressource francilien des traumatises craniens) for their valuable help. The first part of this study was funded by a grant from the French Ministry of Health (Programme hospitalier de recherche clinique 2004, AOM04084) and sponsored by AP-HP (Departement de la recherche clinique et du developpement). The second part of this study was funded by a grant from the Institut de recherche en sante publique (IRESP).	Andelic N, 2014, PM&R, V6, P1013, DOI 10.1016/j.pmrj.2014.05.005; Azouvi P, 2014, NEUROPSYCHOL REHABIL, V18, P1; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bayen E, 2014, J HEAD TRAUMA REHABI; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Hours M, 2010, ACCIDENT ANAL PREV, V42, P412, DOI 10.1016/j.aap.2009.09.002; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Jaeger M., 2014, Annals of Physical and Rehabilitation Medicine, V57, P436, DOI 10.1016/j.rehab.2014.06.001; JENNETT B, 1975, LANCET, V1, P480; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Jourdan C, 2015, J HEAD TRAUMA REHABI; Jourdan C, 2015, BRAIN INJURY, V29, P701, DOI 10.3109/02699052.2015.1004646; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; MAHONEY F I, 1965, Md State Med J, V14, P61; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mazaux JM, 2002, ACT NEUR S, V79, P49; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Nash S., 2014, Annals of Physical and Rehabilitation Medicine, V57, P600, DOI 10.1016/j.rehab.2014.08.010; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Peeters W, 2015, ACTA NEUROCHIR WIEN; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Pradat-Diehl P., 2012, Annals of Physical and Rehabilitation Medicine, V55, P546, DOI 10.1016/j.rehab.2012.07.002; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; TEASDALE G, 1974, LANCET, V2, P81; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Ubukata S, 2014, NEUROPSYCH DIS TREAT, V10, P2061, DOI 10.2147/NDT.S68156; Vallat-Azouvi C, PRM SOFMER 2015 MONT; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; von Steinbuechel N, 2012, J NEUROL NEUROSUR PS, V83, P1041, DOI 10.1136/jnnp-2012-302361; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	42	51	52	0	5	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	1877-0657	1877-0665		ANN PHYS REHABIL MED	Ann. Phys. Rehabil. Med.	APR	2016	59	2					100	106		10.1016/j.rehab.2015.10.009			7	Rehabilitation	Rehabilitation	FO5OL	WOS:000416909600005	26704071	Other Gold			2021-06-18	
J	Nelson, LD; Guskiewicz, KM; Marshall, SW; Hammeke, T; Barr, W; Randolph, C; McCrea, MA				Nelson, Lindsay D.; Guskiewicz, Kevin M.; Marshall, Stephen W.; Hammeke, Thomas; Barr, William; Randolph, Christopher; McCrea, Michael A.			Multiple Self-Reported Concussions Are More Prevalent in Athletes With ADHD and Learning Disability	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						learning disability; concussion; standardized assessment of concussion; attention deficit	COLLEGIATE FOOTBALL PLAYERS; POSITION STATEMENT; RECOVERY-TIME; SPORT; INJURIES; HYPERACTIVITY; CHILDREN; PERFORMANCE; MANAGEMENT; DISORDERS	Objective: We evaluated how attention deficit-hyperactivity disorder (ADHD) and learning disability (LD) are associated with concussion history and performance on standard concussion assessment measures. Based on previous reports that developmental disorders are associated with increased injury proneness and poorer cognitive performance, we anticipated that ADHD and LD would be associated with increased history of concussion and poorer baseline performance on assessment measures. Design: Cross-sectional study. Setting: Clinical research center. Participants: The study sample aggregated data from two separate projects: the National Collegiate Athletic Association Concussion Study and Project Sideline. Interventions: We analyzed preseason baseline data from 8056 high school and collegiate athletes (predominantly male football players) enrolled in prior studies of sport-related concussion. Main Outcome Measures: Measures included demographic/health history, symptoms, and cognitive performance. Results: Attention deficit-hyperactivity disorder and LD were associated with 2.93 and 2.08 times the prevalence, respectively, of 3+ historical concussions (for comorbid ADHD/LD the prevalence ratio was 3.38). In players without histories of concussion, individuals with ADHD reported more baseline symptoms, and ADHD and LD were associated with poorer performance on baseline cognitive tests. Interactive effects were present between ADHD/LD status and concussion history for self-reported symptoms. Conclusions: Neurodevelopmental disorders and concussion history should be jointly considered in evaluating concussed players. Clinical Relevance: Clinical judgments of self-reported symptoms and cognitive performance should be adjusted based on athletes' individual preinjury baselines or comparison with appropriate normative samples.	[Nelson, Lindsay D.; Hammeke, Thomas; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; Hammeke, Thomas; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Guskiewicz, Kevin M.; Marshall, Stephen W.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Orthoped, Chapel Hill, NC USA; [Guskiewicz, Kevin M.; Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Hammeke, Thomas] Milwaukee VA Med Ctr, Dept Mental Behav Hlth, Milwaukee, WI USA; [Barr, William] NYU, Sch Med, Dept Neurol, New York, NY USA; [Randolph, Christopher] Loyola Univ, Med Ctr, Dept Neurol, Chicago, IL 60611 USA	Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurol, Div Neuropsychol, 9200 West Wisconsin Ave, Milwaukee, WI 53226 USA.	linelson@mcw.edu		Barr, William/0000-0001-7711-7758	National Collegiate Athletic Association (NCAA); National Operating Committee on Standards for Athletic Equipment (NOCSAE); Center for Disease Control's National Center for Injury Prevention and Control; University of North Carolina Injury Prevention Research Center; Waukesha Memorial Hospital Foundation; National Academy of Neuropsychology; National Federation of State High School Associations; NFL Charities; Green Bay Packer Foundation; Milwaukee Bucks; Herbert H. Kohl Charities; Waukesha Service Club; Medical College of Wisconsin General Clinical Research Center from the National Institutes of Health [M01 RR00058]	Supported in part by funding from the National Collegiate Athletic Association (NCAA) and the National Operating Committee on Standards for Athletic Equipment (NOCSAE), Center for Disease Control's National Center for Injury Prevention and Control, University of North Carolina Injury Prevention Research Center, Waukesha Memorial Hospital Foundation, National Academy of Neuropsychology, National Federation of State High School Associations, NFL Charities, Green Bay Packer Foundation, Milwaukee Bucks, Herbert H. Kohl Charities, Waukesha Service Club, Michael Emme, and the Medical College of Wisconsin General Clinical Research Center (M01 RR00058 from the National Institutes of Health).	Alosco ML, 2014, BRAIN INJURY, V28, P472, DOI 10.3109/02699052.2014.887145; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Brehaut JC, 2003, PEDIATRICS, V111, P262, DOI 10.1542/peds.111.2.262; Christoffel KK, 1996, PEDIATRICS, V97, P33; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; DAVIDSON LL, 1987, J DEV BEHAV PEDIATR, V8, P335; DiScala C, 1998, PEDIATRICS, V102, P1415, DOI 10.1542/peds.102.6.1415; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Gillberg C, 2004, EUR CHILD ADOLES PSY, V13, P80, DOI 10.1007/s00787-004-1008-4; Golden CJ, 2002, STROOP COLOR WORD TE; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jerome L, 2003, CAN MED ASSOC J, V169, P16; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M., 2000, STANDARDIZED ASSESSM; McCrea M, OXFROD HDB IN PRESS; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Pastor Patricia N, 2008, Vital Health Stat 10, P1; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Reitan RM., 1985, HALSTEAD REITAN NEUR; Smith A, 1982, SYMBOL DIGITS MODALI; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Wisniewska B, 2007, Adv Med Sci, V52 Suppl 1, P215	37	51	51	1	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2016	26	2					120	127		10.1097/JSM.0000000000000207			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	DF4DM	WOS:000371297600005	25915144	Green Accepted			2021-06-18	
J	Gunawardana, CG; Mehrabian, M; Wang, XZ; Mueller, I; Lubambo, IB; Jonkman, JEN; Wang, H; Schmitt-Ulms, G				Gunawardana, C. Geeth; Mehrabian, Mohadeseh; Wang, Xinzhu; Mueller, Iris; Lubambo, Isabela B.; Jonkman, James E. N.; Wang, Hansen; Schmitt-Ulms, Gerold			The Human Tau Interactome: Binding to the Ribonucleoproteome, and Impaired Binding of the Proline-to-Leucine Mutant at Position 301 (P301L) to Chaperones and the Proteasome	MOLECULAR & CELLULAR PROTEOMICS			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; PROTEIN-TAU; ALPHA-SYNUCLEIN; PATHOGENETIC IMPLICATIONS; NEUROFIBRILLARY TANGLES; CEREBROSPINAL-FLUID; MASS-SPECTROMETRY; TRANSGENIC MICE; NEURONAL CELLS	The tau protein is central to the etiology of several neurodegenerative diseases, including Alzheimer's disease, a subset of frontotemporal dementias, progressive supranuclear palsy and dementia following traumatic brain injury, yet the proteins it interacts with have not been studied using a systematic discovery approach. Here we employed mild in vivo crosslinking, isobaric labeling, and tandem mass spectrometry to characterize molecular interactions of human tau in a neuroblastoma cell model. The study revealed a robust association of tau with the ribonucleoproteome, including major protein complexes involved in RNA processing and translation, and documented binding of tau to several heat shock proteins, the proteasome and microtubule-associated proteins. Follow-up experiments determined the relative contribution of cellular RNA to the tau interactome and mapped interactions to N- or C-terminal tau domains. We further document that expression of P301L mutant tau disrupts interactions of the C-terminal half of tau with heat shock proteins and the proteasome. The data are consistent with a model whereby a higher propensity of P301L mutant tau to aggregate may reflect a perturbation of its chaperone-assisted stabilization and proteasome-dependent degradation. Finally, using a global proteomics approach, we show that heterologous expression of a tau construct that lacks the C-terminal domain, including the microtubule binding domain, does not cause a discernible shift of the proteome except for a significant direct correlation of steady-state levels of tau and cystatin B.	[Gunawardana, C. Geeth; Mehrabian, Mohadeseh; Wang, Xinzhu; Mueller, Iris; Lubambo, Isabela B.; Wang, Hansen; Schmitt-Ulms, Gerold] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5T 2S8, Canada; [Mehrabian, Mohadeseh; Wang, Xinzhu; Schmitt-Ulms, Gerold] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; [Jonkman, James E. N.] Univ Hlth Network, Adv Opt Microscopy Facil, Toronto, ON M5G 1L7, Canada	Schmitt-Ulms, G (corresponding author), Tanz Ctr Res Neurodegenerat Dis, 60 Leonard Ave,Krembil Discovery Tower, Toronto, ON M5T 2S8, Canada.	g.schmittulms@utoronto.ca	wang, hansen/I-2510-2019	wang, hansen/0000-0003-4414-3372; Muller, Iris/0000-0001-8542-0175; Jonkman, James/0000-0001-6888-8550; Wang, Xinzhu/0000-0002-1438-1153	China-Canada Initiative on Alzheimer's Disease and Related Disorders; Canadian Institute of Health Research (CIHR), CanadaCanadian Institutes of Health Research (CIHR); National Natural Science Foundation NNSF, ChinaNational Natural Science Foundation of China (NSFC); postdoctoral CIHR fellowship; Ontario Trillium Scholarship; W. Garfield Weston Foundation; Canadian Foundation for Innovation (CFI)Canada Foundation for Innovation	This work was supported by an operating grant from the "China-Canada Initiative on Alzheimer's Disease and Related Disorders," a partnership initiative between the Canadian Institute of Health Research (CIHR), Canada, and the National Natural Science Foundation NNSF, China. The mass spectrometry component was enabled by a generous donation, kindly provided by the Irwin family, and a leading edge fund (LEF) infrastructure grant from the Canadian Foundation for Innovation (CFI). C.G.G. gratefully acknowledges support from a postdoctoral CIHR fellowship, M.M. contributed to this project supported by funding from an Ontario Trillium Scholarship, and G.S. received generous support from the W. Garfield Weston Foundation.	Arnaud LT, 2009, J NEUROCHEM, V110, P328, DOI 10.1111/j.1471-4159.2009.06142.x; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benussi L, 2005, EXP CELL RES, V308, P78, DOI 10.1016/j.yexcr.2005.04.021; Blair LJ, 2013, J CLIN INVEST, V123, P4158, DOI 10.1172/JCI69003; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; Chambraud B, 2010, P NATL ACAD SCI USA, V107, P2658, DOI 10.1073/pnas.0914957107; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; Dawson HN, 2001, J CELL SCI, V114, P1179; Dorval V, 2006, J BIOL CHEM, V281, P9919, DOI 10.1074/jbc.M510127200; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; Farias GA, 2002, J CELL BIOCHEM, V85, P315, DOI 10.1002/jcb.10133; Fulga TA, 2007, NAT CELL BIOL, V9, P139, DOI 10.1038/ncb1528; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Hanger DP, 2007, J BIOL CHEM, V282, P23645, DOI 10.1074/jbc.M703269200; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; Horiguchi T, 2003, AM J PATHOL, V163, P1021, DOI 10.1016/S0002-9440(10)63462-1; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Iseki E, 2001, ACTA NEUROPATHOL, V102, P285; Ittner LM, 2011, NAT REV NEUROSCI, V12, P67, DOI 10.1038/nrn2967; Ittner LM, 2010, CELL, V142, P387, DOI 10.1016/j.cell.2010.06.036; Kall L, 2007, NAT METHODS, V4, P923, DOI 10.1038/NMETH1113; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; Karagoz GE, 2014, CELL, V156, P963, DOI 10.1016/j.cell.2014.01.037; King ME, 2006, J CELL BIOL, V175, P541, DOI 10.1083/jcb.200605187; King OD, 2012, BRAIN RES, V1462, P61, DOI 10.1016/j.brainres.2012.01.016; Kozielski F, 2011, AMINO ACIDS, V41, P363, DOI 10.1007/s00726-010-0649-5; Lee G, 1998, J CELL SCI, V111, P3167; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Leverenz JB, 2007, BRAIN, V130, P1360, DOI 10.1093/brain/awm069; Lewis J, 2000, NAT GENET, V25, P402; Li QW, 1998, BIOCHEM BIOPH RES CO, V250, P502, DOI 10.1006/bbrc.1998.9271; Liu YY, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.403451; Marcus JN, 2011, J NEUROGENET, V25, P127, DOI 10.3109/01677063.2011.626471; Mehrabian M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114594; Min SW, 2010, NEURON, V67, P953, DOI 10.1016/j.neuron.2010.08.044; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Mukrasch MD, 2009, PLOS BIOL, V7, P399, DOI 10.1371/journal.pbio.1000034; NELSON PT, 1993, BRAIN RES, V600, P285, DOI 10.1016/0006-8993(93)91385-6; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; PAPASOZOMENOS SC, 1989, LAB INVEST, V60, P123; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; PAPASOZOMENOS SC, 1989, LAB INVEST, V60, P375; Patterson KR, 2011, BIOCHEMISTRY-US, V50, P10300, DOI 10.1021/bi2009147; Perreault S, 2009, J NEUROPATH EXP NEUR, V68, P503, DOI 10.1097/NEN.0b013e3181a1fc49; Portelius E, 2008, J PROTEOME RES, V7, P2114, DOI 10.1021/pr7008669; Qureshi HY, 2011, J BIOL CHEM, V286, P5055, DOI 10.1074/jbc.M110.178905; Reynolds CH, 2008, J BIOL CHEM, V283, P18177, DOI 10.1074/jbc.M709715200; Rothbauer U, 2008, MOL CELL PROTEOMICS, V7, P282, DOI 10.1074/mcp.M700342-MCP200; Rudrabhatla P, 2011, FASEB J, V25, P3896, DOI 10.1096/fj.11-181297; Saman S, 2012, J BIOL CHEM, V287, P3842, DOI 10.1074/jbc.M111.277061; Sandberg A, 2014, J PROTEOMICS, V96, P133, DOI 10.1016/j.jprot.2013.10.035; Schraen-Maschke S, 2008, BIOMARK MED, V2, P363, DOI 10.2217/17520363.2.4.363; Shaner NC, 2007, J CELL SCI, V120, P4247, DOI 10.1242/jcs.005801; Sjoberg MK, 2006, J CELL SCI, V119, P2025, DOI 10.1242/jcs.02907; SMITH CJ, 1995, FEBS LETT, V375, P243, DOI 10.1016/0014-5793(95)01221-Y; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; SUPRENANT KA, 1993, J CELL SCI, V104, P445; Terwel D, 2005, J BIOL CHEM, V280, P3963, DOI 10.1074/jbc.M409876200; Thompson AD, 2012, ACS CHEM BIOL, V7, P1677, DOI 10.1021/cb3002599; Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839; Vizcaino JA, 2013, NUCLEIC ACIDS RES, V41, pD1063, DOI 10.1093/nar/gks1262; Wang XS, 2006, PROTEIN PEPTIDE LETT, V13, P679, DOI 10.2174/092986606777790566; Wang YP, 2007, P NATL ACAD SCI USA, V104, P10252, DOI 10.1073/pnas.0703676104; Watts JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000608; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509; Yang DS, 2011, BRAIN, V134, P258, DOI 10.1093/brain/awq341; Zhang XM, 2013, J BIOL CHEM, V288, DOI 10.1074/jbc.M112.436402; Zieske LR, 2006, J EXP BOT, V57, P1501, DOI 10.1093/jxb/erj168	74	51	52	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	1535-9476	1535-9484		MOL CELL PROTEOMICS	Mol. Cell. Proteomics	NOV	2015	14	11					3000	3014		10.1074/mcp.M115.050724			15	Biochemical Research Methods	Biochemistry & Molecular Biology	CX3ZA	WOS:000365636800013	26269332	Green Published, Other Gold			2021-06-18	
J	Liu, M; Wu, W; Li, H; Li, S; Huang, LT; Yang, YQ; Sun, Q; Wang, CX; Yu, Z; Hang, CH				Liu, Ming; Wu, Wei; Li, Hua; Li, Song; Huang, Li-tian; Yang, Yi-qing; Sun, Qing; Wang, Chun-xi; Yu, Zhuang; Hang, Chun-hua			Necroptosis, a novel type of programmed cell death, contributes to early neural cells damage after spinal cord injury in adult mice	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Functional outcome; Necroptosis; Necrostatin-1; Spinal cord injury	BRAIN-INJURY; IN-VIVO; APOPTOSIS; NECROSIS; RATS; INFLAMMATION; NECROSTATIN; ANTAGONIST; RECOVERY; NEURONS	Background: Necroptosis is an emerging programmed necrosis other than traditional necrosis and apoptosis. Until recently, there have not been studies that have investigated a relationship between necroptosis and pathogenesis of cell death after spinal cord injury (SCI). Objective: To investigate whether necroptosis takes part in the early pathophysiological processes of traumatic SCI in mice. Methods: Female ICR mice were randomized equally into three groups: the sham, the vehicle-treated + SCI group, and the Nec-1-treated + SCI group. To induce SCI, the mice were subjected to a laminectomy at T9 and compression with a vascular clip. After mice were sacrificed 24 hours post-SCI, propidium iodide (PI)positive cells were detected using in vivo PI labeling. Morphological analyses were performed by hematoxylin and eosin staining and Nissl staining. The samples were evaluated for apoptosis by the in situ TUNEL assay. The expression of caspase-3 was assessed by western blot. Locomotor behavior of hindlimb was evaluated by BMS (Basso mouse scale) score at 1, 3, 5, 7, and 14 days post-injury. Results: Compared with dimethyl sulfoxide -treated mice, necrostatin-1-treated mice showed decreased PI-positive cells (P < 0.05), alleviated tissue damage, more surviving neuron at 24 hours after SCI (P < 0.05), and improved functional recovery from days 7 to 14 (P < 0.05). Necrostatin-1 did not reduce the expression of caspase-3 and the number of TUNEL-positive cells at 24 hours after SCI (P > 0.05). Conclusions: Necroptosis contributes to necroptotic cell death and influences functional outcome after SCI in adult mice. The inhibition of necroptosis by necrostatin-1 may have therapeutic potential for patients with SCI.	[Liu, Ming; Li, Song; Huang, Li-tian; Hang, Chun-hua] Southern Med Univ Guangzhou, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Liu, Ming] Ningde Municipal Hosp, Dept Neurosurg, Ningde, Peoples R China; [Wu, Wei; Li, Hua; Yang, Yi-qing; Sun, Qing; Wang, Chun-xi; Yu, Zhuang] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China	Hang, CH (corresponding author), Southern Med Univ Guangzhou, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	hang_neurosurgery@163.com		Li, Hua/0000-0001-5893-535X	National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81171170, 81371294]; Nature Science Foundation of Jiangsu Province, ChinaNatural Science Foundation of Jiangsu Province [BK2010459]; Scientific Research and Innovation Foundation of Universities in Jiangsu Province, China [CXZZ12_0067]	This work was funded in part by grants from the National Natural Science Foundation, China (No. 81171170, 81371294) and Nature Science Foundation of Jiangsu Province, China (BK2010459) and Scientific Research and Innovation Foundation of Universities in Jiangsu Province, China (CXZZ12_0067).	Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; Chen KB, 2011, SPINE, V36, P1350, DOI 10.1097/BRS.0b013e3181f014ec; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Dunai Z, 2011, PATHOL ONCOL RES, V17, P791, DOI 10.1007/s12253-011-9433-4; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Mao L, 2012, J TRAUMA ACUTE CARE, V72, P189, DOI 10.1097/TA.0b013e31821bf541; Northington FJ, 2011, J CEREBR BLOOD F MET, V31, P178, DOI 10.1038/jcbfm.2010.72; Oerlemans MIFJ, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-012-0270-8; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Rosenbaum DM, 2010, J NEUROSCI RES, V88, P1569, DOI 10.1002/jnr.22314; Smith CCT, 2007, CARDIOVASC DRUG THER, V21, P227, DOI 10.1007/s10557-007-6035-1; Tep C, 2013, J NEUROSCI, V33, P397, DOI 10.1523/JNEUROSCI.0399-12.2013; Vidal PM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.466; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; Wang ZF, 2013, EXP THER MED, V5, P107, DOI 10.3892/etm.2012.745; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhang N, 2012, INDIAN J MED RES, V135, P287	29	51	53	0	16	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	NOV	2015	38	6					745	753		10.1179/2045772314Y.0000000224			9	Clinical Neurology	Neurosciences & Neurology	CU8KC	WOS:000363790300008	24970278	Green Published			2021-06-18	
J	Lafrenaye, AD; Todani, M; Walker, SA; Povlishock, JT				Lafrenaye, Audrey D.; Todani, Masaki; Walker, Susan A.; Povlishock, John T.			Microglia processes associate with diffusely injured axons following mild traumatic brain injury in the micro pig	JOURNAL OF NEUROINFLAMMATION			English	Article						Mild traumatic brain injury; Diffuse axonal injury; Neuroinflammation; Microglia; Micro pig	SYNAPSE INTERACTIONS; OPTIC-NERVE; ACTIVATION; INFLAMMATION; MATTER; WHITE; NEUROINFLAMMATION; MACROPHAGES; ATROPHY; PATHOPHYSIOLOGY	Background: Mild traumatic brain injury (mTBI) is an all too common occurrence that exacts significant personal and societal costs. The pathophysiology of mTBI is complex, with reports routinely correlating diffuse axonal injury (DAI) with prolonged morbidity. Progressive chronic neuroinflammation has also recently been correlated to morbidity, however, the potential association between neuroinflammatory microglia and DAI is not well understood. The majority of studies exploring neuroinflammatory responses to TBI have focused on more chronic phases of injury involving phagocytosis associated with Wallerian change. Little, however, is known regarding the neuroinflammatory response seen acutely following diffuse mTBI and its potential relationship to early DAI. Additionally, while inflammation is drastically different in rodents compared to humans, pigs and humans share very similar inflammatory profiles and responses. Methods: In the current study, we employed a modified central fluid percussion model in micro pigs. Using this model of diffuse mTBI, paired with various immunohistological endpoints, we assessed the potential association between acute thalamic DAI and neuroinflammation 6 h following injury. Results: Injured micro pigs displayed substantial axonal damage reflected in the presence of APP+ proximal axonal swellings, which were particularly prominent in the thalamus. In companion, the same thalamic sites displayed extensive neuroinflammation, which was observed using Iba-1 immunohistochemistry. The physical relationship between microglia and DAI, assessed via confocal 3D analysis, revealed a dramatic increase in the number of Iba-1+ microglial processes that contacted APP+ proximal axonal swellings compared to uninjured myelinated thalamic axons in sham animals. Conclusions: In aggregate, these studies reveal acute microglial process convergence on proximal axonal swellings undergoing DAI, an interaction not previously recognized in the literature. These findings transform our understanding of acute neuroinflammation following mTBI and may suggest its potential as a diagnostic and/or a therapeutic target.	[Lafrenaye, Audrey D.; Todani, Masaki; Walker, Susan A.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Todani, Masaki] Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr, Yamaguchi, Japan	Lafrenaye, AD (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	forrestad@vcu.edu			U.S. ArmyUnited States Department of Defense [W81XWH-10-1-0623, WH81XWH-14-2-0018]; NIH-NINDS CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463] Funding Source: NIH RePORTER	The authors would like to thank Dr. Scott Henderson for his expertise in microscopy and image analysis, Dr. Robert Hamm for his biostatistical assistance and knowledge as well as Drs. David Loane, Kevin Wang, Patrick Kochanek, and Michelle Block for invigorating scientific discussions and suggestions. We would also like to recognize Lynn Davis, Jesse Sims, Karen Gorse, Judy Williamson, Frances White, and Dr. Thomas Taetzsch for invaluable technical assistance. This work was performed as a component of the Operation Brain Trauma Therapy consortium, which is supported by U.S. Army grants W81XWH-10-1-0623 and WH81XWH-14-2-0018. Microscopy was performed at the VCU Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS Center core grant 5P30NS047463.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Baalman K, 2015, J NEUROSCI, V35, P2283, DOI 10.1523/JNEUROSCI.3751-14.2015; Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bove AA, 2014, AM J RESP CRIT CARE, V189, P1479, DOI 10.1164/rccm.201309-1662CI; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Chen ZH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5486; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eyo UB, 2015, J NEUROSCI, V35, P2417, DOI 10.1523/JNEUROSCI.3279-14.2015; Eyo UB, 2014, J NEUROSCI, V34, P10528, DOI 10.1523/JNEUROSCI.0416-14.2014; Fairbairn L, 2011, J LEUKOCYTE BIOL, V89, P855, DOI 10.1189/jlb.1110607; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Girard S, 2013, GLIA, V61, P813, DOI 10.1002/glia.22478; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gyoneva S, 2015, TRENDS PHARMACOL SCI, P1; Hanell A, 2015, ACTA NEUROPATHOL, V129, P317, DOI 10.1007/s00401-014-1376-x; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Heinz S, 2003, J BIOL CHEM, V278, P21502, DOI 10.1074/jbc.M301476200; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Howell OW, 2010, J NEUROPATH EXP NEUR, V69, P1017, DOI 10.1097/NEN.0b013e3181f3a5b1; Jebelli J, 2015, ANN NY ACAD SCI, V1351, P1, DOI 10.1111/nyas.12711; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Karve I.P., 2015, BR J PHARM; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kondo Y, 2011, J NEUROSCI, V31, P3610, DOI 10.1523/JNEUROSCI.6344-10.2011; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Krabbe G, 2012, BRAIN BEHAV IMMUN, V26, P419, DOI 10.1016/j.bbi.2011.12.002; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kyritsis N, 2012, SCIENCE, V338, P1353, DOI 10.1126/science.1228773; Lafrenaye AD, 2014, J CEREBR BLOOD F MET, V34, P1628, DOI 10.1038/jcbfm.2014.122; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood-2012-06-436212; McGinn Melissa J, 2015, Handb Clin Neurol, V127, P67, DOI 10.1016/B978-0-444-52892-6.00005-2; Mckay SM, 2007, J NEUROPATH EXP NEUR, V66, P698, DOI 10.1097/nen.0b013e3181256b32; Miyamoto A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00070; MURPHY PM, 1993, CELL, V72, P823, DOI 10.1016/0092-8674(93)90571-7; Nemeth CL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0174-7; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; OGURA K, 1994, NEUROREPORT, V5, P1224, DOI 10.1097/00001756-199406020-00016; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Roshick C, 2006, INFECT IMMUN, V74, P225, DOI 10.1128/IAI.74.1.225-238.2006; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Ryu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0153-3; Schafer DP, 2013, GLIA, V61, P24, DOI 10.1002/glia.22389; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Taetzsch T, 2015, GLIA, V63, P423, DOI 10.1002/glia.22762; Tam WY, 2014, SCI REP-UK, V4, DOI 10.1038/srep07279; Tang Y., 2015, MOL NEUROBIOL; Thomson L, 2014, PAEDIATR RESPIR REV, V15, P120, DOI 10.1016/j.prrv.2014.03.003; Tonges L, 2014, GLIA, V62, P217, DOI 10.1002/glia.22601; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Wake H, 2013, TRENDS NEUROSCI, V36, P209, DOI 10.1016/j.tins.2012.11.007; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Wernersson R, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-70; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477	94	51	53	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	OCT 6	2015	12								186	10.1186/s12974-015-0405-6			15	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CS6AH	WOS:000362158900001	26438203	DOAJ Gold, Green Published			2021-06-18	
J	Frontera, JA; Curtis, JR; Nelson, JE; Campbell, M; Gabriel, M; Mosenthal, AC; Mulkerin, C; Puntillo, KA; Ray, DE; Bassett, R; Boss, RD; Lustbader, DR; Brasel, KJ; Weiss, SP; Weissman, DE				Frontera, Jennifer A.; Curtis, J. Randall; Nelson, Judith E.; Campbell, Margaret; Gabriel, Michelle; Mosenthal, Anne C.; Mulkerin, Colleen; Puntillo, Kathleen A.; Ray, Daniel E.; Bassett, Rick; Boss, Renee D.; Lustbader, Dana R.; Brasel, Karen J.; Weiss, Stefanie P.; Weissman, David E.		Improving Palliative Care ICU Proj	Integrating Palliative Care Into the Care of Neurocritically Ill Patients: A Report From the Improving Palliative Care in the ICU Project Advisory Board and the Center to Advance Palliative Care	CRITICAL CARE MEDICINE			English	Article						end-of-life care; intensive care unit; neurocritical care; neurointensive care unit; palliative care	TRAUMATIC BRAIN-INJURY; PRIMARY INTRACEREBRAL HEMORRHAGE; MIDDLE-CEREBRAL-ARTERY; REFRACTORY STATUS EPILEPTICUS; ADMISSION BLOOD-PRESSURE; ORGAN DONOR DONATION; OF-LIFE CARE; SUBARACHNOID HEMORRHAGE; PROGNOSTIC VALUE; DECISION-MAKING	Objectives: To describe unique features of neurocritical illness that are relevant to provision of high-quality palliative care; to discuss key prognostic aids and their limitations for neurocritical illnesses; to review challenges and strategies for establishing realistic goals of care for patients in the neuro-ICU; and to describe elements of best practice concerning symptom management, limitation of life support, and organ donation for the neurocritically ill. Data Sources: A search of PubMed and MEDLINE was conducted from inception through January 2015 for all English-language articles using the term "palliative care," "supportive care," "end-of-life care," "withdrawal of life-sustaining therapy," "limitation of life support," "prognosis," or "goals of care" together with "neurocritical care," "neurointensive care," "neurological," "stroke," "subarachnoid hemorrhage," "intracerebral hemorrhage," or "brain injury." Data Extraction and Synthesis: We reviewed the existing literature on delivery of palliative care in the neurointensive care unit setting, focusing on challenges and strategies for establishing realistic and appropriate goals of care, symptom management, organ donation, and other considerations related to use and limitation of life-sustaining therapies for neurocritically ill patients. Based on review of these articles and the experiences of our interdisciplinary/interprofessional expert advisory board, this report was prepared to guide critical care staff, palliative care specialists, and others who practice in this setting. Conclusions: Most neurocritically ill patients and their families face the sudden onset of devastating cognitive and functional changes that challenge clinicians to provide patient-centered palliative care within a complex and often uncertain prognostic environment. Application of palliative care principles concerning symptom relief, goal setting, and family emotional support will provide clinicians a framework to address decision making at a time of crisis that enhances patient/family autonomy and clinician professionalism.	[Frontera, Jennifer A.] Cleveland Clin, Neurol Inst, Cerebrovasc Ctr, Cleveland, OH 44106 USA; [Curtis, J. Randall] Univ Washington, Harborview Med Ctr, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98104 USA; [Nelson, Judith E.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; [Nelson, Judith E.] Mem Sloan Kettering Canc Ctr, Dept Anesthesia & Crit Care, New York, NY 10021 USA; [Campbell, Margaret] Wayne State Univ, Coll Nursing, Detroit, MI 48202 USA; [Gabriel, Michelle] VA Palo Alto Hlth Care Syst, Off Qual Safety & Value, Palo Alto, CA USA; [Mosenthal, Anne C.] Rutgers New Jersey Med Sch, Dept Surg, Newark, NJ USA; [Mulkerin, Colleen] Hartford Hosp, Palliat Med & Social Work Serv, Hartford, CT 06115 USA; [Puntillo, Kathleen A.] Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA; [Ray, Daniel E.] Lehigh Valley Hlth Network, Sect Palliat Med & Hosp Med, Allentown, PA USA; [Bassett, Rick] St Lukes Boise Med Ctr, Boise, ID USA; [Boss, Renee D.] Johns Hopkins Univ, Sch Med, Div Neonatal Perinatal Med, Baltimore, MD USA; [Lustbader, Dana R.] Hofstra North Shore Long Isl Jewish Hlth Syst, ProHEALTH, Lake Success, NY USA; [Brasel, Karen J.] Oregon Hlth & Sci Univ, Dept Surg, Div Trauma Crit Care & Acute Care Surg, Portland, OR 97201 USA; [Weiss, Stefanie P.] Icahn Sch Med Mt Sinai, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA; [Weissman, David E.] Med Coll Wisconsin, Milwaukee, WI 53226 USA	Frontera, JA (corresponding author), Cleveland Clin, Neurol Inst, Cerebrovasc Ctr, Cleveland, OH 44106 USA.	frontej@ccf.org	Viani, Rafael/V-1196-2018; Boss, Renee/AAN-4091-2020	Curtis, J. Randall/0000-0001-9529-845X	Center to Advance Palliative Care; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute on Aging for the Improving Palliative Care in the ICU Project (Academic Career Leadership Award) [K07-034234]; National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR); Healthcare Foundation of New Jersey; Center for Health Quality and Innovation Quality Enterprise Risk Management program; National Institute on Aging (K07 Academic Career Leadership Award); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K07AG034234] Funding Source: NIH RePORTER	Supported, in part, by the Center to Advance Palliative Care.	Altman DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b605; Apatira L, 2008, ANN INTERN MED, V149, P861, DOI 10.7326/0003-4819-149-12-200812160-00005; Back A., 2009, MASTERING COMMUNICAT; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Benejam B, 2009, J NEUROL, V256, P1126, DOI 10.1007/s00415-009-5083-9; Bernacki RE, 2014, JAMA INTERN MED, V174, P1994, DOI 10.1001/jamainternmed.2014.5271; Brieva J, 2013, CRIT CARE MED, V41, P2677, DOI 10.1097/CCM.0b013e3182987f38; BRODY H, 1981, JAMA-J AM MED ASSOC, V246, P1411, DOI 10.1001/jama.246.13.1411; Campbell ML, 2013, J PALLIAT MED, V16, P1255, DOI 10.1089/jpm.2013.0122; CARLBERG B, 1993, STROKE, V24, P1372, DOI 10.1161/01.STR.24.9.1372; Carter BS, 2000, NEUROSURGERY, V46, P1326, DOI 10.1097/00006123-200006000-00008; Cherny N I, 1994, J Palliat Care, V10, P31; Christakis N.A., 1999, DEATH FORETOLD PROPH; Claassen J, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.2002.28501.x; Clarke EB, 2003, CRIT CARE MED, V31, P2255, DOI 10.1097/01.CCM.0000084849.96385.85; Cook D, 2014, NEW ENGL J MED, V370, P2506, DOI 10.1056/NEJMra1208795; Cramer SC, 2008, ANN NEUROL, V63, P272, DOI 10.1002/ana.21393; Curtis JR, 2014, INTENS CARE MED, V40, P1374, DOI 10.1007/s00134-014-3421-6; Davis CG, 2013, REHABIL PSYCHOL, V58, P287, DOI 10.1037/a0033400; de Groot YJ, 2012, CRIT CARE MED, V40, P233, DOI 10.1097/CCM.0b013e31822f0633; DELORENZO RJ, 1995, J CLIN NEUROPHYSIOL, V12, P316; Diringer MN, 1998, STROKE, V29, P1352, DOI 10.1161/01.STR.29.7.1352; Diringer MN, 2001, CRIT CARE MED, V29, P1792, DOI 10.1097/00003246-200109000-00023; DRAKE CG, 1988, J NEUROSURG, V68, P985; Ehlenbach WJ, 2013, CRIT CARE MED, V41, P1136, DOI 10.1097/CCM.0b013e31827c03eb; Engelberg RA, 2008, J CRIT CARE, V23, P565, DOI 10.1016/j.jcrc.2007.12.018; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; Da Silva IRF, 2015, JAMA NEUROL, V72, P112, DOI 10.1001/jamaneurol.2014.3083; Flemming KD, 2001, CEREBROVASC DIS, V11, P183, DOI 10.1159/000047636; Fogelholm R, 2005, J NEUROL NEUROSUR PS, V76, P1534, DOI 10.1136/jnnp.2004.055145; Fogelholm R, 1997, STROKE, V28, P1396, DOI 10.1161/01.STR.28.7.1396; Fried TR, 2007, J GEN INTERN MED, V22, P495, DOI 10.1007/s11606-007-0104-9; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Frontera JA, 2010, NEUROCRIT CARE, V12, P103, DOI 10.1007/s12028-009-9292-y; Frontera JA, 2010, NEUROCRIT CARE, V12, P111, DOI 10.1007/s12028-009-9294-9; GARDE A, 1983, EUR NEUROL, V22, P161, DOI 10.1159/000115555; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Glozier N, 2008, STROKE, V39, P1526, DOI 10.1161/STROKEAHA.107.503219; Goettler CE, 2010, J TRAUMA, V68, P1279, DOI 10.1097/TA.0b013e3181de3b99; GREENE WR, 1991, SOUTHERN MED J, V84, P332, DOI 10.1097/00007611-199103000-00009; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Grysiewicz RA, 2008, NEUROL CLIN, V26, P871, DOI 10.1016/j.ncl.2008.07.003; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hadley MN, 2013, NEUROSURGERY, V72, P40, DOI 10.1227/NEU.0b013e318276edda; Hankey GJ, 2007, NEUROLOGY, V68, P1583, DOI 10.1212/01.wnl.0000260967.77422.97; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Holloway RG, 2014, STROKE, V45, P1887, DOI 10.1161/STR.0000000000000015; Holloway RG, 2010, J PALLIAT MED, V13, P407, DOI 10.1089/jpm.2009.0278; Holzer M, 2002, NEW ENGL J MED, V346, P549; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Izzy S, 2013, NEUROCRIT CARE, V19, P347, DOI 10.1007/s12028-013-9925-z; Jauss M, 1999, J NEUROL, V246, P257, DOI 10.1007/s004150050344; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jorgensen H S, 1999, Phys Med Rehabil Clin N Am, V10, P887; Juttler E, 2014, NEW ENGL J MED, V370, P1091, DOI 10.1056/NEJMoa1311367; Kelso CM, 2007, J PALLIAT MED, V10, P118, DOI 10.1089/jpm.2006.0118; Kerr CW, 2014, AM J HOSP PALLIAT ME, V31, P105, DOI 10.1177/1049909112474111; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Kong KH, 2014, NEUROREHABILITATION, V35, P221, DOI 10.3233/NRE-141110; Korfage IJ, 2007, QUAL LIFE RES, V16, P1627, DOI 10.1007/s11136-007-9265-6; Kowalski RG, 2004, JAMA-J AM MED ASSOC, V291, P866, DOI 10.1001/jama.291.7.866; Kowalski RG, 2013, NEUROCRIT CARE, V19, P269, DOI 10.1007/s12028-013-9929-8; Lee VH, 2014, NEUROCRIT CARE, V21, P14, DOI 10.1007/s12028-013-9952-9; Legriel S, 2008, INTENS CARE MED, V34, P476, DOI 10.1007/s00134-007-0915-5; Legriel S, 2010, CRIT CARE MED, V38, P2295, DOI 10.1097/CCM.0b013e3181f859a6; Logroscino G, 1997, EPILEPSIA, V38, P1344, DOI 10.1111/j.1528-1157.1997.tb00073.x; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Luce JM, 2001, MANAGING DEATH INTEN, P19; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mayer SA, 2002, ARCH NEUROL-CHICAGO, V59, P205, DOI 10.1001/archneur.59.2.205; McIntyre A, 2013, BRAIN INJURY, V27, P31, DOI 10.3109/02699052.2012.700086; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Menikoff J., 2001, LAW BIOETHICS INTRO; Mocco J, 2006, NEUROSURGERY, V59, P529, DOI 10.1227/01.NEU.0000228680.22550.A2; Moons KGM, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b606; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; Murata Y, 1999, J NEUROL SCI, V167, P107, DOI 10.1016/S0022-510X(99)00150-1; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Naidech AM, 2009, NEUROCRIT CARE, V11, P45, DOI 10.1007/s12028-009-9186-z; Nelson JE, 2011, J HOSP PALLIAT NURS, V13, P89, DOI 10.1097/NJH.0b013e318203d9ff; Nelson JE, 2010, CRIT CARE MED, V38, P1765, DOI 10.1097/CCM.0b013e3181e8ad23; Nelson JE, 2010, CRIT CARE MED, V38, P808, DOI 10.1097/CCM.0b013e3181c5887c; Neurocritical Care Society, WHAT IS NEUR CAR; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nilsson OG, 2002, J NEUROSURG, V97, P531, DOI 10.3171/jns.2002.97.3.0531; Oshiro EM, 1997, NEUROSURGERY, V41, P140, DOI 10.1097/00006123-199707000-00029; Pullicino PM, 1997, NEUROLOGY, V49, P1090, DOI 10.1212/WNL.49.4.1090; Puntillo K, 2014, INTENS CARE MED, V40, P235, DOI 10.1007/s00134-013-3153-z; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Quill TE, 2011, JAMA-J AM MED ASSOC, V306, P1483, DOI 10.1001/jama.2011.1413; Qureshi AI, 2014, WORLD NEUROSURG, V82, pE579, DOI 10.1016/j.wneu.2014.07.008; Qureshi AI, 2013, MED CARE, V51, P1094, DOI 10.1097/MLR.0b013e3182a95db4; Rabinstein AA, 2002, NEUROLOGY, V58, P1367, DOI 10.1212/WNL.58.9.1367; Rabinstein AA, 2012, LANCET NEUROL, V11, P414, DOI 10.1016/S1474-4422(12)70060-1; RANKIN J, 1957, Scott Med J, V2, P200; Rincon F, 2013, NEUROCRIT CARE, V19, P95, DOI 10.1007/s12028-012-9793-y; Rincon F, 2013, NEUROSURGERY, V73, P217, DOI 10.1227/01.neu.0000430290.93304.33; Rosenbaum BP, 2014, J CLIN NEUROSCI, V21, P1874, DOI 10.1016/j.jocn.2014.05.006; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rost NS, 2008, STROKE, V39, P2304, DOI 10.1161/STROKEAHA.107.512202; Rousseau P, 1996, ARCH INTERN MED, V156, P1785, DOI 10.1001/archinte.156.16.1785; Sacco S, 2009, STROKE, V40, P394, DOI 10.1161/STROKEAHA.108.523209; SAEKI S, 1995, STROKE, V26, P399, DOI 10.1161/01.STR.26.3.399; SALAZAR J, 1986, ACTA NEUROCHIR, V79, P80, DOI 10.1007/BF01407449; Scheunemann LP, 2012, AM J RESP CRIT CARE, V186, P480, DOI 10.1164/rccm.201204-0710CP; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shea AM, 2007, NEUROSURGERY, V61, P1131, DOI 10.1227/01.neu.0000306090.30517.ae; Smith EE, 2010, CIRCULATION, V122, P1496, DOI 10.1161/CIRCULATIONAHA.109.932822; Smith GP, 1998, CAMB Q HEALTHC ETHIC, V7, P382, DOI 10.1017/S0963180198704074; St Louis EK, 1998, NEUROLOGY, V51, P1364, DOI 10.1212/WNL.51.5.1364; St Louis EK, 2000, CAN J NEUROL SCI, V27, P32; Tealea E, 2013, CEREBROVASC DIS EXTR, V3, P97, DOI 10.1159/000351142; TEASDALE G, 1974, LANCET, V2, P81; Terayama Y, 1997, STROKE, V28, P1185, DOI 10.1161/01.STR.28.6.1185; Thompson DR, 2014, INTENS CARE MED, V40, P1372, DOI 10.1007/s00134-014-3422-5; Treece PD, 2004, CRIT CARE MED, V32, P1141, DOI 10.1097/01.CCM.0000125509.34805.0C; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; Truog RD, 2001, AM J KIDNEY DIS, V38, P901, DOI 10.1053/ajkd.2001.27855; TUHRIM S, 1988, ANN NEUROL, V24, P258, DOI 10.1002/ana.410240213; Turgeon AF, 2013, CRIT CARE MED, V41, P1086, DOI 10.1097/CCM.0b013e318275d046; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Unroe KT, 2015, J AM MED DIR ASSOC, V16, P90, DOI 10.1016/j.jamda.2014.11.010; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Varelas PN, 2008, SEMIN NEUROL, V28, P726, DOI 10.1055/s-0028-1105969; Wee B, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005177.pub2; Weil AG, 2011, CAN J NEUROL SCI, V38, P434, DOI 10.1017/S0317167100011835; Wendler D, 2011, ANN INTERN MED, V154, P336, DOI 10.7326/0003-4819-154-5-201103010-00008; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Wijdicks EFM, 2006, MAYO CLIN PROC, V81, P1332, DOI 10.4065/81.10.1332; Wijdicks EFM, 1997, NEUROLOGY, V49, P1342, DOI 10.1212/WNL.49.5.1342; Wijdicks EFM, 2006, NEUROLOGY, V66, P1300, DOI 10.1212/01.wnl.0000210497.62202.e9; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wijdicks EFM, 2004, CRIT CARE MED, V32, P2332, DOI 10.1097/01.CCM.0000145949.34618.E1; Wozniak MA, 1999, STROKE, V30, P2568, DOI 10.1161/01.STR.30.12.2568; Zahuranec DB, 2007, NEUROLOGY, V68, P1651, DOI 10.1212/01.wnl.0000261906.93238.72	145	51	52	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2015	43	9					1964	1977		10.1097/CCM.0000000000001131			14	Critical Care Medicine	General & Internal Medicine	DC5JH	WOS:000369256800043	26154929	Green Accepted			2021-06-18	
J	Alberts, JL; Hirsch, JR; Koop, MM; Schindler, DD; Kana, DE; Linder, SM; Campbell, S; Thota, AK				Alberts, Jay L.; Hirsch, Joshua R.; Koop, Mandy Miller; Schindler, David D.; Kana, Daniel E.; Linder, Susan M.; Campbell, Scott; Thota, Anil K.			Using Accelerometer and Gyroscopic Measures to Quantify Postural Stability	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; motor function; motor control; biomechanics	TRAUMATIC BRAIN-INJURY; DWELLING OLDER-ADULTS; PARKINSONS-DISEASE; CEREBRAL CONCUSSION; MULTIPLE-SCLEROSIS; STANDING BALANCE; HEAD-INJURY; BASE-LINE; INSTABILITY; GAIT	Context: Force platforms and 3-dimensional motion-capture systems provide an accurate method of quantifying postural stability. Substantial cost, space, time to administer, and need for trained personnel limit widespread use of biomechanical techniques in the assessment of postural stability in clinical or field environments. Objective: To determine whether accelerometer and gyroscope data sampled from a consumer electronics device (iPad2) provide sufficient resolution of center-of-gravity (COG) movements to accurately quantify postural stability in healthy young people. Design: Controlled laboratory study. Setting: Research laboratory in an academic medical center. Patients or Other Participants: A total of 49 healthy individuals (age = 19.5 +/- 3.1 years, height = 167.7 +/- 13.2 cm, mass = 68.5 +/- 17.5 kg). Intervention(s): Participants completed the NeuroCom Sensory Organization Test (SOT) with an iPad2 affixed at the sacral level. Main Outcome Measure(s): Primary outcomes were equilibrium scores from both systems and the time series of the angular displacement of the anteroposterior COG sway during each trial. A Bland-Altman assessment for agreement was used to compare equilibrium scores produced by the NeuroCom and iPad2 devices. Limits of agreement was defined as the mean bias (NeuroCom - iPad) +/- 2 standard deviations. Mean absolute percentage error and median difference between the NeuroCom and iPad2 measurements were used to evaluate how closely the real-time COG sway measured by the 2 systems tracked each other. Results: The limits between the 2 devices ranged from -0.5 degrees to 0.5 degrees in SOT condition 1 to -2.9 degrees to 1.3 degrees in SOT condition 5. The largest absolute value of the measurement error within the 95% confidence intervals for all conditions was 2.9 degrees. The mean absolute percentage error analysis indicated that the iPad2 tracked NeuroCom COG with an average error ranging from 5.87% to 10.42% of the NeuroCom measurement across SOT conditions. Conclusions: The iPad2 hardware provided data of sufficient precision and accuracy to quantify postural stability. Accuracy, portability, and affordability make using the iPad2 a reasonable approach for assessing postural stability in clinical and field environments.	[Alberts, Jay L.; Hirsch, Joshua R.; Koop, Mandy Miller; Schindler, David D.; Kana, Daniel E.; Linder, Susan M.; Campbell, Scott; Thota, Anil K.] Cleveland Clin, Dept Biomed Engn, Cleveland, OH 44195 USA; [Alberts, Jay L.; Thota, Anil K.] Cleveland Clin, Ctr Neurol Restorat, Cleveland, OH 44195 USA; [Alberts, Jay L.; Hirsch, Joshua R.; Schindler, David D.; Linder, Susan M.; Campbell, Scott] Cleveland Clin, Concuss Ctr, Cleveland, OH 44195 USA; [Alberts, Jay L.] L Stokes Cleveland VA Med Ctr, Cleveland Funct Elect Stimulat Ctr, Cleveland, OH USA	Alberts, JL (corresponding author), Cleveland Clin, Concuss Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA.	albertj@ccf.org	Thota, Anil/J-3305-2019	Thota, Anil/0000-0003-0605-2269	Lincy Foundation; Edward F. and Barbara S. Bell Family Endowed Chair	This study was supported by the Lincy Foundation and Edward F. and Barbara S. Bell Family Endowed Chair (Dr Alberts). We thank Patrick Cummings, PTA, ATC, for participating in initial discussions about the clinical utility of this approach and Sarah Ozinga and Emma Phillips for assisting in data collection.	Adlerton Anna-Karin, 2003, Physiother Res Int, V8, P187, DOI 10.1002/pri.289; Alberts JL, 2015, MED SCI SPORT EXER, V47, P2233, DOI 10.1249/MSS.0000000000000656; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Blum L, 2008, PHYS THER, V88, P559, DOI 10.2522/ptj.20070205; Borah Diganta, 2007, Indian J Physiol Pharmacol, V51, P395; Boulgarides LK, 2003, PHYS THER, V83, P328, DOI 10.1093/ptj/83.4.328; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Frzovic D, 2000, ARCH PHYS MED REHAB, V81, P215, DOI 10.1053/apmr.2000.0810215; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hamilton J, 1994, TIME SERIES ANAL, P435; Horak FB, 2006, AGE AGEING, V35, P7, DOI 10.1093/ageing/afl077; Horak FB, 1996, J NEUROPHYSIOL, V75, P2380; Horak FB, 2005, EXP NEUROL, V193, P504, DOI 10.1016/j.expneurol.2004.12.008; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; JANKOVIC J, 1990, NEUROLOGY, V40, P1529, DOI 10.1212/WNL.40.10.1529; Mancini M, 2011, PARKINSONISM RELAT D, V17, P557, DOI 10.1016/j.parkreldis.2011.05.010; Martin CL, 2006, MULT SCLER J, V12, P620, DOI 10.1177/1352458506070658; Martinez-Ramirez A, 2011, J BIOMECH, V44, P2213, DOI 10.1016/j.jbiomech.2011.06.007; Mathie MJ, 2004, J TELEMED TELECARE, V10, P144, DOI 10.1258/135763304323070788; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Melzer I, 2004, AGE AGEING, V33, P602, DOI 10.1093/ageing/afh218; Menz HB, 2003, AGE AGEING, V32, P137, DOI 10.1093/ageing/32.2.137; Morris M, 2000, GAIT POSTURE, V12, P205, DOI 10.1016/S0966-6362(00)00076-X; Morris ME, 2002, J NEUROL NEUROSUR PS, V72, P361, DOI 10.1136/jnnp.72.3.361; Nashner LM., 1993, HDB BALANCE FUNCTION, P280; O'Sullivan M, 2009, AGE AGEING, V38, P308, DOI 10.1093/ageing/afp009; Pardasaney PK, 2012, PHYS THER, V92, P388, DOI 10.2522/ptj.20100398; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; PRINCE F, 1994, GAIT POSTURE, V2, P19, DOI 10.1016/0966-6362(94)90013-2; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Tarantola J, 1997, NEUROSCI LETT, V228, P75, DOI 10.1016/S0304-3940(97)00370-4; Teasdale N, 2001, GAIT POSTURE, V14, P203, DOI 10.1016/S0966-6362(01)00134-5; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Whitney SL, 2011, GAIT POSTURE, V33, P594, DOI 10.1016/j.gaitpost.2011.01.015; Whitney SL, 2006, ARCH PHYS MED REHAB, V87, P402, DOI 10.1016/j.apmr.2005.11.002; Wrisley DM, 2007, ARCH PHYS MED REHAB, V88, P1049, DOI 10.1016/j.apmr.2007.05.003	53	51	52	1	31	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUN	2015	50	6					578	588		10.4085/1062-6050-50.2.01			11	Sport Sciences	Sport Sciences	CW7MK	WOS:000365183100003	25844853	Bronze, Green Published			2021-06-18	
J	Cuthbert, JP; Harrison-Felix, C; Corrigan, JD; Bell, JM; Haarbauer-Krupa, JK; Miller, AC				Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia; Corrigan, John D.; Bell, Jeneita M.; Haarbauer-Krupa, Juliet K.; Miller, A. Cate			Unemployment in the United States After Traumatic Brain Injury for Working-Age Individuals: Prevalence and Associated Factors 2 Years Postinjury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						injury outcomes; prevalence; TBI; traumatic brain injury; unemployment	EMPLOYMENT OUTCOME 2; GALVESTON ORIENTATION; RACIAL-DIFFERENCES; AMNESIA TEST; RETURN; REPRESENTATIVENESS; REHABILITATION; PREDICTORS; DISABILITY; MODERATE	Objective: To estimate the prevalence of unemployment and part-time employment in the United States for working-age individuals completing rehabilitation for a primary diagnosis of traumatic brain injury (TBI) between 2001 and 2010. Design: Secondary data analysis. Setting: Acute inpatient rehabilitation facilities. Participants: Patients aged 16 to 60 years at injury who completed inpatient rehabilitation for TBI between 2001 and 2010. Main Outcome Measures: Unemployment; Part-time employment. Results: The prevalence of unemployment for persons in the selected cohort was 60.4% at 2-year postinjury. Prevalence of unemployment at 2-year postinjury was significantly associated with the majority of categories of age group, race, gender, marital status, primary inpatient rehabilitation payment source, education, preinjury vocational status, length of stay, and Disability Rating Scale. The direction of association for the majority of these variables complement previous research in this area, with only Hispanic ethnicity and the FIM Cognitive subscale demonstrating disparate findings. For those employed at 2-year postinjury, the prevalence of part-time employment was 35.0%. The model of prevalence for part-time employment at 2-year postinjury was less robust, with significant relationships with some categorical components of age group, gender, marital status, primary payment source, preinjury vocational status, and Disability Rating Scale. Conclusions: The prevalence of unemployment for patients completing inpatient rehabilitation for TBI was substantial (60.4%). The majority of factors found to associate with 2 years' unemployment were complementary of previously published research; however, these were often smaller in magnitude than previous reports. The prevalence of part-time employment was also an issue for this cohort and included 35.0% of all employed individuals. In regard to the determination of factors associated with part-time employment, additional analyses that include more fine-grained factors associated with employment, including physical and psychosocial functioning, are recommended.	[Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO 80113 USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Bell, Jeneita M.; Haarbauer-Krupa, Juliet K.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Miller, A. Cate] Natl Inst Disabil & Rehabil Res, Dept Educ, Washington, DC USA	Cuthbert, JP (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	JCuthbert@craighospital.org			Intramural CDC HHS [CC999999] Funding Source: Medline		Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Battaglia M.P., 2000, P 25 ANN SAS US GROU; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Bureau of Labor Statistics, 2016, BLS INF GLOSS; Coronado V. G., 2012, BRAIN INJURY MED, P45; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, TECHNICAL REPORT PRO; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; eRehabData, EREHABDATA; Forslund MV, 2013, J REHABIL MED, V45, P801, DOI 10.2340/16501977-1168; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Fraser R, 2006, J VOCAT REHABIL, V25, P141; Gary KW, 2010, J VOCAT REHABIL, V33, P65, DOI 10.3233/JVR-2010-0516; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JOHNSON RW, 2001, RETIRING TOGETHER WO; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; National Center for Injury Prevention and Control Centers for Disease Control and Prevention, WHAT AR POT EFF TBI; National Center for Injury Prevention and Control Centers for Disease Control and Prevention, 2010, NAT HOSP DISCH SURV; National Institute of Neurological Disorders and Stroke, NINDS TRAUM BRAIN IN; Office of Special Education and Rehabilitative Services Department of Education, 1998, FIN PRIOR, P26030; Office of Special Education and Rehabilitative Services Department of Education, 2013, FIN PRIOR, P27038; Shigaki CL, 2009, DISABIL REHABIL, V31, P484, DOI 10.1080/09638280802240449; The Traumatic Brain Injury Model Systems National Data and Statistical Center, TBI MOD SYST PRES; Tsaousides T, 2009, REHABIL PSYCHOL, V54, P299, DOI 10.1037/a0016807; UDS, 2014, UN DAT SYST MED REH; US Department of Labor Bureau of Labor Statistics, UN RAT LEV; van Velzen JM, 2011, DISABIL REHABIL, V33, P2237, DOI 10.3109/09638288.2011.563821; Viera AJ, 2008, SOUTH MED J, V101, P730, DOI 10.1097/SMJ.0b013e31817a7ee4; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	48	51	51	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2015	30	3					160	174		10.1097/HTR.0000000000000090			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CH8PJ	WOS:000354298100129	25955703	Green Accepted			2021-06-18	
J	Webster, SJ; Van Eldik, LJ; Watterson, DM; Bachstetter, AD				Webster, Scott J.; Van Eldik, Linda J.; Watterson, D. Martin; Bachstetter, Adam D.			Closed Head Injury in an Age-Related Alzheimer Mouse Model Leads to an Altered Neuroinflammatory Response and Persistent Cognitive Impairment	JOURNAL OF NEUROSCIENCE			English	Article						amyloid plaque; astrocytes; cytokines; microglia; neuroinflammation; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; A-BETA DEPOSITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ATTENUATES SYNAPTIC DYSFUNCTION; CYTOKINE UP-REGULATION; GENE-TARGETED MICE; PROINFLAMMATORY CYTOKINE; REACTIVE ASTROCYTES; INDUCED INCREASES	Epidemiological studies have associated increased risk of Alzheimer's disease (AD)-related clinical symptoms with a medical history of head injury. Currently, little is known about pathophysiology mechanisms linked to this association. Persistent neuroinflammation is one outcome observed in patients after a single head injury. Neuroinflammation is also present early in relevant brain regions during AD pathology progression. In addition, previous mechanistic studies in animal models link neuroinflammation as a contributor to neuropathology and cognitive impairment in traumatic brain injury (TBI) or AD-related models. Therefore, we explored the potential interplay of neuroinflammatory responses in TBI and AD by analysis of the temporal neuroinflammatory changes after TBI in an AD model, the APP/PS1 knock-in (KI) mouse. Discrete temporal aspects of astrocyte, cytokine, and chemokine responses in the injured KI mice were delayed compared with the injured wild-type mice, with a peak neuroinflammatory response in the injured KI mice occurring at 7 d after injury. The neuroinflammatory responses were more persistent in the injured KI mice, leading to a chronic neuroinflammation. At late time points after injury, KI mice exhibited a significant impairment in radial arm water maze performance compared with sham KI mice or injured wild-type mice. Intervention with a small-molecule experimental therapeutic (MW151) that selectively attenuates proinflammatory cytokine production yielded improved cognitive behavior outcomes, consistent with a link between neuroinflammatory responses and altered risk for AD-associated pathology changes with head injury.	[Webster, Scott J.; Van Eldik, Linda J.; Bachstetter, Adam D.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Van Eldik, Linda J.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Van Eldik, Linda J.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Watterson, D. Martin] Northwestern Univ, Dept Pharmacol, Chicago, IL 60611 USA	Watterson, DM (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 800 S Limestone, Lexington, KY 40536 USA.	adam.bachstetter@uky.edu		Watterson, Daniel/0000-0001-7605-5866; Bachstetter, Adam/0000-0003-4646-6757	National Institutes of Health/National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K99AG044445]; National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32 NS084605]; Kentucky Spinal Cord and Head Injury Research Trust [12-20A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS084605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K99AG044445] Funding Source: NIH RePORTER	This research was supported in part by National Institutes of Health/National Institute on Aging K99AG044445 to A.D.B., National Institutes of Health/National Institute of Neurological Disorders and Stroke F32 NS084605 to S.J.W., and the Kentucky Spinal Cord and Head Injury Research Trust 12-20A to L.J.V.E. We thank Danielle Goulding and Edgardo Dimayuga for assistance with various aspects of this work.	Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Alamed J, 2006, NAT PROTOC, V1, P1671, DOI 10.1038/nprot.2006.275; Allaman I, 2011, TRENDS NEUROSCI, V34, P76, DOI 10.1016/j.tins.2010.12.001; Bachstetter AD, 2015, J NEUROINFL IN PRESS; Bachstetter AD, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-146; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bachstetter AD, 2012, J NEUROSCI, V32, P10201, DOI 10.1523/JNEUROSCI.1496-12.2012; Berard JL, 2012, GLIA, V60, P1145, DOI 10.1002/glia.22342; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Chiu IM, 2013, CELL REP, V4, P385, DOI 10.1016/j.celrep.2013.06.018; Chrzaszcz M, 2010, J NEUROTRAUM, V27, P1283, DOI 10.1089/neu.2009.1227; Clarke LE, 2013, NAT REV NEUROSCI, V14, P311, DOI 10.1038/nrn3484; Craft JM, 2006, GLIA, V53, P484, DOI 10.1002/glia.20306; Craft JM, 2004, NEUROBIOL AGING, V25, P1283, DOI 10.1016/j.neurobiolaging.2004.01.006; Craft JM, 2004, J MOL NEUROSCI, V24, P115, DOI 10.1385/JMN:24:1:115; Cui W, 2001, GLIA, V34, P272, DOI 10.1002/glia.1061; Daigo K, 2014, IMMUNOL LETT, V161, P38, DOI 10.1016/j.imlet.2014.04.012; Deacon R, 2012, JOVE-J VIS EXP, DOI 10.3791/2607; Deacon RMJ, 2006, NAT PROTOC, V1, P1117, DOI 10.1038/nprot.2006.170; Egashira Y, 2014, STROKE, V45, P2141, DOI 10.1161/STROKEAHA.114.005307; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Flood DG, 2002, NEUROBIOL AGING, V23, P335, DOI 10.1016/S0197-4580(01)00330-X; Furman JL, 2012, J NEUROSCI, V32, P16129, DOI 10.1523/JNEUROSCI.2323-12.2012; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gouras GK, 2010, ACTA NEUROPATHOL, V119, P523, DOI 10.1007/s00401-010-0679-9; Halassa MM, 2010, ANNU REV PHYSIOL, V72, P335, DOI 10.1146/annurev-physiol-021909-135843; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Hu WH, 2007, BIOORG MED CHEM LETT, V17, P414, DOI 10.1016/j.bmcl.2006.10.028; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jenrow KA, 2013, RADIAT RES, V179, P549, DOI 10.1667/RR3026.1; Jin M, 2014, J CEREBR BLOOD F MET, V34, P1306, DOI 10.1038/jcbfm.2014.83; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Karpus WJ, 2008, J NEUROIMMUNOL, V203, P73, DOI 10.1016/j.jneuroim.2008.06.039; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Macauley SL, 2014, J NEUROSCI, V34, P13077, DOI 10.1523/JNEUROSCI.2518-14.2014; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mosher KI, 2014, BIOCHEM PHARMACOL, V88, P594, DOI 10.1016/j.bcp.2014.01.008; Murphy MP, 2007, NEUROBIOL DIS, V27, P301, DOI 10.1016/j.nbd.2007.06.002; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; Obara M, 2008, NEUROCHEM INT, V52, P905, DOI 10.1016/j.neuint.2007.10.015; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rathore KI, 2011, J NEUROSCI, V31, P13412, DOI 10.1523/JNEUROSCI.0116-11.2011; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; Reyes RC, 2012, ASN NEURO, V4, P33, DOI 10.1042/AN20110059; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rodriguez-Grande B, 2014, J CEREBR BLOOD F MET, V34, P480, DOI 10.1038/jcbfm.2013.224; Sama DM, 2013, AGEING RES REV, V12, P982, DOI 10.1016/j.arr.2013.05.008; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Schousboe A, 2004, NEUROCHEM INT, V45, P521, DOI 10.1016/j.neuint.2003.11.001; Schwetye KE, 2010, NEUROBIOL DIS, V40, P555, DOI 10.1016/j.nbd.2010.06.018; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Siman R, 2000, J NEUROSCI, V20, P8717; Simard M, 2004, NEUROSCIENCE, V129, P877, DOI 10.1016/j.neuroscience.2004.09.053; Sofroniew MV, 2014, NEUROSCIENTIST, V20, P160, DOI 10.1177/1073858413504466; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Somera-Molina KC, 2009, BRAIN RES, V1282, P162, DOI 10.1016/j.brainres.2009.05.073; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Ubogu EE, 2006, TRENDS PHARMACOL SCI, V27, P48, DOI 10.1016/j.tips.2005.11.002; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Van Eldik LJ, 2007, INT REV NEUROBIOL, V82, P277, DOI 10.1016/S0074-7742(07)82015-0; Viola A, 2008, ANNU REV PHARMACOL, V48, P171, DOI 10.1146/annurev.pharmtox.48.121806.154841; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Webster SJ, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt182; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wyss-Coray T, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006346; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhang C, 2007, EXP NEUROL, V204, P77, DOI 10.1016/j.expneurol.2006.09.018	90	51	51	0	9	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 22	2015	35	16					6554	6569		10.1523/JNEUROSCI.0291-15.2015			16	Neurosciences	Neurosciences & Neurology	CG6HL	WOS:000353399800027	25904805	Green Published, Bronze			2021-06-18	
J	Chin, LM; Keyser, RE; Dsurney, J; Chan, L				Chin, Lisa M.; Keyser, Randall Eugene; Dsurney, John; Chan, Leighton			Improved Cognitive Performance Following Aerobic Exercise Training in People With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Cognition; Exercise; Neuropsychological tests; Questionnaires; Rehabilitation	DEPRESSION FOLLOWING MILD; OLDER-ADULTS; IMPAIRMENT; QUALITY; MUSCULOSKELETAL; INTERVENTIONS; EPIDEMIOLOGY; INDIVIDUALS; RECOVERY; DISEASE	Objective: To examine cognitive function in individuals with traumatic brain injury (TBI) prior to and after participation in an aerobic exercise training program. Design: Pre-post intervention study. Setting: Medical research center. Participants: Volunteer sample of individuals (N=7) (age, 33.3 +/- 7.9y) with chronic nonpenetrating TBI (injury severity: 3=mild, 4=moderate; time since most current injury: 4.0 +/- 5.5y) who were ambulatory. Intervention: Twelve weeks of supervised vigorous aerobic exercise training performed 3 times a week for 30 minutes on a treadmill. Main Outcome Measures: Cognitive function was assessed using the Trail Making Test Part A (TMT-A), Trail Making Test Part B (TMT-B), and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Sleep quality and depression were measured with the Pittsburgh Sleep Quality Index (PSQI) and Beck Depression Inventory, version 2 (BDI-II). Indices of cardiorespiratory fitness were used to examine the relation between improvements in cognitive function and cardiorespiratory fitness. Results: After training, improvements in cognitive function were observed with greater scores on the TMT-A (10.3 +/- 6.8; P=.007), TMT-B (9.6 +/- 7.0; P=.011), and RBANS total scale (13.3 +/- 9.3; P=.009). No changes were observed in measures of the PSQI and BDI-II. The magnitude of cognitive improvements was also strongly related to the gains in cardiorespiratory fitness. Conclusions: These findings suggest that vigorous aerobic exercise training may improve specific aspects of cognitive function in individuals with TBI and cardiorespiratory fitness gains may be a determinant of these improvements. Archives of Physical Medicine and Rehabilitation 2015;96:754-9 (C) 2015 by the American Congress of Rehabilitation Medicine	[Chin, Lisa M.; Keyser, Randall Eugene] George Mason Univ, Dept Rehabil Sci, Fairfax, VA 22030 USA; [Chin, Lisa M.; Keyser, Randall Eugene; Dsurney, John; Chan, Leighton] NIH, Dept Rehabil Med, Ctr Clin, Bethesda, MD 20892 USA; [Dsurney, John; Chan, Leighton] Ctr Neurosci & Regenerat Med, Bethesda, MD USA	Chin, LM (corresponding author), George Mason Univ, Dept Rehabil Sci, 4400 Univ Dr, Fairfax, VA 22030 USA.	lchin2@gmu.edu	Chin, Lisa MK/O-4706-2014	Chin, Lisa MK/0000-0002-0178-739X	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G192HI-H]; National Institutes of Health Clinical CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Supported by the Center for Neuroscience and Regenerative Medicine (grant no. G192HI-H) and the National Institutes of Health Clinical Center (rehabilitation medicine department intramural funds).	Ahlskog JE, 2011, MAYO CLIN PROC, V86, P876, DOI 10.4065/mcp.2011.0252; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Banks S, 2011, ENCY CLIN NEUROPSYCH, P506; Beck AT., 1996, BECK DEPRESSION INVE, V2; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chin LMK, 2015, J HEAD TRAUMA REHAB, V30, P382, DOI 10.1097/HTR.0000000000000062; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Farina N, 2014, INT PSYCHOGERIATR, V26, P9, DOI 10.1017/S1041610213001385; Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Gates N, 2013, AM J GERIAT PSYCHIAT, V21, P1086, DOI 10.1016/j.jagp.2013.02.018; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Heaton RK, 2004, REVISED COMPREHENSIV; Hindin SB, 2012, J AM GERIATR SOC, V60, P136, DOI 10.1111/j.1532-5415.2011.03761.x; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Hootman JM, 2002, MED SCI SPORT EXER, V34, P838, DOI 10.1097/00005768-200205000-00017; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Kluding PM, 2011, J NEUROL PHYS THER, V35, P11, DOI 10.1097/NPT.0b013e318208ee6c; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McDonnell MN, 2011, ARCH PHYS MED REHAB, V92, P1044, DOI 10.1016/j.apmr.2011.01.021; McMillan T, 2002, NEUROPSYCHOL REHABIL, V12, P117, DOI 10.1080/09602010143000202; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Reitan RM, 1993, TUCSON NEUROPSYCHOLO; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Stuchlik A, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00106; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; Voss MW, 2013, HUM BRAIN MAPP, V34, P2972, DOI 10.1002/hbm.22119; WENGER HA, 1986, SPORTS MED, V3, P346, DOI 10.2165/00007256-198603050-00004; Wu A, 2013, NEUROSCIENCE, V248, P655, DOI 10.1016/j.neuroscience.2013.06.041	42	51	53	0	41	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2015	96	4					754	759		10.1016/j.apmr.2014.11.009			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CE9RC	WOS:000352180100025	25433219	Green Accepted			2021-06-18	
J	Katz, PS; Sulzer, JK; Impastato, RA; Teng, SX; Rogers, EK; Molina, PE				Katz, Paige S.; Sulzer, Jesse K.; Impastato, Renata A.; Teng, Sophie X.; Rogers, Emily K.; Molina, Patricia E.			Endocannabinoid Degradation Inhibition Improves Neurobehavioral Function, Blood-Brain Barrier Integrity, and Neuroinflammation following Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						TBI; neuroinflammation; endocannabinoids; AEA; 2-AG	CLOSED-HEAD INJURY; FLUID-PERCUSSION MODEL; THERAPEUTIC IMPLICATIONS; CLINICAL-TRIAL; MOUSE MODEL; RAT MODEL; NEUROPROTECTION; CANNABINOIDS; CYCLOOXYGENASE-2; PATHOPHYSIOLOGY	Traumatic brain injury (TBI) is an increasingly frequent and poorly understood condition lacking effective therapeutic strategies. Inflammation and oxidative stress (OS) are critical components of injury, and targeted interventions to reduce their contribution to injury should improve neurobehavioral recovery and outcomes. Recent evidence reveals potential protective, yet short-lived, effects of the endocannabinoids (ECs), 2-arachidonoyl glycerol (2-AG) and N-arachidonoyl-ethanolamine (AEA), on neuroinflammatory and OS processes after TBI. The aim of this study was to determine whether EC degradation inhibition after TBI would improve neurobehavioral recovery by reducing inflammatory and oxidative damage. Adult male Sprague-Dawley rats underwent a 5-mm left lateral craniotomy, and TBI was induced by lateral fluid percussion. TBI produced apnea (17 +/- 5 sec) and a delayed righting reflex (479 +/- 21 sec). Thirty minutes post-TBI, rats were randomized to receive intraperitoneal injections of vehicle (alcohol, emulphor, and saline; 1:1:18) or a selective inhibitor of 2-AG (JZL184, 16 mg/kg) or AEA (URB597, 0.3 mg/kg) degradation. At 24 h post-TBI, animals showed significant neurological and -behavioral impairment as well as disruption of blood-brain barrier (BBB) integrity. Improved neurological and -behavioral function was observed in JZL184-treated animals. BBB integrity was protected in both JZL184- and URB597-treated animals. No significant differences in ipsilateral cortex messenger RNA expression of interleukin (IL)-1 beta, IL-6, chemokine (C-C motif) ligand 2, tumor necrosis factor alpha, cyclooxygenase 2 (COX2), or nicotinamide adenine dinucleotide phosphate oxidase (NOX2) and protein expression of COX2 or NOX2 were observed across experimental groups. Astrocyte and microglia activation was significantly increased post-TBI, and treatment with JZL184 or URB597 blocked activation of both cell types. These findings suggest that EC degradation inhibition post-TBI exerts neuroprotective effects. Whether repeated dosing would achieve greater protection remains to be examined.	[Katz, Paige S.; Sulzer, Jesse K.; Impastato, Renata A.; Teng, Sophie X.; Rogers, Emily K.; Molina, Patricia E.] Louisiana State Univ, Hlth Sci Ctr, Alcohol & Drug Abuse Ctr Excellence, Dept Physiol, New Orleans, LA 70112 USA	Molina, PE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Alcohol & Drug Abuse Ctr Excellence, Dept Physiol, 1901 Perdido St,Room 7205, New Orleans, LA 70112 USA.	pmolin@lsuhsc.edu	Molina, Patricia E./AAK-9814-2021	Molina, Patricia E./0000-0002-3598-384X	Department of DefenseUnited States Department of Defense [DOD-W81XWH-11-2-0011]; National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [NIAAA-007577, NIAAA-19587]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [F30AA019587, T32AA007577] Funding Source: NIH RePORTER	The authors thank Drs. Nicole LeCapitaine and Robert Siggins for their scientific guidance, Jane Schexnayder for her technical assistance, as well as Rebecca Gonzales for her editorial support. This work was supported by the Department of Defense (DOD-W81XWH-11-2-0011) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA-007577 and NIAAA-19587).	Biegon A, 2004, CURR PHARM DESIGN, V10, P2177, DOI 10.2174/1381612043384196; Boyko M, 2011, BEHAV BRAIN RES, V223, P17, DOI 10.1016/j.bbr.2011.03.019; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Correa F, 2005, MINI-REV MED CHEM, V5, P671, DOI 10.2174/1389557054368790; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Downer EJ, 2011, THESCIENTIFICWORLDJO, V11, P855, DOI 10.1100/tsw.2011.84; Dubois RN, 1998, FASEB J, V12, P1063; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Euser AG, 2008, EXP PHYSIOL, V93, P254, DOI 10.1113/expphysiol.2007.039966; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hwang J, 2010, LIFE SCI, V86, P615, DOI 10.1016/j.lfs.2009.06.003; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; Kozak KR, 2004, CURR PHARM DESIGN, V10, P659, DOI 10.2174/1381612043453081; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Ling G.S, 2004, CURR PROTOC NEUROSCI, V2; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Mackie K, 2006, AAPS J, V8, pE298, DOI 10.1007/BF02854900; Mauler F, 2003, CNS DRUG REV, V9, P343; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Nagayama T, 1999, J NEUROSCI, V19, P2987; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pitkanen A., 2005, DRUG DISCOV TODAY DI, V2, P409, DOI DOI 10.1016/J.DDMEC.2005.11.011; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; Savinainen JR, 2001, BRIT J PHARMACOL, V134, P664, DOI 10.1038/sj.bjp.0704297; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Stella N, 2009, NEUROPHARMACOLOGY, V56, P244, DOI 10.1016/j.neuropharm.2008.07.037; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Teng SX, 2014, J NEUROTRAUM, V31, P378, DOI 10.1089/neu.2013.3093; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wang ZY, 2013, FREE RADICAL BIO MED, V65, P942, DOI 10.1016/j.freeradbiomed.2013.08.166; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weiss JM, 1998, J IMMUNOL, V161, P6896; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545; Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181	63	51	51	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2015	32	5					297	306		10.1089/neu.2014.3508			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CC0SD	WOS:000350045700002	25166905	Green Published			2021-06-18	
J	Robinson, ME; Lindemer, ER; Fonda, JR; Milberg, WP; McGlinchey, RE; Salat, DH				Robinson, Meghan E.; Lindemer, Emily R.; Fonda, Jennifer R.; Milberg, William P.; McGlinchey, Regina E.; Salat, David H.			Close-Range Blast Exposure is Associated With Altered Functional Connectivity in Veterans Independent of Concussion Symptoms at Time of Exposure	HUMAN BRAIN MAPPING			English	Article						fMRI; Veterans; blast injuries; traumatic brain injury; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; INDUCED NEUROTRAUMA; MILITARY PERSONNEL; MOTOR CORTEX; IMPACT; AFGHANISTAN; NETWORKS; PAIN; IRAQ	Although there is emerging data on the effects of blast-related concussion (or mTBI) on cognition, the effects of blast exposure itself on the brain have only recently been explored. Toward this end, we examine functional connectivity to the posterior cingulate cortex, a primary region within the default mode network (DMN), in a cohort of 134 Iraq and Afghanistan Veterans characterized for a range of common military-associated comorbidities. Exposure to a blast at close range (<10 meters) was associated with decreased connectivity of bilateral primary somatosensory and motor cortices, and these changes were not different from those seen in participants with blast-related mTBI. These results remained significant when clinical factors such as sleep quality, chronic pain, or post traumatic stress disorder were included in the statistical model. In contrast, differences in functional connectivity based on concussion history and blast exposures at greater distances were not apparent. Despite the limitations of a study of this nature (e.g., assessments long removed from injury, self-reported blast history), these data demonstrate that blast exposure per se, which is prevalent among those who served in Iraq and Afghanistan, may be an important consideration in Veterans' health. It further offers a clinical guideline for determining which blasts (namely, those within 10 meters) are likely to lead to long-term health concerns and may be more accurate than using concussion symptoms alone. Hum Brain Mapp 36:911-922, 2015.Published 2014. This article is a U.S. Government work and is in the public domain in the USA.	[Robinson, Meghan E.; Lindemer, Emily R.; Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr NeRVe, Boston, MA 02130 USA; [Robinson, Meghan E.; Lindemer, Emily R.; Fonda, Jennifer R.; Milberg, William P.; McGlinchey, Regina E.; Salat, David H.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA 02130 USA; [Milberg, William P.; McGlinchey, Regina E.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, GRECC, Boston, MA 02130 USA; [Salat, David H.] AA Martinos Ctr Biomed Imaging, Charlestown, MA USA	Robinson, ME (corresponding author), VA Boston Healthcare Syst, TRACTS 182, 150 S Huntington Ave, Boston, MA 02130 USA.	meghan.robinson@va.gov	McGlinchey, Regina E/R-1971-2016		Translational Research Center for TBI and Stress Disorders (TRACTS) VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B9254-C]	Contract grant sponsor: Translational Research Center for TBI and Stress Disorders (TRACTS) VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence; Contract grant number: B9254-C (R.E.M. and W.P.M).	Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Blake D, 2006, J TRAUMA STRESS, V8, P75; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chai XQJ, 2012, NEUROIMAGE, V59, P1420, DOI 10.1016/j.neuroimage.2011.08.048; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Defense, 2012, DEM PROF MIL COMM; First M.B., 1996, STRUCTURED CLIN INTE; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holdnack H, 2001, WECHSLER TEST ADULT; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Keller CJ, 2013, J NEUROSCI, V33, P6333, DOI 10.1523/JNEUROSCI.4837-12.2013; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Lee MH, 2013, AM J NEURORADIOL, V34, P1866, DOI 10.3174/ajnr.A3263; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; RAND, 2008, INVISIBLE WOUNDS WAR; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shehzad Z, 2009, CEREB CORTEX, V19, P2209, DOI 10.1093/cercor/bhn256; Sripada RK, 2012, PSYCHOSOM MED, V74, P904, DOI 10.1097/PSY.0b013e318273bf33; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4	53	51	51	1	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAR	2015	36	3					911	922		10.1002/hbm.22675			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CB4QI	WOS:000349612500008	25366378	Green Published			2021-06-18	
J	Defrin, R; Riabinin, M; Feingold, Y; Schreiber, S; Pick, CG				Defrin, Ruth; Riabinin, Miri; Feingold, Yelena; Schreiber, Shaul; Pick, Chaim G.			Deficient Pain Modulatory Systems in Patients with Mild Traumatic Brain and Chronic Post-Traumatic Headache: Implications for its Mechanism	JOURNAL OF NEUROTRAUMA			English	Article						post-traumatic headache; brain injury; pain modulation; pain adaptation	NOXIOUS INHIBITORY CONTROLS; STRESS-DISORDER SYMPTOMS; TENSION-TYPE HEADACHE; PRESSURE PAIN; REDUCED HABITUATION; TEMPORAL SUMMATION; SPATIAL SUMMATION; MIGRAINE PATIENTS; US SOLDIERS; INJURY	Although the prevalence rate of chronic post-traumatic headache (CPTHA) after mild traumatic brain injury (TBI) reaches up to 95%, its mechanism is unknown, and little is known about the characteristics of the pain system in this condition. Our aim was to investigate the capabilities of two pain modulatory systems among individuals with CPTHA and study their association with CPTHA, here for the first time. Forty-six subjects participated; 16 with TBI and CPTHA, 12 with TBI without CPTHA, and 18 healthy controls. Testing included the measurement of heat-pain (HPT) and pressure-pain (PPT) thresholds in the forehead and forearm, pain adaptation to tonic noxious heat, and conditioned pain modulation (CPM).The participants completed a post-traumatic stress disorder (PTSD) questionnaire. The two TBI groups did not differ in the TBI and background characteristics. However, TBI patients with CPTHA had significantly higher HPT and lower PPT in the cranium and higher PTSD symptomatology than TBI patients without CPTHA and healthy controls. Adaptation to pain and CPM were diminished in the CPTHA group compared with the two control groups. The intensity of CPTHA correlated negatively with cranial PPT, magnitude of pain adaptation, and CPM. CPTHA intensity correlated positively with PTSD symptomatology. CPTHA appears to be characterized by cranial hyperalgesia and dysfunctional pain modulation capabilities, which are associated with CPTHA magnitude. It is concluded that damage to pain modulatory systems along with chronic cranial sensitization underlies the development of CPTHA. PTSD may reinforce CPTHA and vice versa. Clinical implications are discussed.	[Defrin, Ruth] Tel Aviv Univ, Sackler Fac Med, Dept Phys Therapy, IL-69978 Tel Aviv, Israel; [Riabinin, Miri; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Riabinin, Miri; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Feingold, Yelena] Chaim Sheba Med Ctr, Dept Neurol, IL-52621 Tel Hashomer, Israel; [Schreiber, Shaul] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-69978 Tel Aviv, Israel; [Schreiber, Shaul] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Defrin, R (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Phys Therapy, IL-69978 Tel Aviv, Israel.	rutidef@post.tau.ac.il	Schreiber, Shaul/E-5821-2010	Schreiber, Shaul/0000-0002-2189-0693	National Association of Insurance Companies [1644063]	The authors thank Yuval Levitan, from the Department of Head Injury at Sheba Medical Center for his help in recruitment, and Hila Gruener for her help in data collection. This work was supported by a grant from the National Association of Insurance Companies (grant number 1644063).	Ashina M, 2000, CEPHALALGIA, V20, P919, DOI 10.1046/j.1468-2982.2000.00150.x; Asmundson GJG, 2009, DEPRESS ANXIETY, V26, P888, DOI 10.1002/da.20600; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bartsch T, 2002, BRAIN, V125, P1496, DOI 10.1093/brain/awf166; BASBAUM AI, 1976, P NATL ACAD SCI USA, V73, P4685, DOI 10.1073/pnas.73.12.4685; Basbaum AI, 2000, PRINCIPLES NEURAL SC; Bendtsen L, 2000, CEPHALALGIA, V20, P486, DOI 10.1046/j.1468-2982.2000.00070.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bezov D, 2011, HEADACHE, V51, P262, DOI 10.1111/j.1526-4610.2010.01768.x; BOUHASSIRA D, 1992, BRAIN RES, V595, P353, DOI 10.1016/0006-8993(92)91071-L; Bowsher D, 1999, Am J Hosp Palliat Care, V16, P593, DOI 10.1177/104990919901600408; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Buchgreitz L, 2006, PAIN, V123, P19, DOI 10.1016/j.pain.2006.01.040; Budai D, 1998, J NEUROPHYSIOL, V79, P677; Burstein R, 2000, ANN NEUROL, V47, P614, DOI 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N; Campbell CM, 2008, J PAIN, V9, P759, DOI 10.1016/j.jpain.2008.03.010; Cathcart S, 2010, HEADACHE, V50, P403, DOI 10.1111/j.1526-4610.2009.01545.x; de Tommaso M, 2003, PAIN, V104, P111, DOI 10.1016/S0304-3959(02)00485-2; de Tommaso Marina, 2005, J Headache Pain, V6, P195; de Tommaso M, 2012, CNS NEUROL DISORD-DR, V11, P110, DOI 10.2174/187152712800269759; Defrin R, 2003, PAIN, V106, P471, DOI 10.1016/j.pain.2003.09.010; Defrin R, 2001, PAIN, V89, P253, DOI 10.1016/S0304-3959(00)00369-9; Defrin R, 2008, PAIN, V138, P450, DOI 10.1016/j.pain.2008.05.006; Defrin R, 2010, PAIN, V151, P489, DOI 10.1016/j.pain.2010.08.009; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; Drummond PD, 2011, HEADACHE, V51, P375, DOI 10.1111/j.1526-4610.2010.01779.x; Edwards RR, 2003, PAIN, V101, P155, DOI 10.1016/S0304-3959(02)00324-X; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Fernandez-De-Las-Penas C, 2007, CEPHALALGIA, V27, P383, DOI 10.1111/j.1468-2982.2007.01295.x; Fernandez-de-las-Penas C, 2009, CEPHALALGIA, V29, P670, DOI 10.1111/j.1468-2982.2008.01831.x; Finnerup NB, 2012, CURR PAIN HEADACHE R, V16, P207, DOI 10.1007/s11916-012-0259-x; Finnerup NB, 2003, BRAIN, V126, P57, DOI 10.1093/brain/awg007; Headache classification Subcommettee of the international headache society, 2004, INT CLASS HEAD DIS; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; Jenewein J, 2009, J TRAUMA STRESS, V22, P540, DOI 10.1002/jts.20453; JENSEN R, 1993, PAIN, V52, P193, DOI 10.1016/0304-3959(93)90131-8; Kasch H, 2001, CEPHALALGIA, V21, P189, DOI 10.1046/j.1468-2982.2001.00179.x; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kjeldgaard D, 2014, CEPHALALGIA, V34, P191, DOI 10.1177/0333102413505236; Kumar B, 2009, ANESTH ANALG, V108, P1645, DOI 10.1213/ane.0b013e31819d644c; Le Bars D, 2002, BRAIN RES REV, V40, P29, DOI 10.1016/S0165-0173(02)00186-8; Leonard G, 2009, PAIN, V147, P217, DOI 10.1016/j.pain.2009.09.009; Lev R, 2010, CEPHALALGIA, V30, P910, DOI 10.1177/0333102409357249; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Mainero C, 2011, ANN NEUROL, V70, P838, DOI 10.1002/ana.22537; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Nahman-Averbuch H, 2013, HEADACHE, V53, P1104, DOI 10.1111/head.12117; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Normand E, 2011, J CLIN PSYCHIAT, V72, P219, DOI 10.4088/JCP.08m04969blu; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; PACKARD RC, 1993, HEADACHE, V33, P133, DOI 10.1111/j.1526-4610.1993.hed3303133.x; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Perrotta A, 2008, CEPHALALGIA, V28, P950, DOI 10.1111/j.1468-2982.2008.01631.x; Perrotta A, 2010, CEPHALALGIA, V30, P272, DOI 10.1111/j.1468-2982.2009.01914.x; Pielsticker A, 2005, PAIN, V118, P215, DOI 10.1016/j.pain.2005.08.019; Restuccia D, 2014, CEPHALALGIA, V34, P201, DOI 10.1177/0333102413508241; Romesser J, 2012, J REHABIL RES DEV, V49, P1127, DOI 10.1682/JRRD.2010.12.0238; Rosenthal JF, 2013, HEADACHE, V53, P1564, DOI 10.1111/head.12200; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Sandrini G, 2006, CEPHALALGIA, V26, P782, DOI 10.1111/j.1468-2982.2006.01130.x; Sandrini G, 2002, NEUROSCI LETT, V317, P135, DOI 10.1016/S0304-3940(01)02447-8; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; Scott D, 2005, CLIN J PAIN, V21, P175, DOI 10.1097/00002508-200503000-00009; Siddall PJ, 2001, SPINAL CORD, V39, P63, DOI 10.1038/sj.sc.3101116; SOLOMON Z, 1993, ISRAEL J PSYCHIAT, V30, P110; Staud R, 2003, PAIN, V101, P167, DOI 10.1016/S0304-3959(02)00325-1; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Theeler BJ, 2012, CURR TREAT OPTION NE, V14, P36, DOI 10.1007/s11940-011-0157-2; Ullrich PM, 2013, ARCH PHYS MED REHAB, V94, P80, DOI 10.1016/j.apmr.2012.07.018; Valeriani M, 2003, PAIN, V105, P57, DOI 10.1016/S0304-3959(03)00137-4; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Wasner G, 2008, BRAIN, V131, P2387, DOI 10.1093/brain/awn169; Weissman-Fogel I, 2003, PAIN, V104, P693, DOI 10.1016/S0304-3959(03)00159-3; Weissman-Fogel I, 2008, EXP BRAIN RES, V186, P79, DOI 10.1007/s00221-007-1206-7; Yarnitsky D, 2008, PAIN, V138, P22, DOI 10.1016/j.pain.2007.10.033; Zeilig G, 2012, BRAIN, V135, P418, DOI 10.1093/brain/awr270	84	51	51	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2015	32	1					28	37		10.1089/neu.2014.3359			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AX4JX	WOS:000346900100005	25068510	Green Published			2021-06-18	
J	Jalloh, I; Carpenter, KLH; Grice, P; Howe, DJ; Mason, A; Gallagher, CN; Helmy, A; Murphy, MP; Menon, DK; Carpenter, TA; Pickard, JD; Hutchinson, PJ				Jalloh, Ibrahim; Carpenter, Keri L. H.; Grice, Peter; Howe, Duncan J.; Mason, Andrew; Gallagher, Clare N.; Helmy, Adel; Murphy, Michael P.; Menon, David K.; Carpenter, T. Adrian; Pickard, John D.; Hutchinson, Peter J.			Glycolysis and the pentose phosphate pathway after human traumatic brain injury: microdialysis studies using 1,2-C-13(2) glucose	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						C-13-labeling; glycolysis; lactate; pentose phosphate pathway; traumatic brain injury (human)	POSITRON-EMISSION-TOMOGRAPHY; TRICARBOXYLIC-ACID CYCLE; C-13-LABELED MICRODIALYSIS; OXIDATIVE STRESS; LACTATE; METABOLISM; FLUX; C-13; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; GLUTATHIONE	Increased 'anaerobic' glucose metabolism is observed after traumatic brain injury (TBI) attributed to increased glycolysis. An alternative route is the pentose phosphate pathway (PPP), which generates putatively protective and reparative molecules. To compare pathways we employed microdialysis to perfuse 1,2-C-13(2) glucose into the brains of 15 TBI patients and macroscopically normal brain in six patients undergoing surgery for benign tumors, and to simultaneously collect products for nuclear magnetic resonance (NMR) analysis. C-13 enrichment for glycolytic 2,3-C-13(2) lactate was the median 5.4% (interquartile range (IQR) 4.6-7.5%) in TBI brain and 4.2% (2.4-4.4%) in 'normal' brain (P < 0.01). The ratio of PPP-derived 3-C-13 lactate to glycolytic 2,3-C-13(2) lactate was median 4.9% (3.6-8.2%) in TBI brain and 6.7% (6.3-8.9%) in 'normal' brain. An inverse relationship was seen for PPP-glycolytic lactate ratio versus PbtO2 (r = -0.5, P = 0.04) in TBI brain. Thus, glycolytic lactate production was significantly greater in TBI than 'normal' brain. Several TBI patients exhibited PPP-lactate elevation above the 'normal' range. There was proportionally greater PPP-derived lactate production with decreasing PbtO2. The study raises questions about the roles of the PPP and glycolysis after TBI, and whether they can be manipulated to achieve a better outcome. This study is the first direct comparison of glycolysis and PPP in human brain.	[Jalloh, Ibrahim; Carpenter, Keri L. H.; Gallagher, Clare N.; Helmy, Adel; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 0QQ, England; [Carpenter, Keri L. H.; Menon, David K.; Carpenter, T. Adrian; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge CB2 0QQ, England; [Grice, Peter; Howe, Duncan J.; Mason, Andrew] Univ Cambridge, Dept Chem, Cambridge CB2 0QQ, England; [Gallagher, Clare N.] Univ Calgary, Dept Clin Neurosci, Div Neurosurg, Calgary, AB, Canada; [Murphy, Michael P.] MRC Mitochondrial Biol Unit, Cambridge, England; [Menon, David K.] Univ Cambridge, Dept Med, Div Anaesthesia, Cambridge CB2 0QQ, England	Jalloh, I (corresponding author), Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Box 167 Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	ij232@cam.ac.uk	Helmy, Adel/AAS-3084-2020; Murphy, Michael/C-2120-2009	Helmy, Adel/0000-0002-0531-0556; Hutchinson, Peter/0000-0002-2796-1835; Grice, Peter/0000-0003-4658-4534; Carpenter, Keri/0000-0001-8236-7727; Murphy, Michael/0000-0003-1115-9618	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986 ID79068, G1002277 ID98489, G1002277 ID 98489]; National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); Medical Research Council/Royal College of Surgeons of EnglandUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802251]; Raymond and Beverly Sackler Fellowship; National Institute for Health ResearchNational Institute for Health Research (NIHR); National Institute for Health Research, Academy of Medical Sciences/Health Foundation; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277, G0001354, G9439390, G0802251, G1000183B, MC_U105663142, G0600986, G0001354B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327, NF-SI-0512-10090, NIHR-RP-R3-12-013, ACF-2006-14-004] Funding Source: researchfish	Medical Research Council (Grant Nos. G0600986 ID79068 and G1002277 ID98489) and the National Institute for Health Research Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme). I.J. was supported by the Medical Research Council ( Grant no. G1002277 ID 98489) and the National Institute for Health Research Biomedical Research Centre, Cambridge; K.L.H.C. was supported by the National Institute for Health Research Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme); C.G. was supported by the the Canadian Institute of Health Research; A.H.-Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship (Grant no. G0802251) and Raymond and Beverly Sackler Fellowship; D.K.M. and J.D.P. were supported by the National Institute for Health Research Senior Investigator Awards; P.J.H. was supported by the National Institute for Health Research Professorship, Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship.	Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bartnik BL, 2007, J NEUROTRAUM, V24, P181, DOI 10.1089/neu.2006.0038; BenYoseph O, 1996, J NEUROCHEM, V66, P2329; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Brekke EMF, 2014, J CEREBR BLOOD F MET, V34, P724, DOI 10.1038/jcbfm.2014.8; Brekke EMF, 2012, J CEREBR BLOOD F MET, V32, P1788, DOI 10.1038/jcbfm.2012.85; Carpenter KLH, 2014, EUR J PHARM SCI, V57, P87, DOI 10.1016/j.ejps.2013.12.012; Cruz F, 1999, NMR BIOMED, V12, P451, DOI 10.1002/(SICI)1099-1492(199911)12:7<451::AID-NBM571>3.3.CO;2-5; DOMANSKAJANIK K, 1988, RESUSCITATION, V16, P79, DOI 10.1016/0300-9572(88)90073-1; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Herrero-Mendez A, 2009, NAT CELL BIOL, V11, P747, DOI 10.1038/ncb1881; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Puskas F, 2000, FASEB J, V14, P1352, DOI 10.1096/fj.14.10.1352; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Riganti C, 2012, FREE RADICAL BIO MED, V53, P421, DOI 10.1016/j.freeradbiomed.2012.05.006; ROSDAHL H, 1993, J PHYSIOL-LONDON, V471, P637, DOI 10.1113/jphysiol.1993.sp019920; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Talukdar I, 2005, J BIOL CHEM, V280, P40660, DOI 10.1074/jbc.M505531200; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tyson RL, 2000, NEUROREPORT, V11, P1845, DOI 10.1097/00001756-200006260-00009; Tyson RL, 2003, BRAIN RES, V992, P43, DOI 10.1016/j.brainres.2003.08.027; Ulrich EL, 2008, NUCLEIC ACIDS RES, V36, pD402, DOI 10.1093/nar/gkm957; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wishart DS, 2007, NUCLEIC ACIDS RES, V35, pD521, DOI 10.1093/nar/gkl923; Wu HM, 2013, J NEUROTRAUM, V30, P352, DOI 10.1089/neu.2012.2610; Zuurbier CJ, 2004, CARDIOVASC RES, V62, P145, DOI 10.1016/j.cardiores.2004.01.010	34	51	51	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2015	35	1					111	120		10.1038/jcbfm.2014.177			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AY2AZ	WOS:000347392200014	25335801	Green Accepted, Green Published, Other Gold			2021-06-18	
J	Miller, RS; Weaver, LK; Bahraini, N; Churchill, S; Price, RC; Skiba, V; Caviness, J; Mooney, S; Hetzell, B; Liu, J; Deru, K; Ricciardi, R; Fracisco, S; Close, NC; Surrett, GW; Bartos, C; Ryan, M; Brenner, LA				Miller, R. Scott; Weaver, Lindell K.; Bahraini, Nazanin; Churchill, Susan; Price, Robert C.; Skiba, Virginia; Caviness, James; Mooney, Scott; Hetzell, Brian; Liu, Jun; Deru, Kayla; Ricciardi, Richard; Fracisco, Susan; Close, Nicole C.; Surrett, Gerald W.; Bartos, Corinna; Ryan, Margaret; Brenner, Lisa A.		HOPPS Trial Team	Effects of Hyperbaric Oxygen on Symptoms and Quality of Life Among Service Members With Persistent Postconcussion Symptoms A Randomized Clinical Trial	JAMA INTERNAL MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYNDROME; MILD TBI; MILITARY; COMPLAINTS; BLAST; RELIABILITY; VALIDITY; DESIGN	IMPORTANCE Improvement has been anecdotally observed in patients with persistent postconcussion symptoms (PCS) after mild traumatic brain injury following treatment with hyperbaric oxygen (HBO). The effectiveness of HBO as an adjunctive treatment for PCS is unknown to date. OBJECTIVES To compare the safety of and to estimate the efficacy for symptomatic outcomes from standard PCS care alone, care supplemented with HBO, or a sham procedure. DESIGN, SETTING, AND PARTICIPANTS Multicenter, double-blind, sham-controlled clinical trial of 72 military service members with ongoing symptoms at least 4 months after mild traumatic brain injury enrolled at military hospitals in Colorado, North Carolina, California, and Georgia between April 26, 2011, and August 24, 2012. Assessments occurred before randomization, at the midpoint, and within 1 month after completing the interventions. INTERVENTIONS Routine PCS care was provided in specialized clinics. In addition, participants were randomized 1: 1: 1 to 40 HBO sessions administered at 1.5 atmospheres absolute (ATA), 40 sham sessions consisting of room air at 1.2 ATA, or no supplemental chamber procedures. MAIN OUTCOMES AND MEASURES The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) served as the primary outcome measure. A change score of at least 2 points on the RPQ-3 subscale (range, 0-12) was defined as clinically significant. Change scores from baseline were calculated for the RPQ-3 and for the total RPQ. Secondary measures included additional patient-reported outcomes and automated neuropsychometric testing. RESULTS On average, participants had sustained 3 lifetime mild traumatic brain injuries; the most recent occurred 23 months before enrollment. No differences were observed between groups for improvement of at least 2 points on the RPQ-3 subscale (25% in the no intervention group, 52% in the HBO group, and 33% in the sham group; P=.24). Compared with the no intervention group (mean change score, 0.5; 95% CI, -4.8 to 5.8; P=.91), both groups undergoing supplemental chamber procedures showed improvement in symptoms on the RPQ (mean change score, 5.4; 95% CI, -0.5 to 11.3; P=.008 in the HBO group and 7.0; 95% CI, 1.0-12.9; P=.02 in the sham group). No difference between the HBO group and the sham group was observed (P=.70). Chamber sessions were well tolerated. CONCLUSIONS AND RELEVANCE Among service members with persistent PCS, HBO showed no benefits over sham compressions. Both intervention groups demonstrated improved outcomes compared with PCS care alone. This finding suggests that the observed improvements were not oxygen mediated but may reflect nonspecific improvements related to placebo effects.	[Miller, R. Scott; Fracisco, Susan] US Army Med Mat Dev Act, Ft Detrick, MD USA; [Weaver, Lindell K.] Univ Utah, Sch Med, Dept Med, Salt Lake City, UT USA; [Weaver, Lindell K.; Churchill, Susan; Deru, Kayla] LDS Hosp, Dept Hyperbar Med, Salt Lake City, UT USA; [Bahraini, Nazanin; Brenner, Lisa A.] Univ Colorado, Aurora, CO USA; [Bahraini, Nazanin; Brenner, Lisa A.] Mental Illness Res Educ & Clin Ctr, Vet Integrated Serv Network 19, Denver, CO USA; [Price, Robert C.; Surrett, Gerald W.] Evans Army Community Hosp, Ft Carson, CO USA; [Skiba, Virginia; Bartos, Corinna] Naval Hosp Camp Lejeune, Camp Lejeune, NC USA; [Caviness, James; Ryan, Margaret] Naval Hosp Camp Pendleton, Camp Pendleton, CA USA; [Mooney, Scott] Eisenhower Army Med Ctr, Ft Gordon, GA USA; [Hetzell, Brian; Liu, Jun] Pharmaceut Prod Dev LLC, Wilmington, NC USA; [Ricciardi, Richard] Def Ctr Excellence Psychol Hlth & Traumat Brain I, Silver Spring, MD USA; [Close, Nicole C.] EmpiriStat Inc, Mt Airy, MD USA	Miller, RS (corresponding author), Uniformed Serv Univ Hlth Sci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	robert.s.miller@us.army.mil	Brenner, Lisa A./AAG-2442-2019		Defense Health Program	The HOPPS trial was funded by the Defense Health Program and was managed by the US Army Medical Materiel Development Activity. The Naval Health Research Center and Army Contracting Command contracted support throughout this trial.	Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Boussi-Gross R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079995; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; Cifu DX, 2014, J HEAD TRAUMA REHAB, V29, P11, DOI 10.1097/HTR.0b013e3182a6aaf0; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; de Craen AJM, 2000, J NEUROL, V247, P183, DOI 10.1007/s004150050560; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Harch PG, 2013, UNDERSEA HYPERBAR M, V40, P469; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Harch Paul G, 2009, Cases J, V2, P6538, DOI 10.4076/1757-1626-2-6538; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Kong J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067485; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lange RT, 2012, ARCH CLIN NEUROPSYCH, V27, P480, DOI 10.1093/arclin/acs059; Linde K, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-75; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Moore DF, 2010, NEUROREHABILITATION, V26, P179, DOI 10.3233/NRE-2010-0553; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Reeves D, 1993, AUTOMATED NEUROPSYCH; Reynolds SK, 2006, SUICIDE LIFE-THREAT, V36, P19, DOI 10.1521/suli.2006.36.1.19; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836; Walker WC, 2014, NEUROREHAB NEURAL RE, V28, P420, DOI 10.1177/1545968313516869; Warriner RA, 2008, HYPERBARIC OXYGEN TH; Weaver LK, 2013, UNDERSEA HYPERBAR M, V40, P439; Weaver LK, 2012, UNDERSEA HYPERBAR M, V39, P801; Weaver LK, 2012, UNDERSEA HYPERBAR M, V39, P807; Weaver LK, 2009, J APPL PHYSIOL, V107, P336, DOI 10.1152/japplphysiol.91012.2008; Wolf G, 2012, J NEUROTRAUM, V29, P2606, DOI 10.1089/neu.2012.2549; Wright JK, 2009, UNDERSEA HYPERBAR M, V36, P391	38	51	53	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6106	2168-6114		JAMA INTERN MED	JAMA Intern. Med.	JAN	2015	175	1					43	52		10.1001/jamainternmed.2014.5479			10	Medicine, General & Internal	General & Internal Medicine	AY1BM	WOS:000347328500013	25401463	Bronze			2021-06-18	
J	Dams-O'Connor, K; Cantor, JB; Brown, M; Dijkers, MP; Spielman, LA; Gordon, WA				Dams-O'Connor, Kristen; Cantor, Joshua B.; Brown, Margaret; Dijkers, Marcel P.; Spielman, Lisa A.; Gordon, Wayne A.			Screening for Traumatic Brain Injury: Findings and Public Health Implications	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						prevention; public health; screening; traumatic brain injury	COLLEGIATE FOOTBALL PLAYERS; UNITED-STATES; ALZHEIMERS-DISEASE; LONG-TERM; RECURRENT CONCUSSION; SUBSTANCE-ABUSE; CO-MORBIDITY; OLDER-ADULTS; MILD; INDIVIDUALS	Objective: To provide an overview of a series of projects that used a structured self-report screening tool in diverse settings and samples to screen for lifetime history of traumatic brain injury (TBI). Setting: Diverse community settings. Participants: Homeless persons (n = 111), individuals with HIV seeking vocational rehabilitation (n = 173), youth in the juvenile justice system (n = 271), public schoolchildren (n = 174), substance users (n = 845), intercollegiate athletes (n = 90), and other community-based samples (n = 396). Design: Cross-sectional. Main Measure: Brain Injury Screening Questionnaire. Results: Screening using the Brain Injury Screening Questionnaire finds that 27% to 54% of those in high-risk populations report a history of TBI with chronic symptoms. Associations between TBI and social, academic, or other problems are evident in several studies. In non-high-risk community samples, 9% to 12% of individuals report TBI with chronic symptoms. Conclusion: Systematic TBI screening can be implemented efficiently and inexpensively in a variety of settings. Lifetime TBI history data gathered using a structured self-report instrument can augment existing estimates of the prevalence of TBI, both as an acute event and as a chronic condition. Identification of individuals with TBI can facilitate primary prevention efforts, such as reducing risk for reinjury in high-risk groups, and provide access to appropriate interventions that can reduce the personal and societal costs of TBI (tertiary prevention).	[Dams-O'Connor, Kristen; Cantor, Joshua B.; Dijkers, Marcel P.; Spielman, Lisa A.; Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Brown, Margaret] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA	Dams-O'Connor, K (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, 5 East 98th St,Box 1163, New York, NY 10029 USA.	kristen.dams-o'connor@mountsinai.org	Meijer, Anna/K-5118-2016		Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1R49CE001171]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER	The preparation of this article was supported in part by grant No. 1R49CE001171 from the Centers for Disease Control and Prevention to Icahn School of Medicine at Mount Sinai, New York City. The Brain Injury Screening Questionnaire discussed in this article as a tool for screening for traumatic brain injury is sometimes sold to agencies/organizations that want to screen people for brain injury. The proceeds of such sales benefit the Brain Injury Research Center of Mount Sinai, with which all authors are associated.	Agrigoroaei S, 2011, J GERONTOL B-PSYCHOL, V66, P130, DOI 10.1093/geronb/gbr017; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P139, DOI 10.1097/01.HTR.0000319930.69343.64; Ashman TA, 2006, MT SINAI J MED, V73, P999; Banks ME, 2007, TRAUMA VIOLENCE ABUS, V8, P290, DOI 10.1177/1524838007303503; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Betz ME, 2008, J AM GERIATR SOC, V56, P2267, DOI 10.1111/j.1532-5415.2008.02001.x; Blackhall LJ, 2001, J URBAN HEALTH, V78, P59, DOI 10.1093/jurban/78.1.59; Brasfield K, 2010, NCAA MEMORANDUM LEGI; Breed S, 2008, J HEAD TRAUMA REHAB, V23, P149, DOI 10.1097/01.HTR.0000319931.76966.ff; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Brenner LA, 2013, J HEAD TRAUMA REHAB, V28, P21, DOI 10.1097/HTR.0b013e31827df0b5; Cantor JB, 2004, ARCH PHYS MED REHAB, V85, pS54, DOI 10.1016/j.apmr.2003.08.113; Cantor J, 2014, ARCH PHYS MED REHAB, V95, P1, DOI 10.1016/j.apmr.2013.08.005; Cantor JB, 2006, J HEAD TRAUMA REHAB, V21, P424, DOI 10.1097/00001199-200609000-00039; Cantu RC, 2013, JAMA NEUROL, V70, P1481, DOI 10.1001/jamaneurol.2013.3231; Centers for Disease Control and Prevention, 2010, WHAT AR SIGNS SYMPT; Centers for Disease Control and Prevention, 2013, TRAUMATIC BRAIN INJU; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Comper P, 2010, BRAIN INJURY, V24, P1257, DOI 10.3109/02699052.2010.506854; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Corrigan JD, 2012, BRAIN INJURY, V26, P139, DOI 10.3109/02699052.2011.648705; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Dettmer J, 2014, J HEAD TRAUMA REHAB, V29, P224, DOI 10.1097/HTR.0b013e3182a1cd68; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; DRICKAMER MA, 1992, NEW ENGL J MED, V326, P947, DOI 10.1056/NEJM199204023261410; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fazel S, 2009, J NEUROL, V256, P1591, DOI 10.1007/s00415-009-5134-2; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Garrison A, 2003, JAMA-J AM MED ASSOC, V290, P1217, DOI 10.1001/jama.290.9.1217; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goldin-Lauretta Y, 2011, ARCH PHYS MED REHAB, V92, P1692; Gordon W. A., 2013, STATE OF THE STATES; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gordon WA, 2005, TXB TRAUMATIC BRAIN, P655; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Hibbard M. R., 2005, COGNITIVE BEHAV THER, P189; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoff Clarissa J B, 2010, J La State Med Soc, V162, P352; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hux K, 2009, BRAIN INJURY, V23, P8, DOI 10.1080/02699050802590353; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Institute of Medicine of the National Academies, 2009, GULF WAR HLTH, V7, P1; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Jaffe MP, 2000, BRAIN INJURY, V14, P35, DOI 10.1080/026990500120916; Jha A, 2001, INT J GERIATR PSYCH, V16, P879, DOI 10.1002/gps.412; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Jones WP, 2008, CLIN NEUROPSYCHOL, V22, P305, DOI 10.1080/13854040701281483; Kaba F, J ADOLESC HLTH, V54, P615; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mitchell TN, 2012, ARCH PHYS MED REHAB, V93, pe27; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Oddy M, 2012, BRAIN INJURY, V26, P1058, DOI 10.3109/02699052.2012.667595; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; Picard M, 1991, INT CTR DISABLED; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Rehabilitation and Neuropsychological Service Department of Physical Medicine and Rehabilitation Medical College of Virginia, TBI SYMPT CHECKL; Resnik DB, 2001, HEALTH POLICY, V55, P129, DOI 10.1016/S0168-8510(00)00121-4; Russell LM, 2013, AM J PUBLIC HEALTH, V103, pS211, DOI 10.2105/AJPH.2013.301485; Sacks AL, 2009, J DUAL DIAGN, V5, P404, DOI 10.1080/15504260903182755; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Shumway-Cook A, 2009, PHYS THER, V89, P324, DOI 10.2522/ptj.20070107; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Silver JM., 2011, TXB TRAUMATIC BRAIN, V2nd ed.; Sosin DM, 1996, BRAIN INJURY, V10, P47; Surbone A, 2000, ANN NY ACAD SCI, V913, P52; Tanev KS, 2014, BRAIN INJURY, V28, P261, DOI 10.3109/02699052.2013.873821; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Topolovec-Vranic Jane, 2014, CMAJ Open, V2, pE69, DOI 10.9778/cmajo.20130046; Topolovec-Vranic J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1059; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; Vanderploeg RD, 2013, J HEAD TRAUMA REHAB, V28, P211, DOI 10.1097/HTR.0b013e31828b50db; Vanderploeg RD, 2012, J REHABIL RES DEV, V49, P545, DOI 10.1682/JRRD.2011.04.0069; Vickery CD, 2008, ARCH PHYS MED REHAB, V89, P48, DOI 10.1016/j.apmr.2007.07.047; Wellington R, 2011, 3 FED INT C TRAUM BR; Wortzel HS, 2012, CURR TREAT OPTION NE, V14, P493, DOI 10.1007/s11940-012-0193-6; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Yi A, 2013, NEUROREHABILITATION, V32, P267, DOI 10.3233/NRE-130843; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	105	51	51	2	34	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2014	29	6					479	489		10.1097/HTR.0000000000000099			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AT7LI	WOS:000345117800008	25370440	Green Accepted			2021-06-18	
J	Dienel, GA				Dienel, Gerald A.			Lactate shuttling and lactate use as fuel after traumatic brain injury: metabolic considerations	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						astrocyte; lactate; microdialysis; neuron; pyruvate; traumatic brain injury	CONCENTRATION-GRADIENT MISINTERPRETATION; INTRACRANIAL HYPERTENSIVE EPISODES; CEREBROSPINAL-FLUID TRANSPORT; CEREBRAL ENERGY-METABOLISM; INTRACELLULAR PH INDICATOR; COMBINED MICRODIALYSIS; OXIDATIVE-METABOLISM; GLUCOSE-UTILIZATION; NEURONAL-ACTIVITY; GLUTAMATE UPTAKE	Lactate is proposed to be generated by astrocytes during glutamatergic neurotransmission and shuttled to neurons as 'preferred' oxidative fuel. However, a large body of evidence demonstrates that metabolic changes during activation of living brain disprove essential components of the astrocyte-neuron lactate shuttle model. For example, some glutamate is oxidized to generate ATP after its uptake into astrocytes and neuronal glucose phosphorylation rises during activation and provides pyruvate for oxidation. Extension of the notion that lactate is a preferential fuel into the traumatic brain injury (TBI) field has important clinical implications, and the concept must, therefore, be carefully evaluated before implementation into patient care. Microdialysis studies in TBI patients demonstrate that lactate and pyruvate levels and lactate/pyruvate ratios, along with other data, have important diagnostic value to distinguish between ischemia and mitochondrial dysfunction. Results show that lactate release from human brain to blood predominates over its uptake after TBI, and strong evidence for lactate metabolism is lacking; mitochondrial dysfunction may inhibit lactate oxidation. Claims that exogenous lactate infusion is energetically beneficial for TBI patients are not based on metabolic assays and data are incorrectly interpreted.	Univ Arkansas Med Sci, Dept Neurol, Little Rock, AR 72205 USA	Dienel, GA (corresponding author), Univ Arkansas Med Sci, Dept Neurol, Slot 500,4301 W Markham St, Little Rock, AR 72205 USA.	gadienel@uams.edu					ADACHI K, 1995, J CEREBR BLOOD F MET, V15, P97, DOI 10.1038/jcbfm.1995.11; Alessandri B, 2009, FUTUR NEUROL, V4, P209, DOI 10.2217/14796708.4.2.209; Ball KK, 2010, J CEREBR BLOOD F MET, V30, P162, DOI 10.1038/jcbfm.2009.206; Bauer DE, 2012, NEUROCHEM INT, V61, P566, DOI 10.1016/j.neuint.2012.01.013; Baxter P, 2014, TRANSL STROKE RES, V5, P136, DOI 10.1007/s12975-013-0283-0; BELT JA, 1979, BIOCHEMISTRY-US, V18, P3506, DOI 10.1021/bi00583a011; Boumezbeur F, 2010, J NEUROSCI, V30, P13983, DOI 10.1523/JNEUROSCI.2040-10.2010; Bouzat P, 2014, INTENS CARE MED, V40, P920, DOI 10.1007/s00134-014-3312-x; Bouzat P, 2014, CURR OPIN CRIT CARE, V20, P133, DOI 10.1097/MCC.0000000000000072; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Bouzier-Sore AK, 2003, J CEREBR BLOOD F MET, V23, P1298, DOI 10.1097/01.WCB.0000091761.61714.25; Bouzier-Sore AK, 2006, EUR J NEUROSCI, V24, P1687, DOI 10.1111/j.1460-9568.2006.05056.x; Boyko M, 2014, J NEURAL TRANSM, V121, P971, DOI 10.1007/s00702-014-1181-7; Boyko M, 2012, NEUROTHERAPEUTICS, V9, P649, DOI 10.1007/s13311-012-0129-6; Bradbury MWB, 1985, EXPT BIOL LYMPHATIC, P355; Cahill G. F., 2003, T AM CLIN CLIMAT ASS, V114, P162; Cahill George F Jr, 2003, Trans Am Clin Climatol Assoc, V114, P149; Carare RO, 2008, NEUROPATH APPL NEURO, V34, P131, DOI 10.1111/j.1365-2990.2007.00926.x; CARPENTER L, 1994, BIOCHEM J, V304, P751, DOI 10.1042/bj3040751; Carre E, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00146; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Choi IY, 2003, J NEUROSCI RES, V72, P25, DOI 10.1002/jnr.10574; CREMER JE, 1982, J CEREBR BLOOD F MET, V2, P394, DOI 10.1038/jcbfm.1982.45; Cruz NF, 2007, J NEUROSCI RES, V85, P3254, DOI 10.1002/jnr.21193; Cruz NF, 2013, J NEUROCHEM, V125, P247, DOI 10.1111/jnc.12166; Cruz NF, 1999, J CEREBR BLOOD F MET, V19, P380, DOI 10.1097/00004647-199904000-00004; Cruz NF, 2002, J CEREBR BLOOD F MET, V22, P1476, DOI 10.1097/01.WCB.0000034362.37277.C0; Desagher S, 1997, J NEUROSCI, V17, P9060; Dienel GA, 2006, NEUROCHEM INT, V48, P586, DOI 10.1016/j.neuint.2006.01.004; Dienel GA, 2005, GLIA, V50, P362, DOI 10.1002/glia.20157; Dienel GA, 2004, NEUROCHEM INT, V45, P321, DOI 10.1016/j.neuint.2003.10.011; DIENEL GA, 1991, J CEREBR BLOOD F MET, V11, P25, DOI 10.1038/jcbfm.1991.3; Dienel GA, 2014, METAB BRAIN DIS, Vdoi:, DOI [10.1007/811011-014-9493-8, DOI 10.1007/811011-014-9493-8]; Dienel GA, 2007, J NEUROCHEM, V102, P466, DOI 10.1111/j.1471-4159.2007.04595.x; Dienel GA, 2013, NEUROCHEM INT, V63, P244, DOI 10.1016/j.neuint.2013.06.015; Dienel GA, 2012, ASN NEURO, V4, P267, DOI 10.1042/AN20120021; Dienel GA, 2012, J CEREBR BLOOD F MET, V32, P1107, DOI 10.1038/jcbfm.2011.175; Dohmen C, 2005, BRAIN RES, V1037, P43, DOI 10.1016/j.brainres.2004.12.046; Dohmen C, 2001, J CEREBR BLOOD F MET, V21, P503, DOI 10.1097/00004647-200105000-00004; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; ERIKSSON G, 1995, GLIA, V15, P152, DOI 10.1002/glia.440150207; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Funfschilling U, 2012, NATURE, V485, P517, DOI 10.1038/nature11007; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Gandhi GK, 2009, J NEUROCHEM, V111, P522, DOI 10.1111/j.1471-4159.2009.06333.x; Garriga-Canut M, 2006, NAT NEUROSCI, V9, P1382, DOI 10.1038/nn1791; Genda EN, 2011, J NEUROSCI, V31, P18275, DOI 10.1523/JNEUROSCI.3305-11.2011; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; HALPERIN ML, 1969, J BIOL CHEM, V244, P384; Haspel HC, 1999, J MEMBRANE BIOL, V169, P45, DOI 10.1007/PL00005900; Hertz L, 2007, J CEREBR BLOOD F MET, V27, P219, DOI 10.1038/sj.jcbfm.9600343; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hillered L, 2008, CRIT CARE MED, V36, P2952, DOI 10.1097/CCM.0b013e3181872178; Holbein M, 2009, CRIT CARE, V13, DOI 10.1186/cc7711; HOLDEN JE, 1991, J CEREBR BLOOD F MET, V11, P171, DOI 10.1038/jcbfm.1991.50; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hu YB, 1997, J NEUROCHEM, V68, P1745; Hu YB, 1997, J NEUROCHEM, V69, P1484; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Ichai C, 2013, INTENS CARE MED, V39, P1413, DOI 10.1007/s00134-013-2978-9; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jackson JG, 2014, J NEUROSCI, V34, P1613, DOI 10.1523/JNEUROSCI.3510-13.2014; Jackson VN, 1996, J BIOL CHEM, V271, P861, DOI 10.1074/jbc.271.2.861; Jalloh I, 2014, J NEUROTRAUM, V31, P1529, DOI 10.1089/neu.2013.3316; Jalloh I, 2013, J NEUROTRAUM, V30, P2031, DOI 10.1089/neu.2013.2947; Johnston M, 2002, NEWS PHYSIOL SCI, V17, P227, DOI 10.1152/nips.01400.2002; Johnston M, 2003, LYMPHAT RES BIOL, V1, P45; Johnston Miles, 2003, Lymphat Res Biol, V1, P41, DOI 10.1089/15396850360495682; Jolivet R, 2010, J CEREBR BLOOD F MET, V30, P1982, DOI 10.1038/jcbfm.2010.132; Koh L, 2005, FLUIDS BARRIERS CNS, V2, DOI 10.1186/1743-8454-2-6; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Kumura E, 1999, J CEREBR BLOOD F MET, V19, P788, DOI 10.1097/00004647-199907000-00009; Larach DB, 2011, NEUROCRIT CARE, V15, P609, DOI 10.1007/s12028-011-9517-8; Levasseur JE, 2006, NEUROSURGERY, V59, P1122, DOI 10.1227/01.NEU.0000245581.00908.AF; LIEBOWITZ MR, 1986, AM J PSYCHIAT, V143, P495; Madsen PL, 1999, J CEREBR BLOOD F MET, V19, P393, DOI 10.1097/00004647-199904000-00005; MADSEN PL, 1995, J CEREBR BLOOD F MET, V15, P485, DOI 10.1038/jcbfm.1995.60; Madsen PL, 1998, J CEREBR BLOOD F MET, V18, P742, DOI 10.1097/00004647-199807000-00005; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Magnoni S, 2012, CRIT CARE MED, V40, P1785, DOI 10.1097/CCM.0b013e318246bd45; Mangia S, 2011, J CEREBR BLOOD F MET, V31, P1346, DOI 10.1038/jcbfm.2011.29; Mangia S, 2009, J NEUROCHEM, V109, P55, DOI 10.1111/j.1471-4159.2009.06003.x; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marklund N, 2009, J NEUROTRAUM, V26, P1281, DOI [10.1089/neu.2008.0827, 10.1089/neu.2008-0827]; McKenna Mary C, 2013, Front Endocrinol (Lausanne), V4, P191, DOI 10.3389/fendo.2013.00191; McKenna MC, 1996, J NEUROCHEM, V66, P386; Meierhans R, 2012, MINERVA ANESTESIOL, V78, P185; Meierhans R, 2010, CRIT CARE, V14, DOI 10.1186/cc8869; Morgenthaler FD, 2006, NEUROCHEM INT, V48, P616, DOI 10.1016/j.neuint.2005.12.034; Moro N, 2011, NEUROSCI LETT, V491, P158, DOI 10.1016/j.neulet.2011.01.029; Moro N, 2010, EXP NEUROL, V225, P391, DOI 10.1016/j.expneurol.2010.07.013; Nagra G, 2006, AM J PHYSIOL-REG I, V291, pR1383, DOI 10.1152/ajpregu.00235.2006; Nakanishi H, 1996, J CEREBR BLOOD F MET, V16, P439, DOI 10.1097/00004647-199605000-00010; NEDERGAARD M, 1993, AM J PHYSIOL, V265, pR282; Nehlig A, 2004, PROSTAG LEUKOTR ESS, V70, P265, DOI 10.1016/j.plefa.2003.07.006; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P793, DOI 10.1111/aas.12092; Nordstrom CH, 2014, J NEUROTRAUM, V31, P1528, DOI 10.1089/neu.2013.3229; Nordstrom CH, 2014, INTENS CARE MED, V40, P919, DOI 10.1007/s00134-014-3297-5; Nordstrom CH, 2013, J REHABIL MED, V45, P710, DOI 10.2340/16501977-1157; Nordstrom CH, 2010, CHILD NERV SYST, V26, P465, DOI 10.1007/s00381-009-1035-z; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Okada Y, 2007, BRAIN ENERGETICS INT, P17, DOI [10.1007/978-0-387-30411-3_2, DOI 10.1007/978-0-387-30411-3_2]; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Patel AB, 2014, P NATL ACAD SCI USA, V111, P5385, DOI 10.1073/pnas.1403576111; Pellerin L, 2010, DIABETES METAB, V36, pS59, DOI 10.1016/S1262-3636(10)70469-9; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pellerin L, 2008, CURR OPIN CLIN NUTR, V11, P701, DOI 10.1097/MCO.0b013e328312c368; Pellerin L, 2007, GLIA, V55, P1251, DOI 10.1002/glia.20528; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; POOLE RC, 1993, AM J PHYSIOL, V264, pC761; Prieto R, 2011, BRAIN RES, V1404, P39, DOI 10.1016/j.brainres.2011.06.006; Purins K, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00064; Quistorff B, 2008, FASEB J, V22, P3443, DOI 10.1096/fj.08-106104; RENNELS ML, 1985, BRAIN RES, V326, P47, DOI 10.1016/0006-8993(85)91383-6; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; ROMIJN JA, 1994, AM J PHYSIOL, V266, pE334; Ronald Zielke H, 2009, J NEUROCHEM, V109, P24, DOI 10.1111/j.1471-4159.2009.05941.x; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; SAVAKI HE, 1980, J NEUROCHEM, V35, P495, DOI 10.1111/j.1471-4159.1980.tb06293.x; Schurr A, 2012, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00096; Siesj_o B K, 1978, BRAIN ENERGY METABOL; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Stein NR, 2012, NEUROCRIT CARE, V17, P49, DOI 10.1007/s12028-012-9708-y; Stephenson KN, 2000, BIOCHEM PHARMACOL, V60, P651, DOI 10.1016/S0006-2952(00)00377-4; Thoresen M, 1998, PEDIATR RES, V44, P746, DOI 10.1203/00006450-199811000-00018; Tian JW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095777; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; TUCEK S, 1974, J NEUROCHEM, V22, P893, DOI 10.1111/j.1471-4159.1974.tb04314.x; Ugbode CI, 2014, J NEUROCHEM, V130, P668, DOI 10.1111/jnc.12759; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; VEECH RL, 1991, NMR BIOMED, V4, P53, DOI 10.1002/nbm.1940040204; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; WOLFE RR, 1988, AM J PHYSIOL, V254, pE532	146	51	53	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2014	34	11					1736	1748		10.1038/jcbfm.2014.153			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AS7HZ	WOS:000344428800002	25204393	Green Published, Bronze			2021-06-18	
J	Croall, ID; Cowie, CJA; He, JB; Peel, A; Wood, J; Aribisala, BS; Mitchell, P; Mendelow, AD; Smith, FE; Millar, D; Kelly, T; Blamire, AM				Croall, Iain D.; Cowie, Christopher J. A.; He, Jiabao; Peel, Anna; Wood, Joshua; Aribisala, Benjamin S.; Mitchell, Patrick; Mendelow, A. David; Smith, Fiona E.; Millar, David; Kelly, Tom; Blamire, Andrew M.			White matter correlates of cognitive dysfunction after mild traumatic brain injury	NEUROLOGY			English	Article							NONDISRUPTIVE AXONAL INJURY; CORPUS-CALLOSUM; CELLULAR EDEMA; VERBAL FLUENCY; DIFFUSION; IMPAIRMENT; ACTIVATION; ANISOTROPY; GLIOSIS; ADULTS	Objective: To relate neurophysiologic changes after mild/moderate traumatic brain injury to cognitive deficit in a longitudinal diffusion tensor imaging investigation. Methods: Fifty-three patients were scanned an average of 6 days postinjury (range = 1-14 days). Twenty-three patients were rescanned 1 year later. Thirty-three matched control subjects were recruited. At the time of scanning, participants completed cognitive testing. Tract-Based Spatial Statistics was used to conduct voxel-wise analysis on diffusion changes and to explore regressions between diffusion metrics and cognitive performance. Results: Acutely, increased axial diffusivity drove a fractional anisotropy (FA) increase, while decreased radial diffusivity drove a negative regression between FA and Verbal Letter Fluency across widespread white matter regions, but particularly in the ascending fibers of the corpus callosum. Raised FA is hypothesized to be caused by astrogliosis and compaction of axonal neurofilament, which would also affect cognitive functioning. Chronically, FA was decreased, suggesting myelin sheath disintegration, but still regressed negatively with Verbal Letter Fluency in the anterior forceps. Conclusions: Acute mild/moderate traumatic brain injury is characterized by increased tissue FA, which represents a clear neurobiological link between cognitive dysfunction and white matter injury after mild/moderate injury.	[Croall, Iain D.; Cowie, Christopher J. A.; Wood, Joshua; Smith, Fiona E.; Blamire, Andrew M.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Croall, Iain D.; Cowie, Christopher J. A.; Wood, Joshua; Smith, Fiona E.; Blamire, Andrew M.] Newcastle Univ, Newcastle MR Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Cowie, Christopher J. A.; Mitchell, Patrick; Mendelow, A. David] Newcastle Upon Tyne Hosp NHS Fdn Trust, Dept Neurosurg, Newcastle Upon Tyne, Tyne & Wear, England; [Kelly, Tom] Newcastle Upon Tyne Hosp NHS Fdn Trust, Dept Neuropsychol, Newcastle Upon Tyne, Tyne & Wear, England; [He, Jiabao] Univ Aberdeen, Sch Med & Dent, Aberdeen Biomed Imaging Ctr, Aberdeen AB9 1FX, Scotland; [Peel, Anna] Univ Durham, Dept Psychol, Durham DH1 3HP, England; [Aribisala, Benjamin S.] Univ Edinburgh, Brain Res Imaging Ctr, Edinburgh EH8 9YL, Midlothian, Scotland; [Millar, David] NeuroCog, Newcastle Upon Tyne, Tyne & Wear, England	Croall, ID (corresponding author), Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	i.d.croall@newcastle.ac.uk		He, Jiabao/0000-0001-7794-7188; Blamire, Andrew/0000-0002-8749-1257; Cowie, Christopher/0000-0003-0439-2278	Sir Jules Thorn Charitable Trust Biomedical Research Award; The Sir Jules Thorn Charitable Trust [05JTA] Funding Source: researchfish	Funding for the study and a studentship to I.D.C. has been provided by Sir Jules Thorn Charitable Trust Biomedical Research Award.	Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Gaillard WD, 2000, NEUROLOGY, V54, P180, DOI 10.1212/WNL.54.1.180; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kriz J, 2000, BRAIN RES, V885, P32, DOI 10.1016/S0006-8993(00)02899-7; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Matsukawa H, 2011, J NEUROSURG, V115, P1019, DOI 10.3171/2011.6.JNS11513; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pihlajamaki M, 2000, ANN NEUROL, V47, P470, DOI 10.1002/1531-8249(200004)47:4<470::AID-ANA10>3.3.CO;2-D; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Voets NL, 2006, BRAIN, V129, P754, DOI 10.1093/brain/awh679; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	38	51	51	2	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	AUG 5	2014	83	6					494	501		10.1212/WNL.0000000000000666			8	Clinical Neurology	Neurosciences & Neurology	AN1XV	WOS:000340378200009	25031282	Green Published			2021-06-18	
J	Romine, J; Gao, X; Chen, JH				Romine, Jennifer; Gao, Xiang; Chen, Jinhui			Controlled Cortical Impact Model for Traumatic Brain Injury	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Medicine; Issue 90; controlled cortical impact; traumatic brain injury; cortical contusion	NEURONAL DEATH; RATS; EXPRESSION; DEFICITS	Every year over a million Americans suffer a traumatic brain injury (TBI). Combined with the incidence of TBIs worldwide, the physical, emotional, social, and economical effects are staggering. Therefore, further research into the effects of TBI and effective treatments is necessary. The controlled cortical impact (CCI) model induces traumatic brain injuries ranging from mild to severe. This method uses a rigid impactor to deliver mechanical energy to an intact dura exposed following a craniectomy. Impact is made under precise parameters at a set velocity to achieve a pre-determined deformation depth. Although other TBI models, such as weight drop and fluid percussion, exist, CCI is more accurate, easier to control, and most importantly, produces traumatic brain injuries similar to those seen in humans. However, no TBI model is currently able to reproduce pathological changes identical to those seen in human patients. The CCI model allows investigation into the short-term and long-term effects of TBI, such as neuronal death, memory deficits, and cerebral edema, as well as potential therapeutic treatments for TBI.	[Romine, Jennifer; Gao, Xiang; Chen, Jinhui] Indiana Univ Sch Med, Dept Neurol Surg, Stark Neurosci Res Inst, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN 46202 USA	Chen, JH (corresponding author), Indiana Univ Sch Med, Dept Neurol Surg, Stark Neurosci Res Inst, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN 46202 USA.	chen204@iupui.edu			Indiana Spinal Cord & Brain Injury Research Grants [SCBI 200-12]; Ralph W. and Grace M. Showalter Research Award; Indiana University Biological Research Grant; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RR025761, 1R21NS072631-01A]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631] Funding Source: NIH RePORTER	This work was supported by funding from the Indiana Spinal Cord & Brain Injury Research Grants (SCBI 200-12), the Ralph W. and Grace M. Showalter Research Award, Indiana University Biological Research Grant, NIH grants RR025761 and 1R21NS072631-01A.	Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	16	51	53	0	10	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	AUG	2014		90							e51781	10.3791/51781			5	Multidisciplinary Sciences	Science & Technology - Other Topics	CB0EV	WOS:000349299200053	25145417	Green Published			2021-06-18	
J	Wu, JF; Stoica, BA; Luo, T; Sabirzhanov, B; Zhao, ZR; Guanciale, K; Nayar, SK; Foss, CA; Pomper, MG; Faden, AI				Wu, Junfang; Stoica, Bogdan A.; Luo, Tao; Sabirzhanov, Boris; Zhao, Zaorui; Guanciale, Kelsey; Nayar, Suresh K.; Foss, Catherine A.; Pomper, Martin G.; Faden, Alan I.			Isolated spinal cord contusion in rats induces chronic brain neuroinflammation, neurodegeneration, and cognitive impairment Involvement of cell cycle activation	CELL CYCLE			English	Article						spinal cord injury; brain; inflammation; cognitive impairment; neurodegeneration; cell cycle activation	ASTROGLIAL SCAR FORMATION; CORTICOSPINAL NEURONS; MICROGLIAL ACTIVATION; NEUROPATHIC PAIN; INJURY; DEATH; CONTRIBUTES; AXOTOMY; INFLAMMATION; EXPRESSION	Cognitive dysfunction has been reported in patients with spinal cord injury (SCI), but it has been questioned whether such changes may reflect concurrent head injury, and the issue has not been addressed mechanistically or in a well-controlled experimental model. Our recent rodent studies examining SCI-induced hyperesthesia revealed neuroinflammatory changes not only in supratentorial pain-regulatory sites, but also in other brain regions, suggesting that additional brain functions may be impacted following SCI. Here we examined effects of isolated thoracic SCI in rats on cognition, brain inflammation, and neurodegeneration. We show for the first time that SCI causes widespread microglial activation in the brain, with increased expression of markers for activated microglia/macrophages, including translocator protein and chemokine ligand 21 (C-C motif). Stereological analysis demonstrated significant neuronal loss in the cortex, thalamus, and hippocampus. SCI caused chronic impairment in spatial, retention, contextual, and fear-related emotional memory-evidenced by poor performance in the Morris water maze, novel objective recognition, and passive avoidance tests. Based on our prior work implicating cell cycle activation (CCA) in chronic neuroinflammation after SCI or traumatic brain injury, we evaluated whether CCA contributed to the observed changes. Increased expression of cell cycle-related genes and proteins was found in hippocampus and cortex after SCI. Posttraumatic brain inflammation, neuronal loss, and cognitive changes were attenuated by systemic post-injury administration of a selective cyclin-dependent kinase inhibitor. These studies demonstrate that chronic brain neurodegeneration occurs after isolated SCI, likely related to sustained microglial activation mediated by cell cycle activation.	[Wu, Junfang; Stoica, Bogdan A.; Luo, Tao; Sabirzhanov, Boris; Zhao, Zaorui; Guanciale, Kelsey; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Wu, Junfang; Stoica, Bogdan A.; Luo, Tao; Sabirzhanov, Boris; Zhao, Zaorui; Guanciale, Kelsey; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Nayar, Suresh K.; Foss, Catherine A.; Pomper, Martin G.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA	Wu, JF (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.	jwu@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Faden, Alan I./0000-0003-0128-2348	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS054221, R01 NR013601, R21 NR014053]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R21NR014053, R01NR013601] Funding Source: NIH RePORTER	We thank Katherine Cardiff and Angela Pan for expert technical support, Dr Soren M Bentzen and Ms Shari Kronsberg for expert statistical consultation and analysis. This study was supported by the National Institutes of Health Grants R01 NS054221 (AIF), R01 NR013601 (AIF), R21 NR014053 (JW).	Ankeny DP, 2009, NEUROSCIENCE, V158, P1112, DOI 10.1016/j.neuroscience.2008.07.001; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bonatz H, 2000, J NEUROSCI METH, V100, P105, DOI 10.1016/S0165-0270(00)00238-7; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Chang CM, 2009, NEUROREPORT, V20, P968, DOI 10.1097/WNR.0b013e32832d0a28; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Crawley AP, 2004, BRAIN RES, V1028, P19, DOI 10.1016/j.brainres.2004.08.060; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dowler R N, 1995, Appl Neuropsychol, V2, P124, DOI 10.1207/s15324826an0203&4_4; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; Endo T, 2007, BRAIN, V130, P2951, DOI 10.1093/brain/awm237; Endres CJ, 2009, J NUCL MED, V50, P1276, DOI 10.2967/jnumed.109.062265; Felix MS, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00045; FERINGA ER, 1985, NEUROSCI LETT, V58, P283, DOI 10.1016/0304-3940(85)90067-9; Fumagalli F, 2009, NEUROSCIENCE, V159, P936, DOI 10.1016/j.neuroscience.2009.01.030; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; GANCHROW D, 1985, J NEUROSCI RES, V14, P71, DOI 10.1002/jnr.490140107; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; Gomez-Pinilla F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032298; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Hains BC, 2003, J COMP NEUROL, V462, P328, DOI 10.1002/cne.10733; Hammond ENL, 1999, NEUROREPORT, V10, P2671, DOI 10.1097/00001756-199908200-00043; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Jegede AB, 2010, CLIN AUTON RES, V20, P3, DOI 10.1007/s10286-009-0036-z; Jensen MP, 2007, ARCH PHYS MED REHAB, V88, P638, DOI 10.1016/j.apmr.2007.02.002; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kaas JH, 2008, EXP NEUROL, V209, P407, DOI 10.1016/j.expneurol.2007.06.014; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; KALIL K, 1975, BRAIN RES, V89, P15, DOI 10.1016/0006-8993(75)90130-4; Klapka N, 2005, EUR J NEUROSCI, V22, P3047, DOI 10.1111/j.1460-9568.2005.04495.x; KOST SA, 1993, BRAIN RES BULL, V30, P469, DOI 10.1016/0361-9230(93)90280-O; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lau BYB, 2011, EXP NEUROL, V228, P283, DOI 10.1016/j.expneurol.2011.02.003; Lazzaro I, 2013, J CLIN NEUROPHYSIOL, V30, P59, DOI 10.1097/WNP.0b013e31827edb0c; Lee BH, 2004, BRAIN RES, V1020, P37, DOI 10.1016/j.brainres.2004.05.113; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; Mason MRJ, 2003, EUR J NEUROSCI, V18, P789, DOI 10.1046/j.1460-9568.2003.02809.x; MERLINE M, 1990, J COMP NEUROL, V296, P506, DOI 10.1002/cne.902960313; MIKUCKI SA, 1991, J NEUROSCI RES, V30, P213, DOI 10.1002/jnr.490300122; Murray RF, 2007, SPINAL CORD, V45, P429, DOI 10.1038/sj.sc.3102022; Nardone R, 2013, BRAIN RES, V1504, P58, DOI 10.1016/j.brainres.2012.12.034; Nielson JL, 2011, J COMP NEUROL, V519, P2852, DOI 10.1002/cne.22661; Nielson JL, 2010, J NEUROSCI, V30, P11516, DOI 10.1523/JNEUROSCI.1433-10.2010; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Guerrero AR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-40; ROTH E, 1989, PARAPLEGIA, V27, P480, DOI 10.1038/sc.1989.75; Strubreither W, 1997, SPINAL CORD, V35, P487, DOI 10.1038/sj.sc.3100495; Tian DS, 2007, BRAIN RES, V1154, P206, DOI 10.1016/j.brainres.2007.04.005; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; Tian DS, 2006, J NEUROSCI RES, V84, P1053, DOI 10.1002/jnr.20999; Wannier T, 2005, J NEUROTRAUM, V22, P703, DOI 10.1089/neu.2005.22.703; Wecht JM, 2013, J SPINAL CORD MED, V36, P74, DOI 10.1179/2045772312Y.0000000056; Wu J., 2012, PLOS ONE, V7; Wu JF, 2013, J NEUROSCI, V33, P12447, DOI 10.1523/JNEUROSCI.0846-13.2013; Wu JF, 2013, NEUROTHERAPEUTICS, V10, P520, DOI 10.1007/s13311-013-0198-1; Wu JF, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-169; Wu JF, 2012, CELL CYCLE, V11, P1782, DOI 10.4161/cc.20153; Wu JF, 2011, NEUROTHERAPEUTICS, V8, P221, DOI 10.1007/s13311-011-0028-2; Zhang B, 2011, J TRAUMA, V71, P1680, DOI 10.1097/TA.0b013e318231bce7; Zhao P, 2007, J NEUROSCI, V27, P8893, DOI 10.1523/JNEUROSCI.2209-07.2007; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	64	51	55	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-4101	1551-4005		CELL CYCLE	Cell Cycle	AUG 1	2014	13	15					2446	2458		10.4161/cc.29420			13	Cell Biology	Cell Biology	AN6QL	WOS:000340720900019	25483194	Bronze, Green Published			2021-06-18	
J	Tremblay, S; Beaule, V; Proulx, S; Tremblay, S; Marjanska, M; Doyon, J; Lassonde, M; Theoret, H				Tremblay, Sara; Beaule, Vincent; Proulx, Sebastien; Tremblay, Sebastien; Marjanska, Malgorzata; Doyon, Julien; Lassonde, Maryse; Theoret, Hugo			Multimodal assessment of primary motor cortex integrity following sport concussion in asymptomatic athletes	CLINICAL NEUROPHYSIOLOGY			English	Article						Sport concussion; Traumatic brain injury; Magnetic resonance spectroscopy; Transcranial magnetic stimulation; GABA; Glutamate	TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; COLLEGIATE FOOTBALL PLAYERS; RECURRENT CONCUSSION; CORTICAL THICKNESS; MR SPECTROSCOPY; LONG-TERM; INHIBITION; RECOVERY; MODERATE	Objective: Recent studies have shown, in asymptomatic concussed athletes, metabolic disruption in the primary motor cortex (M1) and abnormal intracortical inhibition lasting for more than six months. The present study aims to assess if these neurochemical and neurophysiological alterations are persistent and linked to M1 cortical thickness. Methods: Sixteen active football players who sustained their last concussion, on average, three years prior to testing and 14 active football players who never sustained a concussion were recruited for a single session of proton magnetic resonance spectroscopy (H-1-MRS) and transcranial magnetic stimulation (TMS). Measures of M1 and whole brain cortical thickness were acquired, and H-1-MRS data were acquired from left M1 using a MEGA-PRESS sequence. Cortical silent period (CSP) and long-interval intracortical inhibition (LICI) were measured with TMS applied over left M1. Results: No significant group differences were observed for metabolic concentrations, TMS measures, and cortical thickness. However, whereas GABA and glutamate levels were positively correlated in control athletes, this relationship was absent in concussed athletes. Conclusion: These data suggest the general absence of neurophysiologic, neurometabolic and neuroanatomical disruptions in M1 three years following the last concussive event. However, correlational analyses suggest the presence of a slight metabolic imbalance between GABA and glutamate concentrations in the primary motor cortex of concussed athletes. Significance: The present study highlights the importance of multimodal assesments of the impacts of sport concussions. (C) 2014 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Tremblay, Sara; Beaule, Vincent; Lassonde, Maryse; Theoret, Hugo] Univ Montreal, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H3C 3J7, Canada; [Tremblay, Sara; Beaule, Vincent; Lassonde, Maryse; Theoret, Hugo] Ctr Hosp Univ Hop St Justine, Ctr Rech, Montreal, PQ, Canada; [Proulx, Sebastien; Tremblay, Sebastien; Doyon, Julien] Inst Univ Geriatrie Montreal, Ctr Rech, Unite Neuroimagerie Fonct, Montreal, PQ, Canada; [Proulx, Sebastien] McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2T5, Canada; [Marjanska, Malgorzata] Univ Minnesota, Ctr Magnet Resonance Res, Minneapolis, MN 55455 USA; [Marjanska, Malgorzata] Univ Minnesota, Dept Radiol, Minneapolis, MN 55455 USA	Theoret, H (corresponding author), Univ Montreal, Dept Psychol, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	hugo.theoret@umontreal.ca	Tremblay, Sara/X-5471-2019; Meijer, Anna/K-5118-2016	Theoret, Hugo/0000-0002-7458-8797; Marjanska, Malgorzata/0000-0002-4727-2447; Tremblay, Sebastien/0000-0001-6251-9797	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Fonds de Recheche du Quebec - Sante; Biotechnology Research Center (BTRC) [P41 RR008079, P41 EB015894 (NIBIB)]; NCC [P30 NS076408]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR008079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015894] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS076408] Funding Source: NIH RePORTER	This work was supported by grants from the Canadian Institutes of Health Research and the Fonds de Recheche du Quebec - Sante to H.T. and M.L. M.M. acknowledges the support from Biotechnology Research Center (BTRC) grant P41 RR008079 and P41 EB015894 (NIBIB), and NCC P30 NS076408. The authors would like to thank Edward J. Auerbach, Ph.D. (Center for Magnetic Resonance Research, University of Minnesota) for implementing MEGA-PRESS sequence on Siemens, and Romain Valabregue, Ph.D. (Centre de NeuroImagerie de Recherche, Paris, France) and Brice Tiret, Ing (Unite de neuroimagerie fonctionnelle, Montreal) for developing processing tools.	Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Babikian T, 2010, J NEUROTRAUM, V27, P473, DOI 10.1089/neu.2009.1058; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Chin LS, 2013, CURR SPORT MED REP, V47, P15; Cimatti M, 2006, J Neurosurg Sci, V50, P83; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12278; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Giza CC, 2001, J ATHL TRAINING, V36, P228; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Govindaraju V, 2000, NMR BIOMED, V13, P129, DOI 10.1002/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hanten G, 2011, NEUROPSYCHOLOGIA, V49, P486, DOI 10.1016/j.neuropsychologia.2010.12.007; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Henry PG, 2006, MAGN RESON MED, V55, P250, DOI 10.1002/mrm.20764; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Kelly JP, 1997, NEUROLOGY, V48, P581; Lerch JP, 2006, NEUROIMAGE, V31, P993, DOI 10.1016/j.neuroimage.2006.01.042; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lyttelton O, 2007, NEUROIMAGE, V34, P1535, DOI 10.1016/j.neuroimage.2006.10.041; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McDonnell MN, 2007, EXP BRAIN RES, V180, P181, DOI 10.1007/s00221-006-0849-0; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Mescher M, 1998, NMR BIOMED, V11, P266, DOI 10.1002/(SICI)1099-1492(199810)11:6<266::AID-NBM530>3.0.CO;2-J; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Prescot AP, 2013, DRUG ALCOHOL DEPEN, V129, P232, DOI 10.1016/j.drugalcdep.2013.02.028; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Stagg CJ, 2011, J PHYSIOL-LONDON, V589, P5845, DOI 10.1113/jphysiol.2011.216978; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Tkac I, 1999, MAGNET RESON MED, V41, P649, DOI 10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G; Tremblay S, 2013, J NEUROPHYSIOL, V109, P1343, DOI 10.1152/jn.00704.2012; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Turken And U, 2009, BMC Med Imaging, V9, P20, DOI 10.1186/1471-2342-9-20; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006	67	51	52	0	23	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JUL	2014	125	7					1371	1379		10.1016/j.clinph.2013.11.040			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AI0AC	WOS:000336507100012	24462505	Green Accepted			2021-06-18	
J	Walko, TD; Bola, RA; Hong, JD; Au, AK; Bell, MJ; Kochanek, PM; Clark, RSB; Aneja, RK				Walko, Thomas D., III; Bola, R. Aaron; Hong, John D.; Au, Alicia K.; Bell, Michael J.; Kochanek, Patrick M.; Clark, Robert S. B.; Aneja, Rajesh K.			CEREBROSPINAL FLUID MITOCHONDRIAL DNA: A NOVEL DAMP IN PEDIATRIC TRAUMATIC BRAIN INJURY	SHOCK			English	Article						Mitochondrial DNA; cerebrospinal fluid; traumatic brain injury	GROUP BOX-1 PROTEIN; UNITED-STATES; CYTOCHROME-C; HMGB1; INFLAMMATION; RESPONSES; CHILDREN; DANGER; PLASMA	Danger-associated molecular patterns (DAMPs) are nuclear or cytoplasmic proteins that are released from the injured tissues and activate the innate immune system. Mitochondrial DNA (mtDNA) is a novel DAMP that is released into the extracellular milieu subsequent to cell death and injury. We hypothesized that cell death within the central nervous system in children with traumatic brain injury (TBI) would lead to the release of mtDNA into the cerebrospinal fluid (CSF) and has the potential to predict the outcome after trauma. Cerebrospinal fluid was collected from children with severe TBI who required intracranial pressure monitoring with Glasgow Coma Scale (GCS) scores of 8 or less via an externalized ventricular drain. Control CSF was obtained in children without TBI or meningoencephalitis who demonstrated no leukocytes in the diagnostic lumbar puncture. The median age for patients with TBI was 6.3 years, and 62% were male. The common mechanisms of injury included motor vehicle collision (35.8%), followed by falls (21.5%) and inflicted TBI (19%); six children (14.2%) died during their intensive care unit course. The mean CSF mtDNA concentration was 1.10E+05 +/- 2.07E+05 and 1.63E+03 +/- 1.80E+03 copies/L in the pediatric TBI and control populations, respectively. Furthermore, the mean CSF mtDNA concentration in pediatric patients who later died or had severe disability was significantly higher than that of the survivors (1.63E+05 +/- 2.77E+05 vs. 5.05E+04 +/- 6.21E+04 copies/L) (P < 0.0001). We found a significant correlation between CSF mtDNA and high mobility group box 1, another prototypical DAMP, concentrations ( = 0.574, P < 0.05), supporting the notion that both DAMPs are increased in the CSF after TBI. Our data suggest that CSF mtDNA is a novel DAMP in TBI and appears to be a useful biomarker that correlates with neurological outcome after TBI. Further inquiry into the components of mtDNA that modulate the innate immune response will be helpful in understanding the mechanism of local and systemic inflammation after TBI.	[Walko, Thomas D., III] SUNY Buffalo, Dept Crit Care Med, Buffalo, NY 14260 USA; [Bola, R. Aaron] SUNY Buffalo, Buffalo, NY 14260 USA; [Hong, John D.] Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA; [Au, Alicia K.; Kochanek, Patrick M.; Clark, Robert S. B.; Aneja, Rajesh K.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Au, Alicia K.; Bell, Michael J.; Kochanek, Patrick M.; Clark, Robert S. B.; Aneja, Rajesh K.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Bell, Michael J.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15224 USA	Aneja, RK (corresponding author), Childrens Hosp Pittsburgh, Dept Crit Care Med, 4401 Penn Ave,Fac Pavil Bldg,Suite 2000, Pittsburgh, PA 15224 USA.	anejar@upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Hong, John/0000-0002-5563-417X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040686] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM098474] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM098474] Funding Source: NIH RePORTER		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; Andersson SGE, 2003, PHILOS T ROY SOC B, V358, P165, DOI 10.1098/rstb.2002.1193; Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Barlow Karen, 2004, Pediatr Rehabil, V7, P195, DOI 10.1080/13638490410001715331; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; CHAN KH, 1990, CHILD NERV SYST, V6, P27, DOI 10.1007/BF00262262; Chiu RWK, 2003, CLIN CHEM, V49, P719, DOI 10.1373/49.5.719; Exo J, 2011, PEDIATR CRIT CARE ME, V12, P560, DOI 10.1097/PCC.0b013e3181e8b3ee; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Kim JY, 2005, AM J PHYSIOL-LUNG C, V288, pL958, DOI 10.1152/ajplung.00359.2004; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Manganelli V, 2010, CRIT CARE, V14, DOI 10.1186/cc9316; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Podlesniy P, 2013, ANN NEUROL, V74, P655, DOI 10.1002/ana.23955; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Simmons JD, 2013, ANN SURG, V258, P591, DOI 10.1097/SLA.0b013e3182a4ea46; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Venereau E, 2013, MOL IMMUNOL, V55, P76, DOI 10.1016/j.molimm.2012.10.037; Wang H, 2004, J INTERN MED, V255, P320, DOI 10.1111/j.1365-2796.2003.01302.x; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; West AP, 2006, ANNU REV CELL DEV BI, V22, P409, DOI 10.1146/annurev.cellbio.21.122303.115827; West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975; Zhang Q, 2010, SHOCK, V34, P55, DOI 10.1097/SHK.0b013e3181cd8c08; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	34	51	53	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JUN	2014	41	6					499	503		10.1097/SHK.0000000000000160			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	AH6CI	WOS:000336217900005	24667615	Green Accepted			2021-06-18	
J	Yeh, PH; Wang, BQ; Oakes, TR; French, LM; Pan, H; Graner, J; Liu, W; Riedy, G				Yeh, Ping-Hong; Wang, Binquan; Oakes, Terrence R.; French, Louis M.; Pan, Hai; Graner, John; Liu, Wei; Riedy, Gerard			Postconcussional Disorder and PTSD Symptoms of Military-Related Traumatic Brain Injury Associated With Compromised Neurocircuitry	HUMAN BRAIN MAPPING			English	Article						traumatic brain injury; diffusion tensor imaging; blast injury; concussion; post-traumatic stress disorder; neurocircuitry	DIFFUSE AXONAL INJURY; TENSOR IMAGING FINDINGS; WHITE-MATTER PATHWAYS; REACTION-TIME; HEAD-INJURY; WALLERIAN DEGENERATION; FIBER TRACTOGRAPHY; WATER DIFFUSION; WORKING-MEMORY; BLAST INJURY	Traumatic brain injury (TBI) is a common combat injury, often through explosive blast, and produces heterogeneous brain changes due to various mechanisms of injury. It is unclear whether the vulnerability of white matter differs between blast and impact injury, and the consequences of microstructural changes on neuropsychological function are poorly understood in military TBI patients. Diffusion tensor imaging (DTI) techniques were used to assess the neurocircuitry in 37 US service members (29 mild, 7 moderate, 1 severe; 17 blast and 20 nonblast), who sustained a TBI while deployed, compared to 14 nondeployed, military controls. High-dimensional deformable registration of MRI diffusion tensor data was followed by fiber tracking and tract-specific analysis along with region-of-interest analysis. DTI results were examined in relation to post-concussion and post-traumatic stress disorder (PTSD) symptoms. The most prominent white matter microstructural injury for both blast and nonblast patients was in the frontal fibers within the fronto-striatal (corona radiata, internal capsule) and fronto-limbic circuits (fornix, cingulum), the fronto-parieto-occipital association fibers, in brainstem fibers, and in callosal fibers. Subcortical superior-inferiorly oriented tracts were more vulnerable to blast injury than nonblast injury, while direct impact force had more detrimental effects on anterior-posteriorly oriented tracts, which tended to cause heterogeneous left and right hemispheric asymmetries of white matter connectivity. The tractography using diffusion anisotropy deficits revealed the cortico-striatal-thalamic-cerebellar-cortical (CSTCC) networks, where increased post-concussion and PTSD symptoms were associated with low fractional anisotropy in the major nodes of compromised CSTCC neurocircuitry, and the consequences on cognitive function were explored as well. Hum Brain Mapp 35:2652-2673, 2014. (c) 2013 Wiley Periodicals, Inc.	[Yeh, Ping-Hong; Wang, Binquan; Pan, Hai; Liu, Wei; Riedy, Gerard] Henry Jackson Fdn Adv Mil Med, Traumat Brain Injury Image Anal Lab, Dept Radiol, Rockville, MD USA; [Oakes, Terrence R.; Graner, John; Riedy, Gerard] Natl Intrepid Ctr Excellence, Bethesda, MD USA; [French, Louis M.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [French, Louis M.; Riedy, Gerard] Uniformed Serv Univ Hlth Sci, CNRM, Bethesda, MD 20814 USA; [Riedy, Gerard] Walter Reed Natl Mil Med Ctr, Natl Capital Neuroimaging Consortium, Bethesda, MD USA	Yeh, PH (corresponding author), 12725 Twinbrook Pkwy,Room 269, Rockville, MD 20852 USA.	pinghongyeh@gmail.com	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604	CDMRPUnited States Department of Defense [PT074437]; NARSAD, Brain Behavior Research Fund Grant [18317]	This research was partly supported by CDMRP to USUHS (CNRM) Grant PT074437 (G.R.) and NARSAD, Brain Behavior Research Fund Grant 18317 (P-H. Y.).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; American Psychiatric Association, DIAGN STAT MAN MENT, V4th; Andersson J.L.R., 2007, TR07JA1 FMRIB; Andreasen NC, 1996, P NATL ACAD SCI USA, V93, P9985, DOI 10.1073/pnas.93.18.9985; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ariza M, 2006, BRAIN INJURY, V20, P1053, DOI 10.1080/02699050600909862; Baird AA, 2005, J COGNITIVE NEUROSCI, V17, P687, DOI 10.1162/0898929053467569; BARKLEY RA, 1990, J CONSULT CLIN PSYCH, V58, P775, DOI 10.1037/0022-006X.58.6.775; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Belanger HG, 2009, J INT NEUROPSYCH SOC, P1; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Blumberg HP, 2007, BIOL PSYCHIAT, V62, P104, DOI 10.1016/j.biopsych.2007.04.035; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Cader S, 2007, NEUROIMAGE, V36, P19, DOI 10.1016/j.neuroimage.2007.02.036; Camara E, 2009, FRONT NEUROSCI-SWITZ, V3, P350, DOI 10.3389/neuro.01.034.2009; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Connell S, 2011, J NEUROTRAUM, V28, P1229, DOI 10.1089/neu.2011.1832; Conners K., 2002, CONNERS CONTINUOUS P; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Eonta SE, 2011, AVIAT SPACE ENVIR MD, V82, P34, DOI 10.3357/ASEM.2799.2011; Epstein JN, 2003, J ABNORM CHILD PSYCH, V31, P543, DOI 10.1023/A:1025405216339; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Haatveit BC, 2010, J CLIN EXP NEUROPSYC, V32, P871, DOI 10.1080/13803391003596421; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; IIZUKA H, 1989, STROKE, V20, P1396, DOI 10.1161/01.STR.20.10.1396; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jack J., 1983, ELECT CURRENT FLOW E; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jiang Q, 2011, NMR BIOMED, V24, P1119, DOI 10.1002/nbm.1667; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lazar M, 2003, HUM BRAIN MAPP, V18, P306, DOI 10.1002/hbm.10102; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; Luo AH, 2011, SCIENCE, V333, P353, DOI 10.1126/science.1204622; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Madden DJ, 2004, NEUROIMAGE, V21, P1174, DOI 10.1016/j.neuroimage.2003.11.004; Margolis EB, 2006, J PHYSIOL-LONDON, V577, P907, DOI 10.1113/jphysiol.2006.117069; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Mukherjee P, 2008, AM J NEURORADIOL, V29, P843, DOI 10.3174/ajnr.A1052; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; O'Bryant SE, 2008, APPL NEUROPSYCHOL, V15, P113, DOI 10.1080/09084280802083921; Oishi K, 2005, NEUROSCI RES, V52, P37, DOI 10.1016/j.neures.2005.01.008; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Palmer HS, 2010, J NEUROTRAUM, V27, P853, DOI 10.1089/neu.2009.1225; PAPEZ JW, 1995, J NEUROPSYCH CLIN N, V7, P103; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Peng HL, 2009, NEUROIMAGE, V46, P967, DOI 10.1016/j.neuroimage.2009.03.046; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Raine A, 2006, SOC COGN AFFECT NEUR, V1, P203, DOI 10.1093/scan/nsl033; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Ruff Robert L, 2010, F1000 Med Rep, V2, P64, DOI 10.3410/M2-64; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sheline YI, 2003, BIOL PSYCHIAT, V54, P338, DOI 10.1016/S0006-3223(03)00347-0; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shirer WR, 2012, CEREB CORTEX, V22, P158, DOI 10.1093/cercor/bhr099; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Sullivan EV, 2003, ALCOHOL CLIN EXP RES, V27, P301, DOI 10.1097/01.ALC.0000052584.05305.98; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tang CY, 2010, INTELLIGENCE, V38, P293, DOI 10.1016/j.intell.2010.03.003; Thiebaut de Schotten M, 2011, NEUROIMAGE, V54, P49, DOI 10.1016/j.neuroimage.2010.07.055; Thomalla G, 2005, J NEUROL NEUROSUR PS, V76, P266, DOI 10.1136/jnnp.2004.046375; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; Tuch DS, 2005, P NATL ACAD SCI USA, V102, P12212, DOI 10.1073/pnas.0407259102; Tuch DS, 2003, NEURON, V40, P885, DOI 10.1016/S0896-6273(03)00758-X; Turken AU, 2008, NEUROIMAGE, V42, P1032, DOI 10.1016/j.neuroimage.2008.03.057; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wiegell MR, 2000, RADIOLOGY, V217, P897, DOI 10.1148/radiology.217.3.r00nv43897; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; Writer BW, 2010, J REHABIL RES DEV, V47, P841, DOI 10.1682/JRRD.2009.10.0162; Yeh P.-H., 2012, OPEN J MED IMAGING, V2, P137, DOI [10.4236/ojmi.2012.24025, DOI 10.4236/OJMI.2012.24025]; Yeh PH, 2010, PSYCHIAT RES-NEUROIM, V184, P177, DOI 10.1016/j.pscychresns.2010.07.007; Yeh PH, 2009, PSYCHIAT RES-NEUROIM, V173, P22, DOI 10.1016/j.pscychresns.2008.07.012; Yushkevich PA, 2008, NEUROIMAGE, V41, P448, DOI 10.1016/j.neuroimage.2008.01.013; Zhang H, 2005, LECT NOTES COMPUT SC, V3749, P172; Zhang SW, 2011, NEUROIMAGE, V54, P974, DOI 10.1016/j.neuroimage.2010.09.008	135	51	51	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JUN	2014	35	6					2652	2673		10.1002/hbm.22358			22	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AF2PX	WOS:000334555100014	24038816	Green Published			2021-06-18	
J	Mosquera, L; Colon, JM; Santiago, JM; Torrado, AI; Melendez, M; Segarra, AC; Rodriguez-Orengo, JF; Miranda, JD				Mosquera, Laurivette; Colon, Jennifer M.; Santiago, Jose M.; Torrado, Aranza I.; Melendez, Margarita; Segarra, Annabel C.; Rodriguez-Orengo, Jose F.; Miranda, Jorge D.			Tamoxifen and estradiol improved locomotor function and increased spared tissue in rats after spinal cord injury: Their antioxidant effect and role of estrogen receptor alpha	BRAIN RESEARCH			English	Article						Trauma; Neuroprotection; Selective estrogen receptor modulators; 17 beta-estradiol; Locomotor recovery; Estrogen receptor expression	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; PROGRAMMED CELL-DEATH; OXIDATIVE STRESS; BREAST-CANCER; FEMALE RAT; 17-BETA-ESTRADIOL; NEUROPROTECTION; ISCHEMIA; ACTIVATION	17 beta-Estradiol is a multi-active steroid that imparts neuroprotection via diverse mechanisms of action. However, its role as a neuroprotective agent after spinal cord injury (SCI), or the involvement of the estrogen receptor-alpha (ER-a) in locomotor recovery, is still a subject of much debate. In this study, we evaluated the effects of estradiol and of Tamoxifen (an estrogen receptor mixed agonist/antagonist) on locomotor recovery following SCI. To control estradiol cyclical variability, ovariectomized female rats received empty or estradiol filled implants, prior to a moderate contusion to the spinal cord. Estradiol improved locomotor function at 7, 14, 21, and 28 days post injury (DPI), when compared to control groups (measured with the BBB open field test). This effect was ER-a mediated, because functional recovery was blocked with an ER-a antagonist. We also observed that ER-a was up-regulated after SCI. Long-term treatment (28 DPI) with estradiol and Tamoxifen reduced the extent of the lesion cavity, an effect also mediated by ER-a. The antioxidant effects of estradiol were seen acutely at 2 DPI but not at 28 DPI, and this acute effect was not receptor mediated. Rats treated with Tamoxifen recovered some locomotor activity at 21 and 28 DPI, which could be related to the antioxidant protection seen at these time points. These results show that estradiol improves functional outcome, and these protective effects are mediated by the ER-a dependent and independent-mechanisms. Tamoxifen's effects during late stages of SCI support the use of this drug as a long-term alternative treatment for this condition. (C) 2014 Elsevier B.V. All rights reserved.	[Mosquera, Laurivette; Colon, Jennifer M.; Torrado, Aranza I.; Segarra, Annabel C.; Miranda, Jorge D.] Univ Puerto Rico, Sch Med, Dept Physiol, San Juan, PR 00936 USA; [Santiago, Jose M.] Univ Puerto Rico, Dept Nat Sci, Carolina, PR 00984 USA; [Melendez, Margarita] Inst Forens Sci, San Juan, PR USA; [Rodriguez-Orengo, Jose F.] Univ Puerto Rico, Sch Med, Dept Biochem, San Juan, PR 00936 USA	Miranda, JD (corresponding author), Univ Puerto Rico, Sch Med, Dept Physiol, San Juan, PR 00936 USA.	jorge.miranda3@upr.edu		Colon-Mercado, Jennifer/0000-0002-2912-554X	COBRE [P20-GM103642]; MBRS-RISE Program [R25-GM061838]; MBRS-SCORE [S06-GM008224]; RCMI Program [G12RR03051]; Division of Biomedical Sciences of the UPR School of Medicine; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [G12RR003051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25GM061838, S06GM008224, P20GM103642, R01GM068138] Funding Source: NIH RePORTER; National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [G12MD007600] Funding Source: NIH RePORTER	Special thanks to Yvonne Torres for her support during the radioimmunoassay experiment and Nildris Cruz for her unconditional help with the oxidative stress analysis. Thanks to Luz C. Arocho, Odrick Rosas and the staff of the Animal Resource Center at the UPR-MSC, for their surgical and technical support. Special thanks to the Institute of Forensic Sciences for the standardization and analysis of tamoxifen in the samples. Finally, our appreciation to Dr. Anne Etgen for her editorial support, critiques, suggestions and recommendations in the preparation of the manuscript. This research project is in partial fulfillment of Mrs. Laurivette Mosquera and Ms. Jennifer Colon doctoral dissertations. This study was supported by COBRE (P20-GM103642), MBRS-RISE Program (R25-GM061838), MBRS-SCORE (S06-GM008224), RCMI Program (G12RR03051) and the Division of Biomedical Sciences of the UPR School of Medicine.	Amtul Z, 2010, NEUROSCIENCE, V169, P781, DOI 10.1016/j.neuroscience.2010.05.031; [Anonymous], 2012, J Spinal Cord Med, V35, P480, DOI 10.1179/1079026812Z.000000000124; Arevalo MA, 2010, BBA-GEN SUBJECTS, V1800, P1106, DOI 10.1016/j.bbagen.2009.10.002; Baker KA, 2005, J NEUROTRAUM, V22, P415, DOI 10.1089/neu.2005.22.415; Barreto G, 2009, ENDOCRINOLOGY, V150, P5010, DOI 10.1210/en.2009-0352; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Behl C, 1997, MOL PHARMACOL, V51, P535; Biegon A, 1996, CANCER RES, V56, P4328; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Breckwoldt M, 2000, EXP CLIN ENDOCR DIAB, V108, P243, DOI 10.1055/s-2000-7751; Bydon M., 2013, WORLD NEUROSURG, P1; Chaovipoch P, 2006, J NEUROTRAUM, V23, P830, DOI 10.1089/neu.2006.23.830; Crespo MJ, 2008, J CARDIOVASC PHARM T, V13, P64, DOI 10.1177/1074248407307854; Cummings SR, 2002, JAMA-J AM MED ASSOC, V287, P216, DOI 10.1001/jama.287.2.216; Cuzzocrea S, 2008, SHOCK, V29, P362, DOI 10.1097/shk.0b013e31814545dc; Dhandapani KM, 2002, BIOL REPROD, V67, P1379, DOI 10.1095/biolreprod.102.003848; DonCarlos LL, 2009, PSYCHONEUROENDOCRINO, V34, P113; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; DZIUK PJ, 1966, ENDOCRINOLOGY, V78, P208, DOI 10.1210/endo-78-1-208; Elkabes S., 2014, EXP NEUROL; Etgen AM, 2011, FRONT NEUROENDOCRIN, V32, P336, DOI 10.1016/j.yfrne.2010.12.005; Farooque M, 2006, SPINAL CORD, V44, P182, DOI 10.1038/sj.sc.3101816; Febo M, 2002, BRAIN RES, V943, P151, DOI 10.1016/S0006-8993(02)02748-8; Feng YZ, 2004, EUR J PHARMACOL, V484, P65, DOI 10.1016/j.ejphar.2003.10.048; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Garcia-Segura LM, 2009, FRONT NEUROENDOCRIN, V30, pV, DOI 10.1016/j.yfrne.2009.04.006; Guptarak J, 2014, J NEUROTRAUM, V31, P268, DOI 10.1089/neu.2013.3108; Hauben E, 2002, EUR J NEUROSCI, V16, P1731, DOI 10.1046/j.1460-9568.2002.02241.x; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Ismailoglu O, 2010, J CLIN NEUROSCI, V17, P1306, DOI 10.1016/j.jocn.2010.01.049; Ismailoglu O, 2013, AM J MED SCI, V345, P39, DOI 10.1097/MAJ.0b013e3182522651; JORDAN VC, 1991, J NATL CANCER I, V83, P492, DOI 10.1093/jnci/83.7.492; Kachadroka S, 2010, J NEUROTRAUM, V27, P611, DOI 10.1089/neu.2009.1069; Kimelberg HK, 2003, J NEUROSURG, V99, P138, DOI 10.3171/jns.2003.99.1.0138; Laliberte F, 2011, MENOPAUSE, V18, P1052, DOI 10.1097/gme.0b013e3182175e5c; Lee JY, 2012, ENDOCRINOLOGY, V153, P3815, DOI 10.1210/en.2012-1068; LEGAN SJ, 1975, ENDOCRINOLOGY, V96, P571, DOI 10.1210/endo-96-3-571; Leon RL, 2012, ENDOCRINOLOGY, V153, P3386, DOI 10.1210/en.2011-1859; Li LZ, 2011, NEUROCHEM INT, V58, P126, DOI 10.1016/j.neuint.2010.11.006; Liu JL, 2010, BRAIN RES, V1316, P101, DOI 10.1016/j.brainres.2009.12.055; Mead R, 1988, DESIGN EXPT, P587; Mehta SH, 2003, NEUROENDOCRINOLOGY, V77, P44, DOI 10.1159/000068332; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Nieuwenhuis S, 2011, NAT NEUROSCI, V14, P1105, DOI 10.1038/nn.2886; Osuka K, 2001, J NEUROCHEM, V76, P1842, DOI 10.1046/j.1471-4159.2001.00198.x; Oudega M, 2012, Handb Clin Neurol, V109, P617, DOI 10.1016/B978-0-444-52137-8.00038-3; Prokai L, 2007, PHARMACOL THERAPEUT, V114, P1, DOI 10.1016/j.pharmthera.2007.01.006; Rau SW, 2003, J NEUROSCI, V23, P11420; Ritz MF, 2008, BRAIN RES, V1203, P177, DOI 10.1016/j.brainres.2008.01.091; Samantaray S, 2011, NEUROCHEM RES, V36, P1809, DOI 10.1007/s11064-011-0498-y; Santiago JM, 2009, J NEUROTRAUM, V26, P1783, DOI 10.1089/neu.2007.0502; Sare GM, 2008, EUR HEART J, V29, P2031, DOI 10.1093/eurheartj/ehn299; Scott E, 2012, FRONT NEUROENDOCRIN, V33, P85, DOI 10.1016/j.yfrne.2011.10.001; Segarra AC, 2004, PRINCIPLES GENDER SP, P96; Siriphorn A, 2012, J COMP NEUROL, V520, P2630, DOI 10.1002/cne.23056; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Sribnick EA, 2006, NEUROSCIENCE, V137, P197, DOI 10.1016/j.neuroscience.2005.08.074; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sribnick EA, 2010, J NEUROSCI RES, V88, P1738, DOI 10.1002/jnr.22337; Sribnick EA, 2006, J NEUROSCI RES, V84, P1064, DOI 10.1002/jnr.21016; SUGIOKA K, 1987, FEBS LETT, V210, P37, DOI 10.1016/0014-5793(87)81293-0; Sugishita K, 2003, J MOL CELL CARDIOL, V35, P331, DOI 10.1016/S0022-2828(03)00017-8; Swartz KR, 2007, J NEUROTRAUM, V24, P473, DOI 10.1089/neu.2006.0167; Tian DS, 2009, J NEUROCHEM, V109, P1658, DOI 10.1111/j.1471-4159.2009.06077.x; Traynor BJ, 2006, NEUROLOGY, V67, P20, DOI 10.1212/01.wnl.0000223353.34006.54; VanderHorst VGJM, 2005, J COMP NEUROL, V488, P152, DOI 10.1002/cne.20569; Winterle JS, 2001, ARCH BIOCHEM BIOPHYS, V392, P233, DOI 10.1006/abbi.2001.2431; WISE PM, 1981, BIOL REPROD, V24, P820, DOI 10.1095/biolreprod24.4.820; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025; Xu W, 2005, SPINAL CORD, V43, P204, DOI 10.1038/sj.sc.3101674; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086; Zhang YH, 2005, EXP NEUROL, V196, P41, DOI 10.1016/j.expneurol.2005.07.002; Zhang YH, 2007, EXP NEUROL, V204, P819, DOI 10.1016/j.expneurol.2007.01.015	75	51	53	0	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 2	2014	1561						11	22		10.1016/j.brainres.2014.03.002			12	Neurosciences	Neurosciences & Neurology	AH3GU	WOS:000336012500002	24637260	Green Accepted			2021-06-18	
J	Darling, SR; Leddy, JJ; Baker, JG; Williams, AJ; Surace, A; Miecznikowski, JC; Willer, B				Darling, Scott R.; Leddy, John J.; Baker, John G.; Williams, Amy J.; Surace, Anthony; Miecznikowski, Jeffrey C.; Willer, Barry			Evaluation of the Zurich Guidelines and Exercise Testing for Return to Play in Adolescents Following Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; computerized neuropsychological testing; return to play; return to sport; exercise; treadmill	SPORTS-RELATED CONCUSSION; NEUROPSYCHOLOGICAL ASSESSMENT; RETEST RELIABILITY; NORMATIVE DATA; TEST FAILURE; RECOVERY; PERFORMANCE; MANAGEMENT; SYMPTOMS	Objective:To evaluate return to play (RTP) and return to classroom outcomes when the Zurich guidelines are combined with a standardized exercise treadmill test [Buffalo Concussion Treadmill Test (BCTT)] and computerized neuropsychological (cNP) testing in adolescent athletes after concussion.Design:Retrospective chart review and follow-up.Setting:University Sports Medicine Concussion Clinic.Participants:One hundred seventeen athletes (75% male) with sport concussion ages 13 to 19 years and telephone follow-up of 91 (77.8%) athletes and their parents.Interventions:Concussed athletes who were asymptomatic at rest completed Automated Neuropsychological Assessment Metrics or Immediate Post-concussion Assessment and Cognitive Test cNP testing followed by the BCTT on the same day. Athletes then followed the Zurich consensus guidelines for RTP.Main Outcome Measures:The primary outcome measure was the degree of success in RTP, that is, RTP with or without return of concussive symptoms. Secondary outcome measure was return to school with or without symptoms.Results:All athletes returned to sport without exacerbation of symptoms. Telephone follow-up revealed that 38.5% experienced new issues upon return to the classroom. Forty-eight percent of athletes had 1 or more cNP subtests below average (<ninth percentile) when asymptomatic. Ultimately, performance on cNP was not predictive of return to school issues.Conclusions:The BCTT in combination with the Zurich consensus guidelines seems to be safe and successful for RTP. There is evidence to suggest that cNP testing performed in athletes who do not have a preinjury baseline test was not related to RTP or problems upon return to school.	[Darling, Scott R.; Leddy, John J.; Baker, John G.; Surace, Anthony] SUNY Buffalo, Dept Orthopaed, Buffalo, NY 14214 USA; [Baker, John G.; Williams, Amy J.] SUNY Buffalo, Dept Nucl Med, Buffalo, NY 14214 USA; [Miecznikowski, Jeffrey C.] SUNY Buffalo, Dept Biostat, Buffalo, NY 14214 USA; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14214 USA	Darling, SR (corresponding author), SUNY Buffalo, Dept Orthopaed & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	sdarling@buffalo.edu			Robert Rich Family Foundation; Program for Understanding Childhood Concussion and Stroke; Buffalo Bills (Ralph Wilson) Team Physician Fund; Buffalo Sabres Foundation	The authors wish to thank the following organizations for financial support of the project described in this article: The Robert Rich Family Foundation, Program for Understanding Childhood Concussion and Stroke, Buffalo Bills (Ralph Wilson) Team Physician Fund and the Buffalo Sabres Foundation.	Baker JG, 2012, REHABIL RES PRACT, DOI [10.1155/2012/70539, DOI 10.1155/2012/70539]; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Coppel DB, 2011, PHYS MED REH CLIN N, V22, P653, DOI 10.1016/j.pmr.2011.08.006; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Development Core Team R., 2008, R LANG ENV STAT COMP; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kirkwood MW, 2012, PSYCHOL ASSESSMENT, V24, P36, DOI 10.1037/a0024628; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lezak M. D., 2010, NEUROPSYCHOLOGICAL A; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2006, J ATHL TRAINING, V41, P137; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McAvoy K, 2009, REAP BENEFITS GOOD C; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory Paul, 2009, Scand J Med Sci Sports, V19, P452, DOI 10.1111/j.1600-0838.2009.00978.x; McGrath N, 2013, BRAIN INJURY, V27, P103, DOI 10.3109/02699052.2012.729282; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Performance CftSoHO, 2009, ANAM4 US MAN VERS 4; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Shrier I, 2012, CLIN J SPORT MED, V22, P211, DOI 10.1097/JSM.0b013e31824cc5f9; Wellek S., 2010, TESTING STAT HYPOTHE	31	51	52	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2014	24	2					128	133		10.1097/JSM.0000000000000026			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	AC0WO	WOS:000332216400005	24184849				2021-06-18	
J	Grabenstatter, HL; Del Angel, YC; Carlsen, J; Wempe, MF; White, AM; Cogswell, M; Russek, SJ; Brooks-Kayal, AR				Grabenstatter, H. L.; Del Angel, Y. Cruz; Carlsen, J.; Wempe, M. F.; White, A. M.; Cogswell, M.; Russek, S. J.; Brooks-Kayal, A. R.			The effect of STAT3 inhibition on status epilepticus and subsequent spontaneous seizures in the pilocarpine model of acquired epilepsy	NEUROBIOLOGY OF DISEASE			English	Article							TRAUMATIC BRAIN-INJURY; SPONTANEOUS RECURRENT SEIZURES; FOCAL CEREBRAL-ISCHEMIA; TEMPORAL-LOBE EPILEPSY; PROGRAMMED CELL-DEATH; CYCLIN D1; SIGNAL TRANSDUCERS; DENTATE GYRUS; KAINIC ACID; JAK-STAT	Pilocarpine-induced status epilepticus (SE), which results in temporal lobe epilepsy (TLE) in rodents, activates the JAK/STAT pathway. In the current study, we evaluate whether brief exposure to a selective inhibitor of the JAK/STAT pathway (WP1066) early after the onset of SE affects the severity of SE or reduces later spontaneous seizure frequency via inhibition of STAT3-regulated gene transcription. Rats that received systemic WP1066 or vehicle at the onset of SE were continuously video-EEG monitored during SE and for one month to assess seizure frequency overtime. Protein and/or mRNA levels for pSTAT3, and STAT3-regulated genes including: ICER, Gabral, c-myc, md-1, cyclin D1, and bcl-xl were evaluated in WP1066 and vehicle-treated rats during stages of epileptogenesis to determine the acute effects of WP1066 administration on SE and chronic epilepsy. WP1066 (two 50 mg/kg doses) administered within the first hour after onset of SE results in transient inhibition of pSTAT3 and long-term reduction in spontaneous seizure frequency. WP1066 alters the severity of chronic epilepsy without affecting SE or cell death. Early WP1066 administration reduces known downstream targets of STAT3 transcription 24 h after SE including cyclin D1 and mcl-1 levels, known for their roles in cell-cycle progression and cell survival, respectively. These findings uncover a potential effect of the JAK/STAT pathway after brain injury that is physiologically important and may provide a new therapeutic target that can be harnessed for the prevention of epilepsy development and/or progression. (C) 2013 Elsevier Inc. All rights reserved.	[Grabenstatter, H. L.; Del Angel, Y. Cruz; Carlsen, J.; White, A. M.; Brooks-Kayal, A. R.] Univ Colorado, Sch Med, Dept Pediat, Div Neurol, Boulder, CO 80309 USA; [Grabenstatter, H. L.; Del Angel, Y. Cruz; Carlsen, J.; White, A. M.; Brooks-Kayal, A. R.] Univ Colorado, Sch Med, Translat Epilepsy Res Program, Boulder, CO 80309 USA; [Wempe, M. F.; Brooks-Kayal, A. R.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Aurora, CO USA; [Cogswell, M.; Russek, S. J.] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA; [Brooks-Kayal, A. R.] Univ Colorado, Sch Med, Dept Neurol, Boulder, CO 80309 USA; [Brooks-Kayal, A. R.] Childrens Hosp Colorado, Aurora, CO USA	Brooks-Kayal, AR (corresponding author), Univ Colorado, Sch Med, Dept Pediat, Div Neurol, Boulder, CO 80309 USA.	amy.brooks-kayal@childrenscolorado.org			NIH, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051710]; Citizens United for Research in Epilepsy (CURE); Epilepsy Foundation; NIH/NCATS Colorado Clinical Translational Science Award [UL1 RR025780]; Colorado Center for Drug Discovery; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051710] Funding Source: NIH RePORTER	The authors would like to thank Dr. Yogendra Raol and the University of Colorado Neurophysiology Core for assistance related to EEG monitoring and Dana Hund for technical assistance with histology. These studies were funded by NIH, National Institute of Neurological Disorders and Stroke R01NS051710 (to ABK and SJR), Citizens United for Research in Epilepsy (CURE) (to ABK and SJR), Epilepsy Foundation (to HG), NIH/NCATS Colorado Clinical Translational Science Award UL1 RR025780 (to the University of Colorado Medicinal Chemistry Core), and the Colorado Center for Drug Discovery (to ABK and MFW).	Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Arbour N, 2008, J NEUROSCI, V28, P6068, DOI 10.1523/JNEUROSCI.4940-07.2008; Azuma Y, 1996, NEUROCHEM INT, V29, P289, DOI 10.1016/0197-0186(95)00157-3; BALISH M, 1991, EPILEPSIA, V32, P642, DOI 10.1111/j.1528-1157.1991.tb04703.x; Bauer J, 2001, SEIZURE-EUR J EPILEP, V10, P239, DOI 10.1053/seiz.2000.0499; Berg AT, 2003, NEUROLOGY, V60, P186, DOI 10.1212/01.WNL.0000031792.89992.EC; Bernard Sandra, 2006, V42, P329, DOI 10.1007/004; Blume WT, 2006, EPILEPSIA, V47, P71, DOI 10.1111/j.1528-1167.2006.00665.x; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cha BH, 2004, BRAIN DEV-JPN, V26, P394, DOI 10.1016/j.braindev.2003.12.006; Choi JS, 2003, MOL BRAIN RES, V119, P10, DOI 10.1016/j.molbrainres.2003.08.010; Crino PB, 2005, J CHILD NEUROL, V20, P330, DOI 10.1177/08830738050200041101; Croll SD, 2004, ADV EXP MED BIOL, V548, P57; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; England MJ, 2012, EPILEPSY BEHAV, V25, P266, DOI 10.1016/j.yebeh.2012.06.016; Ferrajoli A, 2007, CANCER RES, V67, P11291, DOI 10.1158/0008-5472.CAN-07-0593; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; Goffin K, 2007, EXP NEUROL, V205, P501, DOI 10.1016/j.expneurol.2007.03.008; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Haut SR, 2006, LANCET NEUROL, V5, P148, DOI 10.1016/S1474-4422(06)70348-9; Haut SR, 2002, EPILEPSIA, V43, P711, DOI 10.1046/j.1528-1157.2002.26401.x; Henshall DC, 2000, NEUROLOGY, V55, P250, DOI 10.1212/WNL.55.2.250; Hu YH, 2008, J BIOL CHEM, V283, P9328, DOI 10.1074/jbc.M705110200; Hussain SF, 2007, CANCER RES, V67, P9630, DOI 10.1158/0008-5472.CAN-07-1243; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Iwamaru A, 2007, ONCOGENE, V26, P2435, DOI 10.1038/sj.onc.1210031; Jeon WJ, 2008, EXP MOL MED, V40, P435, DOI 10.3858/emm.2008.40.4.435; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Kim R, 2005, BIOCHEM BIOPH RES CO, V333, P336, DOI 10.1016/j.bbrc.2005.04.161; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Koeller HB, 2008, NEUROBIOL DIS, V31, P230, DOI 10.1016/j.nbd.2008.04.010; Kupferman Michael E, 2009, J Exp Ther Oncol, V8, P117; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lindsten T, 2005, NEUROSCIENTIST, V11, P10, DOI 10.1177/1073858404269267; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Lopez E, 1999, NEUROSCIENCE, V91, P1461, DOI 10.1016/S0306-4522(98)00704-0; Lund IV, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1162396; Malone CD, 2012, MOL CELL NEUROSCI, V49, P439, DOI 10.1016/j.mcn.2012.02.003; Mankan AK, 2011, EXPERT OPIN INV DRUG, V20, P1263, DOI 10.1517/13543784.2011.601739; Masuda M, 2002, CANCER RES, V62, P3351; Mohapel P, 2004, NEUROBIOL DIS, V15, P196, DOI 10.1016/j.nbd.2003.11.010; Mori M, 2004, CELL DEATH DIFFER, V11, P1223, DOI 10.1038/sj.cdd.4401483; Murashima YL, 2007, EPILEPSIA, V48, P119, DOI 10.1111/j.1528-1167.2007.01299.x; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Orlova KA, 2010, J NEUROPATH EXP NEUR, V69, P850, DOI 10.1097/NEN.0b013e3181eac1f5; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Planas AM, 1996, EUR J NEUROSCI, V8, P2612, DOI 10.1111/j.1460-9568.1996.tb01556.x; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raible DJ, 2012, J NEUROTRAUM, V29, P2548, DOI 10.1089/neu.2012.2483; Reich NC, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.290pe61; Ribak CE, 2002, PROG BRAIN RES, V136, P319; Scharfman HE, 2004, ADV EXP MED BIOL, V548, P192; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Shukla Garima, 2012, Epilepsy Res Treat, V2012, P195073, DOI 10.1155/2012/195073; SIMONATO M, 1991, MOL BRAIN RES, V11, P115, DOI 10.1016/0169-328X(91)90113-C; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Suzuki S, 2001, EXP NEUROL, V170, P63, DOI 10.1006/exnr.2001.7701; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; Wang YZ, 2011, ONCOL REP, V26, P1173, DOI 10.3892/or.2011.1396; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; Xu ZC, 2011, NEUROCHEM RES, V36, P2208, DOI 10.1007/s11064-011-0576-1; Yang-Yen HF, 2006, J BIOMED SCI, V13, P201, DOI 10.1007/s11373-005-9064-4; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4	75	51	52	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2014	62						73	85		10.1016/j.nbd.2013.09.003			13	Neurosciences	Neurosciences & Neurology	301SY	WOS:000330553600008	24051278	Green Accepted			2021-06-18	
S	Omalu, B		Niranjan, A; Lunsford, LD		Omalu, Bennet			Chronic Traumatic Encephalopathy	CONCUSSION	Progress in Neurological Surgery		English	Article; Book Chapter							ALZHEIMERS ASSOCIATION GUIDELINES; POSTTRAUMATIC EPILEPSY; BRAIN-INJURY; NEUROPATHOLOGIC ASSESSMENT; MOLECULAR-MECHANISMS; NATIONAL INSTITUTE; DISEASE; PATHOLOGY; SPECTRUM; PLAYERS	Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative syndrome, which is caused by single, episodic, or repetitive blunt force impacts to the head and transfer of acceleration-deceleration forces to the brain. CTE presents clinically as a composite syndrome of mood disorders and behavioral and cognitive impairment, with or without sensorimotor impairment. Symptoms of CTE may begin with persistent symptoms of acute traumatic brain injury (TBI) following a documented episode of brain trauma or after a latent period that may range from days to weeks to months and years, up to 40 years following a documented episode of brain trauma or cessation of repetitive TBI. Posttraumatic encephalopathy is distinct from CTE, can be comorbid with CTE, and is a clinicopathologic syndrome induced by focal and/or diffuse, gross and/or microscopic destruction of brain tissue following brain trauma. The brain of a CTE sufferer may appear grossly unremarkable, but shows microscopic evidence of primary and secondary proteinopathies. The primary proteinopathy of CTE is tauopathy, while secondary proteinopathies may include, but are not limited to, amyloidopathy and TDP proteinopathy. Reported prevalence rates of CTE in cohorts exposed to TBI ranges from 3 to 80% across age groups. (C) 2014 S. Karger AG, Basel	[Omalu, Bennet] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA; [Omalu, Bennet] San Joaquin Gen Hosp, French Camp, CA USA; [Omalu, Bennet] San Joaquin Cty Coroners Div, French Camp, CA 95231 USA	Omalu, B (corresponding author), San Joaquin Cty Coroners Div, 7000 Michael Canlis Blvd, French Camp, CA 95231 USA.	bomalu@sjgov.org					Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; [Anonymous], 2014, HDB NEUROLO IN PRESS; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; BIGLER ED, 1987, J LEARN DISABIL, V20, P458, DOI 10.1177/002221948702000804; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Casson Ira R, 2006, Neurosurgery, V59, pE1152; Casson Ira R, 2006, Neurosurgery, V58, pE1003, DOI 10.1227/01.NEY.0000217313.15590.C5; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Chen-Plotkin AS, 2010, NAT REV NEUROL, V6, P211, DOI 10.1038/nrneurol.2010.18; Clavaguera F, 2013, BRAIN PATHOL, V23, P342, DOI 10.1111/bpa.12044; Congress of Neurological Surgeon, 1966, CLIN NEUROSURG, V12, P386; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Critchley M., 1949, NEUROCHIRURG HOMMAGE, P131; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Jucker M, 2013, NATURE, V501, P45, DOI 10.1038/nature12481; KAPLAN HA, 1954, JAMA-J AM MED ASSOC, V156, P1138, DOI 10.1001/jama.1954.02950120012004; Le Meghan N, 2012, Am J Neurodegener Dis, V1, P316; Mackenzie IRA, 2009, ACTA NEUROPATHOL, V117, P15, DOI 10.1007/s00401-008-0460-5; MCCOWN IA, 1959, AM J SURG, V98, P509, DOI 10.1016/0002-9610(59)90545-8; MCCOWN IA, 1959, JAMA-J AM MED ASSOC, V169, P1409, DOI 10.1001/jama.1959.03000300005002; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Patt S, 1999, EXP TOXICOL PATHOL, V51, P119, DOI 10.1016/S0940-2993(99)80084-0; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Roberts AH, 1969, STUD PREV TRAUM ENC; Royal College of Physicians of London. Committee on Boxing, 1969, COMM BOX, P11; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209; Valsamis M P, 1994, Neurosurg Clin N Am, V5, P175; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029	54	51	51	1	17	KARGER	BASEL	POSTFACH, CH-4009 BASEL, SWITZERLAND	0079-6492		978-3-318-02649-8; 978-3-318-02648-1	PROG NEUROL SURG			2014	28						38	49		10.1159/000358761	10.1159/isbn.978-3-318-02649-8		12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	BC8EJ	WOS:000355566000005	24923391				2021-06-18	
J	Srinivasan, VM; O'Neill, BR; Jho, D; Whiting, DM; Oh, MY				Srinivasan, Visish M.; O'Neill, Brent R.; Jho, Diana; Whiting, Donald M.; Oh, Michael Y.			The history of external ventricular drainage	JOURNAL OF NEUROSURGERY			English	Article						external ventricular drainage; intracranial pressure monitoring; ventriculostomy; history	CATHETER PLACEMENT; VIRTUAL-REALITY; PRESSURE; HYDROCEPHALUS; ANTIBIOTICS; INFECTIONS; ACCURACY; EFFICACY; MONITOR	External ventricular drainage (EVD) is one of the most commonly performed neurosurgical procedures. It was first performed as early as 1744 by Claude-Nicholas Le Cat. Since then, there have been numerous changes in technique, materials used, indications for the procedure, and safety. The history of EVD is best appreciated in 4 eras of progress: development of the technique (1850-1908), technological advancements (1927-1950), expansion of indications (1960-1995), and accuracy, training, and infection control (1995 present). While EVD was first attempted in he 18th century, it was not until 1890 that the first thorough report of EVD technique and outcomes was published by William Williams Keen. He was followed by H. Tillmanns, who described the technique that would be used for many years. Following this, many improvements were made to the EVD apparatus itself, including the addition of manometry by Adson and Lillie in 1927, and continued experimentation in cannulation/drainage materials. Technological advancements allowed a great expansion of indications for EVD, sparked by Nils Lundberg, who published a thorough analysis of the use of intracranial pressure (ICP) monitoring in patients with brain tumors in 1960. This led to the application of EVD and ICP monitoring in subarachnoid hemorrhage, Reye syndrome, and traumatic brain injury. Recent research in EVD has focused on improving the overall safety of the procedure, which has included the development of guidance-based systems, virtual reality simulators for trainees, and antibiotic-impregnated catheters.	[Srinivasan, Visish M.; Whiting, Donald M.; Oh, Michael Y.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA; [Srinivasan, Visish M.; Jho, Diana; Whiting, Donald M.; Oh, Michael Y.] Allegheny Gen Hosp, Dept Neurosurg, Pittsburgh, PA 15212 USA; [O'Neill, Brent R.] Univ Colorado, Sch Med, Div Pediat Neurosurg, Aurora, CO USA	Srinivasan, VM (corresponding author), Baylor Coll Med, Dept Neurosurg, 1709 Dryden Rd,Ste 750, Houston, TX 77030 USA.	visishs@glink.drexel.edu	Srinivasan, Visish M./H-9811-2019	Srinivasan, Visish M./0000-0001-7673-6805			Adson AW, 1927, T AM ACAD OPHTHALMOL, V30, P138; Aschoff A, 1999, NEUROSURG REV, V22, P67, DOI 10.1007/s101430050035; Banerjee PP, 2007, J NEUROSURG, V107, P515, DOI 10.3171/JNS-07/09/0515; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERING EA, 1951, J NEUROSURG, V8, P450, DOI 10.3171/jns.1951.8.4.0450; BINGHAM WF, 1986, J NEUROSURG, V64, P705, DOI 10.3171/jns.1986.64.5.0705; BRUNORI A, 1993, J NEUROSURG, V78, P515, DOI 10.3171/jns.1993.78.3.0515; Bullock MR, 1996, J NEUROTRAUM, V13, P685; CHAN KH, 1988, NEUROSURGERY, V23, P436, DOI 10.1227/00006123-198810000-00005; Crawford AS, 1943, ANN SURG, V117, P798, DOI 10.1097/00000658-194305000-00021; Dandy WE, 1922, B JOHNS HOPKINS HOSP, V33, P189; Dandy WE, 1918, ANN SURG, V68, P5, DOI 10.1097/00000658-191807000-00002; FRIEDMAN WA, 1980, J NEUROSURG, V53, P662, DOI 10.3171/jns.1980.53.5.0662; Greenberg MS., 2010, HDB NEUROSURGERY, V7th; Greer B, 2009, MONT MATH ENTHUS MON, V6, P3, DOI 10.1016/B978-141602908-3.50004-2; Haynes IS, 1913, ANN SURG, V57, P449, DOI 10.1097/00000658-191304000-00001; Hill BL, 1866, LECT AM ECLECTIC SYS; Huyette DR, 2008, J NEUROSURG, V108, P88, DOI 10.3171/JNS/2008/108/01/0088; INGRAHAM FD, 1947, JAMA-J AM MED ASSOC, V135, P82, DOI 10.1001/jama.1947.02890020012005; Ingraham FD, 1941, ANN SURG, V114, P1096, DOI 10.1097/00000658-194112000-00017; Kakarla UK, 2008, NEUROSURGERY S1, V63; KAUFMANN GE, 1970, J NEUROSURG, V33, P226, DOI 10.3171/jns.1970.33.2.0226; Keen WW., 1890, LANCET, V136, P553, DOI DOI 10.1016/S0140-6736(00)48676-9; Keong NCH, 2012, NEUROSURGERY, V71, P394, DOI 10.1227/NEU.0b013e318257bebb; Kompanje EJO, 2003, PEDIATR NEUROSURG, V39, P10, DOI 10.1159/000070872; Krombach G, 2000, MINIM INVAS NEUROSUR, V43, P171, DOI 10.1055/s-2000-11376; KUSSKE JA, 1973, J NEUROSURG, V38, P591, DOI 10.3171/jns.1973.38.5.0591; Lemole GM, 2007, NEUROSURGERY, V61, P142, DOI 10.1227/01.neu.0000279734.22931.21; Lifshutz J, 2001, NEUROSURG FOCUS, V11, P1; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MATSON DD, 1966, J NEUROSURG, V24, P945; McCarthy PJ, 2010, NEUROCRIT CARE, V12, P220, DOI 10.1007/s12028-009-9284-y; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; O'Leary ST, 2000, J NEUROSURG, V92, P801, DOI 10.3171/jns.2000.92.5.0801; O'Neill BR, 2008, SURG NEUROL, V70, P268, DOI 10.1016/j.surneu.2007.05.007; PIZZI FJ, 1976, CHILD BRAIN, V2, P59; Pople I, 2012, NEUROSURGERY, V71, P6, DOI 10.1227/NEU.0b013e3182544e31; Poppen JL, 1943, ARCH NEURO PSYCHIATR, V50, P587, DOI 10.1001/archneurpsyc.1943.02290230099011; RAJSHEKHAR V, 1992, ACTA NEUROCHIR, V115, P8, DOI 10.1007/BF01400584; Rengachary SS, 2005, PRINCIPLES NEUROSURG; Retzius MG, 1875, STUDIEN ANATOMIE NER; ROBINSON F, 1948, J NEUROSURG, V5, P320, DOI 10.3171/jns.1948.5.3.0320; ROSEGAY H, 1992, J NEUROSURG, V76, P1032, DOI 10.3171/jns.1992.76.6.1032; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SAUNDERS RL, 1978, NEUROSURGERY, V3, P130, DOI 10.1097/00006123-197807000-00021; SAUNDERS RL, 1979, CRIT CARE MED, V7, P556, DOI 10.1097/00003246-197912000-00010; Schultke E, 2009, NEUROSURGERY, V64, P1001, DOI 10.1227/01.NEU.0000344003.72056.7F; Sekula RF, 2008, BRIT J NEUROSURG, V22, P213, DOI 10.1080/02688690701832084; Selden NR, 2012, NEUROSURGERY, V70, P971, DOI 10.1227/NEU.0b013e31823d7a45; SHAPIRO HM, 1972, J NEUROSURG, V36, P798, DOI 10.3171/jns.1972.36.6.0798; SMITH RW, 1976, J NEUROSURG, V44, P567, DOI 10.3171/jns.1976.44.5.0567; Sonabend AM, 2011, NEUROSURGERY, V68, P996, DOI 10.1227/NEU.0b013e3182096d84; STONE JL, 1985, NEUROSURGERY, V17, P997, DOI 10.1227/00006123-198512000-00024; Tillmanns H, 1908, BRIT MED J, V1908, P983; Walker ML, 2001, NEUROSURG CLIN N AM, V12, P101, DOI 10.1016/S1042-3680(18)30070-6; WHITE RJ, 1969, J NEUROSURG, V30, P264, DOI 10.3171/jns.1969.30.3part1.0264; Whytt R, 1768, OBSERVATIONS DROPSY; WILKINS RH, 1964, J NEUROSURG, V21, P240, DOI 10.3171/jns.1964.21.3.0240; WYLER AR, 1972, J NEUROSURG, V37, P185, DOI 10.3171/jns.1972.37.2.0185; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725	63	51	52	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2014	120	1					228	236		10.3171/2013.6.JNS121577			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	281GL	WOS:000329087900033	23889138				2021-06-18	
J	Chen, T; Yang, YF; Luo, P; Liu, W; Dai, SH; Zheng, XR; Fei, Z; Jiang, XF				Chen, Tao; Yang, Yue-fan; Luo, Peng; Liu, Wei; Dai, Shu-hui; Zheng, Xin-rui; Fei, Zhou; Jiang, Xiao-fan			Homer1 knockdown protects dopamine neurons through regulating calcium homeostasis in an in vitro model of Parkinson's disease	CELLULAR SIGNALLING			English	Article						Parkinson's disease; Homer; Calcium channel; Endoplasmic reticulum	METABOTROPIC GLUTAMATE RECEPTORS; TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL DYSFUNCTION; NEUROLOGICAL DISEASES; SUBUNIT EXPRESSION; CORTICAL-NEURONS; DOWN-REGULATION; IP3 RECEPTORS; CHANNEL; PROTEINS	Homer1 protein is an important scaffold protein at postsynaptic density and has been demonstrated to play a central role in calcium signaling in the central nervous system. The aim of this study was to investigate the effects of Horner1 knockdown on MPP+ induced neuronal injury in cultured dopamine (DA) neurons. We found that down-regulating Homer1 expression with specific small interfering RNA (siRNA) significantly suppressed LDH release, reduced Propidium iodide (PI) or Hoechst staining, increased the number of tyrosine hydroxylase (TH) positive cells and DA uptake, and attenuated apoptotic and necrotic cell death after MPP+ injury. Homer1 knock-down decreased intracellular reactive oxygen species (ROS) generation through inhibition of intracellular calcium overload, but did not affect the endogenous antioxidant enzyme activities. Calcium imaging was used to examine the changes of intracellular Ca2+ concentration ([Ca2+](cyt)) and Ca2+ in endoplasmic reticulum (ER) ([Ca2+](ER)), and the results showed that Homer1 siRNA transfection attenuated ER Ca2+ release up to 120 min after MPP+ injury. Furthermore, decrease of [Ca2+](cyt) induced by Homer1 knockdown in MPP+ treated neurons was further enhanced by NMDA receptor antagonists MK-801 and AP-5, but not canonical transient receptor potential (TRPC) channel antagonist SKF-96365. L-type calcium antagonist isradipine but not nimodipine further inhibited intracellular calcium overload after MPP+ insult in Homer1 down-regulated neurons. These results suggest that Homer1 knockdown has protective effects against neuronal injury in in vitro PD model by reducing calcium overload mediated ROS generation, and this protection may be dependent at least in part on the regulatory effects on the function of calcium channels in both plasma membrane and ER. (C) 2013 Elsevier Inc. All rights reserved.	[Chen, Tao; Yang, Yue-fan; Luo, Peng; Liu, Wei; Dai, Shu-hui; Zheng, Xin-rui; Fei, Zhou; Jiang, Xiao-fan] Fourth Mil Med Univ, Xijing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi Provinc, Peoples R China; [Chen, Tao] 123th Hosp PLA, Dept Neurosurg, Bengbu 233000, Anhui, Peoples R China	Jiang, XF (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi Provinc, Peoples R China.	fmmuzhoufei@163.com; fmmujiangxiaofan@163.com	Yang, Yuefan/AAJ-9136-2020	Luo, Peng/0000-0003-0746-939X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81071034, 81371447, 81301037, 30930093]; National Science & Technology Pillar Program [2012BAI11B02]; Research Foundation of PEA [2010gxjs078, AWS11J008]	This work was financially supported by the National Natural Science Foundation of China (No. 81071034, 81371447, 81301037, and No. 30930093), National Science & Technology Pillar Program (No. 2012BAI11B02) and Research Foundation of PEA (No. 2010gxjs078 and No. AWS11J008).	Abramov AY, 2003, CELL CALCIUM, V33, P101, DOI 10.1016/S0143-4160(02)00203-8; Ary AW, 2007, BRAIN RES, V1184, P295, DOI 10.1016/j.brainres.2007.09.035; Becker C, 2008, NEUROLOGY, V70, P1438, DOI 10.1212/01.wnl.0000303818.38960.44; Ben-Shahar O, 2009, SYNAPSE, V63, P598, DOI 10.1002/syn.20640; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bouron A, 2006, EUR J NEUROSCI, V24, P699, DOI 10.1111/j.1460-9568.2006.04946.x; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Chan CS, 2009, TRENDS NEUROSCI, V32, P249, DOI 10.1016/j.tins.2009.01.006; Chen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055601; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Cristofanilli M, 2006, J PHYSIOL-LONDON, V575, P543, DOI 10.1113/jphysiol.2006.114108; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Duchen MR, 2012, PFLUG ARCH EUR J PHY, V464, P111, DOI 10.1007/s00424-012-1112-0; Gandhi S, 2009, MOL CELL, V33, P627, DOI 10.1016/j.molcel.2009.02.013; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Igosheva N, 2005, NEUROCHEM INT, V47, P216, DOI 10.1016/j.neuint.2005.02.011; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ilijic E, 2011, NEUROBIOL DIS, V43, P364, DOI 10.1016/j.nbd.2011.04.007; Karst H, 2002, EUR J NEUROSCI, V16, P1083, DOI 10.1046/j.1460-9568.2002.02172.x; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Kotake Y, 2003, CURR MED CHEM, V10, P2507, DOI 10.2174/0929867033456558; Kupsch A, 1996, BRAIN RES, V741, P185, DOI 10.1016/S0006-8993(96)00917-1; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Liu CY, 2009, J FORMOS MED ASSOC, V108, P599, DOI 10.1016/S0929-6646(09)60380-6; Luo P, 2012, NEUROCHEM INT, V61, P731, DOI 10.1016/j.neuint.2012.06.014; Luo P, 2012, FREE RADICAL RES, V46, P766, DOI 10.3109/10715762.2012.678340; Maret S, 2007, P NATL ACAD SCI USA, V104, P20090, DOI 10.1073/pnas.0710131104; MASLIAH E, 1992, J NEUROPATH EXP NEUR, V51, P404, DOI 10.1097/00005072-199207000-00003; Mattson MP, 2007, AGING CELL, V6, P337, DOI 10.1111/j.1474-9726.2007.00275.x; Nedergaard M, 2010, CELL CALCIUM, V47, P140, DOI 10.1016/j.ceca.2009.11.010; Nedergaard M, 2010, CELL CALCIUM, V47, P101, DOI 10.1016/j.ceca.2009.12.011; Rego AC, 2003, NEUROCHEM RES, V28, P1563, DOI 10.1023/A:1025682611389; Ritz B, 2010, ANN NEUROL, V67, P600, DOI 10.1002/ana.21937; Scheife RT, 2000, AM J HEALTH-SYST PH, V57, P953, DOI 10.1093/ajhp/57.10.953; Schreibelt G, 2007, BRAIN RES REV, V56, P322, DOI 10.1016/j.brainresrev.2007.07.005; Shiraishi Y, 2003, MOL CELL NEUROSCI, V22, P188, DOI 10.1016/S1044-7431(03)00037-X; Surmeier DJ, 2011, NEUROSCIENCE, V198, P221, DOI 10.1016/j.neuroscience.2011.08.045; Szumlinski KK, 2006, CURR OPIN NEUROBIOL, V16, P251, DOI 10.1016/j.conb.2006.05.002; Szumlinski KK, 2006, NEUROPSYCHOPHARMACOL, V31, P768, DOI 10.1038/sj.npp.1300890; Szumlinski KK, 2004, NEURON, V43, P401, DOI 10.1016/j.neuron.2004.07.019; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Vanden Berghe T, 2010, CELL DEATH DIFFER, V17, P922, DOI 10.1038/cdd.2009.184; Vila M, 2004, NAT MED, V10, pS58, DOI 10.1038/nm1068; Witte ME, 2010, MITOCHONDRION, V10, P411, DOI 10.1016/j.mito.2010.05.014; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Yamamoto K, 2005, EUR J NEUROSCI, V22, P1338, DOI 10.1111/j.1460-9568.2005.04278.x; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649	49	51	51	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0898-6568	1873-3913		CELL SIGNAL	Cell. Signal.	DEC	2013	25	12					2863	2870		10.1016/j.cellsig.2013.09.004			8	Cell Biology	Cell Biology	268OG	WOS:000328179800056	24036210				2021-06-18	
J	Luo, T; Wu, JF; Kabadi, SV; Sabirzhanov, B; Guanciale, K; Hanscom, M; Faden, J; Cardiff, K; Bengson, CJ; Faden, AI				Luo, Tao; Wu, Junfang; Kabadi, Shruti V.; Sabirzhanov, Boris; Guanciale, Kelsey; Hanscom, Marie; Faden, Juliane; Cardiff, Katherine; Bengson, Charles Jeremy; Faden, Alan I.			Propofol Limits Microglial Activation after Experimental Brain Trauma through Inhibition of Nicotinamide Adenine Dinucleotide Phosphate Oxidase	ANESTHESIOLOGY			English	Article							NADPH OXIDASE; CELL-DEATH; NITRIC-OXIDE; PROVIDES NEUROPROTECTION; INFLAMMATORY RESPONSES; COGNITIVE DEFICITS; PREFRONTAL CORTEX; SPATIAL MEMORY; CDK INHIBITOR; MOUSE MODEL	Background: Microglial activation is implicated in delayed tissue damage after traumatic brain injury (TBI). Activation of microglia causes up-regulation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, with the release of reactive oxygen species and cytotoxicity. Propofol appears to have antiinflammatory actions. The authors evaluated the neuroprotective effects of propofol after TBI and examined in vivo and in vitro whether such actions reflected modulation of NADPH oxidase. Methods: Adult male rats were subjected to moderate lateral fluid percussion TBI. Effect of propofol on brain microglial activation and functional recovery was assessed up to 28 days postinjury. By using primary microglial and BV2 cell cultures, the authors examined propofol modulation of lipopolysaccharide and interferon-gamma-induced microglial reactivity and neurotoxicity. Results: Propofol improved cognitive recovery after TBI in novel object recognition test (48 +/- 6% for propofol [n = 15] vs. 30 +/- 4% for isoflurane [n = 14]; P = 0.005). The functional improvement with propofol was associated with limited microglial activation and decreased cortical lesion volume and neuronal loss. Propofol also attenuated lipopolysaccharide- and interferon-gamma-induced microglial activation in vitro, with reduced expression of inducible nitric oxide synthase, nitric oxide, tumor necrosis factor-alpha, interlukin-1 beta, reactive oxygen species, and NADPH oxidase. Microglial-induced neurotoxicity in vitro was also markedly reduced by propofol. The protective effect of propofol was attenuated when the NADPH oxidase subunit p22(phox) was knocked down by small interfering RNA. Moreover, propofol reduced the expression of p22(phox) and gp91(phox), two key components of NADPH oxidase, after TBI. Conclusion: The neuroprotective effects of propofol after TBI appear to be mediated, in part, through the inhibition of NADPH oxidase.	[Luo, Tao; Wu, Junfang; Kabadi, Shruti V.; Sabirzhanov, Boris; Guanciale, Kelsey; Hanscom, Marie; Faden, Juliane; Cardiff, Katherine; Bengson, Charles Jeremy; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, HSF 2,Room S247,20 Penn St, Baltimore, MD 21201 USA; [Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Faden, Alan I.] Univ Maryland, Sch Med, Ctr STAR, Baltimore, MD 21201 USA	Faden, AI (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, HSF 2,Room S247,20 Penn St, Baltimore, MD 21201 USA.	afaden@anes.umm.edu		Faden, Alan I./0000-0003-0128-2348; Hanscom, Marie/0000-0001-8308-135X	National Institutes of Health, Bethesda, MarylandUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS061839, NS037313]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061839, R01NS037313] Funding Source: NIH RePORTER	This work was supported by grants R01 NS061839 and NS037313 from National Institutes of Health, Bethesda, Maryland (to Dr. Faden). Dr. Luo received departmental salary support. The authors declare no competing interests. The first two authors contributed equally to this article.	Adachi YU, 2005, ACTA ANAESTH SCAND, V49, P331, DOI 10.1111/j.1399-6576.2005.00564.x; Adembri C, 2007, CNS DRUG REV, V13, P333, DOI 10.1111/j.1527-3458.2007.00015.x; Akirav I, 2006, CEREB CORTEX, V16, P1759, DOI 10.1093/cercor/bhj114; Barger SW, 2007, J NEUROCHEM, V101, P1205, DOI 10.1111/j.1471-4159.2007.04487.x; Bhat R, 2010, P NATL ACAD SCI USA, V107, P2580, DOI 10.1073/pnas.0915139107; Biscaro B, 2012, NEURODEGENER DIS, V9, P187, DOI 10.1159/000330363; Block ML, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S2-S8; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cheret C, 2008, J NEUROSCI, V28, P12039, DOI 10.1523/JNEUROSCI.3568-08.2008; Cho SH, 2011, J BIOL CHEM, V286, P32713, DOI 10.1074/jbc.M111.254268; Choi SH, 2012, J NEUROCHEM, V120, P292, DOI 10.1111/j.1471-4159.2011.07572.x; Cross L, 2013, LEARN MEMORY, V20, P41, DOI 10.1101/lm.028266.112; Culley DJ, 2004, ANESTHESIOLOGY, V100, P309, DOI 10.1097/00000542-200402000-00020; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Franks NP, 2006, BRIT J PHARMACOL, V147, pS72, DOI 10.1038/sj.bjp.0706441; Garcia PS, 2010, CURR NEUROPHARMACOL, V8, P2, DOI 10.2174/157015910790909502; Gibbons HM, 2006, BRAIN RES, V1084, P1, DOI 10.1016/j.brainres.2006.02.032; Gui B, 2012, INFLAMMATION, V35, P1632, DOI 10.1007/s10753-012-9478-x; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; HARA M, 1994, ANESTHESIOLOGY, V81, P988, DOI 10.1097/00000542-199410000-00026; He Y, 2003, J NEUROCHEM, V86, P1338, DOI 10.1046/j.1471-4159.2003.01938.x; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412; Hsing CH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017598; Hsu BG, 2005, CLIN EXP PHARMACOL P, V32, P24, DOI 10.1111/j.1440-1681.2005.04155.x; Iijima T, 2006, BRAIN RES, V1099, P25, DOI 10.1016/j.brainres.2006.04.117; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Ito H, 1999, ACTA ANAESTH SCAND, V43, P153, DOI 10.1034/j.1399-6576.1999.430206.x; Jeohn GH, 2000, BRAIN RES, V880, P173, DOI 10.1016/S0006-8993(00)02737-2; Jiang F, 2011, PHARMACOL REV, V63, P218, DOI 10.1124/pr.110.002980; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kim JA, 2009, ANESTHESIOLOGY, V111, P566, DOI 10.1097/ALN.0b013e3181af5b3d; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee IH, 2008, ANESTH ANALG, V107, P1211, DOI 10.1213/ane.0b013e31817ee879; Lee M, 2011, GLIA, V59, P152, DOI 10.1002/glia.21087; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li JM, 2005, MOL CELL BIOL, V25, P2320, DOI 10.1128/MCB.25.6.2320-2330.2005; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Luh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019948; Mander P, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-20; Mander PK, 2006, J IMMUNOL, V176, P1046, DOI 10.4049/jimmunol.176.2.1046; Munch G, 2003, EXP BRAIN RES, V150, P1, DOI 10.1007/s00221-003-1389-5; Murasaki O, 2003, J PHARMACOL EXP THER, V307, P995, DOI 10.1124/jpet.103.055772; Murphy PG, 1996, BRIT J ANAESTH, V76, P536; Nguyen HT, 2009, ANESTHESIOLOGY, V110, P326, DOI 10.1097/ALN.0b013e3181942b5b; ORSER BA, 1994, J NEUROSCI, V14, P7747; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Redish AD, 1998, NEURAL COMPUT, V10, P73, DOI 10.1162/089976698300017908; Richardson JE, 2007, ANESTHESIOLOGY, V107, P412, DOI 10.1097/01.anes.0000278875.36639.2c; Sanders RD, 2013, CRIT CARE MED, V41, P1627, DOI 10.1097/CCM.0b013e31827c0c8d; Shibakawa YS, 2005, BRIT J ANAESTH, V95, P803, DOI 10.1093/bja/aei256; Smith AM, 2013, GLIA, V61, P929, DOI 10.1002/glia.22486; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Someya A, 1999, J LEUKOCYTE BIOL, V66, P851; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Tang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027890; Taylor DL, 2005, J NEUROSCI, V25, P2952, DOI 10.1523/JNEUROSCI.4456-04.2005; Terrando N, 2011, ANN NEUROL, V70, P986, DOI 10.1002/ana.22664; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Terrando N, 2010, CRIT CARE, V14, DOI 10.1186/cc9019; Thiry JC, 2004, EUR J PHARMACOL, V499, P29, DOI 10.1016/j.ejphar.2004.05.043; Todd MM, 1996, J NEUROSURG ANESTH, V8, P296, DOI 10.1097/00008506-199610000-00007; Tsao CM, 2008, CRIT CARE MED, V36, P887, DOI 10.1097/CCM.0B013E318165395E; Vanlersberghe C., 2008, V182, P227, DOI 10.1007/978-3-540-74806-9_11; Violet JM, 1997, ANESTHESIOLOGY, V86, P866, DOI 10.1097/00000542-199704000-00017; Wu JF, 2010, GLIA, V58, P315, DOI 10.1002/glia.20925; Wu JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044027; Xu X, 2008, NEUROSCIENCE, V154, P1002, DOI 10.1016/j.neuroscience.2008.04.013; Ye XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052887; Yu GX, 2011, SURGERY, V150, P887, DOI 10.1016/j.surg.2011.04.002; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhao XR, 2001, J NEUROSCI RES, V64, P121, DOI 10.1002/jnr.1059; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zou JY, 2005, BRAIN RES, V1034, P11, DOI 10.1016/j.brainres.2004.11.014	83	51	55	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	DEC	2013	119	6					1370	1388		10.1097/ALN.0000000000000020			19	Anesthesiology	Anesthesiology	301JJ	WOS:000330528300018	24121215	Bronze			2021-06-18	
J	Tompkins, P; Tesiram, Y; Lerner, M; Gonzalez, LP; Lightfoot, S; Rabb, CH; Brackett, DJ				Tompkins, Paul; Tesiram, Yasvir; Lerner, Megan; Gonzalez, Larry P.; Lightfoot, Stan; Rabb, Craig H.; Brackett, Daniel J.			Brain Injury: Neuro-Inflammation, Cognitive Deficit, and Magnetic Resonance Imaging in a Model of Blast Induced Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast injury; cognitive deficit; inflammatory response; traumatic brain injury	MORRIS WATER MAZE; INDUCED NEUROTRAUMA; RATS; MEMORY; PERSEVERATION; INVOLVEMENT; NAVIGATION; EXPOSURE; SHOCK; PTSD	Blast wave-induced traumatic injury from terrorist explosive devices can occur at any time in either military or civilian environments. To date, little work has focused on the central nervous system response to a non-penetrating blast injury. We have evaluated the effect of a single 80-psi blast-overpressure wave in a rat model. Histological and immunochemical studies showed an early inflammatory response, tissue damage and the initiation of apoptosis. With regard to inflammation, polymorphonuclear leukocytes and lymphocytes infiltrated brain parenchyma within 1h post-blast. Glial-fibrillary protein, cyclo-oxygenase-2ir, interleukin-1 and tumor necrosis factor were present by 1h and remained detectable at three weeks post-injury. High mobility group box-1 protein was detectable at three weeks. With regard to tissue damage, S100 and 4-hydroxynonenal were present at 1h and remained detectable at three weeks. Amyloid precursor protein was detectable at three weeks. As for apoptosis, Cleaved Caspase-3 was detectable at three weeks. Morris water maze assessment of cognitive function showed that blast injured animals required significantly more time to reach the platform on day 1 of training and traveled a greater distance to get to the platform on days 1 and 2. Blast-injured animals showed a significant increase in swimming speed (p<0.001), increased total distance traveled (p<0.001) and increased number of entries into the previous quadrant that had contained the escape platform (p<0.05). Magnetic resonance imaging showed hyperintense regions in the somatosensory area within 1h. T2 relaxation times and apparent diffusion coefficients show increasing trends in both somatosensory and cortical regions. These data indicate an early and lasting response of brain tissue to non-penetrating blast over-pressure injury. This early inflammatory response is indicative of a mild traumatic brain injury. There is evidence of early hippocampal dysfunction.	[Tompkins, Paul; Rabb, Craig H.] Univ Oklahoma, HSC, Dept Neurosurg, Oklahoma City, OK 73104 USA; [Gonzalez, Larry P.] Univ Oklahoma, HSC, Dept Psychiat & Behav Sci, Oklahoma City, OK 73104 USA; [Tesiram, Yasvir] Oklahoma Med Res Fdn, Adv Magnet Resonance Ctr, Free Rad Biol & Aging Res Program, Oklahoma City, OK 73104 USA; [Lerner, Megan; Brackett, Daniel J.] Univ Oklahoma, HSC, Dept Surg, Oklahoma City, OK 73104 USA; [Lightfoot, Stan] Univ Oklahoma, HSC, Dept Pathol, Oklahoma City, OK 73104 USA; [Lightfoot, Stan] Vet Adm Med Ctr, Oklahoma City, OK 73104 USA	Tompkins, P (corresponding author), Univ Oklahoma, HSC, Dept Neurosurg, 1122 NE 13th St,Room 340, Oklahoma City, OK 73104 USA.	Paul-Tompkins@ouhsc.edu	Tesiram, Yasvir A/B-7332-2016; Gonzalez, Larry P/A-4362-2008	Tesiram, Yasvir A/0000-0003-3008-2927; 			Arkhipov V, 2008, PHARMACOL BIOCHEM BE, V88, P299, DOI 10.1016/j.pbb.2007.08.012; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hollup SA, 2001, J NEUROSCI, V21, P4505, DOI 10.1523/JNEUROSCI.21-12-04505.2001; Irwin R J, 1998, J Okla State Med Assoc, V91, P387; Irwin RJ, 1997, J TRAUMA, V43, P650, DOI 10.1097/00005373-199710000-00015; Irwin RJ, 1999, J TRAUMA, V47, P105, DOI 10.1097/00005373-199907000-00023; Kaufmann W, 2012, TOXICOL PATHOL, V40, P87, DOI 10.1177/0192623312439125; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kaur C, 1996, ARCH HISTOL CYTOL, V59, P239, DOI 10.1679/aohc.59.239; Kita T, 2000, INT J LEGAL MED, V113, P221, DOI 10.1007/s004149900095; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Mann PC, 2012, TOXICOL PATHOL, V40, P7, DOI 10.1177/0192623312438738; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Regitnig P, 2002, VIRCHOWS ARCH, V441, P328, DOI 10.1007/s00428-002-0646-5; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Whishaw IQ, 1997, HIPPOCAMPUS, V7, P361, DOI 10.1002/(SICI)1098-1063(1997)7:4<361::AID-HIPO2>3.0.CO;2-M	42	51	52	0	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2013	30	22					1888	1897		10.1089/neu.2012.2674			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	243PH	WOS:000326328400007	23777197				2021-06-18	
J	Sticozzi, C; Belmonte, G; Meini, A; Carbotti, P; Grasso, G; Palmi, M				Sticozzi, C.; Belmonte, G.; Meini, A.; Carbotti, P.; Grasso, G.; Palmi, M.			IL-1 beta INDUCES GFAP EXPRESSION IN VITRO AND IN VIVO AND PROTECTS NEURONS FROM TRAUMATIC INJURY-ASSOCIATED APOPTOSIS IN RAT BRAIN STRIATUM VIA NF kappa B/CA(2+)-CALMODULIN/ERK MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING PATHWAY	NEUROSCIENCE			English	Article						interleukin-1beta; CNS; astrogliosis; apoptosis; signal transduction	ASTROCYTOMA CELL-LINE; NITRIC-OXIDE SYNTHASE; SPINAL-CORD-INJURY; U-373 MG CELLS; NF-KAPPA-B; INTRACELLULAR CA2+; REACTIVE ASTROCYTES; PANCREATIC-ISLETS; CALCIUM INFLUX; BETA-CELLS	Reactive astrogliosis, a feature of neuro-inflammation is induced by a number of endogenous mediators including cytokines. Despite interleukin-1 beta (IL-1 beta) stands out as the major inducer of this process, the underlying mechanism and its role on neuronal viability remain elusive. We investigated in human astrocytoma cells and the rat brain striatum, the role of the nuclear factor-kB (NF-kB) intracellular Ca2+ concentration ([Ca2+](i)) calmodulin (CaM) and extracellular regulated mitogen-activated protein kinases (ERK1/2) in IL-1 beta-induced expression of glial fibrillary acidic protein (GFAP) and neuronal apoptosis associated to a brain trauma. Cell data showed that IL-1 beta (1 ng/ml) increased NF-kB, pERK1/2 and GFAP expression. Nevertheless, further increase in IL-1 beta levels reversed progressively these responses. Preventing ERK1/2 activation with 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthiol]-butadiene antagonized 1L-1 beta-induced GFAP expression while inhibiting selectively nuclear translocation of NF-kB with caffeic-acid phenethyl-ester down-regulated both ERK1/2 and GFAP expression induced by IL-1 beta. The GFAP response was also prevented by antagonizing selectively increase in [Ca2+](i), CaM activity or inducible nitric oxide synthase expression with respectively ryanodine plus 2-aminoethoxydiphenyl-borate, N-(6-aminohexyl)-5-chloro-1-naphthalensulfonamide hydrochloride and N-[(3-(aminomethyl)-phenyl]methyl]-ethanimidamide dihydrochloride. Data in vivo supported these findings and showed that GFAP expression induced by IL-1 beta (50 ng/ml) correlated with attenuated glial scar formation and reduced neuronal apoptosis. Our data identified the NF-kB/Ca2+-CaM/ERK signaling pathway as a novel in vivo key regulator of IL-1 beta-induced astrogliosis which may represent a potential target in neurodegeneration. (C) 2013 Published by Elsevier Ltd. on behalf of IBRO.	[Sticozzi, C.] Univ Ferrara, Dept Life Sci & Biotechnol, I-44121 Ferrara, Italy; [Belmonte, G.; Meini, A.; Carbotti, P.; Grasso, G.; Palmi, M.] Univ Siena, Dept Med & Surg Sci & Neurosci, I-53100 Siena, Italy	Palmi, M (corresponding author), Univ Siena, Dept Med & Surg Sci & Neurosci, Via A Moro 2, I-53100 Siena, Italy.	palmi@unisi.it			Piano di Ateneo per la ricerca; Universite di Siena, Siena, Italy; Fondazione Monte dei Paschi di Siena	This study was supported by contribution from the Piano di Ateneo per la ricerca (PAR 2009-2010) Universite di Siena, Siena, Italy and grants (2011-2012) from Fondazione Monte dei Paschi di Siena.	Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Aktan F, 2004, LIFE SCI, V75, P639, DOI 10.1016/j.lfs.2003.10.042; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; BALASINGAM V, 1994, J NEUROSCI, V14, P846; Belanger Mireille, 2009, Dialogues Clin Neurosci, V11, P281; BERTOGLIO JH, 1987, LYMPHOKINE RES, V6, P83; Beskina O, 2007, AM J PHYSIOL-CELL PH, V293, pC1103, DOI 10.1152/ajpcell.00249.2007; Boran MS, 2007, J NEUROCHEM, V102, P216, DOI 10.1111/j.1471-4159.2007.04464.x; Brahmachari S, 2006, J NEUROSCI, V26, P4930, DOI 10.1523/JNEUROSCI.5480-05.2006; Clementi E, 1998, BIOCHEM PHARMACOL, V55, P713, DOI 10.1016/S0006-2952(97)00375-4; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KASAHARA T, 1990, BIOCHEM BIOPH RES CO, V167, P1242, DOI 10.1016/0006-291X(90)90657-9; Kim MJ, 2004, BIOCHEM PHARMACOL, V68, P1775, DOI 10.1016/j.bcp.2004.06.031; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Lieb K, 1996, J NEUROCHEM, V66, P1496; Maedler K, 2006, DIABETES, V55, P2713, DOI 10.2337/db05-1430; Matyash V, 2001, MOL CELL NEUROSCI, V18, P664, DOI 10.1006/mcne.2001.1047; Meini A, 2006, EUR J NEUROSCI, V23, P1690, DOI 10.1111/j.1460-9568.2006.04705.x; Meini A, 2003, EUR J NEUROSCI, V17, P692, DOI 10.1046/j.1460-9568.2003.02483.x; Meini A, 2000, J NEUROSCI, V20, P8980; Meini A, 2008, BRIT J PHARMACOL, V153, P1718; MOLLACE V, 1993, BIOCHEM BIOPH RES CO, V191, P327, DOI 10.1006/bbrc.1993.1221; Mosley RL, 2006, CLIN NEUROSCI RES, V6, P261, DOI 10.1016/j.cnr.2006.09.006; Nanetti L, 2005, BRAIN RES, V1054, P38, DOI 10.1016/j.brainres.2005.06.025; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Pahan K, 2000, FEBS LETT, V472, P203, DOI 10.1016/S0014-5793(00)01465-4; Palmi M, 2002, MOL NEUROBIOL, V25, P133, DOI 10.1385/MN:25:2:133; Palmi M, 1996, BRIT J PHARMACOL, V118, P1705, DOI 10.1111/j.1476-5381.1996.tb15595.x; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Sama MA, 2008, J BIOL CHEM, V283, P21953, DOI 10.1074/jbc.M800148200; Schofl C, 1999, ENDOCRINOLOGY, V140, P5516, DOI 10.1210/en.140.12.5516; Suryadevara R, 2003, GLIA, V44, P47, DOI 10.1002/glia.10266; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; Thornton P, 2006, J NEUROCHEM, V98, P258, DOI 10.1111/j.1471-4159.2006.03872.x; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Voutsinos-Porche B, 2003, NEURON, V37, P275, DOI 10.1016/S0896-6273(02)01170-4; Willmott NJ, 2000, FEBS LETT, V487, P239, DOI 10.1016/S0014-5793(00)02359-0; Woiciechowsky C, 2004, MED SCI MONITOR, V10, pBR325; Xia ZG, 1996, J NEUROSCI, V16, P5425; XIE QW, 1994, J BIOL CHEM, V269, P4705; YONG VW, 1992, J NEUROL SCI, V111, P92; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012	56	51	57	0	28	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	NOV 12	2013	252						367	383		10.1016/j.neuroscience.2013.07.061			17	Neurosciences	Neurosciences & Neurology	236YS	WOS:000325836000033	23928073				2021-06-18	
J	Sala, N; Suys, T; Zerlauth, JB; Bouzat, P; Messerer, M; Bloch, J; Levivier, M; Magistretti, PJ; Meuli, R; Oddo, M				Sala, Nathalie; Suys, Tamarah; Zerlauth, Jean-Baptiste; Bouzat, Pierre; Messerer, Mahmoud; Bloch, Jocelyne; Levivier, Marc; Magistretti, Pierre J.; Meuli, Reto; Oddo, Mauro			Cerebral extracellular lactate increase is predominantly nonischemic in patients with severe traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral blood flow; cerebral metabolism; cerebral microdialysis; lactate; traumatic brain injury	SEVERE HEAD TRAUMA; POSITRON-EMISSION-TOMOGRAPHY; NUCLEAR-MAGNETIC-RESONANCE; ENERGY-METABOLISM; PERFUSION-CT; SUBARACHNOID HEMORRHAGE; COMBINED MICRODIALYSIS; SYNAPTIC FUNCTION; BLOOD LACTATE; GLUCOSE	Growing evidence suggests that endogenous lactate is an important substrate for neurons. This study aimed to examine cerebral lactate metabolism and its relationship with brain perfusion in patients with severe traumatic brain injury (TBI). A prospective cohort of 24 patients with severe TBI monitored with cerebral microdialysis (CMD) and brain tissue oxygen tension (PbtO(2)) was studied. Brain lactate metabolism was assessed by quantification of elevated CMD lactate samples (>4 mmol/L); these were matched to CMD pyruvate and PbtO(2) values and dichotomized as glycolytic (CMD pyruvate >119 mu mol/L vs. low pyruvate) and hypoxic (PbtO(2) <20 mm Hg vs. nonhypoxic). Using perfusion computed tomography (CT), brain perfusion was categorized as oligemic, normal, or hyperemic, and was compared with CMD and PbtO(2) data. Samples with elevated CMD lactate were frequently observed (41 +/- 8%), and we found that brain lactate elevations were predominantly associated with glycolysis and normal PbtO(2) (73 8%) rather than brain hypoxia (14 +/- 6%). Furthermore, glycolytic lactate was always associated with normal or hyperemic brain perfusion, whereas all episodes with hypoxic lactate were associated with diffuse oligemia. Our findings suggest predominant nonischemic cerebral extracellular lactate release after TBI and support the concept that lactate may be used as an energy substrate by the injured human brain.	[Sala, Nathalie; Suys, Tamarah; Bouzat, Pierre; Oddo, Mauro] CHUV Lausanne Univ Hosp, Neurosci Crit Care Res Unit, Dept Intens Care Med, CH-1011 Lausanne, Switzerland; [Zerlauth, Jean-Baptiste; Meuli, Reto] CHUV Lausanne Univ Hosp, Dept Radiol, CH-1011 Lausanne, Switzerland; [Bouzat, Pierre] Univ Grenoble 1, Grenoble, France; [Messerer, Mahmoud; Bloch, Jocelyne; Levivier, Marc] CHUV Lausanne Univ Hosp, Serv Neurosurg, Dept Clin Neurosci, CH-1011 Lausanne, Switzerland; [Magistretti, Pierre J.] Ecole Polytech Fed Lausanne, Brain Mind Inst, Lab Neuroenerget & Cellular Dynam, CH-1015 Lausanne, Switzerland; [Magistretti, Pierre J.] Univ Lausanne, Lausanne, Switzerland	Oddo, M (corresponding author), CHUV Lausanne Univ Hosp, Neurosci Crit Care Res Unit, Dept Intens Care Med, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland.	mauro.oddo@chuv.ch	Bloch, Jocelyne/A-9668-2017; Oddo, Mauro/R-3370-2016; Bouzat, Pierre/L-6881-2014; Bouzat, Pierre/AAC-4105-2019; Messerer, Mahmoud/AAZ-3527-2020	Bloch, Jocelyne/0000-0002-6405-1590; Oddo, Mauro/0000-0002-6155-2525; Bouzat, Pierre/0000-0003-4667-6738; Levivier, Marc/0000-0002-6273-2595; Messerer, Mahmoud/0000-0002-0493-6151; Magistretti, Pierre Julius/0000-0002-6678-320X	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [320030_138191]; European Critical Care Research Network, European Society of Intensive Care Medicine	This work was supported by grants from the Swiss National Science Foundation (Grant No. 320030_138191) and the European Critical Care Research Network, European Society of Intensive Care Medicine.	Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Berthet C, 2012, CEREBROVASC DIS, V34, P329, DOI 10.1159/000343657; Berthet C, 2009, J CEREBR BLOOD F MET, V29, P1780, DOI 10.1038/jcbfm.2009.97; Bhatia A, 2007, INTENS CARE MED, V33, P1322, DOI 10.1007/s00134-007-0660-9; Boumezbeur F, 2010, J NEUROSCI, V30, P13983, DOI 10.1523/JNEUROSCI.2040-10.2010; Bouzier-Sore AK, 2003, J CEREBR BLOOD F MET, V23, P1298, DOI 10.1097/01.WCB.0000091761.61714.25; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Lee YJ, 2012, NATURE, V487, P443, DOI 10.1038/nature11314; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Schurr A, 1999, J NEUROSCI, V19, P34; Schurr A, 1997, BRAIN RES, V744, P105, DOI 10.1016/S0006-8993(96)01106-7; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wintermark M, 2006, J NEURORADIOLOGY, V33, P27, DOI 10.1016/S0150-9861(06)77225-X; Wintermark M, 2004, CRIT CARE MED, V32, P1579, DOI 10.1097/01.CCM.0000130171.08842.72; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Wintermark M, 2001, AM J NEURORADIOL, V22, P905	37	51	54	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2013	33	11					1815	1822		10.1038/jcbfm.2013.142			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	246SL	WOS:000326559300019	23963367	Bronze, Green Published			2021-06-18	
J	Katzenberger, RJ; Loewen, CA; Wassarman, DR; Petersen, AJ; Ganetzky, B; Wassarman, DA				Katzenberger, Rebeccah J.; Loewen, Carin A.; Wassarman, Douglas R.; Petersen, Andrew J.; Ganetzky, Barry; Wassarman, David A.			A Drosophila model of closed head traumatic brain injury	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						concussion; insect; chronic traumatic encephalopathy	APOLIPOPROTEIN-E; IMMUNE-RESPONSE; TNF-ALPHA; AGE; NEURODEGENERATION; ENCEPHALOPATHY; ORGANIZATION; RESVERATROL; ACTIVATION; GENETICS	Traumatic brain injury (TBI) is a substantial health issue worldwide, yet the mechanisms responsible for its complex spectrum of pathologies remains largely unknown. To investigate the mechanisms underlying TBI pathologies, we developed a model of TBI in Drosophila melanogaster. The model allows us to take advantage of the wealth of experimental tools available in flies. Closed head TBI was inflicted with a mechanical device that subjects flies to rapid acceleration and deceleration. Similar to humans with TBI, flies with TBI exhibited temporary incapacitation, ataxia, activation of the innate immune response, neurodegeneration, and death. Our data indicate that TBI results in death shortly after a primary injury only if the injury exceeds a certain threshold and that age and genetic background, but not sex, substantially affect this threshold. Furthermore, this threshold also appears to be dependent on the same cellular and molecular mechanisms that control normal longevity. This study demonstrates the potential of flies for providing key insights into human TBI that may ultimately provide unique opportunities for therapeutic intervention.	[Katzenberger, Rebeccah J.; Wassarman, Douglas R.; Petersen, Andrew J.; Wassarman, David A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Cell & Regenerat Biol, Madison, WI 53706 USA; [Loewen, Carin A.; Ganetzky, Barry] Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	Ganetzky, B (corresponding author), Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.	ganetzky@wisc.edu; dawassarman@wisc.edu		Wassarman, Douglas/0000-0002-6922-9378	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS059001, R01 AG033620]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033620] Funding Source: NIH RePORTER	We thank Nicole Bertram, Grace Boekhoff- Falk, members of the D.A.W. and B.G. laboratories, and Ron Kalil for their insights that greatly improved this research; Russell Little for help in determining the impact velocity; and Satoshi Kinoshita for performing the histology. This work was supported by National Institutes of Health Grants R01 NS059001 (to D.A.W.) and R01 AG033620 (to B.G.).	Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; Ang LS, 2008, EXP GERONTOL, V43, P615, DOI 10.1016/j.exger.2008.03.010; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Boyan GS, 2011, TRENDS NEUROSCI, V34, P247, DOI 10.1016/j.tins.2011.02.002; Bushey D, 2011, INT REV NEUROBIOL, V99, P213, DOI 10.1016/B978-0-12-387003-2.00009-4; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Desalvo MK, 2011, GLIA, V59, P1322, DOI 10.1002/glia.21147; Dhandapani SS, 2012, J NEUROSCI RURAL PRA, V3, P131, DOI 10.4103/0976-3147.98208; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fristrom D., 1993, DEV DROSOPHILA MELAN, P843; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; Hellewell SC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/356494; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861; Kahsai L, 2011, INT REV NEUROBIOL, V99, P139, DOI 10.1016/B978-0-12-387003-2.00006-9; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Lessing D, 2009, NAT REV GENET, V10, P359, DOI 10.1038/nrg2563; Li YJ, 2002, AM J HUM GENET, V70, P985, DOI 10.1086/339815; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Mahley RW, 2012, NEURON, V76, P871, DOI 10.1016/j.neuron.2012.11.020; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Petersen AJ, 2013, GENETICS, V194, P133, DOI 10.1534/genetics.113.150854; Petersen AJ, 2012, P NATL ACAD SCI USA, V109, pE656, DOI 10.1073/pnas.1110470109; Piyankarage SC, 2012, ANAL CHEM, V84, P4460, DOI 10.1021/ac3002319; Ramsden S, 2008, AGING CELL, V7, P225, DOI 10.1111/j.1474-9726.2008.00370.x; Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644; Reichert H, 2005, BRAIN RES BULL, V66, P491, DOI 10.1016/j.brainresbull.2004.11.028; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Stork Tobias, 2012, Cold Spring Harb Protoc, V2012, P1, DOI 10.1101/pdb.top067587; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tanzi Rudolph E, 2012, Cold Spring Harb Perspect Med, V2, DOI 10.1101/cshperspect.a006296; Timmers S, 2012, AGING-US, V4, P146, DOI 10.18632/aging.100445; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407	42	51	51	1	32	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	OCT 29	2013	110	44					E4152	E4159		10.1073/pnas.1316895110			8	Multidisciplinary Sciences	Science & Technology - Other Topics	242LJ	WOS:000326243100010	24127584	Bronze, Green Published			2021-06-18	
J	Whyte, J; Nakase-Richardson, R; Hammond, FM; McNamee, S; Giacino, JT; Kalmar, K; Greenwald, BD; Yablon, SA; Horn, LJ				Whyte, John; Nakase-Richardson, Risa; Hammond, Flora M.; McNamee, Shane; Giacino, Joseph T.; Kalmar, Kathleen; Greenwald, Brian D.; Yablon, Stuart A.; Horn, Lawrence J.			Functional Outcomes in Traumatic Disorders of Consciousness: 5-Year Outcomes From the National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Cognition; Consciousness disorders; Minimally conscious state; Prognosis; Rehabilitation; Rehabilitation outcome; Traumatic brain injuries; Vegetative state	RECOVERY; ADMISSION; SCALE; STATE; COMA	Objective: To characterize the 5-year outcomes of patients with traumatic brain injury (TBI) not following commands when admitted to acute inpatient rehabilitation. Design: Secondary analysis of prospectively collected data from the National Institute on Disability and Rehabilitation Research funded Traumatic Brain Injury Model Systems (TRIMS). Setting: Inpatient rehabilitation hospitals participating in the TRIMS program. Participants: Patients (N=108) with TBI not following commands at admission to acute inpatient rehabilitation were divided into 2 groups (early recovery: followed commands before discharge [n=72]; late recovery: did not follow commands before discharge [n=36]). Interventions: Not applicable. Main Outcome Measures: FIM items. Results: For the early recovery group, depending on the FIM item, 8% to 21% of patients were functioning independently at discharge, increasing to 56% to 85% by 5 years postinjury. The proportion functioning independently increased from discharge to 1 year, 1 to 2 years, and 2 to 5 years. In the late recovery group, depending on the FIM item, 19% to 36% of patients were functioning independently by 5 years postinjury. The proportion of independent patients increased significantly from discharge to 1 year and from 1 to 2 years, but not from 2 to 5 years. Conclusions: Substantial proportions of patients admitted to acute inpatient rehabilitation before following commands recover independent functioning over as long as 5 years, particularly if they begin to follow commands before hospital discharge. (c) 2013 by the American Congress of Rehabilitation Medicine	[Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Nakase-Richardson, Risa] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Nakase-Richardson, Risa] Ctr Excellence Maximizing Rehabil Outcomes, Tampa, FL USA; [Nakase-Richardson, Risa] Univ S Florida, Tampa, FL USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [McNamee, Shane] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA; [Giacino, Joseph T.] Spaulding Rehabil Hosp, Boston, MA USA; [Kalmar, Kathleen] JFK Johnson Rehabil Inst, Edison, NJ USA; [Greenwald, Brian D.] Mt Sinai Sch Med, New York, NY USA; [Yablon, Stuart A.] Univ Alberta, Edmonton, AB, Canada; [Yablon, Stuart A.] Glenrose Rehabil Hosp, Edmonton, AB, Canada; [Horn, Lawrence J.] Wayne State Univ, Detroit, MI USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	jwhyte@einstein.edu	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698; Whyte, John/0000-0002-4381-1474	National Institute on Disability and Rehabilitation Research, United States Department of EducationUS Department of Education [H133A060038, H133A070040, H133A070042, H133A070030, H133A070033, H133A070027, H133A080044]; Health Services Research and Development/Rehabilitation Research and Development Center of Excellence for Maximizing Rehabilitation Outcomes [COE - HFP 09-156]	Supported by the National Institute on Disability and Rehabilitation Research, United States Department of Education (grant nos. H133A060038 [TBI Model System National Data and Statistical Center], H133A070040 [Moss TBI Model System], H133A070042 [Carolinas Traumatic Brain Injury Rehabilitation and Research System], H133A070030 [JFK-Johnson Rehabilitation Institute TBI Model System], H133A070033 [New York TBI Model System], H133A070027 [North Texas TBI Model System], H133A080044 [Southeastern Michigan TBI System]). The contents of the article do not necessarily represent the policy of the Department of Education, and endorsement by the Federal Government should not be assumed. Statistical support provided by the Health Services Research and Development/Rehabilitation Research and Development Center of Excellence for Maximizing Rehabilitation Outcomes (grant no. COE - HFP 09-156).	Deguise E, 2008, J HEAD TRAUMA REHAB, V23, P294, DOI 10.1097/01.HTR.0000336842.53338.f4; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Hammond F, 2009, J NEUROTRAUM, V26, pA83; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; KOTWICA Z, 1995, ACTA NEUROCHIR, V133, P56, DOI 10.1007/BF01404948; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; 1994, J NEUROTRAUMA, V330, P1499; 1994, J NEUROTRAUMA, V330, P1572	16	51	51	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2013	94	10					1855	1860		10.1016/j.apmr.2012.10.041			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	231TU	WOS:000325442100002	23732164				2021-06-18	
J	Bloodgood, B; Inokuchi, D; Shawver, W; Olson, K; Hoffman, R; Cohen, E; Sarmiento, K; Muthuswamy, K				Bloodgood, Bonny; Inokuchi, Derek; Shawver, Willis; Olson, Kristina; Hoffman, Rosanne; Cohen, Elyse; Sarmiento, Kelly; Muthuswamy, Kavitha			Exploration of Awareness, Knowledge, and Perceptions of Traumatic Brain Injury Among American Youth Athletes and Their Parents	JOURNAL OF ADOLESCENT HEALTH			English	Article						Brain injuries; Traumatic brain injury; Concussion; Adolescents; Athletic injuries; Awareness; Health knowledge; Health attitudes; Health practices	SPORT-RELATED CONCUSSION; HIGH-SCHOOL; FOOTBALL PLAYERS; UNITED-STATES; MISCONCEPTIONS; RECOVERY; CHILDREN	Purpose: Although much effort is underway by the Centers for Disease Control and Prevention (CDC) and other organizations to highlight the seriousness of traumatic brain injury, including concussions, among young athletes, little is known about how these athletes and their parents view this injury and how much they know about it. Methods: Online surveys were conducted with youth who participate in sports (n = 252) and with the parents of youth who participate in sports (n = 300) to explore the ways in which these audiences view concussion and messaging related to concussion. Results: More than four out of five youth and parents reported that they had heard about concussions, although awareness was significantly higher for some subgroups, including parents of children 10-13 years old, and parents who reported using the Internet several times daily. Youth ages 13-15 years were significantly more likely to strongly agree that concussions are a "critical issue," as compared with youth ages 16-18 years. Among parents, significantly more mothers than fathers agreed that concussions are a critical issue. More than half of youth participants strongly disagreed that their friends would think they were "dumb for caring about concussions," with girls significantly more likely to strongly disagree than boys. When parents were asked to identify organizations they would trust as a reliable source of information for concussions, the most frequently cited organization was the CDC. Conclusions: Results of this study demonstrate a high level of awareness about concussion among youth athletes and parents of youth athletes. However, important distinctions among subgroups of both youth and parents-such as by race/ethnicity, age, sex, and Internet use-suggest directions for future communication and research efforts. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved.	[Bloodgood, Bonny; Hoffman, Rosanne; Cohen, Elyse] ICF Int, Fairfax, VA USA; [Inokuchi, Derek; Shawver, Willis; Olson, Kristina] FHI 360, Washington, DC USA; [Sarmiento, Kelly; Muthuswamy, Kavitha] Ctr Dis Control & Prevent, Atlanta, GA USA	Shawver, W (corresponding author), FHI 360 Social Mkt & Commun Ctr, 1875 Connecticut Ave NW, Washington, DC 20009 USA.	wshawver@fhi360.org			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [200-2007-20009]	This research was supported by the Centers for Disease Control and Prevention through Contract no. 200-2007-20009, Order 0014. The authors would like to thank Sanda Pecina, of FHI 360, for her contributions to the project.	Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bertakis KD, 2000, J FAM PRACTICE, V49, P147; Bruce D A, 1982, Clin Sports Med, V1, P495; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chapman RCG, 2010, BRAIN INJURY, V24, P797, DOI 10.3109/02699051003709607; Coghlin Craig J, 2009, J Can Chiropr Assoc, V53, P233; COLLINS M, 2004, CURR OPIN ORTHOP, V15, P100; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Freimuth VS, 2001, SOC SCI MED, V52, P797, DOI 10.1016/S0277-9536(00)00178-7; Galdas PM, 2005, J ADV NURS, V49, P616, DOI 10.1111/j.1365-2648.2004.03331.x; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Michigan Governor's Council on Physical Fitness Health and Sports, POS STAT PREV INJ AM; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Russo S, 2006, CURR OPIN PEDIATR, V18, P376; Springer JA, 1997, J HEAD TRAUMA REHAB, V12, P41, DOI 10.1097/00001199-199706000-00005; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Theye Fred, 2004, Clin Med Res, V2, P165; Wakefield M, 2003, J HEALTH COMMUN, V8, P229, DOI 10.1080/10810730305686; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	37	51	51	0	51	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1054-139X	1879-1972		J ADOLESCENT HEALTH	J. Adolesc. Health	JUL	2013	53	1					34	39		10.1016/j.jadohealth.2013.01.022			6	Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics	Psychology; Public, Environmental & Occupational Health; Pediatrics	169GP	WOS:000320768200007	23583508	Green Accepted			2021-06-18	
J	Greer, JE; Hanell, A; McGinn, MJ; Povlishock, JT				Greer, John E.; Hanell, Anders; McGinn, Melissa J.; Povlishock, John T.			Mild traumatic brain injury in the mouse induces axotomy primarily within the axon initial segment	ACTA NEUROPATHOLOGICA			English	Article						Diffuse axonal injury; Traumatic brain injury; Axon initial segment	AMYLOID PRECURSOR PROTEIN; SPINAL-CORD-INJURY; CALPAIN-MEDIATED PROTEOLYSIS; OPTIC-NERVE FIBERS; HEAD-INJURY; STRETCH-INJURY; RETROGRADE CONVERSION; TRANSPORTED VESICLES; NEURONAL INJURY; SODIUM-CHANNELS	Traumatic axonal injury (TAI) is a consistent component of traumatic brain injury (TBI), and is associated with much of its morbidity. Increasingly, it has also been recognized as a major pathology of mild TBI (mTBI). In terms of its pathogenesis, numerous studies have investigated the susceptibility of the nodes of Ranvier, the paranode and internodal regions to TAI. The nodes of Ranvier, with their unique composition and concentration of ion channels, have been suggested as the primary site of injury, initiating a cascade of abnormalities in the related paranodal and internodal domains that lead to local axonal swellings and detachment. No investigation, however, has determined the effect of TAI upon the axon initial segment (AIS), a segment critical to regulating polarity and excitability. The current study sought to identify the susceptibility of these different axon domains to TAI within the neocortex, where each axonal domain could be simultaneously assessed. Utilizing a mouse model of mTBI, a temporal and spatial heterogeneity of axonal injury was found within the neocortical gray matter. Although axonal swellings were found in all domains along myelinated neocortical axons, the majority of TAI occurred within the AIS, which progressed without overt structural disruption of the AIS itself. The finding of primary AIS involvement has important implications regarding neuronal polarity and the fate of axotomized processes, while also raising therapeutic implications, as the mechanisms underlying such axonal injury in the AIS may be distinct from those described for nodal/paranodal injury.	[Greer, John E.; Hanell, Anders; McGinn, Melissa J.; Povlishock, John T.] Virginia Commonwealth Univ, Sch Med, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu	Hanell, Anders/E-4776-2011	Hanell, Anders/0000-0001-9369-3886	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS077675, NS047463]; NIH-NINDS CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463-02]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS077675] Funding Source: NIH RePORTER	The authors would like to thank C. Lynn Davis, Jesse Sims and Sue Walker for their technical support. Funding was provided by NIH Grants NS077675 and NS047463. Microscopy was performed at the VCU Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS Center core Grant (5P30NS047463-02).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bender KJ, 2012, ANNU REV NEUROSCI, V35, P249, DOI 10.1146/annurev-neuro-062111-150339; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; BISBY MA, 1977, J NEUROCHEM, V29, P313, DOI 10.1111/j.1471-4159.1977.tb09624.x; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Carter LM, 2008, J NEUROSCI, V28, P14107, DOI 10.1523/JNEUROSCI.2217-08.2008; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Duflocq A, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-66; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Grubb MS, 2010, NATURE, V465, P1070, DOI 10.1038/nature09160; Hedstrom KL, 2008, J CELL BIOL, V183, P635, DOI 10.1083/jcb.200806112; Hinman JD, 2013, STROKE, V44, P182, DOI 10.1161/STROKEAHA.112.668749; Huh JW, 2006, DEV NEUROSCI-BASEL, V28, P466, DOI 10.1159/000094172; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Kaphzan H, 2011, J NEUROSCI, V31, P17637, DOI 10.1523/JNEUROSCI.4162-11.2011; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kole MHP, 2012, NEURON, V73, P235, DOI 10.1016/j.neuron.2012.01.007; Kuba H, 2012, J PHYSIOL-LONDON, V590, P5571, DOI 10.1113/jphysiol.2012.237305; Lafrenaye AD, 2012, J CEREBR BLOOD F MET, V32, P1919, DOI 10.1038/jcbfm.2012.95; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MARTZ D, 1989, BRAIN RES, V476, P199, DOI 10.1016/0006-8993(89)91559-X; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Povlishock JT, 1999, ACT NEUR S, V73, P15; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rasband MN, 2011, SEMIN CELL DEV BIOL, V22, P178, DOI 10.1016/j.semcdb.2010.09.010; Reeves TM, 2010, BRAIN PATHOL, V20, P1055, DOI 10.1111/j.1750-3639.2010.00412.x; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SAHENK Z, 1988, BRAIN RES, V460, P199, DOI 10.1016/0006-8993(88)91224-3; Schafer DP, 2009, J NEUROSCI, V29, P13242, DOI 10.1523/JNEUROSCI.3376-09.2009; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; SMITH RS, 1991, BRAIN RES, V552, P215, DOI 10.1016/0006-8993(91)90085-A; SNYDER RE, 1994, BRAIN RES, V635, P49, DOI 10.1016/0006-8993(94)91422-2; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Sugino K, 2006, NAT NEUROSCI, V9, P99, DOI 10.1038/nn1618; von Reyn CR, 2012, J NEUROCHEM, V121, P793, DOI 10.1111/j.1471-4159.2012.07735.x; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	77	51	52	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	JUL	2013	126	1					59	74		10.1007/s00401-013-1119-4			16	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	169LK	WOS:000320781500005	23595276	Green Accepted			2021-06-18	
J	Niyonkuru, C; Wagner, AK; Ozawa, H; Amin, K; Goyal, A; Fabio, A				Niyonkuru, Christian; Wagner, Amy K.; Ozawa, Haishin; Amin, Krutika; Goyal, Akash; Fabio, Anthony			Group-Based Trajectory Analysis Applications for Prognostic Biomarker Model Development in Severe TBI: A Practical Example	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; prognosis; S100b; trajectory analysis; traumatic brain injury	NEURON-SPECIFIC-ENOLASE; TRAUMATIC BRAIN-INJURY; SERUM S-100B PROTEIN; CEREBROSPINAL-FLUID; HEAD-INJURY; OUTCOME PREDICTION; MARKER; DAMAGE; S100B; REHABILOMICS	Over the last decade, biomarker research has identified potential biomarkers for the diagnosis, prognosis, and management of traumatic brain injury (TBI). Several cerebrospinal fluid (CSF) and serum biomarkers have shown promise in predicting long-term outcome after severe TBI. Despite this increased focus on identifying biomarkers for outcome prognostication after a severe TBI, several challenges still exist in effectively modeling the significant heterogeneity observed in TBI-related pathology, as well as the biomarker-outcome relationships. Biomarker data collected over time are usually summarized into single-point estimates (e.g., average or peak biomarker levels), which are, in turn, used to examine the relationships between biomarker levels and outcomes. Further, many biomarker studies to date have focused on the prediction power of biomarkers without controlling for potential clinical and demographic confounders that have been previously shown to affect long-term outcome. In this article, we demonstrate the application of a practical approach to delineate and describe distinct subpopulations having similar longitudinal biomarker profiles and to model the relationships between these biomarker profiles and outcomes while taking into account potential confounding factors. As an example, we demonstrate a group-based modeling technique to identify temporal S100 calcium-binding protein B (S100b) profiles, measured from CSF over the first week post-injury, in a sample of adult subjects with TBI, and we use multivariate logistic regression to show that the prediction power of S100b biomarker profiles can be superior to the prediction power of single-point estimates.	[Niyonkuru, Christian; Wagner, Amy K.; Ozawa, Haishin; Amin, Krutika; Goyal, Akash] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Fabio, Anthony] Univ Pittsburgh, Epidemiol Data Ctr, Dept Epidemiol, Pittsburgh, PA 15213 USA	Fabio, A (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, Dept Epidemiol, 130 DeSoto St,127 Parran Hall, Pittsburgh, PA 15213 USA.	afabio@pitt.edu		Fabio, Anthony/0000-0002-6808-4939	 [DODW81XWH-071-0701];  [R49 CCR 323155-03]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER	This study was supported by DODW81XWH-071-0701 (to A. F., A. K. W., C.N., H.O., K. A., and A. G.) and R49 CCR 323155-03 (to A. F. and A. K. W.).	Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BRYK AS, 1987, PSYCHOL BULL, V101, P147, DOI 10.1037/0033-2909.101.1.147; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Demidenko E., 2004, MIXED MODELS THEORY; Duncan TE, 2004, BEHAV THER, V35, P333, DOI 10.1016/S0005-7894(04)80042-X; Goyal A, 2012, J NEUROTRAUMA; Hall KM, 1998, NEUROREHABILITATION, V10, P3, DOI 10.3233/NRE-1998-10102; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; JENNETT B, 1975, LANCET, V1, P480; Johnson N.L., 2000, WILEY SER PROB STAT; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Kirchhoff C, 2008, EUR J MED RES, V13, P511; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; MEREDITH W, 1990, PSYCHOMETRIKA, V55, P107, DOI 10.1007/BF02294746; Naeimi ZS, 2006, BRAIN INJURY, V20, P463, DOI 10.1080/02699050600664418; Nagin D., 2005, GROUP BASED MODELING; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Ucar T, 2004, J TRAUMA, V57, P95, DOI 10.1097/01.TA.0000071352.95491.75; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Wagner AK, 2011, PM&R, V3, pS28, DOI 10.1016/j.pmrj.2011.04.013; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	35	51	54	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2013	30	11					938	945		10.1089/neu.2012.2578			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	166WD	WOS:000320589300004	23421760				2021-06-18	
J	Hylin, MJ; Orsi, SA; Zhao, J; Bockhorst, K; Perez, A; Moore, AN; Dash, PK				Hylin, Michael J.; Orsi, Sara A.; Zhao, Jing; Bockhorst, Kurt; Perez, Alec; Moore, Anthony N.; Dash, Pramod K.			Behavioral and Histopathological Alterations Resulting from Mild Fluid Percussion Injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; concussion; DTI; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; DIFFUSE AXONAL INJURY; UNMYELINATED AXONS; CORPUS-CALLOSUM; CORTICAL IMPACT; RATS; CONCUSSION; DEFICITS; MEMORY	The majority of people who sustain a traumatic brain injury (TBI) have an injury that can be classified as mild (often referred to as concussion). Although head CT scans for most subjects who have sustained a mild TBI (mTBI) are negative, these persons may still suffer from neurocognitive and neurobehavioral deficits. In order to expedite pre-clinical research and develop therapies, there is a need for well-characterized animal models of mTBI that reflect the neurological, neurocognitive, and pathological changes seen in human patients. In the present study, we examined the motor, cognitive, and histopathological changes resulting from 1.0 and 1.5 atmosphere (atm) overpressure fluid percussion injury (FPI). Both 1.0 and 1.5 atm FPI injury caused transient suppression of acute neurological functions, but did not result in visible brain contusion. Animals injured with 1.0 atm FPI did not show significant motor, vestibulomotor, or learning and memory deficits. In contrast, 1.5 atm injury caused transient motor disturbances, and resulted in a significant impairment of spatial learning and short-term memory. In addition, 1.5 atm FPI caused a marked reduction in cerebral perfusion at the site of injury that lasted for several hours. Consistent with previous studies, 1.5 atm FPI did not cause visible neuronal loss in the hippocampus or in the neocortex. However, a robust inflammatory response (as indicated by enhanced GFAP and Iba1 immunoreactivity) in the corpus callosum and the thalamus was observed. Examination of fractional anisotropy color maps after diffusion tensor imaging (DTI) revealed a significant decrease of FA values in the cingulum, an area found to have increased silver impregnation, suggesting axonal injury. Increased silver impregnation was also observed in the corpus callosum, and internal and external capsules. These findings are consistent with the deficits and pathologies associated with mild TBI in humans, and support the use of mild FPI as a model to evaluate putative therapeutic options.	[Hylin, Michael J.; Orsi, Sara A.; Zhao, Jing; Perez, Alec; Moore, Anthony N.; Dash, Pramod K.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Bockhorst, Kurt] Univ Texas Hlth Sci Ctr Houston, Dept Radiol, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, POB 20036, Houston, TX 77225 USA.	p.dash@uth.tmc.edu	Hylin, Michael/U-2878-2019	Dash, Pramod/0000-0001-6746-1002	DODUnited States Department of Defense [W81XWH-08-2-0134]; TIRR Foundation	The authors would like to thank Dr. Bruce Lyeth of the University of California, Davis for kindly providing the hubs used to mount the rats to the FPI device. We also thank the Imaging Core of the Mission Connect Mild TBI Translational Consortium under the direction of Dr. Ponada Narayana for their assistance with the MRI. The work performed in the authors' laboratories were made possible by grants from DOD (W81XWH-08-2-0134) and TIRR Foundation.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Armstead WM, 2010, CRIT CARE MED, V38, P1868, DOI 10.1097/CCM.0b013e3181e8ac1a; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bedell EA, 1998, J NEUROTRAUM, V15, P985, DOI 10.1089/neu.1998.15.985; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Blum S, 1999, J NEUROSCI, V19, P3535; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; d'Hemecourt P, 2011, CLIN SPORT MED, V30, P63, DOI 10.1016/j.csm.2010.08.008; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eakin K, 2012, J NEUROTRAUM, V29, P1180, DOI 10.1089/neu.2011.2192; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Long JB, 1996, J NEUROTRAUM, V13, P149, DOI 10.1089/neu.1996.13.149; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Robertson CS, 2012, J NEUROTRAUM, V29, P1156, DOI 10.1089/neu.2011.1827; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	52	51	51	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2013	30	9			SI		702	715		10.1089/neu.2012.2630			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	145BJ	WOS:000318987600003	23301501	Green Published			2021-06-18	
J	Hellyer, PJ; Leech, R; Ham, TE; Bonnelle, V; Sharp, DJ				Hellyer, Peter J.; Leech, Robert; Ham, Timothy E.; Bonnelle, Valerie; Sharp, David J.			Individual prediction of white matter injury following traumatic brain injury	ANNALS OF NEUROLOGY			English	Article							AXONAL INJURY; DIFFUSION; ADULTS; CONNECTIVITY; DETECTS; LESIONS; DAMAGE; NERVE; MODEL; TIME	Objective Traumatic brain injury (TBI) often results in traumatic axonal injury (TAI). This can be difficult to identify using conventional imaging. Diffusion tensor imaging (DTI) offers a method of assessing axonal damage in vivo, but has previously mainly been used to investigate groups of patients. Machine learning techniques are increasingly used to improve diagnosis based on complex imaging measures. We investigated whether machine learning applied to DTI data can be used to diagnose white matter damage after TBI and to predict neuropsychological outcome in individual patients. Methods We trained pattern classifiers to predict the presence of white matter damage in 25 TBI patients with microbleed evidence of TAI compared to neurologically healthy age-matched controls. We then applied these classifiers to 35 additional patients with no conventional imaging evidence of TAI. Finally, we used regression analyses to predict indices of neuropsychological outcome for information processing speed, executive function, and associative memory in a group of 70 heterogeneous patients. Results The classifiers discriminated between patients with microbleeds and age-matched controls with a high degree of accuracy, and outperformed other methods. When the trained classifiers were applied to patients without microbleeds, patients having likely TAI showed evidence of greater cognitive impairment in information processing speed and executive function. The classifiers were also able to predict the extent of impairments in information processing speed and executive function. Interpretation The work provides a proof of principle that multivariate techniques can be used with DTI to provide diagnostic information about clinically significant TAI. ANN NEUROL 2013;73:489-499	[Hellyer, Peter J.; Leech, Robert; Ham, Timothy E.; Bonnelle, Valerie; Sharp, David J.] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, Computat Cognit & Clin Neuroimaging Lab, London, England; [Bonnelle, Valerie] Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC Clin Sci Ctr, Expt & Clin Neurosci Sect,Cognit Neuroimaging Res, London, England	Leech, R (corresponding author), Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, 3rd Floor,Burlington Danes Bldg,Cane Rd, London W12 0NN, England.	r.leech@imperial.ac.uk	Hellyer, Peter J/F-7112-2013; Sharp, David J/A-2119-2013; Leech, Robert/AAE-8254-2019	Hellyer, Peter J/0000-0002-5139-3401; Leech, Robert/0000-0002-5801-6318	Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Imperial College Healthcare Charity; Research Councils United Kingdom; PfizerPfizer; Homerton Hospital (UK); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701951, 1110783] Funding Source: researchfish	This work was supported by grants from the Medical Research Council (UK) to D.J.S. and P.J.H., Imperial College Healthcare Charity to D.J.S., Research Councils United Kingdom to R.L, and Pfizer to D.J.S. We thank the subjects who took part in this study.; D.J.S.: speaking fees, Homerton Hospital (UK).	ADAMS JH, 1982, INJURY, V13, P444, DOI 10.1016/0020-1383(82)90105-X; Baddeley A., 1994, DOORS PEOPLE TEST TE; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Efron B., 1993, INTRO BOOTSTRAP, P237; Good P. I, 2005, PERMUTATION PARAMETR; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Klawiter EC, 2011, NEUROIMAGE, V55, P1454, DOI 10.1016/j.neuroimage.2011.01.007; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Platt JC, 2000, ADV NEUR IN, P61; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sajda P, 2006, ANNU REV BIOMED ENG, V8, P537, DOI 10.1146/annurev.bioeng.8.061505.095802; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; WAXMAN SG, 1980, MUSCLE NERVE, V3, P141, DOI 10.1002/mus.880030207; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246	36	51	53	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	APR	2013	73	4					489	499		10.1002/ana.23824			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	152HY	WOS:000319523800010	23426980				2021-06-18	
J	Hopkins, RO; Suchyta, MR; Farrer, TJ; Needham, D				Hopkins, Ramona O.; Suchyta, Mary R.; Farrer, Thomas J.; Needham, Dale			Improving Post-Intensive Care Unit Neuropsychiatric Outcomes Understanding Cognitive Effects of Physical Activity	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						cognitive outcome; critical illness; early mobility; physical rehabilitation; depression	QUALITY-OF-LIFE; RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN-INJURY; WHITE-MATTER INTEGRITY; GROWTH-FACTOR-I; NEUROTROPHIC FACTOR; AEROBIC EXERCISE; CRITICAL ILLNESS; CARDIOPULMONARY FITNESS; PSYCHOLOGICAL OUTCOMES	Critical illness and its treatment often result in long-term neuropsychiatric morbidities. Consequently, there is a need to focus on means to prevent or ameliorate these morbidities. Animal models provide important data regarding the neurobiological effects of physical activity, including angiogenesis, neurogenesis, and release of neurotrophic factors that enhance plasticity. Studies in noncritically ill patients demonstrate that exercise is associated with increased cerebral blood flow, neurogenesis, and brain volume, which are associated with improved cognition. Clinically, research in both healthy and diseased human subjects suggests that exercise improves neuropsychiatric outcomes. In the critical care setting, early physical rehabilitation and mobilization are safe and feasible, with demonstrated improvements in physical functional outcomes. Such activity may also reduce the duration of delirium in the intensive care unit (ICU) and improve neuropsychiatric outcomes, although data are limited. Barriers exist regarding implementing ICU rehabilitation in routine care, including use of sedatives and lack of awareness of post-ICU cognitive impairments. Further research is necessary to determine whether prior animal and human research, in conjunction with preliminary results from existing ICU studies, can translate into improvements for neuropsychiatric outcomes in critically ill patients. Studies are needed to evaluate biological mechanisms, risk factors, the role of pre-ICU functional level, and the timing, duration, and type of physical activity for optimal patient outcomes.	[Hopkins, Ramona O.; Suchyta, Mary R.] Intermt Med Ctr, Dept Med, Pulm & Crit Care Med Div, Murray, UT 84107 USA; [Hopkins, Ramona O.; Farrer, Thomas J.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Suchyta, Mary R.] Univ Utah, ARUP Labs Informat Dept, Salt Lake City, UT USA; [Needham, Dale] Johns Hopkins Univ, Sch Med, Outcomes Crit Illness & Surg OACIS Grp, Div Pulm & Crit Care Med, Baltimore, MD USA; [Needham, Dale] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA	Hopkins, RO (corresponding author), Intermt Med Ctr, Dept Med, Pulm & Crit Care Div, Murray, UT 84107 USA.	mona.hopkins@imail.org		Farrer, Thomas J./0000-0001-8092-6214			Bailey P, 2007, CRIT CARE MED, V35, P139, DOI 10.1097/01.CCM.0000251130.69568.87; Baker LD, 2010, ARCH NEUROL-CHICAGO, V67, P71, DOI 10.1001/archneurol.2009.307; Barnes DE, 2008, J AM GERIATR SOC, V56, P1658, DOI 10.1111/j.1532-5415.2008.01841.x; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Brummel NE, PHYS THER IN PRESS; Buchman AS, 2012, NEUROLOGY, V78, P1323, DOI 10.1212/WNL.0b013e3182535d35; Bullitt E, 2009, AM J NEURORADIOL, V30, P1857, DOI 10.3174/ajnr.A1695; Bullitt E, 2010, NEUROBIOL AGING, V31, P290, DOI 10.1016/j.neurobiolaging.2008.03.022; Carro E, 2001, J NEUROSCI, V21, P5678; Chen SY, 2011, J FORMOS MED ASSOC, V110, P572, DOI 10.1016/j.jfma.2011.07.008; Chiang LL, 2006, PHYS THER, V86, P1271, DOI 10.2522/ptj.20050036; Churchill JD, 2002, NEUROBIOL AGING, V23, P941, DOI 10.1016/S0197-4580(02)00028-3; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; Colcombe SJ, 2003, J GERONTOL A-BIOL, V58, P176; Colcombe SJ, 2006, J GERONTOL A-BIOL, V61, P1166, DOI 10.1093/gerona/61.11.1166; Connolly B, 2012, CRIT CARE, V16, DOI [10.1186/cc11219, 10.1186/CC11219]; Cumming TB, INT PSYCHOG IN PRESS; Davis JC, 2010, ARCH INTERN MED, V170, P2036, DOI 10.1001/archinternmed.2010.462; Davydow DS, 2008, PSYCHOSOM MED, V70, P512, DOI 10.1097/PSY.0b013e31816aa0dd; Deary IJ, 2009, BRIT MED BULL, V92, P135, DOI 10.1093/bmb/ldp033; Ding YH, 2004, CURR NEUROVASC RES, V1, P411, DOI 10.2174/1567202043361875; Duning T, 2010, DIABETES CARE, V33, P639, DOI 10.2337/dc09-1740; Eadie BD, 2005, J COMP NEUROL, V486, P39, DOI 10.1002/cne.20493; Ehlenbach WJ, 2010, JAMA-J AM MED ASSOC, V303, P763, DOI 10.1001/jama.2010.167; Emery CF, 2003, HEALTH PSYCHOL, V22, P598, DOI 10.1037/0278-6133.22.6.598; Emery CF, 1998, HEALTH PSYCHOL, V17, P232, DOI 10.1037/0278-6133.17.3.232; EMERY CF, 1991, CHEST, V100, P613, DOI 10.1378/chest.100.3.613; Erickson KI, 2010, NEUROLOGY, V75, P1415, DOI 10.1212/WNL.0b013e3181f88359; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Erickson KI, 2009, HIPPOCAMPUS, V19, P1030, DOI 10.1002/hipo.20547; Etnier JL, 2001, MED SCI SPORT EXER, V33, P1620, DOI 10.1097/00005768-200110000-00002; Fabel K, 2008, NEUROMOL MED, V10, P59, DOI 10.1007/s12017-008-8031-4; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Gomez-Pinilla F, 2008, EUR J NEUROSCI, V28, P2278, DOI 10.1111/j.1460-9568.2008.06524.x; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gustafsson T, 2001, FRONT BIOSCI-LANDMRK, V6, pD75, DOI 10.2741/gustafss; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Heyn P, 2004, ARCH PHYS MED REHAB, V85, P1694, DOI 10.1016/j.apmr.2004.03.019; Hollman W, 2005, EUR REV AGING PHYS A, V2, P35; Hopkins RO, 2006, CHEST, V130, P869, DOI 10.1378/chest.130.3.869; Hopkins RO, 2012, SEMIN RESP CRIT CARE, V33, P348, DOI 10.1055/s-0032-1321984; Hopkins RO, 2010, BRAIN INJURY, V24, P1478, DOI 10.3109/02699052.2010.506861; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, PHYS THER IN PRESS; Hopkins RO, LEGACY CRIT IN PRESS; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; Jackson JC, 2012, CRIT CARE MED, V40, P1088, DOI 10.1097/CCM.0b013e3182373115; Jackson James C, 2011, Anesthesiol Clin, V29, P751, DOI 10.1016/j.anclin.2011.09.012; Jackson JC, 2009, CRIT CARE CLIN, V25, P615, DOI 10.1016/j.ccc.2009.04.005; Jackson JC, 2004, INTENS CARE MED, V30, P2009, DOI 10.1007/s00134-004-2422-2; Jones C, 2007, INTENS CARE MED, V33, P978, DOI 10.1007/s00134-007-0600-8; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Leditschke I Anne, 2012, Cardiopulm Phys Ther J, V23, P26; Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494; Luo CX, 2007, J NEUROSCI RES, V85, P1637, DOI 10.1002/jnr.21317; Marks BL, 2011, BRIT J SPORT MED, V45, P1208, DOI 10.1136/bjsm.2009.068114; Marks BL, 2007, ANN NY ACAD SCI, V1097, P171, DOI 10.1196/annals.1379.022; Mikkelsen ME, 2012, AM J RESP CRIT CARE, V185, P1307, DOI 10.1164/rccm.201111-2025OC; Morandi A, 2012, CRIT CARE MED, V40, P2182, DOI 10.1097/CCM.0b013e318250acdc; Morandi A, 2011, CURR OPIN CRIT CARE, V17, P43, DOI 10.1097/MCC.0b013e3283427243; Morris PE, 2008, CRIT CARE MED, V36, P2238, DOI 10.1097/CCM.0b013e318180b90e; Morris PE, 2011, AM J MED SCI, V341, P373, DOI 10.1097/MAJ.0b013e31820ab4f6; Nagamatsu LS, 2012, ARCH INTERN MED, V172, P666, DOI 10.1001/archinternmed.2012.379; Needham DM, 2007, J CRIT CARE, V22, P275, DOI 10.1016/j.jcrc.2007.02.001; Needham DM, 2012, CRIT CARE MED, V40, P1340, DOI 10.1097/CCM.0b013e31823b8df7; Needham DM, 2012, CRIT CARE MED, V40, P502, DOI 10.1097/CCM.0b013e318232da75; Needham DM, 2011, AM J RESP CRIT CARE, V183, P962, DOI 10.1164/rccm.201012-2042ED; Needham DM, 2010, ARCH PHYS MED REHAB, V91, P536, DOI 10.1016/j.apmr.2010.01.002; Ozdemir F, 2001, ARCH PHYS MED REHAB, V82, P1375, DOI 10.1053/apmr.2001.25973; Palleschi L, 1996, ARCH GERONTOL GERIAT, P47; Ploughman M, 2005, NEUROSCIENCE, V136, P991, DOI 10.1016/j.neuroscience.2005.08.037; Ploughman M, 2007, BRAIN RES, V1150, P207, DOI 10.1016/j.brainres.2007.02.065; Pyoria O, 2007, DISABIL REHABIL, V29, P503, DOI 10.1080/09638280600902497; Quaney BM, 2009, NEUROREHAB NEURAL RE, V23, P879, DOI 10.1177/1545968309338193; Rand D, 2010, NEUROREHAB NEURAL RE, V24, P722, DOI 10.1177/1545968310368684; Rhyu IJ, 2010, NEUROSCIENCE, V167, P1239, DOI 10.1016/j.neuroscience.2010.03.003; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Seifert T, 2010, AM J PHYSIOL-REG I, V298, pR372, DOI 10.1152/ajpregu.00525.2009; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Swain RA, 2003, NEUROSCIENCE, V117, P1037, DOI 10.1016/S0306-4522(02)00664-4; Swardfager W, 2011, BRAIN BEHAV IMMUN, V25, P1264, DOI 10.1016/j.bbi.2011.04.017; Swardfager W, 2010, J AM GERIATR SOC, V58, P1519, DOI 10.1111/j.1532-5415.2010.02966.x; Thomsen GE, 2008, CRIT CARE MED, V36, P1119, DOI 10.1097/CCM.0b013e318168f986; van den Boogaard M, 2012, CRIT CARE MED, V40, P112, DOI 10.1097/CCM.0b013e31822e9fc9; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; Vasilevskis EE, 2010, CRIT CARE MED, V38, pS683, DOI 10.1097/CCM.0b013e3181f245d3; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vreugdenhil A, 2012, SCAND J CARING SCI, V26, P12, DOI 10.1111/j.1471-6712.2011.00895.x; Yaffe K, 2001, ARCH INTERN MED, V161, P1703, DOI 10.1001/archinte.161.14.1703; Yaguez L, 2011, INT J GERIATR PSYCH, V26, P173, DOI 10.1002/gps.2510; Zanni JM, 2010, J CRIT CARE, V25, P254, DOI 10.1016/j.jcrc.2009.10.010	96	51	53	0	32	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 15	2012	186	12					1220	1228		10.1164/rccm.201206-1022CP			9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	057OZ	WOS:000312574200008	23065013				2021-06-18	
J	Moran, LM; Taylor, HG; Rusin, J; Bangert, B; Dietrich, A; Nuss, KE; Wright, M; Minich, N; Yeates, KO				Moran, Lisa M.; Taylor, H. Gerry; Rusin, Jerome; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn E.; Wright, Martha; Minich, Nori; Yeates, Keith O.			Quality of Life in Pediatric Mild Traumatic Brain Injury and its Relationship to Postconcussive Symptoms	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						brain injuries; child; postconcussive symptoms; quality of life	POST-CONCUSSIVE SYMPTOMS; CLOSED-HEAD INJURIES; CHILD HEALTH; NEUROBEHAVIORAL SYMPTOMS; FAMILY BURDEN; 1ST YEAR; INSTRUMENTS; ADOLESCENTS; AGREEMENT; OUTCOMES	Objectives Mild traumatic brain injury (TBI) and injury-related outcomes such as postconcussive symptoms (PCS) may influence health-related quality of life (HRQOL) in children. Methods We evaluated HRQOL in 186 8- to 15-year-old children with mild TBI and 99 children with orthopedic injuries (OI). Parents rated the frequency and severity of PCS at an initial assessment within 2-weeks postinjury and rated HRQOL at 3- and 12-months postinjury. Results The mild TBI and OI groups did not differ in psychosocial HRQOL, but the mild TBI group showed lower physical HRQOL at the 12-month follow-up. Somatic PCS were a significant predictor of physical HRQOL over time, and both cognitive and somatic PCS were significant predictors of psychosocial HRQOL over time. Children with higher PCS at the initial assessment had lower HRQOL scores at later time points. Conclusions Effective management of PCS may be associated with improvements in HRQOL following pediatric mild TBI.	[Yeates, Keith O.] Nationwide Childrens Hosp, Dept Psychol, Ctr Biobehav Hlth, Res Inst, Columbus, OH 43205 USA; [Moran, Lisa M.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; [Taylor, H. Gerry; Wright, Martha; Minich, Nori] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Wright, Martha] Univ Hosp, Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, San Antonio, TX USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, San Antonio, TX USA; [Dietrich, Ann; Nuss, Kathryn E.] Ohio State Univ, Dept Pediat, Coll Med, Columbus, OH 43210 USA; [Dietrich, Ann; Nuss, Kathryn E.] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Ctr Biobehav Hlth, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; Nuss, Kathryn/0000-0003-2185-7364	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD39834, HD44099] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER		Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Davis E, 2006, DEV MED CHILD NEUROL, V48, P311, DOI 10.1017/S0012162206000673; Drotar D, 2004, AMBUL PEDIATR, V4, P353, DOI 10.1367/1539-4409(2004)4<353:MCHSQC>2.0.CO;2; Eiser C, 2001, QUAL LIFE RES, V10, P347, DOI 10.1023/A:1012253723272; Eiser C, 2001, J DEV BEHAV PEDIATR, V22, P248, DOI 10.1097/00004703-200108000-00007; Eiser C, 2001, ARCH DIS CHILD, V84, P205, DOI 10.1136/adc.84.3.205; Eiser C, 2007, ARCH DIS CHILD, V92, P348, DOI 10.1136/adc.2005.086405; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Erickson SJ, 2010, DEV NEUROREHABIL, V13, P175, DOI 10.3109/17518420903479867; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Hajek CA, 2011, CHILD NEUROPSYCHOL, V17, P17, DOI 10.1080/09297049.2010.495058; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Landgraf JM, 1996, CHILD HLTH QUESTIONN, V1st; Leeuw J.D., 2008, HDB MULTILEVEL ANAL; Limond J, 2009, BRAIN INJURY, V23, P617, DOI 10.1080/02699050902997870; Matza LS, 2004, VALUE HEALTH, V7, P79, DOI 10.1111/j.1524-4733.2004.71273.x; McCarthy ML, 2007, J TRAUMA, V63, pS122, DOI 10.1097/TA.0b013e31815accdf; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Mittenberg W., 1997, CLIN NEUROPSYCHOL, V11, P305; Palermo TM, 2008, J PEDIATR PSYCHOL, V33, P983, DOI 10.1093/jpepsy/jsn038; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Raat H, 2006, CURR OPIN ALLERGY CL, V6, P180, DOI 10.1097/01.all.0000225157.67897.c2; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V2nd ed; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Taylor H. G., 2010, PEDIAT TRAUMATIC BRA, P145; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; TEASDALE G, 1974, LANCET, V2, P81; Theunissen NCM, 1998, QUAL LIFE RES, V7, P387, DOI 10.1023/A:1008801802877; Tilford JM, 2007, NEUROCRIT CARE, V7, P64, DOI 10.1007/s12028-007-0037-5; Upton P, 2008, QUAL LIFE RES, V17, P895, DOI 10.1007/s11136-008-9350-5; Winthrop AL, 2010, CURR OPIN PEDIATR, V22, P346, DOI 10.1097/MOP.0b013e3283394351; World Health Organization [WHO], 2020, CONST; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	50	51	51	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	AUG	2012	37	7					736	744		10.1093/jpepsy/jsr087			9	Psychology, Developmental	Psychology	981KC	WOS:000306965500004	21994421	Green Published, Bronze			2021-06-18	
J	Ajao, DO; Pop, V; Kamper, JE; Adami, A; Rudobeck, E; Huang, L; Vlkolinsky, R; Hartman, RE; Ashwal, S; Obenaus, A; Badaut, J				Ajao, David O.; Pop, Viorela; Kamper, Joel E.; Adami, Arash; Rudobeck, Emil; Huang, Lei; Vlkolinsky, Roman; Hartman, Richard E.; Ashwal, Stephen; Obenaus, Andre; Badaut, Jerome			Traumatic Brain Injury in Young Rats Leads to Progressive Behavioral Deficits Coincident with Altered Tissue Properties in Adulthood	JOURNAL OF NEUROTRAUMA			English	Article						behavior; CNPase; juvenile traumatic brain injury; magnetic resonance imaging; myelin; neurofilament-200	CONTROLLED CORTICAL IMPACT; COGNITIVE DEFICITS; AXONAL INJURY; IMMATURE RAT; CHILDREN; TERM; PROTEIN; EXPRESSION; CONTUSION; RECOVERY	Traumatic brain injury (TBI) affects many infants and children, and results in enduring motor and cognitive impairments with accompanying changes in white matter tracts, yet few experimental studies in rodent juvenile models of TBI (jTBI) have examined the timeline and nature of these deficits, histologically and functionally. We used a single controlled cortical impact (CCI) injury to the parietal cortex of rats at post-natal day (P) 17 to evaluate behavioral alterations, injury volume, and morphological and molecular changes in gray and white matter, with accompanying measures of electrophysiological function. At 60 days post-injury (dpi), we found that jTBI animals displayed behavioral deficits in foot-fault and rotarod tests, along with a left turn bias throughout their early developmental stages and into adulthood. In addition, anxiety-like behaviors on the zero maze emerged in jTBI animals at 60 dpi. The final lesion constituted only similar to 3% of brain volume, and morphological tissue changes were evaluated using MRI, as well as immunohistochemistry for neuronal nuclei (NeuN), myelin basic protein (MBP), neurofilament-200 (NF200), and oligodendrocytes (CNPase). White matter morphological changes were associated with a global increase in MBP immunostaining and reduced compound action potential amplitudes at 60 dpi. These results suggest that brain injury early in life can induce long-term white matter dysfunction, occurring in parallel with the delayed development and persistence of behavioral deficits, thus modeling clinical and longitudinal TBI observations.	[Badaut, Jerome] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92354 USA; [Ajao, David O.; Badaut, Jerome] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92354 USA; [Kamper, Joel E.; Hartman, Richard E.] Loma Linda Univ, Dept Psychol, Loma Linda, CA 92354 USA; [Huang, Lei; Vlkolinsky, Roman; Obenaus, Andre] Loma Linda Univ, Dept Radiat Med, Loma Linda, CA 92354 USA; [Obenaus, Andre] Loma Linda Univ, Dept Biophys & Bioengn, Loma Linda, CA 92354 USA; [Obenaus, Andre] Loma Linda Univ, Dept Radiol, Loma Linda, CA 92354 USA; [Adami, Arash] Univ Calif Riverside, Dept Neurosci, Riverside, CA 92521 USA; [Rudobeck, Emil] Univ Calif Riverside, Dept Phys, Riverside, CA 92521 USA	Badaut, J (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Room A1120,11175 Campus St, Loma Linda, CA 92354 USA.	jbadaut@llu.edu	Hartman, Richard/C-5767-2008; Kamper, Joel/V-2450-2019	Hartman, Richard/0000-0001-9235-3169; Kamper, Joel/0000-0001-5098-5176; Rudobeck, Emil/0000-0001-7949-4282	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD061946]; Pediatric Research Fund; Swiss Science FoundationSwiss National Science Foundation (SNSF) [FN 31003A-122166, IZK0Z3-128973]; Department of Pediatrics; NASANational Aeronautics & Space Administration (NASA) [NCC9-149]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946] Funding Source: NIH RePORTER	The authors thank Mr. Dane W. Sorensen for his technical help in this work, and Monica Rubalcava at the Advanced Imaging and Microscopy facility at Loma Linda. This work was supported in part by the National Institutes of Health (R01HD061946), the Pediatric Research Fund, the Swiss Science Foundation (FN 31003A-122166 and IZK0Z3-128973), the Department of Pediatrics, and a NASA Cooperative Agreement (NCC9-149) to the Radiobiology Program, Department of Radiation Medicine, at Loma Linda University.	Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Akiyama K, 2002, J NEUROSCI RES, V68, P19, DOI 10.1002/jnr.10188; Badaut J, 2007, PEDIATR RES, V62, P248, DOI 10.1203/PDR.0b013e3180db291b; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Barreto G, 2010, J NEUROSURG ANESTH, V22, P214, DOI 10.1097/ANA.0b013e3181d56c98; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BJELKE B, 1989, INT J DEV NEUROSCI, V7, P145, DOI 10.1016/0736-5748(89)90065-8; Bloch J, 2011, J COMP NEUROL, V519, P775, DOI 10.1002/cne.22547; BOLTON CF, 1980, J NEUROL NEUROSUR PS, V43, P925, DOI 10.1136/jnnp.43.10.925; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Brenner LA, 2007, J HEAD TRAUMA REHAB, V22, P56, DOI 10.1097/00001199-200701000-00007; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chan JR, 1998, P NATL ACAD SCI USA, V95, P10459, DOI 10.1073/pnas.95.18.10459; Choo AMT, 2009, J NEUROSCI METH, V181, P6, DOI 10.1016/j.jneumeth.2009.04.007; Fujii Daryl, 2002, Cogn Neuropsychiatry, V7, P41, DOI 10.1080/135468000143000131; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Glezer I, 2004, NEUROSCIENTIST, V10, P538, DOI 10.1177/1073858404263494; Goold D, 2009, J TRAUMA, V67, P71, DOI 10.1097/TA.0b013e3181b021ae; Hartman RE, 2005, J NEUROSCI, V25, P6213, DOI 10.1523/JNEUROSCI.0664-05.2005; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Huh JW, 2007, J NEUROTRAUM, V24, P1460, DOI 10.1089/neu.2006.3787; Iannotti CA, 2011, EXP NEUROL, V230, P3, DOI 10.1016/j.expneurol.2010.03.010; Ihara M, 2010, ACTA NEUROPATHOL, V119, P579, DOI 10.1007/s00401-009-0635-8; Jane JA, 1996, NEUROTRAUMA, P723; Kodama Y, 2008, DEV PSYCHOBIOL, V50, P332, DOI 10.1002/dev.20289; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lippert-Gruner M, 2006, BRAIN INJURY, V20, P569, DOI 10.1080/02699050600664467; Liu F, 2009, J NEUROSCI METH, V179, P1, DOI 10.1016/j.jneumeth.2008.12.028; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Obenaus A, 2011, ANN NEUROL, V69, P282, DOI 10.1002/ana.22168; Ono M, 2008, NEUROSCIENCE, V156, P1103, DOI 10.1016/j.neuroscience.2008.07.078; Prigatano GP, 2008, J HEAD TRAUMA REHAB, V23, P414, DOI 10.1097/01.HTR.0000341438.97745.ee; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Recker R, 2009, J CEREBR BLOOD F MET, V29, P1305, DOI 10.1038/jcbfm.2009.56; RUSSELL PA, 1973, ANIM BEHAV, V21, P109, DOI 10.1016/S0003-3472(73)80047-8; Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Tanaka H, 2009, J NEUROSCI, V29, P8363, DOI 10.1523/JNEUROSCI.3216-08.2009; Velumian AA, 2011, J NEUROPHYSIOL, V105, P929, DOI 10.1152/jn.00435.2010; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201; Wong SKF, 2004, ANAL BIOCHEM, V333, P265, DOI 10.1016/j.ab.2004.05.011; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	55	51	53	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	11					2060	2074		10.1089/neu.2011.1883			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	983CX	WOS:000307095800007	22697253	Green Published			2021-06-18	
J	Hallert, O; Li, Y; Brismar, H; Lindgren, U				Hallert, Ola; Li, Yan; Brismar, Harald; Lindgren, Urban			The direct anterior approach: initial experience of a minimally invasive technique for total hip arthroplasty	JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH			English	Article						MIS arthroplasty; Anterior incision; Complication; THR	APPLIED ANATOMY; REPLACEMENT	Background: Less invasive approaches for hip arthroplasty have been developed in order to decrease traumatisation of soft tissue and shorten hospital stay. However, the benefits with a new technique can be at the expense of a new panorama of problems. This manuscript describes, with emphasis on postoperative complications, our experience from the first 200 cases of unilateral hip replacement using the direct anterior minimally invasive (MIS) approach. Methods: A straight incision in front of the greater trochanter was used and the tensor muscle was approached subfascially and retracted laterally. The joint was opened and the femoral head was removed. Usually excellent acetabular exposure was obtained. In order to get access to the proximal femur, the hip capsule was released posterolaterally so that the femur could be lifted using a special retractor behind the tip of the trochanter. After insertion of the prostheses, the wound was closed using running sutures in the fascia overlying the tensor, sub- and intracutaneously. Results: There was a small influence of BMI on the duration of surgery, and obese patients tended to have the cup positioned at a higher degree of deviation. There were in total 17 complications of which 5 necessitated revision surgery; 3 peroperative femoral fractures and 2 dislocations. Another 4 dislocations were treated with closed reduction and did not recur. 3 cases of nerve injury were noted, all resolved within 12 months. Three cases of DVT were diagnosed as well as 2 cases of postoperative infection; none of these led to chronic disability. Conclusions: The technique is perhaps more technically demanding than the lateral approaches used today due to the somewhat limited surgical exposure. Morbidly obese or very muscular patients as well as patients with a short femoral neck or acetabular protrusion can represent particular problems. Our results indicate that there are certain risks when adopting this procedure but the complications noted are avoidable.	[Hallert, Ola; Li, Yan; Brismar, Harald; Lindgren, Urban] Karolinska Inst, Div Orthoped, Dept Clin Sci Intervent & Technol CLINTEC, Stockholm, Sweden	Li, Y (corresponding author), Karolinska Inst, Div Orthoped, Dept Clin Sci Intervent & Technol CLINTEC, Stockholm, Sweden.	Yan.Li@ki.se	Brismar, Hjalmar/E-8524-2011	Brismar, Hjalmar/0000-0003-0578-4003	Stryker(R) Sweden	Funds were received from Stryker (R) Sweden.	ACKLAND MK, 1986, J BONE JOINT SURG BR, V68, P409; Barton C, 2009, ORTHOP CLIN N AM, V40, P371, DOI 10.1016/j.ocl.2009.04.004; Benoit B, 2009, ORTHOP CLIN N AM, V40, P357, DOI 10.1016/j.ocl.2009.02.002; Bremer AK, 2011, J BONE JT SURG B, V7, P886; Chen LH, 2009, CLIN ANAT, V22, P250, DOI 10.1002/ca.20750; de Verteuil R, 2008, HEALTH TECHNOL ASSES, V12, DOI 10.3310/HTA12260; Howell JR, 2004, ORTHOP CLIN N AM, V35, P107, DOI 10.1016/S0030-5898(03)00112-3; Howell JR, 2004, ORTHOP CLIN N AM, V35, P153, DOI 10.1016/S0030-5898(03)00137-8; Jewett BA, 2011, CLIN ORTHOP RELAT R, V469, P503, DOI 10.1007/s11999-010-1568-1; Masonis J, 2008, ORTHOPEDICS, V31, P129; Matta JM, 2005, CLIN ORTHOP RELAT R, P115, DOI 10.1097/01.blo.0000194309.70518.cb; Mayr E, 2009, CLIN BIOMECH, V24, P812, DOI 10.1016/j.clinbiomech.2009.07.010; Meneghini RM, 2006, CLIN ORTHOP RELAT R, P293, DOI 10.1097/01.blo.0000238859.46615.34; Nakata K, 2009, J ARTHROPLASTY, V24, P698, DOI 10.1016/j.arth.2008.04.012; Rachbauer F, 2006, ORTHOPADE, V35, P723, DOI 10.1007/s00132-006-0964-4; Rosenberg AG, 2007, J ARTHROPLASTY, V22, P102, DOI 10.1016/j.arth.2006.12.114; Siguier T, 2004, CLIN ORTHOP RELAT R, P164, DOI 10.1097/01.blo.0000136651.21191.9f; Woolson ST, 2009, J ARTHROPLASTY, V24, P999, DOI 10.1016/j.arth.2009.04.001	18	51	56	1	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1749-799X			J ORTHOP SURG RES	J. Orthop. Surg. Res.	APR 25	2012	7								17	10.1186/1749-799X-7-17			6	Orthopedics	Orthopedics	993JF	WOS:000307853900001	22533964	DOAJ Gold, Green Published			2021-06-18	
J	Lutton, C; Young, YW; Williams, R; Meedeniya, ACB; Mackay-Sim, A; Goss, B				Lutton, Cameron; Young, Yun Wai; Williams, Richard; Meedeniya, Adrian C. B.; Mackay-Sim, Alan; Goss, Ben			Combined VEGF and PDGF Treatment Reduces Secondary Degeneration after Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; degeneration; immunohistochemistry; inflammation; plasma membrane; synaptic loss and deafferentation; traumatic brain injury; vascular reactivity	ENDOTHELIAL GROWTH-FACTOR; BLOOD-VESSEL FORMATION; CELLS; INFLAMMATION; ANGIOGENESIS; CONTUSION; SYSTEM; BB; REGENERATION; MACROPHAGES	Trauma to the spinal cord creates an initial physical injury damaging neurons, glia, and blood vessels, which then induces a prolonged inflammatory response, leading to secondary degeneration of spinal cord tissue, and further loss of neurons and glia surrounding the initial site of injury. Angiogenesis is a critical step in tissue repair, but in the injured spinal cord angiogenesis fails; blood vessels formed initially later regress. Stabilizing the angiogenic response is therefore a potential target to improve recovery after spinal cord injury (SCI). Vascular endothelial growth factor (VEGF) can initiate angiogenesis, but cannot sustain blood vessel maturation. Platelet-derived growth factor (PDGF) can promote blood vessel stability and maturation. We therefore investigated a combined application of VEGF and PDGF as treatment for traumatic spinal cord injury, with the aim to reduce secondary degeneration by promotion of angiogenesis. Immediately after hemisection of the spinal cord in the rat we delivered VEGF and PDGF and to the injury site. One and 3 months later the size of the lesion was significantly smaller in the treated group compared to controls, and there was significantly reduced gliosis surrounding the lesion. There was no significant effect of the treatment on blood vessel density, although there was a significant reduction in the numbers of macrophages/microglia surrounding the lesion, and a shift in the distribution of morphological and immunological phenotypes of these inflammatory cells. VEGF and PDGF delivered singly exacerbated secondary degeneration, increasing the size of the lesion cavity. These results demonstrate a novel therapeutic intervention for SCI, and reveal an unanticipated synergy for these growth factors whereby they modulated inflammatory processes and created a microenvironment conducive to axon preservation/sprouting.	[Lutton, Cameron; Williams, Richard; Goss, Ben] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane Spine Reference Ctr, Brisbane, Qld 4059, Australia; [Young, Yun Wai; Meedeniya, Adrian C. B.; Mackay-Sim, Alan] Griffith Univ Brisbane, Natl Ctr Adult Stem Cell Res, Eskitis Inst Cell & Mol Therapies, Brisbane, Qld, Australia	Lutton, C (corresponding author), Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane Spine Reference Ctr, Musk Ave, Brisbane, Qld 4059, Australia.	c.lutton@qut.edu.au	Williams, Richard P/B-2029-2012; Mackay-Sim, Alan/C-3431-2008; Lutton, Cameron J/H-2020-2011; Goss, Ben/F-1867-2010	Mackay-Sim, Alan/0000-0003-4446-5371; Goss, Ben/0000-0003-0518-1229	Institute of Health and Biomedical Innovation, Queensland University of Technology; National Centre for Adult Stem Cell Research, Griffith University; Australian Department of Health and AgeingAustralian GovernmentDepartment of Health & Ageing; Queensland Government; Queensland Orthopaedic Research Trust	The authors are grateful to The Institute of Health and Biomedical Innovation, Queensland University of Technology, for seed funding, the National Centre for Adult Stem Cell Research, Griffith University, and the Australian Department of Health and Ageing for a Ph.D. stipend for Y.-W.Y. We appreciate the assistance of the animal house staff at the Medical Engineering Research Facility (Queensland University of Technology). B. G. gratefully acknowledges the Queensland Government for a Smart State Fellowship, and the Queensland Orthopaedic Research Trust for ongoing support.	BARD JBL, 1986, J HISTOCHEM CYTOCHEM, V34, P1237, DOI 10.1177/34.9.3734422; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Benton RL, 2003, NEUROCHEM RES, V28, P1693, DOI 10.1023/A:1026013106016; Bezuidenhout L, 2007, J LEUKOCYTE BIOL, V81, P1496, DOI 10.1189/jlb.1106687; Bittner B, 2000, INT J PHARM, V205, P195, DOI 10.1016/S0378-5173(00)00481-6; Casella GTB, 2002, EXP NEUROL, V173, P63, DOI 10.1006/exnr.2001.7827; Chen RR, 2007, PHARM RES, V24, P258, DOI 10.1007/s11095-006-9173-4; Choo AM, 2008, EXP NEUROL, V212, P490, DOI 10.1016/j.expneurol.2008.04.038; Croll SD, 2004, EXP NEUROL, V187, P388, DOI 10.1016/j.expneurol.2004.02.010; Darland DC, 1999, J CLIN INVEST, V103, P157, DOI 10.1172/JCI6127; DAYNES RA, 1991, J EXP MED, V174, P1323, DOI 10.1084/jem.174.6.1323; Enge M, 2003, NEUROCHEM RES, V28, P271, DOI 10.1023/A:1022421001288; Facchiano F, 2002, J NEUROSURG, V97, P161, DOI 10.3171/jns.2002.97.1.0161; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GLENN JA, 1992, J ANAT, V180, P109; Hao XJ, 2007, CARDIOVASC RES, V75, P178, DOI 10.1016/j.cardiores.2007.03.028; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hiersemenzel LP, 2000, NEUROLOGY, V54, P1574, DOI 10.1212/WNL.54.8.1574; Iihara K, 1997, J CEREBR BLOOD F MET, V17, P1097, DOI 10.1097/00004647-199710000-00012; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Kataru RP, 2009, BLOOD, V113, P5650, DOI 10.1182/blood-2008-09-176776; Kim HM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004987; Korpisalo P, 2008, CIRC RES, V103, P1092, DOI 10.1161/CIRCRESAHA.108.182287; Kwon B.K., 2010, J NEUROTRAUM, V27, P1; Kwon BK, 2002, SPINE, V27, P1504, DOI 10.1097/00007632-200207150-00005; Liu Y, 2010, NEUROBIOL DIS, V37, P384, DOI 10.1016/j.nbd.2009.10.018; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; Norazit A, 2011, NEUROSCIENCE, V192, P652, DOI 10.1016/j.neuroscience.2011.06.035; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Romero-Sandoval A, 2008, BRAIN RES, V1219, P116, DOI 10.1016/j.brainres.2008.05.004; Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792; Smirkin A, 2010, J CEREBR BLOOD F MET, V30, P603, DOI 10.1038/jcbfm.2009.233; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Sundberg LM, 2011, J NEUROTRAUM, V28, P565, DOI 10.1089/neu.2010.1533; Tchaikovski V, 2008, ARTERIOSCL THROM VAS, V28, P322, DOI 10.1161/ATVBAHA.107.158022; van Neerven S, 2010, J NEUROTRAUM, V27, P1781, DOI 10.1089/neu.2010.1484; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; WILLIAMS RW, 1988, J COMP NEUROL, V278, P344, DOI 10.1002/cne.902780305; WILSON E, 1987, P NATL ACAD SCI USA, V84, P2213, DOI 10.1073/pnas.84.8.2213; Xiyang YB, 2009, J NEUROTRAUM, V26, P275, DOI 10.1089/neu.2007.0374; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	49	51	53	2	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					957	+		10.1089/neu.2010.1423			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900023	21568693	Green Published			2021-06-18	
J	Seli, P; Cheyne, JA; Smilek, D				Seli, Paul; Cheyne, James Allan; Smilek, Daniel			Attention failures versus misplaced diligence: Separating attention lapses from speed-accuracy trade-offs	CONSCIOUSNESS AND COGNITION			English	Article						Sustained attention; Speed accuracy trade-off; Attention lapses; Alerts; Vigilance	TRAUMATIC BRAIN-INJURY; DEFICIT HYPERACTIVITY DISORDER; TASK UNRELATED THOUGHT; SUSTAINED-ATTENTION; DEFICIT/HYPERACTIVITY DISORDER; RESPONSE VARIABILITY; EXECUTIVE FUNCTION; PERFORMANCE; ADHD; MIND	In two studies of a GO-NOGO task assessing sustained attention, we examined the effects of (1) altering speed-accuracy trade-offs through instructions (emphasizing both speed and accuracy or accuracy only) and (2) auditory alerts distributed throughout the task. Instructions emphasizing accuracy reduced errors and changed the distribution of GO trial RTs. Additionally, correlations between errors and increasing RTs produced a U-function; excessively fast and slow RTs accounted for much of the variance of errors. Contrary to previous reports, alerts increased errors and RT variability. The results suggest that (1) standard instructions for sustained attention tasks, emphasizing speed and accuracy equally, produce errors arising from attempts to conform to the misleading requirement for speed, which become conflated with attention-lapse produced errors and (2) auditory alerts have complex, and sometimes deleterious, effects on attention. We argue that instructions emphasizing accuracy provide a more precise assessment of attention lapses in sustained attention tasks. (C) 2011 Elsevier Inc. All rights reserved.	[Seli, Paul; Cheyne, James Allan; Smilek, Daniel] Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada	Seli, P (corresponding author), Univ Waterloo, Dept Psychol, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	pseli@uwaterloo.ca					Beilock SL, 2008, J EXP PSYCHOL-APPL, V14, P340, DOI 10.1037/a0012859; Beilock SL, 2004, PSYCHON B REV, V11, P373, DOI 10.3758/BF03196585; Bellgrove MA, 2006, CORTEX, V42, P838, DOI 10.1016/S0010-9452(08)70426-X; Carriere JSA, 2010, PSYCHOL AGING, V25, P569, DOI 10.1037/a0019363; Castellanos FX, 2005, BIOL PSYCHIAT, V57, P1416, DOI 10.1016/j.biopsych.2004.12.005; Castellanos FX, 2002, NAT REV NEUROSCI, V3, P617, DOI 10.1038/nrn896; Chan RCK, 2009, COGN BEHAV NEUROL, V22, P180, DOI 10.1097/WNN.0b013e3181b7ef84; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050119721; Cheyne D. O., 2009, NCM ANN M WAIK HAW A; Cheyne J. A., 2006, CONSCIOUS COGN, V18, P481; Cheyne JA, 2009, COGNITION, V111, P98, DOI 10.1016/j.cognition.2008.12.009; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; Cheyne JA, 2011, COGNITION, V121, P437, DOI 10.1016/j.cognition.2011.07.010; Christoff K, 2009, P NATL ACAD SCI USA, V106, P8719, DOI 10.1073/pnas.0900234106; Davies D.R., 1982, PSYCHOL VIGILANCE; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; EDWARDS W, 1961, PSYCHOL REV, V68, P275, DOI 10.1037/h0044699; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Greene CM, 2009, NEUROPSYCHOLOGIA, V47, P591, DOI 10.1016/j.neuropsychologia.2008.10.003; Helton WS, 2011, CONSCIOUS COGN, V20, P1732, DOI 10.1016/j.concog.2011.02.011; Helton WS, 2010, CONSCIOUS COGN, V19, P77, DOI 10.1016/j.concog.2010.01.006; Helton WS, 2009, CONSCIOUS COGN, V18, P600, DOI 10.1016/j.concog.2009.06.002; Helton WS, 2009, J CLIN EXP NEUROPSYC, V31, P39, DOI 10.1080/13803390801978856; Helton WS, 2005, BRIT J PSYCHOL, V96, P249, DOI 10.1348/000712605X38369; HOWELL WC, 1963, J EXP PSYCHOL, V65, P39, DOI 10.1037/h0038982; Imbo I, 2010, EUR J COGN PSYCHOL, V22, P964, DOI 10.1080/09541440903150196; James W., 1890, PRINCIPLES PSYCHOL, VII; Johnson KA, 2008, NEUROPSYCHOLOGIA, V46, P1532, DOI 10.1016/j.neuropsychologia.2008.01.002; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P2234, DOI 10.1016/j.neuropsychologia.2007.02.019; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Juncos-Rabadan O, 2008, ACTA PSYCHOL, V127, P237, DOI 10.1016/j.actpsy.2007.05.003; Kuntsi J, 2001, J CHILD PSYCHOL PSYC, V42, P211, DOI 10.1111/1469-7610.00712; MACKAY DG, 1971, AM J PSYCHOL, V84, P35, DOI 10.2307/1421223; MACKAY DG, 1982, PSYCHOL REV, V89, P483, DOI 10.1037/0033-295X.89.5.483; Manly T, 2004, NEUROPSYCHOL REHABIL, V14, P89, DOI 10.1080/09602010343000110; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Matthews G, 2000, HUMAN PERFORMANCE CO; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; McVay JC, 2009, J EXP PSYCHOL LEARN, V35, P196, DOI 10.1037/a0014104; Molenberghs P, 2009, NEUROPSYCHOLOGIA, V47, P2866, DOI 10.1016/j.neuropsychologia.2009.06.012; Mullins C, 2005, J AM ACAD CHILD PSY, V44, P169, DOI 10.1097/00004583-200502000-00009; NEWELL KM, 1980, TUTORIALS MOTOR BEHA; O'Connell RG, 2008, NEUROPSYCHOLOGIA, V46, P1379, DOI 10.1016/j.neuropsychologia.2007.12.018; O'Connell RG, 2006, NEUROPSYCHOL REHABIL, V16, P653, DOI 10.1080/09602010500200250; O'Connell RG, 2004, NEUROREPORT, V15, P2535, DOI 10.1097/00001756-200411150-00021; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Prinz W., 2009, OXFORD HDB HUMAN ACT; Reason J.T., 1979, ASPECTS CONSCIOUSNES, V1, P67; REASON JT, 1977, ADULT LEARNING; Ridderinkhof KR, 2002, PSYCHOL RES-PSYCH FO, V66, P312, DOI 10.1007/s00426-002-0104-7; Ridderinkhof KR, 2002, ATTENTION PERFORM, V19, P494; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Rupp H., 1932, PSYCHOTECHNISCHES Z, V7, P161; SALTHOUSE TA, 1979, ERGONOMICS, V22, P811, DOI 10.1080/00140137908924659; Schneider W., 2002, E PRIME USERS GUIDE; SEE JE, 1995, PSYCHOL BULL, V117, P230, DOI 10.1037/0033-2909.117.2.230; Seli P, 2012, CAN J EXP PSYCHOL, V66, P44, DOI 10.1037/a0025111; Shallice T, 2002, DEV NEUROPSYCHOL, V21, P43, DOI 10.1207/S15326942DN2101_3; Smallwood J, 2004, CONSCIOUS COGN, V13, P789, DOI 10.1016/j.concog.2004.07.004; Smallwood J, 2003, CONSCIOUS COGN, V12, P169, DOI 10.1016/S1053-8100(02)00003-X; Smallwood JM, 2003, CONSCIOUS COGN, V12, P452, DOI 10.1016/S1053-8100(03)00018-7; Smallwood J, 2007, COGNITION EMOTION, V21, P816, DOI 10.1080/02699930600911531; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; Smilek D, 2010, NEUROPSYCHOLOGIA, V48, P2564, DOI 10.1016/j.neuropsychologia.2010.05.002; Smilek D, 2010, PSYCHOL SCI, V21, P786, DOI 10.1177/0956797610368063; Smith-Chant BL, 2003, MEM COGNITION, V31, P516, DOI 10.3758/BF03196093; Stevenson H., 2011, BRAIN COGNITION, V20, P1732; STINS JF, 2007, ADV COGN PSYCHOL, V3, P389; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; van den Wildenberg WPM, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00222; Van der Linden D, 2005, WORK STRESS, V19, P23, DOI 10.1080/02678370500065275; Warm J. S., 1984, SUSTAINED ATTENTION; Warm JS, 2008, HUM FACTORS, V50, P433, DOI 10.1518/001872008X312152; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; WING AM, 1973, PERCEPT PSYCHOPHYS, V14, P5, DOI 10.3758/BF03198607; Woodworth R. S., 1899, PSYCHOL MONOGRAPHS, V3; Wylie SA, 2009, NEUROPSYCHOLOGIA, V47, P1844, DOI 10.1016/j.neuropsychologia.2009.02.025	81	51	51	0	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8100	1090-2376		CONSCIOUS COGN	Conscious. Cogn.	MAR	2012	21	1					277	291		10.1016/j.concog.2011.09.017			15	Psychology, Experimental	Psychology	911YZ	WOS:000301761900027	22001770				2021-06-18	
J	Tian, LL; Guo, RB; Yue, XY; Lv, QS; Ye, XC; Wang, ZZ; Chen, ZY; Wu, B; Xu, GL; Liu, XF				Tian, Lili; Guo, Ruibing; Yue, Xuanye; Lv, Qiushi; Ye, Xinchun; Wang, Zhenzhen; Chen, Zhaoyao; Wu, Bo; Xu, Gelin; Liu, Xinfeng			Intranasal administration of nerve growth factor ameliorate beta-amyloid deposition after traumatic brain injury in rats	BRAIN RESEARCH			English	Article						Alzheimer's disease; Amyloid-beta peptide; Intranasal delivery; Nerve growth factor; Traumatic brain injury	P75 NEUROTROPHIN RECEPTOR; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; TRANSGENIC MICE; FACTOR-I; NGF; DELIVERY; MEMORY; SURVIVAL; THERAPY	The marked increase of amyloid-beta (A beta) peptide after traumatic brain injury (TBI), confers a risk factor for Alzheimer's disease (AD) in patients' later life. Nerve growth factor (NGF) is great potential to repair brain injury. But its clinical application is limited because of lacking feasible methods for delivering NGF into brain. This study investigated the effects of NGF, delivered intranasally, on the A beta burden in the injured ipsilateral cortex and hippocampus of rats with TBI. Adult male Sprague-Dawley rats were subjected to the modified Feeney's weight-drop model and treated without or with NGF by intranasal route. Motor and cognitive functional outcome, immunostaining, ELISA assay and western blot were performed. Compared to sham operated rats, TBI rats exhibited significantly increased APP and A beta(42) expression as well as decreased functional outcome after TBI. Intranasal administration of NGF significantly attenuated A beta(42) deposits, and improved functional outcome after TBI. Thus, intranasal delivery of NGF provides a potential strategy for reducing the risk of developing AD in the later life of TBI patients. (C) 2012 Elsevier B.V. All rights reserved.	[Tian, Lili; Guo, Ruibing; Yue, Xuanye; Lv, Qiushi; Ye, Xinchun; Chen, Zhaoyao; Xu, Gelin; Liu, Xinfeng] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurol, Nanjing 210002, Jiangsu, Peoples R China; [Yue, Xuanye; Ye, Xinchun] Xuzhou Med Coll, Affiliated Hosp, Dept Neurol, Xuzhou 221002, Jiangsu, Peoples R China; [Wang, Zhenzhen] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Geriatr, Nanjing 210029, Jiangsu, Peoples R China; [Chen, Zhaoyao] Jiangsu Prov Hosp Tradit Chinese Med, Dept Neurol, Nanjing 210029, Jiangsu, Peoples R China; [Wu, Bo] Nanjing Univ, Sch Med, Jinling Hosp, Dept Pathol, Nanjing 210002, Jiangsu, Peoples R China	Xu, GL (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurol, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	xfliu2@yahoo.com.cn		Xu, Gelin/0000-0002-6194-0341; Chen, Zhaoyao/0000-0002-8441-5355; Tian, Lili/0000-0001-9421-1535	Nature Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [30870848]	This work was supported by the grant from Nature Science Foundation of China to GX (NSFC 30870848). We are thankful for the excellent technical assistance of Genbao Feng, Henghui Ma and Bo Yu.	Aboulkassim T, 2011, MOL PHARMACOL, V80, P498, DOI 10.1124/mol.111.071332; Barker PA, 2004, NEURON, V42, P529, DOI 10.1016/j.neuron.2004.04.001; BARONE S, 1991, EXP NEUROL, V114, P351, DOI 10.1016/0014-4886(91)90161-5; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849; Bulbarelli A, 2009, MOL CELL NEUROSCI, V40, P365, DOI 10.1016/j.mcn.2008.12.006; Cai Zhi-You, 2008, Neurosci Bull, V24, P305, DOI 10.1007/s12264-008-0324-y; Calissano P, 2010, DEV NEUROBIOL, V70, P372, DOI 10.1002/dneu.20759; Capsoni S, 2002, P NATL ACAD SCI USA, V99, P12432, DOI 10.1073/pnas.192442999; Chen Xue-Qing, 1998, J Alzheimers Dis, V1, P35; Cheng SM, 2009, NEUROL RES, V31, P753, DOI 10.1179/174313209X382557; Covaceuszach S, 2009, CURR ALZHEIMER RES, V6, P158, DOI 10.2174/156720509787602870; Culmsee C, 2002, NEUROSCIENCE, V115, P1089, DOI 10.1016/S0306-4522(02)00539-0; De Rosa R, 2005, P NATL ACAD SCI USA, V102, P3811, DOI 10.1073/pnas.0500195102; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924; Ding J, 2011, J NEUROSCI RES, V89, P222, DOI 10.1002/jnr.22535; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Djupesland PG, 2008, NEUROLOGY, V71, P864, DOI 10.1212/01.wnl.0000327291.47162.ed; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Frey WH, 1997, DRUG DELIV, V4, P87, DOI 10.3109/10717549709051878; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Hock C, 1998, EUR NEUROL, V39, P111, DOI 10.1159/000007917; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Knowles JK, 2009, J NEUROSCI, V29, P10627, DOI 10.1523/JNEUROSCI.0620-09.2009; Lawrence D, 2002, LANCET, V359, P1674, DOI 10.1016/S0140-6736(02)08601-4; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Liu XF, 2001, J NEUROL SCI, V187, P91, DOI 10.1016/S0022-510X(01)00532-9; Matrone C, 2009, P NATL ACAD SCI USA, V106, P11358, DOI 10.1073/pnas.0904998106; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Neugroschl J, 2010, MT SINAI J MED, V77, P3, DOI 10.1002/msj.20165; Pedraza CE, 2005, AM J PATHOL, V166, P533, DOI 10.1016/S0002-9440(10)62275-4; PRADIER P, 1994, J PHYSIOLOGY-PARIS, V88, P273, DOI 10.1016/0928-4257(94)90008-6; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Reger MA, 2008, J ALZHEIMERS DIS, V13, P323, DOI 10.3233/jad-2008-13309; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shi CG, 2010, NEUROCHEM RES, V35, P1302, DOI 10.1007/s11064-010-0183-6; Sotthibundhu A, 2008, J NEUROSCI, V28, P3941, DOI 10.1523/JNEUROSCI.0350-08.2008; Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029; Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; Vaka SRK, 2009, J PHARM SCI-US, V98, P3640, DOI 10.1002/jps.21674; Visser PJ, 2009, LANCET NEUROL, V8, P619, DOI 10.1016/S1474-4422(09)70139-5; Wang CS, 2000, BRAIN RES, V865, P157, DOI 10.1016/S0006-8993(00)02183-1; Wang YJ, 2010, NEUROTOX RES, V17, P257, DOI 10.1007/s12640-009-9098-x; Wirths O, 2002, BRAIN PATHOL, V12, P275, DOI 10.1111/j.1750-3639.2002.tb00442.x; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Zhang YW, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-3	56	51	58	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 27	2012	1440						47	55		10.1016/j.brainres.2011.12.059			9	Neurosciences	Neurosciences & Neurology	915RW	WOS:000302046100005	22284619				2021-06-18	
J	Barnes, SM; Walter, KH; Chard, KM				Barnes, Sean M.; Walter, Kristen H.; Chard, Kathleen M.			Does a History of Mild Traumatic Brain Injury Increase Suicide Risk in Veterans With PTSD?	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; posttraumatic stress disorder; PTSD; suicide; veteran	POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; PERSONALITY-DISORDERS; MAJOR DEPRESSION; US VETERANS; IRAQ; ASSOCIATION; AFGHANISTAN; BEHAVIOR; SYMPTOMS	Objective: Research shows that posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) independently increase suicide risk; however, scant research has investigated whether mTBI increases suicide risk above and beyond the risk associated with PTSD alone. Design: The current research compared suicide risk factors among a matched sample of Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) military personnel and veterans with PTSD alone or PTSD and a history of an mTBI. Results: Differences in the assessed risk factors were small and suggest that if PTSD and mTBI are associated with elevations in suicide risk relative to PTSD alone, the added risk is likely mediated or confounded by PTSD symptom severity. Conclusion: This finding highlights the importance of screening and treating military personnel and veterans for PTSD. Future explication of the impact of TBI-related impairments on suicide risk will be critical as we strive to ensure safety and optimize care for our military personnel and veterans.	[Barnes, Sean M.; Walter, Kristen H.; Chard, Kathleen M.] Cincinnati VA Med Ctr, PTSD, Cincinnati, OH 45220 USA; [Barnes, Sean M.; Walter, Kristen H.; Chard, Kathleen M.] Cincinnati VA Med Ctr, Anxiety Disorders Clin, Cincinnati, OH 45220 USA; [Barnes, Sean M.] VA VISN 19 Mental Illness Res Educ & Clin Ctr, Denver, CO USA; [Chard, Kathleen M.] Univ Cincinnati, Sch Med, Cincinnati, OH 45221 USA	Chard, KM (corresponding author), Cincinnati VA Med Ctr, PTSD, 3200 Vine St, Cincinnati, OH 45220 USA.	Kathleen.Chard@va.gov	Walter, Kristen H/S-1827-2019				American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; BECK AT, 1990, AM J PSYCHIAT, V147, P190; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bernal M, 2007, J AFFECT DISORDERS, V101, P27, DOI 10.1016/j.jad.2006.09.018; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blakely TA, 2003, J EPIDEMIOL COMMUN H, V57, P594, DOI 10.1136/jech.57.8.594; Borges G, 2010, CURR OPIN PSYCHIATR, V23, P195, DOI 10.1097/YCO.0b013e3283386322; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; BULLMAN TA, 1994, J NERV MENT DIS, V182, P604, DOI 10.1097/00005053-199411000-00002; Defense and Veterans Brain Injury Center, 2010, DEP DEF NUMB TRAUM B; Department of Defence Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; Duerden Martin, 2009, WHAT ARE HAZARD RATI; Ferraro KF, 2003, AM SOCIOL REV, V68, P707, DOI 10.2307/1519759; Field T, 2001, ADOLESCENCE, V36, P241; First M.B., 1996, STRUCTURED CLIN INTE; Freeman TW, 2000, J NERV MENT DIS, V188, P460, DOI 10.1097/00005053-200007000-00011; Gradus JL, 2010, AM J EPIDEMIOL, V171, P721, DOI 10.1093/aje/kwp456; HENDIN H, 1991, AM J PSYCHIAT, V148, P586; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Ilgen MA, 2008, GEN HOSP PSYCHIAT, V30, P521, DOI 10.1016/j.genhosppsych.2008.09.003; Ilgen MA, 2010, SUICIDE LIFE-THREAT, V40, P597, DOI 10.1521/suli.2010.40.6.597; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Joiner TE, 2005, J ABNORM PSYCHOL, V114, P291, DOI 10.1037/0021-843X.114.2.291; Jurisic B, 2009, CRISIS, V30, P34, DOI 10.1027/0227-5910.30.1.34; Kalivas PW, 2003, AM J PSYCHIAT, V160, P1, DOI 10.1176/appi.ajp.160.1.1; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kposowa AJ, 2000, J EPIDEMIOL COMMUN H, V54, P254, DOI 10.1136/jech.54.4.254; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Maffei C, 1997, J PERS DISORD, V11, P279, DOI 10.1521/pedi.1997.11.3.279; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McMillan D, 2007, PSYCHOL MED, V37, P769, DOI 10.1017/S0033291706009664; Morgan C, 2008, PSYCHOL MED, V38, P1701, DOI 10.1017/S0033291708004534; Nock MK, 2008, EPIDEMIOL REV, V30, P133, DOI 10.1093/epirev/mxn002; NORSTROM T, 1995, SOC FORCES, V74, P293, DOI 10.2307/2580633; Nye EC, 2007, MIL MED, V172, P1144; Oquendo M, 2005, AM J PSYCHIAT, V162, P560, DOI 10.1176/appi.ajp.162.3.560; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Oquendo MA, 2003, AM J PSYCHIAT, V160, P580, DOI 10.1176/appi.ajp.160.3.580; Pfeiffer PN, 2009, DEPRESS ANXIETY, V26, P752, DOI 10.1002/da.20583; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rudd MD, 1996, J ABNORM PSYCHOL, V105, P541, DOI 10.1037/0021-843X.105.4.541; Sareen J, 2005, J TRAUMA STRESS, V18, P313, DOI 10.1002/jts.20040; Schell T.L., 2008, INVISIBLE WOUNDS WAR, DOI [10.7249/mg720-1ccf.12, DOI 10.7249/MG720-1CCF.12]; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seguin M, 2007, PSYCHOL MED, V37, P1575, DOI 10.1017/S0033291707000955; Shear MK, 2000, AM J PSYCHIAT, V157, P581, DOI 10.1176/appi.ajp.157.4.581; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; United States Department of Defense Defense Manpower Data Center Data Analysis & Programs Division, 2011, US ACT DUT MIL DEATH; Van Orden KA, 2008, J CONSULT CLIN PSYCH, V76, P72, DOI 10.1037/0022-006X.76.1.72; Van Orden KA, 2010, PSYCHOL REV, V117, P575, DOI 10.1037/a0018697; Weathers F. W., 1993, ANN M INT SOC TRAUM; Weathers FW, 1991, PCL S DSM 4; Wingate LR, 2004, BEHAV SCI LAW, V22, P651, DOI 10.1002/bsl.612; Zanarini MC, 2000, J PERS DISORD, V14, P291, DOI 10.1521/pedi.2000.14.4.291; Zivin K, 2007, AM J PUBLIC HEALTH, V97, P2193, DOI 10.2105/AJPH.2007.115477	70	51	51	1	19	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2012	57	1					18	26		10.1037/a0027007			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	901JX	WOS:000300964300004	22369114				2021-06-18	
J	Miele, AS; Gunner, JH; Lynch, JK; McCaffrey, RJ				Miele, Andrea S.; Gunner, Jessica H.; Lynch, Julie K.; McCaffrey, Robert J.			Are Embedded Validity Indices Equivalent to Free-Standing Symptom Validity Tests?	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Symptom validity tests; Embedded validity indices; Embedded measures; Effort; Word Memory Test; Test of Memory Malingering; Victoria Symptom Validity Test; Rey 15-Item Test; Reliable Digit Span; Medico-legal	ADULT INTELLIGENCE SCALE; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; CROSS-VALIDATION; CATEGORY TEST; NEUROPSYCHOLOGICAL ASSESSMENT; AMERICAN-ACADEMY; SEASHORE RHYTHM; PERFORMANCE; IMPAIRMENT	Symptom validity assessment is an important part of neuropsychological evaluation. There are currently several free-standing symptom validity tests (SVTs), as well as a number of empirically derived embedded validity indices, that have been developed to assess that an examinee is putting forth an optimal level of effort during testing. The use of embedded validity indices is attractive since they do not increase overall testing time and may also be less vulnerable to coaching. In addition, there are some instances where embedded validity indices are the only tool available to the neuropsychological practitioner for assessing an examinee's level of effort. As with free-standing measures, the sensitivity and specificity of embedded validity indices to suboptimal effort varies. The present study evaluated the diagnostic validity of 17 embedded validity indices by comparing performance on these indices to performance on combinations of free-standing SVTs. Results from the current medico-legal sample revealed that of the embedded validity indices, Reliable Digit Span had the best classification accuracy; however, the findings do not support the use of this embedded validity index in the absence of free-standing SVTs.	[Miele, Andrea S.; Gunner, Jessica H.] SUNY Albany, Dept Psychol, Albany, NY 12222 USA; [Lynch, Julie K.] Albany Neuropsychol Associates, Guilderland, NY USA; [McCaffrey, Robert J.] SUNY Albany, Albany Neuropsychol Associates, Albany, NY 12222 USA	Miele, AS (corresponding author), SUNY Albany, Dept Psychol, 1400 Washington Ave, Albany, NY 12222 USA.	amiele@albany.edu					Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; BOLTER JF, 1985, ANN M NAT AC NEUR PH; Boone, 2007, ASSESSMENT FEIGNED C; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Committee on Mild Traumatic Brain Injury American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86; DiCarlo MA, 2000, ARCH CLIN NEUROPSYCH, V15, P399, DOI 10.1016/S0887-6177(99)00031-1; Forrest TJ, 2004, CLIN NEUROPSYCHOL, V18, P334, DOI 10.1080/13854040490501673; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gfeller JD, 1998, J CLIN PSYCHOL, V54, P431, DOI 10.1002/(SICI)1097-4679(199806)54:4<431::AID-JCLP5>3.0.CO;2-Q; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Green P., 2003, GREENS WORD MEMORY T; Green P., 2005, MANUAL WORD MEMORY T; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Jasinski LJ, 2011, J CLIN EXP NEUROPSYC, V33, P300, DOI 10.1080/13803395.2010.516743; Laatsch L., 1991, J CONSULT CLIN PSYCH, V3, P701; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Lee D., 2003, J FORENSIC NEUROPSYC, V3, P55, DOI [https://doi.org/10.1300/J151v03n03_04, DOI 10.1300/J151V03N03_04]; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lezak M. D., 1976, NEUROPSYCHOLOGICAL A; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; PANKRATZ L, 1979, J CONSULT CLIN PSYCH, V47, P409, DOI 10.1037/0022-006X.47.2.409; Reitan R.M., 1993, HALSTEADREITAN NEURO; Rey A, 1964, EXAMEN CLIN PSYCHOL; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ross SR, 2006, CLIN NEUROPSYCHOL, V20, P798, DOI 10.1080/13854040500328477; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sweet J. J., 2002, J FORENSIC NEUROPSYC, V3, P241; Tabachnick BG, 2007, USING MULTIVARIATE S; Tenhula W. N., 1994, ANN M NAT AC NEUR OR; Tenhula W. N., 1994, ANN M INT NEUR SOC C; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	49	51	51	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2012	27	1					10	22		10.1093/arclin/acr084			13	Psychology, Clinical; Psychology	Psychology	885TE	WOS:000299802900002	22068442				2021-06-18	
J	Kasahara, M; Menon, DK; Salmond, CH; Outtrim, JG; Tavares, JVT; Carpenter, TA; Pickard, JD; Sahakian, BJ; Stamatakis, EA				Kasahara, Maki; Menon, David K.; Salmond, Claire H.; Outtrim, Joanne G.; Tavares, Joana V. Taylor; Carpenter, T. Adrian; Pickard, John D.; Sahakian, Barbara J.; Stamatakis, Emmanuel A.			Traumatic brain injury alters the functional brain network mediating working memory	BRAIN INJURY			English	Article						fMRI; plasticity; right inferior frontal gyrus; working memory	INHIBITORY CONTROL; MILD; ACTIVATION; FMRI; METHYLPHENIDATE; CONNECTIVITY; IMPAIRMENT; COMPONENTS; COMMON; LOAD	Primary objective: Investigation of the impact of traumatic brain injury (TBI) on the functional brain network that mediates working memory function. Research design: Functional magnetic resonance imaging (fMRI) during an n-back working memory task in nine chronic-stage patients with TBI and nine age-matched healthy controls. In addition to classical analyses investigating regional activity, the authors examined functional connectivity of the brain regions critical to working memory performance using psychophysiological interaction (PPI) analyses. Main outcomes and results: Patients with TBI made a greater percentage of errors than controls at high working memory load conditions. The fMRI data showed that the activation of the left inferior parietal gyrus (LIPG) was significantly reduced, whereas the activation of the right inferior frontal gyrus (RIFG) was significantly increased in patients compared with controls. Task performance accuracy was significantly associated with the activation of the LIPG in controls and the activation of the RIFG in patients. PPI analyses on fMRI data further suggested that the functional connectivity between the RIFG and LIPG was compromised in patients. Conclusion: The abnormal functional connectivity between LIPG and RIFG may underlie the observed working memory deficits and abnormal brain activation pattern in patients.	[Kasahara, Maki; Menon, David K.; Outtrim, Joanne G.; Stamatakis, Emmanuel A.] Univ Cambridge, Div Anaesthesia, Addenbrookes Hosp, Cambridge CB2 0QQ, England; [Salmond, Claire H.; Tavares, Joana V. Taylor; Sahakian, Barbara J.] Univ Cambridge, Dept Psychiat, Addenbrookes Hosp, Cambridge CB2 0QQ, England; [Carpenter, T. Adrian] Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge, England; [Pickard, John D.] Addenbrookes Hosp, Neurosurg Unit, Dept Clin Neurosci, Cambridge, England; [Sahakian, Barbara J.] Addenbrookes Hosp, MRC Wellcome Trust Behav & Clin Neurosci Inst, Cambridge, England	Stamatakis, EA (corresponding author), Univ Cambridge, Div Anaesthesia, Addenbrookes Hosp, Box 93,Hills Rd, Cambridge CB2 0QQ, England.	eas46@cam.ac.uk	Sahakian, Barbara/AAW-1198-2020	Sahakian, Barbara/0000-0001-7352-1745; Stamatakis, Emmanuel Andreas/0000-0001-6955-9601; Outtrim, Joanne/0000-0001-8118-6430	Evelyn Trust [RUAG/018]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390]; National Institute for Health ResearchNational Institute for Health Research (NIHR); Addenbrooke's Charitable Trust (Cambridge, UK); NHS National Institute for Health ResearchNational Institute for Health Research (NIHR); Glaxo SmithKlineGlaxoSmithKline; Solvay; Linde; Medical Research Council grant (Wolfson Brain Imaging Centre)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986]; McDonnell Foundation; Queens' College, Cambridge; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001354, G0001354B, G0001237, G1000183B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This study was supported by the Evelyn Trust (grant number RUAG/018 to D. K. M. (principal investigator), J.D.P., and B.J.S.); Medical Research Council program grant (grant number G9439390 to D. K. M., J.D.P., T. A. C., and B.J.S.); and funds given to the neuroscience theme of the Cambridge Biomedical Research Centre by the National Institute for Health Research (to D. K. M. and J.D.P.).; M.K. was funded by Addenbrooke's Charitable Trust (Cambridge, UK) during the analysis of the data.; D.K.M. is supported by a senior investigator grant from the NHS National Institute for Health Research. He has received lecture fees, consultancy fees and support for research from Glaxo SmithKline, Solvay and Linde. He is on the editorial boards of PloS Medicine, Critical Care, and Neurocritical Care.; J.D.P. is supported by NHS National Institute for Health Research senior investigator award. He is also a lead principal investigator for Medical Research Council grant G0600986 (Wolfson Brain Imaging Centre Acute Brain Injury Collaborative Grant), together with being co-applicant on grants from the Medical Research Council and McDonnell Foundation on vegetative state. He is a director of Medicam/Technicam, Ltd., and is on the scientific advisory board for Codman (Johnson & Johnson). He is an honorary civilian consultant (neurosurgery) for the UK Army.; E.A.S. is supported by the Stephen Erskine Fellowship, Queens' College, Cambridge. He is on the editorial board of Neuroscience Imaging.	Backman L, 2009, NEUROBIOLOGY AGING; Baddeley A., 1974, PSYCHOL LEARN MOTIV, P47, DOI [10.1016/s0079-7421(08)60452-1, DOI 10.1016/S0079-7421(08)60452-1]; Chamberlain SR, 2009, BIOL PSYCHIAT, V65, P550, DOI 10.1016/j.biopsych.2008.10.014; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Ciaramelli E, 2006, BRAIN COGNITION, V60, P198; Clark L, 2007, BIOL PSYCHIAT, V61, P1395, DOI 10.1016/j.biopsych.2006.07.020; Collette F, 2002, NEUROSCI BIOBEHAV R, V26, P105, DOI 10.1016/S0149-7634(01)00063-X; D'Arcy RCN, 2005, COGNITIVE BRAIN RES, V22, P177, DOI 10.1016/j.cogbrainres.2004.08.007; Friston KJ, 1997, NEUROIMAGE, V6, P218, DOI 10.1006/nimg.1997.0291; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; Goghari VM, 2009, BRAIN COGNITION, V71, P72, DOI 10.1016/j.bandc.2009.04.004; Hampshire A, 2010, NEUROIMAGE, V50, P1313, DOI 10.1016/j.neuroimage.2009.12.109; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kim J, 2010, J NEUROTRAUMA; Kim JJ, 2003, AM J PSYCHIAT, V160, P919, DOI 10.1176/appi.ajp.160.5.919; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; KIRCHNER WK, 1958, J EXP PSYCHOL, V55, P352, DOI 10.1037/h0043688; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Maruishi M, 2009, J NEUROL NEUROSUR PS, V78, P168; Marvel CL, 2009, CORTEX; Mayer JS, 2007, NEUROIMAGE, V36, P441, DOI 10.1016/j.neuroimage.2007.03.007; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McHugh T, 2006, BRAIN COGNITION, V60, P209; Mcnab F, 2008, NEUROPSYCHOLOGIA, V46, P2668, DOI 10.1016/j.neuropsychologia.2008.04.023; Mehta MA, 2000, J NEUROSCI, V20; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Raboyeau G, 2008, NEUROLOGY, V70, P290, DOI 10.1212/01.wnl.0000287115.85956.87; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Smith EE, 1997, COGNITIVE PSYCHOL, V33, P5, DOI 10.1006/cogp.1997.0658; Smith EE, 1998, P NATL ACAD SCI USA, V95, P876, DOI 10.1073/pnas.95.3.876; Stricker JL, 2006, J INT NEUROPSYCH SOC, V12, P591, DOI 10.1017/S1355617706060851; Tsukiura T, 2001, COGNITIVE BRAIN RES, V11, P13, DOI 10.1016/S0926-6410(00)00059-8; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Weissman DH, 2002, NEUROIMAGE, V17, P1266, DOI 10.1006/nimg.2002.1284	42	51	51	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2011	25	12					1170	1187		10.3109/02699052.2011.608210			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	829WF	WOS:000295615200004	21932994				2021-06-18	
J	Pleasant, JM; Carlson, SW; Mao, HJ; Scheff, SW; Yang, KH; Saatman, KE				Pleasant, Jennifer M.; Carlson, Shaun W.; Mao, Haojie; Scheff, Stephen W.; Yang, King H.; Saatman, Kathryn E.			Rate of Neurodegeneration in the Mouse Controlled Cortical Impact Model Is Influenced by Impactor Tip Shape: Implications for Mechanistic and Therapeutic Studies	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; behavior; contusion; finite element modeling; neuronal death; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; AXONAL INJURY; COGNITIVE DEFICITS; DEPENDENT CHANGES; CLINICAL-TRIALS; FLUORO-JADE; MICE; CLASSIFICATION	Controlled cortical impact (CCI), one of the most common models of traumatic brain injury, is being increasingly used with mice for exploration of cell injury mechanisms and pre-clinical evaluation of therapeutic strategies. Although CCI brain injury was originally effected using an impactor with a rounded tip, the majority of studies with mouse CCI use a flat or beveled tip. Recent finite element modeling analyses demonstrate that tip geometry is a significant determinant of predicted cortical tissue strains in rat CCI, and that cell death is proportional to predicted tissue strains. In the current study, a three-dimensional finite element model of a C57BL/6J mouse brain predicted higher maximum principal strains during a simulated 1.0-mm, 3.5-m/s CCI injury with a flat tip when compared to a rounded tip. Consistent with this prediction, experimental CCI with a flat-tip impactor resulted in greater acute cortical hemorrhage and neuron loss in adult male C57BL/6J mice. The amount of neocortical tissue damage was equivalent for the two tip geometries at 9 days following injury, but the rate of neocortical neurodegeneration was markedly slower following CCI with a rounded-tip impactor, with damage reaching a plateau after 24 h as opposed to after 4 h for the flat tip. The flat-tip impactor was associated in general with more regional hippocampal neurodegeneration, especially at early time points such as 4 h. Impactor tip geometry did not have a notable effect on blood-brain barrier breakdown, traumatic axonal injury, or motor and cognitive dysfunction. Execution of CCI injury with a rounded-tip impactor is posited to provide a substantially enhanced temporal window for the study of cellular injury mechanisms and therapeutic intervention while maintaining critical aspects of the pathophysiological response to contusion brain injury.	[Pleasant, Jennifer M.; Carlson, Shaun W.; Saatman, Kathryn E.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Coll Med, Lexington, KY 40536 USA; [Pleasant, Jennifer M.; Carlson, Shaun W.; Saatman, Kathryn E.] Univ Kentucky, Dept Physiol, Coll Med, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Coll Med, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA; [Mao, Haojie; Yang, King H.] Wayne State Univ, Ctr Bioengn, Detroit, MI USA	Saatman, KE (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Coll Med, B473 Biomed & Biol Sci Res Bldg BBSRB,741 S Limes, Lexington, KY 40536 USA.	k.saatman@uky.edu	Mao, Haojie/Q-7514-2018	Mao, Haojie/0000-0002-7563-9234; Carlson, Shaun/0000-0002-1413-5075	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 NS058484, P30 NS051220]; KSCHIRT [6-12, 7-20, 8-15A]; Injury Control Research Center at University of Alabama at Birmingham	This work was funded by NIH P01 NS058484, P30 NS051220 and KSCHIRT 6-12 and 7-20 (K. E. S.), KSCHIRT 8-15A (S. W. S.), and by the Injury Control Research Center at University of Alabama at Birmingham (K.Y.).	Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Elkin BS, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000164; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Ma Y, 2005, NEUROSCIENCE, V135, P1203, DOI 10.1016/j.neuroscience.2005.07.014; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Mao HJ, 2010, BIOMECH MODEL MECHAN, V9, P763, DOI 10.1007/s10237-010-0212-z; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SAATMAN KE, 2009, HDB NEUROCHEMISTRY M, V15, P343; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	65	51	53	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2011	28	11			SI		2245	2262		10.1089/neu.2010.1499			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	849VY	WOS:000297154600005	21341976	Green Published			2021-06-18	
J	Schneider, HJ; Schneider, M; Kreitschmann-Andermahr, I; Tuschy, U; Wallaschofski, H; Fleck, S; Faust, M; Renner, CIE; Kopczak, A; Saller, B; Buchfelder, M; Jordan, M; Stalla, GK				Schneider, Harald J.; Schneider, Manfred; Kreitschmann-Andermahr, Ilonka; Tuschy, Ulrich; Wallaschofski, Henri; Fleck, Steffen; Faust, Michael; Renner, Caroline I. E.; Kopczak, Anna; Saller, Bernhard; Buchfelder, Michael; Jordan, Martina; Stalla, Guenter K.			Structured Assessment of Hypopituitarism after Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage in 1242 Patients: The German Interdisciplinary Database	JOURNAL OF NEUROTRAUMA			English	Article						growth hormone deficiency; Hypopituitarism; subarachnoid hemorrhage; traumatic brain injury	ANTERIOR-PITUITARY FUNCTION; GROWTH-HORMONE DEFICIENCY; DYSFUNCTION; PREVALENCE; INSUFFICIENCY; ADULTS	Clinical studies have demonstrated that traumatic brain injury (TBI) and aneurysmal subarachnoid hemorrhage (SAH) are frequent causes of long-term disturbances of hypothalamo-pituitary function. This study aimed to assess the prevalence and associated factors of post-traumatic hypopituitarism in a large national registry of patients with TBI and SAH. Data were collected from 14 centers in Germany and Austria treating patients for TBI or SAH and performing endocrine assessments. Data were collected using a structured, internet-based study sheet, obtaining information on clinical, radiological, and hormonal parameters. A total of 1242 patients (825 TBI, age 43.5 +/- 19.7 years; 417 SAH, age 49.7 +/- 11.8 years) were included. We studied the prevalence of hypopituitarism reported based on different definitions of laboratory values and stimulation tests. Stimulation tests for the corticotropic and somatotropic axes were performed in 26% and 22% of the patients, respectively. The prevalence of hypopituitarism in the chronic phase (at least 5 months after the event) by laboratory values, physician diagnoses, and stimulation tests, was 35%, 36%, and 70%, respectively. Hypopituitarism was less common in the acute phase. According to the frequency of endocrine dysfunction, pituitary hormone secretion was impaired in the following sequence: ACTH, LH/FSH, GH, and TSH. TBI patients with abnormal stimulation tests had suffered from more severe TBI than patients with normal stimulation tests. In conclusion, our data confirm that hypopituitarism is a common complication of TBI and SAH. It is possible that patients with a higher likelihood of hypopituitarism were selected for endocrine stimulation tests.	[Schneider, Harald J.] Univ Munich, Med Klin Innenstadt, D-80336 Munich, Germany; [Schneider, Manfred; Kopczak, Anna] Neurol Clin Bad Aibling, Aibling, Germany; [Kreitschmann-Andermahr, Ilonka] RWTH Hosp Aachen, Dept Neurosurg, Aachen, Germany; [Tuschy, Ulrich] Helios Hosp, Div Endocrinol, Dept Med 2, Erfurt, Germany; [Wallaschofski, Henri] Ernst Moritz Arndt Univ Greifswald, Inst Clin Chem & Lab Med, Greifswald, Germany; [Fleck, Steffen] Ernst Moritz Arndt Univ Greifswald, Dept Neurosurg, Greifswald, Germany; [Faust, Michael] Univ Hosp Cologne, Dept Internal Med 2, Cologne, Germany; [Renner, Caroline I. E.] Univ Leipzig, NRZ Ctr Neurorehabil, Leipzig, Germany; [Buchfelder, Michael] Univ Hosp Erlangen, Dept Neurosurg, Erlangen, Germany; [Jordan, Martina] ClinSupport GmbH, Erlangen, Germany; [Stalla, Guenter K.] Max Planck Inst Psychiat, Neuroendcrinol Grp, D-80804 Munich, Germany	Schneider, HJ (corresponding author), Univ Munich, Med Klin Innenstadt, Ziemssenstr 1, D-80336 Munich, Germany.	harald.schneider@med.uni-muenchen.de		Renner, Caroline/0000-0003-4047-7017; Kopczak, Anna/0000-0002-5037-2342	Pfizer Pharma GmbHPfizer; PfizerPfizer; NovartisNovartis; LillyEli Lilly; Novo NordiskNovo Nordisk	The authors are grateful to all the centers who contributed patient data to the registry. The database is supported by an independent investigator grant from Pfizer Pharma GmbH. Data storage and statistical analyses were performed by Elmar Beck, Anfomed, Germany. The members of the advisory board of the database were: Prof. Gunther-Karl Stalla, Prof. Ilonka Kreitschmann-Andermahr, Prof. Eberhard Konig, Prof. Michael Buchfelder, and Prof. Eberhard Uhl. The following investigators recruited more than one patient to the database: Dr. Kreitschmann-Andermahr, RWTH Aachen; Dr. Stalla, MPI Munchen; Dr. Konig/Dr. Schneider, Bad Aibling; Dr. Tuschy, Helios-Kliniken Erfurt; Dr. Steube, Neurol. Kl. Bad Neustadt; Dr. Buchfelder/Dr. Kreutzer, Kopfklinik Erlangen; Dr. Sudhoff, Fachklinik Enzensberg; Dr. Faust, Universitat Koln; Dr. Lange, VS Schwenningen; Dr. Oertel, Universitat Giessen; Dr. Renner, Universitat Leipzig; Dr. Fleck/Dr. Wallaschofski, University Greifswald; Dr. Berg, Uni Essen; and Dr. Uhl, Klagenfurt.; H.J.S. received research grants from Pfizer, travel grants from Novartis, Pfizer, and Lilly, speaker fees from Novo Nordisk, Pfizer, and Lilly, and is a member of the German KIMS (Pfizer International Metabolic Survey) board. M.S. received research grants and travel grants from Pfizer and Novo Nordisk. I.K.A. received research grants form Pfizer and Novo Nordisk, and travel grants from Pfizer, Novo Nordisk, and Novartis, and is a member of the German KIMS (Pfizer International Metabolic Survey) board. H.W. received research grants, speaker fees, and travel grants from Pfizer and Novo Nordisc, and is a member of the German KIMS (Pfizer International Metabolic Survey) board. S.F. received travel grants from Novo Nordisk and Pfizer. M.F. is a member of the German KIMS (Pfizer International Metabolic Survey) board. A.K. received travel grants from Pfizer. B.S. is an employee of Pfizer Global Pharmaceuticals. M.B. received research grants, speaker fees, and travel grants from Pfizer, Novo Nordisk, and Novartis, and is a member of the German KIMS (Pfizer International Metabolic Survey) board. M.J. is an employee of Clinsupport, Erlangen. G.K.S. received research grants, speaker fees, and travel grants from Pfizer, Novo Nordisk, and Novartis. C.I.E.R., and U.T. report no conflicts of interest.	Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Klose M, 2010, CLIN ENDOCRINOL, V73, P95, DOI 10.1111/j.1365-2265.2010.03791.x; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; Kreitschmann-Andermahr I, 2011, EXP CLIN ENDOCR DIAB, V119, P15, DOI 10.1055/s-0030-1253414; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Pavlovic D, 2010, EUR J NEUROL, V17, P696, DOI 10.1111/j.1468-1331.2009.02910.x; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; van der Eerden AW, 2010, EUR J ENDOCRINOL, V162, P19, DOI 10.1530/EJE-09-0436	27	51	53	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1693	1698		10.1089/neu.2011.1887			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000002	21671796				2021-06-18	
J	Simpson, GK; Tate, RL; Whiting, DL; Cotter, RE				Simpson, Grahame K.; Tate, Robyn L.; Whiting, Diane L.; Cotter, Rachel E.			Suicide Prevention After Traumatic Brain Injury: A Randomized Controlled Trial of a Program for the Psychological Treatment of Hopelessness	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						hopelessness; randomized controlled trial; suicide ideation; suicide prevention; traumatic brain injury	EVENTUAL SUICIDE; POSTTRAUMATIC GROWTH; PROTECTIVE FACTORS; HOSPITAL ANXIETY; SELF-ESTEEM; DEPRESSION; ASSOCIATION; THERAPY; PHARMACOTHERAPY; INDIVIDUALS	Objective: To evaluate the efficacy of a psychological treatment to reduce moderate to severe hopelessness after severe traumatic brain injury (TBI). Method: Randomized controlled trial. Participants were aged between 18 and 65 years, experienced posttraumatic amnesia more than 1day and moderate to severe hopelessness (Beck Hopelessness Scale [BHS]) and/or suicide ideation. Intervention comprised a 20-hour manualized group cognitive behavior therapy program. Participants were randomly allocated using concealed allocation (treatment n = 8; wait-list n = 9); all remained in their allocated group. Outcome variables were collected by assessors blind to group allocation. Results: No between-groups differences were observed on demographic, injury, cognitive, and psychosocial variables at baseline (time 1). A significant group-by-time interaction was found for BHS in the treatment group (F-1,F-15 = 13.20, P = .002), reflecting a reduction in mean BHS scores between time 1 and time 2 (posttreatment) with no main effects for group or time. At 3-month follow-up (time 3), the treatment gains were maintained or improved for 75% (6/8) of participants. Secondary outcome variables (suicide ideation, depression, social problem solving, self-esteem, hopefulness) displayed no significant group-by-time interactions or main effects. Conclusions: This trial provides initial evidence for the efficacy of a psychological intervention in reducing hopelessness among long-term survivors with severe TBI.	[Simpson, Grahame K.; Whiting, Diane L.; Cotter, Rachel E.] Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Simpson, Grahame K.; Tate, Robyn L.] Univ Sydney, Fac ofMedicine, Rehabil Studies Unit, Sydney, NSW 2006, Australia	Simpson, GK (corresponding author), Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool Bc, NSW 1871, Australia.	grahame.simpson@sswahs.nsw.gov.au	Simpson, Grahame K/W-1074-2019; Whiting, Diane/AAN-2522-2021	Simpson, Grahame K/0000-0001-8156-9060; Whiting, Diane/0000-0003-1912-6626	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [ID 358769]	This project was funded by a National Health and Medical Research Council Health Professional Fellowship grant (ID 358769).	ACHTE KA, 1971, ACTA PSYCHIAT SCAND, P1; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Beck A., 1988, MANUAL BECK HOPELESS; Beck A.T., 1991, MANUAL BECK SCALE SU; BECK AT, 1989, J AFFECT DISORDERS, V17, P203, DOI 10.1016/0165-0327(89)90001-3; BECK AT, 1989, J CONSULT CLIN PSYCH, V57, P309, DOI 10.1037/0022-006X.57.2.309; BECK AT, 1985, AM J PSYCHIAT, V142, P559; Benton A., 1976, MULTILINGUAL APHASIA; BLACKBURN IM, 1983, BRIT J PSYCHIAT, V143, P609, DOI 10.1192/bjp.143.6.609; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; Dahlsgaard KK, 1998, SUICIDE LIFE-THREAT, V28, P197; DIXON RA, 1999, COGNITIVE NEUROREHAB; DZurilla T. J., 2002, SOCIAL PROBLEM SOLVI; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fergusson D, 2005, BMJ-BRIT MED J, V330, P396, DOI 10.1136/bmj.330.7488.396; GrayLittle B, 1997, PERS SOC PSYCHOL B, V23, P443, DOI 10.1177/0146167297235001; Hawton K, 2000, COCHRANE DB SYST REV, V2; HERTH K, 1992, J ADV NURS, V17, P1251, DOI 10.1111/j.1365-2648.1992.tb01843.x; Hopewell S, 2008, LANCET, V371, P281, DOI 10.1016/S0140-6736(07)61835-2; Jacobs D.G., 2003, PRACTICE GUIDELINE A; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; Kuipers P, 2000, J HEAD TRAUMA REHAB, V15, P1275, DOI 10.1097/00001199-200012000-00007; LINEHAN MM, 1991, ARCH GEN PSYCHIAT, V48, P1060; Malone KM, 2000, AM J PSYCHIAT, V157, P1084, DOI 10.1176/appi.ajp.157.7.1084; Manchester D, 2001, BRAIN DAM B, P157; McGrath JC, 2006, BRAIN INJURY, V20, P767, DOI 10.1080/02699050600664566; Moher D, 2010, BMJ-BRIT MED J, V340, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; MOOREY S, 1991, BRIT J PSYCHIAT, V158, P255, DOI 10.1192/bjp.158.2.255; Nordentoft M, 2002, BRIT J PSYCHIAT, V181, pS98, DOI 10.1192/bjp.181.43.s98; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; Rosenberg M., 1986, CONCEIVING SELF; RUSH AJ, 1982, AM J PSYCHIAT, V139, P862; SILBER E, 1965, PSYCHOL REP, V16, P1017, DOI 10.2466/pr0.1965.16.3c.1017; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; SIMPSON GK, 2001, SUICIDE PREVENTION T; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Soo C, 2007, COCHRANE DB SYST REV, V3; Spreen O., 1991, COMPENDIUM NEUROPSYC; Tabachnik BG, 1996, USING MULTIVARIATE S; Tate RL, 2004, BRAIN IMPAIR, V5, P81, DOI [10.1375/brim.5.1.81.35408, DOI 10.1375/brim.5.1.81.35408, DOI 10.1375/BRIM.5.1.81.35408]; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tedeschi R.G., 1995, TRAUMA TRANSFORMATIO; Tedeschi RG, 2004, PSYCHOL INQ, V15, P1, DOI 10.1207/s15327965pli1501_01; Tsaousides T, 2011, J HEAD TRAUMA REHAB, V26, P265, DOI 10.1097/HTR.0b013e3182225271; vanderSande R, 1997, ACTA PSYCHIAT SCAND, V96, P43; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; WESCHLER D, 1981, WAIS R MANUAL; Wilson BA, 1996, BEHAV ASSESSMENT DYS; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	56	51	51	2	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2011	26	4					290	300		10.1097/HTR.0b013e3182225250			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	789FZ	WOS:000292501700006	21734512				2021-06-18	
J	Thal, SC; Heinemann, M; Luh, C; Pieter, D; Werner, C; Engelhard, K				Thal, Serge C.; Heinemann, Marius; Luh, Clara; Pieter, Dana; Werner, Christian; Engelhard, Kristin			Pioglitazone Reduces Secondary Brain Damage after Experimental Brain Trauma by PPAR-gamma-Independent Mechanisms	JOURNAL OF NEUROTRAUMA			English	Article						inflammation; pioglitazone; peroxisome proliferator-activated receptor-gamma; rosiglitazone; traumatic brain injury	ACTIVATED-RECEPTOR-GAMMA; TRANSIENT FOCAL ISCHEMIA; CONTROLLED CORTICAL IMPACT; GENE-EXPRESSION; INFLAMMATORY CYTOKINES; AGONIST ROSIGLITAZONE; NITRIC-OXIDE; IN-VITRO; INJURY; NEUROPROTECTION	Inflammatory and ischemic processes contribute to the development of secondary brain damage after mechanical brain injury. Recent data suggest that thiazolidinediones (TZDs), a class of drugs approved for the treatment of non-insulin-dependent diabetes mellitus, effectively reduces inflammation and brain lesion by stimulation of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma). The present study investigates the influence of the TZD pioglitazone and rosiglitazone on inflammation and secondary brain damage after experimental traumatic brain injury (TBI). A controlled cortical impact (CCI) injury was induced in male C57BL/6 mice to investigate following endpoints: (1) mRNA expression of PPAR-gamma and PPAR-gamma target genes (LPL, GLT1, and IRAP/Lnpep), and inflammatory markers (TNF-alpha, IL-1 beta, IL-6, and iNOS), at 15 min, 3 h, 6 h, 12 h, and 24 h post-trauma; (2) contusion volume, neurological function, and gene expression after 24 h in mice treated with pioglitazone (0.5 and 1 mg/kg) or rosiglitazone (5 and 10 mg/kg IP at 30 min post-trauma); and (3) the role of PPAR-gamma to mediate protection was determined in animals treated with pioglitazone, the PPAR-gamma inhibitor T0070907, and a combination of both. Inflammatory marker genes, but not PPAR-gamma gene expression, was up-regulated after trauma. Pioglitazone reduced the histological damage and inflammation in a dose-dependent fashion. In contrast, rosiglitazone failed to suppress inflammation and histological damage. PPAR-gamma and PPAR-gamma target gene expression was not induced by pioglitazone and rosiglitazone. In line with these results, pioglitazone-mediated protection was not reversed by T0070907. The results indicate that the neuroprotective effects of pioglitazone are not solely related to PPAR-gamma-dependent mechanisms.	[Thal, Serge C.; Heinemann, Marius; Luh, Clara; Pieter, Dana; Werner, Christian; Engelhard, Kristin] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, D-55131 Mainz, Germany	Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, Langenbeckstr 1, D-55131 Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729	Takeda Pharma, Germany	Takeda Pharma, Germany, supported this project with an unrestricted grant. The authors want to thank Dr. Joachim Fuchs, M. D., Ph.D. (Takeda Pharma) and Dr. Kristian Lobner, Ph.D. (GlaxoSmithKline) for providing pioglitazone and rosiglitazone.	Aoun P, 2003, INVEST OPHTH VIS SCI, V44, P2999, DOI 10.1167/iovs.02-1060; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Chawla A, 2001, NAT MED, V7, P48; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Collino M, 2006, EUR J PHARMACOL, V530, P70, DOI 10.1016/j.ejphar.2005.11.049; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; Ferger B, 2004, J NEUROCHEM, V89, P822, DOI 10.1111/j.1471-4159.2004.02399.x; Gemma C, 2004, NEUROREPORT, V15, P2255, DOI 10.1097/00001756-200410050-00023; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Heneka MT, 2000, J NEUROSCI, V20, P6862, DOI 10.1523/JNEUROSCI.20-18-06862.2000; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Jiang CY, 1998, NATURE, V391, P82; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Katayama Y, 1998, ACT NEUR S, V71, P289; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lemay DG, 2006, J LIPID RES, V47, P1583, DOI 10.1194/jlr.M500504-JLR200; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Luna-Medina R, 2005, J BIOL CHEM, V280, P21453, DOI 10.1074/jbc.M414390200; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maeshiba Y, 1997, ARZNEIMITTEL-FORSCH, V47, P29; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Moore KJ, 2001, NAT MED, V7, P41; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Orasanu G, 2008, J AM COLL CARDIOL, V52, P869, DOI 10.1016/j.jacc.2008.04.055; Overbergh L, 2003, J Biomol Tech, V14, P33; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Romera C, 2007, J CEREBR BLOOD F MET, V27, P1327, DOI 10.1038/sj.jcbfm.9600438; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Shimazu T, 2005, STROKE, V36, P353, DOI 10.1161/01.STR.0000152271.21943.a2; Sundararajan S, 2005, NEUROSCIENCE, V130, P685, DOI 10.1016/j.neuroscience.2004.10.021; Takeuchi Y, 2007, CARCINOGENESIS, V28, P1692, DOI 10.1093/carcin/bgm095; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Tureyen K, 2007, J NEUROCHEM, V101, P41, DOI 10.1111/j.1471-4159.2006.04376.x; Uryu S, 2002, BRAIN RES, V924, P229, DOI 10.1016/S0006-8993(01)03242-5; Victor NA, 2006, EUR J NEUROSCI, V24, P1653, DOI 10.1111/j.1460-9568.2006.05037.x; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zhao Y, 2005, EUR J NEUROSCI, V22, P278, DOI 10.1111/j.1460-9568.2005.04200.x; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P320, DOI 10.1007/BF00395288; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	51	51	55	1	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					983	993		10.1089/neu.2010.1685			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600012	21501066				2021-06-18	
J	Heinemann, AW; Lai, JS; Magasi, S; Hammel, J; Corrigan, JD; Bogner, JA; Whiteneck, GG				Heinemann, Allen W.; Lai, Jin-Shei; Magasi, Susan; Hammel, Joy; Corrigan, John D.; Bogner, Jennifer A.; Whiteneck, Gale G.			Measuring Participation Enfranchisement	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Conference on the American-Psychological-Association-Division	APR 06, 2008	Tucson, AZ	Amer Psychol Assoc Div		Patient participation; Psychometrics; Rehabilitation	REHABILITATION; INTEGRATION; COMMUNITY; HANDICAP; PEOPLE	Heinemann AW, Lai J-S, Magasi S, Hammel J, Corrigan JD, Bogner JA, Whiteneck GG. Measuring participation enfranchisement. Arch Phys Med Rehabil 2011;92:564-71. Objective: To reflect the perspectives of rehabilitation stakeholders in a measure of participation enfranchisement that can be used by people with and without disabilities. Design: Survey. Setting: Community settings. Participants: We pilot-tested a draft instrument with 326 adults who had sustained stroke, spinal cord injury, traumatic brain injury, or other disabling condition, as well as a general population sample. We administered a revised version of the instrument to a statewide sample drawn from the 2006 Colorado Behavioral Risk Factors Surveillance System that included persons with (N=461) and without (N=451) self-identified activity limitations. Interventions: None. Main Outcome Measure: Participation enfranchisement. Results: We used multidimensional scaling, exploratory factor analysis (EFA) and confirmatory factor analysis (CFA), followed by rating scale analysis to evaluate the psychometric properties of the instrument. EFA identified 3 participation enfranchisement factors that describe perceived choice and control, contributing to one's community, and feeling valued; the factors were supported marginally by CFA. Rating scale analysis revealed marginal person separation and no misfitting items. Conclusions: Participation enfranchisement constitutes a new, previously unmeasured aspect of participation one that addresses subjective perceptions rather than objective performance with items that are clearly distinct from more generalized satisfaction with participation. The 19 enfranchisement items describe aspects of participation that may prove useful in characterizing longer-term rehabilitation outcomes.	[Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Heinemann, Allen W.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA; [Lai, Jin-Shei; Magasi, Susan] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA; [Hammel, Joy] Univ Illinois, Chicago, IL USA; [Corrigan, John D.; Bogner, Jennifer A.] Ohio State Univ, Columbus, OH 43210 USA; [Whiteneck, Gale G.] Craig Hosp, Englewood, CO USA	Heinemann, AW (corresponding author), Rehabil Inst Chicago, 345 E Super St, Chicago, IL 60611 USA.	a-heinemann@northwestern.edu	Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021; Corrigan, John D./E-2921-2011; Bogner, Jennifer/E-2773-2011	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326; 			Ader DN, 2007, MED CARE, V45, pS1, DOI 10.1097/01.mlr.0000260537.45076.74; *ASS CLASS EP GROU, 1999, INT CLASS FUNCT DIS; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Cardol M, 1999, CLIN REHABIL, V13, P411, DOI 10.1191/026921599668601325; Cox MF, 2001, MULTIDIMENSIONAL SCA; Field Marilyn J., 2007, FUTURE DISABILITY AM; Gandek B, 2007, AM J PHYS MED REHAB, V86, P57, DOI 10.1097/01.PHM.0000233200.43822.21; Gray DB, 2006, ARCH PHYS MED REHAB, V87, P189, DOI 10.1016/j.apmr.2005.09.014; Haley SM, 2008, ARCH PHYS MED REHAB, V89, P275, DOI 10.1016/j.apmr.2007.08.150; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; Magasi SR, 2008, J SPINAL CORD MED, V31, P145, DOI 10.1080/10790268.2008.11760705; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; MUTHEN BO, 1987, ROBUST INFERENCE USI; Rasch, 1960, PROBABILISTIC MODELS; Townley G, 2009, J COMMUNITY PSYCHOL, V37, P362, DOI 10.1002/jcop.20301; US Census Bureau, 2006 2008 AM COMM SU; van de Ven L, 2005, DISABIL SOC, V20, P311, DOI 10.1080/09687590500060778; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Willis G., 1994, 7 CDCP NAT CTR HLTH; World Health Organization, 2001, INT CLASS FUNCT DIS; Wright B. D., 1999, MEASUREMENT ESSENTIA; 2000, MORB MORTAL WKLY REP, V49, P711	26	51	51	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2011	92	4					564	571		10.1016/j.apmr.2010.07.220			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	743VT	WOS:000289047500006	21367395				2021-06-18	
J	Hajek, CA; Yeates, KO; Taylor, HG; Bangert, B; Dietrich, A; Nuss, KE; Rusin, J; Wright, M				Hajek, Christine A.; Yeates, Keith Owen; Taylor, H. Gerry; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn E.; Rusin, Jerome; Wright, Martha			Agreement between Parents and Children on Ratings of Post-Concussive Symptoms Following Mild Traumatic Brain Injury	CHILD NEUROPSYCHOLOGY			English	Article						Head injury; Post-concussion syndrome; Interrater agreement; Correlational agreement; Outcome	POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; SCALE; INTERVIEW; BEHAVIOR; CRITERIA	The level of parent-child agreement on post-concussive symptoms (PCS) was examined in children following mild traumatic brain injuries (TBI). As part of a larger longitudinal study, 186 children with mild TBI and 99 with orthopedic injuries (OI), from 8 to 15 years of age, were recruited prospectively. Parents and children completed the PCS Interview (PCS-I) and the Health and Behavior Inventory (HBI) at 2 weeks, 1 month, 3 months, and 12 months postinjury. Item-level correlations between child and parent ratings on both measures of PCS were significant but modest in both groups. Parent-child correlations for composite scales on the HBI and the total score on the PCS-I were significant in both groups, but somewhat higher in the OI group than in the mild TBI group. Mean symptom ratings tended to be significantly higher for children as compared to parents, especially for somatic symptoms. Parents and children display modest agreement when reporting PCS; their ratings correlate significantly, but children report higher mean levels of symptoms than parents.	[Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Columbus, OH 43205 USA; [Hajek, Christine A.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; [Hajek, Christine A.; Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathryn E.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn E.] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD39834, K02 HD44099]; National Center for Medical Rehabilitation Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER	The larger study on which the research was based was supported by grants R01 HD39834 and K02 HD44099 from the National Institute of Child Health and Human Development and the National Center for Medical Rehabilitation Research to Keith Owen Yeates. The authors wish to acknowledge the contributions of Lauren Ayr, Anne Birnbaum, Amy Clemens, Taryn Fay, Kalaichelvi Ganesalingham, Amanda Lininger, Melissa Ginn, Katie Pestro, Elizabeth Roth, Elizabeth Shaver, and Heidi Walker in conducting the study. Portions of the research were presented at the annual meeting of the International Neuropsychological Society in Atlanta, GA, February 2009.	ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Chambers CT, 1998, CLIN J PAIN, V14, P336, DOI 10.1097/00002508-199812000-00011; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Choudhury MS, 2003, J AM ACAD CHILD PSY, V42, P957, DOI 10.1097/01.CHI.0000046898.27264.A2; Comer JS, 2004, J AM ACAD CHILD PSY, V43, P878, DOI 10.1097/01.chi.0000125092.35109.c5; Cremeens J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-58; De Los Reyes A, 2005, PSYCHOL BULL, V131, P483, DOI 10.1037/0033-2909.131.4.483; de Vries APJ, 1999, PEDIATRICS, V104, P1293, DOI 10.1542/peds.104.6.1293; EDELBROCK C, 1986, J CHILD PSYCHOL PSYC, V27, P181, DOI 10.1111/j.1469-7610.1986.tb02329.x; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Hemphill JF, 2003, AM PSYCHOL, V58, P78, DOI 10.1037/0003-066X.58.1.78; HODGES K, 1990, J CHILD PSYCHOL PSYC, V31, P427, DOI 10.1111/j.1469-7610.1990.tb01579.x; Karver MS, 2006, J ABNORM CHILD PSYCH, V34, P251, DOI 10.1007/s10802-005-9015-6; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Martin JL, 2004, J DEV BEHAV PEDIATR, V25, P150, DOI 10.1097/00004703-200406000-00002; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Munoz SR, 1997, J APPL STAT, V24, P105, DOI 10.1080/02664769723918; Raghunathan TE, 1996, PSYCHOL METHODS, V1, P178, DOI 10.1037/1082-989X.1.2.178; REY JM, 1992, J ADOLESCENCE, V15, P219, DOI 10.1016/0140-1971(92)90026-2; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; TEASDALE G, 1974, LANCET, V2, P81; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	37	51	51	0	3	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.		2011	17	1					17	33	PII 925012785	10.1080/09297049.2010.495058			17	Clinical Neurology	Neurosciences & Neurology	716BK	WOS:000286939700002	20680882	Green Accepted			2021-06-18	
J	Azari, MF; Mathias, L; Ozturk, E; Cram, DS; Boyd, RL; Petratos, S				Azari, Michael F.; Mathias, Louisa; Ozturk, Ezgi; Cram, David S.; Boyd, Richard L.; Petratos, Steven			Mesenchymal Stem Cells for Treatment of CNS Injury	CURRENT NEUROPHARMACOLOGY			English	Article						Mesenchymal Stem Cell; Spinal Cord Injury; Traumatic Brain Injury	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; MARROW STROMAL CELLS; PROMOTE AXONAL REGENERATION; BDNF-PRODUCING FIBROBLASTS; MESSENGER-RNA EXPRESSION; ARTERY OCCLUSION MODEL; ADULT-MOUSE BRAIN; BONE-MARROW; FUNCTIONAL RECOVERY	Brain and spinal cord injuries present significant therapeutic challenges. The treatments available for these conditions are largely ineffective, partly due to limitations in directly targeting the therapeutic agents to sites of pathology within the central nervous system (CNS). The use of stem cells to treat these conditions presents a novel therapeutic strategy. A variety of stem cell treatments have been examined in animal models of CNS trauma. Many of these studies have used stem cells as a cell-replacement strategy. These investigations have also highlighted the significant limitations of this approach. Another potential strategy for stem cell therapy utilises stem cells as a delivery mechanism for therapeutic molecules. This review surveys the literature relevant to the potential of mesenchymal stem cells for delivery of therapeutic agents in CNS trauma in humans.	[Azari, Michael F.; Mathias, Louisa; Ozturk, Ezgi; Cram, David S.; Boyd, Richard L.; Petratos, Steven] Monash Univ, MISCL, Sch Biomed Sci, Fac Med, Clayton, Vic 3800, Australia; [Petratos, Steven] RMIT Univ, Mol Neuropathol & Expt Neurol Lab, Hlth Innovat Res Inst, Bundoora, Vic, Australia; [Petratos, Steven] RMIT Univ, Sch Med Sci, Bundoora, Vic, Australia	Azari, MF (corresponding author), Monash Univ, MISCL, Sch Biomed Sci, Fac Med, Level 3,Bldg 75, Clayton, Vic 3800, Australia.	Michael.Azari@med.monash.edu.au		Azari, Dr Michael F./0000-0003-0674-9322			Azari MF, 2006, J NEUROPATH EXP NEUR, V65, P914, DOI 10.1097/01.jnen.0000235855.77716.25; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Bensidhoum M, 2004, BLOOD, V103, P3313, DOI 10.1182/blood-2003-04-1121; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Cao QL, 2005, J NEUROSCI, V25, P6947, DOI 10.1523/JNEUROSCI.1065-05.2005; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chapel A, 2003, J GENE MED, V5, P1028, DOI 10.1002/jgm.452; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chidgey AP, 2008, NATURE, V453, P330, DOI 10.1038/nature07041; Croft AP, 2006, STEM CELLS, V24, P1841, DOI 10.1634/stemcells.2005-0609; Dasari VR, 2008, NEUROCHEM RES, V33, P134, DOI 10.1007/s11064-007-9426-6; Dasari VR, 2007, NEUROCHEM RES, V32, P2080, DOI 10.1007/s11064-007-9368-z; Dasari VR, 2007, J NEUROTRAUM, V24, P391, DOI 10.1089/neu.2006.0142; Dasari VR, 2008, NEUROBIOL DIS, V32, P486, DOI 10.1016/j.nbd.2008.09.005; Davies Jeannette E, 2008, J Biol, V7, P24, DOI 10.1186/jbiol85; Deumens R, 2008, MOL NEUROBIOL, V37, P52, DOI 10.1007/s12035-008-8016-1; Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301-472X(00)00635-4; Dihne M, 2006, STEM CELLS, V24, P1458, DOI 10.1634/stemcells.2005-0413; Eftekharpour E, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E18; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; Ferguson IA, 2001, EUR J NEUROSCI, V13, P1059, DOI 10.1046/j.1460-9568.2001.01482.x; FERON F, 2010, STEM CELLS DEV, V19, P853; FitzGerald J, 2007, J BONE JOINT SURG BR, V89B, P1413, DOI 10.1302/0301-620X.89B11; FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890-196803000-00009; Grill R, 1997, J NEUROSCI, V17, P5560; Han JY, 2007, J KOREAN MED SCI, V22, P242, DOI 10.3346/jkms.2007.22.2.242; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Himes BT, 2001, J NEUROSCI RES, V65, P549, DOI 10.1002/jnr.1185; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Jin Y, 2002, EXP NEUROL, V177, P265, DOI 10.1006/exnr.2002.7980; Jung DI, 2009, J NEUROL SCI, V285, P67, DOI 10.1016/j.jns.2009.05.027; Kang SK, 2006, STEM CELLS DEV, V15, P583, DOI 10.1089/scd.2006.15.583; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; King VR, 1999, NEUROSCIENCE, V92, P935, DOI 10.1016/S0306-4522(99)00072-X; Kobayashi NR, 1997, J NEUROSCI, V17, P9583; Koc ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Kurozumi K, 2005, MOL THER, V11, P96, DOI 10.1016/j.ymthe.2004.09.020; Kurozumi K, 2004, MOL THER, V9, P189, DOI 10.1016/j.ymthe.2003.10.012; Le Blanc K, 2007, LEUKEMIA, V21, P1733, DOI 10.1038/sj.leu.2404777; Le Blanc K, 2006, CURR OPIN IMMUNOL, V18, P586, DOI 10.1016/j.coi.2006.07.004; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Liu Y, 2002, EXP NEUROL, V178, P150, DOI 10.1006/exnr.2002.7977; Macias MY, 2006, EXP NEUROL, V201, P335, DOI 10.1016/j.expneurol.2006.04.035; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2003, NEUROSURGERY, V53, P702; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Mitsui T, 2005, EXP NEUROL, V194, P410, DOI 10.1016/j.expneurol.2005.02.022; Murray M, 2002, BRAIN RES REV, V40, P292, DOI 10.1016/S0165-0173(02)00211-4; Nakagami H, 2005, ARTERIOSCL THROM VAS, V25, P2542, DOI 10.1161/01.ATV.0000190701.92007.6d; Nakahara Y, 1996, CELL TRANSPLANT, V5, P191, DOI 10.1016/0963-6897(95)02028-4; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100; Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104; Park HC, 2005, TISSUE ENG, V11, P913, DOI 10.1089/ten.2005.11.913; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Sadat S, 2007, BIOCHEM BIOPH RES CO, V363, P674, DOI 10.1016/j.bbrc.2007.09.058; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sykova E, 2006, CELL MOL NEUROBIOL, V26, P1113, DOI 10.1007/s10571-006-9007-2; Tobias CA, 2001, J NEUROTRAUM, V18, P287, DOI 10.1089/08977150151070937; Tome M, 2009, STEM CELLS, V27, P2196, DOI 10.1002/stem.130; Tondreau T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-166; TUSZYNSKI MH, 1994, EXP NEUROL, V126, P1, DOI 10.1006/exnr.1994.1037; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Vallieres L, 2003, J NEUROSCI, V23, P5197; Veeravalli KK, 2009, NEUROBIOL DIS, V36, P200, DOI 10.1016/j.nbd.2009.07.012; Vroemen M, 2003, EUR J NEUROSCI, V18, P743, DOI 10.1046/j.1460-9568.2003.02804.x; Wang H, 2009, STEM CELLS, V27, P1548, DOI 10.1002/stem.81; Wei X, 2009, STEM CELLS, V27, P478, DOI 10.1634/stemcells.2008-0333; Wislet-Gendebien S, 2005, BRAIN RES BULL, V68, P95, DOI 10.1016/j.brainresbull.2005.08.016; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061	77	51	52	2	5	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1570-159X	1875-6190		CURR NEUROPHARMACOL	Curr. Neuropharmacol.	DEC	2010	8	4					316	323					8	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	685IX	WOS:000284623500001	21629440	Green Published			2021-06-18	
J	Covassin, T; Elbin, RJ; Nakayama, Y				Covassin, Tracey; Elbin, R. J.; Nakayama, Yusuke			Tracking Neurocognitive Performance Following Concussion in High School Athletes	PHYSICIAN AND SPORTSMEDICINE			English	Article						concussion; neurocognitive function; high school athletes; ImPACT	AGREEMENT STATEMENT; SPORTS CONCUSSION; RECOVERY; IMPACT; SENSITIVITY; VALIDITY; FOOTBALL; PLAY	Objective: To extend previous research designs and examine cognitive performance up to 30 days postconcussion. Method: A prospective cohort design was used to examine 2000 athletes from 8 mid-Michigan area high schools to compare baseline neurocognitive performance with postconcussion neurocognitive performance. All concussed athletes were readministered the Immediate Post Assessment and Cognitive Test (ImPACT) at 2, 7, 14, 21, and 30 days postconcussion. Results: A total of 72 high school athletes (aged 15.8 +/- 1.34 years) sustained a concussion. A significant within-subjects effect for reaction time (F = 10.01; P = 0.000), verbal memory (F = 3.05; P = 0.012), motor processing speed (F = 18.51; P = 0.000), and total symptoms following an injury (F = 16.45; P = 0.000) was found. Concussed athletes demonstrated a significant decrease in reaction time up to 14 days postconcussion (P = 0.001) compared with baseline reaction time. Reaction time returned to baseline levels at 21 days postinjury (P = 0.25). At 7 days postinjury, impairments in verbal memory (P = 0.003) and motor processing speed (P = 0.000) were documented and returned to baseline levels by 14 days postinjury. Concussed athletes self-reported significantly more symptoms at 2 days postconcussion (P = 0.000) and exhibited a resolution of symptoms by 7 days postinjury (P = 0.06). Conclusion: High school athletes could take up to 21 days to return to baseline levels for reaction time. These data support current recommendations for the conservative management of concussion in the high school athlete.	[Covassin, Tracey; Nakayama, Yusuke] Michigan State Univ, E Lansing, MI 48824 USA; [Elbin, R. J.] E Tennessee State Univ, Dept Kinesiol Leisure & Sport Sci, Johnson City, TN 37614 USA	Covassin, T (corresponding author), Michigan State Univ, 105 IM Sport Circle, E Lansing, MI 48824 USA.	covassin@msu.edu			Michigan State University	We would like to acknowledge Michigan State University for an IRPG grant.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; Kontos AP, 2004, J APPL SPORT PSYCHOL, V16, P220, DOI 10.1080/10413200490485568; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Sadovsky R, 2004, AM FAM PHYSICIAN, V69, P171; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	25	51	51	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0091-3847	2326-3660		PHYSICIAN SPORTSMED	Physician Sportsmed.	DEC	2010	38	4					87	93		10.3810/psm.2010.12.1830			7	Primary Health Care; Orthopedics; Sport Sciences	General & Internal Medicine; Orthopedics; Sport Sciences	764LL	WOS:000290630900019	21150147				2021-06-18	
J	Max, JE; Bruce, M; Keatley, E; Delis, D				Max, Jeffrey E.; Bruce, Margaret; Keatley, Eva; Delis, Dean			Pediatric Stroke: Plasticity, Vulnerability, and Age of Lesion Onset	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							UNILATERAL BRAIN-LESIONS; CLOSED-HEAD-INJURY; LOW-BIRTH-WEIGHT; PSYCHIATRIC-DISORDERS; HEMIPLEGIC CHILDREN; CHILDHOOD STROKE; RECOVERY; RELIABILITY; SCHEDULE; VALIDITY	The authors aim to investigate brain plasticity and vulnerability through the study of the relationship of age at the time of brain injury and neurocognitive and psychiatric outcome. Children with early stroke performed more poorly compared with children with late stroke in a wide variety of domains including intellectual function, language, memory, visuospatial function, academic function, and psychiatric problems. The exception to this pattern was that children with late stroke performed more poorly in two of three executive function tests. These findings suggest that in children with focal brain injury, as in those with more diffuse brain insults, younger age at injury predicts worse neurocognitive outcomes, although this may not apply to selected executive function outcomes. Adverse psychiatric outcome after early stroke is less direct but is evident in terms of severity in affected cases. (The Journal of Neuropsychiatry and Clinical Neurosciences 2010; 22:30-39)	[Max, Jeffrey E.; Bruce, Margaret; Keatley, Eva; Delis, Dean] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA	Max, JE (corresponding author), Rady Childrens Hosp, 3020 Childrens Way,MC 5018, San Diego, CA 92123 USA.	jmax@ucsd.edu			NARSADNARSAD [NIMH K-08MH01800]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER	This work was completed at the Department of Psychiatry, University of California, San Diego. This study was supported in part by a NARSAD Young Investigator Award (Dr. Max) and a Career Development Award (NIMH K-08MH01800) (Dr. Max). We acknowledge: Katherine Mathews, M. D., for help with selection and recruitment of stroke participants; Fred Dietz, M. D., Scott Mubarak, M. D., and Peter Newton, M. D., for selection and recruitment of orthopedic controls; Brigitte Robertson, M. D., for psychiatric assessment interrater reliability studies; Peter Fox, M. D., and Jack Lancaster, Ph.D., for image analysis; Amy Lansing, Ph.D., for database management; Don Slymen, Ph.D., for statistical consultation; and Damien Ihrig for data collection.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; ARAM DM, 1994, NEUROPSYCHOLOGIA, V32, P85, DOI 10.1016/0028-3932(94)90071-X; BANICH MT, 1990, NEUROPSYCHOLOGIA, V28, P35, DOI 10.1016/0028-3932(90)90084-2; Bates E, 1999, CHANGING NERVOUS SYSTEM, P214; Beery K, 1989, VMI DEV TEST VISUAL; Benton A., 1994, MULTILINGUAL APHASIA; Breslau N, 2000, BIOL PSYCHIAT, V47, P1005, DOI 10.1016/S0006-3223(99)00312-1; Chapman SB, 2003, PEDIATR NEUROL, V29, P34, DOI 10.1016/S0887-8994(03)00012-2; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis D.C., 1994, CVLT C CALIFORNIA VE; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FINGER S, 1991, DEV NEUROPSYCHOL, V7, P261, DOI 10.1080/87565649109540494; Ganesan V, 2000, DEV MED CHILD NEUROL, V42, P455, DOI 10.1017/S0012162200000852; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; GOODMAN R, 1989, BRIT J PSYCHIAT, V154, P292, DOI 10.1192/bjp.154.3.292; Hammill D.D., 1996, TEST WRITTEN LANGUAG; Heaton R., 1993, WISCONSIN CARD SORTI; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; HICKS SP, 1984, EARLY BRAIN DAMAGE, P127; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Jacobs R, 2007, CORTEX, V43, P792, DOI 10.1016/S0010-9452(08)70507-0; Jastak S, 1984, WIDE RANGE ACHIEVEME; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kennard MA, 1936, AM J PHYSIOL, V115, P138; Kennard MA, 1942, MT SINAI J MED, V9, P594; Kolb B, 2007, DEV PSYCHOBIOL, V49, P107, DOI 10.1002/dev.20199; LANSDELL H, 1969, J COMP PHYSIOL PSYCH, V69, P734, DOI 10.1037/h0028306; LEHMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; LEVINE SC, 1987, DEV MED CHILD NEUROL, V29, P27; Max JE, 2004, J INT NEUROPSYCH SOC, V10, P698, DOI 10.1017/S1355617704105092; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2002, J AM ACAD CHILD PSY, V41, P555, DOI 10.1097/00004583-200205000-00013; Meyers J., 1995, MEYERS SCORING SYSTE; Mosch SC, 2005, COGN BEHAV NEUROL, V18, P5, DOI 10.1097/01.wnn.0000152207.80819.3c; Pavlovic J, 2006, NEUROPEDIATRICS, V37, P13, DOI 10.1055/s-2006-923932; RIVA D, 1986, NEUROPSYCHOLOGIA, V24, P423, DOI 10.1016/0028-3932(86)90029-1; Schaller BJ, 2007, EXP NEUROL, V205, P9, DOI 10.1016/j.expneurol.2006.01.017; SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228; Spreen O., 1998, COMPENDIUM NEUROPSYC; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2004, J INT NEUROPSYCH SOC, V10, P987, DOI 10.1017/S1355617704107078; VARGHAKHADEM F, 1985, BRAIN, V108, P677, DOI 10.1093/brain/108.3.677; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Wechsler D., 1991, WECHSLER INTELLIGENC; WOODS BT, 1979, ANN NEUROL, V6, P405, DOI 10.1002/ana.410060505; Yakovlev P.I., 1967, RETIONAL DEV BRAIN E, P3	50	51	51	0	8	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2010	22	1					30	39		10.1176/appi.neuropsych.22.1.30			10	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	555VO	WOS:000274544500004	20160207				2021-06-18	
J	Schneider, KJ; Emery, CA; Kang, JA; Schneider, GM; Meeuwisse, WH				Schneider, Kathryn J.; Emery, Carolyn A.; Kang, Jian; Schneider, Geoff M.; Meeuwisse, Willem H.			Examining Sport Concussion Assessment Tool ratings for male and female youth hockey players with and without a history of concussion	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INTERNATIONAL-CONFERENCE; RISK-FACTORS; STATEMENT; INJURY	Background Concussion is one of the most commonly occurring injuries in sport today. The Sport Concussion Assessment Tool (SCAT) is a commonly used paper neurocognitive tool. To date, little is known about SCAT baseline normative values in youth athletes. Objective The purpose of this study was to determine normative values on the SCAT for male and female youth hockey players. Methods This is a secondary data analysis of pooled data from three prospective cohort studies examining the risk of injury in paediatric ice hockey players aged 9-17 years. A preseason baseline demographic and injury history questionnaire was completed by each player. Results A total of 4193 players completed SCATs at baseline and were included in the analysis. 781 players (18.6%) reported a previous history of concussion. Fatigue and low energy followed by headache were the most commonly reported symptoms in all players. The majority of youth players could recite all five words immediately but only three words when delayed. A smaller proportion of the males were able to report the months of the year in reverse order compared with females of a similar age. The median number of digits recited in reverse order was 4. Conclusions Youth ratings varied between age groups, gender and from previously reported ratings of varsity athletes, possibly reflecting developmental and gender differences. An understanding of these differences in youth athletes is important to ensure appropriate performance expectations on the SCAT and when making clinical decisions following a concussion.	[Schneider, Kathryn J.; Emery, Carolyn A.; Kang, Jian; Meeuwisse, Willem H.] Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; [Emery, Carolyn A.; Meeuwisse, Willem H.] Univ Calgary, Dept Community Hlth Sci, Fac Med, Calgary, AB T2N 1N4, Canada; [Emery, Carolyn A.] Univ Calgary, Res Inst Child & Maternal Hlth, Fac Med, Alberta Childrens Hosp, Calgary, AB T2N 1N4, Canada; [Schneider, Geoff M.] Univ Calgary, Dept Med Sci, Fac Med, Calgary, AB T2N 1N4, Canada	Schneider, KJ (corresponding author), Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	kjschnei@ucalgary.ca	Emery, Carolyn/AAI-2761-2020	Schneider, Kathryn/0000-0002-5951-5899	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Max Bell Foundation; Alberta Centre for Child, Family and Community Research; Alberta Heritage Foundation for Medical ResearchAlberta Heritage Foundation for Medical Research; Children's Hospital Foundation through the Alberta Children's Hospital Research Institute for Child and Maternal Health	These studies were funded by the Canadian Institutes of Health Research, Max Bell Foundation and Alberta Centre for Child, Family and Community Research. KJS is funded by an Alberta Heritage Foundation for Medical Research Doctoral Award. CAE is funded by a Canadian Institutes of Health Research New Investigator Award, Alberta Heritage Foundation for Medical Research Population Health Investigator Award and a Professorship in Pediatric Rehabilitation funded by the Children's Hospital Foundation through the Alberta Children's Hospital Research Institute for Child and Maternal Health.	Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Decloe M, 2009, CLIN J SPORT MED, V19, P247; Emery C, 2009, J SCI MED SPORT, V12, P180; Emery C, 2009, CLIN J SPORT MED, V19, P245; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43	19	51	51	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC	2010	44	15					1112	1117		10.1136/bjsm.2009.071266			6	Sport Sciences	Sport Sciences	696CW	WOS:000285420500008	20966034				2021-06-18	
J	Colantonio, A; Saverino, C; Zagorski, B; Swaine, B; Lewko, J; Jaglal, S; Vernich, L				Colantonio, Angela; Saverino, Cristina; Zagorski, Brandon; Swaine, Bonnie; Lewko, John; Jaglal, Susan; Vernich, Lee			Hospitalizations and Emergency Department Visits for TBI in Ontario	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							TRAUMATIC-BRAIN-INJURY; UNITED-STATES; HEAD-INJURY; POPULATION; PATHOPHYSIOLOGY; EPIDEMIOLOGY; TRENDS; CODES; CARE; US	Objective: The aim of this study was to determine the number of annual hospitalizations and overall episodes of care that involve a traumatic brain injury (Tiff) by age and gender in the province of Ontario. To provide a more accurate assessment of the prevalence of TBI, episodes of care included visits to the emergency department (ED), as well as admissions to hospital. Mechanisms of injury for overall episodes were also investigated. Methods: Traumatic brain injury cases from fiscal years 2002/03-2006/07 were identified by means of ICD-10 codes. Data were collected from the National Ambulatory Care Reporting System and the Discharge Abstract Database. Results: The rate of hospitalization was highest for elderly persons over 75 years-of-age. Males generally had higher rates for both hospitalizations and episodes of care than did females. The inclusion of ED visits to hospitalizations had the greatest impact on the rates of TBI in the youngest age groups. Episodes of care for TBI were greatest in youth under the age of 14 and elderly over the age of 85. Falls (41.6%) and being struck by or against an object (31.1%) were the most frequent causes for a TBI. Conclusions: The study provides estimates for TBI from the only Canadian province that has systematically captured ED visits in a national registry. It shows the importance of tracking ED visits, in addition to hospitalizations, to capture the burden of TBI on the health care system. Prevention strategies should include information on ED visits, particularly for those at younger ages.	[Colantonio, Angela; Saverino, Cristina] Univ Toronto, Toronto Rehabil Inst, Dept Occupat Therapy, Toronto, ON M5G 1V7, Canada; [Jaglal, Susan] Univ Toronto, Toronto Rehabil Inst, Dept Phys Therapy, Toronto, ON M5G 1V7, Canada; [Vernich, Lee] Univ Toronto, Dalla Lana Sch Publ Hlth, Res Serv, Toronto, ON M5G 1V7, Canada; [Zagorski, Brandon] Inst Clin Evaluat Sci, Dept Programming & Biostat, Toronto, ON, Canada; [Lewko, John] Laurentian Univ, Ctr Res Human Dev, Sudbury, ON P3E 2C6, Canada; [Swaine, Bonnie] Univ Montreal, Sch Rehabil, Physiotherapy Program, Montreal, PQ, Canada	Colantonio, A (corresponding author), Univ Toronto, Toronto Rehabil Inst, Dept Occupat Therapy, 160-500 Univ Ave,Room 950, Toronto, ON M5G 1V7, Canada.			Jaglal, Susan/0000-0002-2930-1443; Colantonio, Angela/0000-0003-2094-4765	Ontario Neurotrauma Foundation; Institute for Clinical and Evaluative Sciences; Toronto Rehabilitation InstituteUniversity of Toronto; Ontario Ministry of Health and Long Term CareMinistry of Health and Long-Term Care, Ontario	The authors thank these :institutions for supporting this project: the Ontario Neurotrauma Foundation, the Institute for Clinical and Evaluative Sciences, and the Toronto Rehabilitation Institute. The Institute for Clinical and Evaluative Sciences and the Toronto Rehabilitation Institute are supported by the Ontario Ministry of Health and Long Term Care.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Boswell JE, 2002, AM J EMERG MED, V20, P177, DOI 10.1053/ajem.2002.32641; Canadian Institute for Health Information (CIHI), 2007, DAT QUAL DOC DISCH A; Canadian Institute of Health Information (CIHI), 2008, DAT QUAL STUD EM DEP, VII; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; *CDCP, 2007, INT COLL EFF INJ STA; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CIHI, 2007, BURD NEUR DIS DIS IN; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Day Heather, 2006, Minn Med, V89, P40; Deb S, 1999, BRAIN INJURY, V13, P369, DOI 10.1080/026990599121557; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hillier SL, 1997, BRAIN INJURY, V11, P649; Jacobsson LJ, 2007, ACTA NEUROL SCAND, V116, P300, DOI 10.1111/j.1600-0404.2007.00896.x; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JUURLINK D, 2006, CAN I HLTH INF DISCH; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Kostylova A, 2005, INJURY PREV, V11, P186, DOI 10.1136/ip.2004.006585; Marr A, 2002, CENTRAL NERVOUS SYST; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; *PHAC, 2002, INJ PREV; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Pickett William, 2004, Chronic Dis Can, V25, P32; RICHARD J, 2001, P STAT CANADA INT S; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Schootman M, 2000, BRAIN INJURY, V14, P373; Selassie AW, 2003, ACAD EMERG MED, V10, P1260, DOI 10.1197/S1069-6563(03)00497-4; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587	38	51	52	0	4	CANADIAN JOURNAL NEUROLOGICAL SCIENCES INC	CALGARY	709-7015 MACLEOD TRAIL SW, CALGARY, AB T2H 2K6, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	NOV	2010	37	6					783	790		10.1017/S0317167100051441			8	Clinical Neurology	Neurosciences & Neurology	686CJ	WOS:000284674100013	21059539	Bronze			2021-06-18	
J	Thurmond, VA; Hicks, R; Gleason, T; Miller, AC; Szuflita, N; Orman, J; Schwab, K				Thurmond, Veronica A.; Hicks, Ramona; Gleason, Theresa; Miller, A. Cate; Szuflita, Nicholas; Orman, Jean; Schwab, Karen			Advancing Integrated Research in Psychological Health and Traumatic Brain Injury: Common Data Elements	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Analysis, demographics; Biomarkers; Brain injuries, traumatic; Outcome measures; Rehabilitation; Stress disorders, posttraumatic	IRAQ	In civilian, military, and veteran populations, there is increased recognition of the interrelationship between traumatic brain injury (TBI) and some psychological health (PH) disorders and the need to better understand the relationships by integrating research for these topics. The use of different measures to assess similar study variables and/or assess outcomes may limit important advances in PH and TBI research. Without a set of common data elements (CDEs; to include variable definitions and recommended measures for the purpose of this discussion), comparison of findings across studies is challenging. The federal agencies involved in PH and TBI research, the National Institute of Neurological Disorders and Stroke, Department of Veterans Affairs, National Institute on Disability and Rehabilitation Research, Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury, and Defense and Veterans Brain Injury Center, therefore cosponsored a scientific initiative to develop CDEs for PH and TBI research. Scientific experts were invited to participate in 1 of 8 working groups to develop recommendations for specific topic-driven CDEs. Draft recommendations were presented and discussed in the workshop "Advancing Integrated Research in Psychological Health and Traumatic Brain Injury: Common Data Elements (CDE)" held on March 23-24, 2009, in Silver Spring, MD. The overall process leading to the workshop and subsequent recommendations by the working groups are presented in this article. Topic-driven recommendations for CDEs are presented in individual reports in this edition.	[Hicks, Ramona] Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA; [Gleason, Theresa; Orman, Jean] Dept Vet Affairs, Washington, DC USA; [Miller, A. Cate] Natl Inst Disabil & Rehabil Res, US Dept Educ, Washington, DC USA; [Schwab, Karen] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Thurmond, Veronica A.; Szuflita, Nicholas] Def Ctr Excellence PH TBI, Silver Spring, MD 20910 USA	Thurmond, VA (corresponding author), Def Ctr Excellence PH TBI, 1335 East West Highway, Silver Spring, MD 20910 USA.	veronica.thurmond@us.anny.mil					Alexander MS, 2009, SPINAL CORD, V47, P582, DOI 10.1038/sc.2009.18; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kupersmith J, 2009, J REHABIL RES DEV, V46, pVII, DOI 10.1682/JRRD.2009.06.0079; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519	7	51	51	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2010	91	11					1633	1636		10.1016/j.apmr.2010.06.034			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	681UQ	WOS:000284346400001	21044705				2021-06-18	
J	Tierney, RT; Mansell, JL; Higgins, M; McDevitt, JK; Toone, N; Gaughan, JP; Mishra, A; Krynetskiy, E				Tierney, Ryan T.; Mansell, Jamie L.; Higgins, Michael; McDevitt, Jane K.; Toone, Nieka; Gaughan, John P.; Mishra, Anarug; Krynetskiy, Evgeny			Apolipoprotein E Genotype and Concussion in College Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						polymorphism; MTBI; APOE E2; APOE E4; APOE promoter g-219t	TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; APOE PROMOTER; ASSOCIATION; EPIDEMIOLOGY; SPORTS	Objective: To evaluate the association between apolipoprotein E (APOE) polymorphisms (E2, C/T Arg158Cys; E4, T/C Cys112Arg; and promoter, g-219t) and the history of concussion in college athletes. We hypothesized that carrying 1 or more APOE rare (or minor) allele assessed in this study would be associated with having a history of 1 or more concussions. Design: Multicenter cross-sectional study. Setting: University athletic facilities. Participants: One hundred ninety-six male football (n = 163) and female soccer (n = 33) college athletes volunteered. Interventions: Written concussion history questionnaire and saliva samples for genotyping. Main Outcome Measures: Self-reported history of a documented concussion and rare APOE genotype (E2, E4, promoter). Results: There was a significant association (Wald chi(2) = 3.82; P = 0.05; odds ratio = 9.8) between carrying all APOE rare alleles and the history of a previous concussion. There was also a significant association (Wald chi(2) = 3.96, P = 0.04, odds ratio = 8.4) between carrying the APOE promoter minor allele and experiencing 2 or more concussions. Conclusions: Carriers of all 3 APOE rare (or minor) alleles assessed in this study were nearly 10 times more likely to report a previous concussion and may be at a greater risk of concussion versus noncarriers. Promoter minor allele carriers were 8.4 times more likely to report multiple concussions and may be at a greater risk of multiple concussions versus noncarriers. Research involving larger samples of individuals with multiple concussions and carriers of multiple APOE rare alleles is warranted.	[Tierney, Ryan T.; McDevitt, Jane K.; Toone, Nieka] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Mansell, Jamie L.] Lincoln Univ, Dept Hlth Phys Educ & Recreat, Philadelphia, PA USA; [Higgins, Michael] Towson Univ, Dept Kinesiol, Towson, MD USA; [Gaughan, John P.] Temple Univ, Sch Med, Biostat Consulting Ctr, Philadelphia, PA 19122 USA; [Mishra, Anarug; Krynetskiy, Evgeny] Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19122 USA	Tierney, RT (corresponding author), Temple Univ, Dept Kinesiol, 018 Pearson Hall,1800 N Broad St, Philadelphia, PA 19122 USA.	rtierney@temple.edu			Jayne Haines Center for Pharmacogenomics and Drug Safety of the Temple University School of Pharmacy	Supported by the Jayne Haines Center for Pharmacogenomics and Drug Safety of the Temple University School of Pharmacy.	Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Caselli RJ, 2004, NEUROLOGY, V62, P1990, DOI 10.1212/01.WNL.0000129533.26544.BF; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; MACCIOCCHI SN, 1999, CLIN SPORTS MED, V45, P138; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; ROTH SM, 2007, GENETICS PRIMER EXER, V54, P15; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	31	51	51	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2010	20	6					464	468		10.1097/JSM.0b013e3181fc0a81			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	682DC	WOS:000284379100013	21079443				2021-06-18	
J	Rangel-Castilla, L; Lara, LR; Gopinath, S; Swank, PR; Valadka, A; Robertson, C				Rangel-Castilla, Leonardo; Lara, Lucia Rivera; Gopinath, Shankar; Swank, Paul R.; Valadka, Alex; Robertson, Claudia			Cerebral Hemodynamic Effects of Acute Hyperoxia and Hyperventilation after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral autoregulation; hyperoxia; hyperventilation; traumatic brain injury	SEVERE HEAD-INJURY; BLOOD-FLOW VELOCITY; CEREBROVASCULAR CO2 REACTIVITY; TISSUE OXYGEN-TENSION; TRANSCRANIAL DOPPLER; AUTOREGULATION; PRESSURE; METABOLISM; HUMANS; INHALATION	The purpose of this study was to examine the effects of hyperventilation or hyperoxia on cerebral hemodynamic parameters over time in patients with severe traumatic brain injury (TBI). We prospectively studied 186 patients with severe TBI. CO2 and O-2 reactivity tests were conducted twice a day on days 1-5 and once daily on days 6-10 after injury. During hyperventilation there was a significant decrease in intracranial pressure (ICP), mean arterial pressure (MAP), jugular venous oxygen saturation (Sjvo(2)), brain tissue Po-2 (Pbto(2)), and flow velocity (FV). During hyperoxia there was an increase in Sjvo(2) and Pbto(2), and a small but consistent decrease in ICP, end-tidal carbon dioxide (ETCO2), partial arterial carbon dioxide pressure (Paco(2)), and FV. Brain tissue oxygen reactivity during the first 12 h after injury averaged 19.7 +/- 3.0%, and slowly decreased over the next 7 days. The autoregulatory index (ARI; normal = 5.3 +/- 1.3) averaged 2.2 +/- 1.5 on day 1 post-injury, and gradually improved over the 10 days of monitoring. The ARI significantly improved during hyperoxia, by an average of 0.4 +/- 1.8 on the left, and by 0.5 +/- 1.8 on the right. However, the change in ARI with hyperoxia was much smaller than that observed with hyperventilation. Hyperventilation increased ARI by an average of 1.3 +/- 1.9 on the left, and 1.5 +/- 2.0 on the right. Pressure autoregulation, as assessed by dynamic testing, was impaired in these head-injured patients. Acute hyperoxia significantly improved pressure autoregulation, although the effect was smaller than that induced by hyperventilation. The very small change in Paco(2) induced by hyperoxia does not appear to explain this finding. Rather, the vasoconstriction induced by acute hyperoxia may allow the cerebral vessels to respond better to transient hypotension. Further studies are needed to define the clinical significance of these observations.	[Lara, Lucia Rivera; Gopinath, Shankar; Robertson, Claudia] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Rangel-Castilla, Leonardo] Methodist Hosp, Methodist Neurol Inst, Dept Neurosurg, Houston, TX 77030 USA; [Swank, Paul R.] Univ Texas Hlth Sci Ctr Houston, Sch Med, Houston, TX USA; [Valadka, Alex] Seton Brain & Spine Inst, Austin, TX USA	Robertson, C (corresponding author), Baylor Coll Med, Dept Neurosurg, 1709 Dryden,Suite 750,MS BCM650, Houston, TX 77030 USA.	Claudiar@Bcm.Tmc.Edu	Rivera-Lara, Lucia/AAX-8233-2020	Rivera-Lara, Lucia/0000-0002-9053-2283	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-NS38660]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER	This work was funded by National Institutes of Health grant P01-NS38660.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; ALBRECHT RF, 1987, STROKE, V18, P649, DOI 10.1161/01.STR.18.3.649; AMANO T, 1983, ARCH NEUROL-CHICAGO, V40, P277, DOI 10.1001/archneur.1983.04050050045005; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Djurberg HG, 1998, J CLIN ANESTH, V10, P646, DOI 10.1016/S0952-8180(98)00107-X; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Hlatky R, 2006, NEUROCRIT CARE, V4, P127, DOI 10.1385/NCC:4:2:127; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Kastrup A, 1997, STROKE, V28, P2353, DOI 10.1161/01.STR.28.12.2353; Kastrup A, 1998, STROKE, V29, P1311, DOI 10.1161/01.STR.29.7.1311; Kawamura Shingo, 1996, Neurologia Medico-Chirurgica, V36, P156, DOI 10.2176/nmc.36.156; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; Longhi L, 2002, ACT NEUR S, V81, P315; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McCulloch TJ, 2005, ANESTH ANALG, V100, P1463, DOI 10.1213/01.ANE.0000148623.06596.7E; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; NAKAJIMA S, 1983, ARCH NEUROL-CHICAGO, V40, P271, DOI 10.1001/archneur.1983.04050050039004; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; Nishimura N, 2007, AVIAT SPACE ENVIR MD, V78, P1121, DOI 10.3357/ASEM.2177.2007; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Omae T, 1998, STROKE, V29, P94, DOI 10.1161/01.STR.29.1.94; Rangel-Castillo L, 2006, CRIT CARE CLIN, V22, P713, DOI 10.1016/j.ccc.2006.06.003; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; SCHULTHEISS R, 1987, ANGIOLOGY, V38, P221, DOI 10.1177/000331978703800303; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valdueza JM, 1997, AM J NEURORADIOL, V18, P1929; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Watson NA, 2000, EUR J ANAESTH, V17, P152, DOI 10.1046/j.1365-2346.2000.00640.x	36	51	51	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2010	27	10					1853	1863		10.1089/neu.2010.1339			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	665OZ	WOS:000283046600009	20684672	Green Published			2021-06-18	
J	Gracies, JM; Bayle, N; Vinti, M; Alkandari, S; Vu, P; Loche, CM; Colas, C				Gracies, J. -M.; Bayle, N.; Vinti, M.; Alkandari, S.; Vu, P.; Loche, C. M.; Colas, C.			Five-step clinical assessment in spastic paresis	EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE			English	Article						Muscle contraction; Spastic paresis; Motor skills disorders	TRAUMATIC BRAIN-INJURY; INDUCED MOVEMENT THERAPY; SPINAL-CORD-INJURY; WALKING SPEED; UPPER-LIMB; INTERRATER RELIABILITY; HEMIPLEGIC PATIENTS; MULTIPLE-SCLEROSIS; BOTULINUM TOXIN; ASHWORTH SCALE	Among the three main factors of motor impairment that emerge in chronological order following a lesion to central motor pathways, the last two antagonize movement: 1) stretch-sensitive paresis, a reduction of agonist motor unit recruitment upon voluntary command, worsened by antagonist stretch; 2) soft tissue contracture, and 3) muscle overactivity. Types of muscle overactivity include 1) spasticity, an increase in the velocity-dependent response to muscle stretch, measured at rest; 2) spastic dystonia, i.e., chronic tonic muscle activity at rest, sensitive to stretch of the dystonic muscle and 3) spastic co-contraction, an inappropriate degree of antagonistic contraction during voluntary agonist command, sensitive to stretch of the co-contracting muscle. A five-step clinical assessment may closely parallel this phenomenology, in which the first four steps aim at quantifying the antagonistic potential of each muscle group. Step-1 measures passive range of motion, i.e., the angle of arrest upon slow stretch of the muscle group assessed (minimizing spastic dystonia), which provides insight on soft tissue length and extensibility. Step-2 measures the angle of catch or clonus upon fast passive stretch of the muscle group assessed, which provides insight on stretch reflex excitability. Step-3 measures the range of active motion against the muscle group assessed, a net result of agonist recruitment minus the combined resistance from passive soft tissue stiffness and spastic co-contraction in the muscle group assessed. Step-4 measures the maximal frequency of rapid alternating movements along the maximal active range of motion, evaluating Step-3 performance repeatability. Step-5 evaluates active function, using for example a walking test (10 m or 2 min) for lower limb and the Modified Frenchay Scale for upper limb assessment, and perceived function through patient global subjective assessment.	[Gracies, J. -M.] Univ Paris Est Creteil, Grp Hosp Henri Mondor, AP HP, Unite Neuroreeduc,Serv Med Phys & Readapt, F-94010 Creteil, France; [Gracies, J. -M.; Bayle, N.; Vinti, M.; Alkandari, S.; Vu, P.; Loche, C. M.; Colas, C.] Henri Mondor Univ Hosp, Phys & Rehabil Med Serv, Unit Neuroreeduc, Creteil, France; [Gracies, J. -M.; Bayle, N.; Vinti, M.] Arts & Metiers ParisTech, LBM, F-75013 Paris, France	Gracies, JM (corresponding author), Univ Paris Est Creteil, Grp Hosp Henri Mondor, AP HP, Unite Neuroreeduc,Serv Med Phys & Readapt, 50 Av Marechal de Lattre de Tassigny, F-94010 Creteil, France.	jean-michel.gracies@hmn.aphp.fr					Ada L, 2005, ARCH PHYS MED REHAB, V86, P230, DOI 10.1016/j.apmr.2004.02.031; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Baptista IL, 2010, MUSCLE NERVE, V41, P800, DOI 10.1002/mus.21578; Blanton S, 1999, PHYS THER, V79, P847, DOI 10.1093/ptj/79.9.847; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; BUTLER P, 1984, DEV MED CHILD NEUROL, V26, P607; Clark M S, 1983, Int Rehabil Med, V5, P41; Collen F M, 1990, Int Disabil Stud, V12, P6; Collin C, 1988, Int Disabil Stud, V10, P61; Crone C, 2003, BRAIN, V126, P495, DOI 10.1093/brain/awg036; Dean CM, 2001, CLIN REHABIL, V15, P415, DOI 10.1191/026921501678310216; Denny-Brown D., 1966, CEREBRAL CONTROL MOV, P124; Desrosiers J, 1993, CAN J OCCUP THER, V60, P9, DOI DOI 10.1177/000841749306000104; Dobkin BH, 2010, NEUROREHAB NEURAL RE, V24, P235, DOI 10.1177/1545968309357558; Flansbjer UB, 2005, J REHABIL MED, V37, P75, DOI 10.1080/16501970410017215; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; Ghosh A, 2009, J NEUROSCI, V29, P12210, DOI 10.1523/JNEUROSCI.1828-09.2009; Giger JM, 2009, J APPL PHYSIOL, V107, P1204, DOI 10.1152/japplphysiol.00344.2009; Giger RJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001867; Gracies J, 2006, MOVEMENT DISORD, V21, pS423; Gracies JM, 2010, ARCH PHYS MED REHAB, V91, P421, DOI 10.1016/j.apmr.2009.11.017; Gracies JM, 2009, ARCH PHYS MED REHAB, V90, P9, DOI 10.1016/j.apmr.2008.04.030; Gracies JM, 2005, MUSCLE NERVE, V31, P535, DOI 10.1002/mus.20284; Gracies JM, 2005, MUSCLE NERVE, V31, P552, DOI 10.1002/mus.20285; Gracies JM, 1997, ANN NEUROL, V42, pT183; Gracies JM, 2000, ARCH PHYS MED REHAB, V81, P1547, DOI 10.1053/apmr.2000.16346; Gracies JM, 2002, HDB BOTULINUM TOXIN, P221; Granat MH, 1996, ARCH PHYS MED REHAB, V77, P19, DOI 10.1016/S0003-9993(96)90214-2; HELLER A, 1987, J NEUROL NEUROSUR PS, V50, P714, DOI 10.1136/jnnp.50.6.714; JEBSEN R H, 1969, Archives of Physical Medicine and Rehabilitation, V50, P311; JOHN J, 1984, INT J REHABIL RES, V7, P173, DOI 10.1097/00004356-198406000-00005; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lance J. W., 1980, SPASTICITY DISORDERE, P485; LEMETAYER M, 1981, NEUROPSYCHIAT ENFAN, V29, P587; Lincoln N, 1979, Physiotherapy, V65, P48; LINDMARK B, 1988, SCAND J REHABIL MED, V20, P111; LYLE RC, 1981, INT J REHABIL RES, V4, P483, DOI 10.1097/00004356-198112000-00001; Maier IC, 2008, J NEUROSCI, V28, P9386, DOI 10.1523/JNEUROSCI.1697-08.2008; MATHIOWETZ V, 1985, AM J OCCUP THER, V39, P386, DOI 10.5014/ajot.39.6.386; Moseley AM, 2004, J HEAD TRAUMA REHAB, V19, P341, DOI 10.1097/00001199-200407000-00008; Nielsen J F, 1996, Mult Scler, V1, P296; Patrick E, 2006, CLIN REHABIL, V20, P173, DOI 10.1191/0269215506cr922oa; Post MWM, 1996, ARCH PHYS MED REHAB, V77, P440, DOI 10.1016/S0003-9993(96)90031-3; PRIMERANO A, 2010, ANN MED PHY IN PRESS; Raineteau O, 2002, EUR J NEUROSCI, V16, P1761, DOI 10.1046/j.1460-9568.2002.02243.x; RAPIN I, 1966, DEV MED CHILD NEUROL, V8, P45; Riddle CN, 2010, J NEUROPHYSIOL, V103, P2821, DOI 10.1152/jn.00491.2009; Roth EJ, 1997, AM J PHYS MED REHAB, V76, P128, DOI 10.1097/00002060-199703000-00008; Simpson DM, 2009, J NEUROL NEUROSUR PS, V80, P380, DOI 10.1136/jnnp.2008.159657; TARDIEU G, 1954, REV NEUROL, V91, P143; TARDIEU G, 1977, NEUROLOGIE; Tardieu G, 1966, EVALUATION CARACTERE, P1; van Loo M, 2003, CLIN REHABIL, V17, P775, DOI 10.1191/0269215503cr677oa; Van Loo MA, 2004, BRAIN INJURY, V18, P1041, DOI 10.1080/02699050410001672314; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521	57	51	53	1	14	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	1973-9087	1973-9095		EUR J PHYS REHAB MED	Eur. J. Phys. Rehabil. Med.	SEP	2010	46	3					411	421					11	Rehabilitation	Rehabilitation	675LP	WOS:000283832500011	20927007				2021-06-18	
J	Harris, NG; Mironova, YA; Hovda, DA; Sutton, RL				Harris, Neil G.; Mironova, Yevgeniya A.; Hovda, David A.; Sutton, Richard L.			Pericontusion Axon Sprouting Is Spatially and Temporally Consistent With a Growth-Permissive Environment After Traumatic Brain Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axon sprouting; Brain-derived neurotrophic factor; Brain trauma; Chondroitin sulfate proteoglycan; Fibronectin; GAP43; Neuroplasticity; Perineuronal nets	CORTICAL IMPACT INJURY; INTRINSIC NEURONAL DETERMINANTS; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD INJURY; ADULT-RAT BRAIN; CEREBRAL-CORTEX; EXTRACELLULAR-MATRIX; MESSENGER-RNA; CHONDROITIN-SULFATE; FUNCTIONAL RECOVERY	We previously reported that pericontusional extracellular chondroitin Sulfate proteoglycans (CSPGs) are profoundly reduced for 3 weeks after experimental traumatic brain injury, indicating a potential growth-permissive window for plasticity. Here, we investigate the extracellular environment of sprouting neurons after controlled cortical impact injury in adult rats to determine the spatial and temporal arrangement of inhibitory and growth-promoting molecules in relation to growth-associated protein 43-positive (GAP43+) neurons. Spontaneous cortical sprouting was maximal in pericontused regions at 7 and 14 days after injury but absent by 28 days. Perineuronal nets containing CSPGs were reduced at 7 days after injury in the pericontused region (p < 0.05), which was commensurate with a reduction in extracellular CSPGs. Sprouting was restricted to the perineuronal nets and CSPG-deficient regions at 7 days, indicating that the pericontused region is temporarily and spatially permissive to new growth. At this time point, GAP43+ neurons were associated with brain regions containing cells positive for polysialic acid neural cell adhesion molecule but not with fibronectin-positive cells. Brain-derived neurotrophic factor was reduced in the immediate pericontused region at 7 days. Along with prior Western blot evidence, these data Suggest that a lowered intrinsic growth stimulus, together with a later return of growth-inhibitory CSPGs, may contribute to the ultimate disappearance of sprouting neurons after traumatic brain injury.	[Harris, Neil G.; Mironova, Yevgeniya A.; Hovda, David A.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Harris, NG (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Brain Injury Res Ctr, Box 957039, Los Angeles, CA 90095 USA.	ngharris@mednet.ucla.edu		Harris, Neil/0000-0002-1965-6750	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS055910]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055910] Funding Source: NIH RePORTER	This work was supported by the UCLA Brain Injury Research Center and Award Number R01 NS055910 from the National Institute of Neurological Disorders and Stroke.	Alonso G, 1997, J COMP NEUROL, V384, P181; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Batchelor PE, 2000, EUR J NEUROSCI, V12, P3462, DOI 10.1046/j.1460-9568.2000.00239.x; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Batchelor PE, 2008, BRAIN RES, V1209, P49, DOI 10.1016/j.brainres.2008.02.098; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Bonfanti L, 2006, PROG NEUROBIOL, V80, P129, DOI 10.1016/j.pneurobio.2006.08.003; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bruckner G, 1998, EXP BRAIN RES, V121, P300, DOI 10.1007/s002210050463; Bruckner G, 1996, J NEUROCYTOL, V25, P333, DOI 10.1007/BF02284806; BRUCKNER G, 1994, BRAIN RES, V658, P67; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Carmichael ST, 2001, NEUROBIOL DIS, V8, P910, DOI 10.1006/nbdi.2001.0425; Carmichael ST, 2005, EXP NEUROL, V193, P291, DOI 10.1016/j.expneurol.2005.01.004; Caroni P, 1997, BIOESSAYS, V19, P767, DOI 10.1002/bies.950190906; Carulli D, 2007, J COMP NEUROL, V501, P83, DOI 10.1002/cne.21231; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen S., 2002, J NEUROTRAUM, V19, P1300; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; DANI JW, 1991, NEUROSCIENCE, V40, P277, DOI 10.1016/0306-4522(91)90190-Y; DARIANSMITH C, 1995, J NEUROSCI, V15, P1631; DELOULME JC, 1990, J CELL BIOL, V111, P1559, DOI 10.1083/jcb.111.4.1559; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Emery DL, 2000, J COMP NEUROL, V424, P521; FAWCETT JW, 1992, TRENDS NEUROSCI, V15, P5, DOI 10.1016/0166-2236(92)90338-9; Feig SL, 2004, J COMP NEUROL, V468, P96, DOI 10.1002/cne.10969; Gascon E, 2007, BRAIN RES REV, V56, P101, DOI 10.1016/j.brainresrev.2007.05.014; Ghiani CA, 2007, GLIA, V55, P966, DOI 10.1002/glia.20521; Gogolla N, 2007, CURR OPIN NEUROBIOL, V17, P516, DOI 10.1016/j.conb.2007.09.002; GREENOUGH WT, 1985, BEHAV NEURAL BIOL, V44, P301, DOI 10.1016/S0163-1047(85)90310-3; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; HARRIS NG, 2003, J CEREB METAB BLOOD, V21, P13; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; HOCKFIELD S, 1990, COLD SH Q B, V55, P505; Hsu JYC, 2005, J NEUROSCI RES, V80, P330, DOI 10.1002/jnr.20472; Huber AB, 2002, J NEUROSCI, V22, P3553; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; JONES TA, 1994, J NEUROSCI, V14, P2140; Jorgensen OS, 1997, EXP NEUROL, V144, P326, DOI 10.1006/exnr.1996.6372; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; King VR, 2003, EXP NEUROL, V182, P383, DOI 10.1016/S0014-4886(03)00033-5; Kleim JA, 1996, J NEUROSCI, V16, P4529; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; KUROKAWA T, 1976, J BIOL CHEM, V251, P5686; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; LI Y, 1995, EXP NEUROL, V134, P102, DOI 10.1006/exnr.1995.1041; LOVINGER DM, 1986, BRAIN RES, V399, P205, DOI 10.1016/0006-8993(86)91510-6; Massey JM, 2006, J NEUROSCI, V26, P4406, DOI 10.1523/JNEUROSCI.5467-05.2006; MILLER JA, 1991, NEUROSCI LETT, V121, P211, DOI 10.1016/0304-3940(91)90687-O; Mironova Y, 2009, J NEUROTRAUM, V26, pA43; Moretti FA, 2007, J BIOL CHEM, V282, P28057, DOI 10.1074/jbc.M611315200; Muir EM, 2002, MOL BRAIN RES, V100, P103, DOI 10.1016/S0169-328X(02)00132-8; MURAKAMI T, 1994, ARCH HISTOL CYTOL, V57, P509, DOI 10.1679/aohc.57.509; NEVE RL, 1989, P NATL ACAD SCI USA, V86, P4781, DOI 10.1073/pnas.86.12.4781; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Plunet W, 2002, J NEUROSCI RES, V68, P1, DOI 10.1002/jnr.10176; Rasband W. S, 2012, IMAGEJ; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Rossi F, 2007, PROG NEUROBIOL, V81, P1, DOI 10.1016/j.pneurobio.2006.12.001; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; STEWART GR, 1987, J NEUROSCI, V7, P3325; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tate CC, 2007, J NEUROTRAUM, V24, P226, DOI 10.1089/neu.2006.0043; TETZLAFF W, 1994, PROG BRAIN RES, V103, P271; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Tobias CA, 2003, EXP NEUROL, V184, P97, DOI 10.1016/S0014-4886(03)00394-7; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; Uryu K, 2001, NEUROSCIENCE, V105, P307, DOI 10.1016/S0306-4522(01)00203-2; Verma P, 2005, J NEUROSCI, V25, P331, DOI 10.1523/JNEUROSCI.3073-04.2005; VITKOVIC L, 1988, P NATL ACAD SCI USA, V85, P8296, DOI 10.1073/pnas.85.21.8296; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Wegner F, 2003, EXP NEUROL, V184, P705, DOI 10.1016/S0014-4886(03)00313-3; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; YAMADA K, 1994, ACTA NEUROPATHOL, V88, P553	86	51	55	1	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	FEB	2010	69	2					139	154		10.1097/NEN.0b013e3181cb5bee			16	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	550FV	WOS:000274114600003	20084019	Green Accepted, Bronze			2021-06-18	
J	Berger, RP; Bazaco, MC; Wagner, AK; Kochanek, PM; Fabio, A				Berger, Rachel Pardes; Bazaco, Michael C.; Wagner, Amy K.; Kochanek, Patrick M.; Fabio, Anthony			Trajectory Analysis of Serum Biomarker Concentrations Facilitates Outcome Prediction after Pediatric Traumatic and Hypoxemic Brain Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Traumatic brain injury, pediatric; Hypoxic ischemic encephalopathy; Outcome; Trajectory analysis; Neuron-specific enolase; S100B; Myelin basic protein	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; GLASGOW COMA SCALE; MAGNETIC-RESONANCE SPECTROSCOPY; CEREBROSPINAL-FLUID; PERIPHERAL MARKERS; CHILDREN; S100B; PROTEIN; DAMAGE	Traumatic brain injury (TBI) and hypoxic ischemic encephalopathy (HIE) are leading causes of morbidity and mortality in children. Several studies over the past several years have evaluated the use of serum biomarkers to predict outcome after pediatric brain injury. These studies have all used simple point estimates such as initial and peak biomarker concentrations to predict outcome. However, this approach does not recognize patterns of change over time. Trajectory analysis is a type of analysis which can capture variance in biomarker concentrations over time and has been used with success in the social sciences. We used trajectory analysis to evaluate the ability of the serum concentrations of 3 brain-specific biomarkers - S100B, neuron-specific enolase (NSE) and myelin basic protein (MBP) - to predict poor outcome (Glasgow Outcome Scale scores 3-5) after pediatric TBI and HIE. Clinical and biomarker data from 100 children with TBI or HIE were evaluated. For each biomarker, we validated 2-, 3- and 4-group models for outcome prediction, using sensitivity and specificity. For S100B, the 3-group model predicted poor outcome with a sensitivity of 59% and specificity of 100%. For NSE, the 3-group model predicted poor outcome with a sensitivity of 48% and specificity of 98%. For MBP, the 3-group model predicted poor outcome with a sensitivity of 73% and specificity of 61%. Thus, when the models predicted a poor outcome, there was a very high probability of a poor outcome. In contrast, 17% of subjects with a poor outcome were predicted to have a good outcome by all 3 biomarker trajectories. These data suggest that trajectory analysis of biomarker data may provide a useful approach for predicting outcome after pediatric brain injury. Copyright (C) 2010 S. Karger AG, Basel	[Berger, Rachel Pardes] UPMC, Childrens Hosp Pittsburgh, Dept Pediat, Safar Ctr Resuscitat Res, Pittsburgh, PA 15227 USA; [Wagner, Amy K.] Safar Ctr Resuscitat Res, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Fabio, Anthony] Univ Pittsburgh, Dept Neurosurg, Ctr Injury Res & Control, Pittsburgh, PA USA; [Bazaco, Michael C.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA	Berger, RP (corresponding author), UPMC, Childrens Hosp Pittsburgh, Dept Pediat, Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15227 USA.	Rachel.p.berger@gmail.com	Bazaco, Michael/I-9026-2012; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Fabio, Anthony/0000-0002-6808-4939	University of Pittsburgh Center for Injury Control and Research/CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA;  [R01HD055986]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055986] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER	The authors would like to thank Keri Feldman for her technical expertise in generating the biomarker measurements. This study was supported by the University of Pittsburgh Center for Injury Control and Research/CDC (P.M.K., R.P.B., A.F., A.W.) and R01HD055986 (R.P.B.).	Abatemarco DJ, 2008, JT COMM J QUAL PATIE, V34, P106, DOI 10.1016/S1553-7250(08)34013-6; Abend NS, 2008, PEDIATR CRIT CARE ME, V9, P32, DOI 10.1097/01.PCC.0000288714.61037.56; Amin K, 2009, J NEUROTRAUM, V26, pA71; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Broidy LM, 2003, DEV PSYCHOL, V39, P222, DOI 10.1037/0012-1649.39.2.222; Brophy G, 2008, J NEUROTRAUM, V25, P902; Carter BG, 2005, INTENS CARE MED, V31, P840, DOI 10.1007/s00134-005-2634-0; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GREWAL M, 1991, J PEDIATR SURG, V26, P1161, DOI 10.1016/0022-3468(91)90323-L; Guan Wei, 2003, Chin J Traumatol, V6, P218; Haviland AM, 2005, PSYCHOMETRIKA, V70, P557, DOI 10.1007/s11336-004-1261-y; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Lo T, 2009, J NEUROTRAUM, V26, pA46; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Nagin D., 2005, GROUP BASED MODELING; Niyonkuru C, 2009, J NEUROTRAUM, V26, pA16; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Ozawa H, 2009, J NEUROTRAUM, V26, pA71; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Sandroni C, 1995, Eur J Emerg Med, V2, P33, DOI 10.1097/00063110-199503000-00008; Schindler MB, 1996, NEW ENGL J MED, V335, P1473, DOI 10.1056/NEJM199611143352001; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Topjian AA, 2009, PEDIATR CRIT CARE ME, V10, P479, DOI 10.1097/PCC.0b013e318198bdb5; Unden J, 2004, BRIT J NEUROSURG, V18, P277, DOI 10.1080/02688690410001732742; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412	50	51	58	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					396	405		10.1159/000316803			10	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900007	20847541	Bronze, Green Published			2021-06-18	
J	Riordan, WP; Norris, PR; Jenkins, JM; Morris, JA				Riordan, William P., Jr.; Norris, Patrick R.; Jenkins, Judith M.; Morris, John A., Jr.			Early Loss of Heart Rate Complexity Predicts Mortality Regardless of Mechanism, Anatomic Location, or Severity of Injury in 2178 Trauma Patients	JOURNAL OF SURGICAL RESEARCH			English	Article; Proceedings Paper	70th Annual Meeting of the Society-of-University-Surgeons/4th Annual Academic Surgical Congress	FEB 03-06, 2009	Ft Myers, FL	Soc Univ Surg, Assoc Acad Surg		heart rate variability; physiologic complexity; trauma; injury etiology; monitoring; intensive care unit; critical care	RATE-VARIABILITY; SPECTRAL-ANALYSIS; BRAIN-INJURY; DEATH; CARE; ICU	Background. Reduced heart rate (HR) complexity (e.g., a lack of randomness or unpatterned variability) is an established predictor of trauma patient mortality. However, this finding has not been validated across the diverse spectrum of traumatic injury, and underlying mechanisms of this relationship are poorly understood. Materials and Methods. Two thousand one hundred seventy-eight trauma patients were admitted directly to the intensive care unit (ICU), and had sufficient (> 6 h) continuous integer heart rate data within the first d. Patients were stratified by location of isolated severe injury (head, torso, both, or neither), primary mechanism (blunt or penetrating), and probability of survival, an accepted scoring system based on age, admission vital signs, and injury type and severity. HR multiscale entropy (MSE) was calculated (sum of scales, Costa's algorithm, physionet.org, m = 2, r = 0.15) to estimate complexity. Univariate analysis was performed by comparing MSE between survivors and nonsurvivors in each subgroup. Multivariate analysis incorporated logistic regression to characterize the relationship between MSE and risk of death, controlling for probability of survival. The MSE odds ratios (OR) and area under the receiver operator curve (AUC) were calculated. Results. Reduced MSE was significantly associated with increasing mortality, and was independent of probability of survival in all multivariate analyses (OR 0.87-0.94). This range of odds ratios implies that a patient with an MSE of 15 has roughly a 2- to 6-fold increase in odds of death versus a patient with an MSE of 25. The relationship between MSE and death was moderately stronger in patients with isolated severe head injury versus torso injury, and significantly stronger in patients with penetrating versus blunt mechanism of injury. MSE measured early in the hospital stay remained a robust predictor of mortality in all subgroups, even stratified by narrow ranges of probability of survival. Conclusions. Early reduction of heart rate complexity is an important risk factor across diverse injury etiology. This suggests common underlying physiologic mechanisms linking the loss of biologic complexity to death. (C) 2009 Elsevier Inc. All rights reserved.	[Riordan, William P., Jr.] Vanderbilt Univ, Med Ctr, Dept Surg, VUMC Trauma, Nashville, TN 37212 USA; [Norris, Patrick R.] Vanderbilt Univ, Dept Biomed Engn, Med Ctr, Nashville, TN 37235 USA	Riordan, WP (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg, VUMC Trauma, 1211 21st Ave S,404 Med Arts Bldg, Nashville, TN 37212 USA.	william.riordan@vanderbilt.edu					Baillard C, 2002, CRIT CARE MED, V30, P306, DOI 10.1097/00003246-200202000-00007; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Buchman Timothy G, 2004, Curr Opin Crit Care, V10, P378, DOI 10.1097/01.ccx.0000139369.65817.b6; Buchman Timothy G, 2002, Curr Opin Crit Care, V8, P311, DOI 10.1097/00075198-200208000-00007; Cancio LC, 2008, J TRAUMA, V65, P813, DOI 10.1097/TA.0b013e3181848241; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Conci F, 2001, J NEUROL NEUROSUR PS, V71, P621, DOI 10.1136/jnnp.71.5.621; Costa M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.021906; Gang Yi, 2002, Curr Opin Crit Care, V8, P371, DOI 10.1097/00075198-200210000-00002; Goldberger AL, 2000, CIRCULATION, V101, pE215, DOI 10.1161/01.CIR.101.23.e215; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P228, DOI 10.1097/00003246-199302000-00014; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; LOWENSOHN RI, 1977, LANCET, V1, P626; Norris PR, 2008, SHOCK, V30, P17, DOI 10.1097/SHK.0b013e318164e4d0; Norris PR, 2006, ANN SURG, V243, P804, DOI 10.1097/01.sla.0000219642.92637.fd; Norris PR, 2005, J SURG RES, V129, P122, DOI 10.1016/j.jss.2005.04.024; Papaioannou VE, 2006, J CRIT CARE, V21, P95, DOI 10.1016/j.jcrc.2005.12.007; Proctor KG, 2007, J TRAUMA, V63, P33, DOI 10.1097/01.ta.0000251593.32396.df; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010; Winchell RJ, 1996, J SURG RES, V63, P11, DOI 10.1006/jsre.1996.0214	23	51	53	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2009	156	2					283	289		10.1016/j.jss.2009.03.086			7	Surgery	Surgery	503TW	WOS:000270564300018	19592027				2021-06-18	
J	Franike, H; Sauer, C; Rudolph, C; Krugel, U; Hengstler, JG; Illes, P				Franike, H.; Sauer, C.; Rudolph, C.; Kruegel, U.; Hengstler, J. G.; Illes, P.			P2 Receptor-Mediated Stimulation of the PI3-K/Akt-Pathway In Vivo	GLIA			English	Article						apoptosis; astrocytes; ATP; active caspase 3; MAPK/ERK-pathway; proliferation; trauma	ACTIVATED PROTEIN-KINASE; TRAUMATIC BRAIN-INJURY; SIGNAL-REGULATED KINASE; PURINERGIC RECEPTORS; NEURONAL SURVIVAL; EXTRACELLULAR ATP; CELL-DEATH; NUCLEOTIDE RECEPTORS; AKT PHOSPHORYLATION; ISCHEMIC TOLERANCE	ATP acts as a growth factor as well as a toxic agent by stimulating P2 receptors. The P2 receptor-activated signaling cascades mediating cellular growth and cell survival after injury are only incompletely understood. Therefore, the aim of the present study was to identify the role of the phosphoinositide 3 kinase (PI3-K/Akt) and the mitogen-activated protein kinase/extracellular signal regulated protein kinase (MAPK/ERK) pathways in P2Y receptor-mediated astrogliosis after traumatic injury and after microinfusion of ADP beta S (P2Y(1,12,13) receptor agonist) into the rat nucleus accumbens (NAc). Mechanical damage and even more the concomitant treatment with ADP beta S, enhanced P2Y, receptor-expression in the NAc, which could be reduced by pretreatment with the P2X/Y receptor antagonist PPADS. Quantitative Western blot analysis indicated a significant increase in phosphorylated (p)Akt and pERK1/2 2 h after ADP beta S-microinjection. Pretreatment with PPADS or wortmannin abolished the up-regulation of pAkt by injury alone or ADP beta S-treatment. The ADP beta S-enhanced expression of the early apoptosis marker active caspase 3 was reduced by PPADS and PD98059, but not by wortmannin. Multiple immunofluorescence labeling indicated a time-dependent expression of pAkt and pMAPK on astrocytes and neurons and additionally the colocalization of pAkt, pMAPK, and active caspase 3 with the P2Y, receptor especially at astrocytes. In conclusion, the data show for the first time the involvement of PI3-K/Akt-pathway in processes of injury-induced astroglial proliferation and anti-apoptosis via activation of P2Y1 receptors in vivo, suggesting specific roles of P2 receptors in glial cell pathophysiology in neurodegenerative diseases. (C) 2008 Wiley-Liss, Inc.	[Franike, H.; Sauer, C.; Kruegel, U.; Illes, P.] Univ Leipzig, Rudolf Boehm Inst Pharmacol & Toxicol, D-04107 Leipzig, Germany; [Rudolph, C.; Hengstler, J. G.] Univ Dortmund, Inst Arbeitsphysiol, Leibniz Res Ctr Working Environm & Human Factors, D-4600 Dortmund, Germany	Franike, H (corresponding author), Univ Leipzig, Rudolf Boehm Inst Pharmacol & Toxicol, Hartelstr 16-18, D-04107 Leipzig, Germany.	frah@medizin.uni-leipzig.de	Hengstler, Jan G./O-1415-2013	Hengstler, Jan/0000-0002-1427-5246	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [KI 677/2-4, FR 1253/3-1]; Medical Faculty of the University of Leipzig [Z10, C31]	Deutsche Forschungsgemeinschaft; Grant number: KI 677/2-4, FR 1253/3-1; Grant sponsor: "Interdisciplinary Center for Clinical Research" at the Medical Faculty of the University of Leipzig; Grant number: Projects Z10, C31.	Abbracchio MP, 1999, PROG BRAIN RES, V120, P333; Acarin L, 2007, GLIA, V55, P954, DOI 10.1002/glia.20518; Arthur DB, 2006, J NEUROSCI, V26, P3798, DOI 10.1523/JNEUROSCI.5338-05.2006; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Brambilla R, 2002, J NEUROCHEM, V83, P1285, DOI 10.1046/j.1471-4159.2002.01239.x; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Burgos M, 2007, J NEUROCHEM, V103, P1785, DOI 10.1111/j.1471-4159.2007.04872.x; Carbonell WS, 2003, J NEUROTRAUM, V20, P327, DOI 10.1089/089771503765172282; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chorna NE, 2004, J NEUROCHEM, V91, P119, DOI 10.1111/j.1471-4159.2004.02699.x; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Fischer W, 2007, CURR MED CHEM, V14, P2429, DOI 10.2174/092986707782023695; Franke H, 2007, PURINERG SIGNAL, V3, P435, DOI 10.1007/s11302-007-9082-y; Franke H, 2006, INT J DEV NEUROSCI, V24, P123, DOI 10.1016/j.ijdevneu.2005.11.016; Franke H, 1999, GLIA, V28, P190, DOI 10.1002/(SICI)1098-1136(199912)28:3<190::AID-GLIA3>3.3.CO;2-S; Franke H, 2004, NEUROSCIENCE, V127, P431, DOI 10.1016/j.neuroscience.2004.05.003; Franke H, 2006, PHARMACOL THERAPEUT, V109, P297, DOI 10.1016/j.pharmthera.2005.06.002; Franke H, 2001, BRIT J PHARMACOL, V134, P1180, DOI 10.1038/sj.bjp.0704353; Gendron Fernand-Pierre, 2003, Biomedical Research (Aligarh), V14, P47; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Huwiler A, 2002, BRIT J PHARMACOL, V136, P520, DOI 10.1038/sj.bjp.0704748; Jacques-Silva MC, 2004, BRIT J PHARMACOL, V141, P1106, DOI 10.1038/sj.bjp.0705685; Khreiss T, 2002, J BIOL CHEM, V277, P40775, DOI 10.1074/jbc.M205378200; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Mamedova LK, 2006, BIOCHEM PHARMACOL, V72, P1031, DOI 10.1016/j.bcp.2006.07.017; Mandell JW, 1999, NEUROREPORT, V10, P3567, DOI 10.1097/00001756-199911260-00019; Milenkovic I, 2004, GRAEF ARCH CLIN EXP, V242, P944, DOI 10.1007/s00417-004-0954-3; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Muscella A, 2003, J CELL PHYSIOL, V195, P234, DOI 10.1002/jcp.10242; Namikawa K, 2000, J NEUROSCI, V20, P2875; Namura S, 2000, J CEREBR BLOOD F MET, V20, P1301, DOI 10.1097/00004647-200009000-00004; Neary JT, 2006, J NEUROSCI RES, V84, P515, DOI 10.1002/jnr.20969; Neary JT, 2005, MOL NEUROBIOL, V31, P95, DOI 10.1385/MN:31:1-3:095; Neary JT, 2005, J NEUROTRAUM, V22, P491, DOI 10.1089/neu.2005.22.491; Neary JT, 1999, J NEUROSCI, V19, P4211, DOI 10.1523/jneurosci.19-11-04211.1999; Neary JT, 1996, TRENDS NEUROSCI, V19, P13, DOI 10.1016/0166-2236(96)81861-3; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; Panenka W, 2001, J NEUROSCI, V21, P7135, DOI 10.1523/JNEUROSCI.21-18-07135.2001; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Sellers LK, 2001, J BIOL CHEM, V276, P16379, DOI 10.1074/jbc.M006617200; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; von Kugelgen I, 2006, PHARMACOL THERAPEUT, V110, P415, DOI 10.1016/j.pharmthera.2005.08.014; Weisman GA, 2005, MOL NEUROBIOL, V31, P169, DOI 10.1385/MN:31:1-3:169; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Yang Xinyu, 2002, Chin J Traumatol, V5, P250; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	53	51	55	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	AUG 1	2009	57	10					1031	1045		10.1002/glia.20827			15	Neurosciences	Neurosciences & Neurology	466FS	WOS:000267647100001	19115395				2021-06-18	
J	Zebrack, M; Dandoy, C; Hansen, K; Scaife, E; Mann, NC; Bratton, SL				Zebrack, Michelle; Dandoy, Christopher; Hansen, Kristine; Scaife, Eric; Mann, N. Clay; Bratton, Susan L.			Early Resuscitation of Children With Moderate-to-Severe Traumatic Brain Injury	PEDIATRICS			English	Article						traumatic brain injury; secondary brain injury; outcome; emergency department; emergency resuscitation; treatment; emergency medical services	SEVERE HEAD-INJURY; HYPOTENSION; HYPOXIA; EPIDEMIOLOGY; EXPERIENCE; ADULTS; CARE	OBJECTIVES: Traumatic brain injury is a leading cause of death and disability in children. Guidelines have been established to prevent secondary brain injury caused by hypotension or hypoxia. The purpose of this study was to identify the prevalence, monitoring, and treatment of hypotension and hypoxia during "early" (prehospital and emergency department) care and to evaluate their relationship to vital status and neurologic outcomes at hospital discharge. METHODS: This was a retrospective study of 299 children with moderate-to-severe traumatic brain injury presenting to a level 1 pediatric trauma center. We recorded vital signs and medical provider response to hypotension and/or hypoxia during all portions of early care. RESULTS: Blood pressure (31%) and oxygenation (34%) were not recorded during some portion of "early care." Documented hypotension occurred in 118 children (39%). An attempt to treat documented hypotension was made in 48% (57 of 118 children). After adjusting for severity of illness, children who did not receive an attempt to treat hypotension had an increased odds of death of 3.4 and were 3.7 times more likely to suffer disability compared with treated hypotensive children. Documented hypoxia occurred in 131 children (44%). An attempt to treat hypoxia was made in 92% (121 of 131 children). Untreated hypoxia was not significantly associated with death or disability, except in the setting of hypotension. CONCLUSIONS: Hypotension and hypoxia are common events in pediatric traumatic brain injury. Approximately one third of children are not properly monitored in the early phases of their management. Attempts to treat hypotension and hypoxia significantly improved outcomes. Pediatrics 2009;124:56-64	[Mann, N. Clay] Univ Utah, Sch Med, Intermt Injury Control Res Ctr, Salt Lake City, UT USA; [Zebrack, Michelle; Bratton, Susan L.] Univ Utah, Sch Med, Div Pediat Crit Care, Salt Lake City, UT USA; [Zebrack, Michelle; Bratton, Susan L.] Univ Utah, Sch Med, Dept Pediat Surg, Salt Lake City, UT USA; [Dandoy, Christopher] Miami Childrens Hosp, Div Pediat, Miami, FL USA; [Hansen, Kristine] Primary Childrens Med Ctr, Trauma Program, Salt Lake City, UT 84103 USA	Zebrack, M (corresponding author), 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA.	michelle.zebrack@hsc.utah.edu	Dandoy, Christopher/I-9883-2019	Dandoy, Christopher/0000-0002-4001-9203; Bratton, Susan/0000-0002-4605-8078	Emergency Medical Services for Children Program in the Health Resources and Services Administration (Rockville, MD)United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [U07MC05036]	We acknowledge and extend our gratitude to the trauma service nurse practitioners at Primary Children's Medical Center who worked diligently to help complete this project.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Banerjee S, 1994, Indian Pediatr, V31, P1511; Buck ML, 2007, ANN PHARMACOTHER, V41, P1679, DOI 10.1345/aph.1K168; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; GLAESER PW, 1993, ANN EMERG MED, V22, P1119, DOI 10.1016/S0196-0644(05)80975-8; *I MED COMM FUT EM, 2007, EM CAR CHILDR GROW P, pR22; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Su E, 2000, ACAD EMERG MED, V7, P779, DOI 10.1111/j.1553-2712.2000.tb02270.x; Su E, 1997, Prehosp Emerg Care, V1, P123, DOI 10.1080/10903129708958803; TSAI A, 1987, ANN EMERG MED, V16, P284; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; 2005, CIRCULATION S, V112, P167	23	51	52	0	1	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUL	2009	124	1					56	64		10.1542/peds.2008-1006			9	Pediatrics	Pediatrics	463QY	WOS:000267448100008	19564283				2021-06-18	
J	Yang, M; Guo, QJ; Zhang, XT; Sun, SG; Wang, YH; Zhao, LW; Hu, EX; Li, CY				Yang Meng; Guo Qingjie; Zhang Xiangtong; Sun Shugang; Wang Yaohua; Zhao Liwei; Hu Enxi; Li Changyu			Intensive insulin therapy on infection rate, days in NICU, in-hospital mortality and neurological outcome in severe traumatic brain injury patients: A randomized controlled trial	INTERNATIONAL JOURNAL OF NURSING STUDIES			English	Article						Intensive insulin therapy; Severe brain trauma; Hyperglycemia; Nursing	INTERVENTION SCORING SYSTEM; HEAD-INJURY; HYPERGLYCEMIA; MANAGEMENT; GLUCOSE; STRESS; STROKE	Objectives: Evaluate the impact of an intensive insulin therapy and conventional glucose control protocol during staying in neurological intensive care unit (NICU) on infection rate, days in NICU, in-hospital mortality and long-term neurological outcome in severe traumatic brain injury (TBI) patients. Methods: A total of 240 patients with severe TBI (GCS score 3-8) admitted to NICU were prospectively enrolled and randomly assigned either to conventional insulin therapy or to intensive insulin therapy. Patients in intensive glucose control group (n = 121) received continuous insulin infusion to maintain glucose levels between 4.4 mmol/l (80 mg/dl) and 6.1 mmol/l (110 mg/dl). Patients in the conventional treatment group (n = 119) were not given insulin unless glucose levels were greater than 11.1 mmol/l (200 mg/dl). Both groups were treated with insulin infusion to maintain normoglycemia after leaving NICU. Comparison was made against conventional insulin therapy using a randomized trial design. The primary outcomes is the mortality rate at 6 Months follow-up. The second outcomes including ICU infection rate, duration of ICU stay, in-hospital mortality rate and neurologic outcome at 6 months follow-up. Results: There was no significant difference in gender (66% vs. 67% male), age (46 +/- 11 years vs. 45 +/- 10 years), APACHE II score (30 vs. 29), TISS-28 score (47 vs. 46), and Glasgow Coma Score (GCS, 5.3 vs. 5.3) between the two groups. Overall mortality rates at 6 months follow-up were similar in the 2 groups (61 of 117, 52.1% vs. 62 of 116, 53.4%; P = 0.8). The infection rate during the study was significantly higher in patients who received conventional insulin therapy than that in patients who received intensive insulin therapy (46.2% vs. 31.4%; P < 0.05). The days stay in NICU was shorter in intensive insulin control group than that in conventional therapy group [4.2 days vs. 5.6 days (medians) P < 0.05]. The in-hospital mortality during the Study was similar in conventional and intensive therapy groups (34 of 119, 28.6% vs. 35 of 121, 28.9% in the conventional and intensive insulin therapy groups; P = 0.85). The neurologic outcome according to Glasgow Outcome Score (COS) at 6 months (GOS 5 and 4) was better in the intensive insulin therapy group (34 of 117, 29.1%) than that in the conventional therapy group (26 of 116, 22.4%, P < 0.05). Conclusions: Mortality rates at 6 months follow-up are not affected by intensive glucose control in patients with severe TBI. Intensive insulin therapy decreases infection rate and days in NICU and improves the neurological outcome at 6 months follow-up, while has no obvious influence on in-hospital mortality of severe TBI patients. (C) 2009 Elsevier Ltd. All rights reserved.	[Guo Qingjie] Harbin Med Coll, Affiliated Hosp 1, Dept Neurosurg, Harbin, Peoples R China; [Yang Meng; Zhang Xiangtong; Sun Shugang; Wang Yaohua; Zhao Liwei; Hu Enxi; Li Changyu] Harbin Med Coll, Affiliated Hosp 1, Dept Emergency Neurosurg, Harbin, Peoples R China; [Yang Meng; Zhang Xiangtong; Sun Shugang; Wang Yaohua; Zhao Liwei; Hu Enxi; Li Changyu] Harbin Med Coll, Affiliated Hosp 1, Neurol Intens Care Unit, Harbin, Peoples R China	Guo, QJ (corresponding author), Harbin Med Coll, Affiliated Hosp 1, Dept Neurosurg, Harbin, Peoples R China.	guoqingjie188@yahoo.com.cn			Nature Science Foundation of Heilongjiang ProvinceNatural Science Foundation of Heilongjiang Province [D200847]	This research was supported partly by the Nature Science Foundation of Heilongjiang Province (D200847).	ARISTEDIS R, 2000, NEUROSURGERY, V46, P335; Bhalla A, 2003, EUR J NEUROL, V10, P25, DOI 10.1046/j.1468-1331.2003.00504.x; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bilotta Federico, 2007, J Neurosurg Anesthesiol, V19, P156, DOI 10.1097/ANA.0b013e3180338e69; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Gandhi GY, 2007, ANN INTERN MED, V146, P233, DOI 10.7326/0003-4819-146-4-200702200-00002; HORAN TC, 2004, HOSP EPIDEMIOLOGY IN, P1659; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Miranda DR, 1996, CRIT CARE MED, V24, P64, DOI 10.1097/00003246-199601000-00012; MIZOCK BA, 1995, AM J MED, V98, P75, DOI 10.1016/S0002-9343(99)80083-7; Scalea TM, 2007, ANN SURG, V246, P605, DOI 10.1097/SLA.0b013e318155a789; SHANGRAW RE, 1989, METABOLISM, V38, P983, DOI 10.1016/0026-0495(89)90010-3; Souba WW, 1997, NEW ENGL J MED, V336, P41, DOI 10.1056/NEJM199701023360107; Sperry JL, 2007, J TRAUMA, V63, P487, DOI 10.1097/TA.0b013e31812e51fc; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4	22	51	57	1	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0020-7489	1873-491X		INT J NURS STUD	Int. J. Nurs. Stud.	JUN	2009	46	6					753	758		10.1016/j.ijnurstu.2009.01.004			6	Nursing	Nursing	452GB	WOS:000266527100002	19232615				2021-06-18	
J	Stein, DM; Dutton, RP; Kramer, ME; Scalea, TM				Stein, Deborah M.; Dutton, Richard P.; Kramer, Mary E.; Scalea, Thomas M.			Reversal of Coagulopathy in Critically III Patients With Traumatic Brain Injury: Recombinant Factor VIIa is More Cost-Effective Than Plasma	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Trauma; Traumatic brain injury; Coagulopathy; rFVIIa; Cost-effectiveness	ACTIVATED FACTOR-VII; CENTRAL-NERVOUS-SYSTEM; FRESH-FROZEN PLASMA; ADJUNCTIVE THERAPY; INTRACEREBRAL HEMORRHAGE; BLOOD-TRANSFUSION; BLEEDING CONTROL; BLUNT TRAUMA; HEAD-INJURY; WARFARIN	Background: Traumatic brain injury (TBI) is the leading cause of death and disability after trauma. Coagulopathy is common in this patient population and requires rapid reversal to allow for safe neurosurgical intervention and prevent worsening of the primary injury. Typically reversal of coagulopathy is accomplished with the use of plasma. Recombinant factor VIIa (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark) has become increasingly used "off-label" in patients with neurosurgical emergencies to rapidly reverse coagulopathy. We hypothesized that the use of rFVIIa in this patient population would prove to be cost-effective as well as demonstrate clinical benefit. Methods: The trauma registry at the R Adams Cowley Shock Trauma Center was used to identify all coagulopatic trauma patients admitted between January 2002 and December 2007 with relatively isolated TBI (head Abbreviated Injury Scale score of >= 4). The medical records of patients were reviewed and demographics, injury-specific data, medications administered, laboratory values, blood product utilization, neurosurgical procedures. length of stay (LOS), discharge disposition, and outcome data were abstracted. Patients who received rFVIIa for reversal of coagulopathy were compared against those who did not receive rFVIIa. t Tests were used to compare differences between continuous variables, and chi(2) analysis was used to compare categorical variables. A p value of <0.05 was considered significant for all statistical tests. Results: During a 6-year period, there were 179 patients who met inclusion criteria. One hundred eleven patients (62.0%) were treated with conventional therapy alone whereas 68 (38.0%) received rFVIIa. Baseline characteristics between the two groups were similar except that Injury Severity Score and admission International normalized ratio were higher in the rFVIIa group and the rFVIIa group had a higher percentage of patients with head Abbreviated Injury Scale score of 5 injuries, patients who underwent neurosurgical procedures and patients with preinjury warfarin use. There was no difference in total charges between these groups (mean US $63,403 in the conventionally treated group vs. $66,086). When patients who required admission to the intensive care unit were analyzed (n = 110, 50% received rFVIIa), total mean charges and costs were significantly lower in the group that received rFVIIa (mean US $108,900 vs. $77,907). Hospital LOS, days of mechanical ventilation, and plasma utilization were lower in the rFVIIa group. Mortality and thromboembolic complication rates were not different between the two groups. Conclusion: In this study, we were able to demonstrate a significant economic benefit of the use of rFVIIa for reversal of coagulopathy in severely injured patients with TBI. Not all patients with coagulopathy and an anatomic brain injury benefit, but in patients who are neurologically or physiologically compromised, using rFVIIa decreases total charges and costs of hospitalization. This decrease in overall cost is directly attributable to the significant decrease in LOS and decrease in the need for mechanical ventilation. This study demonstrates that in coagulopathic patients with TBI who require intensive care unit admission, rFVIIa is cost-effective and safe. Prospective studies are needed to confirm these findings and establish clinical effectiveness.	[Stein, Deborah M.; Dutton, Richard P.; Kramer, Mary E.; Scalea, Thomas M.] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA	Stein, DM (corresponding author), Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu		Stein, Deborah/0000-0003-3683-3963			Bartal C, 2007, J TRAUMA, V63, P725, DOI 10.1097/TA.0b013e318031ccca; Bochicchio GV, 2008, WORLD J SURG, V32, P2185, DOI 10.1007/s00268-008-9655-0; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Boulis NM, 1999, NEUROSURGERY, V45, P1113, DOI 10.1097/00006123-199911000-00020; Brody DL, 2005, NEUROCRIT CARE, V2, P263, DOI 10.1385/NCC:2:3:263; Bulger EM, 2008, ARCH SURG-CHICAGO, V143, P139, DOI 10.1001/archsurg.2007.41; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Cortiana M, 1986, J Neurosurg Sci, V30, P133; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Dara SI, 2005, CRIT CARE MED, V33, P2667, DOI [10.1097/01.CCM.0000186745.53059.F0, 10.1097/01.CCM.0000151062.00501.60]; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; Earnshaw SR, 2006, STROKE, V37, P2751, DOI 10.1161/01.STR.0000246611.21999.5d; Etemadrezaie H, 2007, CLIN NEUROL NEUROSUR, V109, P166, DOI 10.1016/j.clineuro.2006.09.001; Freeman WD, 2004, MAYO CLIN PROC, V79, P1495, DOI 10.4065/79.12.1495; Galanaud JP, 2003, PHARMACOECONOMICS, V21, P699, DOI 10.2165/00019053-200321100-00002; Ganguly S, 2006, CLIN LAB HAEMATOL, V28, P309, DOI 10.1111/j.1365-2257.2006.00815.x; Harrison TD, 2005, J TRAUMA, V59, P150, DOI 10.1097/01.TA.0000171470.39742.8E; Hawryluk GWJ, 2006, J NEUROSURG, V105, P859, DOI 10.3171/jns.2006.105.6.859; Hedner U, 2006, SEMIN THROMB HEMOST, V32, P77, DOI 10.1055/s-2006-939557; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Karadimov D, 2003, J NEUROSURG ANESTH, V15, P330, DOI 10.1097/00008506-200310000-00008; Kenet G, 1999, LANCET, V354, P1879, DOI 10.1016/S0140-6736(99)05155-7; Kian H, 2007, CHEST, V131, P1308, DOI 10.1378/chest.06-3048; KISSELA BM, 2002, BMC NEUROLOGY, V8, P17; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; Loudon B, 2005, INTERN MED J, V35, P463, DOI 10.1111/j.1445-5994.2005.00878.x; Lyseng-Williamson KA, 2007, PHARMACOECONOMICS, V25, P1007, DOI 10.2165/00019053-200725120-00004; May AK, 1997, AM SURGEON, V63, P233; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Morris S, 2007, ANAESTHESIA, V62, P43, DOI 10.1111/j.1365-2044.2006.04896.x; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; Park P, 2003, NEUROSURGERY, V53, P34, DOI 10.1227/01.NEU.0000068830.54968.A8; Perkins JG, 2007, J TRAUMA, V62, P1095, DOI 10.1097/TA.0b013e31804798a4; Powner DJ, 2005, NEUROSURGERY, V57, P823, DOI 10.1227/01.NEU.0000179915.74429.b2; Ranucci M, 2008, ARCH SURG-CHICAGO, V143, P296, DOI 10.1001/archsurg.2007.66; Rizoli SB, 2006, CRIT CARE, V10, DOI 10.1186/cc5133; Rizoli SB, 2006, J TRAUMA, V61, P1419, DOI 10.1097/01.ta.0000243045.56579.74; Roitberg B, 2005, NEUROSURGERY, V57, P832, DOI 10.1227/01.NEU.0000180816.80626.C2; Rudisill CN, 2006, AM J HEALTH-SYST PH, V63, P1641, DOI 10.2146/ajhp060093; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Sorensen B, 2003, BLOOD COAGUL FIBRIN, V14, P469, DOI 10.1097/00001721-200307000-00007; Stein DM, 2008, INJURY, V39, P1054, DOI 10.1016/j.injury.2008.03.032; Stein DM, 2008, J TRAUMA, V64, P620, DOI 10.1097/TA.0b013e3181650fc7; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Steiner T, 2006, NEUROSURGERY, V59, P767, DOI 10.1227/01.NEU.0000232837.34992.32; Tawil I, 2008, J TRAUMA, V64, P849, DOI 10.1097/TA.0b013e318160c08a; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Traynor K, 2004, AM J HEALTH-SYST PH, V61, P866, DOI 10.1093/ajhp/61.9.866; Uhrig L, 2007, PEDIATR CRIT CARE ME, V8, P576, DOI 10.1097/01.PCC.0000282734.17597.00; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; White Christopher E, 2006, Curr Surg, V63, P310, DOI 10.1016/j.cursur.2006.04.013; Yusim Y, 2006, J CLIN ANESTH, V18, P545, DOI 10.1016/j.jclinane.2006.02.012; Zaaroor M, 2008, ACTA NEUROCHIR, V150, P663, DOI 10.1007/s00701-008-1593-y; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	61	51	60	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2009	66	1					63	75		10.1097/TA.0b013e318191bc8a			13	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	395SJ	WOS:000262543500008	19131807				2021-06-18	
J	Yu, D; Neeley, WL; Pritchard, CD; Slotkin, JR; Woodard, EJ; Langer, R; Teng, YD				Yu, Dou; Neeley, William L.; Pritchard, Christopher D.; Slotkin, Jonathan R.; Woodard, Eric J.; Langer, Robert; Teng, Yang D.			Blockade of Peroxynitrite-Induced Neural Stem Cell Death in the Acutely Injured Spinal Cord by Drug-Releasing Polymer	STEM CELLS			English	Article						Spinal cord injury; Neural stem cell; Nitric oxide; Peroxynitrite; PLGA scaffold; Neuroinflammation	NITRIC-OXIDE SYNTHASE; 4-BENZOIC ACID PORPHYRIN; ISCHEMIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; FUNCTIONAL RECOVERY; INDUCED APOPTOSIS; OXIDATIVE STRESS; PROGENITOR CELLS; MOTOR-NEURONS; IN-VIVO	Therapeutic impact of neural stem cells (NSCs) for acute spinal cord injury (SCI) has been limited by the rapid loss of donor cells. Neuroinflammation is likely the cause. As there are close temporal-spatial correlations between the inducible nitric oxide (NO) synthase expression and the donor NSC death after neurotrauma, we reasoned that NO-associated radical species might be the in. ammatory effectors which eliminate NSC grafts and kill host neurons. To test this hypothesis, human NSCs (hNSCs: 5 x 10(4) to 2 x 10(6) per milliliter) were treated in vitro with "plain'' medium, 20 mu M glutamate, or donors of NO and peroxynitrite (ONOO-; 100 and 400 mu M of spermine or DETA NONOate, and SIN-1, respectively). hNSC apoptosis primarily resulted from SIN-1 treatment, showing ONOO--triggered protein nitration and the activation of p38 MAPK, cytochrome c release, and caspases. Therefore, cell death following post-SCI (p.i.) NO serge may be mediated through conversion of NO into ONOO-. We subsequently examined such causal relationship in a rat model of dual penetrating SCI using a retrievable design of poly-lactic-co-glycolic acid (PLGA) scaffold seeded with hNSCs that was shielded by drug-releasing polymer. Besides confirming the ONOO--induced cell death signaling, we demonstrated that cotransplantation of PLGA film embedded with ONOO- scavenger, manganese (III) tetrakis (4-benzoic acid) porphyrin, or uric acid (1 mu mol per film), markedly protected hNSCs 24 hours p.i. (total: n = 5 10). Our findings may provide a bioengineering approach for investigating mechanisms underlying the host microenvironment and donor NSC interaction and help formulate strategies for enhancing graft and host cell survival after SCI. STEM CELLS 2009;27:1212-1222	[Yu, Dou; Pritchard, Christopher D.; Slotkin, Jonathan R.; Teng, Yang D.] Harvard Univ, Sch Med, Dept Neurosurg, Brigham & Womens Hosp, Boston, MA 02115 USA; [Yu, Dou; Teng, Yang D.] Vet Affairs Boston Healthcare Syst, Div SCI Res, Boston, MA USA; [Neeley, William L.; Pritchard, Christopher D.; Langer, Robert] New England Baptist Hosp, Dept Chem Engn, Boston, MA USA; [Slotkin, Jonathan R.; Woodard, Eric J.] New England Baptist Hosp, Div Neurol Surg, Boston, MA USA; [Langer, Robert] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Teng, Yang D.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA 02115 USA	Teng, YD (corresponding author), Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA 02115 USA.	yang_teng@hms.harvard.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS053935, DE013023, HL060435]; VA biomedical laboratory research; Massachusetts SCI cure research; National Research Service AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1F32EY018285-01]; New England Baptist Hospital (Teng Lab); NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [F32EY018285] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL060435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE013023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS053935] Funding Source: NIH RePORTER	Support was received from NIH NS053935, the VA biomedical laboratory research grant and Massachusetts SCI cure research grant (Teng Lab); and NIH Ruth L. Kirschstein National Research Service Award 1F32EY018285-01 for W.L.N., NIH DE013023 and HL060435 (Langer Lab). The authors thank InVivo Therapeutics for the support to their labs. We are grateful to Dr. Martin Feelisch and Dr. William D. Eldred of Boston University for advice on the biochemistry and biology of nitric oxide, and Dr. Robert M. Friedlander of Harvard Medical School for help in studying cell death pathways. We greatly appreciate the grant support from New England Baptist Hospital (Teng Lab).	Bao F, 2003, J NEUROSCI RES, V71, P220, DOI 10.1002/jnr.10481; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Bjugstad KB, 2008, EXP NEUROL, V211, P362, DOI 10.1016/j.expneurol.2008.01.025; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Brunori M, 2004, BBA-BIOENERGETICS, V1655, P365, DOI 10.1016/j.bbabio.2003.06.008; Cai ZW, 2003, BRAIN RES, V975, P37, DOI 10.1016/S0006-8993(03)02545-9; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Conti A, 2007, BRAIN RES REV, V54, P205, DOI 10.1016/j.brainresrev.2007.01.013; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Crutcher KA, 2006, J NEUROIMMUNE PHARM, V1, P195, DOI 10.1007/s11481-006-9021-7; DALKARA T, 1994, NEUROPHARMACOLOGY, V33, P1447, DOI 10.1016/0028-3908(94)90048-5; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; Deckel AW, 2001, J NEUROSCI RES, V64, P99, DOI 10.1002/jnr.1057; Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017; Diaz-Ruiz A, 2002, NEUROSCI LETT, V319, P129, DOI 10.1016/S0304-3940(01)02540-X; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; Easton AS, 1998, J PHYSIOL-LONDON, V507, P541, DOI 10.1111/j.1469-7793.1998.541bt.x; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; Fischer I, 2000, PROG BRAIN RES, V128, P253; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Gibbs SM, 2003, MOL NEUROBIOL, V27, P107, DOI 10.1385/MN:27:2:107; Goldman SA, 2006, PHILOS T R SOC B, V361, P1463, DOI 10.1098/rstb.2006.1886; Grayson ACR, 2005, BIOMATERIALS, V26, P2137, DOI 10.1016/j.biomaterials.2004.06.033; Hachmeister JE, 2006, J NEUROTRAUM, V23, P1766, DOI 10.1089/neu.2006.23.1766; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; HARRIMAN A, 1979, J CHEM SOC FARAD T 2, V75, P1532, DOI 10.1039/f29797501532; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hsieh WY, 2003, J NEUROSCI RES, V71, P272, DOI 10.1002/jnr.10476; Hunt JA, 1997, CHEM BIOL, V4, P845, DOI 10.1016/S1074-5521(97)90117-4; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Iarikov DE, 2007, J NEUROTRAUM, V24, P690, DOI 10.1089/neu.2006.0172; Kaji T, 2002, NITRIC OXIDE-BIOL CH, V6, P125, DOI 10.1006/niox.2001.0389; KALCKAR HM, 1947, J BIOL CHEM, V167, P429; Karp JM, 2007, CURR OPIN BIOTECH, V18, P454, DOI 10.1016/j.copbio.2007.09.008; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Keynes RG, 2004, CURR MOL MED, V4, P179, DOI 10.2174/1566524043479176; Kulbatski I, 2005, CURR DRUG TARGETS, V6, P111, DOI 10.2174/1389450053345037; Kwon KJ, 2005, J NEUROSCI RES, V81, P73, DOI 10.1002/jnr.20520; LAZAREWICZ JW, 1988, NEUROPHARMACOLOGY, V27, P765, DOI 10.1016/0028-3908(88)90088-3; Li SX, 2000, J NEUROSCI, V20, P1190, DOI 10.1523/JNEUROSCI.20-03-01190.2000; Liu DX, 2005, J NEUROTRAUM, V22, P1123, DOI 10.1089/neu.2005.22.1123; Liu NK, 2006, ANN NEUROL, V59, P606, DOI 10.1002/ana.20798; Llado J, 2004, MOL CELL NEUROSCI, V27, P322, DOI 10.1016/j.mcn.2004.07.010; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Madhavan L, 2008, STEM CELLS, V26, P254, DOI 10.1634/stemcells.2007-0221; Manabe Y, 2004, ANN NEUROL, V55, P668, DOI 10.1002/ana.20078; Murray M, 2001, NEUROSCIENTIST, V7, P28, DOI 10.1177/107385840100700107; Nakahara S, 2002, J NEUROTRAUM, V19, P1467, DOI 10.1089/089771502320914697; Palmer LA, 2000, MOL PHARMACOL, V58, P1197; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; Peterson DA, 1996, J NEUROSCI, V16, P886; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; Raisman G, 2007, NAT REV NEUROSCI, V8, P312, DOI 10.1038/nrn2099; Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Shamash S, 2002, J NEUROSCI, V22, P3052, DOI 10.1523/JNEUROSCI.22-08-03052.2002; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; Teng YD, 2006, REGEN MED, V1, P763, DOI 10.2217/17460751.1.6.763; Teng YD, 1998, EUR J NEUROSCI, V10, P798, DOI 10.1046/j.1460-9568.1998.00100.x; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Teng YD, 1997, J NEUROSCI, V17, P4359; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Xu M, 2000, EXP NEUROL, V161, P472, DOI 10.1006/exnr.1999.7278; YU D, 2008, SOC NEUR ABSTR; Zhang YM, 2006, J BIOL CHEM, V281, P9460, DOI 10.1074/jbc.M510650200; Zhou LH, 2006, EXP NEUROL, V197, P84, DOI 10.1016/j.expneurol.2005.08.019	72	51	53	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells		2009	27	5					1212	1222		10.1002/stem.26			11	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	447GL	WOS:000266179500024	19418456	Green Accepted, Bronze			2021-06-18	
J	Foley, N; Marshall, S; Pikul, J; Salter, K; Teasell, R				Foley, Norine; Marshall, Shawn; Pikul, Jill; Salter, Katherine; Teasell, Robert			Hypermetabolism following Moderate to Severe Traumatic Acute Brain Injury: A Systematic Review	JOURNAL OF NEUROTRAUMA			English	Article						energy expenditure; head injury; nutrition; review	SEVERE HEAD-INJURY; MEASURED ENERGY-EXPENDITURE; PARENTERAL-NUTRITION; METABOLIC-RESPONSE; NITROGEN-EXCRETION; OXYGEN-CONSUMPTION; REQUIREMENTS; PATIENT; SEDATION; THERAPY	Elevations of metabolic rate following traumatic brain injury (TBI) have been reported previously, with estimates ranging from 32% to 2009% above normal values. Die aim of this systematic review was to describe the pattern of energy expenditure during the first 30 days following TBI. We searched six databases for trials that measured the energy expenditure at least once during the first 30 days post-injury and compared that value to one that would be predicted in the non-injured state. We identified 24 studies, three of which were randomized controlled trials (RCTs). The sample sizes of the included studies ranged from 6 to 80 (mean, 24.7), and the mean Glasgow Coma Scale (GCS) score of subjects was 4.8. Mean energy expenditure, expressed as a percentage of a predicted value, ranged from 75% to 2009%. The lowest values were reported in patients admitted in brain death. Several factors were found to have modulating effects on energy expenditure. The administration of paralyzing agents, sedatives, or barbiturates reduced metabolic rate by approximately 12-32%. Propranolol and morphine were associated with smaller decreases in energy expenditure. Factors that do not appear to augment the hypermetabolic response included the administration of steroids and method of feeding (enteral vs. parenteral). Based on our results, it was unclear if elevated temperature, the presence of extracranial injury, or the severity of injury further exacerbate hypermetabolism. We conclude that energy expenditure following TBI is highly variable, and the use of standard factors to estimate the energy needs of individual patients are inappropriate and should be discouraged.	[Foley, Norine; Salter, Katherine] Parkwood Hosp, Lawson Hlth Res Inst, Aging Rehabil & Geriatr Care Program, London, ON N6C 5J1, Canada; [Marshall, Shawn] Univ Ottawa, Dept Med, Ottawa Hosp Rehabil Ctr, Ottawa, ON, Canada; [Pikul, Jill] London Hlth Sci Ctr, Trauma & Transplant Program, London, ON, Canada; [Teasell, Robert] Parkwood Hosp, Dept Phys Med & Rehabil, London, ON N6C 5J1, Canada	Foley, N (corresponding author), Parkwood Hosp, Lawson Hlth Res Inst, Aging Rehabil & Geriatr Care Program, Room B-3019B,801 Commissioners Rd E, London, ON N6C 5J1, Canada.	norine.foley@sjhc.london.on.ca			Ontario Neurotrauma Foundation	This project was funded in part by a grant from the Ontario Neurotrauma Foundation.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bitzani M, 1999, INTENS CARE MED, V25, P970, DOI 10.1007/s001340050991; Boothby WM, 1936, AM J PHYSIOL, V116, P468; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; *BRAIN TRAUMA FDN, 2000, NUTR J NEUROTRAUMA, V17, P539; Brain Trauma Foundation, 2007, NUTR J NEUROTRAUMA, V24, pS77; Bratton SL., 2007, J NEUROTRAUM, V24, pS91, DOI [10.1089/neu.2007.9981, DOI 10.1089/NEU.2007.9981]; Bruder N, 1998, CRIT CARE MED, V26, P568, DOI 10.1097/00003246-199803000-00033; BRUDER N, 1994, CRIT CARE MED, V22, P1114, DOI 10.1097/00003246-199407000-00011; BRUDER N, 1991, CRIT CARE MED, V19, P43, DOI 10.1097/00003246-199101000-00013; BURSZTEIN S, 1978, CRIT CARE MED, V6, P162, DOI 10.1097/00003246-197805000-00008; CARLSON GL, 1994, AM J PHYSIOL, V266, pE845; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; DEMPSEY DT, 1985, SURG GYNECOL OBSTET, V160, P128; DICKERSON RN, 1990, J AM COLL NUTR, V9, P86; Elia M, 1992, World Rev Nutr Diet, V70, P68; ELWYN DH, 1980, CRIT CARE MED, V8, P9, DOI 10.1097/00003246-198001000-00003; Esper DH, 2006, JPEN-PARENTER ENTER, V30, P71, DOI 10.1177/014860710603000271; FORSBERG E, 1994, CLIN NUTR, V13, P291, DOI 10.1016/0261-5614(94)90052-3; HADFIELD JM, 1992, INJURY, V23, P177, DOI 10.1016/S0020-1383(05)80040-3; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P19, DOI 10.1007/BF00735865; Harris J.A., 1919, BIOMETRIC STUDY BASA; HEYMSFIELD SB, 1987, AM J CLIN NUTR, V45, P526; KOLPEK JH, 1989, JPEN-PARENTER ENTER, V13, P277, DOI 10.1177/0148607189013003277; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; LEWIS WD, 1988, CRIT CARE MED, V16, P117, DOI 10.1097/00003246-198802000-00004; Loan T, 1999, NUTRITION, V15, P809; LONG CL, 1979, JPEN-PARENTER ENTER, V3, P69, DOI 10.1177/014860717900300269; McCall M, 2003, JPEN-PARENTER ENTER, V27, P27, DOI 10.1177/014860710302700127; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; OTT L, 1989, NUTRITION, V5, P75; OTT M, 1994, CRIT CARE MED, V22, P393, DOI 10.1097/00003246-199403000-00007; OWEN OE, 1988, MAYO CLIN PROC, V63, P503, DOI 10.1016/S0025-6196(12)65649-3; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; PEVSNER PH, 1971, JOHNS HOPKINS MED J, V128, P134; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; RAURICH JM, 1994, JPEN-PARENTER ENTER, V18, P521, DOI 10.1177/0148607194018006521; Roberts P R, 1995, New Horiz, V3, P506; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; ROZA AM, 1984, AM J CLIN NUTR, V40, P168; VERNET O, 1986, AM J PHYSIOL, V250, pE47; Villet S, 2005, CLIN NUTR, V24, P502, DOI 10.1016/j.clnu.2005.03.006; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131; Wilson RF, 1998, J HEAD TRAUMA REHAB, V13, P11, DOI 10.1097/00001199-199802000-00005; Yanagawa T, 2002, COCHRANE DB SYST REV; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25; YOUNG B, 1992, J NEUROTRAUM, V9, pS375; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010	54	51	58	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2008	25	12					1415	1431		10.1089/neu.2008.0628			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	400IY	WOS:000262862500003	19118457				2021-06-18	
J	Sanchez-Carrion, R; Fernandez-Espejo, D; Junque, C; Falcon, C; Bargallo, N; Roig, T; Bernabeu, M; Tormos, JM; Vendrell, P				Sanchez-Carrion, Rocio; Fernandez-Espejo, Davinia; Junque, Carme; Falcon, Carles; Bargallo, Nuria; Roig, Teresa; Bernabeu, Montserrat; Tormos, Jose M.; Vendrell, Pere			A longitudinal fMRI study of working memory in severe TBI patients with diffuse axonal injury	NEUROIMAGE			English	Article						Traumatic brain injury; Longitudinal; Functional MRI; Ddiffuse axonal injury; Working memory	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; COGNITIVE REHABILITATION THERAPY; MULTIPLE-SCLEROSIS; FUNCTIONAL MRI; HEAD-INJURY; NEUROPSYCHOLOGICAL REHABILITATION; CORTICAL REORGANIZATION; MOTOR RECOVERY; MS PATIENTS	Traumatic brain injury (TBI) patients have working memory deficits and altered patterns of brain activation during this function. The evolution of the impairment has not been examined to date. This study investigated longitudinal changes in brain activation during a working memory task. Twelve patients with severe and diffuse TBI and ten healthy matched controls were fMRI scanned twice at a 6-month interval during an n-back task (0-, 2- and 3-back). All the TBI patients selected presented signs of diffuse axonal injury on CT but had no evidence of focal lesions on MRI clinical examination. Significant changes in brain activation over time were observed in patients, but not in controls. During the first examination, though both groups engaged bilateral fronto-parietal regions known to be involved in working memory, activation of the right superior frontal gyrus was low in the TBI group. However, the difference between TBI and controls had decreased significantly after 6 months. A factor analysis confirmed the greater increase in activation in the right superior frontal cortex in the TBI group than in healthy controls, leading to normalization of the brain activation pattern. In conclusion, this longitudinal study provides evidence of a progressive normalization of the working memory activation pattern after diffuse axonal injury in severe TBI, coinciding with an improvement in performance on this function. (C) 2008 Elsevier Inc. All rights reserved.	[Junque, Carme; Vendrell, Pere] Univ Barcelona, IDIBAPS, Dept Psychiat & Clin Psychobiol, E-08036 Barcelona, Spain; [Sanchez-Carrion, Rocio; Roig, Teresa] Inst Univ Neurorehabil Guttmann, Dept Neuropsychol, Badalona, Spain; [Junque, Carme; Falcon, Carles; Bargallo, Nuria; Vendrell, Pere] Inst Biomed Res August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Falcon, Carles; Bargallo, Nuria] Hosp Clin Barcelona, CDI, Neuroradiol Sect, Dept Radiol, Barcelona, Spain; [Bernabeu, Montserrat] Inst Univ Neurorehabil Guttmann, Head Injury Unit, Badalona, Spain	Junque, C (corresponding author), Univ Barcelona, IDIBAPS, Dept Psychiat & Clin Psychobiol, Casanova 143, E-08036 Barcelona, Spain.	cjunque@ub.edu	Vendrell, Pere/B-4392-2011; Junque, Carme/B-4400-2011; Bargallo, Nuria/G-6854-2016	Vendrell, Pere/0000-0001-8918-5440; Junque, Carme/0000-0002-6381-3063; Bargallo, Nuria/0000-0001-6284-5402; Fernandez-Espejo, Davinia/0000-0001-5941-7546; Tormos Munoz, Jose Maria/0000-0002-8764-2289	Distincio per a la Promocio de Recerca Universitaria [2005SGR00836]; Generalitat de Catalunya to Neuropsychology research groupGeneralitat de Catalunya	This study was supported by the grants: Award "Distincio per a la Promocio de Recerca Universitaria" Generalitat de Catalunya to C. Junque and 2005SGR00836 Generalitat de Catalunya to Neuropsychology research group.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Audoin B, 2003, HUM BRAIN MAPP, V20, P51, DOI 10.1002/hbm.10128; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; BACHYRITA P, 1981, ARCH PHYS MED REHAB, V62, P413; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Brett M., 2002, 8 INT C FUNCT MAPP H, V16; Buckle GJ, 2005, J NEUROIMAGING, V15, p82S, DOI 10.1177/1051228405284093; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cader S, 2006, BRAIN, V129, P527, DOI 10.1093/brain/awh670; Caramia MD, 1998, NEUROLOGY, V51, P196, DOI 10.1212/WNL.51.1.196; Cardebat D, 2003, STROKE, V34, P2900, DOI 10.1161/01.STR.0000099965.99393.83; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cifelli A, 2002, MULT SCLER, V8, P193, DOI 10.1191/1352458502ms820oa; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; de Boissezon X, 2005, STROKE, V36, P1467, DOI 10.1161/01.STR.0000169947.08972.4f; Evangelou N, 2000, ANN NEUROL, V47, P391, DOI 10.1002/1531-8249(200003)47:3<391::AID-ANA20>3.3.CO;2-A; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Forn C, 2006, NEUROIMAGE, V31, P686, DOI 10.1016/j.neuroimage.2005.12.030; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GIANUTSOS R, 1991, Brain Injury, V5, P353, DOI 10.3109/02699059109008108; Grady C. L., 1999, COGNITIVE NEUROREHAB, P47; HEISS WD, 1993, ARCH NEUROL-CHICAGO, V50, P958, DOI 10.1001/archneur.1993.00540090059011; Heiss WD, 1997, J NEUROL SCI, V145, P213, DOI 10.1016/S0022-510X(96)00252-3; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P965, DOI 10.1076/jcen.25.7.965.16490; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Honey GD, 1999, P NATL ACAD SCI USA, V96, P13432, DOI 10.1073/pnas.96.23.13432; Jang SH, 2003, NEUROREPORT, V14, P1305, DOI 10.1097/01.wnr.0000078700.79393.09; Johansen-Berg H, 2002, BRAIN, V125, P2731, DOI 10.1093/brain/awf282; Jones JA, 2003, NEUROREPORT, V14, P1129, DOI 10.1097/00001756-200306110-00006; Jonides J, 1998, P NATL ACAD SCI USA, V95, P8410, DOI 10.1073/pnas.95.14.8410; Junque C, 1999, REV NEUROLOGIA, V28, P423, DOI 10.33588/rn.2804.98420; Laatsch L, 1999, BRAIN INJURY, V13, P555, DOI 10.1080/026990599121304; Laatsch L, 1997, BRAIN INJURY, V11, P851; Laatsch L, 2006, BRAIN INJURY, V20, P1367, DOI 10.1080/02699050600983743; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mainero C, 2004, NEUROIMAGE, V21, P858, DOI 10.1016/j.neuroimage.2003.10.004; Mainero C, 2006, J NEUROL SCI, V245, P93, DOI 10.1016/j.jns.2005.08.024; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Matthews PM, 2004, RESTOR NEUROL NEUROS, V22, P245; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Meisenzahl EM, 2006, EUR ARCH PSY CLIN N, V256, P522, DOI 10.1007/s00406-006-0687-x; MEZZAPESA DM, 2007, FUNCTIONAL CORTICAL, DOI DOI 10.1002/HBM.20418; Mountz J M, 2007, Eura Medicophys, V43, P221; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Ohyama M, 1996, STROKE, V27, P897, DOI 10.1161/01.STR.27.5.897; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Pantano P, 2005, BRAIN, V128, P2146, DOI 10.1093/brain/awh549; PANTANO P, 1992, INT J NEUROSCI, V66, P153; Penades R, 2000, PSYCHIAT RES-NEUROIM, V98, P127, DOI 10.1016/S0925-4927(99)00050-5; Penades R, 2002, ACTA PSYCHIAT SCAND, V105, P202, DOI 10.1034/j.1600-0447.2002.1o421.x; Penner IK, 2007, J NEUROL, V254, P53, DOI 10.1007/s00415-007-2013-6; Penner IK, 2006, J PHYSIOL-PARIS, V99, P455, DOI 10.1016/j.jphysparis.2006.03.008; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Poldrack Russell A, 2002, Top Magn Reson Imaging, V13, P61, DOI 10.1097/00002142-200202000-00005; Rausch M, 2000, EXP BRAIN RES, V135, P34, DOI 10.1007/s002210000499; Reddy H, 2000, NEUROLOGY, V54, P236, DOI 10.1212/WNL.54.1.236; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Rijntjes M, 2002, PROG NEUROBIOL, V66, P109, DOI 10.1016/S0301-0082(01)00027-2; Rios-Lago M, 2004, REV NEUROLOGIA, V38, P366, DOI 10.33588/rn.3804.2003559; Rocca MA, 2007, J NEUROIMAGING, V17, p36S, DOI 10.1111/j.1552-6569.2007.00135.x; Roux FE, 2000, J NEUROL NEUROSUR PS, V69, P453, DOI 10.1136/jnnp.69.4.453; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Schlosser MJ, 1997, STROKE, V28, P1130, DOI 10.1161/01.STR.28.6.1130; SEITZ RJ, 1995, NEUROREPORT, V6, P742, DOI 10.1097/00001756-199503270-00009; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Talairach J., 1988, COPLANAR STEREOTAXIC; Thimm M, 2006, NEUROPSYCHOLOGIA, V44, P1230, DOI 10.1016/j.neuropsychologia.2005.09.008; WALSH ND, 2007, LONGITUDINAL FUNCTIO, DOI DOI 10.1016/J.BIOPSYCH.2006.12.022; WECHSLER D, 1999, ESCALA INTENTELIGENC; Weiller C, 1998, EXP BRAIN RES, V123, P13, DOI 10.1007/s002210050539; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; Wexler BE, 2000, AM J PSYCHIAT, V157, P1694, DOI 10.1176/appi.ajp.157.10.1694; Wishart HA, 2004, NEUROLOGY, V62, P234, DOI 10.1212/01.WNL.0000103238.91536.5F; Wykes T, 2002, BRIT J PSYCHIAT, V181, P144	98	51	51	1	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	NOV 15	2008	43	3					421	429		10.1016/j.neuroimage.2008.08.003			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	392JY	WOS:000262300200001	18771738	Other Gold			2021-06-18	
J	Parker, TM; Osternig, LR; van Donkelaar, P; Chou, LS				Parker, Tonya M.; Osternig, Louis R.; van Donkelaar, Paul; Chou, Li-Shan			Balance control during gait in athletes and non-athletes following concussion	MEDICAL ENGINEERING & PHYSICS			English	Article; Proceedings Paper	International Symposium on Biomedical Engineering	DEC 14-16, 2006	Natl Taiwan Univ, Taipei, TAIWAN		Natl Taiwan Univ	Concussion; Gait; Sub-concussion; Uninjured controls; Dual-task; Balance control	TRAUMATIC BRAIN-INJURY; STABILITY FOLLOWING CONCUSSION; PROFESSIONAL FOOTBALL; NEUROPSYCHOLOGICAL IMPAIRMENT; COGNITIVE IMPAIRMENT; POSTURAL STABILITY; HUMAN WALKING; HEAD-INJURY; SPORTS; MANAGEMENT	Current literature provides only limited information regarding performance on dynamic motor tasks following concussion. However, recent investigations have suggested that participation in contact sports may have a negative effect on cognitive function without the existence of a medically diagnosed concussion. The purpose of this study was to examine balance control during gait in concussed and uninjured athletes and non-athletes. Twenty-eight Grade 2 concussed individuals (14 athletes and 14 non-athletes) and 28 uninjured matched controls (14 athletes and 14 non-athletes) were assessed for their gait performance within 48 h, 5, 14, and 28 days post-injury under conditions of divided and undivided attention. Athletes, whether concussed or not, walked slower and swayed more and faster than non-athletes. Athletes consistently demonstrated gait imbalance even in the absence of concussion. The findings of this study support the supposition that participation in high-impact sports has a measurable and possibly detrimental effect on balance control in the absence of a medically diagnosed concussion. (C) 2007 Elsevier Ltd. All rights reserved. Published by Elsevier Ltd. All rights reserved.	[Parker, Tonya M.; Osternig, Louis R.; van Donkelaar, Paul; Chou, Li-Shan] 1240 Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA	Chou, LS (corresponding author), 1240 Univ Oregon, Dept Human Physiol, 122 Esslinger Hall, Eugene, OR 97403 USA.	chou@uoregon.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR021735, CCR023203] Funding Source: Medline		Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bauby CE, 2000, J BIOMECH, V33, P1433, DOI 10.1016/S0021-9290(00)00101-9; BELL R, 1977, AM FAM PHYSICIAN, V16, P145; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Donelan JM, 2004, J BIOMECH, V37, P827, DOI 10.1016/j.jbiomech.2003.06.002; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Johnson PD, 2002, CLIN J SPORT MED, V12, P12, DOI 10.1097/00042752-200201000-00006; Kelly JP, 1997, NEUROLOGY, V48, P581; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rutherford A, 2005, J CLIN EXP NEUROPSYC, V27, P299, DOI 10.1080/13803390490515504; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Winter DA, 1990, BIOMECHANICS MOTOR C, P56; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	30	51	51	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1350-4533			MED ENG PHYS	Med. Eng. Phys.	OCT	2008	30	8			SI		959	967		10.1016/j.medengphy.2007.12.006			9	Engineering, Biomedical	Engineering	367IR	WOS:000260546200004	18243036				2021-06-18	
J	Das, A; Belagodu, A; Reiter, RJ; Ray, SK; Banik, NL				Das, Arabinda; Belagodu, Amogh; Reiter, Russel J.; Ray, Swapan K.; Banik, Naren L.			Cytoprotective effects of melatonin on C6 astroglial cells exposed to glutamate excitotoxicity and oxidative stress	JOURNAL OF PINEAL RESEARCH			English	Article						apoptosis; C6 astroglial cells; cytoprotective effects; glutamate; H2O2; melatonin	INDUCED APOPTOSIS; REACTIVE OXYGEN; GLIOMA-CELLS; RAT-BRAIN; MITOCHONDRIAL; INHIBITION; INVOLVEMENT; ACTIVATION; PATHWAYS; CALPAIN	To preserve the central nervous system (CNS) function after a traumatic injury, therapeutic agents must be administered to protect neurons as well as glial cells. Cell death in CNS injuries and diseases are attributed to many factors including glutamate toxicity and oxidative stress. We examined whether melatonin, a potent anti-oxidant and free radical scavenger, would attenuate apoptotic death of rat C6 astroglial cells under glutamate excitotoxicity and oxidative stress. Exposure of C6 cells to 500 mu M-glutamic acid (LGA) and 100 mu M hydrogen peroxide (H2O2) for 24 hr caused significant increases in apoptosis. Apoptosis was evaluated by Wright staining and ApopTag assay. Melatonin receptor 1 appeared to be involved in the protection of these cells from excitotoxic and oxidative damage. Cells undergoing excitotoxic and oxidative stress for 15 min were then treated with 150 nM melatonin, which prevented Ca2+ influx and cell death. Western blot analyses showed alterations in Bax and Bcl-2 expression resulting in increased Bax:Bcl-2 ratio during apoptosis. Western blot analyses also showed increases in calpain and caspase-3 activities, which cleaved 270 kD alpha-spectrin at specific sites to generate 145 kD spectrin breakdown product (SBDP) and 120 kD SBDP, respectively. However, 15-min post-treatment of C6 cells with melatonin dramatically reduced Bax:Bcl-2 ratio and proteolytic activities, decreasing LGA or H2O2-induced apoptosis. Our data showed that melatonin prevented proteolysis and apoptosis in C6 astroglial cells. The results suggest that melatonin may be an effective cytoprotective agent against glutamate excitotoxicity and oxidative stress in CNS injuries and diseases.	[Das, Arabinda; Belagodu, Amogh; Banik, Naren L.] Med Univ S Carolina, Dept Neurosci, Div Neurol, Charleston, SC 29425 USA; [Reiter, Russel J.] Univ Texas San Antonio, Dept Cellular & Struct Biol, San Antonio, TX USA; [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC USA	Banik, NL (corresponding author), Med Univ S Carolina, Dept Neurosci, Div Neurol, 96 Jonathan Lucas St,Suite 309 CSB, Charleston, SC 29425 USA.	baniknl@musc.edu			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA-91460, R01 CA091460, R01 CA091460-03, R01 CA091460-04] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS031622-10, R01 NS-31622, R01 NS045967-04, R01 NS057811-02, R01 NS041088-07, R01 NS045967, R01 NS041088-08, R01 NS031622, R01 NS-45967, R01 NS-41088, R01 NS031622-11, R01 NS031622-12, R01 NS045967-03, R01 NS-57811, R01 NS041088, R01 NS057811] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA091460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041088, R01NS045967, R01NS031622, R01NS057811] Funding Source: NIH RePORTER		Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje; Armstrong KJ, 2002, NEUROREPORT, V13, P473, DOI 10.1097/00001756-200203250-00023; Borlongan CV, 2000, FASEB J, V14, P1307, DOI 10.1096/fj.14.10.1307; Cabrera J, 2000, NEUROPHARMACOLOGY, V39, P507, DOI 10.1016/S0028-3908(99)00128-8; Castro LMR, 2005, J NEUROCHEM, V95, P1227, DOI 10.1111/j.1471-4159.2005.03457.x; Das A, 2005, J NEUROSCI RES, V81, P551, DOI 10.1002/jnr.20581; Das A, 2007, NEUROCHEM RES, V32, P2167, DOI 10.1007/s11064-007-9413-y; Das A, 2007, CANCER-AM CANCER SOC, V110, P1083, DOI 10.1002/cncr.22888; Fowler G, 2003, FREE RADICAL BIO MED, V34, P77, DOI 10.1016/S0891-5849(02)01186-3; Hardeland R, 2007, J PINEAL RES, V43, P382, DOI 10.1111/j.1600-079X.2007.00489.x; Jou MJ, 2007, J PINEAL RES, V43, P389, DOI 10.1111/j.1600-079X.2007.00490.x; Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Li XJ, 2002, J PINEAL RES, V32, P47, DOI 10.1034/j.1600-079x.2002.10831.x; Lin AMY, 2007, J PINEAL RES, V43, P163, DOI 10.1111/j.1600-079X.2007.00456.x; Livrea MA, 1997, FREE RADICAL BIO MED, V23, P706, DOI 10.1016/S0891-5849(97)00018-X; Macias M, 2003, EUR J BIOCHEM, V270, P832, DOI 10.1046/j.1432-1033.2003.03430.x; Martin V, 2006, CANCER RES, V66, P1081, DOI 10.1158/0008-5472.CAN-05-2354; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Polster BM, 2001, J BIOL CHEM, V276, P37887; Radogna F, 2007, J PINEAL RES, V43, P154, DOI 10.1111/j.1600-079X.2007.00455.x; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237; SAMANTARAY S, 2007, J PINEAL RE IN PRESS; Sribnick EA, 2006, NEUROSCIENCE, V137, P197, DOI 10.1016/j.neuroscience.2005.08.074; Sur P, 2003, BRAIN RES, V971, P178, DOI 10.1016/S0006-8993(03)02349-7; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4	31	51	51	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	SEP	2008	45	2					117	124		10.1111/j.1600-079X.2008.00582.x			8	Endocrinology & Metabolism; Neurosciences; Physiology	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	336QT	WOS:000258380400001	18373557	Green Accepted			2021-06-18	
J	Muscara, F; Catroppa, C; Anderson, V				Muscara, Frank; Catroppa, Cathy; Anderson, Vicki			The impact of injury severity on executive function 7-10 years following pediatric traumatic brain injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							FRONTAL LOBES; HEAD-INJURY; SHORT-TERM; CHILDHOOD; CHILDREN; OUTCOMES; ADOLESCENCE; ATTENTION; BEHAVIOR; DEFICITS	The impact of pediatric traumatic brain injury (TBI) on executive function (EF) development is well documented, with more severe injury associated with poorer Outcome. Few studies have investigated the impact of pediatric TBI oil EF in the long-term post-injury. The current Study explored the relationship between injury severity and EF in participants with childhood TBI, following the transition into adulthood. The sample included 36 participants who had sustained TBI between 8-12 years of age. At 7-10 years post-injury, they now ranged between 16-22 years of age. Findings indicated that adolescents and young adults who suffered a more severe TBI during childhood tended to display a higher degree of executive dysfunction. but Only in specific EF domains.	[Muscara, Frank; Catroppa, Cathy; Anderson, Vicki] Australian Ctr Child Neuropsychol Studies, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Muscara, Frank; Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Melbourne, Vic 3010, Australia; [Catroppa, Cathy; Anderson, Vicki] Royal Childrens Hosp, Melbourne, Vic, Australia	Muscara, F (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	frank.muscara@meri.edu.au			Royal Children's Research Institute; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	This research was supported by grants front the Royal Children's Research Institute, and the National Health and Medical Research Council. We also thank the participants and their families who generously contributed their time to this research.	Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; ANDERSON P, 2000, CLIN NEUROPSYCHOL, V4, P14; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson V.A, 2001, DEV NEUROPSYCHOLOGY; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; CASE R, 1992, BRAIN COGNITION, V20, P51, DOI 10.1016/0278-2626(92)90061-P; Cohen JA., 2001, TRAUMA VIOLENCE ABUS, V2, P155; Daniel A. E., 1983, POWER PRIVILEGE PRES; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DENNIS M, 1989, CLIN NEUROPSYCHOLOGY, P203; ESLINGER PJ, 1993, NEUROPSYCHOLOGIA, V31, P17, DOI 10.1016/0028-3932(93)90077-D; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEZAK MD, 1993, NEUROPSYCHOLOGICAL A; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Luciana M, 2005, CHILD DEV, V76, P697, DOI 10.1111/j.1467-8624.2005.00872.x; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; Rey A, 1964, EXAMEN CLIN PSYCHOL; Sparrow S., 1984, VINELAND ADAPTIVE BE; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Tabachnick B., 2001, USING MULTIVARIATE S; Taylor HG, 2000, CHILD DEV, V71, P1495, DOI 10.1111/1467-8624.00242; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TAYLOR HG, 1992, ADV CHILD NEUROPSYCH, V1, P50; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V6, P555; TEASDALE G, 1974, LANCET, V2, P81; WECHSLER D, 1991, MANUAL WECHSLER SCAL, V3; Wechsler D, 1997, WAIS 3 ADM SCORING M; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	44	51	52	0	15	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	SEP-OCT	2008	33	5					623	636		10.1080/87565640802171162			14	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	354YW	WOS:000259676800004	18788014				2021-06-18	
J	Leon-Carrion, J; Martin-Rodriguez, JF; Damas-Lopez, J; Martin, JMBY; Dominguez-Morales, MR				Leon-Carrion, J.; Martin-Rodriguez, J. F.; Damas-Lopez, J.; Barroso y Martin, J. M.; Dominguez-Morales, M. R.			Brain function in the minimally conscious state: A quantitative neurophysiological study	CLINICAL NEUROPHYSIOLOGY			English	Article						vegetative state; severe neurocognitive disorder; consciousness; minimally conscious state; LORETA	INDEPENDENT COMPONENT ANALYSIS; REGIONAL CEREBRAL METABOLISM; PERSISTENT VEGETATIVE STATE; HEAD-INJURY; EEG; DISORDERS; COMA; INFORMATION; DEFINITION; RECOVERY	Objective: To explore possible EEG power spectrum and coherence differences between patients in minimally conscious state (MCS) and patients with severe neurocognitive disorders (SND), who show signs of awareness. We also try to find EEG cortical sources that differentiate between both conditions using LORETA source analysis. Methods: We studied 16 patients with traumatic brain injury (7 MCS, 9 SND; aged 18-49) and compared EEG power spectra, coherence, and LORETA sources at rest for both groups. Results: EEG power spectra revealed significant differences in the delta range of both conditions. Patients in MCS showed a notably increased power in this band, compared to SND patients. LORETA analysis showed that posterior sources of delta and theta frequencies had higher amplitude in MCS patients than in SND patients. Regarding fast frequencies, lower source magnitudes in temporal and frontal lobes were found for MCS patients. Conclusions: Our results stress the importance of fronto-temporal-parietal associative cortices within the "awareness-regions" model. Our results also suggest a relation between excess of slow wave activity and diminished level of awareness in brain injury population. Significance: Neurophysiological correlates in brain damaged patients who are severely impaired could be used to assess the integrity of brain areas responsible for awareness. (C) 2008 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Leon-Carrion, J.; Martin-Rodriguez, J. F.; Barroso y Martin, J. M.] Univ Seville, Sch Psychol, Dept Expt Psychol, Human Neuropsychol Lab, Seville 41018, Spain; [Leon-Carrion, J.; Martin-Rodriguez, J. F.; Damas-Lopez, J.; Dominguez-Morales, M. R.] Ctr Brain Injury Rehabil CRECER, Seville, Spain	Leon-Carrion, J (corresponding author), Univ Seville, Sch Psychol, Dept Expt Psychol, Human Neuropsychol Lab, C Camilo Jose Cela S-N, Seville 41018, Spain.	leoncarrion@us.es	Barroso y Martin, Juan Manuel/AAB-9758-2020	Martin Rodriguez, Juan Francisco/0000-0003-1392-8775			Babiloni C, 2004, NEUROIMAGE, V22, P57, DOI 10.1016/j.neuroimage.2003.09.028; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Borthwick CJ, 2004, NEUROREHABILITATION, V19, P381; Broicolo A, 1973, J NEUROSURG SCI, V17, P278; Davey MP, 2000, CLIN NEUROPHYSIOL, V111, P1949, DOI 10.1016/S1388-2457(00)00435-1; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Greicius MD, 2004, J COGNITIVE NEUROSCI, V16, P1484, DOI 10.1162/0898929042568532; Groenewegen HJ, 2000, PROG BRAIN RES, V126, P3; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hagen C., 1972, LEVELS COGNITIVE FUN; HALL K, 1997, J REHABIL OUTCOMES M, V1, P63; Iriarte J, 2003, J CLIN NEUROPHYSIOL, V20, P249, DOI 10.1097/00004691-200307000-00004; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; John ER, 2006, CLIN EEG NEUROSCI, V37, P135, DOI 10.1177/155005940603700210; KAISER DA, 2001, J NEUROTHER, V15, P1; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kobylarz EJ, 2005, NEUROPSYCHOL REHABIL, V15, P323, DOI 10.1080/09602010443000605; KOBYLARZ EJ, 2003, ASS SCI STUD CONSC A; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S., 2003, European Journal of Neurology, V10, P224; Laureys S, 2006, J CLIN INVEST, V116, P1823, DOI 10.1172/JCI29172; Leon-Carrion J, 2002, NEUROREHABILITATION, V17, P115; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Pascual-Marqui RD, 1994, ISBET NEWSLETTER ISN, V5, P4; Phillips C, 2002, NEUROIMAGE, V17, P287, DOI 10.1006/nimg.2002.1175; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; Schiff ND, 1999, TRENDS COGN SCI, V3, P43, DOI 10.1016/S1364-6613(98)01268-6; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Talairach J., 1988, COPLANAR STEREOTAXIC; Thatcher RW, 1999, INTRO QUANTITATIVE E, P29; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021	39	51	61	0	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JUL	2008	119	7					1506	1514		10.1016/j.clinph.2008.03.030			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	326KK	WOS:000257657300006	18486547				2021-06-18	
J	Smits, M; Hunink, MGM; van Rijssel, DA; Dekker, HM; Vos, PE; Kool, DR; Nederkoorn, PJ; Hofman, PAM; Twijnstra, A; Tanghe, HLJ; Dippel, DWJ				Smits, M.; Hunink, M. G. M.; van Rijssel, D. A.; Dekker, H. M.; Vos, P. E.; Kool, D. R.; Nederkoorn, P. J.; Hofman, P. A. M.; Twijnstra, A.; Tanghe, H. L. J.; Dippel, D. W. J.			Outcome after complicated minor head injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; INTEROBSERVER AGREEMENT; COMPUTED-TOMOGRAPHY; STROKE PATIENTS; HIGH-RISK; SCALE; SYMPTOMS; VALIDATION; DISABILITY; MANAGEMENT	BACKGROUND AND PURPOSE: Functional outcome in patients with minor head injury with neurocranial traumatic findings on CT is largely unknown. We hypothesized that certain CT findings may be predictive of poor functional outcome. MATERIALS AND METHODS: All patients from the CT in Head Injury Patients (CHIP) study with neurocranial traumatic CT findings were included. The CHIP study is a prospective, multicenter study of consecutive patients, >= 16 years of age, presenting within 24 hours of blunt head injury, with a Glasgow Coma Scale (GCS) score of 13-14 or a GCS score of 15 and a risk factor. Primary outcome was functional outcome according to the Glasgow Outcome Scale (GOS). Other outcome measures were the modified Rankin Scale (mRS), the Barthel Index (BI), and number and severity of postconcussive symptoms. The association between CT findings and outcome was assessed by using univariable and multivariable regression analysis. RESULTS: GOS was assessed in 237/312 patients (76%) at an average of 15 months after injury. There was full recovery in 150 patients (63%), moderate disability in 70 (30%), severe disability in 7 (3.0%), and death in 10 (4.2%). Outcome according to the mRS and BI was also favorable in most patients, but 82% of patients had postconcussive symptoms. Evidence of parenchymal damage was the only independent predictor of poor functional outcome (odds ratio = 1.89, P =.022). CONCLUSION: Patients with neurocranial complications after minor head injury generally make a good functional recovery, but postconcussive symptoms may persist. Evidence of parenchymal damage on CT was predictive of poor functional outcome.	[Dippel, D. W. J.] Univ Med Ctr Rotterdam, Dept Neurol, Erasmus MC, NL-3000 CA Rotterdam, Netherlands; [Smits, M.; Hunink, M. G. M.; van Rijssel, D. A.; Tanghe, H. L. J.] Univ Med Ctr Rotterdam, Dept Radiol, Erasmus MC, NL-3000 CA Rotterdam, Netherlands; [Hunink, M. G. M.; van Rijssel, D. A.] Univ Med Ctr Rotterdam, Dept Epidemiol & Biostat, Erasmus MC, NL-3000 CA Rotterdam, Netherlands; [Hunink, M. G. M.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Dekker, H. M.] Uni Med Ctr Nijmegen, Dept Radiol, Nijmegen, Netherlands; [Vos, P. E.] Uni Med Ctr Nijmegen, Dept Neurol, Nijmegen, Netherlands; [Kool, D. R.] Univ Amsterdam, Acad Med Ctr, Dept Radiol, NL-1105 AZ Amsterdam, Netherlands; [Nederkoorn, P. J.] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; [Hofman, P. A. M.] Univ Hosp Maastricht, Dept Radiol, Maastricht, Netherlands; [Twijnstra, A.] Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands	Dippel, DWJ (corresponding author), Univ Med Ctr Rotterdam, Dept Neurol, Erasmus MC, POB 2040, NL-3000 CA Rotterdam, Netherlands.	d.dippel@erasmusmc.nl	Dekker, H.M./L-4262-2015; Smits, Marion/AAB-3985-2019; Dippel, Diederik/AAJ-2192-2020; Vos, Pieter/A-6043-2012; Smits, Marion/E-4795-2011	Smits, Marion/0000-0001-5563-2871; Dippel, Diederik/0000-0002-9234-3515; 			af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALTMAN DG, 1999, PRACTICAL STAT MED R, P349; Atzema C, 2004, ANN EMERG MED, V44, P47, DOI 10.1016/j.annemergmed.2004.02.032; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; de Andrade AF, 2006, SURG NEUROL, V65, pS10, DOI 10.1016/j.surneu.2005.11.034; EVANS RW, 1992, NEUROL CLIN, V10, P815; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; JENNETT B, 1975, LANCET, V1, P480; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LIU HM, 1995, J TRAUMA, V38, P330, DOI 10.1097/00005373-199503000-00003; MAHONEY F I, 1965, Md State Med J, V14, P61; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MCDANIEL T, 2000, NEUROANAGING CLIN PH, P700; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; NORLUND A, 2006, BMJ-BRIT MED J, V333, P455; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUCLEHILL A, 2002, J NEUROTRAUNIA, V19, P855; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TWIJNSTRA A, GUIDELINES DIAGNOSIS; Udstuen GJ, 2001, SEMIN ULTRASOUND CT, V22, P135, DOI 10.1016/S0887-2171(01)90041-1; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; VANDENBROUCKE JP, 1991, BRIT MED J, V302, P249, DOI 10.1136/bmj.302.6771.249; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276	49	51	51	0	3	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAR	2008	29	3					506	513		10.3174/ajnr.A0852			8	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	275JC	WOS:000254066700019	18065509	Green Published, Other Gold			2021-06-18	
J	Collins, CL; Micheli, LJ; Yard, EE; Comstock, RD				Collins, Christy L.; Micheli, Lyle J.; Yard, Ellen E.; Comstock, R. Dawn			Injuries sustained by high school rugby players in the United States, 2005-2006	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							PERFORMANCE PROJECT; FOOTBALL INJURIES; RISK-FACTORS; ICE HOCKEY; EPIDEMIOLOGY; SPORTS; SOCCER; COHORT; SEASON; UNION	Objectives: To describe the incidence and characteristics of injuries among US high school rugby players and to identify possible injury risk factors. Design: Descriptive epidemiological study. Setting: The 2005 and 2006 US high school rugby seasons. Participants: A convenience sample of 121 boys' and girls' US high school rugby clubs. Main Exposures: Exposure to playing rugby. Main Outcome Measures: Incidence, characteristics, and risk factors of rugby injuries. Results: Enrolled clubs reported 594 injuries during 113 641 total high school rugby athletic exposures (81 627 practice exposures and 32 014 match exposures). Rugby injury rates were 5.2 injuries per 1000 total athletic exposures, 1.3 injuries per 1000 practice exposures, and 15.2 injuries per 1000 match exposures. The mean age of the injured athletes was 16.5 years (SD, 1.2 years; range, 13-19 years) and 87.0% were male. The most commonly injured body sites were the head (21.7%), ankle (13.3%), and shoulder (12.8%). Fractures (16.0%), concussions (15.8%), and ligament sprains ( incomplete tears) (15.7%) were the most common diagnoses. Practice and competition injuries were similar with respect to the proportion of concussions and head, shoulder, ankle, and knee injuries. More than half of all injuries resulted from being tackled (30.8%) and tackling (28.8%). Conclusions: As the popularity of youth rugby continues to grow in the United States, increasing numbers of physicians and certified athletic trainers will find themselves treating rugby-related injuries and answering questions from parents about the comparative safety of rugby. To our knowledge, this is the first large-scale study to describe injury rates and identify possible injury risk among US high school rugby players.	[Collins, Christy L.; Yard, Ellen E.; Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA; [Micheli, Lyle J.] Harvard Univ, Childrens Hosp, Sch Med, Div Sports Med, Boston, MA 02115 USA	Collins, CL (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	christy.collins@nationwidechildrens.org					Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; Fernandez WG, 2007, ACAD EMERG MED, V14, P641, DOI [10.1197/j.aem.2007.03.1354, 10.1111/j.1553-2712.2007.tb01851.x]; GARRAWAY M, 1995, LANCET, V345, P1485; GERRARD DF, 1994, BRIT J SPORT MED, V28, P229, DOI 10.1136/bjsm.28.4.229; *INT RUGB BOARD, 2007, LAWS GAM RUGB UN 200; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Kucera KL, 2005, BRIT J SPORT MED, V39, P462, DOI 10.1136/bjsm.2004.013672; Leininger RE, 2007, AM J SPORT MED, V35, P288, DOI 10.1177/0363546506294060; MAFFULI N, 2005, EPIDEMIOLOGY PEDIAT, P49; McIntosh Andrew S, 2005, Med Sport Sci, V49, P120, DOI 10.1159/000085394; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McManus A, 2004, J SCI MED SPORT, V7, P438, DOI 10.1016/S1440-2440(04)80261-5; Michael M, 2002, Clin Colorectal Cancer, V2, P93, DOI 10.3816/CCC.2002.n.015; MUELLER FO, FINAL REPORT N CARLO; *NAT COLL ATHL ASS, PAST ISS APPL; *NAT CTR CAT SPORT, 23 ANN REP FALL 1982; NATHAN M, 1983, S AFR MED J, V64, P132; Nelson AJ, 2007, J ATHL TRAINING, V42, P381; Pasque CB, 2000, AM J SPORT MED, V28, P509, DOI 10.1177/03635465000280041101; Powell JW, 1999, J ATHL TRAINING, V34, P277; Quarrie KL, 1996, BRIT J SPORT MED, V30, P53, DOI 10.1136/bjsm.30.1.53; Quarrie KL, 1995, BRIT J SPORT MED, V29, P263, DOI 10.1136/bjsm.29.4.263; Quarrie KL, 2001, BRIT J SPORT MED, V35, P157, DOI 10.1136/bjsm.35.3.157; ROUX CE, 1987, S AFR MED J, V71, P307; *RUGBYSMART, NZ RUGBYSMART PROGR; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Smith AM, 1997, AM J SPORT MED, V25, P500, DOI 10.1177/036354659702500413; Sparks J P, 1985, Br J Sports Med, V19, P71; Sparks J P, 1981, Br J Sports Med, V15, P30; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Turbeville SD, 2003, AM J SPORT MED, V31, P974, DOI 10.1177/03635465030310063801; *US RUGB REF ASS, US RUGB GUID APPL LA; WALLER AE, 1994, BRIT J SPORT MED, V28, P223, DOI 10.1136/bjsm.28.4.223; Weir MA, 1996, IRISH J MED SCI, V165, P165, DOI 10.1007/BF02940243; Yard EE, 2006, PEDIATRICS, V118, pE1342, DOI 10.1542/peds.2006-0834; 2004, RUGBY MAGAZINE	40	51	52	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	JAN	2008	162	1					49	54		10.1001/archpediatrics.2007.1			6	Pediatrics	Pediatrics	248SQ	WOS:000252176100008	18180412	Bronze			2021-06-18	
J	King, NS				King, Nigel S.			PTSD and traumatic brain injury: Folklore and fact?	BRAIN INJURY			English	Article						post-traumatic stress disorder; traumatic brain injury; dual diagnosis	POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; SYMPTOMS; IMPAIRMENT; AMNESIA	A number of contraversies and debates have arisen over the years surrounding the dual diagnosis of post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). Many of these have centred around the around the degree of protection provided by TBI against developing the disorder. The following is brief review of the literature in this area to help resolve some of these issues and to address a number of specific challenges which arise when working with this patient group.	[King, Nigel S.] Camborne Ctr, Community Head Injury Serv, Aylesbury HP21 7ET, Bucks, England; [King, Nigel S.] Univ Oxford, Warneford Hosp, Oxford Doctoral Course Clin Psychol, Oxford, England	King, NS (corresponding author), Camborne Ctr, Community Head Injury Serv, Jansel Sq, Aylesbury HP21 7ET, Bucks, England.	nigel.king@hmc.ox.ac.uk					Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bisson J, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003388.pub2; Blake D. D., 1990, BEHAV THER, V13, P187; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 2001, CURR OPIN PSYCHIATR, V14, P119, DOI 10.1097/00001504-200103000-00004; CLARK DM, 1999, COGNITIVE BEHAV TREA; Eisendrath SJ, 1995, NEUROLOGY, V45, pS26, DOI 10.1212/WNL.45.12_Suppl_9.S26; GIL G, 2005, AM J PSYCHIAT, V162, P936; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 2001, J TRAUMA STRESS, V14, P277, DOI 10.1023/A:1011108816888; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; Jobe PC, 2005, EPILEPSY BEHAV, V7, P602, DOI 10.1016/j.yebeh.2005.07.014; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 2002, BRAIN INJURY, V16, P65, DOI 10.1080/02699050110088263; KING NS, 2008, IN PRESS PSYCHOL APP; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; Macleod AD, 1999, AUST NZ J PSYCHIAT, V33, P102, DOI 10.1046/j.1440-1614.1999.00514.x; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 2003, NEUROPSYCHOL REHABIL, V13, P149, DOI 10.1080/09602010244000453; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; *NAT I CLIN EX, 2005, CLIN GUID POST STRES; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; REITHER AM, 1988, SOUTH MED J, V81, P568; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; TAYLOR ST, 2001, J CONSULT CLIN PSYCH, V67, P13; Williams W H, 2003, Cogn Neuropsychiatry, V8, P1, DOI 10.1080/713752238; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861	38	51	51	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	1					1	5		10.1080/02699050701829696			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	250QF	WOS:000252314400001	18183503				2021-06-18	
J	Reid-Arndt, SA; Nehl, C; Hinkebein, J				Reid-Arndt, Stephanie A.; Nehl, Carissa; Hinkebein, Joseph			The Frontal Systems Behaviour Scale (FrSBe) as a predictor of community integration following a traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; community integration; neuropsychological; executive functioning; functional status	BLUNT HEAD-INJURY; DRUG-USE; EXECUTIVE DYSFUNCTION; COGNITIVE IMPAIRMENT; FOCAL LESIONS; REHABILITATION; QUESTIONNAIRE; DEMENTIA; OUTCOMES; IMPACT	Primary objective: This study examined the relationships between the Frontal Systems Behaviour Scale (FrSBe), neuropsychological tests and community integration outcomes among individuals with a history of TBI. Methods: Seventy-six individuals with a history of TBI were consecutively recruited from patients seen in a Neuropsychology clinic in an academic healthcare setting. Participants completed neuropsychological tests, the FrSBe and the Community Integration Questionnaire (CIQ) as part of a standard clinical neuropsychological evaluation. Results: The FrSBe was a significant predictor of community integration (CIQ) outcomes. Specifically, poorer executive functioning (FrSBe Executive Functioning) predicted lower CIQ Total Scores, while increased apathy (FrSBe Apathy) was associated with reduced CIQ Productivity. Regarding neuropsychological tests, only Delayed Memory remained as a predictor: higher scores were associated with enhanced CIQ Total Scores and CIQ Social Integration. Finally, female gender was associated with superior CIQ Total Scores, CIQ Home Integration and CIQ Productivity. Conclusions: While neuropsychological tests of executive functioning failed to add predictive power to models of community integration following TBI with this sample, the FrSBe, a measure of behavioural manifestations of frontal lobe dysfunction, did predict these important functional outcomes. This suggests that use of the FrSBe may enhance the ecological validity of information gathered during a clinical neuropsychological assessment.	[Reid-Arndt, Stephanie A.; Nehl, Carissa; Hinkebein, Joseph] Univ Missouri, Dept Hlth Psychol, Columbia, MO 65212 USA	Reid-Arndt, SA (corresponding author), Univ Missouri, Dept Hlth Psychol, 1 Hosp Dr,DC 116-88, Columbia, MO 65212 USA.	reidarndts@health.missouri.edu					Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Cahn-Weiner DA, 2002, NEUROPSY NEUROPSY BE, V15, P79, DOI 10.1097/01.WNN.0000012908.05122.F4; Chiaravalloti ND, 2003, COGN BEHAV NEUROL, V16, P54, DOI 10.1097/00146965-200303000-00007; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Davis JD, 2007, J NEUROPSYCH CLIN N, V19, P43, DOI 10.1176/appi.neuropsych.19.1.43; Doninger NA, 2003, REHABIL PSYCHOL, V48, P67, DOI 10.1037/0090-5550.48.2.67; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; EDWARD K, 2002, NEUROREHABILITATION, V17, P297; Gioia G.A., 2000, BEHAV RATING INVENTO; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Goverover Y, 2005, MULT SCLER J, V11, P203, DOI 10.1191/1352458505ms1153oa; GRAHAM DI, 1999, REHABILITATION ADULT, P19; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hamilton JM, 2003, J NEUROL NEUROSUR PS, V74, P120, DOI 10.1136/jnnp.74.1.120; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Linden MA, 2005, DISABIL REHABIL, V27, P1353, DOI 10.1080/09638280500164180; Malloy P, 2005, COGN BEHAV NEUROL, V18, P18, DOI 10.1097/01.wnn.0000152232.47901.88; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Millis S R, 1994, Int J Neurosci, V79, P165; NABORS NA, 2000, ANN M INT NEUR SOC; Nyenhuis DL, 2004, CLIN NEUROPSYCHOL, V18, P41, DOI 10.1080/13854040490507145; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Ready RE, 2003, AM J GERIAT PSYCHIAT, V11, P222, DOI 10.1176/appi.ajgp.11.2.222; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sbordone R. J., 1996, ECOLOGICAL VALIDITY, P15; Sbordone RJ, 2001, NEUROREHABILITATION, V16, P199; Schopp LH, 2006, J HEAD TRAUMA REHAB, V21, P213, DOI 10.1097/00001199-200605000-00002; Spinella M, 2004, INT J NEUROSCI, V114, P1323, DOI 10.1080/00207450490476011; Spinella M, 2004, INT J NEUROSCI, V114, P83, DOI 10.1080/00207450490249356; Spinella M, 2003, ADDICT BIOL, V8, P67, DOI 10.1080/1355621031000069909; Stout JC, 2003, AM J GERIAT PSYCHIAT, V11, P683; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; Van den Broek M.D., 1999, REV CLIN GERONTOLOGY, V9, P257, DOI 10.1017/S0959259899009363; Velligan DI, 2002, PSYCHIAT RES, V113, P227, DOI 10.1016/S0165-1781(02)00264-0; Verdejo-Garcia A, 2006, J INT NEUROPSYCH SOC, V12, P405, DOI 10.1017/S1355617706060486; Verdejo-Garcia A, 2006, ADDICT BEHAV, V31, P1373, DOI 10.1016/j.addbeh.2005.11.003; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WECHSLER D, 1997, WAIS 3 ADMINISTRATIO; WECHSLER D, 1977, WMS 3 ADMINISTRATION; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Zawacki TM, 2002, J NEUROPSYCH CLIN N, V14, P296, DOI 10.1176/appi.neuropsych.14.3.296; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	53	51	51	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2007	21	13-14					1361	1369		10.1080/02699050701785062			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	253AA	WOS:000252488200004	18066938				2021-06-18	
J	Brown, CN; Guskiewicz, KM; Bleiberg, J				Brown, Cathleen N.; Guskiewicz, Kevin M.; Bleiberg, Joseph			Athlete characteristics and outcome scores for computerized neuropsychological assessment: A preliminary analysis	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; cognitive testing	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN INJURY; CONFIDENCE-INTERVALS; COGNITIVE ASSESSMENT; SPORTS CONCUSSION; TEST-PERFORMANCE; NCAA CONCUSSION; TEST PROTOCOL; MILD; RECOVERY	Context. Computerized neuropsychological testing is used in athletics; however, normative data on an athletic population are lacking. Objective: To investigate factors, such as sex, SAT score, alertness, and sport, and their effects on baseline neuropsychological test scores. A secondary purpose was to begin establishing preliminary reference data for nonsymptomatic collegiate athletes. Design: Observational study. Setting: Research laboratory. Patients or Other Participants: The study population comprised 327 National Collegiate Athletic Association Division I athletes from 12 men's and women's sports. Main Outcome Measure(s): Athletes were baseline tested before their first competitive season. Athletes completed demographics forms and self-reported history of concussion (11 or no concussion and 2 or more concussions) and SAT scores (< 1000, 1000 to 1200, and > 1200). The 108 women had a mean age of 18.39 +/- 0.09 years, height of 167.94 +/- 0.86 cm, and mass of 62.36 +/- 1.07 kg. The 219 men had a mean age of 18.49 +/- 0.07 years, height of 183.24 +/- 1.68 cm, and mass of 88.05 +/- 1.82 kg. Sports participation included women's soccer, lacrosse, basketball, and field hockey; men's football, soccer, lacrosse, and wrestling; and women's and men's track and cheerleading. We used the Automated Neuropsychological Assessment Metrics (Army Medical Research and Materiel Command, Ft Detrick, MID) and measured throughput scores (the number of correct responses per minute) as the dependent variable for each subtest, with higher scores reflecting increased speed and accuracy of responses. Subsets included 2 simple reaction time (SRT) tests, math processing (MTH), Sternberg memory search (ST6), matching to sample pairs (MSP), procedural reaction time (PRO), code digit substitution (CDS), and the Stanford sleep scale Likert-type score. Results: Women scored better than men on the ST6 (P <.05), while men scored significantly better than women on the SRT and MSP tests. The highest-scoring SAT group performed better than other SAT groups on selected subtests (SRT, MTH, ST6, MSP, and CDS) (P <.05), and athletes tested during their season were more likely to score lower on the alertness scale (chi(2)(2)[n = 322] = 11.32, P =.003). The lowest alertness group performed worse on the MSP and CDS subtests (P <.05). No differences were found between the group with a history of 1 or no concussion and the group with a history of 2 or more concussions (P >.05). Conclusions: Performance on computerized neuropsychological tests may be affected by a number of factors, including sex, SAT scores, alertness at the time of testing, and the athlete's sport. To avoid making clinical misinterpretations, clinicians should acknowledge that individual baselines vary over time and should account for this variation.	[Brown, Cathleen N.] Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Chapel Hill, NC USA; [Bleiberg, Joseph] Natl Rehabil Hosp, Washington, DC USA	Brown, CN (corresponding author), Univ Georgia, Dept Kinesiol, 330 River Rd, Athens, GA 30602 USA.	browncn@uga.edu	Brown, Cathleen/A-6626-2013	Brown, Cathleen/0000-0002-3414-7938; Guskiewicz, Kevin/0000-0002-8682-2130			Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Beatty WW, 2003, J CLIN EXP NEUROPSYC, V25, P1065, DOI 10.1076/jcen.25.8.1065.16732; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; BLEIBERG J, 2005, ANAM SPORTS MED BATT, P12; Brown CN, 2003, J ATHL TRAINING, V38, pS24; BROWN CN, 2004, J ATHL TRAINING, V39, pS17; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Heaton RK., 1996, NEUROPSYCHOL ASSESS, V2, P141; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; *INJ SURV SYST, SPORT SPEC INJ DAT 2; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Marshall SW, 2004, J SCI MED SPORT, V7, P135, DOI 10.1016/S1440-2440(04)80002-1; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; Poole C, 2001, EPIDEMIOLOGY, V12, P291, DOI 10.1097/00001648-200105000-00005; Proctor MR, 2000, CLIN SPORT MED, V19, P693, DOI 10.1016/S0278-5919(05)70233-7; Purnell MT, 2002, J SLEEP RES, V11, P219, DOI 10.1046/j.1365-2869.2002.00309.x; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Rollinson DC, 2003, ANN EMERG MED, V41, P400, DOI 10.1067/mem.2003.77; Sefton J. M., 2004, J ATHL TRAINING, V39, pS52; Sosin DM, 1996, BRAIN INJURY, V10, P47; The College Board, 2004, 2004 COLL BOUND SEN; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wilken JA, 2003, MULT SCLER, V9, P119, DOI 10.1191/1352458503ms893oa; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; Wolfe R, 2004, J SCI MED SPORT, V7, P138, DOI 10.1016/S1440-2440(04)80003-3; ZURI RE, 2004, J ATHL TRAINING, V39, pS57	46	51	51	1	25	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2007	42	4					515	523					9	Sport Sciences	Sport Sciences	251AQ	WOS:000252343100012	18174940				2021-06-18	
J	Kuss, O; McLerran, D				Kuss, Oliver; McLerran, Dale			A note on the estimation of the multinomial logistic model with correlated responses in SAS	COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE			English	Article						multinomial logistic model; random effects; marginal models; SAS; GEE	GENERALIZED ESTIMATING EQUATIONS; LINEAR MIXED MODELS; POLYTOMOUS DATA; LOGIT MODEL; REGRESSION	We show how multinomial logistic models with correlated responses can be estimated within SAS software. To achieve this, random effects and marginal models are introduced and the respective SAS code is given. An example data set on physicians' recommendations and preferences in traumatic brain injury rehabilitation is used for illustration. The main motivation for this work are two recent papers that recommend estimating multinomial logistic models with correlated responses by using a Poisson likelihood which is statistically correct but computationally inefficient. (C) 2007 Elsevier Ireland Ltd. All rights reserved.	Univ Halle Wittenberg, Inst Med Epidemiol Biostats & Informat, D-06097 Halle, Germany; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Kuss, O (corresponding author), Univ Halle Wittenberg, Inst Med Epidemiol Biostats & Informat, D-06097 Halle, Germany.	Oliver.Kuss@medizin.uni-halle.de; dmclerra@fhcrc.org		Kuss, Oliver/0000-0003-3301-5869			BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; Brownstone D, 1999, J ECONOMETRICS, V89, P109; Chen Z, 2001, AM STAT, V55, P89, DOI 10.1198/000313001750358545; Daniels MJ, 1997, STAT MED, V16, P2311, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2311::AID-SIM654>3.3.CO;2-5; Davidian M., 1995, NONLINEAR MODELS REP; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Hartzel J, 2001, STAT MODEL, V1, P81, DOI 10.1177/1471082X0100100201; Hasenbein U, 2003, DISABIL REHABIL, V25, P136, DOI 10.1080/0963828021000024889; Hedeker D, 2003, STAT MED, V22, P1433, DOI 10.1002/sim.1522; HEDEKER D, 1998, J STAT SOFTW, V80, P647; Hines RJO, 1997, BIOMETRICS, V53, P1552, DOI 10.2307/2533523; Kuss O, 2003, P 18 INT WORKSH STAT, P245; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LIPSITZ SR, 1994, STAT MED, V13, P1149, DOI 10.1002/sim.4780131106; LURNLEY T, 1996, BIOMETRICS, V52, P354; Malchow-Moller N, 2003, APPL ECON LETT, V10, P389, DOI 10.1080/1350485032000082018; McCullagh P., 1989, GEN LINEAR MODELS; MILLER ME, 1993, BIOMETRICS, V49, P1033, DOI 10.2307/2532245; Revelt D, 1998, REV ECON STAT, V80, P647, DOI 10.1162/003465398557735; RODRIGUEZ G, 1995, J ROY STAT SOC A STA, V158, P73, DOI 10.2307/2983404; Schabenberger O., 2005, P 30 ANN SAS US GROU; Skrondal A, 2003, PSYCHOMETRIKA, V68, P267, DOI 10.1007/BF02294801; Thiebaut R, 2002, COMPUT METH PROG BIO, V69, P249, DOI 10.1016/S0169-2607(02)00017-2; Williamson JM, 1999, COMPUT METH PROG BIO, V58, P25; WOLFINGER R, 1993, J STAT COMPUT SIM, V48, P233, DOI 10.1080/00949659308811554; Wright S. P., 1998, P 23 ANN SAS US GROU	26	51	51	0	17	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0169-2607			COMPUT METH PROG BIO	Comput. Meth. Programs Biomed.	SEP	2007	87	3					262	269		10.1016/j.cmpb.2007.06.002			8	Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Medical Informatics	Computer Science; Engineering; Medical Informatics	209DK	WOS:000249369000010	17686544				2021-06-18	
J	Beckwith, JG; Chu, JJ; Greenwald, RM				Beckwith, Jonathan G.; Chu, Jeffrey J.; Greenwald, Richard M.			Validation of a noninvasive system for measuring head acceleration for use during boxing competition	JOURNAL OF APPLIED BIOMECHANICS			English	Article						mild traumatic brain injury (MTBI); concussion; biomechanics; amateur boxing	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; CONCUSSION; IMPACTS; TIME; ACCELEROMETERS; AMATEUR; BOXER	Although the epidemiology and mechanics of concussion in sports have been investigated for many years, the biomechanical factors that contribute to mild traumatic brain injury remain unclear because of the difficulties in measuring impact events in the field. The purpose of this study was to validate an instrumented boxing headgear (IBH) that can be used to measure impact severity and location during play. The instrumented boxing headgear data were processed to determine linear and rotational acceleration at the head center of gravity, impact location, and impact severity metrics, such as the Head Injury Criterion (HIC) and Gadd Severity Index (GSI). The instrumented boxing headgear was fitted to a Hybrid III (HIII) head form and impacted with a weighted pendulum to characterize accuracy and repeatability. Fifty-six impacts over 3 speeds and 5 locations were used to simulate blows most commonly observed in boxing. A high correlation between the HIII and instrumented boxing headgear was established for peak linear and rotational acceleration (r(2) = 0.91), HIC (r(2) = 0.88), and GSI (r(2)= 0.89). Mean location error was 9.7 5.2 degrees. Based on this study, the IBH is a valid system for measuring head acceleration and impact location that can be integrated into training and competition.	Simbex, Lebanon, NH USA; Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA	Beckwith, JG (corresponding author), Simbex, Lebanon, NH USA.						CHU JJ, 2006, PUBL C P 5 WORLD C B; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; DUMA S, 2004, AM SOC BIOM POTL OR; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; GADD CW, 1966, SOC AUTOMOTIVE ENG, P164; GERBEDING JL, 2003, STEPS PREVENT SERIOU, P1; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; MASTER EJT, 2000, PHYS SPORTSMEDICINE, V28; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Miele VJ, 2004, MED SCI SPORT EXER, V36, P1852, DOI 10.1249/01.MSS.0000145470.16938.7A; MITAL NK, 1979, J APPL MECH-T ASME, V46, P925, DOI 10.1115/1.3424679; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Ravdin LD, 2003, CLIN J SPORT MED, V13, P21, DOI 10.1097/00042752-200301000-00005; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Zazryn T, 2006, BRIT J SPORT MED, V40, P670, DOI 10.1136/bjsm.2006.025924; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	23	51	51	0	17	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1065-8483			J APPL BIOMECH	J. Appl. Biomech.	AUG	2007	23	3					238	244		10.1123/jab.23.3.238			7	Engineering, Biomedical; Sport Sciences	Engineering; Sport Sciences	199NR	WOS:000248703000009	18089922				2021-06-18	
J	Ganesalingam, K; Sanson, A; Anderson, V; Yeates, KO				Ganesalingam, Kalaichelvi; Sanson, Ann; Anderson, Vicki; Yeates, Keith Owen			Self-regulation as a mediator of the effects of childhood traumatic brain injury on social and behavioral functioning	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; children; self-regulation; social and behavioral functioning; multiple mediators; specific indirect effects	EXECUTIVE FUNCTION; RATING-SCALE; HEAD-INJURY; CHILDREN; ATTENTION; DELAY; GRATIFICATION; PREDICTION; INVENTORY; TERM	This study builds on our earlier investigation (see Ganesalingam et at., 2006). We showed previously that children with moderate to severe traumatic brain injuries (TBI) had poorer self-regulation and social and behavioral functioning than their uninjured peers and that self-regulation predicted significant variance in parent- and teacher-rated social and behavioral outcomes, regardless of the presence or absence of TBI. In this study, we examine self-regulation as a mediator of the relationship between TBI and the outcomes. Participants included 65 children with moderate to severe TBI and 65 children without TBI matched for age and gender. Participants were between 6 and 11 years of age. Children completed an assessment of cognitive, emotional, and behavioral self-regulation, and social and behavioral functioning. Mediation was assessed using a bootstrapping approach (a relatively novel statistical method for assessing specific indirect effects in models with multiple mediators). Analyses indicated that, after controlling for socioeconomic status (SES), aspects of self-regulation accounted for individual variation in the outcomes, and acted as a significant mediator of the effects of TBI on the outcomes. Self-regulatory deficits may reflect the relative vulnerability of the prefrontal cortex to TBI and may help account for post-injury difficulties in social and behavioral functioning.	Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia; Murdoch Childrens Res Ctr, Melbourne, Vic, Australia; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Childrens Res Inst, Columbus, OH USA	Ganesalingam, K (corresponding author), Childrens Hosp, Columbus Childrens Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	GaiiesaKa@chi.osu.edu	Yeates, Keith/AAJ-4223-2020	Sanson, Ann/0000-0003-4910-3310; Yeates, Keith/0000-0001-7680-2892			Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; *AUSTR BUR STAT, 2001, POP AUSTR NZ COMP; Banerjee M., 1997, DEV SOCIAL COGNITION, P241; Barkley R. A., 1997, ADHD NATURE SELF CON; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bradley S.J., 2000, AFFECT REGULATION DE; CASEY RJ, 1993, DEV PSYCHOL, V29, P119, DOI 10.1037/0012-1649.29.1.119; CICCHETTI D, 1994, MONOGRAPHS SOC RES C, V59, P228; COOK ET, 1994, J ABNORM CHILD PSYCH, V22, P205, DOI 10.1007/BF02167900; Dagenbach D., 1994, INHIBITORY PROCESSES; Dodge KA, 2002, PSYCHOL ASSESSMENT, V14, P60, DOI 10.1037//1040-3590.14.1.60; Eisenberg N, 2000, CHILD DEV, V71, P1367, DOI 10.1111/1467-8624.00233; EISENBERG N, 1995, CHILD DEV, V66, P1360, DOI 10.1111/j.1467-8624.1995.tb00940.x; Eisenberg N, 1997, CHILD DEV, V68, P642, DOI 10.2307/1132116; Eisenberg N., 1992, REV PERSONALITY SOCI, P119; EYBERG SM, 1983, J CLIN CHILD PSYCHOL, V12, P347, DOI 10.1207/s15374424jccp1203_19; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FUNDERBURK BW, 1989, BEHAV ASSESS, V11, P297; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; Gresham F. M., 1990, SOCIAL SKILLS RATING; Isquith PK, 2005, MENT RETARD DEV D R, V11, P209, DOI 10.1002/mrdd.20075; KAGAN J, 1966, J ABNORM PSYCHOL, V71, P17, DOI 10.1037/h0022886; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Krueger RF, 1996, J PERS, V64, P107, DOI 10.1111/j.1467-6494.1996.tb00816.x; Lemerise EA, 2000, CHILD DEV, V71, P107, DOI 10.1111/1467-8624.00124; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Luria A. R, 1973, WORKING BRAIN; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Manly T., 1999, TEST EVERYDAY ATTENT; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1017/S0021963001006667; MISCHEL W, 1970, J PERS SOC PSYCHOL, V16, P329, DOI 10.1037/h0029815; *NAT HLTH INF MAN, 2001, NAT HLTH PLAN AUSTR; Olson SL, 2005, DEV PSYCHOPATHOL, V17, P25, DOI 10.1017/S0954579405050029; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; RODRIGUEZ ML, 1989, J PERS SOC PSYCHOL, V57, P358, DOI 10.1037/0022-3514.57.2.358; Rothbart M.K., 2006, HDB CHILD PSYCHOL, P99, DOI DOI 10.1002/9780470147658.CHPSY0303; Rothbart M. K., 1989, TEMPERAMENT CHILDHOO, P59; Rueda MR, 2005, DEV NEUROPSYCHOL, V28, P573, DOI 10.1207/s15326942dn2802_2; Saarni C., 1997, EMOTIONAL DEV EMOTIO; Schore A. N., 1994, AFFECT REGULATION OR; Sethi A, 2000, DEV PSYCHOL, V36, P767, DOI 10.1037//0012-1649.36.6.767; Shields A, 1998, J CLIN CHILD PSYCHOL, V27, P381, DOI 10.1207/s15374424jccp2704_2; Shields A., 1998, EMOTION REGULATION C; SHIELDS AM, 1994, DEV PSYCHOPATHOL, V6, P57, DOI 10.1017/S0954579400005885; Sobel M. E., 1988, COMMON PROBLEMS PROP, P46; Stuss D.T., 1986, FRONTAL LOBES; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; YEATES KO, IN PRESS PSYCHOL B	56	51	51	0	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2007	13	2					298	311		10.1017/S1355617707070324			14	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	144XD	WOS:000244828800013	17286887				2021-06-18	
J	Bruce-Keller, AJ; Dimayuga, FO; Reed, JL; Wang, CM; Angers, R; Wilson, ME; Dimayuga, VM; Scheff, SW				Bruce-Keller, Annadora J.; Dimayuga, Filomena O.; Reed, Janelle L.; Wang, Chunmei; Angers, Rachel; Wilson, Melinda E.; Dimayuga, Vanessa M.; Scheff, Stephen W.			Gender and estrogen manipulation do not affect traumatic brain injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						cytokines; inflammation; neurodegeneration; sex steroids	CELL-DEATH; INFLAMMATORY RESPONSE; MULTIPLE-SCLEROSIS; ESTRADIOL PROTECTS; PROGESTERONE; PREGNANCY; EXPRESSION; TAT; NORETHISTERONE; MECHANISMS	As epidemiological data have suggested that female patients may have improved clinical prognoses following traumatic brain injury (TBI) compared to males, we designed experiments to determine the role of gender and estrogen in TBI-induced brain injury and inflammation in rodents. To this end, male and female C57111/6 mice were separated into the following four groups: intact males, intact females with vehicle supplementation, ovariectomized females with vehicle supplementation, and ovariectomized females with estrogen supplementation. All mice were subjected to a controlled cortical impact model of TBI, and cortical injury, hippocampal degeneration, microglial activation, and brain cytokine expression were analyzed after injury. Additionally, the spleens were harvested and cytokine release from cultured splenic cells was measured in response to specific stimuli. Data indicate that TBI-induced cortical and hippocampal injury, as well as injury-related microglial activation were not significantly affected by gender or estrogen manipulation. Conversely, brain levels of MCP-1 and IL-6 were significantly increased in males and intact females following TBI, but not in female mice that had been ovariectomized and supplemented with either estrogen or vehicle. Evaluation of splenic responses showed that the spleen was only moderately affected by TBI, and furthermore that spleens isolated from mice that had been given estrogen supplementation showed significantly higher release of the anti-inflammatory cytokine IL-4, regardless of the presence of absence of TBI. Overall, these data indicate that while estrogen can modulate immune responses, and indeed can predispose splenic responses towards and anti-inflammatory phenotype, these effects do not translate to decreased brain injury or inflammation following TBI in mice.	Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Bruce-Keller, AJ (corresponding author), Univ Kentucky, Dept Anat & Neurobiol, Mn 222 Chandler Med Ctr, Lexington, KY 40536 USA.	abruce@uky.edu	Bruce-Keller, Annadora/N-1954-2017		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20 RR 15592] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 046267, NS 45601] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046267, R01NS045601] Funding Source: NIH RePORTER		Adamski J, 2004, MOL ENDOCRINOL, V18, P1963, DOI 10.1210/me.2004-0098; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; Bruce-Keller AJ, 2003, J NEUROSCI, V23, P8417; Bruce-Keller AJ, 2001, J NEUROCHEM, V78, P1315, DOI 10.1046/j.1471-4159.2001.00511.x; CUTOLO M, 1995, CLIN EXP RHEUMATOL, V13, P217; Cutolo M, 2000, RHEUM DIS CLIN N AM, V26, P825, DOI 10.1016/S0889-857X(05)70171-X; DEKOSKY ST, 1984, NEUROENDOCRINOLOGY, V38, P33, DOI 10.1159/000123862; Dimayuga FO, 2005, J NEUROIMMUNOL, V161, P123, DOI 10.1016/j.jneuroim.2004.12.016; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dodel RC, 1999, J NEUROCHEM, V73, P1453, DOI 10.1046/j.1471-4159.1999.0731453.x; Doria A, 2006, ANN NY ACAD SCI, V1069, P247, DOI 10.1196/annals.1351.022; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, ENDOCRINOLOGY, V142, P43, DOI 10.1210/en.142.1.43; Elenkov IJ, 1997, MOL MED TODAY, V3, P379; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Ito A, 2001, J IMMUNOL, V167, P542, DOI 10.4049/jimmunol.167.1.542; Kim HS, 2005, J TOXICOL ENV HEAL A, V68, P2249, DOI 10.1080/15287390500182354; Knoferl MW, 2002, ANN SURG, V235, P105, DOI 10.1097/00000658-200201000-00014; Knoferl MW, 2001, AM J PHYSIOL-CELL PH, V281, pC1131, DOI 10.1152/ajpcell.2001.281.4.C1131; Lang TJ, 2004, CLIN IMMUNOL, V113, P224, DOI 10.1016/j.clim.2004.05.011; Lee YW, 2004, CARDIOVASC RES, V63, P139, DOI 10.1016/j.cardiores.2004.03.006; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Mor G, 1999, J NEUROBIOL, V40, P484, DOI 10.1002/(SICI)1097-4695(19990915)40:4<484::AID-NEU6>3.0.CO;2-C; Mueck AO, 2002, MENOPAUSE, V9, P273, DOI 10.1097/00042192-200207000-00008; Nakamura T, 2006, ACTA NEUROCHIR SUPPL, V96, P218; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Owens W, 2003, ENVIRON HEALTH PERSP, V111, P1527, DOI 10.1289/ehp.6413; PAXINOS G, 2004, MOUSE BRAIN STEOREOT; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Raivich Gennadij, 1996, Keio Journal of Medicine, V45, P239; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Salem Mohamed Labib, 2004, Current Drug Targets - Inflammation and Allergy, V3, P97, DOI 10.2174/1568010043483944; Scheff SW, 2004, NEUROCHEM RES, V29, P469, DOI 10.1023/B:NERE.0000013753.22615.59; Sicotte NL, 2002, ANN NEUROL, V52, P421, DOI 10.1002/ana.10301; Soldan SS, 2003, J IMMUNOL, V171, P6267, DOI 10.4049/jimmunol.171.11.6267; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Turchan J, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-3; Vegeto E, 2000, EXP GERONTOL, V35, P1309, DOI 10.1016/S0531-5565(00)00161-3; Viviani B, 2002, J NEUROCHEM, V83, P1180, DOI 10.1046/j.1471-4159.2002.01235.x; Voskuhl R R, 2003, Int MS J, V10, P60; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wilson ME, 2000, BRAIN RES, V873, P235, DOI 10.1016/S0006-8993(00)02479-3; Wise PM, 2001, ENDOCRINOLOGY, V142, P969, DOI 10.1210/en.142.3.969; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086; Zitzmann M, 2005, J CLIN ENDOCR METAB, V90, P6603, DOI 10.1210/jc.2005-0847	64	51	52	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					203	215		10.1089/neu.2006.0163			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100020	17263684				2021-06-18	
J	Hu, Y; Cui, Q; Harvey, AR				Hu, Ying; Cui, Qi; Harvey, Alan R.			Interactive effects of C3, cyclic AMP and ciliary neurotrophic factor on adult retinal ganglion cell survival and axonal regeneration	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						optic nerve injury; neurotrauma; cyclic nucleotides; cytokines; C3 transferase	MYELIN-ASSOCIATED GLYCOPROTEIN; SIGNAL-REGULATED KINASE; PERIPHERAL-NERVE GRAFTS; OPTIC-NERVE; IN-VIVO; MEDIATED EXPRESSION; INHIBITORY-ACTIVITY; NEURITE OUTGROWTH; SCHWANN-CELLS; RHO	We tested whether combined therapy involving Rho inactivation, elevation of cAMP and supply of ciliary neurotrophic factor (CNTF) (i) increased axotomized adult retinal ganglion cell (RGC) survival and (ii) promoted axonal regeneration into peripheral nerve (PN) autografted onto the cut optic nerve. PN-grafted eyes were injected with combinations of a Rho-inactivating enzyme C3 transferase (C3-11), CNTF and a cell-permeant analogue of cAMP (CPT-cAMP). Four weeks after PN transplantation, RGC survival was quantified using beta-III tubulin immunohistochemistry. Regeneration was assessed using retrograde fluorogold tracing and pan-neurofilament immunostaining of grafts. Treatment with C3-11 increased RGC survival but co-injection with CPT-cAMP, CNTF or combined CNTF/CPT-cAMP did not further enhance RGC viability. There were greater numbers of regenerating RGCs after multiple C3-11 injections and regeneration was further and significantly increased after intravitreal injections of all three factors. In the combined C3-11/CNTF/CPT-cAMP treatment group about 15% of RGCs remained viable of which more than half regenerated an axon. These data emphasize the power of combinatorial pharmacotherapeutic and transplant strategies in the treatment of neurotrauma. (c) 2006 Elsevier Inc. All rights reserved.	Univ Western Australia, Sch Anat & Human Biol M309, Perth, WA 6009, Australia	Harvey, AR (corresponding author), Univ Western Australia, Sch Anat & Human Biol M309, 35 Stirling Highway, Perth, WA 6009, Australia.	arharvey@anhb.uwa.edu.au	Ying, Hu/F-3581-2010; Harvey, Alan/A-4911-2008	, Alan/0000-0002-2590-831X			Ahmed Z, 2006, BRAIN, V129, P1517, DOI 10.1093/brain/awl080; BAHR M, 1995, EXP NEUROL, V134, P87, DOI 10.1006/exnr.1995.1039; Bandtlow CE, 2003, EXP GERONTOL, V38, P79, DOI 10.1016/S0531-5565(02)00165-1; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bertrand J, 2007, NEUROBIOL DIS, V25, P65, DOI 10.1016/j.nbd.2006.08.008; Bertrand J, 2005, J NEUROSCI, V25, P1113, DOI 10.1523/JNEUROSCI.3931-04.2005; Borisoff JF, 2003, MOL CELL NEUROSCI, V22, P405, DOI 10.1016/S1044-7431(02)00032-5; Bregman BS, 2002, PROG BRAIN RES, V137, P257; Bruce JH, 2000, J NEUROTRAUM, V17, P781, DOI 10.1089/neu.2000.17.781; Cai DM, 2002, NEURON, V35, P711, DOI 10.1016/S0896-6273(02)00826-7; Castro C, 2006, EXP NEUROL, V200, P19, DOI 10.1016/j.expneurol.2006.02.001; Chen H, 2004, BRAIN RES, V1011, P99, DOI 10.1016/j.brainres.2004.03.024; CHO EYP, 1987, BRAIN RES, V419, P369, DOI 10.1016/0006-8993(87)90610-X; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Cui Q, 2004, J NEUROTRAUM, V21, P617, DOI 10.1089/089771504774129946; Cui Q, 2002, INVEST OPHTH VIS SCI, V43, P1954; Cui Q, 1999, INVEST OPHTH VIS SCI, V40, P760; Danias J, 2002, INVEST OPHTH VIS SCI, V43, P587; Dergham P, 2002, J NEUROSCI, V22, P6570; Desagher S, 2005, J BIOL CHEM, V280, P5693, DOI 10.1074/jbc.M408971200; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Dusart I, 2005, BRAIN RES REV, V49, P300, DOI 10.1016/j.brainresrev.2004.11.007; FILBIN MT, 1995, CURR OPIN NEUROBIOL, V5, P588, DOI 10.1016/0959-4388(95)80063-8; Fischer D, 2004, J NEUROSCI, V24, P8726, DOI 10.1523/JNEUROSCI.2774-04.2004; Fouad K, 2005, J NEUROSCI, V25, P1169, DOI 10.1523/JNEUROSCI.3562-04.2005; Fournier AE, 2003, J NEUROSCI, V23, P1416; Frade JM, 1999, DEVELOPMENT, V126, P683; Gao Y, 2004, NEURON, V44, P609, DOI 10.1016/j.neuron.2004.10.030; Gao Y, 2003, J NEUROSCI, V23, P11770; Gillon RS, 2003, J NEUROSCI RES, V74, P524, DOI 10.1002/jnr.10788; Goldberg JL, 2002, NEURON, V33, P689, DOI 10.1016/S0896-6273(02)00602-5; Grandpre T, 2001, NEUROSCIENTIST, V7, P377, DOI 10.1177/107385840100700507; Han SI, 2001, J MOL BIOL, V305, P95, DOI 10.1006/jmbi.2000.4292; Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002; Hou B, 2004, INVEST OPHTH VIS SCI, V45, P662, DOI 10.1167/iovs.03-0281; Hu Y, 2005, MOL THER, V11, P906, DOI 10.1016/j.ymthe.2005.01.016; Isenmann S, 1998, EUR J NEUROSCI, V10, P2751, DOI 10.1046/j.1460-9568.1998.00325.x; Isenmann S, 2003, PROG RETIN EYE RES, V22, P483, DOI 10.1016/S1350-9462(03)00027-2; Kanekura K, 2005, J BIOL CHEM, V280, P4532, DOI 10.1074/jbc.M410508200; Kitaoka Y, 2004, BRAIN RES, V1018, P111, DOI 10.1016/j.brainres.2004.05.070; Klocker N, 1997, NEUROREPORT, V8, P3439; Klocker N, 1998, J NEUROSCI, V18, P1038; Kobayashi K, 2004, J NEUROSCI, V24, P3480, DOI 10.1523/JNEUROSCI.0295-04.2004; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; Kuramoto H, 1997, MOL CHEM NEUROPATHOL, V31, P85, DOI 10.1007/BF02815163; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Li YM, 2003, J NEUROSCI, V23, P7830; Lindqvist N, 2004, EXP NEUROL, V187, P487, DOI 10.1016/j.expneurol.2004.02.002; Logan A, 2006, BRAIN, V129, P490, DOI 10.1093/brain/awh706; Loucks FA, 2006, J NEUROCHEM, V97, P957, DOI 10.1111/j.1471-4159.2006.03802.x; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; Monnier PP, 2003, MOL CELL NEUROSCI, V22, P319, DOI 10.1016/S1044-7431(02)00035-0; Morgenstern DA, 2003, MOL CELL NEUROSCI, V24, P787, DOI 10.1016/S1044-7431(03)00245-8; MUIR D, 1989, J CELL BIOL, V109, P2353, DOI 10.1083/jcb.109.5.2353; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Nakazawa T, 2002, INVEST OPHTH VIS SCI, V43, P3319; NG TF, 1995, J NEUROCYTOL, V24, P487, DOI 10.1007/BF01179974; Nickells RW, 2004, BRAIN RES BULL, V62, P439, DOI 10.1016/j.brainresbull.2003.07.007; Orlando KA, 2006, EXP CELL RES, V312, P5, DOI 10.1016/j.yexcr.2005.09.012; Oshitari T, 2003, NEUROREPORT, V14, P289, DOI 10.1097/00001756-200302100-00027; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; PARK K, 2006, P AUS NEUROSCI SOC, V17, P155; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Saito K., 1997, Geophysical Magazine, Series 2, V2, P109; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Schafer M, 1996, NEURON, V16, P1107, DOI 10.1016/S0896-6273(00)80137-3; Selles-Navarro I, 2001, EXP NEUROL, V167, P282, DOI 10.1006/exnr.2000.7573; Shearer MC, 2003, MOL CELL NEUROSCI, V24, P913, DOI 10.1016/j.mcn.2003.09.004; Shen SL, 1999, NEURON, V23, P285, DOI 10.1016/S0896-6273(00)80780-1; Shen YJ, 1998, MOL CELL NEUROSCI, V12, P79, DOI 10.1006/mcne.1998.0700; Snider WD, 2002, NEURON, V35, P13, DOI 10.1016/S0896-6273(02)00762-6; SO KF, 1985, BRAIN RES, V328, P349, DOI 10.1016/0006-8993(85)91047-9; Spencer T, 2004, J ANAT, V204, P49, DOI 10.1111/j.1469-7580.2004.00259.x; Torigoe K, 1998, EXP NEUROL, V150, P254, DOI 10.1006/exnr.1997.6775; Weise J, 2000, NEUROBIOL DIS, V7, P212, DOI 10.1006/nbdi.2000.0285; Winton MJ, 2002, J BIOL CHEM, V277, P32820, DOI 10.1074/jbc.M201195200; Yan Q, 1999, J NEUROBIOL, V38, P382, DOI 10.1002/(SICI)1097-4695(19990215)38:3<382::AID-NEU7>3.0.CO;2-5; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zuo J, 1998, J NEUROBIOL, V34, P41, DOI 10.1002/(SICI)1097-4695(199801)34:1<41::AID-NEU4>3.3.CO;2-4	88	51	53	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	JAN	2007	34	1					88	98		10.1016/j.mcn.2006.10.005			11	Neurosciences	Neurosciences & Neurology	127PG	WOS:000243598200010	17126028				2021-06-18	
J	Niemeier, JP; Marwitz, JH; Lesher, K; Walker, WC; Bushnik, T				Niemeier, Janet P.; Marwitz, Jennifer H.; Lesher, Katrina; Walker, William C.; Bushnik, Tamara			Gender differences in executive functions following traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CARD SORTING TEST; DISABILITY RATING-SCALE; CEREBRAL-BLOOD-FLOW; HEAD-INJURY; TEST-PERFORMANCE; PREFRONTAL CORTEX; CONTUSION INJURY; SEX-DIFFERENCES; SCHIZOPHRENIA; RECOVERY	The present study used the National Institute on Disability Rehabilitation and Research (NIDRR) funded Traumatic Brain Injury Model Systems (TBIMS) database to examine the effect of gender on presentation of executive dysfunction following traumatic brain injury (TBI) and variables that might impact the course and degree of recovery. The Wisconsin Card Sort Test (WCST) was chosen as a measure of executive function which has good credentials without reports of gender effects. Female subjects performed significantly better on the WCST than male subjects as shown by analyses of variance on scores of 1,331 patients for Categories Achieved (means for females = 4.09, males = 3.67, p =.003) and Perseverative Responses (means for females = 32.17, males = 36.42, p =.003). Outperformance by females was also noted in additional ANOVAs examining the interaction of education and gender, and ethnicity and gender in relation to Categories Achieved (p < .01), and for ethnicity and gender in relation to Perseverative Responses (p < .01). A multiple logistic regression revealed that gender, minority status, education level, history of illicit drug use, cause of injury, and length of coma each contributed uniquely to predicting Categories Achieved on the WCST. Simple logistic regression analyses showed that, of these variables, gender and cause of injury ( violent vs. non-violent) were the strongest predictors. In contrast, when examining Perseverative Responses, regression analyses found gender, minority status and length of coma predicted impairment. Simple logistic regression analyses showed that, of these three variables, gender and minority status were most robust in predicting impaired Perseverative Responses scores. Implications of these findings are discussed and recommendations for further research are offered.	Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Santa Clara Valley Med Ctr, Rehabil Res Ctr Traumat Brain Injury & Spinal Cor, San Jose, CA 95128 USA	Niemeier, JP (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980661, Richmond, VA 23298 USA.	jniemeir@mail2.vcu.edu		Bushnik, Tamara/0000-0003-3328-257X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A020516, H133A011403] Funding Source: Medline		Alexander M, 2006, J INT NEUROPSYCH SOC, V12, P192, DOI 10.1017/S1355617706060292; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Axelrod BN, 1996, J CLIN EXP NEUROPSYC, V18, P338, DOI 10.1080/01688639608408991; Barcelo F, 2000, REV NEUROLOGIA, V30, P855, DOI 10.33588/rn.3009.99451; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Bartok E, 2005, PROG NEURO-PSYCHOPH, V29, P621, DOI 10.1016/j.pnpbp.2005.01.008; BASSO A, 1982, CORTEX, V18, P469, DOI 10.1016/S0010-9452(82)80044-0; Bengtson M, 2000, EPILEPSY BEHAV, V1, P112, DOI 10.1006/ebeh.2000.0051; Blume AW, 2005, ADDICT BEHAV, V30, P301, DOI 10.1016/j.addbeh.2004.05.019; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Brodsky MB, 2003, J SPEECH LANG HEAR R, V46, P1124, DOI 10.1044/1092-4388(2003/088); CHELUNE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P219, DOI 10.1080/01688638608401314; CROCKETT D, 1986, INT J NEUROSCI, V30, P241, DOI 10.3109/00207458608985674; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Denckla M.B., 1994, FRAMES REFERENCE ASS, P117; Dolan M, 2002, MED SCI LAW, V42, P34, DOI 10.1177/002580240204200107; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Drake RJ, 2003, SCHIZOPHR RES, V62, P165, DOI 10.1016/S0920-9964(02)00382-1; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; FEY ET, 1951, J CONSULT PSYCHOL, V15, P311; Gansler DA, 1996, BRAIN COGNITION, V30, P194, DOI 10.1006/brcg.1996.0012; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRAFMAN J, 1990, PERCEPT MOTOR SKILL, V71, P1120, DOI 10.2466/PMS.71.8.1120-1122; Granger CV., 1997, GUIDE UNIFORM DATA S; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HAALAND KY, 1987, J GERONTOL, V42, P345, DOI 10.1093/geronj/42.3.345; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC27; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HALLAHAN DP, 1997, ADV LEARN BEHAV DISA, V11, P27; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Heaton R., 1981, MANUAL WISCONSIN CAR; Heaton R., 1993, WISCONSIN CARD SORTI; HECK ET, 1986, J CLIN EXP NEUROPSYC, V8, P313, DOI 10.1080/01688638608401321; Heyer EJ, 2000, J CLIN EXP NEUROPSYC, V22, P633; Jensen O K, 2001, Ugeskr Laeger, V163, P5029; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; KIMURA D, 1983, CAN J PSYCHOL, V37, P19, DOI 10.1037/h0080696; Konishi S, 1999, CEREB CORTEX, V9, P745, DOI 10.1093/cercor/9.7.745; Lacerda ALT, 2003, PROG NEURO-PSYCHOPH, V27, P657, DOI 10.1016/S0278-5846(03)00076-9; Lacreuse A, 2004, BEHAV PROCESS, V67, P313, DOI 10.1016/j.beproc.2004.05.004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LYON GR, 1994, FRAMES REFERENCE ASS; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Perecman E., 1987, FRONTAL LOBES REVISI; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; Schwartz JRL, 2004, CLIN NEUROPHARMACOL, V27, P74, DOI 10.1097/00002826-200403000-00005; Shad MU, 2004, NEUROIMAGE, V22, P1315, DOI 10.1016/j.neuroimage.2004.03.016; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; STEIN DG, 1999, COGNITIVE NEUROREHAB, P73; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; SUMMERFELT AT, 1991, J ABNORM PSYCHOL, V100, P613, DOI 10.1037/0021-843X.100.4.613; Taras HL, 2003, PEDIATRICS, V112, P1206, DOI 10.1542/peds.2012-3932; van der Naalt J, 2000, BRAIN INJURY, V14, P781; WAGNER AK, 2004, 65 ANN AM AC PHYS ME; Weigl E, 1941, J ABNORM SOC PSYCH, V36, P3, DOI 10.1037/h0055544; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483	73	51	55	2	15	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2007	17	3					293	313		10.1080/09602010600814729			21	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	165IQ	WOS:000246298500002	17474058				2021-06-18	
J	Suh, M; Basu, S; Kolster, R; Sarkar, R; McCandliss, B; Ghajar, J				Suh, Minah; Basu, Sambrita; Kolster, Rachel; Sarkar, Ranjeeta; McCandliss, Bruce; Ghajar, Jamshid			Increased oculomotor deficits during target blanking as an indicator of mild traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						mild TBI; diffuse axonal injury (DAI); predictive smooth pursuit eye movement; variability; cognitive deficits	SMOOTH-PURSUIT; INTRAINDIVIDUAL VARIABILITY; TRANSIENT DISAPPEARANCE; COGNITIVE PERFORMANCE; EYE-MOVEMENT; OLDER-ADULTS; HEAD-INJURY; ATTENTION; PREDICTION	Given the susceptibility of cerebellar-cortical tracts to shearing injury from traumatic brain injury (TBI), we investigated impairment in the generation of predictive eye movements and its relationship to cognitive deficits in mild TBI patients using a smooth pursuit target-blanking paradigm. Compared to a target-tracking paradigm without blanking, this paradigm more greatly necessitates the generation of predictive eye movements, which are subserved by brain regions involved in cognitive processing. Mild TBI patients showed impaired prediction of target trajectories during target blanking, demonstrated by generation of saccades at earlier and more variable time points, as well as greater and more variable oculomotor error compared to controls. In addition, California Verbal Learning Test (CVLT-II) scores related to working memory, learning, and executive function were more highly correlated with oculomotor variability during target blanking than during target tracking. Our results suggest that a disruption of cerebellar-cortical connections in TBI may account for both oculomotor and cognitive impairment, and that measures of predictive eye movements during target blanking may be a sensitive metric of cognitive deficits after mild TBI. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Weill Cornell Med Coll, Dept Neurol Surg, New York, NY 10021 USA; Brain Trauma Fdn, New York, NY 10021 USA; Weill Cornell Med Coll, Dept Psychiat, Sackler Inst, New York, NY 10021 USA	Suh, M (corresponding author), Weill Cornell Med Coll, Dept Neurol Surg, New York, NY 10021 USA.	mis2032@med.cornell.edu					Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barnes GR, 2005, EXP BRAIN RES, V160, P10, DOI 10.1007/s00221-004-1981-3; BECKER W, 1985, EXP BRAIN RES, V57, P562; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Chen Y, 2002, PROG BRAIN RES, V140, P255; Courchesne E, 1997, LEARN MEMORY, V4, P1, DOI 10.1101/lm.4.1.1; de Xivry JJO, 2006, J NEUROPHYSIOL, V95, P418, DOI 10.1152/jn.00596.2005; Delis DC, 2000, CALIFORNIA VERBAL LE; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hultsch DF, 2000, NEUROPSYCHOLOGY, V14, P588, DOI 10.1037/0894-4105.14.4.588; Hutton SB, 2005, EXP BRAIN RES, V163, P306, DOI 10.1007/s00221-004-2171-z; Kalashnikova L A, 2005, Neurosci Behav Physiol, V35, P773, DOI 10.1007/s11055-005-0123-0; KHURANA B, 1987, VISION RES, V27, P1603, DOI 10.1016/0042-6989(87)90168-4; KOWLER E, 1989, VISION RES, V29, P1049, DOI 10.1016/0042-6989(89)90052-7; Leth-Steensen C, 2000, ACTA PSYCHOL, V104, P167, DOI 10.1016/S0001-6918(00)00019-6; Machner B, 2005, NEUROREPORT, V16, P1507, DOI 10.1097/01.wnr.0000177015.75096.b6; Madelain L, 2003, J NEUROPHYSIOL, V90, P972, DOI 10.1152/jn.00869.2002; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Middleton FA, 2001, J NEUROSCI, V21, P700, DOI 10.1523/JNEUROSCI.21-02-00700.2001; MISSAL M, 2004, J NEUROPHYS, V92; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Murtha S, 2002, J INT NEUROPSYCH SOC, V8, P360, DOI 10.1017/S1355617702813170; MUSHIAKE H, 1993, J NEUROPHYSIOL, V70, P2660; Nagel M, 2006, NEUROIMAGE, V29, P1319, DOI 10.1016/j.neuroimage.2005.08.050; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; POSNER MI, 1984, J NEUROSCI, V4, P1863; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Rosenberg DR, 1997, PSYCHIAT RES, V66, P121, DOI 10.1016/S0165-1781(96)02975-7; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Strauss E, 2002, J INT NEUROPSYCH SOC, V8, P893, DOI 10.1017/S1355617702870035; Stuss D. T., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Suh M, 2000, J NEUROPHYSIOL, V84, P1835; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Theoret H, 2001, NEUROSCI LETT, V306, P29, DOI 10.1016/S0304-3940(01)01860-2; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925	42	51	51	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	DEC 27	2006	410	3					203	207		10.1016/j.neulet.2006.10.001			5	Neurosciences	Neurosciences & Neurology	120NR	WOS:000243092200011	17055156				2021-06-18	
J	Huynh, T; Jacobs, DG; Dix, S; Sing, RF; Miles, WS; Thomason, MH				Huynh, Toan; Jacobs, David G.; Dix, Stephanie; Sing, Ronald F.; Miles, William S.; Thomason, Michael H.			Utility of neurosurgical consultation for mild traumatic brain injury	AMERICAN SURGEON			English	Article; Proceedings Paper	74th Annual Scientific Meeting of the Southeastern-Surgical-Congress	FEB 18-21, 2006	Lake Buena Vista, FL	SE Surg Congress			COMPUTED-TOMOGRAPHY; HEAD TRAUMA; MANAGEMENT	Trauma patients presenting with a Glasgow Coma Scale (GCS) score of 14-15 are considered to have mild traumatic brain injury (TBI) with overall good neurologic outcomes. Current practice consists of initial stabilization, followed by a head CT, and neurosurgical consultation. Aside from serial neurologic examinations, patients with a GCS of 15 rarely require neurosurgical intervention. In this study, we examined the added value of neurosurgical consultation in the care of patients after TBI with a GCS of 15. We retrospectively reviewed the medical records of patients presenting after blunt trauma with an abnormal head CT and GCS of 15 between January 2004 and January 2005. Patients with a normal head CT and < 48 hours hospital stay were excluded. Data included demographics, mechanisms of injury, Injury Severity Score, the radiologists' dictated interpretations of the head CT, and neurosurgical interventions. Fifty-six patients met the inclusion criteria. The mean age was 41 +/- 2.3 years, and the mean Injury Severity Scores was 10.2 +/- 0.6. Mechanisms of injury included 64 per cent motor vehicle crash, 16 per cent motorcycle crash, 13 per cent fall, and 7 per cent all-terrain vehicle crash. The initial CT scans showed 43 per cent parenchymal contusions, 38 per cent subarachnoid hemorrhage, 14 per cent subdural hematomas, and 5 per cent epidural hematomas. All patients received a routine follow-up head CT, and 16 per cent showed changes (five improved and four were worse compared with initial CT scans). None of these patients received a neurosurgical intervention, and two were transferred to a rehabilitation service. In this era of limited resources, trauma patients who present with a GCS score of 15 after mild TBI can be safely managed without neurosurgical consultation, even in the presence of an abnormal head CT scan.	Carolinas Med Ctr, Sammy Ross Jr Trauma Ctr, Charlotte, NC 28232 USA	Huynh, T (corresponding author), Carolinas Med Ctr, Sammy Ross Jr Trauma Ctr, 1000 Blythe Blvd,POB 32861, Charlotte, NC 28232 USA.						Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X	17	51	52	0	1	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	DEC	2006	72	12					1162	1165					4	Surgery	Surgery	114OQ	WOS:000242675900005	17216813				2021-06-18	
J	Sperry, JL; Gentilello, LM; Minei, JP; Diaz-Arrastia, RR; Friese, RS; Shafi, S				Sperry, Jason L.; Gentilello, Larry M.; Minei, Joseph P.; Diaz-Arrastia, Ramon R.; Friese, Randall S.; Shafi, Shahid			Waiting for the patient to "sober up": Effect of alcohol intoxication on Glasgow Coma Scale score of brain injured patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	36th Annual Meeting of the Western-Trauma-Association	FEB 26-MAR 03, 2006	Big Sky, MT	Western Trauma Assoc		alcohol; intoxication; traumatic brain injury; Glasgow Coma Scale	TRAUMA PATIENTS; BASE DEFICIT; HEAD-INJURY; LEVEL; SEVERITY	Background: Between 35% to 50% of traumatic brain injury (TBI) patients are under the influence of alcohol. Alcohol intoxication may limit the ability of the Glasgow Coma Scale (GCS) to accurately assess severity of TBI. We hypothesized that alcohol intoxication significantly depresses GCS scores of TBI patients. Methods. A 10-year, retrospective analysis of a Level I trauma center registry was undertaken. The study population consisted of all blunt injured TBI patients tested for blood alcohol concentration (BAC, n = 1,075). Patients were divided into two groups; intoxicated (mean BAC 202 +/- 77 mg/dL, n = 504) and nonintoxicated (BAC = 0, n = 571). TBI was classified using ICD-9 codes as concussion alone (ICD-9 850, n = 90) and intracranial injury (ICI, ICD-9 851-854, n = 985). Severity was further classified using the Abbreviated Injury Score (AIS). Mean GCS score was compared between the two groups. Patients who were either intubated or hypotensive upon arrival were analyzed separately to rule out confounding effects on GCS score. Severely intoxicated patients (BAC > 250 mg/dL, [mean +/- SD] 309 +/- 54 SD, n = 118) were similarly compared. Finally, multivariate linear regression analysis was undertaken to determine whether BAC level was an independent predictor of GCS score while controlling for confounding factors. Results: Intoxicated and nonintoxicated TBI patients were clinically similar. Alcohol intoxication had little effect on GCS score, with less than a single point difference in all types of TBI, except the most severely injured (AIS 5 injuries, GCS score difference 1.4 points). These results were not altered by endotracheal intubation, systemic hypotension, or severe intoxication. Similarly, BAC was not a significant independent predictor of GCS score in a. multivariate model. Conclusions: Alcohol intoxication does not result in clinically significant changes in GCS score for patients with blunt TBI. Hence, alterations in GCS score after TBI should not be attributed to alcohol intoxication, as doing so might result in inappropriate delays in monitoring and therapeutic interventions.	Univ Texas, SW Med Ctr, Dept Surg, Div Burns Trauma & Crit Care, Dallas, TX 75390 USA	Shafi, S (corresponding author), Univ Texas, SW Med Ctr, Dept Surg, Div Burns Trauma & Crit Care, 5323 Harry Hines Blvd,Mail Stop 9158, Dallas, TX 75390 USA.	shahid.shafi@utsouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594			Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; *AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P463; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; ChathamShowalter PE, 1996, PSYCHOSOMATICS, V37, P285, DOI 10.1016/S0033-3182(96)71567-0; DELANEY KA, 2000, HEAD INJURY; Dunham CM, 2000, J EMERG MED, V18, P165, DOI 10.1016/S0736-4679(99)00188-2; Dunne JR, 2005, J TRAUMA, V58, P959, DOI 10.1097/01.TA.0000158508.84009.49; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; Gentilello LM, 1999, J TRAUMA, V47, P1131, DOI 10.1097/00005373-199912000-00027; HOLT S, 1980, BRIT MED J, V281, P638, DOI 10.1136/bmj.281.6241.638; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; MINION GE, 1989, J TOXICOL-CLIN TOXIC, V27, P375, DOI 10.3109/15563658909000358; No authors listed. Rating the severity of tissue damage, 1971, JAMA-J AM MED ASSOC, V215, P277; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; TEASDALE G, 1974, LANCET, V2, P81; *TRAUM ACOS CO, 1997, ADV TRAUM LIF SUPP; TRENO AJ, 1994, ALCOHOL CLIN EXP RES, V18, P1306, DOI 10.1111/j.1530-0277.1994.tb01428.x; VALADKA AB, 2000, TRAUMA, P377; WISNER DH, 1992, ARCH SURG-CHICAGO, V127, P111	23	51	52	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2006	61	6					1305	1311		10.1097/01.ta.0000240113.13552.96			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	119CI	WOS:000242989400003	17159670				2021-06-18	
J	Otani, N; Nawashiro, H; Fukui, S; Ooigawa, H; Ohsumi, A; Toyooka, T; Shima, K; Gomi, H; Brenner, M				Otani, Naoki; Nawashiro, Hiroshi; Fukui, Shinji; Ooigawa, Hidetoshi; Ohsumi, Atsushi; Toyooka, Terushige; Shima, Katsuji; Gomi, Hiroshi; Brenner, Michael			Enhanced hippocampal neurodegeneration after traumatic or kainate excitotoxicity in GFAP-null mice	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						astrocytes; glial fibrillary acidic protein; hippocampus; excitotoxicity; kainate; seizures; traumatic brain injury	FIBRILLARY ACIDIC PROTEIN; PERCUSSION BRAIN-INJURY; LONG-TERM POTENTIATION; REACTIVE ASTROCYTES; TEMPORAL PROFILES; INDUCED LESIONS; EXPRESSION; JUVENILE	Astrocytes perform a variety of functions in the adult central nervous system. Recent evidence suggests that the upregulation of glial fibrillary acidic protein (GFAP), an astrocyte-specific intermediate filament component, is a biological marker of neurotoxicity after cerebral injury. We herein compared the response to traumatic brain injury or kainic acid (KA)-induced neurotoxicity in GFAP knockout (GFAP-KO) and wild-type (WT) mice. Seventy-two hours after injury, all GFAP-KO mice showed hippocampal CA3 neurodegeneration, whereas WT mice did not show neurodegeneration. Seventy-two hours after KA administration, GFAP-KO mice were more susceptible to KA-induced seizures and had an increased number of pyknotic damaged CA3 neurons than did WT mice. These results indicate that GFAP plays a crucial role in pyramidal neuronal survival after injury or KA-induced neurotoxicity. (C) 2006 Elsevier Ltd. All rights reserved.	Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan; Gunma Univ, Lab Gene Engn, Inst Mol & Cellular Regulat, Gunma, Japan; Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA	Otani, N (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	gra006@ad.ndmc.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17390109] Funding Source: KAKEN		Bolton SJ, 1998, EXP NEUROL, V154, P231, DOI 10.1006/exnr.1998.6927; BRENNER M, 1994, BRAIN PATHOL, V4, P245, DOI 10.1111/j.1750-3639.1994.tb00840.x; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; FITZPATRICK JS, 1992, INT J DEV NEUROSCI, V10, P313, DOI 10.1016/0736-5748(92)90020-Z; GORNI H, 1995, NEURON, V14, P29; GRAMSBERGEN JBP, 1994, BRAIN RES, V667, P216, DOI 10.1016/0006-8993(94)91499-0; Hu RQ, 1998, BRAIN RES, V810, P229, DOI 10.1016/S0006-8993(98)00863-4; JORGENSEN MB, 1993, EXP NEUROL, V120, P70, DOI 10.1006/exnr.1993.1041; Lenz G, 1997, BRAIN RES, V764, P188, DOI 10.1016/S0006-8993(97)00456-3; LIEBERMAN AP, 1992, J BIOL CHEM, V267, P2123; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; McKeon RJ, 1997, EXP NEUROL, V148, P558, DOI 10.1006/exnr.1997.6698; NADLER JV, 1980, BRAIN RES, V195, P47; Nawashiro H, 1998, NEUROREPORT, V9, P1691, DOI 10.1097/00001756-199806010-00004; Nawashiro H, 2000, J CEREBR BLOOD F MET, V20, P1040, DOI 10.1097/00004647-200007000-00003; REPRESA A, 1987, NEUROSCIENCE, V20, P739, DOI 10.1016/0306-4522(87)90237-5; Sporbert A, 1999, MOL BRAIN RES, V67, P258, DOI 10.1016/S0169-328X(99)00067-4; WENZEL J, 1991, BRAIN RES, V560, P122, DOI 10.1016/0006-8993(91)91222-M; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0	24	51	53	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	NOV	2006	13	9					934	938		10.1016/j.jocn.2005.10.018			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	116ZK	WOS:000242842100010	17085299				2021-06-18	
J	Ooigawa, H; Nawashiro, H; Fukui, S; Otani, N; Osumi, A; Toyooka, T; Shima, K				Ooigawa, Hidetoshi; Nawashiro, Hiroshi; Fukui, Shinji; Otani, Naoki; Osumi, Atsushi; Toyooka, Terushige; Shima, Katsuji			The fate of Nissl-stained dark neurons following traumatic brain injury in rats: difference between neocortex and hippocampus regarding survival rate	ACTA NEUROPATHOLOGICA			English	Article						dark neuron; Nissl stain; traumatic brain injury; extracellular signal-regulated protein kinase	SIGNAL-REGULATED KINASE; LIGHT MICROSCOPIC RESPONSE; INDUCED STATUS EPILEPTICUS; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; CONCUSSIVE HEAD-INJURY; SELECTIVE VULNERABILITY; FLUORO-JADE; SPATIAL PROFILE; CELL-DEATH	We studied the fate of Nissl-stained dark neurons (N-DNs) following traumatic brain injury (TBI). N-DNs were investigated in the cerebral neocortex and the hippocampus using a rat lateral fluid percussion injury model. Nissl stain, acid fuchsin stain and immunohistochemistry with phosphorylated extracellular signal-regulated protein kinase (pERK) antibody were used in order to assess posttraumatic neurons. In the neocortex, the number of dead neurons at 24 h postinjury was significantly less than that of the observed N-DNs in the earlier phase. Only a few N-DNs increased their pERK immunoreactivity. On the other hand, in the hippocampus the number of dead neurons was approximately the same number as that of the N-DNs, and most N-DNs showed an increased pERK immunoreactivity. These data suggest that not all N-DNs inevitably die especially in the neocortex after TBI. The fate of N-DNs is thus considered to differ depending on brain subfields.	Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan	Nawashiro, H (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	nawa1957@ndmc.ac.jp					Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ATILLO A, 1983, ACTA NEUROPATHOL, V59, P11, DOI 10.1007/BF00690312; AUER RN, 1985, ACTA NEUROPATHOL, V67, P13, DOI 10.1007/BF00688120; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Cheung Eric C C, 2004, Sci STKE, V2004, pPE45; Chu CT, 2004, EUR J BIOCHEM, V271, P2060, DOI 10.1111/j.1432-1033.2004.04132.x; Conti AC, 1998, J NEUROSCI, V18, P5663; COOPER JD, 1988, J ANAT, V157, P13; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Csordas A, 2003, ACTA NEUROPATHOL, V106, P37, DOI 10.1007/s00401-003-0694-1; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P394, DOI 10.1007/BF00713531; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P386, DOI 10.1007/BF00713530; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Ishida K, 2004, NEUROSCIENCE, V125, P633, DOI 10.1016/j.neuroscience.2004.02.002; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Konigsmark BW, 1970, CONT RES METHODS NEU, P315, DOI DOI 10.1007/978-3-642-85986-1_14; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsushita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P207; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIDHA R, 1987, BRAIN RES, V410, P299, DOI 10.1016/0006-8993(87)90328-3; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Otani N, 2003, ACT NEUR S, V86, P287; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Pei JJ, 2002, MOL BRAIN RES, V109, P45, DOI 10.1016/S0169-328X(02)00488-6; PETITO CK, 1984, J NEUROPATH EXP NEUR, V43, P141, DOI 10.1097/00005072-198403000-00004; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Poirier JL, 2000, NEUROSCIENCE, V97, P59, DOI 10.1016/S0306-4522(00)00026-9; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Subramaniam S, 2003, J BIOL CHEM, V278, P8904, DOI 10.1074/jbc.M210037200; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2	50	51	55	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	OCT	2006	112	4					471	481		10.1007/s00401-006-0108-2			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	089QC	WOS:000240894600008	16858608				2021-06-18	
J	Holshouser, BA; Tong, KA; Ashwal, S; Oyoyo, U; Ghamsary, M; Saunders, D; Shutter, L				Holshouser, Barbara A.; Tong, Karen A.; Ashwal, Stephen; Oyoyo, Udochukwu; Ghamsary, Mark; Saunders, David; Shutter, Lori			Prospective longitudinal proton magnetic resonance spectroscopic imaging in adult traumatic brain injury	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						spectroscopy; magnetic resonance spectroscopy; traumatic brain injury; outcome prediction; diffuse axonal injury	IN-VIVO; AXONAL INJURY; HEAD; DYSFUNCTION	Purpose: To investigate whether longitudinal magnetic resonance proton spectroscopic imaging (MRSI) demonstrates regional metabolite abnormalities after traumatic brain injury (TBI) that predict long-term neurologic outcome. Materials and Methods: Two-dimensional-MRSI (point resolved spectroscopy sequence [PRESS]; TR/TE = 3000/ 144 msec: 10 mm) was acquired prospectively in 42 adults with severe TBI through the level of the corpus callosum 7 4 days after injury. Measurements were repeated in 31 patients six to 12 months after injury. Regional and pooled (all regions combined) mean ratios were compared with control values and then used to predict long-term (six- to -12-month) neurologic outcome (good vs. poor) using a logistic regression model. Results: Initial pooled mean N-acetylaspartate (NAA) ratios were lower (P < 0.01) and choline (Cho)/creatine (Cr) ratios higher (P < 0.01) in all TBI patients compared to controls. Ratios from the corpus callosum region were affected most and predicted long-term dichotomized outcome with 83% accuracy. When repeated at six to 12 months after injury, pooled mean NAA/Cr remained lower (P = 0.03) and Cho/Cr remained higher (P = 0.01) in patients with poor outcomes. Conclusion; The NAA/Cr ratio from the corpus callosum was most, useful for outcome prediction. Chronic alterations of metabolite ratios are likely due to neuronal loss and glial proliferation long after injury.	Loma Linda Univ, Med Ctr, Sch Med, Dept Radiol, Loma Linda, CA 92354 USA; Loma Linda Univ, Med Ctr, Sch Med, Dept Pediat, Loma Linda, CA 92354 USA; Loma Linda Univ, Med Ctr, Sch Med, Dept Epidemiol & Biostat, Loma Linda, CA 92354 USA; Univ Cincinnati, Med Ctr, Dept Neurosurg, Cincinnati, OH 45221 USA; Univ Cincinnati, Med Ctr, Dept Neurol, Cincinnati, OH 45221 USA	Holshouser, BA (corresponding author), Loma Linda Univ, Med Ctr, Sch Med, Dept Radiol, MRI-B624,12354 Anderson St, Loma Linda, CA 92354 USA.	bholshouser@ahs.llumc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628			Adams A, 2001, BCS CONF SERIES, P49; Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P117; Baslow MH, 2000, J NEUROCHEM, V75, P453, DOI 10.1046/j.1471-4159.2000.0750453.x; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Graham DI, 1996, NEUROTRAUMA, P43; GUIMARAES AR, 1995, NEUROSCIENCE, V69, P1095, DOI 10.1016/0306-4522(95)00300-8; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2002, ACT NEUR S, V81, P373; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Wild JM, 1999, MAGN RESON MATER PHY, V8, P109; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; 2003, AM ASS NEUR SURG C N	22	51	54	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	JUL	2006	24	1					33	40		10.1002/jmri.20607			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	061TG	WOS:000238894900004	16755529	Bronze			2021-06-18	
J	Cheng, SKW; Man, DWK				Cheng, S. K. W.; Man, D. W. K.			Management of impaired self-awareness in persons with traumatic brain injury	BRAIN INJURY			English	Article						TBI; impaired self-awareness; training; intervention; feedback	INSTRUMENTAL ACTIVITIES; DEFICITS; UNAWARENESS; ADULTS	Aim: To develop and evaluate a systematic intervention programme for the management of impaired self-awareness (ISD) in people with traumatic brain injury. Methods: This study adopted a pre-test-post-test control group design. Twenty-one patients with traumatic brain injury were randomly assigned to an experimental group and a control group according to their admission sequence. The groups joined a newly developed Awareness Intervention Programme (AIP) and a conventional rehabilitation programme respectively for 4 weeks. Pre- and post-intervention outcome measures taken from the two groups were compared. Wilcoxon Signed-Ranks Tests were conducted to compare the within-group changes of the outcome measures of the Self-Awareness of Deficits Interview (SADI), the Functional Independence Measure (FIM) and the Lawton Instrumental Activities of Daily Living Score ( Lawton IADL) in the control and experimental groups. Mann Whitney U-tests were conducted to compare the across-group differences of improvements of outcome measures between the participants in the two groups. Results: After AIP training, the participants in the experimental group demonstrated significant improvement in their level of awareness as compared to the control group. However, the functional outcomes of the participants in experimental group did not show significant differences. Conclusion: The AIP can promote improvement in the level of self-awareness of people with traumatic brain injury. This new programme can be further developed to extend a better carryover treatment effect to functional improvement in daily activities.	Hong Kong Polytech Univ, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China; Hosp Author, MacLehose Med Rehabil Ctr, Occupat Therapy Dept, Hong Kong, Hong Kong, Peoples R China	Man, DWK (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China.	rsdavid@polyu.edu.hk					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Bergquist Thomas F., 1993, Brain Injury, V7, P275, DOI 10.3109/02699059309029680; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Fiedler R.C., 1996, FUNCTIONAL EVALUATIO, P75; Fleming JM, 1996, BRAIN INJURY, V10, P1; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Langer K.G., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [https://doi.org/10.1080/09602019208401395, DOI 10.1080/09602019208401395]; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LESLIE GP, 2000, FDN CLIN RES APPL PR, P193; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; PRIGATANO GP, 1991, DISTURBANCE SELF AWA, P3; PRIGATANO GP, 1995, BLACKWELL DICT NEURO, P80; Rebmann MJ, 1995, REHABIL PSYCHOL, V40, P279, DOI 10.1037/0090-5550.40.4.279; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; SODERBACK I, 1992, ARCH PHYS MED REHAB, V73, P1140; Sohlberg M, 2001, COGNITIVE REHABILITA, P269; Sohlberg McKay Moore, 2000, Seminars in Speech and Language, V21, P135; Tham K, 1997, ARCH PHYS MED REHAB, V78, P410, DOI 10.1016/S0003-9993(97)90234-3; Tong AYC, 2002, OTJR-OCCUP PART HEAL, V22, P132, DOI 10.1177/153944920202200402	21	51	52	0	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	6					621	628		10.1080/02699050600677196			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LU	WOS:000238947100007	16754287				2021-06-18	
J	Chamberlain, DJ				Chamberlain, DJ			The experience of surviving traumatic brain injury	JOURNAL OF ADVANCED NURSING			English	Article						disability; head injury; narrative methodologies; rehabilitation nursing; self-recovery	SCALE	Aim: This paper reports a study describing the experience of surviving traumatic brain injury as narrated by individuals 1 year after injury. Background: The experience of surviving traumatic brain injury is an individual and invisible experience. Healing and resolution of grief is still problematic for many years after injury. This experience includes those with severe injury. There is limited literature focusing on the survivor. Methodology: Sixty people with hospital admission diagnoses of traumatic brain injury were interviewed 1 year after injury using the Extended Glasgow Outcome Score questionnaire. Survivors then described their experiences of recovery. Data were collected through unstructured in-depth interviews, transcribed from audio-tapes and analysed into references. Qualitative content analysis was used to compile their frequencies from recurring themes. Findings: Sixty survivors with a median age of 35 years were enrolled in the study, with 100% follow-up. Twelve per cent returned to full preinjury functioning, 35% had residual psychosocial and physical sequelae, 38% had significant restrictions in lifestyle and work capacity, and 15% were unable to care for themselves throughout the 24-hour period. The common narratives were classified into five categories: 'regret and grief within self'; 'insensitivity of health professionals'; 'invisibility of self'; 'stranded self'; and 'recovery in self'. These self-narratives reflected renewed ways to view the self, which were conceptualized to be intact 'in spite of' or to be worthwhile 'because of' the traumatic brain injury. Conclusion: Self-narratives could be a worthwhile focus of psychological intervention by substituting positive narratives for negative ones, demonstrating hope and a positive outlook on life in order to enhance self-reflection and improve mental health. They can assist people to minimize, avoid or overcome devaluation and, as such, provide a basis for considerable nursing rehabilitation practice, even in those with severe injury.	Flinders Univ S Australia, Sch Nursing & Midwifery, Adelaide, SA 5001, Australia	Chamberlain, DJ (corresponding author), Flinders Univ S Australia, Sch Nursing & Midwifery, GPO Box 2100, Adelaide, SA 5001, Australia.	di.chamberlain@flinders.edu.au		Chamberlain, Diane/0000-0002-4157-9966			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; Berg B.L., 1989, QUALITATIVE RES METH; Bowlby J., 1980, ATTACHMENT LOSS LOSS, V3; BUGEN LA, 1979, DEATH DYING THEORY R; Burnard P, 1991, Nurse Educ Today, V11, P461, DOI 10.1016/0260-6917(91)90009-Y; Charmaz K, 1987, RES SOCIOLOGY HLTH C, V6, P283, DOI DOI 10.1111/1467-9566.EP10491512; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); CONNOR P, 2002, HOSPITALISATION DUE; Deegan P, 1996, PSYCHIATR REHABIL J, V19, P91, DOI 10.1037/h0101301; Eadie TL, 2003, AM J SPEECH-LANG PAT, V12, P189, DOI 10.1044/1058-0360(2003/065); FOUCAULT M, 1982, CRIT INQUIRY, V8, P777, DOI 10.1086/448181; Foucault M., 1997, ESSENTIAL WORKS, P223, DOI DOI 10.1111/J.1083-6101.1995.TB00328.X; Foucault M., 1973, BIRTH CLIN ARCHAEOLO; FRAK AW, 1991, WILL BODY REFLECTION; FRANK AW, 1993, SOCIOL QUART, V34, P39, DOI 10.1111/j.1533-8525.1993.tb00129.x; FRANK AW, 1994, LIT MED, V13, P1, DOI 10.1353/lm.2011.0180; Freud S., 1957, STANDARD EDITION, VXIV, P243; GOLDSTEIN G, 1998, REHABILITATION; JENNETT B, 1975, LANCET, V1, P480; Kothari S, 2003, J HEAD TRAUMA REHAB, V18, P379, DOI 10.1097/00001199-200307000-00008; LEVIN HS, 2000, CEREBRAL REOARGANIZA; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; NOCHI M, 2001, EVIDENCE BASED MENTA, V4, P127; RAMSAY RW, 1979, TRENDS BEHAVIOUR THE, P217; Rapp CA, 1998, STRENGTHS MODEL CASE; Rubin S. S, 1996, CONTINUING BONDS NEW, P217; Sanders C., 1989, GRIEF MOURNING DEALI; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; STUSS DT, 1999, COGNITIVE NEUROREHAB; Tishelman C, 1998, QUAL HEALTH RES, V8, P48, DOI 10.1177/104973239800800104; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Worden J.W., 1991, GRIEF COUNSELLING GR; World Health Organization, 2002, INT CLASS FUNCT DIS	36	51	51	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0309-2402	1365-2648		J ADV NURS	J. Adv. Nurs.	MAY	2006	54	4					407	417		10.1111/j.1365-2648.2006.03840.x			11	Nursing	Nursing	038VN	WOS:000237257700001	16671970				2021-06-18	
J	Testa, JA; Malec, JF; Moessner, AM; Browt, AW				Testa, Julie A.; Malec, James F.; Moessner, Anne M.; Browt, Allen W.			Predicting family functioning after TBI - Impact of neurobehavioral factors	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; depression; family functioning; rehabilitation	TRAUMATIC BRAIN-INJURY; DEPRESSION; REHABILITATION; CAREGIVERS	Objective: To identify risk factors for poor family functioning and neurobehavioral problems after traumatic brain injury (TBI) or orthopedic injuries (OI). Design: Longitudinal analyses of data from an inception cohort. Participants: Seventy-five patients with moderate/severe TBI, 47 patients with mild TBI, and 44 patients with OI at discharge; and 49 patients with moderate/severe TBI, 24 patients with mild TBI, and 33 patients with OI at 1-year follow-up. Outcome measures: Measures of family functioning (Family Assessment Device) and Neurobehavioral Functioning Index at hospital discharge and 1-year follow-up. Results: At discharge, patients with moderate/severe TBI had more symptoms of depression, memory/attention problems, and motor impairments than patients with OI and greater communication difficulties than patients with OI or mild TBI. At follow-up, patients with moderate/severe TBI continued to have more problems in memory/attention, depression, and communication. Approximately one third of each group had unhealthy family functioning at each assessment period. Few patients reported both impaired family functioning and clinical depression. Distressed family functioning correlated strongly with increased rates of neurobehavioral symptoms. Family dysfunction at follow-up was best predicted by family dysfunction at discharge and depression or memory/attention deficits at follow-up. Conclusions: After TBI, patients at the greatest risk for distress at follow-up were those with family dysfunction at discharge and continued neurobehavioral problems. High-risk families need to be identified so that necessary referrals and/or treatment can be offered.	Mayo Clin & Mayo Fdn, Dept Psychiat & Psychol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Nursing, Rochester, MN 55905 USA	Testa, JA (corresponding author), Mayo Clin & Mayo Fdn, Dept Psychiat & Psychol, 200 1st St SW, Rochester, MN 55905 USA.	testa.julie@mayo.edu		Brown, Allen W./0000-0001-7228-3351	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A020507] Funding Source: Medline		Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Anderson-Parente JK, 1990, COGNITIVE REHABILITA, P22; Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Rush BK, 2006, REHABIL PSYCHOL, V51, P257, DOI 10.1037/0090-5550.51.3.257; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	29	51	52	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2006	21	3					236	247		10.1097/00001199-200605000-00004			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	044YL	WOS:000237709600004	16717501				2021-06-18	
J	Dhaliwal, A; West, AL; Trobe, JD; Musch, DC				Dhaliwal, A; West, AL; Trobe, JD; Musch, DC			Third, fourth, and sixth cranial nerve palsies following closed head injury	JOURNAL OF NEURO-OPHTHALMOLOGY			English	Article							SUPERIOR OBLIQUE PALSY; 6TH CRANIAL NERVES; OCULOMOTOR NERVE; CERVICAL-SPINE; INITIAL SIGN; TRAUMA; PARALYSIS; 3RD; TROCHLEAR; 4TH	Background: The relationship between the circumstances and severity of closed head injury (CHI) and the clinical and imaging features of cranial nerve 3, 4, and 6 palsies has not been rigorously addressed in a large study. Methods: Retrospective chart review of 210 consecutive patients with CHI examined at a single tertiary care center from 1987 to 2002. Patients were located by searching the ophthalmology inpatient consultation and neuro-ophthalmology outpatient databases and hospital emergency room billing codes for a diagnosis of traumatic 3, 4, or 6 cranial nerve palsy (Cranial Nerve Injury Group) and a diagnosis of CHI without traumatic 3, 4, or 6 nerve palsy (Control Group). The Cranial Nerve Injury Group was then subdivided into two groups: those with injuries to an individual cranial nerve and those with multiple (including bilateral) cranial nerve injuries. Comparisons between groups were based on age, gender, type of accident, Glasgow Coma Scale (GCS), documented loss of consciousness (LOC), type of ocular injury, presence of systemic injury, need for rehabilitation, physical therapy and cognitive scores, and imaging features. Results: The Cranial Nerve Injury Group had a significantly higher severity of head injury, more CT abnormalities, and worse short-term neurologic outcomes as compared with the Control Group. These trends were also found when each cranial nerve injury subgroup was compared with the Control Group. Those with cranial nerve 3 palsy had the most severe head injury; those with cranial nerve 4 palsy had an intermediate level of head injury; and those with cranial nerve 6 palsy had the lowest level of head injury. There were no consistent associations between the location of the imaging abnormalities and which cranial nerve was damaged. Conclusions: CHI with palsy of an ocular motor nerve was more severe than CHI without ocular motor nerve palsy, as measured by the GCS, intracranial and skull imaging abnormalities, and a greater frequency of inpatient rehabilitation. Palsy of cranial nerve 3 was associated with relatively more severe CHI than was palsy of cranial nerves 4 or 6. The location of the imaging abnormalities did not correlate with a particular cranial nerve injury.	Univ Michigan, Med Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA	Trobe, JD (corresponding author), Univ Michigan, Med Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.	jdtrobe@umich.edu		Musch, David/0000-0002-4164-3841; Trobe, Jonathan/0000-0003-0728-6729			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BAKER RS, 1991, SURV OPHTHALMOL, V35, P245, DOI 10.1016/0039-6257(91)90046-I; Balcer LJ, 1996, AM J OPHTHALMOL, V122, P437, DOI 10.1016/S0002-9394(14)72078-1; BURGER LJ, 1970, BRAIN, V93, P567, DOI 10.1093/brain/93.3.567; BURGERMAN RS, 1989, NEUROSURGERY, V25, P978, DOI 10.1227/00006123-198912000-00023; CHAPMAN L I, 1970, Archives of Ophthalmology, V84, P137; COPPETO JR, 1983, ANN OPHTHALMOL, V15, P681; CROUCH ER, 1975, AM J OPHTHALMOL, V79, P990, DOI 10.1016/0002-9394(75)90683-2; ELSTON JS, 1984, BRIT J OPHTHALMOL, V68, P538, DOI 10.1136/bjo.68.8.538; EYSTER EF, 1972, J AMER MED ASSOC, V220, P1083, DOI 10.1001/jama.220.8.1083; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GREEN WR, 1964, ARCH OPHTHALMOL-CHIC, V72, P154; HEINZE J, 1969, MED J AUSTRALIA, V2, P1246, DOI 10.5694/j.1326-5377.1969.tb103371.x; Holmes JM, 1999, AM J OPHTHALMOL, V127, P388, DOI 10.1016/S0002-9394(98)00424-3; HOOPER RS, 1951, BRIT J SURG, V39, P126, DOI 10.1002/bjs.18003915406; ING EB, 1992, J PEDIATR OPHTHALMOL, V29, P331; JACOBSON DM, 1988, J CLIN NEURO-OPHTHAL, V8, P263; KEEFE WP, 1960, ARCH OPHTHALMOL-CHIC, V63, P585; KHAWAM E, 1967, ARCH OPHTHALMOL-CHIC, V77, P761, DOI 10.1001/archopht.1967.00980020763009; KODSI SR, 1992, AM J OPHTHALMOL, V114, P568, DOI 10.1016/S0002-9394(14)74484-8; KROHEL GB, 1979, AM J OPHTHALMOL, V88, P598, DOI 10.1016/0002-9394(79)90521-X; LAVIN PJM, 1984, ARCH NEUROL-CHICAGO, V41, P679, DOI 10.1001/archneur.1984.04210080091022; LEPORE FE, 1995, ARCH NEUROL-CHICAGO, V52, P924, DOI 10.1001/archneur.1995.00540330106022; LINDENBERG R, 1970, ARCH PATHOL, V90, P509; Lindenberg R, 1964, Clin Neurosurg, V12, P129; MEMON MY, 1971, J NEUROSURG, V35, P461, DOI 10.3171/jns.1971.35.4.0461; MOSTER ML, 1984, ARCH OPHTHALMOL-CHIC, V102, P1328; Neetens A, 1981, Bull Soc Belge Ophtalmol, V193, P161; ROSA L, 1984, J NEUROSURG, V61, P172, DOI 10.3171/jns.1984.61.1.0172; RUCKER CW, 1958, AM J OPHTHALMOL, V46, P787, DOI 10.1016/0002-9394(58)90989-9; RUCKER CW, 1966, AM J OPHTHALMOL, V61, P1293, DOI 10.1016/0002-9394(66)90258-3; RUSH JA, 1981, ARCH OPHTHALMOL-CHIC, V99, P76, DOI 10.1001/archopht.1981.03930010078006; RUSSELL WR, 1949, J NEUROL NEUROSUR PS, V12, P52, DOI 10.1136/jnnp.12.1.52; SABATES NR, 1991, J CLIN NEURO-OPHTHAL, V11, P273; SCHNEIDER RC, 1971, J NEUROSURG, V34, P33, DOI 10.3171/jns.1971.34.1.0033; SUMMERS CG, 1979, J NEUROSURG, V50, P508, DOI 10.3171/jns.1979.50.4.0508; SYDNOR CF, 1982, OPHTHALMOLOGY, V89, P134; TELLER J, 1988, ANN OPHTHALMOL, V20, P424; WALTER KA, 1994, NEUROLOGY, V44, P148, DOI 10.1212/WNL.44.1.148; YOUNGE BR, 1977, MAYO CLIN PROC, V52, P11	41	51	51	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1070-8022	1536-5166		J NEURO-OPHTHALMOL	J. Neuro-Ophthal.	MAR	2006	26	1					4	10		10.1097/01.wno.0000204661.48806.1d			7	Clinical Neurology; Ophthalmology	Neurosciences & Neurology; Ophthalmology	020TB	WOS:000235932200002	16518159				2021-06-18	
J	Ucar, T; Tanriover, G; Gurer, I; Onal, MZ; Kazan, S				Ucar, T; Tanriover, G; Gurer, I; Onal, MZ; Kazan, S			Modified experimental mild traumatic brain injury model	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						mild head injury; experimental; model	LATERAL FLUID-PERCUSSION; CEREBRAL-BLOOD-FLOW; HEAD-INJURY; AXONAL INJURY; RATS; PATHOPHYSIOLOGY; PATTERNS	Background: Experimental models of traumatic brain injury (TBI), using a variety of techniques and species, have been devised with the aim of producing repeatable lesions resembling those found in head injuries. There are various TBI models mentioned in the literature. In experimental head trauma models, emphasis has been placed on the severe head injuries. There are only a few models developed to study mild traumatic brain injury (MTBI). In fact, MTBI is as an important a problem as severe head injuries for neurosurgeons. Methods: Fifty-six male Sprague-Dawley rats were subjected to MTBI with a weight-drop device, which was described by Marmarou et al. The said model was used in its original form as well as in modified forms by employing different weights dropped from the same height. Animals were divided into four groups of 14 rats as follows: Group I (n = 14), head injury was induced using 450 g-1 m weight-height impact; Group II (n = 14), head injury was induced using 350 g-1 m weight-height impact; Group III (n = 14), head injury was induced using 300 g-1 m weight-height impact; Group IV (n = 14), control group, no injury was applied. Animals were evaluated neurologically, physiologically, electrophysiologically, and histopathologically. Results: Group I and II animals (450 and 350 g-1 m weight-height impact, respectively) showed the symptoms of severe head injury, whereas Group III animals (300 g-1 m) showed more MTBI symptoms. Conclusions: We recommend the application of the modified MTBI model used for group III (300 g-1 m weightheight impact) as the most appropriate and the simplest model for future MTBI studies.	Univ Akdeniz, Sch Med, Dept Neurosurg, TR-07070 Antalya, Turkey; Univ Akdeniz, Sch Med, Dept Histol, TR-07070 Antalya, Turkey; Univ Akdeniz, Sch Med, Dept Pathol, TR-07070 Antalya, Turkey; Univ Akdeniz, Sch Med, Dept Neurol, TR-07070 Antalya, Turkey	Ucar, T (corresponding author), Univ Akdeniz, Sch Med, Dept Neurosurg, TR-07070 Antalya, Turkey.	tucar@akdeniz.edu.tr	Gurer, Inanc Elif/C-3042-2016; Kazan, Saim/G-1782-2016; Tanriover, Gamze/A-3196-2012	Tanriover, Gamze/0000-0002-8002-5544			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1982, HEAD INJURY BASIC CL; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDREWS R J, 1992, Neurological Research, V14, P12; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Cenci MA, 2002, NAT REV NEUROSCI, V3, P574, DOI 10.1038/nrn877; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; KRUIKJ JR, 2001, BRAIN INJURY, V15, P99; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Leker RR, 2002, ACTA NEUROCHIR SUPPL, V83, P49; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1966, NEUROTRAUMA; Marmarou A, 1990, Adv Neurol, V52, P233; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mathew P, 1996, J NEUROSURG, V85, P860, DOI 10.3171/jns.1996.85.5.0860; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1974, NEURAL TRAUMA; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARK HK, 1992, CRIT REV NEUROSURG, V26, P44; Parsons LC, 1997, J NEUROTRAUM, V14, P549, DOI 10.1089/neu.1997.14.549; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Ricker JH, 2000, J HEAD TRAUMA REHAB, V15, P859, DOI 10.1097/00001199-200004000-00007; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613	39	51	51	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2006	60	3					558	565		10.1097/01.ta.0000209172.75637.db			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	026WX	WOS:000236374900020	16531854				2021-06-18	
J	Rutigliano, D; Egnor, MR; Priebe, CJ; McCormack, JE; Strong, N; Scriven, RJ; Lee, TK				Rutigliano, D; Egnor, MR; Priebe, CJ; McCormack, JE; Strong, N; Scriven, RJ; Lee, TK			Decompressive craniectomy in pediatric patients with traumatic brain injury with intractable elevated intracranial pressure	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	36th Annual Meeting of the American-Pediatric-Surgical-Association	MAY, 2005	Phoenix, AZ	Amer Pediat Surg Assoc		decompressive craniectomy; traumatic brain injury; cerebral perfusion pressure; intracranial pressure; children; adolescents	SEVERE HEAD-INJURY; AGGRESSIVE TREATMENT; CHILDREN; HYPERTENSION; CRANIOTOMY	Background: Care of pediatric traumatic brain injury (TBI) has placed emphasis on maximizing cerebral perfusion to prevent ischemia and reperfusion injury. A subset of patients with TBI will continue to have refractory intracranial pressure (ICP) elevation despite aggressive therapy including ventriculostomy, pentobarbital coma, hypertonic saline, and diuretics. Decompressive craniectomy (DC) is a controversial treatment of severe TBI. It is our hypothesis that DC can enhance survival and minimize secondary brain injury in this patient subset. Methods: Patients younger than 20 years treated at a level I regional trauma center between November 2001 and November 2004, who met inclusion criteria for the Brain Trauma Foundation TBI-trac clinical database were included. All patients with a mechanism of injury consistent with TBI and Glasgow Coma Scale score of less than 9 for at least 6 hours after resuscitation and who did not die in the emergency department are entered into a clinical database. Patients who arrived at the study hospital more than 24 hours after injury are excluded. Results: There were 30 patients with TBI identified. The mean Glasgow Coma Scale score at presentation was 8 with a range of 3 to 13. Six patients underwent DC for intractable elevated ICP. Of 6 patient's postoperative ICP, 5 were less than 20 mm Hg. One patient required a return to the operating room where further debridement of brain was performed. All patients who received a DC survived and were discharged to a TBI rehabilitation facility. Conclusion: Although this is a small sample, DC should be considered in patients with TBI with refractory elevated ICP. Long-term follow-up of this patient population should consist of neuropsychiatric evaluation in conjunction with measurement of social function. (c) 2006 Elsevier Inc. All rights reserved.	SUNY Stony Brook, Hlth Sci Ctr, Dept Surg, Div Pediat Surg, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Neurosurg, Stony Brook, NY 11794 USA	Lee, TK (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Surg, Div Pediat Surg, T-19,090, Stony Brook, NY 11794 USA.	tklee@notes.cc.sunysb.edu					ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; GAAB MR, 1990, ACT NEUR S, V51, P326; Gower DJ, 1988, NEUROSURGERY, V90, P187; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Kunze E, 1998, ACT NEUR S, V71, P16; Langlois JA., 2004, TRAUMATIC BRAIN INJU; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; PFENNINGER J, 1983, INTENS CARE MED, V9, P13, DOI 10.1007/BF01693699; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; PUTTS LH, 1980, INTRACRANIAL PRESSUR, V4, P5; Schwab S, 1997, NEUROLOGY, V48, P412, DOI 10.1212/WNL.48.2.412; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410	24	51	52	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	JAN	2006	41	1					83	87		10.1016/j.jpedsurg.2005.10.010			5	Pediatrics; Surgery	Pediatrics; Surgery	010JZ	WOS:000235189400023	16410113				2021-06-18	
J	Shavelle, RM; DeVivo, MJ; Strauss, DJ; Paculdo, DR; Lammertse, DP; Day, SM				Shavelle, Robert M.; DeVivo, Michael J.; Strauss, David J.; Paculdo, David R.; Lammertse, Daniel P.; Day, Steven M.			Long-term survival of persons ventilator dependent after spinal cord injury	JOURNAL OF SPINAL CORD MEDICINE			English	Article						spinal cord injuries; model systems; tetraplegia; ventilator dependence; mortality; life expectancies; national spinal cord injury statistical center	TRAUMATIC BRAIN-INJURY; LIFE EXPECTANCY; CEREBRAL-PALSY; MORTALITY; TRENDS; DEATH; CHILDREN; SYSTEMS; CARE	Background/Objective: Identify factors related to long-term survival, and quantify their effect on mortality and life expectancy. Setting: Model spinal cord injury systems of care across the United States. Study Design: Survival analysis of persons with traumatic spinal cord injury who are ventilator dependent at discharge from inpatient rehabilitation and who survive at least I year after injury. Methods: Logistic regression analysis on a data set of 1,986 person-years occurring among 319 individuals injured from 1973 through 2003. Results: The key factors related to long-term survival were age, time since injury, neurologic level, and degree of completeness of injury. The life expectancies were modestly lower than previous estimates. Pneumonia and other respiratory conditions remain the leading cause of death but account for only 31% of deaths of known causes. Conclusions: Whereas previous research has suggested a dramatic improvement in survival over the last few decades in this population, this is only the case during the critical first few years after injury. There was no evidence for such a trend in the subsequent period.	Life Expectancy Project, San Francisco, CA 94122 USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA; Craig Hosp, Denver, CO USA	Shavelle, RM (corresponding author), Life Expectancy Project, 1439 17th Ave, San Francisco, CA 94122 USA.	shavelle@lifeexpectancy.com	Day, Steven/P-1002-2019	Day, Marc/0000-0002-1711-3963; Lammertse, Daniel/0000-0003-4590-2481; Day, Steven/0000-0001-8305-5813; Paculdo, David/0000-0002-2184-4603			AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; American Spinal Injury Association, 2002, INT STAND NEUR CLASS; Anderson TW, 2002, LIFE EXPECTANCY COUR; ARIAS E, 2004, NATL VITAL STAT REPO, V52; Baguley I, 2000, BRAIN INJURY, V14, P505; Brown AW, 2004, NEUROREHABILITATION, V19, P37; CARTER RE, 1993, PARAPLEGIA, V31, P150, DOI 10.1038/sc.1993.28; CARTER RE, 1979, PARAPLEGIA, V17, P140, DOI 10.1038/sc.1979.28; Collett D., 1994, MODELLING SURVIVAL D; Devivo Michael J., 1995, P289; DeVivo Michael J, 2002, J Spinal Cord Med, V25, P335; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; DEVIVO MJ, 1989, ARCH INTERN MED, V149, P1761, DOI 10.1001/archinte.149.8.1761; DEVIVO MJ, 1992, ARCH PHYS MED REHAB, V73, P156; DEVIVO MJ, 1993, ARCH PHYS MED REHAB, V74, P248; DEVIVO MJ, 1995, CHEST, V108, P226, DOI 10.1378/chest.108.1.226; Frankel H L, 1969, Paraplegia, V7, P179; FUHRER MJ, 1987, ARCH PHYS MED REHAB, V68, P353; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hosmer D, 1989, APPL LOGISTIC REGRES; Kirshblum S, 1999, ARCH PHYS MED REHAB, V80, P1101, DOI 10.1016/S0003-9993(99)90068-0; Krause JS, 2004, ARCH PHYS MED REHAB, V85, P1764, DOI 10.1016/j.apmr.2004.06.062; Marino RJ, 1999, ARCH PHYS MED REHAB, V80, P1391, DOI 10.1016/S0003-9993(99)90249-6; Marsolais EB, 2005, J SPINAL CORD MED, V28, P259; McCullagh P., 1989, GEN LINEAR MODELS; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; SCHOEN R, 1988, MODELLING MULTIGROUP; Shavelle RM, 2006, BRAIN INJURY MED PRI; Stover SL, 1999, ARCH PHYS MED REHAB, V80, P1365, DOI 10.1016/S0003-9993(99)90246-0; Strauss D, 1998, DEV MED CHILD NEUROL, V40, P369; Strauss D, 1997, J PEDIATR-US, V131, P712, DOI 10.1016/S0022-3476(97)70098-2; Strauss D, 2000, J Insur Med, V32, P217; Strauss David J, 2005, J Insur Med, V37, P20; Strauss DJ, 2006, ARCH PHYS MED REHAB, V87, P1079, DOI 10.1016/j.apmr.2006.04.022; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; WHITENECK G, 1989, MANAGEMENT HIGH QUAD, P353; WICKS AB, 1986, CHEST, V90, P406, DOI 10.1378/chest.90.3.406	38	51	52	0	5	AMER PARAPLEGIA SOC	JACKSON HWIGHTS	75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA	1079-0268			J SPINAL CORD MED	J. Spinal Cord. Med.		2006	29	5					511	519		10.1080/10790268.2006.11753901			9	Clinical Neurology	Neurosciences & Neurology	121GC	WOS:000243145100006	17274490	Green Published			2021-06-18	
J	Schmitt, A; Bertsch, T; Henning, U; Tost, H; Klimke, A; Henn, FA; Falkai, P				Schmitt, A; Bertsch, T; Henning, U; Tost, H; Klimke, A; Henn, FA; Falkai, P			Increased serum S100B in elderly, chronic schizophrenic patients: Negative correlation with deficit symptoms	SCHIZOPHRENIA RESEARCH			English	Article						.S100B; schizophrenia; negative symptoms; clozapine; haloperidol	CALCIUM-BINDING PROTEINS; TRAUMATIC BRAIN INJURY; NEUROTROPHIC ACTIVITY; ANTIPSYCHOTIC-DRUGS; ALZHEIMERS-DISEASE; S100-BETA PROTEIN; PREFRONTAL CORTEX; 5-HT1A RECEPTORS; S-100B PROTEIN; VERBAL FLUENCY	In schizophrenia, elevations of serum and CSF S100B levels have been reported and related to state of the disease and negative symptoms. In elderly chronic schizophrenic inpatients with stable medication, S100B may be increased and correlated to psychopathology and neuropsychological deficits. We have measured serum levels of S100B in 41 elderly, chronic schizophrenic patients and 23 age- and gender-matched controls using an immunoluminometric assay. In patients, we assessed detailed psychopathology and neuropsychological performance and determined serum levels of haloperidol, clozapine and its two main metabolites desmethylclozapine and clozapine metabolite N-oxid by HPLC. S100B levels were increased in elderly chronic schizophrenic patients compared to healthy controls. In patients, levels were negatively correlated with deficit symptoms and positively with age. There were no significant differences of S100B between medication groups and no correlation with serum levels of antipsychotics or neuropsychological scores. Elevations of S100B in elderly chronic schizophrenic patients may be related to an active disease process lasting until old-age. Correlations point to the impact of S100B in neuroplasticity and ageing. Post-mortem studies should clarify the presence of altered S100B function in the brain and its relationship to neuroplastic or neurodegenerative processes. (c) 2005 Elsevier B.V. All rights reserved.	Cent Inst Mental Hlth, D-68070 Mannheim, Germany; Clin Nuremberg, Inst Clin Chem & Lab Med, D-90419 Nurnberg, Germany; Univ Dusseldorf, Dept Psychiat, Neurobiochem Res Unit, D-40629 Dusseldorf, Germany; Univ Saarland, Dept Psychiat, D-66421 Homburg, Germany	Schmitt, A (corresponding author), Cent Inst Mental Hlth, POB 12 21 20, D-68070 Mannheim, Germany.	schmitt@zi-mannheim.de	Falkai, Peter/E-3273-2017; Tost, med. Dr. phil. Heike/AAX-8305-2020; Schmitt, Andrea/V-3003-2018	Falkai, Peter/0000-0003-2873-8667; Schmitt, Andrea/0000-0002-5426-4023; Klimke, Ansgar/0000-0002-1160-5270			Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; Andreasen N.C., 1983, SCALE ASSESSMENT POS; Andreasen N.C., 1983, SCALE ASSESSMENT NEG; *ASS AM PSYCH, 1994, DSM 4 DIAGN STAT MAN; Azmitia EC, 2002, PROG BRAIN RES, V136, P87; AZMITIA EC, 1990, BRAIN RES, V516, P354, DOI 10.1016/0006-8993(90)90942-5; BENES FM, 1991, SCHIZOPHR RES, V5, P187, DOI 10.1016/0920-9964(91)90063-W; BHATTACHARYYA A, 1992, J NEUROBIOL, V23, P451, DOI 10.1002/neu.480230410; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Bymaster FP, 1996, NEUROPSYCHOPHARMACOL, V14, P87, DOI 10.1016/0893-133X(94)00129-N; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRITH CD, 1995, BRIT J PSYCHIAT, V167, P343, DOI 10.1192/bjp.167.3.343; Gattaz WF, 2000, SCHIZOPHR RES, V43, P91, DOI 10.1016/S0920-9964(99)00146-2; GRIFFIN WST, 1995, J NEUROCHEM, V65, P228; Griffin WST, 1998, NEUROBIOL AGING, V19, P401, DOI 10.1016/S0197-4580(98)00074-8; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; Hu JR, 1997, J NEUROCHEM, V69, P2294; Ichikawa J, 1998, EUR J PHARMACOL, V351, P163, DOI 10.1016/S0014-2999(98)00308-2; Jahn T., 1989, Z KLIN PSYCHOL, V18, P257; Joyce EM, 1996, PSYCHOL MED, V26, P39, DOI 10.1017/S0033291700033705; KIRCH DG, 1992, J NEURAL TRANSM-GEN, V89, P219, DOI 10.1007/BF01250674; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Lara DR, 2001, J PSYCHIATR RES, V35, P11, DOI 10.1016/S0022-3956(01)00003-6; Lewis DA, 2001, AM J PSYCHIAT, V158, P1411, DOI 10.1176/appi.ajp.158.9.1411; Lewis DA, 2000, BRAIN RES REV, V31, P270, DOI 10.1016/S0165-0173(99)00042-9; Li YK, 1998, J NEUROCHEM, V71, P1421; MARSHAK DR, 1992, NEUROBIOL AGING, V13, P1, DOI 10.1016/0197-4580(92)90002-F; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; McKeating EG, 1998, ACT NEUR S, V71, P117; MELTZER HY, 1991, PHARMACOL REV, V43, P587; MELTZER HY, 1998, AM PSYCHIAT PRESS TX, P747; Newman-Tancredi A, 1998, EUR J PHARMACOL, V355, P245, DOI 10.1016/S0014-2999(98)00483-X; OKADO N, 1993, J NEUROBIOL, V24, P687, DOI 10.1002/neu.480240512; Oswald W. D., 1986, NURNBERGER ALTERS IN; OVERALL JE, 1962, PSYCHOL REP, V10, P799; PENA LA, 1995, MOL BRAIN RES, V34, P118, DOI 10.1016/0169-328X(95)00145-I; Portela LVC, 2002, CLIN CHEM, V48, P950; Poyurovsky M, 1997, INT CLIN PSYCHOPHARM, V12, P263, DOI 10.1097/00004850-199709000-00003; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Reitan R. M, 1992, TRAIL MAKING TEST; Rothermundt M, 2001, MOL PSYCHIATR, V6, P445, DOI 10.1038/sj.mp.4000889; Rothermundt M, 2004, NEUROPSYCHOPHARMACOL, V29, P1004, DOI 10.1038/sj.npp.1300403; Rothermundt M, 2004, INT REV NEUROBIOL, V59, P445; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schroeter ML, 2003, SCHIZOPHR RES, V62, P231, DOI 10.1016/S0920-9964(02)00383-3; Schroeter ML, 1999, FEBS LETT, V449, P241, DOI 10.1016/S0014-5793(99)00451-2; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SHENG JG, 1994, J NEUROSCI RES, V39, P398, DOI 10.1002/jnr.490390406; Thune JJ, 2000, BRAIN RES REV, V31, P200, DOI 10.1016/S0165-0173(99)00038-7; UEDA S, 1995, MOL BRAIN RES, V29, P365, DOI 10.1016/0169-328X(94)00269-K; VANELDIK LJ, 1994, BBA-MOL CELL RES, V1223, P398, DOI 10.1016/0167-4889(94)90101-5; VANELDIK LJ, 1991, BRAIN RES, V542, P280, DOI 10.1016/0006-8993(91)91579-P; WHITAKERAZMITIA PM, 1994, PERSPECT DEV NEUROBI, V2, P233; Wiesmann M, 1999, BIOL PSYCHIAT, V45, P1508, DOI 10.1016/S0006-3223(98)00217-0; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	60	51	57	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-9964			SCHIZOPHR RES	Schizophr. Res.	DEC 15	2005	80	2-3					305	313		10.1016/j.schres.2005.04.013			9	Psychiatry	Psychiatry	004MT	WOS:000234757600017	15964742				2021-06-18	
J	Barut, S; Unlu, YA; Karaoglan, A; Tuncdemir, M; Dagistanli, FK; Ozturk, M; Colak, A				Barut, S; Unlu, YA; Karaoglan, A; Tuncdemir, M; Dagistanli, FK; Ozturk, M; Colak, A			The neuroprotective effects of z-DEVD.fmk, a caspase-3 inhibitor, on traumatic spinal cord injury in rats	SURGICAL NEUROLOGY			English	Article						apoptotic cell death; caspase 3; programmed cell death; spinal cord injury; z-DEVD.fmk	CELL-DEATH; NEURONAL APOPTOSIS; BRAIN-INJURY; ACTIVATION; IDENTIFICATION; EXPRESSION; ISCHEMIA; NECROSIS; HOMOLOG; ICE	Background: Apoptosis is one of the most important forms of cell death seen in a variety of physiological and pathological conditions, including traumatic injuries. This type of cell death occurs via mediators known as caspases. Previous studies have investigated the roles that apoptosis and different caspases play in the pathogenesis of secondary damage after spinal cord injury (SCI). The aim of this research was to assess the neuroprotective effect of z-DEVD.frnk, a caspase-3 inhibitor, in a rat model of SCI. Methods: Forty-five Wistar albino rats were studied in 3 groups of 15 animals: sham-operated control animals (group 1); trauma-only control animals (group 2); and rats subjected to trauma + z-DEVD.ftnk treatment (group 3). Spinal cord injury was produced at the thoracic level using the weight-drop technique. Responses to injury and the efficacy of z-DEVD.fmk were assessed by light microscopy and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling staining in cord tissues collected at 4 and 24 hours posttrauma. Five rats from each group were used to assess functional recovery at 7 days after SCI. The functional evaluations were done using the inclined-plane technique and a modified Tarlov motor grading scale. Results: At 4 hours postinjury, the mean apoptotic index in groups 1, 2, and 3 was 0, 33.01 +/- 6.62, and 16.40 +/- 4.91, respectively. The group 3 count was significantly lower than the group 2 count (P <.01). At 24 hours postinjury, light microscopic examination of group 2 tissues showed widespread hemorrhage, necrosis, polymorphonuclear leukocyte infiltration, and vascular thrombi. The group 3 tissues showed similar features. The prominent findings in group 2 were hemorrhage and necrosis, whereas the prominent findings in group 3 were focal hemorrhage and leukocyte infiltration. The mean inclined-plane angles in groups 1, 2, and 3 were 64.5 +/- 1.0, 41.5 +/- 1.3, and 47 +/- 2.0, respectively. Motor scale results in all groups showed a similar trend. Conclusion: Local application of z-DEVD.fmk after SCI in rats reduces secondary tissue injury and helps preserve motor function. These effects can be explained by inhibition of apoptotic death in all cell types in the spinal cord. (c) 2005 Elsevier Inc. All rights reserved.	Taksim Educ & Res Hosp, Neurosurg Clin, TR-34144 Istanbul, Turkey; Istanbul Univ, Cerrahpasa Sch Med, Dept Med Biol, TR-34144 Istanbul, Turkey	Colak, A (corresponding author), Terakki Caddesi 47-7, Istanbul, Turkey.	drahmetcolak@yahoo.com	Tuncdemir, Matem/P-3054-2018; dagistanli, Fatma Kaya/D-7548-2019	Tuncdemir, Matem/0000-0002-5300-4449; 			Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Bresnahan J. C., 1996, Society for Neuroscience Abstracts, V22, P1185; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; CROVE MJ, 1997, NAT MED, V3, P73; Deveraux QL, 1999, J CLIN IMMUNOL, V19, P388, DOI 10.1023/A:1020502800208; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Katoh K, 1996, NEUROSCI LETT, V216, P9; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li H, 2000, STROKE, V31, P176, DOI 10.1161/01.STR.31.1.176; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Namura S, 1998, J NEUROSCI, V18, P3659; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; RINK A, 1995, AM J PATHOL, V147, P1575; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Rudel T, 1999, HERZ, V24, P236, DOI 10.1007/BF03044967; Samali A, 1999, CELL DEATH DIFFER, V6, P495, DOI 10.1038/sj.cdd.4400520; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; TARLOV IM, 1957, SPINAL CORD COMPRESS; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Van de Craen M, 1998, CELL DEATH DIFFER, V5, P838, DOI 10.1038/sj.cdd.4400444; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355; Zurita M, 2001, J NEUROSURG, V94, P257, DOI 10.3171/spi.2001.94.2.0257	41	51	58	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	SEP	2005	64	3					213	220		10.1016/j.surneu.2005.03.042			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	961UI	WOS:000231686900006	16099247				2021-06-18	
J	Lu, KT; Wang, YW; Wo, YY; Yang, YL				Lu, KT; Wang, YW; Wo, YY; Yang, YL			Extracellular signal-regulated kinase-mediated IL-1-induced cortical neuron damage during traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						traumatic brain injuries; IL-1; mitogen-activated protein kinase	I-KAPPA-B; TRANSDUCTION PATHWAYS; PROTEIN-KINASES; INTERLEUKIN-1; RECEPTOR; VIVO; HIPPOCAMPUS; EXPRESSION; ISCHEMIA; TARGETS	Traumatic brain injury (TBI) is one of the most prevalent causes of morbidity and mortality in youth. Interleukin-1 (IL-1) has many roles in the brain in addition to mediating glial inflammatory response; it has also been implicated in neurodegenerative diseases. We demonstrated the signal transduction pathway of IL-1 overproduction-induced cortical neuron loss during TBI. A calibrated weight-drop device (450 g weight and 2 m height) was used to induce TBI in adult male Sprague-Dawley rats under general anesthesia (sodium pentobarbital: 40 mg/kg, i.p.). Expression of interleukin-1 alpha (IL-1 alpha), interleukin-1 beta (IL-1 beta), extracellular signal-regulated kinase (ERK), Jun, and p-38 were determined by Western blotting and RT-PCR. Neuronal damage was evaluated by microscopic examination. We found both mRNA and proteins of cortical IIL-1 alpha and IL-1 beta increased three hours after TBI. Phosphorylation of ERK significantly increased but there were no significant effects on cortical expression of ERK, Jun and p-38. Administration of ERK inhibitor, PD98059, IL-1 alpha antibody and IL-1 beta antibody protected animals from TBI-induced neuronal damage. Our results suggest that TBI-induced cortical neuron death was mediated by the IL-1 receptor through ERK phosphorylation. (C) 2005 Elsevier Ireland Ltd. All rights reserved.	Natl Chia Yi univ, Inst Biotechnol, Dept Mol Biol & Biochem, Chiayi, Taiwan; Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan	Yang, YL (corresponding author), Natl Chia Yi univ, Inst Biotechnol, Dept Mol Biol & Biochem, 300 Univ Rd, Chiayi, Taiwan.	ylyang@mail.ncyu.edu.tw					Arbabi S, 2002, CRIT CARE MED, V30, pS74, DOI 10.1097/00003246-200201001-00010; BAN E, 1991, NEUROSCIENCE, V43, P21, DOI 10.1016/0306-4522(91)90412-H; Boutin H, 2001, J NEUROSCI, V21, P5528; CALDWELL J, 1995, BLOOD, V86, P3364, DOI 10.1182/blood.V86.9.3364.bloodjournal8693364; Daun JM, 2000, J INTERF CYTOK RES, V20, P843, DOI 10.1089/10799900050163217; Davis S, 2000, J NEUROSCI, V20, P4563, DOI 10.1523/JNEUROSCI.20-12-04563.2000; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FARRAR WL, 1987, J IMMUNOL, V139, P459; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hallegua DS, 2002, ANN RHEUM DIS, V61, P960, DOI 10.1136/ard.61.11.960; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; Hommes DW, 2003, GUT, V52, P144, DOI 10.1136/gut.52.1.144; Kyriakis JM, 2001, PHYSIOL REV, V81, P807; LaPointe MC, 1999, HYPERTENSION, V33, P276, DOI 10.1161/01.HYP.33.1.276; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Molina-Holgado F, 2000, J NEUROIMMUNOL, V111, P1, DOI 10.1016/S0165-5728(00)00344-1; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Paxino G, 1997, RAT BRAIN STEREOTAXI; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rosengart MR, 2000, SHOCK, V13, P183, DOI 10.1097/00024382-200003000-00003; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009	28	51	56	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP	2005	386	1					40	45		10.1016/j.neulet.2005.05.057			6	Neurosciences	Neurosciences & Neurology	955GR	WOS:000231214300009	16024175				2021-06-18	
J	Adani, R; Tarallo, L; Marcoccio, I; Cipriani, R; Gelati, C; Innocenti, M				Adani, R; Tarallo, L; Marcoccio, I; Cipriani, R; Gelati, C; Innocenti, M			Hand reconstruction using the thin anterolateral thigh flap	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article; Proceedings Paper	2nd Congress of the World-Society-for-Reconstructive-Microsurgery	JUN 11-14, 2003	HEIDELBERG, GERMANY	World Soc Reconstruct Microsurg			FOREARM ISLAND FLAP; SOFT-TISSUE DEFECTS; PERFORATOR FLAP; RADIAL ARTERY; CLINICAL-APPLICATIONS; NECK DEFECTS; DONOR-SITE; EXPERIENCE; HEAD; PRESERVATION	Background: Perforator flaps have been introduced for various kinds of reconstruction and resurfacing; in particular, the free thin anterolateral thigh flap is becoming one of the most preferred options for reconstruction of soft-tissue defects. Methods: Between 1999 and 2002, the authors used this flap as a free flap for nine cases for covering hand defects after burn, crushing injuries, or severe scar contracture release. There were eight men and one woman, the mean age of the patients was 31 years, and the size of the flaps ranged from 7 X 3.5 cm to 15 X 9 cm; thinning was performed in all flaps. Results: All flaps survived completely, and the donor site was closed directly in seven cases; in two cases, the exposed muscle was covered with split thickness skin graft. Conclusions: The anterolaterul thigh flap was thin enough for defects on the dorsum and/ or palm of the hand and for first web reconstruction after scar contracture release. It has many advantages in free flap surgery including a long pedicle with a suitable vessel diameter, and the donor-site morbidity is acceptable. The thin anterolateral thigh flap is a versatile soft tissue flap that achieves good hand contour with low donor-site morbidity.	St Orsola Marcello Malpighi Hosp, Clin Ortoped & Traumatol, Plast Surg Unit, I-41100 Modena, Italy; Univ Modena & Reggio Emilia, Dept Orthoped Surg, Modena, Italy; Orthopaed Traumatol Ctr, Hand & Microsurg Unit, Florence, Italy	Adani, R (corresponding author), St Orsola Marcello Malpighi Hosp, Clin Ortoped & Traumatol, Plast Surg Unit, Largo Pozzo 71, I-41100 Modena, Italy.	adani.roberto@unimo.it		Tarallo, Luigi/0000-0002-7999-8154			Alkureishi LWT, 2003, BRIT J PLAST SURG, V56, P401, DOI 10.1016/S0007-1226(03)00125-5; ANGRIGIANI C, 1993, PLAST RECONSTR SURG, V92, P285, DOI 10.1097/00006534-199308000-00014; Blondeel PN, 2003, PLAST RECONSTR SURG, V112, P1378, DOI 10.1097/01.PRS.0000081071.83805.B6; Brunelli F, 2001, ANN PLAS SURG, V47, P25, DOI 10.1097/00000637-200107000-00005; Celik N, 2002, PLAST RECONSTR SURG, V109, P2211, DOI 10.1097/00006534-200206000-00005; Chang SM, 2003, MICROSURG, V23, P328, DOI 10.1002/micr.10155; Chen HC, 1997, PLAST RECONSTR SURG, V99, P454, DOI 10.1097/00006534-199702000-00021; Chen HC, 1999, HAND CLIN, V15, P541; Giunta R, 2002, PLAST RECONSTR SURG, V109, P1460, DOI 10.1097/00006534-200204010-00045; Hsieh CH, 2003, PLAST RECONSTR SURG, V112, P976, DOI 10.1097/01.PRS.0000076221.25738.66; Javaid M, 2003, J HAND SURG-BRIT EUR, V28B, P21, DOI 10.1054/jhsb.2002.0863; Jeng SF, 1998, PLAST RECONSTR SURG, V102, P400, DOI 10.1097/00006534-199808000-00017; Kim KS, 2003, ANN PLAS SURG, V50, P77, DOI 10.1097/00000637-200301000-00013; Kimata Y, 1997, ARCH OTOLARYNGOL, V123, P1325; Kimata Y, 1998, PLAST RECONSTR SURG, V102, P1517, DOI 10.1097/00006534-199810000-00026; Kimata Y, 2000, PLAST RECONSTR SURG, V106, P584, DOI 10.1097/00006534-200009030-00009; Kimura N, 1996, PLAST RECONSTR SURG, V97, P985, DOI 10.1097/00006534-199604001-00016; Kimura N, 2001, PLAST RECONSTR SURG, V108, P1197, DOI 10.1097/00006534-200110000-00015; KOSHIMA I, 1995, PLAST RECONSTR SURG, V95, P252, DOI 10.1097/00006534-199502000-00004; KOSHIMA I, 1993, PLAST RECONSTR SURG, V92, P411, DOI 10.1097/00006534-199309000-00004; KOSHIMA I, 1993, PLAST RECONSTR SURG, V92, P421, DOI 10.1097/00006534-199309000-00005; Kuo YR, 2002, ANN PLAS SURG, V48, P161, DOI 10.1097/00000637-200202000-00008; Kuo YR, 2001, PLAST RECONSTR SURG, V107, P1766, DOI 10.1097/00006534-200106000-00019; Luo SK, 1999, MICROSURG, V19, P232, DOI 10.1002/(SICI)1098-2752(1999)19:5<232::AID-MICR5>3.3.CO;2-J; Muneuchi G, 2002, ANN PLAS SURG, V49, P312, DOI 10.1097/00000637-200209000-00013; Rajacic N, 2002, ANN PLAS SURG, V48, P252, DOI 10.1097/00000637-200203000-00004; Ross GL, 2003, BRIT J PLAST SURG, V56, P409, DOI 10.1016/S0007-1226(03)00126-7; Rui YJ, 2004, MICROSURG, V24, P59, DOI 10.1002/micr.10204; SCHEKER LR, 1988, J HAND SURG-BRIT EUR, V13B, P146, DOI 10.1016/0266-7681(88)90123-4; SONG YG, 1984, BRIT J PLAST SURG, V37, P149, DOI 10.1016/0007-1226(84)90002-X; Wei FC, 2002, PLAST RECONSTR SURG, V109, P2219, DOI 10.1097/00006534-200206000-00007; Wei FC, 2001, PLAST RECONSTR SURG, V107, P874, DOI 10.1097/00006534-200103000-00037; WEINZWEIG N, 1994, PLAST RECONSTR SURG, V94, P675, DOI 10.1097/00006534-199410000-00016; XU DC, 1988, PLAST RECONSTR SURG, V82, P305; Yang DP, 2003, PLAST RECONSTR SURG, V112, P1012, DOI 10.1097/01.PRS.0000076192.14536.90; Yang JY, 2002, PLAST RECONSTR SURG, V110, P39, DOI 10.1097/00006534-200207000-00009; Yidirim S, 2003, ANN PLAS SURG, V51, P37, DOI 10.1097/01.SAP.0000054179.04469.8C; ZANCOLLI EA, 1988, J HAND SURG-BRIT EUR, V13B, P130, DOI 10.1016/0266-7681(88)90121-0; ZHOU G, 1991, BRIT J PLAST SURG, V44, P91, DOI 10.1016/0007-1226(91)90038-L	39	51	61	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	AUG	2005	116	2					467	473		10.1097/01.prs.0000173059.73982.50			7	Surgery	Surgery	951NM	WOS:000230937400020	16079675				2021-06-18	
J	Magee, WL				Magee, WL			Music therapy with patients in low awareness states: Approaches to assessment and treatment in multidisciplinary care	NEUROPSYCHOLOGICAL REHABILITATION			English	Article; Proceedings Paper	Conference of the International-Neuropsychological-Society	JUL 16-19, 2003	Berlin, GERMANY	Int Neuropsychol Soc			TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; REHABILITATION; STROKE; SPEECH; INSTRUCTION; PEOPLE; MOOD	This paper outlines the rationale for and role of music therapy as a clinical intervention and diagnostic tool in multidisciplinary (MDT) rehabilitation programmes for patients in low awareness states. A review of the literature indicates that music is a useful clinical tool in stimulating a range of behavioural, physiological and expressive responses in patients in low awareness states. Referral criteria for music therapy with this patient group are provided, along with suggested methods for collaborative multidisciplinary work. A case vignette is presented of a client whose diagnosis of vegetative state (VS) was contradicted by her purposeful responses within music therapy assessment, contributing towards a changed diagnosis to minimally conscious state (MCS). The case illustrates the particular role of music therapy in assisting with diagnosis in complex cases. Music therapy provides a clinical forum in which recovery of function can be assessed in an informal way, using a medium which does not rely on language, is non-evasive and elicits emotional responses.	Univ Sheffield, Sheffield, S Yorkshire, England		drwmagee@rhn.org.uk	Magee, Wendy L./AAP-6839-2020	Magee, Wendy L./0000-0003-4350-1289			ALDRIDGE D, 1990, J ROY SOC MED, V83, P345; ALDRIDGE D, 1991, ART PSYCHOTHER, V18, P359, DOI 10.1016/0197-4556(91)90077-N; Baker F, 2001, J MUSIC THER, V38, P170, DOI 10.1093/jmt/38.3.170; Baker FA, 2000, MUSIC THER PERSPECT, V18, P110, DOI [10.1093/mtp/18.2.110, DOI 10.1093/MTP/18.2.110]; Blacking J., 1976, MUSICAL IS MAN; BOYLE ME, 1983, J APPL BEHAV ANAL, V16, P3, DOI 10.1901/jaba.1983.16-3; Boyle ME, 1995, LONELY WATERS P INT, P163; Bruscia KE., 1998, DEFINING MUSIC THERA, V2nd ed.; Burke D, 2000, BRAIN INJURY, V14, P463; COHEN NS, 1988, J MUSIC THER, V25, P85, DOI 10.1093/jmt/25.2.85; COHEN NS, 1992, J MUSIC THER, V29, P87, DOI 10.1093/jmt/29.2.102; COHEN NS, 1993, J MUSIC THER, V30, P81, DOI 10.1093/jmt/30.2.81; FACHNER J, 2004, DIALOGUE DEBATE P 10; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; GUSTORFF D, 2002, INFO CD ROM, V4, P353; Hurt CP, 1998, J MUSIC THER, V35, P228, DOI 10.1093/jmt/35.4.228; ITO S, 2000, P 9 ANN M SOC TREATM, V9, P25; JOCHIMS S, 1995, ART PSYCHOTHER, V22, P21, DOI 10.1016/0197-4556(94)00061-U; Kennelly J, 1997, AUSTR J MUSIC THERAP, V8, P18; Magee W., 1999, MUSIC THERAPY PERSPE, V17, P20, DOI DOI 10.1093/MTP/17.1.20; Magee WL, 2002, J MUSIC THER, V39, P20, DOI 10.1093/jmt/39.1.20; MAGEE WL, 2002, MUSICAL IDENTITIES, P179; Malec JF, 1996, BRAIN INJURY, V10, P781, DOI 10.1080/026990596123909; McIntosh GC, 1995, J NEUROLOGIC REHABIL, V9, P131; McIntosh GC, 1993, CANADIAN J NEUROLOGI, V20, P168; MOCHIZUKI E, 2002, P 11 ANN M SOC TREAT, V11, P69; MOCHIZUKI E, 2003, P 12 ANN M SOC TREAT, V12, P117; Nayak S, 2000, REHABIL PSYCHOL, V45, P274, DOI 10.1037/0090-5550.45.3.274; Noda R, 2004, BRAIN INJURY, V18, P509, DOI 10.1080/02699050310001645810; O'Callaghan C., 1999, MUSIC THERAPY PERSPE, V17, P32; OYAMA A, 2003, P 12 ANN M SOC TREAT, V12, P121; Papousek H., 1996, MUSICAL BEGINNINGS O, P37, DOI DOI 10.1093/ACPROF:OSO/9780198523321.003.0002; Pilon MA, 1998, BRAIN INJURY, V12, P793, DOI 10.1080/026990598122188; Prassas S, 1997, GAIT POSTURE, V6, P218, DOI 10.1016/S0966-6362(97)00010-6; Purdie H, 1997, INT J REHABIL RES, V20, P325, DOI 10.1097/00004356-199709000-00009; Rosenfeld JV, 1999, MUSICMEDICINE 3 EXPA, V3, P35; SATO Y, 2002, P 11 ANN M SOC TREAT, V11, P73; SERGENT J, 1992, SCIENCE, V257, P106, DOI 10.1126/science.1621084; Sloboda J. A., 1991, COGNITIVE BASES MUSI, P33; Sloboda JA, 1991, PSYCHOL MUSIC, V19, P110, DOI [DOI 10.1177/, DOI 10.1177/0305735691192002]; Tamplin J., 2000, AUSTR J MUSIC THERAP, V11, P38; Thaut M, 1997, J NEUROL REHABIL, V11, P131; THAUT M H, 1992, Neurology, V42, P208; Thaut MH, 1997, J NEUROL SCI, V151, P207, DOI 10.1016/S0022-510X(97)00146-9; Thaut MH, 1993, PHYS THER, V73, P107; Thaut MH, 1995, J STROKE CEREBROVASC, V5, P100; Thaut MH, 1993, NEUROREHABIL NEURAL, V7, P9, DOI DOI 10.1177/136140969300700103; Thaut MH, 1997, J NEUROL SCI, V151, P7; Trevarthen C., 2002, MUSICAL IDENTITIES, P21; Trevarthen Colwyn, 1999, MUSIC SCI, P155, DOI DOI 10.1177/10298649000030S109; TSUNAKAWA K, 2000, P 9 ANN M SOC TREATM, V9, P31; Wilson BA, 2001, BRAIN INJURY, V15, P1083, DOI 10.1080/02699050110082197; Wilson S. L., 1992, CLIN REHABIL, V6, P181, DOI [10.1177/026921559200600301, DOI 10.1177/026921559200600301]; YAMAMOTO K, 2003, P 12 ANN M SOC TREAT, V12, P109	55	51	52	0	17	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-SEP	2005	15	3-4					522	536		10.1080/09602010443000461			15	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	965PE	WOS:000231961900037	16350993				2021-06-18	
J	Glantz, L; Avramovich, A; Trembovler, V; Gurvitz, V; Kohen, R; Eidelman, LA; Shohami, E				Glantz, L; Avramovich, A; Trembovler, V; Gurvitz, V; Kohen, R; Eidelman, LA; Shohami, E			Ischemic preconditioning increases antioxidants in the brain and peripheral organs after cerebral ischemia	EXPERIMENTAL NEUROLOGY			English	Article						biological oxidation potential; brain ischemia; reactive oxygen species; uric acid; ascorbic acid	CLOSED-HEAD INJURY; EXTRACELLULAR ASCORBATE RELEASE; AKT/PROTEIN KINASE-B; ARTERY OCCLUSION; NITRIC-OXIDE; URIC-ACID; IN-VIVO; FOREBRAIN ISCHEMIA; OXIDATIVE STRESS; FOCAL ISCHEMIA	Background and purpose. Low molecular weight antioxidants (LMWA), which reflect tissue reducing power, are among the endogenous mechanisms for neutralizing reactive oxygen species (ROS). Ischemic preconditioning (IPC) was associated with decreased oxidative stress. We examined the effect of focal ischemia on LMWA and on prostaglandin E-2 (PGE(2), a product of arachidonic acid oxidation) in the brain, heart, liver, and lungs of rats subjected to 90 min of ischemia and in IPC rats subjected to similar insult. Methods. Transient right middle cerebral artery occlusion (MCAO) was performed for 90 min and at 0, 5, 30, 60, or 240 min of reperfusion, LMWA and PGE2 were evaluated by cyclic voltametry (CV) and radioimmunoassay, respectively. IPC was induced by 2 min of MCAO, 24 h prior to the major ischemic episode. Results. LMWA decreased at 5 min of reperfusion in the brain, heart, liver, and lung and rose 4 h later only in the brain. PGE2 levels increased three to fivefold in all tissues examined. Surprisingly, in IPC rats a dramatic increase of LMWA occurred at 5 min of reperfusion in the brain and in the peripheral organs. Uric acid, but not ascorbic, is the major LMWA increased. Conclusions. We propose that after ischemia, ROS rapidly consume the antioxidants reserves in the brain and also in peripheral organs, suggesting that the whole body is under oxidative stress. Moreover, part of the neuroprotection afforded by IPC is mediated by the brain's ability to mobilize antioxidants, especially uric acid, that attenuate the massive ROS-mediated oxidative stress. (C) 2004 Elsevier Inc. All rights reserved.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Pharmaceut, IL-91120 Jerusalem, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il					Ames BN, 1993, FREE RADICAL BIO MED, V6, P303; Ashwal S, 1998, STROKE, V29, P1037, DOI 10.1161/01.STR.29.5.1037; Back T, 1998, CELL MOL NEUROBIOL, V18, P621, DOI 10.1023/A:1020265701407; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Belayev L, 2003, STROKE, V34, P758, DOI 10.1161/01.STR.0000056169.45365.15; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Cheung RTF, 1997, BRAIN RES, V747, P181, DOI 10.1016/S0006-8993(96)01137-7; Chua HC, 1999, CLIN NEUROL NEUROSUR, V101, P44; Davenport RJ, 1996, STROKE, V27, P421, DOI 10.1161/01.STR.27.3.421; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; HILLERED L, 1988, NEUROSCI LETT, V95, P286, DOI 10.1016/0304-3940(88)90672-6; Hooper DC, 2000, FASEB J, V14, P691; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Kato H, 1999, CELL MOL NEUROBIOL, V19, P93, DOI 10.1023/A:1006920725663; Klingelhofer J, 1997, BAILLIERE CLIN NEUR, V6, P309; Kontos HA, 2001, STROKE, V32, P2712, DOI 10.1161/hs1101.098653; Leker RR, 2002, EXP NEUROL, V176, P355, DOI 10.1006/exnr.2002.7910; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Mathews KS, 2000, J NEUROSCI METH, V102, P43, DOI 10.1016/S0165-0270(00)00277-6; MIELE M, 1994, NEUROSCIENCE, V62, P87, DOI 10.1016/0306-4522(94)90316-6; Moor E, 2001, NEUROSCI LETT, V316, P169, DOI 10.1016/S0304-3940(01)02394-1; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724; Paciaroni M, 2000, EUR NEUROL, V43, P30, DOI 10.1159/000008125; Prass K, 2002, J CEREBR BLOOD F MET, V22, P520, DOI 10.1097/00004647-200205000-00003; RADI R, 1991, J BIOL CHEM, V266, P4244; Rauca C, 2000, BRAIN RES, V868, P147, DOI 10.1016/S0006-8993(00)02388-X; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; RYAN M, 1997, ANN CLIN BIOCHEM, V35, P553; Saito A, 2003, J NEUROSCI, V23, P1710; SEVANIAN A, 1991, AM J CLIN NUTR, V54, pS1129, DOI 10.1093/ajcn/54.6.1129s; SHOHAMI E, 1982, STROKE, V13, P494, DOI 10.1161/01.STR.13.4.494; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIMON RP, 1993, NEUROL CLIN, V11, P309; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tayag EC, 1996, BRAIN RES, V733, P287, DOI 10.1016/0006-8993(96)00669-5; UEMURA Y, 1991, STROKE, V22, P1548, DOI 10.1161/01.STR.22.12.1548; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yu ZF, 1998, J NEUROSCI RES, V53, P613, DOI 10.1002/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1; Yusa T, 2000, NEUROSCI LETT, V293, P123, DOI 10.1016/S0304-3940(00)01501-9; Yusa T, 2001, BRAIN RES, V897, P104, DOI 10.1016/S0006-8993(01)02099-6	44	51	54	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2005	192	1					117	124		10.1016/j.expneurol.2004.11.012			8	Neurosciences	Neurosciences & Neurology	899LZ	WOS:000227147200013	15698625				2021-06-18	
J	Genovese, T; Mazzon, E; Muia, C; Patel, NSA; Threadgill, MD; Bramanti, P; De Sarro, A; Thiemermann, C; Cuzzocrea, S				Genovese, T; Mazzon, E; Muia, C; Patel, NSA; Threadgill, MD; Bramanti, P; De Sarro, A; Thiemermann, C; Cuzzocrea, S			Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							ADP-RIBOSE POLYMERASE; FACTOR-KAPPA-B; NITRIC-OXIDE; POTENT INHIBITOR; BRAIN-INJURY; OXIDATIVE STRESS; RAT MODEL; ACTIVATION; SYNTHETASE; 5-AMINOISOQUINOLINONE	Poly(ADP-ribose) polymerase ( PARP), a nuclear enzyme activated by strand breaks in DNA, plays an important role in the tissue injury associated with stroke and neurotrauma. The aim of our study was to evaluate the therapeutic efficacy of in vivo inhibition of PARP in an experimental model of spinal cord trauma, which was induced by the application of vascular clips ( force of 24g) to the dura via a four-level T5-T8 laminectomy. Spinal cord injury in mice resulted in severe trauma characterized by edema, neutrophil infiltration ( measured as an increase in myeloperoxidase activity), and apoptosis ( measured by terminal deoxynucleotidyltransferase-mediated UTP end labeling coloration). Infiltration of spinal cord tissue with neutrophils was associated with a marked increase in immunoreactivity for poly(ADP-ribose) ( PAR), index of PARP activation, in the spinal cord tissue. These inflammatory events were associated with the activation of nuclear factor-kappaB (NF-kappaB) at 4 h after spinal cord damage. Treatment of the mice with the PARP inhibitors 3-aminobenzamide (3-AB) or 5-aminoisoquinolinone (5-AIQ) significantly reduced the degree of 1) spinal cord inflammation and tissue injury ( histological score), 2) PAR formation, 3) neutrophil infiltration, and 4) apoptosis. Treatment with these PARP inhibitors also reduced DNA binding of NF-kappaB and inhibitory kappaB degradation. In a separate set of experiments, we have also demonstrated that PARP inhibitors significantly ameliorated the recovery of limb function ( evaluated by motor recovery score). Taken together, our results clearly demonstrate that treatment with PARP inhibitors reduces the development of inflammation and tissue injury events associated with spinal cord trauma.	Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Torre Biol, I-98100 Messina, Italy; Queen Mary Univ London, William Harvey Res Inst, Ctr Expt Med Nephrol & Crit Care, London, England; Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England; Univ Messina, Sch Med, Ctr Studio & Trattamento Neurolesi Lungodegenti, Messina, Italy	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Torre Biol, Policlin Univ Via C Valeria, I-98100 Messina, Italy.	salvator@unime.it	Mazzon, Emanuela/AAL-4334-2020; Threadgill, Michael/C-3925-2009; Bramanti, Placido/K-5117-2016	GENOVESE, Tiziana/0000-0002-3335-7327; mazzon, emanuela/0000-0002-5073-717X; Patel, Nimesh/0000-0001-9280-5815; Thiemermann, Christoph/0000-0003-4228-9722			Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Besson VC, 2003, FREE RADICAL RES, V37, P1201, DOI 10.1080/10715760310001612568; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Chatterjee PK, 1999, KIDNEY INT, V56, P973, DOI 10.1046/j.1523-1755.1999.00644.x; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Cuzzocrea S, 2002, BRIT J PHARMACOL, V135, P496, DOI 10.1038/sj.bjp.0704463; Cuzzocrea S, 2002, BIOCHEM PHARMACOL, V63, P293, DOI 10.1016/S0006-2952(01)00864-4; DEMURCIA G, 1988, BIOCHEM CELL BIOL, V66, P626, DOI 10.1139/o88-072; Di Paola R, 2004, EUR J PHARMACOL, V492, P203, DOI 10.1016/j.ejphar.2004.03.033; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hauschildt S, 1997, ADV EXP MED BIOL, V419, P249; Joshi M, 2002, J NEUROTRAUM, V19, P175, DOI 10.1089/08977150252806947; Kim GM, 2001, J NEUROSCI, V21, P6617; La Rosa G, 2004, J NEUROSURG-SPINE, V1, P311, DOI 10.3171/spi.2004.1.3.0311; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; Li F, 2004, DIABETOLOGIA, V47, P710, DOI 10.1007/s00125-004-1356-0; Mao JR, 1997, PAIN, V72, P355, DOI 10.1016/S0304-3959(97)00063-8; Mazzon E, 2002, SHOCK, V18, P434, DOI 10.1097/00024382-200211000-00008; McDonald MC, 2000, BRIT J PHARMACOL, V130, P843, DOI 10.1038/sj.bjp.0703391; Mota-Filipe Helder, 2002, Med Sci Monit, V8, pBR444; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; POPOVICH PG, 1994, BRAIN RES, V633, P348, DOI 10.1016/0006-8993(94)91560-1; Schwartz MD, 1996, CRIT CARE MED, V24, P1285, DOI 10.1097/00003246-199608000-00004; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 2003, GLIA, V41, P105, DOI 10.1002/glia.10137; Southan GJ, 2003, CURR MED CHEM, V10, P321, DOI 10.2174/0929867033368376; SUTO MJ, 1991, ANTI-CANCER DRUG DES, V6, P107; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo G, 2002, CIRC RES, V90, P100, DOI 10.1161/hh0102.102657; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wayman N, 2001, EUR J PHARMACOL, V430, P93, DOI 10.1016/S0014-2999(01)01359-0; XIE QW, 1994, J BIOL CHEM, V269, P4705; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Zingarelli B, 2003, EUR J PHARMACOL, V469, P183, DOI 10.1016/S0014-2999(03)01726-6; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	44	51	59	0	1	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	FEB	2005	312	2					449	457		10.1124/jpet.104.076711			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	888IJ	WOS:000226367100005	15452194				2021-06-18	
J	Mauler, F; Hinz, V; Horvath, E; Schuhmacher, J; Hofmann, HA; Wirtz, S; Hahn, MG; Urbahns, K				Mauler, F; Hinz, V; Horvath, E; Schuhmacher, J; Hofmann, HA; Wirtz, S; Hahn, MG; Urbahns, K			Selective intermediate-/small-conductance calcium-activated potassium channel (KCNN4) blockers are potent and effective therapeutics in experimental brain oedema and traumatic brain injury caused by acute subdural haematoma	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						brain water content; ICP; neuroprotection; rat	CANNABINOID RECEPTOR AGONIST; BARRIER BREAKDOWN; K+ TRANSPORT; INHIBITION; RAT; CLOTRIMAZOLE; MODEL; RESUSCITATION; ERYTHROCYTES; DEHYDRATION	Early deterioration and death after brain injury is often the result of oedema in the injured and peri-lesional tissue. So far, no pharmacotherapy is available that exhibits significant brain oedema-reducing efficacy in patients. We selected two low molecular weight compounds from different chemical classes, a triazole (1-[(2-chlorophenyl)diphenylmethyl]-1,2,3-triazole) and a cyclohexadiene (methyl 4-[4-chloro-3-(trifluoromethyl)phenyl]-6-methyl-3-oxo-1,4,7-tetrahydroisobenzofuran-5-carboxylate) to characterize their pharmacological properties on KCNN4 channels (intermediate/small conductance calcium-activated potassium channel, subfamily N, member 4) in vitro as well as in vivo. In vitro we replaced potassium by rubidium (Rb+) and determined Rb+ fluxes evoked by 10 mum of the calcium ionophore A23187 on C6BU1 rat glioma cells. Compared with known KCNN4 blockers, such as clotrimazole (IC50 = 360 +/- 12 nm) and charybdotoxin (IC50 = 3.3 +/- 1.9 nm), the triazole and cyclohexadiene were considerably more potent than clotrimazole and displayed similar potencies (IC50 = 12.1 +/- 8.8 and 13.3 +/- 4.7 nm, respectively). In the rat acute subdural haematoma model, both the triazole and cyclohexadiene displayed reduction of brain water content (-26% at 0.3 mg/kg and -24% at 0.01 mg/kg) and reduction of the intracranial pressure (-46% at 0.1 mg/kg and -60% at 0.003 mg/kg) after 24 h when administered as a 4-h infusion immediately after brain injury. When infarct volumes were determined after 7 days, the triazole as well as the cyclohexadiene displayed strong neuroprotective efficacy (-52% infarct volume reduction at 1.2 mg/kg and -43% at 0.04 mg/kg, respectively). It is concluded that blockade of KCNN4 channels is a new pharmacological approach to attenuate acute brain damage caused by traumatic brain injury.	Bayer HealthCare, CNS Res, D-42096 Wuppertal, Germany; Bayer HealthCare, Inst Pharmacokinet, D-42096 Wuppertal, Germany	Mauler, F (corresponding author), Bayer HealthCare, CNS Res, Aprather Weg 18a, D-42096 Wuppertal, Germany.	Frank.Mauler@bayerhealthcare.com	Hofmann, Hans A/E-4538-2016	Hofmann, Hans A/0000-0002-3335-330X			ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; Asbun J, 1998, P W PHARMACOL SOC, V41, P145; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; BRUGNARA C, 1993, J BIOL CHEM, V268, P8760; Brugnara C, 1996, J CLIN INVEST, V97, P1227, DOI 10.1172/JCI118537; BRUGNARA C, 1993, J CLIN INVEST, V92, P520, DOI 10.1172/JCI116597; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; DOUKAS J, 1994, AM J PATHOL, V145, P211; Eilig I, 2001, ANESTH ANALG, V92, P669, DOI 10.1213/00000539-200103000-00023; ELLORY JC, 1994, BRIT J PHARMACOL, V111, P903, DOI 10.1111/j.1476-5381.1994.tb14823.x; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hastie LE, 1997, FREE RADICAL BIO MED, V22, P955, DOI 10.1016/S0891-5849(96)00482-0; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Horvath E., 1997, Society for Neuroscience Abstracts, V23, P1923; Isaev NK, 2002, NEUROSCIENCE, V113, P47, DOI 10.1016/S0306-4522(02)00164-1; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Kawai N, 2000, ACT NEUR S, V76, P529; Kayser ST, 1998, EUR J CELL BIOL, V76, P119, DOI 10.1016/S0171-9335(98)80024-1; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; Malek AM, 1996, J CELL SCI, V109, P713; Mauler F, 2003, BRAIN RES, V989, P99, DOI 10.1016/S0006-8993(03)03376-6; Mauler F, 2002, J PHARMACOL EXP THER, V302, P359, DOI 10.1124/jpet.302.1.359; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Mizuno T, 2004, NEUROPHARMACOLOGY, V46, P404, DOI 10.1016/j.neuropharm.2003.09.009; MORLEY NCD, 2004, COCHRANE LIB; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; PAXINOS G, 1996, RAT BRAIN STEREOTAXI; Rittenhouse AR, 1997, J MEMBRANE BIOL, V157, P177, DOI 10.1007/s002329900227; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; Schuhmacher J, 2003, RAPID COMMUN MASS SP, V17, P1950, DOI 10.1002/rcm.1139; Schwab A, 1999, PFLUG ARCH EUR J PHY, V438, P330, DOI 10.1007/s004240050917; SCHWAB A, 1996, PFLUEGERS ARCH, V432, P87; SCHWAB A, 1998, CURR RES ION CHANNEL, V3, P126; TAS PWL, 1988, NEUROSCI LETT, V94, P279, DOI 10.1016/0304-3940(88)90031-6; Urbahns K, 2003, BIOORG MED CHEM LETT, V13, P2637, DOI 10.1016/S0960-894X(03)00560-2; Wickenden AD, 2002, PHARMACOL THERAPEUT, V94, P157, DOI 10.1016/S0163-7258(02)00201-2; Xi GH, 2001, STROKE, V32, P162, DOI 10.1161/01.STR.32.1.162; Xiao F, 2002, ACAD EMERG MED, V9, P933, DOI 10.1197/aemj.9.9.933; Zwienenberg M, 1999, J NEUROTRAUM, V16, P1095, DOI 10.1089/neu.1999.16.1095	43	51	52	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	OCT	2004	20	7					1761	1768		10.1111/j.1460-9568.2004.03615.x			8	Neurosciences	Neurosciences & Neurology	855TJ	WOS:000223996900008	15379997				2021-06-18	
J	Williams, AJ; Tortella, FC; Lu, XM; Moreton, JE; Hartings, JA				Williams, AJ; Tortella, FC; Lu, XM; Moreton, JE; Hartings, JA			Antiepileptic drug treatment of nonconvulsive seizures induced by experimental focal brain ischemia	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							INTENSIVE-CARE-UNIT; CONVULSIVE STATUS EPILEPTICUS; SODIUM-CHANNEL BLOCKER; CONTINUOUS EEG; THERAPEUTIC WINDOW; SPECTRAL-ANALYSIS; DELTA-ACTIVITY; KINDLED RATS; MODEL; VALPROATE	Nonconvulsive seizures (NCSs) after traumatic and ischemic brain injury are often refractory to antiepileptic drug therapy and are associated with a decline in patient outcome. We recently characterized an in vivo rat model of focal brain ischemia-induced NCS and here sought to evaluate potential pharmacological treatments. Electroencephalographic activity was recorded continuously for 24 h in freely behaving rats subjected to permanent middle cerebral artery occlusion (MCAo). Rats were treated with an antiepileptic drug from one of seven different drug classes at ED50 and 2 x ED50 doses (as reported in other rat seizure models), delivered as a single i.v. injection 20 min post-MCAo. Vehicle-treated rats (n=9) had an 89% incidence of NCS with an average number of NCS of 8.6+/-1.9. The latency to onset of NCS was 32.5+/-3.4 min post-MCAo with an average duration of 49.1+/-8.2 s/event. The high doses of ethosuximide, gabapentin, fos-phenytoin, and valproate significantly reduced the incidence of NCS (11, 14, 14, and 38%, respectively), whereas midazolam, phenobarbital, and dextromethorphan had no significant effect at either dose. Across treatment groups, there was a low but significant correlation between the number of NCS events per animal and volume of brain infarction (r=0.352). Antiepileptic drug therapy that prevented the occurrence of NCS also reduced mortality from 26 to 7%. Based on combined effects on NCS, infarction, neurological recovery, and mortality, ethosuximide and gabapentin were identified as having the best therapeutic profile.	Walter Reed Army Inst Res, Div Neurosci, Dept Appl Neurobiol, Silver Spring, MD 20910 USA; Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	Williams, AJ (corresponding author), Walter Reed Army Inst Res, Div Neurosci, Dept Appl Neurobiol, Silver Spring, MD 20910 USA.	anthony.williams@na.amedd.army.mil		Hartings, Jed/0000-0001-8583-3471			BERNASCONI R, 1985, J NEURAL TRANSM, V63, P169, DOI 10.1007/BF01252616; Bertrand S, 2003, SYNAPSE, V50, P95, DOI 10.1002/syn.10247; Calabresi P, 2003, ANN NEUROL, V53, P693, DOI 10.1002/ana.10603; Czuczwar SJ, 2001, CNS DRUGS, V15, P339, DOI 10.2165/00023210-200115050-00001; Danober L, 1998, PROG NEUROBIOL, V55, P27, DOI 10.1016/S0301-0082(97)00091-9; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; GRANDMAISON F, 1991, ELECTROEN CLIN NEURO, V79, P264, DOI 10.1016/0013-4694(91)90121-J; Hartings JA, 2003, EXP NEUROL, V179, P139, DOI 10.1016/S0014-4886(02)00013-4; Horn J, 2001, STROKE, V32, P570, DOI 10.1161/01.STR.32.2.570; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P14, DOI 10.1097/00004691-199901000-00002; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; Lado FA, 2001, EPILEPSIA, V42, P458, DOI 10.1046/j.1528-1157.2001.30900.x; LEITE JP, 1995, EPILEPSY RES, V20, P93, DOI 10.1016/0920-1211(94)00070-D; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; LOSCHER W, 1993, EUR J PHARMACOL, V238, P191, DOI 10.1016/0014-2999(93)90847-B; Loscher W, 1998, EPILEPSY RES, V30, P69, DOI 10.1016/S0920-1211(97)00098-3; Lu XCM, 2001, NEUROPATH APPL NEURO, V27, P481, DOI 10.1046/j.1365-2990.2001.00357.x; Manning JPA, 2004, NEUROSCIENCE, V123, P5, DOI 10.1016/j.neuroscience.2003.09.026; Meltzer CC, 2000, EPILEPSIA, V41, P193, DOI 10.1111/j.1528-1157.2000.tb00139.x; NEVANDER G, 1985, ANN NEUROL, V18, P281, DOI 10.1002/ana.410180303; Perucca E, 2002, CNS DRUGS, V16, P695, DOI 10.2165/00023210-200216100-00004; RATAUD J, 1994, NEUROSCI LETT, V172, P19, DOI 10.1016/0304-3940(94)90652-1; Rekling JC, 2003, NEUROSCI LETT, V335, P167, DOI 10.1016/S0304-3940(02)01193-X; SHENOY AK, 1982, EPILEPSIA, V23, P399, DOI 10.1111/j.1528-1157.1982.tb05426.x; Tortella FC, 1999, J PHARMACOL EXP THER, V291, P399; Tortella FC, 1997, J PHARMACOL EXP THER, V282, P286; TORTELLA FC, 1986, BRAIN RES, V383, P314, DOI 10.1016/0006-8993(86)90031-4; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Trojnar MK, 2002, POL J PHARMACOL, V54, P557; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Williams AJ, 2003, FUND CLIN PHARMACOL, V17, P581, DOI 10.1046/j.1472-8206.2003.00183.x; Williams AJ, 2002, BRAIN RES, V932, P45, DOI 10.1016/S0006-8993(02)02275-8; Williams AJ, 2001, J PHARMACOL EXP THER, V299, P48; Williams AJ, 2000, J PHARMACOL EXP THER, V294, P378; Yang Y, 2000, NEUROSCI LETT, V285, P119, DOI 10.1016/S0304-3940(00)01048-X; Young GB, 1998, ARCH NEUROL-CHICAGO, V55, P117, DOI 10.1001/archneur.55.1.117; Young GB, 1996, NEUROLOGY, V47, P83	40	51	51	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	OCT	2004	311	1					220	227		10.1124/jpet.104.069146			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	854IK	WOS:000223896100026	15140918				2021-06-18	
J	Kennepohl, S; Shore, D; Nabors, N; Hanks, R				Kennepohl, S; Shore, D; Nabors, N; Hanks, R			African American acculturation and neuropsychological test performance following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article; Proceedings Paper	111th Annual Convention of the American-Psychological-Association	AUG 07-10, 2003	Toronto, CANADA	Amer Psychol Assoc		culture; neuropsychology; acculturation; assessment	COGNITIVE-ABILITY; SPANISH-SPEAKING; ENGLISH-SPEAKING; RACE; ETHNICITY; EDUCATION	The present study examined the influence of African American acculturation on the performance of neuropsychological tests following traumatic brain injury (TBI). Seventy one participants already enrolled in a larger-scale study assessing the impact of TBI (i.e., the South Eastern Michigan Traumatic Brain Injury Model Systems project) completed a self-report measure of African American acculturation (African American Acculturation Scale-Short Form; Landrine & Klonoff, 1995) in addition to a standardized battery of neuropsychological tests. Hierarchical regression analyses were conducted to evaluate the relationship between level of acculturation and test performance after controlling for injury-related (initial Glasgow Coma Scale score, time since injury) and demographic variables (age, sex, years of education, and socioeconomic status). Lower levels of acculturation were associated with significantly poorer performances on the Galveston Orientation & Amnesia Test, MAE Tokens test, WAIS-R Block Design, Rey Auditory Verbal Learning Test, and Symbol Digit Modalities Test. Decreased levels of acculturation were also significantly related to lower scores on a composite indicator of overall neuropsychological test performance. In addition, the examiner's ethnicity (Black or White) was related with scores on a few of the tests (i.e., Block Design, Trail Making Test), but was not significantly associated with the overall neuropsychological test performance. Overall, these findings suggest that differences in cultural experience may be an important factor in the neuropsychological assessment of African Americans following TBI, and provide additional support for the hypothesis that cultural factors may partially account for the differences among ethnic/cultural groups on neuropsychological tests.	Hotel Dieu CHUM, Psychol Serv, Montreal, PQ H2W 1T8, Canada; Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; Eastern Michigan Univ, Dept Psychol, Ypsilanti, MI 48197 USA; Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Detroit, MI USA	Kennepohl, S (corresponding author), Hotel Dieu CHUM, Psychol Serv, 3840 Rue St Urbain, Montreal, PQ H2W 1T8, Canada.	stephan.kennepohl.chum@ssss.gouv.qc.ca					Arnold B. R., 1994, ASSESSMENT, V1, P239, DOI [10.1177/107319119400100303., DOI 10.1177/107319119400100303]; BENTON AL, 1994, MULTILINGUAL APHASI; BENTON AL, 1983, CONTRIBUTIONS NEURO; Berry J W, 1989, Nebr Symp Motiv, V37, P201; BETANCOURT H, 1993, AM PSYCHOL, V48, P629, DOI 10.1037/0003-066X.48.6.629; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Cuellar IHL., 1980, HISP J BEHAV SCI, V2, P199; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DEVIVO MJ, 1992, ARCH PHYS MED REHAB, V73, P424; Flynn JR, 1999, AM PSYCHOL, V54, P5, DOI 10.1037/0003-066X.54.1.5; GILES WH, 1995, ARCH INTERN MED, V155, P1319, DOI 10.1001/archinte.155.12.1319; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heaton RK., 1996, NEUROPSYCHOL ASSESS, V2, P141; HELMS JE, 1992, AM PSYCHOL, V47, P1083, DOI 10.1037/0003-066X.47.9.1083; HELMS JE, 1997, CONT INTELLECTUAL AS, P517; Hollingshead A.B., 1957, 2 FACTOR INDEX SOCIA; HOLLINGSHEAD AB, 1975, UNPUB 4 FACTOR INDEX; Jacobs DM, 1997, J CLIN EXP NEUROPSYC, V19, P331, DOI 10.1080/01688639708403862; Johnson-Selfridge MT, 1998, ARCH CLIN NEUROPSYCH, V13, P319, DOI 10.1016/S0887-6177(97)00003-6; KAUFMAN AS, 1988, J CLIN PSYCHOL, V44, P231, DOI 10.1002/1097-4679(198803)44:2<231::AID-JCLP2270440224>3.0.CO;2-J; Kennepohl S, 1999, BRAIN COGNITION, V41, P365, DOI 10.1006/brcg.1999.1138; Kraus P, 1999, J HIGH ENERGY PHYS; Landrine H., 1996, AFRICAN AM ACCULTURA; Landrine H., 1995, J BLACK PSYCHOL, V21, P124, DOI [DOI 10.1177/00957984950212003, 10.1177/00957984950212003]; LANDRINE H, 1994, J BLACK PSYCHOL, V20, P104, DOI DOI 10.1177/00957984940202002; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOEWENSTEIN DA, 1995, ARCH CLIN NEUROPSYCH, V10, P75, DOI 10.1016/0887-6177(93)E0005-V; LOEWENSTEIN DA, 1993, J GERONTOL, V48, P389; MAJ M, 1993, ARCH CLIN NEUROPSYCH, V8, P123, DOI 10.1016/0887-6177(93)90030-5; MANLY J, 2000, J INT NEUROPSYCH SOC, V6, P245; Manly JJ, 1998, J INT NEUROPSYCH SOC, V4, P291, DOI 10.1017/S1355617798002914; Manly JJ, 1998, NEUROLOGY, V50, P1238, DOI 10.1212/WNL.50.5.1238; Manly JJ, 2002, STUD NEUROPSYCHOL DE, P79; MARCOPOULOS BA, 1997, J CLIN EXPT NEUROPSY, P112; MILLER EN, 1993, J CLIN EXP NEUROPSYC, V15, P66; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; Myerson J, 1998, PSYCHOL SCI, V9, P139, DOI 10.1111/1467-9280.00026; Nabors NA, 2000, CRIT ISS NE, P31; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; NOBLES WW, 1972, BLACK PSYCHOL, P18; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P151, DOI 10.1080/13854049508401597; REYNOLDS CR, 1987, J SCHOOL PSYCHOL, V25, P323, DOI 10.1016/0022-4405(87)90035-5; Reynolds CR, 2000, CRIT ISS NE, P249; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; SHADE BJ, 1991, BLACK PSYCHOL, P231; Smith A., 1991, SYMBOL DIGIT MODALIT; Spreen O, 1998, COMPENDIUM NEUROPSY; Steele CM, 1997, AM PSYCHOL, V52, P613, DOI 10.1037/0003-066X.52.6.613; Tabachnick B.G., 1989, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; TERRELL F, 1981, J CONSULT CLIN PSYCH, V49, P750, DOI 10.1037/0022-006X.49.5.750; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; VINCENT KR, 1991, J CLIN PSYCHOL, V47, P266, DOI 10.1002/1097-4679(199103)47:2<266::AID-JCLP2270470213>3.0.CO;2-S; Wechsler D., 1987, WECHSLER MEMORY SCAL; Welsh KA, 1995, NEUROLOGY, V45, P2207, DOI 10.1212/WNL.45.12.2207; Willis M., 1989, J BLACK PSYCHOL, V16, P47, DOI 10.1177/009579848901600105; Wong TM, 2000, CRIT ISS NE, P3	59	51	51	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2004	10	4					566	577		10.1017/S1355617704104128			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	833VA	WOS:000222367200010	15327735				2021-06-18	
J	Davis, GA; Coelho, CA				Davis, GA; Coelho, CA			Referential cohesion and logical coherence of narration after closed head injury	BRAIN AND LANGUAGE			English	Article						discourse; narrative; language production; coherence; cohesion; closed head injury	TRAUMATIC BRAIN-INJURY; DISCOURSE PRODUCTION; CAUSAL RELATEDNESS; ELICITATION TASK; CONNECTED SPEECH; ADULTS; DISORDERS; PATTERNS; MILD	A group with closed head injury was compared to neurologically intact controls regarding the referential cohesion and logical coherence of narrative production. A sample of six stories was obtained with tasks of cartoon-elicited story-telling and auditory-oral retelling. We found deficits in the clinical group with respect to referential cohesion, logical coherence, and accuracy of narration. The occurrence of deficits depended on the condition of narrative production and, to some extent, on the particular story used. The primary implications of this study pertain to the attention given by researchers to the feature of discourse production being studied and processing demands of the task. (C) 2004 Elsevier Inc. All rights reserved.	Univ Massachusetts, Amherst, MA 01003 USA; Univ Connecticut, Storrs, CT 06269 USA	Davis, GA (corresponding author), Univ Massachusetts, Arnold House,Box 30410, Amherst, MA 01003 USA.	albyn@comdis.umass.edu					Albrecht J. E., 1995, SOURCES COHERENCE RE, P263; Bloom Ronald L., 1994, DISCOURSE ANAL APPL, P81; Britton B.K., 1994, HDB PSYCHOLINGUISTIC, P641; BROWNELL HH, 1988, APHASIOLOGY, V2, P247, DOI 10.1080/02687038808248918; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); COELHO CA, 1993, CLIN APHASIOLOGY, V21, P183; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Damico JS, 1985, COMMUNICATION SKILLS, P165; Davis GA, 1997, BRAIN LANG, V56, P183; DAVIS GA, 2000, APHASIOLOGY DISORDER; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; FLETCHER CR, 1988, J MEM LANG, V27, P235, DOI 10.1016/0749-596X(88)90052-6; FREDERIKSEN CH, 1993, NARRATIVE DISCOURSE IN NEUROLOGICALLY IMPAIRED AND NORMAL AGING ADULTS, P239; GARDNER H, 1983, COGNITIVE PROCESSING, P169; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; GLOSSER G, 1993, NARRATIVE DISCOURSE IN NEUROLOGICALLY IMPAIRED AND NORMAL AGING ADULTS, P191; GORDON PC, 1993, NARRATIVE DISCOURSE IN NEUROLOGICALLY IMPAIRED AND NORMAL AGING ADULTS, P23; HAGEN C, 1980, REHABILITATION HEAD; Hagen C, 1984, LANGUAGE DISORDERS A, P245; Halliday M. A. K., 1985, INTRO FUNCTIONAL GRA; Haravon A., 1994, DISCOURSE ANAL APPL, P47; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; HUBER W, 1982, BRAIN LANG, V16, P1, DOI 10.1016/0093-934X(82)90069-4; Kintsch W., 1994, HDB PSYCHOLINGUISTIC, P721; Kintsch W., 1998, COMPREHENSION PARADI; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LUZZATTI C, 1989, APHASIOLOGY, V3, P643, DOI 10.1080/02687038908249030; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENN L, 1994, APHASIOLOGY, V8, P343, DOI 10.1080/02687039408248664; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; MYERS JL, 1987, J MEM LANG, V26, P453, DOI 10.1016/0749-596X(87)90101-X; Myers P.S., 1999, RIGHT HEMISPHERE DAM; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; Norusis M.J., 1993, SPSS WINDOWS BASE SY; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; RIVERS DL, 1980, BRAIN LANG, V10, P348, DOI 10.1016/0093-934X(80)90061-9; Shadden B.B., 1991, CLIN APHASIOLOGY, V20, P327; Simmons-Mackie N, 2002, APHASIOLOGY, V16, P837, DOI 10.1080/02687030244000185; SINGER M, 1992, J MEM LANG, V31, P507, DOI 10.1016/0749-596X(92)90026-T; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1997, BRAIN INJURY, V11, P409; Stein N. L., 1979, NEW DIRECTIONS DISCO, V2, P53; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; TRABASSO T, 1985, J MEM LANG, V24, P595, DOI 10.1016/0749-596X(85)90048-8; TRABASSO T, 1985, J MEM LANG, V24, P612, DOI 10.1016/0749-596X(85)90049-X; Trabasso T., 1984, LEARNING COMPREHENSI; TREXLER LE, 1988, BRAIN COGNITION, V8, P291, DOI 10.1016/0278-2626(88)90056-5; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; van den Broek P.W., 1994, HDB PSYCHOLINGUISTIC, P539; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; WYCKOFF LH, 1984, THESIS U FLORIDA; YORKSTON KM, 1980, J SPEECH HEAR DISORD, V45, P27, DOI 10.1044/jshd.4501.27	62	51	51	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	JUN	2004	89	3					508	523		10.1016/j.bandl.2004.01.003			16	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	820TO	WOS:000221412500010	15120542				2021-06-18	
J	Roncadin, C; Guger, S; Archibald, J; Barnes, M; Dennis, M				Roncadin, C; Guger, S; Archibald, J; Barnes, M; Dennis, M			Working memory after mild, moderate, or severe childhood closed head injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	28th Annual Meeting of the International-Neuropsychological-Society	FEB 09-12, 2000	DENVER, CO	Int Neuropsychol Soc			TRAUMATIC BRAIN-INJURY; INHIBITORY CONTROL; EXECUTIVE FUNCTION; FRONTAL LOBES; CHILDREN; DISCOURSE; ABILITY; AGE; COMPREHENSION; ADOLESCENTS	Children with closed head injury (CHI) perform poorly on complex tasks requiring working memory (WM). It is unclear to what extent WM itself is compromised, and whether WM varies with factors related to the CHI, such as injury severity, age at injury, and time since injury. We studied verbal WM in 126 school-age children with CHI, divided into mild, moderate, and severe injury severity groups. WM distributions were significantly skewed toward lower scores in the moderate and severe groups, although the distribution in the mild group was normal. Age at injury and time since injury predicted WM components only for the moderate group. Survivors of moderate or severe childhood CHI have persisting WM deficits limiting the computational workspace required for many cognitive tasks.	Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada	Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01NS21889-16] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Alloway TP., 1997, DEV MEMORY CHILDHOOD, P163; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Awh E, 1995, ANN NY ACAD SCI, V769, P97, DOI 10.1111/j.1749-6632.1995.tb38134.x; Baddeley A. D., 1986, WORKING MEMORY; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; Barrouillet P, 2001, J MEM LANG, V45, P1, DOI 10.1006/jmla.2001.2767; BJORKLUND DF, 1990, DEV REV, V10, P48, DOI 10.1016/0273-2297(90)90004-N; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Bull R, 2001, DEV NEUROPSYCHOL, V19, P273, DOI 10.1207/S15326942DN1903_3; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Carlson SM, 2001, CHILD DEV, V72, P1032, DOI 10.1111/1467-8624.00333; Case R., 1985, INTELLECTUAL DEV BIR; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; D'Esposito M, 1999, BRAIN COGNITION, V41, P66, DOI 10.1006/brcg.1999.1096; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Dennis Maureen, 1988, CLIN NEUROPSYCHOLOGY, P89; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Gathercole SE, 2000, BRIT J EDUC PSYCHOL, V70, P177, DOI 10.1348/000709900158047; GOLDMAN R, 1974, TECHNICAL MANUAL GOL; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; HULME C, 1995, J CHILD PSYCHOL PSYC, V36, P373, DOI 10.1111/j.1469-7610.1995.tb01297.x; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; LOGIE RH, 1996, WORKING MEMORY HUMAN, P31; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MONTGOMERY JW, 1995, J SPEECH HEAR RES, V38, P187, DOI 10.1044/jshr.3801.187; Palmer HM, 2000, BRAIN COGNITION, V44, P103; Passolunghi MC, 2001, J EXP CHILD PSYCHOL, V80, P44, DOI 10.1006/jecp.2000.2626; Petrides M, 2000, J NEUROSCI, V20, P7496; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; Postle BR, 1999, P NATL ACAD SCI USA, V96, P12959, DOI 10.1073/pnas.96.22.12959; Proctor A, 2000, BRAIN INJURY, V14, P633; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RICHARDSON JTE, 1996, WORKING MEMORY HUMAN, P3; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; RONCADIN C, 2003, UNPUB DEV RELATIONS; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Swanson HL, 2001, J EXP CHILD PSYCHOL, V79, P294, DOI 10.1006/jecp.2000.2587; SWANSON HL, 1993, J EXP CHILD PSYCHOL, V56, P87, DOI 10.1006/jecp.1993.1027; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; Verger K, 2000, BRAIN INJURY, V14, P495; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1991, WECHSLER INTELLIGENC; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeo RA, 2000, DEV NEUROPSYCHOL, V17, P143, DOI 10.1207/S15326942DN1702_01	65	51	51	0	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	25	1-2					21	36					16	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	774CG	WOS:000188961700003	14984327				2021-06-18	
J	Pearse, DD; Chatzipanteli, K; Marcillo, AE; Bunge, MB; Dietrich, WD				Pearse, DD; Chatzipanteli, K; Marcillo, AE; Bunge, MB; Dietrich, WD			Comparison of NOS inhibition by antisense and pharmacological inhibitors after spinal cord injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						aminoguanidine; antisense; inducible nitric oxide synthase; spinal cord injury; 140OW	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; L-ARGININE; IN-VIVO; AMINOGUANIDINE TREATMENT; INFLAMMATORY RESPONSE; SELECTIVE-INHIBITION; CEREBROSPINAL-FLUID; MOUSE PLEURISY	Inducible nitric oxide synthase (iNOS) is a key mediator of inflammation during pathological conditions. We examined, through the use of selective iNOS inhibitors, the role of iNOS in specific pathophysiological processes after spinal cord injury (SCI), including astrogliosis, blood-spinal cord barrier (BSCB) permeability, polymorphonuclear leukocyte infiltration, and neuronal cell death. Administration of iNOS antisense oligonucleotides (ASOs) (intraspinally at 3 h) or the pharmacological inhibitors, N-[3(Aminomethyl) benzyl] acetamidine (1400W) (i.v./i.p. 3 and 9 h) or aminoguanidine (i.p. at 3 and 9 h) after moderate contusive injury decreased the number of iNOS immunoreactive cells at the injury site by 65.6% (iNOS ASOs), 62.1% (1400W), or 59% (aminoguanidine) 24 h postinjury. iNOS activity was reduced 81.8% (iNOS ASOs), 56.7% (1400W), or 67.9% (aminoguanidine) at this time. All iNOS inhibitors reduced the degree of BSCB disruption (plasma leakage of rat immunoglobulins), with iNOS ASO inhibition being more effective (reduced by 58%). Neutrophil accumulation within the injury site was significantly reduced by iNOS ASOs and 1400W by 78.8% and 20.9%, respectively. Increased astrogliosis was diminished with iNOS ASOs but enhanced following aminoguanidine. Detection of necrotic and apoptotic neuronal cell death by propidium iodide and an FITC-conjugated Annexin V antibody showed that iNOS inhibition could significantly retard neuronal cell death rostral and caudal to the injury site. These novel findings indicate that acute inhibition of iNOS is beneficial in reducing several pathophysiological processes after SCI. Furthermore, we demonstrate that the antisense inhibition of iNOS is more efficacious than currently available pharmacological agents.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, 1095 NW 14th Terrace,R-48, Miami, FL 33136 USA.	DDietrich@miami.edu	Pearse, Damien D/D-3176-2011	Pearse, Damien D/0000-0003-1783-221X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038665] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P0I NS38665] Funding Source: Medline		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; Bacso Z, 2000, CANCER RES, V60, P4623; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, ANN NY ACAD SCI, V738, P69; BELENKY SN, 1993, J LEUKOCYTE BIOL, V53, P498; Bethea JR, 1998, J NEUROSCI, V18, P3251; BOADO RJ, 1995, DRUG METAB DISPOS, V23, P1297; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Campbell IL, 1996, J NEUROIMMUNOL, V71, P31, DOI 10.1016/S0165-5728(96)00129-4; Cartwright JE, 2000, BRIT J PHARMACOL, V131, P131, DOI 10.1038/sj.bjp.0703539; Cassina P, 2002, J NEUROSCI RES, V67, P21, DOI 10.1002/jnr.10107; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHI OZ, 1994, PHARMACOLOGY, V48, P367, DOI 10.1159/000139202; Chu D, 2002, NEUROCHEM RES, V27, P97, DOI 10.1023/A:1014858707218; Cifone MG, 1999, BLOOD, V93, P3876, DOI 10.1182/blood.V93.11.3876.411k25_3876_3884; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DING AH, 1988, J IMMUNOL, V141, P2407; Fiscus RR, 2002, NEUROSIGNALS, V11, P175, DOI 10.1159/000065431; Franco-Penteado CF, 2001, BIOCHEM PHARMACOL, V61, P1305, DOI 10.1016/S0006-2952(01)00573-1; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; GILLARDON F, 1994, EUR J NEUROSCI, V6, P880, DOI 10.1111/j.1460-9568.1994.tb00999.x; Gloor SM, 2001, BRAIN RES REV, V36, P258, DOI 10.1016/S0165-0173(01)00102-3; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HALIM A, 1995, THROMB RES, V77, P321, DOI 10.1016/0049-3848(95)93835-N; Hamilton LC, 1998, BRIT J PHARMACOL, V125, P335, DOI 10.1038/sj.bjp.0702077; Hinz B, 2000, BIOCHEM BIOPH RES CO, V271, P353, DOI 10.1006/bbrc.2000.2632; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; Huang DY, 2000, FASEB J, V14, P407; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JANIGRO D, 1994, CIRC RES, V75, P528, DOI 10.1161/01.RES.75.3.528; Kankuri E, 2001, J PHARMACOL EXP THER, V298, P1128; KAPLAN SS, 1989, BLOOD, V74, P1885; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Larfars G, 1999, BLOOD, V93, P1399, DOI 10.1182/blood.V93.4.1399.404k07_1399_1405; LARROUY B, 1992, GENE, V121, P189, DOI 10.1016/0378-1119(92)90121-5; Liu C, 2001, Chin J Traumatol, V4, P231; Liu CL, 2002, CHINESE MED J-PEKING, V115, P740; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Menchen LA, 2001, LIFE SCI, V69, P479, DOI 10.1016/S0024-3205(01)01139-0; MenezesdeLimaJunior O, 1997, J LEUKOCYTE BIOL, V62, P778; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1989, BIOCHEM SOC T, V17, P642, DOI 10.1042/bst0170642; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nag S, 2001, LAB INVEST, V81, P41, DOI 10.1038/labinvest.3780210; Nagayama T, 2000, J NEUROCHEM, V75, P1716, DOI 10.1046/j.1471-4159.2000.0751716.x; Nakahara S, 2002, J NEUROTRAUM, V19, P1467, DOI 10.1089/089771502320914697; Nishisho T, 1996, NEUROSURGERY, V39, P950, DOI 10.1097/00006123-199611000-00014; Okamura T, 2001, HYPERTENS RES, V24, P47, DOI 10.1291/hypres.24.47; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Pan W, 2001, Arch Physiol Biochem, V109, P350, DOI 10.1076/apab.109.4.350.4238; Pan WH, 1997, EXP NEUROL, V146, P367, DOI 10.1006/exnr.1997.6533; Parmentier S, 1999, BRIT J PHARMACOL, V127, P546, DOI 10.1038/sj.bjp.0702549; Parmentier-Batteur S, 2001, J CEREBR BLOOD F MET, V21, P15, DOI 10.1097/00004647-200101000-00003; Paterson I S, 1993, Ann Vasc Surg, V7, P68, DOI 10.1007/BF02042662; Perez-Sala D, 2001, AM J PHYSIOL-RENAL, V280, pF466; Peters CM, 2003, EXP NEUROL, V180, P1, DOI 10.1016/S0014-4886(02)00023-7; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; Tasaka Y, 1996, ENDOCR J, V43, P725, DOI 10.1507/endocrj.43.725; TAYLOR WF, 1993, AM J PHYSIOL, V264, pH1355; Uzan M, 2001, SURG NEUROL, V56, P350, DOI 10.1016/S0090-3019(01)00633-4; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Vianna RMJ, 1998, BRIT J PHARMACOL, V123, P281, DOI 10.1038/sj.bjp.0701590; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; West AR, 2002, SYNAPSE, V44, P227, DOI 10.1002/syn.10076; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317	79	51	51	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	NOV	2003	62	11					1096	1107		10.1093/jnen/62.11.1096			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	744CV	WOS:000186611100002	14656068	Bronze			2021-06-18	
J	Kay, AD; Petzold, A; Kerr, M; Keir, G; Thompson, E; Nicoll, JAR				Kay, AD; Petzold, A; Kerr, M; Keir, G; Thompson, E; Nicoll, JAR			Alterations in cerebrospinal fluid apolipoprotein E and amyloid beta-protein after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						A beta; apoE; brain injury; CSF analysis; S100B; Tau	GLOBAL CEREBRAL-ISCHEMIA; ONSET ALZHEIMER-DISEASE; CLOSED-HEAD INJURY; E-DEFICIENT MICE; E GENOTYPE; MOUSE MODEL; PRECURSOR PROTEIN; NEURONAL DAMAGE; TRANSGENIC MICE; E POLYMORPHISM	There is evidence that apolipoprotein E (apoE) and amyloid beta-protein (Abeta), which are implicated in the pathology of chronic neurodegenerative disorders, are involved in the response of the brain to acute injury; however, human in vivo evidence is sparse. We conducted a prospective observational study to determine the magnitude and time-course of alterations in cerebrospinal fluid (CSF) apoE and Abeta concentrations after traumatic brain injury (TBI), and the relationship of these changes to severity of injury and clinical outcome. Enzyme linked immunosorbant assay (ELISA) was used to assay apoE, Abeta(1-40) and Abeta(1-42) in serial CSF samples from 13 patients with TBI and 13 controls. CSF S100B and tau were assayed as surrogate markers of brain injury. There was a significant decrease in CSF apoE (p < 0.001) and A&beta; (p < 0.001) after TBI contrasting the observed elevation in CSF S100B (p < 0.001) and tau (p < 0.001) concentration. There was significant correlation (r = 0.67, p = 0.01) between injury severity and the decrease in Abeta(1-40) concentration after TBI. In vivo, changes in apoE and Abeta concentration occur after TBI and may be important in the response of the human brain to injury.	Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland; Univ London, Inst Neurol & Neurosurg, Dept Neuroimmunol, London, England; Dept Neurosurg, Pittsburgh, PA USA; Ctr Nursing Res, Pittsburgh, PA USA; Univ Southampton, Southampton Gen Hosp, Div Clin Neurosci, Southampton, Hants, England	Kay, AD (corresponding author), Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.		Petzold, Axel/C-1090-2009; Nicoll, James/I-9253-2017	Petzold, Axel/0000-0002-0344-9749; Nicoll, James/0000-0002-9444-7246			Andreasen N, 2001, ARCH NEUROL-CHICAGO, V58, P373, DOI 10.1001/archneur.58.3.373; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Beffert U, 1999, BRAIN RES, V843, P87, DOI 10.1016/S0006-8993(99)01894-6; BLENNOW K, 1994, NEUROREPORT, V5, P2534, DOI 10.1097/00001756-199412000-00032; Blennow K, 1995, MOL CHEM NEUROPATHOL, V26, P231, DOI 10.1007/BF02815140; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; Delphin C, 1999, J BIOL CHEM, V274, P10539, DOI 10.1074/jbc.274.15.10539; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Fagan AM, 2000, ANN NEUROL, V48, P201, DOI 10.1002/1531-8249(200008)48:2<201::AID-ANA10>3.0.CO;2-X; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Fleming LM, 1996, EXP NEUROL, V138, P252, DOI 10.1006/exnr.1996.0064; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Goedert M, 1999, PHILOS T ROY SOC B, V354, P1101, DOI 10.1098/rstb.1999.0466; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; Green AJE, 1997, J IMMUNOL METHODS, V205, P35, DOI 10.1016/S0022-1759(97)00050-1; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; Ikura M, 2000, NAT STRUCT BIOL, V7, P525, DOI 10.1038/76721; Kay A, 2003, STROKE, V34, P637, DOI 10.1161/01.STR.0000057579.25430.16; KAY A, 2003, J NEUROTRAUM, V109, P536; Koistinaho M, 2002, STROKE, V33, P1905, DOI 10.1161/01.STR.0000020124.61998.BC; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; LUXTON RW, 1989, CLIN CHEM, V35, P1731; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; McCarron MO, 2000, ARCH NEUROL-CHICAGO, V57, P1480, DOI 10.1001/archneur.57.10.1480; McColl BW, 2003, AM J PATHOL, V162, P273, DOI 10.1016/S0002-9440(10)63818-7; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nicoll JAR, 2001, NEUROREPORT, V12, P695, DOI 10.1097/00001756-200103260-00016; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; NITSCH RM, 1995, ANN NEUROL, V37, P512, DOI 10.1002/ana.410370414; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; RIFAI N, 1987, CLIN CHEM, V33, P1155; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROSENBERG RN, 1993, NEUROLOGY, V43, P851; Schenk DB, 2000, ARCH NEUROL-CHICAGO, V57, P934, DOI 10.1001/archneur.57.7.934; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Shoji M, 1998, J NEUROL SCI, V158, P134, DOI 10.1016/S0022-510X(98)00122-1; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Sorci G, 1998, BBA-MOL CELL RES, V1448, P277, DOI 10.1016/S0167-4889(98)00134-7; Starck M, 2000, CELL BIOCHEM FUNCT, V18, P9, DOI 10.1002/(SICI)1099-0844(200001/03)18:1<9::AID-CBF841>3.0.CO;2-X; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; THOMPSON EJ, 1990, ANN CLIN BIOCHEM, V27, P425, DOI 10.1177/000456329002700503; White F, 2001, EXP NEUROL, V169, P307, DOI 10.1006/exnr.2001.7655; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x	71	51	51	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2003	20	10					943	952		10.1089/089771503770195795			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734RX	WOS:000186072300003	14588111				2021-06-18	
J	Ibarra, A; Correa, D; Willms, K; Merchant, MT; Guizar-Sahagun, G; Grijalva, I; Madrazo, I				Ibarra, A; Correa, D; Willms, K; Merchant, MT; Guizar-Sahagun, G; Grijalva, I; Madrazo, I			Effects of cyclosporin-A on immune response, tissue protection and motor function of rats subjected to spinal cord injury	BRAIN RESEARCH			English	Article						autoimmunity; cellular response; demyelination; neuroprotection; paraplegia	TRAUMATIC BRAIN-INJURY; PROMOTES AXONAL REGENERATION; CENTRAL-NERVOUS-SYSTEM; MYELIN BASIC-PROTEIN; TRANSVERSE SECTION; LIPID-PEROXIDATION; FOREBRAIN ISCHEMIA; RATING-SCALE; ADULT-RATS; DAMAGE	The aim of this work was to test the effect of cyclosporin-A (CsA) on some immunological, morphological and functional aspects developed after spinal cord injury. The specific cellular immune response against spinal cord constituents, the amount of spared tissue and myelination at the site of injury, and the motor function outcome were assessed in a first series of experiments. Rats were subjected to spinal cord compression and treated with cyclosporin-A before lesion and during the entire study. A specific lymphocyte response against spinal cord antigens was found in untreated spinal cord injured rats but not in cyclosporine-A treated injured rats. A significantly better myelination index was also found in injured cyclosporin-A-treated rats, as compared to untreated animals. The amount of spared spinal cord tissue at the epicenter was not significantly different comparing CsA-treated with vehicle-treated rats. Looking for a potential therapeutic use of CsA, in a second series of experiments, rats were subjected to spinal cord contusion and treated with cyclosporin-A from 1 to 72 h after lesion. Motor recovery and red nuclei neurons survival, were evaluated, and found to be significantly better in spinal cord injured rats treated with cyclosporin-A than in injured-untreated rats. This work confirms the existence of an autoimmune cellular reaction after injury that can be inhibited by cyclosporin-A treatment. Furthermore, cyclosporin-A promotes neuroprotection by diminishing both demyelination and neuronal cell death, resulting in a better motor outcome after spinal cord injury. (C) 2003 Elsevier B.V. All rights reserved.	Ctr Med Nacl Siglo XXI, IMSS, Unidad Invest Med Enfermedades Neurol, Mexico City, DF, Mexico; Proyecto Camina AC, Mexico City 14050, DF, Mexico; Inst Nacl Pediat, SSA, Mexico City, DF, Mexico; Univ Nacl Autonoma Mexico, Fac Med, Dept Microbiol & Immunoparasitol, Mexico City, DF, Mexico	Ibarra, A (corresponding author), Ctr Med Nacl Siglo XXI, IMSS, Unidad Invest Med Enfermedades Neurol, Mexico City, DF, Mexico.	iantonio65@yahoo.com		Ibarra, Antonio/0000-0003-2489-4689; Guizar-Sahagun, Gabriel/0000-0002-2722-5758			Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; BALENTINE JD, 1988, J NEUROPATH EXP NEUR, V47, P77, DOI 10.1097/00005072-198803000-00001; BANIK NL, 1992, CRIT REV NEUROBIOL, V6, P257; BANIK NL, 1986, J NEUROL SCI, V73, P245, DOI 10.1016/0022-510X(86)90149-8; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Bluml S, 1999, EXP NEUROL, V158, P121, DOI 10.1006/exnr.1999.7073; Borlongan CV, 2002, BRAIN RES, V956, P211, DOI 10.1016/S0006-8993(02)03474-1; CAMPAGNOLO DI, 1994, AM J PHYS MED REHAB, V73, P387, DOI 10.1097/00002060-199411000-00003; Cruse JM, 2000, EXP MOL PATHOL, V68, P38, DOI 10.1006/exmp.1999.2292; DAWSON TM, 1994, J NEUROSCI, V14, P5147; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Diaz-Ruiz A, 2000, NEUROREPORT, V11, P1765, DOI 10.1097/00001756-200006050-00033; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; FERINGA ER, 1975, ARCH NEUROL-CHICAGO, V32, P676, DOI 10.1001/archneur.1975.00490520046007; Friberg H, 1998, J NEUROSCI, V18, P5151; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; GOLDMAN L, 1968, BIOPHYS J, V8, P596, DOI 10.1016/S0006-3495(68)86510-5; GRIJALVA I, 1994, NEURODEGENERATION, V3, P159; GUIZARSAHAGUN G, 1994, RESTOR NEUROL NEUROS, V7, P61, DOI 10.3233/RNN-1994-7201; GUIZARSAHAGUN G, 1994, SURG NEUROL, V41, P241, DOI 10.1016/0090-3019(94)90131-7; HALL DE, 1994, FREE RADICAL DAMAGE, P217; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2001, J CLIN INVEST, V108, P591, DOI 10.1172/JCI12837; Hauben E, 2002, EUR J NEUROSCI, V16, P1731, DOI 10.1046/j.1460-9568.2002.02241.x; Ibarra A, 1996, J NEUROTRAUM, V13, P267, DOI 10.1089/neu.1996.13.267; Ibarra A, 1996, J NEUROTRAUM, V13, P569, DOI 10.1089/neu.1996.13.569; Ibarra A, 2000, NEUROSCIENCE, V96, P3, DOI 10.1016/S0306-4522(99)00541-2; Jones TB, 2002, J NEUROSCI, V22, P2690, DOI 10.1523/JNEUROSCI.22-07-02690.2002; KHAN M, 1983, CAN J NEUROL SCI, V10, P161, DOI 10.1017/S031716710004484X; KHAN M, 1985, CAN J NEUROL SCI, V12, P259, DOI 10.1017/S0317167100047120; Kil K, 1999, J NEUROIMMUNOL, V98, P201, DOI 10.1016/S0165-5728(99)00057-0; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Loy DN, 2002, EXP NEUROL, V177, P575, DOI 10.1006/exnr.2002.7959; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P102, DOI 10.1097/00002060-199903000-00002; Miyata K, 2001, NEUROSCIENCE, V105, P571, DOI 10.1016/S0306-4522(01)00225-1; MIZRACHI Y, 1983, PARAPLEGIA, V21, P287, DOI 10.1038/sc.1983.48; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Montgomerie JZ, 1997, CLIN INFECT DIS, V25, P1285, DOI 10.1086/516144; MORRIS RE, 1995, THER DRUG MONIT, V17, P564, DOI 10.1097/00007691-199512000-00003; Nevo U, 2001, MAGN RESON MED, V45, P1, DOI 10.1002/1522-2594(200101)45:1<1::AID-MRM1001>3.0.CO;2-I; Nottingham S, 2002, EXP NEUROL, V177, P242, DOI 10.1006/exnr.2002.7975; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Ouary S, 2000, NEUROSCIENCE, V97, P521, DOI 10.1016/S0306-4522(00)00020-8; Palladini G, 1996, J BRAIN RES, V37, P145; PALLADINI G, 1987, EXP NEUROL, V95, P639, DOI 10.1016/0014-4886(87)90305-0; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; ROITT I, 1996, IMMUNOLOGY, P122; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 2002, J NEUROTRAUM, V19, P1251, DOI 10.1089/08977150260338038; Schnell L, 1997, EUR J NEUROSCI, V9, P1000, DOI 10.1111/j.1460-9568.1997.tb01450.x; Schwab ME, 1996, PHYSIOL REV, V76, P319; Schwartz M, 2001, J NEUROIMMUNOL, V113, P185, DOI 10.1016/S0165-5728(00)00447-1; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SMOLEN AJ, 1983, J NEUROCYTOL, V12, P739, DOI 10.1007/BF01258148; Springer JE, 2000, J NEUROSCI, V20, P7246; STERNBERG EM, 1992, BRAIN RES, V570, P54, DOI 10.1016/0006-8993(92)90563-O; Sugawara T, 1999, NEUROREPORT, V10, P3949, DOI 10.1097/00001756-199912160-00041; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Teichner A, 1993, J Hirnforsch, V34, P343; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; WEIBEL ER, 1979, STEREOLOGICAL METHOD, V1, P101; WILLIAMS RW, 1983, J NEUROSCI, V3, P1554; WRATHALL JR, 1992, J NEUROTRAUM, V9, pS129; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zeman RJ, 1999, EXP NEUROL, V159, P267, DOI 10.1006/exnr.1999.7146	77	51	59	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 25	2003	979	1-2					165	178		10.1016/S0006-8993(03)02898-1			14	Neurosciences	Neurosciences & Neurology	705LT	WOS:000184397100020	12850583				2021-06-18	
J	Rugg-Gunn, FJ; Eriksson, SH; Boulby, PA; Symms, MR; Barker, GJ; Duncan, JS				Rugg-Gunn, FJ; Eriksson, SH; Boulby, PA; Symms, MR; Barker, GJ; Duncan, JS			Magnetization transfer imaging in focal epilepsy	NEUROLOGY			English	Article							TEMPORAL-LOBE EPILEPSY; CEREBRAL CORTICAL DYSPLASIA; TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; WHITE-MATTER; TRANSFER RATIO; NEOCORTICAL EPILEPSY; NEURONAL MIGRATION; MR; ABNORMALITIES	Objectives: To test the hypothesis that magnetization transfer imaging (MTI), analyzed on a voxel-by-voxel basis, would identify areas of abnormal magnetization transfer ratio (MTR) in patients with focal epilepsy. Methods: The authors used MTI maps and statistical parametric mapping (SPM) to objectively compare the cerebral structures of 15 patients with malformations of cortical development (MCD), 10 with partial seizures and acquired lesions, and 42 with partial seizures and normal conventional MRI with those of 30 control subjects. Results: Significant reductions of MTR were identified in all 10 patients with acquired nonprogressive cerebral lesions and partial seizures. In all, the areas of decreased MTR concurred with abnormalities identified on visual inspection of conventional MRI. In 13 of the 15 patients with MCD, SPM detected regions of significantly reduced MTR, all of which corresponded to abnormalities identified on visual inspection of conventional MRI. In addition, in both groups, there were areas that were normal on conventional imaging that demonstrated abnormal MTR. There was a significant reduction of MTR in 15 of the 42 patients with cryptogenic focal epilepsy. In all of these, the areas of reduced MTR concurred with epileptiform EEG abnormality and clinical seizure semiology. Conclusions: Magnetization transfer imaging analyzed using statistical parametric mapping was sensitive in identifying malformations of cortical development and acquired cerebral lesions. Abnormalities of magnetization transfer ratio in individual MRI-negative patients suggest that minor structural disorganization exists in occult epileptogenic cerebral lesions.	Natl Soc Epilepsy, MRI Unit, Gerrards Cross SL9 0RJ, Bucks, England; UCL, Inst Neurol, Dept Clin & Expt Epilepsy, London, England; UCL, Inst Neurol, NMR Res Unit, London, England; UCL, Inst Neurol, Dept Neuroinflammat, London, England	Duncan, JS (corresponding author), Natl Soc Epilepsy, MRI Unit, Gerrards Cross SL9 0RJ, Bucks, England.	j.duncan@ion.ucl.ac.uk	Barker, Gareth J/C-9616-2009	Barker, Gareth J/0000-0002-5214-7421; Duncan, John S/0000-0002-1373-0681			Adams JH, 1992, GREENFIELDS NEUROPAT, P106; ALLEN IV, 1979, J NEUROL SCI, V41, P81, DOI 10.1016/0022-510X(79)90142-4; Ashburner J, 1997, NEUROIMAGE, V6, P209, DOI 10.1006/nimg.1997.0290; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Barker GJ, 1996, MAGN RESON IMAGING, V14, P403, DOI 10.1016/0730-725X(96)00019-7; BARKOVICH AJ, 1988, AM J ROENTGENOL, V150, P179, DOI 10.2214/ajr.150.1.179; BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; BOULBY PA, 2000, P 16 M EUR SOC MAGN, P483; Brochet B, 1999, NEUROLOGY, V53, pS12; Burke JW, 1996, AM J NEURORADIOL, V17, P773; CASCINO GD, 1992, EPILEPSY RES, V11, P51, DOI 10.1016/0920-1211(92)90021-K; Castillo M, 1996, RADIOGRAPHICS, V16, P241, DOI 10.1148/radiographics.16.2.8966284; Cendes F, 1997, ANN NEUROL, V42, P737, DOI 10.1002/ana.410420510; Dousset V, 1997, AM J NEURORADIOL, V18, P895; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; Duncan JS, 1997, BRAIN, V120, P339, DOI 10.1093/brain/120.2.339; DUONG T, 1994, ACTA NEUROPATHOL, V87, P493, DOI 10.1007/BF00294176; Ferini-Strambi L, 2000, NEUROLOGY, V54, P2331, DOI 10.1212/WNL.54.12.2331; Filippi M, 1998, ANN NEUROL, V43, P809, DOI 10.1002/ana.410430616; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; GASS A, 1994, ANN NEUROL, V36, P62, DOI 10.1002/ana.410360113; Hammers A, 2001, BRAIN, V124, P1555, DOI 10.1093/brain/124.8.1555; HARDING BN, 1992, GREENFIELDS NEUROPAT, P521; Jay V, 1998, CHILD NERV SYST, V14, P15, DOI 10.1007/s003810050167; Juhasz C, 2001, NEUROLOGY, V56, P1650, DOI 10.1212/WNL.56.12.1650; KUCHARCZYK W, 1994, RADIOLOGY, V192, P521, DOI 10.1148/radiology.192.2.8029426; Lemieux L, 1999, MAGN RESON MED, V42, P127; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; Li LM, 2000, AM J NEURORADIOL, V21, P1853; MANZ HJ, 1979, ACTA NEUROPATHOL, V45, P97, DOI 10.1007/BF00691886; MARCHAL G, 1989, ARCH NEUROL-CHICAGO, V46, P430, DOI 10.1001/archneur.1989.00520400090025; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; Mehta RC, 1996, AM J NEURORADIOL, V17, P1051; MEHTA RC, 1995, AM J NEURORADIOL, V16, P2085; MITCHISON G, 1991, P ROY SOC B-BIOL SCI, V245, P151, DOI 10.1098/rspb.1991.0102; PALMINI A, 1995, ANN NEUROL, V37, P476, DOI 10.1002/ana.410370410; Plummer D., 1992, RIV NEURORADIOL, V5, P489, DOI DOI 10.1177/197140099200500413; PRAGER JM, 1994, AM J NEURORADIOL, V15, P1497; Richardson MP, 1998, NEUROLOGY, V51, P485, DOI 10.1212/WNL.51.2.485; Rugg-Gunn FJ, 2002, LANCET, V359, P1748, DOI 10.1016/S0140-6736(02)08615-4; Rugg-Gunn FJ, 2001, BRAIN, V124, P627, DOI 10.1093/brain/124.3.627; Silver NC, 1997, J NEUROL NEUROSUR PS, V62, P223, DOI 10.1136/jnnp.62.3.223; Sinson G, 2001, AM J NEURORADIOL, V22, P143; SISODIYA SM, 1995, BRAIN, V118, P1039, DOI 10.1093/brain/118.4.1039; Sisodiya SM, 1997, BRAIN, V120, P271, DOI 10.1093/brain/120.2.271; SYMMS M, 1996, P 4 M INT SOC MAGN R, P588; THEODORE WH, 1990, NEUROLOGY, V40, P797, DOI 10.1212/WNL.40.5.797; TOFTS PS, 1995, AM J NEURORADIOL, V16, P1862; van Waesberghe JHTM, 1999, ANN NEUROL, V46, P747; VANWAESBERGHE JHT, 1998, MULT SCLER, V4, P272; Woermann FG, 1999, BRAIN, V122, P2101, DOI 10.1093/brain/122.11.2101; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; WOLFF SD, 1994, RADIOLOGY, V192, P593, DOI 10.1148/radiology.192.3.8058919; Woo TU, 1996, CEREB CORTEX, V6, P446, DOI 10.1093/cercor/6.3.446; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; ZENTNER J, 1995, J NEUROL NEUROSUR PS, V58, P666, DOI 10.1136/jnnp.58.6.666	59	51	54	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 27	2003	60	10					1638	1645		10.1212/01.WNL.0000065891.93179.CC			8	Clinical Neurology	Neurosciences & Neurology	682LD	WOS:000183092400017	12771255				2021-06-18	
J	Temkin, NR; Machamer, JE; Dikmen, SS				Temkin, NR; Machamer, JE; Dikmen, SS			Correlates of functional status 3-5 years after traumatic brain injury with CT abnormalities	JOURNAL OF NEUROTRAUMA			English	Article						craniocerebral trauma; criterion-related validity; functional status; head injury; health status; measurement development; outcome assessment; traumatic brain injury	GLASGOW-OUTCOME-SCALE; HEAD-INJURY; POSTTRAUMATIC SEIZURES; ALCOHOL-USE; DEPRESSION; RECOVERY	The Functional Status Examination (FSE) is a relatively new measure of functional outcome after traumatic brain injury (TBI). This study examines functional status limitations and what contributes to them to further enhance interpretability of the FSE and to continue its development as an outcome measure. The measure was given to 209 adults sustaining TBI with CT abnormalities who were followed prospectively until three to five years after injury. Relationships between functional status change as assessed by the FSE and characteristics of the injury and pre-injury characteristics of the person injured were evaluated as were relationships with concurrent measures of neuropsychological, emotional, and psychosocial functioning, health status, quality of life, and other functional status measures. Groups based on degree of functional status limitations due to the injury differ significantly on injury severity, especially length of impaired consciousness. They do not differ on most pre-injury characteristics of the person injured, although pre-existing conditions, primarily alcohol abuse, are more common in those with more negative functional changes after injury. All concurrent measures examined differ significantly among FSE groups with strongest relationships with measures of quality of life, psychosocial functioning, and other measures of health status and functional status (each p < 0.001). The Functional Status Examination shows promise as a measure reflecting a broad range of functional limitations. The FSE is an excellent tool combining clinical relevance, face validity, strong relationships to other measures of relevant constructs (criterion-related validity), and reasonable sensitivity to TBI severity even long after the injury and in a mostly moderately injured group.	Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; Univ Washington, Dept Biostat, Seattle, WA 98104 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA	Temkin, NR (corresponding author), Univ Washington, Dept Neurol Surg, Box 359924,325 9th Ave, Seattle, WA 98104 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019463] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS19463] Funding Source: Medline		BOMBARDIER C, IN PRESS ARCH PHYS M; Cherner M, 2001, ARCH PHYS MED REHAB, V82, P780, DOI 10.1053/apmr.2001.23263; DELIS D, 1987, CALIFORNIA VERBAL LE; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Food and Drug Administration, 1997, FED REGISTER, V62, P66113; JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reitan R.M., 1993, HALSTEADREITAN NEURO; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Ware JE., 1993, SF 36 HLTH SURVEY MA; *WHO, 1993, WHO INT CLASS IMP DI; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	28	51	56	0	9	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2003	20	3					229	241		10.1089/089771503321532815			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	661GU	WOS:000181883500001	12820677				2021-06-18	
J	Wilken, JA; Kane, R; Sullivan, CL; Wallin, M; Usiskin, JB; Quig, ME; Simsarian, J; Saunders, C; Crayton, H; Mandler, R; Kerr, D; Reeves, D; Fuchs, K; Manning, C; Keller, M				Wilken, JA; Kane, R; Sullivan, CL; Wallin, M; Usiskin, JB; Quig, ME; Simsarian, J; Saunders, C; Crayton, H; Mandler, R; Kerr, D; Reeves, D; Fuchs, K; Manning, C; Keller, M			The utility of computerized neuropsychological assessment of cognitive dysfunction in patients with relapsing-remitting multiple sclerosis	MULTIPLE SCLEROSIS			English	Article						automated assessment; cognition; cognitive dysfunction; computerized neuropsychological assessment; multiple sclerosis; prediction of cognitive impairment	MILD BRAIN INJURY; MONITORING RECOVERY; IMPAIRMENT; CONCUSSION; MEMORY; PERFORMANCE; EFFICIENCY; DISABILITY; MIGRAINE; PATTERNS	Traditional paper-and-pencil neuropsychological batteries used to document cognitive deficits in multiple sclerosis (MS) patients lack timing precision. This makes it difficult to accurately measure psychomotor slowing, a central cognitive symptom of MS. Additionally, traditional batteries lack multiple alternate forms necessary to control for practice effects when assessing cognition over time. Finally, such batteries are lengthy and expensive. Computerized neuropsychological batteries address many of these shortcomings. They measure response time more precisely, require less administration time, include alternate forms, and are ideal for rapid screening/triage. Although there are normative data on the reliability and validity of computerized measures, there have been no controlled validation studies with MS patients. The current study was designed to validate a computerized neuropsychological battery (ANAM) for use with relapsingremitting (RR) MS patients. Prior to initiation of interferon-beta-1a (Avonex) treatment, subjects participated in a neuropsychological evaluation consisting of traditional and computerized measures. Moderate-to-high correlations were found between computerized and traditional measures. Computerized tests accurately predicted performance on key traditional tests. The battery was also concordant with traditional measures in identifying RR MS patients with and without neurocognitive impairment. Findings are discussed with respect to increased accuracy and accessibility of neuropsychological evaluations for MS patients.	Vet Affairs Med Ctr, Dept Psychol, Washington, DC 20422 USA; Vet Affairs Med Ctr, Dept Neurol, Washington, DC 20422 USA; Vet Affairs Med Ctr, Mental Hlth Serv Line, Baltimore, MD 21201 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20057 USA; Neurol Ctr, Fairfax, VA USA; Johns Hopkins Univ, Med Ctr, Dept Neurol, Baltimore, MD 21218 USA; USN, San Diego, CA 92055 USA; Univ Virginia, Med Ctr, Charlottesville, VA 22908 USA	Wilken, JA (corresponding author), Vet Affairs Med Ctr, Dept Psychol, 50 Irving St NW, Washington, DC 20422 USA.		Wallin, Mitchell T./J-8190-2019; Weiderpass, Elisabete/AAP-2747-2021; KERR, Douglas A/B-9270-2008	Wallin, Mitchell T./0000-0003-1061-5714; Weiderpass, Elisabete/0000-0003-2237-0128; 			AMATO MP, 1995, ARCH NEUROL-CHICAGO, V52, P168, DOI 10.1001/archneur.1995.00540260072019; Arnett PA, 1997, NEUROPSYCHOLOGY, V11, P535, DOI 10.1037/0894-4105.11.4.535; BEATTY WW, 1995, NEUROPSYCHOLOGY, V9, P198, DOI 10.1037/0894-4105.9.2.198; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DELIS C, 1987, CALIFORNIA VERBAL LE; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; Diamond BJ, 1997, J CLIN EXP NEUROPSYC, V19, P34, DOI 10.1080/01688639708403834; ELPERN SJ, 1984, INT NEUR SOC HOUST T; ELSASS P, 1983, ACTA NEUROL SCAND, V68, P257, DOI 10.1111/j.1600-0404.1983.tb04835.x; Farmer K, 2000, HEADACHE, V40, P657, DOI 10.1046/j.1526-4610.2000.040008657.x; Farmer K, 2001, HEADACHE, V41, P377, DOI 10.1046/j.1526-4610.2001.111006377.x; Gottschalk LA, 2000, COMPR PSYCHIAT, V41, P326, DOI 10.1053/comp.2000.9015; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HEATON RK, 1985, J CONSULT CLIN PSYCH, V53, P103, DOI 10.1037/0022-006X.53.1.103; HEGGE FW, 1985, UNIFIED TRISERVICE C; KABAT, 2001, CLIN NEUROPSYCHOL, V15, P498; Kail R, 1998, J CLIN EXP NEUROPSYC, V20, P98, DOI 10.1076/jcen.20.1.98.1483; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; Krupp LB, 2000, NEUROLOGY, V55, P934, DOI 10.1212/WNL.55.7.934; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; Ling ND, 1998, PERCEPT MOTOR SKILL, V86, P987, DOI 10.2466/pms.1998.86.3.987; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MAHLER ME, 1992, PSYCHIAT CLIN N AM, V15, P427; Rao S.M., 1993, NEUROPSYCHOLOGY, V7, P364, DOI [10.1037/0894-4105.7.3.364, DOI 10.1037/0894-4105.7.3.364]; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1995, CURR OPIN NEUROL, V8, P216, DOI 10.1097/00019052-199506000-00010; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; Reeves D, 1992, AUTOMATED NEUROPSYCH, VI; REEVES DL, 1992, ANN M AM PSYCH ASS A; Reitan RM., 1985, HALSTEAD REITAN NEUR; Reitan RM, 1979, MANUAL ADM NEUROPSYC; RON MA, 1991, PSYCHOL MED, V21, P59, DOI 10.1017/S0033291700014653; Ryan L, 1996, NEUROPSYCHOLOGY, V10, P176, DOI 10.1037/0894-4105.10.2.176; SAMET M, 1986, COMPLEX COGNITIVE AS; THORNE DR, 1985, NEUROBEH TOXICOL TER, V7, P415; Thornton AE, 1997, NEUROPSYCHOLOGY, V11, P357, DOI 10.1037/0894-4105.11.3.357; VANDENBURG W, 1987, ARCH NEUROL-CHICAGO, V44, P494, DOI 10.1001/archneur.1987.00520170024017; Wechsler D., 1997, WECHSLER ADULT INTEL; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wishart H, 1997, J CLIN EXP NEUROPSYC, V19, P810, DOI 10.1080/01688639708403762	44	51	53	1	7	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	1352-4585			MULT SCLER	Mult. Scler.	MAR	2003	9	2					119	127		10.1191/1352458503ms893oa			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	666QC	WOS:000182187100002	12708806				2021-06-18	
J	Royo, NC; Shimizu, S; Schouten, J; Stover, JF; McIntosh, TK				Royo, NC; Shimizu, S; Schouten, J; Stover, JF; McIntosh, TK			Pharmacology of traumatic brain injury	CURRENT OPINION IN PHARMACOLOGY			English	Article							CORTICAL IMPACT INJURY; CHANNEL BLOCKER ZICONOTIDE; NITRIC-OXIDE SYNTHASE; RECEPTOR ANTAGONIST; BARRIER BREAKDOWN; OXIDATIVE STRESS; CYCLOSPORINE-A; NMDA RECEPTOR; DOSE-RESPONSE; CELL-DEATH	The intensity of experimental and clinical research to identify a neuroprotective drug for the treatment of traumatic brain injury is motivated by the devastating morbidity and mortality of this condition. Encouraging experimental work has led so far to disappointing clinical trials and the identification of new potential therapeutic targets is critically dependent on a better understanding of the chronic pathophysiology triggered by the initial insult. Future advances in the pharmacological treatment of traumatic brain injury are likely to include the evaluation of sequentially timed therapies combining multiple and targeted agents, and manipulation of the newly discovered neurogenic potential of the adult brain together with the refinement of traditional interventions to block specific cytotoxic cascades.	Univ Penn, Dept Neurosurg, Head Injury Ctr, Philadelphia, PA 19104 USA	Royo, NC (corresponding author), Univ Penn, Dept Neurosurg, Head Injury Ctr, 3320 Smith Walk,105 C Hayden Hall, Philadelphia, PA 19104 USA.	nroyo@mail.med.upenn.edu; joost@mail.med.upenn.edu; saori2@mail.med.upenn.edu; stover@mail.med.upenn.edu; mcintosh@seas.upenn.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34790] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS40978] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P50NS008803] Funding Source: NIH RePORTER		Akasu T, 2002, NEUROSCI LETT, V329, P305, DOI 10.1016/S0304-3940(02)00707-3; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Aoyama N, 2002, BRAIN RES, V934, P117, DOI 10.1016/S0006-8993(02)02366-1; Atlante A, 2001, FEBS LETT, V497, P1, DOI 10.1016/S0014-5793(01)02437-1; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Bareyre FM, 2002, J NEUROSCI, V22, P7097; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Beaumont A, 2000, NEUROL RES, V22, P665; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Belayev L, 2002, J NEUROSURG, V96, P1077, DOI 10.3171/jns.2002.96.6.1077; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; Berman RF, 2000, J NEUROSURG, V93, P821, DOI 10.3171/jns.2000.93.5.0821; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Chabrier PE, 1999, P NATL ACAD SCI USA, V96, P10824, DOI 10.1073/pnas.96.19.10824; Cheney JA, 2001, J CEREBR BLOOD F MET, V21, P396, DOI 10.1097/00004647-200104000-00008; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Katoh-Semba R, 2002, FASEB J, V16, P1328, DOI 10.1096/fj.02-0143fje; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Khaldi A, 2002, ANN NY ACAD SCI, V962, P53, DOI 10.1111/j.1749-6632.2002.tb04055.x; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Laurer HL, 2001, CURR PHARM DESIGN, V7, P1505, DOI 10.2174/1381612013397285; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LENZLINGER PM, 2002, J NEUROTRAUM, V19, P1276; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Movsesyan VA, 2001, J PHARMACOL EXP THER, V296, P41; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newcomer JW, 2001, HIPPOCAMPUS, V11, P529, DOI 10.1002/hipo.1069; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao VLR, 2001, BRAIN RES, V911, P96; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Stutzmann JM, 2002, CNS DRUG REV, V8, P1; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; Wahl F, 1999, ACT NEUR S, V73, P103; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	74	51	56	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1471-4892	1471-4973		CURR OPIN PHARMACOL	Curr. Opin. Pharmacol.	FEB	2003	3	1					27	32		10.1016/S1471-4892(02)00006-1			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	637EA	WOS:000180497600005	12550738				2021-06-18	
J	McCullagh, S; Feinstein, A				McCullagh, S; Feinstein, A			Outcome after mild traumatic brain injury: an examination of recruitment bias	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							MINOR HEAD-INJURY; GLASGOW-COMA-SCALE; FOLLOW-UP; SYMPTOMS; CLASSIFICATION; PREDICTION; AMNESIA; TRIAL	Objectives: Research concerning the natural history after mild traumatic brain injury (TBI) faces a number of methodological challenges, including those related to subject recruitment. The aim of this study was to determine whether subjects who agree to participate in longitudinal research differ from those who do not. The presence of identifiable, selective factors operating during recruitment may be an important source of systematic bias. In Canada, given the presence of universal healthcare coverage, this issue can be examined using population based, administrative databases to obtain information about a cohort that was approached for study enrolment, regardless of whether they ultimately agreed to participate. Methods: A sample of 626 consecutive patients with mild TBI was invited to enrol in TBI outcome research. Those who agreed to participate (n=272) were compared with those who refused (n=354) on demographic, past health, and injury related variables. Thereafter, using encrypted health card data, the two groups were contrasted with respect to pre-injury and post-injury healthcare utilisation. Results: No premorbid differences between the groups emerged. However, all early indices of TBI severity were significantly worse for the participants group (p<0.001). Consistent with these findings, healthcare utilisation rates were no different before injury, but were significantly increased after injury for the participants (p<0.001), even beyond the period of study enrolment (p<0.001). Differences remained even after controlling for those with significant non-TBI injuries. Conclusions: Premorbid factors did not predict whether patients comply with, or refuse study participation. However, the participants group was biased toward those with more significant injuries, which translated into higher rates of healthcare utilisation after injury. These results strike a cautionary note, given the apparent systematic bias influencing enrolment in longitudinal studies of mild TBI.	Sunnybrook & Womens Coll Hosp, Neuropsychiat Program, Toronto, ON M4N 3M5, Canada	McCullagh, S (corresponding author), Sunnybrook & Womens Coll Hosp, Neuropsychiat Program, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	scott.mccullagh@swchsc.on.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Barth JT., 1989, MILD HEAD INJURY, P257; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; Britton A, 1999, J Health Serv Res Policy, V4, P112; CHAN B, 1999, ICES ATLAS REPORTS, P1; CONDON JT, 1986, AUST NZ J PSYCHIAT, V20, P87, DOI 10.3109/00048678609158870; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIKMEN SS, 1989, MILD HEAD INJURY, P229; EDLUND MJ, 1985, AM J PSYCHIAT, V142, P624; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P468; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; HOLDEN G, 1993, SOC WORK HEALTH CARE, V19, P1, DOI 10.1300/J010v19n02_01; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kraus J, 2000, HEAD INJURY, P1; KROENKE K, 1993, ARCH INTERN MED, V153, P2474, DOI 10.1001/archinte.153.21.2474; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P159; Simon G, 1996, PSYCHOSOM MED, V58, P481, DOI 10.1097/00006842-199609000-00010; *SPSS, 1999, SPSS WIND REL 10 0; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; *STAT CAN, 1997, STAT CAN POP CENS 19; VANHEMERT AM, 1993, PSYCHOL MED, V23, P167, DOI 10.1017/S0033291700038952; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; 1992, LANCET, V340, P823	40	51	51	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	2003	74	1					39	43		10.1136/jnnp.74.1.39			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	632DA	WOS:000180207400011	12486264	Green Published, Bronze			2021-06-18	
J	Rapoport, M; McCauley, S; Levin, H; Song, J; Feinstein, A				Rapoport, M; McCauley, S; Levin, H; Song, J; Feinstein, A			The role of injury severity in neurobehavioral outcome 3 months after Traumatic Brain Injury	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article							CLOSED-HEAD-INJURY; RATING-SCALE; BEHAVIORAL SEQUELAE; DISORDERS; RECOVERY; DEPRESSION; VALIDITY	Objective/Background: To assess neurobehavioral outcome using the Neurobehavioral Rating Scale-Revised (NRS-R), an instrument with established specificity and validity in Traumatic Brain Injury (TBI) in a sample including the full spectrum of TBI severity 3 months after injury. Method: A cohort group of 102 subjects with mild TBI, 41 with moderate TBI, and 139 with severe TBI, from multiple academic trauma centers, were assessed using the NRS-R and the Glasgow Outcome Scale. Results: Principal components analysis of the NRS-R resulted in a 3-factor model: (1) Cognitive, (2) Emotional, and (3) Hyperarousal. At 3 months, subjects with severe TBI show greater difficulties in cognitive and hyper-arousal, but not emotional domains, than those with mild to moderate TBI. More than one third of subjects in all injury severity groups showed evidence of anxiety, depression, irritability, mental fatigability, and memory dysfunction. Scores on the NRS-R were related to outcome on the Glasgow Outcome Scale. Conclusions: Three months after injury, subjects with severe TBI have more dysfunction in cognitive and behavioral (but not emotional) domains than those with mild-to-moderate TBI. The NRS-R is a useful tool for assessing the full spectrum of neurobehavioral dysfunction at all ranges of TBI severity.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA	Rapoport, M (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, FG37-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	mark.rapoport@swchsc.on.ca	Rapoport, Mark/AAD-8581-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; ODCDC CDC HHS [R49CCR 612707] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Brooks D N, 1979, Int Rehabil Med, V1, P166; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CORRIGAN J D, 1990, Brain Injury, V4, P215, DOI 10.3109/02699059009026170; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; EPSTEIN RS, 1994, NEUROPSYCHIATRY TRAU, P25; GUALTIERI CT, 1991, J CLIN PSYCHOPHARM, V11, P280, DOI 10.1097/00004714-199108000-00027; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; PRIGATANO GP, 1986, NEUROPSYCHOLOGIC REH; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Silver Jonathan M., 1994, P313; Smeltzer Donald J., 1994, P251; Stevens J., 1996, APPL MULTIVARIATE ST; Tabachnick B.G., 1989, USING MULTIVARIATE S; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643	42	51	53	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	JUN	2002	15	2					123	132		10.1097/01.WNN.0000016801.80266.36			10	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	560XW	WOS:000176107500008	12050475				2021-06-18	
J	Paschall, MJ; Fishbein, DH				Paschall, MJ; Fishbein, DH			Executive cognitive functioning and aggression: a public health perspective	AGGRESSION AND VIOLENT BEHAVIOR			English	Article						aggression; violence; executive function; cognition; public health; treatment	TRAUMATIC BRAIN-INJURY; DEFICIT-HYPERACTIVITY DISORDER; UNITED-STATES; FOLLOW-UP; ANTISOCIAL-BEHAVIOR; VIOLENT BEHAVIOR; CONDUCT DISORDER; HEAD-INJURY; CHILD-DEVELOPMENT; MALE-ADOLESCENTS	A large body of research from diverse fields suggests that impaired executive cognitive functioning (ECF) may play an important role in the etiology of aggression and violent behavior (AVB). A number of studies examining subjects without significant psychopathology has found compelling evidence for a relationship between subclinical impaired ECF and AVB. These findings provide an empirical foundation for research on the epidemiology of impaired ECF as a risk factor for AVB in the general population, Unfortunately, however, most research on the ECF-AVB relationship has been limited to clinical, incarcerated, and other small nonrepresentative samples of human subjects. Thus, little is known about the public health significance of impaired ECF and its implications for behavioral disorders. Research is reviewed that may shed light on the epidemiology of impaired ECF and its relationship to AVB. Other conditions that correlate with, define, or contribute to ECF impairments that may also relate to AVB are discussed. Because ECF is considered to be malleable, an introduction to interventions with potential to improve ECF and, in turn, AVB is included. Finally, an agenda, along with a conceptual framework to guide this work, is proposed for future research on the ECF-AVB relationship from a public health perspective, with attention to anticipated methodological and ethical challenges. (C) 2002 Elsevier Science Ltd. All rights reserved.	Pacific Inst Res & Evaluat, Chapel Hill, NC 27514 USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA	Paschall, MJ (corresponding author), Pacific Inst Res & Evaluat, 104 S Estes Dr,Suite 206, Chapel Hill, NC 27514 USA.	paschall@pire.org		fishbein, diana/0000-0003-1644-2762			Alderman N, 1997, BRAIN INJURY, V11, P79, DOI 10.1080/026990597123683; ALDERMAN N, 1990, COGNITIVE REHABILITA, P204; ALDERMAN N, 1991, NEUROPSYCHOL REHABIL, V1, P65, DOI DOI 10.1080/09602019108401380; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; Barratt ES, 1997, BIOL PSYCHIAT, V41, P1045, DOI 10.1016/S0006-3223(96)00175-8; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; BIERMAN KL, 1992, DEV PSYCHOPATHOL, V4, P509, DOI 10.1017/S0954579400004855; BOTVIN GJ, 1995, JAMA-J AM MED ASSOC, V273, P1106, DOI 10.1001/jama.273.14.1106; BROWN CS, 1994, CNS DRUGS, V1, P95, DOI 10.2165/00023210-199401020-00002; BROWN M, 1989, J METAMORPH GEOL, V7, P1, DOI 10.1111/j.1525-1314.1989.tb00569.x; Burgess P. W., 1990, COGNITIVE REHABILITA, P183; BUSCH KG, 1990, J CLIN PSYCHOL, V46, P472, DOI 10.1002/1097-4679(199007)46:4<472::AID-JCLP2270460416>3.0.CO;2-F; Disney ER, 1999, AM J PSYCHIAT, V156, P1515, DOI 10.1176/ajp.156.10.1515; DUNCAN GJ, 1994, CHILD DEV, V65, P296, DOI 10.1111/j.1467-8624.1994.tb00752.x; Eggert L L, 1994, Am J Health Promot, V8, P202; Elia J, 1999, NEW ENGL J MED, V340, P780, DOI 10.1056/NEJM199903113401007; Ellickson PL, 2000, AM J PUBLIC HEALTH, V90, P566, DOI 10.2105/AJPH.90.4.566; Embry DD, 1996, AM J PREV MED, V12, P91; FABIANO E, 1990, PRELIMINARY ASSESSME; FABIANO E, 1990, REHABILITATION CLEAR; Fabiano E. A., 1991, CORRECTIONS TODAY, V53, P102; Fishbein D, 2000, Prev Sci, V1, P89, DOI 10.1023/A:1010090114858; Giancola PR, 1998, J ABNORM PSYCHOL, V107, P629, DOI 10.1037/0021-843X.107.4.629; Giancola PR, 1995, AGGRESSIVE BEHAV, V21, P431, DOI 10.1002/1098-2337(1995)21:6<431::AID-AB2480210604>3.0.CO;2-Q; GIANCOLA PR, 2000, SCI TREATMENT PREVEN; GINACOLA PR, 1994, J ABNORM PSYCHOL, V103, P832; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Green MA, 1996, PROG PHOTOVOLTAICS, V4, P1; Greenberg M. T., 1999, PREVENTING MENTAL DI; GREENBERG MT, 1995, DEV PSYCHOPATHOL, V7, P117, DOI 10.1017/S0954579400006374; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HAMMOND R, 1991, J HEALTH CARE POOR U, V2, P359; HAWKINS DF, 1993, HEALTH AFFAIR, V12, P80, DOI 10.1377/hlthaff.12.4.80; Hawkins KA, 2000, AGGRESS VIOLENT BEH, V5, P147, DOI 10.1016/S1359-1789(98)00033-0; HEILBRUN AB, 1990, J PERS ASSESS, V54, P617, DOI 10.1207/s15327752jpa5403&4_16; Hermann D., 1996, RETRAINING COGNITION; HETHERINGTON EM, 1994, SEPARATE SOCIAL WORL; Higgins ST, 2000, J CONSULT CLIN PSYCH, V68, P64, DOI 10.1037/0022-006X.68.1.64; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; KAKAR S, 1996, CHILD ABUSE DELINQUE; Kann L, 1998, MMWR CDC Surveill Summ, V47, P1; Kellam SG, 1998, DEV PSYCHOPATHOL, V10, P165, DOI 10.1017/S0954579498001564; Kellam SG, 1998, AM J PUBLIC HEALTH, V88, P1490, DOI 10.2105/AJPH.88.10.1490; KELLAM SG, 1994, DEV PSYCHOPATHOL, V6, P463, DOI 10.1017/S0954579400006052; KELLEY BT, 1997, WAKE CHILDHOOD MALTR; KORENMAN S, 1995, CHILD YOUTH SERV REV, V17, P127, DOI 10.1016/0190-7409(95)00006-X; LAROSE S, 1989, PERCEPT MOTOR SKILL, V69, P851, DOI 10.2466/pms.1989.69.3.851; LAU MA, 1995, J ABNORM PSYCHOL, V104, P150, DOI 10.1037/0021-843X.104.1.150; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; LEWIS DO, 1982, J ADOLESCENT HEALTH, V3, P160, DOI 10.1016/S0197-0070(82)80119-8; LEWIS DO, 1988, AM J PSYCHIAT, V44, P527; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Loeber R., 1998, NEW PERSPECTIVES ADO, P90, DOI DOI 10.1017/CBO978051138.005; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; Lyketsos CG, 1999, AM J PSYCHIAT, V156, P58, DOI 10.1176/ajp.156.1.58; Manchester D, 1997, BRAIN INJURY, V11, P605, DOI 10.1080/026990597123296; Mateer C. A., 1999, COGNITIVE NEUROREHAB, P314; McDermott PA, 1996, J ABNORM CHILD PSYCH, V24, P53, DOI 10.1007/BF01448373; McDermott PA, 1997, YOUTH SOC, V28, P387, DOI 10.1177/0044118X97028004001; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McLoyd VC, 1998, AM PSYCHOL, V53, P185, DOI 10.1037/0003-066X.53.2.185; MILLER L, 1994, J OFFENDER REHABILIT, V21, P91, DOI DOI 10.1300/J076; MILNER B, 1995, ADV NEUROL, V66, P67; Moffitt T. E., 1989, DEV PSYCHOPATHOL, V1, P105, DOI DOI 10.1017/S0954579400000298; MOFFITT TE, 1994, CRIMINOLOGY, V32, P277, DOI 10.1111/j.1745-9125.1994.tb01155.x; MOFFITT TE, 1991, NEUROPSYCHOLOGY AGGR, P131; Morgan AB, 2000, CLIN PSYCHOL REV, V20, P113, DOI 10.1016/S0272-7358(98)00096-8; MYERS WC, 1995, J AM ACAD CHILD PSY, V34, P1483, DOI 10.1097/00004583-199511000-00015; NEWMAN JP, 1987, J RES PERS, V21, P464, DOI 10.1016/0092-6566(87)90033-X; Olds D, 1998, JAMA-J AM MED ASSOC, V280, P1238, DOI 10.1001/jama.280.14.1238; Paschall MJ, 1996, J YOUTH ADOLESCENCE, V25, P177, DOI 10.1007/BF01537343; Paschall MJ, 1998, J RES CRIME DELINQ, V35, P148, DOI 10.1177/0022427898035002002; Paschall MJ, 1998, J CONSULT CLIN PSYCH, V66, P825, DOI 10.1037/0022-006X.66.5.825; Pineda DA, 2000, INT J NEUROSCI, V101, P133, DOI 10.3109/00207450008986497; RAINE A, 1997, NATO ASI SERIES A; Raine A., 1993, PSYCHOPATHOLOGY CRIM; RANTAKALLIO P, 1992, ARCH DIS CHILD, V67, P1459, DOI 10.1136/adc.67.12.1459; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Roth J. A., 1993, UNDERSTANDING PREVEN; Rothwell NA, 1999, BRAIN INJURY, V13, P521; SAMPSON RJ, 1987, AM J SOCIOL, V93, P348, DOI 10.1086/228748; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; SCHONFELD IS, 1988, CHILD DEV, V59, P993, DOI 10.2307/1130266; Schroder J, 1998, J NEURAL TRANSM-SUPP, P51; SEGUIN JR, 1995, J ABNORM PSYCHOL, V104, P614, DOI 10.1037/0021-843X.104.4.614; SHURE MB, 1982, AM J COMMUN PSYCHOL, V10, P341, DOI 10.1007/BF00896500; Silberstein RB, 1998, ARCH GEN PSYCHIAT, V55, P1105, DOI 10.1001/archpsyc.55.12.1105; Snyder H. N., 1999, 178257 NCJ US DEP JU; SPARACELLI S, 1995, VIOLENCE VICTIMS, V10, P163; Spoth R, 1998, J CONSULT CLIN PSYCH, V66, P385, DOI 10.1037/0022-006X.66.2.385; Thompson EA, 1997, J DRUG EDUC, V27, P19, DOI 10.2190/G6XY-U2CQ-GFQF-PNEV; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WebsterStratton C, 1997, J CONSULT CLIN PSYCH, V65, P93, DOI 10.1037/0022-006X.65.1.93; WIDOM CS, 1994, CHILD ABUSE NEGLECT, V18, P303, DOI 10.1016/0145-2134(94)90033-7; WILSON BA, 1997, J INT NEUROPSYCH SOC, V3, P196	95	51	53	0	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-1789	1873-6335		AGGRESS VIOLENT BEH	Aggress. Violent Behav.	MAY-JUN	2002	7	3					215	235	PII S1359-1789(00)00044-6	10.1016/S1359-1789(00)00044-6			21	Criminology & Penology; Psychology, Multidisciplinary	Criminology & Penology; Psychology	563NX	WOS:000176263400002					2021-06-18	
J	Lengenfelder, J; Schultheis, MT; Al-Shibabi, T; Mourant, R; DeLuca, J				Lengenfelder, J; Schultheis, MT; Al-Shibabi, T; Mourant, R; DeLuca, J			Divided attention and driving: A pilot study using virtual reality technology	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injured; divided attention; driving; virtual reality	TRAUMATIC BRAIN INJURY; DUAL-TASK PERFORMANCE; HEAD-INJURY; DAMAGE; ENVIRONMENTS; IMPAIRMENTS; PREDICTION; EXPOSURE	Background: Virtual reality (VR) was used to investigate the influence of divided attention (simple versus complex) on driving performance (speed control). Design: Three individuals with traumatic brain injury (TBI) and three healthy controls (HC), matched for age, education, and gender, were examined. Results: Preliminary results revealed no differences on driving speed between TBI and HC, In contrast, TBI subjects demonstrated a greater number of errors on a secondary task performed while driving, Conclusion: The findings suggest that VR may provide an innovative medium for direct evaluation of basic cognitive functions (ie, divided attention) and its impact on everyday tasks (ie, driving) not previously available through traditional neuropsychological measures.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Northeastern Univ, Virtual Environm Lab, Boston, MA 02115 USA	Schultheis, MT (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	mschultheis@kmrrec.org		Schultheis, Maria/0000-0002-6558-548X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD7522-01, HD08589-01] Funding Source: Medline		Adcock RA, 2000, P NATL ACAD SCI USA, V97, P3567, DOI 10.1073/pnas.060588897; Ball K, 1993, J Am Optom Assoc, V64, P71; Ball K., 1998, UFOV USEFUL FIELD VI; Bieliauskas LA, 1998, CLIN NEUROPSYCHOL, V12, P206, DOI 10.1076/clin.12.2.206.1994; BOAKE C, 1993, ARCH PHYS MED REHAB, V74, P1246; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; Brown DJ, 1997, COMMUN ACM, V40, P72, DOI 10.1145/257874.257891; BROWN DJ, 1998, P 2 EUR C DIS VIRT R, P11; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Cox D J, 1998, J Am Board Fam Pract, V11, P264; FINKELMAN JM, 1977, J APPL PSYCHOL, V62, P713, DOI 10.1037/0021-9010.62.6.713; Fisk GD, 1998, BRAIN INJURY, V12, P683; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Haikonen S, 1998, Appl Neuropsychol, V5, P24, DOI 10.1207/s15324826an0501_3; Hinkin CH, 2000, J CLIN EXP NEUROPSYC, V22, P16, DOI 10.1076/1380-3395(200002)22:1;1-8;FT016; Hoffman HG, 2000, PAIN, V85, P305, DOI 10.1016/S0304-3959(99)00275-4; Kostyniuk L. P, 1998, UMTRI9852; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; LEVINE O, 1998, P HUM FACT ERG SOC 4, P1136; Lewis RF., 1979, MANUAL REPEATABLE CO; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MOSCOWITZ H, 1973, J SAFETY RES, V5, P185; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Rizzo AA, 1997, ST HEAL T, V44, P123; ROTHBAUM BO, 1995, AM J PSYCHIAT, V152, P626; SATAVA RM, 1996, P MED MEETS VIRT REA, P100; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; Schultheis MT, 2001, NEUROLOGY, V56, P1089, DOI 10.1212/WNL.56.8.1089; SIVAK M, 1995, HS041692 U MICH TRAN; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; VANZOMEREN AH, 1987, NEUROBEHAVIORAL RECO; WESTWOOD JD, 2000, MED MEETS VIRTUAL RE, P207; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]	45	51	53	1	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2002	17	1					26	37		10.1097/00001199-200202000-00005			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	519MM	WOS:000173730100006	11860327				2021-06-18	
J	Kreutzer, JS; Kolakowksy-Hayner, SA; Ripley, D; Cifu, DX; Rosenthal, M; Bushnik, T; Zafonte, R; Englander, J; High, W				Kreutzer, JS; Kolakowksy-Hayner, SA; Ripley, D; Cifu, DX; Rosenthal, M; Bushnik, T; Zafonte, R; Englander, J; High, W			Charges and lengths of stay for acute and inpatient rehabilitation treatment of traumatic brain injury 1990-1996	BRAIN INJURY			English	Article							MEDICARE PAYMENT SYSTEM; COST-EFFECTIVENESS; CARE; INTEGRATION; DISEASE; TRENDS	This investigation evaluated yearly trends in charges and lengths of stay for patients with brain injury in acute care and rehabilitation settings over a 7 year period. Data was collected from 800 consecutive patients enrolled in four NIDRR Model Systems Traumatic Brain Injury programmes. Acute care daily charges showed almost routine increases, averaging nearly $550 per year. Conversely, lengths of stay generally showed a downward trend, with annual reductions averaging 2.25 days. Admission lengths of stay averaged 22-29 days between 1990-1994. Admissions averaged less than 20 days beginning in 1995, with the 1996 average of 16 days, nearly half that of the 1993 average. Between 1990-1996, average daily rehabilitation charges increased each year, with the rise averaging $83 or 7%. The rise in daily rehabilitation charges was offset by corresponding decreases in lengths of stay averaging 3.65 days or 8% annually. Increases in daily charges for brain injury rehabilitation care were roughly comparable to those for general medical care prices. However, the rate of change in acute care charges was substantially greater, with annual increases averaging 10% more than national medical care prices. The steady downward trend in lengths of stay raises serious concerns about the future availability of health care services to persons with brain injury.	Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Santa Clara Valley Med Ctr, Dept Rehabil, San Jose, CA 95128 USA; Rehabil Inst Michigan, SE Michigan Traumat Brain Injury Syst, Detroit, MI USA; Inst Rehabil & Res, Brain Injury Rehabil Program, Houston, TX USA	Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Med Coll Virginia Campus,POB 980542, Richmond, VA 23298 USA.	jskreutz@hsc.vcu.edu		Bushnik, Tamara/0000-0003-3328-257X; Cifu, David/0000-0003-1600-9387; Ripley, David/0000-0002-5349-1830			ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BARRY P, 1993, J HEAD TRAUMA REHAB, V8, P48; Barth J T, 2000, Dent Clin North Am, V44, P67; Brown AID, 2000, MED CLIN N AM, V84, P279, DOI 10.1016/S0025-7125(05)70219-4; Bryant ET, 1993, J HEAD TRAUMA REHAB, V8, P15; Chan L, 2000, ARCH PHYS MED REHAB, V81, P715, DOI 10.1016/S0003-9993(00)90098-4; Chan L, 1997, NEW ENGL J MED, V337, P978, DOI 10.1056/NEJM199710023371406; Cifu DX, 1999, J NEUROTRAUM, V16, P805, DOI 10.1089/neu.1999.16.805; COPE DN, 1994, J HEAD TRAUMA REHAB, V9, P1, DOI 10.1097/00001199-199409000-00003; Dea RA, 2000, PSYCHIAT QUART, V71, P17, DOI 10.1023/A:1004610616732; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; GALVIN RS, 1998, INTEGRATED HEALTHCAR, V53, P1; GRAVES EJ, 1994, VITAL HLTH STAT 13, V140, P1; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HOLLOWAY R, 1995, ARCH NEUROL-CHICAGO, V55, P25; Kephart W, 1999, AM J MANAG CARE, V5, pS309; KIZER KW, 1995, JAMA-J AM MED ASSOC, V273, P1768, DOI 10.1001/jama.273.22.1768; Lee SJ, 2000, J CLIN ONCOL, V18, P64, DOI 10.1200/JCO.2000.18.1.64; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Miller TR, 2000, MED CARE, V38, P562, DOI 10.1097/00005650-200006000-00003; Phipps EJ, 1999, J HEAD TRAUMA REHAB, V14, P329, DOI 10.1097/00001199-199906000-00014; Robinson JC, 1996, JAMA-J AM MED ASSOC, V276, P1060, DOI 10.1001/jama.276.13.1060; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Roth A, 2000, CLIN CARDIOL, V23, P271, DOI 10.1002/clc.4960230410; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Taheri PA, 1998, ANN SURG, V227, P720, DOI 10.1097/00000658-199805000-00012; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; WACHTER RM, 1995, JAMA-J AM MED ASSOC, V273, P230, DOI 10.1001/jama.273.3.230; Wimo A, 1997, ALZ DIS ASSOC DIS, V11, P191; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746	30	51	52	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2001	15	9					763	774		10.1080/02699050010025786			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400002	11516345				2021-06-18	
J	Yan, HQ; Kline, AE; Ma, XC; Hooghe-Peters, EL; Marion, DW; Dixon, CE				Yan, HQ; Kline, AE; Ma, XC; Hooghe-Peters, EL; Marion, DW; Dixon, CE			Tyrosine hydroxylase, but not dopamine beta-hydroxylase, is increased in rat frontal cortex after traumatic brain injury	NEUROREPORT			English	Article						dopamine beta-hydroxylase (DBH); frontal cortex; immunohistochemistry; rat; traumatic brain injury (TBI); tyrosine hydroxylase (TH); Western blot	WATER MAZE PERFORMANCE; PREFRONTAL CORTEX; NORADRENALINE; INNERVATION	Chronic frontal lobe functional deficits after traumatic brain injury (TBI) may be associated with altered catecholamine systems in the frontal cortex. To test this, tyrosine hydroxylase (TH) and dopamine beta-hydroxylase (DBH) levels were examined by immunohistochemistry and Western blot at 1, 7, 14, and 28 days after TBI or sham surgery. No alterations in DBH levels were observed by Western blot at any time point examined, but there was a significant increase in TH expression 28 days after TBI (optical density 334 +/- 68% or 3.3-fold, ipsilateral and 218 +/- 39% or 2.2-fold. contralateral) relative to the sham controls. The increase in TH may reflect a compensatory response of dopaminergic neurons to upregulate their synthesizing capacity and increase the efficiency of dopamine neurotransmission chronically after TBI. NeuroReport 12:2323-2327 (C) 2001 Lippincott Williams & Wilkins.	Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Free Univ Brussels, Dept Pharmacol, B-1090 Brussels, Belgium	Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40125, NS 33150, NS 30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, R01NS033150, P50NS030318, P20NS030318, R01NS040125] Funding Source: NIH RePORTER		BERGER B, 1976, BRAIN RES, V106, P133, DOI 10.1016/0006-8993(76)90078-0; BLANCHARD V, 1995, J NEUROCHEM, V64, P1669; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FRITSCHY JM, 1990, J CHEM NEUROANAT, V3, P309; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVITT P, 1978, BRAIN RES, V139, P219, DOI 10.1016/0006-8993(78)90925-3; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; ROSIN DL, 1992, NEUROSCIENCE, V48, P831, DOI 10.1016/0306-4522(92)90271-3; Soriano MA, 1997, NEUROBIOL DIS, V4, P376, DOI 10.1006/nbdi.1997.0166; Venator DK, 1999, NEUROSCIENCE, V93, P497, DOI 10.1016/S0306-4522(99)00131-1; VERNEY C, 1993, J COMP NEUROL, V336, P331, DOI 10.1002/cne.903360303; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	20	51	56	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	AUG 8	2001	12	11					2323	2327		10.1097/00001756-200108080-00009			5	Neurosciences	Neurosciences & Neurology	457MP	WOS:000170141600010	11496104				2021-06-18	
J	Lenzlinger, PM; Hans, VHJ; Joller-Jemelka, HI; Trentz, O; Morganti-Kossmann, MC; Kossmann, T				Lenzlinger, PM; Hans, VHJ; Joller-Jemelka, HI; Trentz, O; Morganti-Kossmann, MC; Kossmann, T			Markers for cell-mediated immune response are elevated in cerebrospinal fluid and serum after severe traumatic brain injury in humans	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; cellular immunity; cerebrospinal fluid; human brain injuries; immune markers; microglia activation; T-cell activation	SEVERE HEAD-INJURY; TUMOR-NECROSIS-FACTOR; ACUTE-PHASE RESPONSE; SPINAL-CORD INJURY; RAT-BRAIN; BETA-2-MICROGLOBULIN LEVELS; INTERLEUKIN-2 RECEPTOR; INFLAMMATORY RESPONSE; MESSENGER-RNA; INTERFERON-GAMMA	The brain is believed to be an immunologically privileged organ, sheltered from the systemic immunological defense by the blood-brain barrier (BBB). However, there is increasing evidence for a marked inflammatory response in the brain after traumatic brain injury (TBI), Markers for cellular immune activation, neopterin, beta2-microglobulin (beta 2M), and soluble interleukin-2 receptor (sIL-2R), were measured for up to 3 weeks in cerebrospinal fluid (CSF) and serum of 41 patients with severe TBI in order to elucidate the time course and the origin of the cellular immune response following TBI. Neopterin gradually increased during the first posttraumatic week in both CSF and serum. Concentrations in CSF were generally higher than in serum, suggesting intrathecal release of this marker. beta 2M showed similar kinetics but with higher serum than CSF concentrations. Nonetheless, intrathecal release as assessed by the beta 2M index could be postulated for most of the patients. The mean levels of sIL-2R in both CSF and serum were elevated during the whole study period, serum concentrations being up to 2 x 10(4) times higher than in CSF. No significant intrathecal production of sIL-2R could be detected. The present data shows that severe TBI leads to a marked cell-mediated immune response within the brain and in the systemic circulation. In the intrathecal compartment the activated cells appear to be predominantly of the macrophage/microglia lineage, while the immune activation in the systemic circulation seems to involve mainly T-lymphocytes.	Univ Zurich Hosp, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Internal Med, Div Clin Immunol, Zurich, Switzerland; Univ Hosp, Inst Neuropathol, Bonn, Germany	Lenzlinger, PM (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.		Lenzlinger, Philipp/A-3822-2008	Morganti-Kossmann, Cristina/0000-0002-0807-2063			ADACHI N, 1991, EUR NEUROL, V31, P181, DOI 10.1159/000116674; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; BALOGH D, 1992, BURNS, V18, P185, DOI 10.1016/0305-4179(92)90068-6; BANATI RB, 1993, GLIA, V7, P11; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CHUGANI DC, 1991, J NEUROSCI, V11, P256; COHEN J, 1991, HUM REPROD, V6, P118, DOI 10.1093/oxfordjournals.humrep.a137244; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hagberg L, 2000, J NEUROIMMUNOL, V102, P51, DOI 10.1016/S0165-5728(99)00150-2; Hamerlinck FFV, 1999, EXP DERMATOL, V8, P167, DOI 10.1111/j.1600-0625.1999.tb00367.x; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; HUBER C, 1984, J EXP MED, V160, P310, DOI 10.1084/jem.160.1.310; IMAMOTO K, 1981, GLIAL NEURONAL CEL A, V59, P125; JENNETT B, 1975, LANCET, V1, P480; KITTUR SD, 1990, ANN NEUROL, V28, P168, DOI 10.1002/ana.410280209; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; KOREMATSU K, 1994, J CEREBR BLOOD F MET, V14, P825, DOI 10.1038/jcbfm.1994.103; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KREUTZBERG GW, 1995, ARZNEIMITTEL-FORSCH, V45-1, P357; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LAMELIN JP, 1982, CLIN IMMUNOL IMMUNOP, V24, P55, DOI 10.1016/0090-1229(82)90088-5; LINK H, 1977, SCAND J CLIN LAB INV, V37, P397, DOI 10.3109/00365517709091498; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARTINEZ M, 1993, J NEUROIMMUNOL, V48, P235, DOI 10.1016/0165-5728(93)90197-7; MATHIESEN T, 1990, J NEUROSURG, V73, P69, DOI 10.3171/jns.1990.73.1.0069; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; NILSSON K, 1974, TRANSPLANT REV, V21, P53; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; OTT M, 1993, J NEUROL, V241, P108, DOI 10.1007/BF00869773; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; QUATTROCCHI KB, 1992, J NEUROTRAUM, V9, P1, DOI 10.1089/neu.1992.9.1; QUATTROCCHI KB, 1992, J NEUROSURG, V77, P694, DOI 10.3171/jns.1992.77.5.0694; REIBER H, 1980, J NEUROL, V224, P89, DOI 10.1007/BF00313347; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rostworowski M, 1997, J NEUROSCI, V17, P3664; RUBIN LA, 1990, ANN INTERN MED, V113, P619, DOI 10.7326/0003-4819-113-8-619; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Soares HD, 1995, J NEUROSCI, V15, P8223; SONNERBORG AB, 1989, AIDS, V3, P277, DOI 10.1097/00002030-198905000-00005; Spranger M, 1996, NEUROSCIENTIST, V2, P293, DOI 10.1177/107385849600200515; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; TENHUNEN R, 1978, ACTA NEUROL SCAND, V58, P366; Teodorczyk-Injeyan J A, 1989, J Burn Care Rehabil, V10, P112, DOI 10.1097/00004630-198903000-00003; TEODORCZYKINJEYAN JA, 1989, CLIN IMMUNOL IMMUNOP, V51, P205, DOI 10.1016/0090-1229(89)90020-2; TEODORCZYKINJEYAN JA, 1991, CLIN EXP IMMUNOL, V85, P515; THOMAS WE, 1992, BRAIN RES REV, V17, P61; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMASHITA K, 1994, J NEUROCHEM, V63, P1042; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375; Zhang ZY, 1996, J COMP NEUROL, V371, P485; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	83	51	54	0	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2001	18	5					479	489		10.1089/089771501300227288			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	435CN	WOS:000168860000001	11393251				2021-06-18	
J	Yan, P; Li, Q; Kim, GM; Xu, J; Hsu, CY; Xu, XM				Yan, P; Li, Q; Kim, GM; Xu, J; Hsu, CY; Xu, XM			Cellular localization of tumor necrosis factor-alpha following acute spinal cord injury in adult rats	JOURNAL OF NEUROTRAUMA			English	Article						inflammation; rat; spinal cord injury; TNF-alpha	CENTRAL NERVOUS-SYSTEM; TRAUMATIC INJURY; BRAIN INJURY; AXONAL REGENERATION; TNF-ALPHA; EXPRESSION; CYTOKINES; INFLAMMATION; DEMYELINATION; APOPTOSIS	Posttraumatic inflammatory reaction may contribute to secondary injury after traumatic spinal cord injury (SCI). Expression of tumor necrosis factor-alpha (TNF-alpha), a key inflammatory mediator, has been demonstrated in the injured cord. However, the specific cell types that are responsible for TN-alpha expression after SCI remain to be identified. In the present study, cellular sources of TNF-alpha were examined in rats that received a spinal cord impact injury at the 9th thoracic (T9) level. Here we demonstrate that, within hours after SCI, increased TNF-alpha immunoreactivity was localized in neurons, glial cells (including astrocytes, oligodendrocytes, and microglia), and endothelial cells in areas of the spinal cord adjacent to the lesion site. Myelin breakdown was noted in oligodendrocytes that are immunopositive for TNF-alpha. In sham-operated controls, a low level of TNF-alpha immunoreactivity was detected. In antigen-absorption experiments, no TNF-alpha immunoreactivity was detected, indicating the specificity of TNF-alpha immunocytochemistry in the present study. Results suggest that various cell types, including neurons, glial cells, and vascular endothelial cells, contribute to TNF-alpha production in the injured cord.	St Louis Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63104 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Xu, XM (corresponding author), St Louis Univ, Sch Med, Dept Anat & Neurobiol, 1402 S Grand Blvd, St Louis, MO 63104 USA.			Xu, Xiao-ming/0000-0002-7229-0081; Hsu, Chung Y./0000-0002-5632-2733	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 36350, NS 37230, NS 28995] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036350, R01NS028995, R01NS037230] Funding Source: NIH RePORTER		Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DeLeo JA, 1997, BRAIN RES, V759, P50, DOI 10.1016/S0006-8993(97)00209-6; DSOUZA S, 1995, J NEUROSCI, V15, P7293; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HOLETS VR, 1987, BRAIN RES, V408, P141, DOI 10.1016/0006-8993(87)90366-0; JENKINS HG, 1992, J NEUROL SCI, V108, P99, DOI 10.1016/0022-510X(92)90194-P; Li Qun, 1998, Society for Neuroscience Abstracts, V24, P738; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Liu XZ, 1997, J NEUROSCI, V17, P5395; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; Qi Y, 1996, J NEUROSCI RES, V45, P364; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SIMMONS RD, 1990, J NEUROL SCI, V100, P37, DOI 10.1016/0022-510X(90)90010-K; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yan P, 1999, J NEUROSCI, V19, P9355	25	51	55	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2001	18	5					563	568		10.1089/089771501300227369			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	435CN	WOS:000168860000009	11393259				2021-06-18	
J	Petrov, T; Rafols, JA				Petrov, T; Rafols, JA			Acute alterations of endothelin-1 and iNOS expression and control of the brain microcirculation after head trauma	NEUROLOGICAL RESEARCH			English	Article						microvessels; blood flow; autoregulation; immunocytochemistry; in situ hybridization; ultrastructure	NITRIC-OXIDE SYNTHASE; CEREBRAL BLOOD-FLOW; INJURY; LOCALIZATION; ISCHEMIA; CORTEX; MODEL; CELLS; RATS	The biosynthetic equilibrium between endothelin-l (ET-1, a vasoconstricting agent) and nitric oxide (NO, a gas with varodilating effects) is thought to play a role in the autoregulation of microvessel contractility and maintenance of adequate perfusion after traumatic brain injury. ET-1 is a constitutively expressed peptide, while the gene that encodes for the inducible nitric oxide synthase (iNOS, an enzyme responsible for the synthesis of excessive and toxic amounts of NO) is solely activated after brain injury. We employed the Marmarou acceleration impact model of brain injury (400 g from 2 m) to study the effect of closed head trauma on the rat brain microcirculation. Following head trauma we analyzed changes of cerebral cortex perfusion using laser Doppler flowmetry and ultrastructural alterations of endothelial cells. We temporally correlated these changes with the expression of ET-1 (immunocytochemistry) and iNOS (in situ hybridization) to assess the role of these vasoactive agents in vascular contractility and cortical perfusion. Cortical perfusion was reduced by similar to 50% during the second hour as compared to values during preceding time points after TBI, reached a peak minutes before 3 h, and subsequently showed a trend towards normalization. A significant reduction in the lumen of microvessels and severe distortion of their shape were observed after the fourth hour post-trauma. At the same time period ET-1 expression in endothelial cells was stronger than in microvessels of control animals. ET-I expression was further increased at 24 h after TBI. iNOS mRNA synthesis was strongly upregulated in the same cells at 4 h but was undetectable at 24 h post trauma. Our combined functional, cellular and molecular approach supports the notion that ET-1 and iNOS are expressed differentially in time within individual endothelial cells of cortical microvessels for the control of cortical blood flow following closed head trauma. This differential expression further indicates a reciprocal interaction in the synthesis of these two molecules which may underlie the control of microvascular autoregulation.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Petrov, T (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	tpetrov@med.wayne.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39860] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER		BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; CAZABON SM, 1998, INTRO BLOOD BRAIN BA, P338; CULOTTA E, 1992, SCIENCE, V258, P1862, DOI 10.1126/science.1361684; EHRENREICH H, 1995, CLEV CLIN J MED, V62, P105, DOI 10.3949/ccjm.62.2.105; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MASAKI T, 1995, ANNU REV PHARMACOL, V35, P235, DOI 10.1146/annurev.pharmtox.35.1.235; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; MULDOON LL, 1991, AM J PHYSIOL, V260, pC1273; Petrov T., 1999, Society for Neuroscience Abstracts, V25, P822; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RADOMSKI MW, 1995, ANN MED, V27, P321, DOI 10.3109/07853899509002585; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Sharma AC, 1998, NEUROL RES, V20, P632; Strijbos PJLM, 1996, J NEUROSCI, V16, P5004; Takahashi A, 1997, ACTA NEUROPATHOL, V93, P354, DOI 10.1007/s004010050627; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; You SJ, 1997, GLIA, V20, P87, DOI 10.1002/(SICI)1098-1136(199706)20:2<87::AID-GLIA1>3.0.CO;2-1; Yuan XQ, 1991, J NEUROTRAUM, V8, P219, DOI 10.1089/neu.1991.8.219; Zimmermann M, 1998, NEUROSURGERY, V43, P863, DOI 10.1097/00006123-199810000-00083	27	51	53	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	MAR-APR	2001	23	2-3					139	143		10.1179/016164101101198479			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	422DX	WOS:000168104200005	11320592				2021-06-18	
J	Galani, R; Hoffman, SW; Stein, DG				Galani, R; Hoffman, SW; Stein, DG			Effects of the duration of progesterone treatment on the resolution of cerebral edema induced by cortical contusions in rats	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						brain injure; edema; frontal cortex; hormones; progesterone; rats; TB1	TRAUMATIC BRAIN INJURY; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; VASCULAR DISRUPTION; LIPID-PEROXIDATION; GLIAL-CELLS; TIME-COURSE; HORMONES; BARRIER; PERMEABILITY	Purpose: The aim of the present Study was to assess the effect of different durations of administration of progesterone (4 mg/kg) on the resolution of edema 6 days after medial frontal cortex contusions (MFC) in male adult rats. Methods: Animals sustaining injury Were injected with progesterone or its vehicle for 33 days or for 5 days beginning the first hour after Surgery. On the 0 day the rats ere killed and their brain water content as measured. Results: We confirmed the presence of edema six days after MFC. However, both 3 and 5 days of treatment with progesterone significantly reduced edema in the injured brains but the five days of treatment were more effective. The effects of progesterone depend upon the duration of the treatment because there are two waves of edema. The first phase begins within a few hours of the injury and the second starts several day's later. Conclusions: Our data are consistent with earlier findings showing that longer durations of progesterone administration lead to more complete behavioral recovery as well as to an increased number Of surviving neurons.	Emory Univ, Brain Res Lab, Dept Psychol, Atlanta, GA 30322 USA; Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Brain Res Lab, Dept Psychol, 575 Rollins Way, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020				Angele MK, 1999, AM J PHYSIOL-CELL PH, V277, pC35; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Barzo P, 1997, ACT NEUR S, V70, P119; Borel IM, 1999, SCAND J IMMUNOL, V49, P244, DOI 10.1046/j.1365-3083.1999.00484.x; CHAO HJ, 1994, IEEE COMMUN MAG, V32, P52, DOI 10.1109/35.299838; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; GarciaSegura LM, 1996, FRONT NEUROENDOCRIN, V17, P180, DOI 10.1006/frne.1996.0005; Gomez F, 1998, CLIN IMMUNOL IMMUNOP, V89, P231, DOI 10.1006/clin.1998.4602; Hariri R J, 1994, Neurosurg Clin N Am, V5, P687; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; JUNGTESTAS I, 1992, J STEROID BIOCHEM, V41, P621, DOI 10.1016/0960-0760(92)90394-X; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1994, ACTA NEUROCHIR, P3; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MATHEW P, 1994, ACTA NEUROCHIR, P428; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Moran MH, 1998, BRAIN RES, V807, P84, DOI 10.1016/S0006-8993(98)00782-3; Moran MH, 1998, BRAIN RES, V807, P91, DOI 10.1016/S0006-8993(98)00781-1; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Nishio S, 1997, ACT NEUR S, V70, P84; PERSSON L, 1976, ACTA NEUROPATHOL, V35, P333; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; Robert R, 1997, NITRIC OXIDE-BIOL CH, V1, P453, DOI 10.1006/niox.1997.0157; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shear D. A., 2000, Journal of Neurotrauma, V17, P967; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SMITH JS, 1998, J NEUROTRAUM, V15, P905; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; STEIN DG, 1993, J NEURAL TRANSP PLAS, V4, P227, DOI 10.1155/NP.1993.227; SUBRAMANIAN M, 1993, NEUROSCI LETT, V155, P151, DOI 10.1016/0304-3940(93)90695-H; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; UNTERBERG A, 1988, ACTA NEUROPATHOL, V76, P238, DOI 10.1007/BF00687770; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	56	51	51	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2001	18	4					161	166					6	Neurosciences	Neurosciences & Neurology	525CK	WOS:000174049500003	11847439				2021-06-18	
J	Leclerc, S; Lassonde, M; Delaney, JS; Lacroix, VJ; Johnston, KM				Leclerc, S; Lassonde, M; Delaney, JS; Lacroix, VJ; Johnston, KM			Recommendations for grading of concussion in athletes	SPORTS MEDICINE			English	Article							MILD HEAD-INJURY; TRAUMATIC BRAIN-INJURY; CEREBRAL CONCUSSION; COLLEGE FOOTBALL; SPORTS; SYMPTOMS; PERFORMANCE; GUIDELINES; RECOVERY; DURATION	Mild sports-related concussions, in which there is no loss of consciousness, account for >75% of all sports-related brain injury. Universal agreement on concussion definition and severity grading does not exist. Grading systems represent expertise of clinicians and researchers yet scientific evidence is lacking. Most used loss of consciousness and post-traumatic amnesia as markers for grading concussion. Although in severe head injury these parameters may have been proven important for prognosis, no study has done the same for sport-related concussion. Post-concussion symptoms are often the main features to help in the diagnosis of concussion in sport. Neuropsychological testing is meant to help physicians and health professionals to have objective indices of some of the neurocognitive symptoms. It is the challenge of physicians, therapists and coaches involved in the care of athletes to know the symptoms of concussion, recognise them when they occur and apply basic, neuropsychological testing to help detect this injury. It is, therefore, recommended to be familiar with one grading system and use it consistently, even though it may not be scientifically validated. Then good clinical judgement and the ability to recognise post-concussion signs and symptoms will assure that an athlete never returns to play while symptomatic.	McGill Univ, McGill Sport Med Clin, Montreal, PQ, Canada; Univ Montreal, Neuropsychol Dept, Montreal, PQ, Canada; McGill Univ, Dept Neurosurg, McGill Univ Hlth Ctr, Montreal, PQ H3A 2T5, Canada	Leclerc, S (corresponding author), 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.						ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Barth JT., 1989, MILD HEAD INJURY, P257; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1997, CLIN J SPORT MED, V7, P83, DOI 10.1097/00042752-199704000-00001; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; EVANS RW, 1992, NEUROL CLIN, V10, P815; GERSOFF W, 1991, SPORTS MED SCH AGE A, P45; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1992, NZ J SPORTS MED, V20, P19; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; JENNETT B, 1975, LANCET, V1, P480; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; JOHNSTON KM, IN PRESS CLIN J SPOR; Jones M, 2001, NEUROIMAGE, V13, P1002, DOI 10.1006/nimg.2001.0808; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KULUND D, 1982, INJURED ATHLETE, P225; Leblanc Kim Edward, 1999, Comprehensive Therapy, V25, P39, DOI 10.1007/BF02889833; Leclerc S., 1999, Medicine and Science in Sports and Exercise, V31, pS400, DOI 10.1097/00005768-199905001-02048; LECLERC S, 2001, PASHBY SPORT CONCUSS; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Maroon J C, 1980, Clin Neurosurg, V27, P414; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; McCrory PR, 1999, BRIT J SPORT MED, V33, P297; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Meeuwisse WH, 2000, CLIN J SPORT MED, V10, P157, DOI 10.1097/00042752-200007000-00001; Mesulam M., 1985, PRINCIPLES BEHAV NEU; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; OMMAYA A, 1990, SPORTS NEUROLOGY, P84; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; SAAL JA, 1991, SPORTS MED, V12, P132, DOI 10.2165/00007256-199112020-00005; Schneider R. C., 1973, HEAD NECK INJURIES F, P163; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; VEGSO JJ, 1991, ATHLETIC INJURIES HE, P225; WALKER AE, 1994, J NEUROSURG, V81, P493, DOI 10.3171/jns.1994.81.3.0493; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44	63	51	51	0	14	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.		2001	31	8					629	636		10.2165/00007256-200131080-00007			8	Sport Sciences	Sport Sciences	453VM	WOS:000169937200008	11475324				2021-06-18	
J	Wagner, AK; Sasser, HC; Hammond, FM; Wiercisiewski, D; Alexander, J				Wagner, AK; Sasser, HC; Hammond, FM; Wiercisiewski, D; Alexander, J			Intentional traumatic brain injury: Epidemiology, risk factors, and associations with injury severity and mortality	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						violence; traumatic brain injury; injury severity; epidemiology; risk factors; outcome	GUNSHOT WOUNDS; VIOLENCE; POPULATION; HEAD	Background: Intentional injury is associated with significant morbidity and mortality and has been associated with certain demographic and socioeconomic groups, Less is known about the relationship of intentional traumatic brain injury (TBI) to injury severity, mortality, and demographic and socioeconomic profile, The objective of this study was to delineate demographic and event-related factors associated with intentional TBI and to evaluate the predictive value of intentional TBI on injury severity and mortality. Methods: Prospective data were obtained for 2,637 adults sustaining TBIs between January 1994 and September 1998, Descriptive, univariate, and multivariate analyses were conducted to determine the predictive value of intentional TBI on injury severity and mortality. Results: Gender, minority status, age, substance abuse, and residence in a zip code with low average income were associated with intentional TBI, Multivariate analysis found minority status and substance abuse to be predictive of intentional injury after adjusting for other demographic variables studied. Intentional TBI was predictive of mortality and anatomic severity of injury to the head. Penetrating intentional TBI was predictive of injury severity with all injury severity markers studied. Conclusion: Many demographic variables are risk factors for intentional TBT, and such injury is a risk factor for both injury severity and mortality, Future studies are needed to definitively link intentional TBI to disability and functional outcome.	Carolinas Hlth Care Syst, Charlotte, NC USA; Charlotte Inst Rehabil, Charlotte, NC USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Kaufmann Bldg Suite 901, Pittsburgh, PA 15213 USA.						BAKER S, 1993, MED HLTH ANN 1993, P331; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BONTKE CF, 1996, PHYSICAL MED REHABIL, P1029; CENTERWALL BS, 1984, AM J PUBLIC HEALTH, V74, P813, DOI 10.2105/AJPH.74.8.813; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; Drubach D A, 1993, Md Med J, V42, P989; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; KAUFMAN HH, 1993, NEUROSURGERY, V32, P962, DOI 10.1227/00006123-199306000-00013; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LINDENBAUM GA, 1989, J TRAUMA, V29, P1654, DOI 10.1097/00005373-198912000-00012; MERCY JA, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.4.7; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; SPRADEO FR, 1989, J HEAD TRAUMA REHAB, V4, P75; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WAGNER A, 2000, J TRAUMA, V49; Wagner AK, 2000, AM J PHYS MED REHAB, V79, P235, DOI 10.1097/00002060-200005000-00004; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Zafonte RD, 1997, BRAIN INJURY, V11, P403	21	51	52	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2000	49	3					404	410		10.1097/00005373-200009000-00004			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	355DA	WOS:000089369300003	11003315				2021-06-18	
J	Chen, T; Qian, YZ; Rice, A; Zhu, JP; Di, X; Bullock, R				Chen, T; Qian, YZ; Rice, A; Zhu, JP; Di, X; Bullock, R			Brain lactate uptake increases at the site of impact after traumatic brain injury	BRAIN RESEARCH			English	Article						C-14-lactate; fluid percussion injury; energy	EXCITATORY AMINO-ACIDS; FLUID-PERCUSSION MODEL; CEREBRAL BLOOD-FLOW; HUMAN HEAD-INJURY; ENERGY-METABOLISM; BARRIER PERMEABILITY; AEROBIC GLYCOLYSIS; SUBSTRATE DELIVERY; SYNAPTIC FUNCTION; KETONE-BODIES	Although glucose is the main carbohydrate energy substrate for the normal brain, several studies published over the last 10 years now challenge this assumption. The activated brain increases its metabolism to meet increased energy demands by glycolysis after injury. In vitro studies now show that lactate alone can serve as an energy source to maintain synaptic function. In this study, we used C-14-lactate to test the hypothesis that blood lactate is acutely taken up by the injured brain, after fluid percussion injury (FPI) in the rat. 50 mu Ci radioactive lactate was injected i.v. immediately after FPI, in injured and sham rats. After 30 min, the brain was removed, frozen, and cut into 20 mu m sections for autoradiography. Uptake of C-14-label was mainly concentrated at the injury site (2.5 times greater) although uninjured brain also took up the C-14-label. This increased concentration of radioactive lactate at the injury site suggests that the injured brain may use the lactate as an energy source. (C) 2000 Elsevier Science B.V. All rights reserved.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631, Richmond, VA 23298 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [12587] Funding Source: Medline		ALM A, 1985, OPHTHALMIC RES, V17, P181, DOI 10.1159/000265371; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; CREMER JE, 1979, J NEUROCHEM, V33, P439, DOI 10.1111/j.1471-4159.1979.tb05173.x; CREMER JE, 1982, J NEUROCHEM, V39, P674, DOI 10.1111/j.1471-4159.1982.tb07945.x; CROCKARD HA, 1972, EUR NEUROL, V8, P151, DOI 10.1159/000114569; Di X, 1996, J NEUROTRAUM, V13, P497, DOI 10.1089/neu.1996.13.497; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DREWES LR, 1973, ARCH NEUROL-CHICAGO, V29, P385, DOI 10.1001/archneur.1973.00490300047005; FERNANDES J, 1982, LANCET, V1, P113; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GJEDDE A, 1975, AM J PHYSIOL, V229, P1165; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HAMBERGER A, 1995, NEUROL RES, V17, P97, DOI 10.1080/01616412.1995.11740295; Hawkins R A, 1988, Ann N Y Acad Sci, V529, P40, DOI 10.1111/j.1749-6632.1988.tb51418.x; HAWKINS RA, 1984, EUR J CLIN INVEST, V14, P313, DOI 10.1111/j.1365-2362.1984.tb01187.x; HOSSMANN KA, 1973, ARCH NEUROL-CHICAGO, V29, P375, DOI 10.1001/archneur.1973.00490300037004; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KING LR, 1974, J NEUROSURG, V40, P617, DOI 10.3171/jns.1974.40.5.0617; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Larrabee MG, 1996, J NEUROCHEM, V67, P1726; LARRABEE MG, 1995, J NEUROCHEM, V64, P1734; LEAR JL, 1991, J CEREBR BLOOD F MET, V11, P576, DOI 10.1038/jcbfm.1991.106; LJUNGGREN B, 1974, BRAIN RES, V77, P173, DOI 10.1016/0006-8993(74)90782-3; LYINGTUNELL U, 1980, ACTA NEUROL SCAND, V62, P265; MAGISTRETTI PJ, 1993, DEV NEUROSCI-BASEL, V15, P306, DOI 10.1159/000111349; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; OLDENDORF W, 1979, STROKE, V10, P577, DOI 10.1161/01.STR.10.5.577; OLDENDORF WH, 1971, EUR NEUROL, V6, P49, DOI 10.1159/000114465; Pellerin L, 1996, DEV NEUROSCI-BASEL, V18, P336, DOI 10.1159/000111426; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PERSSON L, 1976, ACTA NEUROPATHOL, V35, P333; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; RICE AC, 1999, J NEUROTRAUM, V16, P955; Schurr A, 1999, J NEUROSCI, V19, P34; Schurr A, 1997, BRAIN RES, V744, P105, DOI 10.1016/S0006-8993(96)01106-7; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; SCHURR A, 1987, BRAIN RES, V421, P1359; SIESJO BK, 1973, ARCH NEUROL-CHICAGO, V29, P400, DOI 10.1001/archneur.1973.00490300062008; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	50	51	51	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	APR 10	2000	861	2					281	287		10.1016/S0006-8993(00)01992-2			7	Neurosciences	Neurosciences & Neurology	303GL	WOS:000086414100008	10760489				2021-06-18	
J	Gomez, PA; Lobato, RD; Boto, GR; De la Lama, A; Gonzalez, PJ; de la Cruz, J				Gomez, PA; Lobato, RD; Boto, GR; De la Lama, A; Gonzalez, PJ; de la Cruz, J			Age and outcome after severe head injury	ACTA NEUROCHIRURGICA			English	Article						age; prognosis; severe head injury; logistic regression	CLINICAL EXAMINATION; PROGNOSIS; PREDICTION; CHILDREN; SURVIVAL; ADULT	The authors analyzed the relationship between patient age and the final outcome in a series of 810 patients aged 14 years or older who were consecutively admitted between 1987 and 1996 after suffering a severe closed head injury. The most relevant clinico-radiological variables were prospectively collected in a Data Bank. Stratified and logistic regression analyses were performed in order to assess the influence of age on adverse outcome and the interaction between patient age and other prognostic indicators. Our results reaffirm that the adverse outcome rate increases steadily with age in severe head injured patients and that age effect on outcome is independent of other prognostic variables. The odds of having an adverse outcome increases significantly over 35 years of age being 10 times higher in patients older than 65 years as compared to those aged 15-25 years (reference age group). The adverse influence of an advanced age on the final outcome has not yet been satisfactorily explained but an older brain may have an impaired ability to recover after a pathological insult as compared to a younger one.	Hosp 12 Octubre, E-28041 Madrid, Spain	Gomez, PA (corresponding author), Hosp 12 Octubre, Carretera de Andalucia Km 5-400, E-28041 Madrid, Spain.		Gomez, Pedro/N-5051-2019	Gomez, Pedro/0000-0002-4185-5238; Gonzalez Leon, Pedro/0000-0002-1120-4047			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; AMACHER AL, 1987, NEUROSURGERY, V20, P954; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BULLOCK R, 1995, AANS; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; FLEISS JL, 1981, STAT METHOD RATES PR; Frowein R A, 1979, Acta Neurochir Suppl (Wien), V28, P3; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Marshall SB, 1991, J NEUROSURG S, V75, P14; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OVERGAARD J, 1973, LANCET, V2, P631; SCHLESSELMAN, 1982, CASE CONTROL STUDIES; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; Vollmer DG, 1991, J NEUROSURG S, V75, P37	26	51	53	0	4	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2000	142	4					373	+		10.1007/s007010050445			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	306XX	WOS:000086624900004	10883332				2021-06-18	
J	Spikman, JM; Deelman, BG; van Zomeren, AH				Spikman, JM; Deelman, BG; van Zomeren, AH			Executive functioning, attention and frontal lesions in patients with chronic CHI	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; TRAUMATIC BRAIN INJURY; CARD SORTING TEST; STRATEGY APPLICATION; REACTION-TIME; LOBE LESIONS; PERFORMANCE; DEFICITS; RECOVERY; DAMAGE	To study the presence and nature of dysexecutive problems after CHI, a series of unstructured tasks tapping executive functioning were selected. These were administered to a group of 51 participants with CHI in the chronic stage (i.e. several years post-injury) and to 45 healthy controls. In addition, well-known structured tests of attention and planning were administered. Of the executive tasks, only the Executive Route Finding task showed a significant difference between both groups. A multivariate analysis on the attention tests showed a significant difference between groups, indicating that patients in the chronic stage still process information slower than controls. Within the patient group, patients with and without frontal focal lesions were also compared on executive and attention tests. No differences were found with respect to the latter. However, patients with frontal lesions performed worse on a measure of the Executive Route Finding task. It is concluded that patients with CHI, especially when they have frontal damage, have to rely more heavily on externally provided cues, but this dysexecutive problem can only be demonstrated in tasks that resemble daily life tasks by providing very little structure.	Groningen State Univ, Dept Clin Psychol, Groningen, Netherlands; Groningen State Univ, Dept Neuropsychol, Groningen, Netherlands; Acad Hosp Groningen, Dept Neuropsychol, Groningen, Netherlands	Spikman, JM (corresponding author), Acad Ziekenhuis, Dept Clin Psychol, Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.	j.m.spikman@ppsw.rug.nl		Spikman, Jacoba/0000-0002-6477-0763			Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A. D., 1986, WORKING MEMORY; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; BROUWER WH, 1985, THESIS STATE U GRONI; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Damasio A., 1994, DESCARTESERROR EMOTI; Fuster JM., 1980, PREFRONTAL CORTEX; GOLDBERG E, 1986, J CLIN EXP NEUROPSYC, V8, P710, DOI 10.1080/01688638608405191; Grant D. A., 1948, WISCONSIN CARD SORTI; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; HARTMAN A, 1992, CLIN REHABIL, V6, P133; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luria A. R., 1966, HIGHER CORTICAL FUNC; Luria A. R, 1973, WORKING BRAIN; Luria A. R., 1963, RESTORATION FUNCTION; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V5, P213, DOI DOI 10.1037/0894-4105.5.3.213; Mesulam M., 1985, PRINCIPLES BEHAV NEU; Miller E, 1970, Cortex, V6, P121; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; Salthouse T.A., 1982, ADULT COGNITION EXPT; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, NEUROPSYCHOLOGY COGN, P199; Sheerer M., 1941, PSYCHOL MONOGRAPHS, V53; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; SPIKMAN JM, UNPUB CONSTRUCT VALI; STOLTZE A, 1991, THESIS U KONSTANZ; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; STUSS DT, 1983, LOCALIZATION NEUROPS, P429; TREXLER LE, 1988, BRAIN COGNITION, V8, P291, DOI 10.1016/0278-2626(88)90056-5; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VELTMAN JC, 1996, NEUROPSYCHOLOGY, V10, P1; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; VILKKI J, 1995, APPL NEUROPSYCHOL, V2, P1; Von Cramon DY, 1992, NEUROPSYCHOL REHABIL, P203; Walsh K. W, 1991, UNDERSTANDING BRAIN; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU	60	51	53	0	8	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2000	22	3					325	338		10.1076/1380-3395(200006)22:3;1-V;FT325			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	327UB	WOS:000087811000003	10855041				2021-06-18	
J	Callahan, CD; Hinkebein, J				Callahan, CD; Hinkebein, J			Neuropsychological significance of anosmia following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							HEAD TRAUMA; COMMUNITY	Objectives: To investigate the incidence of anosmia following traumatic brain injury (TBI) using a standardized instrument and to test hypotheses that post-TBI anosmics perform significantly more poorly than do post-TBI normosmics on measures of executive skills and functional outcome. Design: Prospective quasi-experimental between-groups design. Participants: Sixty-eight adults diagnosed with TBI. Setting: Brain injury rehabilitation program based at a Midwestern medical center. Main Outcome Measures: University of Pennsylvania Smell Identification Test (UPSIT), selected neuropsychological measures of executive skills, the Disability Rating Scale (DRS), and the Community Integration Questionnaire (CIQ). Results: Forty-four subjects (65%) demonstrated impaired olfaction; only 13 (30%) acknowledged smell dysfunction. Anosmic and normosmic groups did not differ in demographics, IQ, chronicity, or admis- sion Glasgow Coma Scale (GCS). Anosmics had longer coma (P = .01), more severe deficits in complex attention (Trailmaking Test, Part B, P = .01), new learning/memory (California Verbal Learning Test Trial V [CVLT-V], P = .001), and problem solving (Wiconsin Card Sorting Test [WCST], P = .001), leading to greater functional impairment (Disability Rating Scale [DRS], P = .003). No differences emerged on the CIQ. Conclusions: Anosmia is a common sequela of TBI, although only a minority of patients are aware of this deficit. Further, anosmics demonstrated greater impairment in a variety of frontal-lobe mediated executive functions, as well as greater functional disability.	Mem Med Ctr, Ctr Neuromuscular Sci, Brain Injury Program, Springfield, IL 62781 USA	Callahan, CD (corresponding author), Mem Med Ctr, Ctr Neuromuscular Sci, Brain Injury Program, 701 N 1st St, Springfield, IL 62781 USA.						BERROL S, 1989, TRAUMATIC BRAIN INJU, V3, P85; CONSTANZO RM, 1992, J HEAD TRAUMA REHAB, V7, P15; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Doty RL, 1995, SMELL IDENTIFICATION; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HENDRIKS A P J, 1988, Rhinology (Utrecht), V26, P229; JENNET B, 1981, MANAGEMENT HEAD INJU; Leigh AD, 1943, LANCET, V1, P38; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; MALLOY PF, 1994, J NEUROPSYCH CLIN N, V6, P455; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SULLIVAN TE, 1995, BRAIN INJURY, V9, P641, DOI 10.3109/02699059509008222; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; VARNEY NR, 1988, J CLIN EXP NEUROPSYC, V10, P250, DOI 10.1080/01688638808408239; Varney NR, 1998, J HEAD TRAUMA REHAB, V13, P63; VARNEY NR, 1995, S COND 15 ANN M NAT; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Zasler ND, 1992, J HEAD TRAUMA REHAB, V7, P66	19	51	54	0	7	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1999	14	6					581	587		10.1097/00001199-199912000-00006			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	269AV	WOS:000084454300005	10671703				2021-06-18	
J	Bramlett, HM; Dietrich, WD; Green, EJ				Bramlett, HM; Dietrich, WD; Green, EJ			Secondary hypoxia following moderate fluid percussion brain injury in rats exacerbates sensorimotor and cognitive deficits	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion; hypoxia; Morris water maze; rats; sensorimotor task; traumatic brain injury	CONTROLLED CORTICAL IMPACT; HEAD-INJURY; MEMORY; HYPOTHERMIA; DAMAGE; HISTOPATHOLOGY; LOCALIZATION; IMPAIRMENTS; EXPRESSION; HYPOXEMIA	Human head trauma is frequently associated with respiratory problems resulting in secondary hypoxic insult. To document the behavioral consequences of secondary hypoxia in an established model of traumatic brain injury (TBI), intubated anesthetized animals were subjected to fluid percussion (FP) injury (1.87-2.17 atm) followed by 30 min of either normoxic (TBI-NO, n = 10) or hypoxic (TBI-HY, n = 11; pO(2) = 30-40 mm Hg) gas levels. Sham animals (n = 19) underwent all manipulations except for the actual trauma. Animals were tested on various sensorimotor tasks beginning 3 days after FP injury along with cognitive testing on days 22 through 29 posttrauma, The secondary hypoxic insult exacerbated the sensorimotor deficits on beam-walking compared to those animals only receiving trauma. Cognitive impairments were also observed in the TBI-HY group in the hidden platform task compared to FP injury alone. These data indicate that a secondary hypoxic insult exacerbates both sensorimotor and cognitive deficits after TBI, This study provides direct evidence that incidences of hypoxia after brain trauma may potentially result in an increase in neurological deficits for the subpopulation of head injured patients undergoing hypoxic conditions further warranting strict monitoring of these events.	Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; Univ Miami, Dept Psychol, Miami, FL 33101 USA; Univ Miami, Dept Neurol, Miami, FL 33101 USA; Univ Miami, Neurotrauma Res Ctr, Miami, FL 33101 USA	Bramlett, HM (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, POB 016960,Mail Locator R-48, Miami, FL 33101 USA.	hbramlet@miamiproject.med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; Chesnut R M, 1995, New Horiz, V3, P366; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Dave JR, 1997, NEUROREPORT, V8, P395, DOI 10.1097/00001756-199701200-00002; DERYCK M, 1992, BRAIN RES, V573, P44; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; SUTHERLAND RJ, 1988, PSYCHOBIOLOGY, V16, P157; SUTHERLAND RJ, 1989, BEHAV BRAIN RES, V32, P265, DOI 10.1016/S0166-4328(89)80059-2; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P125, DOI 10.1016/0166-4328(87)90250-6; ZILLES L, 1985, CORTEX RAT STEREOTAX	43	51	54	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	1999	16	11					1035	1047		10.1089/neu.1999.16.1035			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	260MM	WOS:000083954500002	10595820				2021-06-18	
J	Spikman, JM; Timmerman, ME; van Zomeren, AH; Deelman, BG				Spikman, JM; Timmerman, ME; van Zomeren, AH; Deelman, BG			Recovery versus retest effects in attention after closed head injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							DEFICITS; PERFORMANCE; MEMORY; TESTS	Recovery in 60 patients with a closed-head injury (CHI) in the first year posttrauma was assessed repeatedly with a series of attention tests. A matched group of healthy subjects was tested at the same intervals to allow us to control for practice effects. The results of a multilevel analysis for longitudinal data show retest effects in all but one of the tests. Patients performed more poorly on all tests, but their results on each test appeared to show recovery over time. The indicator of recovery was an improvement in test performance that was greater than the retest effect shown by the controls. On most tests, the performance of the more severely injured patients was initially worse, but showed more recovery over time. Test results differed with respect to changes over time, sensitivity to severity of injury, and subject specific characteristics Like age and vocational level. Recovery rate was not related to age or vocational status. Despite their recovery, the patient group was still impaired 1 year posttrauma on all tests sensitive to mental slowness. Outcome after 1 year, scored on a modified Glasgow Outcome Scale, was predicted to a small extent by PTA duration and initial performance on the RT-Distraction task. Return to work 2 to 5 years posttrauma was predicted by initial performance and improvement over time on the Stroop Color Word Test.	Acad Ziekenhuis, Dept Neuropsychol, NL-9713 GZ Groningen, Netherlands; Groningen State Univ, Dept Neuropsychol, Groningen, Netherlands; Groningen State Univ, Heymans Inst Psychol, Groningen, Netherlands	Spikman, JM (corresponding author), Acad Ziekenhuis, Dept Neuropsychol, Poortweg 4,Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.			Spikman, Jacoba/0000-0002-6477-0763			BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; BERG IJ, 1993, THESIS STATE U GRONI; BROOKS DN, 1987, NEUROBEHAVIORAL RECO, P57; BROUWER WH, 1985, THESIS STATE U GRONI; Bryk A.S., 1992, HIERARCHICAL LINEAR; BRYK AS, 1987, PSYCHOL BULL, V101, P147, DOI 10.1037/0033-2909.101.1.147; DEELMAN BG, 1990, TRAUMATIC BRAIN INJU; DEJONG P, 1991, THESIS FREE U AMSTER; DELAND N, 1995, THESIS U MONTREAL; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1987, NEUROBEHAVIORAL RECO, P73; FEINSTEIN A, 1994, J CLIN EXP NEUROPSYC, V16, P436, DOI 10.1080/01688639408402654; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Goldstein H, 1995, MULTILEVEL STAT MODE; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; Hays W. L., 1988, STATISTICS; Heaton R. K, 1981, WISCONSIN CARD SORTI; JENNETT B, 1975, LANCET, V1, P480; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luria A. R., 1966, HIGHER CORTICAL FUNC; Luria A. R, 1973, WORKING BRAIN; Mesulam M., 1985, PRINCIPLES BEHAV NEU; MUTTER SA, 1990, COGNITIVE NEUROPSYCH, V7, P329, DOI 10.1080/02643299008253447; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; RASBASH J, 1995, MLN COMMAND REFERENC; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; Salthouse T.A., 1982, ADULT COGNITION EXPT; SCHACTER DL, 1986, J CLIN EXP NEUROPSYC, V8, P727, DOI 10.1080/01688638608405192; SHALLICE T, 1982, NEUROPSYCHOLOGY COGN, P199; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; Snijders T, 1996, QUAL QUANT, V30, P405; Snijders T.A.B., 1999, MULTILEVEL ANAL INTR; SPIKMAN JM, 1995, J CLIN EXP NEUROPSYC, V17, P29, DOI 10.1080/13803399508406578; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; SPIKMAN JM, 1999, UNPUB CONSTRUCT VALI; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; STUSS DT, 1983, LOCALIZATION NEUROPS, P429; VAKIL E, 1994, J CLIN EXP NEUROPSYC, V16, P539, DOI 10.1080/01688639408402665; VANDERNAALT J, J NEUROLOGY NEUROSUR, V62; VANZOMEREN AH, 1981, THESIS STATE U GRONI; Verhage F, 1964, INTELLIGENTIE LEEFTI; Zomeren A. H., 1994, CLIN NEUROPSYCHOLOGY; ZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452; ZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	51	51	51	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1999	21	5					585	605		10.1076/jcen.21.5.585.874			21	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	264XG	WOS:000084207900001	10572280				2021-06-18	
J	Lomnitski, L; Chapman, S; Hochman, A; Kohen, R; Shohami, E; Chen, Y; Trembovler, V; Michaelson, DM				Lomnitski, L; Chapman, S; Hochman, A; Kohen, R; Shohami, E; Chen, Y; Trembovler, V; Michaelson, DM			Antioxidant mechanisms in apolipoprotein E deficient mice prior to and following closed head injury	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						Alzheimer's disease; apolipoprotein E; oxidation stress; antioxidant; mouse; brain	CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; BRAIN; GLUTATHIONE; RAT; ALPHA; ACID; PEROXIDASE	Apolipoprotein E deficient mice have distinct memory deficits and neurochemical derangements and their recovery from closed head injury is impaired. In the present study, we examined the possibility that the neuronal derangements of apolipoprotein E deficient mice are associated with oxidative stress, which in turn affects their ability to recover from close head injury. It was found that brain phospholipid levels in apolipoprotein E deficient mice are lower than those of the controls (55 +/- 15% of control, P < 0.01), that the cholesterol levels of the two mice groups are similar and that the levels of conjugated dienes of the apolipoprotein E deficient mice are higher than those of control mice (132 +/- 15% of P < 0.01). Brains of apolipoprotein E deficient mice had higher Mn-superoxide dismutase (134 +/- 7%), catalase (122 +/- 8%) and glutathione reductase (167 +/- 7%) activities than control (P < 0.01), whereas glutathione peroxidase activity and the levels of reduced glutathione and ascorbic acid were similar in the two mouse groups, Closed head injury increased catalase and glutathione peroxidase activities in both mouse groups, whereas glutathione reductase increased only in control mice. The superoxide dismutase activity was unaffected in both groups. These findings suggest that the antioxidative metabolism of apolipoprotein E deficient mice is altered both prior to and following head injury and that antioxidative mechanisms may play a role in mediating the neuronal maintenance and repair derangements of the apolipoprotein E deficient mice. (C) 1999 Elsevier Science B.V. All rights reserved.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Dept Pharm, Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel	Michaelson, DM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	dmichael@ccsg.tau.ac.il					ADAMS JD, 1983, J PHARMACOL EXP THER, V227, P749; Aviram M, 1996, EUR J CLIN CHEM CLIN, V34, P599; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; BENBASSAT A, 1980, BIOCHIM BIOPHYS ACTA, V611, P1, DOI 10.1016/0005-2744(80)90036-4; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BLIGH BG, 1959, CAN J BIOCH PHYSL, V37, P497; BOCHICCHIO M, 1990, INTENS CARE MED, V16, P444, DOI 10.1007/BF01711223; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Chapman S, 1998, J NEUROCHEM, V70, P708; Chen L, 1994, Int J Neurosci, V75, P83; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHN Y, 1997, NEUROSCIENCE, V30, P1255; Fiske CH, 1925, J BIOL CHEM, V66, P375; Flohe L., 1984, METHOD ENZYMOL, V105, P115; GENIS I, 1995, NEUROSCI LETT, V199, P5, DOI 10.1016/0304-3940(95)12007-Q; GINSBERG L, 1993, MOL CHEM NEUROPATHOL, V19, P37, DOI 10.1007/BF03160167; GORDON I, 1995, NEUROSCI LETT, V199, P1, DOI 10.1016/0304-3940(95)12006-P; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAJIMOHAMMADREZ.I, 1992, NEUROSCI LETT, V112, P333; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HOCHMAN A, 1987, J BIOL CHEM, V262, P6871; Hochman A, 1998, J NEUROCHEM, V71, P741; Hussain S, 1995, INT J DEV NEUROSCI, V13, P811, DOI 10.1016/0736-5748(95)00071-2; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; Johansson K, 1997, LANCET, V349, P1143, DOI 10.1016/S0140-6736(97)24016-X; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Mahley RW, 1996, ANN NY ACAD SCI, V777, P139, DOI 10.1111/j.1749-6632.1996.tb34412.x; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; Matthews RT, 1996, BRAIN RES, V718, P181, DOI 10.1016/0006-8993(95)01576-0; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MOTCHNIK PA, 1994, METHOD ENZYMOL, V234, P269; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Otero G, 1996, MOL CARCINOGEN, V17, P175, DOI 10.1002/(SICI)1098-2744(199612)17:4<175::AID-MC1>3.0.CO;2-D; Packer L, 1997, FREE RADICAL BIO MED, V22, P359, DOI 10.1016/S0891-5849(96)00269-9; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; PAPPOLLA MA, 1992, AM J PATHOL, V140, P621; PATTICHIS K, 1994, ANAL BIOCHEM, V221, P428, DOI 10.1006/abio.1994.1441; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; RECKNAGEL RO, 1984, METHOD ENZYMOL, V105, P331; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Tayag EC, 1996, BRAIN RES, V733, P287, DOI 10.1016/0006-8993(96)00669-5; VIANI P, 1991, J NEUROCHEM, V56, P253, DOI 10.1111/j.1471-4159.1991.tb02589.x; Wells K, 1995, NEUROCHEM RES, V20, P1329, DOI 10.1007/BF00992508	47	51	52	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-4439	0006-3002		BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	MAR 30	1999	1453	3					359	368		10.1016/S0925-4439(99)00010-1			10	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	185BX	WOS:000079649200006	10101254				2021-06-18	
J	Bogner, JA; Corrigan, JD; Stange, M; Rabold, D				Bogner, JA; Corrigan, JD; Stange, M; Rabold, D			Reliability of the agitated behavior scale	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Agitated Behavior Scale; agitation; brain injury; dementia; long-term care	BRAIN INJURY	Objective: The objective of this study was to investigate the interrater reliability of the Agitated Behavior Scale. Design: Ratings made by research assistants and nursing staff were compared. Participants and setting: Forty-five persons with brain injury and 23 persons with progressive dementia were studied at an acute rehabilitation unit and a long-term-care facility. Results: Ratings of persons with brain injury by research assistants yielded a correlation coefficient for the Total score of .920. The correlation coefficients for the factors Disinhibition, Aggression, and Lability were .902,.909, and .726, respectively. Lower coefficients were obtained when the ratings of the research assistants and nursing staff were correlated; these ranged from .364 to .604. The ratings by research assistants of long-term-care facility residents yielded coefficients ranging from .860 to .906 for the Total and factor scores. Conclusion: This study shows that the Agitated Behavior Scale is a reliable instrument for measuring agitation in persons with traumatic brain injury, as well as with long-term-care facility residents experiencing dementia.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Ohio State Univ, Coll Nursing, Columbus, OH 43210 USA	Bogner, JA (corresponding author), Dodd Hall,480 W 9th Ave, Columbus, OH 43210 USA.		Corrigan, John D./E-2921-2011				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BOGNER J, 1995, NEUROREHABILITATION, V5, P293, DOI 10.3233/NRE-1995-5403; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1995, NEUROREHABILITATION, V5, P205, DOI 10.3233/NRE-1995-5303; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; Corrigan JD, 1996, AM J ALZHEIMERS DIS, V11, P20; Kelly G. A., 1955, PSYCHOL PERSONAL CON, V1-2; TERI L, 1992, ALZ DIS ASSOC DIS, V6, P77, DOI 10.1097/00002093-199206020-00003	10	51	51	0	9	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	1999	14	1					91	96		10.1097/00001199-199902000-00012			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	165LT	WOS:000078523100012	9949251				2021-06-18	
J	Ray, SK; Shields, DC; Saido, TC; Matzelle, DC; Wilford, GG; Hogan, EL; Banik, NL				Ray, SK; Shields, DC; Saido, TC; Matzelle, DC; Wilford, GG; Hogan, EL; Banik, NL			Calpain activity and translational expression increased in spinal cord injury	BRAIN RESEARCH			English	Article						calpain; calpastatin; calcium; neutral proteinase; spinal cord injury	ACTIVATED NEUTRAL PROTEINASE; TRAUMATIC BRAIN INJURY; DEGRADATION; RAT; PROTEOLYSIS; INHIBITOR	Calpain, a calcium-activated neutral proteinase, has been implicated in myelin and cytoskeletal protein degradation following spinal cord injury. In the present study, we examined the activity and transcriptional expression of calpain in spinal cord injury lesions via Western blotting analysis and RT-PCR, respectively. No increases in transcriptional expression of calpain or calpastatin, the endogenous inhibitor, were observed in the lesion at 1, 4, 24, and 72 h following injury. However, calpain activity (as measured by calpain-specific degradation of the endogenous substrate fodrin) was marginally increased at 4 h and significantly increased by 129.8% at 48 h compared to sham controls after injury. Calpain translational expression was localized in injured spinal cords using double immunofluorescent labeling which revealed increased calpain expression in astrocytes compared to sham controls. These results suggest that calpain produced by astrocytes located in or near spinal cord injury lesions may participate in myelin/axon degeneration following injury. (C) 1999 Published by Elsevier Science B.V. All rights reserved.	Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA; RIKEN, Brain Sci Inst, Wako, Saitama 3500198, Japan	Banik, NL (corresponding author), Med Univ S Carolina, Dept Neurol, 171 Ashley Ave, Charleston, SC 29425 USA.	baniknl@musc.edu	Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-31622] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031622] Funding Source: NIH RePORTER		Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; BALENTINE JD, 1985, TRAUMA CENTRAL NERVO, P285; BANAYSCHWARTZ M, 1994, NEUROCHEM RES, V19, P563, DOI 10.1007/BF00971331; Banik N, 1997, J NEUROCHEM, V69, pS144; Banik Naren L., 1992, P571; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BANIK NL, 1980, J NEUROPATH EXP NEUR, V39, P232, DOI 10.1097/00005072-198005000-00002; BANIK NL, 1986, J NEUROL SCI, V73, P245, DOI 10.1016/0022-510X(86)90149-8; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P92; CHAKRABARTI AK, 1988, J NEUROSCI RES, V20, P351, DOI 10.1002/jnr.490200309; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HATA A, 1989, J BIOL CHEM, V264, P6404; HOGAN EL, 1985, HDB NEUROCHEMISTRY, V10, P285; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; Li ZH, 1996, NEUROCHEM RES, V21, P441, DOI 10.1007/BF02527708; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIXON RA, 1986, J NEUROSCI, V6, P1264; Perot P L Jr, 1987, Cent Nerv Syst Trauma, V4, P149; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Shields DC, 1998, BRAIN RES, V794, P68, DOI 10.1016/S0006-8993(98)00193-0; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Yano T, 1997, EUR J BIOCHEM, V245, P260, DOI 10.1111/j.1432-1033.1997.00260.x; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1	33	51	52	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JAN 23	1999	816	2					375	380		10.1016/S0006-8993(98)01128-7			6	Neurosciences	Neurosciences & Neurology	158WH	WOS:000078140100013	9878837				2021-06-18	
J	Berrouane, Y; Daudenthun, I; Riegel, B; Emery, MN; Martin, G; Krivosic, R; Grandbastien, B				Berrouane, Y; Daudenthun, I; Riegel, B; Emery, MN; Martin, G; Krivosic, R; Grandbastien, B			Early onset pneumonia in neurosurgical intensive care unit patients	JOURNAL OF HOSPITAL INFECTION			English	Article						neuro-surgical intensive care unit; nosocomial pneumonia; early onset pneumonia; incidence	RISK-FACTORS; NOSOCOMIAL PNEUMONIA; VENTILATED PATIENTS; TRAUMA PATIENTS; CONSCIOUSNESS; MULTICENTER; PROGNOSIS	To investigate early onset pneumonia in a neurosurgical intensive care unit, we studied a cohort of patients over a 13-month period and compared neurotrauma (T) with non-neurotrauma (NT) patients. Data were abstracted from the infection surveillance database. Five hundred and sixty-five adults were hospitalized in the neurosurgical intensive care unit. 57.9% had trauma and 129 patients developed 152 episodes of pneumonia. Incidence rates, restricted to the 129 first episodes of pneumonia, were 20.1 versus 15.7/1000 patient days and 34.2 versus 27.9/1000 ventilation days, in the T and NT groups respectively. In both groups, the distribution of risk stratified by hospital days was bimodal, being highest during the first three days. However, the risk was higher for T patients (at day 3, 20/1000 ventilation days versus 10.2/1000 ventilation days). The daily risk peaked again at days 5 and 6, and thereafter remained low. Pneumonia occurring within the first three days, or early onset pneumonia (EOP), was associated with trauma (P=0.036) and, in the NT group only, with a Glasgow coma scale score lower than 9 (P=0.062). EOP was caused by Staphylococcus aureus (33%), Haemophilus spp. (23%), other Gram-positive cocci (22%), and other Gram-negative bacilli (GNB) (19%); whereas after the third day GNB other than Haemophilus spp. accounted for 45.4% of isolates (P=0.11). This large series confirms the high incidence of EOP in neurosurgical intensive care units, particularly among trauma patients, in relation to risk factors different from those seen in other intensive care patients. Further studies are needed to elaborate specific preventive measures during early care.	Ctr Hosp Reg Univ Lille, Lab Bacteriol Hyg, Lille, France; Ctr Hosp Reg Univ Lille, Lab Anesthesie Reanimat Chirurg 1, Lille, France; Ctr Hosp Reg Univ Lille, Serv Epidemiol & Sante Publ, Lille, France; Ctr Hosp Reg Univ Lille, Unite Lutte Contre Infect Nosocomiales, Lille, France	Berrouane, Y (corresponding author), CHRU Lille, Hop A Calmette, Lab Bacteriol Hyg, Bd Du Pr J Leclercq, F-59037 Lille, France.						ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; BARREIRO B, 1995, EUR RESPIR J, V8, P1543; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; *CONS SUP HYG PUBL, 1992, B EPIDEMIOLOGIQUE HE, P11; FREEMAN J, 1996, HOSP EPIDEMIOLOGY IN, P12; GARIBALDI RA, 1981, AM J MED, V70, P677, DOI 10.1016/0002-9343(81)90595-7; GARNER JS, 1988, AM J INFECT CONTROL, V16, P28; George DL, 1996, HOSP EPIDEMIOLOGY IN, P175; GROSS PA, 1991, AM J MED, V91, pS16, DOI 10.1016/0002-9343(91)90338-X; HANSON LC, 1992, AM J MED, V92, P161, DOI 10.1016/0002-9343(92)90107-M; HONGHAO A, 1992, AM REV RESPIR DIS, V146, P290; INGLIS TJJ, 1993, J HOSP INFECT, V25, P207, DOI 10.1016/0195-6701(93)90039-3; JARVIS WR, 1991, AM J MED S3B, V91, P185; JIMENEZ P, 1989, CRIT CARE MED, V17, P882, DOI 10.1097/00003246-198909000-00007; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; LANGER M, 1987, INTENS CARE MED, V13, P342; LEGALL JR, 1984, CRIT CARE MED, V12, P975; MARQUETTE CH, 1995, AM J RESP CRIT CARE, V151, P1878, DOI 10.1164/ajrccm.151.6.7767535; MEERT KL, 1995, CRIT CARE MED, V23, P822, DOI 10.1097/00003246-199505000-00008; RELLO J, 1992, CHEST, V102, P525, DOI 10.1378/chest.102.2.525; TEASDALE G, 1974, LANCET, V2, P81; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523	24	51	54	0	0	W B SAUNDERS CO LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0195-6701			J HOSP INFECT	J. Hosp. Infect.	DEC	1998	40	4					275	280		10.1016/S0195-6701(98)90303-6			6	Public, Environmental & Occupational Health; Infectious Diseases	Public, Environmental & Occupational Health; Infectious Diseases	147CR	WOS:000077470800003	9868618				2021-06-18	
J	Chae, J; Hart, R				Chae, J; Hart, R			Comparison of discomfort associated with surface and percutaneous intramuscular electrical stimulation for persons with chronic hemiplegia	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						pain; neuromuscular stimulation; hemiplegia	FUNCTIONAL NEUROMUSCULAR STIMULATION; UPPER-EXTREMITY FNS; HEMIPARETIC PATIENTS; STROKE PATIENTS; GRASP SYNTHESIS; MOTOR CONTROL; MESH-GLOVE; HUMAN-SKIN; PAIN; FIBERS	Neuromuscular stimulation may facilitate motor recovery after stroke or brain injury, reduce shoulder pain associated with hemiplegia, and reduce cerebral spasticity However, the discomfort of surface neuromuscular stimulation significantly limits the clinical implementation of this modality for persons with hemiplegia, The study contained herein tests the hypothesis that stroke and brain injury survivors with chronic hemiplegia (>6 mo) and intact sensation tolerate percutaneous intramuscular stimulation better than surface stimulation. Four stroke and two traumatic brain injury survivors participated in the study contained within this article. Each subject received three pairs of percutaneous and surface stimulations of the paretic finger extensors. The order of the type of stimulation within each pair was randomly assigned. The stimulation parameters for each type of stimulation were normalized to produce the same torque at the metacarpophalangeal joint. Subjects rated their perceived level of discomfort using a 10-cm visual analog scale and the McGill Pain Questionnaire. A blinded evaluator administered the pain measures, Percutaneous stimulation was associated with significantly lower discomfort as reflected by the visual analog scale (0.74 v 3.3; 95% confidence interval of difference, -3.84, -1.28). The McGill Pain Questionnaire produced similar results with percutaneous stimulation associated with a significantly fewer number of words chosen to describe the discomfort (0.87 v 3.30; 95% confidence interval of difference, -3.50, -1.30) and significantly lower Pain Rating index (1.47 v 6.27; 95% confidence interval of difference, -7.77, -1.83). Data suggest that percutaneous intramuscular stimulation is significantly better tolerated than surface stimulation and that percutaneous stimulation may enhance patient compliance with neuromuscular stimulation treatments.	Case Western Reserve Univ, Metrohlth Med Ctr, Ctr Phys Med & Rehabil, Cleveland, OH 44109 USA; Case Western Reserve Univ, Metrohlth Med Ctr, Dept Phys Med & Rehabil, Cleveland, OH 44109 USA; Case Western Reserve Univ, Metrohlth Med Ctr, Dept Orthoped, Cleveland, OH 44109 USA; Vet Affairs Med Ctr, Cleveland, OH USA	Chae, J (corresponding author), Case Western Reserve Univ, Metrohlth Med Ctr, Ctr Phys Med & Rehabil, 2500 MetroHlth Dr, Cleveland, OH 44109 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K12 HD01097-01A1] Funding Source: Medline		ADRIAENSEN H, 1983, J NEUROPHYSIOL, V49, P111; ALFIERI V, 1982, SCAND J REHABIL MED, V14, P177; BAKER LL, 1986, PHYS THER, V66, P1930, DOI 10.1093/ptj/66.12.1930; BAKER LL, 1988, CLIN ORTHOP RELAT R, P75; BAKER LL, 1979, PHYS THER, V59, P1495; BESSOU P, 1969, J NEUROPHYSIOL, V32, P1025; BOWMAN BR, 1979, ARCH PHYS MED REHAB, V60, P497; BUCKETT JR, 1988, IEEE T BIO-MED ENG, V35, P897, DOI 10.1109/10.8669; CHAE J, 1998, REHABILITATION MED P, P611; DELITTO A, 1986, PHYS THER, V66, P1704, DOI 10.1093/ptj/66.11.1704; Dimitrijevic MM, 1996, ARCH PHYS MED REHAB, V77, P252; DIMITRIJEVIC MM, 1994, SCAND J REHABIL MED, V26, P187; DUBNER R, 1977, PAIN TRIGEMINAL REGI, P57; FAGHRI PD, 1994, ARCH PHYS MED REHAB, V75, P73; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; GEORGOPOULOS AP, 1977, BRAIN RES, V128, P547, DOI 10.1016/0006-8993(77)90181-0; Glanz M, 1996, ARCH PHYS MED REHAB, V77, P549, DOI 10.1016/S0003-9993(96)90293-2; GRACANIN F, 1975, ARCH PHYS MED REHAB, V56, P243; HALLIN RG, 1982, J NEUROL NEUROSUR PS, V45, P313, DOI 10.1136/jnnp.45.4.313; HANDA Y, 1987, MED PROG TECHNOL, V12, P51; Handa Y, 1989, AUTOMEDICA, V1, P221; HANDA Y, 1984, P 8 INT S ECHE DUBR, P169; HANSEN G, 1979, SCAND J REHABIL MED, V11, P189; KEITH MW, 1988, CLIN ORTHOP RELAT R, P25; KILGORE K, 1994, P 16 ANN INT C IEEE; KILGORE KL, 1993, MED BIOL ENG COMPUT, V31, P607, DOI 10.1007/BF02441809; Kilgore KL, 1997, J BONE JOINT SURG AM, V79A, P533, DOI 10.2106/00004623-199704000-00008; KILGORE KL, 1993, MED BIOL ENG COMPUT, V31, P615, DOI 10.1007/BF02441810; Kobetic R., 1994, IEEE Transactions on Rehabilitation Engineering, V2, P66, DOI 10.1109/86.313148; KOBETIC R, 1994, HUMAN WALKING, P225; KRAFT GH, 1992, ARCH PHYS MED REHAB, V73, P220; LAMOTTE RH, 1978, J NEUROPHYSIOL, V41, P509; LEVIN M F, 1989, Society for Neuroscience Abstracts, V15, P916; LEVIN MF, 1992, ELECTROEN CLIN NEURO, V85, P131, DOI 10.1016/0168-5597(92)90079-Q; Lieberson W., 1961, ARCH PHYS MED REHAB, V42, P101; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Memberg W. D., 1993, IEEE Transactions on Rehabilitation Engineering, V1, P126, DOI 10.1109/86.242426; MENSE S, 1977, J PHYSIOL-LONDON, V267, P75, DOI 10.1113/jphysiol.1977.sp011802; MENSE S, 1983, J PHYSIOL-LONDON, V342, P383, DOI 10.1113/jphysiol.1983.sp014857; MENSE S, 1981, BRAIN RES, V225, P95, DOI 10.1016/0006-8993(81)90320-6; MERLETTI R, 1978, SCAND J REHABIL MED, V10, P147; MERLETTI R, 1975, ARCH PHYS MED REHAB, V56, P507; PAINTAL AS, 1960, J PHYSIOL-LONDON, V152, P250, DOI 10.1113/jphysiol.1960.sp006486; Peckham P., 1992, NEURAL PROSTHESES RE, P162; REBERSEK S, 1973, ARCH PHYS MED REHAB, V54, P378; Shimada Y, 1996, ARCH PHYS MED REHAB, V77, P1014, DOI 10.1016/S0003-9993(96)90061-1; SMITH BT, 1994, ARCH PHYS MED REHAB, V75, P939; TAKEBE K, 1975, ARCH PHYS MED REHAB, V56, P237; VANHEES J, 1972, BRAIN RES, V48, P397, DOI 10.1016/0006-8993(72)90198-9; VODOVNIK L, 1965, Arch Phys Med Rehabil, V46, P187; WINCHESTER P, 1983, PHYS THER, V63, P1096, DOI 10.1093/ptj/63.7.1096; WONG RA, 1986, PHYS THER, V66, P1209, DOI 10.1093/ptj/66.8.1209	52	51	52	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV-DEC	1998	77	6					516	522		10.1097/00002060-199811000-00013			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	147RZ	WOS:000077487100010	9862539				2021-06-18	
J	Harvey, AG; Bryant, RA				Harvey, AG; Bryant, RA			Acute stress disorder after mild traumatic brain injury	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article								The debate continues over whether a posttraumatic response occurs in those who have sustained a traumatic brain injury (TBI). The aim of this study was to investigate the incidence of acute stress disorder (ASD) in the mild TBI population. Patients who sustained a mild TBI after a motor vehicle accident (N = 79) were assessed for the presence of ASD. ASD was diagnosed in 13.9% of patients, and 5.1% were diagnosed with subsyndromal ASD. Dissociative, reexperiencing, and avoidance symptoms were found to have moderate to high predictive power. This study highlights the significant number of patients who experience an acute trauma response after TBI and raises the possibility that those with ASD denote those for whom an early intervention may prevent longer-term psychopathology. Diagnostic difficulties in defining ASD after TBI are discussed.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	Harvey, AG (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; *ASS ADV AUT MED, 1990, ABBR INJ SCALE; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; BRYANT RA, 1997, PSYCHOMETRIC PROPERT; BRYANT RA, IN PRESS J CONSULT C; CREAMER M, 1992, J ABNORM PSYCHOL, V101, P452, DOI 10.1037/0021-843X.101.3.452; FEINSTEIN A, 1989, AM J PSYCHIAT, V146, P665; FLEMINGER S, 1993, BIOL PSYCHIAT, V33, P22, DOI 10.1016/0006-3223(93)90274-H; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; HARVEY AG, IN PRESS J CONSULT C; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SIVEC HJ, 1995, CLIN PSYCHOL REV, V15, P297, DOI 10.1016/0272-7358(95)00012-E	21	51	53	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	JUN	1998	186	6					333	337		10.1097/00005053-199806000-00002			5	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	ZV640	WOS:000074326100002	9653416				2021-06-18	
J	Hickling, EJ; Gillen, R; Blanchard, EB; Buckley, T; Taylor, A				Hickling, EJ; Gillen, R; Blanchard, EB; Buckley, T; Taylor, A			Traumatic brain injury and posttraumatic stress disorder: a preliminary investigation of neuropsychological test results in PTSD secondary to motor vehicle accidents	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; MEMORY; DEFICITS; CONCUSSION; EVENTS	This study investigated the effect of traumatic brain injury on the development of posttraumatic stress disorder (PTSD). Subjects were 107 motor vehicle accident survivors including 38 individuals who were diagnosed with posttraumatic stress disorder (PTSD). Neuropsychological testing was administered to all subjects during an initial diagnostic evaluation. Results showed that subjects who had lost consciousness during their MVA had greater impairment on speed dependent tests and delayed recall of verbal material. Subjects who suffered traumatic brain injury (TBI) were also found to have developed PTSD as often as those who had not reported TBI. Implications for future research and clinical utility are discussed.	Capital Psychol Associates, Albany, NY 12205 USA; Russell Sage Coll, Albany, NY 12205 USA; SUNY Albany, Ctr Stress & Anxiety Disorders, Albany, NY 12222 USA	Hickling, EJ (corresponding author), Capital Psychol Associates, 4 Atrium Dr,Suite 240, Albany, NY 12205 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BIGLER ED, 1989, J CLIN PSYCHOL, V45, P277, DOI 10.1002/1097-4679(198903)45:2<277::AID-JCLP2270450216>3.0.CO;2-M; Blake D., 1990, CLIN ADMINISTERED PT; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; BLANCHARD EB, 1997, CRASH PSYCHOL ASS TR; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; CURRY LM, 1991, PHILADELPHIA HEAD IN; EVERLY GS, 1989, PERCEPT MOTOR SKILL, V68, p807N; GOLDEN CJ, 1985, LUNA NEBRASKA NEUROP; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; KLONOFF H, 1976, J NERV MENT DIS, V163, P246, DOI 10.1097/00005053-197610000-00003; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; MILLER L, 1993, J COGNITIVE REHABILI, V11, P18; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Price K. P., 1994, DEF LAW J, V43, P113; Reitan RM., 1985, HALSTEAD REITAN NEUR; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHACTER DL, 1992, AM PSYCHOL, V47, P559, DOI 10.1037/0003-066X.47.4.559; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; SUTKER PB, 1995, NEUROPSYCHOLOGY, V9, P118, DOI 10.1037/0894-4105.9.1.118; *US DEP TRANSP, 1995, TRAFF SAF FACTS 1994; YEHUDA R, 1995, AM J PSYCHIAT, V152, P137	30	51	51	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1998	12	4					265	274		10.1080/026990598122566			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZF942	WOS:000072948700002	9562909				2021-06-18	
J	Hicks, RR; Baldwin, SA; Scheff, SW				Hicks, RR; Baldwin, SA; Scheff, SW			Serum extravasation and cytoskeletal alterations following traumatic brain injury in rats - Comparison of lateral fluid percussion and cortical impact models	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article						MAP2; blood-brain barrier; head injury	MICROTUBULE-ASSOCIATED PROTEIN-2; HEAD-INJURY; VASCULAR DISRUPTION; HIPPOCAMPAL-LESIONS; BARRIER; DAMAGE; MAP2; IMMUNOREACTIVITY; CONTUSION; NEURONS	Disruption of the blood-brain barrier (BBB) and neuronal cytoskeletal damage were evaluated in two commonly used rat models of traumatic brain injury. Adult rats received a lateral cortical impact (CI) or lateral fluid percussion (FP) injury of mild or moderate severity or a sham procedure. Six hours after trauma, the brains were removed and analyzed with immunocytochemical techniques for alterations in the serum protein, IgG, and the cytoskeletal protein, microtubule-associated protein 2 (MAP2). Both models induced profound alterations in these proteins in the ipsilateral cortex and hippocampus compared to sham-injured controls. Following an injury of moderate severity, the CI injury resulted in greater IgG extravasation in the cortex and hippocampus than the FP injury. Conversely, after a mild injury, IgG extravasation in the hippocampus was greater for FP than CI. All of the animals in the CI group and most of the FP group showed a loss of MAP2 in the hippocampus. The specific subregions within the cortex and hippocampus that were affected by the injury varied between models, despite having identical impact sites. These data demonstrate that there are both similarities and differences between a CI and FP injury on vascular and neuronal cystoskeletal integrity which should be considered when utilizing these animal models to study selected features of human head injury.	Univ Kentucky, Div Phys Therapy, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Hicks, RR (corresponding author), Univ Kentucky, Div Phys Therapy, Lexington, KY 40536 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220] Funding Source: NIH RePORTER		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; AIHARA N, 1994, J COMP NEUROL, V342, P481, DOI 10.1002/cne.903420402; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BLACK MM, 1989, TRENDS NEUROSCI, V12, P211, DOI 10.1016/0166-2236(89)90124-0; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; BOTHE HW, 1984, ACTA NEUROPATHOL, V64, P37, DOI 10.1007/BF00695604; BRALET J, 1992, BIOCHEM PHARMACOL, V43, P979, DOI 10.1016/0006-2952(92)90602-F; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CZURKO A, 1994, NEUROSCI LETT, V166, P51, DOI 10.1016/0304-3940(94)90838-9; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon C. E., 1995, CENTRAL NERVOUS SYST, P255; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FRIEDRICH P, 1991, FEBS LETT, V295, P5, DOI 10.1016/0014-5793(91)81371-E; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HATAKEYAMA T, 1988, STROKE, V19, P1526, DOI 10.1161/01.STR.19.12.1526; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JANE JA, 1982, HEAD INJURY BASIC CL, P229; Jensen MB, 1997, EXP NEUROL, V143, P103, DOI 10.1006/exnr.1996.6337; KITIGAWA K, 1989, NEUROSCIENCE, V31, P401; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Kruger L., 1995, PHOTOGRAPHIC ATLAS R; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moos T, 1996, J HISTOCHEM CYTOCHEM, V44, P591, DOI 10.1177/44.6.8666744; MOSER E, 1993, J NEUROSCI, V13, P3916; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PAXINOS G, 1986, RAT BRAINF STEREOTAX; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SEISJO BK, 1988, CRIT CARE MED, V16, P954; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROSCI, V15, P8223; StubleyWeatherly L, 1996, BRAIN RES, V716, P29, DOI 10.1016/0006-8993(95)01589-2; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SZENTISTVANYI I, 1984, AM J PHYSIOL, V246, pF835; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; VANDENBRINK WA, 1994, ACT NEUR S, V60, P456; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YOSHIMI K, 1991, BRAIN RES, V560, P149, DOI 10.1016/0006-8993(91)91225-P	60	51	51	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	SEP-DEC	1997	32	1-3					1	16		10.1007/BF02815164			16	Neurosciences; Pathology	Neurosciences & Neurology; Pathology	YN074	WOS:000071130500001	9437655				2021-06-18	
J	Ersahin, Y; Mutluer, S; Saydam, S; Barcin, E				Ersahin, Y; Mutluer, S; Saydam, S; Barcin, E			Cerebellar mutism: Report of two unusual cases and review of the literature	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						brain stem surgery; cerebellar injury; head injury; mutism; posterior cranial fossa; brain tumour	POSTERIOR-FOSSA SURGERY; TRANSIENT MUTISM; TRAUMATIC MUTISM; DENTATE NUCLEUS; CHILDREN; REMOVAL; TUMOR; MEDULLOBLASTOMA; DYSARTHRIA; LESIONS	Mutism is not a common condition following cerebellar damage. Mutism following posterior cranial fossa surgery was first reported by Rekate et al. and Yonemasu in 1985. Since then, many case reports of mutism have appeared in the English literature. Very few cases developed mutism following brain stem surgery. Although mutism has been described in patients with head injury, only one case of mutism caused by a cerebellar injury has been reported, to our knowledge. We report on two patients in which the cerebellar mutism following a radical excision of an exophytic brain stem glioma and cerebellar injury developed. We reviewed the relevant literature and discussed the mechanism of cerebellar mutism. (C) 1997 Elsevier Science B.V.	EGE UNIV,FAC MED,DEPT NEUROSURG,DIV PAEDIAT NEUROSURG,IZMIR,TURKEY							ALJARALLAH A, 1994, J SURG ONCOL, V55, P126, DOI 10.1002/jso.2930550214; AMMIRATI M, 1989, CHILD NERV SYST, V5, P12, DOI 10.1007/BF00706739; ASAMOTO M, 1994, CHILD NERV SYST, V10, P275, DOI 10.1007/BF00301168; CAKIR Y, 1994, SURG NEUROL, V41, P342, DOI 10.1016/0090-3019(94)90188-0; CATSMANBERREVOETS CE, 1992, DEV MED CHILD NEUROL, V34, P1102; CRUTCHFIELD JS, 1994, J NEUROSURG, V81, P115, DOI 10.3171/jns.1994.81.1.0115; D'Avanzo R, 1993, Acta Neurol (Napoli), V15, P289; DAILEY AT, 1995, J NEUROSURG, V83, P467, DOI 10.3171/jns.1995.83.3.0467; DIETZE DD, 1990, PEDIATR NEUROSURG, V16, P25; Ersahin Y, 1996, NEUROSURGERY, V38, P60; FERRANTE L, 1990, J NEUROSURG, V72, P959, DOI 10.3171/jns.1990.72.6.0959; FERRARA VL, 1985, SURG NEUROL, V23, P573, DOI 10.1016/0090-3019(85)90005-9; FRAIOLI B, 1975, APPL NEUROPHYSIOL, V38, P81; FRIM DM, 1995, NEUROSURGERY, V36, P854, DOI 10.1227/00006123-199504000-00031; HERB E, 1992, NEUROPEDIATRICS, V23, P144, DOI 10.1055/s-2008-1071330; Humphreys RP, 1989, CONCEPTS PEDIATR NEU, P57; NAGATANI K, 1991, SURG NEUROL, V36, P307, DOI 10.1016/0090-3019(91)90094-P; Ozek MM, 1993, TURK NEUROSURG, V3, P37; REKATE HL, 1985, ARCH NEUROL-CHICAGO, V42, P697, DOI 10.1001/archneur.1985.04060070091023; SALVATI M, 1991, CLIN NEUROL NEUROSUR, V93, P313, DOI 10.1016/0303-8467(91)90096-8; SIEGFRIE.J, 1970, CONFIN NEUROL, V32, P1; VANDONGEN HR, 1994, NEUROLOGY, V44, P2040, DOI 10.1212/WNL.44.11.2040; VOLCAN I, 1986, ARCH NEUROL-CHICAGO, V43, P313, DOI 10.1001/archneur.1986.00520040003002; VONCRAMON D, 1981, NEUROPSYCHOLOGIA, V19, P801, DOI 10.1016/0028-3932(81)90092-0; VUILLEUMIER P, 1995, NEUROCHIRURGIE, V41, P98; YOKOTA H, 1990, Neurological Surgery, V18, P67; Yonemasu Y, 1985, 13 ANN M JAP SOC PED	27	51	52	0	1	VAN GORCUM CO BV	ASSEN	PO BOX 43, 9400 AA ASSEN, NETHERLANDS	0303-8467			CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	MAY	1997	99	2					130	134		10.1016/S0303-8467(96)00597-5			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	XG391	WOS:A1997XG39100010	9213058				2021-06-18	
J	Givon, U; Pritsch, M; Levy, O; Yosepovich, A; Amit, Y; Horoszowski, H				Givon, U; Pritsch, M; Levy, O; Yosepovich, A; Amit, Y; Horoszowski, H			Monteggia and equivalent lesions - A study of 41 cases	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							FRACTURE-DISLOCATIONS; RADIAL HEAD; CHILDREN	Forty-one patients who suffered from a Monteggia fracture and were treated between 1984 and 1993 were reviewed retrospectively using a new motion score of the elbow joint, There were 14 children and 27 adults of whom 34 were available for review The results in children were significantly better than those of the adults, Among the adults, the final results of the patients who had a Bado Type 1 equivalent injury were significantly worse than those of the other groups, especially when associated with a fracture of the radial head, The type of fracture, open or closed, the presence of a fracture of the olecranon, and the energy level of the trauma did not have any significant prognostic value, Good correlation was shown between the new motion score and the Figgie elbow score, The Bado Type 1 equivalent injuries should be considered as a special subgroup of the Monteggia lesion, necessitating extra attention in treatment and rehabilitation, and a close followup of the patient.		Givon, U (corresponding author), CHAIM SHEBA MED CTR,DEPT ORTHOPAED SURG,IL-52621 TEL HASHOMER,ISRAEL.						Bado J L, 1967, Clin Orthop Relat Res, V50, P71; BARQUET A, 1981, INJURY, V12, P471, DOI 10.1016/0020-1383(81)90166-2; Boyd H B, 1969, Clin Orthop Relat Res, V66, P94; BRUCE HE, 1974, J BONE JOINT SURG AM, VA 56, P1563, DOI 10.2106/00004623-197456080-00003; BRYAN RS, 1971, J TRAUM, V11, P992, DOI 10.1097/00005373-197112000-00002; DORMANS JP, 1990, ORTHOP CLIN N AM, V21, P251; ENGBER WD, 1983, CLIN ORTHOP RELAT R, V174, P133; FIGGIE MP, 1989, J BONE JOINT SURG AM, V71A, P1058, DOI 10.2106/00004623-198971070-00013; FOWLES JV, 1983, J BONE JOINT SURG AM, V65, P1276, DOI 10.2106/00004623-198365090-00008; GIUSTRA PE, 1974, RADIOLOGY, V110, P45, DOI 10.1148/110.1.45; HUME AC, 1957, J BONE JOINT SURG BR, V39, P508; JESSING P, 1975, ACTA ORTHOP SCAND, V46, P601, DOI 10.3109/17453677508989242; KAMALI M, 1974, J BONE JOINT SURG AM, VA 56, P841, DOI 10.2106/00004623-197456040-00026; LETTS M, 1985, J BONE JOINT SURG BR, V67, P724; LICHTER RL, 1975, J BONE JOINT SURG AM, VA 57, P124, DOI 10.2106/00004623-197557010-00026; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P454, DOI 10.2106/00004623-198163030-00021; MORRIS AH, 1974, J BONE JOINT SURG AM, VA 56, P1744, DOI 10.2106/00004623-197456080-00033; MULLICK S, 1977, J BONE JOINT SURG AM, V59, P543, DOI 10.2106/00004623-197759040-00024; OLNEY BW, 1989, J PEDIATR ORTHOPED, V9, P219; PEIRO A, 1977, J BONE JOINT SURG AM, V59, P92, DOI 10.2106/00004623-197759010-00017; RECKLING FW, 1982, J BONE JOINT SURG AM, V64, P857, DOI 10.2106/00004623-198264060-00007; SPAR I, 1977, CLIN ORTHOP RELAT R, V122, P207; SPINNER M, 1968, CLIN ORTHOPAEDICS, V58, P141; STEIN F, 1971, J BONE JOINT SURG AM, VA 53, P1432, DOI 10.2106/00004623-197153070-00022; STOLL TM, 1992, J BONE JOINT SURG BR, V74, P436; TOMPKINS DG, 1971, J BONE JOINT SURG AM, VA 53, P1109, DOI 10.2106/00004623-197153060-00007; WILEY JJ, 1985, J BONE JOINT SURG BR, V67, P728	27	51	54	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	APR	1997		337					208	215					8	Orthopedics; Surgery	Orthopedics; Surgery	WT707	WOS:A1997WT70700023	9137192				2021-06-18	
J	Godfrey, HPD; Knight, RG; Partridge, FM				Godfrey, HPD; Knight, RG; Partridge, FM			Emotional adjustment following traumatic brain injury: A stress appraisal-coping formulation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adjustment; brain injury; rehabilitation; stress	CLOSED-HEAD-INJURY; SOCIAL-INTERACTION; MANAGEMENT; DISORDER	This article conceptualizes emotional adjustment to traumatic brain injury (TBI) within a stress-appraisal-coping (SAG) model. In this model the emotional adjustment of the individual with TBI is seen as a response to neuropsychological symptoms and associated losses. This response is mediated, however, by the individual's coping skills, social support, and appraisal (insight). Evidence regarding the course of emotional dysfunction following TBI and the role of mediating variables is reviewed and found to provide strong preliminary support for the model. In addition, the effects of neuropsychological symptoms on mediators of emotional adjustment are discussed. Finally, the implications of the SAC model for rehabilitation are discussed and recent rehabilitation outcome findings presented.		Godfrey, HPD (corresponding author), UNIV OTAGO,DEPT PSYCHOL,CLIN PSYCHOL RES & TRAINING CTR,POB 56,DUNEDIN,NEW ZEALAND.						BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BOND G, 1993, THESIS U OTAGO; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FOLEY FW, 1987, J CONSULT CLIN PSYCH, V55, P919, DOI 10.1037/0022-006X.55.6.919; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GODFREY H P D, 1991, Brain Injury, V5, P207, DOI 10.3109/02699059109008091; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; GODFREY HPD, 1991, J CLIN EXP NEUROPSYC, V13, P428; Janis I. L, 1958, PSYCHOL STRESS; Kahneman D., 1973, ATTENTION EFFORT; KIHLSTROM JF, 1991, AWARENESS DEFICIT BR; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Lazarus R.S., 1984, STRESS APPRAISAL COP; Lazarus R.S., 1966, PSYCHOL STRESS COPIN; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; McGill C.W., 1984, FAMILY CARE SCHIZOPH; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1986, REHABIL PSYCHOL, V31, P217; SERLE H, 1957, STRESS LIFE; SKINNER BF, 1983, AM PSYCHOL, V38, P239, DOI 10.1037/0003-066X.38.3.239; Smith L.M., 1995, FAMILY SUPPORT PROGR; SPENCE SE, 1993, BRIT J CLIN PSYCHOL, V32, P309, DOI 10.1111/j.2044-8260.1993.tb01061.x; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TAYLOR SE, 1988, PSYCHOL BULL, V103, P193, DOI 10.1037/0033-2909.103.2.193; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WOLFOLK R, 1984, PRINCIPLES PRACTICE; Zarit S., 1985, HIDDEN VICTIMS ALZHE	35	51	52	0	13	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1996	11	6					29	40		10.1097/00001199-199612000-00006			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VW427	WOS:A1996VW42700005					2021-06-18	
J	Temple, MD; Hamm, RJ				Temple, MD; Hamm, RJ			Chronic, post-injury administration of D-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury	BRAIN RESEARCH			English	Article						D-cycloserine; glycine site; memory; Morris water maze; N-methyl-D-aspartate; rat; treatment	D-ASPARTATE RECEPTOR; CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; EXCITATORY AMINO-ACIDS; GLYCINE RECEPTOR; MEMORY IMPAIRMENT; SPATIAL MEMORY; RATS; HIPPOCAMPAL; ANTAGONIST	The purpose of this study was to determine the effect of augmenting NMDA receptor activation on cognitive deficits produced by traumatic brain injury (TBI). Specifically, D-cycloserine (DCS), a partial agonist of the NMDA-associated glycine site, was tested as a potential cognitive enhancer. Rats were injured using lateral fluid percussion TBI (2.8+/-.10 atm). On days 1-15 post-injury, animals were injected (i.p.) with vehicle (n=8), 10 mg/kg (n=9), or 30 mg/kg (n=8) of DCS. Sham-injured animals treated with either vehicle (n=8) or 30 mg/kg of DCS (n=8) were used for comparison. On days 11-15 post-injury, cognitive function was assessed using the Morris water maze (MWM). Results indicate that the 30 mg/kg dose of DCS significantly attenuated memory deficits as compared to injured vehicle-treated animals (P <0.01). Analysis also revealed that performance of the injured-DCS (30 mg/kg) group was not significantly different from sham-injured animals treated with vehicle (P >0.10). In contrast, the 10 mg/kg dose of DCS was ineffective in reducing injury-induced memory deficits. DCS (30 mg/kg) also significantly improved the spatial memory of sham-injured animals when compared with sham-injured animals treated with vehicle (P <0.05). In conclusion, chronic, post-injury enhancement of the NMDA receptor is an effective strategy for ameliorating TBI-associated cognitive deficits.	VIRGINIA COMMONWEALTH UNIV,DEPT PSYCHOL,RICHMOND,VA 23284					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER		BAXTER MG, 1994, NEUROBIOL AGING, V15, P207, DOI 10.1016/0197-4580(94)90114-7; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Dixon C. E., 1992, Society for Neuroscience Abstracts, V18, P171; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DSOUZA SW, 1993, ARCH DIS CHILD, V69, P212, DOI 10.1136/adc.69.2.212; EMMETT MR, 1991, NEUROPHARMACOLOGY, V30, P1167, DOI 10.1016/0028-3908(91)90161-4; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FISHKIN RJ, 1993, BEHAV NEURAL BIOL, V59, P150, DOI 10.1016/0163-1047(93)90886-M; FLOOD JF, 1992, EUR J PHARMACOL, V221, P249, DOI 10.1016/0014-2999(92)90709-D; FOSTER AC, 1989, NATURE, V338, P377, DOI 10.1038/338377a0; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; HANDELMANN G E, 1987, Society for Neuroscience Abstracts, V13, P705; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOOD WF, 1989, NEUROSCI LETT, V98, P91, DOI 10.1016/0304-3940(89)90379-0; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAYER ML, 1989, NATURE, V338, P425, DOI 10.1038/338425a0; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; ROBINSON G, 1988, Society for Neuroscience Abstracts, V14, P248; SARTER M, 1990, PSYCHOPHARMACOLOGY, V101, P1, DOI 10.1007/BF02253710; SCHENK F, 1985, EXP BRAIN RES, V58, P11; SCHUSTER GM, 1992, EUR J PHARMACOL, V224, P97, DOI 10.1016/0014-2999(92)94825-G; SIRVIO J, 1992, NEUROSCI LETT, V146, P215, DOI 10.1016/0304-3940(92)90081-H; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; WOOD PL, 1995, LIFE SCI, V57, P301, DOI 10.1016/0024-3205(95)00288-H	41	51	52	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 25	1996	741	1-2					246	251		10.1016/S0006-8993(96)00940-7			6	Neurosciences	Neurosciences & Neurology	VZ081	WOS:A1996VZ08100032	9001729				2021-06-18	
J	Biagas, KV; Grundl, PD; Kochanek, PM; Schiding, JK; Nemoto, EM				Biagas, KV; Grundl, PD; Kochanek, PM; Schiding, JK; Nemoto, EM			Posttraumatic hyperemia in immature, mature, and aged rats: Autoradiographic determination of cerebral blood flow	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; immature; aged; head trauma hypoperfusion	PERCUSSION BRAIN INJURY; SEVERE HEAD-INJURIES; INTRACRANIAL-PRESSURE; GLUCOSE-UTILIZATION; METABOLISM; CHILDREN; ISOFLURANE; HALOTHANE; ANESTHESIA; TRAUMA	Clinical studies suggest that increased cerebral blood flow (CBF), or hyperemia, after traumatic brain injury (TBI) is commonly found in children and young adults, but is less often found in adults older than 40 years. However, whether posttraumatic cerebral hyperemia is truly an age-related phenomenon has not been proven, Using a model of focal percussive TBI, we hypothesized that (1) local CBF (ICBF) is increased by 24 after injury, and (2) the magnitude of the ICBF increase is age-related and is greatest in immature rats. Wistar rats that were immature (3.5-4.5 weeks), mature (2-3 months), and aged (14.5-15.5 months) were anesthetized and ventilated, TBI was produced by dropping a weight on the exposed right parietal cortex. LCBF was determined by [C-14]iodoantipyrine autoradiography at 24 h posttrauma in all three age groups, at 48 h posttrauma in immature and mature rats, and at 7 days posttrauma in mature rats. In all age groups, low ICBF (<50 mt 100 g(-1) min(-1)) was present in the area of impact at all times studied. At 24 h, hyperemia was observed (vs, corresponding regions of age-matched control rats) in immature and mature rats (7/17 and 5/17 regions, respectively, both p < 0.05), Tout not in aged rats, Comparisons of ICBF between the three age groups revealed a hyperemic response in the peritrauma region in immature rats, Hyperemia persisted to 48 h in both immature and mature rats (2 and 7 of 17 structures with increased ICBF in immature and mature rats, respectively, both p < 0.05). By 7 days posttrauma no regions of increased ICBF were found. Posttraumatic hyperemia appears to be an age-dependent phenomenon, These results suggest possible age-related differences in vasoreactivity or regional metabolism after TBI.	UNIV PITTSBURGH, SCH MED, DEPT ANESTHESIOL CRIT CARE MED, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SCH MED, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; YALE UNIV, SCH MED, DEPT PEDIAT, NEW HAVEN, CT 06510 USA; FAIRFAX HOSP, DEPT PEDIAT, FALLS CHURCH, VA 22046 USA	Biagas, KV (corresponding author), UNIV PITTSBURGH, SCH MED, SAFAR CTR RESUSITAT RES, 3434 5TH AVE, PITTSBURGH, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X			BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BRYAN RM, 1994, J NEUROTRAUM, V11, P104; CHRISTENSEN MS, 1967, BRIT J ANAESTH, V39, P927, DOI 10.1093/bja/39.12.927; CLARK RS, 1995, PEDIATR RES, V57, pA43; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; DARBY JM, 1988, NEUROSURGERY, V23, P84, DOI 10.1227/00006123-198807000-00014; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HANSEN TD, 1988, ANESTHESIOLOGY, V69, P332, DOI 10.1097/00000542-198809000-00008; HE Z, 1993, J CEREB BLOOD FLOW M, V13, pS405; HOVDA DA, 1993, J CEREB BLOOD FLOW M, V13, pS574; JAKOBSEN J, 1990, DIABETES, V39, P437, DOI 10.2337/diabetes.39.4.437; KAIEDA R, 1989, ANESTHESIOLOGY, V71, P571, DOI 10.1097/00000542-198910000-00016; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LUCIGNANI G, 1987, J CEREBR BLOOD F MET, V7, P309, DOI 10.1038/jcbfm.1987.68; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; MARTIN AJ, 1991, J CEREBR BLOOD F MET, V11, P684, DOI 10.1038/jcbfm.1991.121; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NEHLIG A, 1989, J CEREBR BLOOD F MET, V9, P579, DOI 10.1038/jcbfm.1989.83; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NORTON WT, 1973, J NEUROCHEM, V21, P759, DOI 10.1111/j.1471-4159.1973.tb07520.x; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1993, J CEREB BLOOD FLO S1, V13, pS571; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Scremin O. U., 1995, Society for Neuroscience Abstracts, V21, P762; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SOKAL RR, 1981, BIOMETRY, P413; TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; WOLLMAN H, 1964, ANESTHESIOLOGY, V25, P180, DOI 10.1097/00000542-196403000-00012; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403	46	51	52	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1996	13	4					189	200		10.1089/neu.1996.13.189			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	UK144	WOS:A1996UK14400002	8860199				2021-06-18	
J	Anderson, CV; Wood, DMG; Bigler, ED; Blatter, DD				Anderson, CV; Wood, DMG; Bigler, ED; Blatter, DD			Lesion volume, injury severity, and thalamic integrity following head injury	JOURNAL OF NEUROTRAUMA			English	Article						magnetic resonance imaging; traumatic brain injury; thalamus	AXONAL INJURY	Magnetic resonance (MR) scans of 63 traumatic brain injury (TBI) patients were analyzed to examine the relationship between injury severity, lesion volume (nonthalamic cortical/subcortical lesions), ventricle-to-brain ratio (VBR), and thalamic volume, For comparison, 33 normal control subjects were used, Patients with visible nonthalamic structural lesions showed significantly smaller thalamic volumes than patients without visible lesions or control subjects. Results also indicated that patients with visible lesions had significantly more severe injuries than patients without lesions, Patients with moderate-severe injuries had significantly smaller thalamic volumes and greater VBRs than patients with mild-moderate injuries. Although several variables related to thalamic volume, the presence of nonthalamic lesions was sufficient to result in smaller thalamic volume. Decreased thalamic volume following head injury suggests that subcortical brain structures may be susceptible to transneuronal degeneration following cortical lesions, and that this can be detected by in vivo MR-based volumetric analysis.	BRIGHAM YOUNG UNIV,DEPT PSYCHOL,PROVO,UT 84602; LATTER DAY ST HOSP,DEPT RADIOL,SALT LAKE CITY,UT 84143							ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; BIGLER ED, 1994, FUNCTIONAL NEUROIMAG, P121; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CLARKE LP, 1995, MAGN RESON IMAGING, V13, P343, DOI 10.1016/0730-725X(94)00124-L; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; GEAN AD, 1994, IMAGING HEAT TRAUMA; JESSELL TM, 1991, PRINCIPLES NEURAL SC, P258; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KUCHARCZYK J, 1994, MAGNETIC RESONANCE I; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; MATTHEWS MA, 1973, J NEUROCYTOL, V2, P265, DOI 10.1007/BF01104030; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; PRAYER LM, 1994, MAGNETIC RESONANCE N; ROBB RA, 1995, 3 DIMENSIONAL BIOMED; ROSENTHAL M, 1993, TRAUMATIC BRAIN INJU; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; STEWARD O, 1989, PRINCIPLES CELL MOL; WHITE RJ, 1992, NEW ENGL J MED, V327, P1507; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29	25	51	52	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	1996	13	2					59	65		10.1089/neu.1996.13.59			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	UE544	WOS:A1996UE54400002	9094376				2021-06-18	
J	Tenhula, WN; Sweet, JJ				Tenhula, WN; Sweet, JJ			Double cross-validation of the booklet Category Test in detecting malingered traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	14th Annual Meeting of the National-Academy-of-Neuropsychology	NOV, 1994	ORLANDO, FL	Natl Acad Neuropsychol			MEMORY DEFICITS; BELIEVABLE DEFICITS; FAKING; PROSPECTS	Two studies were conducted to determine whether the Category Test (CT), in booklet form, can effectively discriminate between groups of brain-injured, malingering, and normal subjects. Discriminant function analyses and clinical decision rules were used to identify malingering on the CT and the relative effectiveness of these two methods was evaluated. Because each of these methods achieved similar classification rates with both samples of subjects, optimal discriminant functions and clinical decision rules were developed combining the subjects from both studies. Discriminant functions correctly classified from 72.5% to 92.2% of subjects and optimal cut-off scores correctly classified from 64.1% to 91.5% of subjects. Effective identification of malingerers was obtained with both higher than expected base rate (29%) and a much lower, more realistic base rate (4%). Thus, the CT performances of individuals who attempt to malinger sequelae of traumatic brain injury appear to be discriminable from genuine brain-injured patients.	EVANSTON HOSP CORP,NEUROPSYCHOL SERV,EVANSTON,IL 60201; NORTHWESTERN UNIV,SCH MED,EVANSTON,IL 60208							ANDERSON EW, 1956, P ROY SOC MED, V49, P513; ANDERSON EW, 1959, ACTA PSYCHIAT NEUROL, V132, P5; Ben-Porath Y. S., 1994, PSYCHOL ASSESSMENT, V6, P14; BENTON AL, 1961, ARCH GEN PSYCHIAT, V4, P79; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERRY DTR, 1994, PSYCHOL ASSESSMENT, V6, P16; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BOLTER JF, 1985, ANN M NAT AC NEUR PH; DeFilippis NA, 1979, BOOKLET CATEGORY TES; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Halstead WC, 1985, HALSTEAD REITAN NEUR; Halstead WC, 1947, BRAIN INTELLIGENCE; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Laatsch L., 1991, PSYCHOL ASSESSMENT J, V3, P701; MARTIN NJ, 1992, CLIN NEUROPSYCHOLOGI, V6, P329; MARTIN RC, 1991, ANN M NAT AC NEUR DA; MARTIN RC, 1993, ANN M INT NEUR SOC G; MEEHL PE, 1955, PSYCHOL BULL, V52, P194, DOI 10.1037/h0048070; MENSCH AJ, 1986, INT J CLIN NEUROPSYC, V8, P59; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; MITTENBERG W, 1990, ANN M INT NEUR SOC K; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; Rawling P, 1990, NEUROPSYCHOLOGY, V4, P223, DOI 10.1037/0894-4105.4.4.223; SNOW WG, 1992, ANN M INT NEUR SOC S; THOMPSON LL, 1991, ARCH CLIN NEUROPSYCH, V6, P231; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	37	51	51	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	1996	10	1					104	116		10.1080/13854049608406669			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	UM353	WOS:A1996UM35300012					2021-06-18	
J	Regan, RF; Panter, SS; Witz, A; Tilly, JL; Giffard, RG				Regan, RF; Panter, SS; Witz, A; Tilly, JL; Giffard, RG			Ultrastructure of excitotoxic neuronal death in murine cortical culture	BRAIN RESEARCH			English	Article						ischemic brain injury; traumatic brain injury; glutamate receptor; neuronal death	PROGRAMMED CELL-DEATH; NERVE GROWTH-FACTOR; INTERNUCLEOSOMAL DNA CLEAVAGE; PROTEIN-SYNTHESIS; CEREBRAL-ISCHEMIA; GLUTAMATE NEUROTOXICITY; SYMPATHETIC NEURONS; GEL-ELECTROPHORESIS; FACTOR DEPRIVATION; RAT HIPPOCAMPUS	Ischemic and traumatic brain injury are likely to involve neuronal injury triggered by glutamate receptor overactivation. Although excitotoxic neuronal injury has been widely studied in the setting of primary culture, the extent to which these in vitro injury paradigms resemble in vivo ischemic injury morphologically has not previously been well studied. We studied glutamate receptor mediated neuronal death by transmission electron microscopy and light microscopy. Morphologic characteristics of neurons injured by 10 min exposure to 500 mu M glutamate include rapid swelling of mitochondria and endoplasmic reticulum, and cytoplasmic and nuclear lucency. Both alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid and kainic acid caused vacuolation, dilatation of the endoplasmic reticulum, cytoplasmic condensation and random condensation of chromatin with preserved mitochondria. None of these injuries was ameliorated by cycloheximide or actinomycin D; all were significantly lessened by aurintricarboxylic acid. Gel electrophoresis showed no increase in DNA fragmentation over control. The morphologic changes seen with alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid and kainate are distinct from the changes induced by glutamate. Excitotoxic injury in this system due to high concentrations of glutamate resembles necrosis while the other agonists produce a different form of cell death which is neither necrosis nor apoptosis.	STANFORD UNIV,SCH MED,DEPT ANESTHESIA,STANFORD,CA 94305; LETTERMAN ARMY INST RES,DIV BLOOD RES,SAN FRANCISCO,CA 94129; HARVARD UNIV,SCH MED,DEPT OBSTET GYNECOL & REPROD BIOL,VINCENT CTR REPROD BIOL,BOSTON,MA 02115				Giffard, Rona/0000-0003-2173-4436			BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BELIZARIO JE, 1993, BRIT J CANCER, V67, P1229, DOI 10.1038/bjc.1993.230; BINASTEIN M, 1976, MOL PHARMACOL, V12, P191; BOE R, 1991, EXP CELL RES, V195, P237, DOI 10.1016/0014-4827(91)90523-W; BROWN AW, 1973, ACTA NEUROPATHOL, V23, P9, DOI 10.1007/BF00689000; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; CHARRIAUTMARLANGUE C, 1995, J CEREBR BLOOD F MET, V15, P385, DOI 10.1038/jcbfm.1995.48; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1988, J NEUROSCI, V8, P185; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLLINS RJ, 1992, INT J RADIAT BIOL, V61, P451, DOI 10.1080/09553009214551201; CSERNANSKY CA, 1994, J NEUROSCI RES, V38, P101, DOI 10.1002/jnr.490380113; DESHPANDE J, 1992, EXP BRAIN RES, V88, P91, DOI 10.1007/BF02259131; DESSI F, 1993, J NEUROCHEM, V60, P1953, DOI 10.1111/j.1471-4159.1993.tb13427.x; DIETRICH WD, 1992, ACTA NEUROPATHOL, V84, P630, DOI 10.1007/BF00227740; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; DUGAN LL, 1995, J NEUROSCI, V15, P4545; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; GIANNAKIS C, 1991, BIOCHEM BIOPH RES CO, V181, P915, DOI 10.1016/0006-291X(91)91278-K; GOTO K, 1990, BRAIN RES, V534, P299, DOI 10.1016/0006-8993(90)90144-Z; HERON A, 1993, J NEUROCHEM, V61, P1973, DOI 10.1111/j.1471-4159.1993.tb09843.x; HORNUNG JP, 1989, J COMP NEUROL, V283, P425, DOI 10.1002/cne.902830310; IGNATOWICZ E, 1991, NEUROREPORT, V2, P651, DOI 10.1097/00001756-199111000-00004; IKONOMIDOU C, 1989, J NEUROSCI, V9, P1693; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F; LEDDACOLUMBANO GM, 1992, AM J PATHOL, V140, P545; LEPPIN C, 1992, BRAIN RES, V581, P168, DOI 10.1016/0006-8993(92)90359-H; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LIN JK, 1992, CANCER RES, V52, P385; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; LUCAS J H, 1990, Journal of Neurotrauma, V7, P169, DOI 10.1089/neu.1990.7.169; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MASTERS JN, 1989, ENDOCRINOLOGY, V124, P3083, DOI 10.1210/endo-124-6-3083; MCCONKEY DJ, 1989, FASEB J, V3, P1843; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; NAVASCUES J, 1988, J COMP NEUROL, V278, P34, DOI 10.1002/cne.902780103; NISHIKAWA Y, 1989, ACTA NEUROPATHOL, V78, P1, DOI 10.1007/BF00687395; OLNEY JW, 1969, J NEUROPATH EXP NEUR, V28, P455, DOI 10.1097/00005072-196907000-00007; PAPAS S, 1992, EUR J NEUROSCI, V4, P758, DOI 10.1111/j.1460-9568.1992.tb00185.x; PETITO CK, 1984, J CEREBR BLOOD F MET, V4, P194, DOI 10.1038/jcbfm.1984.28; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; RATAN RR, 1994, J NEUROCHEM, V62, P376; Regan R. F., 1993, Society for Neuroscience Abstracts, V19, P1344; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SELLINS KS, 1991, RADIAT RES, V126, P88, DOI 10.2307/3578175; SHIGENO T, 1990, NEUROSCI LETT, V120, P117, DOI 10.1016/0304-3940(90)90182-9; SPERK G, 1983, NEUROSCIENCE, V10, P1301, DOI 10.1016/0306-4522(83)90113-6; STRAIN SM, 1991, NEUROSCIENCE, V44, P343, DOI 10.1016/0306-4522(91)90059-W; TAKANO YS, 1991, J PATHOL, V163, P329, DOI 10.1002/path.1711630410; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WALLEN CA, 1983, CELL TISSUE KINET, V16, P357; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZEEVALK GD, 1993, J NEUROCHEM, V61, P386, DOI 10.1111/j.1471-4159.1993.tb03585.x	67	51	52	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	DEC 24	1995	705	1-2					188	198		10.1016/0006-8993(95)01170-6			11	Neurosciences	Neurosciences & Neurology	TQ998	WOS:A1995TQ99800023	8821749				2021-06-18	
J	SHATNEY, CH; BRUNNER, RD; NGUYEN, TQ				SHATNEY, CH; BRUNNER, RD; NGUYEN, TQ			THE SAFETY OF OROTRACHEAL INTUBATION IN PATIENTS WITH UNSTABLE CERVICAL-SPINE FRACTURE OR HIGH SPINAL-CORD INJURY	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	47th Annual Meeting of the Southwestern Surgical Congress	APR 23-26, 1995	SAN ANTONIO, TX				AIRWAY MANAGEMENT; ENDOTRACHEAL INTUBATION; TRAUMA PATIENTS; NASOTRACHEAL; INDUCTION	BACKGROUND: The potential merits and dangers of orotracheal and nasotracheal intubation in patients with injury to the cervical spine or spinal cord continue to be debated. To address this issue, a prospective study was conducted at a level 1 trauma center in patients with respiratory embarrassment and either or both of these injuries. MATERIALS AND METHODS: Over a 7-year period, all such patients underwent neurologic examination by a trauma surgeon on arrival at the trauma center, immediately after endotracheal intubation, and at frequent intervals throughout hospitalization. Cervical immobilization was maintained manually during endotracheal intubation, When necessary, patients were sedated or paralyzed with short-acting pharmacologic agents. RESULTS: During the study period, there were 81 patients with 98 cervical vertebral body fractures, but without evidence of spinal cord injury on initial examination, Sixty-seven patients (83%) were legally intoxicated, and 12 patients had closed head injury. Endotracheal intubation was performed in 26 patients with unstable fractures, and 22 patients were intubated via the oral route. No patient manifested a subsequent neurologic deficit. Sixty-nine additional patients presented with high spinal cord injury; 16 had no cervical spine fracture, and 53 patients had 61 fractures of the cervical vertebrae. Sixty patients (87%) were intoxicated, and 8 patients had closed head injury. Endotracheal intubation was performed in 29 of these patients, and 26 patients were intubated via the oral route. No patient experienced further neurologic deficit following endotracheal intubation. CONCLUSION: In trauma victims with or at high risk of cervical spinal cord injury, orotracheal intubation is a rapid, safe means of achieving airway control.	UNIV FLORIDA,HLTH SCI CTR,DEPT SURG,JACKSONVILLE,FL; UNIV FLORIDA,HLTH SCI CTR,DEPT NEUROSURG,JACKSONVILLE,FL							APRAHAMIAN C, 1984, ANN EMERG MED, V13, P584, DOI 10.1016/S0196-0644(84)80278-4; BIVINS HG, 1988, ANN EMERG MED, V17, P25, DOI 10.1016/S0196-0644(88)80498-0; CRISWELL JC, 1994, ANAESTHESIA, V49, P900, DOI 10.1111/j.1365-2044.1994.tb04271.x; DINNER M, 1987, ANESTH ANALG, V66, P461; DRONEN SC, 1987, ANN EMERG MED, V16, P650, DOI 10.1016/S0196-0644(87)80063-X; HASTINGS RH, 1993, ANESTHESIOLOGY, V78, P580, DOI 10.1097/00000542-199303000-00022; HASTINGS RH, 1991, ANESTH ANALG, V73, P471; KAPP JP, 1975, J NEUROSURG, V42, P731, DOI 10.3171/jns.1975.42.6.0731; KNOPP RK, 1990, ANN EMERG MED, V19, P603, DOI 10.1016/S0196-0644(05)82203-6; LIGIER B, 1991, SURG GYNECOL OBSTET, V173, P477; MAJERNICK TG, 1986, ANN EMERG MED, V15, P417, DOI 10.1016/S0196-0644(86)80178-0; MAULL KI, 1977, SOUTHERN MED J, V70, P477, DOI 10.1097/00007611-197704000-00033; MESCHINO A, 1992, CAN J ANAESTH, V39, P114, DOI 10.1007/BF03008639; NORWOOD S, 1994, J AM COLL SURGEONS, V179, P646; REDAN JA, 1991, J TRAUMA, V31, P371, DOI 10.1097/00005373-199103000-00010; RHEE KJ, 1990, ANN EMERG MED, V19, P511, DOI 10.1016/S0196-0644(05)82179-1; ROSEN P, 1989, Journal of Emergency Medicine, V7, P387, DOI 10.1016/0736-4679(89)90312-0; SCANNEL G, 1993, ARCH SURG-CHICAGO, V128, P903; TALUCCI RC, 1988, AM SURGEON, V54, P185; TINTINALLI JE, 1981, ANN EMERG MED, V10, P142, DOI 10.1016/S0196-0644(81)80379-4; WALLS RM, 1992, CAN J SURG, V35, P27; WOOD PR, 1992, ANAESTHESIA, V47, P792, DOI 10.1111/j.1365-2044.1992.tb03259.x; WRIGHT SW, 1992, AM J EMERG MED, V10, P104, DOI 10.1016/0735-6757(92)90039-Z	23	51	53	1	1	CAHNERS PUBL CO	NEW YORK	249 WEST 17 STREET, NEW YORK, NY 10011	0002-9610			AM J SURG	Am. J. Surg.	DEC	1995	170	6					676	680		10.1016/S0002-9610(99)80040-3			5	Surgery	Surgery	TH942	WOS:A1995TH94200032	7492025				2021-06-18	
J	DIXON, CE; BAO, JL; BERGMANN, JS; JOHNSON, KM				DIXON, CE; BAO, JL; BERGMANN, JS; JOHNSON, KM			TRAUMATIC BRAIN INJURY REDUCES HIPPOCAMPAL HIGH-AFFINITY [H-3] CHOLINE UPTAKE BUT NOT EXTRACELLULAR CHOLINE LEVELS IN RATS	NEUROSCIENCE LETTERS			English	Article						CHOLINE; HIGH AFFINITY CHOLINE UPTAKE; HIPPOCAMPUS; MICRODIALYSIS; BRAIN INJURY	CONTROLLED CORTICAL IMPACT; MEMORY	Hippocampal cholinergic hypofunction may contribute to memory deficits following experimental traumatic brain injury. These studies examined two important factors in acetylcholine synthesis: choline availability and neuronal uptake. No reductions in basal extracellular choline levels, using microdialysis, were observed 2 weeks after cortical impact injury. However, studies of high affinity [H-3]choline uptake in the hippocampus, measured in a synaptosomal preparation, found a reduction in the maximum velocity of choline uptake (V-max), while no differences in affinity constants (K-m) were found. The results suggest that post-traumatic cholinergic deficits are not attributable to decreased availability of choline, but may be associated with either a decreased ability of cholinergic neurons to take up choline and/or a loss of cholinergic neurons.	UNIV TEXAS,MED BRANCH,DEPT PHARMACOL & TOXICOL,GALVESTON,TX 77555	DIXON, CE (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,6431 FANNIN ST,SUITE 7148,HOUSTON,TX 77030, USA.		Johnson, Kenneth/E-7944-2014		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031998, R01NS021458] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [CDC-R49-CCR303547] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458, P01 NS31998] Funding Source: Medline		BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; Dixon C. E., 1993, Society for Neuroscience Abstracts, V19, P1486; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1991, J NEUROSCI METH, V39, P253; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; JOHNSON KM, 1978, PHARMACOLOGY, V17, P83, DOI 10.1159/000136839; LEONARD JR, IN PRESS J NEUROTRAU; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MASH DC, 1985, SCIENCE, V228, P1115, DOI 10.1126/science.3992249; MOGHADDAM B, 1989, SYNAPSE, V4, P156, DOI 10.1002/syn.890040209; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	15	51	53	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	OCT 24	1994	180	2					127	130		10.1016/0304-3940(94)90503-7			4	Neurosciences	Neurosciences & Neurology	PQ428	WOS:A1994PQ42800011	7700564				2021-06-18	
J	COSTER, WJ; HALEY, S; BARYZA, MJ				COSTER, WJ; HALEY, S; BARYZA, MJ			FUNCTIONAL PERFORMANCE OF YOUNG-CHILDREN AFTER TRAUMATIC BRAIN INJURY - A 6-MONTH FOLLOW-UP-STUDY	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						BRAIN INJURIES; INFANT	CLOSED HEAD-INJURY; PEDIATRIC TRAUMA; MORBIDITY; SEQUELAE; SEVERITY; SERVICES; AGE	Objectives, A.follow-up study is reported of 40 children between the ages of 1 month and 5.6 years who had sustained a brain injury either with (n = 11) or without (n = 29) additional injuries. Method. Children and their families were assessed at both 1 and 6 months after hospital discharge with standardized measures of functional performance and family functioning, including the Child Behavior Checklist, the Pediatric Evaluation of Disability Inventory, and the Impact on Family Scale. In addition to within-group analyses, functional outcome was compared to that of a group of 17 children who bad sustained non-central nervous system injuries. Results. Mean scores for both groups of injured children were within the average range at both 1-month and 6-month follow-up testing. There was a general trend toward improved performance across the follow-up period, although only a few of these changes reached statistical significance. The effect of the injury as reported by the family was significantly associated with children's function as reflected by number of behavior problems and increased need for caregiver assistance. Conclusion. Results point to the need for systematic follow-up of young children after brain injury using sensitive measures to enable early identification of children whose further development may be at risk and to provide support to families whose children are displaying changes in functional behavior.	TUFTS UNIV,SCH MED,DEPT REHABIL MED,RES & TRAINING CTR REHABIL & CHILDHOOD TRAUMA,BOSTON,MA 02111; TUFTS UNIV NEW ENGLAND MED CTR,INST HLTH,BOSTON,MA 02111; SHRINERS BURN INST,BOSTON,MA	COSTER, WJ (corresponding author), BOSTON UNIV,SARGENT COLL,DEPT OCCUPAT THERAPY,635 COMMONWEALTH AVE,BOSTON,MA 02215, USA.						ACHENBACH TM, 1987, J ABNORM CHILD PSYCH, V15, P629, DOI 10.1007/BF00917246; ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Bagnato S. J., 1989, INFANT YOUNG CHILD, V2, P1; BAGNATO SJ, 1989, TOP EARLY CHILD SPEC, V2, P72; Bagnato SJ, 1986, REM SPEC EDUC, V7, P31, DOI 10.1177/074193258600700507; Bagnato SJ, 1986, DEV NEUROPSYCHOL, V2, P213, DOI 10.1080/87565648609540343; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; Black P, 1981, BRAIN DYSFUNCTION CH, P171; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1986, PEDIATRICS, V78, P497; CATALDO MF, 1986, CHILD HLTH BEHAVIOR; CLYDESDALE TT, 1990, ARCH PHYS MED REHAB, V71, P469; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HALEY SM, 1992, ADM MANUAL PEDIATRIC; HANFT B, 1988, AM J OCCUP THER, V42, P724, DOI 10.5014/ajot.42.11.724; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LARSON CP, 1988, AM J DIS CHILD, V142, P1052, DOI 10.1001/archpedi.1988.02150100046023; Lehr E, 1990, PSYCHOL MANAGEMENT T; LUNDAR T, 1985, CHILD NERV SYST, V1, P24, DOI 10.1007/BF00706726; MULHERN RK, 1993, J PEDIATR PSYCHOL, V18, P339, DOI 10.1093/jpepsy/18.3.339; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; Paris R., 1974, CLIN NEUROPSYCHOLOGY, P179; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; SINGER L, 1989, FAM RELAT, V38, P444, DOI 10.2307/585751; SOLLEE ND, 1987, J ABNORM CHILD PSYCH, V15, P479, DOI 10.1007/BF00917235; STEIN REK, 1980, MED CARE, V18, P462; SUNDBERG KB, 1992, THESIS BOSTON U; TEASDALE G, 1974, LANCET, V2, P81; TIMKO C, 1992, J PEDIATR PSYCHOL, V17, P705, DOI 10.1093/jpepsy/17.6.705; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008	42	51	51	0	1	AMER OCCUPATION THERAPY ASSN	ROCKVILLE	1383 PICCARD DRIVE PO BOX ROCKVILLE, MD 20850-4375	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	MAR	1994	48	3					211	218		10.5014/ajot.48.3.211			8	Rehabilitation	Rehabilitation	MW828	WOS:A1994MW82800003	8178914				2021-06-18	
J	SANDER, D; KLINGELHOFER, J				SANDER, D; KLINGELHOFER, J			CEREBRAL VASOSPASM FOLLOWING POSTTRAUMATIC SUBARACHNOID HEMORRHAGE EVALUATED BY TRANSCRANIAL DOPPLER ULTRASONOGRAPHY	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						VASOSPASM; SUBARACHNOID HEMORRHAGE; HEAD INJURY; INTRACRANIAL PRESSURE; TRANSCRANIAL DOPPLER; CLINICAL OUTCOME	CLOSED HEAD-INJURY; BLOOD-FLOW CHANGES; ULTRASOUND; VELOCITY; SPASM; DIAGNOSIS	We studied the incidence and time course of flow velocity changes suggesting a vasospasm following post-traumatic subarachnoid hemorrhage (SAH) considering the intracranial pressure (ICP) in 38 SAH patients as compared to 30 patients with spontaneous SAH. The first investigation was done within 24 h after onset of hemorrhage and regularly followed up during the clinical course. Additionally, the index of cerebral circulatory resistance was calculated and the ICP was measured using an epidural transducer. A significant correlation between middle cerebral artery maximum mean flow velocity and the quantity of blood seen on a computed tomographic scan in patients with post-traumatic SAH indicates a similar pathogenetic mechanism of the development of vasospasm to that after spontaneous SAH. In contrast, there was a significantly earlier occurrence of mean flow velocities over 120 cm/s following post-traumatic SAH irrespective of the ICP. Therefore, additional factors must be considered in the evaluation of these pathologically raised flow velocities after posttraumatic SAH. In both SAH groups there was a highly significant correlation between clinical outcome and clinical grade on admission, ICP and resistance index. The weak correlation between maximum mean flow velocity and clinical outcome following post-traumatic SAH supports the notion that final clinical outcome of these patients is of multifactorial origin.	TECH UNIV MUNICH, DEPT NEUROL, MOHLSTR 28, W-8000 MUNICH 80, GERMANY							AASLID R, 1986, NEURORADIOLOGY, V28, P11, DOI 10.1007/BF00341759; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BACKMUND H, 1972, NEURORADIOLOGY, V4, P46, DOI 10.1007/BF00344809; BRUCE DA, 1978, PATHOPHYSIOLOGY INCR; BRUNO A, 1988, STROKE, V19, P135, DOI 10.1161/01.STR.19.10.1300; COLD GE, 1980, ACTA ANAESTH SCAND, V24, P245, DOI 10.1111/j.1399-6576.1980.tb01544.x; COLUMELLA F, 1963, ACTA RADIOL DIAGN, V1, P239, DOI 10.1177/028418516300100217; DIETRICH K, 1977, NEUROPADIATRIE, V8, P21, DOI 10.1055/s-0028-1091501; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; GROSSET DG, 1992, STROKE, V23, P674, DOI 10.1161/01.STR.23.5.674; GURUSINGHE NT, 1984, J NEUROSURG, V60, P763, DOI 10.3171/jns.1984.60.4.0763; HARDERS AG, 1987, J NEUROSURG, V66, P718, DOI 10.3171/jns.1987.66.5.0718; HASSLER W, 1987, HEMODYNAMICS ASPECTS, P9; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; JAKOBSEN M, 1990, ACTA NEUROL SCAND, V82, P311; JENNETT B, 1975, LANCET, V1, P480; KLINGELHOFER J, 1991, J NEUROSURG, V75, P752, DOI 10.3171/jns.1991.75.5.0752; LEEDS NE, 1966, ACTA RADIOL DIAGN, V5, P320, DOI 10.1177/02841851660050P135; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; Pourcelot L, 1976, PRESENT FUTURE DIAGN, P141; SEILER RW, 1986, J NEUROSURG, V64, P594, DOI 10.3171/jns.1986.64.4.0594; SEKHAR LN, 1988, NEUROSURGERY, V22, P813, DOI 10.1227/00006123-198805000-00002; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; TEASDALE G, 1974, LANCET, V2, P81; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626	34	51	53	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	OCT	1993	119	1					1	7		10.1016/0022-510X(93)90185-2			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	MA596	WOS:A1993MA59600001	7902422				2021-06-18	
J	SWAINE, BR; SULLIVAN, SJ				SWAINE, BR; SULLIVAN, SJ			RELIABILITY OF THE SCORES FOR THE FINGER-TO-NOSE TEST IN ADULTS WITH TRAUMATIC BRAIN INJURY	PHYSICAL THERAPY			English	Article						COORDINATION; RELIABILITY; TESTS AND MEASUREMENTS; TRAUMATIC BRAIN INJURY	AGREEMENT; SCALES; SYSTEM	Background and Purpose. The Purpose of this study was to determine the intrarater and interrater reliability of measurements of three clinical features of coordination based on the performance of the ''finger-to-nose'' test. Subjects. Thirty-seven Persons with traumatic brain injury (26 male, 11 female), aged 17 to 64 years (XBAR = 29.1, SD = 9.9), participated in the study. Methods. Each subject's performance was videotaped and evaluated for the right and left upper extremities (UEs) (two trials each) with respect to the following variables: time of execution, degree of dysmetria, and degree of tremor (four-point ordinal ratings). One year later, five experienced physical therapists (including the original investigator) independently rated each patient''s videotaped performance in the same manner as described above. Results. Intraclass correlation coefficients (ICC[3,1]) for intrarater reliability were .971 and .986 and ICCs for interrater reliability were .920 and .913 for right and left UEs, respectively, for the time of execution. A generalized Kappa statistic of .54 was calculated for the scoring of dysmetria (both UEs) and Kappa statistics calculated for the scoring of tremor were .18 and .31 for right and left UEs, respectively. Interrater reliability was lower for the scoring of these variables and varied from .36 to .40 for dysmetria and from .27 to .26 for tremor (right and left UEs, respectively). Conclusion and Discussion. These results indicate that physical therapist demonstrate low reliability in assessment of the presence of dysmetria and tremor using videotaped performances of the finger-to-nose test. The results suggest, however, that therapists reliably measure the time of execution of this test. If the limitations associated with therapists' capacity for objective measurement of subjective phenomena cannot be overcome (eg, by establishment of more definitive scoring criteria for the measures of dysmetria and tremor), then therapy should seek alternative methods of evaluation of UE coordination.	UNIV MONTREAL,FAC MED,ECOLE READAPTAT,BIOMED SCI PROGRAM,MONTREAL H3C 3J7,QUEBEC,CANADA; CONCORDIA UNIV,DEPT EXERCISE SCI,MONTREAL H3G 1M8,QUEBEC,CANADA							ADAMS RD, 1989, PRINCIPLES NEUROLOGY; BEHBEHANI K, 1990, ARCH PHYS MED REHAB, V71, P106; CARONNA JJ, 1984, REHABILITATION ADULT, P59; COHADON F, 1983, NEUROCHIRURGIE, V29, P303; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; EASTLACK ME, 1991, PHYS THER, V71, P465, DOI 10.1093/ptj/71.6.465; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L; GRINKER RR, 1966, NEUROLOGY, P40; HELD JP, 1975, ANN MED PHYS, V18, P337; HENDERSON L, 1991, J NEUROL NEUROSUR PS, V54, P18, DOI 10.1136/jnnp.54.1.18; Jennett B, 1972, Scand J Rehabil Med, V4, P16; Jones R D, 1981, Int Rehabil Med, V3, P71; KONDRASKE GV, 1984, IEEE T BIO-MED ENG, V31, P401, DOI 10.1109/TBME.1984.325279; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MAYO NE, 1991, AM J PHYS MED REHAB, V70, P118, DOI 10.1097/00002060-199106000-00002; MERBITZ C, 1989, ARCH PHYS MED REHAB, V70, P308; RINEHART MA, 1983, PHYS THER, V63, P1975, DOI 10.1093/ptj/63.12.1975; ROSECRANCE JC, 1991, PHYS THER, V71, P334, DOI 10.1093/ptj/71.4.334; ROTHSTEIN JM, 1985, MEASUREMENT PHYSICAL, P8; SCHMITZ TJ, 1988, PHYSICAL REHABILITAT, P121; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SMITH SS, 1987, PHYS THER, V67, P1860, DOI 10.1093/ptj/67.12.1860; SULLIVAN SJ, 1989, P EVALUATION MESURAB; SWAINE BR, 1992, ARCH PHYS MED REHAB, V73, P55; TURTON A J, 1987, Physiotherapy Practice, V3, P117, DOI 10.3109/09593988709044173; WHYTE J, 1988, REHABILITATION MED P, P585	26	51	51	0	5	AMER PHYS THER ASSN	ALEXANDRIA	1111 N FAIRFAX ST, ALEXANDRIA, VA 22314	0031-9023			PHYS THER	Phys. Ther.	FEB	1993	73	2					71	78		10.1093/ptj/73.2.71			8	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	KJ866	WOS:A1993KJ86600004	8421720				2021-06-18	
J	SCHMOKER, JD; ZHUANG, J; SHACKFORD, SR; ROSNER, MJ; POOLE, GV; SIEGEL, JH; TRASK, AL; SCHMOKER, J				SCHMOKER, JD; ZHUANG, J; SHACKFORD, SR; ROSNER, MJ; POOLE, GV; SIEGEL, JH; TRASK, AL; SCHMOKER, J			HEMORRHAGIC HYPOTENSION AFTER BRAIN INJURY CAUSES AN EARLY AND SUSTAINED REDUCTION IN CEREBRAL OXYGEN DELIVERY DESPITE NORMALIZATION OF SYSTEMIC OXYGEN DELIVERY	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	51ST ANNUAL SESSION OF THE AMERICAN ASSOC FOR THE SURGERY OF TRAUMA	SEP 11-14, 1991	PHILADELPHIA, PA	AMER ASSOC SURG TRAUMA			6-PERCENT DEXTRAN-70; HYPERTONIC SALINE; 7.5-PERCENT NACL; SHOCK; RESUSCITATION; SWINE	Morbidity and mortality are doubled when hemorrhagic hypotension (HEM) accompanies a traumatic brain injury (TBI). Hemorrhagic hypotension initiates a "secondary" injury (SI) that has been attributed to ischemia, but this has not been confirmed in the laboratory. All previous studies have been of relatively short duration (<6 hours), allowing insufficient time to study the pathophysiology of SI, since maximal intracranial pressure (ICP) elevations may occur 16 to 20 hours after injury. We hypothesized that HEM combined with TBI would reduce cerebral oxygen delivery (cO2del) and cerebral metabolic rate for oxygen (cMR(o2)) to a greater degree than would occur with TBI alone. In a porcine model of TBI and HEM we recorded systemic oxygen delivery (sO2del), ICP, cerebral blood flow (CBF), cO2del, cMRO2, brain oxygen extraction ratio (cO2ER), and cortical water content (CWC) over a 24-hour study period. Controls (n = 7) were instrumented only, group 1 (n = 14) received a focal cryogenic lesion only, group 2 (n = 21) received a cryogenic lesion plus hemorrhage to 50 mm Hg for 45 minutes. Animals were resuscitated with crystalloid solutions; shed blood in group 2 animals was returned after one hour. Hemorrhagic hypotension following TBI produced a significant and sustained reduction in cO2del associated with a lower cMR(O)2 and CO2ER, and higher ICP and CWC, than seen with lesion alone. This occurred despite adequate early restoration of sO2del. This confirms that cerebral ischemia is ongoing despite restoration of systemic hemodynamics.	UNIV VERMONT,COLL MED,DEPT SURG,BURLINGTON,VT 05405					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1-R01-NS 28637-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028637] Funding Source: NIH RePORTER		CHESNUT RM, 1991, JAMA; CLASEN RA, 1953, SURG GYNECOL OBSTET, V96, P605; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; GAZITUA S, 1969, AM J PHYSIOL, V217, P1216; GAZITUA S, 1971, AM J PHYSIOL, V220, P384; Gennarelli T.A., 1985, CENTRAL NERVOUS SYST, P391; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; MANINGAS PA, 1987, CRIT CARE MED, V15, P1121, DOI 10.1097/00003246-198712000-00009; MANINGAS PA, 1986, ANN EMERG MED, V15, P1131, DOI 10.1016/S0196-0644(86)80852-6; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; NERLICH M, 1983, CIRC SHOCK, V10, P179; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; Pasztor E, 1973, STROKE, V4, P556, DOI 10.1161/01.STR.4.4.556; PITTS LH, 1980, INTRACRANIAL PRESSUR, V4, P5; READ RC, 1960, CIRC RES, V8, P538, DOI 10.1161/01.RES.8.3.538; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; WALD S, 1991, Journal of Trauma, V31, P1041, DOI 10.1097/00005373-199107000-00102; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; ZHUANG J, 1992, IN PRESS J TRAUMA	24	51	53	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1992	32	6					714	722		10.1097/00005373-199206000-00007			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	JB335	WOS:A1992JB33500008	1613830				2021-06-18	
J	DEUTSCHMAN, CS; KONSTANTINIDES, FN; RAUP, S; THIENPRASIT, P; CERRA, FB				DEUTSCHMAN, CS; KONSTANTINIDES, FN; RAUP, S; THIENPRASIT, P; CERRA, FB			PHYSIOLOGICAL AND METABOLIC RESPONSE TO ISOLATED CLOSED-HEAD INJURY .1. BASAL METABOLIC STATE - CORRELATIONS OF METABOLIC AND PHYSIOLOGICAL-PARAMETERS WITH FASTING AND STRESSED CONTROLS	JOURNAL OF NEUROSURGERY			English	Article									UNIV MINNESOTA, SCH MED, DEPT SURG, MINNEAPOLIS, MN 55455 USA; ST PAUL RAMSEY MED CTR, DEPT SURG, DIV NEUROSURG, ST PAUL, MN 55101 USA; ST PAUL RAMSEY MED CTR, SURG METAB RES FACIL, ST PAUL, MN 55101 USA			Deutschman, Clifford/AAN-2742-2021				ALEXANDER JW, 1980, ANN SURG, V192, P505, DOI 10.1097/00000658-198010000-00009; ASKANAZI J, 1980, ANN SURG, V191, P40, DOI 10.1097/00000658-198001000-00008; ASKANAZI J, 1980, JAMA-J AM MED ASSOC, V243, P1444, DOI 10.1001/jama.243.14.1444; BEISEL WR, 1980, JPEN-PARENTER ENTER, V4, P277, DOI 10.1177/0148607180004003277; BESSEY PQ, 1982, P METABOLIC NUTRITIO, P9; BIRGE SJ, 1984, ADV EXP MED BIOL, V171, P53; BISTRIAN BR, 1975, AM J CLIN NUTR, V28, P1148; BORDER JR, 1976, SURG CLIN N AM, V56, P1147; CERRA FB, 1979, J TRAUMA, V19, P621, DOI 10.1097/00005373-197908000-00010; CERRA FB, 1980, ANN SURG, V192, P570, DOI 10.1097/00000658-198010000-00015; CERRA FB, 1980, CRIT CARE MED, V8, P230, DOI 10.1097/00003246-198004000-00027; CERRA FB, 1982, CRITICAL CARE STATE, pL1; CERRA FB, 1982, PROFILES NUTRITION M; CERRA FB, 1982, PATHOPHYSIOLOGY SHOC, P254; CLIFTON GL, 1983, SURG FORUM, V34, P538; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CLOWES GHA, 1980, SURGERY, V88, P531; CLOWES GHA, 1976, SURG CLIN N AM, V56, P1169; CUTHBERTSON DP, 1979, JPEN-PARENTER ENTER, V3, P108, DOI 10.1177/0148607179003003108; DALE G, 1977, SURGERY, V81, P295; DEITRICK JE, 1948, AM J MED, V4, P3, DOI 10.1016/0002-9343(48)90370-2; FELIG P, 1969, J CLIN INVEST, V48, P584, DOI 10.1172/JCI106017; FELIG P, 1970, NEW ENGL J MED, V282, P166; FELL D, 1984, CRIT CARE MED, V12, P649, DOI 10.1097/00003246-198408000-00009; FISCHER JE, 1976, SURGERY, V80, P77; FREUND HR, 1978, ANN SURG, V188, P423, DOI 10.1097/00000658-197809000-00017; GUMP FE, 1975, J TRAUMA, V15, P704, DOI 10.1097/00005373-197508000-00013; GUYTON AC, 1981, TXB MED PHYSL, P720; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P19, DOI 10.1007/BF00735865; HASSETT J, 1983, WORLD J SURG, V7, P125, DOI 10.1007/BF01655920; KAMINSKI MV, 1977, JPEN, V1, P22; LAW DK, 1973, ANN INTERN MED, V79, P545, DOI 10.7326/0003-4819-79-4-545; LEVENSON SM, 1983, SURGICAL NUTRITION, P423; LINDSAY DB, 1980, P NUTR SOC, V39, P53, DOI 10.1079/PNS19800008; LONG CL, 1979, JPEN-PARENTER ENTER, V3, P69, DOI 10.1177/014860717900300269; LONG CL, 1981, METABOLISM, V30, P765, DOI 10.1016/0026-0495(81)90022-6; LONG CL, 1977, AM J CLIN NUTR, V30, P1349; LONG CL, 1971, J APPL PHYSIOL, V31, P110; LONG CL, 1983, NUTRITIONAL MANAGEME, P5; MCMENAMY RH, 1981, J TRAUMA, V21, P228, DOI 10.1097/00005373-198103000-00006; MEGUID MM, 1974, ARCH SURG-CHICAGO, V109, P776; MILLER SL, 1984, S AFR MED J, V65, P90; MULLEN JL, 1980, ANN SURG, V192, P604, DOI 10.1097/00000658-198019250-00004; MULLIN TJ, 1981, SURGERY, V90, P610; OWEN OE, 1973, J CLIN INVEST, V52, P2596, DOI 10.1172/JCI107452; PENTELENYI T, 1984, INJURY, V15, P397, DOI 10.1016/0020-1383(84)90205-5; POPP AJ, 1982, J SURG RES, V32, P416, DOI 10.1016/0022-4804(82)90121-4; POPP MB, 1983, SURGICAL NUTRITION, P479; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; SCHONHEYDER F, 1954, SCAND J CLIN LAB INV, V6, P178, DOI 10.3109/00365515409136355; Siegel J H, 1979, Adv Shock Res, V2, P177; SIEGEL JH, 1979, SURGERY, V86, P163; SPANIER AH, 1977, AM J SURG, V133, P99, DOI 10.1016/0002-9610(77)90201-X; SPANIER AH, 1976, SURG FORUM, V27, P332; STONER HB, 1979, CLIN SCI, V56, P563, DOI 10.1042/cs0560563; VINNARS E, 1979, ACTA CHIR SCAND    S, V494, P133; WATERS DC, 1984, SURG FORUM, V35, P482; WILMORE DW, 1980, ANN SURG, V192, P491, DOI 10.1097/00000658-198010000-00008; WILMORE DW, 1976, SURG CLIN N AM, V56, P999; WISE BL, 1984, J NEUROSURG, V61, P620	62	51	52	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	1986	64	1					89	98		10.3171/jns.1986.64.1.0089			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AWW31	WOS:A1986AWW3100014	3079825				2021-06-18	
J	LEVIN, HS; GROSSMAN, RG; SARWAR, M; MEYERS, CA				LEVIN, HS; GROSSMAN, RG; SARWAR, M; MEYERS, CA			LINGUISTIC RECOVERY AFTER CLOSED HEAD-INJURY	BRAIN AND LANGUAGE			English	Article										LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.						ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BARR AN, 1978, NEUROLOGY, V28, P1196, DOI 10.1212/WNL.28.11.1196; BARRON SA, 1976, NEUROLOGY, V26, P1011, DOI 10.1212/WNL.26.11.1011; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Benton AL, 1967, CORTEX, V3, P32, DOI [10.1016/S0010-9452(67)80005-4, DOI 10.1016/S0010-9452(67)80005-4]; Goodglass H., 1972, ASSESSMENT APHASIA R; Hecaen H., 1978, HUMAN NEUROPSYCHOLOG; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Heilman KM, 1979, CLIN NEUROPSYCHOLOGY, P159; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; NAJENSON T, 1978, SCAND J REHABIL MED, V10, P15; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; SPREEN O, 1969, MANUAL NEUROSENSORY; Strich S J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P166; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SYNEK V, 1976, BRIT J RADIOL, V49, P233, DOI 10.1259/0007-1285-49-579-233; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713	22	51	51	0	3	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0093-934X			BRAIN LANG	Brain Lang.		1981	12	2					360	374		10.1016/0093-934X(81)90025-0			15	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	LG902	WOS:A1981LG90200012	6163504				2021-06-18	
J	NOSEWORTHY, JH; MILLER, J; MURRAY, TJ; REGAN, D				NOSEWORTHY, JH; MILLER, J; MURRAY, TJ; REGAN, D			AUDITORY BRAIN-STEM RESPONSES IN POST-CONCUSSION SYNDROME	ARCHIVES OF NEUROLOGY			English	Article									DALHOUSIE UNIV,HALIFAX INFIRM,DEPT PHYSIOL,HALIFAX B35 1B6,NS,CANADA; DALHOUSIE UNIV,HALIFAX INFIRM,DEPT MED,HALIFAX B35 1B6,NS,CANADA; DALHOUSIE UNIV,HALIFAX INFIRM,DEPT BIOPHYS,HALIFAX B35 1B6,NS,CANADA							ACHOR LJ, 1980, ELECTROEN CLIN NEURO, V48, P174, DOI 10.1016/0013-4694(80)90302-8; ACHOR LJ, 1980, ELECTROEN CLIN NEURO, V48, P154, DOI 10.1016/0013-4694(80)90301-6; ALLEN AR, 1978, ELECTROEN CLIN NEURO, V45, P53, DOI 10.1016/0013-4694(78)90341-3; BUCHWALD JS, 1975, SCIENCE, V189, P382, DOI 10.1126/science.1145206; CHIAPPA KH, 1979, ARCH NEUROL-CHICAGO, V36, P81, DOI 10.1001/archneur.1979.00500380051005; CROMPTON MR, 1971, LANCET, V1, P669; CRONWALL DNA, 1974, LANCET, V2, P605; ERICHSEN JE, 1866, RAILWAY OTHER INJURI, P144; GOLDENBERG RA, 1975, J SPEECH HEAR RES, V18, P420, DOI 10.1044/jshr.1803.420; JENNETT B, 1975, BRIT MED J, V3, P267, DOI 10.1136/bmj.3.5978.267; JEWETT DL, 1970, ELECTROEN CLIN NEURO, V28, P609, DOI 10.1016/0013-4694(70)90203-8; KAY DWK, 1971, LANCET, V2, P1052; KHONOFF H, 1977, J NEUROL NEUROSURG P, V40, P1211; LeCount ER, 1920, J AMER MED ASSOC, V74, P501, DOI 10.1001/jama.1920.02620080003002; LEV A, 1972, ARCH KLIN EXP OHR, V201, P79, DOI 10.1007/BF00341066; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; MILLER, 1972, LANCET, V1, P580; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MILLER H, 1966, P R SOC MED, V69, P257; MODLIN HC, 1967, AM J PSYCHIAT, V123, P1008, DOI 10.1176/ajp.123.8.1008; NEVIN NC, THESIS BELFAST; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PAXSON CL, 1976, PEDIATRICS, V57, P893; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; REGLAR J, 1967, BRIT MED J, V3, P67; ROWE MJ, 1978, ELECTROEN CLIN NEURO, V44, P459, DOI 10.1016/0013-4694(78)90030-5; ROWE MJ, 1977, ELECTROEN CLIN NEURO, V43, P454; ROWE MJ, UNPUBLISHED; RUTHERFORD WH, 1977, LANCET, V1, P1; STARR A, 1976, ELECTROEN CLIN NEURO, V41, P595, DOI 10.1016/0013-4694(76)90005-5; STARR A, 1975, ARCH NEUROL-CHICAGO, V32, P761, DOI 10.1001/archneur.1975.00490530083009; STOCKARD JJ, 1978, AM J EEG TECHNOL, V27, P316; SYMONDS C, 1962, LANCET, V1, P1; TAYLOR AR, 1966, LANCET, V2, P178; TAYLOR AR, 1967, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5557.67; TOGLIA JU, 1976, NEUROLOGY, V26, P808, DOI 10.1212/WNL.26.9.808; Toglia JU, 1969, LATE EFFECTS HEAD IN, P72; VANWOERKOM TCAM, 1977, LANCET, V1, P812; ZETTERHOLM S, 1947, ACTA PSYCHIAT NEUR S, V45, P1; 1969, REPORT MED ASPECTS B	42	51	56	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.		1981	38	5					275	278		10.1001/archneur.1981.00510050041004			4	Clinical Neurology	Neurosciences & Neurology	LP323	WOS:A1981LP32300003	7224910				2021-06-18	
J	Pischiutta, F; Micotti, E; Hay, JR; Marongiu, I; Sammali, E; Tolomeo, D; Vegliante, G; Stocchetti, N; Forloni, G; De Simoni, MG; Stewart, W; Zanier, ER				Pischiutta, Francesca; Micotti, Edoardo; Hay, Jennifer R.; Marongiu, Ines; Sammali, Eliana; Tolomeo, Daniele; Vegliante, Gloria; Stocchetti, Nino; Forloni, Gianluigi; De Simoni, Maria-Grazia; Stewart, William; Zanier, Elisa R.			Single severe traumatic brain injury produces progressive pathology with ongoing contralateral white matter damage one year after injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Long-term outcome; Neurodegeneration; White matter damage; Neuroimaging; Inflammation	CONTROLLED CORTICAL IMPACT; MORRIS WATER MAZE; FOLLOW-UP; WALLERIAN DEGENERATION; RODENT MODELS; AXONAL INJURY; MOUSE MODEL; MICE BRAIN; ENCEPHALOPATHY; RECOVERY	There is increasing recognition that traumatic brain injury (TBI) may initiate long-term neurodegenerative processes, particularly chronic traumatic encephalopathy. However, insight into the mechanisms transforming an initial biomechanical injury into a neurodegenerative process remain elusive, partly as a consequence of the paucity of informative pre-clinical models. This study shows the functional, whole brain imaging and neuropathological consequences at up to one year survival from single severe TBI by controlled cortical impact in mice. TBI mice displayed persistent sensorimotor and cognitive deficits. Longitudinal T2 weighted magnetic resonance imaging (MRI) showed progressive ipsilateral (il) cortical, hippocampal and striatal volume loss, with diffusion tensor imaging demonstrating decreased fractional anisotropy (FA) at up to one year in the il-corpus callosum (CC: - 30%) and external capsule (EC: - 21%). Parallel neuropathological studies indicated reduction in neuronal density, with evidence of microgliosis and astrogliosis in the il-cortex, with further evidence of microgliosis and astrogliosis in the il-thalamus. One year after TBI there was also a decrease in FA in the contralateral (cl) CC (- 17%) and EC (- 13%), corresponding to histopathological evidence of white matter loss (cl-CC: 68%; cl-EC: 30%) associated with ongoing microgliosis and astrogliosis. These findings indicate that a single severe TBI induces bilateral, long-term and progressive neuropathology at up to one year after injury. These observations support this model as a suitable platform for exploring the mechanistic link between acute brain injury and late and persistent neurodegeneration.	[Pischiutta, Francesca; Micotti, Edoardo; Marongiu, Ines; Sammali, Eliana; Tolomeo, Daniele; Vegliante, Gloria; Forloni, Gianluigi; De Simoni, Maria-Grazia; Zanier, Elisa R.] Ist Ric Farmacol Mario Negri, IRCCS, Dept Neurosci, Milan, Italy; [Hay, Jennifer R.; Stewart, William] Univ Glasgow, Inst Neurosci & Psychol, Glasgow, Lanark, Scotland; [Hay, Jennifer R.; Stewart, William] Queen Elizabeth Univ Hosp, Dept Lab Med, Glasgow, Lanark, Scotland; [Sammali, Eliana] Fdn IRCCS Ist Neurol Carlo Besta, Dept Cerebrovasc Dis, Milan, Italy; [Stocchetti, Nino] Milan Univ, Dept Physiopathol & Transplantat, Milan, Italy; [Stocchetti, Nino] ICU Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy	Zanier, ER (corresponding author), Ist Ric Farmacol Mario Negri, IRCCS, Dept Neurosci, Lab Acute Brain Injury & Therapeut Strategies, Via Giuseppe La Masa 19, I-20156 Milan, Italy.	elisa.zanier@marionegri.it	Sammali, Eliana/AAA-2464-2019; Forloni, Gianluigi/AAB-2115-2020; Micotti, Edoardo/J-9359-2018; Zanier, Elisa/AAA-8095-2020; De Simoni, Maria Grazia/I-6021-2012; Pischiutta, Francesca/AAA-7927-2020	Forloni, Gianluigi/0000-0001-5374-3914; Micotti, Edoardo/0000-0002-5995-2992; De Simoni, Maria Grazia/0000-0001-6695-5297; Pischiutta, Francesca/0000-0002-7151-0812; Zanier, Elisa/0000-0002-3011-8718; Tolomeo, Daniele/0000-0002-5219-6397; Stewart, William/0000-0003-2199-2582	Ministero della SaluteMinistry of Health, Italy [RG86200]; ESICM Rita Levi Montalcini Award; IBRO/PERC InEurope Short Stay Funding Program; "Fondazione Umberto Veronesi" (FUV)Fondazione Umberto Veronesi; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038104, NS094003]; NHS Research Scotland Career Researcher Fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094003, R01NS038104] Funding Source: NIH RePORTER; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/R005036/1] Funding Source: researchfish	Partially supported by Ministero della Salute (within the framework of ERA-NET NEURON, RG86200), ESICM Rita Levi Montalcini Award to Elisa R. Zanier, and IBRO/PERC InEurope Short Stay Funding Program to Francesca Pischiutta. Francesca Pischiutta received a fellowship from "Fondazione Umberto Veronesi" (FUV, 2016). Dr. William Stewart is supported by NIH grants NS038104, NS094003 and by an NHS Research Scotland Career Researcher Fellowship.	Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brooks SP, 2009, NAT REV NEUROSCI, V10, P519, DOI 10.1038/nrn2652; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Buss A, 2003, GLIA, V42, P424, DOI 10.1002/glia.10220; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; De Blasio D, 2017, J CEREBR BLOOD F MET, V37, P938, DOI 10.1177/0271678X16647397; DEAN RL, 1981, EXP AGING RES, V7, P427, DOI 10.1080/03610738108259823; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Green REA, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00067; Griesbach Grace S, 2015, Handb Clin Neurol, V128, P681, DOI 10.1016/B978-0-444-63521-1.00042-X; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Harris NG, 2016, NEUROIMAGE, V133, P129, DOI 10.1016/j.neuroimage.2016.03.012; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McMillan TM, 2012, J NEUROL NEUROSUR PS, V83, P1086, DOI 10.1136/jnnp-2012-302746; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Naude PJW, 2014, BEHAV BRAIN RES, V258, P43, DOI 10.1016/j.bbr.2013.10.006; Okie S, 2016, NEW ENGL J MED, V375, P180, DOI 10.1056/NEJMms1604272; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Osier ND, 2015, J NEUROTRAUM, V32, P1861, DOI 10.1089/neu.2014.3680; PALMGREN AXEL, 1960, ACTA ZOOL [STOCKHOLM], V41, P239; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Perez AM, 2014, J NEUROTRAUM, V31, P1478, DOI 10.1089/neu.2013.3216; PerrotSinal TS, 1996, BEHAV NEUROSCI, V110, P1309, DOI 10.1037/0735-7044.110.6.1309; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pischiutta F, 2016, CRIT CARE MED, V44, pE1118, DOI 10.1097/CCM.0000000000001864; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Rigon A, 2016, J NEUROTRAUM, V33, P977, DOI 10.1089/neu.2014.3847; Robinson S, 2016, J NEUROSURG-PEDIATR, V17, P739, DOI 10.3171/2015.10.PEDS15554; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shelton SB, 2008, J NEUROSCI METH, V168, P431, DOI 10.1016/j.jneumeth.2007.11.003; Shinjo R, 2014, NEUROSCI LETT, V579, P80, DOI 10.1016/j.neulet.2014.07.018; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stewart W, 2016, QJM-INT J MED, V109, P11, DOI 10.1093/qjmed/hcv070; Stocchetti N, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1318-1; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Winston CN, 2016, AM J PATHOL, V186, P552, DOI 10.1016/j.ajpath.2015.11.006; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Zanier ER, 2016, J NEUROTRAUM, V33, P1060, DOI 10.1089/neu.2015.4041; Zanier Elisa R, 2015, Intensive Care Med Exp, V3, P39, DOI 10.1186/s40635-015-0039-0; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zanier ER, 2013, CNS NEUROSCI THER, V19, P695, DOI 10.1111/cns.12128; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zarruk JG, 2011, REV NEUROLOGIA, V53, P607, DOI 10.33588/rn.5310.2011016; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	72	50	50	1	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2018	300						167	178		10.1016/j.expneurol.2017.11.003			12	Neurosciences	Neurosciences & Neurology	FT1JZ	WOS:000422893300016	29126888	Green Accepted			2021-06-18	
J	Ding, MG; Ning, J; Feng, N; Li, ZY; Liu, ZH; Wang, YB; Wang, YM; Li, X; Huo, C; Jia, X; Xu, R; Fu, F; Wang, XM; Pei, JM				Ding, Mingge; Ning, Jiao; Feng, Na; Li, Zeyang; Liu, Zhenhua; Wang, Yuanbo; Wang, Yueming; Li, Xing; Huo, Cong; Jia, Xin; Xu, Rong; Fu, Feng; Wang, Xiaoming; Pei, Jianming			Dynamin-related protein 1-mediated mitochondrial fission contributes to post-traumatic cardiac dysfunction in rats and the protective effect of melatonin	JOURNAL OF PINEAL RESEARCH			English	Article						cardiac dysfunction; Drp1; mechanical trauma; melatonin; mitochondrial dynamics	ISCHEMIA-REPERFUSION INJURY; ACUTE MYOCARDIAL-INFARCTION; OXIDATIVE STRESS; BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; APOPTOSIS; HEART; FUSION; HEALTH; INFLAMMATION	Mechanical trauma (MT) causes myocardial injury and cardiac dysfunction. However, the underlying mechanism remains largely unclear. This study investigated the role of mitochondrial dynamics in post-traumatic cardiac dysfunction and the protective effects of melatonin. Adult male Sprague Dawley rats were subjected to 5-minute rotations (200 revolutions at a rate of 40rpm) to induce MT model. Melatonin was administrated intraperitoneally 5minute after MT. Mitochondrial morphology, myocardial injury, and cardiac function were determined in vivo. There was smaller size of mitochondria and increased number of mitochondria per m(2) in the hearts after MT when the secondary myocardial injury was induced. Melatonin treatment at the dose of 30mg/kg reduced serine 616 phosphorylation of Drp1 and inhibited mitochondrial Drp1 translocation and mitochondrial fission in the hearts of rats subjected to MT, which contributed to the reduction of myocardial injury and the improvement of cardiac function. In vitro, H9c2 cells cultured in 20% traumatic plasma (TP) for 12hour showed enhanced mitochondrial fission, mitochondrial membrane potential (m) loss, mitochondrial cytochrome c release, and decreased mitochondrial complex I-IV activities. Pretreatment with melatonin (100mol/L) efficiently inhibited TP-induced mitochondrial fission, m loss, cytochrome c release, and improved mitochondrial function. Melatonin's protective effects were attributed to its role in suppressing plasma TNF- overproduction, which was responsible for Drp1-mediated mitochondrial fission. Taken together, our results demonstrate for the first time that abnormal mitochondrial dynamics is involved in post-traumatic cardiac dysfunction. Melatonin has significant pharmacological potential in protecting against MT-induced cardiac dysfunction by preventing excessive mitochondrial fission.	[Ding, Mingge] Xi An Jiao Tong Univ, Dept Geriatr, Xian Cent Hosp, Xian, Shaanxi, Peoples R China; [Ding, Mingge; Ning, Jiao; Feng, Na; Li, Zeyang; Liu, Zhenhua; Wang, Yuanbo; Wang, Yueming; Fu, Feng; Pei, Jianming] Fourth Mil Med Univ, Dept Physiol, Xijing Hosp, Xian, Shaanxi, Peoples R China; [Ding, Mingge; Li, Xing; Huo, Cong; Jia, Xin; Xu, Rong; Wang, Xiaoming] Fourth Mil Med Univ, Dept Geriatr, Xijing Hosp, Xian, Shaanxi, Peoples R China	Wang, XM (corresponding author), Fourth Mil Med Univ, Dept Geriatr, Xijing Hosp, Xian, Shaanxi, Peoples R China.; Fu, F; Pei, JM (corresponding author), Fourth Mil Med Univ, Dept Physiol, Xian, Shaanxi, Peoples R China.	fufeng048@126.com; xmwang@fmmu.edu.cn; jmpei8@fmmu.edu.cn		Liu, Zhenhua/0000-0003-4228-2504; Ding, Mingge/0000-0002-6136-6394; Fu, Feng/0000-0003-3752-4628	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81600235, 81670354, 81770243, 81270169]; Natural Science Foundation of ShaanxiNatural Science Foundation of Shaanxi Province [2016KTCL03-11, 2016ZDJC-13]	National Natural Science Foundation of China, Grant/Award Number: 81600235, 81670354, 81770243 and 81270169; Key Project of Natural Science Foundation of Shaanxi, Grant/Award Number: 2016KTCL03-11, 2016ZDJC-13	Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Bock JS, 2012, CARDIOL CLIN, V30, P545, DOI 10.1016/j.ccl.2012.07.001; Chen JY, 2015, J PINEAL RES, V59, P469, DOI 10.1111/jpi.12278; Chen L, 2009, CARDIOVASC RES, V84, P91, DOI 10.1093/cvr/cvp181; Chuang JI, 2016, J PINEAL RES, V61, P230, DOI 10.1111/jpi.12343; Ding MG, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933-017-0501-2; Ding MG, 2017, AM J CHINESE MED, V45, P53, DOI 10.1142/S0192415X17500057; Dong YS, 2016, J PINEAL RES, V60, P253, DOI 10.1111/jpi.12300; El-Menyaru A, 2012, ANN CARD ANAESTH, V15, P287, DOI 10.4103/0971-9784.101875; Fu F, 2014, AM J CHINESE MED, V42, P95, DOI 10.1142/S0192415X14500062; Galano A, 2011, J PINEAL RES, V51, P1, DOI 10.1111/j.1600-079X.2011.00916.x; Garcia JJ, 2014, J PINEAL RES, V56, P225, DOI 10.1111/jpi.12128; He B, 2016, J PINEAL RES, V60, P313, DOI 10.1111/jpi.12312; Hu CX, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010144; Hu JQ, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12368; Ismailov RM, 2005, INT J CARDIOL, V105, P141, DOI 10.1016/j.ijcard.2004.11.025; Jing ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep30812; Li SH, 2007, AM J PHYSIOL-HEART C, V293, pH1847, DOI 10.1152/ajpheart.00578.2007; Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008; Liu Z, 2017, J PINEAL RES, V62; Ma S, 2017, SCI REP-UK, V7, DOI 10.1038/srep44623; Marcolini EG, 2015, EMERG MED CLIN N AM, V33, P519, DOI 10.1016/j.emc.2015.04.003; Marin-Garcia J, 2016, HEART FAIL REV, V21, P123, DOI 10.1007/s10741-016-9530-2; Mauriz JL, 2013, J PINEAL RES, V54, P1, DOI 10.1111/j.1600-079X.2012.01014.x; Meng G., 2017, BR J PHARM; Nan JL, 2017, BBA-MOL CELL RES, V1864, P1260, DOI 10.1016/j.bbamcr.2017.03.006; Ong SB, 2017, CARDIOVASC DRUG THER, V31, P87, DOI 10.1007/s10557-016-6710-1; Ong SB, 2013, ANTIOXID REDOX SIGN, V19, P400, DOI 10.1089/ars.2012.4777; Ong SB, 2010, CIRCULATION, V121, P2012, DOI 10.1161/CIRCULATIONAHA.109.906610; Pei HF, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12371; Poyet R, 2015, J Emerg Trauma Shock, V8, P110, DOI 10.4103/0974-2700.155513; Reiter RJ, 2016, J PINEAL RES, V61, P253, DOI 10.1111/jpi.12360; Rogers MA, 2017, CIRC RES, V121, P220, DOI 10.1161/CIRCRESAHA.116.310293; Simko F, 2014, J PINEAL RES, V57, P177, DOI 10.1111/jpi.12154; Tan DX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122124; Tao L, 2005, AM J PHYSIOL-HEART C, V288, pH2811, DOI 10.1152/ajpheart.01252.2004; Vasquez-Trincado C, 2016, J PHYSIOL-LONDON, V594, P509, DOI 10.1113/JP271301; Vasudevan AR, 2003, LANCET, V362, P370, DOI 10.1016/S0140-6736(03)14024-X; Wei TM, 2002, HEART VESSELS, V17, P77, DOI 10.1007/s003800200048; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Wu HJ, 2016, J PINEAL RES, V61, P241, DOI 10.1111/jpi.12344; Xu SC, 2016, J PINEAL RES, V60, P291, DOI 10.1111/jpi.12310; Yang Y, 2014, J PINEAL RES, V57, P357, DOI 10.1111/jpi.12175; Yoon Young Won, 2007, J Trauma, V63, pE73, DOI 10.1097/01.ta.0000246896.89156.70; Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855; Yu LM, 2014, J PINEAL RES, V57, P228, DOI 10.1111/jpi.12161; Zepeda R, 2014, J CARDIOVASC PHARM, V63, P477, DOI 10.1097/FJC.0000000000000071; Zhao L, 2015, J PINEAL RES, V59, P230, DOI 10.1111/jpi.12254; Zhao XM, 2016, J PINEAL RES, V60, P132, DOI 10.1111/jpi.12290; Zhao YC, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12378; Zhou H, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12413	51	50	51	1	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	JAN	2018	64	1							e12447	10.1111/jpi.12447			13	Endocrinology & Metabolism; Neurosciences; Physiology	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	FP8HZ	WOS:000417884900002	29024001				2021-06-18	
J	Kamdar, BB; Huang, M; Dinglas, VD; Colantuoni, E; von Wachter, TM; Hopkins, RO; Needham, DM				Kamdar, Biren B.; Huang, Minxuan; Dinglas, Victor D.; Colantuoni, Elizabeth; von Wachter, Till M.; Hopkins, Ramona O.; Needham, Dale M.		Natl Heart Lung Blood Inst Acute R	Joblessness and Lost Earnings after ARDS in a 1-Year National Multicenter Study Abstracts	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						employment; intensive care unit; income; health insurance	ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; CARE RESOURCE USE; ONE-YEAR OUTCOMES; INTENSIVE-CARE; CRITICAL ILLNESS; UNITED-STATES; FOLLOW-UP	Rationale: Following acute respiratory distress syndrome (ARDS), joblessness is common but poorly understood. Objectives: To evaluate the timing of return to work after ARDS, and associated risk factors, lost earnings, and changes in healthcare coverage Methods: Over 12-month longitudinal follow-up, ARDS survivors from 43 U.S. ARDSNet hospitals provided employment and healthcare coverage data via structured telephone interviews. Factors associated with the timing of return to work were assessed using Fine and Gray regression analysis. Lost earnings were estimated using Bureau of Labor Statistics data. Measurements and Main Results: Of 922 consenting survivors, 386 (42%) were employed before ARDS (56% male; mean +/- SD age, 45 +/- 13 yr), with seven dying by 12-month follow-up. Of 379 previously employed 12-month survivors, 166 (44%) were jobless at 12-month follow-up. Accounting for competing risks of death and retirement, half of enrolled and previously employed survivors returned to work by 13 weeks after hospital discharge, with 68% ever returning by 12 months. Delays in return to work were associated with longer hospitalization and older age among nonwhite survivors. Over 12-month follow-up, 274 (71%) survivors accrued lost earnings, averaging $26,9496 +/- 22,447 (60% of pre-ARDS annual earnings). Jobless survivors experienced a 14% (95% confidence interval, 5-22%; P = 0.002) absolute decrease in private health insurance (from 44% pre-ARDS) and a 16% (95% confidence interval, 7-24%; P < 0.001) absolute increase in Medicare and Medicaid (from 33%). Conclusions: At 12 months after ARDS, nearly one-half of previously employed survivors were jobless. Post-ARDS joblessness is associated with readily identifiable patient and hospital variables and accompanied by substantial lost earnings and a shift toward government-funded healthcare coverage.	[Kamdar, Biren B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; [Huang, Minxuan; Dinglas, Victor D.; Colantuoni, Elizabeth; Needham, Dale M.] Johns Hopkins Univ, Outcomes Crit Illness & Surg Grp, Baltimore, MD USA; [Huang, Minxuan; Dinglas, Victor D.; Needham, Dale M.] Johns Hopkins Univ, Div Pulm & Crit Care Med, 1830 East Monument St,5th Floor, Baltimore, MD 21205 USA; [Needham, Dale M.] Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD USA; [Colantuoni, Elizabeth] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [von Wachter, Till M.] Univ Calif Los Angeles, Dept Econ, Los Angeles, CA 90024 USA; [Hopkins, Ramona O.] Intermt Med Ctr, Dept Med, Pulm & Crit Care Div, Murray, UT USA; [Hopkins, Ramona O.] Intermt Med Ctr, Ctr Humanizing Crit Care, Murray, UT USA; [Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Hopkins, Ramona O.] Brigham Young Univ, Neurosci Ctr, Provo, UT 84602 USA	Needham, DM (corresponding author), Johns Hopkins Univ, Div Pulm & Crit Care Med, 1830 East Monument St,5th Floor, Baltimore, MD 21205 USA.	dale.needham@jhmi.edu	/AAV-9838-2020	/0000-0002-9245-6229; Hite, Robert Duncan/0000-0002-2625-8750; Dinglas, Victor/0000-0001-5238-2790; Lanspa, Michael/0000-0003-0968-4755; Colantuoni, Elizabeth/0000-0002-0091-9434	Career Development Award from UCLA Clinical and Translational Science Institute (National Institutes of Health-National Center for Advancing Translational Science UCLA) [UL1TR000124, UL1TR001881]; NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [N01HR56170, R01HL091760, 3R01HL091760-02S1]; ARDS Network trials [HHSN268200536165C, HHSN268200536176C, HHSN268200536179C]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P2CHD041022] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000124, UL1TR001881] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL091760, R01HL056170] Funding Source: NIH RePORTER	Supported by a Career Development Award from the UCLA Clinical and Translational Science Institute (National Institutes of Health-National Center for Advancing Translational Science UCLA UL1TR000124 and UL1TR001881, B.B.K.). NHLBI funded this follow-up study (N01HR56170, R01HL091760, and 3R01HL091760-02S1) and the ARDS Network trials (contracts HHSN268200536165C to HHSN268200536176C and HHSN268200536179C).	Adhikari NKJ, 2009, CHEST, V135, P678, DOI 10.1378/chest.08-0974; Babor TF., 2001, AUDIT ALCOHOL USE DI, V2nd; Bernard G., 1997, SEPSIS, V1, P43, DOI [10.1023/A:1009711301483, DOI 10.1023/A:1009711301483]; Cameron JI, 2016, NEW ENGL J MED, V374, P1831, DOI 10.1056/NEJMoa1511160; Chelluri L, 2002, CHEST, V121, P549; Coopersmith CM, 2012, CRIT CARE MED, V40, P1072, DOI 10.1097/CCM.0b013e31823c8d03; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Cuthbertson BH, 2005, ANAESTHESIA, V60, P332, DOI 10.1111/j.1365-2044.2004.04109.x; Desai SV, 2011, CRIT CARE MED, V39, P371, DOI 10.1097/CCM.0b013e3181fd66e5; Dobkin C. C, 2016, EC CONSEQUENCES HOSP; Dupont J, 2008, PRODUCTIVITY MEASURE; Fakhry SM, 1996, J TRAUMA, V41, P999, DOI 10.1097/00005373-199612000-00010; Fan E, 2014, CRIT CARE MED, V42, P849, DOI 10.1097/CCM.0000000000000040; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Geskus RB, 2011, BIOMETRICS, V67, P39, DOI 10.1111/j.1541-0420.2010.01420.x; GOLDSTEIN RL, 1986, CRIT CARE MED, V14, P783, DOI 10.1097/00003246-198609000-00005; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Huang MX, 2016, CRIT CARE MED, V44, P954, DOI 10.1097/CCM.0000000000001621; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC; McGee HM, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-9; MCHUGH LG, 1994, AM J RESP CRIT CARE, V150, P90, DOI 10.1164/ajrccm.150.1.8025779; MUNDT DJ, 1989, ARCH INTERN MED, V149, P68, DOI 10.1001/archinte.149.1.68; Myhren H, 2010, CRIT CARE MED, V38, P1554, DOI 10.1097/CCM.0b013e3181e2c8b1; Needham DM, 2014, AM J RESP CRIT CARE, V189, P1214, DOI 10.1164/rccm.201401-0158OC; Needham DM, 2013, AM J RESP CRIT CARE, V188, P567, DOI 10.1164/rccm.201304-0651OC; Norman BC, 2016, CRIT CARE MED, V44, P2003, DOI 10.1097/CCM.0000000000001849; PARNO JR, 1984, MED CARE, V22, P167, DOI 10.1097/00005650-198402000-00008; Radford K, 2013, BRAIN INJURY, V27, P507, DOI 10.3109/02699052.2013.766929; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Rice TW, 2011, JAMA-J AM MED ASSOC, V306, P1574, DOI 10.1001/jama.2011.1435; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Ruhl AP, 2017, CRIT CARE MED, V45, P196, DOI 10.1097/CCM.0000000000002088; Ruhl AP, 2015, ANN AM THORAC SOC, V12, P392, DOI 10.1513/AnnalsATS.201409-422OC; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Taylor TN, 1996, STROKE, V27, P1459, DOI 10.1161/01.STR.27.9.1459; Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520; Weinert CR, 1997, AM J RESP CRIT CARE, V156, P1120, DOI 10.1164/ajrccm.156.4.9611047	40	50	51	1	4	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 15	2017	196	8								10.1164/rccm.201611-2327OC			16	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	FJ8CG	WOS:000412988500003	28448162	Green Published			2021-06-18	
J	Schonenberg, M; Wiedemann, E; Schneidt, A; Scheeff, J; Logemann, A; Keune, PM; Hautzinger, M				Schoenenberg, Michael; Wiedemann, Eva; Schneidt, Alexander; Scheeff, Jonathan; Logemann, Alexander; Keune, Philipp M.; Hautzinger, Martin			Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in adults with attention-deficit hyperactivity disorder: a triple-blind, randomised, controlled trial	LANCET PSYCHIATRY			English	Article							DEFICIT/HYPERACTIVITY DISORDER; ADHD; CHILDREN; EEG; BRAIN	Background Many studies suggest that electroencephalographic (EEG) neurofeedback might be beneficial in the treatment of attention-deficit hyperactivity disorder (ADHD). However, numbers of well controlled studies are low and neurofeedback techniques are regarded as highly controversial. The present trial examined the efficacy (compared with sham neurofeedback) and efficiency (compared with meta-cognitive therapy) of a standard EEG neurofeedback protocol in adults with ADHD. Methods We did a concurrent, triple-blind, randomised, controlled trial using authorised deception in adults with ADHD from one centre (University of Tubingen) in Tubingen, Germany. Participants were eligible if they fulfilled the DSM-IV-TR criteria for ADHD, were aged between 18 years and 60 years, and had no or stable use of medication for at least 2 months with no intention to change. We excluded participants who had comorbid schizophrenia or schizoaffective disorder, bipolar disorder, borderline personality disorder, epilepsy, or traumatic brain injury; substance abuse or dependence; or current or planned other psychological treatment. Those eligible were randomly assigned to three groups: a neurofeedback group which received 30 verum theta-to-beta neurofeedback sessions over 15 weeks, a sham neurofeedback group which received 15 sham followed by 15 verum theta-to-beta neurofeedback sessions over 15 weeks, or a meta-cognitive group therapy group which received 12 sessions over 12 weeks. Participants were assigned equally to one of the three interventions through a computerised minimisation randomisation procedure stratified by sex, age, and baseline symptom severity of ADHD. Participants were masked as to whether they were receiving neurofeedback or sham neurofeedback, but those receiving metacognitive therapy were aware of their treatment. Clinical assessors (ie, those assessing outcomes) and research staff who did the neurofeedback training were masked to participants' randomisation status only for neurofeedback and sham neurofeedback. The primary outcome was symptom score on the Conners' adult ADHD rating scale, assessed before treatment, at midtreatment (after 8 weeks), after treatment (after 16 weeks), and 6 months later. All individuals with at least one observation after randomisation were included in the analyses. This trial is registered with ClinicalTrials.gov, number NCT01883765. Findings Between Feb 1, 2013, and Dec 1, 2015, 761 people were assessed for eligibility. 656 (86%) were excluded and 118 (15%) were eligible for participation in this study. Eligible participants were randomly assigned to neurofeedback (38 [32%]), sham neurofeedback (39 [33%]), or meta-cognitive therapy (41 [35%]). 37 (97%) individuals for neurofeedback, 38 (97%) for sham neurofeedback, and 38 (93%) for meta-cognitive therapy were included in analyses. Self-reported ADHD symptoms decreased substantially for all treatment groups (B=-2.58 [95% CI -3.48 to -1.68]; p< 0.0001) between pretreatment and the end of 6 month follow-up, independent of treatment condition (neurofeedback vs sham neurofeedback B=-0.89 [95% CI -2.14 to 0.37], p= 0.168; neurofeedback vs meta-cognitive therapy -0.30 [-1.55 to 0.95], p= 0.639). No treatment-related or trial-related serious adverse events were reported. Interpretation Our findings suggest that neurofeedback training is not superior to a sham condition or group psychotherapy. All three treatments were equivalently effective in reducing ADHD symptoms. This first randomised, sham-controlled trial did not show any specific effects of neurofeedback on ADHD symptoms in adults.	[Schoenenberg, Michael; Wiedemann, Eva; Schneidt, Alexander; Scheeff, Jonathan; Hautzinger, Martin] Univ Tubingen, Dept Clin Psychol & Psychotherapy, D-72076 Tubingen, Germany; [Logemann, Alexander] Eotvos Lorand Univ, Inst Psychol, Budapest, Hungary; [Keune, Philipp M.] Univ Bamberg, Dept Physiol Psychol, Bamberg, Germany; [Keune, Philipp M.] Klinikum Bayreuth, Dept Neurol, Bayreuth, Germany	Schonenberg, M (corresponding author), Univ Tubingen, Dept Clin Psychol & Psychotherapy, D-72076 Tubingen, Germany.	michael.schoenenberg@uni-tuebingen.de	Logemann, Herman NA/I-7443-2017; Keune, Philipp/AAZ-2837-2020; Logemann, Alexander/I-3702-2019	Logemann, Herman NA/0000-0002-4147-1269; Logemann, Alexander/0000-0002-4147-1269	German Research FoundationGerman Research Foundation (DFG)	German Research Foundation.	Arns M, 2014, BIOL PSYCHOL, V95, P108, DOI 10.1016/j.biopsycho.2013.11.013; Christiansen H, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00943; Conners C.K., 1999, CONNERS ADULT ADHD R; Cortese S, 2016, J AM ACAD CHILD PSY, V55, P444, DOI 10.1016/j.jaac.2016.03.007; Formann A., 2011, WIENER MATRIZEN TEST; Gevensleben H, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00846; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Haavik J, 2010, EXPERT REV NEUROTHER, V10, P1569, DOI 10.1586/ERN.10.149; Hautzinger M., 2006, BECK DEPRESSION INVE; Heyde G., 2000, INVENTORY COMPLEX AT; Hillard B, 2013, CLIN EEG NEUROSCI, V44, P193, DOI 10.1177/1550059412458262; KNYE M, 1996, CPT CONTINUOUS PERFO; Kratochvil CJ, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200207000-00008; Lansbergen MM, 2011, J NEURAL TRANSM, V118, P275, DOI 10.1007/s00702-010-0524-2; Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924-9338(97)83296-8; LEHRL S, 1989, MULTIPLE CHOICE VOCA; Logemann HNA, 2010, NEUROSCI LETT, V479, P49, DOI 10.1016/j.neulet.2010.05.026; Martin AL, 2010, PAIN, V149, P208, DOI 10.1016/j.pain.2009.12.004; Meisel V, 2013, BIOL PSYCHOL, V94, P12, DOI 10.1016/j.biopsycho.2013.04.015; Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942; Retz-Junginger P, 2002, NERVENARZT, V73, P830, DOI 10.1007/s00115-001-1215-x; Rosler M, 2008, HASE HOMBURG ADHD SC; Schotte CKW, 1998, PSYCHOL MED, V28, P1179, DOI 10.1017/S0033291798007041; Schuhfried G., 2000, WIENER TEST SYSTEM P; Schulz H, 2003, DIAGNOSTICA, V49, P83, DOI 10.1026//0012-1924.49.2.83; Sharma A, 2014, ANN PHARMACOTHER, V48, P209, DOI 10.1177/1060028013510699; Solanto MV, 2010, AM J PSYCHIAT, V167, P958, DOI 10.1176/appi.ajp.2009.09081123; Spielberger C, 1970, STAI MANUAL STATE TR; StorebO O J, 2015, COCHRANE DB SYST REV, pCD009885, DOI DOI 10.1002/14651858.CD009885; Thibault RT, 2016, CORTEX, V74, P247, DOI 10.1016/j.cortex.2015.10.024; van Dongen-Boomsma M, 2013, J CLIN PSYCHIAT, V74, P821, DOI 10.4088/JCP.12m08321; Wilens Timothy E, 2002, J Atten Disord, V5, P189; Zimmermann P, 2009, TEST ATTENTIONAL PER; Zuberer A, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00135	34	50	50	6	60	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2215-0374			LANCET PSYCHIAT	Lancet Psychiatry	SEP	2017	4	9					673	684		10.1016/S2215-0366(17)30291-2			12	Psychiatry	Psychiatry	FE7DW	WOS:000408368800027	28803030				2021-06-18	
J	Yang, WY; Huang, JD				Yang, Wuyang; Huang, Judy			Chronic Subdural Hematoma: Epidemiology and Natural History	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Chronic subdural hematoma; Epidemiology; Natural history; Pathogenesis	TRAUMATIC BRAIN-INJURY; PACHYMENINGITIS HEMORRHAGICA INTERNA; SPONTANEOUS RESOLUTION; SURGICAL-TREATMENT; NONSURGICAL TREATMENT; RISK-FACTORS; RECURRENCE; MANAGEMENT; ANTICOAGULATION; POPULATION	This article discusses the epidemiology and natural history of chronic subdural hematoma (CSDH), a common disease prevalent in the elderly population. The incidence of CSDH ranges from 1.72 to 20.6 per 100,000 persons per year. Risk factors include advancing age, male gender, and antiplatelet or anticoagulant use. Clinical progression is separated into 3 distinct periods, including the initial traumatic event, the latency period, and the clinical presentation period. The recurrence of CSDH and nonsurgical predictive factors are described in detail to provide a comprehensive understanding of the outcome of this disease.	[Yang, Wuyang; Huang, Judy] Johns Hopkins Univ, Sch Med, Dept Neurosurg, 1800 Orleans St,Zayed Tower,Suite 6115F, Baltimore, MD 21287 USA	Huang, JD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, 1800 Orleans St,Zayed Tower,Suite 6115F, Baltimore, MD 21287 USA.	jhuang24@jhmi.edu	BAJAJ, JITIN/N-6601-2016; Yang, Wuyang/G-6367-2016	BAJAJ, JITIN/0000-0002-1638-0015; Yang, Wuyang/0000-0001-5934-7795; Huang, Judy/0000-0002-0675-1935			Adhiyaman V, 2002, POSTGRAD MED J, V78, P71, DOI 10.1136/pmj.78.916.71; Almenawer SA, 2014, ANN SURG, V259, P449, DOI 10.1097/SLA.0000000000000255; Asghar M, 2002, J ROY SOC MED, V95, P290, DOI 10.1258/jrsm.95.6.290; Aspegren OP, 2013, CLIN NEUROL NEUROSUR, V115, P981, DOI 10.1016/j.clineuro.2012.10.008; Baechli H, 2004, NEUROSURG REV, V27, P263, DOI 10.1007/s10143-004-0337-6; Balser D, 2015, J NEUROSURG, V123, P1209, DOI 10.3171/2014.9.JNS141550; BENDER MB, 1974, ARCH NEUROL-CHICAGO, V31, P73, DOI 10.1001/archneur.1974.00490380021001; CAMERON MM, 1978, J NEUROL NEUROSUR PS, V41, P834, DOI 10.1136/jnnp.41.9.834; Chen JCT, 2000, NEUROSURG CLIN N AM, V11, P399, DOI 10.1016/S1042-3680(18)30101-3; Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y; FARHAT NETO JAMIL, 2015, Rev. Col. Bras. Cir., V42, P283, DOI 10.1590/0100-69912015005003; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; FOGELHOLM R, 1975, ACTA NEUROCHIR, V32, P247, DOI 10.1007/BF01405457; Gardner JW, 1932, ARCH NEUROL PSYCHIAT, V1932, P847; Gelabert-Gonzalez M, 2005, CLIN NEUROL NEUROSUR, V107, P223, DOI 10.1016/j.clineuro.2004.09.015; Gonugunta V, 2001, BRIT J NEUROSURG, V15, P514, DOI 10.1080/02688690120097822; Guha D, 2016, J NEUROSURG, V124, P750, DOI 10.3171/2015.2.JNS141889; Holmes WH, 1928, ARCH NEURO PSYCHIATR, V20, P162, DOI 10.1001/archneurpsyc.1928.02210130165011; Horikoshi T, 1998, NEUROL MED-CHIR, V38, P527, DOI 10.2176/nmc.38.527; Iliescu I A, 2015, J Med Life, V8 Spec Issue, P26; Ivamoto HS, 2016, WORLD NEUROSURG, V86, P399, DOI 10.1016/j.wneu.2015.10.025; Kageyama H, 2013, J NEUROSURG, V119, P332, DOI 10.3171/2013.3.JNS122162; Karibe Hiroshi, 2011, No Shinkei Geka, V39, P1149; Kim Junhak, 2015, Korean J Neurotrauma, V11, P63, DOI 10.13004/kjnt.2015.11.2.63; Kolias AG, 2014, NAT REV NEUROL, V10, P570, DOI 10.1038/nrneurol.2014.163; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; KOTWICA Z, 1987, ACTA NEUROCHIR, V85, P44, DOI 10.1007/BF01402369; KUDO H, 1992, Neurologia Medico-Chirurgica, V32, P207, DOI 10.2176/nmc.32.207; Lee KS, 1998, BRAIN INJURY, V12, P901; Lee KS, 2004, BRAIN INJURY, V18, P351, DOI 10.1080/02699050310001645801; Lee Kyeong-Seok, 2015, Korean J Neurotrauma, V11, P27, DOI 10.13004/kjnt.2015.11.2.27; Liliang PC, 2002, INJURY, V33, P345, DOI 10.1016/S0020-1383(02)00020-7; Liu WM, 2014, J NEUROSURG, V121, P665, DOI 10.3171/2014.5.JNS132715; MARKWALDER TM, 1981, J NEUROSURG, V54, P637, DOI 10.3171/jns.1981.54.5.0637; Maurice-Williams RS, 1999, BRIT J NEUROSURG, V13, P547, DOI 10.1080/02688699943033; Mellergard P, 1996, ACTA NEUROCHIR, V138, P708, DOI 10.1007/BF01411476; Miranda LB, 2011, J NEUROSURG, V114, P72, DOI 10.3171/2010.8.JNS10298; Mori K, 2001, NEUROL MED-CHIR, V41, P371, DOI 10.2176/nmc.41.371; NAGANUMA H, 1986, NEUROSURGERY, V19, P794, DOI 10.1227/00006123-198611000-00013; Nakaguchi H, 2001, J NEUROSURG, V95, P256, DOI 10.3171/jns.2001.95.2.0256; Parlato C, 2000, SURG NEUROL, V53, P312, DOI 10.1016/S0090-3019(00)00200-7; Putnam TJ, 1925, ARCH SURG-CHICAGO, V11, P329, DOI 10.1001/archsurg.1925.01120150002001; Rust T, 2006, J CLIN NEUROSCI, V13, P823, DOI 10.1016/j.jocn.2004.12.013; Sambasivan M, 1997, SURG NEUROL, V47, P418, DOI 10.1016/S0090-3019(97)00188-2; Santarius Thomas, 2010, Clin Neurosurg, V57, P112; SARTI C, 1991, STROKE, V22, P848, DOI 10.1161/01.STR.22.7.848; Scholten AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110905; Schwartz AB, 1916, AM J DIS CHILD, V11, P23; SUZUKI J, 1970, J NEUROSURG, V33, P548, DOI 10.3171/jns.1970.33.5.0548; Tanaka Yoji, 2013, J Med Dent Sci, V60, P55; Torihashi K, 2008, NEUROSURGERY, V63, P1125, DOI 10.1227/01.NEU.0000335782.60059.17; Trotter W, 1914, BRIT J SURG, V2, P271, DOI 10.1002/bjs.1800020608; Ventsel G, 2008, NEUROEPIDEMIOLOGY, V30, P20, DOI 10.1159/000113302; Virchow R., 1857, VERH PHYS MED GES WU, V7, P134; Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937; WEIR B, 1980, J NEUROSURG, V53, P512, DOI 10.3171/jns.1980.53.4.0512; WEIR B, 1971, J NEUROSURG, V34, P528, DOI 10.3171/jns.1971.34.4.0528; Zollinger R, 1934, J AMER MED ASSOC, V103, P0245, DOI 10.1001/jama.1934.02750300019008	58	50	53	1	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	APR	2017	28	2					205	+		10.1016/j.nec.2016.11.002			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	ES1AJ	WOS:000399260000003	28325454				2021-06-18	
J	Amico, E; Marinazzo, D; Di Perri, C; Heine, L; Annen, J; Martial, C; Dzemidzic, M; Kirsch, M; Bonhomme, V; Laureys, S; Goni, J				Amico, Enrico; Marinazzo, Daniele; Di Perri, Carol; Heine, Lizette; Annen, Jitka; Martial, Charlotte; Dzemidzic, Mario; Kirsch, Murielle; Bonhomme, Vincent; Laureys, Steven; Goni, Joaquin			Mapping the functional connectome traits of levels of consciousness	NEUROIMAGE			English	Article						fMRI; Brain connectivity; Network science; Consciousness	TRAUMATIC BRAIN-INJURY; HUMAN CEREBRAL-CORTEX; COMA RECOVERY SCALE; RESTING-STATE; NETWORK CONNECTIVITY; DEFAULT NETWORK; DISORDERS; RECOMMENDATIONS; SYSTEM	Examining task-free functional connectivity (FC) in the human brain offers insights on how spontaneous integration and segregation of information relate to human cognition, and how this organization may be altered in different conditions, and neurological disorders. This is particularly relevant for patients in disorders of consciousness (DOC) following severe acquired brain damage and coma, one of the most devastating conditions in modern medical care. We present a novel data-driven methodology, connfCA, which implements Independent Component Analysis (ICA) for the extraction of robust independent FC patterns (FC-traits) from a set of individual functional connectomes, without imposing any a priori data stratification into groups. We here apply connlCA to investigate associations between network traits derived from task-free FC and cognitive/clinical features that define levels of consciousness. Three main independent FC-traits were identified and linked to consciousness-related clinical features. The first one represents the functional configuration of a "resting" human brain, and it is associated to a sedative (sevoflurane), the overall effect of the pathology and the level of arousal. The second FC-trait reflects the disconnection of the visual and sensory-motor connectivity patterns. It also relates to the time since the insult and to the ability of communicating with the external environment. The third FC-trait isolates the connectivity pattern encompassing the fronto-parietal and the default-mode network areas as well as the interaction between left and right hemispheres, which are also associated to the awareness of the self and its surroundings. Each FC-trait represents a distinct functional process with a role in the degradation of conscious states of functional brain networks, shedding further light on the functional sub-circuits that get disrupted in severe brain-damage.	[Amico, Enrico; Di Perri, Carol; Heine, Lizette; Annen, Jitka; Martial, Charlotte; Laureys, Steven] Univ Liege, GIGA Res Ctr, Coma Sci Grp, Liege, Belgium; [Amico, Enrico; Marinazzo, Daniele] Univ Ghent, Dept Data Anal, B-9000 Ghent, Belgium; [Di Perri, Carol; Heine, Lizette; Annen, Jitka; Martial, Charlotte; Kirsch, Murielle; Bonhomme, Vincent; Laureys, Steven] Univ Hosp Liege, Liege, Belgium; [Dzemidzic, Mario] Indiana Univ Sch Med, Dept Neurol & Radiol & Imaging Sci, Indianapolis, IN 46202 USA; [Goni, Joaquin] Purdue Univ, Sch Ind Engn, W Lafayette, IN 47907 USA; [Goni, Joaquin] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Goni, Joaquin] Purdue Univ, Purdue Inst Integrat Neurosci, W Lafayette, IN 47907 USA	Goni, J (corresponding author), Purdue Univ, Sch Ind Engn, W Lafayette, IN 47907 USA.	steven.laureys@ulg.ac.be; jgonicor@purdue.edu	Annen, Jitka/ABH-5297-2020; Amico, Enrico/AAB-2581-2019; Martial, Charlotte/O-6703-2016; Bonhomme, Vincent/J-7144-2019; Laureys, Steven/AAN-2097-2021; Marinazzo, Daniele/H-4793-2019; Laureys, Steven/A-3349-2011	Annen, Jitka/0000-0002-7459-4345; Amico, Enrico/0000-0001-6705-9689; Martial, Charlotte/0000-0001-6291-3460; Bonhomme, Vincent/0000-0001-6356-547X; Laureys, Steven/0000-0002-3096-3807; Marinazzo, Daniele/0000-0002-9803-0122; Heine, Lizette/0000-0003-1369-8199; Di Perri, Carol/0000-0003-0284-770X	Belgian Funds for Scientific Research (FRS)Fonds de la Recherche Scientifique - FNRS; European CommissionEuropean CommissionEuropean Commission Joint Research Centre; James McDonnell Foundation; European Space AgencyEuropean Space AgencyEuropean Commission; Belgian Science Policy (CEREBNET, BELSPO); Wallonia-Brussels Federation Concerted Research Action; Mind Science Foundation; Public Utility Foundation "Universite Europeenne du Travail"; "Fondazione Europea di Ricerca Biomedica", University; University Hospital of Liege; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01 MI-1108467-01]	We thank Marie-Aurelie Bruno, Athena Demertzi and Audrey Vanhaudenhuyse for help in acquiring the data. We thank Prof. Jaroslaw Harezlak and Prof. Thomas Talavage for useful comments. This research was supported by the This research was supported by the Belgian Funds for Scientific Research (FRS), European Commission, James McDonnell Foundation, European Space Agency, Belgian Science Policy (CEREBNET, BELSPO), Wallonia-Brussels Federation Concerted Research Action, Mind Science Foundation, Public Utility Foundation "Universite Europeenne du Travail" and "Fondazione Europea di Ricerca Biomedica", University and University Hospital of Liege. LH is a research fellow and SL a research director at FNRS. JG was supported by the National Institute of Health (1R01 MI-1108467-01).	Achard S, 2012, P NATL ACAD SCI USA, V109, P20608, DOI 10.1073/pnas.1208933109; Amico E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100012; Bernat JL, 2009, ANNU REV MED, V60, P381, DOI 10.1146/annurev.med.60.060107.091250; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Boly M, 2012, BRAIN CONNECT, V2, P1, DOI 10.1089/brain.2011.0049; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Calhoun VD, 2009, NEUROIMAGE, V45, pS163, DOI 10.1016/j.neuroimage.2008.10.057; Coupe P, 2012, IET IMAGE PROCESS, V6, P558, DOI 10.1049/iet-ipr.2011.0161; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; Crone J. S., 2016, CEREB CORTEX; Crone JS, 2014, NEUROIMAGE-CLIN, V4, P240, DOI 10.1016/j.nicl.2013.12.005; Dehaene S, 2011, NEURON, V70, P200, DOI 10.1016/j.neuron.2011.03.018; Demertzi A, 2015, BRAIN, V138, P2619, DOI 10.1093/brain/awv169; Demertzi A, 2014, CORTEX, V52, P35, DOI 10.1016/j.cortex.2013.11.005; Deshpande G, 2010, BRAIN RES, V1318, P110, DOI 10.1016/j.brainres.2009.12.075; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Di Perri C, 2014, EPILEPSY BEHAV, V30, P28, DOI 10.1016/j.yebeh.2013.09.014; DisPerri C, 2016, LANCET NEUROL; Erhardt EB, 2011, HUM BRAIN MAPP, V32, P2075, DOI 10.1002/hbm.21170; Fernandez-Espejo D, 2012, ANN NEUROL, V72, P335, DOI 10.1002/ana.23635; Fiset P, 2005, PROG BRAIN RES, V150, P245, DOI 10.1016/S0079-6123(05)50018-9; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Gazzaniga MS, 2014, P NATL ACAD SCI USA, V111, P18093, DOI 10.1073/pnas.1417892111; Gazzaniga MS, 2005, NAT REV NEUROSCI, V6, P653, DOI 10.1038/nrn1723; Giacino J., 2006, BRAIN INJURY, P36; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Gomez S, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.016114; Gordon EM, 2016, CEREB CORTEX, V26, P288, DOI 10.1093/cercor/bhu239; Greicius M, 2008, CURR OPIN NEUROL, V21, P424, DOI 10.1097/WCO.0b013e328306f2c5; Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060; Guldenmund P, 2013, BRAIN CONNECT, V3, P273, DOI 10.1089/brain.2012.0117; Heine L, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00295; Hudetz AG, 2012, BRAIN CONNECT, V2, P291, DOI 10.1089/brain.2012.0107; Hyvarinen A, 1999, IEEE T NEURAL NETWOR, V10, P626, DOI 10.1109/72.761722; Iraji A., 2016, NEUROIMAGE; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Koch C, 2016, NAT REV NEUROSCI, V17, P307, DOI 10.1038/nrn.2016.22; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lancichinetti A, 2012, SCI REP-UK, V2, DOI 10.1038/srep00336; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Marinsek N, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00839; Misic B., 2016, CEREB CORTEX; Monti MM, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003271; Mucha PJ, 2010, SCIENCE, V328, P876, DOI 10.1126/science.1184819; Newman MEJ, 2004, PHYS REV E, V69, DOI [10.1103/PhysRevE.69.026113, 10.1103/PhysRevE.69.066133]; Owen AM, 2009, PROG BRAIN RES, V177, P399, DOI 10.1016/S0079-6123(09)17728-2; Palanca BA, 2015, ANESTHESIOLOGY, V123, P346, DOI 10.1097/ALN.0000000000000731; Peltier SJ, 2005, NEUROREPORT, V16, P285, DOI 10.1097/00001756-200502280-00017; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Ranft A, 2016, ANESTHESIOLOGY, V125, P861, DOI 10.1097/ALN.0000000000001322; Samann P. G., 2011, CEREB CORTEX; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Shen X, 2013, NEUROIMAGE, V82, P403, DOI 10.1016/j.neuroimage.2013.05.081; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smyser CD, 2011, NEUROIMAGE, V56, P1437, DOI 10.1016/j.neuroimage.2011.02.073; Soddu A, 2012, HUM BRAIN MAPP, V33, P778, DOI 10.1002/hbm.21249; Sporns O., 2011, NETWORKS BRAIN; Stamatakis EA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014224; Tagliazucchi E, 2012, NEUROIMAGE, V63, P63, DOI 10.1016/j.neuroimage.2012.06.036; Traag VA, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.036115; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011; Zalesky A., 2016, FUNDAMENTALS BRAIN N	76	50	51	4	26	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	MAR 1	2017	148						201	211		10.1016/j.neuroimage.2017.01.020			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EO6LD	WOS:000396803100020	28093358	Green Published			2021-06-18	
J	Wooten, DW; Guehl, NJ; Verwer, EE; Shoup, TM; Yokell, DL; Zubcevik, N; Vasdev, N; Zafonte, RD; Johnson, KA; El Fakhri, G; Normandin, MD				Wooten, Dustin W.; Guehl, Nicolas J.; Verwer, Eline E.; Shoup, Timothy M.; Yokell, Daniel L.; Zubcevik, Nevena; Vasdev, Neil; Zafonte, Ross D.; Johnson, Keith A.; El Fakhri, Georges; Normandin, Marc D.			Pharmacokinetic Evaluation of the Tau PET Radiotracer F-18-T807 (F-18-AV-1451) in Human Subjects	JOURNAL OF NUCLEAR MEDICINE			English	Article						tau; PET; F-18-T807; pharmacokinetics; kinetic modeling	POSITRON-EMISSION-TOMOGRAPHY; CHRONIC TRAUMATIC ENCEPHALOPATHY; ALZHEIMERS-DISEASE; NEUROFIBRILLARY PATHOLOGY; GRAPHICAL ANALYSIS; RADIOLIGAND; BINDING; TRACER; BRAIN; RADIOSYNTHESIS	F-18-T807 is a PET radiotracer developed for imaging tau protein aggregates, which are implicated in neurologic disorders including Alzheimer disease and traumatic brain injury (TBI). The current study characterizes F-18-T807 pharmacokinetics in human subjects using dynamic PET imaging and metabolite-corrected arterial input functions. Methods: Nine subjects (4 controls, 3 with a history of TBI, 2 with mild cognitive impairment due to suspected Alzheimer disease) underwent dynamic PET imaging for up to 120 min after bolus injection of F-18-T807 with arterial blood sampling. Total volume of distribution (V-T) was estimated using compartmental modeling (1- and 2-tissue configurations) and graphical analysis techniques (Logan and multilinear analysis 1 [MA1] regression methods). Reference region-based methods of quantification were explored including Logan distribution volume ratio (DVR) and static SUV ratio (SUVR) using the cerebellum as a reference tissue. Results: The percentage of unmetabolized F-18-T807 in plasma followed a single exponential with a half-life of 17.0 +/- 4.2 min. Metabolite-corrected plasma radioactivity concentration fit a biexponential (half-lives, 18.1 +/- 5.8 and 2.4 +/- 0.5 min). F-18-T807 in gray matter peaked quickly (SUV > 2 at similar to 5 min). Compartmental modeling resulted in good fits, and the 2-tissue model with estimated blood volume correction (2Tv) performed best, particularly in regions with elevated binding. V-T was greater in mild cognitive impairment subjects than controls in the occipital, parietal, and temporal cortices as well as the posterior cingulate gyrus, precuneus, and mesial temporal cortex. High focal uptake was found in the posterior corpus callosum of a TBI subject. Plots from Logan and MA1 graphical methods became linear by 30 min, yielding regional estimates of V-T in excellent agreement with compartmental analysis and providing high-quality parametric maps when applied in voxelwise fashion. Reference region-based approaches including Logan DVR (t* 5 55 min) and SUVR (80-to 100-min interval) were highly correlated with DVR estimated using 2Tv (R-2 - 0.97, P < 0.0001). Conclusion: F-18-T807 showed rapid clearance from plasma and properties suitable for tau quantification with PET. Furthermore, simplified approaches using DVR (t* 5 55 min) and static SUVR (80-100 min) with cerebellar reference tissue were found to correlate highly with compartmental modeling outcomes.	[Wooten, Dustin W.; Guehl, Nicolas J.; Verwer, Eline E.; Shoup, Timothy M.; Yokell, Daniel L.; Vasdev, Neil; El Fakhri, Georges; Normandin, Marc D.] Massachusetts Gen Hosp, Gordon Ctr Med Imaging, Harvard Med Sch, Boston, MA USA; [Wooten, Dustin W.; Guehl, Nicolas J.; Verwer, Eline E.; Shoup, Timothy M.; Yokell, Daniel L.; Vasdev, Neil; Johnson, Keith A.; El Fakhri, Georges; Normandin, Marc D.] Massachusetts Gen Hosp, Harvard Med Sch, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA USA; [Zubcevik, Nevena; Zafonte, Ross D.] Massachusetts Gen Hosp, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Zafonte, Ross D.] Brigham & Womens Hosp, Harvard Med Sch, Boston, MA USA	Normandin, MD (corresponding author), Massachusetts Gen Hosp, 55 Fruit St,White 427, Boston, MA 02114 USA.	normandin@mgh.harvard.edu	Normandin, Marc/C-6728-2015	Normandin, Marc/0000-0003-1645-523X	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01 AG036694, P50 AG005134] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG036694, P50AG005134] Funding Source: NIH RePORTER		Agdeppa ED, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0004.2001; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Alpert NM, 1996, NEUROIMAGE, V3, P10, DOI 10.1006/nimg.1996.0002; Ariza M, 2015, J MED CHEM, V58, P4365, DOI 10.1021/jm5017544; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRANTZAWADZKI M, 1992, RADIOLOGY, V182, P769, DOI 10.1148/radiology.182.3.1535892; Burnham K. P., 2002, MODEL SELECTION INFE; CARSON RE, 1993, J CEREBR BLOOD F MET, V13, P24, DOI 10.1038/jcbfm.1993.6; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Collier T., 2013, J NUCL MED, V54, P1133; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Grabner G, 2006, LECT NOTES COMPUT SC, V4191, P58; Harada R, 2016, J NUCL MED, V57, P208, DOI 10.2967/jnumed.115.164848; Hashimoto H, 2014, J NUCL MED, V55, P1532, DOI 10.2967/jnumed.114.139550; Hilton J, 2000, NUCL MED BIOL, V27, P627, DOI 10.1016/S0969-8051(00)00125-6; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Ichise M, 2002, J CEREBR BLOOD F MET, V22, P1271; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Iqbal K, 2010, CURR ALZHEIMER RES, V7, P656, DOI 10.2174/156720510793611592; James OG, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00038; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johnson KA, 2016, ANN NEUROL, V79, P110, DOI 10.1002/ana.24546; Kimura Y, 2015, J NUCL MED, V56, P1359, DOI 10.2967/jnumed.115.160127; LOGAN J, 1990, J CEREBR BLOOD F MET, V10, P740, DOI 10.1038/jcbfm.1990.127; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Marquie M, 2015, ANN NEUROL, V78, P787, DOI 10.1002/ana.24517; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Okamura N, 2014, BRAIN, V137, P1762, DOI 10.1093/brain/awu064; Shcherbinin S, 2016, J NUCL MED, V57, P1535, DOI 10.2967/jnumed.115.170027; Shoup TM, 2013, J LABELLED COMPD RAD, V56, P736, DOI 10.1002/jlcr.3098; Slifstein M, 2008, J NUCL MED, V49, P176, DOI 10.2967/jnumed.107.046631; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008; Zhang W, 2012, J ALZHEIMERS DIS, V31, P601, DOI 10.3233/JAD-2012-120712	35	50	50	0	15	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	MAR 1	2017	58	3					484	491		10.2967/jnumed.115.170910			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	EN1AN	WOS:000395742700024	27660144	Green Accepted, Green Published, Bronze			2021-06-18	
J	Finley, JW; Gao, S				Finley, John W.; Gao, Song			A Perspective on Crocus sativus L. (Saffron) Constituent Crocin: A Potent Water-Soluble Antioxidant and Potential Therapy for Alzheimer's Disease	JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY			English	Article						Alzheimer's disease; crocin; crocetin; saffron; Crocus sativus	LONG-TERM POTENTIATION; ISCHEMIA-REPERFUSION INJURY; ETHANOL-INDUCED IMPAIRMENT; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; ACTIVE CONSTITUENTS; CEREBRAL-ISCHEMIA; SAFETY EVALUATION; EXTRACT PREVENTS	Alzheimer's disease (AD) is the most common form of dementia, in which the death of brain cells causes memory loss and cognitive decline. Several factors are thought to play roles in the development and course of AD. Existing medical therapies only modestly alleviate and delay cognitive symptoms. Current research has been focused on developing antibodies to remove the aggregates of amyloid-beta (A beta) and tau protein. This approach has achieved removal of A beta; however, no cognitive improvement in AD patients has been reported. The biological properties of saffron, the dry stigma of the plant Crocus sativus L., and particularly its main constituent crocin, have been studied extensively for many conditions including dementia and traumatic brain injury. Crocin is a unique antioxidant because it is a water-soluble carotenoid. Crocin has shown potential to improve learning and memory as well as protect brain cells. A search of the studies on saffron and crocin that have been published in recent years for their impact on AD as well as crocin's effects on A beta and tau protein has been conducted. This review demonstrates that crocin exhibits multifunctional protective activities in the brain and could be a promising agent applied as a supplement or drug for prevention or treatment of AD.	[Finley, John W.] Louisiana State Univ, Dept Nutr & Food Sci, 111 Food Sci Bldg, Baton Rouge, LA 70803 USA; [Finley, John W.] 14719 Secret Harbor Pl, Bradenton, FL 34202 USA; [Gao, Song] Qual Phytochem LLC, 13 Dexter Rd, East Brunswick, NJ 08816 USA	Finley, JW (corresponding author), Louisiana State Univ, Dept Nutr & Food Sci, 111 Food Sci Bldg, Baton Rouge, LA 70803 USA.; Finley, JW (corresponding author), 14719 Secret Harbor Pl, Bradenton, FL 34202 USA.	jfinle5@lsu.edu					ABDULLAEV FI, 1993, BIOFACTORS, V4, P83; Abdullaev FI, 2002, EXP BIOL MED, V227, P20; Abe K, 2000, PHYTOTHER RES, V14, P149, DOI 10.1002/(SICI)1099-1573(200005)14:3&lt;149::AID-PTR665&gt;3.0.CO;2-5; Abe K, 1998, BRAIN RES, V787, P132, DOI 10.1016/S0006-8993(97)01505-9; Abe K, 1999, BRAIN RES, V851, P287, DOI 10.1016/S0006-8993(99)02174-5; Ahn JH, 2011, BIOCHEM BIOPH RES CO, V414, P79, DOI 10.1016/j.bbrc.2011.09.025; Akhondzadeh S, 2010, J CLIN PHARM THER, V35, P581, DOI 10.1111/j.1365-2710.2009.01133.x; Akhondzadeh S, 2010, PSYCHOPHARMACOLOGY, V207, P637, DOI 10.1007/s00213-009-1706-1; Alavizadeh SH, 2014, FOOD CHEM TOXICOL, V64, P65, DOI 10.1016/j.fct.2013.11.016; Alonso GL, 2001, J FOOD QUALITY, V24, P219, DOI 10.1111/j.1745-4557.2001.tb00604.x; Alonso GL, 1999, P 1 INT C PFT PIGM F, P341; Asadi F, 2015, PHARMACOL BIOCHEM BE, V139, P47, DOI 10.1016/j.pbb.2015.10.011; Asai A, 2005, J AGR FOOD CHEM, V53, P7302, DOI 10.1021/jf0509355; Asdaq SMB, 2010, APPL BIOCHEM BIOTECH, V162, P358, DOI 10.1007/s12010-009-8740-7; Ayatollahi H, 2014, PHYTOTHER RES, V28, P539, DOI 10.1002/ptr.5021; Bandegi AR, 2014, ADV PHARM BULL, V4, P493, DOI 10.5681/apb.2014.073; BASKER D, 1983, ECON BOT, V37, P228, DOI 10.1007/BF02858789; Bathaie SZ, 2010, CRIT REV FOOD SCI, V50, P761, DOI 10.1080/10408390902773003; Bhargava V., 2011, INT J PHARM PHARM SC, V3, P22; Bie XD, 2011, FITOTERAPIA, V82, P997, DOI 10.1016/j.fitote.2011.06.001; Bolhassani A, 2014, BBA-REV CANCER, V1845, P20, DOI 10.1016/j.bbcan.2013.11.001; Caballero-Ortega H., 2004, J FOOD QUALITY, V24, P219; Caballero-Ortega H, 2007, FOOD CHEM, V100, P1126, DOI 10.1016/j.foodchem.2005.11.020; Chryssanthi DG, 2011, J PHARMACEUT BIOMED, V55, P563, DOI 10.1016/j.jpba.2011.02.018; Dashti-R MH, 2012, EXCLI J, V11, P328; Deslauriers AM, 2011, J IMMUNOL, V187, P4788, DOI 10.4049/jimmunol.1004111; DHINGRA VK, 1975, INDIAN J CHEM, V13, P339; El-Beshbishy HA, 2012, ECOTOX ENVIRON SAFE, V83, P47, DOI 10.1016/j.ecoenv.2012.06.003; Fadai F, 2014, PHARMACOPSYCHIATRY, V47, P156, DOI 10.1055/s-0034-1382001; Farokhnia M, 2014, HUM PSYCHOPHARM CLIN, V29, P351, DOI 10.1002/hup.2412; Forchetti Concetta M, 2005, Prim Care Companion J Clin Psychiatry, V7, P155; Georgiadou G, 2014, PSYCHOPHARMACOLOGY, V231, P717, DOI 10.1007/s00213-013-3293-4; Geromichalos GD, 2012, J AGR FOOD CHEM, V60, P6131, DOI 10.1021/jf300589c; Ghadami MR, 2009, PHYSIOL PHARMACOL, V12, P287; Ghadrdoost B, 2011, EUR J PHARMACOL, V667, P222, DOI 10.1016/j.ejphar.2011.05.012; Ghaffari S, 2015, RES PHARM SCI, V10, P222; Ghahghaei A, 2013, CELL MOL BIOL LETT, V18, P328, DOI 10.2478/s11658-013-0092-1; Ghahghaei A, 2012, INT J PEPT RES THER, V18, P347, DOI 10.1007/s10989-012-9308-x; Hirota S, 2013, FOOD SCI TECHNOL RES, V19, P1121, DOI 10.3136/fstr.19.1121; Hosseinzadeh H., 2006, Journal of Medicinal Plants, V5, P40; Hosseinzadeh H, 2013, PHYTOTHER RES, V27, P475, DOI 10.1002/ptr.4784; Hosseinzadeh H, 2012, PHYTOTHER RES, V26, P381, DOI 10.1002/ptr.3566; Hosseinzadeh H, 2009, PHARMACOGN MAG, V5, P419; Hosseinzadeh H, 2010, PHYTOTHER RES, V24, P726, DOI 10.1002/ptr.3011; Howes MJR, 2011, DRUG AGING, V28, P439, DOI 10.2165/11591310-000000000-00000; Hsiung GYR, 2008, EXPERT OPIN PHARMACO, V9, P2575, DOI [10.1517/14656566.9.15.2575, 10.1517/14656566.9.15.2575 ]; Iqbal K, 2010, CURR ALZHEIMER RES, V7, P656, DOI 10.2174/156720510793611592; Jaliani HZ, 2013, IRAN J BASIC MED SCI, V16, P101; [金玉燕 Jin Yuyan], 2004, [中国药科大学学报, Journal of China Pharmaceutical University], V35, P283; Jnaneshwari S, 2013, J PHARM PHARMACOL, V65, P604, DOI 10.1111/jphp.12016; Johnson, 1999, Eur J Clin Nutr, V53, P830, DOI 10.1038/sj.ejcn.1600846; Karakani AM, 2015, IRAN J BASIC MED SCI, V18, P485; Kawabata K., 2012, ALTERN MED; Khajuria DK, 2010, LAT AM J PHARM, V29, P713; Khalili Mohsen, 2010, Iran Biomed J, V14, P59; Khan MB, 2012, NEUROL SCI, V33, P1011, DOI 10.1007/s10072-011-0880-1; Khazdair MR, 2015, AVICENNA J PHYTOMEDI, V5, P376; Konoshima T, 1998, PHYTOTHER RES, V12, P400, DOI 10.1002/(SICI)1099-1573(199809)12:6&lt;400::AID-PTR321&gt;3.0.CO;2-4; Lage M, 2009, SCI HORTIC-AMSTERDAM, V121, P366, DOI 10.1016/j.scienta.2009.02.017; Lautenschlager M, 2015, PHYTOMEDICINE, V22, P36, DOI 10.1016/j.phymed.2014.10.009; Lechtenberg M, 2008, PLANTA MED, V74, P764, DOI 10.1055/s-2008-1074535; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Li N, 1999, J CHROMATOGR A, V849, P349, DOI 10.1016/S0021-9673(99)00600-7; [李向阳 LI Xiang-yang], 2009, [中草药, Chinese Traditional and Herbal Drugs], V40, P1425; Liakopoulou-Kyriakides M., 2002, STUD NAT PROD CHEM, V26, P293, DOI DOI 10.1016/S1572-5995(02)80009-6]; Linardaki ZI, 2013, FOOD CHEM TOXICOL, V52, P163, DOI 10.1016/j.fct.2012.11.016; Lockhart IA, 2009, DEMENT GERIATR COGN, V28, P389, DOI 10.1159/000255578; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Massoud F, 2011, CAN J PSYCHIAT, V56, P579, DOI 10.1177/070674371105601003; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mehri S, 2012, CELL MOL NEUROBIOL, V32, P227, DOI 10.1007/s10571-011-9752-8; Melnyk JP, 2010, FOOD RES INT, V43, P1981, DOI 10.1016/j.foodres.2010.07.033; Milajerdi A., 2016, J NUTR INTERMED META, V3, P23, DOI [10.1016/j.jnim.2015.12.332, DOI 10.1016/J.JNIM.2015.12.332]; Modaghegh MH, 2008, PHYTOMEDICINE, V15, P1032, DOI 10.1016/j.phymed.2008.06.003; Mohamadpour AH, 2013, IRAN J BASIC MED SCI, V16, P39; Mondragon-Rodriguez S., 2012, INT J ALZHEIMERS DIS; Moshiri M, 2015, DRUG RES, V65, P287, DOI 10.1055/s-0034-1375681; Mousavi B, 2015, AVICENNA J PHYTOMEDI, V5, P413; Mousavi SH, 2010, CELL MOL NEUROBIOL, V30, P185, DOI 10.1007/s10571-009-9441-z; Mousavi SZ, 2011, AVICENNA J PHYTOMEDI, V1, P57; Naghibi SM, 2012, ADV PHARMACOL SCI, V2012, DOI 10.1155/2012/494367; Naghizadeh B, 2013, PHYTOMEDICINE, V20, P537, DOI 10.1016/j.phymed.2012.12.019; Naghizadeh Bahareh, 2014, Acta Med Iran, V52, P101; Nam KN, 2010, EUR J PHARMACOL, V648, P110, DOI 10.1016/j.ejphar.2010.09.003; Nemati H, 2008, PHYTOMEDICINE, V15, P1038, DOI 10.1016/j.phymed.2008.07.008; Nikbakht-Jam I, 2016, EUR J INTEGR MED, V8, P307, DOI 10.1016/j.eujim.2015.12.008; Nisbet RM, 2015, ACTA NEUROPATHOL, V129, P207, DOI 10.1007/s00401-014-1371-2; Nygaard HB, 2013, CLIN THER, V35, P1480, DOI 10.1016/j.clinthera.2013.09.009; Ochiai T, 2004, NEUROSCI LETT, V362, P61, DOI 10.1016/j.neulet.2004.02.067; Ochiai T, 2004, NEUROCHEM INT, V44, P321, DOI 10.1016/S0197-0186(03)00174-8; Ochiai T, 2007, BBA-GEN SUBJECTS, V1770, P578, DOI 10.1016/j.bbagen.2006.11.012; Ordoudi SA, 2009, J AGR FOOD CHEM, V57, P3080, DOI 10.1021/jf804041g; Oruc S, 2016, LIFE SCI, V154, P79, DOI 10.1016/j.lfs.2016.04.028; Papandreou MA, 2006, J AGR FOOD CHEM, V54, P8762, DOI 10.1021/jf061932a; Papandreou MA, 2011, BEHAV BRAIN RES, V219, P197, DOI 10.1016/j.bbr.2011.01.007; Parsons CG, 2007, NEUROPHARMACOLOGY, V53, P699, DOI 10.1016/j.neuropharm.2007.07.013; Perry George, 2002, Journal of Biomedicine & Biotechnology, V2, P120, DOI 10.1155/S1110724302203010; PFANDER H, 1975, HELV CHIM ACTA, V58, P2233, DOI 10.1002/hlca.19750580736; Pitsikas N., 2015, EVID-BASED COMPL ALT, V2015; Pitsikas N, 2007, BEHAV BRAIN RES, V183, P141, DOI 10.1016/j.bbr.2007.06.001; Rao SV, 2016, NEUROTOXICOLOGY, V52, P230, DOI 10.1016/j.neuro.2015.12.010; Rashedinia M, 2015, ACTA NEUROBIOL EXP, V75, P208; Reddy, 2015, INT J BIOASSAY, V4, P4223, DOI 10.21746/ IJBIO.2015.08.0012; Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI 10.1038/nrneurol.2011.2; Rios JL, 1996, PHYTOTHER RES, V10, P189, DOI 10.1002/(SICI)1099-1573(199605)10:3&lt;189::AID-PTR754&gt;3.0.CO;2-C; Rodda J, 2009, INT J GERIATR PSYCH, V24, P437, DOI 10.1002/gps.2165; Russo P, 2013, CURR MED CHEM, V20, P1686; Sarshoori JR, 2014, IRAN J BASIC MED SCI, V17, P895; Sekler A, 2008, DIS TREAT, V4, P715; Soeda S, 2001, LIFE SCI, V69, P2887, DOI 10.1016/S0024-3205(01)01357-1; Soeda S, 2007, J NAT MED, V61, P102, DOI 10.1007/s11418-006-0120-9; SPERANZA G, 1984, GAZZ CHIM ITAL, V114, P189; Steiner GZ, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-0989-0; Sugiura M, 1995, P JPN ACAD B-PHYS, V71, P319, DOI 10.2183/pjab.71.319; SUGIURA M, 1995, JPN J PHARMACOL, V67, P395, DOI 10.1254/jjp.67.395; SUGIURA M, 1995, PHYTOTHER RES, V9, P100, DOI 10.1002/ptr.2650090204; SUGIURA M, 1994, J PHARMACOL EXP THER, V271, P703; Talaei A, 2015, J AFFECT DISORDERS, V174, P51, DOI 10.1016/j.jad.2014.11.035; Tamaddonfard E, 2013, IRAN J BASIC MED SCI, V16, P91; Tanaka T., 2015, GLOBAL J GASTOENTERO, V3, P31; TARANTILIS PA, 1995, J CHROMATOGR A, V699, P107, DOI 10.1016/0021-9673(95)00044-N; Tashakori-Sabzevar F, 2013, CURR NEUROVASC RES, V10, P325, DOI 10.2174/15672026113109990032; Terry AV, 2003, J PHARMACOL EXP THER, V306, P821, DOI 10.1124/jpet.102.041616; Torres LL, 2011, J ALZHEIMERS DIS, V26, P59, DOI 10.3233/JAD-2011-110284; Tsolaki M, 2016, J ALZHEIMERS DIS, V54, P129, DOI 10.3233/JAD-160304; Umigai N, 2011, PHYTOMEDICINE, V18, P575, DOI 10.1016/j.phymed.2010.10.019; Vakili A, 2014, J STROKE CEREBROVASC, V23, P106, DOI 10.1016/j.jstrokecerebrovasdis.2012.10.008; Wallin AK, 2011, NEUROPSYCH DIS TREAT, V7, P565, DOI 10.2147/NDT.S24196; Wang K, 2015, NEUROSCI LETT, V591, P53, DOI 10.1016/j.neulet.2015.02.016; WHO, 2007, MON SEL MED PLANTS, V3, P126; Willard P., 2002, SECRETS FAFFRON VAGA; Xi L, 2007, PHYTOMEDICINE, V14, P633, DOI 10.1016/j.phymed.2006.11.028; Yoshino F, 2011, J CLIN BIOCHEM NUTR, V49, P182, DOI 10.3164/jcbn.11-01; Yoshino Y., 2014, Pharmacology and Pharmacy, V5, P37, DOI 10.4236/pp.2014.51007; Zhang GF, 2015, NEUROCHEM INT, V89, P101, DOI 10.1016/j.neuint.2015.07.011; [张颖 Zhang Ying], 2012, [中国药学杂志, Chinese Pharmaceutical Journal], V47, P136; ZHANG YX, 1994, BIOL PHARM BULL, V17, P217, DOI 10.1248/bpb.17.217; Zheng YQ, 2007, BRAIN RES, V1138, P86, DOI 10.1016/j.brainres.2006.12.064	138	50	53	1	63	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0021-8561	1520-5118		J AGR FOOD CHEM	J. Agric. Food Chem.	FEB 8	2017	65	5					1005	1020		10.1021/acs.jafc.6b04398			16	Agriculture, Multidisciplinary; Chemistry, Applied; Food Science & Technology	Agriculture; Chemistry; Food Science & Technology	EK3SU	WOS:000393848600002	28098452				2021-06-18	
J	Egawa, J; Pearn, ML; Lemkuil, BP; Patel, PM; Head, BP				Egawa, Junji; Pearn, Matthew L.; Lemkuil, Brian P.; Patel, Piyush M.; Head, Brian P.			Membrane lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function	JOURNAL OF PHYSIOLOGY-LONDON			English	Article; Proceedings Paper	Symposium on Membrane/Lipid Rafts - Age-Associated Changes in Membrane Biology and Function	APR 10-11, 2015	Edinburgh, SCOTLAND				TRAUMATIC BRAIN-INJURY; DENSITY-LIPOPROTEIN RECEPTOR; SYNAPTIC PLASMA-MEMBRANES; LONG-TERM POTENTIATION; GROWTH CONE MOTILITY; CHOLESTEROL 24-HYDROXYLASE; ALZHEIMERS-DISEASE; KINASE-I; GM1 GANGLIOSIDE; SNARE PROTEINS	A better understanding of the cellular physiological role that plasma membrane lipids, fatty acids and sterols play in various cellular systems may yield more insight into how cellular and whole organ function is altered during the ageing process. Membrane lipid rafts (MLRs) within the plasma membrane of most cells serve as key organizers of intracellular signalling and tethering points of cytoskeletal components. MLRs are plasmalemmal microdomains enriched in sphingolipids, cholesterol and scaffolding proteins; they serve as a platform for signal transduction, cytoskeletal organization and vesicular trafficking. Within MLRs are the scaffolding and cholesterol binding proteins named caveolin (Cav). Cavs not only organize a multitude of receptors including neurotransmitter receptors (NMDA and AMPA receptors), signalling proteins that regulate the production of cAMP (G protein-coupled receptors, adenylyl cyclases, phosphodiesterases (PDEs)), and receptor tyrosine kinases involved in growth (Trk), but also interact with components that modulate actin and tubulin cytoskeletal dynamics (e.g. RhoGTPases and actin binding proteins). MLRs are essential for the regulation of the physiology of organs such as the brain, and age-related loss of cholesterol from the plasma membrane leads to loss of MLRs, decreased presynaptic vesicle fusion, and changes in neurotransmitter release, all of which contribute to different forms of neurodegeneration. Thus, MLRs provide an active membrane domain that tethers and reorganizes the cytoskeletal machinery necessary for membrane and cellular repair, and genetic interventions that restore MLRs to normal cellular levels maybe exploited as potential therapeutic means to reverse the ageing and neurodegenerative processes.	[Egawa, Junji; Pearn, Matthew L.; Lemkuil, Brian P.; Patel, Piyush M.; Head, Brian P.] Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA; [Egawa, Junji; Pearn, Matthew L.; Lemkuil, Brian P.; Patel, Piyush M.; Head, Brian P.] Univ Calif San Diego, Sch Med, Dept Anesthesiol, La Jolla, CA 92093 USA	Head, BP (corresponding author), Univ Calif San Diego, Dept Anesthesiol, VASDHS 9125,3350 La Jolla Village Dr, San Diego, CA 92161 USA.	bhead@ucsd.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS073653] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073653] Funding Source: NIH RePORTER		Allen JA, 2007, NAT REV NEUROSCI, V8, P128, DOI 10.1038/nrn2059; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Atkins CM, 2013, NEUROSCI LETT, V532, P1, DOI 10.1016/j.neulet.2012.10.019; Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Aziz R, 2013, PSYCHIAT CLIN N AM, V36, P497, DOI 10.1016/j.psc.2013.08.001; BARNES CA, 1980, J PHYSIOL-LONDON, V309, P473, DOI 10.1113/jphysiol.1980.sp013521; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bassani S., 2012, BIOARCHITECTURE, V2, P95; Begley DJ, 2003, PROG DRUG RES, V61, P39; Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P2209, DOI 10.1161/01.ATV.0000148704.72481.28; Bjorkhem I, 1998, J LIPID RES, V39, P1594; Bjorkhem I, 2010, J LIPID RES, V51, P2489, DOI 10.1194/jlr.R006338; Breceda EY, 2013, CURR OPIN NEUROL, V26, P595, DOI 10.1097/WCO.0000000000000024; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BU GJ, 1994, J BIOL CHEM, V269, P18521; Bulloj A, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-22; BURGER M, 1958, Z Alternsforsch, V12, P52; Calabrese F, 2013, NEUROBIOL AGING, V34, P2768, DOI 10.1016/j.neurobiolaging.2013.06.014; CARTER HE, 1947, J BIOL CHEM, V169, P77; Cecchi C, 2008, J CELL MOL MED, V12, P1990, DOI 10.1111/j.1582-4934.2008.00216.x; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Churchward MA, 2005, J CELL SCI, V118, P4833, DOI 10.1242/jcs.02601; Chytrova G, 2008, EUR J NEUROSCI, V27, P1, DOI 10.1111/j.1460-9568.2007.05982.x; Cole AA, 2010, BIOCHEM J, V427, P535, DOI 10.1042/BJ20091344; Conte V, 2008, RESTOR NEUROL NEUROS, V26, P45; Crutcher KA, 2002, AUTON NEUROSCI-BASIC, V96, P25, DOI 10.1016/S1566-0702(01)00373-3; de Chaves EP, 2010, FEBS LETT, V584, P1748, DOI 10.1016/j.febslet.2009.12.010; Denisova NA, 2001, FREE RADICAL BIO MED, V30, P671, DOI 10.1016/S0891-5849(00)00513-X; Dent EW, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a001800; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; DEUTSCH JW, 1981, BIOCHEMISTRY-US, V20, P378, DOI 10.1021/bi00505a024; Ledesma MD, 2012, PROG LIPID RES, V51, P23, DOI 10.1016/j.plipres.2011.11.004; Egawa J, 2014, J NEUROSURG ANESTHES, V26, P478; Fantini J, 2009, BBA-BIOMEMBRANES, V1788, P2345, DOI 10.1016/j.bbamem.2009.08.016; Fjell AM, 2014, PROG NEUROBIOL, V117, P20, DOI 10.1016/j.pneurobio.2014.02.004; Fjell AM, 2013, NEUROBIOL AGING, V34, P2239, DOI 10.1016/j.neurobiolaging.2013.04.006; Fjell AM, 2009, J NEUROSCI, V29, P15223, DOI 10.1523/JNEUROSCI.3252-09.2009; Frank C, 2008, EXP NEUROL, V212, P407, DOI 10.1016/j.expneurol.2008.04.019; Frank C, 2004, FEBS LETT, V566, P25, DOI 10.1016/j.febslet.2004.03.113; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Gao Y, 2003, J NEUROSCI, V23, P11770; Garg S, 2011, BIOPHYS J, V101, P370, DOI 10.1016/j.bpj.2011.06.014; Garmy N, 2005, J LIPID RES, V46, P36, DOI 10.1194/jlr.M400199-JLR200; Gil C, 2006, BIOCHEM BIOPH RES CO, V348, P1334, DOI 10.1016/j.bbrc.2006.07.201; GORIO A, 1986, CRC CR REV CL NEUROB, V2, P241; Gresack JE, 2010, BEHAV BRAIN RES, V209, P80, DOI 10.1016/j.bbr.2010.01.018; Hall A, 2010, COLD SPRING HARB PER, V2; Haque ME, 2001, BIOCHEMISTRY-US, V40, P4340, DOI 10.1021/bi002030k; Head BP, 2008, FASEB J, V22, P828, DOI 10.1096/fj.07-9299com; Head BP, 2014, BBA-BIOMEMBRANES, V1838, P532, DOI 10.1016/j.bbamem.2013.07.018; Head BP, 2011, J BIOL CHEM, V286, P33310, DOI 10.1074/jbc.M111.255976; Head BP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015697; Henley Jeremy M, 2013, Dialogues Clin Neurosci, V15, P11; Hering H, 2003, J NEUROSCI, V23, P3262; Heverin M, 2005, J LIPID RES, V46, P1047, DOI 10.1194/jlr.M500024-JLR200; Heverin M, 2015, BEHAV BRAIN RES, V278, P356, DOI 10.1016/j.bbr.2014.10.018; Igbavboa U, 1996, J NEUROCHEM, V66, P1717; Jiang L, 2010, NEUROBIOL AGING, V31, P2146, DOI 10.1016/j.neurobiolaging.2008.11.005; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Jurevics HA, 1997, J LIPID RES, V38, P723; Kalaitzakis ME, 2008, J NEUROPATH EXP NEUR, V67, P155, DOI 10.1097/NEN.0b013e31816362aa; Kamiguchi H, 2006, J NEUROCHEM, V98, P330, DOI 10.1111/j.1471-4159.2006.03888.x; Kao PF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013337; Kelly A, 2000, NEUROSCIENCE, V95, P359; Kong MMC, 2007, MOL PHARMACOL, V72, P1157, DOI 10.1124/mol.107.034769; Kudinov A. R., 2006, Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, P61; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; Leal SL, 2013, AGEING RES REV, V12, P823, DOI 10.1016/j.arr.2013.01.006; LENTZ BR, 1987, BIOCHEMISTRY-US, V26, P5389, DOI 10.1021/bi00391a026; LESKAWA KC, 1979, NEUROCHEM RES, V4, P483, DOI 10.1007/BF00964643; Linetti A, 2010, J CELL SCI, V123, P595, DOI 10.1242/jcs.060681; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; Lowery LA, 2009, NAT REV MOL CELL BIO, V10, P332, DOI 10.1038/nrm2679; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MacDonald E, 2007, NEUROREHAB NEURAL RE, V21, P486, DOI 10.1177/1545968307305521; Mailman T, 2011, J NEUROCHEM, V119, P1002, DOI 10.1111/j.1471-4159.2011.07474.x; Maioli S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068534; Mandal PK, 2006, NEUROCHEM RES, V31, P1153, DOI 10.1007/s11064-006-9140-9; Martin M, 2010, BBA-MOL CELL BIOL L, V1801, P934, DOI 10.1016/j.bbalip.2010.03.011; Martin MG, 2008, MOL BIOL CELL, V19, P2101, DOI 10.1091/mbc.E07-09-0897; Martin MG, 2014, EMBO REP, V15, P1036, DOI 10.15252/embr.201439225; Mesulam NM, 1999, NEURON, V24, P521, DOI 10.1016/S0896-6273(00)81109-5; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Mishra M, 2011, J CELL MOL MED, V15, P1713, DOI 10.1111/j.1582-4934.2010.01134.x; Morrison JH, 2014, JAMA PSYCHIAT, V71, P835, DOI 10.1001/jamapsychiatry.2014.380; Murray AJ, 2009, J NEUROSCI, V29, P15434, DOI 10.1523/JNEUROSCI.3071-09.2009; Neumann Aaron K, 2010, F1000 Biol Rep, V2, P31, DOI 10.3410/B2-31; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Ohyama Y, 2006, J BIOL CHEM, V281, P3810, DOI 10.1074/jbc.M505179200; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; Paila YD, 2009, BBA-BIOMEMBRANES, V1788, P295, DOI 10.1016/j.bbamem.2008.11.020; Paul G, 2015, J CLIN INVEST, V125, P1339, DOI 10.1172/JCI79635; Peri A, 2008, J MOL ENDOCRINOL, V41, P251, DOI 10.1677/JME-08-0071; Phillips C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00170; Prinetti A, 2001, J BIOL CHEM, V276, P21136, DOI 10.1074/jbc.M010666200; Remy F, 2004, NEUROSCI LETT, V358, P25, DOI 10.1016/j.neulet.2003.12.122; Renner M, 2009, J NEUROSCI, V29, P2926, DOI 10.1523/JNEUROSCI.4445-08.2009; ROMAN F, 1987, BRAIN RES, V418, P221, DOI 10.1016/0006-8993(87)90089-8; Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0; ROUSER G, 1968, LIPIDS, V3, P284, DOI 10.1007/BF02531202; RUNQUIST M, 1995, J NEUROCHEM, V65, P2299; Russell DW, 2009, ANNU REV BIOCHEM, V78, P1017, DOI 10.1146/annurev.biochem.78.072407.103859; Sacket SJ, 2009, ACTA PHARMACOL SIN, V30, P1454, DOI 10.1038/aps.2009.136; Salaun C, 2004, TRAFFIC, V5, P255, DOI 10.1111/j.1600-0854.2004.0162.x; Schilling JM, 2014, BEHAV BRAIN RES, V267, P6, DOI 10.1016/j.bbr.2014.03.014; Schmitt JM, 2004, J BIOL CHEM, V279, P24064, DOI 10.1074/jbc.M401501200; Shafaati M, 2011, J LIPID RES, V52, P1004, DOI 10.1194/jlr.M014548; SODERBERG M, 1990, J NEUROCHEM, V54, P415, DOI 10.1111/j.1471-4159.1990.tb01889.x; Sodero AO, 2011, J NEUROCHEM, V116, P747, DOI 10.1111/j.1471-4159.2010.07079.x; Steck TL, 2012, BIOPHYS J, V102, P945, DOI 10.1016/j.bpj.2011.10.059; Stiess M, 2011, DEV NEUROBIOL, V71, P430, DOI 10.1002/dneu.20849; Suzuki T, 2002, NEUROSCI RES, V44, P1, DOI 10.1016/S0168-0102(02)00080-9; SVENNERHOLM L, 1994, J NEUROCHEM, V63, P1802; Thelen KM, 2006, NEUROSCI LETT, V403, P15, DOI 10.1016/j.neulet.2006.04.034; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Thudichum JLW, 1884, TREATISE CHEM CONSTI; Titus DJ, 2013, NEUROSCIENCE, V231, P182, DOI 10.1016/j.neuroscience.2012.12.002; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Tong J, 2011, NEUROBIOL DIS, V41, P458, DOI 10.1016/j.nbd.2010.10.017; Trovo L, 2011, J CELL SCI, V124, P1308, DOI 10.1242/jcs.078766; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099; Valaperta R, 2006, FASEB J, V20, P1227, DOI 10.1096/fj.05-5077fje; Vance JE, 2010, BBA-MOL CELL BIOL L, V1801, P806, DOI 10.1016/j.bbalip.2010.02.007; Vanmierlo T, 2010, J ALZHEIMERS DIS, V19, P117, DOI 10.3233/JAD-2010-1209; Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569; Wasser CR, 2009, NEUROSCIENCE, V158, P177, DOI 10.1016/j.neuroscience.2008.03.028; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; Wayman GA, 2006, NEURON, V50, P897, DOI 10.1016/j.neuron.2006.05.008; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917; Wood WG, 2011, J NEUROCHEM, V116, P684, DOI 10.1111/j.1471-4159.2010.07017.x; Wu GS, 1997, MOL BRAIN RES, V44, P341, DOI 10.1016/S0169-328X(96)00281-1; Xie CL, 2003, J LIPID RES, V44, P1780, DOI 10.1194/jlr.M300164-JLR200; Yamamoto N, 2008, BBA-BIOMEMBRANES, V1778, P2717, DOI 10.1016/j.bbamem.2008.07.028	137	50	50	0	32	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	AUG 15	2016	594	16					4565	4579		10.1113/JP270590			15	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	DV5GV	WOS:000382956100009	26332795	Bronze, Green Published			2021-06-18	
J	Melcangi, RC; Giatti, S; Garcia-Segura, LM				Melcangi, Roberto C.; Giatti, Silvia; Garcia-Segura, Luis M.			Levels and actions of neuroactive steroids in the nervous system under physiological and pathological conditions: Sex-specific features	NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS			English	Article; Proceedings Paper	8th International Meeting on Steroids and Nervous System	2015	Torino, ITALY			Aromatase; 5alpha-Reductase; Dihydroprogesterone; Dihydrotestosterone; Estradiol; Pregnenolone; Progesterone; Testosterone; Tetrahydroprogesterone	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ESTROGEN-RECEPTOR MODULATORS; MYELIN BASIC-PROTEIN; SPINAL-CORD-INJURY; KAINIC ACID EXCITOTOXICITY; HUMAN NEUROBLASTOMA-CELLS; ACUTE REGULATORY PROTEIN; HORMONE PULSE FREQUENCY; ADULT-RAT HIPPOCAMPUS	Neuroactive steroids regulate the physiology of the central and peripheral nervous system, exert neuroprotective actions and represent interesting tools for therapeutic strategies against neurodegenerative and psychiatric disorders. Sex differences in their levels are detected not only under physiological conditions but are also modified in a sex-dependent way in different pathological alterations such as Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, traumatic brain injury, spinal cord injury, stroke, diabetic encephalopathy, psychiatric disorders and peripheral neuropathy. Interestingly, many of these disorders show sex differences in their incidence, symptomatology and/or neurodegenerative outcome. The neuroprotective actions of neuroactive steroids, together with the sex specific regulation of its levels might provide the basis to design sex-specific neuroprotective therapies. Indeed, some experiments here discussed suggest the viability of this approach. (C) 2015 Elsevier Ltd. All rights reserved.	[Melcangi, Roberto C.; Giatti, Silvia] Univ Milan, Dipartimento Sci Farmacol & Biomol, Milan, Italy; [Garcia-Segura, Luis M.] CSIC, Ist Cajal, Ave Doctor Arce 37, Madrid 28002, Spain	Melcangi, RC (corresponding author), Univ Milan, Dipartimento Sci Farmacol & Biomol, Milan, Italy.	roberto.melcangi@unimi.it	Garcia-Segura, Luis M/U-3711-2017; Giatti, Silvia/G-9334-2016	Garcia-Segura, Luis M/0000-0002-2450-2916; Giatti, Silvia/0000-0001-7741-826X; MELCANGI, COSIMO ROBERTO/0000-0003-0861-8967			Aaberg ML, 2008, J DIABETES COMPLICAT, V22, P83, DOI 10.1016/j.jdiacomp.2007.06.009; Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; Afifi M., 2007, SMJ Singapore Medical Journal, V48, P385; Albers JW, 1996, NEUROLOGY, V46, P85, DOI 10.1212/WNL.46.1.85; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Ammendola A, 2000, ALCOHOL ALCOHOLISM, V35, P368, DOI 10.1093/alcalc/35.4.368; Andersen K, 1999, NEUROLOGY, V53, P1992, DOI 10.1212/WNL.53.9.1992; ANDREASEN NC, 1994, JAMA-J AM MED ASSOC, V272, P1763, DOI 10.1001/jama.272.22.1763; ANDREASEN NC, 1990, ARCH GEN PSYCHIAT, V47, P35; Arevalo MA, 2013, HORM BEHAV, V63, P216, DOI 10.1016/j.yhbeh.2012.02.021; Arevalo MA, 2012, J STEROID BIOCHEM, V131, P52, DOI 10.1016/j.jsbmb.2011.09.004; Arad M, 2010, NEUROPSYCHOPHARMACOL, V35, P2179, DOI 10.1038/npp.2010.89; Ardeshiri A, 2006, EUR J NEUROSCI, V24, P2567, DOI 10.1111/j.1460-9568.2006.05142.x; Arevalo MA, 2015, HORM BEHAV, V74, P19, DOI 10.1016/j.yhbeh.2015.04.016; Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856; Ayhan S, 2003, MICROSURG, V23, P49, DOI 10.1002/micr.10088; Ayoola C, 2014, PSYCHOPHARMACOLOGY, V231, P3503, DOI 10.1007/s00213-014-3588-0; Azcoitia I, 1999, J NEUROSCI RES, V58, P815, DOI 10.1002/(SICI)1097-4547(19991215)58:6<815::AID-JNR8>3.0.CO;2-R; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Azcoitia I, 2001, J NEUROBIOL, V47, P318, DOI 10.1002/neu.1038; Backstrom T, 2014, PROG NEUROBIOL, V113, P88, DOI 10.1016/j.pneurobio.2013.07.005; BARFIELD RJ, 1984, PSYCHONEUROENDOCRINO, V9, P217, DOI 10.1016/0306-4530(84)90002-7; BARRACLOUGH CA, 1986, NEUROENDOCRINOLOGY, V42, P6, DOI 10.1159/000124241; Barreto G, 2007, EUR J NEUROSCI, V25, P3039, DOI 10.1111/j.1460-9568.2007.05563.x; Barreto G, 2009, ENDOCRINOLOGY, V150, P5010, DOI 10.1210/en.2009-0352; Barreto GE, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00132; Basit Abdul, 2004, J Coll Physicians Surg Pak, V14, P79; Baudry M, 2013, NEUROSCIENCE, V239, P280, DOI 10.1016/j.neuroscience.2012.10.051; Bauman ML, 2005, INT J DEV NEUROSCI, V23, P183, DOI 10.1016/j.ijdevneu.2004.09.006; Bebo BF, 1999, J NEUROSCI RES, V55, P432, DOI 10.1002/(SICI)1097-4547(19990215)55:4<432::AID-JNR4>3.0.CO;2-2; Bebo BF, 1999, J IMMUNOL, V162, P35; Beinhoff U, 2008, J NEUROL, V255, P117, DOI 10.1007/s00415-008-0726-9; Lopez-Rodriguez AB, 2015, PSYCHONEUROENDOCRINO, V56, P1, DOI 10.1016/j.psyneuen.2015.02.018; Bender RA, 2010, CEREB CORTEX, V20, P2985, DOI 10.1093/cercor/bhq047; Benito-Leon J, 2003, MOVEMENT DISORD, V18, P267, DOI 10.1002/mds.10362; Biamonte F, 2009, NEUROBIOL DIS, V36, P103, DOI 10.1016/j.nbd.2009.07.001; Biessels GJ, 2008, LANCET NEUROL, V7, P184, DOI 10.1016/S1474-4422(08)70021-8; Biessels GJ, 2002, EUR J PHARMACOL, V441, P1, DOI 10.1016/S0014-2999(02)01486-3; Blanchard V, 2003, EXP NEUROL, V184, P247, DOI 10.1016/S0014-4886(03)00252-8; Bloch Y, 2005, J AFFECT DISORDERS, V84, P99, DOI 10.1016/j.jad.2004.10.002; Bode FJ, 2008, HUM MOL GENET, V17, P2595, DOI 10.1093/hmg/ddn159; Booya F, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-24; Bourque M, 2009, FRONT NEUROENDOCRIN, V30, P142, DOI 10.1016/j.yfrne.2009.04.014; Bowers J Michael, 2010, Biol Sex Differ, V1, P8, DOI 10.1186/2042-6410-1-8; Bryant NL, 1999, AM J PSYCHIAT, V156, P603; Calabrese D, 2014, J ENDOCRINOL, V221, P1, DOI 10.1530/JOE-13-0541; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; Callier S, 2001, SYNAPSE, V41, P131, DOI 10.1002/syn.1067; Calmarza-Font I, 2012, BEHAV BRAIN RES, V227, P287, DOI 10.1016/j.bbr.2011.10.036; Caruso D, 2010, J NEUROENDOCRINOL, V22, P1137, DOI 10.1111/j.1365-2826.2010.02064.x; Caruso D, 2008, J MOL NEUROSCI, V34, P249, DOI 10.1007/s12031-007-9029-3; Caruso D, 2014, J NEUROCHEM, V130, P591, DOI 10.1111/jnc.12745; Caruso D, 2013, PSYCHONEUROENDOCRINO, V38, P2278, DOI 10.1016/j.psyneuen.2013.04.016; Caruso D, 2013, NEUROBIOL AGING, V34, P1080, DOI 10.1016/j.neurobiolaging.2012.10.007; Caruso D, 2010, J NEUROCHEM, V114, P921, DOI 10.1111/j.1471-4159.2010.06825.x; Celec P, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00012; Cermenati G, 2013, J ENDOCRINOL INVEST, V36, P435, DOI 10.3275/8941; Cermenati G, 2012, J LIPID RES, V53, P300, DOI 10.1194/jlr.M021188; Chan JR, 2000, MOL BIOL CELL, V11, P2283, DOI 10.1091/mbc.11.7.2283; Chan JR, 1998, P NATL ACAD SCI USA, V95, P10459, DOI 10.1073/pnas.95.18.10459; Chavez-Delgado ME, 2005, J BIOMED MATER RES B, V74B, P589, DOI 10.1002/jbm.b.30243; Chisholm N. C., 2015, NEUROBIOL DIS; Chisholm NC, 2015, EPIGENETICS-US, V10, P142, DOI 10.1080/15592294.2014.1001219; Cho T, 2012, J NEUROENDOCRINOL, V24, P789, DOI 10.1111/j.1365-2826.2011.02272.x; CHOWEN JA, 1992, NEUROENDOCRINOLOGY, V56, P895, DOI 10.1159/000126321; Ciriza I, 2004, J NEUROBIOL, V61, P209, DOI 10.1002/neu.20043; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Clinton LK, 2007, NEUROBIOL DIS, V28, P76, DOI 10.1016/j.nbd.2007.06.013; Coers S, 2002, METAB BRAIN DIS, V17, P55, DOI 10.1023/A:1015415226799; Coirini H, 2002, NEUROSCIENCE, V113, P883, DOI 10.1016/S0306-4522(02)00224-5; Colciago A, 2015, J STEROID BIOCHEM, V150, P64, DOI 10.1016/j.jsbmb.2015.02.008; Confavreux C, 2003, BRAIN, V126, P770, DOI 10.1093/brain/awg081; Corbo RM, 2014, J NEUROL SCI, V344, P149, DOI 10.1016/j.jns.2014.06.045; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Czlonkowska A, 2006, ENDOCRINE, V29, P243, DOI 10.1385/ENDO:29:2:243; Dalal M, 1997, J IMMUNOL, V159, P3; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Day NL, 2013, J NEUROTRAUM, V30, P1531, DOI 10.1089/neu.2013.2854; de Lau LML, 2004, NEUROLOGY, V63, P1240, DOI 10.1212/01.WNL.0000140706.52798.BE; de Michele F, 2003, NEUROL SCI, V24, P172, DOI 10.1007/s10072-003-0115-1; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Devroey D, 2003, CEREBROVASC DIS, V16, P272, DOI 10.1159/000071127; Dina OA, 2007, NEUROSCIENCE, V145, P350, DOI 10.1016/j.neuroscience.2006.11.053; Diz-Chaves Y, 2012, EXP GERONTOL, V47, P93, DOI 10.1016/j.exger.2011.10.008; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dooley MA, 2003, CURR OPIN RHEUMATOL, V15, P99, DOI 10.1097/00002281-200303000-00002; Dorner JL, 2007, BEHAV BRAIN RES, V178, P90, DOI 10.1016/j.bbr.2006.12.004; Doulazmi M, 1999, J COMP NEUROL, V411, P267; El-Etr M, 2015, GLIA, V63, P104, DOI 10.1002/glia.22736; Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008; Eriksson M, 2008, CEREBROVASC DIS, V25, P423, DOI 10.1159/000121343; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fernandez HH, 2000, MOVEMENT DISORD, V15, P490, DOI 10.1002/1531-8257(200005)15:3<490::AID-MDS1011>3.0.CO;2-E; Fombonne E, 1999, PSYCHOL MED, V29, P769, DOI 10.1017/S0033291799008508; Fombonne E, 2003, J AUTISM DEV DISORD, V33, P365, DOI 10.1023/A:1025054610557; Foot M, 2004, DEPRESS ANXIETY, V20, P123, DOI 10.1002/da.20031; Foroud T, 1999, J NEUROL NEUROSUR PS, V66, P52, DOI 10.1136/jnnp.66.1.52; Foy MR, 2008, LEARN MEMORY, V15, P820, DOI 10.1101/lm.1124708; Frankfurt M, 2015, HORM BEHAV, V74, P28, DOI 10.1016/j.yhbeh.2015.05.004; Fratiglioni L, 1997, NEUROLOGY, V48, P132, DOI 10.1212/WNL.48.1.132; Frye CA, 2000, PSYCHONEUROENDOCRINO, V25, P407, DOI 10.1016/S0306-4530(99)00068-2; Frye CA, 2008, HORM BEHAV, V54, P726, DOI 10.1016/j.yhbeh.2008.07.013; Frye CA, 2009, EPILEPSY BEHAV, V16, P418, DOI 10.1016/j.yebeh.2009.09.008; Galea LAM, 2008, BRAIN RES REV, V57, P332, DOI 10.1016/j.brainresrev.2007.05.008; Garay L, 2011, NEUROSCIENCE, V192, P588, DOI 10.1016/j.neuroscience.2011.06.065; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Garay L, 2010, HORM MOL BIOL CLIN I, V1, P43, DOI 10.1515/HMBCI.2010.006; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; GARCIASEGURA LM, 1994, PROG NEUROBIOL, V44, P279, DOI 10.1016/0301-0082(94)90042-6; GARCIASEGURA LM, 1989, DEV BRAIN RES, V47, P298, DOI 10.1016/0165-3806(89)90186-7; Gemignani F, 2006, MOVEMENT DISORD, V21, P1254, DOI 10.1002/mds.20928; Ghorbanpoor S, 2014, ENDOCRINOLOGY, V155, P4341, DOI 10.1210/en.2014-1158; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Giatti S, 2012, J NEUROENDOCRINOL, V24, P851, DOI 10.1111/j.1365-2826.2012.02284.x; Giatti S, 2015, NEUROENDOCRINOLOGY, V101, P296, DOI 10.1159/000381064; Giatti S, 2012, J MOL ENDOCRINOL, V49, pR125, DOI 10.1530/JME-12-0127; Giatti S, 2010, NEUROCHEM INT, V56, P118, DOI 10.1016/j.neuint.2009.09.009; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Giraud SN, 2010, P NATL ACAD SCI USA, V107, P8416, DOI 10.1073/pnas.0910627107; Gispen WH, 2000, TRENDS NEUROSCI, V23, P542, DOI 10.1016/S0166-2236(00)01656-8; Gleicher N, 2007, J AUTOIMMUN, V28, P1, DOI 10.1016/j.jaut.2006.12.004; Goldstein JM, 2007, BIOL PSYCHIAT, V61, P935, DOI 10.1016/j.biopsych.2006.06.027; Goldstein JM, 2006, HORM BEHAV, V50, P612, DOI 10.1016/j.yhbeh.2006.06.029; Goldstein JM, 2002, ARCH GEN PSYCHIAT, V59, P154, DOI 10.1001/archpsyc.59.2.154; Goldstein JM, 1998, AM J PSYCHIAT, V155, P1358, DOI 10.1176/ajp.155.10.1358; GOLDSTEIN JM, 1988, J PSYCHIAT RES, V22, P141, DOI 10.1016/0022-3956(88)90078-7; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gudemez E, 2002, MICROSURG, V22, P234, DOI 10.1002/micr.10039; Guennoun R, 2001, MOL BRAIN RES, V90, P75, DOI 10.1016/S0169-328X(01)00094-8; Guerra-Araiza C, 2007, DEV NEUROBIOL, V67, P510, DOI 10.1002/dneu.20383; Gur RE, 2004, BIOL PSYCHIAT, V55, P512, DOI 10.1016/j.biopsych.2003.10.009; Haaxma CA, 2007, J NEUROL NEUROSUR PS, V78, P819, DOI 10.1136/jnnp.2006.103788; HadjSahraoui N, 1996, J NEUROGENET, V11, P45, DOI 10.3109/01677069609107062; Hafner H, 2003, PSYCHONEUROENDOCRINO, V28, P17, DOI 10.1016/S0306-4530(02)00125-7; Halbreich U, 2003, PSYCHONEUROENDOCRINO, V28, P1, DOI 10.1016/S0306-4530(03)00098-2; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Hammond J, 2001, J NEUROCHEM, V77, P1319, DOI 10.1046/j.1471-4159.2001.00345.x; Hankin BL, 1999, ANN MED, V31, P372, DOI 10.3109/07853899908998794; Hawkins SA, 1999, J NEUROL NEUROSUR PS, V67, P148, DOI 10.1136/jnnp.67.2.148; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Holroyd-Leduc JM, 2000, STROKE, V31, P1833, DOI 10.1161/01.STR.31.8.1833; Homann CN, 2003, J NEURAL TRANSM, V110, P885, DOI 10.1007/s00702-003-0009-7; Huppenbauer CB, 2005, J NEUROSCI, V25, P4004, DOI 10.1523/JNEUROSCI.5279-04.2005; Ibanez C, 2003, PROG NEUROBIOL, V71, P49, DOI 10.1016/j.pneurobio.2003.09.002; Ishihara Y, 2014, LIFE SCI, V99, P24, DOI 10.1016/j.lfs.2014.01.061; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Islamov RR, 2002, BRAIN RES, V943, P283, DOI 10.1016/S0006-8993(02)02827-5; JACKSON GL, 1991, BIOL REPROD, V45, P188, DOI 10.1095/biolreprod45.1.188; Jacobson AM, 2002, INT REV NEUROBIOL, V51, P455, DOI 10.1016/S0074-7742(02)51013-8; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Jiang C, 2011, INT IMMUNOPHARMACOL, V11, P1925, DOI 10.1016/j.intimp.2011.08.001; JO D-H, 1989, Steroids, V54, P287, DOI 10.1016/0039-128X(89)90003-2; Jones KJ, 2001, BRAIN RES REV, V37, P372, DOI 10.1016/S0165-0173(01)00107-2; Perez-Alvarez MJ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-157; Joseph EK, 2003, NEUROSCIENCE, V120, P907, DOI 10.1016/S0306-4522(03)00400-7; JungTestas I, 1996, CELL MOL NEUROBIOL, V16, P439, DOI 10.1007/BF02088110; Kapral MK, 2005, STROKE, V36, P809, DOI 10.1161/01.STR.0000157662.09551.e5; Kaye W, 2008, PHYSIOL BEHAV, V94, P121, DOI 10.1016/j.physbeh.2007.11.037; Kessing LV, 2005, SOC PSYCH PSYCH EPID, V40, P197, DOI 10.1007/s00127-005-0885-2; Khasnavis S, 2013, J BIOL CHEM, V288, P20843, DOI 10.1074/jbc.M112.443556; Kim HJ, 2003, MOL BRAIN RES, V115, P39, DOI 10.1016/S0169-328X(03)00177-3; Kimura K, 2005, CEREBROVASC DIS, V19, P171, DOI 10.1159/000083252; Kiziltan ME, 2007, J NEUROL SCI, V258, P75, DOI 10.1016/j.jns.2007.02.028; Kodl CT, 2008, ENDOCR REV, V29, P494, DOI 10.1210/er.2007-0034; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kovacic U, 2004, EXP NEUROL, V189, P94, DOI 10.1016/j.expneurol.2004.05.015; Kovacic U, 2003, EXP NEUROL, V184, P479, DOI 10.1016/S0014-4886(03)00269-3; Kramar EA, 2013, NEUROSCIENCE, V239, P3, DOI 10.1016/j.neuroscience.2012.10.038; Kraszpulski M, 2001, ACTA NEUROL SCAND, V103, P88, DOI 10.1034/j.1600-0404.2001.103002088.x; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Kumar P, 2014, EUR J PHARMACOL, V723, P38, DOI 10.1016/j.ejphar.2013.11.036; Kumsar S, 2014, J SEX MED, V11, P529, DOI 10.1111/jsm.12394; Kurth F, 2014, NEUROIMAGE-CLIN, V4, P454, DOI 10.1016/j.nicl.2014.03.001; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Lagunas N, 2010, HORM BEHAV, V58, P786, DOI 10.1016/j.yhbeh.2010.07.014; Lavaque E, 2006, NEUROSCIENCE, V138, P741, DOI 10.1016/j.neuroscience.2005.05.060; Lavaque E, 2006, J NEUROBIOL, V66, P308, DOI 10.1002/neu.20221; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Liu HL, 2005, J NEUROSCI RES, V79, P861, DOI 10.1002/jnr.20424; Liu MY, 2007, J CEREBR BLOOD F MET, V27, P135, DOI 10.1038/sj.jcbfm.9600331; Liu SB, 2011, CLIN EXP PHARMACOL P, V38, P577, DOI 10.1111/j.1440-1681.2011.05549.x; Lloret A, 2008, FREE RADICAL BIO MED, V44, P2019, DOI 10.1016/j.freeradbiomed.2008.02.017; Rodriguez ABL, 2011, CEREB CORTEX, V21, P2046, DOI 10.1093/cercor/bhq277; Luchetti S, 2011, NEUROSCIENCE, V191, P6, DOI 10.1016/j.neuroscience.2011.04.010; Luchetti S, 2014, J NEUROPATH EXP NEUR, V73, P123, DOI 10.1097/NEN.0000000000000037; Luchetti S, 2011, NEUROBIOL AGING, V32, P1964, DOI 10.1016/j.neurobiolaging.2009.12.014; Luchetti S, 2010, BRAIN PATHOL, V20, P945, DOI 10.1111/j.1750-3639.2010.00396.x; LUQUIN S, 1993, J NEUROBIOL, V24, P913, DOI 10.1002/neu.480240705; Magnaghi V, 1999, MOL BRAIN RES, V70, P36, DOI 10.1016/S0169-328X(99)00124-2; Magnaghi V, 2004, MOL BRAIN RES, V126, P67, DOI 10.1016/j.molbrainres.2004.03.009; Magnaghi V, 2007, J MOL NEUROSCI, V31, P149, DOI 10.1385/JMN/31:02:149; Magnaghi V, 2006, J PERIPHER NERV SYST, V11, P111, DOI 10.1111/j.1085-9489.2006.00075.x; Mannix R, 2014, J NEUROSURG, V121, P1337, DOI 10.3171/2014.8.JNS14715; Manwani B, 2015, J CEREBR BLOOD F MET, V35, P221, DOI 10.1038/jcbfm.2014.186; Manwani B, 2013, EXP NEUROL, V249, P120, DOI 10.1016/j.expneurol.2013.08.011; Marcus SM, 2008, COMPR PSYCHIAT, V49, P238, DOI 10.1016/j.comppsych.2007.06.012; Markianos M, 2005, ANN NEUROL, V57, P520, DOI 10.1002/ana.20428; Martinelli P, 2003, NEUROL SCI, V24, P192, DOI 10.1007/s10072-003-0125-z; Martinez-Cerdeno V, 2006, EUR J NEUROSCI, V24, P3475, DOI 10.1111/j.1460-9568.2006.05239.x; Marx CE, 2011, NEUROSCIENCE, V191, P78, DOI 10.1016/j.neuroscience.2011.06.076; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Marx CE, 2009, NEUROPSYCHOPHARMACOL, V34, P1885, DOI 10.1038/npp.2009.26; Matarese G, 2001, EUR J IMMUNOL, V31, P1324, DOI 10.1002/1521-4141(200105)31:5<1324::AID-IMMU1324>3.0.CO;2-Y; McCall AL, 2002, INT REV NEUROBIOL, V51, P415, DOI 10.1016/S0074-7742(02)51012-6; McCarthy MM, 2008, J NEUROENDOCRINOL, V20, P777, DOI 10.1111/j.1365-2826.2008.01723.x; McCarthy MM, 2003, ANN NY ACAD SCI, V1007, P283, DOI 10.1196/annals.1286.027; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; McHenry J, 2014, FRONT NEUROENDOCRIN, V35, P42, DOI 10.1016/j.yfrne.2013.09.001; McIntyre RS, 2006, PSYCHONEUROENDOCRINO, V31, P1029, DOI 10.1016/j.psyneuen.2006.06.005; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Melcangi RC, 1999, J NEUROSCI RES, V56, P349, DOI 10.1002/(SICI)1097-4547(19990515)56:4<349::AID-JNR3>3.3.CO;2-8; Melcangi RC, 2005, BRAIN RES REV, V48, P328, DOI 10.1016/j.brainresrev.2004.12.021; Melcangi RC, 2003, PROG NEUROBIOL, V71, P57, DOI 10.1016/j.pneurobio.2003.09.003; Melcangi RC, 1998, NEUROSCIENCE, V85, P569, DOI 10.1016/S0306-4522(97)00628-3; Melcangi RC, 2000, J NEUROCYTOL, V29, P327, DOI 10.1023/A:1007105121765; Melcangi RC, 2000, PROG NEUROBIOL, V60, P291, DOI 10.1016/S0301-0082(99)00028-3; Melcangi RC, 2012, J MOL NEUROSCI, V46, P177, DOI 10.1007/s12031-011-9570-y; Mensah-Nyagan Ayikoe G, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS169, DOI 10.1016/j.psyneuen.2009.06.004; Mercier G, 2001, MOL BRAIN RES, V97, P137, DOI 10.1016/S0169-328X(01)00311-4; Meyer L, 2011, PAIN, V152, P170, DOI 10.1016/j.pain.2010.10.015; Meyer L, 2010, CELL MOL LIFE SCI, V67, P3017, DOI 10.1007/s00018-010-0372-0; Micevych P, 2008, ENDOCRINOLOGY, V149, P2739, DOI 10.1210/en.2008-0011; Mitro N, 2014, J STEROID BIOCHEM, V143, P115, DOI 10.1016/j.jsbmb.2014.02.015; Moldovan IR, 2008, J NEUROIMMUNOL, V193, P161, DOI 10.1016/j.jneuroim.2007.10.010; Morales LBJ, 2006, J NEUROSCI, V26, P6823, DOI 10.1523/JNEUROSCI.0453-06.2006; Moriarty PJ, 2001, SCHIZOPHRENIA BULL, V27, P103, DOI 10.1093/oxfordjournals.schbul.a006850; Mosquera L, 2014, BRAIN RES, V1561, P11, DOI 10.1016/j.brainres.2014.03.002; Mottron L, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0024-1; Murphy DD, 2000, NEUROENDOCRINOLOGY, V72, P133, DOI 10.1159/000054580; Murray HE, 2003, NEUROSCIENCE, V116, P213, DOI 10.1016/S0306-4522(02)00578-X; Ng I, 2006, BRIT J NEUROSURG, V20, P73, DOI 10.1080/02688690600682259; Nguyen TV, 2010, J NEUROENDOCRINOL, V22, P1013, DOI 10.1111/j.1365-2826.2010.02044.x; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Niewada M, 2005, NEUROEPIDEMIOLOGY, V24, P123, DOI 10.1159/000082999; Nitkowska M, 2015, ACTA NEUROL SCAND, V131, P411, DOI 10.1111/ane.12334; Noonan CW, 2002, NEUROLOGY, V58, P136, DOI 10.1212/WNL.58.1.136; Noorbakhsh F, 2011, BRAIN, V134, P2703, DOI 10.1093/brain/awr200; Ooishi Y, 2012, J STEROID BIOCHEM, V131, P37, DOI 10.1016/j.jsbmb.2011.10.004; Orton SM, 2006, LANCET NEUROL, V5, P932, DOI 10.1016/S1474-4422(06)70581-6; Osborne DM, 2009, AGE, V31, P119, DOI 10.1007/s11357-009-9088-1; Ozacmak VH, 2009, PHYSIOL RES, V58, P909, DOI 10.33549/physiolres.931647; Padua L, 2006, NEUROL SCI, V27, P417, DOI 10.1007/s10072-006-0722-8; Palaszynski KM, 2004, J NEUROIMMUNOL, V146, P144, DOI 10.1016/j.jneuroim.2003.11.004; Palmen SJMC, 2004, BRAIN, V127, P2572, DOI 10.1093/brain/awh287; Pariante CM, 2004, BRIT J PSYCHIAT, V185, P5, DOI 10.1192/bjp.185.1.5; Parmenter BA, 2007, MULT SCLER J, V13, P25, DOI 10.1177/1352458506070682; Patte-Mensah C, 2014, PROG NEUROBIOL, V113, P70, DOI 10.1016/j.pneurobio.2013.07.004; PAUL SM, 1992, FASEB J, V6, P2311; Pekmezovic T, 2007, EUR J EPIDEMIOL, V22, P523, DOI 10.1007/s10654-007-9157-7; Pelfrey CM, 2002, J NEUROIMMUNOL, V130, P211, DOI 10.1016/S0165-5728(02)00224-2; Pesaresi M, 2011, NEUROSCIENCE, V199, P401, DOI 10.1016/j.neuroscience.2011.09.013; Pesaresi M, 2011, EXP NEUROL, V228, P215, DOI 10.1016/j.expneurol.2011.01.005; Pesaresi M, 2010, J MOL NEUROSCI, V42, P135, DOI 10.1007/s12031-010-9344-y; Pesaresi M, 2010, HORM BEHAV, V57, P46, DOI 10.1016/j.yhbeh.2009.04.008; Peterson BL, 2015, BEHAV BRAIN RES, V286, P152, DOI 10.1016/j.bbr.2015.03.005; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Pike CJ, 2009, FRONT NEUROENDOCRIN, V30, P239, DOI 10.1016/j.yfrne.2009.04.015; Platania P, 2005, NEUROBIOL DIS, V20, P461, DOI 10.1016/j.nbd.2005.03.025; Pozzilli C, 2003, EUR J NEUROL, V10, P95, DOI 10.1046/j.1468-1331.2003.00519.x; Quillinan N, 2014, EXP NEUROL, V259, P10, DOI 10.1016/j.expneurol.2014.02.004; Ramsden M, 2003, NEUROSCIENCE, V122, P573, DOI 10.1016/j.neuroscience.2003.08.048; Rao ML, 2003, PSYCHONEUROENDOCRINO, V28, P83, DOI 10.1016/S0306-4530(02)00126-9; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Reddy J, 2005, J IMMUNOL, V175, P5591, DOI 10.4049/jimmunol.175.9.5591; Reeves MJ, 2008, LANCET NEUROL, V7, P915, DOI 10.1016/S1474-4422(08)70193-5; Reite M, 1997, ARCH GEN PSYCHIAT, V54, P433; Reyna-Neyra A, 2002, BRAIN RES BULL, V58, P607, DOI 10.1016/S0361-9230(02)00829-8; Riecher-Rossler A, 2000, ACTA PSYCHIAT SCAND, V102, P58, DOI 10.1034/j.1600-0447.2000.00011.x; Rodriguez-Perez AI, 2013, NEUROBIOL DIS, V58, P209, DOI 10.1016/j.nbd.2013.06.004; Roglio I, 2008, NEUROSCIENCE, V155, P673, DOI 10.1016/j.neuroscience.2008.06.034; Roglio I, 2007, CELL MOL LIFE SCI, V64, P1158, DOI 10.1007/s00018-007-7002-5; Roglio I, 2009, J PERIPHER NERV SYST, V14, P36, DOI 10.1111/j.1529-8027.2009.00204.x; Romeo E, 1998, AM J PSYCHIAT, V155, P910, DOI 10.1176/ajp.155.7.910; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOS RAC, 1991, J MED GENET, V28, P515, DOI 10.1136/jmg.28.8.515; Roquer J, 2003, STROKE, V34, P1581, DOI 10.1161/01.STR.0000078562.82918.F6; Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918; Rosario ER, 2012, BRAIN RES, V1466, P137, DOI 10.1016/j.brainres.2012.05.011; Rosario ER, 2011, NEUROBIOL AGING, V32, P604, DOI 10.1016/j.neurobiolaging.2009.04.008; Rosario ER, 2010, BRAIN RES, V1359, P281, DOI 10.1016/j.brainres.2010.08.068; Rupprecht R, 1999, STEROIDS, V64, P83, DOI 10.1016/S0039-128X(98)00101-9; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Safarinejad MR, 2008, J NEUROENDOCRINOL, V20, P1368, DOI 10.1111/j.1365-2826.2008.01791.x; Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050; Savettieri G, 2004, J NEUROL, V251, P1208, DOI 10.1007/s00415-004-0508-y; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schaeffer V, 2008, NEUROSCIENCE, V151, P758, DOI 10.1016/j.neuroscience.2007.11.032; Schaeffer V, 2008, NEUROCHEM INT, V52, P948, DOI 10.1016/j.neuint.2008.01.010; Schaeffer V, 2006, J NEUROBIOL, V66, P868, DOI 10.1002/neu.20267; Schneider T, 2008, PSYCHONEUROENDOCRINO, V33, P728, DOI 10.1016/j.psyneuen.2008.02.011; Schule C, 2014, PROG NEUROBIOL, V113, P79, DOI 10.1016/j.pneurobio.2013.09.003; Schwendimann RN, 2007, INT REV NEUROBIOL, V79, P377, DOI 10.1016/S0074-7742(07)79017-7; Seidman LJ, 1997, BIOL PSYCHIAT, V42, P104, DOI 10.1016/S0006-3223(96)00300-9; Selvamani A, 2014, CLIN SCI, V127, P77, DOI 10.1042/CS20130565; Shores MM, 2004, ARCH GEN PSYCHIAT, V61, P162, DOI 10.1001/archpsyc.61.2.162; Sicotte NL, 2007, ARCH NEUROL-CHICAGO, V64, P683, DOI 10.1001/archneur.64.5.683; Simonds VA, 2003, J AFFECT DISORDERS, V77, P197, DOI 10.1016/S0165-0327(02)00113-1; Singh M, 2005, ANN NY ACAD SCI, V1052, P145, DOI 10.1196/annals.1347.010; Siriphorn A, 2012, J COMP NEUROL, V520, P2630, DOI 10.1002/cne.23056; Skinner DC, 1998, P NATL ACAD SCI USA, V95, P10978, DOI 10.1073/pnas.95.18.10978; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Sohrabji F, 2015, FRONT NEUROENDOCRIN, V36, P1, DOI 10.1016/j.yfrne.2014.05.003; Spence RD, 2012, FRONT NEUROENDOCRIN, V33, P105, DOI 10.1016/j.yfrne.2011.12.001; Stack CM, 2008, EXP NEUROL, V211, P67, DOI 10.1016/j.expneurol.2008.01.003; STEINER RA, 1982, ENDOCRINOLOGY, V111, P2055, DOI 10.1210/endo-111-6-2055; Svenningsen AF, 1999, J NEUROSCI RES, V57, P124, DOI 10.1002/(SICI)1097-4547(19990701)57:1<124::AID-JNR13>3.3.CO;2-G; SZYMANSKI S, 1995, AM J PSYCHIAT, V152, P698; Takahashi T, 2003, BIOL PSYCHIAT, V53, P593, DOI 10.1016/S0006-3223(02)01483-X; Tanzer L, 2004, HORM BEHAV, V45, P339, DOI 10.1016/j.yhbeh.2004.01.002; Taylor LC, 2010, NEUROBIOL DIS, V39, P127, DOI 10.1016/j.nbd.2010.03.016; TORRESALEMAN I, 1992, GLIA, V6, P180, DOI 10.1002/glia.440060305; Tsutsui Kazuyoshi, 2011, Front Endocrinol (Lausanne), V2, P61, DOI 10.3389/fendo.2011.00061; Tsutsui K, 2012, CEREBELLUM, V11, P414, DOI 10.1007/s12311-011-0341-7; Tunez I, 2006, NEUROCHEM INT, V48, P367, DOI 10.1016/j.neuint.2005.11.011; Turtzo LC, 2008, CEREBROVASC DIS, V26, P462, DOI 10.1159/000155983; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Veiga S, 2006, NEUROSCI LETT, V402, P150, DOI 10.1016/j.neulet.2006.03.058; Velazquez-Zamora DA, 2012, HORM BEHAV, V61, P512, DOI 10.1016/j.yhbeh.2012.01.010; Veliskova J, 2006, NEUROSCIENCE, V138, P837, DOI 10.1016/j.neuroscience.2005.07.005; VITA G, 1983, EXP NEUROL, V80, P279, DOI 10.1016/0014-4886(83)90282-0; VOLKMAR FR, 1993, J AUTISM DEV DISORD, V23, P579, DOI 10.1007/BF01046103; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Walf A. A., 2014, PHYSIOL BEHAV, V99, P169; Walf AA, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00040; Walf AA, 2010, PHYSIOL BEHAV, V99, P169, DOI 10.1016/j.physbeh.2009.09.017; Walf AA, 2009, PSYCHONEUROENDOCRINO, V34, P909, DOI [10.1016/j.psyneuen.2009.01.004, 10.1016/j.psyneuen.2009.07.005]; Wang JM, 2008, BRAIN RES REV, V57, P398, DOI 10.1016/j.brainresrev.2007.08.010; Wei T, 1997, BRAIN, V120, P1067, DOI 10.1093/brain/120.6.1067; Wirth M.M., 2010, FRONT ENDOCRINOL, V2, P1, DOI [10.3389/fendo.2011.00019., DOI 10.3389/FENDO.2011.00019, 10.3389/fendo.2011.00019]; Wooten GF, 2004, J NEUROL NEUROSUR PS, V75, P637, DOI 10.1136/jnnp.2003.020982; Yang SY, 2014, J STEROID BIOCHEM, V143, P460, DOI 10.1016/j.jsbmb.2014.07.001; Yorek MA, 2002, AM J PHYSIOL-ENDOC M, V283, pE1067, DOI 10.1152/ajpendo.00173.2002; YU WHA, 1989, BRAIN RES, V491, P379, DOI 10.1016/0006-8993(89)90075-9; YU WHA, 1982, EXP NEUROL, V77, P129; Yue X, 2005, P NATL ACAD SCI USA, V102, P19198, DOI 10.1073/pnas.0505203102; Zappia M, 2005, ARCH NEUROL-CHICAGO, V62, P601, DOI 10.1001/archneur.62.4.601; Zhang QG, 2014, MOL CELL ENDOCRINOL, V389, P84, DOI 10.1016/j.mce.2013.12.019; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zhang Y, 2004, J NEUROSCI, V24, P5315, DOI 10.1523/JNEUROSCI.0913-04.2004; Zhu H, 2012, NEURAL REGEN RES, V7, P2424, DOI 10.3969/j.issn.1673-5374.2012.31.003; Zorumski CF, 2013, NEUROSCI BIOBEHAV R, V37, P109, DOI 10.1016/j.neubiorev.2012.10.005; Zuloaga KL, 2012, ENDOCRINOLOGY, V153, P5949, DOI 10.1210/en.2012-1316; Zup SL, 2014, NEUROSCIENCE, V281, P77, DOI 10.1016/j.neuroscience.2014.09.040	356	50	51	1	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-7634	1873-7528		NEUROSCI BIOBEHAV R	Neurosci. Biobehav. Rev.	AUG	2016	67						25	40		10.1016/j.neubiorev.2015.09.023			16	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	DS2QD	WOS:000380627700004	26657814				2021-06-18	
J	Baker, JG; Leddy, JJ; Darling, SR; Shucard, J; Makdissi, M; Willer, BS				Baker, John G.; Leddy, John J.; Darling, Scott R.; Shucard, Jennifer; Makdissi, Michael; Willer, Barry S.			Gender Differences in Recovery From Sports-Related Concussion in Adolescents	CLINICAL PEDIATRICS			English	Article							SEX-DIFFERENCES; SYMPTOMS; INJURY; RELIABILITY		[Baker, John G.; Leddy, John J.; Darling, Scott R.; Shucard, Jennifer; Makdissi, Michael; Willer, Barry S.] Univ Buffalo, Buffalo, NY USA; [Makdissi, Michael] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia	Baker, JG (corresponding author), Univ Buffalo, Orthoped & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	jgbaker@buffalo.edu			Robert Rich Family Foundation; Program for Understanding Childhood Concussion and Stroke; Buffalo Bills (Ralph Wilson) Team Physician Fund; Buffalo Sabres Foundation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was financially supported by The Robert Rich Family Foundation, Program for Understanding Childhood Concussion and Stroke, Buffalo Bills (Ralph Wilson) Team Physician Fund, and the Buffalo Sabres Foundation.	Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Darling SR, 2014, CLIN J SPORT MED, V24, P128, DOI 10.1097/JSM.0000000000000026; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Esposito G, 1996, J NUCL MED, V37, P559; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; King N, 2014, NEUROREHABILITATION, V34, P741, DOI 10.3233/NRE-141072; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; McCrory P, 2009, BRIT J SPORT MED S1, V43, pi85; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	18	50	50	0	24	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	JUL	2016	55	8					771	775		10.1177/0009922815606417			5	Pediatrics	Pediatrics	DP3NV	WOS:000378402500013	26378093				2021-06-18	
J	Wright, AD; Jarrett, M; Vavasour, I; Shahinfard, E; Kolind, S; van Donkelaar, P; Taunton, J; Li, D; Rauscher, A				Wright, Alexander D.; Jarrett, Michael; Vavasour, Irene; Shahinfard, Elham; Kolind, Shannon; van Donkelaar, Paul; Taunton, Jack; Li, David; Rauscher, Alexander			Myelin Water Fraction Is Transiently Reduced after a Single Mild Traumatic Brain Injury - A Prospective Cohort Study in Collegiate Hockey Players	PLOS ONE			English	Article							SPORTS-RELATED CONCUSSION; TENSOR IMAGING FINDINGS; WHITE-MATTER INTEGRITY; DIFFUSE AXONAL INJURY; MULTIPLE-SCLEROSIS; CORPUS-CALLOSUM; UNMYELINATED AXONS; N-ACETYLASPARTATE; NERVOUS-SYSTEM; DAMAGE	Impact-related mild traumatic brain injuries (mTBI) are a major public health concern, and remain as one of the most poorly understood injuries in the field of neuroscience. Currently, the diagnosis and management of such injuries are based largely on patient-reported symptoms. An improved understanding of the underlying pathophysiology of mTBI is urgently needed in order to develop better diagnostic and management protocols. Specifically, dynamic post-injury changes to the myelin sheath in the human brain have not been examined, despite 'compromised white matter integrity' often being described as a consequence of mTBI. In this preliminary cohort study, myelin water imaging was used to prospectively evaluate changes in myelin water fraction, derived from the T2 decay signal, in two varsity hockey teams (45 players) over one season of athletic competition. 11 players sustained a concussion during competition, and were scanned at 72 hours, 2 weeks, and 2 months post-injury. Results demonstrated a reduction in myelin water fraction at 2 weeks post-injury in several brain areas relative to preseason scans, including the splenium of the corpus callosum, right posterior thalamic radiation, left superior corona radiata, left superior longitudinal fasciculus, and left posterior limb of the internal capsule. Myelin water fraction recovered to pre-season values by 2 months post-injury. These results may indicate transient myelin disruption following a single mTBI, with subsequent remyelination of affected neurons. Myelin disruption was not apparent in the athletes who did not experience a concussion, despite exposure to repetitive subconcussive trauma over a season of collegiate hockey. These findings may help to explain many of the metabolic and neurological deficits observed clinically following mTBI.	[Wright, Alexander D.] Univ British Columbia, MD PhD Program, Vancouver, BC V5Z 1M9, Canada; [Wright, Alexander D.] Univ British Columbia Okanagan, Southern Med Program, Kelowna, BC, Canada; [Wright, Alexander D.] Univ British Columbia, Dept Expt Med, Vancouver, BC V5Z 1M9, Canada; [Jarrett, Michael; Vavasour, Irene; Shahinfard, Elham; Rauscher, Alexander] Univ British Columbia, UBC MRI Res Ctr, Vancouver, BC V5Z 1M9, Canada; [Kolind, Shannon] Univ British Columbia, Div Neurol, Fac Med, Vancouver, BC V5Z 1M9, Canada; [van Donkelaar, Paul] Univ British Columbia Okanagan, Sch Hlth & Exercise Sci, Kelowna, BC, Canada; [Taunton, Jack] Univ British Columbia, Fac Med, Div Sports Med, Vancouver, BC, Canada; [Li, David] Univ British Columbia, Fac Med, Dept Radiol, Vancouver, BC, Canada; [Rauscher, Alexander] Univ British Columbia, Dept Pediat, Div Neurol, Vancouver, BC V6T 1W5, Canada	Rauscher, A (corresponding author), Univ British Columbia, UBC MRI Res Ctr, Vancouver, BC V5Z 1M9, Canada.	rauscher@physics.ubc.ca		Shahinfard, Elham/0000-0002-3526-0086; Rauscher, Alexander/0000-0002-1961-8252	London Drugs Award for Research Excellence in Radiology; Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [201109MSH-261306-183304]; Vanier Canada Graduate Scholarships program	This research was funded by a London Drugs Award for Research Excellence in Radiology (no grant number) and by a New Investigator Award to Alexander Rauscher from the Canadian Institutes for Health Research (CIHR, grant #201109MSH-261306-183304). Alexander Rauscher is also a Canada Research Chair in Developmental Neuroimaging. Alexander D. Wright was supported by the Vanier Canada Graduate Scholarships program. No persons other than the listed authors had substantial scientific input into this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armstrong R.C., 2015, EXP NEUROL; Bailes JE, 2014, PROG NEUROL SURG, V28, P50, DOI 10.1159/000358765; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Benarroch EE, 2009, NEUROLOGY, V72, P1779, DOI 10.1212/WNL.0b013e3181a6b123; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Blennow K, 2011, ACTA NEUROL SCAND, V123, P245, DOI 10.1111/j.1600-0404.2010.01408.x; Chong CD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0485-0; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Gareau PJ, 2000, J MAGN RESON IMAGING, V11, P586, DOI 10.1002/1522-2586(200006)11:6<586::AID-JMRI3>3.0.CO;2-V; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hsieh S-T, 1993, BRAIN PATHOL, V3, P307; Jarrett M, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00011; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kozlowski P, 2008, MAGN RESON MED, V59, P796, DOI 10.1002/mrm.21527; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Laule C, 2006, MULT SCLER, V12, P747, DOI 10.1177/1352458506070928; Laule C, 2007, NEUROTHERAPEUTICS, V4, P460, DOI 10.1016/j.nurt.2007.05.004; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Liang ALW, 2012, J NEUROL, V259, P1151, DOI 10.1007/s00415-011-6318-0; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; MacKay A, 2006, MAGN RESON IMAGING, V24, P515, DOI 10.1016/j.mri.2005.12.037; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Maxwell WL, 2015, J NEUROTRAUMA; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MEHTA V, 1995, MOL BRAIN RES, V31, P151, DOI 10.1016/0169-328X(95)00044-S; Meier TB, 2015, JAMA NEUROL; Meyers SM, 2013, J MAGN RESON IMAGING, V38, P1445, DOI 10.1002/jmri.24106; Meyers SM, 2009, MAGN RESON IMAGING, V27, P1096, DOI 10.1016/j.mri.2009.02.001; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Miyamoto N, 2013, STROKE, V44, P3516, DOI 10.1161/STROKEAHA.113.002813; Narayanan S, 1997, ANN NEUROL, V41, P385, DOI 10.1002/ana.410410314; NEISHABOURI AM, 2011, BMC NEUROSCI, V12(S, DOI DOI 10.1186/1471-2202-12-S1-P100; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nordengen K, 2015, BRAIN STRUCT FUNCT, V220, P899, DOI 10.1007/s00429-013-0691-7; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Oh J, 2007, J NEUROIMAGING, V17, P156, DOI 10.1111/j.1552-6569.2007.00098.x; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prasloski T, 2012, NEUROIMAGE, V63, P533, DOI 10.1016/j.neuroimage.2012.06.064; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Sanchez I, 1996, J NEUROSCI, V16, P5095; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shi H., 2015, EXP NEUROL; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stanisz GJ, 2004, MAGNET RESON MED, V51, P473, DOI 10.1002/mrm.20008; STEWART WA, 1993, MAGNET RESON MED, V29, P767, DOI 10.1002/mrm.1910290608; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Tsunoda I, 2002, SPRINGER SEMIN IMMUN, V24, P105, DOI 10.1007/s00281-002-0105-z; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vavasour IM, 2009, J NEUROL SCI, V276, P49, DOI 10.1016/j.jns.2008.08.022; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; WAXMAN SG, 1977, ARCH NEUROL-CHICAGO, V34, P585, DOI 10.1001/archneur.1977.00500220019003; Webb S, 2003, MAGNET RESON MED, V49, P638, DOI 10.1002/mrm.10411; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	81	50	50	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2016	11	2							e0150215	10.1371/journal.pone.0150215			16	Multidisciplinary Sciences	Science & Technology - Other Topics	DF2LW	WOS:000371175700062	26913900	DOAJ Gold, Green Published			2021-06-18	
J	Failla, MD; Conley, YP; Wagner, AK				Failla, Michelle D.; Conley, Yvette P.; Wagner, Amy K.			Brain-Derived Neurotrophic Factor (BDNF) in Traumatic Brain Injury-Related Mortality: Interrelationships Between Genetics and Acute Systemic and Central Nervous System BDNF Profiles	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; aging; BDNF; genetics; mortality; Rehabilomics	ACTIVITY-DEPENDENT SECRETION; TRKB MESSENGER-RNA; VAL66MET POLYMORPHISM; REHABILITATION RESEARCH; OUTCOME PREDICTION; HUMAN PLATELETS; TRUNCATED TRKB; RESEARCH MODEL; SEVERE TBI; LIFE-SPAN	Background. Older adults have higher mortality rates after severe traumatic brain injury (TBI) compared to younger adults. Brain-derived neurotrophic factor (BDNF) signaling is altered in aging and is important to TBI given its role in neuronal survival/plasticity and autonomic function. Following experimental TBI, acute BDNF administration has not been efficacious. Clinically, genetic variation in BDNF (reduced signaling alleles: rs6265, Met-carriers; rs7124442, C-carriers) can be protective against acute mortality. Postacutely, these genotypes carry lower mortality risk in older adults and greater mortality risk among younger adults. Objective. Investigate BDNF levels in mortality/outcome following severe TBI in the context of age and genetic risk. Methods. Cerebrospinal fluid (CSF) and serum BDNF were assessed prospectively during the first week following severe TBI (n = 203) and in controls (n = 10). Age, BDNF genotype, and BDNF levels were assessed as mortality/outcome predictors. Results. CSF BDNF levels tended to be higher post-TBI (P = .061) versus controls and were associated with time until death (P = .042). In contrast, serum BDNF levels were reduced post-TBI versus controls (P < .0001). Both gene * BDNF serum and gene * age interactions were mortality predictors post-TBI in the same multivariate model. CSF and serum BDNF tended to be negatively correlated post-TBI (P = .07). Conclusions. BDNF levels predicted mortality, in addition to gene * age interactions, suggesting levels capture additional mortality risk. Higher CSF BDNF post-TBI may be detrimental due to injury and age-related increases in pro-apoptotic BDNF target receptors. Negative CSF and serum BDNF correlations post-TBI suggest blood-brain barrier transit alterations. Understanding BDNF signaling in neuronal survival, plasticity, and autonomic function may inform treatment.	[Failla, Michelle D.; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Hlth Promot & Dev, Pittsburgh, PA 15213 USA; [Conley, Yvette P.; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Phys Med & Rehabil, 3471 Fifth Ave Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Failla, Michelle/AAI-3788-2021	Failla, Michelle/0000-0001-9734-3373; Conley, Yvette/0000-0002-1784-6067	National Institute on Disability and Rehabilitation Research [NIDRR H133A120087]; National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR008424, R01NR013342]; US Department of DefenseUnited States Department of Defense [W81XWH-07-1-0701]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR008424, R01NR013342] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: National Institute on Disability and Rehabilitation Research (Grant Number: NIDRR H133A120087, Wagner); National Institute of Nursing Research (Grant Number: R01NR008424, Conley; R01NR013342, Conley); US Department of Defense (Grant Number: W81XWH-07-1-0701, Wagner); National Institute of Child Health and Human Development (Grant Number: R01HD048162, Wagner).	Alexander N, 2010, PSYCHONEUROENDOCRINO, V35, P949, DOI 10.1016/j.psyneuen.2009.12.008; Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barker PA, 2009, NAT NEUROSCI, V12, P105, DOI 10.1038/nn0209-105; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Brady R, 1999, J NEUROSCI, V19, P2131; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Brunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309; Bus BAA, 2012, WORLD J BIOL PSYCHIA, V13, P39, DOI 10.3109/15622975.2010.545187; Caporali A, 2009, PHYSIOL REV, V89, P279, DOI 10.1152/physrev.00007.2008; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; COX DR, 1972, J R STAT SOC B, V34, P187; Dawood T, 2007, MOL PSYCHIATR, V12, P981, DOI 10.1038/sj.mp.4002059; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Erickson KI, 2010, J NEUROSCI, V30, P5368, DOI 10.1523/JNEUROSCI.6251-09.2010; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Freedman ML, 2004, NAT GENET, V36, P388, DOI 10.1038/ng1333; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Gomes JR, 2012, J NEUROSCI, V32, P4610, DOI 10.1523/JNEUROSCI.0374-12.2012; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hallden S, 2013, HEART, V99, P949, DOI 10.1136/heartjnl-2013-303634; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1975, LANCET, V1, P480; Kalish H, 2010, J CHROMATOGR B, V878, P194, DOI 10.1016/j.jchromb.2009.10.022; Kernie SG, 2000, EMBO J, V19, P1290, DOI 10.1093/emboj/19.6.1290; Krabbe KS, 2009, J AM GERIATR SOC, V57, P1447, DOI 10.1111/j.1532-5415.2009.02345.x; Kudielka BM, 2004, PSYCHONEUROENDOCRINO, V29, P83, DOI 10.1016/S0306-4530(02)00146-4; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; Lommatzsch M, 2005, NEUROBIOL AGING, V26, P115, DOI 10.1016/j.neurobiolaging.2004.03.002; Martinowich K, 2008, NEUROPSYCHOPHARMACOL, V33, P73, DOI 10.1038/sj.npp.1301571; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; Nettiksimmons J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091339; Oakley R, 2014, AGING DIS, V5, P114, DOI 10.14336/AD.2014.0500114; Orefice LL, 2013, J NEUROSCI, V33, P11618, DOI 10.1523/JNEUROSCI.0012-13.2013; Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5; PELLEYMOUNTER MA, 1995, EXP NEUROL, V131, P229, DOI 10.1016/0014-4886(95)90045-4; Piccinni A, 2008, CHRONOBIOL INT, V25, P819, DOI 10.1080/07420520802387773; Pillai A, 2010, INT J NEUROPSYCHOPH, V13, P535, DOI 10.1017/S1461145709991015; Rasmussen P, 2009, EXP PHYSIOL, V94, P1062, DOI 10.1113/expphysiol.2009.048512; Ritter C, 2012, CRIT CARE, V16, DOI 10.1186/cc11902; Romanczyk TB, 2002, EUR J NEUROSCI, V15, P269, DOI 10.1046/j.0953-816x.2001.01858.x; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Rothman SM, 2012, ANN NY ACAD SCI, V1264, P49, DOI 10.1111/j.1749-6632.2012.06525.x; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; Shalev I, 2009, PSYCHONEUROENDOCRINO, V34, P382, DOI 10.1016/j.psyneuen.2008.09.017; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tapia-Arancibia L, 2008, BRAIN RES REV, V59, P201, DOI 10.1016/j.brainresrev.2008.07.007; Terracciano A, 2013, WORLD J BIOL PSYCHIA, V14, P583, DOI 10.3109/15622975.2011.616533; Trajkovska V, 2007, BRAIN RES BULL, V73, P143, DOI 10.1016/j.brainresbull.2007.03.009; Tsuchimine S, 2014, NEUROPSYCHOBIOLOGY, V69, P83, DOI 10.1159/000358061; Vidaurre OG, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.143; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wan RQ, 2014, J NEUROCHEM, V129, P573, DOI 10.1111/jnc.12656; Wang H, 2002, NEUROSCIENCE, V112, P967, DOI 10.1016/S0306-4522(02)00085-4; Webster MJ, 2006, GENE EXPR PATTERNS, V6, P941, DOI 10.1016/j.modgep.2006.03.009; Wise EK, 2012, ARCH PHYS MED REHAB, V93, P1319, DOI 10.1016/j.apmr.2012.05.009; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; Yang AC, 2010, AM J MED GENET B, V153B, P1024, DOI 10.1002/ajmg.b.31069; Zuccato C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022966	72	50	52	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JAN	2016	30	1					83	93		10.1177/1545968315586465			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CZ5VH	WOS:000367169900008	25979196	Green Accepted			2021-06-18	
J	Baulac, M; de Boer, H; Elger, C; Glynn, M; Kalviainen, R; Little, A; Mifsud, J; Perucca, E; Pitkanen, A; Ryvlin, P				Baulac, Michel; de Boer, Hanneke; Elger, Christian; Glynn, Mike; Kalviainen, Reetta; Little, Ann; Mifsud, Janet; Perucca, Emilio; Pitkanen, Asla; Ryvlin, Philippe			Epilepsy priorities in Europe: A report of the ILAE-IBE Epilepsy Advocacy Europe Task Force	EPILEPSIA			English	Article						Advocacy; Biomarkers; Cure; Epileptogenesis; Epilepsy; European Commission; Horizon 2020; Research; Treatment	PSYCHIATRIC COMORBIDITY; ANTIEPILEPTIC DRUGS; GENE-THERAPY; SEIZURES; CHILDREN; CARE; EPIDEMIOLOGY; HEALTH; MECHANISMS; DEPRESSION	The European Forum on Epilepsy Research (ERF2013), which took place in Dublin, Ireland, on May 26-29, 2013, was designed to appraise epilepsy research priorities in Europe through consultation with clinical and basic scientists as well as representatives of lay organizations and health care providers. The ultimate goal was to provide a platform to improve the lives of persons with epilepsy by influencing the political agenda of the EU. The Forum highlighted the epidemiologic, medical, and social importance of epilepsy in Europe, and addressed three separate but closely related concepts. First, possibilities were explored as to how the stigma and social burden associated with epilepsy could be reduced through targeted initiatives at EU national and regional levels. Second, ways to ensure optimal standards of care throughout Europe were specifically discussed. Finally, a need for further funding in epilepsy research within the European Horizon 2020 funding programme was communicated to politicians and policymakers participating to the forum. Research topics discussed specifically included (1) epilepsy in the developing brain; (2) novel targets for innovative diagnostics and treatment of epilepsy; (3) what is required for prevention and cure of epilepsy; and (4) epilepsy and comorbidities, with a special focus on aging and mental health. This report provides a summary of recommendations that emerged at ERF2013 about how to (1) strengthen epilepsy research, (2) reduce the treatment gap, and (3) reduce the burden and stigma associated with epilepsy. Half of the 6 million European citizens with epilepsy feel stigmatized and experience social exclusion, stressing the need for funding trans-European awareness campaigns and monitoring their impact on stigma, in line with the global commitment of the European Commission and with the recommendations made in the 2011 Written Declaration on Epilepsy. Epilepsy care has high rates of misdiagnosis and considerable variability in organization and quality across European countries, translating into huge societal cost (0.2% GDP) and stressing the need for cost-effective programs of harmonization and optimization of epilepsy care throughout Europe. There is currently no cure or prevention for epilepsy, and 30% of affected persons are not controlled by current treatments, stressing the need for pursuing research efforts in the field within Horizon 2020. Priorities should include (1) development of innovative biomarkers and therapeutic targets and strategies, from gene and cell-based therapies to technologically advanced surgical treatment; (2) addressing issues raised by pediatric and aging populations, as well as by specific etiologies and comorbidities such as traumatic brain injury (TBI) and cognitive dysfunction, toward more personalized medicine and prevention; and (3) translational studies and clinical trials built upon well-established European consortia.	[Baulac, Michel] Salpetriere Hosp, Dept Neurol, Paris, France; [Baulac, Michel] Salpetriere Hosp, ICM A IHU, Paris, France; [de Boer, Hanneke] SEIN Epilepsy Inst Netherlands, Heemstede, Netherlands; [Elger, Christian] Univ Bonn, Dept Epileptol, Bonn, Germany; [Glynn, Mike] Epilepsy Ireland, Dublin, Ireland; [Kalviainen, Reetta] Kuopio Univ Hosp, Kuopio Epilepsy Ctr, SF-70210 Kuopio, Finland; [Kalviainen, Reetta] Univ Eastern Finland, Dept Neurol, Kuopio, Finland; [Little, Ann] Int Bur Epilepsy, Dublin, Ireland; [Mifsud, Janet] Univ Malta, Dept Clin Pharmacol & Therapeut, Msida, Malta; [Perucca, Emilio] Univ Pavia, Dept Internal Med & Therapeut, C Mondino Natl Neurol Inst, I-27100 Pavia, Italy; [Pitkanen, Asla] Univ Eastern Finland, Dept Neurol, AI Virtanen Inst Mol Sci, Kuopio, Finland; [Ryvlin, Philippe] CHU Vaudois, Dept Clin Neurosci, CH-1011 Lausanne, Switzerland	Ryvlin, P (corresponding author), CHU Vaudois, Dept Clin Neurosci, BH-10-137,Rue Bugnon 46, CH-1011 Lausanne, Switzerland.	philipperyvlin@gmail.com	Ryvlin, Philippe/K-7402-2019; Ryvlin, Philippe/O-5214-2016; Mifsud, Janet/AAP-3121-2021; Perucca, Emilio/Q-7308-2019	Ryvlin, Philippe/0000-0001-7775-6576; Mifsud, Janet/0000-0002-7047-6827	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [Health-F1-2012-306020]	The ERF 2013 was made possible through a grant from the European Commission, within the 7th Framework Program; Grant Agreement No.: Health-F1-2012-306020.	ANNEGERS JF, 1988, NEUROLOGY, V38, P1407, DOI 10.1212/WNL.38.9.1407; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 2012, EP SPECTR; Baker GA, 2000, EPILEPSIA, V41, P98, DOI 10.1111/j.1528-1157.2000.tb01512.x; Baulac M, 2012, SEIZURE-EUR J EPILEP, V21, P75, DOI 10.1016/j.seizure.2011.11.001; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Brodie MJ, 2012, NEUROLOGY, V78, P1548, DOI 10.1212/WNL.0b013e3182563b19; Brodie MJ, 1997, EPILEPSIA, V38, P1245, DOI 10.1111/j.1528-1157.1997.tb01224.x; Burn J, 1997, BRIT MED J, V315, P1582, DOI 10.1136/bmj.315.7122.1582; Catena-Dell'Osso M, 2013, CURR MED CHEM, V20, P2861; Cleaver A, CALL CHARITIES CHALL; Cowan LD, 2002, MENT RETARD DEV D R, V8, P171, DOI 10.1002/mrdd.10035; Curry DJ, 2012, EPILEPSY BEHAV, V24, P408, DOI 10.1016/j.yebeh.2012.04.135; de Boer HM, 2008, EPILEPSY BEHAV, V12, P540, DOI 10.1016/j.yebeh.2007.12.019; de Curtis M, 2009, EPILEPSIA, V50, P2514, DOI 10.1111/j.1528-1167.2009.02249.x; Devinsky O, 2013, TRENDS NEUROSCI, V36, P174, DOI 10.1016/j.tins.2012.11.008; Engel J, 2013, EPILEPSIA, V54, P61, DOI 10.1111/epi.12299; England MJ, 2012, EPILEPSY BEHAV, V25, P266, DOI 10.1016/j.yebeh.2012.06.016; EUCARE, 2003, Epilepsia, V44 Suppl 6, P1; Fitzsimons M, 2012, EPILEPSY BEHAV, V23, P1, DOI 10.1016/j.yebeh.2011.10.019; Forsgren L, 2005, EUR J NEUROL, V12, P245, DOI 10.1111/j.1468-1331.2004.00992.x; Gaitatzis A, 2004, EPILEPSIA, V45, P1613, DOI 10.1111/j.0013-9580.2004.17504.x; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Guerrini R, 2006, LANCET, V367, P499, DOI 10.1016/S0140-6736(06)68182-8; Helmstaedter Christoph, 2012, Handb Clin Neurol, V107, P437, DOI 10.1016/B978-0-444-52898-8.00036-7; Hermann B, 2006, BRAIN, V129, P2609, DOI 10.1093/brain/awl196; Hesdorffer DC, 2006, ANN NEUROL, V59, P35, DOI 10.1002/ana.20685; Hunt RF, 2013, NAT NEUROSCI, V16, P692, DOI 10.1038/nn.3392; Jacoby A, 2004, EPILEPSIA, V45, P1405, DOI 10.1111/j.0013-9580.2004.02904.x; Jedrzejczak J, 2013, SEIZURE-EUR J EPILEP, V22, P452, DOI 10.1016/j.seizure.2013.03.001; Jimenez-Mateos EM, 2013, NEUROSCIENCE, V238, P218, DOI 10.1016/j.neuroscience.2013.02.027; Jones JE, 2007, EPILEPSIA, V48, P2357; Jones JE, 2007, DEV MED CHILD NEUROL, V49, P493, DOI 10.1111/j.1469-8749.2007.00493.x; Kaindl AM, 2006, CELL MOL LIFE SCI, V63, P399, DOI 10.1007/s00018-005-5348-0; Kerr MP, 2012, ACTA NEUROL SCAND, V126, P1, DOI 10.1111/ane.12014; Kokaia M, 2013, NEUROPHARMACOLOGY, V69, P89, DOI 10.1016/j.neuropharm.2012.05.049; Lin JJ, 2012, LANCET, V380, P1180, DOI 10.1016/S0140-6736(12)61455-X; Lombroso CT, 2007, EPILEPSIA, V48, P83, DOI 10.1111/j.1528-1167.2007.01070.x; Luoni C, 2011, EPILEPSIA, V52, P2181, DOI 10.1111/j.1528-1167.2011.03325.x; Malmgren K, 2003, EPILEPSIA, V44, P727, DOI 10.1046/j.1528-1157.2003.58402.x; Marsh ED, 2006, EPILEPSIA, V47, P1999, DOI 10.1111/j.1528-1167.2006.00894.x; Nikolas H, 2007, EPILEPSY BEHAV, V10, P363, DOI 10.1016/j.yebeh.2007.01.005; Noe FM, 2012, JASPERS BASIC MECH E, P1; Ortinski P, 2004, EPILEPSY BEHAV, V5, pS60, DOI 10.1016/j.yebeh.2003.11.008; Pahl K, 2005, ATLAS EPILEPSY CARE; Perucca E, 2011, CNS DRUGS, V25, P907, DOI 10.2165/11587900-000000000-00000; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Potschka H, 2012, ADV DRUG DELIVER REV, V64, P943, DOI 10.1016/j.addr.2011.12.007; Rai D, 2012, EPILEPSIA, V53, P1095, DOI 10.1111/j.1528-1167.2012.03500.x; Ryvlin P, 2014, LANCET NEUROL, V13, P1114, DOI 10.1016/S1474-4422(14)70156-5; Simonato M, 2014, EPILEPSY BEHAV, V38, P125, DOI 10.1016/j.yebeh.2013.09.013; Sun FT, 2014, NEUROTHERAPEUTICS, V11, P553, DOI 10.1007/s13311-014-0280-3; Taylor D, 2013, HAND CLINIC, V111, P697, DOI 10.1016/B978-0-444-52891-9.00072-5; Tomson T, 2005, EPILEPSIA, V46, P54, DOI 10.1111/j.1528-1167.2005.00411.x; Tovar-Spinoza Z, 2013, CHILD NERV SYST, V29, P2089, DOI 10.1007/s00381-013-2169-6; Vezzani Annamaria, 2012, Handb Clin Neurol, V107, P163, DOI 10.1016/B978-0-444-52898-8.00010-0; Walker MC, 2013, EPILEPSIA, V54, P43, DOI 10.1111/epi.12275; Wilcox KS, 2014, ADV EXP MED BIOL, V813, P169, DOI 10.1007/978-94-017-8914-1_14; Witt JA, 2012, J NEUROL, V259, P1727, DOI 10.1007/s00415-012-6526-2; Wykes RC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004190	60	50	50	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	NOV	2015	56	11					1687	1695		10.1111/epi.13201			9	Clinical Neurology	Neurosciences & Neurology	CU9RZ	WOS:000363884100009	26415919	Other Gold, Green Published			2021-06-18	
J	Zhang, B; Bailey, WM; Braun, KJ; Gensel, JC				Zhang, Bei; Bailey, William M.; Braun, Kaitlyn J.; Gensel, John C.			Age decreases macrophage IL-10 expression: Implications for functional recovery and tissue repair in spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						Microglia; Contusion; Brain; Monocyte: IL-12p40; IL-12; Neuroprotection; Inflammation; Macrophage polarization; Macrophage polarity; Traumatic; Neurotrauma; Aged; Aging; Adult; Digigait; Grid walk; Locomotor; BMS	MONOCYTE-DERIVED MACROPHAGES; ALTERNATIVE ACTIVATION; LOCOMOTOR RECOVERY; SYNAPTIC PROTEINS; OXIDATIVE STRESS; DOWN-REGULATION; TIME-COURSE; BRAIN; INTERLEUKIN-10; MICROGLIA	Macrophages with different activation states are present after spinal cord injury (SCI). M1 macrophages purportedly promote secondary injury processes while M2 cells support axon growth. The average age at the time of SCI has increased in recent decades, however, little is known about how different physiological factors contribute to macrophage activation states after SCI. Here we investigate the effect of age on IL-10, a key indicator of M2 macrophage activation. Following mild-moderate SCI in 4 and 14 month old (MO) mice we detected significantly reduced IL-10 expression with age in the injured spinal cord. Specifically, CD86/IL-10 positive macrophages, also known as M2b or regulatory macrophages, were reduced in 14 vs. 4 MO SCI animals. This age-dependent shift in macrophage phenotype was associated with impaired functional recovery and enhanced tissue damage in 14-month-old SCI mice. In vitro, M2b macrophages release anti-inflammatory cytokines without causing neurotoxicity, suggesting that imbalances in the M2b response in 14-month-old mice may be contributing to secondary injury processes. Our data indicate that age is an important factor that regulates SCI inflammation and recovery even to mild-moderate injury. Further, alterations in macrophage activation states may contribute to recovery and we have identified the M2b phenotype as a potential target for therapeutic intervention. (C) 2015 Elsevier Inc. All rights reserved.	[Zhang, Bei; Bailey, William M.; Braun, Kaitlyn J.; Gensel, John C.] Univ Kentucky, Dept Physiol, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Gensel, JC (corresponding author), Univ Kentucky, Dept Physiol, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.	gensel.1@uky.edu		, John/0000-0001-8980-108X	Cardinal Hill Endowment; Craig H. Neilsen Foundation; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS051220 P30]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220] Funding Source: NIH RePORTER	We would like to thank Peter Rock, John Godbout, Ashley Fenn, Phillip Popovich, Amy Tovar, Linda Simmerman, Michael Orr, and Chris Richards for technical advice and support. The current project was made possible by support from a Cardinal Hill Endowment to Joe Springer, the Craig H. Neilsen Foundation, and the NINDS NS051220 P30 grant to the University of Kentucky.	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; BURGESS AW, 1985, J BIOL CHEM, V260, P6004; Didangelos A, 2014, J NEUROSCI, V34, P16424, DOI 10.1523/JNEUROSCI.2927-14.2014; Dlakic WM, 2007, J VIROL, V81, P4615, DOI 10.1128/JVI.02628-06; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Elcombe SE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060086; Fassett DR, 2007, J NEUROSURG-SPINE, V7, P277, DOI 10.3171/SPI-07/09/277; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Frank MG, 2006, NEUROBIOL AGING, V27, P717, DOI 10.1016/j.neurobiolaging.2005.03.013; Furlan JC, 2009, J NEUROTRAUM, V26, P1707, DOI [10.1089/neu.2009.0888, 10.1089/neu.2009-0888]; Furlan JC, 2010, NEUROBIOL AGING, V31, P434, DOI 10.1016/j.neurobiolaging.2008.05.003; Genovese T, 2009, J NEUROCHEM, V108, P1360, DOI 10.1111/j.1471-4159.2009.05899.x; Gensel JC, 2015, BRAIN RES, V1619, P1, DOI 10.1016/j.brainres.2014.12.045; Gensel JC, 2015, J NEUROSCI, V35, P9966, DOI 10.1523/JNEUROSCI.0337-15.2015; Gensel JC, 2009, J NEUROSCI, V29, P3956, DOI 10.1523/JNEUROSCI.3992-08.2009; Gershkoff A M, 1993, Arch Phys Med Rehabil, V74, pS402; Gomez-Nicola D, 2013, J NEUROSCI, V33, P2481, DOI 10.1523/JNEUROSCI.4440-12.2013; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gwak YS, 2004, J NEUROTRAUM, V21, P983, DOI 10.1089/0897715041650999; Gwak YS, 2004, NEUROSCI LETT, V362, P232, DOI 10.1016/j.neulet.2004.03.019; Hayashi Y, 2008, J NEUROSCI, V28, P8624, DOI 10.1523/JNEUROSCI.1957-08.2008; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Hooshmand MJ, 2014, IMMUN AGEING, V11, DOI 10.1186/1742-4933-11-15; Huang W, 2014, PM&R, V6, P332, DOI 10.1016/j.pmrj.2013.10.006; Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kuo HS, 2011, J NEUROSCI, V31, P4137, DOI 10.1523/JNEUROSCI.2592-10.2011; Kuzumaki N, 2010, SYNAPSE, V64, P721, DOI 10.1002/syn.20800; London A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00034; Longbrake EE, 2007, J NEUROCHEM, V102, P1083, DOI 10.1111/j.1471-4159.2007.04617.x; Ma SF, 2015, BRAIN BEHAV IMMUN, V45, P157, DOI 10.1016/j.bbi.2014.11.007; Maher FO, 2005, NEUROBIOL AGING, V26, P717, DOI 10.1016/j.neurobiolaging.2004.07.002; Maher FO, 2004, NEUROBIOL AGING, V25, P795, DOI 10.1016/j.neurobiolaging.2003.08.007; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2009, ARTERIOSCL THROM VAS, V29, P1419, DOI 10.1161/ATVBAHA.108.180497; McEwen ML, 2006, J NEUROTRAUM, V23, P1632, DOI 10.1089/neu.2006.23.1632; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; Mosser David M, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1402s83; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; National Spinal Cord Injury Statistical Center, 2013, J Spinal Cord Med, V36, P1, DOI 10.1179/1079026813Z.000000000136; Nolan Y, 2005, J BIOL CHEM, V280, P9354, DOI 10.1074/jbc.M412170200; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Richwine AF, 2005, BRAIN BEHAV IMMUN, V19, P512, DOI 10.1016/j.bbi.2004.12.005; Guerrero AR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-40; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Shin T, 2013, MOL NEUROBIOL, V47, P1011, DOI 10.1007/s12035-013-8398-6; Siegenthaler MM, 2008, EXP NEUROL, V213, P363, DOI 10.1016/j.expneurol.2008.06.015; Soblosky JS, 1997, J NEUROSCI METH, V78, P75, DOI 10.1016/S0165-0270(97)00131-3; Stirling DP, 2014, BRAIN, V137, P707, DOI 10.1093/brain/awt341; Stout RD, 2005, IMMUNOL REV, V205, P60, DOI 10.1111/j.0105-2896.2005.00260.x; Sudduth TL, 2013, J NEUROSCI, V33, P9684, DOI 10.1523/JNEUROSCI.1220-13.2013; Thawer SG, 2013, J NEUROIMMUNOL, V261, P7, DOI 10.1016/j.jneuroim.2013.04.008; Thompson CD, 2013, J NEUROTRAUM, V30, P1311, DOI 10.1089/neu.2012.2651; Wang X, 2007, J NEUROCHEM, V103, P2380, DOI 10.1111/j.1471-4159.2007.04978.x; Ye SM, 2001, NEUROIMMUNOMODULAT, V9, P183, DOI 10.1159/000049025; Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yonutas HM, 2015, J BIOENERG BIOMEMBR, V47, P149, DOI 10.1007/s10863-014-9593-5; Zhang B, 2014, EXP NEUROL, V258, P112, DOI 10.1016/j.expneurol.2014.04.007; Zhou ZG, 2009, J NEUROCHEM, V110, P1617, DOI 10.1111/j.1471-4159.2009.06263.x	67	50	53	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2015	273						83	91		10.1016/j.expneurol.2015.08.001			9	Neurosciences	Neurosciences & Neurology	CW7BB	WOS:000365151800008	26263843	Green Accepted			2021-06-18	
J	Howell, D; Osternig, L; Chou, LS				Howell, David; Osternig, Louis; Chou, Li-Shan			Monitoring recovery of gait balance control following concussion using an accelerometer	JOURNAL OF BIOMECHANICS			English	Article						Acceleration; Center-of-mass; Balance; Locomotion; Mild traumatic brain injury	ERROR SCORING SYSTEM; STABILITY FOLLOWING CONCUSSION; OF-MASS ACCELERATION; TO-STAND MOVEMENT; DIVIDED ATTENTION; ADOLESCENTS; SPORTS; VALIDATION; PARAMETERS; STATEMENT	Despite medical best-practice recommendations, no consistent standard exists to systematically monitor recovery from concussion. Studies utilizing camera-based systems have reported center-of-mass (COM) motion control deficits persisting in individuals with concussion up to two months post-injury. The use of an accelerometer may provide an efficient and sensitive method to monitor COM alterations following concussion that can be employed in clinical settings. This study examined: (1) frontal/sagittal plane acceleration characteristics during dual-task walking for individuals with concussion and healthy controls; and (2) the effectiveness of utilizing acceleration characteristics to classify concussed and healthy individuals via receiver operating characteristic (ROC) curve analyses. Individuals with concussion completed testing within 72 h as well as I week, 2 weeks, 1 month, and 2 months post-injury. Control subjects completed the same protocol in similar time increments. Participants walked and simultaneously completed a cognitive task while wearing an accelerometer attached to L5. Participants with concussion walked with significantly less peak medial-lateral acceleration during 55-75% gait cycle (p= 0.04) throughout the testing period compared with controls. Moderate levels of sensitivity and specificity were found at the 72 h and I week testing times (sensitivity=0.70, specificity= 0.71). ROC analysis revealed significant AUC values at the 72 h (AUC= 0.889) and two week (AUC= 0.810) time points. Accelerometer-derived measurements may assist in detecting frontal plane control deficits during dual-task walking post-concussion, consistent with camera-based studies. These initial findings demonstrate potential for using accelerometry as a tool for clinicians to monitor gait balance control following concussion. (C) 2015 Elsevier Ltd. All rights reserved.	[Howell, David; Osternig, Louis; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA	Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, 122 Esslinger Hall,1240, Eugene, OR 97403 USA.	chou@uoregon.edu	Meijer, Anna/K-5118-2016	Chou, Li-Shan/0000-0002-2777-7034	Veterans AdministrationUS Department of Veterans Affairs [A4842C8, A4843C]; Translational Research Award from the University of Oregon; Peace Health Oregon Region; Department of Defense-TATRCUnited States Department of Defense [W81XWH-11-1-0717]; Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology	This work was supported by Veterans Administration subcontract awards [A4842C8 & A4843C], Translational Research Award from the University of Oregon and Peace Health Oregon Region, the Department of Defense-TATRC Award (W81XWH-11-1-0717), and the Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology. The authors would like to acknowledge Mr. Quinn Peterson and Ms. Madison Murray for their assistance with data collection.	Brown HJ, 2014, MED SCI SPORT EXER, V46, P1610, DOI 10.1249/MSS.0000000000000263; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Bugane F, 2012, COMPUT METH PROG BIO, V108, P129, DOI 10.1016/j.cmpb.2012.02.003; Doi S.A.R., 2013, SPRINGER SERIES EPID, P69; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Fan Jerome, 2006, CJEM, V8, P19; Fujimoto M, 2014, ANN BIOMED ENG, V42, P733, DOI 10.1007/s10439-013-0945-9; Fujimoto M, 2012, J BIOMECH, V45, P543, DOI 10.1016/j.jbiomech.2011.11.037; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Perry J, 1992, GAIT ANAL NORMAL PAT, P10; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Zijlstra W, 2003, GAIT POSTURE, V18, P1, DOI 10.1016/S0966-6362(02)00190-X	25	50	50	1	22	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	SEP 18	2015	48	12					3364	3368		10.1016/j.jbiomech.2015.06.014			5	Biophysics; Engineering, Biomedical	Biophysics; Engineering	CT8ME	WOS:000363069900058	26152463				2021-06-18	
J	Febinger, HY; Thomasy, HE; Pavlova, MN; Ringgold, KM; Barf, PR; George, AM; Grillo, JN; Bachstetter, AD; Garcia, JA; Cardona, AE; Opp, MR; Gemma, C				Febinger, Heidi Y.; Thomasy, Hannah E.; Pavlova, Maria N.; Ringgold, Kristyn M.; Barf, Paulien R.; George, Amrita M.; Grillo, Jenna N.; Bachstetter, Adam D.; Garcia, Jenny A.; Cardona, Astrid E.; Opp, Mark R.; Gemma, Carmelina			Time-dependent effects of CX3CR1 in a mouse model of mild traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						CX3CR1; TBI; Microglia; Cognitive function; Cytokines	CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; FRACTALKINE-RECEPTOR; MICROGLIAL ACTIVATION; ALZHEIMERS-DISEASE; ALTERNATIVE ACTIVATION; CHEMOKINE FRACTALKINE; AMYLOID DEPOSITION; MACROPHAGE SUBSETS	Background: Neuroinflammation is an important secondary mechanism that is a key mediator of the long-term consequences of neuronal injury that occur in traumatic brain injury (TBI). Microglia are highly plastic cells with dual roles in neuronal injury and recovery. Recent studies suggest that the chemokine fractalkine (CX3CL1, FKN) mediates neural/microglial interactions via its sole receptor CX3CR1. CX3CL1/CX3CR1 signaling modulates microglia activation, and depending upon the type and time of injury, either protects or exacerbates neurological diseases. Methods: In this study, mice deficient in CX3CR1 were subjected to mild controlled cortical impact injury (CCI), a model of TBI. We evaluated the effects of genetic deletion of CX3CR1 on histopathology, cell death/survival, microglia activation, and cognitive function for 30 days post-injury. Results: During the acute post-injury period (24 h-15 days), motor deficits, cell death, and neuronal cell loss were more profound in injured wild-type than in CX3CR1(-/-) mice. In contrast, during the chronic period of 30 days post-TBI, injured CX3CR1(-/-) mice exhibited greater cognitive dysfunction and increased neuronal death than wild-type mice. The protective and deleterious effects of CX3CR1 were associated with changes in microglia phenotypes; during the acute phase CX3CR1(-/-) mice showed a predominant anti-inflammatory M2 microglial response, with increased expression of Ym1, CD206, and TGF beta. In contrast, increased M1 phenotypic microglia markers, Marco, and CD68 were predominant at 30 days post-TBI. Conclusion: Collectively, these novel data demonstrate a time-dependent role for CX3CL1/CX3CR1 signaling after TBI and suggest that the acute and chronic responses to mild TBI are modulated in part by distinct microglia phenotypes.	[Febinger, Heidi Y.; Thomasy, Hannah E.; Pavlova, Maria N.; Ringgold, Kristyn M.; Barf, Paulien R.; George, Amrita M.; Grillo, Jenna N.; Opp, Mark R.; Gemma, Carmelina] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98001 USA; [Thomasy, Hannah E.] Univ Washington, Neurosci Grad Program, Seattle, WA 98104 USA; [Grillo, Jenna N.] Univ Washington, Dept Biol, Seattle, WA 98104 USA; [Bachstetter, Adam D.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Garcia, Jenny A.; Cardona, Astrid E.] Univ Texas San Antonio, Dept Biol, San Antonio, TX 78249 USA; [Garcia, Jenny A.; Cardona, Astrid E.] Univ Texas San Antonio, South Texas Ctr Emerging Infect Dis, San Antonio, TX 78249 USA	Gemma, C (corresponding author), Univ Washington, Dept Anesthesiol & Pain Med, BOX 359724, Seattle, WA 98001 USA.	cgemma@u.washington.edu	Cardona, Astrid E/K-4749-2013	Cardona, Astrid E/0000-0002-5093-8078; Gemma, Carmelina/0000-0002-4480-0056; Bachstetter, Adam/0000-0003-4646-6757	Department of Anesthesiology and Pain Medicine of the University of Washington; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [SC1GM095426]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [SC1GM095426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG044919] Funding Source: NIH RePORTER	This study was supported by the Department of Anesthesiology and Pain Medicine of the University of Washington and by NIH SC1GM095426.	Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075; Bhaskar K, 2010, NEURON, V68, P19, DOI 10.1016/j.neuron.2010.08.023; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Cameron B, 2010, NEUROBIOL DIS, V37, P503, DOI 10.1016/j.nbd.2009.10.006; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Cho SH, 2011, J BIOL CHEM, V286, P32713, DOI 10.1074/jbc.M111.254268; Cipriani R, 2011, J NEUROSCI, V31, P16327, DOI 10.1523/JNEUROSCI.3611-11.2011; Colton CA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-27; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Combadiere C, 2008, CIRCULATION, V117, P1649, DOI 10.1161/CIRCULATIONAHA.107.745091; Denes A, 2008, J CEREBR BLOOD F MET, V28, P1707, DOI 10.1038/jcbfm.2008.64; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Fuhrmann M, 2010, NAT NEUROSCI, V13, P411, DOI 10.1038/nn.2511; Fumagalli S, 2013, GLIA, V61, P827, DOI 10.1002/glia.22474; Gaetani P, 2013, J NEUROSURG SCI, V57, P55; Garcia JA, 2013, J IMMUNOL, V191, P1063, DOI 10.4049/jimmunol.1300040; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hatori K, 2002, J NEUROSCI RES, V69, P418, DOI 10.1002/jnr.10304; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kubova H, 2001, J NEUROSCI, V21, P3593, DOI 10.1523/JNEUROSCI.21-10-03593.2001; Lee S, 2010, AM J PATHOL, V177, P2549, DOI 10.2353/ajpath.2010.100265; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Limatola C, 2005, J NEUROIMMUNOL, V166, P19, DOI 10.1016/j.jneuroim.2005.03.023; Lin SL, 2009, J IMMUNOL, V183, P6733, DOI 10.4049/jimmunol.0901473; Liu ZQ, 2010, J NEUROSCI, V30, P17091, DOI 10.1523/JNEUROSCI.4403-10.2010; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Meucci O, 2000, P NATL ACAD SCI USA, V97, P8075, DOI 10.1073/pnas.090017497; Mizuno T, 2003, BRAIN RES, V979, P65, DOI 10.1016/S0006-8993(03)02867-1; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Neher JJ, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00027; Nishiyori A, 1998, FEBS LETT, V429, P167, DOI 10.1016/S0014-5793(98)00583-3; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Pino PA, 2011, JOVE-J VIS EXP, DOI 10.3791/2348; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rancan M, 2004, J CEREBR BLOOD F MET, V24, P1110, DOI 10.1097/01.WCB.0000133470.91843.72; Ransohoff RM, 2007, INT REV NEUROBIOL, V82, P187, DOI 10.1016/S0074-7742(07)82010-1; Rogers JT, 2011, J NEUROSCI, V31, P16241, DOI 10.1523/JNEUROSCI.3667-11.2011; Sierra A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00006; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Tang ZW, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-26; Thawer SG, 2013, J NEUROIMMUNOL, V261, P7, DOI 10.1016/j.jneuroim.2013.04.008; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Yoshida H, 2001, NEUROSCI LETT, V303, P132, DOI 10.1016/S0304-3940(01)01699-8; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y	58	50	51	0	20	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	SEP 2	2015	12								154	10.1186/s12974-015-0386-5			16	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CQ1CC	WOS:000360333900001	26329692	DOAJ Gold, Green Published			2021-06-18	
J	Gilbert, KS; Kark, SM; Gehrman, P; Bogdanova, Y				Gilbert, Karma Stavitsky; Kark, Sarah M.; Gehrman, Philip; Bogdanova, Yelena			Sleep disturbances, TBI and PTSD: Implications for treatment and recovery	CLINICAL PSYCHOLOGY REVIEW			English	Article						Sleep; PTSD; TBI; Veterans; Cognition; Interventions; Sleep physiology; Neuromodulation; Paradoxical insomnia; Actigraphy	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; VENTROLATERAL PREOPTIC NUCLEUS; RANDOMIZED CONTROLLED-TRIAL; IMAGERY REHEARSAL THERAPY; WAKING DISCHARGE PATTERNS; RETURNING COMBAT VETERANS; CHRONIC PRIMARY INSOMNIA; PITUITARY-ADRENAL AXIS	Post-Traumatic Stress Disorder (PTSD), traumatic brain injury (TBI), and sleep problems significantly affect recovery and functional status in military personnel and Veterans returning from combat. Despite recent attention, sleep is understudied in the Veteran population. Few treatments and rehabilitation protocols target sleep, although poor sleep remains at clinical levels and continues to adversely impact functioning even after the resolution of PTSD or mild TBI symptoms. Recent developments in non-pharmacologic sleep treatments have proven efficacious as stand-alone interventions and have potential to improve treatment outcomes by augmenting traditional behavioral and cognitive therapies. This review discusses the extensive scope of work in the area of sleep as it relates to TBI and PTSD, including pathophysiology and neurobiology of sleep; existing and emerging treatment options; as well as methodological issues in sleep measurements for TBI and PTSD. Understanding sleep problems and their role in the development and maintenance of PTSD and TBI symptoms may lead to improvement in overall treatment outcomes while offering a non-stigmatizing entry in mental health services and make current treatments more comprehensive by helping to address a broader spectrum of difficulties. Published by Elsevier Ltd.	[Gilbert, Karma Stavitsky; Kark, Sarah M.; Bogdanova, Yelena] VA Boston Healthcare Syst, Psychol Res, Boston, MA 02130 USA; [Gilbert, Karma Stavitsky; Bogdanova, Yelena] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Gehrman, Philip] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Gehrman, Philip] Philadelphia VA Med Ctr, Philadelphia, PA USA	Bogdanova, Y (corresponding author), VA Boston Healthcare Syst, Psychol Res 151A, 150 South Huntington Ave, Boston, MA 02130 USA.	bogdanov@bu.edu	Kark, Sarah/O-3285-2019	Kark, Sarah/0000-0003-2930-9645	Rehabilitation Research and Development Service of the Department of Veterans Affairs (VA) [D6996W, I21RX001773-01]; Boston University Clinical and Translational Science Institute [UL1-RR025771]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; VA Translation Research Center for TBI and Stress Disorders (TRACTS); VA Psychology Research Service; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025771] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I21RX001773] Funding Source: NIH RePORTER	This work was supported by the Rehabilitation Research and Development Service of the Department of Veterans Affairs (VA) grants D6996W and I21RX001773-01 to YB, the National Institutes of Health and Boston University Clinical and Translational Science Institute grant UL1-RR025771 to YB, the VA Translation Research Center for TBI and Stress Disorders (TRACTS) [YB], and the VA Psychology Research Service [YB and KSG].	American Academy of Sleep Medicine, 2014, INT CLASS SLEEP DIS, V3rd; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; [Anonymous], 2010, VA CONS C; Armed Forces Health Surveillance Center (AFHSC), 2013, MSMR, V20, P9; Arnedt JT, 2013, SLEEP, V36, P353, DOI 10.5665/sleep.2448; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Babson K, 2011, J ANXIETY DISORD, V25, P706, DOI 10.1016/j.janxdis.2011.03.007; Babson KA, 2010, J ANXIETY DISORD, V24, P1, DOI 10.1016/j.janxdis.2009.08.002; Backhaus J, 2004, PSYCHONEUROENDOCRINO, V29, P1184, DOI 10.1016/j.psyneuen.2004.01.010; Baddeley Jenna L, 2013, Am J Psychother, V67, P203; Baglioni C, 2011, J AFFECT DISORDERS, V135, P10, DOI 10.1016/j.jad.2011.01.011; Bailey SL, 2001, CHRONOBIOL INT, V18, P249, DOI 10.1081/CBI-100103189; Bajor LA, 2011, HARVARD REV PSYCHIAT, V19, P240, DOI 10.3109/10673229.2011.614483; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Belanger L, 2004, J ANXIETY DISORD, V18, P561, DOI 10.1016/S0887-6185(03)00031-8; Belleville G, 2011, J PSYCHOSOM RES, V70, P318, DOI 10.1016/j.jpsychores.2010.09.022; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Bennion K.A., 2013, CEREBRAL CORTEX; Bertini M, 2004, SLEEP, V27, P875, DOI 10.1093/sleep/27.5.875; Blechert J, 2007, BEHAV RES THER, V45, P2019, DOI 10.1016/j.brat.2007.02.012; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Bogdanova Y., 2014, ARCH PHYS MED REHAB, V95, pe77; Bogdanova Y, 2015, J HEAD TRAUMA REHAB, V30, pE101; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Boynton L, 2009, J PSYCHIATR PRACT, V15, P454, DOI 10.1097/01.pra.0000364287.63210.92; Bramoweth AD, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0401-4; Bremner JD, 2007, NEUROIMAG CLIN N AM, V17, P523, DOI 10.1016/j.nic.2007.07.003; Bremner JD, 1995, PSYCHIAT RES, V59, P97; Brenner Lisa A, 2011, Dialogues Clin Neurosci, V13, P311; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Breslau N, 2004, ARCH GEN PSYCHIAT, V61, P508, DOI 10.1001/archpsyc.61.5.508; Brownlow JA, 2014, J TRAUMA STRESS, V27, P217, DOI 10.1002/jts.21906; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Bryant RA, 2006, COGN BEHAV PRACT, V13, P17, DOI 10.1016/j.cbpra.2005.03.002; Bryant RA, 2010, SLEEP, V33, P69, DOI 10.1093/sleep/33.1.69; Buchmann A, 2011, J SLEEP RES, V20, P506, DOI 10.1111/j.1365-2869.2011.00916.x; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Buysse DJ, 2008, SLEEP, V31, P473, DOI 10.1093/sleep/31.4.473; Calhoun PS, 2007, J TRAUMA STRESS, V20, P1009, DOI 10.1002/jts.20255; Capaldi VF, 2011, MIL MED, V176, P879, DOI 10.7205/MILMED-D-10-00440; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Casement MD, 2012, CLIN PSYCHOL REV, V32, P566, DOI 10.1016/j.cpr.2012.06.002; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chao LL, 2014, SLEEP, V37, P445, DOI 10.5665/sleep.3472; Chen MJ, 2006, BRAIN RES BULL, V68, P257, DOI 10.1016/j.brainresbull.2005.08.013; Chiu HY, 2014, INT J NURS STUD, V51, P892, DOI 10.1016/j.ijnurstu.2013.10.020; Chou TC, 2003, J NEUROSCI, V23, P10691; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Clow A, 2004, STRESS, V7, P29, DOI 10.1080/10253890410001667205; Clum GA, 2001, J NERV MENT DIS, V189, P618, DOI 10.1097/00005053-200109000-00008; Cohen DJ, 2013, J SLEEP RES, V22, P76, DOI 10.1111/j.1365-2869.2012.01040.x; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; Cook JM, 2010, J TRAUMA STRESS, V23, P553, DOI 10.1002/jts.20569; Dagan Y, 1999, CHRONOBIOL INT, V16, P213, DOI 10.3109/07420529909019087; Dagan Y, 1997, J PSYCHOSOM RES, V42, P577, DOI 10.1016/S0022-3999(97)00013-5; Davis Joanne L, 2006, J Trauma Dissociation, V7, P5, DOI 10.1300/J229v07n01_02; de Kloet CS, 2006, J PSYCHIATR RES, V40, P550, DOI 10.1016/j.jpsychires.2005.08.002; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Dell'Osso L, 2009, PROG NEURO-PSYCHOPH, V33, P899, DOI 10.1016/j.pnpbp.2009.04.018; Deppermann S, 2014, NEUROSCIENCE, V283, P166, DOI 10.1016/j.neuroscience.2014.08.037; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DOD (Department of Defense), 2009, DOD VA COD PROP FIN; Dombovy Mary L, 2011, Continuum (Minneap Minn), V17, P688, DOI 10.1212/01.CON.0000399095.90652.e7; Drake CL, 2003, DEPRESS ANXIETY, V18, P163, DOI 10.1002/da.10151; Edinger JD, 2005, CLIN PSYCHOL REV, V25, P539, DOI 10.1016/J.CPR.2005.04.003; Edinger JD, 2001, JAMA-J AM MED ASSOC, V285, P1856, DOI 10.1001/jama.285.14.1856; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Epstein DR, 2013, REHABIL NURS, V38, P120, DOI 10.1002/rnj.67; Epstein DR, 2012, J REHABIL RES DEV, V49, P867, DOI 10.1682/JRRD.2011.06.0114; Espie CA, 2012, SLEEP, V35, P769, DOI 10.5665/sleep.1872; Faestel PM, 2013, J CLIN SLEEP MED, V9, P577, DOI 10.5664/jcsm.2754; Faraguna U, 2008, J NEUROSCI, V28, P4088, DOI 10.1523/JNEUROSCI.5510-07.2008; Farrell-Carnahan L, 2013, MIL MED, V178, P951, DOI 10.7205/MILMED-D-13-00037; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Flanagan SR, 2007, J HEAD TRAUMA REHAB, V22, P67, DOI 10.1097/00001199-200701000-00009; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Fries E, 2009, INT J PSYCHOPHYSIOL, V72, P67, DOI 10.1016/j.ijpsycho.2008.03.014; Galovski TE, 2009, J TRAUMA STRESS, V22, P197, DOI 10.1002/jts.20418; Galuszko-Wegielnik M, 2012, PSYCHIAT DANUB, V24, pS51; Gamaldo CE, 2012, NEUROL CLIN, V30, P1313, DOI 10.1016/j.ncl.2012.08.007; Gaus SE, 2002, NEUROSCIENCE, V115, P285, DOI 10.1016/S0306-4522(02)00308-1; Gehrman P, 2013, SLEEP, V36, P1009, DOI 10.5665/sleep.2798; Gerhart JI, 2014, HEALTH PSYCHOL, V33, P365, DOI 10.1037/a0032572; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Germain A, 2007, BEHAV RES THER, V45, P627, DOI 10.1016/j.brat.2006.04.009; Germain A, 2006, ANN NY ACAD SCI, V1071, P438, DOI 10.1196/annals.1364.038; Germain A, 2013, PSYCHIAT RES-NEUROIM, V211, P176, DOI 10.1016/j.pscychresns.2012.05.007; Germain A, 2012, J PSYCHOSOM RES, V72, P89, DOI 10.1016/j.jpsychores.2011.11.010; Ghadami M.R., 2014, J INJURY VIOLENCE RE; GILLIN JC, 1990, NEW ENGL J MED, V322, P239; Gong H, 2004, J PHYSIOL-LONDON, V556, P935, DOI 10.1113/jphysiol.2003.056622; Gourley SL, 2009, NEUROPSYCHOPHARMACOL, V34, P707, DOI 10.1038/npp.2008.123; Gujar N, 2011, J NEUROSCI, V31, P4466, DOI 10.1523/JNEUROSCI.3220-10.2011; Habukawa M, 2007, BIOL PSYCHIAT, V62, P1179, DOI 10.1016/j.biopsych.2007.01.007; Harb GC, 2013, J TRAUMA STRESS, V26, P570, DOI 10.1002/jts.21854; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hu P, 2006, PSYCHOL SCI, V17, P891, DOI 10.1111/j.1467-9280.2006.01799.x; Huber R, 2007, SLEEP, V30, P129, DOI 10.1093/sleep/30.2.129; Hucklebridge F, 2005, PSYCHONEUROENDOCRINO, V30, P51, DOI 10.1016/j.psyneuen.2004.04.007; Hughes KC, 2011, EXPERT REV NEUROTHER, V11, P275, DOI [10.1586/ern.10.198, 10.1586/ERN.10.198]; Institute of Medicine, 2011, COGN REH THER TRAUM; Jackson ML, 2014, ARCH WOMEN MENT HLTH, V17, P189, DOI 10.1007/s00737-014-0417-8; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kan EM, 2012, BRAIN RES BULL, V87, P359, DOI 10.1016/j.brainresbull.2012.01.007; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kark S., 2013, J INT NEUROPSYCH SOC, V19; Karlin BE, 2013, J CONSULT CLIN PSYCH, V81, P912, DOI 10.1037/a0032554; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KELLNER R, 1992, AM J PSYCHIAT, V149, P659; Kellner R., 1991, ANN CLIN PSYCHIATRY, V3, P67; Kemp S, 2004, BRAIN INJURY, V18, P911, DOI 10.1080/02699050410001671892; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kerkhof GA, 2010, PROG BRAIN RES, V185, P49, DOI 10.1016/B978-0-444-53702-7.00004-X; Khawaja IS, 2014, PAK J MED SCI, V30, P438; Klein E, 2003, J SLEEP RES, V12, P35, DOI 10.1046/j.1365-2869.2003.00334.x; Kobayashi I, 2012, SLEEP, V35, P957, DOI 10.5665/sleep.1960; Kobayashi I, 2012, BEHAV SLEEP MED, V10, P180, DOI 10.1080/15402002.2011.654296; Koffel E, 2013, J ANXIETY DISORD, V27, P512, DOI 10.1016/j.janxdis.2013.07.003; Krakow B, 2001, JAMA-J AM MED ASSOC, V286, P537, DOI 10.1001/jama.286.5.537; Krakow Barry, 2006, Behav Sleep Med, V4, P45, DOI 10.1207/s15402010bsm0401_4; Kramer TL, 2003, J TRAUMA STRESS, V16, P211, DOI 10.1023/A:1023783705062; Krystal AD, 2008, SLEEP, V31, P79, DOI 10.1093/sleep/31.1.79; Kudielka BM, 2006, BIOL PSYCHOL, V72, P141, DOI 10.1016/j.biopsycho.2005.08.003; Kudielka BM, 2007, BIOL PSYCHOL, V74, P92, DOI 10.1016/j.biopsycho.2006.08.008; Kumari M, 2009, J CLIN ENDOCR METAB, V94, P4801, DOI 10.1210/jc.2009-0555; Lancee J, 2012, BEHAV RES THER, V50, P22, DOI 10.1016/j.brat.2011.09.012; Lang KP, 2014, J HEAD TRAUMA REHAB, V29, P44, DOI 10.1097/HTR.0b013e31829c85d0; Larson EB, 2010, J HEAD TRAUMA REHAB, V25, P61, DOI 10.1097/HTR.0b013e3181c1d1e1; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lewis V, 2009, MIL MED, V174, P948, DOI 10.7205/MILMED-D-04-0208; Li Y, 2013, SLEEP MED, V14, P98, DOI 10.1016/j.sleep.2012.08.020; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Lofaso F, 1996, CHEST, V109, P896, DOI 10.1378/chest.109.4.896; Long ME, 2011, J ANXIETY DISORD, V25, P531, DOI 10.1016/j.janxdis.2010.12.007; Lu J, 2000, J NEUROSCI, V20, P3830; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Macera CA, 2013, SLEEP, V36, P83, DOI 10.5665/sleep.2306; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Maguen S, 2012, J REHABIL RES DEV, V49, P1115, DOI 10.1682/JRRD.2011.02.0015; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Margolies SO, 2013, J CLIN PSYCHOL, V69, P1026, DOI 10.1002/jclp.21970; Marshall KR, 2012, MIL MED, V177, P67, DOI 10.7205/MILMED-D-12-00110; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Matthews EE, 2013, SLEEP MED REV, V17, P453, DOI 10.1016/j.smrv.2013.01.001; McGinty D, 2004, ARCH ITAL BIOL, V142, P501; MCGINTY DJ, 1968, SCIENCE, V160, P1253, DOI 10.1126/science.160.3833.1253; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Mellman TA, 2002, AM J PSYCHIAT, V159, P1696, DOI 10.1176/appi.ajp.159.10.1696; MELLMAN TA, 1995, AM J PSYCHIAT, V152, P110; Mellman TA, 2014, SLEEP, V37, P1321, DOI 10.5665/sleep.3922; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Milad MR, 2008, J PSYCHIATR RES, V42, P515, DOI 10.1016/j.jpsychires.2008.01.017; Mitchell MD, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-40; Sanchez-Ortuno MM, 2012, CURR PSYCHIAT REP, V14, P519, DOI 10.1007/s11920-012-0312-9; Moore BA, 2007, AM J PSYCHIAT, V164, P683, DOI 10.1176/appi.ajp.164.4.683; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Morgenthaler TI, 2007, SLEEP, V30, P1705, DOI 10.1093/sleep/30.12.1705; Morin CM, 2006, SLEEP, V29, P1398, DOI 10.1093/sleep/29.11.1398; Mustafa Masroor, 2005, Sleep Breath, V9, P57, DOI 10.1007/s11325-005-0016-z; Mysliwiec V, 2013, CHEST, V144, P549, DOI 10.1378/chest.13-0088; Mysliwiec V, 2013, SLEEP, V36, P167, DOI 10.5665/sleep.2364; Nakamura Y, 2011, J PSYCHOSOM RES, V70, P335, DOI 10.1016/j.jpsychores.2010.09.007; Nappi CM, 2012, NEUROPHARMACOLOGY, V62, P576, DOI 10.1016/j.neuropharm.2011.02.029; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; NIELSEN T, 1992, J SLEEP RES, V1, P197, DOI 10.1111/j.1365-2869.1992.tb00038.x; Nishida M, 2009, CEREB CORTEX, V19, P1158, DOI 10.1093/cercor/bhn155; Ohayon Maurice M, 2007, Rev Prat, V57, P1521; Olff M, 2006, PSYCHONEUROENDOCRINO, V31, P1220, DOI 10.1016/j.psyneuen.2006.09.003; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Orr N., 2010, CHEST HON HAW; Orr SP, 2000, J ABNORM PSYCHOL, V109, P290, DOI 10.1037//0021-843X.109.2.290; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pace-Schott EF, 2012, J PSYCHIATR RES, V46, P1036, DOI 10.1016/j.jpsychires.2012.04.015; Pace-Schott EF, 2009, SLEEP, V32, P19; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Patel R, 2012, NEUROSCI BIOBEHAV R, V36, P2130, DOI 10.1016/j.neubiorev.2012.06.003; Payne JD, 2012, FRONT INTEGR NEUROSC, V6, DOI 10.3389/fnint.2012.00108; Payne JD, 2011, J COGNITIVE NEUROSCI, V23, P1285, DOI 10.1162/jocn.2010.21526; Peppard PE, 2006, ARCH INTERN MED, V166, P1709, DOI 10.1001/archinte.166.16.1709; Pervanidou P, 2010, PROG BRAIN RES, V182, P149, DOI 10.1016/S0079-6123(10)82005-9; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Pigeon Wilfred R, 2012, J Clin Psychiatry, V73, pe1160, DOI 10.4088/JCP.11r07586; Pigeon WR, 2012, AM J PUBLIC HEALTH, V102, pS93, DOI 10.2105/AJPH.2011.300470; Pillar G, 2000, SLEEP MED REV, V4, P183, DOI 10.1053/smrv.1999.0095; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Pruessner JC, 1997, LIFE SCI, V61, P2539, DOI 10.1016/S0024-3205(97)01008-4; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; Randler C, 2010, BIOL PSYCHOL, V85, P14, DOI 10.1016/j.biopsycho.2010.04.006; Rao V, 2014, BRAIN INJURY, V28, P20, DOI 10.3109/02699052.2013.847210; Raskind MA, 2003, AM J PSYCHIAT, V160, P371, DOI 10.1176/appi.ajp.160.2.371; Raskind MA, 2002, J CLIN PSYCHIAT, V63, P565, DOI 10.4088/JCP.v63n0705; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Raskind MA, 2013, AM J PSYCHIAT, V170, P1003, DOI 10.1176/appi.ajp.2013.12081133; Rasmusson AM, 2002, NEUROPSYCHOPHARMACOL, V27, P133, DOI 10.1016/S0893-133X(02)00286-5; Ribeiro JD, 2012, J AFFECT DISORDERS, V136, P743, DOI 10.1016/j.jad.2011.09.049; Richey SM, 2011, CURR PHARM DESIGN, V17, P1471; Rodenbeck A, 2002, NEUROSCI LETT, V324, P159, DOI 10.1016/S0304-3940(02)00192-1; Rosenberg Russell P, 2006, Ann Clin Psychiatry, V18, P49, DOI 10.1080/10401230500464711; ROSS RJ, 1995, BRAIN RES, V701, P129, DOI 10.1016/0006-8993(95)00984-X; Rowe RK, 2014, BRAIN INJURY, V28, P504, DOI 10.3109/02699052.2014.888768; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; Saper CB, 2005, J COMP NEUROL, V493, P92, DOI 10.1002/cne.20770; Saper CB, 2001, TRENDS NEUROSCI, V24, P726, DOI 10.1016/S0166-2236(00)02002-6; Saper CB, 2010, NEURON, V68, P1023, DOI 10.1016/j.neuron.2010.11.032; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schiehser DM, 2011, J CLIN EXP NEUROPSYC, V33, P704, DOI 10.1080/13803395.2011.553587; Schober ME, 2012, METAB BRAIN DIS, V27, P167, DOI 10.1007/s11011-012-9309-7; Schoenfeld FB, 2012, J REHABIL RES DEV, V49, P729, DOI 10.1682/JRRD.2011.09.0164; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Sherin JE, 1998, J NEUROSCI, V18, P4705; Sherin JE, 1996, SCIENCE, V271, P216, DOI 10.1126/science.271.5246.216; Sinclair KL, 2014, NEUROREHAB NEURAL RE, V28, P303, DOI 10.1177/1545968313508472; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Spoormaker VI, 2008, SLEEP MED REV, V12, P169, DOI 10.1016/j.smrv.2007.08.008; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Stickgold R, 2005, SLEEP, V28, P1225, DOI 10.1093/sleep/28.10.1225; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Stickgold R, 2007, SLEEP MED, V8, P331, DOI 10.1016/j.sleep.2007.03.011; Stocker RPJ, 2014, NEUROIMAGE, V99, P207, DOI 10.1016/j.neuroimage.2014.05.067; Straus LD, 2015, J TRAUMA STRESS, V28, P8, DOI 10.1002/jts.21982; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Suntsova N, 2002, J PHYSIOL-LONDON, V543, P665, DOI 10.1113/jphysiol.2002.023085; Swinkels CM, 2013, SLEEP, V36, P1019, DOI 10.5665/sleep.2800; Szklo-Coxe M, 2010, AM J EPIDEMIOL, V171, P709, DOI 10.1093/aje/kwp454; Szymusiak R, 1998, BRAIN RES, V803, P178, DOI 10.1016/S0006-8993(98)00631-3; Takahashi K, 2009, NEUROSCIENCE, V161, P269, DOI 10.1016/j.neuroscience.2009.02.075; Talbot LS, 2014, SLEEP, V37, P327, DOI 10.5665/sleep.3408; Taylor F, 2002, J CLIN PSYCHOPHARM, V22, P82, DOI 10.1097/00004714-200202000-00013; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Terrio HP, 2011, REHABIL PSYCHOL, V56, P26, DOI 10.1037/a0022685; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Ulmer CS, 2011, J CLIN SLEEP MED, V7, P57; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; van Liempt S, 2012, EUR J PSYCHOTRAUMATO, V3, DOI 10.3402/ejpt.v3i0.19142; van Liempt S, 2013, PSYCHONEUROENDOCRINO, V38, P155, DOI 10.1016/j.psyneuen.2012.05.015; van Liempt S, 2011, PSYCHONEUROENDOCRINO, V36, P1361, DOI 10.1016/j.psyneuen.2011.03.009; Vandekerckhove M, 2010, SLEEP MED REV, V14, P219, DOI 10.1016/j.smrv.2010.01.002; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Vgontzas AN, 2013, SLEEP MED CLIN, V8, P309, DOI 10.1016/j.jsmc.2013.04.009; Vgontzas AN, 2001, J CLIN ENDOCR METAB, V86, P3787, DOI 10.1210/jc.86.8.3787; Vincent N, 2013, BEHAV RES THER, V51, P161, DOI 10.1016/j.brat.2012.12.003; Wagner U, 2001, LEARN MEMORY, V8, P112, DOI 10.1101/lm.36801; Wagner U, 2006, BIOL PSYCHIAT, V60, P788, DOI 10.1016/j.biopsych.2006.03.061; Wahbeh H, 2013, J TRAUMA STRESS, V26, P241, DOI 10.1002/jts.21798; Wallace DM, 2011, SLEEP MED, V12, P850, DOI 10.1016/j.sleep.2011.06.004; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Westermeyer J, 2007, J ANXIETY DISORD, V21, P966, DOI 10.1016/j.janxdis.2006.11.009; Wilhelm I, 2007, PSYCHONEUROENDOCRINO, V32, P358, DOI 10.1016/j.psyneuen.2007.01.008; Williams JM, 2013, J GERONTOL B-PSYCHOL, V68, P712, DOI 10.1093/geronb/gbt030; Wiseman-Hakes C, 2013, BRAIN INJURY, V27, P1364, DOI 10.3109/02699052.2013.823663; Wittmann L, 2007, PSYCHOTHER PSYCHOSOM, V76, P25, DOI 10.1159/000096362; Woodward SH, 1996, J TRAUMA STRESS, V9, P137, DOI 10.1007/BF02116839; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Woznica AA, 2014, SLEEP MED REV; Wright KM, 2011, J CLIN PSYCHOL, V67, P1240, DOI 10.1002/jclp.20845; Wust S, 2000, PSYCHONEUROENDOCRINO, V25, P707, DOI 10.1016/S0306-4530(00)00021-4; Xu C., 2002, PRACTICE J MED PHARM, V19, P407; Xu C., 2001, QIAN WEI J MED PHARM, V18, P337; Yehuda R, 2002, PSYCHIAT CLIN N AM, V25, P341, DOI 10.1016/S0193-953X(02)00002-3; Yoo SS, 2007, CURR BIOL, V17, pR877, DOI 10.1016/j.cub.2007.08.007; Zayfert C, 2004, J TRAUMA STRESS, V17, P69, DOI 10.1023/B:JOTS.0000014679.31799.e7; Zhang JH, 2011, SLEEP, V34, P225, DOI 10.1093/sleep/34.2.225; Zhao JX, 2012, J ATHL TRAINING, V47, P673, DOI 10.4085/1062-6050-47.6.08	282	50	51	2	46	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0272-7358	1873-7811		CLIN PSYCHOL REV	Clin. Psychol. Rev.	AUG	2015	40						195	212		10.1016/j.cpr.2015.05.008			18	Psychology, Clinical	Psychology	CP9ZJ	WOS:000360254100015	26164549	Green Accepted			2021-06-18	
J	Kerr, ZY; Yeargin, S; McLeod, TCV; Nittoli, VC; Mensch, J; Dodge, T; Hayden, R; Dompier, TP				Kerr, Zachary Y.; Yeargin, Susan; McLeod, Tamara C. Valovich; Nittoli, Vincent C.; Mensch, James; Dodge, Thomas; Hayden, Ross; Dompier, Thomas P.			Comprehensive Coach Education and Practice Contact Restriction Guidelines Result in Lower Injury Rates in Youth American Football	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						epidemiology; pediatrics; prevention	HEAD IMPACT EXPOSURE; PLAYERS; CONCUSSION	Background: Research evaluating the effect of comprehensive coach education and practice contact restriction in youth football injury rates is sparse. In 2012, USA Football released their Heads Up Football coaching education program (HUF), and Pop Warner Football (PW) instituted guidelines to restrict contact during practice. Purpose: To compare injury rates among youth football players aged 5 to 15 years by whether their leagues implemented HUF and/or were PW-affiliated. Study Design: Cohort study; Level of evidence, 2. Methods: Athletic trainers (ATs) evaluated and tracked injuries at each practice and game during the 2014 youth football season. Players were drawn from 10 leagues across 4 states. The non-Heads Up Football (NHUF) group consisted of 704 players (none of whom were PW-affiliated) from 29 teams within 4 leagues. The HUF+PW group consisted of 741 players from 27 teams within 2 leagues. The HUF-only group consisted of 663 players from 44 teams within 4 leagues. Injury rates and injury rate ratios (IRRs) were reported with 95% CIs. Results: A total of 370 injuries were reported during 71,262 athlete-exposures (AEs) (rate, 5.19/1000 AEs). Compared with the NHUF group (7.32/1000 AEs), the practice injury rates were lower for the HUF+PW group (0.97/1000 AEs; IRR, 0.13; 95% CI, 0.08-0.21) and the HUF-only group (2.73/1000 AEs; IRR, 0.37; 95% CI, 0.26-0.53). Compared with the NHUF group (13.42/1000 AEs), the game injury rate was lower for the HUF+PW group (3.42/1000 AEs; IRR, 0.25; 95% CI, 0.15-0.44) but not for the HUF-only group (13.76/1000 AEs; IRR, 1.02; 95% CI, 0.73-1.43). Also, the HUF+PW game injury rate was lower than that of HUF-only (IRR, 0.20; 95% CI, 0.12-0.36). Higher injury rates were typically found in those aged 11 to 15 years compared with those aged 5 to 10 years. However, stronger effects related to HUF implementation and PW affiliation were seen among 11- to 15-year-olds. When restricted to concussions only, the sole difference was found between the practice concussion rates among 11-to 15-yearolds in the HUF+PW (0.14/1000 AEs) and NHUF groups (0.79/1000 AEs) (IRR, 0.18; 95% CI, 0.04-0.85). Conclusion: These findings support comprehensive coach education and practice contact restrictions as effective methods of injury mitigation. Future research should continue evaluating similar programming within other levels of competition and sports.	[Kerr, Zachary Y.; Yeargin, Susan; McLeod, Tamara C. Valovich; Nittoli, Vincent C.; Mensch, James; Dodge, Thomas; Hayden, Ross; Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA	Dompier, TP (corresponding author), Datalys Ctr Sports Injury Res & Prevent, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	tdompier@datalyscenter.org	McLeod, Tamara/AAU-9435-2020; Mensch, James/P-9291-2017	Mensch, James/0000-0001-5644-0580; Kerr, Zachary/0000-0003-1423-1259			Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Dompier TP, 2007, J ATHL TRAINING, V42, P395; Dompier TP, 2015, J ATHL TRAINING, V50, P862, DOI 10.4085/1062-6050-50.5.04; Fainaru S, YOUTH FOOTBALL PARTI; Institute of Medicine, SPORTS REL CONC YOUT; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; Malina RM, 2006, CLIN J SPORT MED, V16, P214, DOI 10.1097/00042752-200605000-00005; Moran M., 2015, NEUROL TODAY, V15, P1; Pop Warner Football, RUL CHANG REG PRACT; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stuart MJ, 2002, MAYO CLIN PROC, V77, P317, DOI 10.4065/77.4.317; USA Football, HEADS UP FOOTB; USA Football, FOOTB SPONS; Wallerson R, YOUTH PARTICIPATION	17	50	50	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2325-9671			ORTHOP J SPORTS MED	Orthop. J. Sports Med.	JUL	2015	3	7							2325967115594578	10.1177/2325967115594578			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DE1KB	WOS:000370384700006	26674011	DOAJ Gold, Green Published			2021-06-18	
J	Hutchison, MG; Comper, P; Meeuwisse, WH; Echemendia, RJ				Hutchison, Michael G.; Comper, Paul; Meeuwisse, Willem H.; Echemendia, Ruben J.			A systematic video analysis of National Hockey League (NHL) concussions, part I: who, when, where and what?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Contact sports; Ice hockey; Injury Prevention	INJURY SURVEILLANCE SYSTEM; MILD HEAD-INJURY; MENS ICE HOCKEY; DESCRIPTIVE EPIDEMIOLOGY; INCIDENT ANALYSIS; FOOTBALL PLAYERS; HIGH-SCHOOL; RECOVERY; SPORT; MECHANISMS	Background Although there is a growing understanding of the consequences of concussions in hockey, very little is known about the precipitating factors associated with this type of injury. Aim To describe player characteristics and situational factors associated with concussions in the National Hockey League (NHL). Methods Case series of medically diagnosed concussions for regular season games over a 3.5-year period during the 2006-2010 seasons using an inclusive cohort of professional hockey players. Digital video records were coded and analysed using the Heads Up Checklist. Results Of 197 medically diagnosed concussions, 88% involved contact with an opponent. Forwards accounted for more concussions than expected compared with on-ice proportional representation (95% CI 60 to 73; p=0.04). Significantly more concussions occurred in the first period (47%) compared with the second and third periods (p=0.047), with the majority of concussions occurring in the defensive zone (45%). Approximately 47% of the concussions occurred in open ice, 53% occurred in the perimeter. Finally, 37% of the concussions involved injured players' heads contacting the boards or glass. Conclusions This study describes several specific factors associated with concussions in the NHL, including period of the game, player position, body size, and specific locations on the ice and particular situations based on a player's position.	[Hutchison, Michael G.; Comper, Paul] Univ Toronto, Fac Kinesiol & Phys Educ, David L MacIntosh Sport Med Clin, Toronto, ON M5S 2W6, Canada; [Hutchison, Michael G.] St Michaels Hosp, Keenan Res Ctr, Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada; [Comper, Paul] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON M5S 2W6, Canada; [Comper, Paul] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5S 2W6, Canada; [Meeuwisse, Willem H.] Univ Calgary, Fac Kinesiol, Calgary, AB, Canada; [Meeuwisse, Willem H.] Univ Calgary, Hotchkiss Brain Inst, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Echemendia, Ruben J.] Psychol & Neurobehav Associates Inc, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA	Hutchison, MG (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, David L MacIntosh Sport Med Clin, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	michael.hutchison@utoronto.ca	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462	Ontario Neurotrauma Foundation (ONF); Pashby Sports Safety Fund	This study received funding by Ontario Neurotrauma Foundation (ONF) and The Pashby Sports Safety Fund. The organisations that contributed funds to the research had no role in the design of the study, the collection, analysis and interpretation of the data.	Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; [Anonymous], MAC OS X VERS 10 5 8; Arnason A, 2004, AM J SPORT MED, V32, P1459, DOI 10.1177/0363546504262973; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Krosshaug T, 2007, AM J SPORT MED, V35, P359, DOI 10.1177/0363546506293899; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Olsen OE, 2004, AM J SPORT MED, V32, P1002, DOI 10.1177/0363546503261724; PASHBY TJ, 1979, CAN MED ASSOC J, V121, P643; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Stevens ST, 2006, J SCI MED SPORT, V9, P238, DOI 10.1016/j.jsams.2006.03.025; Stevens Sean T, 2008, Res Sports Med, V16, P68, DOI 10.1080/15438620701879020; Tommasone BA, 2006, J ATHL TRAINING, V41, P470	30	50	50	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2015	49	8					547	551		10.1136/bjsports-2013-092234			5	Sport Sciences	Sport Sciences	CF4OI	WOS:000352529000012	23766438				2021-06-18	
J	Ulam, F; Shelton, C; Richards, L; Davis, L; Hunter, B; Fregni, F; Higgins, K				Ulam, F.; Shelton, C.; Richards, L.; Davis, L.; Hunter, B.; Fregni, F.; Higgins, K.			Cumulative effects of transcranial direct current stimulation on EEG oscillations and attention/working memory during subacute neurorehabilitation of traumatic brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						Transcranial direct current stimulation; Traumatic brain injury, EEG oscillations	WORKING-MEMORY; NEUROPLASTICITY; MECHANISMS; DEFICITS; CORTEX	Objective: To investigate in a randomized, double-blind design, cumulative effects of anodal tDCS on EEG oscillations and neuropsychological tests among patients with traumatic brain injury (TBI) undergoing subacute neurorehabilitation. Methods: Twenty-six patients were randomly assigned to active (n = 13) or sham (n = 13) tDCS groups. EEGs were recorded at 6 different time points, assessing both immediate and cumulative effects of tDCS on EEG oscillations. Twenty minute sessions of 1 mA anodal stimulation to the left dorsolateral prefrontal cortex (F3, cathode placed at right supraorbital site, Fp2), were provided on 10 consecutive days. Neuropsychological tests were administered before and after the series of tDCS sessions. Results: Theta was significantly reduced for active tDCS patients following the first tDCS session. Delta decreased and alpha increased, both significantly, for the active tDCS group after 10 consecutive tDCS sessions. No significant changes were seen for sham group. Decreases in delta were significantly correlated with improved performance on neuropsychological tests for the active tDCS group to far greater degree than for the sham group. Participants in the active tDCS group who had excess slow EEG activity in their initial recordings showed greater improvement on neuropsychological tests than other groups. Conclusion: Results suggest that 10 anodal tDCS sessions may beneficially modulate regulation of cortical excitability for patients with TBI. Significance: EEG-guided tDCS warrants further investigation as a potential intervention for TBI during subacute neurorehabilitation. (C) 2014 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Ulam, F.; Shelton, C.; Richards, L.; Davis, L.; Hunter, B.; Fregni, F.; Higgins, K.] Univ Missouri Hlth Syst, Missouri Rehabil Ctr, Kansas City, MO USA	Ulam, F (corresponding author), 600 North Main St, Mt Vernon, MO 65712 USA.	ulamf@health.missouri.edu		Fregni, Felipe/0000-0001-9359-8643	Missouri Rehabilitation Center; University of Missouri Healthcare System	We would like to thank Missouri Rehabilitation Center and the University of Missouri Healthcare System for supporting us in our endeavors to conduct this research. We would especially like to thank Dr. Kusai Umran for medical oversight of patients in the study. We would like to thank Dr. Steve Patterson, former Executive Director of MRC, and Mike Powell, MBA, Current Executive Director, for their encouragement and flexibility in allowing us to pursue our research interests. We also appreciate the assistance of Sarah Atallah with data preparation and entry.	Alvarez XA, 2008, J NEURAL TRANSM, V115, P683, DOI 10.1007/s00702-008-0024-9; Ardolino G, 2005, J PHYSIOL-LONDON, V568, P653, DOI 10.1113/jphysiol.2005.088310; Arul-Anandam AP, 2009, J AFFECT DISORDERS, V117, P137, DOI 10.1016/j.jad.2009.01.016; Baker JM, 2010, STROKE, V41, P1229, DOI 10.1161/STROKEAHA.109.576785; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; De Rojas JO, 2013, NEUROSURGERY, V72, P267, DOI 10.1227/NEU.0b013e31827b93c0; DeFina P, 2009, CLIN NEUROPSYCHOL, V23, P1391, DOI 10.1080/13854040903058978; Deguise E, 2008, J HEAD TRAUMA REHAB, V23, P294, DOI 10.1097/01.HTR.0000336842.53338.f4; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Dockery CA, 2009, J NEUROSCI, V29, P7271, DOI 10.1523/JNEUROSCI.0065-09.2009; Dockree PM, 2011, INT J PSYCHOPHYSIOL, V82, P53, DOI 10.1016/j.ijpsycho.2011.01.004; Faria P, 2012, EPILEPSY BEHAV, V25, P417, DOI 10.1016/j.yebeh.2012.06.027; Faul F., 2010, TRAUMATIC BRAIN INJU; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2005, NEUROREPORT, V16, P1551, DOI 10.1097/01.wnr.0000177010.44602.5e; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Hyun June, 2011, Clin Psychopharmacol Neurosci, V9, P78, DOI 10.9758/cpn.2011.9.2.78; Jacobson L, 2012, CLIN NEUROPHYSIOL, V123, P979, DOI 10.1016/j.clinph.2011.09.016; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Keeser D, 2011, NEUROIMAGE, V55, P644, DOI 10.1016/j.neuroimage.2010.12.004; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Llinas RR, 2006, J NEUROPHYSIOL, V95, P3297, DOI 10.1152/jn.00166.2006; McCullagh S, 2011, TXB TRAUMATIC BRAIN, P279; MOULTON RJ, 1988, CAN J NEUROL SCI, V15, P82, DOI 10.1017/S0317167100027244; Naunheim RS, 2010, BRAIN INJURY, V24, P1324, DOI 10.3109/02699052.2010.506862; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Ulam F, 2013, J NEUROTHER, V17, P275; Villamar MF, 2012, NEUROMODULATION, V15, P326, DOI 10.1111/j.1525-1403.2012.00474.x; Williams JA, 2009, J REHABIL MED, V41, P305, DOI 10.2340/16501977-0356; Wirth M, 2011, NEUROPSYCHOLOGIA, V49, P3989, DOI 10.1016/j.neuropsychologia.2011.10.015; Zaghi S, 2010, NEUROSCIENTIST, V16, P285, DOI 10.1177/1073858409336227	36	50	53	0	24	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	MAR	2015	126	3					486	496		10.1016/j.clinph.2014.05.015			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CB4RX	WOS:000349616700011	24947595				2021-06-18	
J	Doshi, H; Wiseman, N; Liu, J; Wang, WT; Welch, RD; O'Neil, BJ; Zuk, C; Wang, X; Mika, V; Szaflarski, JP; Haacke, EM; Kou, ZF				Doshi, Hardik; Wiseman, Natalie; Liu, Jun; Wang, Wentao; Welch, Robert D.; O'Neil, Brian J.; Zuk, Conor; Wang, Xiao; Mika, Valerie; Szaflarski, Jerzy P.; Haacke, E. Mark; Kou, Zhifeng			Cerebral Hemodynamic Changes of Mild Traumatic Brain Injury at the Acute Stage	PLOS ONE			English	Article							OXYGEN EXTRACTION FRACTION; DEOXYGENATED BLOOD-VOLUME; IN-VIVO MEASUREMENT; HEAD-INJURY; AXONAL INJURY; INTRACRANIAL HYPERTENSION; QUANTITATIVE MEASUREMENTS; GLUCOSE-METABOLISM; ENERGY-METABOLISM; MR SUSCEPTOMETRY	Mild traumatic brain injury (mTBI) is a significant public health care burden in the United States. However, we lack a detailed understanding of the pathophysiology following mTBI and its relation to symptoms and recovery. With advanced magnetic resonance imaging (MRI), we can investigate brain perfusion and oxygenation in regions known to be implicated in symptoms, including cortical gray matter and subcortical structures. In this study, we assessed 14 mTBI patients and 18 controls with susceptibility weighted imaging and mapping (SWIM) for blood oxygenation quantification. In addition to SWIM, 7 patients and 12 controls had cerebral perfusion measured with arterial spin labeling (ASL). We found increases in regional cerebral blood flow (CBF) in the left striatum, and in frontal and occipital lobes in patients as compared to controls (p = 0.01, 0.03, 0.03 respectively). We also found decreases in venous susceptibility, indicating increases in venous oxygenation, in the left thalamostriate vein and right basal vein of Rosenthal (p = 0.04 in both). mTBI patients had significantly lower delayed recall scores on the standardized assessment of concussion, but neither susceptibility nor CBF measures were found to correlate with symptoms as assessed by neuropsychological testing. The increased CBF combined with increased venous oxygenation suggests an increase in cerebral blood flow that exceeds the oxygen demand of the tissue, in contrast to the regional hypoxia seen in more severe TBI. This may represent a neuroprotective response following mTBI, which warrants further investigation.	[Doshi, Hardik; Liu, Jun; Wang, Xiao; Mika, Valerie; Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48202 USA; [Wiseman, Natalie; Kou, Zhifeng] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Translat Neurosci Program, Detroit, MI USA; [Liu, Jun] Cent S Univ, Sch Publ Hlth, Xiangya Hosp 2, Dept Radiol, Changsha, Hunan, Peoples R China; [Wang, Wentao] South Cent Univ Nationalities, Coll Comp Sci, Wuhan, Peoples R China; [Welch, Robert D.; O'Neil, Brian J.; Mika, Valerie] Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI USA; [Zuk, Conor; Wang, Xiao; Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Sch Med, Dept Radiol, Detroit, MI USA; [Wang, Xiao] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan Province, Peoples R China; [Szaflarski, Jerzy P.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA	Kou, ZF (corresponding author), Wayne State Univ, Dept Biomed Engn, Detroit, MI 48202 USA.	zhifeng_kou@wayne.edu	Mika, Valerie H./AAO-2816-2020		International Society for Magnetic Resonance in Medicine; Department of DefenseUnited States Department of Defense [W81XWH-11-1-0493]	Supported by a Seed Grant from the International Society for Magnetic Resonance in Medicine (PI: ZFK) and a research grant from the Department of Defense (award number W81XWH-11-1-0493; PI: EMH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abate MG, 2008, NEUROCRIT CARE, V9, P319, DOI 10.1007/s12028-008-9119-2; Abdul-Khaliq H, 2000, BIOMED TECH, V45, P328, DOI 10.1515/bmte.2000.45.11.328; An HY, 2001, NMR BIOMED, V14, P441, DOI 10.1002/nbm.717; An HY, 2002, MAGNET RESON MED, V47, P958, DOI 10.1002/mrm.10148; An HY, 2000, J CEREBR BLOOD F MET, V20, P1225, DOI 10.1097/00004647-200008000-00008; Ashburner John, 1997, HUMAN BRAIN FUNCTION, P43; BARCLAY L, 1985, BIOL PSYCHIAT, V20, P146, DOI 10.1016/0006-3223(85)90074-5; Barnes SRS, 2009, MAGN RESON IMAGING C, V17, P47, DOI 10.1016/j.mric.2008.12.002; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Bouma G J, 1995, New Horiz, V3, P384; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BOUMA GJ, 1993, ACTA NEUROCHIR, P34; BRANDT RB, 1984, P SOC EXP BIOL MED, V175, P328; BUCHEL C, 1997, HUMAN BRAIN FUNCTION, P127; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; CHIEN D, 1994, MAGNET RESON MED, V32, P540, DOI 10.1002/mrm.1910320419; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fernandez-Seara MA, 2006, MAGN RESON MED, V55, P967, DOI 10.1002/mrm.20892; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Golay X, 2001, MAGN RESON MED, V46, P282, DOI 10.1002/mrm.1189; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke EM, 1997, HUM BRAIN MAPP, V5, P341, DOI 10.1002/(SICI)1097-0193(1997)5:5<341::AID-HBM2>3.0.CO;2-3; Harris NG, 2012, J NEUROTRAUM, V29, P1469, DOI 10.1089/neu.2011.2161; He X, 2008, MAGN RESON MED, V60, P882, DOI 10.1002/mrm.21719; He X, 2007, MAGN RESON MED, V57, P115, DOI 10.1002/mrm.21108; Holmes A., 1997, HUMAN BRAIN FUNCTION, P59; HOPPEL BE, 1993, MAGN RESON MED, V30, P715, DOI 10.1002/mrm.1910300609; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Jost SC, 2005, J NEUROSURG, V103, P25, DOI 10.3171/jns.2005.103.1.0025; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Krep H, 2004, RESUSCITATION, V63, P73, DOI 10.1016/j.resuscitation.2004.03.023; Langham MC, 2010, J AM COLL CARDIOL, V55, P598, DOI 10.1016/j.jacc.2009.08.068; Langham MC, 2009, MAGN RESON MED, V62, P333, DOI 10.1002/mrm.21981; Langham MC, 2009, MAGN RESON MED, V61, P626, DOI 10.1002/mrm.21499; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Li DB, 1998, MAGNET RESON MED, V39, P685, DOI 10.1002/mrm.1910390503; Li DB, 1998, JMRI-J MAGN RESON IM, V8, P1236, DOI 10.1002/jmri.1880080609; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; Liu YJ, 1999, MAGNET RESON MED, V41, P407, DOI 10.1002/(SICI)1522-2594(199902)41:2<407::AID-MRM27>3.0.CO;2-4; Lu HZ, 2008, MAGN RESON MED, V60, P357, DOI 10.1002/mrm.21627; Macmillan CSA, 2000, INTENS CARE MED, V26, P1028, DOI 10.1007/s001340051315; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; MCKENNA MC, 1994, DEV NEUROSCI-BASEL, V16, P291, DOI 10.1159/000112122; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; Nonaka H, 2003, NEUROPATHOLOGY, V23, P111, DOI 10.1046/j.1440-1789.2003.00486.x; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Oja JME, 1999, J CEREBR BLOOD F MET, V19, P1289, DOI 10.1097/00004647-199912000-00001; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Pandian DSJ, 2008, J MAGN RESON IMAGING, V28, P727, DOI 10.1002/jmri.21487; Pomschar A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055447; Prat R, 1997, NEUROL RES, V19, P393, DOI 10.1080/01616412.1997.11740832; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Qin Q, 2011, MAGN RESON MED, V65, P471, DOI 10.1002/mrm.22556; Sedlacik J, 2010, MAGN RESON MED, V63, P910, DOI 10.1002/mrm.22274; Sedlacilk J, 2009, Z MED PHYS, V19, P48, DOI 10.1016/j.zemedi.2008.07.005; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Tang J, 2013, MAGN RESON MED, V69, P1396, DOI 10.1002/mrm.24384; Tang J., 2012, MAGN RESON MED; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; van Zijl PCM, 1998, NAT MED, V4, P159, DOI 10.1038/nm0298-159; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Weiskoff R, 1991, QUANTITATIVE VIVO BL, P307; WRIGHT GA, 1991, JMRI-J MAGN RESON IM, V1, P275, DOI 10.1002/jmri.1880010303; Xu F, 2009, MAGN RESON MED, V62, P141, DOI 10.1002/mrm.21994; Yablonskiy DA, 1997, MAGN RESON MED, V37, P214, DOI 10.1002/mrm.1910370213; Yablonskiy DA, 1997, MAGNET RESON MED, V37, P872, DOI 10.1002/mrm.1910370611; YABLONSKIY DA, 1994, MAGNET RESON MED, V32, P749, DOI 10.1002/mrm.1910320610; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zheng WL, 2013, NEUROIMAGE, V78, P68, DOI 10.1016/j.neuroimage.2013.04.022; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670; Zwienenberg M, 2001, NEUROL RES, V23, P167, DOI 10.1179/016164101101198505	86	50	51	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2015	10	2							e0118061	10.1371/journal.pone.0118061			18	Multidisciplinary Sciences	Science & Technology - Other Topics	CB2GK	WOS:000349444900257	25659079	DOAJ Gold, Green Published			2021-06-18	
S	Montenigro, PH; Corp, DT; Stein, TD; Cantu, RC; Stern, RA		Cannon, TD; Widiger, T		Montenigro, Philip H.; Corp, Daniel T.; Stein, Thor D.; Cantu, Robert C.; Stern, Robert A.			Chronic Traumatic Encephalopathy: Historical Origins and Current Perspective	ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 11	Annual Review of Clinical Psychology		English	Article; Book Chapter						chronic traumatic encephalopathy; concussion; traumatic brain injury; neurodegenerative disorders; football; history	APOLIPOPROTEIN-E-GENOTYPE; REPETITIVE BRAIN TRAUMA; LONG-TERM CONSEQUENCES; WHITE-MATTER INTEGRITY; MILD HEAD-INJURY; HIGH-SCHOOL; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; RECURRENT CONCUSSION; FOOTBALL PLAYERS	Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that is most often identified in postmortem autopsies of individuals exposed to repetitive head impacts, such as boxers and football players. The neuropathology of CTE is characterized by the accumulation of hyperphosphorylated tau protein in a pattern that is unique from that of other neurodegenerative diseases, including Alzheimer's disease. The clinical features of CTE are often progressive, leading to dramatic changes in mood, behavior, and cognition, frequently resulting in debilitating dementia. In some cases, motor features, including parkinsonism, can also be present. In this review, the historical origins of CTE are revealed and an overview of the current state of knowledge of CTE is provided, including the neuropathology, clinical features, proposed clinical and pathological diagnostic criteria, potential in vivo biomarkers, known risk factors, and treatment options.	[Montenigro, Philip H.; Corp, Daniel T.; Stein, Thor D.; Stern, Robert A.] Boston Univ, Sch Med, Chron Traumat Encephalopathy Ctr, Boston, MA 02118 USA; [Montenigro, Philip H.; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Corp, Daniel T.] Deakin Univ, Sch Psychol, Cognit Neurosci Unit, Burwood, Vic 3125, Australia; [Stein, Thor D.] Dept Vet Affairs Med Ctr, Bedford, MA 02130 USA; [Stein, Thor D.] Dept Vet Affairs Med Ctr, Boston, MA 01730 USA; [Stein, Thor D.; Stern, Robert A.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Stein, Thor D.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Cantu, Robert C.] Sports Legacy Inst, Waltham, MA 02451 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA 01742 USA	Stern, RA (corresponding author), Boston Univ, Sch Med, Chron Traumat Encephalopathy Ctr, Boston, MA 02118 USA.	valmont@bu.edu; dcorp@deakin.edu.au; tdstein@bu.edu; rcantu@emersonhosp.org; bobstern@bu.edu	, Bob/ABA-8507-2020	Stein, Thor/0000-0001-6954-4477; Corp, Daniel/0000-0003-2435-077X; Stern, Robert/0000-0002-5008-077X; Montenigro, Philip/0000-0003-4442-9207	VAUS Department of Veterans Affairs [5I01CX001038-04] Funding Source: Federal RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG13846] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS078337] Funding Source: Medline; CSRD VA [I01 CX001038] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER		Abbas K, 2014, BRAIN CONNE IN PRESS; [Anonymous], 1936, N Y STATE J MED, V36, P1654; [Anonymous], 1933, HAHNEMANNIAN MON, V68, P305; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Beach TG, 2012, J NEUROPATH EXP NEUR, V71, P266, DOI 10.1097/NEN.0b013e31824b211b; Bernick C, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt177; Bowman KM, 1940, INJURIES SKULL BRAIN, P309; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Brock S, 1940, INJURIES SKULL BRAIN; Carroll EJ, 1936, AM J MED SCI, V191, P706, DOI 10.1097/00000441-193619150-00014; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Fainaru-Wada M., 2013, LEAGUE DENIAL NFL CO; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Finnoff JT, 2011, PM&R, V3, pS452, DOI 10.1016/j.pmrj.2011.07.014; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Ford JH, 2013, J NEUROTRAUM, V30, P1683, DOI 10.1089/neu.2012.2535; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gandy S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004274; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 1998, NEUROBIOLOGY OF PRIMARY DEMENTIA, P191; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jordan BD, 1992, MED ASPECTS BOXING, P150; Kapogiannis D, 2015, FASEB J, V29, P589, DOI 10.1096/fj.14-262048; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Koerte IK, 2015, IMAGING NEU IN PRESS; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Landau SM, 2013, J NUCL MED, V54, P70, DOI 10.2967/jnumed.112.109009; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Levin B, 2014, NEUROCRIT CARE, V20, P334, DOI 10.1007/s12028-013-9931-1; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Martland H, 1928, N Y PATHOL SOC T ARC, V6, P542; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Martland HS, 1943, THER INT DIS, V3, P291; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Mueller FO, 2001, J ATHL TRAINING, V36, P312; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Osnato M, 1930, AM J PSYCHIAT, V9, P643; Osnato M, 1927, ARCH NEURO PSYCHIATR, V18, P181, DOI 10.1001/archneurpsyc.1927.02210020025002; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Provenzano FA, 2010, NUCL MED COMMUN, V31, P952, DOI 10.1097/MNM.0b013e32833e37c4; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Scully F, 1937, MILWAUKEE J     0929, P3; Scully F, 1937, LIBERTY, V14, P35; Shah SA, 2006, EXP GERONTOL, V41, P1201, DOI 10.1016/j.exger.2006.07.006; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Stamm JM, 2015, NEUROLOGY IN PRESS; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; THORNDIKE A, 1952, NEW ENGL J MED, V247, P554, DOI 10.1056/NEJM195210092471504; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Victoroff J, 2013, NEUROREHABILITATION, V32, P211, DOI 10.3233/NRE-130839; Zazryn T, 2007, SPORTS MED, V37, P467; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	98	50	50	2	42	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1548-5943		978-0-8243-3911-1	ANNU REV CLIN PSYCHO	Annu. Rev. Clin. Psychol.		2015	11						309	330		10.1146/annurev-clinpsy-032814-112814			22	Psychology, Clinical; Psychology	Psychology	BC3WH	WOS:000352014000013	25581233				2021-06-18	
J	Flint, AC; Conell, C; Rao, VA; Klingman, JG; Sidney, S; Johnston, C; Hemphill, JC; Kamel, H; Davis, SM; Donnan, GA				Flint, Alexander C.; Conell, Carol; Rao, Vivek A.; Klingman, Jeff G.; Sidney, Stephen; Johnston, Claiborne; Hemphill, J. Claude; Kamel, Hooman; Davis, Stephen M.; Donnan, Geoffrey A.			Effect of Statin Use During Hospitalization for Intracerebral Hemorrhage on Mortality and Discharge Disposition	JAMA NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; ISCHEMIC-STROKE; INTRAVENOUS THROMBOLYSIS; INSTRUMENTAL VARIABLES; METAANALYSIS; THERAPY; IMPROVE; RISK; ATORVASTATIN; ASSOCIATION	IMPORTANCE Statin use during hospitalization is associated with improved survival and a better discharge disposition among patients with ischemic stroke. It is unclear whether inpatient statin use has a similar effect among patients with intracerebral hemorrhage (ICH). OBJECTIVE To determine whether inpatient statin use in ICH is associated with improved outcomes and whether the cessation of statin use is associated with worsened outcomes. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of 3481 patients with ICH admitted to any of 20 hospitals in a large integrated health care delivery system over a 10-year period. Detailed electronic medical and pharmacy records were analyzed to explore the association between inpatient statin use and outcomes. MAIN OUTCOMES AND MEASURES The primary outcome measureswere survival to 30 days after ICH and discharge to home or inpatient rehabilitation facility. We used multivariable logistic regression, controlling for demographics, comorbidities, initial severity, and code status. In addition, we used instrumental variable modeling to control for confounding by unmeasured covariates at the individual patient level. RESULTS Among patients hospitalized for ICH, inpatient statin users were more likely than nonusers to be alive 30 days after ICH (odds ratio [OR], 4.25 [95% CI, 3.46-5.23]; P < .001) and were more likely than nonusers to be discharged to their home or an acute rehabilitation facility (OR, 2.57 [95% CI, 2.16-3.06]; P < .001). Patients whose statin therapy was discontinued were less likely than statin users to survive to 30 days (OR, 0.16 [95% CI, 0.12-0.21]; P < .001) and were less likely than statin users to be discharged to their home or an acute rehabilitation facility (OR, 0.26 [95% CI, 0.20-0.35]; P < .001). Instrumental variable models of local treatment environment (to control for confounding by unmeasured covariates) confirmed that a higher probability of statin therapy was associated with a higher probability of 30-day survival (with an increase in probability of 0.15 [95% CI, 0.04-0.25]; P = .01) and a better chance of being discharged to home or an acute rehabilitation facility (with an increase in probability of 0.13 [95% CI, 0.02-0.24]; P = .02). CONCLUSIONS AND RELEVANCE Inpatient statin use is associated with improved outcomes after ICH, and the cessation of statin use is associated with worsened outcomes after ICH. Given the association between statin cessation and substantially worsened outcomes, the risk-benefit balance of discontinuing statin therapy in the acute setting of ICH should be carefully considered.	[Flint, Alexander C.; Rao, Vivek A.] Kaiser Permanente No Calif, Dept Neurosci, Redwood City, CA 94025 USA; [Conell, Carol; Sidney, Stephen] Kaiser Permanente No Calif, Div Res, Oakland, CA USA; [Klingman, Jeff G.] Kaiser Permanente, Dept Neurol, Walnut Creek, CA USA; [Johnston, Claiborne] Univ Texas Austin, Dell Med Sch, Austin, TX 78712 USA; [Hemphill, J. Claude] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Kamel, Hooman] Weill Cornell Med Coll, Dept Neurol, New York, NY USA; [Kamel, Hooman] Weill Cornell Med Coll, Dept Neurosci, New York, NY USA; [Davis, Stephen M.] Univ Melbourne, Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic, Australia; [Donnan, Geoffrey A.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic 3050, Australia	Flint, AC (corresponding author), Kaiser Permanente No Calif, Dept Neurosci, 1150 Vet Blvd, Redwood City, CA 94025 USA.	alexander.c.flint@kp.org	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Flint, Alexander/0000-0002-3721-2694; Donnan, Geoffrey/0000-0001-6324-3403; Hemphill, Claude/0000-0003-4019-7525	Kaiser Foundation Research Institute; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK092317] Funding Source: NIH RePORTER	The present study was supported by a Community Benefit grant from the Kaiser Foundation Research Institute.	Amarenco P, 2006, NEW ENGL J MED, V355, P549; Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; Antonopoulos AS, 2012, CURR PHARM DESIGN, V18, P1519; Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718; Biffi A, 2011, NEUROLOGY, V76, P1581, DOI 10.1212/WNL.0b013e3182194be9; Blanco M, 2007, NEUROLOGY, V69, P904, DOI 10.1212/01.wnl.0000269789.09277.47; Brookhart MA, 2007, MED CARE, V45, pS116, DOI 10.1097/MLR.0b013e318070c057; Brookhart MA, 2006, EPIDEMIOLOGY, V17, P268, DOI 10.1097/01.ede.0000193606.58671.c5; Bustamante A, 2013, STROKE, V44, P2060, DOI 10.1161/STROKEAHA.113.000916; de Oliveira CV, 2013, PHARMACOL RES, V71, P1, DOI 10.1016/j.phrs.2013.02.003; Flint AC, 2012, NEUROLOGY, V78, P1678, DOI 10.1212/WNL.0b013e3182575142; Flint AC, 2012, STROKE, V43, P147, DOI 10.1161/STROKEAHA.111.627729; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Goldstein LB, 2008, NEUROLOGY, V70, P2364, DOI 10.1212/01.wnl.0000296277.63350.77; Goldstein LB, 2013, STROKE, V44, P2058, DOI 10.1161/STROKEAHA.113.000915; Hackam DG, 2011, CIRCULATION, V124, P2233, DOI 10.1161/CIRCULATIONAHA.111.055269; Hernan MA, 2006, EPIDEMIOLOGY, V17, P360, DOI 10.1097/01.ede.0000222409.00878.37; Indraswari F, 2012, J NEUROTRAUM, V29, P1388, DOI 10.1089/neu.2011.2117; Karki K, 2009, STROKE, V40, P3384, DOI 10.1161/STROKEAHA.108.544395; Lee JG, 2012, KOREAN J INTERN MED, V27, P317, DOI 10.3904/kjim.2012.27.3.317; Lei C, 2014, EUR J NEUROL, V21, P192, DOI 10.1111/ene.12273; Levesque LE, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5087; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; McKinney JS, 2012, STROKE, V43, P2149, DOI 10.1161/STROKEAHA.112.655894; Nardi K, 2012, NEUROLOGY, V79, P1101, DOI 10.1212/WNL.0b013e3182608c82; Naval NS, 2008, NEUROCRIT CARE, V8, P6, DOI 10.1007/s12028-007-0080-2; Naval NS, 2008, NEUROCRIT CARE, V8, P13, DOI 10.1007/s12028-007-0081-1; Newhouse JP, 1998, ANNU REV PUBL HEALTH, V19, P17, DOI 10.1146/annurev.publhealth.19.1.17; Rassen JA, 2010, EUR HEART J, V31, P561, DOI 10.1093/eurheartj/ehp437; Rocco A, 2012, CEREBROVASC DIS, V33, P362, DOI 10.1159/000335840; Scheitz JF, 2014, STROKE, V45, P509, DOI 10.1161/STROKEAHA.113.002751; Scheitz JF, 2013, STROKE, V44, P1472, DOI 10.1161/STROKEAHA.111.000001; Spence JD, 2012, NEUROLOGY, V79, P1076, DOI 10.1212/WNL.0b013e3182608caf; Tapia-Perez JH, 2013, NEUROSURG REV, V36, P279, DOI 10.1007/s10143-012-0431-0; Tapia-Perez JH, 2013, NEUROSURG REV, V36, P287; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0	36	50	53	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	NOV	2014	71	11					1364	1371		10.1001/jamaneurol.2014.2124			8	Clinical Neurology	Neurosciences & Neurology	AT7WN	WOS:000345145300005	25244578	Bronze			2021-06-18	
J	Bolton, AN; Saatman, KE				Bolton, Amanda N.; Saatman, Kathryn E.			Regional Neurodegeneration and Gliosis Are Amplified by Mild Traumatic Brain Injury Repeated at 24-Hour Intervals	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Astrocytosis; Axonal injury; Cerebellum; Concussion; Entorhinal cortex; Loss of consciousness; Microgliosis; Traumatic brain injury	FLUID PERCUSSION MODEL; CLOSED-HEAD-INJURY; AXONAL INJURY; MOUSE MODEL; COGNITIVE DEFICITS; MICE; RATS; PATHOPHYSIOLOGY; VULNERABILITY; CONCUSSION	Most traumatic brain injuries (TBIs) that occur every year are classified as "mild.'' Individuals involved in high-risk activities may sustain multiple mild TBIs. We evaluated the acute physiologic and histopathologic consequences of mild TBI in a mouse model, comparing sham injury, single impact, or 5 impacts at a 24- or 48-hour interinjury interval. A single closed skull impact resulted in bilateral gliosis in the hippocampus and entorhinal cortex that was proportional to impact depth. Midline impact, at a depth just above the threshold to induce transient unconsciousness, produced occasional axonal injury and degenerating neurons accompanied by astrogliosis in the entorhinal cortex and cerebellum. Mild TBI repeated every 24 hours resulted in bilateral hemorrhagic lesions in the entorhinal cortex along with significantly increased neurodegeneration and microglial activation despite diminished durations of apnea and unconsciousness with subsequent impacts. Astrogliosis and diffusely distributed axonal injury were also observed bilaterally in the cerebellum and the brainstem. When the interval between mild TBIs was increased to 48 hours, the pathologic consequences were comparable to those of a single TBI. Together, these data suggest that, in mice, the brain remains at an increased risk for damage for 24 hours after mild TBI despite reduced acute physiologic responses to subsequent mild impacts.	[Bolton, Amanda N.; Saatman, Kathryn E.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; [Bolton, Amanda N.; Saatman, Kathryn E.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY USA; [Saatman, Kathryn E.] Univ Kentucky, Coll Med, Dept Neurosurg, Lexington, KY USA	Saatman, KE (corresponding author), Spinal Cord & Brain Injury Res Ctr, B473 Biomed & Biol Res Bldg,741 S Limestone St, Lexington, KY 40536 USA.	k.saatman@uky.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 NS077889, P01 NS058484, P30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS077889, P30NS051220, P01NS058484] Funding Source: NIH RePORTER	This study was supported by grants from the National Institutes of Health (T32 NS077889 to Amanda N. Bolton and P01 NS058484 and P30 NS051220 to Kathryn E. Saatman).	Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Centers for Disease Control and Prevention (CDC), 2003, REP C MILD TRAUM BRA, P1; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; de Hoz R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083733; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Diniz LP, 2012, J BIOL CHEM, V287, P41432, DOI 10.1074/jbc.M112.380824; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FRANK GB, 1963, BRIT J PHARM CHEMOTH, V21, P1; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Hardman R, 1997, BRAIN RES, V758, P187, DOI 10.1016/S0006-8993(97)00223-0; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kubo K, 2009, J PHARMACOL EXP THER, V329, P592, DOI 10.1124/jpet.109.151456; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; Veasey Sigrid C, 2012, Front Neurol, V3, P139, DOI 10.3389/fneur.2012.00139; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	50	50	51	1	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	OCT	2014	73	10					933	947		10.1097/NEN.0000000000000115			15	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	AQ3JN	WOS:000342688800003	25232942	Green Accepted			2021-06-18	
J	Baugh, CM; Kroshus, E; Daneshvar, DH; Stern, RA				Baugh, Christine M.; Kroshus, Emily; Daneshvar, Daniel H.; Stern, Robert A.			Perceived Coach Support and Concussion Symptom-Reporting: Differences between Freshmen and Non-Freshmen College Football Players	JOURNAL OF LAW MEDICINE & ETHICS			English	Article							TRAUMATIC BRAIN-INJURY; SCHOOL; EDUCATION; DISEASE; EPIDEMIOLOGY; SPORTS; IMPACT	This paper examines college athletes' perceived support for concussion reporting from coaches and teammates and its variation by year-in-school, finding significant differences in perceived coach support. It also examines the effects of perceived coach support on concussion reporting behaviors, finding that greater perceived coach support is associated with fewer undiagnosed concussions and returning to play while symptomatic less frequently in the two weeks preceding the survey. Coaches play a critical role in athlete concussion reporting.	[Baugh, Christine M.] Boston Univ, Chron Traumat Encephalopathy Ctr, Boston, MA 02215 USA; [Baugh, Christine M.; Daneshvar, Daniel H.; Stern, Robert A.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Baugh, Christine M.] Harvard Univ, Edmond J Safra Ctr Eth, Cambridge, MA 02138 USA; [Daneshvar, Daniel H.] Sports Legacy Inst Community Educ SLICE Program, Waltham, MA USA; [Stern, Robert A.] Boston Univ, Clin Core, Alzheimers Dis Ctr, Boston, MA 02215 USA; [Stern, Robert A.] Boston Univ, Ctr Study Traumat Encephalopathy, Boston, MA 02215 USA	Baugh, CM (corresponding author), Boston Univ, Chron Traumat Encephalopathy Ctr, Boston, MA 02215 USA.		Baugh, Christine/AAG-2324-2020; , Bob/ABA-8507-2020	Baugh, Christine/0000-0002-9340-6338; Daneshvar, Daniel/0000-0003-3691-9513; Stern, Robert/0000-0002-5008-077X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56 NS078337] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS078337] Funding Source: NIH RePORTER		ADLER PA, 1988, ADMIN SCI QUART, V33, P401, DOI 10.2307/2392716; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; [Anonymous], 2013, US TODAY; Baker JF, 2013, IRISH J MED SCI, V182, P121, DOI 10.1007/s11845-012-0846-1; Baugh CM, 2014, J LAW MED ETHICS, V42, P297, DOI 10.1111/jlme.12147; Bazarian J. J., 2013, MAGNETIC RESONANCE I, V30, P171; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio S. P., 2014, CONCUSSIONS ATHLETIC, P313; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2010, J SPORT SCI MED, V9, P418; BRONFENBRENNER U, 1977, AM PSYCHOL, V32, P513, DOI 10.1037/0003-066x.32.7.513; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Faure C., 2011, SPORT J, V14, P34; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Holmes P, 2011, J SPORT ECON, V12, P157, DOI 10.1177/1527002510378820; Hudd S. S., 2000, COLL STUD J, V34, P217, DOI DOI 10.1037/A0018745; Institute of Medicine, 2013, SPORTS REL CONC YOUT; Kelly JP, 1997, NEUROLOGY, V48, P581; Kerr Z. Y., 2014, BRAIN INJUR IN PRESS; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Kroshus E., 2014, ANN BEHAV M IN PRESS; Kroshus E., 2014, J ADOLESCENT HEALTH, V54, pe2; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2010, ATHLET THER TODAY, V15, P1, DOI 10.1123/att.15.2.1; O'Donoghue EM., 2009, ATHLETIC TRAINING SP, V1, DOI [DOI 10.3928/19425864-20090427-07, 10.3928/19425864-20090427-07]; OPPENHEIMER BT, 1984, J COUNS PSYCHOL, V31, P45, DOI 10.1037/0022-0167.31.1.45; Papanikolaou Z., 2003, ATHLETIC INSIGHT ONL, V5; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sarris CE, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12224; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; United States Bureau of Labor Statistics, 2013, OCC EMPL WAG; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Wilson G.W., 2005, ATHLETIC INSIGHT ONL, V7, P1	52	50	50	1	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1105	1748-720X		J LAW MED ETHICS	J. Law Med. Ethics	FAL	2014	42	3			SI		314	322		10.1111/jlme.12148			9	Ethics; Law; Medical Ethics; Medicine, Legal	Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine	AQ4ED	WOS:000342745000006	25264089				2021-06-18	
J	Choudhary, AK; Ishak, R; Zacharia, TT; Dias, MS				Choudhary, Arabinda K.; Ishak, Ramsay; Zacharia, Thomas T.; Dias, Mark S.			Imaging of spinal injury in abusive head trauma: a retrospective study	PEDIATRIC RADIOLOGY			English	Article						Abusive head trauma; Spine trauma; Spinal subdural hemorrhage; Infant; Magnetic resonance imaging; Nuchal ligament injury	SHAKEN BABY SYNDROME; CLINICAL ARTICLE; DURA-MATER; CONNECTIVE-TISSUE; LIGAMENTUM NUCHAE; ANATOMIC RELATION; MYODURAL BRIDGE; POSTERIOR MINOR; BRAIN INJURY; CHILDREN	Spinal imaging has been a neglected part of abusive head trauma (AHT) imaging. As most of the radiographs and CT spine are negative in AHT in infants, the cervical spine is assumed to be normal. There is increasing evidence in the role of injury to brainstem and cervical cord in the pathogenesis of AHT. In addition, in courts of law, there is fierce debate about AHT, its mimics and other disparate nontraumatic diagnoses explaining the neuroradiological and skeletal findings. However, this discussion ignores the evidence and significance of spinal injury. We sought to study the cervical spine in an AHT cohort to understand the true prevalence of spinal injuries in AHT and contrast it with cohorts of accidental and nontraumatic groups to give the clinicians a robust diagnostic tool in evaluating AHT. The purpose of this study is to compare the relative incidence of spinal ligamentous and soft-tissue abnormalities on spinal MRI among three groups of children ages < 48 months: 1) those with AHT, 2) those with accidental trauma, and 3) those with nontraumatic conditions. This comparative study included 183 children who underwent spine MRI: 67 with AHT, 46 with accidental trauma and a clinical suspicion of spinal injury, and 70 with nontraumatic conditions. Clinical and radiographic findings were collected in all cases and were analyzed retrospectively to identify MRI evidence of traumatic spinal injuries. The incidence of spinal injuries among the three groups was compared. The incidence of spinal ligamentous injuries was calculated for those with and without radiographic evidence of hypoxic-ischemic encephalopathy. All comparisons were performed using Fisher exact test with P < 0.05 considered statistically significant. Cervical spine ligamentous injuries (predominantly the nuchal, atlanto-occipital and atlanto-axial ligaments) were present in 78% of the AHT group, 46% of the accidental trauma group and 1% of the nontraumatic group; all of these differences were statistically significant. Among the AHT group, ligamentous injuries were statistically correlated with evidence of brain ischemia. Injury to the cervical spinal posterior ligamentous complex is common in AHT and even more prevalent than in clinically symptomatic traumatic cases. The high correlation between the radiographic findings of occipitocervical ligamentous injuries and hypoxic-ischemic brain injury is consistent with an interpretation that transient upper occipitocervical spinal cord injury in AHT leads to disordered breathing and results in hypoxic-ischemic encephalopathy. We recommend imaging the entire spine in AHT to properly identify and classify these injuries.	[Choudhary, Arabinda K.] Nemours AI DuPont Children Hosp, Dept Radiol, Wilmington, DE 19803 USA; [Ishak, Ramsay; Zacharia, Thomas T.] Hershey Med Ctr, Dept Radiol, Hershey, PA USA; [Dias, Mark S.] Hershey Med Ctr, Dept Neurosurg, Hershey, PA USA	Choudhary, AK (corresponding author), Nemours AI DuPont Children Hosp, Dept Radiol, 1600 Rockland Rd, Wilmington, DE 19803 USA.	arabinda.choudhary@nemours.org	choudhary, arabinda/AAP-1220-2021	choudhary, arabinda/0000-0002-2338-5906; Zacharia, Thomas/0000-0002-6908-9440			Anderson RCE, 2010, J NEUROS-PEDIATR, V5, P292, DOI 10.3171/2009.10.PEDS09159; Bandak FA, 2005, FORENSIC SCI INT, V151, P71, DOI 10.1016/j.forsciint.2005.02.033; Bradford R, 2013, J NEUROSURG-PEDIATR, V12, P110, DOI 10.3171/2013.4.PEDS12596; Brennan LK, 2009, J NEUROS-PEDIATR, V3, P232, DOI 10.3171/2008.11.PEDS0835; Choudhary AK, 2012, RADIOLOGY, V262, P216, DOI 10.1148/radiol.11102390; Dean NA, 2002, CLIN ANAT, V15, P182, DOI 10.1002/ca.10001; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; HACK GD, 1995, SPINE, V20, P2484, DOI 10.1097/00007632-199512000-00003; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Humphreys BK, 2003, CLIN ANAT, V16, P152, DOI 10.1002/ca.10109; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Johnson GM, 2000, SPINE, V25, P5, DOI 10.1097/00007632-200001010-00003; Judkins AR, 2004, AM J FOREN MED PATH, V25, P29, DOI 10.1097/01.paf.0000113811.85110.54; Kadri PAS, 2007, NEUROSURGERY, V61, P301, DOI 10.1227/01.neu.0000303985.65117.ea; Kahkeshani K, 2012, CLIN ANAT, V25, P415, DOI 10.1002/ca.21261; Katz JS, 2010, J NEUROSURG-PEDIATR, V5, P470, DOI 10.3171/2009.11.PEDS09291; Kemp AM, 2010, ARCH DIS CHILD, V95, P355, DOI 10.1136/adc.2009.169110; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; Matshes EW, 2011, ACAD FOR PATHOL, V1, P82; Mitchell BS, 1998, J MANIP PHYSIOL THER, V21, P145; Mulcahey MJ, 2007, SPINAL CORD, V45, P452, DOI 10.1038/sj.sc.3101987; Nash L, 2005, SPINE, V30, P1359, DOI 10.1097/01.brs.0000166159.31329.92; NICHOLAS DS, 1988, J NEUROSURG, V69, P276, DOI 10.3171/jns.1988.69.2.0276; Polk-Williams A, 2008, J PEDIATR SURG, V43, P1718, DOI 10.1016/j.jpedsurg.2008.06.002; Pontell ME, 2013, CLIN ANAT, V26, P450, DOI 10.1002/ca.22134; Shannon P, 2001, LANCET, V358, P686, DOI 10.1016/S0140-6736(01)05849-4; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Takeshita K, 2004, SPINE, V29, pE388, DOI 10.1097/01.brs.0000138309.11926.72; Zumpano MP, 2006, CLIN ANAT, V19, P522, DOI 10.1002/ca.20220	31	50	50	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-0449	1432-1998		PEDIATR RADIOL	Pediatr. Radiol.	SEP	2014	44	9					1130	1140		10.1007/s00247-014-2959-3			11	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	AN8RA	WOS:000340870400012	24687620				2021-06-18	
J	Hammond, FM; Bickett, AK; Norton, JH; Pershad, R				Hammond, Flora M.; Bickett, Allison K.; Norton, James H.; Pershad, Rashmi			Effectiveness of Amantadine Hydrochloride in the Reduction of Chronic Traumatic Brain Injury Irritability and Aggression	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aggression; agitation; amantadine; brain injuries; dopamine; irritability	NMDA RECEPTOR ANTAGONIST; NEUROPSYCHIATRIC INVENTORY; NEUROTROPHIC FACTOR; MEMANTINE; EXPRESSION; PERSPECTIVES; ENHANCEMENT; COGNITION; SYMPTOMS; RECOVERY	Background: Following traumatic brain injury (TBI), individuals may experience chronic problems with irritability or aggression, which may need treatment to minimize the negative impact on their relationships, home life, social interactions, community participation, and employment. Objective: To test the a priori hypothesis that amantadine reduces irritability (primary hypothesis) and aggression (secondary hypothesis) among individuals greater than 6 months post-TBI. Methods: A total of 76 individuals greater than 6 months post-TBI referred for irritability management were enrolled in a parallel-group, randomized, double-blind, placebo-controlled trial of amantadine (n = 38) versus placebo (n = 38). Study participants were randomly assigned to receive amantadine hydrochloride 100 mg twice daily versus equivalent placebo for 28 days. Symptoms of irritability and aggression were measured before and after treatment using the Neuropsychiatric Inventory Irritability (NPI-I) and Aggression (NPI-A) domains, as well as the NPI-Distress for these domains. Results: In the amantadine group, 80.56% improved at least 3 points on the NPI-I, compared with 44.44% in the group that received placebo (P = .0016). Mean change in NPI-I was -4.3 in the amantadine group and -2.6 in the placebo group (P = .0085). When excluding individuals with minimal to no baseline aggression, mean change in NPI-A was -4.56 in the amantadine group and -2.46 in the placebo group (P = .046). Mean changes in NPI-I and NPI-A Distress were not statistically significant between the amantadine and placebo groups. Adverse event occurrence did not differ between the 2 groups. Conclusions: Amantadine 100 mg every morning and at noon appears an effective and safe means of reducing frequency and severity of irritability and aggression among individuals with TBI and sufficient creatinine clearance.	[Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN 46254 USA; Rehabil Hosp Indiana, Indianapolis, IN USA	Hammond, FM (corresponding author), Indiana Univ Sch Med, 4141 Shore Dr, Indianapolis, IN 46254 USA.	Flora.hammond@rhin.com			US Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation ResearchUS Department of Education [H133A20016]	The research reported in this article was supported by US Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation Research grant H133A20016. The study sponsor had no role in the design and conduct of this study; the collection, management, analysis, and interpretation of the data; or the preparation review, or approval of the manuscript.	ALLEN RM, 1983, CLIN NEUROPHARMACOL, V6, pS64; Andersson Stein, 1992, Tidsskrift for den Norske Laegeforening, V112, P2070; AOKI FY, 1988, CLIN PHARMACOKINET, V14, P35, DOI 10.2165/00003088-198814010-00003; Beck AT., 1996, BECK DEPRESSION INVE, V2; Beers SR, 2005, J HEAD TRAUMA REHAB, V20, P450, DOI 10.1097/00001199-200509000-00006; Berwick DM, 1991, MED CARE, V29, P87; Bradley PB, 1989, INTRO NEUROPHARMACOL; Caumont AS, 2006, NEUROSCI LETT, V394, P196, DOI 10.1016/j.neulet.2005.10.027; Chandler M C, 1988, Brain Inj, V2, P309; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Derogatis L.R., 2000, BSI 18 BRIEF SYMPTOM; Evans SM, 2007, ALCOHOL CLIN EXP RES, V31, P775, DOI 10.1111/j.1530-0277.2007.00360.x; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FISK JD, 1994, CLIN INFECT DIS, V18, pS79, DOI 10.1093/clinids/18.Supplement_1.S79; FLEMINGER S, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003299; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; Glennon RA, 2000, PHARMACOL BIOCHEM BE, V66, P483, DOI 10.1016/S0091-3057(00)00174-X; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Hammond F, 2006, J HEAD TRAUMA REHAB, V21, P412, DOI 10.1097/00001199-200609000-00014; Hammond FM, 2011, J HEAD TRAUMA REHAB, V26, P69, DOI 10.1097/HTR.0b013e318205174d; KASAMATSU T, 1979, J COMP NEUROL, V185, P139, DOI 10.1002/cne.901850109; Kasamatusu T, 1981, J NEUROPHYSIOL, V45, P139; Kaufer DI, 1998, J AM GERIATR SOC, V46, P210, DOI 10.1111/j.1532-5415.1998.tb02542.x; Kilmer RP, 2006, REHABIL PSYCHOL, V51, P232, DOI 10.1037/0090-5550.51.3.232; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leone H, 2005, J CLIN PHARM THER, V30, P101, DOI 10.1111/j.1365-2710.2005.00628.x; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Moresco RM, 2002, J NEURAL TRANSM, V109, P1265, DOI 10.1007/s00702-002-0694-7; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Parsons CG, 2007, NEUROPHARMACOLOGY, V53, P699, DOI 10.1016/j.neuropharm.2007.07.013; Peeters M, 2003, NEUROSCI LETT, V343, P205, DOI 10.1016/S0304-3940(03)00398-7; Rogoz Z, 2007, J PHYSIOL PHARMACOL, V58, P219; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Schneider WN, 1999, BRAIN INJURY, V13, P863; Siever LJ, 2008, AM J PSYCHIAT, V165, P429, DOI 10.1176/appi.ajp.2008.07111774; Tenovuo O, 2006, CURR OPIN NEUROL, V19, P528, DOI 10.1097/WCO.0b013e328010944f; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wechsler ME, 2011, NEW ENGL J MED, V365, P119, DOI 10.1056/NEJMoa1103319; Werling LL, 2007, EXP NEUROL, V207, P248, DOI 10.1016/j.expneurol.2007.06.013; Wyman PA, 1999, CHILD DEV, V70, P645, DOI 10.1111/1467-8624.00047; Zafonte RD, 1998, BRAIN INJURY, V12, P617; ZASLER N D, 1992, Brain Injury, V6, P1, DOI 10.3109/02699059209008117	49	50	50	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2014	29	5					391	399		10.1097/01.HTR.0000438116.56228.de			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AP2GW	WOS:000341891700007	24263176				2021-06-18	
J	Yang, T; Kong, B; Gu, JW; Kuang, YQ; Cheng, L; Yang, WT; Xia, X; Shu, HF				Yang, Tao; Kong, Bin; Gu, Jian-Wen; Kuang, Yong-Qin; Cheng, Lin; Yang, Wen-Tao; Xia, Xun; Shu, Hai-Feng			Anti-apoptotic and Anti-oxidative Roles of Quercetin After Traumatic Brain Injury	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; Quercetin; Oxidative stress; Inflammation; Apoptosis	SPINAL-CORD-INJURY; INFLAMMATORY RESPONSE; LIPID-PEROXIDATION; HYPERBARIC-OXYGEN; CEREBRAL-ISCHEMIA; SIGNALING PATHWAY; RATS; PATHOPHYSIOLOGY; PEROXYNITRITE; STROKE	Experimental studies have demonstrated significant secondary damage (including cell apoptosis, blood-brain barrier disruption, inflammatory responses, excitotoxic damage, and free radical production) after traumatic brain injury (TBI). Quercetin is a natural flavonoid found in high quantities in fruits and vegetables, and may be a potential antioxidant and free radical scavenger. The purpose of this study was to determine the effects of quercetin on TBI-induced upregulation of oxidative stress, inflammation, and apoptosis in adult Sprague-Dawley rats. Animals were subjected to Feeney's weight-drop injury, thus inducing the parietal contusion brain injury model. Quercetin was administered (30 mg/kg intraperitoneal injection) 0, 24, 48, and 72 h after TBI. Quercetin reduced cognitive deficits, the number of TUNEL- and ED-1-positive cells, the protein expressions of Bax and cleaved-caspase-3 proteins, and the levels of TBARS and proinflammatory cytokines, and increased the activity of antioxidant enzymes (GSH-Px, SOD, and CAT) at 1 week after TBI. Our results suggest that in TBI rats, quercetin improves cognitive function owing to its neuroprotective action via the inhibition of oxidative stress, leading to a reduced inflammatory response, thereby reducing neuronal death.	[Yang, Tao; Kong, Bin; Gu, Jian-Wen; Kuang, Yong-Qin; Cheng, Lin; Yang, Wen-Tao; Xia, Xun; Shu, Hai-Feng] Chengdu Mil Gen Hosp, Dept Neurosurg, Chengdu 610083, Sichuan, Peoples R China; [Yang, Tao; Kong, Bin; Xia, Xun] Third Mil Med Univ, Chongqing 400038, Peoples R China	Gu, JW (corresponding author), Chengdu Mil Gen Hosp, Dept Neurosurg, 270 Rong Du Rd, Chengdu 610083, Sichuan, Peoples R China.	zht0723@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81071037, 81271395]	This work was supported by a grant from the National Natural Science Foundation of China (Nos. 81071037 and 81271395).	Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Cho JY, 2006, NEUROSCI LETT, V404, P330, DOI 10.1016/j.neulet.2006.06.010; Dok-Go H, 2003, BRAIN RES, V965, P130, DOI 10.1016/S0006-8993(02)04150-1; Fujimoto T, 2000, SPINE, V25, P24, DOI 10.1097/00007632-200001010-00006; Gogel S, 2011, GENE THER, V18, P1, DOI 10.1038/gt.2010.130; Imam SZ, 2000, BRAIN RES, V855, P186, DOI 10.1016/S0006-8993(99)02249-0; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Kahraman S, 2007, NEUROCHEM RES, V32, P1547, DOI 10.1007/s11064-007-9354-5; Kelso ML, 2006, BRAIN RES, V1083, P204, DOI 10.1016/j.brainres.2006.01.127; Kinaci MK, 2012, EXP THER MED, V3, P249, DOI 10.3892/etm.2011.382; Lee JK, 2011, ACTA NEUROCHIR, V153, P1321, DOI 10.1007/s00701-010-0889-x; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Mahmoud MF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063784; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Pearse D, 2010, CURR OPIN INVEST DR, V11, P1207; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; SCHMIDLEY JW, 1990, STROKE, V21, P1086, DOI 10.1161/01.STR.21.7.1086; Schultke E, 2005, J NEUROTRAUM, V22, P1475, DOI 10.1089/neu.2005.22.1475; Schultke E, 2003, J NEUROTRAUM, V20, P583, DOI 10.1089/089771503767168500; Serarslan Y, 2010, J CLIN NEUROSCI, V17, P349, DOI 10.1016/j.jocn.2009.03.036; Song YX, 2013, LIFE SCI, V92, P1215, DOI 10.1016/j.lfs.2013.05.007; Talmadge RJ, 2002, J APPL PHYSIOL, V93, P1487, DOI 10.1152/japplphysiol.00053.2002; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Yan ZJ, 2013, NEUROCHEM RES, V38, P1022, DOI 10.1007/s11064-013-1012-5; Yao RQ, 2012, NEUROCHEM RES, V37, P2777, DOI 10.1007/s11064-012-0871-5; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	29	50	52	1	18	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	AUG	2014	34	6					797	804		10.1007/s10571-014-0070-9			8	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	AL8IT	WOS:000339382500003	24846663				2021-06-18	
J	Zhou, YX; Lui, YW; Zuo, XN; Milham, MP; Reaume, J; Grossman, RI; Ge, YL				Zhou, Yongxia; Lui, Yvonne W.; Zuo, Xi-Nian; Milham, Michael P.; Reaume, Joseph; Grossman, Robert I.; Ge, Yulin			Characterization of Thalamo-cortical Association Using Amplitude and Connectivity of Functional MRI in Mild Traumatic Brain Injury	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						fractional amplitude of low frequency fluctuation; functional connectivity (fcMRI); coherence; mild traumatic brain injury; thalamus; resting-state fMRI	RESTING-STATE FMRI; GAMMA OSCILLATIONS; ALPHA-RHYTHM; BOLD SIGNAL; THALAMUS; FREQUENCY; HUMANS; STIMULATION; COHERENCE; SCHIZOPHRENIA	PurposeTo examine thalamic and cortical injuries using fractional amplitude of low-frequency fluctuations (fALFFs) and functional connectivity MRI (fcMRI) based on resting state (RS) and task-related fMRI in patients with mild traumatic brain injury (MTBI). Materials and MethodsTwenty-seven patients and 27 age-matched controls were recruited. The 3 Tesla fMRI at RS and finger tapping task were used to assess fALFF and fcMRI patterns. fALFFs were computed with filtering (0.01-0.08 Hz) and scaling after preprocessing. fcMRI was performed using a standard seed-based correlation method, and delayed fcMRI (coherence) in frequency domain were also performed between thalamus and cortex. ResultsIn comparison with controls, MTBI patients exhibited significantly decreased fALFFs in the thalamus (and frontal/temporal subsegments) and cortical frontal and temporal lobes; as well as decreased thalamo-thalamo and thalamo-frontal/ thalamo-temporal fcMRI at rest based on RS-fMRI (corrected P < 0.05). This thalamic and cortical disruption also existed at task-related condition in patients. ConclusionThe decreased fALFFs (i.e., lower neuronal activity) in the thalamus and its segments provide additional evidence of thalamic injury in patients with MTBI. Our findings of fALFFs and fcMRI changes during motor task and resting state may offer insights into the underlying cause and primary location of disrupted thalamo-cortical networks after MTBI. J. Magn. Reson. Imaging 2014;39:1558-1568. (c) 2013 Wiley Periodicals, Inc.	[Zhou, Yongxia; Lui, Yvonne W.; Reaume, Joseph; Grossman, Robert I.; Ge, Yulin] NYU, Langone Med Ctr, Dept Radiol, Ctr Biomed Imaging, New York, NY 10016 USA; [Zuo, Xi-Nian] Chinese Acad Sci, Inst Psychol, Lab Funct Connectome & Dev, Key Lab Behav Sci,Magnet Resonance Imaging Res Ct, Beijing 100101, Peoples R China; [Milham, Michael P.] Child Mind Inst, New York, NY USA	Ge, YL (corresponding author), NYU, Sch Med, Dept Radiol, Ctr Biomed Imaging, 660 First Ave,4th Floor, New York, NY 10016 USA.	yulin.ge@nyumc.org	Ge, Yulin/D-9060-2019; Zuo, Xi-Nian/A-7273-2009; Ge, Yulin/L-7052-2019; Milham, Michael P./Y-3160-2019; Milham, Michael P/K-9501-2014	Ge, Yulin/0000-0002-2320-6031; Zuo, Xi-Nian/0000-0001-9110-585X; Zhou, Yongxia (Sharon)/0000-0002-4931-2318	NIH-RO1United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS039135-10]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029029, R01NS039135] Funding Source: NIH RePORTER	Contract grant sponsor: NIH-RO1; Contract grant number: NS039135-10.	Aron AR, 2003, BRAIN, V126, P713, DOI 10.1093/brain/awg067; Bajo R, 2010, J ALZHEIMERS DIS, V22, P183, DOI 10.3233/JAD-2010-100177; Ben-Simon E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003984; Bennett CM, 2009, SOC COGN AFFECT NEUR, V4, P417, DOI 10.1093/scan/nsp053; Biswal BB, 2012, NEUROIMAGE, V62, P938, DOI 10.1016/j.neuroimage.2012.01.090; Buzsaki G, 2012, ANNU REV NEUROSCI, V35, P203, DOI 10.1146/annurev-neuro-062111-150444; CHATILA M, 1993, CR ACAD SCI III-VIE, V316, P51; DASILVA FHL, 1974, KYBERNETIK, V15, P27, DOI DOI 10.1007/BF00270757; Duff EP, 2008, HUM BRAIN MAPP, V29, P778, DOI 10.1002/hbm.20601; Engel AK, 1999, CONSCIOUS COGN, V8, P128, DOI 10.1006/ccog.1999.0389; Garcia-Panach J, 2011, J NEUROTRAUM, V28, P1707, DOI 10.1089/neu.2011.1851; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Hoptman MJ, 2010, SCHIZOPHR RES, V117, P13, DOI 10.1016/j.schres.2009.09.030; Jones E.G., 2007, THALAMUS; Kalcher K, 2013, NEUROIMAGE, V70, P80, DOI 10.1016/j.neuroimage.2012.12.019; Kempf F, 2009, EUR J NEUROSCI, V29, P943, DOI 10.1111/j.1460-9568.2009.06655.x; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Muller K, 2004, J MAGN RESON IMAGING, V20, P145, DOI 10.1002/jmri.20064; Muthukumaraswamy SD, 2009, P NATL ACAD SCI USA, V106, P8356, DOI 10.1073/pnas.0900728106; Pollack Robert, 1999, MISSING MOMENT UNCON; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Saad ZS, 2001, HUM BRAIN MAPP, V13, P74, DOI 10.1002/hbm.1026; Salomon RM, 2012, DRUG ALCOHOL DEPEN, V120, P41, DOI 10.1016/j.drugalcdep.2011.06.022; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schreckenberger M, 2004, NEUROIMAGE, V22, P637, DOI 10.1016/j.neuroimage.2004.01.047; Shim WH, 2013, J NEUROPHYSIOL, V109, P238, DOI 10.1152/jn.00332.2012; Silver JM., 2011, TXB TRAUMATIC BRAIN, V2nd ed.; Sparing R, 2007, EUR J NEUROSCI, V25, P319, DOI 10.1111/j.1460-9568.2006.05252.x; Steriade M, 2005, TRENDS NEUROSCI, V28, P317, DOI 10.1016/j.tins.2005.03.007; Sun FT, 2004, NEUROIMAGE, V21, P647, DOI 10.1016/j.neuroimage.2003.09.056; Sun YM, 2011, BRAIN RES, V1413, P98, DOI 10.1016/j.brainres.2011.06.065; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Zang YF, 2007, BRAIN DEV-JPN, V29, P83, DOI 10.1016/j.braindev.2006.07.002; Zhang G, 2012, J ALTERN COMPLEM MED, V18, P387, DOI 10.1089/acm.2010.0205; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zou QH, 2008, J NEUROSCI METH, V172, P137, DOI 10.1016/j.jneumeth.2008.04.012; Zou QH, 2009, HUM BRAIN MAPP, V30, P3066, DOI 10.1002/hbm.20728; Zuo XN, 2010, NEUROIMAGE, V49, P1432, DOI 10.1016/j.neuroimage.2009.09.037	40	50	53	2	17	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	JUN	2014	39	6					1558	1568		10.1002/jmri.24310			11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	AG5LM	WOS:000335460500028	24014176	Green Accepted			2021-06-18	
J	Aarabi, B; Tofighi, B; Kufera, JA; Hadley, J; Ahn, ES; Cooper, C; Malik, JM; Naff, NJ; Chang, L; Radley, M; Kheder, A; Uscinski, RH				Aarabi, Bizhan; Tofighi, Babak; Kufera, Joseph A.; Hadley, Jeffrey; Ahn, Edward S.; Cooper, Carnell; Malik, Jacek M.; Naff, Neal J.; Chang, Louis; Radley, Michael; Kheder, Ashker; Uscinski, Ronald H.			Predictors of outcome in civilian gunshot wounds to the head	JOURNAL OF NEUROSURGERY			English	Article						trauma; gunshot wound; traumatic brain injury; penetrating brain injury; Glasgow Outcome Scale; decompressive craniectomy	TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; PROGNOSTIC-FACTORS; ENDOVASCULAR MANAGEMENT; INTRACRANIAL ANEURYSMS; MULTIVARIATE-ANALYSIS; MISSILE INJURIES; WARTIME; EXPERIENCE; MORTALITY	Object. Civilian gunshot wounds to the head (GSWH) are often deadly, but some patients with open cranial wounds need medical and surgical management and are potentially good candidates for acceptable functional recovery. The authors analyzed predictors of favorable clinical outcome (Glasgow Outcome Scale scores of 4 and 5) after GSWH over a 24-month period. Methods. The authors posited 2 questions: First, what percentage of civilians with GSWH died in the state of Maryland in a given period of time? Second, what were the predictors of favorable outcome after GSWH? The authors examined demographic, clinical, imaging, and acute care data for 786 civilians who sustained GSWH. Univariate and logistic regression analyses were used to analyze the data. Results. Of the 786 patients in this series, 712(91%) died and 74(9%) completed acute care in 9 trauma centers. Of the 69 patients admitted to one Maryland center, 46 (67%) eventually died. In 48 patients who were resuscitated, the Injury Severity Score was 26.2, Glasgow Coma Scale (GCS) score was 7.8, and an abnormal pupillary response (APR) to light was present in 41% of patients. Computed tomography indicated midline shift in 17%, obliteration of basal cisterns in 41.3%, intracranial hematomas in 34.8%, and intraventricular hemorrhage in 49% of cases. When analyzed for trajectory, 57.5% of bullet slugs crossed midcoronal, midsagittal, or both planes. Two subsets of admissions were studied: 27 patients (65%) who had poor outcome (25 patients who died and 2 who had severe disability) and 15 patients (35%) who had a favorable outcome when followed for a mean period of 40.6 months. Six patients were lost to follow-up. Univariate analysis indicated that admission GCS score (p < 0.001), missile trajectory (p <0.001), surgery (p < 0.001), APR to light (p = 0.002), patency of basal cisterns (p = 0.01), age (p = 0.01), and intraventricular bleed (p = 0.03) had a significant relationship to outcome. Multivariable logistic regression analysis indicated that GCS score and patency of the basal cistern were significant determinants of outcome. Exclusion of GCS score from the regression models indicated missile trajectory and APR to light were significant in determining outcome. Conclusions. Admission GCS score, trajectory of the missile track, APR to light, and patency of basal cisterns were significant determinants of outcome in civilian GSWH.	[Aarabi, Bizhan; Kufera, Joseph A.; Cooper, Carnell] Dept Neurosurg, Baltimore, MD USA; [Tofighi, Babak] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Tofighi, Babak; Hadley, Jeffrey] Johns Hopkins Univ, 0ff Chief Med Examiner State Maryland, Baltimore, MD USA; [Ahn, Edward S.; Naff, Neal J.] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD USA; [Malik, Jacek M.] Peninsula Neurosurg Associates, Salisbury, PA USA; [Chang, Louis] Cent Maryland Neurosurg Associates, Baltimore, MD USA; [Radley, Michael] Pkwy Neurosci & Spine Inst, Div Neurosurg, Hagerstown, MD USA; [Kheder, Ashker] Western Maryland Hlth, Cumberland, MD USA; [Uscinski, Ronald H.] Georgetown Univ, Dept Neurosurg, Washington, DC USA	Aarabi, B (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St,Ste S-12-D, Baltimore, MD 21201 USA.	baarabi@smail.umaryland.edu	Chang, Louis/AAZ-2488-2020	Tofighi, Babak/0000-0001-7393-7564			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Allison PD, 2008, SAS GLOB FOR SAN ANT; Ambrosi PB, 2012, NEUROSURG REV, V35, P429, DOI 10.1007/s10143-012-0377-2; Amirjamshidi A, 2003, SURG NEUROL, V60, P105, DOI 10.1016/S0090-3019(03)00358-6; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1025; Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1022; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; Carey ME, 2004, YOUMANS NEUROLOGICAL, V4, P5223; CAVALIERE R, 1988, ACTA NEUROCHIR, V94, P133, DOI 10.1007/BF01435866; Cohen JE, 2005, J NEUROSURG, V102, P555, DOI 10.3171/jns.2005.102.3.0555; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cosar A, 2005, MINIM INVAS NEUROSUR, V48, P113, DOI 10.1055/s-2004-830222; Frankowski RF, 1999, MISSILE WOUNDS HEAD, V1, P17; Glapa M, 2009, AM SURGEON, V75, P223; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P199, DOI 10.1007/BF01808959; Hofbauer M, 2010, J TRAUMA, V69, P770, DOI 10.1097/TA.0b013e3181c81d7d; Horowitz MB, 1999, SURG NEUROL, V51, P31, DOI 10.1016/S0090-3019(98)00029-9; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; Kaufman H H, 1991, Neurosurg Clin N Am, V2, P387; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1983, ACTA NEUROCHIR, V67, P115, DOI 10.1007/BF01401671; KAUFMAN HH, 1995, NEUROSURG CLIN N AM, V6, P701, DOI 10.1016/s1042-3680(18)30426-1; KAUFMAN HH, 1993, NEUROSURGERY, V32, P962, DOI 10.1227/00006123-199306000-00013; KAUFMAN HH, 1991, NEUROSURGERY, V29, P479; KRIEGER MD, 1995, NEUROSURG CLIN N AM, V6, P605; LEVI L, 1990, ISRAEL J MED SCI, V26, P548; Levi L, 1999, MISSILE WOUNDS HEAD, V1, P411; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; Lin David J, 2012, Surg Neurol Int, V3, P98, DOI 10.4103/2152-7806.100187; Mao ZQ, 2012, ACTA NEUROCHIR, V154, P2187, DOI 10.1007/s00701-012-1487-x; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; McNatt SA, 2005, NEUROSURGERY, V57, pE191, DOI [10.1227/01.NEU.0000175727.76530.94, 10.1227/01.NEU.0000164174.07281.F9]; Murano T, 2005, AM SURGEON, V71, P1009; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pai BS, 2008, NEUROL INDIA, V56, P488, DOI 10.4103/0028-3886.44821; Peek-Asa C, 2001, BRAIN INJURY, V15, P801, DOI 10.1080/02699050010025768; Petridis AK, 2011, CENT EUR NEUROSURG, V72, P5, DOI 10.1055/s-0029-1241850; POLIN RS, 1995, NEUROSURG CLIN N AM, V6, P689; Pruitt BA, 2001, J TRAUMA, V51, pS1, DOI 10.1097/00005373-200108001-00001; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Rosenfeld JV, 2010, INJURY, V41, P899, DOI 10.1016/j.injury.2010.06.010; SELDEN BS, 1988, ANN EMERG MED, V17, P247, DOI 10.1016/S0196-0644(88)80117-3; SHAFFREY ME, 1992, J NEUROTRAUM, V9, pS279; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; STONE JL, 1995, NEUROSURGERY, V37, P1104, DOI 10.1227/00006123-199512000-00010; SUDDABY L, 1987, CAN J NEUROL SCI, V14, P268, DOI 10.1017/S0317167100026597; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007; Zafonte RD, 2001, NEUROL RES, V23, P219, DOI 10.1179/016164101101198370; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	58	50	51	1	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2014	120	5					1138	1146		10.3171/2014.1.JNS131869			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AF7OD	WOS:000334903500017	24506239				2021-06-18	
J	Baym, CL; Khan, NA; Monti, JM; Raine, LB; Drollette, ES; Moore, RD; Scudder, MR; Kramer, AF; Hillman, CH; Cohen, NJ				Baym, Carol L.; Khan, Naiman A.; Monti, Jim M.; Raine, Lauren B.; Drollette, Eric S.; Moore, R. Davis; Scudder, Mark R.; Kramer, Arthur F.; Hillman, Charles H.; Cohen, Neal J.			Dietary lipids are differentially associated with hippocampal-dependent relational memory in prepubescent children	AMERICAN JOURNAL OF CLINICAL NUTRITION			English	Article							HIGH-FAT DIET; TRAUMATIC BRAIN-INJURY; SYNAPTIC PLASTICITY; PREADOLESCENT CHILDREN; NEUROTROPHIC FACTOR; OXIDATIVE STRESS; AEROBIC FITNESS; COGNITIVE PERFORMANCE; INDUCED OBESITY; MALE RATS	Background: Studies in rodents and older humans have shown that the hippocampus a brain structure critical to relational/associative memory has remarkable plasticity as a result of lifestyle factors (eg, exercise). However, the effect of dietary intake on hippocampal-dependent memory during childhood has remained unexamined. Objective: We investigated the cross-sectional relation of dietary components characteristic of the Western diet, including saturated fatty acids (SFAs), omega-3 (n-3) fatty acids, and refined sugar, with hippocampal-dependent relational memory in prepubescent children. Design: Participants aged 7-9 y (n = 52) reported their dietary intake by using the Youth-Adolescent Food-Frequency Questionnaire and completed memory tasks designed to assess relational (hippocampal-dependent) and item (hippocampal-independent) memory. Performance on the memory tasks was assessed with both direct (accuracy) and indirect (eye movement) measures. Results: Partial correlations adjusted for body mass index showed a positive relation between relational memory accuracy and intake of omega-3 fatty acids and a negative relation of both relational and item memory accuracy with intake of SFAs. Potential confounding factors of age, sex, intelligence quotient, socioeconomic status, pubertal timing, and aerobic fitness (maximal oxygen volume) were not significantly related to any of the dietary intake measures. Eye movement measures of relational memory (preferential viewing to the target stimulus) showed a negative relation with intake of added sugar. Conclusions: SFA intake was negatively associated with both forms of memory, whereas omega-3 fatty acid intake was selectively positively. associated with hippocampal-dependent relational memory. These findings are among the first to show a link between habitual dietary intake and cognitive health as pertaining to hippocampal function in childhood. The Fitness Improves Thinking Kids (FITKids) and FITKids2 trials were registered at www.clinicaltrials.gov as NCT01334359 and NCT01619826, respectively.	[Baym, Carol L.; Monti, Jim M.; Kramer, Arthur F.; Hillman, Charles H.; Cohen, Neal J.] Univ Illinois, Dept Psychol, Urbana, IL 61801 USA; [Baym, Carol L.; Monti, Jim M.; Kramer, Arthur F.; Hillman, Charles H.; Cohen, Neal J.] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; [Khan, Naiman A.; Raine, Lauren B.; Drollette, Eric S.; Moore, R. Davis; Scudder, Mark R.; Kramer, Arthur F.; Hillman, Charles H.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Kramer, Arthur F.; Hillman, Charles H.; Cohen, Neal J.] Univ Illinois, Ctr Nutr Learning & Memory, Urbana, IL 61801 USA; [Kramer, Arthur F.; Hillman, Charles H.; Cohen, Neal J.] Univ Illinois, Neurosci Program, Urbana, IL 61801 USA	Cohen, NJ (corresponding author), Univ Illinois, Beckman Inst Adv Sci & Technol, 405 North Mathews Ave, Urbana, IL 61801 USA.	cbaym@illinois.edu; njc@illinois.edu	Hillman, Charles/AAD-4828-2019; Meijer, Anna/K-5118-2016; Kramer, Arthur/AAB-2937-2019	Kramer, Arthur/0000-0001-5870-2724; Khan, Naiman/0000-0002-6135-9389; Hillman, Charles/0000-0002-3722-5612	Eunice Kennedy Shriver National Institute of Child Health and Human Development grant [HD055352]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055352] Funding Source: NIH RePORTER	Supported by Eunice Kennedy Shriver National Institute of Child Health and Human Development grant HD055352 (CHH).	Aberg MA, 2009, ACTA PAEDIATR, V98, P555, DOI 10.1111/j.1651-2227.2008.01103.x; Agrawal R, 2012, J PHYSIOL-LONDON, V590, P2485, DOI 10.1113/jphysiol.2012.230078; Alsaif MA, 2004, NUTR RES, V24, P417, DOI 10.1016/j.nutres.2003.11.011; Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005; Benton D, 2007, PHYSIOL BEHAV, V92, P717, DOI 10.1016/j.physbeh.2007.05.065; Bhatia HS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028451; Birnbaum AS, 2002, AM J HEALTH BEHAV, V26, P284, DOI 10.5993/AJHB.26.4.5; Block G, 2002, AM J EPIDEMIOL, V156, P274, DOI 10.1093/aje/kwf029; Boitard C, 2012, HIPPOCAMPUS, V22, P2095, DOI 10.1002/hipo.22032; Boucher O, 2011, AM J CLIN NUTR, V93, P1025, DOI 10.3945/ajcn.110.000323; Chaddock L, 2010, BRAIN RES, V1358, P172, DOI 10.1016/j.brainres.2010.08.049; Cohen N.J., 2001, CONDITIONING CONSCIO; Dalton A, 2009, PROSTAG LEUKOTR ESS, V80, P143, DOI 10.1016/j.plefa.2008.12.006; Davachi L, 2002, J NEUROPHYSIOL, V88, P982, DOI 10.1152/jn.2002.88.2.982; Davachi L, 2006, CURR OPIN NEUROBIOL, V16, P693, DOI 10.1016/j.conb.2006.10.012; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Eskelinen MH, 2008, INT J GERIATR PSYCH, V23, P741, DOI 10.1002/gps.1969; Ghys A, 2002, EARLY HUM DEV, V69, P83, DOI 10.1016/S0378-3782(02)00067-1; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; GREENHOUSE SW, 1959, PSYCHOMETRIKA, V24, P95, DOI 10.1007/BF02289823; Innis SM, 2007, J NUTR, V137, P855; Jurdak N, 2008, NUTR NEUROSCI, V11, P48, DOI 10.1179/147683008X301333; Jurdak N, 2009, PHYSIOL BEHAV, V96, P1, DOI 10.1016/j.physbeh.2008.07.023; Kamijo K, 2011, DEVELOPMENTAL SCI, V14, P1046, DOI 10.1111/j.1467-7687.2011.01054.x; Kanoski SE, 2007, BEHAV BRAIN RES, V182, P57, DOI 10.1016/j.bbr.2007.05.004; Kanoski SE, 2011, PHYSIOL BEHAV, V103, P59, DOI 10.1016/j.physbeh.2010.12.003; Kanoski SE, 2010, J EXP PSYCHOL-ANIM B, V36, P313, DOI 10.1037/a0017228; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kaufman A, 1990, TEST KBI; Kirby A, 2010, BRIT EDUC RES J, V36, P699, DOI 10.1080/01411920903111557; Kosari S, 2012, BEHAV BRAIN RES, V235, P98, DOI 10.1016/j.bbr.2012.07.017; Kuczmarski R. J., 2000, VITAL HLTH STAT, V11, P1, DOI DOI 10.1016/J.BBRC.2015.06.114; Lindqvist A, 2006, EUR J NEUROL, V13, P1385, DOI 10.1111/j.1468-1331.2006.01500.x; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; McGrew K., 2001, WOODCOCKJOHNSON 3; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Monti JM, 2012, HIPPOCAMPUS, V22, P1876, DOI 10.1002/hipo.22023; Muthayya S, 2009, AM J CLIN NUTR, V89, P1766, DOI 10.3945/ajcn.2008.26993; NEMO Study Grp, 2007, AM J CLIN NUTR, V86, P1082; Okereke OI, 2012, ANN NEUROL, V72, P124, DOI 10.1002/ana.23593; Park HR, 2010, NEUROSCI LETT, V482, P235, DOI 10.1016/j.neulet.2010.07.046; Pistell PJ, 2010, J NEUROIMMUNOL, V219, P25, DOI 10.1016/j.jneuroim.2009.11.010; Radecki DT, 2005, HIPPOCAMPUS, V15, P246, DOI 10.1002/hipo.20048; Rockett HRH, 1997, PREV MED, V26, P808, DOI 10.1006/pmed.1997.0200; Stockhorst U, 2004, PHYSIOL BEHAV, V83, P47, DOI 10.1016/j.physbeh.2004.07.022; Taylor SJC, 2001, PAEDIATR PERINAT EP, V15, P88; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Voss MW, 2011, NEUROSCIENCE, V199, P166, DOI 10.1016/j.neuroscience.2011.10.009; Voss MW, 2013, TRENDS COGN SCI, V17, P525, DOI 10.1016/j.tics.2013.08.001; Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Yaffe K, 2003, NEUROLOGY, V61, P76, DOI 10.1212/01.WNL.0000073620.42047.D7; Zhang J, 2005, J NUTR, V135, P1967	57	50	50	0	38	AMER SOC NUTRITION-ASN	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0002-9165	1938-3207		AM J CLIN NUTR	Am. J. Clin. Nutr.	MAY	2014	99	5					1026	1033		10.3945/ajcn.113.079624			8	Nutrition & Dietetics	Nutrition & Dietetics	AF7LD	WOS:000334895700010	24522447	Green Published, Bronze			2021-06-18	
J	Yan, EB; Satgunaseelan, L; Paul, E; Bye, N; Nguyen, P; Agyapomaa, D; Kossmann, T; Rosenfeld, JV; Morganti-Kossmann, MC				Yan, Edwin B.; Satgunaseelan, Laveniya; Paul, Eldho; Bye, Nicole; Phuong Nguyen; Agyapomaa, Doreen; Kossmann, Thomas; Rosenfeld, Jeffrey V.; Morganti-Kossmann, Maria Cristina			Post-Traumatic Hypoxia Is Associated with Prolonged Cerebral Cytokine Production, Higher Serum Biomarker Levels, and Poor Outcome in Patients with Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						TBI; CSF/serum-albumin quotient; inflammation; biomarker; hypoxia	SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; BARRIER FUNCTION; CELL-DEATH; TNF-ALPHA; PROTEIN; CHILDREN; S100B; NEUROINFLAMMATION; MARKERS	Secondary hypoxia is a known contributor to adverse outcomes in patients with traumatic brain injury (TBI). Based on the evidence that hypoxia and TBI in isolation induce neuroinflammation, we investigated whether TBI combined with hypoxia enhances cerebral cytokine production. We also explored whether increased concentrations of injury biomarkers discriminate between hypoxic (Hx) and normoxic (Nx) patients, correlate to worse outcome, and depend on blood-brain barrier (BBB) dysfunction. Forty-two TBI patients with Glasgow Coma Scale <= 8 were recruited. Cerebrospinal fluid (CSF) and serum were collected over 6 days. Patients were divided into Hx (n=22) and Nx (n=20) groups. Eight cytokines were measured in the CSF; albumin, S100, myelin basic protein (MBP) and neuronal specific enolase (NSE) were quantified in serum. CSF/serum albumin quotient was calculated for BBB function. Glasgow Outcome Scale Extended (GOSE) was assessed at 6 months post-TBI. Production of granulocye macrophage-colony stimulating factor (GM-CSF) was higher, and profiles of GM-CSF, interferon (IFN)-gamma and, to a lesser extent, tumor necrosis factor (TNF), were prolonged in the CSF of Hx but not Nx patients at 4-5 days post-TBI. Interleukin (IL)-2, IL-4, IL-6, and IL-10 increased similarly in both Hx and Nx groups. S100, MBP, and NSE were significantly higher in Hx patients with unfavorable outcome. Among these three biomarkers, S100 showed the strongest correlations to GOSE after TBI-Hx. Elevated CSF/serum albumin quotients lasted for 5 days post-TBI and displayed similar profiles in Hx and Nx patients. We demonstrate for the first time that post-TBI hypoxia is associated with prolonged neuroinflammation, amplified extravasation of biomarkers, and poor outcome. S100 and MBP could be implemented to track the occurrence of post-TBI hypoxia, and prompt adequate treatment.	[Yan, Edwin B.; Satgunaseelan, Laveniya; Bye, Nicole; Phuong Nguyen; Morganti-Kossmann, Maria Cristina] Monash Univ, Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3181, Australia; [Satgunaseelan, Laveniya; Rosenfeld, Jeffrey V.] Monash Univ, Alfred Hosp, Dept Neurosurg, Melbourne, Vic 3181, Australia; [Yan, Edwin B.; Bye, Nicole; Rosenfeld, Jeffrey V.; Morganti-Kossmann, Maria Cristina] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Paul, Eldho; Morganti-Kossmann, Maria Cristina] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Paul, Eldho; Morganti-Kossmann, Maria Cristina] Australian New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Kossmann, Thomas] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Morganti-Kossmann, Maria Cristina] Univ Arizona, Dept Child Hlth, Barrow Neurol Inst, Phoenix, AZ USA	Morganti-Kossmann, MC (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, 99 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@monash.edu	Rosenfeld, Jeffrey V/B-7249-2011	Morganti-Kossmann, Cristina/0000-0002-0807-2063; Satgunaseelan, Laveniya/0000-0002-7435-0834; Paul, Eldho/0000-0003-1263-7255	Victorian Neurotrauma Initiative/Traffic Accident Commission [D009]; National Health Medical Research CouncilNational Health and Medical Research Council of Australia [436815]; Henry O'Hara Surgical Research Trust; L.E.W. Carty Charitable Fund.	We thank Ann Sutherland from Victorian State Trauma Outcomes Registry and Department of Epidemiology, Monash University, and Shirley Vallance and Lynne Murray from the Intensive Care Unit, Alfred Health, for providing the GOSE scores, and David O'Reilly for partial albumin measurements. We thank Sarah Hellewell for her intellectual input on this project, and for manuscript preparation. This study was funded by Victorian Neurotrauma Initiative/Traffic Accident Commission project grant D009 and Research Fellowships to Drs. Morganti-Kossmann, Yan, and Bye; the National Health Medical Research Council Project Grant #436815; The Henry O'Hara Surgical Research Trust to Dr. Satgunaseelan, and the L.E.W. Carty Charitable Fund.	Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2011, PM&R, V3, pS31, DOI 10.1016/j.pmrj.2011.03.016; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Deng Yi Yu, 2011, Front Biosci (Schol Ed), V3, P884; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jellema RK, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-13; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kong T, 2009, J NEUROSURG, V111, P155, DOI 10.3171/2008.12.JNS08172; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Marshall SB, 1991, J NEUROSURG S, V75, P14; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morganti-Kossmann C. M., 1997, MOL PSYCHIATR, V2, P133; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; Roman J, 2010, AM J RESP CELL MOL, V42, P123, DOI 10.1165/rcmb.2008-0139OC; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149; Sugiyama Y, 2011, STROKE, V42, P770, DOI 10.1161/STROKEAHA.110.597799; Uldrick TS, 2010, CLIN INFECT DIS, V51, P350, DOI 10.1086/654798; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	60	50	51	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2014	31	7					618	629		10.1089/neu.2013.3087			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AD7PB	WOS:000333455000003	24279428	Green Published			2021-06-18	
J	Niesman, IR; Schilling, JM; Shapiro, LA; Kellerhals, SE; Bonds, JA; Kleschevnikov, AM; Cui, WH; Voong, A; Krajewski, S; Ali, SS; Roth, DM; Patel, HH; Patel, PM; Head, BP				Niesman, Ingrid R.; Schilling, Jan M.; Shapiro, Lee A.; Kellerhals, Sarah E.; Bonds, Jacqueline A.; Kleschevnikov, Alexander M.; Cui, Weihua; Voong, April; Krajewski, Stan; Ali, Sameh S.; Roth, David M.; Patel, Hemal H.; Patel, Piyush M.; Head, Brian P.			Traumatic brain injury enhances neuroinflammation and lesion volume in caveolin deficient mice	JOURNAL OF NEUROINFLAMMATION			English	Article							STATUS EPILEPTICUS; A(2A) RECEPTOR; POSTTRAUMATIC SEIZURES; ADENOSINE RECEPTORS; SPATIAL MEMORY; MESSENGER-RNA; EXPRESSION; EPILEPTOGENESIS; ACTIVATION; MECHANISMS	Background: Traumatic brain injury (TBI) enhances pro-inflammatory responses, neuronal loss and long-term behavioral deficits. Caveolins (Cavs) are regulators of neuronal and glial survival signaling. Previously we showed that astrocyte and microglial activation is increased in Cav-1 knock-out (KO) mice and that Cav-1 and Cav-3 modulate microglial morphology. We hypothesized that Cavs may regulate cytokine production after TBI. Methods: Controlled cortical impact (CCI) model of TBI (3 m/second; 1.0 mm depth; parietal cortex) was performed on wild-type (WT; C57Bl/6), Cav-1 KO, and Cav-3 KO mice. Histology and immunofluorescence microscopy (lesion volume, glia activation), behavioral tests (open field, balance beam, wire grip, T-maze), electrophysiology, electron paramagnetic resonance, membrane fractionation, and multiplex assays were performed. Data were analyzed by unpaired t tests or analysis of variance (ANOVA) with post-hoc Bonferroni's multiple comparison. Results: CCI increased cortical and hippocampal injury and decreased expression of MLR-localized synaptic proteins (24 hours), enhanced NADPH oxidase (Nox) activity (24 hours and 1 week), enhanced polysynaptic responses (1 week), and caused hippocampal-dependent learning deficits (3 months). CCI increased brain lesion volume in both Cav-3 and Cav-1 KO mice after 24 hours (P < 0.0001, n = 4; one-way ANOVA). Multiplex array revealed a significant increase in expression of IL-1 beta, IL-9, IL-10, KC (keratinocyte chemoattractant), and monocyte chemoattractant protein 1 (MCP-1) in ipsilateral hemisphere and IL-9, IL-10, IL-17, and macrophage inflammatory protein 1 alpha (MIP-1 alpha) in contralateral hemisphere of WT mice after 4 hours. CCI increased IL-2, IL-6, KC and MCP-1 in ipsilateral and IL-6, IL-9, IL-17 and KC in contralateral hemispheres in Cav-1 KO and increased all 10 cytokines/chemokines in both hemispheres except for IL-17 (ipsilateral) and MIP-1 alpha (contralateral) in Cav-3 KO (versus WT CCI). Cav-3 KO CCI showed increased IL-1 beta, IL-9, KC, MCP-1, MIP-1 alpha, and granulocyte-macrophage colony-stimulating factor in ipsilateral and IL-1 beta, IL-2, IL-9, IL-10, and IL-17 in contralateral hemispheres (P = 0.0005, n = 6; two-way ANOVA) compared to Cav-1 KO CCI. Conclusion: CCI caused astrocyte and microglial activation and hippocampal neuronal injury. Cav-1 and Cav-3 KO exhibited enhanced lesion volume and cytokine/chemokine production after CCI. These findings suggest that Cav isoforms may regulate neuroinflammatory responses and neuroprotection following TBI.	[Niesman, Ingrid R.; Schilling, Jan M.; Kellerhals, Sarah E.; Bonds, Jacqueline A.; Cui, Weihua; Voong, April; Ali, Sameh S.; Roth, David M.; Patel, Hemal H.; Patel, Piyush M.; Head, Brian P.] Vet Affairs San Diego Healthcare Syst, La Jolla, CA 92161 USA; [Niesman, Ingrid R.; Schilling, Jan M.; Kellerhals, Sarah E.; Bonds, Jacqueline A.; Cui, Weihua; Voong, April; Ali, Sameh S.; Roth, David M.; Patel, Hemal H.; Patel, Piyush M.; Head, Brian P.] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; [Shapiro, Lee A.] Cent Texas Vet Hlth Syst, Scott & White Hosp, Neurosci Res Inst, Temple, TX USA; [Shapiro, Lee A.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, Dept Surg,Dept Neurosurg, Temple, TX USA; [Kleschevnikov, Alexander M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Krajewski, Stan] Sanford Burnham Med Res Inst, La Jolla, CA USA; [Cui, Weihua] Capital Med Univ, Beijing Tiantan Hosp, Dept Anesthesiol, Beijing, Peoples R China; [Ali, Sameh S.] Zewail City Sci & Technol, Ctr Aging & Associated Dis, Helmy Inst Med Sci, Giza, Egypt	Head, BP (corresponding author), Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	bhead@ucsd.edu	Patel, Hemal/C-7325-2019; Kleschevnikov, Alexander/R-6926-2016	Patel, Hemal/0000-0001-6722-9625; Ali, Sameh Saad/0000-0002-0339-6106; Kleschevnikov, Alexander/0000-0002-1562-6706	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL107200, R01HL091071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073653] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX001963, I01BX000783] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL107200, HL091071, HL107200] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS073653, NS073653] Funding Source: Medline; BLRD VA [I01 BX001963, I01 BX000783] Funding Source: Medline; VAUS Department of Veterans Affairs [5I01BX001963-04] Funding Source: Federal RePORTER		Adewuya AO, 2005, EPILEPSY BEHAV, V7, P497, DOI 10.1016/j.yebeh.2005.07.011; Adibhatla Rao Muralikrishna, 2008, V49, P241, DOI 10.1007/978-1-4020-8831-5_9; Ali SS, 2011, BRAIN RES, V1368, P65, DOI 10.1016/j.brainres.2010.11.009; Andjelkovic AV, 2002, J NEUROSCI RES, V70, P219, DOI 10.1002/jnr.10372; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Babb TL, 2000, EPILEPSIA, V41, pS76, DOI 10.1111/j.1528-1157.2000.tb01561.x; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Biagini G, 2012, JASPERS BASIC MECH E; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Boison D, 2010, CELL DEATH DIFFER, V17, P1071, DOI 10.1038/cdd.2009.131; Brambilla R, 2003, GLIA, V43, P190, DOI 10.1002/glia.10243; Carter R J, 2001, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0812s15; Cheret C, 2008, J NEUROSCI, V28, P12039, DOI 10.1523/JNEUROSCI.3568-08.2008; Chidlow JH, 2010, CARDIOVASC RES, V86, P219, DOI 10.1093/cvr/cvq075; Conte V, 2008, RESTOR NEUROL NEUROS, V26, P45; Deacon RMJ, 2006, NAT PROTOC, V1, P7, DOI 10.1038/nprot.2006.2; Di Virgilio F, 2009, TRENDS NEUROSCI, V32, P79, DOI 10.1016/j.tins.2008.11.003; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Dixon AK, 1997, J NEUROCHEM, V69, P315; Duchowny M, 2000, NEUROLOGY, V55, P423, DOI 10.1212/WNL.55.3.423; Fedele DE, 2006, EXP NEUROL, V200, P184, DOI 10.1016/j.expneurol.2006.02.133; Fields RD, 2006, NAT REV NEUROSCI, V7, P423, DOI 10.1038/nrn1928; Foresti ML, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-40; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Ge SJ, 2004, J BIOL CHEM, V279, P6688, DOI 10.1074/jbc.M311769200; Gioiosa L, 2008, BEHAV BRAIN RES, V188, P255, DOI 10.1016/j.bbr.2007.11.002; Gomes C, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-16; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Gu Y, 2012, J NEUROCHEM, V120, P147, DOI 10.1111/j.1471-4159.2011.07542.x; Guzik-Kornacka A, 2011, ACTA NEUROBIOL EXP, V71, P193; Hagiwara Y, 2000, HUM MOL GENET, V9, P3047, DOI 10.1093/hmg/9.20.3047; Hasko G, 2005, TRENDS PHARMACOL SCI, V26, P511, DOI 10.1016/j.tips.2005.08.004; Head BP, 2008, FASEB J, V22, P828, DOI 10.1096/fj.07-9299com; Head BP, 2011, J BIOL CHEM, V286, P33310, DOI 10.1074/jbc.M111.255976; Head BP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015697; Heverin M, 2012, BRAIN RES, V1480, P81, DOI 10.1016/j.brainres.2012.08.018; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Jasmin JF, 2011, AM J PHYSIOL-HEART C, V300, pH1274, DOI 10.1152/ajpheart.01173.2010; Kim JH, 2013, BRAIN RES, V1499, P163, DOI 10.1016/j.brainres.2013.01.007; Kleschevnikov AM, 2012, J NEUROSCI, V32, P9217, DOI 10.1523/JNEUROSCI.1673-12.2012; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Krajewska M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024341; Krajewska M, 2009, J HISTOCHEM CYTOCHEM, V57, P649, DOI 10.1369/jhc.2009.952812; Mirza MK, 2010, AM J PATHOL, V176, P2344, DOI 10.2353/ajpath.2010.091088; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neary JT, 2005, J NEUROTRAUM, V22, P491, DOI 10.1089/neu.2005.22.491; Niesman IR, 2013, MOL CELL NEUROSCI, V56, P283, DOI 10.1016/j.mcn.2013.07.002; Orr AG, 2009, NAT NEUROSCI, V12, P872, DOI 10.1038/nn.2341; Patel H. H., 2008, V186, P167, DOI 10.1007/978-3-540-72843-6_7; Paylor R, 1998, LEARN MEMORY, V5, P302; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Ribeiro JA, 2002, PROG NEUROBIOL, V68, P377, DOI 10.1016/S0301-0082(02)00155-7; Schierhout G, 2001, COCHRANE DB SYST REV, V4; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Sharma S, 2010, LIFE SCI, V87, P521, DOI 10.1016/j.lfs.2010.09.004; Shen HY, 2009, CURR NEUROPHARMACOL, V7, P195, DOI 10.2174/157015909789152191; Shin T, 2005, J NEUROIMMUNOL, V165, P11, DOI 10.1016/j.jneuroim.2005.03.019; Silva WI, 2007, J NEUROCHEM, V103, P101, DOI 10.1111/j.1471-4159.2007.04712.x; Spuch C, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00269; Stern CM, 2010, CELL MOL LIFE SCI, V67, P3785, DOI 10.1007/s00018-010-0447-y; Truong TQ, 2006, BBA-MOL CELL BIOL L, V1761, P24, DOI 10.1016/j.bbalip.2005.12.004; Watts LT, 2013, J NEUROTRAUM, V30, P55, DOI 10.1089/neu.2012.2488; Wu LH, 2005, J CELL BIOCHEM, V96, P1021, DOI 10.1002/jcb.20596	68	50	53	0	19	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAR 3	2014	11								39	10.1186/1742-2094-11-39			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	AD4SN	WOS:000333240900001	24593993	DOAJ Gold, Green Published			2021-06-18	
J	Crack, PJ; Zhang, M; Morganti-Kossmann, MC; Morris, AJ; Wojciak, JM; Fleming, JK; Karve, I; Wright, D; Sashindranath, M; Goldshmit, Y; Conquest, A; Daglas, M; Johnston, LA; Medcalf, RL; Sabbadini, RA; Pebay, A				Crack, Peter J.; Zhang, Moses; Morganti-Kossmann, Maria Cristina; Morris, Andrew J.; Wojciak, Jonathan M.; Fleming, Jonathan K.; Karve, Ila; Wright, David; Sashindranath, Maithili; Goldshmit, Yona; Conquest, Alison; Daglas, Maria; Johnston, Leigh A.; Medcalf, Robert L.; Sabbadini, Roger A.; Pebay, Alice			Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes	JOURNAL OF NEUROINFLAMMATION			English	Article						Lysophosphatidic acid; Traumatic brain injury; Human cerebrospinal fluid; Control cortical impact; Magnetic resonance imaging; Anti-LPA antibody; IL-6	CEREBROSPINAL-FLUID; NERVOUS-SYSTEM; AUTOTAXIN; MICE; IDENTIFICATION; RECEPTOR; HYPOXIA	Background: Lysophosphatidic acid (LPA) is a bioactive phospholipid with a potentially causative role in neurotrauma. Blocking LPA signaling with the LPA-directed monoclonal antibody B3/Lpathomab is neuroprotective in the mouse spinal cord following injury. Findings: Here we investigated the use of this agent in treatment of secondary brain damage consequent to traumatic brain injury (TBI). LPA was elevated in cerebrospinal fluid (CSF) of patients with TBI compared to controls. LPA levels were also elevated in a mouse controlled cortical impact (CCI) model of TBI and B3 significantly reduced lesion volume by both histological and MRI assessments. Diminished tissue damage coincided with lower brain IL-6 levels and improvement in functional outcomes. Conclusions: This study presents a novel therapeutic approach for the treatment of TBI by blocking extracellular LPA signaling to minimize secondary brain damage and neurological dysfunction.	[Crack, Peter J.; Zhang, Moses; Karve, Ila] Univ Melbourne, Dept Pharmacol, Parkville, Vic 3052, Australia; [Morganti-Kossmann, Maria Cristina] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Morganti-Kossmann, Maria Cristina] Univ Arizona, Phoenix Childrens Hosp, Dept Child Hlth, Barrow Neurol Inst, Phoenix, AZ USA; [Morris, Andrew J.] Univ Kentucky, Coll Med, Div Cardiovasc Med, Lexington, KY USA; [Wojciak, Jonathan M.; Fleming, Jonathan K.; Sabbadini, Roger A.] San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; [Wojciak, Jonathan M.; Fleming, Jonathan K.; Sabbadini, Roger A.] Lpath Inc, San Diego, CA USA; [Wright, David; Johnston, Leigh A.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia; [Wright, David] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia; [Sashindranath, Maithili; Daglas, Maria; Medcalf, Robert L.] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia; [Goldshmit, Yona; Conquest, Alison; Pebay, Alice] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia; [Goldshmit, Yona; Conquest, Alison; Pebay, Alice] Univ Melbourne, Dept Ophthalmol, East Melbourne, Australia; [Goldshmit, Yona] Monash Univ, Australian Regenerat Med Inst, Clayton, Vic, Australia; [Conquest, Alison] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic, Australia; [Conquest, Alison] Monash Univ, Melbourne, Vic 3004, Australia; [Johnston, Leigh A.] Univ Melbourne, Dept Elect & Elect Engn, Neuroengn Lab, Parkville, Vic 3052, Australia	Crack, PJ (corresponding author), Univ Melbourne, Dept Pharmacol, Parkville, Vic 3052, Australia.	pcrack@unimelb.edu.au; apebay@unimelb.edu.au	Crack, Peter/ABE-2065-2020; Sashindranath, Maithili/AAI-7408-2021; Johnston, Leigh A/D-7102-2014; Medcalf, Robert L/E-9632-2011	Crack, Peter/0000-0002-5030-0330; Sashindranath, Maithili/0000-0002-9712-4784; Johnston, Leigh A/0000-0002-5032-4674; Pebay, Alice/0000-0002-7408-9453; Wright, David/0000-0002-7535-8651; Morganti-Kossmann, Cristina/0000-0002-0807-2063	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [628391]; NHMRCNational Health and Medical Research Council of Australia; Transport Accident Commission project grant; ANZ Trustees Program - Medical Research & Technology in Victoria - William Buckland Foundation; United States National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R43CA132395-01A2]; Australian Research Council Future FellowshipAustralian Research Council; University of Melbourne Collaboration Grant; Victorian State Government's Department of Innovation, Industry and Regional Development's Operational Infrastructure Support Program; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R43CA132395] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR024598, S10RR026884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103527] Funding Source: NIH RePORTER	The authors thank Mr Duncan Crombie (Centre for Eye Research Australia and University of Melbourne) for his technical assistance. This work was supported by a National Health and Medical Research Council of Australia Project Grant 628391 (PJC), a NHMRC Career Development Award Fellowship (AP), a Transport Accident Commission project grant (AP), the ANZ Trustees Program - Medical Research & Technology in Victoria - William Buckland Foundation (AP), the United States National Institutes of Health (1R43CA132395-01A2 to RM), an Australian Research Council Future Fellowship (PJC), a University of Melbourne Collaboration Grant and the Victorian State Government's Department of Innovation, Industry and Regional Development's Operational Infrastructure Support Program.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Boutin JA, 2009, CELL MOL LIFE SCI, V66, P3009, DOI 10.1007/s00018-009-0056-9; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Darling RJ, 2004, ASSAY DRUG DEV TECHN, V2, P647, DOI 10.1089/adt.2004.2.647; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Federico L, 2012, MOL ENDOCRINOL, V26, P786, DOI 10.1210/me.2011-1229; Frisca F, 2012, INT REV CEL MOL BIO, V296, P273, DOI 10.1016/B978-0-12-394307-1.00005-9; Frugier T, 2011, CELL MOL NEUROBIOL, V31, P569, DOI 10.1007/s10571-011-9650-0; Fujiwara Y, 2005, J BIOL CHEM, V280, P35038, DOI 10.1074/jbc.M504351200; Goldshmit Y, 2012, AM J PATHOL, V181, P978, DOI 10.1016/j.ajpath.2012.06.007; Goldshmit Y, 2010, CELL TISSUE RES, V341, P23, DOI 10.1007/s00441-010-0977-5; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Koike S, 2006, GENES CELLS, V11, P133, DOI 10.1111/j.1365-2443.2006.00924.x; Mandal R, 2012, GENOME MED, V4, DOI 10.1186/gm337; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Nakamura K, 2007, ANAL BIOCHEM, V367, P20, DOI 10.1016/j.ab.2007.05.004; On NH, 2013, J CEREBR BLOOD F MET, V33, P1944, DOI 10.1038/jcbfm.2013.154; Rasouli J, 2012, NEUROSCI LETT, V519, P4, DOI 10.1016/j.neulet.2012.03.089; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419-05; Yanagida K, 2009, J BIOL CHEM, V284, P17731, DOI 10.1074/jbc.M808506200; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037	26	50	50	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	FEB 27	2014	11								37	10.1186/1742-2094-11-37			11	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	AF8CX	WOS:000334944100001	24576351	DOAJ Gold, Green Published			2021-06-18	
J	Apetz, N; Munch, G; Govindaraghavan, S; Gyengesi, E				Apetz, Nadine; Muench, Gerald; Govindaraghavan, Suresh; Gyengesi, Erika			Natural Compounds and Plant Extracts as Therapeutics Against Chronic Inflammation in Alzheimer's Disease - A Translational Perspective	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Alzheimer's disease; inflammation; non-steroidal anti-inflammatory drugs; plant secondary metabolites; reactive oxygen species; treatment	GINKGO-BILOBA EXTRACT; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; AMYLOID PRECURSOR PROTEIN; TRANSGENIC MOUSE MODEL; POLYUNSATURATED FATTY-ACIDS; ACTIVATED RECEPTOR-GAMMA; NF-KAPPA-B; OMEGA-3-FATTY-ACID DOCOSAHEXAENOIC ACID; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE	Alzheimer's disease (AD) is a progressive neurodegenerative disorder, characterized by deposition of amyloid beta, neurofibrillary tangles, astrogliosis and microgliosis, leading to neuronal dysfunction and loss in the brain. Bio- and histochemical evidence suggests a pivotal role of central and peripheral inflammation in its aetiopathology, linked to the production of free radicals. Numerous epidemiological studies support that the long-term use of non-steroidal anti-inflammatory drugs is preventive against AD, but these medications do not slow down the progression of the disease in already diagnosed patients. There are a number of studies focusing on traditional herbal medicines and small molecules (usually plant secondary metabolites) as potential anti-inflammatory drugs, particulary in respect to cytokine suppression. For instance, omega-3 polyunsaturated fatty acids and a number of polyphenolic phytochemicals have been shown to be effective against inflammation in animal and cell models. Some of these plant secondary metabolites have also been shown to possess antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and cognition-enhancing effects. This review will provide an overview the effects of catechins/proanthocyanidins from green tea, curcumin from turmeric, extracts enriched in bacosides from Brahmi (Bacopa monnieri), flavone glycosides from Ginkgo biloba, and omega-3 polyunsaturated fatty acids. They do not only counteract one pathophysiological aspect of AD in numerous in vitro and in vivo studies of models of AD, but also ameliorate several of the above mentioned pathologies. The evidence suggests that increased consumption of these compounds might lead to a safe strategy to delay the onset of AD. The continuing investigation of the potential of these substances is necessary as they are promising to yield a possible remedy for this pervasive disease.	[Apetz, Nadine; Muench, Gerald; Gyengesi, Erika] Univ Western Sydney, Sch Med, Dept Pharmacol, Campbelltown, NSW, Australia; [Muench, Gerald] Univ Western Sydney, Ctr Complementary Med Res, Penrith, NSW 2751, Australia; [Muench, Gerald; Gyengesi, Erika] Univ Western Sydney, Mol Med Res Grp, Penrith, NSW 2751, Australia; [Govindaraghavan, Suresh] IMCD Australia Ltd, Network Nutr Capitol Ingredients, Bella Vista, NSW, Australia	Munch, G (corresponding author), Univ Western Sydney, Sch Med, Locked Bag 1797, Penrith, NSW 2751, Australia.	g.muench@uws.edu.au	Gyengesi, Erika/S-1251-2019	Gyengesi, Erika/0000-0001-7371-7385	Commonwealth Government; University of Western Sydney	The authors would like to thank the Commonwealth Government and the University of Western Sydney for granting an Australian Postgraduate Award and scholarship to Nadine Apetz. The authors thank Mrs. Margaret Clarke for the final editing of the manuscript.	Ahmed S, 2002, FREE RADICAL BIO MED, V33, P1097, DOI 10.1016/S0891-5849(02)01004-3; Aisen PS, 2008, CURR ALZHEIMER RES, V5, P73, DOI 10.2174/156720508783884602; Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Aisen PS, 2002, LANCET NEUROL, V1, P279, DOI 10.1016/S1474-4422(02)00133-3; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; ANDERSEN K, 1995, NEUROLOGY, V45, P1441, DOI 10.1212/WNL.45.8.1441; Apelt J, 2001, BRAIN RES, V894, P21, DOI 10.1016/S0006-8993(00)03176-0; Augustin S, 2009, ARCH BIOCHEM BIOPHYS, V481, P177, DOI 10.1016/j.abb.2008.10.032; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Bastianetto S, 2000, EUR J NEUROSCI, V12, P1882, DOI 10.1046/j.1460-9568.2000.00069.x; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; Baum L, 2008, J CLIN PSYCHOPHARM, V28, P110, DOI 10.1097/jcp.0b013e318160862c; Beard CM, 1998, MAYO CLIN PROC, V73, P951, DOI 10.4065/73.10.951; Begum AN, 2008, J PHARMACOL EXP THER, V326, P196, DOI 10.1124/jpet.108.137455; Bellucci A, 2004, AM J PATHOL, V165, P1643, DOI 10.1016/S0002-9440(10)63421-9; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; Cabrera C, 2006, J AM COLL NUTR, V25, P79, DOI 10.1080/07315724.2006.10719518; CACABELOS R, 1994, METHOD FIND EXP CLIN, V16, P141; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Calabrese C, 2008, J ALTERN COMPLEM MED, V14, P707, DOI 10.1089/acm.2008.0018; Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S; Camacho IE, 2004, J NEUROSCI, V24, P10908, DOI 10.1523/JNEUROSCI.3987-04.2004; Channa S, 2006, J ETHNOPHARMACOL, V104, P286, DOI 10.1016/j.jep.2005.10.009; Chinetti G, 2001, NAT MED, V7, P53; Cho JW, 2007, INT J MOL MED, V19, P469; Choi YT, 2001, LIFE SCI, V70, P603, DOI 10.1016/S0024-3205(01)01438-2; Clostre F, 1999, ANN PHARM FR, V57, P8; Cole GM, 2007, ADV EXP MED BIOL, V595, P197; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Crews L, 2010, HUM MOL GENET, V19, pR12, DOI 10.1093/hmg/ddq160; Das UN, 2007, MED SCI MONITOR, V13, pRA214; Deepak M, 2005, PHYTOCHEM ANALYSIS, V16, P24, DOI 10.1002/pca.805; Di Virgilio F, 2004, CURR PHARM DESIGN, V10, P1647; Dreiseitel A, 2009, BRIT J PHARMACOL, V158, P1942, DOI 10.1111/j.1476-5381.2009.00495.x; Dyall SC, 2010, J NEUROSCI RES, V88, P2091, DOI 10.1002/jnr.22390; Dzenko KA, 1997, J NEUROIMMUNOL, V80, P6, DOI 10.1016/S0165-5728(97)00128-8; Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Fang L, 2013, MINI-REV MED CHEM, V13, P870, DOI 10.2174/1389557511313060009; Fialkow L, 2007, FREE RADICAL BIO MED, V42, P153, DOI 10.1016/j.freeradbiomed.2006.09.030; Finder VH, 2007, NEURODEGENER DIS, V4, P13, DOI 10.1159/000100355; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fotuhi M, 2009, NAT CLIN PRACT NEURO, V5, P140, DOI 10.1038/ncpneuro1044; Freund-Levi Y, 2008, INT J GERIATR PSYCH, V23, P161, DOI 10.1002/gps.1857; Freund-Levi Y, 2006, ARCH NEUROL-CHICAGO, V63, P1402, DOI 10.1001/archneur.63.10.1402; Ganguli M, 2000, ARCH NEUROL-CHICAGO, V57, P824, DOI 10.1001/archneur.57.6.824; Garai S, 1996, PHYTOCHEMISTRY, V42, P815, DOI 10.1016/0031-9422(95)00936-1; Garcia-Alloza M, 2007, J NEUROCHEM, V102, P1095, DOI 10.1111/j.1471-4159.2007.04613.x; Gella A, 2009, CELL ADHES MIGR, V3, P88, DOI 10.4161/cam.3.1.7402; GENTLEMAN S, 1992, BRIT MED J, V304, P118, DOI 10.1136/bmj.304.6819.118-d; Giacalone M, 2011, NUTR NEUROSCI, V14, P119, DOI 10.1179/1476830511Y.0000000007; Good PF, 1996, AM J PATHOL, V149, P21; Goyarzu F, 2004, NUTR NEUROSCI, V7, P75, DOI 10.1080/10284150410001710410; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Gu YA, 2010, ARCH NEUROL-CHICAGO, V67, P699, DOI 10.1001/archneurol.2010.84; Gustaw-Rothenberg K, 2009, INT J ENV RES PUB HE, V6, P1335, DOI 10.3390/ijerph6041335; Han Guang-Liang, 2005, Wei Sheng Yan Jiu, V34, P581; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Haque AM, 2006, J NUTR, V136, P1043; Hashimoto M, 2002, J NEUROCHEM, V81, P1084, DOI 10.1046/j.1471-4159.2002.00905.x; Hawkes CA, 2009, P NATL ACAD SCI USA, V106, P1261, DOI 10.1073/pnas.0805453106; He Y, 2009, NEUROSCIENTIST, V15, P333, DOI 10.1177/1073858409334423; Holcomb LA, 2006, J ALZHEIMERS DIS, V9, P243; Ilieva I, 2004, EXP EYE RES, V79, P181, DOI 10.1016/j.exer.2004.03.009; In 't Veld BA, 2000, NEUROBIOL AGING S1, V21, P204; Ireson CR, 2002, CANCER EPIDEM BIOMAR, V11, P105; Jain P., 1994, Indian Journal of Experimental Biology, V32, P633; Jain SK, 2009, ANTIOXID REDOX SIGN, V11, P241, DOI 10.1089/ars.2008.2140; Jantzen PT, 2002, J NEUROSCI, V22, P2246, DOI 10.1523/JNEUROSCI.22-06-02246.2002; Jicha GA, 2010, CLIN INTERV AGING, V5, P45; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jurenka JS, 2009, ALTERN MED REV, V14, P141; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; Kamphuis PJGH, 2010, J ALZHEIMERS DIS, V20, P765, DOI 10.3233/JAD-2010-091558; Kanowski S, 1997, PHYTOMEDICINE, V4, P3, DOI 10.1016/S0944-7113(97)80021-9; Katiyar SK, 1999, PHOTOCHEM PHOTOBIOL, V69, P148, DOI 10.1111/j.1751-1097.1999.tb03267.x; Khairallah Mervat Ibrahim, 2011, Pak J Biol Sci, V14, P257, DOI 10.3923/pjbs.2011.257.272; Kim J, 2010, J NEUROCHEM, V112, P1415, DOI 10.1111/j.1471-4159.2009.06562.x; Kotilinek LA, 2008, BRAIN, V131, P651, DOI 10.1093/brain/awn008; Krikorian R, 2010, J AGR FOOD CHEM, V58, P3996, DOI 10.1021/jf9029332; Kuka S., 2012, ACTA MED MART, V12, P5; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Kukull WA, 2002, MED CLIN N AM, V86, P573, DOI 10.1016/S0025-7125(02)00010-X; Kuriyama S, 2006, AM J CLIN NUTR, V83, P355; Kwak WJ, 2002, PLANTA MED, V68, P316, DOI 10.1055/s-2002-26742; Lau FC, 2005, NEUROBIOL AGING, V26, pS128, DOI 10.1016/j.neurobiolaging.2005.08.007; Lau FC, 2007, J NEUROSCI RES, V85, P1010, DOI 10.1002/jnr.21205; Lau FC, 2009, J FUNCT FOODS, V1, P274, DOI 10.1016/j.jff.2009.05.001; Laurin D, 2003, J ALZHEIMERS DIS, V5, P315, DOI 10.3233/JAD-2003-5407; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Lee HS, 2007, PHARMAZIE, V62, P937, DOI 10.1691/ph.2007.12.7563; Lee JW, 2009, J NUTR, V139, P1987, DOI 10.3945/jn.109.109785; Lee JW, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-37; Lee SY, 2005, MOL BRAIN RES, V140, P45, DOI 10.1016/j.molbrainres.2005.07.009; Lee YM, 2010, ARCH PHARM RES, V33, P231, DOI 10.1007/s12272-010-0207-4; Lev-Ari Shahar, 2006, J Soc Integr Oncol, V4, P21; Li H, 2005, KIDNEY INT, V67, P867, DOI 10.1111/j.1523-1755.2005.00151.x; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Lim GP, 2000, J NEUROSCI, V20, P5709; Lim GP, 2001, J NEUROSCI, V21, P8370; Limpeanchob N, 2008, J ETHNOPHARMACOL, V120, P112, DOI 10.1016/j.jep.2008.07.039; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Lipton SA, 2004, J ALZHEIMERS DIS, V6, pS61; Lu CH, 2012, INDIAN J PHARMACOL, V44, P118, DOI 10.4103/0253-7613.91881; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P676, DOI 10.1016/j.pnpbp.2010.05.004; Mandel SA, 2008, CNS NEUROSCI THER, V14, P352, DOI 10.1111/j.1755-5949.2008.00060.x; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Martorana Adriana, 2012, Longev Healthspan, V1, P8, DOI 10.1186/2046-2395-1-8; Massoud F, 2010, CURR NEUROPHARMACOL, V8, P69, DOI 10.2174/157015910790909520; Matsuoka Y, 2001, AM J PATHOL, V158, P1345, DOI 10.1016/S0002-9440(10)64085-0; Maurer K, 1997, J PSYCHIATR RES, V31, P645, DOI 10.1016/S0022-3956(97)00022-8; McCusker SM, 2001, LANCET, V357, P436, DOI 10.1016/S0140-6736(00)04008-3; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; McGeer PL, 2002, J NEUROVIROL, V8, P529, DOI 10.1080/13550280290100969; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Menon VP, 2007, ADV EXP MED BIOL, V595, P105; Mereles D, 2011, INT J MOL SCI, V12, P5592, DOI 10.3390/ijms12095592; MEYDANI SN, 1991, J NUTR, V121, P547; Migliore L, 2005, NEUROBIOL AGING, V26, P587, DOI 10.1016/j.neurobiolaging.2004.10.002; Mishra S, 2008, ANN INDIAN ACAD NEUR, V11, P13, DOI 10.4103/0972-2327.40220; Moreira PI, 2010, METHODS MOL BIOL, V610, P419, DOI 10.1007/978-1-60327-029-8_25; Mori Trevor A, 2004, Curr Atheroscler Rep, V6, P461, DOI 10.1007/s11883-004-0087-5; Morris MC, 2003, ARCH NEUROL-CHICAGO, V60, P940, DOI 10.1001/archneur.60.7.940; Munch G, 1998, J NEURAL TRANSM, V105, P439, DOI 10.1007/s007020050069; Munoz DG, 2000, CAN MED ASSOC J, V162, P65; Narala VR, 2009, GENE THER MOL BIOL, V13, P20; Narayanan BA, 2003, CANCER RES, V63, P972; Netland EE, 1998, NEUROBIOL AGING, V19, P201, DOI 10.1016/S0197-4580(98)00047-5; NETTLETON JA, 1991, J AM DIET ASSOC, V91, P331; Ng TP, 2006, AM J EPIDEMIOL, V164, P898, DOI 10.1093/aje/kwj267; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; Nunomura A, 2005, ANTIOXIDANT THERAPIE, P131; Nunomura A, 2006, J NEUROPATH EXP NEUR, V65, P631, DOI 10.1097/01.jnen.0000228136.58062.bf; Papassotiropoulos A, 1999, ANN NEUROL, V45, P666, DOI 10.1002/1531-8249(199905)45:5<666::AID-ANA18>3.0.CO;2-3; PAPPOLLA MA, 1992, AM J PATHOL, V140, P621; Perry RT, 2001, AM J MED GENET, V105, P332, DOI 10.1002/ajmg.1371; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Prosperi C, 2004, INT J IMMUNOPATH PH, V17, P317, DOI 10.1177/039463200401700312; Reid AT, 2013, EUR NEUROPSYCHOPHARM, V23, P63, DOI 10.1016/j.euroneuro.2012.11.010; Retz W, 1998, J NEURAL TRANSM-SUPP, P221; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Rezai-Zadeh K, 2005, J NEUROSCI, V25, P8807, DOI 10.1523/JNEUROSCI.1521-05.2005; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ringman John M., 2005, Current Alzheimer Research, V2, P131, DOI 10.2174/1567205053585882; Ringman JM, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt146; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; Routray W, 2011, COMPR REV FOOD SCI F, V10, P303, DOI 10.1111/j.1541-4337.2011.00164.x; Russo A, 2003, LIFE SCI, V73, P1517, DOI 10.1016/S0024-3205(03)00476-4; Ruxton CHS, 2004, J HUM NUTR DIET, V17, P449, DOI 10.1111/j.1365-277X.2004.00552.x; Saini N, 2012, NEUROCHEM RES, V37, P1928, DOI 10.1007/s11064-012-0811-4; Sanchez-Ferro A, 2013, NEUROPSYCH DIS TREAT, V9, P55, DOI [10.2147/NDT.529105, 10.2147/NDT.S29105]; Sastre M, 2003, J NEUROSCI, V23, P9796; Sastre M, 2006, P NATL ACAD SCI USA, V103, P443, DOI 10.1073/pnas.0503839103; Schaefer EJ, 2006, ARCH NEUROL-CHICAGO, V63, P1545, DOI 10.1001/archneur.63.11.1545; Scharf S, 1999, NEUROLOGY, V53, P197, DOI 10.1212/WNL.53.1.197; Schneider Lon S., 2005, Current Alzheimer Research, V2, P541, DOI 10.2174/156720505774932287; Shi J, 2000, NEUROBIOL AGING, V21, P357, DOI 10.1016/S0197-4580(00)00119-6; Siddiqui R, 2012, VIRULENCE, V3, P159, DOI 10.4161/viru.17631; Simopoulos AP, 2008, EXP BIOL MED, V233, P674, DOI 10.3181/0711-MR-311; Singh VK, 1997, J PSYCHIAT RES, V31, P657, DOI 10.1016/S0022-3956(97)00023-X; Sly LM, 2001, BRAIN RES BULL, V56, P581, DOI 10.1016/S0361-9230(01)00730-4; Smith JV, 2003, J ALZHEIMERS DIS, V5, P287, DOI 10.3233/JAD-2003-5404; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Stackman RW, 2003, EXP NEUROL, V184, P510, DOI 10.1016/S0014-4886(03)00399-6; Stevenson DE, 2007, CELL MOL LIFE SCI, V64, P2900, DOI 10.1007/s00018-007-7237-1; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Stough C, 2001, PSYCHOPHARMACOLOGY, V156, P481, DOI 10.1007/s002130100815; Stough C, 2008, PHYTOTHER RES, V22, P1629, DOI 10.1002/ptr.2537; Strohmeyer R, 2001, J ALZHEIMERS DIS, V3, P131, DOI 10.3233/JAD-2001-3118; Sun XT, 2012, DRUG DISCOV THER, V6, P285, DOI 10.5582/ddt.2012.v6.6.285; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; Szekely CA, 2008, NEUROLOGY, V70, P2291, DOI 10.1212/01.wnl.0000313933.17796.f6; Tarkowski E, 1999, J CLIN IMMUNOL, V19, P223, DOI 10.1023/A:1020568013953; Thal LJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1204, DOI 10.1038/sj.npp.1300690; TIMELL TE, 1978, WOOD SCI TECHNOL, V12, P89; Torri E, 2007, J PHARM PHARMACOL, V59, P591, DOI 10.1211/jpp.59.4.0015; Townsend KP, 2005, FASEB J, V19, P1592, DOI 10.1096/fj.04-3620rev; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Uabundit N, 2010, J ETHNOPHARMACOL, V127, P26, DOI 10.1016/j.jep.2009.09.056; VANE J, 1987, FASEB J, V1, P89; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; VANE JR, 1998, AM J MED, V104, P2, DOI [DOI 10.1016/S0002-9343(97)00203-9, 10.1016/S0002-9343(97)00203-9]; Vareed SK, 2008, CANCER EPIDEM BIOMAR, V17, P1411, DOI 10.1158/1055-9965.EPI-07-2693; Vauzour D, 2010, NUTRIENTS, V2, P1106, DOI 10.3390/nu2111106; Veld BAI, 1998, NEUROBIOL AGING, V19, P607, DOI 10.1016/S0197-4580(98)00096-7; Viji V, 2008, J ETHNOPHARMACOL, V118, P305, DOI 10.1016/j.jep.2008.04.017; Vlad SC, 2008, NEUROLOGY, V70, P1672, DOI 10.1212/01.wnl.0000311269.57716.63; Wadsworth TL, 2001, CHEM-BIOL INTERACT, V137, P43, DOI 10.1016/S0009-2797(01)00208-3; Watkins BA, 2001, EXP BIOL MED, V226, P485; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weih M, 2007, J NEURAL TRANSM, V114, P1187, DOI 10.1007/s00702-007-0704-x; Weinreb O, 2004, J NUTR BIOCHEM, V15, P506, DOI 10.1016/j.jnutbio.2004.05.002; WHEELAN L, 1959, ANN HUM GENET, V23, P300, DOI 10.1111/j.1469-1809.1959.tb01473.x; Williams R, 2014, FOOD FUNCT, V5, P517, DOI 10.1039/c3fo60467e; Willis LM, 2010, GLIA, V58, P679, DOI 10.1002/glia.20954; Wong A, 2001, EUR J NEUROSCI, V14, P1961, DOI 10.1046/j.0953-816x.2001.01820.x; WOOD JA, 1993, BRAIN RES, V629, P245, DOI 10.1016/0006-8993(93)91327-O; Xie CH, 2011, MOL NUTR FOOD RES, V55, P1587, DOI 10.1002/mnfr.201100344; Yan Q, 2003, J NEUROSCI, V23, P7504; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Yoshikawa T, 1999, ANTIOXID REDOX SIGN, V1, P469, DOI 10.1089/ars.1999.1.4-469; Yves C., 2005, GINKGO BILOBA EXTRAC, P43; Zhang LL, 2013, NEUROPHARMACOLOGY, V70, P200, DOI 10.1016/j.neuropharm.2012.10.023; Zhu YY, 2008, REJUV RES, V11, P891, DOI 10.1089/rej.2008.0757	208	50	53	1	60	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2014	13	7					1175	1191		10.2174/1871527313666140917110635			17	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AS0UG	WOS:000343993400008	25230232				2021-06-18	
J	Pawlikowska-Pawlega, B; Dziubhiska, H; Krol, E; Trebacz, K; Jarosz-Wilkolazka, A; Paduch, R; Gawron, A; Gruszecki, WI				Pawlikowska-Pawlega, Bolena; Dziubhiska, Halina; Krol, Elzbieta; Trebacz, Kazimierz; Jarosz-Wilkolazka, Anna; Paduch, Roman; Gawron, Antoni; Gruszecki, Wieslaw I.			Characteristics of quercetin interactions with liposomal and vacuolar membranes	BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES			English	Article						Flavonoids; DPPC liposomes; Spectroscopy study; Patch-clamp; Electron microscopy	ANTIBIOTIC AMPHOTERICIN-B; HYDROGEN-PEROXIDE; LIPID-MEMBRANES; FLAVONOID QUERCETIN; OXIDATIVE STRESS; ANTIOXIDANT; TRANSPORT; CELLS; APIGENIN; BINDING	Quercetin (3,3',4',5,7-pentahydroxyflavone) is claimed to exert many beneficial health effects. With application of H-1 NMR (nuclear magnetic resonance) and FTIR (Fourier-transform infrared) techniques, quercetin interaction with liposomes formed with dipalmitoylphosphatidylcholine (DPPC) was analyzed. Patch-clamp technique was employed to study quercetin effects at single channel level of vacuolar membranes in the liverwort Conocephalum conicum. Light and electron microscopy were applied to study quercetin effects on human negroid cervix carcinoma cells (HeLa). Enzymatic measurements along with DPPH (1,1-diphenyl-2-picrylhydrazyl) bioassay were performed to investigate the influence of quercetin on antioxidant enzymes and reactive oxygen species (ROS) production. The inclusion of quercetin to the membrane exerted pronounced ordering effect on the motional freedom of lipids in the head group region as manifested by broadening of the H-1 NMR spectral line representing the choline groups. FTIR analysis revealed quercetin incorporation into DPPC liposomes via hydrogen bonding between its own hydroxyl groups and lipid polar head groups in the C-O-P-O-C segment Both, FUR and NMR techniques indicated also quercetin spectral effects in the region corresponding to alkyl chains. Patch-clamp experiments showed that quercetin stabilizes tonoplast and promotes a close state of SV channels. Microscopic observations of HeLa cells revealed characteristic changes in ultrastructure and morphology of the examined cells in comparison to control cells. Pretreatment of HeLa cells with quercetin alleviated H2O2-induced cell injury by improving redox balance as indicated by the increase in glutathione content and SOD (superoxide dismutase) levels as well as by the decrease in ROS level. \In conclusion, the incorporation, distribution and the changes of biophysical properties of the membranes are very important for the effectiveness of phenolic compounds as antioxidant and anticancer factors. (C) 2013 Elsevier B.V. All rights reserved.	[Pawlikowska-Pawlega, Bolena; Gawron, Antoni] Marie Curie Sklodowska Univ, Dept Comparat Anat & Anthropol, PL-20033 Lublin, Poland; [Pawlikowska-Pawlega, Bolena] Marie Curie Sklodowska Univ, Electron Microscopy Lab, PL-20033 Lublin, Poland; [Dziubhiska, Halina; Krol, Elzbieta; Trebacz, Kazimierz] Marie Curie Sklodowska Univ, Dept Biophys, PL-20033 Lublin, Poland; [Jarosz-Wilkolazka, Anna] Marie Curie Sklodowska Univ, Dept Biochem, PL-20033 Lublin, Poland; [Paduch, Roman] Marie Curie Sklodowska Univ, Dept Virol & Immunol, PL-20033 Lublin, Poland; [Gruszecki, Wieslaw I.] Marie Curie Sklodowska Univ, Dept Biophys, PL-20031 Lublin, Poland	Pawlikowska-Pawlega, B (corresponding author), Marie Curie Sklodowska Univ, Dept Comparat Anat & Anthropol, PL-20033 Lublin, Poland.	bozka1996@o2.pl; halinadziubinska@umcs.lublin.pl; elzbietakrol@uni-wuerzburg.de; kazimierz.trebacz@poczta.umcs.lublin.pl; anna.wilkolazka@poczta.umcs.lublin.pl; rpaduch@poczta.umcs.lublin.pl; agawron@poczta.umcs.lublin.pl; wieslaw.gruszecki@umcs.pl	Jarosz-Wilkolazka, Anna/AAM-8144-2021; Jarosz-Wilkolazka, Anna/B-3763-2014	Jarosz-Wilkolazka, Anna/0000-0002-8222-4379; Gruszecki, Wieslaw/0000-0002-8245-3913; Pawlikowska-Pawlega, Bozena/0000-0001-5559-8546; Paduch, Roman/0000-0001-9779-7252; Trebacz, Kazimierz/0000-0001-5642-9955	Foundation for Polish Science within the framework of the TEAM program	This work has been partially performed within the project "Molecular Spectroscopy for BioMedical studies" financed by the Foundation for Polish Science within the framework of the TEAM program.	Adamkiewicz P, 2013, J MOL STRUCT, V1046, P44, DOI 10.1016/j.molstruc.2013.04.053; AEBI H, 1984, METHOD ENZYMOL, V105, P121; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Areias FM, 2001, BIOCHEM PHARMACOL, V62, P111, DOI 10.1016/S0006-2952(01)00621-9; Bei WJ, 2005, LIFE SCI, V76, P1975, DOI 10.1016/j.lfs.2004.09.031; BERTL A, 1992, SCIENCE, V258, P873, DOI 10.1126/science.1439795; Boots AW, 2008, EUR J PHARMACOL, V585, P325, DOI 10.1016/j.ejphar.2008.03.008; Boue SM, 2003, J CHROMATOGR A, V991, P61, DOI 10.1016/S0021-9673(03)00209-7; Burda S, 2001, J AGR FOOD CHEM, V49, P2774, DOI 10.1021/jf001413m; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Cazarolli LH, 2008, MINI-REV MED CHEM, V8, P1429, DOI 10.2174/138955708786369564; Chen JW, 2002, ACTA PHARMACOL SIN, V23, P667; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen TJ, 2006, TOXICOLOGY, V223, P113, DOI 10.1016/j.tox.2006.03.007; Choi YJ, 2003, J NUTR, V133, P985; Cieslik-Boczula K, 2012, VIB SPECTROSC, V62, P64, DOI 10.1016/j.vibspec.2012.05.010; Cogolludo A, 2007, CARDIOVASC RES, V73, P424, DOI 10.1016/j.cardiores.2006.09.008; Conseil G, 1998, P NATL ACAD SCI USA, V95, P9831, DOI 10.1073/pnas.95.17.9831; Desiraju GR, 2005, CHEM COMMUN, P2995, DOI 10.1039/b504372g; Dixon RA, 1999, TRENDS PLANT SCI, V4, P394, DOI 10.1016/S1360-1385(99)01471-5; DUDEJA PK, 1995, ARCH BIOCHEM BIOPHYS, V319, P309, DOI 10.1006/abbi.1995.1298; ELIAS KS, 1987, APPL ENVIRON MICROB, V53, P1928, DOI 10.1128/AEM.53.8.1928-1933.1987; Erlejman AG, 2004, FREE RADICAL RES, V38, P1311, DOI 10.1080/10715760400016105; Formica JV, 1995, FOOD CHEM TOXICOL, V33, P1061, DOI 10.1016/0278-6915(95)00077-1; Frangne N, 2002, PLANT PHYSIOL, V128, P726, DOI 10.1104/pp.010590; Gabrielska J, 1996, BBA-BIOMEMBRANES, V1285, P167, DOI 10.1016/S0005-2736(96)00152-6; Gabrielska J, 2006, FEBS LETT, V580, P2677, DOI 10.1016/j.febslet.2006.04.021; Gagos M, 2005, MOL MEMBR BIOL, V22, P433, DOI 10.1080/09687860500287832; Ganbold M, 2010, J ETHNOPHARMACOL, V131, P396, DOI 10.1016/j.jep.2010.07.014; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; Goutman JD, 2004, BRIT J PHARMACOL, V141, P717, DOI 10.1038/sj.bjp.0705657; Goutman JD, 2003, EUR J PHARMACOL, V461, P79, DOI 10.1016/S0014-2999(03)01309-8; Gutla PVK, 2010, BIOPHYS J, V98, p534A, DOI 10.1016/j.bpj.2009.12.2900; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hendrich AB, 2006, ACTA PHARMACOL SIN, V27, P27, DOI 10.1111/j.1745-7254.2006.00238.x; Hendrich AB, 2002, EUR J PHARM SCI, V16, P201, DOI 10.1016/S0928-0987(02)00106-9; HUNT GRA, 1980, BIOCHIM BIOPHYS ACTA, V601, P678, DOI 10.1016/0005-2736(80)90568-4; JACOBS M, 1988, SCIENCE, V241, P346, DOI 10.1126/science.241.4863.346; Klein M, 1997, FEBS LETT, V420, P86, DOI 10.1016/S0014-5793(97)01492-0; Kondo N, 2000, J PLANT RES, V113, P311, DOI 10.1007/PL00013863; Lee EH, 2002, BIOPHYS J, V82, P1266, DOI 10.1016/S0006-3495(02)75483-0; Lenne-Gouverneur AF, 1999, MOL MEMBR BIOL, V16, P157, DOI 10.1080/096876899294616; Li WG, 2000, ARTERIOSCL THROM VAS, V20, P1473, DOI 10.1161/01.ATV.20.6.1473; Lopez-Revuelta A, 2006, CHEM-BIOL INTERACT, V161, P79, DOI 10.1016/j.cbi.2006.03.004; Mansour R.B., 2011, LIPIDS HLTH DIS, V10, P1; Movileanu L, 2000, INT J PHARMACEUT, V205, P135, DOI 10.1016/S0378-5173(00)00503-2; Murota K, 2002, J NUTR, V132, P1956; Nguyen H, 2003, J PHARM SCI-US, V92, P250, DOI 10.1002/jps.10283; Nurminskii V.N., 2009, IZV AKAD NAUK BIOL+, V1, P5; Ollila F, 2002, ARCH BIOCHEM BIOPHYS, V399, P103, DOI 10.1006/abbi.2001.2759; Oteiza Patricia I, 2005, Clin Dev Immunol, V12, P19, DOI 10.1080/10446670410001722168; Paduch R, 2008, POL J ENVIRON STUD, V17, P569; Pampel A, 2003, CHEM PHYS LETT, V379, P555, DOI 10.1016/j.cplett.2003.08.093; Pawlikowska-Pawle B, 2007, ACTA PHYSIOL PLANT, V29, P143, DOI 10.1007/s11738-006-0018-x; Pawlikowska-Pawlega B, 2000, ACTA PHYSIOL PLANT, V22, P61, DOI 10.1007/s11738-000-0009-2; Pawlikowska-Pawlega B, 2003, BIOCHEM PHARMACOL, V66, P605, DOI 10.1016/S0006-2952(03)00344-7; Pawlikowska-Pawlega B, 2007, BBA-BIOMEMBRANES, V1768, P2195, DOI 10.1016/j.bbamem.2007.05.027; Pawlikowska-Pawlega B, 2013, BBA-BIOMEMBRANES, V1828, P518, DOI 10.1016/j.bbamem.2012.10.013; Pawlikowska-Pawlega B, 2012, BBA-BIOMEMBRANES, V1818, P1785, DOI 10.1016/j.bbamem.2012.03.020; Pawlikowska-Pawlega B, 2011, ACTA PHYSIOL PLANT, V33, P1335, DOI 10.1007/s11738-010-0666-8; Pawlikowska-Pawlega B, 2009, J PLANT PHYSIOL, V166, P712, DOI 10.1016/j.jplph.2008.09.014; Pazdzioch-Czochra M, 2003, CELL BIOL INT, V27, P325, DOI 10.1016/S1065-6995(02)00282-2; Psotova J, 2004, PHYTOTHER RES, V18, P516, DOI 10.1002/ptr.1462; Rice-Evans C, 2001, CURR MED CHEM, V8, P797, DOI 10.2174/0929867013373011; SAIJA A, 1995, FREE RADICAL BIO MED, V19, P481, DOI 10.1016/0891-5849(94)00240-K; Scheidt HA, 2004, BBA-BIOMEMBRANES, V1663, P97, DOI 10.1016/j.bbamem.2004.02.004; Schonknecht G, 2008, PLANT SIGNAL BEHAV, V3, P404, DOI 10.1093/pcp/pcm147; Shirley BW, 1996, TRENDS PLANT SCI, V1, P377, DOI 10.1016/S1360-1385(96)80312-8; Siarheyeva A, 2006, BIOCHEMISTRY-US, V45, P6203, DOI 10.1021/bi0524870; Singh M, 2007, MITOCHONDRION, V7, P367, DOI 10.1016/j.mito.2007.07.003; Sinha R., 2012, INT J CURR PHARM RES, V4, P70; SINICROPE FA, 1992, J BIOL CHEM, V267, P24995; Suhara T, 1998, J IMMUNOL, V160, P4042; Summanen J, 2001, EUR J PHARMACOL, V414, P125, DOI 10.1016/S0014-2999(01)00774-9; SUN M, 1978, ANAL BIOCHEM, V90, P81, DOI 10.1016/0003-2697(78)90010-6; Takahashi L, 1998, PLANT PHYSIOL BIOCH, V36, P495, DOI 10.1016/S0981-9428(98)80174-5; Tarahovsky YS, 2008, MOL CELL BIOCHEM, V314, P65, DOI 10.1007/s11010-008-9766-9; TERAO J, 1994, ARCH BIOCHEM BIOPHYS, V308, P278, DOI 10.1006/abbi.1994.1039; Trebacz K, 2000, PROTOPLASMA, V213, P39, DOI 10.1007/BF01280503; Trebacz K, 2007, PLANT CELL PHYSIOL, V48, P1747, DOI 10.1093/pcp/pcm147; Treutter D, 2006, ENVIRON CHEM LETT, V4, P147, DOI 10.1007/s10311-006-0068-8; Tsuchiya H, 2002, BIOFACTORS, V16, P45, DOI 10.1002/biof.5520160301; Tsuchiya H, 2010, FOOD CHEM, V120, P1089, DOI 10.1016/j.foodchem.2009.11.057; Ulug M, 2011, AFR J PHARM PHARMACO, V5, P894; van Dijk C, 2000, BIOCHEM PHARMACOL, V60, P1593, DOI 10.1016/S0006-2952(00)00488-3; vanAcker SABE, 1996, FREE RADICAL BIO MED, V20, P331, DOI 10.1016/0891-5849(95)02047-0; Vargas AJ, 2010, NUTR REV, V68, P418, DOI 10.1111/j.1753-4887.2010.00301.x; Wattanatho J, 2007, AM J AGR BIOL SCI, V2, P31, DOI DOI 10.3844/AJABSSP.2007.31.35; Wojtowicz K, 1996, FOLIA HISTOCHEM CYTO, V34, P49; Zhang F, 1997, PLANT SOIL, V192, P141, DOI 10.1023/A:1004284727885	91	50	50	1	40	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0005-2736	1879-2642		BBA-BIOMEMBRANES	Biochim. Biophys. Acta-Biomembr.	JAN	2014	1838	1	B				254	265		10.1016/j.bbamem.2013.08.014			12	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	AA0UX	WOS:000330814000018	24001508	Bronze			2021-06-18	
J	Takano, T; He, W; Han, XN; Wang, FS; Xu, QW; Wang, XH; Bush, NAO; Cruz, N; Dienel, GA; Nedergaard, M				Takano, Takahiro; He, Wei; Han, Xiaoning; Wang, Fushun; Xu, Qiwu; Wang, Xiaohai; Bush, Nancy Ann Oberheim; Cruz, Nancy; Dienel, Gerald A.; Nedergaard, Maiken			Rapid Manifestation of Reactive Astrogliosis in Acute Hippocampal Brain Slices	GLIA			English	Article						astrohcytes; interstitial space; NADH; two-photon microscopy; mitochondria; electron microscopy; purinergic receptors	GREEN FLUORESCENT PROTEIN; DIFFERENTIAL EXPRESSION; OXIDATIVE-METABOLISM; ENERGY-METABOLISM; GUINEA-PIG; ASTROCYTES; CALCIUM; GLYCOGEN; CONNEXIN-43; INHIBITION	A flurry of studies over the past decade has shown that astrocytes play a more active role in neural function than previously recognized. Hippocampal slices prepared from young rodent pups have served as a popular model for studying the pathways by which astrocytes participate in synaptic transmission. It is, however, not known how well astrocytes tolerate traumatic injury and hypoxia, which are unavoidable when preparing acute slices. We here showed that astrocytes exhibit striking changes in expression of several receptors and structural proteins, including re-expression of the developmental marker nestin within 90 min following preparation of live vibratome slices. Moreover, immunoelectron microscopy showed a 2.7-fold loss of astrocytic processes in acute hippocampal slices prepared from glial fibrillary acidic protein-green fluorescent protein reporter mice. A sharp decrease in the number of mitochondria was also noted in acute slices, concurrently with an increase in mitochondrial size. Glycogen content decreased 3-fold upon slice preparation and did not recover despite stable recordings of field excitatory postsynaptic current. Analysis of Ca2+ signaling showed that astrocytic responses to purine receptor and mGluR5 agonists differed in slice versus in vivo. These observations suggest that the functional properties and the fine structure of astrocytes in slices may be reflective of early stages of reactive gliosis and should be confirmed in vivo when possible. GLIA 2013;62:78-95	[Takano, Takahiro; He, Wei; Han, Xiaoning; Wang, Fushun; Xu, Qiwu; Wang, Xiaohai; Bush, Nancy Ann Oberheim; Nedergaard, Maiken] Univ Rochester, Med Ctr, Div Glial Dis & Therapeut, Ctr Translat Neuromed, Rochester, NY 14642 USA; [Cruz, Nancy; Dienel, Gerald A.] Univ Arkansas Med Sci, Dept Neurol, Little Rock, AR 72205 USA	Nedergaard, M (corresponding author), Univ Rochester, Med Ctr, Div Glial Dis & Therapeut, Ctr Translat Neuromed, Rochester, NY 14642 USA.	Nedergaard@urmc.rochester.edu		Wang, Xiaohai/0000-0001-5814-4072; Takano, Takahiro/0000-0002-6235-6673	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS075177, NS078304, DK081936]; Novo Nordisk FondenNovo Nordisk Foundation [NNF13OC0004258] Funding Source: researchfish; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE022743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK081936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078167, R01NS075177, R01NS078304] Funding Source: NIH RePORTER	Grant sponsor: NIH, NS075177, NS078304 (to MN); DK081936 (to GAD).	Abbracchio MP, 2009, TRENDS NEUROSCI, V32, P19, DOI 10.1016/j.tins.2008.10.001; Agulhon C, 2008, NEURON, V59, P932, DOI 10.1016/j.neuron.2008.09.004; AITKEN PG, 1995, J NEUROSCI METH, V59, P139, DOI 10.1016/0165-0270(94)00204-T; Allen NJ, 2009, NATURE, V457, P675, DOI 10.1038/457675a; Ball KK, 2007, J NEUROSCI RES, V85, P3267, DOI 10.1002/jnr.21376; Bekar L, 2008, NAT MED, V14, P75, DOI 10.1038/nm1693; BOOTH RFG, 1980, J NEUROCHEM, V34, P17, DOI 10.1111/j.1471-4159.1980.tb04616.x; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; CLARKE SR, 1994, NEUROREPORT, V5, P1885, DOI 10.1097/00001756-199410000-00011; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Cruz NF, 2002, J CEREBR BLOOD F MET, V22, P1476, DOI 10.1097/01.WCB.0000034362.37277.C0; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; Dienel GA, 2002, J CEREBR BLOOD F MET, V22, P1490, DOI 10.1097/01.WCB.0000034363.37277.89; Dienel GA, 2012, ASN NEURO, V4, P267, DOI 10.1042/AN20120021; DODT HU, 1990, BRAIN RES, V537, P333, DOI 10.1016/0006-8993(90)90380-T; Duchen MR, 2010, ESSAYS BIOCHEM, V47, P115, DOI [10.1042/BSE0470115, 10.1042/bse0470115]; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Fiala JC, 2003, J COMP NEUROL, V465, P90, DOI 10.1002/cne.10825; Franke H, 2012, PURINERG SIGNAL, V8, P629, DOI 10.1007/s11302-012-9300-0; Galic MA, 2012, FRONT NEUROENDOCRIN, V33, P116, DOI 10.1016/j.yfrne.2011.12.002; Gibbs ME, 2006, GLIA, V54, P214, DOI 10.1002/glia.20377; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Hertz L, 2007, J CEREBR BLOOD F MET, V27, P219, DOI 10.1038/sj.jcbfm.9600343; Hom JR, 2007, J CELL PHYSIOL, V212, P498, DOI 10.1002/jcp.21051; Huang CL, 2012, J NEUROSCI, V32, P3333, DOI 10.1523/JNEUROSCI.1216-11.2012; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Kaneko Y, 2012, CELL MED, V4, P55, DOI 10.3727/215517912X639306; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Kasischke KA, 2004, SCIENCE, V305, P99, DOI 10.1126/science.1096485; Kasischke KA, 2011, J CEREBR BLOOD F MET, V31, P68, DOI 10.1038/jcbfm.2010.158; Kerkut GA, 1981, ELECTROPHYSIOLOGY IS, P107; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kimelberg HK, 2007, NEURON GLIA BIOL, V3, P181, DOI 10.1017/S1740925X08000094; KNULL HR, 1982, NEUROCHEM RES, V7, P1307, DOI 10.1007/BF00965901; Koizumi S, 2013, GLIA, V61, P47, DOI 10.1002/glia.22358; Langmoen I, 1981, ELECTROPHYSIOLOGY IS, P51; Li Y, 1999, BRAIN RES, V838, P1, DOI 10.1016/S0006-8993(99)01502-4; Liem RKH, 2009, J CLIN INVEST, V119, P1814, DOI 10.1172/JCI38003; Lin JHC, 2008, J NEUROSCI, V28, P681, DOI 10.1523/JNEUROSCI.3827-07.2008; LIPTON P, 1989, J NEUROSCI METH, V28, P147, DOI 10.1016/0165-0270(89)90019-8; LIPTON P, 1995, J NEUROSCI METH, V59, P151, DOI 10.1016/0165-0270(94)00205-U; LLANO I, 1988, P NATL ACAD SCI USA, V85, P3221, DOI 10.1073/pnas.85.9.3221; Lovatt D, 2007, J NEUROSCI, V27, P12255, DOI 10.1523/JNEUROSCI.3404-07.2007; Mathiisen TM, 2010, GLIA, V58, P1094, DOI 10.1002/glia.20990; Nakase T, 2006, GLIA, V54, P369, DOI 10.1002/glia.20399; Nedergaard M, 2012, GLIA, V60, P1013, DOI 10.1002/glia.22288; NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799a0; NICHOLSON C, 1992, CAN J PHYSIOL PHARM, V70, pS314, DOI 10.1139/y92-278; Nicholson C, 2011, COMPUT VIS SCI, V14, P309, DOI 10.1007/s00791-012-0185-9; Nielsen S, 1997, J NEUROSCI, V17, P171; Oberheim NA, 2008, J NEUROSCI, V28, P3264, DOI 10.1523/JNEUROSCI.4980-07.2008; Oberheim NA, 2009, J NEUROSCI, V29, P3276, DOI 10.1523/JNEUROSCI.4707-08.2009; Peters A, 1991, FINE STRUCTURE NERVO; PFEIFFER B, 1993, HISTOCHEMISTRY, V100, P265, DOI 10.1007/BF00270045; Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265; Regan MR, 2007, J NEUROSCI, V27, P6607, DOI 10.1523/JNEUROSCI.0790-07.2007; SARVEY JM, 1989, J NEUROSCI METH, V28, P109, DOI 10.1016/0165-0270(89)90016-2; SCHWARTZKROIN PA, 1975, BRAIN RES, V89, P107, DOI 10.1016/0006-8993(75)90138-9; SIGWORTH FJ, 1980, NATURE, V287, P447, DOI 10.1038/287447a0; Skrede K, 1971, BRAIN RES B, V5, P391; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sun W, 2013, SCIENCE, V339, P197, DOI 10.1126/science.1226740; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Sykova E, 2008, PHYSIOL REV, V88, P1277, DOI 10.1152/physrev.00027.2007; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Torres A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002160; Tulapurkar ME, 2006, J NEUROCHEM, V96, P624, DOI 10.1111/j.1471-4159.2005.03594.x; VanSlyke JK, 2005, MOL BIOL CELL, V16, P5247, DOI 10.1091/mbc.E05-05-0415; Verkhratsky A, 2012, ASN NEURO, V4, DOI 10.1042/AN20120010; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; WHITTINGHAM TS, 1984, J NEUROCHEM, V43, P689, DOI 10.1111/j.1471-4159.1984.tb12788.x; YAMAMOTO C, 1966, J NEUROCHEM, V13, P1333, DOI 10.1111/j.1471-4159.1966.tb04296.x; Zhuo L, 1997, DEV BIOL, V187, P36, DOI 10.1006/dbio.1997.8601; Zonta M, 2003, NAT NEUROSCI, V6, P43, DOI 10.1038/nn980	75	50	50	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JAN	2014	62	1					78	95		10.1002/glia.22588			18	Neurosciences	Neurosciences & Neurology	255JM	WOS:000327235200007	24272704	Green Accepted			2021-06-18	
J	Kou, ZF; Gattu, R; Kobeissy, F; Welch, RD; O'Neil, BJ; Woodard, JL; Ayaz, SI; Kulek, A; Kas-Shamoun, R; Mika, V; Zuk, C; Tomasello, F; Mondello, S				Kou, Zhifeng; Gattu, Ramtilak; Kobeissy, Firas; Welch, Robert D.; O'Neil, Brian J.; Woodard, John L.; Ayaz, Syed Imran; Kulek, Andrew; Kas-Shamoun, Robert; Mika, Valerie; Zuk, Conor; Tomasello, Francesco; Mondello, Stefania			Combining Biochemical and Imaging Markers to Improve Diagnosis and Characterization of Mild Traumatic Brain Injury in the Acute Setting: Results from a Pilot Study	PLOS ONE			English	Article							FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE; WHITE-MATTER INJURY; DIFFUSE AXONAL INJURY; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL LESIONS; BREAKDOWN PRODUCTS; SERUM-LEVELS; BIOMARKERS; CONCUSSION	Background: Mild traumatic brain injury (mTBI) is a significant healthcare burden and its diagnosis remains a challenge in the emergency department. Serum biomarkers and advanced magnetic resonance imaging (MRI) techniques have already demonstrated their potential to improve the detection of brain injury even in patients with negative computed tomography (CT) findings. The objective of this study was to determine the clinical value of a combinational use of both blood biomarkers and MRI in mTBI detection and their characterization in the acute setting (within 24 hours after injury). Methods: Nine patients with mTBI were prospectively recruited from the emergency department. Serum samples were collected at the time of hospital admission and every 6 hours up to 24 hours post injury. Neuronal (Ubiquitin C-terminal Hydrolase-L1 [UCH-L1]) and glial (glial fibrillary acidic protein [GFAP]) biomarker levels were analyzed. Advanced MRI data were acquired at 9 +/- 6.91 hours after injury. Patients' neurocognitive status was assessed by using the Standard Assessment of Concussion (SAC) instrument. Results: The median serum levels of UCH-L1 and GFAP on admission were increased 4.9 folds and 10.6 folds, respectively, compared to reference values. Three patients were found to have intracranial hemorrhages on SWI, all of whom had very high GFAP levels. Total volume of brain white matter (WM) with abnormal fractional anisotropy (FA) measures of diffusion tensor imaging (DTI) were negatively correlated with patients' SAC scores, including delayed recall. Both increased and decreased DTI-FA values were observed in the same subjects. Serum biomarker level was not correlated with patients' DTI data nor SAC score. Conclusions: Blood biomarkers and advanced MRI may correlate or complement each other in different aspects of mTBI detection and characterization. GFAP might have potential to serve as a clinical screening tool for intracranial bleeding. UCH-L1 complements MRI in injury detection. Impairment at WM tracts may account for the patients' neurocognitive symptoms.	[Kou, Zhifeng] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48202 USA; [Kou, Zhifeng; Gattu, Ramtilak; Zuk, Conor] Wayne State Univ, Sch Med, Dept Radiol, Detroit, MI USA; [Kobeissy, Firas] Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Welch, Robert D.; O'Neil, Brian J.; Ayaz, Syed Imran; Kulek, Andrew; Kas-Shamoun, Robert; Mika, Valerie] Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI USA; [Welch, Robert D.; O'Neil, Brian J.] Wayne State Univ, Sch Med, Cardiovasc Res Inst, Detroit, MI USA; [Woodard, John L.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Tomasello, Francesco; Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy	Kou, ZF (corresponding author), Wayne State Univ, Dept Biomed Engn, Detroit, MI 48202 USA.	zhifeng_kou@wayne.edu	Mondello, Stefania/A-1813-2012; Kobeissy, Firas/E-7042-2017; Mika, Valerie H./AAO-2816-2020	Mondello, Stefania/0000-0002-8587-3614; Kobeissy, Firas/0000-0002-5008-6944; Woodard, John/0000-0001-9196-3336	International Society for Magnetic Resonance in Medicine; Department of DefenseUnited States Department of Defense; Banyan Biomarkers, Inc.	This work was supported by a Seed Grant from the International Society for Magnetic Resonance in Medicine (PI: Zhifeng Kou) and a research grant from the Department of Defense. Drs. Mondello and Kobeissy were employees and received salaries from Banyan Biomarkers, Inc. Dr. Welch is a site PI of a clinical trial from Banyan Biomarkers, Inc., supported by the Department of Defense. Dr. O'Neil is a site PI for BrainScope Technologies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; CDC, 2003, REP C MILD TRAUM BRA; Conturo TE, 1996, MAGNET RESON MED, V35, P399, DOI 10.1002/mrm.1910350319; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Foerch C, 2006, J NEUROL NEUROSUR PS, V77, P181, DOI 10.1136/jnnp.2005.074823; Foerch C, 2012, BIOMARKERS TRAUMATIC; Foerch C, 2012, CLIN CHEM, V58, P237, DOI 10.1373/clinchem.2011.172676; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kou Z, 2010, CLIN MR NEUROIMAGING; Kou Z, 2008, REGION INTEREST ANAL; Kou Z, 2007, JOINT ANN M ISMRM ES; Kou ZF, 2012, RSC DRUG DISCOV, V24, P19, DOI 10.1039/9781849734745-00019; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Lincoln S, 1999, NEUROREPORT, V10, P427, DOI 10.1097/00001756-199902050-00040; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M., 2000, STANDARDIZED ASSESSM; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2012, NEUROSURGERY; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; National Academy of Neuropsychology, 2002, MILD TRAUM BRAIN INJ; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; Neuwelt EA, 2011, NAT REV NEUROSCI, V12, P169, DOI 10.1038/nrn2995; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Papa L, ANN EMER MED    1108; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saigoh K, 1999, NAT GENET, V23, P47; Shimony JS, 1999, RADIOLOGY, V212, P770, DOI 10.1148/radiology.212.3.r99au51770; Unden J, 2009, J NEUROL, V256, P72, DOI 10.1007/s00415-009-0054-8; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	77	50	52	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2013	8	11							e80296	10.1371/journal.pone.0080296			14	Multidisciplinary Sciences	Science & Technology - Other Topics	256LO	WOS:000327311900061	24260364	DOAJ Gold, Green Published			2021-06-18	
J	Kim, J; Kim, TY; Cho, KS; Kim, HN; Koh, JY				Kim, Jean; Kim, Tae-Youn; Cho, Kyung-Sook; Kim, Ha Na; Koh, Jae-Young			Autophagy activation and neuroprotection by progesterone in the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis	NEUROBIOLOGY OF DISEASE			English	Article						Steroid hormone; Spinal cord; hSOD1; LC3; ALS	TRAUMATIC BRAIN-INJURY; SPINAL-CORD; MITOCHONDRIAL DYSFUNCTION; ALZHEIMER-DISEASE; MUTANT MICE; ALS MODEL; SOD1; PROGRESSION; TOXICITY; TRIAL	Progesterone (PG) exerts neuroprotective effects under conditions such as brain ischemia, traumatic brain injury, and spinal cord injury. Previously, we reported that PG activates autophagy, a potential neuroprotective mechanism, in cortical astrocytes. In the present study, we explored the possibility that PG, by activating autophagy in spinal cord cells, protects against motoneuron degeneration in transgenic (Tg) mice expressing the human G93A-SOD1 (superoxide dismutase 1) mutant, a model of amyotrophic lateral sclerosis. PG treatment increased autophagic flux in G93A-SOD1 Tg spinal cord astrocyte cultures and mice. In addition, PG treatment reduced mutant SOD1 protein levels and motoneuronal death. Inhibition of autophagy with 3-methyladenine (3MA) reversed these PG effects, indicating that activation of autophagy contributed to the PG neuroprotection. PG effects in vivo were tested by intraperitoneally injecting male G93A-SOD1 Tg mice with different doses of PG (2, 4, or 8 mg/kg) or vehicle from 70 days of age until death. Measurements of motor functions using rota-rod tests showed that the onset of symptoms was not different among groups, but the progression of motor dysfunction was significantly delayed in the PG-treated group compared with the vehicle control group. The average lifespan was also prolonged in the PG-injected group. Histological examinations revealed that PG treatment substantially reduced the death of spinal motoneurons at 14 weeks of age with a concomitant decrease in mutant SOD1 levels. Our results demonstrated that PG delays neurodegenerative progress in G93A-SOD1 transgenic mice, possibly through activation of autophagy in the spinal cord. (C) 2013 Elsevier Inc All rights reserved.	[Kim, Jean; Kim, Tae-Youn; Cho, Kyung-Sook; Kim, Ha Na; Koh, Jae-Young] Univ Ulsan, Coll Med, Neural Injury Res Lab, Seoul 138736, South Korea; [Koh, Jae-Young] Univ Ulsan, Coll Med, Dept Neurol, Seoul 138736, South Korea	Koh, JY (corresponding author), Univ Ulsan, Coll Med, Dept Neurol, 388-1 Poongnap Dong, Seoul 138736, South Korea.	jkko@amc.seoul.kr	Koh, Jae-Young/C-9014-2011	Koh, Jae-Young/0000-0002-4318-495X	National Research Foundation of KoreaNational Research Foundation of Korea [2009-0081487, 2005-0093836]; Asan Institute for Life Sciences [2012-193]	This work was supported by the National Research Foundation of Korea (2009-0081487, 2005-0093836), and by Asan Institute for Life Sciences (2012-193).	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Arciello M, 2010, J NEUROCHEM, V112, P183, DOI 10.1111/j.1471-4159.2009.06441.x; Beretta S, 2003, NEUROBIOL DIS, V13, P213, DOI 10.1016/S0969-9961(03)00043-3; Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Chen S, 2012, BRAIN PATHOL, V22, P110, DOI 10.1111/j.1750-3639.2011.00546.x; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Ferri A, 2006, P NATL ACAD SCI USA, V103, P13860, DOI 10.1073/pnas.0605814103; Fornai F, 2008, P NATL ACAD SCI USA, V105, P2052, DOI 10.1073/pnas.0708022105; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Deniselle MCG, 2012, J NEUROCHEM, V122, P185, DOI 10.1111/j.1471-4159.2012.07753.x; Harraz MM, 2008, J CLIN INVEST, V118, P659, DOI 10.1172/JCI34060; Irwin RW, 2008, ENDOCRINOLOGY, V149, P3167, DOI 10.1210/en.2007-1227; Ishrat T, 2012, NEUROSCIENCE, V210, P442, DOI 10.1016/j.neuroscience.2012.03.008; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Kaur P, 2007, J NEUROSCI RES, V85, P2441, DOI 10.1002/jnr.21370; Kikuchi H, 2006, P NATL ACAD SCI USA, V103, P6025, DOI 10.1073/pnas.0509227103; Kim HN, 2012, NEUROCHEM INT, V60, P125, DOI 10.1016/j.neuint.2011.11.015; Kim J, 2009, NEUROBIOL DIS, V34, P221, DOI 10.1016/j.nbd.2009.01.004; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Li L, 2008, AUTOPHAGY, V4, P290, DOI 10.4161/auto.5524; Luoma JI, 2011, STEROIDS, V76, P845, DOI 10.1016/j.steroids.2011.02.013; Maitra R, 1998, CAN J PHYSIOL PHARM, V76, P909, DOI 10.1139/cjpp-76-9-909; Manjaly ZR, 2010, AMYOTROPH LATERAL SC, V11, P439, DOI 10.3109/17482961003610853; Menzies FM, 2002, BRAIN, V125, P1522, DOI 10.1093/brain/awf167; Meredith GE, 2002, BRAIN RES, V956, P156, DOI 10.1016/S0006-8993(02)03514-X; Mizushima N, 2007, AUTOPHAGY, V3, P542; Morimoto N, 2007, BRAIN RES, V1167, P112, DOI 10.1016/j.brainres.2007.06.045; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Nixon RA, 2007, J CELL SCI, V120, P4081, DOI 10.1242/jcs.019265; Pizzasegola C, 2009, AMYOTROPH LATERAL SC, V10, P221, DOI 10.1080/17482960902803440; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823; Sasaki S, 2011, J NEUROPATH EXP NEUR, V70, P349, DOI 10.1097/NEN.0b013e3182160690; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Sayeed I, 2009, BRAIN RES, V1263, P165, DOI 10.1016/j.brainres.2009.01.045; Song CY, 2012, INT J NEUROSCI, V122, P695, DOI 10.3109/00207454.2012.714430; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Verstraete E, 2012, J NEUROL NEUROSUR PS, V83, P557, DOI 10.1136/jnnp-2011-302021; Wang IF, 2012, P NATL ACAD SCI USA, V109, P15024, DOI 10.1073/pnas.1206362109; Weydt P, 2003, NEUROREPORT, V14, P1051, DOI 10.1097/01.wnr.0000073685.00308.89; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zhang XJ, 2011, AUTOPHAGY, V7, P412, DOI 10.4161/auto.7.4.14541	49	50	51	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	NOV	2013	59						80	85		10.1016/j.nbd.2013.07.011			6	Neurosciences	Neurosciences & Neurology	221MV	WOS:000324663900008	23891729				2021-06-18	
J	Hampshire, A; MacDonald, A; Owen, AM				Hampshire, Adam; MacDonald, Alex; Owen, Adrian M.			Hypoconnectivity and Hyperfrontality in Retired American Football Players	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; FUNCTIONAL ABNORMALITIES; IMPACT; ENCEPHALOPATHY; CONCUSSION; PERMUTATION; EXPOSURE; DISEASE; TESTS	Recent research has raised concerns about the long-term neurological consequences of repetitive concussive and sub-concussive injuries in professional players of American Football. Despite this interest, the neural and psychological status of retired players remains unknown. Here, we evaluated the performances and brain activation patterns of retired National Football League players (NFL alumni) relative to controls using an fMRI-optimised neuropsychological test of executive function. Behaviourally, the NFL alumni showed only modest performance deficits on the executive task. By contrast, they showed pronounced hyperactivation and hypoconnectivity of the dorsolateral frontal and frontopolar cortices. Critically, abnormal frontal-lobe function was correlated with the number of times that NFL alumni reported having been removed from play after head injury and was evident in individual players. These results support the hypothesis that NFL alumni have a heightened probability of developing executive dysfunction and suggest that fMRI provides the most sensitive biomarker of the underlying neural abnormality.	[Hampshire, Adam] Imperial Coll London, Div Brain Sci, Computat Cognit & Clin Neuroimaging Lab, London, England; [Hampshire, Adam; MacDonald, Alex; Owen, Adrian M.] Univ Western Ontario, Ctr Nat Sci, Brain & Mind Inst, London, ON N6A 5B7, Canada	Hampshire, A (corresponding author), Imperial Coll London, Div Brain Sci, Computat Cognit & Clin Neuroimaging Lab, London, England.	adamdghampshire@gmail.com	Owen, Adrian M/B-4997-2015; Williams, Jackie/B-3495-2015		Hubbard Foundation; Canada Excellence Research Chair Program	Funding was provided by the Hubbard Foundation and the Canada Excellence Research Chair Program. Participants were enrolled and scanned by David Hubbard MD at the Applied fMRI Institute.	Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bressler SL, 2011, NEUROIMAGE, V58, P323, DOI 10.1016/j.neuroimage.2010.02.059; Brett M, 8 INT C FUNCT MAPP H; Bullmore ET, 1999, IEEE T MED IMAGING, V18, P32, DOI 10.1109/42.750253; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Grant JE, 2013, EUROPEAN NEUROPSYCHO; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hampshire A, 2012, NEURON, V76, P1225, DOI 10.1016/j.neuron.2012.06.022; Hanna-Pladdy B, 2007, J Neurol Phys Ther, V31, P119; Hayasaka S, 2003, NEUROIMAGE, V20, P2343, DOI 10.1016/j.neuroimage.2003.08.003; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Russo Michael B, 2010, Continuum (Minneap Minn), V16, P161, DOI 10.1212/01.CON.0000391462.98911.26; Seth AK, 2010, J NEUROSCI METH, V186, P262, DOI 10.1016/j.jneumeth.2009.11.020; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Weir Dr, 2009, NATL FOOTBALL LEAGUE; Williams-Gray CH, 2007, J NEUROSCI, V27, P4832, DOI 10.1523/JNEUROSCI.0774-07.2007; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014	32	50	51	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	OCT 17	2013	3								2972	10.1038/srep02972			8	Multidisciplinary Sciences	Science & Technology - Other Topics	237IJ	WOS:000325862500001	24135857	DOAJ Gold, Green Published			2021-06-18	
J	Baxter, D; Sharp, DJ; Feeney, C; Papadopoulou, D; Ham, TE; Jilka, S; Hellyer, PJ; Patel, MC; Bennett, AN; Mistlin, A; McGilloway, E; Midwinter, M; Goldstone, AP				Baxter, David; Sharp, David J.; Feeney, Claire; Papadopoulou, Debbie; Ham, Timothy E.; Jilka, Sagar; Hellyer, Peter J.; Patel, Maneesh C.; Bennett, Alexander N.; Mistlin, Alan; McGilloway, Emer; Midwinter, Mark; Goldstone, Anthony P.			Pituitary Dysfunction after Blast Traumatic Brain Injury: The UK BIOSAP Study	ANNALS OF NEUROLOGY			English	Article							GLUCAGON STIMULATION TESTS; GROWTH-HORMONE; AXONAL INJURY; HYPOPITUITARISM; PREVALENCE; SECRETION; MILITARY; TIME	ObjectivePituitary dysfunction is a recognized consequence of traumatic brain injury (TBI) that causes cognitive, psychological, and metabolic impairment. Hormone replacement offers a therapeutic opportunity. Blast TBI (bTBI) from improvised explosive devices is commonly seen in soldiers returning from recent conflicts. We investigated: (1) the prevalence and consequences of pituitary dysfunction following moderate to severe bTBI and (2) whether it is associated with particular patterns of brain injury. MethodsNineteen male soldiers with moderate to severe bTBI (median age = 28.3 years) and 39 male controls with moderate to severe nonblast TBI (nbTBI; median age = 32.3 years) underwent full dynamic endocrine assessment between 2 and 48 months after injury. In addition, soldiers had structural brain magnetic resonance imaging, including diffusion tensor imaging (DTI), and cognitive assessment. ResultsSix of 19 (32.0%) soldiers with bTBI, but only 1 of 39 (2.6%) nbTBI controls, had anterior pituitary dysfunction (p = 0.004). Two soldiers had hyperprolactinemia, 2 had growth hormone (GH) deficiency, 1 had adrenocorticotropic hormone (ACTH) deficiency, and 1 had combined GH/ACTH/gonadotrophin deficiency. DTI measures of white matter structure showed greater traumatic axonal injury in the cerebellum and corpus callosum in those soldiers with pituitary dysfunction than in those without. Soldiers with pituitary dysfunction after bTBI also had a higher prevalence of skull/facial fractures and worse cognitive function. Four soldiers (21.1%) commenced hormone replacement(s) for hypopituitarism. InterpretationWe reveal a high prevalence of anterior pituitary dysfunction in soldiers suffering moderate to severe bTBI, which was more frequent than in a matched group of civilian moderate to severe nbTBI subjects. We recommend that all patients with moderate to severe bTBI should routinely have comprehensive assessment of endocrine function. Ann Neurol 2013;74:527-536	[Baxter, David; Sharp, David J.; Feeney, Claire; Ham, Timothy E.; Jilka, Sagar; Hellyer, Peter J.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Div Brain Sci, Computat Cognit & Clin Neuroimaging Lab, London W12 0NN, England; [Baxter, David; Midwinter, Mark] Acad Dept Mil Surg & Trauma, Royal Ctr Def Med, Birmingham, W Midlands, England; [Feeney, Claire; Papadopoulou, Debbie; Goldstone, Anthony P.] Charing Cross Hosp, Imperial Coll Healthcare NHS Trust, Imperial Ctr Endocrinol, London, England; [Patel, Maneesh C.] Charing Cross Hosp, Imperial Coll Healthcare NHS Trust, Dept Imaging, London, England; [Bennett, Alexander N.; Mistlin, Alan; McGilloway, Emer] Def Med Rehabil Ctr, Epsom, Surrey, England; [Midwinter, Mark] Univ Leeds, Chapel Allerton Hosp, Acad Sect Musculoskeletal Dis, Leeds, W Yorkshire, England; [Goldstone, Anthony P.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC Clin Sci Ctr, Metab & Mol Imaging Grp, London W12 0NN, England	Goldstone, AP (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC Clin Sci Ctr, Metab & Mol Imaging Grp, Du Cane Rd, London W12 0NN, England.	tony.goldstone@imperial.ac.uk	Midwinter, Mark J/P-6264-2015; Sharp, David J/A-2119-2013; Midwinter, Mark/AAB-6527-2019; Hellyer, Peter J/F-7112-2013	Midwinter, Mark J/0000-0003-1836-7137; Midwinter, Mark/0000-0003-1836-7137; Hellyer, Peter J/0000-0002-5139-3401; Goldstone, Anthony/0000-0001-8179-7071	UK Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute for Health Research (NIHR)National Institute for Health Research (NIHR) [NIHR-RP-011-048]; Imperial College Healthcare Charity [7006/R21U]; Royal Centre for Defence Medicine; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1110783, MR/K023926/1, G0701951] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	This study was supported by the UK Medical Research Council (MRC), National Institute for Health Research (NIHR, ref. NIHR-RP-011-048), Imperial College Healthcare Charity (ref. 7006/R21U), and the Royal Centre for Defence Medicine. D.J.S. is supported by the MRC (Clinician Scientist Fellowship) and NIHR, A. P. G. by the MRC, and C. F. by Imperial College Healthcare Charity.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Cegla J, 2013, CLIN ENDOCRINOL, V78, P738, DOI 10.1111/cen.12043; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cherrier MM, 2009, FRONT HORM RES, V37, P150, DOI 10.1159/000176051; Chesser GS, 2012, AFGHANISTAN CASUALTI; Colao A, 2009, J CLIN ENDOCR METAB, V94, P4414, DOI 10.1210/jc.2009-1134; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Grossman AB, 2010, J CLIN ENDOCR METAB, V95, P4855, DOI 10.1210/jc.2010-0982; Guerrero AF, 2010, MIL MED, V175, P574, DOI 10.7205/MILMED-D-09-00189; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kokshoorn NE, 2011, EUR J ENDOCRINOL, V165, P225, DOI 10.1530/EJE-11-0365; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Leong KS, 2001, CLIN ENDOCRINOL, V54, P463, DOI 10.1046/j.1365-2265.2001.01169.x; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Molitch ME, 2011, J CLIN ENDOCR METAB, V96, P1587, DOI 10.1210/jc.2011-0179; Pervanidou P, 2010, PROG BRAIN RES, V182, P149, DOI 10.1016/S0079-6123(10)82005-9; Ruff RL, 2012, JAMA-J AM MED ASSOC, V308, P2032, DOI 10.1001/jama.2012.14008; Ruff RL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000312; Salvatori R, 2005, JAMA-J AM MED ASSOC, V294, P2481, DOI 10.1001/jama.294.19.2481; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Tanielian T, 2008, INVISIBLE WOUNDS WAR; van Dam PS, 2005, HORM RES, V64, P109, DOI 10.1159/000089326; van Liempt S, 2011, PSYCHONEUROENDOCRINO, V36, P1361, DOI 10.1016/j.psyneuen.2011.03.009; Vuong C, 2010, ENDOCR REV, V31, P98, DOI 10.1210/er.2009-0009; Webb S M, 2008, J Endocrinol Invest, V31, P52; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yuen KCJ, 2009, J CLIN ENDOCR METAB, V94, P2702, DOI 10.1210/jc.2009-0299	35	50	51	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	OCT	2013	74	4					527	536		10.1002/ana.23958			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	257FN	WOS:000327369100007	23794460	Other Gold, Green Published			2021-06-18	
J	Abo-Zaid, G; Guo, BL; Deeks, JJ; Debray, TPA; Steyerberg, EW; Moons, KGM; Riley, RD				Abo-Zaid, Ghada; Guo, Boliang; Deeks, Jonathan J.; Debray, Thomas P. A.; Steyerberg, Ewout W.; Moons, Karel G. M.; Riley, Richard David			Individual participant data meta-analyses should not ignore clustering	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						Individual participant data meta-analysis; Individual patient data; Evidence synthesis; Cluster; Simulation; Binary outcome; Pooled analysis	DEEP-VEIN THROMBOSIS; RANDOMIZED CONTROLLED-TRIALS; LINEAR MIXED-MODEL; PATIENT DATA; COVARIATE ADJUSTMENT; CLINICAL-TRIALS; AGGREGATE DATA; D-DIMER; MANAGEMENT; FRAMEWORK	Objectives: Individual participant data (IPD) meta-analyses often analyze their IPD as if coming from a single study. We compare this approach with analyses that rather account for clustering of patients within studies. Study Design and Setting: Comparison of effect estimates from logistic regression models in real and simulated examples. Results: The estimated prognostic effect of age in patients with traumatic brain injury is similar, regardless of whether clustering is accounted for. However, a family history of thrombophilia is found to be a diagnostic marker of deep vein thrombosis [odds ratio, 1.30; 95% confidence interval (CI): 1.00, 1.70; P = 0.05] when clustering is accounted for but not when it is ignored (odds ratio, 1.06; 95% CI: 0.83, 1.37; P = 0.64). Similarly, the treatment effect of nicotine gum on smoking cessation is severely attenuated when clustering is ignored (odds ratio, 1.40; 95% CI: 1.02, 1.92) rather than accounted for (odds ratio, 1.80; 95% CI: 1.29, 2.52). Simulations show models accounting for clustering perform consistently well, but downwardly biased effect estimates and low coverage can occur when ignoring clustering. Conclusion: Researchers must routinely account for clustering in IPD meta-analyses; otherwise, misleading effect estimates and conclusions may arise. (C) 2013 Elsevier Inc. All rights reserved.	[Abo-Zaid, Ghada] Univ Exeter, Royal Cornwall Hosp, European Ctr Environm & Human Hlth, Peninsula Coll Med & Dent, Truro TR1 3HD, Cornwall, England; [Guo, Boliang] Univ Nottingham, Sch Community Hlth Sci, Fac Med & Hlth Sci, Nottingham NG8 1BB, England; [Deeks, Jonathan J.] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England; [Debray, Thomas P. A.; Moons, Karel G. M.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands	Riley, RD (corresponding author), Univ Birmingham, Sch Hlth & Populat Sci, Public Hlth Bldg, Birmingham B15 2TT, W Midlands, England.	r.d.riley@bham.ac.uk	Steyerberg, Ewout W/C-1509-2018; Deeks, Jon/AAV-5745-2020; Riley, Richard David/ABE-5877-2020; GUO, Boliang/ABG-6506-2020; Riley, Richard/G-2406-2011; Debray, Thomas/J-7413-2012; Abo-Zaid, Ghada/AAY-7516-2020	Steyerberg, Ewout W/0000-0002-7787-0122; Deeks, Jon/0000-0002-8850-1971; Riley, Richard David/0000-0001-8699-0735; GUO, Boliang/0000-0002-1844-705X; Debray, Thomas/0000-0002-1790-2719; 	MRC Midlands Hub for Trials Methodology Research, at the University of Birmingham (Medical Research Council) [G0800808]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800808] Funding Source: researchfish	Although undertaking this work, G.A.-Z., J.J.D., and R.D.R. were supported by funding from the MRC Midlands Hub for Trials Methodology Research, at the University of Birmingham (Medical Research Council grant ID G0800808).	Abo-Zaid G, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-56; Ahmed I, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d7762; Altman Douglas G, 2002, BMC Med Res Methodol, V2, P3, DOI 10.1186/1471-2288-2-3; Anderson DR, 2003, J THROMB HAEMOST, V1, P645, DOI 10.1046/j.1538-7836.2003.00131.x; Bland J Martin, 2004, BMC Med Res Methodol, V4, P21, DOI 10.1186/1471-2288-4-21; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Chu HT, 2006, J CLIN EPIDEMIOL, V59, P1331, DOI 10.1016/j.jclinepi.2006.06.011; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; GAIL MH, 1984, BIOMETRIKA, V71, P431; Greenland S, 1999, STAT SCI, V14, P29; Hamza TH, 2008, J CLIN EPIDEMIOL, V61, P41, DOI 10.1016/j.jclinepi.2007.03.016; Hernandez AV, 2004, J CLIN EPIDEMIOL, V57, P454, DOI 10.1016/j.jclinepi.2003.09.014; Higgins JPT, 2001, STAT MED, V20, P2219, DOI 10.1002/sim.918; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jackson D, 2009, STAT MED, V28, P338, DOI 10.1002/sim.3487; Jones AP, 2009, CLIN TRIALS, V6, P16, DOI 10.1177/1740774508100984; Kraaijenhagen RA, 2002, ARCH INTERN MED, V162, P907, DOI 10.1001/archinte.162.8.907; Lee KJ, 2005, CLIN TRIALS, V2, P163, DOI 10.1191/1740774505cn082oa; MANTEL N, 1959, J NATL CANCER I, V22, P719; Mathew T, 1999, BIOMETRICS, V55, P1221, DOI 10.1111/j.0006-341X.1999.01221.x; Mathew T, 2010, BIOMETRICAL J, V52, P271, DOI 10.1002/bimj.200900143; Olkin I, 1998, BIOMETRICS, V54, P317, DOI 10.2307/2534018; Peters TJ, 2003, INT J EPIDEMIOL, V32, P840, DOI 10.1093/ije/dyg228; Rice VH, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001188.pub3; Riley RD, 2008, STAT MED, V27, P1870, DOI 10.1002/sim.3165; Riley RD, 2007, J CLIN EPIDEMIOL, V60, P431, DOI 10.1016/j.jclinepi.2006.09.009; Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221; Riley RD, 2008, STAT MED, V27, P6111, DOI 10.1002/sim.3441; ROBINSON LD, 1991, INT STAT REV, V59, P227, DOI 10.2307/1403444; Simmonds MC, 2005, CLIN TRIALS, V2, P209, DOI 10.1191/1740774505cn087oa; Smith CT, 2007, CLIN TRIALS, V4, P621, DOI 10.1177/1740774507085276; Smith CT, 2005, STAT MED, V24, P1307, DOI 10.1002/sim.2050; Sterne JAC, 2009, METAANALYSIS STATA U; Stevens SM, 2004, ANN INTERN MED, V140, P985, DOI 10.7326/0003-4819-140-12-200406150-00007; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; Stewart LA, 2002, EVAL HEALTH PROF, V25, P76, DOI 10.1177/0163278702025001006; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; Stijnen T, 2010, STAT MED, V29, P3046, DOI 10.1002/sim.4040; Toll DB, 2008, FAM PRACT, V25, P3, DOI 10.1093/fampra/cmm075; Toll DB, 2006, J FAM PRACTICE, V55, P613; Turner EL, 2012, J CLIN EPIDEMIOL, V65, P474, DOI 10.1016/j.jclinepi.2011.08.012; Turner RM, 2000, STAT MED, V19, P3417, DOI 10.1002/1097-0258(20001230)19:24<3417::AID-SIM614>3.3.CO;2-C; Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153; Whitehead A, 2001, STAT MED, V20, P2243, DOI 10.1002/sim.919; Whitehead A., 2002, METAANALYSIS CONTROL; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	47	50	50	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	AUG	2013	66	8					865	873		10.1016/j.jclinepi.2012.12.017			9	Health Care Sciences & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	188PZ	WOS:000322207300008	23651765	Other Gold, Green Published			2021-06-18	
J	Dal Monte, O; Krueger, F; Solomon, JM; Schintu, S; Knutson, KM; Strenziok, M; Pardini, M; Leopold, A; Raymont, V; Grafman, J				Dal Monte, Olga; Krueger, Frank; Solomon, Jeffrey M.; Schintu, Selene; Knutson, Kristine M.; Strenziok, Maren; Pardini, Matteo; Leopold, Anne; Raymont, Vanessa; Grafman, Jordan			A voxel-based lesion study on facial emotion recognition after penetrating brain injury	SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE			English	Article						facial emotion recognition; voxel-based lesion symptom mapping; labeling task; basic emotions; traumatic brain injury	ANTERIOR TEMPORAL INVOLVEMENT; IMPAIRED RECOGNITION; FUNCTIONAL NEUROANATOMY; COGNITIVE-ABILITIES; PREFRONTAL CORTEX; RIGHT-HEMISPHERE; FRONTAL-CORTEX; HUMAN AMYGDALA; NEURAL BASES; EXPRESSIONS	The ability to read emotions in the face of another person is an important social skill that can be impaired in subjects with traumatic brain injury (TBI). To determine the brain regions that modulate facial emotion recognition, we conducted a whole-brain analysis using a well-validated facial emotion recognition task and voxel-based lesion symptom mapping (VLSM) in a large sample of patients with focal penetrating TBIs (pTBIs). Our results revealed that individuals with pTBI performed significantly worse than normal controls in recognizing unpleasant emotions. VLSM mapping results showed that impairment in facial emotion recognition was due to damage in a bilateral fronto-temporo-limbic network, including medial prefrontal cortex (PFC), anterior cingulate cortex, left insula and temporal areas. Beside those common areas, damage to the bilateral and anterior regions of PFC led to impairment in recognizing unpleasant emotions, whereas bilateral posterior PFC and left temporal areas led to impairment in recognizing pleasant emotions. Our findings add empirical evidence that the ability to read pleasant and unpleasant emotions in other people's faces is a complex process involving not only a common network that includes bilateral fronto-temporo-limbic lobes, but also other regions depending on emotional valence.	[Dal Monte, Olga; Schintu, Selene; Knutson, Kristine M.; Raymont, Vanessa; Grafman, Jordan] NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Dal Monte, Olga] Univ Turin, Dept Neuropsychol, I-10123 Turin, Italy; [Dal Monte, Olga; Schintu, Selene] Henry M Jackson Fdn, Rockville, MD 20852 USA; [Krueger, Frank; Strenziok, Maren] George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; [Solomon, Jeffrey M.] Expert Image Anal LLC, Potomac, MD 20859 USA; [Pardini, Matteo] Univ Genoa, Dept Neurosci Ophthalmol & Genet, I-16132 Genoa, Italy; [Leopold, Anne] Univ Utrecht, Social & Hlth Psychol Dept, NL-3508 Utrecht, Netherlands; [Raymont, Vanessa] Johns Hopkins Univ, Dept Radiol, Baltimore, MD 21287 USA; [Raymont, Vanessa] Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW72WY, England; [Grafman, Jordan] Kessler Fdn Res Ctr, Traumat Brain Injury Res Lab, W Orange, NJ 07052 USA	Krueger, F (corresponding author), George Mason Univ, Dept Mol Neurosci, 4400 Univ Dr,Mail Stop 2A1, Fairfax, VA 22030 USA.	fkrueger@gmu.edu	Dal Monte, Olga/P-3759-2018; Pardini, Matteo/F-8414-2010; Schintu, Selene/ABF-7032-2020	Dal Monte, Olga/0000-0002-7823-4769; Pardini, Matteo/0000-0002-4740-1982; Schintu, Selene/0000-0002-6362-3905; Grafman, Jordan H./0000-0001-8645-4457; Knutson, Kristine/0000-0003-4626-4514	National Naval Medical Center	The authors are grateful to all the Vietnam veterans who participated in this study. Without their long-term commitment to improving the health care of veterans, this study could not have been completed. We thank the National Naval Medical Center for their support and provision of their facilities as well as S. Bonifant, B. Cheon, C. Ngo, A. Greathouse, K. Reding and G. Tasick for their invaluable help with the testing of participants and organization of this study. For further information about the Vietnam Head Injury Study, please contact Dr. Grafman at: jgrafman@kesslerfoundation.org	Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056; Adolphs R, 1996, J NEUROSCI, V16, P7678; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P516, DOI 10.1037//0894-4105.15.4.516; ADOLPHS R, 1995, J NEUROSCI, V15, P5879; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; AHERN GL, 1979, NEUROPSYCHOLOGIA, V17, P693, DOI 10.1016/0028-3932(79)90045-9; Alves NT, 2009, LATERALITY, V14, P256, DOI 10.1080/13576500802362927; Anderson AK, 2000, PSYCHOL SCI, V11, P106, DOI 10.1111/1467-9280.00224; Anderson ND, 2011, J COGNITIVE NEUROSCI, V23, P3804, DOI 10.1162/jocn_a_00050; Beck AT., 1996, BECK DEPRESSION INVE, V2; Beer JS, 2003, J PERS SOC PSYCHOL, V85, P594, DOI 10.1037/0022-3514.85.4.594; Benedetti F, 2009, SCHIZOPHR RES, V114, P154, DOI 10.1016/j.schres.2009.06.021; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883; BLONDER LX, 1991, BRAIN, V114, P1115, DOI 10.1093/brain/114.3.1115; Bora E, 2008, PSYCHIAT RES, V160, P23, DOI 10.1016/j.psychres.2007.05.017; BOROD JC, 1980, NEUROPSYCHOLOGIA, V18, P237, DOI 10.1016/0028-3932(80)90070-6; BOROD JC, 1990, J COMMUN DISORD, V23, P247, DOI 10.1016/0021-9924(90)90003-H; Borod JC, 1998, NEUROPSYCHOLOGY, V12, P446, DOI 10.1037/0894-4105.12.3.446; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586; Carver CS, 2001, PERS SOC PSYCHOL REV, V5, P345, DOI 10.1207/S15327957PSPR0504_4; Clark US, 2010, J INT NEUROPSYCH SOC, V16, P1127, DOI 10.1017/S1355617710001037; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; DAVIDSON RJ, 1992, BRAIN COGNITION, V20, P125, DOI 10.1016/0278-2626(92)90065-T; Davidson RJ, 2000, MED RAD DIA IMG, P487; Decety J, 2006, THESCIENTIFICWORLDJO, V6, P1146, DOI 10.1100/tsw.2006.221; Decety J, 2010, DEV NEUROSCI-BASEL, V32, P257, DOI 10.1159/000317771; Derntl B, 2011, SOC NEUROSCI-UK, V6, P482, DOI 10.1080/17470919.2011.579800; Drevets WC, 1998, COGNITION EMOTION, V12, P353, DOI 10.1080/026999398379646; EKMAN P, 1992, PSYCHOL REV, V99, P550, DOI 10.1037/0033-295X.99.3.550; Ekman P., 1976, PICTURES FACIAL AFFE; Eslinger PJ, 2002, CURR OPIN NEUROL, V15, P91, DOI 10.1097/00019052-200202000-00014; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Frank MG, 2001, J PERS SOC PSYCHOL, V80, P75, DOI 10.1037/0022-3514.80.1.75; Fusar-Poli P, 2009, J PSYCHIATR NEUROSCI, V34, P418; GEORGE MS, 1993, J NEUROPSYCH CLIN N, V5, P384; Geva S, 2011, BRAIN, V134, P3071, DOI 10.1093/brain/awr232; Glascher J, 2010, P NATL ACAD SCI USA, V107, P4705, DOI 10.1073/pnas.0910397107; Glascher J, 2009, NEURON, V61, P681, DOI 10.1016/j.neuron.2009.01.026; Goodkind MS, 2012, HUM BRAIN MAPP, V33, P753, DOI 10.1002/hbm.21251; Gorno-Tempini ML, 2001, NEUROIMAGE, V14, P465, DOI 10.1006/nimg.2001.0811; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Grossmann T, 2007, EUR J NEUROSCI, V25, P909, DOI 10.1111/j.1460-9568.2007.05379.x; Habel U, 2007, NEUROPSYCHOLOGIA, V45, P2369, DOI 10.1016/j.neuropsychologia.2007.01.023; Hall J, 2004, BRIT J PSYCHIAT, V185, P169, DOI 10.1192/bjp.185.2.169; Hariri AR, 2000, NEUROREPORT, V11, P43, DOI 10.1097/00001756-200001170-00009; Harmer CJ, 2001, NAT NEUROSCI, V4, P17, DOI 10.1038/82854; Heberlein AS, 2008, J COGNITIVE NEUROSCI, V20, P721, DOI 10.1162/jocn.2008.20049; Heberlein AS, 2004, J COGNITIVE NEUROSCI, V16, P1143, DOI 10.1162/0898929041920423; Heller W, 1998, CURR DIR PSYCHOL SCI, V7, P26, DOI 10.1111/1467-8721.ep11521823; Henry JD, 2009, J INT NEUROPSYCH SOC, V15, P277, DOI 10.1017/S1355617709090195; Henson RNA, 2002, NEUROIMAGE, V15, P83, DOI 10.1006/nimg.2001.0940; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ille R, 2011, J PSYCHIATR NEUROSCI, V36, P383, DOI 10.1503/jpn.100143; Izard C., 1971, FACE EMOTION; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kaplan E., 2001, Boston naming test; Kessels RPC, 2007, BEHAV NEUROL, V18, P31, DOI 10.1155/2007/868431; Kimberg DY, 2007, J COGNITIVE NEUROSCI, V19, P1067, DOI 10.1162/jocn.2007.19.7.1067; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; Koenigs M, 2010, J NEUROSCI, V30, P16041, DOI 10.1523/JNEUROSCI.3745-10.2010; Koenigs M, 2008, J NEUROSCI, V28, P12341, DOI 10.1523/JNEUROSCI.2324-08.2008; Krueger F, 2009, P NATL ACAD SCI USA, V106, P22486, DOI 10.1073/pnas.0912568106; LABARBERA JD, 1976, CHILD DEV, V47, P535, DOI 10.2307/1128816; Leopold A, 2012, SOC COGN AFFECT NEUR, V7, P871, DOI 10.1093/scan/nsr071; Mah L, 2004, AM J PSYCHIAT, V161, P1247, DOI 10.1176/appi.ajp.161.7.1247; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Marinkovic K, 2000, COGN NEUROPSYCHOL, V17, P187, DOI 10.1080/026432900380562; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McNeil M. M., 1994, REVISED TOKEN TEST; Miller LA, 2012, BEHAV NEUROL, V25, P53, DOI [10.3233/BEN-2012-0349, 10.1155/2012/683052]; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Murphy FC, 2003, COGN AFFECT BEHAV NE, V3, P207, DOI 10.3758/CABN.3.3.207; Nakamura K, 1999, J NEUROPHYSIOL, V82, P1610; Narumoto J, 2000, NEUROREPORT, V11, P2571, DOI 10.1097/00001756-200008030-00044; Nelson CA, 1996, DEV PSYCHOBIOL, V29, P577; Nelson CA, 2001, INFANT CHILD DEV, V10, P3, DOI 10.1002/icd.239; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Philippi CL, 2009, J NEUROSCI, V29, P15089, DOI 10.1523/JNEUROSCI.0796-09.2009; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Rosen HJ, 2006, NEUROPSYCHOLOGIA, V44, P365, DOI 10.1016/j.neuropsychologia.2005.06.012; Schwartz MF, 2009, BRAIN, V132, P3411, DOI 10.1093/brain/awp284; SILBERMAN EK, 1986, BRAIN COGNITION, V5, P322, DOI 10.1016/0278-2626(86)90035-7; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; Sprengelmeyer R, 1998, P ROY SOC B-BIOL SCI, V265, P1927, DOI 10.1098/rspb.1998.0522; Szekely E, 2011, EMOTION, V11, P425, DOI 10.1037/a0022587; Tsuchida A, 2012, CEREB CORTEX, V22, P2904, DOI 10.1093/cercor/bhr370; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vuilleumier P, 2001, NEURON, V30, P829, DOI 10.1016/S0896-6273(01)00328-2; Wager TD, 2003, NEUROIMAGE, V19, P513, DOI 10.1016/S1053-8119(03)00078-8; Walker GM, 2011, BRAIN LANG, V117, P110, DOI 10.1016/j.bandl.2010.09.008; Warrington E., 1991, VISUAL OBJECT SPACE; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Whalen PJ, 1998, J NEUROSCI, V18, P411; Wiedemann G, 1999, ARCH GEN PSYCHIAT, V56, P78, DOI 10.1001/archpsyc.56.1.78; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P113, DOI 10.1080/13803390902806543; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; Young A., 2002, FACIAL EXPRESSIONS E	107	50	50	0	37	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1749-5016	1749-5024		SOC COGN AFFECT NEUR	Soc. Cogn. Affect. Neurosci.	AUG	2013	8	6					632	639		10.1093/scan/nss041			8	Neurosciences; Psychology; Psychology, Experimental	Neurosciences & Neurology; Psychology	205OU	WOS:000323454700004	22496440	Green Published, Bronze			2021-06-18	
J	Buckley, TA; Munkasy, BA; Tapia-Lovler, TG; Wikstrom, EA				Buckley, Thomas A.; Munkasy, Barry A.; Tapia-Lovler, Tiffen G.; Wikstrom, Erik A.			Altered gait termination strategies following a concussion	GAIT & POSTURE			English	Article						Concussion; Gait termination; Postural control	ANKLE INSTABILITY; DEFICITS	The purpose was to determine if planned gait termination can identify acute and lingering motor control strategy alterations in post-concussion individuals. Controls completed two standard gait and five planned gait termination trials once while concussed individuals were tested on Day-1 and Day-10 post-concussion. Dependent variables included gait velocity and normalized, relative to standard gait, peak propulsive and braking forces. Control and only Day-1 post-concussion gait velocity differed. Normalized peak propulsive and braking forces were altered on both Day-1 and Day-10. Altered propulsive and braking forces persisted despite all concussion participants achieving their baseline values on standard concussion clinical tests. Thus gait termination can detect both acute and lingering motor control strategy alterations following concussion. (C) 2013 Elsevier B.V. All rights reserved.	[Buckley, Thomas A.; Munkasy, Barry A.; Tapia-Lovler, Tiffen G.] Georgia So Univ, Dept Hlth & Kinesiol, Statesboro, GA 30460 USA; [Wikstrom, Erik A.] Univ N Carolina, Dept Kinesiol, Charlotte, NC 28223 USA	Buckley, TA (corresponding author), Georgia So Univ, Dept Hlth & Kinesiol, Box 8076, Statesboro, GA 30460 USA.	TBuckley@Georgiasouthern.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150; Wikstrom, Erik/0000-0002-7260-0502	National Institute of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R15NS135 070744-01A1]; Georgia Southern University Faculty Research Committee; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS070744] Funding Source: NIH RePORTER	This project was funded by the National Institute of Health/National Institute of Neurological Disorders and Stroke (1R15NS135 070744-01A1) and the Georgia Southern University Faculty Research Committee. The funding source had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.	Bishop M, 2006, NEUROSCI LETT, V397, P240, DOI 10.1016/j.neulet.2005.12.031; Bishop M, 2004, GAIT POSTURE, V20, P134, DOI 10.1016/j.gaitpost.2003.07.004; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; O'Kane FW, 2003, GAIT POSTURE, V17, P170, DOI 10.1016/S0966-6362(02)00104-2; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Perry SD, 2001, BRAIN RES, V913, P27, DOI 10.1016/S0006-8993(01)02748-2; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Wang JJ, 2009, J NEURAL TRANSM, V116, P1087, DOI 10.1007/s00702-009-0269-y; Wikstrom EA, 2012, CLIN BIOMECH, V27, P619, DOI 10.1016/j.clinbiomech.2012.01.001; Wikstrom EA, 2010, MED SCI SPORT EXER, V42, P197, DOI 10.1249/MSS.0b013e3181ad1e2f	15	50	50	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	JUL	2013	38	3					549	551		10.1016/j.gaitpost.2013.02.008			3	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	216KZ	WOS:000324283600034	23489951	Green Accepted			2021-06-18	
J	Fife, TD; Giza, C				Fife, Terry D.; Giza, Christopher			Posttraumatic Vertigo and Dizziness	SEMINARS IN NEUROLOGY			English	Article						postconcussive syndrome; postconcussive dizziness; vertigo; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PAROXYSMAL POSITIONAL VERTIGO; POST-CONCUSSION SYNDROME; MINOR HEAD-INJURY; TEMPORAL BONE-FRACTURES; POSTCONCUSSION SYNDROME; CLINICAL CHARACTERISTICS; CEREBELLAR INJURY; MENIERES-DISEASE; STEM INJURY	Dizziness and vertigo are common symptoms following minor head trauma. Although these symptoms resolve within a few weeks in many patients, in some the symptoms may last much longer and impede ability to return to work and full functioning. Causes of persisting or recurrent dizziness may include benign paroxysmal positional vertigo, so-called labyrinthine concussion, unilateral vestibular nerve injury or damage to the utricle or saccule, perilymphatic fistula, or less commonly traumatic endolymphatic hydrops. Some dizziness after head trauma is due to nonlabyrinthine causes that may be related to structural or microstructural central nervous system injury or to more complicated interactions between migraine, generalized anxiety, and issues related to patients self-perception, predisposing psychological states, and environmental and stress-related factors. In this article, the authors review both the inner ear causes of dizziness after concussion and also the current understanding of chronic postconcussive dizziness when no peripheral vestibular cause can be identified.	[Fife, Terry D.] Barrow Neurol Inst, Phoenix, AZ 85013 USA; [Fife, Terry D.] Univ Arizona, Dept Neurol, Coll Med, Phoenix, AZ USA; [Giza, Christopher] Mattel Childrens Hosp UCLA, Div Neurol, Dept Pediat, Los Angeles, CA USA; [Giza, Christopher] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Fife, TD (corresponding author), Barrow Neurol Inst, 240 W Thomas Rd,Suite 301, Phoenix, AZ 85013 USA.	tfife@email.arizona.edu	Fife, Terry/M-1135-2019				Agrup C, 2007, J NEUROL NEUROSUR PS, V78, P114, DOI 10.1136/jnnp.2006.092064; Ahn SK, 2011, J TRAUMA, V70, P442, DOI 10.1097/TA.0b013e3181d0c3d9; Balaban CD, 2011, J VESTIBUL RES-EQUIL, V21, P315, DOI 10.3233/VES-2011-0428; Best C, 2006, J NEUROL NEUROSUR PS, V77, P658, DOI 10.1136/jnnp.2005.072934; Bisdorff Alexandre R, 2011, Ther Adv Neurol Disord, V4, P183, DOI 10.1177/1756285611401647; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; CANNON CR, 1983, ARCH OTOLARYNGOL, V109, P285; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chew BG, 2012, J NEUROSURG, V117, P722, DOI 10.3171/2012.6.JNS111736; Curthoys IS, 2013, SEMIN NEUROL, V33, P231, DOI 10.1055/s-0033-1354595; Curthoys IS, 2000, CURR OPIN NEUROL, V13, P27, DOI 10.1097/00019052-200002000-00006; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; de Guise E, 2010, CLIN NEUROPSYCHOL, V24, P1113, DOI 10.1080/13854046.2010.506199; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; DiBiase P, 1997, OTOLARYNG CLIN N AM, V30, P1117; Donaldson CJ, 2010, OTOLARYNG HEAD NECK, V143, P820, DOI 10.1016/j.otohns.2010.09.024; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Fife TD, 2013, ENCY NEUROLOGICAL SC; Fife Terry D, 2012, Continuum (Minneap Minn), V18, P1060, DOI 10.1212/01.CON.0000418376.80099.24; Fife TD, 2009, SEMIN NEUROL, V29, P500, DOI 10.1055/s-0029-1241041; Fotuhi M, 2009, J NEUROL, V256, P711, DOI 10.1007/s00415-009-5050-5; Fourtassi M, 2011, CLIN NEUROL NEUROSUR, V113, P716, DOI 10.1016/j.clineuro.2011.07.010; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; GLASSCOCK ME, 1992, AM J OTOL, V13, P333; GOODHILL V, 1980, J LARYNGOL OTOL, V94, P123, DOI 10.1017/S0022215100088563; Goodman B, 2013, NEUROL, V80; Gordon CR, 2004, ARCH NEUROL-CHICAGO, V61, P1590, DOI 10.1001/archneur.61.10.1590; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kleffelgaard I, 2012, DISABIL REHABIL, V34, P788, DOI 10.3109/09638288.2011.619624; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; LINDSAY JR, 1970, ANN OTO RHINOL LARYN, V79, P699, DOI 10.1177/000348947007900403; Liu HJ, 2012, ACTA OTO-LARYNGOL, V132, P803, DOI 10.3109/00016489.2012.657359; Loder E, 2012, HEADACHE, V52, P930, DOI 10.1111/j.1526-4610.2012.02185.x; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; Macleod AD, 2010, MED HYPOTHESES, V74, P1033, DOI 10.1016/j.mehy.2010.01.002; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Manzari L, 2012, EUR ARCH OTO-RHINO-L, V269, P2441, DOI 10.1007/s00405-012-2127-z; Margulies S, 2000, J CLIN NEUROSCI, V7, P495, DOI 10.1054/jocn.1999.0773; Marzo SJ, 2004, LARYNGOSCOPE, V114, P1720, DOI 10.1097/00005537-200410000-00008; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Middleton K, 2010, CLIN J SPORT MED, V20, P491, DOI 10.1097/JSM.0b013e3181fac088; Mihalik JP, 2013, AM J SPORT MED, V41, P1490, DOI 10.1177/0363546513487982; MONSELL EM, 1995, OTOLARYNG HEAD NECK, V113, P181, DOI 10.1016/S0194-5998(95)70102-8; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Park E, 2007, PROG BRAIN RES, V161, P327, DOI 10.1016/S0079-6123(06)61023-6; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; PULEC JL, 1972, LARYNGOSCOPE, V82, P1703, DOI 10.1288/00005537-197209000-00011; Rowlands RG, 2009, J LARYNGOL OTOL, V123, P182, DOI 10.1017/S0022215108002569; Segal S, 2003, OTOL NEUROTOL, V24, P387, DOI 10.1097/00129492-200305000-00007; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Smitherman TA, 2013, HEADACHE, V53, P775, DOI 10.1111/head.12063; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Staab JP, 2007, ARCH OTOLARYNGOL, V133, P170, DOI 10.1001/archotol.133.2.170; Staab JP, 2003, LARYNGOSCOPE, V113, P1714, DOI 10.1097/00005537-200310000-00010; Ulug T, 2006, J OTOLARYNGOL, V35, P380, DOI 10.2310/7070.2006.0069; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; WEISSMAN JL, 1992, AM J NEURORADIOL, V13, P1183; Wood RL, 2011, BRAIN INJURY, V25, P1296, DOI 10.3109/02699052.2011.624569; Zakzanis KK, 2011, ARCH CLIN NEUROPSYCH, V26, P461, DOI 10.1093/arclin/acr021; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	74	50	51	0	30	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	JUL	2013	33	3					238	243		10.1055/s-0033-1354599			6	Clinical Neurology	Neurosciences & Neurology	220ZC	WOS:000324625300011	24057827				2021-06-18	
J	Patz, S; Trattnig, C; Grunbacher, G; Ebner, B; Gully, C; Novak, A; Rinner, B; Leitinger, G; Absenger, M; Tomescu, OA; Thallinger, GG; Fasching, U; Wissa, S; Archelos-Garcia, J; Schafer, U				Patz, Silke; Trattnig, Christa; Gruenbacher, Gerda; Ebner, Birgit; Guelly, Christian; Novak, Alexandra; Rinner, Beate; Leitinger, Gerd; Absenger, Markus; Tomescu, Oana A.; Thallinger, Gerhard G.; Fasching, Ulrike; Wissa, Sonja; Archelos-Garcia, Juan; Schaefer, Ute			More than Cell Dust: Microparticles Isolated from Cerebrospinal Fluid of Brain Injured Patients Are Messengers Carrying mRNAs, miRNAs, and Proteins	JOURNAL OF NEUROTRAUMA			English	Article						cerebrospinal fluid; microparticles; microRNA; traumatic brain injury	MICROMETER-SIZED PARTICLES; PERIPHERAL-BLOOD; MICRORNA EXPRESSION; NEURAL PROGENITORS; BETA-ENDORPHIN; NERVOUS-SYSTEM; TUMOR-GROWTH; MICROVESICLES; COMMUNICATION; LUMBAR	Microparticles are cell-derived, membrane-sheathed structures that are believed to shuttle proteins, mRNA, and miRNA to specific local or remote target cells. To date best described in blood, we now show that cerebrospinal fluid (CSF) contains similar structures that can deliver RNAs and proteins to target cells. These are, in particular, molecules associated with neuronal RNA granules and miRNAs known to regulate neuronal processes. Small RNA molecules constituted 50% of the shuttled ribonucleic acid. Using microarray analysis, we identified 81 mature miRNA molecules in CSF microparticles. Microparticles from brain injured patients were more abundant than in non-injured subjects and contained distinct genetic information suggesting that they play a role in the adaptive response to injury. Notably, miR-9 and miR-451 were differentially packed into CSF microparticles derived from patients versus non-injured subjects. We confirmed the transfer of genetic material from CSF microparticles to adult neuronal stem cells in vitro and a subsequent microRNA-specific repression of distinct genes. This first indication of a regulated transport of functional genetic material in human CSF may facilitate the diagnosis and analysis of cerebral modulation in an otherwise inaccessible organ.	[Patz, Silke; Trattnig, Christa; Gruenbacher, Gerda; Fasching, Ulrike; Schaefer, Ute] Med Univ Graz, Res Unit Expt Neurotraumatol, Dept Neurosurg, A-8036 Graz, Austria; [Ebner, Birgit; Guelly, Christian; Novak, Alexandra; Rinner, Beate; Absenger, Markus] Med Univ Graz, Med Res Ctr, A-8036 Graz, Austria; [Leitinger, Gerd] Med Univ Graz, Inst Cell Biol Histol & Embryol, A-8036 Graz, Austria; [Tomescu, Oana A.; Thallinger, Gerhard G.] Med Univ Graz, Inst Genom & Bioinformat, ACIB, A-8036 Graz, Austria; [Wissa, Sonja] Med Univ Graz, Dept Neurosurg, A-8036 Graz, Austria; [Archelos-Garcia, Juan] Med Univ Graz, Dept Neurol, Clin Div Gen Neurol, A-8036 Graz, Austria	Schafer, U (corresponding author), Med Univ Graz, Res Unit Expt Neurotraumatol, Auenbruggerpl 2, A-8036 Graz, Austria.	ute.schaefer@medunigraz.at	Zeleznik, Oana Alina/S-6015-2019	Zeleznik, Oana Alina/0000-0002-8705-1163; Leitinger, Gerd/0000-0002-5281-9830; Thallinger, Gerhard G./0000-0002-2864-5404	Styria government	We thank Chris Wrighton for editing the article and helpful comments. This work was supported by a grant from the Styria government.	Aliotta JM, 2010, EXP HEMATOL, V38, P233, DOI 10.1016/j.exphem.2010.01.002; ATACK JR, 1990, NEUROCHEM INT, V16, P533, DOI 10.1016/0197-0186(90)90013-J; BACH FW, 1992, CLIN CHEM, V38, P847; Bonev B, 2011, DEV CELL, V20, P19, DOI 10.1016/j.devcel.2010.11.018; Bruno S, 2013, STEM CELLS DEV, V22, DOI 10.1089/scd.2012.0304; Burnier L, 2009, THROMB HAEMOSTASIS, V101, P439, DOI 10.1160/TH08-08-0521; Cantaluppi V, 2012, KIDNEY INT, V82, P412, DOI 10.1038/ki.2012.105; Collino F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011803; De Maio A, 2011, CELL STRESS CHAPERON, V16, P235, DOI 10.1007/s12192-010-0236-4; Diehl P, 2012, CARDIOVASC RES, V93, P633, DOI 10.1093/cvr/cvs007; Ekelund J, 2003, NEUROSCI LETT, V349, P68, DOI 10.1016/S0304-3940(03)00654-2; FACCHINETTI F, 1987, NEUROSCI LETT, V77, P349, DOI 10.1016/0304-3940(87)90526-X; Faull KF, 1999, NEUROCHEM RES, V24, P1249, DOI 10.1023/A:1020973023059; Garcia BA, 2005, J PROTEOME RES, V4, P1516, DOI 10.1021/pr0500760; Gibbings DJ, 2009, NAT CELL BIOL, V11, P1143, DOI 10.1038/ncb1929; Harrington MG, 2009, FLUIDS BARRIERS CNS, V6, DOI 10.1186/1743-8454-6-10; Huang M, 2009, SURG NEUROL, V72, P481, DOI 10.1016/j.surneu.2008.12.016; Hunter MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003694; Kiebler MA, 2006, NEURON, V51, P685, DOI 10.1016/j.neuron.2006.08.021; Langlois Agnes, 1997, Methods in Cell Science, V19, P213, DOI 10.1023/A:1009731707443; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046957; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Marzesco AM, 2005, J CELL SCI, V118, P2849, DOI 10.1242/jcs.02439; Mause SF, 2010, CIRC RES, V107, P1047, DOI 10.1161/CIRCRESAHA.110.226456; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Mrvar-Brecko A, 2010, BLOOD CELL MOL DIS, V44, P307, DOI 10.1016/j.bcmd.2010.02.003; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Pluskota E, 2008, BLOOD, V112, P2327, DOI 10.1182/blood-2007-12-127183; Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296; Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Sadallah S, 2008, J LEUKOCYTE BIOL, V84, P1316, DOI 10.1189/jlb.0108013; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shet AS, 2003, BLOOD, V102, P2678, DOI 10.1182/blood-2003-03-0693; Shibata M, 2011, J NEUROSCI, V31, P3407, DOI 10.1523/JNEUROSCI.5085-10.2011; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Sinauridze EI, 2007, THROMB HAEMOSTASIS, V97, P425, DOI 10.1160/TH06-06-0313; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Smalheiser Neil R, 2009, Cardiovasc Psychiatry Neurol, V2009, P383086, DOI 10.1155/2009/383086; Smalheiser NR, 2007, BIOL DIRECT, V2, DOI 10.1186/1745-6150-2-35; Sommer JB, 2002, EUR NEUROL, V47, P224, DOI 10.1159/000057904; Tarnaris A, 2011, NEUROCHEM RES, V36, P528, DOI 10.1007/s11064-010-0374-1; van der Vos KE, 2011, CELL MOL NEUROBIOL, V31, P949, DOI 10.1007/s10571-011-9697-y; VanWijk MJ, 2003, CARDIOVASC RES, V59, P277, DOI 10.1016/S0008-6363(03)00367-5; Waldenstrom A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034653; Wetterberg L, 2002, NEUROSCI LETT, V329, P91, DOI 10.1016/S0304-3940(02)00580-3; WOLF P, 1967, BRIT J HAEMATOL, V13, P269, DOI 10.1111/j.1365-2141.1967.tb08741.x; Yuan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004722	50	50	54	0	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1232	1242		10.1089/neu.2012.2596			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100003	23360174				2021-06-18	
J	Tosetti, P; Hicks, RR; Theriault, E; Phillips, A; Koroshetz, W; Draghia-Akli, R				Tosetti, Patrizia; Hicks, Ramona R.; Theriault, Elizabeth; Phillips, Anthony; Koroshetz, Walter; Draghia-Akli, Ruxandra		Workshop Participants	Toward an International Initiative for Traumatic Brain Injury Research	JOURNAL OF NEUROTRAUMA			English	Article						geriatric brain injury; head trauma; human studies; pediatric brain injury	COMMON DATA ELEMENTS; SEVERE HEAD-INJURY; OUTCOME MEASURES; CLINICAL-TRIALS; RECOMMENDATIONS; MANAGEMENT; CARE	The European Commission (EC) and the National Institutes of Health (NIH) jointly sponsored a workshop on October 18-20, 2011 in Brussels to discuss the feasibility and benefits of an international collaboration in the field of traumatic brain injury (TBI) research. The workshop brought together scientists, clinicians, patients, and industry representatives from around the globe as well as funding agencies from the EU, Spain, the United States, and Canada. Sessions tackled both the possible goals and governance of a future initiative and the scientific questions that would most benefit from an integrated international effort: how to optimize data collection and sharing; injury classification; outcome measures; clinical study design; and statistical analysis. There was a clear consensus that increased dialogue and coordination of research at an international level would be beneficial for advancing TBI research, treatment, and care. To this end, the EC, the NIH, and the Canadian Institutes of Health Research expressed interest in developing a framework for an international initiative for TBI Research (InTBIR). The workshop participants recommended that InTBIR initially focus on collecting, standardizing, and sharing clinical TBI data for comparative effectiveness research, which will ultimately result in better management and treatments for TBI.	[Tosetti, Patrizia; Draghia-Akli, Ruxandra] DG RTD, European Commiss, Brussels, Belgium; [Hicks, Ramona R.] NINDS, Bethesda, MD 20892 USA; [Theriault, Elizabeth; Phillips, Anthony; Koroshetz, Walter] Canadian Inst Hlth Res, Inst Neurosci Mental Hlth & Addict, Vancouver, BC, Canada	Hicks, RR (corresponding author), NINDS, Ctr Neurosci, 6001 Executive Blvd,Room 2208, Bethesda, MD 20892 USA.	hicksra@ninds.nih.gov	Sahuquillo, Juan/B-3577-2008	Sahuquillo, Juan/0000-0003-0713-5875; Draghia-Akli, Ruxandra/0000-0001-6372-4039	National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish		Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Bauer R, 2009, INJURIES EUROPEAN UN; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Duhaime AC, 2012, J NEUROTRAUM, V29, P629, DOI 10.1089/neu.2011.1927; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Honeybul S, 2011, J NEUROSURG SCI, V55, P343; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Institute of Medicine, 2009, IN NAT PRIOR COMP EF; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Lingsma HF, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-201; Maas AI, 2008, J TRAUMA, V65, P966, DOI 10.1097/TA.0b013e318184ee7b; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Stocchetti N, 2001, Eur J Emerg Med, V8, P215, DOI 10.1097/00063110-200109000-00009; TEASDALE G, 1974, LANCET, V2, P81; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Weiner Michael W, 2012, Alzheimers Dement, V8, pS1, DOI 10.1016/j.jalz.2011.09.172; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033	35	50	51	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1211	1222		10.1089/neu.2013.2896			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100001	23731282	Green Published			2021-06-18	
J	Berz, K; Divine, J; Foss, KB; Heyl, R; Ford, KR; Myer, GD				Berz, Kate; Divine, Jon; Foss, Kim Barber; Heyl, Rachel; Ford, Kevin R.; Myer, Gregory D.			Sex-Specific Differences in the Severity of Symptoms and Recovery Rate Following Sports-Related Concussion in Young Athletes	PHYSICIAN AND SPORTSMEDICINE			English	Article						concussion; sports-related concussion; athletes; sex differences; symptom scores	TRAUMATIC BRAIN-INJURY; SEGMENT DYNAMIC STABILIZATION; STATES HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; GENDER-DIFFERENCES; HEAD-INJURIES; CHILDREN; ZURICH	Introduction: While research on adult recovery from concussion indicates sex-specific symptoms and recovery rates, there is little existing data on younger patient populations. Objective: To determine sex-specific differences in the severity of presenting symptoms and recovery rate between groups of young athletes who presented <= 7 or. 7 days after sports-related concussion. Methods: This study was a retrospective review of athletes aged 9 to 17 years who were referred for evaluation of a sports-related concussion over a 24-month period. The study groups were divided by sex and post-injury presentation to the clinic at <= 7 days and. 7 days from the date of injury. Athletes with learning disabilities were excluded from the study and data analysis. Age, height, and weight were recorded for each subject. Each subject also reported their initial degree of confusion, amnesia, or loss of consciousness, and whether a helmet was worn when the injury was sustained. A 22-item post-concussion symptom score (SS) scale was completed by both groups on initial assessment (SS1) and follow-up visit (SS2). The recovery rate (SSR) was calculated as (SS2-SS1)/days between SS2 and SS1. Sex and group comparisons for SS1 and SSR were performed using 2 x 2 analysis of variance. A similar analysis was also performed for effects of sex on SS1 and SSR in patients who were not wearing a helmet. Results: Thirty-seven athletes aged 15.0 +/- 1.9 years were evaluated. Males, regardless of day of presentation, had a lower SS1 evaluation than females (15.8 vs 30.9; P, < 0.05). Males without helmets did not differ from females without helmets, but this was not significantly different (14.1 vs 29.6; P = 0.1). There was not a significant difference in SS1 evaluation between the groups who presented at <= 7 or. 7 days. The overall mean SSR was -1.2/day, with no significant difference seen between groups or sex. There were no significant differences in degree of loss of consciousness, amnesia, confusion, or age between the sexes or groups. Conclusion: Whether presenting at <= 7 or. 7 days following a sports-related concussion, female athletes reported a higher SS1 evaluation. With SSR being similar between sexes, the current data suggest that young, female athletes may take longer to become symptom free following sports-related concussion. This information may be an important factor in returning a young athlete to sport after sports-related concussion.	[Berz, Kate; Foss, Kim Barber; Ford, Kevin R.; Myer, Gregory D.] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Berz, Kate; Ford, Kevin R.; Myer, Gregory D.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Divine, Jon; Myer, Gregory D.] Univ Cincinnati, Coll Med, Dept Orthopaed & Sports Med, Cincinnati, OH USA; [Foss, Kim Barber] Coll Mt St Joseph, Dept Athlet Training, Div Hlth Sci, Cincinnati, OH USA; [Heyl, Rachel] Wellington Orthopaed & Sports Med, Cincinnati, OH USA; [Ford, Kevin R.] High Point Univ, Dept Phys Therapy, Sch Hlth Sci, High Point, NC USA; [Myer, Gregory D.] Ohio State Univ, Sch Allied Med Profess, Athlet Training Div, Columbus, OH 43210 USA	Berz, K (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA.		Ford, Kevin/L-3986-2013; Myer, Gregory/H-6572-2016	Ford, Kevin/0000-0001-5402-6845; Myer, Gregory/0000-0002-9983-8422			Adirim TA, 2003, SPORTS MED, V33, P75, DOI 10.2165/00007256-200333010-00006; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Covassin T, 2003, J ATHL TRAINING, V38, P238; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Granito VJ., 2002, J SPORT BEHAV, V25, P243; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Knowles SB, 2006, AM J EPIDEMIOL, V164, P1209, DOI 10.1093/aje/kwj337; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Mansell J, 2005, J ATHL TRAINING, V40, P310; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Myer GD, 2010, CLIN BIOMECH, V25, P700, DOI 10.1016/j.clinbiomech.2010.04.001; Orchard J, 1998, J Sci Med Sport, V1, P83, DOI 10.1016/S1440-2440(98)80016-9; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Spinos P, 2010, J TRAUMA, V69, P789, DOI 10.1097/TA.0b013e3181edea67; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	41	50	50	0	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0091-3847	2326-3660		PHYSICIAN SPORTSMED	Physician Sportsmed.	MAY	2013	41	2					58	63		10.3810/psm.2013.05.2015			6	Primary Health Care; Orthopedics; Sport Sciences	General & Internal Medicine; Orthopedics; Sport Sciences	AR2EZ	WOS:000343397700007	23703518				2021-06-18	
J	Caicco, MJ; Zahir, T; Mothe, AJ; Ballios, BG; Kihm, AJ; Tator, CH; Shoichet, MS				Caicco, Matthew J.; Zahir, Tasneem; Mothe, Andrea J.; Ballios, Brian G.; Kihm, Anthony J.; Tator, Charles H.; Shoichet, Molly S.			Characterization of hyaluronan-methylcellulose hydrogels for cell delivery to the injured spinal cord	JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A			English	Article						hydrogel; cell therapy; spinal cord injury; hyaluronan; cell scaffold	TRANSPLANTATION; TISSUE; STIMULATION; THERAPY; REPAIR; SYSTEM; BRAIN	No effective clinical treatment currently exists for traumatic spinal cord injury. Cell replacement therapy holds promise for attaining functional repair. Cells may be delivered directly or near the injury site; however, this strategy requires a delivery vehicle to maintain cell viability. We have identified an injectable, biocompatible, and biodegradable hydrogel scaffold composed of hyaluronan (HA) and methylcellulose (MC) that may be an effective scaffold for therapeutic cell delivery. The purpose of the present study was to determine the effects of polymer concentration on HAMC mechanical strength, gelation time, and cell viability. The yield stress of HAMC, a measure of mechanical stiffness, was tunable via manipulation of MC and HA content. Measurement of the elastic and storage moduli as functions of time revealed that HAMC gels in less than 5 min at physiological temperatures. Human umbilical tissue-derived cells encapsulated in HAMC were homogenously and stably distributed over 3 days in culture and extended processes into the scaffold. Cell viability was stable over this period in all but the most concentrated HAMC formulation. Because of its strength-tunability, rapid gelation, and ability to maintain cell viability, HAMC is a promising vehicle for cell delivery and is being tested in ongoing in vivo studies. (c) 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2013.	[Caicco, Matthew J.; Zahir, Tasneem; Shoichet, Molly S.] Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON M5S 3E5, Canada; [Caicco, Matthew J.; Shoichet, Molly S.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON M5S 3G9, Canada; [Mothe, Andrea J.; Tator, Charles H.] Toronto Western Hosp, Toronto Western Res Inst, Div Genet & Dev, Toronto, ON M5T 2S8, Canada; [Mothe, Andrea J.; Tator, Charles H.] Toronto Western Hosp, Krembil Neurosci Ctr, Toronto, ON M5T 2S8, Canada; [Ballios, Brian G.; Shoichet, Molly S.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; [Kihm, Anthony J.] Ethicon Inc, Adv Technol & Regenerat Med LLC, Somerville, NJ 08876 USA	Shoichet, MS (corresponding author), Univ Toronto, Dept Chem Engn & Appl Chem, 200 Coll St, Toronto, ON M5S 3E5, Canada.	molly.shoichet@utoronto.ca			Johnson & Johnson Corporate Office of Science and Technology and Advanced Technologies and Regenerative Medicine, LLC (ATRM); CIHR TPRM Graduate FellowshipCanadian Institutes of Health Research (CIHR); Ontario Graduate ScholarshipOntario Graduate Scholarship; CIHR CGSD Graduate FellowshipCanadian Institutes of Health Research (CIHR)	Contract grant sponsors: Johnson & Johnson Corporate Office of Science and Technology and Advanced Technologies and Regenerative Medicine, LLC (ATRM); CIHR TPRM Graduate Fellowship; The Ontario Graduate Scholarship; CIHR CGSD Graduate Fellowship	Allison DD, 2006, TISSUE ENG, V12, P2131, DOI 10.1089/ten.2006.12.2131; Ballios BG, 2010, BIOMATERIALS, V31, P2555, DOI 10.1016/j.biomaterials.2009.12.004; Baumann MD, 2009, J CONTROL RELEASE, V138, P205, DOI 10.1016/j.jconrel.2009.05.009; CHANG GL, 1988, J BIOMECH ENG-T ASME, V110, P115, DOI 10.1115/1.3108415; Cooke MJ, 2011, BIOMATERIALS, V32, P5688, DOI 10.1016/j.biomaterials.2011.04.032; Dado D, 2009, SEMIN CELL DEV BIOL, V20, P656, DOI 10.1016/j.semcdb.2009.02.001; Enzmann GU, 2006, J NEUROTRAUM, V23, P479, DOI 10.1089/neu.2006.23.479; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Gupta D, 2006, BIOMATERIALS, V27, P2370, DOI 10.1016/j.biomaterials.2005.11.015; Harris IR, 2005, US Pat, Patent No. [2006/022,317,7A1, 20060223177]; Hsieh A, 2010, SOFT MATTER, V6, P2227, DOI 10.1039/b924349f; Joh T, 2001, GELS HDB, P51; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Mooney DJ, 2008, CELL STEM CELL, V2, P205, DOI 10.1016/j.stem.2008.02.005; Parr AM, 2007, J NEUROTRAUM, V24, P835, DOI 10.1089/neu.2006.3771; Reir PJ, 2004, NEURORX, V1, P424; SARKAR N, 1979, J APPL POLYM SCI, V24, P1073, DOI 10.1002/app.1979.070240420; Shoichet MS, 2010, MACROMOLECULES, V43, P581, DOI 10.1021/ma901530r; Shoichet MS, 2000, ADV DRUG DELIVER REV, V42, P81, DOI 10.1016/S0169-409X(00)00055-7; Tator CH, 2006, NEUROSURGERY, V59, P957, DOI 10.1227/01.NEU.0000245591.16087.89; Wang CM, 2010, ADV DRUG DELIVER REV, V62, P699, DOI 10.1016/j.addr.2010.02.001; Wang YF, 2012, BIOMATERIALS, V33, P2681, DOI 10.1016/j.biomaterials.2011.12.031	22	50	52	0	80	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1549-3296	1552-4965		J BIOMED MATER RES A	J. Biomed. Mater. Res. Part A	MAY	2013	101	5					1472	1477		10.1002/jbm.a.34454			6	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	115MG	WOS:000316815700027	23129254				2021-06-18	
J	Dehghan, F; Hadad, MK; Asadikram, G; Najafipour, H; Shahrokhi, N				Dehghan, Fatemeh; Hadad, Mohammad Khaksari; Asadikram, Gholamreza; Najafipour, Hamid; Shahrokhi, Nader			Effect of Melatonin on Intracranial Pressure and Brain Edema Following Traumatic Brain Injury: Role of Oxidative Stresses	ARCHIVES OF MEDICAL RESEARCH			English	Article						Brain edema; Melatonin; Intracranial pressure; Neurological outcomes	FOCAL CEREBRAL-ISCHEMIA; SEX STEROID-HORMONES; CLOSED-HEAD INJURY; BARRIER PERMEABILITY; CEREBROSPINAL-FLUID; BLOOD-FLOW; ANTIOXIDANT THERAPIES; RADICAL SCAVENGER; DAMAGE; RATS	Background and Aims. Traumatic brain injury (TBI) is one of the main causes of brain edema and increased intracranial pressure (ICP). In the clinic it is essential to limit the development of ICP after TBI. In the present study, the effects of melatonin on these parameters at different time points and alterations of oxidant factors as one of the probable involved mechanisms have been evaluated. Methods. Albino N-Mary rats were divided into five groups of sham, TBI, TBI + vehicle, TBI + Mel5 and TBI + Mel20. Brain injury was induced by Marmarou method. Melatonin was injected i.p. at 1, 24, 48 and 72 h after brain trauma. Brain water and Evans blue dye contents as well as oxidant/antioxidant factors were measured 72 h after TBI. ICP and neurological scores were determined at -1, 1, 24, 48 and 72 h post-TBI. Results. Brain water and Evans blue dye contents in melatonin-treated groups decreased as compared to the TBI + vehicle group (p <0.001). Veterinary coma scale (VCS) at 24, 48 and 72 h after TBI showed a significant increase in melatonin groups (TBI + Mel5: p <0.01and TBI + Mel20: p <0.001) in comparison to the TBI + vehicle group. ICP at 24, 48 and 72 h after TBI decreased in melatonin groups as compared to the TBI + vehicle group (p <0.001). Superoxide dismutase and glutathione peroxidase activities showed a significant increase, whereas malondialdehyde level in these groups was significantly lower in melatonin groups in comparison to the TBI + vehicle group (p <0.001). Conclusion. Melatonin decreases brain edema, BBB permeability and ICP, but increases VCS after TBI. These effects are probably due to inhibition of oxidative stress. 2013 IMSS. Published by Elsevier Inc.	[Dehghan, Fatemeh; Shahrokhi, Nader] Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran; [Hadad, Mohammad Khaksari; Asadikram, Gholamreza; Najafipour, Hamid] Kerman Univ Med Sci, Physiol Res Ctr, Kerman, Iran	Shahrokhi, N (corresponding author), Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran.	nshahrokhisa@yahoo.com	Asadikaram, Gholamreza/AAG-4437-2021; Najafipour, Hamid/U-7922-2017; Shahrokhi, Nader/AAV-3747-2020	Asadikaram, Gholamreza/0000-0002-9100-0756; Najafipour, Hamid/0000-0002-8030-8704; Shahrokhi, Nader/0000-0002-0149-7819; Asadi karam, Gholamreza/0000-0002-6417-5200; Khaksari, Mohammad/0000-0003-0770-4281	Neuroscience Research Centre of Kerman University of Medical sciences	The present study was financially supported by the Neuroscience Research Centre of Kerman University of Medical sciences. Data reported are part of the Master of Science thesis presented by Fatemeh Dehghan.	Ates O, 2006, INT J DEV NEUROSCI, V24, P357, DOI 10.1016/j.ijdevneu.2006.08.003; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Aygun D, 2012, HISTOL HISTOPATHOL, V27, P417, DOI 10.14670/HH-27.417; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Chen HY, 2006, J PINEAL RES, V41, P175, DOI 10.1111/j.1600-079X.2006.00351.x; Chen TY, 2006, J PINEAL RES, V40, P242, DOI 10.1111/j.1600-079X.2005.00307.x; Chern CM, 2012, FREE RADICAL BIO MED, V52, P1634, DOI 10.1016/j.freeradbiomed.2012.01.030; Chieregato A, 2007, NEUROSURGERY, V60, P115, DOI 10.1227/01.NEU.0000249194.76527.28; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; del Zoppo GJ, 2006, NEW ENGL J MED, V354, P553, DOI 10.1056/NEJMp058312; Dubocovich ML, 2005, ENDOCRINE, V27, P101, DOI 10.1385/ENDO:27:2:101; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; Ercan M, 2001, NEUROSURG REV, V24, P127, DOI 10.1007/PL00012396; Erol FS, 2008, J CLIN NEUROSCI, V15, P784, DOI 10.1016/j.jocn.2007.06.009; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Fujimoto T, 2000, SPINE, V25, P769, DOI 10.1097/00007632-200004010-00003; Ganguly K, 2009, J PINEAL RES, V47, P43, DOI 10.1111/j.1600-079X.2009.00687.x; Gasche Y, 2001, J CEREBR BLOOD F MET, V21, P1393, DOI 10.1097/00004647-200112000-00003; Gnezdilova A. V., 2010, Eksperimental'naya i Klinicheskaya Farmakologiya, V73, P11; Goren S, 2001, J NEUROSURG ANESTH, V13, P113, DOI 10.1097/00008506-200104000-00008; Gorgulu AK, 2001, NEUROSURGERY, V49, P1434; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Gursoy-Ozdemir Y, 2004, STROKE, V35, P1449, DOI 10.1161/01.STR.0000126044.83777.f4; Gutierrez-Cuesta J, 2007, J PINEAL RES, V42, P394, DOI 10.1111/j.1600-079X.2007.00433.x; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hung YC, 2008, J PINEAL RES, V45, P459, DOI 10.1111/j.1600-079X.2008.00617.x; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Jamali S, 1998, BRAIN INJURY, V12, P525, DOI 10.1080/026990598122485; Kabadi SV, 2010, ANN NY ACAD SCI, V1199, P105, DOI 10.1111/j.1749-6632.2009.05352.x; Kahveci FS, 2001, SURG NEUROL, V56, P206, DOI 10.1016/S0090-3019(01)00555-9; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Kerman M, 2005, EXP BRAIN RES, V163, P406, DOI 10.1007/s00221-005-2338-2; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Klussmann S, 2005, J MOL MED, V83, P657, DOI 10.1007/s00109-005-0663-3; Kondoh T, 2002, LIFE SCI, V72, P583, DOI 10.1016/S0024-3205(02)02256-7; Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003; Li ZQ, 2009, BRAIN RES, V1264, P98, DOI 10.1016/j.brainres.2009.01.055; Lisa Hill CG, 2007, ANAESTHESIA, P30; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Maslennikov D, 2011, EUR NEUROPSYCHOPHARM, V21, pS127, DOI 10.1016/S0924-977X(11)70143-2; Meki ARMA, 2001, COMP BIOCHEM PHYS C, V130, P305, DOI 10.1016/S1532-0456(01)00248-4; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Niles LP, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-41; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Oliveira Carla Oliveira de, 2008, Rev Bras Ter Intensiva, V20, P411; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Ozdemir D, 2005, PHYSIOL RES, V54, P631; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; Pugliese F, 2007, TRANSPL P, V39, P1883, DOI 10.1016/j.transproceed.2007.05.062; RAO BR, 1980, AUSTRALAS RADIOL, V24, P24, DOI 10.1111/j.1440-1673.1980.tb02150.x; Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237; Reiter RJ, 2000, ANN NY ACAD SCI, V917, P376; Reiter RJ, 2010, MARMARA PHARM J, V14, P1, DOI 10.12991/201014457; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rogatsky GG, 2005, BRAIN RES, V1047, P131, DOI 10.1016/j.brainres.2005.02.049; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; Rowlands HE, 2007, PAEDIAT CHILD HLTH, V17, P82, DOI DOI 10.1016/J.PAED.2007.01.011; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Savaskan E, 2001, NEUROBIOL AGING, V22, P541, DOI 10.1016/S0197-4580(00)00259-1; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Shahlaie K, 2009, NEUROCRIT CARE, V10, P61, DOI 10.1007/s12028-008-9138-z; Shahrokhi N, 2012, PAK J PHARM SCI, V25, P219; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Smith M, 2008, ANESTH ANALG, V106, P240, DOI 10.1213/01.ane.0000297296.52006.8e; Soustiel JF, 2010, NEUROTHERAPEUTICS, V7, P13, DOI 10.1016/j.nurt.2009.11.001; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Swarnakar S, 2011, J PINEAL RES, V50, P8, DOI 10.1111/j.1600-079X.2010.00812.x; Takasugi Y, 2005, EXP ANIM TOKYO, V54, P193, DOI 10.1538/expanim.54.193; Toklu H, 2009, MARMARA MED J, V22, P34; Tomas-Zapico C, 2005, J PINEAL RES, V39, P99, DOI 10.1111/j.1600-079X.2005.00248.x; Turgut M, 2007, BRAIN RES, V1175, P117, DOI 10.1016/j.brainres.2007.07.056; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wakatsuki A, 2001, J PINEAL RES, V31, P167, DOI 10.1034/j.1600-079x.2001.310211.x; Xiao F, 2002, ACAD EMERG MED, V9, P933, DOI 10.1197/aemj.9.9.933	81	50	52	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0188-4409	1873-5487		ARCH MED RES	Arch. Med. Res.	MAY	2013	44	4					251	258		10.1016/j.arcmed.2013.04.002			8	Medicine, Research & Experimental	Research & Experimental Medicine	185TV	WOS:000321994100001	23608674				2021-06-18	
J	Sword, J; Masuda, T; Croom, D; Kirov, SA				Sword, Jeremy; Masuda, Tadashi; Croom, Deborah; Kirov, Sergei A.			Evolution of neuronal and astroglial disruption in the peri-contusional cortex of mice revealed by in vivo two-photon imaging	BRAIN			English	Article						acute brain injury; dendritic beading; astroglial swelling; cortical spreading depolarization; in vivo; two-photon microscopy	TRAUMATIC BRAIN-INJURY; CORTICAL SPREADING DEPRESSION; CEREBRAL-ARTERY OCCLUSION; HEMODYNAMIC DEPRESSION; DENDRITIC STRUCTURE; ISCHEMIA; IMPACT; GLUTAMATE; RAT; NEURODEGENERATION	In traumatic brain injury mechanical forces applied to the cranium and brain cause irreversible primary neuronal and astroglial damage associated with terminal dendritic beading and spine loss representing acute damage to synaptic circuitry. Oedema develops quickly after trauma, raising intracranial pressure that results in a decrease of blood flow and consequently in cerebral ischaemia, which can cause secondary injury in the peri-contusional cortex. Spreading depolarizations have also been shown to occur after traumatic brain injury in humans and in animal models and are thought to accelerate and exacerbate secondary tissue injury in at-risk cortical territory. Yet, the mechanisms of acute secondary injury to fine synaptic circuitry within the peri-contusional cortex after mild traumatic brain injury remain unknown. A mild focal cortical contusion model in adult mouse sensory-motor cortex was implemented by the controlled cortical impact injury device. In vivo two-photon microscopy in the peri-contusional cortex was used to monitor via optical window yellow fluorescent protein expressing neurons, enhanced green fluorescent protein expressing astrocytes and capillary blood flow. Dendritic beading in the peri-contusional cortex developed slowly and the loss of capillary blood flow preceded terminal dendritic injury. Astrocytes were swollen indicating oedema and remained swollen during the next 24 h throughout the imaging session. There were no recurrent spontaneous spreading depolarizations in this mild traumatic brain injury model; however, when spreading depolarizations were repeatedly induced outside the peri-contusional cortex by pressure-injecting KCl, dendrites undergo rapid beading and recovery coinciding with passage of spreading depolarizations, as was confirmed with electrophysiological recordings in the vicinity of imaged dendrites. Yet, accumulating metabolic stress resulting from as few as four rounds of spreading depolarization significantly added to the fraction of beaded dendrites that were incapable to recover during repolarization, thus facilitating terminal injury. In contrast, similarly induced four rounds of spreading depolarization in another set of control healthy mice caused no accumulating dendritic injury as dendrites fully recovered from beading during repolarization. Taken together, our data suggest that in the mild traumatic brain injury the acute dendritic injury in the peri-contusional cortex is gated by the decline in the local blood flow, most probably as a result of developing oedema. Furthermore, spreading depolarization is a specific mechanism that could accelerate injury to synaptic circuitry in the metabolically compromised peri-contusional cortex, worsening secondary damage following traumatic brain injury.	[Sword, Jeremy] Georgia Hlth Sci Univ, Grad Program Neurosci, Augusta, GA 30912 USA; [Masuda, Tadashi; Kirov, Sergei A.] Georgia Hlth Sci Univ, Brain & Behav Discovery Inst, Augusta, GA 30912 USA; [Croom, Deborah; Kirov, Sergei A.] Georgia Hlth Sci Univ, Dept Neurosurg, Augusta, GA 30912 USA	Kirov, SA (corresponding author), Georgia Hlth Sci Univ, Dept Neurosurg, Brain & Behav Discovery Inst, 1120 15th St,CB-3706, Augusta, GA 30912 USA.	skirov13@gmail.com			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057113]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057113] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grants NS057113 (S.A.K.).	Andrew RD, 2007, CEREB CORTEX, V17, P787, DOI 10.1093/cercor/bhk032; Ayata C, 2004, J CEREBR BLOOD F MET, V24, P744, DOI 10.1097/01.WCB.0000122745.72175.D5; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BINDOKAS VP, 1995, J NEUROSCI, V15, P6999; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Church AJ, 2005, J NEUROTRAUM, V22, P277, DOI 10.1089/neu.2005.22.277; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Dienel GA, 2005, GLIA, V50, P362, DOI 10.1002/glia.20157; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dixon C. Edward, 2009, P385, DOI 10.1007/978-1-60327-185-1_33; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dreier JP, 2013, NEUROSCIENTIST, V19, P25, DOI 10.1177/1073858412453340; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dunn AK, 2001, J CEREBR BLOOD F MET, V21, P195, DOI 10.1097/00004647-200103000-00002; Enright LE, 2007, J CEREBR BLOOD F MET, V27, P1185, DOI 10.1038/sj.jcbfm.9600428; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; HORI N, 1994, EXP NEUROL, V129, P279, DOI 10.1006/exnr.1994.1170; Jagt TAV, 2008, J NEUROSCI, V28, P5029, DOI 10.1523/JNEUROSCI.5069-07.2008; Kasischke KA, 2011, J CEREBR BLOOD F MET, V31, P68, DOI 10.1038/jcbfm.2010.158; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Kimelberg HK, 2005, GLIA, V50, P389, DOI 10.1002/glia.20174; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; Kleinfeld D, 1998, P NATL ACAD SCI USA, V95, P15741, DOI 10.1073/pnas.95.26.15741; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Li P, 2008, J NEUROSCI, V28, P11970, DOI 10.1523/JNEUROSCI.3724-08.2008; Maeda T, 1997, ACT NEUR S, V70, P102; Masuda T, 2010, BRAIN RES, V1355, P228, DOI 10.1016/j.brainres.2010.07.101; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Mongin A. A., 2005, NEUROGLIA, P550; Mongin AA, 2002, AM J PHYSIOL-CELL PH, V283, pC569, DOI 10.1152/ajpcell.00438.2001; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Murphy TH, 2008, J NEUROSCI, V28, P1756, DOI 10.1523/JNEUROSCI.5128-07.2008; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Orellana JA, 2011, J NEUROCHEM, V118, P826, DOI 10.1111/j.1471-4159.2011.07210.x; OZAWA Y, 1991, Neurologia Medico-Chirurgica, V31, P685, DOI 10.2176/nmc.31.685; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; Risher WC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022351; Risher WC, 2010, J NEUROSCI, V30, P9859, DOI 10.1523/JNEUROSCI.1917-10.2010; Risher WC, 2009, GLIA, V57, P207, DOI 10.1002/glia.20747; Rogatsky G, 1996, J Basic Clin Physiol Pharmacol, V7, P23; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Rosidi NL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026612; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Shuttleworth CWR, 2001, J NEUROSCI, V21, P4225, DOI 10.1523/JNEUROSCI.21-12-04225.2001; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Tom WJ, 2008, IEEE T MED IMAGING, V27, P1728, DOI 10.1109/TMI.2008.925081; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Yuzawa I, 2012, J CEREBR BLOOD F MET, V32, P376, DOI 10.1038/jcbfm.2011.148; Zhang SX, 2007, PLOS BIOL, V5, P1152, DOI 10.1371/journal.pbio.0050119; Zhang SX, 2005, J NEUROSCI, V25, P5333, DOI 10.1523/JNEUROSCI.1085-05.2005	76	50	50	0	15	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAY	2013	136		5				1446	1461		10.1093/brain/awt026			16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	140DN	WOS:000318634600010	23466395	Green Published, Bronze			2021-06-18	
J	Becker, EH; Watson, JD; Dreese, JC				Becker, Edward H.; Watson, Jeffrey D.; Dreese, James C.			Investigation of Multiligamentous Knee Injury Patterns With Associated Injuries Presenting at a Level I Trauma Center	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						multiligamentous knee injury; peroneal nerve injury; anterior cruciate ligament; posterior cruciate ligament; posterolateral corner	COMMON PERONEAL NERVE; VASCULAR INJURIES; COMPLETE DISLOCATION; SURGICAL FINDINGS; RECONSTRUCTION; ARTERIOGRAPHY; MANAGEMENT; REPAIR	Objectives: To characterize multiligamentous knee injury patterns and describe associated morbidities. Design: Retrospective. Setting: Level I trauma center. Patients: One hundred two patients (106 knees) with multiligamentous knee injuries and/or dislocations from 2000 through 2008. Subgroup of 82 knees with appropriate magnetic resonance images available assessed for ligamentous injury patterns. Intervention: Data obtained from medical records for 106 knees. Main Outcome Measurements: Presence of arterial injuries, nerve injuries, associated fracture patterns, and whole-body morbidities. Results: The most common (43%) injury pattern was a combined disruption of the anterior cruciate ligament, posterior cruciate ligament, and posterolateral corner. Twenty-five percent of knees had associated ipsilateral tibial plateau fractures, and 19% had associated ipsilateral femoral fractures. Peroneal nerve injury occurred in 25% of knees, arterial injury in 21%, and compartment syndrome in 16%. An intra-abdominal injury was present in 13% of patients, a severe closed head injury in 10%, and a symptomatic pulmonary embolism in 5%. Conclusions: Nearly half the multiligamentous knee injuries involved the anterior cruciate ligament, posterior cruciate ligament, and posterolateral corner; one-fourth had associated ipsilateral tibial plateau fractures. The incidence of peroneal nerve injury (25%) was higher than previously reported (20%), whereas the incidence of arterial injury (21%) was comparable to previous reports (19%). Posterolateral corner injuries were more prevalent than previously reported and were highly associated with peroneal nerve injury. We found a substantial incidence of associated morbidities of the whole body. Multiligamentous knee injuries are a marker of concomitant trauma and should be closely evaluated at presentation and during the hospital course to allow for early intervention for life-or limb-threatening comorbidities.	[Becker, Edward H.; Watson, Jeffrey D.; Dreese, James C.] Univ Maryland, Dept Orthopaed, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA	Dreese, JC (corresponding author), 2200 Kernan Dr,Suite 1154, Baltimore, MD 21207 USA.	jdreese@umoa.umm.edu					ALMEKINDERS LC, 1992, CLIN ORTHOP RELAT R, P203; BOISRENOULT P, 2009, REV CHIR ORTHOP TRAU, V95, P621, DOI DOI 10.1016/J.OTSR.2009.10.002; Bottomley N, 2005, J BONE JOINT SURG BR, V87B, P1225, DOI 10.1302/0301-620X.87B9.16122; Bui KL, 2008, SKELETAL RADIOL, V37, P653, DOI 10.1007/s00256-008-0490-z; FRASSICA FJ, 1991, CLIN ORTHOP RELAT R, P200; Good, 1995, J Am Acad Orthop Surg, V3, P284; GREEN NE, 1977, J BONE JOINT SURG AM, V59, P236, DOI 10.2106/00004623-197759020-00017; Harner CD, 2004, J BONE JOINT SURG AM, V86A, P262, DOI 10.2106/00004623-200402000-00008; Hegyes MS, 2000, CLIN SPORT MED, V19, P519, DOI 10.1016/S0278-5919(05)70222-2; Johnson ME, 2008, AM J SPORT MED, V36, P2448, DOI 10.1177/0363546508325669; KAUFMAN SL, 1992, RADIOLOGY, V184, P153, DOI 10.1148/radiology.184.1.1609074; KENDALL RW, 1993, J TRAUMA, V35, P875, DOI 10.1097/00005373-199312000-00013; Liow RYL, 2003, J BONE JOINT SURG BR, V85B, P845, DOI 10.1302/0301-620X.85B6.13972; Lustig S, 2009, ORTHOP TRAUMATOL-SUR, V95, P614, DOI 10.1016/j.otsr.2009.10.005; MCCOY GF, 1987, J BONE JOINT SURG BR, V69, P285; McDonough EB, 2009, AM J SPORT MED, V37, P156, DOI 10.1177/0363546508324313; Niall DM, 2005, J BONE JOINT SURG BR, V87B, P664, DOI 10.1302/0301-620X.87B5.15607; OMALLEY KF, 1990, J TRAUMA, V30, P748, DOI 10.1097/00005373-199006000-00018; Peltola EK, 2009, AM J ROENTGENOL, V192, P101, DOI 10.2214/AJR.07.3593; Potter HG, 2000, CLIN SPORT MED, V19, P425, DOI 10.1016/S0278-5919(05)70216-7; Richter M, 2002, AM J SPORT MED, V30, P718, DOI 10.1177/03635465020300051601; Rios A, 2003, J TRAUMA, V55, P489, DOI 10.1097/01.TA.0000043921.09208.76; Robertson A, 2006, J BONE JOINT SURG BR, V88B, P706, DOI 10.1302/0301-620X.88B6; SISTO DJ, 1985, CLIN ORTHOP RELAT R, P94; Stannard JP, 2004, J BONE JOINT SURG AM, V86A, P910, DOI 10.2106/00004623-200405000-00004; TREIMAN GS, 1992, ARCH SURG-CHICAGO, V127, P1056; Twaddle BC, 2003, J ORTHOP TRAUMA, V17, P198, DOI 10.1097/00005131-200303000-00008; Twaddle BC, 1996, J BONE JOINT SURG BR, V78B, P573; VARNELL RM, 1989, AM SURGEON, V55, P699; Wascher DC, 1997, J ORTHOP TRAUMA, V11, P525, DOI 10.1097/00005131-199710000-00011; Wascher DC, 2000, CLIN SPORT MED, V19, P457, DOI 10.1016/S0278-5919(05)70218-0; Werier J, 1998, KNEE, V5, P255, DOI 10.1016/S0968-0160(98)00015-5; WRIGHT DG, 1995, J ORTHOP TRAUMA, V9, P135, DOI 10.1097/00005131-199504000-00008	33	50	52	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	APR	2013	27	4					226	231		10.1097/BOT.0b013e318270def4			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	112SY	WOS:000316614900015	22955332				2021-06-18	
J	Moye, J; Marson, DC; Edelstein, B				Moye, Jennifer; Marson, Daniel C.; Edelstein, Barry			Assessment of Capacity in an Aging Society	AMERICAN PSYCHOLOGIST			English	Article						capacity; competency; decision making; informed consent; assessment	MILD COGNITIVE IMPAIRMENT; DECISION-MAKING CAPACITY; DECLINING FINANCIAL CAPACITY; TRAUMATIC BRAIN-INJURY; TO-MODERATE DEMENTIA; ALZHEIMERS-DISEASE; OLDER-ADULTS; PHYSICIAN JUDGMENTS; DRIVING SIMULATOR; MEDICAL DECISIONS	Over the past 40 years, the assessment and scientific study of capacity in older adults has emerged as a distinct field of clinical and research activity for psychologists. This new field reflects the convergence of several trends: the aging of American society, the growing incidence and prevalence of dementia, and the patient rights, deinstitutionalization, and disability rights movements. Because of these forces, capacity issues now permeate the fabric of everyday life, whether in the form of guardianship petitions, questions of capacity to consent to treatment, the ability to make a new will, or participation in human research. In seeking to resolve these issues, families, clinicians, and legal professionals increasingly turn to psychologists to assess a capacity and to provide empirically supported judgments that properly balance autonomy and protection for the individual. Psychologists have taken a leading role in the development of functional assessment instruments that measure important aspects of the capacity construct. In addition, psychology has been a major contributor to the scientific study of capacity. In collaboration with colleagues from medicine and law, psychologists have articulated crucial theoretical frameworks that integrate legal, clinical, and ethical dimensions of the capacity problem. This article focuses on the evolution of theory, law, science, and practice in the evaluation of capacity in older adults and its recent culmination in a series of interdisciplinary handbooks sponsored by the American Psychological Association and the American Bar Association.	[Moye, Jennifer] VA Boston Healthcare Syst, Brockton, MA 02301 USA; [Moye, Jennifer] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA; [Marson, Daniel C.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL USA; [Marson, Daniel C.] Univ Alabama Birmingham, Alzheimers Dis Ctr, Birmingham, AL USA; [Edelstein, Barry] W Virginia Univ, Dept Psychol, Morgantown, WV 26506 USA	Moye, J (corresponding author), VA Boston Healthcare Syst, Brockton Campus,940 Belmont St, Brockton, MA 02301 USA.	jennifer.moye@va.gov	Moye, Jennifer A/F-2240-2017; Moye, Jennifer/AAM-1282-2021	Moye, Jennifer A/0000-0002-3434-347X; Moye, Jennifer/0000-0002-3434-347X	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG021927, AG021927, R56 AG021927] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD053074, R01 HD053074] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R29 MH057104] Funding Source: Medline; Intramural VA [VA999999] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD053074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R29MH057104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R56AG021927, R01AG021927] Funding Source: NIH RePORTER		Administration on Aging, 2010, PROF OLD AM 2009; American Bar Association Commission on Law and Aging American Psychological Association, 2005, ASS OLD AD DIM CAP H; American Bar Association Commission on Law and Aging American Psychological Association, 2006, JUD DET CAP OLD AD G; American Bar Association Commission on Law and Aging & American Psychological Association, 2008, ASS OLD AD DIM CAP H; American Psychological Association Office on Aging, 2012, CAP ASS TRAIN NEEDS; Anderer S. J., 1997, THESIS ALLEGHENY U H; Appelbaum P. S., 1992, MANUAL PERCEPTIONS D; APPELBAUM PS, 1981, AM J PSYCHIAT, V138, P1462; APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; APPELBAUM PS, 1991, CLIN HDB PSYCHIAT LA; BAGENSTOS SAMUEL R, 2009, LAW CONTRADICTIONS D; Berg JW, 2001, INFORM CONSENT LEGAL; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Braun MM, 2009, GENERATIONS, V33, P78; BRAVO MJ, 1992, PERCEPT PSYCHOPHYS, V51, P465, DOI 10.3758/BF03211642; Brown PJ, 2011, ARCH GEN PSYCHIAT, V68, P617, DOI 10.1001/archgenpsychiatry.2011.57; Burgdorf Jr R. L., 2008, TEXAS J CIVIL LIBERT, V13, P242; Centers for Disease Control and Prevention, 2007, STAT AG HLTH AM 2007; Clow HE, 2002, J AM GERIATR SOC, V50, P1879, DOI 10.1046/j.1532-5415.2002.50520.x; Department of Veterans Affairs, 1997, CLIN ASS COMP DET PR; DIEHL M, 1995, PSYCHOL AGING, V10, P478, DOI 10.1037/0882-7974.10.3.478; Dreer LE, 2008, REHABIL PSYCHOL, V53, P486, DOI 10.1037/a0013798; Dumont MP, 2008, INT J MENT HEALTH, V37, P61, DOI 10.2753/IMH0020-7411370405; Dymek MP, 2001, NEUROLOGY, V56, P17, DOI 10.1212/WNL.56.1.17; Dymek MP, 1999, J FORENSIC NEUROPSYC, V1, P27, DOI DOI 10.1300/J151V01N01_; Edelstein B, 1993, M AM PSYCH ASS TOR O; Edelstein B., 1999, HOPEMONT CAPACITY AS; Fairchild AL, 2004, PUBLIC HEALTH REP, V119, P362, DOI 10.1016/j.phr.2004.04.016; Financial Industry Regulatory Authority, 2010, SEN INV ISS DIM CAP; Ganzini L, 2003, PSYCHOSOMATICS, V44, P237, DOI 10.1176/appi.psy.44.3.237; Gold DA, 2012, J CLIN EXP NEUROPSYC, V34, P11, DOI 10.1080/13803395.2011.614598; Griffith HR, 2010, J AM GERIATR SOC, V58, P265, DOI 10.1111/j.1532-5415.2009.02679.x; Griffith HR, 2003, NEUROLOGY, V60, P449, DOI 10.1212/WNL.60.3.449; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P149, DOI 10.1007/BF01499323; Grisso T., 2003, EVALUATING COMPETENC; GRISSO T, 1993, MANUAL THINKING RATI; Grisso T, 1992, MANUAL UNDERSTANDING; Grisso T, 1998, MACARTHUR COMPETENCE; Grisso T., 1986, EVALUATING COMPETENC; GRISSO T, 1994, NEUROPSYCHOLOGICAL A, P119, DOI DOI 10.1037/10157-006; Gurrera RJ, 2006, NEUROLOGY, V66, P1367, DOI 10.1212/01.wnl.0000210527.13661.d1; GUTHEIL TG, 1982, CLIN HDB PSYCHIAT LA; Hastie R, 2010, RATIONAL CHOICE UNCE; Havens JJ, 2003, J GIFT PLANNING, V7, P11; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hornung CA, 1998, J AM GERIATR SOC, V46, P280, DOI 10.1111/j.1532-5415.1998.tb01038.x; Jacoby R, 2007, BRIT MED J, V335, P155, DOI 10.1136/bmj.39232.706840.AD; Jankowiak J. L., 2011, CLIN NEUROLOGY AGING, P159; Karlawish JHT, 2002, J AM GERIATR SOC, V50, P2019, DOI 10.1046/j.1532-5415.2002.50615.x; Kim SYH, 2002, PSYCHIATR SERV, V53, P1322, DOI 10.1176/appi.ps.53.10.1322; Kim SYH, 2001, AM J PSYCHIAT, V158, P712, DOI 10.1176/appi.ajp.158.5.712; Lee HC, 2003, AM J OCCUP THER, V57, P324, DOI 10.5014/ajot.57.3.324; little william, 1955, OXFORD UNIVERSAL DIC; Liu KRY, 2007, ACTA NEUROL SCAND, V116, P91, DOI 10.1111/j.1600-0404.2007.00800.x; Loeb P. A., 1996, INDEPENDENT LIVING S; Lockenhoff CE, 2011, PSYCHOL AGING, V26, P274, DOI 10.1037/a0023280; Marson D., 2000, NEURODEGENERATIVE DE, P425; Marson DC, 2000, ARCH NEUROL-CHICAGO, V57, P877, DOI 10.1001/archneur.57.6.877; Marson DC, 2000, J AM GERIATR SOC, V48, P911, DOI 10.1111/j.1532-5415.2000.tb06887.x; Marson DC, 2005, ARCH PHYS MED REHAB, V86, P889, DOI 10.1016/j.apmr.2004.09.020; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P949, DOI 10.1001/archneur.1995.00540340029010; Marson DC, 1997, J AM GERIATR SOC, V45, P458, DOI 10.1111/j.1532-5415.1997.tb05171.x; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P955, DOI 10.1001/archneur.1995.00540340035011; Marson DC, 1996, NEUROLOGY, V46, P666, DOI 10.1212/WNL.46.3.666; Marson DC, 1997, J AM GERIATR SOC, V45, P453, DOI 10.1111/j.1532-5415.1997.tb05170.x; Marson DC, 2008, ENCY PSYCHOL LAW, V1, P313; Marson DC, 2012, FORENSIC NEUROPSYCHO, P401; Marson DC, 2012, CIVIL CAPACITIES CLI, P39; Martin R, 2008, AM J GERIAT PSYCHIAT, V16, P209, DOI 10.1097/JGP.0b013e318157cb00; Mata R, 2011, ANN NY ACAD SCI, V1235, P18, DOI 10.1111/j.1749-6632.2011.06200.x; MAZUR DJ, 1986, MED DECIS MAKING, V6, P224, DOI 10.1177/0272989X8600600407; McGwin G, 2000, ACCIDENT ANAL PREV, V32, P735, DOI 10.1016/S0001-4575(99)00123-2; Misra S, 2008, BIPOLAR DISORD, V10, P303, DOI 10.1111/j.1399-5618.2007.00525.x; Moye J, 2006, J GEN INTERN MED, V21, P78, DOI 10.1111/j.1525-1497.2005.00288.x; Moye J, 2004, GERONTOLOGIST, V44, P166, DOI 10.1093/geront/44.2.166; Moye J., 2004, ETHICS LAW AGING REV, V10, P39; Moye J, 2007, J GERONTOL B-PSYCHOL, V62, pP3, DOI 10.1093/geronb/62.1.P3; Moye J, 2007, BEHAV SCI LAW, V25, P425, DOI 10.1002/bsl.762; Moye J, 2006, CLIN PSYCHOL REV, V26, P1054, DOI 10.1016/j.cpr.2005.04.013; Moye J, 2011, JAMA-J AM MED ASSOC, V305, P936, DOI 10.1001/jama.2011.247; Moye J, 2007, CLIN GERONTOLOGIST, V31, P37, DOI 10.1080/07317110802072140; National Center on Elder Abuse, 2005, 15 QUEST ANSW ELD AB; National Conference of Commissioners on Uniform State Laws, 1982, UN GUARD PROPT P ACT; National Conference of Commissioners on Uniform State Laws, 1997, UN GUARD PROPT P ACT; Nedd H., 1998, US TODAY, P1; Palmer B. W., 2012, CIVIL CAPACITIES CLI, P69; Palmer BW, 2007, J INT NEUROPSYCH SOC, V13, P1047, DOI 10.1017/S1355617707071299; Palmer BW, 2007, J CLIN PSYCHIAT, V68, P689, DOI 10.4088/JCP.v68n0505; Park D. C., 2011, HDB PSYCHOL AGING, P109, DOI DOI 10.1016/B978-0-12-380882-0.00007-3; PARK DC, 1992, PSYCHOL AGING, V7, P252, DOI 10.1037/0882-7974.7.2.252; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, MAK HLTH CAR DEC ETH; Quinn M. J., 2004, GUARDIANSHIPS ADULTS; Roenker DL, 2003, HUM FACTORS, V45, P218, DOI 10.1518/hfes.45.2.218.27241; Rogerson MD, 2011, AM PSYCHOL, V66, P614, DOI 10.1037/a0025215; ROTH LH, 1977, AM J PSYCHIAT, V134, P279; Sabatino C. P., 2000, J MENTAL HLTH AGING, V6, P119; Salthouse T, 2012, ANNU REV PSYCHOL, V63, P201, DOI 10.1146/annurev-psych-120710-100328; Sherod MG, 2009, J INT NEUROPSYCH SOC, V15, P258, DOI 10.1017/S1355617709090365; Strough J, 2011, ANN NY ACAD SCI, V1235, P57, DOI 10.1111/j.1749-6632.2011.06208.x; Triebel KL, 2009, NEUROLOGY, V73, P928, DOI 10.1212/WNL.0b013e3181b87971; Twamley EW, 2002, AM J PSYCHIAT, V159, P2013, DOI 10.1176/appi.ajp.159.12.2013; Viertio S, 2012, EUR PSYCHIAT, V27, P409, DOI 10.1016/j.eurpsy.2010.12.005; Widera E, 2011, JAMA-J AM MED ASSOC, V305, P698, DOI 10.1001/jama.2011.164; WILLIS SL, 1993, LIFE SPAN DEV PSYCH, P33; Wong JG, 2000, PSYCHOL MED, V30, P295, DOI 10.1017/S0033291700001768; Woodhead EL, 2011, PSYCHOL AGING, V26, P285, DOI 10.1037/a0021608	106	50	51	0	49	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0003-066X	1935-990X		AM PSYCHOL	Am. Psychol.	APR	2013	68	3					158	171		10.1037/a0032159			14	Psychology, Multidisciplinary	Psychology	125EO	WOS:000317522000004	23586491	Green Accepted			2021-06-18	
J	Genet, GF; Johansson, PI; Meyer, MAS; Solbeck, S; Sorensen, AM; Larsen, CF; Welling, KL; Windelov, NA; Rasmussen, LS; Ostrowski, SR				Genet, Gustav Folmer; Johansson, Par Ingemar; Meyer, Martin Abild Stengaard; Solbeck, Sacha; Sorensen, Anne Marie; Larsen, Claus Falck; Welling, Karen Lise; Windelov, Nis Agerlin; Rasmussen, Lars S.; Ostrowski, Sisse Rye			Trauma-Induced Coagulopathy: Standard Coagulation Tests, Biomarkers of Coagulopathy, and Endothelial Damage in Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						coagulopathy; pathogenesis; TBI; trauma	DISSEMINATED INTRAVASCULAR COAGULATION; SYMPATHOADRENAL ACTIVATION; GLYCOCALYX DEGRADATION; EARLY RELEASE; HYPOPERFUSION; MORTALITY; SHOCK; INFLAMMATION; SEVERITY; RECEPTOR	It remains to be debated whether traumatic brain injury (TBI) induces a different coagulopathy than does non-TBI. This study investigated traditional coagulation tests, biomarkers of coagulopathy, and endothelial damage in trauma patients with and without TBI. Blood from 80 adult trauma patients was sampled (median of 68 min [IQR 48-88] post-injury) upon admission to our trauma center. Plasma/serum were retrospectively analyzed for biomarkers reflecting sympathoadrenal activation (adrenaline, noradrenaline), coagulation activation/inhibition and fibrinolysis (protein C, activated protein C, tissue factor pathway inhibitor, antithrombin, prothrombin fragment 1 + 2, thrombin/antithrombin complex, von Willebrand factor, factor XIII, d-dimer, tissue-type plasminogen activator, plasminogen activator inhibitor-1), immunology (interleukin [IL]6), endothelial cell/glycocalyx damage (soluble thrombomodulin, syndecan-1), and vasculogenesis (angiopoietin-1, -2). Patients were stratified according to: 1) isolated severe head/neck injuries (Abbreviated Injury Score [AIS]-head/neck >= 3, AIS-other < 3) (isoTBI); 2) severe head/neck and extracranial injuries (AIS-head/neck >= 3, AIS-other > 3) (sTBI + other); and 3) injuries without significant head/neck injuries (AIS-head/neck < 3, including all AIS-other scores) (non-TBI). Twenty-three patients presented with isoTBI, 15 with sTBI + other and 42 with non-TBI. Acute coagulopathy of trauma shock, defined as activated partial thromboplastin time (APTT) and/or international normalized ratio (INR) > 35 sec and > 1.2, was found in 13%, 47%, and 5%, respectively (p = 0.000). sTBI + other had significantly higher plasma levels of adrenaline, noradrenaline, annexin V, d-dimer, IL-6, syndecan-1, soluble thrombomodulin, and reduced protein C and factor XIII levels (all p < 0.05). No significant biomarker differences were found between isoTBI and non-TBI patients. Injury Severity Scale (ISS) rather than the presence or absence of head/neck injuries determined the hemostatic and biomarker response to the injury. The coagulopathy identified thus reflected the severity of injury rather than its localization.	[Genet, Gustav Folmer; Johansson, Par Ingemar; Meyer, Martin Abild Stengaard; Solbeck, Sacha; Windelov, Nis Agerlin; Ostrowski, Sisse Rye] Univ Copenhagen, Rigshosp, Copenhagen Univ Hosp, Transfus Med Sect,Capital Reg Blood Bank, DK-2100 Copenhagen, Denmark; [Sorensen, Anne Marie; Windelov, Nis Agerlin; Rasmussen, Lars S.] Univ Copenhagen, Rigshosp, Copenhagen Univ Hosp, Dept Anaesthesia, DK-2100 Copenhagen, Denmark; [Sorensen, Anne Marie; Larsen, Claus Falck] Univ Copenhagen, Rigshosp, Copenhagen Univ Hosp, Ctr Trauma,Ctr Head & Orthopaed, DK-2100 Copenhagen, Denmark; [Welling, Karen Lise] Univ Copenhagen, Rigshosp, Copenhagen Univ Hosp, Dept Neurointens Care, DK-2100 Copenhagen, Denmark; [Johansson, Par Ingemar] Univ Texas Houston, Sch Med, Dept Surg, Ctr Translat Injury Res, Houston, TX USA	Genet, GF (corresponding author), Univ Copenhagen, Capital Reg Blood Bank, Rigshosp, Transfus Med Sect, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	gustavgenet@hotmail.com	Solbeck, Sacha/A-2220-2016; Johansson, Par I/P-9283-2015; Meyer, Martin A. S./J-2951-2013; Ostrowski, Sisse R/E-7423-2011	Johansson, Par I/0000-0001-9778-5964; Meyer, Martin A. S./0000-0002-6312-2457; Ostrowski, Sisse R/0000-0001-5288-3851; Rasmussen, Lars/0000-0002-7480-3004	Danish Council for Independent Research (Medical Sciences)Det Frie Forskningsrad (DFF); Lundbeck FoundationLundbeckfonden; Aase and Ejnar Danielsens Foundation; L. F. Foghts Foundation; A. P. Moller and wife Chastine Mc-Kinney Mollers Foundation (Medical Sciences); Haemonectics Corp. (MA, USA); University of Copenhagen (Faculty of Health Sciences)	We thank Karen Dyerermose and Marie Helena Andersson for their skilled technical assistance. This work was supported by The Danish Council for Independent Research (Medical Sciences), The Lundbeck Foundation, Aase and Ejnar Danielsens Foundation, L. F. Foghts Foundation, A. P. Moller and wife Chastine Mc-Kinney Mollers Foundation (Medical Sciences), Haemonectics Corp. (MA, USA) and University of Copenhagen (Faculty of Health Sciences).	Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, CURR OPIN CRIT CARE, V13, P680, DOI 10.1097/MCC.0b013e3282f1e78f; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Cohen MJ, 2010, J TRAUMA, V68, P1273, DOI 10.1097/TA.0b013e3181db323e; Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152; Dirks J, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-65; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; Frith D, 2012, THROMB RES, V129, P551, DOI 10.1016/j.thromres.2011.11.053; Frith D, 2012, CURR OPIN ANESTHESIO, V25, P229, DOI 10.1097/ACO.0b013e3283509675; Frith D, 2010, SURG-J R COLL SURG E, V8, P159, DOI 10.1016/j.surge.2009.10.022; Ganter MT, 2008, ANN SURG, V247, P320, DOI 10.1097/SLA.0b013e318162d616; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Johansson PI, 2012, J THROMB HAEMOST, V10, P207, DOI 10.1111/j.1538-7836.2011.04589.x; Johansson PI, 2010, MED HYPOTHESES, V75, P564, DOI 10.1016/j.mehy.2010.07.031; Johansson PI, 2012, CRIT CARE MED, V40, P1844, DOI 10.1097/CCM.0b013e31823e9d15; Johansson PI, 2011, CRIT CARE, V15, DOI 10.1186/cc10553; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Johansson PI, 2012, J TRAUMA ACUTE CARE, V72, P428, DOI 10.1097/TA.0b013e31821e0f93; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Nag S, 2005, LAB INVEST, V85, P1189, DOI 10.1038/labinvest.3700325; Ostrowski SR, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-27; Ostrowski SR, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-64; Skaga N.O., 2012, INJURY; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1	29	50	58	0	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2013	30	4					301	306		10.1089/neu.2012.2612			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	093CM	WOS:000315169300007	23134525				2021-06-18	
J	Nichols, JE; Niles, JA; DeWitt, D; Prough, D; Parsley, M; Vega, S; Cantu, A; Lee, E; Cortiella, J				Nichols, Joan E.; Niles, Jean A.; DeWitt, Douglas; Prough, Donald; Parsley, Margaret; Vega, Stephanie; Cantu, Andrea; Lee, Eric; Cortiella, Joaquin			Neurogenic and neuro-protective potential of a novel subpopulation of peripheral blood-derived CD133+ABCG2+CXCR4+mesenchymal stem cells: development of autologous cell-based therapeutics for traumatic brain injury	STEM CELL RESEARCH & THERAPY			English	Article							CENTRAL-NERVOUS-SYSTEM; RETINOIC ACID; INFLAMMATORY RESPONSE; CHONDROITIN SULFATE; CORD BLOOD; DIFFERENTIATION; SURVIVAL; EXPRESSION; APOPTOSIS; FLUID	Introduction: Nervous system injuries comprise a diverse group of disorders that include traumatic brain injury (TBI). The potential of mesenchymal stem cells (MSCs) to differentiate into neural cell types has aroused hope for the possible development of autologous therapies for central nervous system injury. Methods: In this study we isolated and characterized a human peripheral blood derived (HPBD) MSC population which we examined for neural lineage potential and ability to migrate in vitro and in vivo. HPBD CD133+, ATP-binding cassette sub-family G member 2 (ABCG2)+, C-X-C chemokine receptor type 4 (CXCR4)+ MSCs were differentiated after priming with beta-mercaptoethanol (beta-ME) combined with trans-retinoic acid (RA) and culture in neural basal media containing basic fibroblast growth factor (FGF2) and epidermal growth factor (EGF) or co-culture with neuronal cell lines. Differentiation efficiencies in vitro were determined using flow cytometry or fluorescent microscopy of cytospins made of FACS sorted positive cells after staining for markers of immature or mature neuronal lineages. RA-primed CD133+ABCG2+CXCR4+ human MSCs were transplanted into the lateral ventricle of male Sprague-Dawley rats, 24 hours after sham or traumatic brain injury (TBI). All animals were evaluated for spatial memory performance using the Morris Water Maze (MWM) Test. Histological examination of sham or TBI brains was done to evaluate MSC survival, migration and differentiation into neural lineages. We also examined induction of apoptosis at the injury site and production of MSC neuroprotective factors. Results: CD133+ABCG2+CXCR4+ MSCs consistently expressed markers of neural lineage induction and were positive for nestin, microtubule associated protein-1 beta (MAP-1 beta), tyrosine hydroxylase (TH), neuron specific nuclear protein (NEUN) or type III beta-tubulin (Tuj1). Animals in the primed MSC treatment group exhibited MWM latency results similar to the uninjured (sham) group with both groups showing improvements in latency. Histological examination of brains of these animals showed that in uninjured animals the majority of MSCs were found in the lateral ventricle, the site of transplantation, while in TBI rats MSCs were consistently found in locations near the injury site. We found that levels of apoptosis were less in MSC treated rats and that MSCs could be shown to produce neurotropic factors as early as 2 days following transplantation of cells. In TBI rats, at 1 and 3 months post transplantation cells were generated which expressed markers of neural lineages including immature as well as mature neurons. Conclusions: These results suggest that PBD CD133+ABCG2+CXCR4+ MSCs have the potential for development as an autologous treatment for TBI and neurodegenerative disorders and that MSC derived cell products produced immediately after transplantation may aid in reducing the immediate cognitive defects of TBI.	[Nichols, Joan E.; Niles, Jean A.; Vega, Stephanie; Cantu, Andrea; Lee, Eric; Cortiella, Joaquin] Univ Texas Med Branch, Lab Tissue Engn & Regenerat Med, Galveston, TX 77555 USA; [Nichols, Joan E.; Niles, Jean A.; Vega, Stephanie] Univ Texas Med Branch, Div Infect Dis, Dept Internal Med, Galveston, TX 77555 USA; [DeWitt, Douglas; Prough, Donald; Parsley, Margaret; Lee, Eric; Cortiella, Joaquin] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA	Nichols, JE (corresponding author), Univ Texas Med Branch, Lab Tissue Engn & Regenerat Med, 301 Univ Blvd,Mail Route 0435, Galveston, TX 77555 USA.	jnichols@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X; Cantu, Andrea/0000-0002-1466-2510	Moody Center for Brain and Spinal Cord Research/Mission Connect (The Moody Center)	This research was supported by The Moody Center for Brain and Spinal Cord Research/Mission Connect (The Moody Center). We would like to thank Dr Gerald Campbell MD PhD from the UTMB Dept of Pathology, Division of Neuropathology for his invaluable support in data analysis. We would like to thank Kenneth D Frohne for his help with images and publishing software. We also need to thank Tatsuo Uchida for doing the statistical analysis of the MWM data. We are indebted to Joe and Nina Brown for their constant support and their belief in the potential of stem cell therapies.	Barraud P, 2007, J NEUROSCI RES, V85, P250, DOI 10.1002/jnr.21116; Caldwell MA, 2005, EUR J NEUROSCI, V22, P2965, DOI 10.1111/j.1460-9568.2005.04504.x; Canas N, 2011, NEUROCHEM INT, V58, P676; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Christopherson GT, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt81; Conti AC, 1998, J NEUROSCI, V18, P5663; Cortiella J, 2006, TISSUE ENG, V12, P1213, DOI 10.1089/ten.2006.12.1213; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Curry DJ, 2004, J NEUROSURG, V101, P91, DOI 10.3171/ped.2004.101.2.0091; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Egea J, 2010, OSTEOARTHR CARTILAGE, V18, pS24, DOI 10.1016/j.joca.2010.01.016; Felszeghy K, 2004, NEUROIMMUNOMODULAT, V11, P404, DOI 10.1159/000080151; Gang EJ, 2007, BLOOD, V109, P1743, DOI 10.1182/blood-2005-11-010504; Habich A, 2006, EXP HEMATOL, V34, P914, DOI 10.1016/j.exphem.2006.03.010; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; HENION PD, 1994, DEV BIOL, V161, P243, DOI 10.1006/dbio.1994.1024; Islam MO, 2005, NEUROSCI RES, V52, P75, DOI 10.1016/j.neures.2005.01.013; Jacobs S, 2006, P NATL ACAD SCI USA, V103, P3902, DOI 10.1073/pnas.0511294103; Jang YK, 2004, J NEUROSCI RES, V75, P573, DOI 10.1002/jnr.10789; Jiao J, 2008, STEM CELLS, V26, P1221, DOI 10.1634/stemcells.2007-0513; Khattak SF, 2005, TISSUE ENG, V11, P974, DOI 10.1089/ten.2005.11.974; Kim S, 2006, BRAIN RES, V1123, P27, DOI 10.1016/j.brainres.2006.09.044; Kuci S, 2008, CELL PROLIFERAT, V41, P12, DOI 10.1111/j.1365-2184.2007.00502.x; Lameu C, 2012, J BIOL CHEM, V287, P29690, DOI 10.1074/jbc.M111.338095; Li LL, 2011, BIOMATERIALS, V32, P4489, DOI 10.1016/j.biomaterials.2011.03.019; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McGuckin C, 2008, NAT PROTOC, V3, P1046, DOI 10.1038/nprot.2008.69; Miller RH, 2010, DISCOV MED, V9, P236; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Molyneaux KA, 2003, DEVELOPMENT, V130, P4279, DOI 10.1242/dev.00640; Morando S, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt94; Nichols JE, 2001, J VIROL, V75, P5921, DOI 10.1128/JVI.73.13.5921-5929.2001; Ohishi M, 2010, J CELL BIOCHEM, V109, P277, DOI 10.1002/jcb.22399; Parish Christopher R, 2009, Curr Protoc Immunol, VChapter 4, DOI 10.1002/0471142735.im0409s84; Pluchino S, 2008, BRAIN, V131, P2564, DOI 10.1093/brain/awn198; Pozzobon M, 2009, STEM CELLS DEV, V18, P497, DOI 10.1089/scd.2008.0003; Pruszak J, 2007, STEM CELLS, V25, P2257, DOI 10.1634/stemcells.2006-0744; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Ross HH, 2008, STEM CELLS, V26, P3218, DOI 10.1634/stemcells.2008-0299; SAS Institute Inc, 2004, SAS 9 1 3 ETL STUD U; Sawamoto K, 2006, SCIENCE, V311, P629, DOI 10.1126/science.1119133; Schurman WT, 1999, J AEROSOL MED, V10, P1; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Shi MX, 2007, HAEMATOLOGICA, V92, P897, DOI 10.3324/haematol.10669; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Shioda N, 2009, INT REV NEUROBIOL, V85, P375, DOI 10.1016/S0074-7742(09)85026-5; Smith GM, 2005, GLIA, V52, P209, DOI 10.1002/glia.20236; Stumm RK, 2002, J NEUROSCI, V22, P5865; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Ukai R, 2007, J NEUROTRAUM, V24, P508, DOI 10.1089/neu.2006.0161; Wang SP, 2012, MOL MED REP, V6, P848, DOI 10.3892/mmr.2012.997; Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006; Willerth SM, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt58; Xiong Y, 2010, DISCOV MED, V10, P434	60	50	53	0	12	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-6512			STEM CELL RES THER	Stem Cell Res. Ther.	JAN 6	2013	4								3	10.1186/scrt151			23	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	086XI	WOS:000314722400001	23290300	DOAJ Gold, Green Published			2021-06-18	
J	Bryan, CJ; Clemans, TA; Hernandez, AM; Rudd, MD				Bryan, Craig J.; Clemans, Tracy A.; Hernandez, Ann Marie; Rudd, Michael David			Loss of Consciousness, Depression, Posttraumatic Stress Disorder, and Suicide Risk Among Deployed Military Personnel With Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; depression; insomnia; loss of consciousness; military; posttraumatic stress disorder; suicide; traumatic brain injury	MENTAL-HEALTH-SERVICES; MAJOR DEPRESSION; INDIVIDUALS; PREVALENCE; VALIDATION	Objective: To identify clinical variables associated with suicidality in military personnel with mild traumatic brain injury (mTBI) while deployed to Iraq. Setting: Outpatient TBI clinic on a US military base in Iraq. Participants: Military personnel (N = 158) referred to an outpatient TBI clinic for a standardized intake evaluation, 135 (85.4%) who had a diagnosis of mTBI and 23 (14.6%) who did not meet criteria for TBI. Main Measures: Suicidal Behaviors Questionnaire-Revised, Depression subscale of the Behavioral Health Measure-20, Posttraumatic Stress Disorder Checklist-Military Version, Insomnia Severity Index, self-report questionnaire, and clinical interview addressing TBI-related symptoms. Results: Among patients with mTBI, increased suicidality was significantly associated with depression and the interaction of depression with posttraumatic stress disorder symptoms. Longer duration of loss of consciousness was associated with decreased likelihood for any suicidality. Conclusion: Assessment after TBI in a combat zone may assist providers in identifying those at risk for suicidality and making treatment recommendations for service members with mTBI.	[Bryan, Craig J.; Rudd, Michael David] Univ Utah, Natl Ctr Vet Studies, Salt Lake City, UT 84112 USA; [Clemans, Tracy A.] Univ Colorado, Sch Med, Dept Psychiat, VISN Mental Illness Res Educ Clin Ctr 19, Denver, CO 80262 USA; [Hernandez, Ann Marie] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA	Bryan, CJ (corresponding author), Univ Utah, Natl Ctr Vet Studies, 260 S Cent Campus Dr,Room 205, Salt Lake City, UT 84112 USA.	craig.bryan@utah.edu	Rudd, M. David/AAF-1359-2019	Bryan, Craig/0000-0002-9714-0733			ANSTEY K, 2002, J CLIN EPIDEMIOL, V57, P1202; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Blount TH, 2011, ANN M ASS BEH COGN T; Brenner LA, 2011, SUICIDE LIFE-THREAT, V41, P416, DOI 10.1111/j.1943-278X.2011.00041.x; Campbell DG, 2007, J GEN INTERN MED, V22, P711, DOI 10.1007/s11606-006-0101-4; Carrion J, 2001, BRAIN INJURY, V15, P175; Deb S, 1999, AM J PSYCHIAT, V156, P374; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fischer H, 2010, US MILITARY CASUALTY; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kishi Y, 2001, J NERV MENT DIS, V189, P623, DOI 10.1097/00005053-200109000-00009; Kopta SM, 2002, PSYCHOTHER RES, V12, P413, DOI 10.1093/ptr/12.4.413; Martin J., 2009, J MENT HEALTH, V31, P101, DOI DOI 10.17744/MEHC.31.2.A6338384R2770383; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Osman A, 2001, ASSESSMENT, V8, P443, DOI 10.1177/107319110100800409; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Rudd MD, 2011, PROF PSYCHOL-RES PR, V42, P354, DOI 10.1037/a0025164; Sher L, 2009, EXPERT REV NEUROTHER, V9, P921, DOI [10.1586/ern.09.61, 10.1586/ERN.09.61]; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; US Army, 2009, ARM HLTH PROM RISK R; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; Weathers FW, 2011, 9 ANN C INT SOC TRAU; Westat US Department of Veterans Affairs, 2010, NAT SURV VET ACT DUT	31	50	50	1	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2013	28	1					13	20		10.1097/HTR.0b013e31826c73cc			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	070ZW	WOS:000313555400002	23076097				2021-06-18	
J	Joseph, B; Hadjizacharia, P; Aziz, H; Kulvatunyou, N; Tang, A; Pandit, V; Wynne, J; O'Keeffe, T; Friese, RS; Rhee, P				Joseph, Bellal; Hadjizacharia, Pantelis; Aziz, Hassan; Kulvatunyou, Narong; Tang, Andrew; Pandit, Viraj; Wynne, Julie; O'Keeffe, Terence; Friese, Randall S.; Rhee, Peter			Prothrombin complex concentrate: An effective therapy in reversing the coagulopathy of traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Prothrombin concentrate complex; rFVIIa; traumatic brain injury; coagulopathy of trauma; craniotomy	RECOMBINANT-FACTOR-VIIA; COAGULATION; COMPLICATIONS; EFFICACY; PLASMA	BACKGROUND: Coagulopathy in patients with traumatic brain injury (TBI) is a well-studied concept. Prothrombin complex concentrate (PCC) has been shown to be an effective treatment modality for correction of TBI coagulopathy. However, its use and effectiveness compared with recombinant factor VII (rFVIIa) in TBI has not been established. The purpose of this study was to compare PCC and rFVIIa for the correction of TBI coagulopathy. METHODS: All patients with a TBI and an induced or acquired coagulopathy whom received rFVIIa or PCC at our Level I trauma center during a 4-year period were reviewed. Data collected included demographics, changes in international normalized ratio and blood products transfusion, craniotomy rates, and time to neurosurgical intervention, thromboembolic complications, and mortality differences. RESULTS: The study was composed of 85 TBI patients, of whom 64 patients received PCC while 21 patients received rFVIIa. PCC group were more likely to be on coumadin (44% vs. 14%, p = 0.01). There was a significant decline in packed red blood cell transfusion and fresh frozen plasma after PCC administration (p < 0.01). There was no statistically significant difference in the craniotomy rate (28% vs. 10%, p = 0.1) or the mean time to intervention between the two groups (201 [33] vs. 230 [10], p = 0.9). Mortality rates were lower in the PCC group compared with rFVIIa (67% vs. 47%, p = 0.02). Subsequent thromboembolic event was seen in one patient on rFVIIa. Mean cost of treatment per patient on PCC was $1,007 compared with $5,757 for rFVIIa (p < 0.01). CONCLUSION: PCC is safe and effective for treating coagulopathy in TBI patients, while reducing costs and resource use. PCC should be considered as an effective therapy to treat both acquired and induced coagulopathy in TBI with or without prehospital coumadin use. (J Trauma Acute Care Surg. 2013;74: 248-253. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Joseph, Bellal; Hadjizacharia, Pantelis; Aziz, Hassan; Kulvatunyou, Narong; Tang, Andrew; Pandit, Viraj; Wynne, Julie; O'Keeffe, Terence; Friese, Randall S.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma, Tucson, AZ 85724 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Rm 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu					Aguilar MI, 2007, MAYO CLIN PROC, V82, P82, DOI 10.1016/s0025-6196(11)60970-1; Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670; Beck KH, 2000, INFUS THER TRANSFUS, V27, P144; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Brohi K, 2009, J R Army Med Corps, V155, P320; Dewall Jeremy, 2010, JEMS, V35, P54, DOI 10.1016/S0197-2510(10)70095-4; Dickneite G, 2010, J TRAUMA, V68, P1151, DOI 10.1097/TA.0b013e3181b06364; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; Fries D, 2006, BRIT J ANAESTH, V97, P460, DOI 10.1093/bja/ael191; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hirsh J, 2003, J AM COLL CARDIOL, V41, P1633, DOI 10.1016/S0735-1097(03)00416-9; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Holland L, 2009, TRANSFUSION, V49, P1171, DOI 10.1111/j.1537-2995.2008.02080.x; Joseph B, 2012, J TRAUMA ACUTE CARE, V72, P828, DOI 10.1097/TA.0b013e318247c944; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Levy JH, 2008, ANESTHESIOLOGY, V109, P918, DOI 10.1097/ALN.0b013e3181895bd8; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Meng ZH, 2003, J TRAUMA, V55, P886, DOI 10.1097/01.TA.0000066184.20808.A5; O'Connell KA, 2006, JAMA-J AM MED ASSOC, V295, P293, DOI 10.1001/jama.295.3.293; Pabinger I, 2008, J THROMB HAEMOST, V6, P622, DOI 10.1111/j.1538-7836.2008.02904.x; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Safaoui MN, 2009, AM J SURG, V197, P785, DOI 10.1016/j.amjsurg.2008.04.003; Spinella PC, 2009, BLOOD REV, V23, P231, DOI 10.1016/j.blre.2009.07.003; Staudinger T, 1999, INTENS CARE MED, V25, P1105, DOI 10.1007/s001340051019; Stein DM, 2008, INJURY, V39, P1054, DOI 10.1016/j.injury.2008.03.032; Stein DM, 2008, J TRAUMA, V64, P620, DOI 10.1097/TA.0b013e3181650fc7; Stein DM, 2009, J TRAUMA, V66, P63, DOI 10.1097/TA.0b013e318191bc8a; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2	28	50	50	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2013	74	1					248	253		10.1097/TA.0b013e3182788a40			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	071VI	WOS:000313623300057	23271101				2021-06-18	
J	Wada, T; Asano, Y; Shinoda, J				Wada, T.; Asano, Y.; Shinoda, J.			Decreased Fractional Anisotropy Evaluated Using Tract-Based Spatial Statistics and Correlated with Cognitive Dysfunction in Patients with Mild Traumatic Brain Injury in the Chronic Stage	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							DIFFUSE AXONAL INJURY; NONMISSILE HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; VOXELWISE ANALYSIS; SYMPTOMS; DAMAGE	BACKGROUND AND PURPOSE: The relationship between white matter disruption and cognitive dysfunction of patients with mTBI in the chronic stage remains unclear. The aim of this study was to identify white matter integrity by using DTI in patients with mTBI without morphologic traumatic abnormalities seen with conventional imaging and to evaluate the association of such regions with cognitive function. MATERIALS AND METHODS: Diffusion tensor images from 51 consecutive patients with mTBI without morphologic traumatic abnormalities on conventional MRI were processed, and FA maps were generated as a measure of white matter integrity. All subjects underwent cognitive examinations (MMSE and WAIS-R FIQ). Correlations between the skeletonized FA values in the white matter and the cognitive function were analyzed by using regression analysis. RESULTS: In patients with mTBI, significantly decreased FA value clusters in the white matter compared with the healthy controls were found in the superior longitudinal fasciculus, superior frontal gyrus, insula, and fornix. Cognitive examination scores positively correlated with FA values in a number of regions in deep brain structures, which were anatomically close or physiologically intimate to the regions with significant FA value reduction, in patients with mTBI. CONCLUSIONS: The present study shows that patients with mTBI in the chronic stage have certain regions with abnormally reduced white matter integrity in the brain. Although the clinical and pathologic-anatomic correlation of these findings remains to be elucidated, these brain regions are strongly suggested to be related to chronic persistent cognitive impairments in these patients.	[Wada, T.] Gifu Univ, Grad Sch Med, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, Kizawa Mem Hosp, Gifu 5050034, Japan; [Wada, T.] Gifu Univ, Grad Sch Med, Dept Clin Brain Sci, Gifu 5050034, Japan	Wada, T (corresponding author), Gifu Univ, Grad Sch Med, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, Kizawa Mem Hosp, 630 Shimokobi,Kobi Cho, Gifu 5050034, Japan.	tetsuya-wada@umin.ac.jp					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; JENNETT B, 1978, PRACTITIONER, V221, P76; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Masutani Y, 2003, EUR J RADIOL, V46, P53, DOI 10.1016/S0720-048X(02)00328-5; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McMillan TM, 2004, BRAIN INJURY, V18, P935, DOI 10.1080/02699050410001675915; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Oishi K., 2011, MRI ATLAS HUMAN WHIT; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Rimrodt SL, 2010, CORTEX, V46, P739, DOI 10.1016/j.cortex.2009.07.008; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sosin DM, 1996, BRAIN INJURY, V10, P47; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	40	50	51	0	9	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	DEC	2012	33	11					2117	2122		10.3174/ajnr.A3141			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	063AU	WOS:000312968500016	22723057	Green Published, Other Gold			2021-06-18	
J	Rivara, FP; Koepsell, TD; Wang, J; Temkin, N; Dorsch, A; Vavilala, MS; Durbin, D; Jaffe, KM				Rivara, Frederick P.; Koepsell, Thomas D.; Wang, Jin; Temkin, Nancy; Dorsch, Andrea; Vavilala, Monica S.; Durbin, Dennis; Jaffe, Kenneth M.			Incidence of Disability Among Children 12 Months After Traumatic Brain Injury	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							QUALITY-OF-LIFE; HEAD; CONCUSSIONS; SPORT	Objectives. We examined the burden of disability resulting from traumatic brain injuries (TBIs) among children younger than 18 years. Methods. We derived our data from a cohort study of children residing in King County, Washington, who were treated in an emergency department for a TBI or for an arm injury during 2007-2008. Disabilities 12 months after injury were assessed according to need for specialized educational and community-based services and scores on standardized measures of adaptive functioning and social community participation. Results. The incidence of children receiving new services at 12 months was about 10-fold higher among those with a mild TBI than among those with a moderate or severe TBI. The population incidence of disability (defined according to scores below the norm means on the outcome measures included) was also consistently much larger (2.8-fold to 28-fold) for mild TBIs than for severe TBIs. Conclusions. The burden of disability caused by TBIs among children is primarily accounted for by mild injuries. Efforts to prevent these injuries as well as to decrease levels of disability following TBIs are warranted. (Am J Public Health. 2012;102:2074-2079. doi:10.2105/AJPH.2012.300696)	[Rivara, Frederick P.; Wang, Jin] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Rivara, Frederick P.; Koepsell, Thomas D.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Koepsell, Thomas D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; [Temkin, Nancy; Jaffe, Kenneth M.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Dorsch, Andrea] Seattle Childrens Hosp, Dept Rehabil Med, Seattle, WA USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Pain Med & Pediat, Seattle, WA 98195 USA; [Durbin, Dennis] Childrens Hosp Philadelphia, Dept Emergency Med, Philadelphia, PA USA; [Durbin, Dennis] Univ Penn, Philadelphia, PA 19104 USA; [Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA	Rivara, FP (corresponding author), Harborview Injury Prevent & Res Ctr, Box 359960,325 9th Ave, Seattle, WA 98104 USA.	fpr@uw.edu			National Center for Injury Prevention and Control, Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE 001021]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001021] Funding Source: NIH RePORTER	This project was supported by the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (grant R49 CE 001021).	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; [Anonymous], 2010, OFFICIAL POPULATION; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Bedell G., 2006, BRAIN INJ PROF, V3, P14; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Centers for Disease Control and Prevention, 2003, REPORT TO CONGRESS O; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guice KS, 2007, J TRAUMA, V63, pS68, DOI 10.1097/TA.0b013e31815acbb6; Harrison PL, 2003, ADAPTIVE BEHAVIOR AS; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Langlois JA, 2000, TRAUMATIC BRAIN INJU; Marr AL., 2004, CENTRAL NERVOUS SYST; McCarthy ML, 2007, J TRAUMA, V63, pS122, DOI 10.1097/TA.0b013e31815accdf; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Mitka M, 2010, JAMA-J AM MED ASSOC, V304, P1775, DOI 10.1001/jama.2010.1487; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Numminen HJ, 2011, EUR J NEUROL, V18, P460, DOI 10.1111/j.1468-1331.2010.03179.x; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Rivara FP, 2011, HEALTH SERV RES, V46, P964, DOI 10.1111/j.1475-6773.2010.01236.x; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Straume-Naesheim TM, 2009, NEUROSURGERY, V64, P719, DOI 10.1227/01.NEU.0000340681.12949.6D; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; US Equal Employment Opportunity Commission, SECTION 902 DEFINITI; Varni JW, 2009, PEDIATR CLIN N AM, V56, P843, DOI 10.1016/j.pcl.2009.05.016; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Washington State Legislature, CHILD WITH A DISABIL; World Health Organization, 2001, INTERNATIONAL CLASSI; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	32	50	50	1	16	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	NOV	2012	102	11					2074	2079		10.2105/AJPH.2012.300696			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	028CB	WOS:000310399300014	22994196	Green Published			2021-06-18	
J	Ross, DE; Ochs, AL; Seabaugh, JM; Demark, MF; Shrader, CR; Marwitz, JH; Havranek, MD				Ross, David E.; Ochs, Alfred L.; Seabaugh, Jan M.; Demark, Michael F.; Shrader, Carole R.; Marwitz, Jennifer H.; Havranek, Michael D.		Alzheimers Dis Neuroimaging Initia	Progressive brain atrophy in patients with chronic neuropsychiatric symptoms after mild traumatic brain injury: A preliminary study	BRAIN INJURY			English	Article						Traumatic brain injury; magnetic resonance imaging; volumetry; cortical atrophy; longitudinal study; medicolegal; vocational outcome; NeuroQuant (R)	DISABILITY RATING-SCALE; VOLUMETRY; MRI	Introduction: NeuroQuant (R) is a recently developed, FDA-approved software program for measuring brain MRI volume in clinical settings. The aims of this study were as follows: (1) to examine the test-retest reliability of NeuroQuant (R); (2) to test the hypothesis that patients with mild traumatic brain injury (TBI) would have abnormally rapid progressive brain atrophy; and (3) to test the hypothesis that progressive brain atrophy in patients with mild TBI would be associated with vocational outcome. Methods: Sixteen patients with mild TBI were compared to 20 normal controls. Vocational outcome was assessed with the Glasgow Outcome Scale-Extended (GOSE) and Disability Rating Scale (DRS). Results: NeuroQuant (R) showed high test-re-test reliability. Patients had abnormally rapid progressive atrophy in several brain regions and the rate of atrophy was associated with inability to return to work. Conclusions: NeuroQuant (R), is a reliable and valid method for assessing the anatomic effects of TBI. Progression of atrophy may continue for years after injury, even in patients with mild TBI.	[Ross, David E.; Ochs, Alfred L.; Seabaugh, Jan M.; Demark, Michael F.; Shrader, Carole R.] Virginia Inst Neuropsychiat, Midlothian, VA 23114 USA; [Ross, David E.; Ochs, Alfred L.; Marwitz, Jennifer H.] Virginia Commonwealth Univ, Richmond, VA USA; [Havranek, Michael D.] Amicus Visual Solut, Richmond, VA USA	Ross, DE (corresponding author), Virginia Inst Neuropsychiat, 364 Browns Hill Court, Midlothian, VA 23114 USA.	dross@vaneuropsychiatry.org		Ochs, Alfred/0000-0003-3932-876X	Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 AG024904]; National Institute on Aging, the National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)NIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 AG010129, K01 AG030514]; Dana Foundation; Virginia Institute of Neuropsychiatry; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG024904, K01AG030514, P30AG010129] Funding Source: NIH RePORTER	Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., as well as non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the US Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education and the study is co-ordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129, K01 AG030514 and the Dana Foundation.; Other than the funding for the ADNI normal controls, as noted above, this project was funded by the Virginia Institute of Neuropsychiatry. The authors report no conflicts of interest, including no financial interests or investments with CorTechs Labs (R), maker of NeuroQuant (R).	BIGLER ED, 2005, TXB TRAUMATIC BRAIN, P79, DOI DOI 10.1007/S00417-005-0003-X; Bigler ED, 2011, TXB TRAUMATIC BRAIN, P73, DOI DOI 10.1177/1753193410381840; Brewer JB, 2009, BEHAV NEUROL, V21, P21, DOI [10.3233/BEN-2009-0226, 10.1155/2009/616581]; Brewer JB, 2009, AM J NEURORADIOL, V30, P578, DOI 10.3174/ajnr.A1402; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Huppertz HJ, 2010, NEUROIMAGE, V49, P2216, DOI 10.1016/j.neuroimage.2009.10.066; Kovacevic S, 2009, ALZ DIS ASSOC DIS, V23, P139, DOI 10.1097/WAD.0b013e318192e745; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Petersen RC, 2010, NEUROLOGY, V74, P201, DOI 10.1212/WNL.0b013e3181cb3e25; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Ross DE, J NEUROPSYCHIATRY CL, V24, pE33; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Silver JM., 2011, TXB TRAUMATIC BRAIN, V2nd ed.; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Weiner MW, 2010, ALZHEIMERS DEMENT, V6, P202, DOI 10.1016/j.jalz.2010.03.007; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	23	50	50	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2012	26	12					1500	1509		10.3109/02699052.2012.694570			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	022DL	WOS:000309935400011	22721509				2021-06-18	
J	Saykally, JN; Rachmany, L; Hatic, H; Shaer, A; Rubovitch, V; Pick, CG; Citron, BA				Saykally, J. N.; Rachmany, L.; Hatic, H.; Shaer, A.; Rubovitch, V.; Pick, C. G.; Citron, B. A.			THE NUCLEAR FACTOR ERYTHROID 2-LIKE 2 ACTIVATOR, TERT-BUTYLHYDROQUINONE, IMPROVES COGNITIVE PERFORMANCE IN MICE AFTER MILD TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						traumatic brain injury; transcription factors; Nrf2; HSP70	OXIDATIVE STRESS; HEAD-INJURY; MEMORY; NEURONS; ASTROCYTES; DEFICITS; DAMAGE; MODEL; IDENTIFICATION; VULNERABILITY	Traumatic Brain injury affects at least 1.7 million people in the United States alone each year. The majority of injuries are categorized as mild but these still produce lasting symptoms that plague the patient and the medical field. Currently treatments are aimed at reducing a patient's symptoms, but there is no effective method to combat the source of the problem, neuronal loss. We tested a mild, closed head traumatic brain injury model for the effects of modulation of the antioxidant transcription factor Nrf2 by the chemical activator, tert-butylhydroquinone (tBHQ). We found that post-injury visual memory was improved by a 7 day course of treatment and that the level of activated caspase-3 in the hippocampus was reduced. The injury-induced memory loss was also reversed by a single injection at 30 min after injury. Since the protective stress response molecule, HSP70, can be upregulated by Nrf2, we examined protein levels in the hippocampus, and found that HSP70 was elevated by the injury and then further increased by the treatment. To test the possible role of HSP70, model neurons in culture exposed to a mild injury and treated with the Nrf2 activator displayed improved survival that was blocked by the HSP70 inhibitor, VER155008. Following mild traumatic brain injury, there may be a partial protective response and patients could benefit from directed enhancement of regulatory pathways such as Nrf2 for neuroprotection. Published by Elsevier Ltd. on behalf of IBRO.	[Saykally, J. N.; Hatic, H.; Citron, B. A.] Mol Biol Lab, Bay Pines, FL 33744 USA; [Saykally, J. N.; Hatic, H.; Citron, B. A.] USF Morsani Coll Med, Dept Mol Med, Tampa, FL 33612 USA; [Rachmany, L.; Shaer, A.; Rubovitch, V.; Pick, C. G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel	Citron, BA (corresponding author), Mol Biol Lab, Res & Dev 151,Bldg 22,Room 123,POB 4125, Bay Pines, FL 33744 USA.	bruce.citron@va.gov	Pick, Chaim/D-4789-2009		Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development)US Department of Veterans Affairs; Florida Department of Health James and Esther King Biomedical Research Program; Bay Pines Foundation; University of South Florida Signature Interdisciplinary Program in Neuroscience	Acknowledgments-The authors thank Andrea Smith for expert assistance with animal studies. This study was supported by the Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development), the Florida Department of Health James and Esther King Biomedical Research Program, the Bay Pines Foundation, and the University of South Florida Signature Interdisciplinary Program in Neuroscience.	Abr`amoff M.D., 2005, BIOPHOTONICS INT, V11, P36, DOI [10.1117/1.3589100, DOI 10.1117/1.3589100]; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beere HM, 2000, NAT CELL BIOL, V2, P469; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hammond RS, 2004, NEUROBIOL LEARN MEM, V82, P26, DOI 10.1016/j.nlm.2004.03.005; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Jakel RJ, 2007, BRAIN RES, V1144, P192, DOI 10.1016/j.brainres.2007.01.131; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Johnson JA, 2008, ANN NY ACAD SCI, V1147, P61, DOI 10.1196/annals.1427.036; Kane MJ, 2011, BRAIN RES, V1425, P123, DOI 10.1016/j.brainres.2011.09.047; Kane Michael J, 2009, Recent Pat CNS Drug Discov, V4, P190; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; RempelClower NL, 1996, J NEUROSCI, V16, P5233; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Saleh A, 2000, NAT CELL BIOL, V2, P476; Shih AY, 2007, J NEUROCHEM, V101, P109, DOI 10.1111/j.1471-4159.2006.04345.x; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shum DHK, 2000, J CLIN EXP NEUROPSYC, V22, P25, DOI 10.1076/1380-3395(200002)22:1;1-8;FT025; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	56	50	52	0	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT 25	2012	223						305	314		10.1016/j.neuroscience.2012.07.070			10	Neurosciences	Neurosciences & Neurology	018VM	WOS:000309694700031	22890082				2021-06-18	
J	Kraft, RH; Mckee, PJ; Dagro, AM; Grafton, ST				Kraft, Reuben H.; Mckee, Phillip Justin; Dagro, Amy M.; Grafton, Scott T.			Combining the Finite Element Method with Structural Connectome-based Analysis for Modeling Neurotrauma: Connectome Neurotrauma Mechanics	PLOS COMPUTATIONAL BIOLOGY			English	Article							GRAPH-THEORETICAL ANALYSIS; TRAUMATIC BRAIN-INJURY; DYNAMIC-RESPONSE; CONNECTIVITY; NETWORKS; LESIONS; SYSTEM; TISSUE; STEM	This article presents the integration of brain injury biomechanics and graph theoretical analysis of neuronal connections, or connectomics, to form a neurocomputational model that captures spatiotemporal characteristics of trauma. We relate localized mechanical brain damage predicted from biofidelic finite element simulations of the human head subjected to impact with degradation in the structural connectome for a single individual. The finite element model incorporates various length scales into the full head simulations by including anisotropic constitutive laws informed by diffusion tensor imaging. Coupling between the finite element analysis and network-based tools is established through experimentally-based cellular injury thresholds for white matter regions. Once edges are degraded, graph theoretical measures are computed on the "damaged" network. For a frontal impact, the simulations predict that the temporal and occipital regions undergo the most axonal strain and strain rate at short times (less than 24 hrs), which leads to cellular death initiation, which results in damage that shows dependence on angle of impact and underlying microstructure of brain tissue. The monotonic cellular death relationships predict a spatiotemporal change of structural damage. Interestingly, at 96 hrs post-impact, computations predict no network nodes were completely disconnected from the network, despite significant damage to network edges. At early times (t<24 hrs) network measures of global and local efficiency were degraded little; however, as time increased to 96 hrs the network properties were significantly reduced. In the future, this computational framework could help inform functional networks from physics-based structural brain biomechanics to obtain not only a biomechanics-based understanding of injury, but also neurophysiological insight.	[Kraft, Reuben H.; Dagro, Amy M.] USA, Soldier Protect Sci Branch, Protect Div, Res Lab, Aberdeen Proving Ground, MD USA; [Mckee, Phillip Justin] Dynamic Sci Inc, Aberdeen Proving Ground, MD USA; [Grafton, Scott T.] Univ Calif Santa Barbara, Dept Psychol, Santa Barbara, CA 93106 USA	Kraft, RH (corresponding author), USA, Soldier Protect Sci Branch, Protect Div, Res Lab, Aberdeen Proving Ground, MD USA.	reuben.kraft@gmail.com		Dagro, Amy/0000-0002-3250-3732	U.S. Department of Defense, Department of the ArmyUnited States Department of Defense	This work was funded by the U.S. Department of Defense, Department of the Army. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acar ZA, 2010, J NEUROSCI METH, V190, P258, DOI 10.1016/j.jneumeth.2010.04.031; Alstott J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000408; Arbogast KB, 1999, J BIOMECH, V32, P865, DOI 10.1016/S0021-9290(99)00042-1; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bassett DS, 2011, NEUROIMAGE, V54, P1262, DOI 10.1016/j.neuroimage.2010.09.006; Belytschko T., 2000, NONLINEAR FINITE ELE; Bernick KB, 2011, ACTA BIOMATER, V7, P1210, DOI 10.1016/j.actbio.2010.10.018; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chafi MS, 2011, INT J APPL MECH, V3, P803, DOI 10.1142/S175882511100124X; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Dauguet J, 2007, NEUROIMAGE, V37, P530, DOI 10.1016/j.neuroimage.2007.04.067; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Effgen G. B., 2012, FRONT NEUROL, V3, P1; Effgen Gwen B, 2012, Front Neurol, V3, P23, DOI 10.3389/fneur.2012.00023; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Hagmann P, 2006, RADIOGRAPHICS, V26, pS205, DOI 10.1148/rg.26si065510; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Honey CJ, 2008, HUM BRAIN MAPP, V29, P802, DOI 10.1002/hbm.20579; Honey CJ, 2010, NEUROIMAGE, V52, P766, DOI 10.1016/j.neuroimage.2010.01.071; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hosmane S, 2011, LAB CHIP, V11, P3888, DOI 10.1039/c1lc20549h; Iturria-Medina Y, 2011, CEREB CORTEX, V21, P56, DOI 10.1093/cercor/bhq058; Jarbo K, 2012, NEUROIMAGE, V59, P1988, DOI 10.1016/j.neuroimage.2011.09.056; Jirsa VK, 2010, ARCH ITAL BIOL, V148, P189; Kaiser M, 2007, EUR J NEUROSCI, V25, P3185, DOI 10.1111/j.1460-9568.2007.05574.x; Kraft RH, 2011, ARLTR5796; Kuceyeski A, 2011, NEUROIMAGE, V58, P109, DOI 10.1016/j.neuroimage.2011.05.087; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Lee WH, 2012, MED ENG PHYS, V34, P85, DOI 10.1016/j.medengphy.2011.07.002; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mendis K., 1992, THESIS OHIO STATE U; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Morrison B, 2011, STUD MECHANOBIOL TIS, V3, P247, DOI 10.1007/8415_2011_79; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nahum A. M., 1977, P 21 STAPP CAR CRASH; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Reijneveld JC, 2007, CLIN NEUROPHYSIOL, V118, P2317, DOI 10.1016/j.clinph.2007.08.010; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Rullmann M, 2009, NEUROIMAGE, V44, P399, DOI 10.1016/j.neuroimage.2008.09.009; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Sanborn B, 2012, J BIOMECH, V45, P434, DOI 10.1016/j.jbiomech.2011.12.017; Saraf H, 2007, J BIOMECH, V40, P1960, DOI 10.1016/j.jbiomech.2006.09.021; Shafieian M, 2011, BIOENG C NEBEC 2011; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Trexler MM, 2011, J MECH BEHAV BIOMED, V4, P1920, DOI 10.1016/j.jmbbm.2011.06.008; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; WOO EJ, 1994, MED BIOL ENG COMPUT, V32, P530, DOI 10.1007/BF02515311; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Yang KH, 2011, STUD MECHANOBIOL TIS, V3, P69, DOI 10.1007/8415_2010_62; Yu Z, 2010, J NEUROPHYSIOL, V103, P499, DOI 10.1152/jn.00775.2009; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang YC, 2006, NEUROIMAGE, V31, P1513, DOI 10.1016/j.neuroimage.2006.02.027	66	50	51	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA		1553-7358		PLOS COMPUT BIOL	PLoS Comput. Biol.	AUG	2012	8	8							e1002619	10.1371/journal.pcbi.1002619			15	Biochemical Research Methods; Mathematical & Computational Biology	Biochemistry & Molecular Biology; Mathematical & Computational Biology	002SA	WOS:000308553500008	22915997	DOAJ Gold, Green Published			2021-06-18	
J	Au, AK; Aneja, RK; Bell, MJ; Bayir, H; Feldman, K; Adelson, PD; Fink, EL; Kochanek, PM; Clark, RSB				Au, Alicia K.; Aneja, Rajesh K.; Bell, Michael J.; Bayir, Huelya; Feldman, Keri; Adelson, P. David; Fink, Ericka L.; Kochanek, Patrick M.; Clark, Robert S. B.			Cerebrospinal Fluid Levels of High-Mobility Group Box 1 and Cytochrome C Predict Outcome after Pediatric Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						abusive head trauma; child abuse; cytochrome c; high mobility group box 1	SPECTRIN BREAKDOWN PRODUCTS; CHROMATIN PROTEIN HMGB1; ABUSIVE HEAD TRAUMA; IN-VIVO; APOPTOSIS; RELEASE; BIOMARKERS; CHILDREN; DANGER; SIGNAL	High-mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that is passively released from damaged and necrotic cells, and actively released from immune cells. In contrast, cytochrome c is released from mitochondria in apoptotic cells, and is considered a reliable biomarker of apoptosis. Thus, HMGB1 and cytochrome c may in part reflect the degree of necrosis and apoptosis present after traumatic brain injury (TBI), where both are felt to contribute to cell death and neurological morbidity. Ventricular cerebrospinal fluid (CSF) was obtained from children admitted to the intensive care unit (ICU) after TBI (n = 37). CSF levels of HMGB1 and cytochrome c were determined at four time intervals (0-24 h, 25-48 h, 49-72 h, and > 72 h after injury) using enzyme-linked immunosorbent assay (ELISA). Lumbar CSF from children without TBI served as controls (n = 12). CSF HMGB1 levels were: control = 1.78 +/- 0.29, 0-24 h = 5.73 +/- 1.45, 25-48 h = 5.16 +/- 1.73, 49-72 h = 4.13 +/- 0.75, > 72 h = 3.80 +/- 0.90 ng/mL (mean +/- SEM). Peak HMGB1 levels were inversely and independently associated with favorable Glasgow Outcome Scale (GOS) scores at 6 mo (0.49 [0.24-0.97]; OR [5-95% CI]). CSF cytochrome c levels were: control = 0.37 +/- 0.10, 0-24 h = 0.69 +/- 0.15, 25-48 h = 0.82 +/- 0.48, 49-72 h = 1.52 +/- 1.08, > 72 h = 1.38 +/- 1.02 ng/mL (mean +/- SEM). Peak cytochrome c levels were independently associated with abusive head trauma (AHT; 24.29 [1.77-334.03]) and inversely and independently associated with favorable GOS scores (0.42 [0.18-0.99]). In conclusion, increased CSF levels of HMGB1 and cytochrome c were associated with poor outcome after TBI in infants and children. These data are also consistent with the designation of HMGB1 as a "danger signal." Distinctly increased CSF cytochrome c levels in infants and children with AHT and poor outcome suggests that apoptosis may play an important role in this unique patient population.	[Au, Alicia K.; Aneja, Rajesh K.; Bell, Michael J.; Bayir, Huelya; Feldman, Keri; Fink, Ericka L.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Bell, Michael J.; Bayir, Huelya] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Dept Pediat, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh UPMC, Pittsburgh, PA USA; [Bayir, Huelya] Ctr Free Rad & Antioxidant Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Adelson, P. David] Phoenix Childrens Hosp, Childrens Neurosci Inst, Phoenix, AZ USA	Au, AK (corresponding author), 4401 Penn Ave,Suite 2000, Pittsburgh, PA 15224 USA.	auak@upmc.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Fink, Ericka/0000-0002-3683-4571	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040686]; National Institute for Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS30318]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM098474] Funding Source: NIH RePORTER	This work was supported by grants from the National Institute of Child Health and Human Development T32 HD040686 (AKA), and the National Institute for Neurological Diseases and Stroke R01 NS30318 (RSBC, PMK).	Adachi N, 2004, CLIN CHIM ACTA, V342, P127, DOI 10.1016/j.cccn.2003.12.011; Adamsbaum C, 2010, PEDIATRICS, V126, P546, DOI 10.1542/peds.2009-3647; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Ahlemeyer B, 2002, BRAIN RES, V934, P107, DOI 10.1016/S0006-8993(02)02365-X; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Barczyk K, 2005, INT J CANCER, V116, P167, DOI 10.1002/ijc.21037; Ben-Ari Z, 2003, J INTERN MED, V254, P168, DOI 10.1046/j.1365-2796.2003.01171.x; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152; Darwish RS, 2010, NEUROCRIT CARE, V12, P337, DOI 10.1007/s12028-009-9328-3; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Exo J, 2011, PEDIATR CRIT CARE ME, V12, P560, DOI 10.1097/PCC.0b013e3181e8b3ee; Fan J, 2007, J IMMUNOL, V178, P6573, DOI 10.4049/jimmunol.178.10.6573; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fink MP, 2007, CRIT CARE, V11, DOI 10.1186/cc6088; Gao HM, 2011, J NEUROSCI, V31, P1081, DOI 10.1523/JNEUROSCI.3732-10.2011; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; GOODWIN GH, 1973, EUR J BIOCHEM, V38, P14, DOI 10.1111/j.1432-1033.1973.tb03026.x; Guenther E, 2010, J PEDIATR-US, V157, P821, DOI 10.1016/j.jpeds.2010.04.072; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Klune JR, 2008, MOL MED, V14, P476, DOI 10.2119/2008-00034.Klune; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Messmer D, 2004, J IMMUNOL, V173, P307, DOI 10.4049/jimmunol.173.1.307; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Nakahara T, 2009, NEUROCRIT CARE, V11, P362, DOI 10.1007/s12028-009-9276-y; Palumbo R, 2004, BIOCHEM PHARMACOL, V68, P1165, DOI 10.1016/j.bcp.2004.03.048; Peltz ED, 2009, SHOCK, V32, P17, DOI 10.1097/SHK.0b013e3181997173; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Raucci A, 2007, AUTOIMMUNITY, V40, P285, DOI 10.1080/08916930701356978; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Rock KL, 2005, SPRINGER SEMIN IMMUN, V26, P231, DOI 10.1007/s00281-004-0173-3; Rouhiainen A, 2004, BLOOD, V104, P1174, DOI 10.1182/blood-2003-10-3536; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Sutrias-Grau M, 1999, J BIOL CHEM, V274, P1628, DOI 10.1074/jbc.274.3.1628; Tang DL, 2008, CRIT CARE MED, V36, P291, DOI 10.1097/01.CCM.0000295316.86942.CE; Yakovlev AG, 2001, J NEUROSCI, V21, P7439	50	50	51	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	11					2013	2021		10.1089/neu.2011.2171			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	983CX	WOS:000307095800002	22540160	Green Published			2021-06-18	
J	Zhang, ZR; Zhang, ZY; Wu, YZ; Schluesener, HJ				Zhang, Zhiren; Zhang, Zhi-Yuan; Wu, Yuzhang; Schluesener, Hermann J.			Lesional Accumulation of CD163(+) Macrophages/microglia in Rat Traumatic Brain Injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; CD163; Macrophages; Heme oxygenase-1	ANTIINFLAMMATORY MACROPHAGE PHENOTYPE; HEMOGLOBIN SCAVENGER RECEPTOR; CENTRAL-NERVOUS-SYSTEM; HEME OXYGENASE-1 HO-1; PERIVASCULAR MACROPHAGES; NEUROVASCULAR UNIT; HUMAN MONOCYTES; MICROGLIA; ACTIVATION; EXPRESSION	A robust neuroinflammation, contributing to the development of secondary injury, is a common histopathological feature of traumatic brain injury (TBI). Characterization of leukocytic subpopulations contributing to the early infiltration of the damaged tissue might aid in further understanding of lesion development. Reactive macrophages/microglia can exert protective or damaging effects in TBI. CD163 is considered a marker of M2 (alternatively activated) macrophages. Therefore we investigated the accumulation of CD163(+) macrophages/microglia in the brain of TB! rats. TBI was induced in rats using an open skull weight-drop contusion model and the accumulation of CD163(+) cells was analyzed by immunohistochemistry. In normal rat brains, CD163 was expressed by meningeal, choroid plexus and perivascular macrophages. Significant parenchymal CD163(+) cell accumulation was observed two days post TBI and continuously increased in the investigated survival time. The accumulated CD163(+) cells were mainly distributed to the lesional areas and exhibited macrophage phenotypes with amoeboid morphologic characteristics but not activated microglial phenotypes with hypertrophic morphology and thick processes. Double-labeling experiments showed that most CD163+ cells co-expressed heme oxygenase-1 (HO-1). In addition, in vitro incubating of macrophage RAW264.7 cells or primary peritoneal macrophages with hemoglobin- haptoglobin (Hb-Hp) complex suppressed LPS-induced inflammatory macrophages phenotype and induced CD163 and HO-1 upregulation, indicating that CD163(+) macrophages/microglia in TBI might have anti-inflammatory effects. And further study is necessary to identify functions of these cells in TBI. (C) 2012 Elsevier B.V. All rights reserved.	[Zhang, Zhiren; Wu, Yuzhang] Third Mil Med Univ PLA, Inst Immunol, Chongqing 400038, Peoples R China; [Zhang, Zhiren; Zhang, Zhi-Yuan; Schluesener, Hermann J.] Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany	Zhang, ZR (corresponding author), Third Mil Med Univ PLA, Inst Immunol, Gaotanyan Main St 30, Chongqing 400038, Peoples R China.	zhangzhiren@yahoo.com	zhang, zhiren/I-1046-2014; Zhang, Zhiren/O-1012-2019	zhang, zhiren/0000-0002-5238-2835; Zhang, Zhiren/0000-0002-5238-2835; Wu, Yuzhang/0000-0002-4049-0214; Zhang, Zhi-Yuan/0000-0001-9067-0670	Natural Science Foundation Project of CQ CSTCNatural Science Foundation Project of CQ CSTC [2010BB5025]; National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070954]	This research was partly supported by Natural Science Foundation Project of CQ CSTC (contract No. 2010BB5025) and National Nature Science Foundation of China (No: 81070954).	Abraham NG, 2006, CIRC RES, V99, P911, DOI 10.1161/01.RES.0000249616.10603.d6; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Borda JT, 2008, AM J PATHOL, V172, P725, DOI 10.2353/ajpath.2008.070848; Bover LC, 2007, J IMMUNOL, V178, P8183, DOI 10.4049/jimmunol.178.12.8183; Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Fabriek BO, 2005, GLIA, V51, P297, DOI 10.1002/glia.20208; Fairweather D, 2009, J AUTOIMMUN, V33, P222, DOI 10.1016/j.jaut.2009.09.012; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Galea I, 2008, NEUROSCI LETT, V448, P41, DOI 10.1016/j.neulet.2008.09.081; Glezer I, 2007, NEUROSCIENCE, V147, P867, DOI 10.1016/j.neuroscience.2007.02.055; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Inta I, 2008, J NEUROL SCI, V275, P117, DOI 10.1016/j.jns.2008.08.005; Jazwa A, 2010, CURR DRUG TARGETS, V11, P1517, DOI 10.2174/1389450111009011517; Kim WK, 2006, AM J PATHOL, V168, P822, DOI 10.2353/ajpath.2006.050215; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Komohara Y, 2006, J HISTOCHEM CYTOCHEM, V54, P763, DOI 10.1369/jhc.5A6871.2006; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Moestrup SK, 2004, ANN MED, V36, P347, DOI 10.1080/07853890410033171; Moreno JA, 2009, ATHEROSCLEROSIS, V207, P103, DOI 10.1016/j.atherosclerosis.2009.04.033; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Napoli I, 2009, NEUROSCIENCE, V158, P1030, DOI 10.1016/j.neuroscience.2008.06.046; Nielsen MJ, 2009, BLOOD, V114, P764, DOI 10.1182/blood-2009-01-198309; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Onofre Gabriela, 2009, Acta Medica (Hradec Kralove), V52, P57, DOI 10.14712/18059694.2016.105; Paine A, 2010, BIOCHEM PHARMACOL, V80, P1895, DOI 10.1016/j.bcp.2010.07.014; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Polavarapu R, 2005, J NEUROSCI, V25, P10094, DOI 10.1523/JNEUROSCI.3382-05.2005; Roberts ES, 2004, J NEUROPATH EXP NEUR, V63, P1255, DOI 10.1093/jnen/63.12.1255; Satoh J, 2008, NEUROPATHOLOGY, V28, P561, DOI 10.1111/j.1440-1789.2008.00915.x; Schaer CA, 2006, CIRC RES, V99, P943, DOI 10.1161/01.RES.0000247067.34173.1b; Schaer DJ, 2006, BLOOD, V107, P373, DOI 10.1182/blood-2005-03-1014; Schwartz M, 2003, J CEREBR BLOOD F MET, V23, P385, DOI 10.1097/01.WCB.0000061881.75234.5E; Shibahara S, 2002, ANTIOXID REDOX SIGN, V4, P593, DOI 10.1089/15230860260220094; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; TOPOLL HH, 1989, J PERIODONTAL RES, V24, P106, DOI 10.1111/j.1600-0765.1989.tb00864.x; Ugocsai P, 2006, CYTOM PART A, V69A, P203, DOI 10.1002/cyto.a.20235; Van Gorp H, 2010, MOL IMMUNOL, V47, P1650, DOI 10.1016/j.molimm.2010.02.008; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Zhang XH, 2007, J CEREBR BLOOD F MET, V27, P534, DOI 10.1038/sj.jcbfm.9600368; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; Zheng TS, 2008, J LEUKOCYTE BIOL, V84, P338, DOI 10.1189/jlb.0308165; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; ZWADLO G, 1987, EXP CELL BIOL, V55, P295	49	50	51	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 21	2012	1461						102	110		10.1016/j.brainres.2012.04.038			9	Neurosciences	Neurosciences & Neurology	966EF	WOS:000305819700011	22583855				2021-06-18	
J	Debert, CT; Herter, TM; Scott, SH; Dukelow, S				Debert, Chantel T.; Herter, Troy M.; Scott, Stephen H.; Dukelow, Sean			Robotic Assessment of Sensorimotor Deficits After Traumatic Brain Injury	JOURNAL OF NEUROLOGIC PHYSICAL THERAPY			English	Article						proprioception; reaching; rehabilitation; robotics; traumatic brain injury	LIMB POSITION SENSE; MOTOR-PERFORMANCE; UNITED-STATES; CHILDREN; RECOVERY; STROKE; JOINT; KINESTHESIA; RELIABILITY; IMPAIRMENT	Background and Purpose: Robotic technology is commonly used to quantify aspects of typical sensorimotor function. We evaluated the feasibility of using robotic technology to assess visuomotor and position sense impairments following traumatic brain injury (TBI). We present results of robotic sensorimotor function testing in 12 subjects with TBI, who had a range of initial severities (9 severe, 2 moderate, 1 mild), and contrast these results with those of clinical tests. We also compared these with robotic test outcomes in persons without disability. Methods: For each subject with TBI, a review of the initial injury and neuroradiologic findings was conducted. Following this, each subject completed a number of standardized clinical measures (Fugl-Meyer Assessment, Purdue Peg Board, Montreal Cognitive Assessment, Rancho Los Amigos Scale), followed by two robotic tasks. A visually guided reaching task was performed to assess visuomotor control of the upper limb. An arm position-matching task was used to assess position sense. Robotic task performance in the subjects with TBI was compared with findings in a cohort of 170 person without disabilities. Results: Subjects with TBI demonstrated a broad range of sensory and motor deficits on robotic testing. Notably, several subjects with TBI displayed significant deficits in one or both of the robotic tasks, despite normal scores on traditional clinical motor and cognitive assessment measures. Discussion and Conclusions: The findings demonstrate the potential of robotic assessments for identifying deficits in visuomotor control and position sense following TBI. Improved identification of neurologic impairments following TBI may ultimately enhance rehabilitation.	[Debert, Chantel T.; Herter, Troy M.; Dukelow, Sean] Univ Calgary, Hotchkiss Brain Inst, Div Phys Med & Rehabil, Dept Clin Neurosci, Calgary, AB, Canada; [Herter, Troy M.; Scott, Stephen H.] Queens Univ, Dept Anat & Cell Biol, Kingston, ON, Canada	Dukelow, S (corresponding author), Univ Calgary, Hotchkiss Brain Inst, Div Phys Med & Rehabil, Dept Clin Neurosci, Calgary, AB, Canada.	sean.dukelow@albertahealthservices.ca		Debert, Chantel/0000-0002-2704-0438; Dukelow, Sean/0000-0002-0609-981X	CIHRCanadian Institutes of Health Research (CIHR) [MOP 81366, NSP 104015]; Heart and Stroke Foundation of Alberta; Heart and Stroke Foundation of Nunavut; Heart and Stroke Foundation of Northwest Territories; Ontario Research Foundation	Dr Scott is the cofounder and scientific officer of BKIN technologies, the company that manufactures the KINARM robotic device. Funding for this project was made possible through CIHR operating grants (MOP 81366 and NSP 104015); a grant-in-aid from the Heart and Stroke Foundation of Alberta, Nunavut, and Northwest Territories; and a research excellence grant from the Ontario Research Foundation.	Adamo DE, 2009, J AGING PHYS ACTIV, V17, P272, DOI 10.1123/japa.17.3.272; Bickley LS, 2007, BATES GUIDE PHYS EXA; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Campbell M, 2000, UNDERSTANDING TRAUMA; Carey LM, 1996, ARCH PHYS MED REHAB, V77, P1271, DOI 10.1016/S0003-9993(96)90192-6; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Coderre AM, 2010, NEUROREHAB NEURAL RE, V24, P528, DOI 10.1177/1545968309356091; Collins DF, 2005, J NEUROPHYSIOL, V94, P1699, DOI 10.1152/jn.00191.2005; Dobkin BH, 2011, NEUROREHAB NEURAL RE, V25, P788, DOI 10.1177/1545968311425908; Dukelow SP, 2010, NEUROREHAB NEURAL RE, V24, P178, DOI 10.1177/1545968309345267; Dukelow SP, 2009, SOC NEUR CHIC IL; Ellis MD, 2008, NEUROREHAB NEURAL RE, V22, P321, DOI 10.1177/1545968307313509; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; GANDEVIA SC, 1976, J PHYSIOL-LONDON, V260, P387, DOI 10.1113/jphysiol.1976.sp011521; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; Goble DJ, 2005, HUM MOVEMENT SCI, V24, P155, DOI 10.1016/j.humov.2005.05.004; GOODWIN GM, 1972, BRAIN RES, V37, P326, DOI 10.1016/0006-8993(72)90679-8; GOODWIN GM, 1972, SCIENCE, V175, P1382, DOI 10.1126/science.175.4028.1382; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Hagen C., 1972, LEVELS COGNITIVE FUN; Incoccia C, 2004, CORTEX, V40, P111, DOI 10.1016/S0010-9452(08)70924-9; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Lincoln N. B., 1991, CLIN REHABIL, V5, P273, DOI DOI 10.1177/026921559100500403; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; MATTHEWS PBC, 1982, ANNU REV NEUROSCI, V5, P189, DOI 10.1146/annurev.ne.05.030182.001201; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Scott SH, 1999, J NEUROSCI METH, V89, P119, DOI 10.1016/S0165-0270(99)00053-9; Scott SH, 2011, J REHABIL RES DEV, V48, P335, DOI 10.1682/JRRD.2010.04.0057; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; Singh K, 2003, NAT NEUROSCI, V6, P399, DOI 10.1038/nn1026; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tiffin J, 1948, J APPL PSYCHOL, V32, P234, DOI 10.1037/h0061266; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; WILSON B, 1987, ARCH PHYS MED REHAB, V68, P98; Wolpert DM, 2010, BMC BIOL, V8, DOI [10.1186/1741-7007-8-92, 10.1186/1741-7007-8-82]; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	42	50	50	0	39	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1557-0576	1557-0584		J NEUROL PHYS THER	J. Neurol. Phys. Ther.	JUN	2012	36	2					58	67		10.1097/NPT.0b013e318254bd4f			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	946QY	WOS:000304370000003	22592061				2021-06-18	
J	Holt, RF; Beer, J; Kronenberger, WG; Pisoni, DB; Lalonde, K				Holt, Rachael Frush; Beer, Jessica; Kronenberger, William G.; Pisoni, David B.; Lalonde, Kaylah			Contribution of Family Environment to Pediatric Cochlear Implant Users' Speech and Language Outcomes: Some Preliminary Findings	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article						cochlear implant; children; executive function; language; family environment	DEFICIT HYPERACTIVITY DISORDER; EARLY VOCABULARY DEVELOPMENT; TRAUMATIC BRAIN-INJURY; HARD-OF-HEARING; EXECUTIVE FUNCTION; DEAF-CHILDREN; YOUNG-CHILDREN; EARLY INTERVENTION; SOCIOECONOMIC-STATUS; TEACHING PARENTS	Purpose: To evaluate the family environments of children with cochlear implants and to examine relationships between family environment and postimplant language development and executive function. Method: Forty-five families of children with cochlear implants completed a self-report family environment questionnaire (Family Environment Scale-Fourth Edition; Moos & Moos, 2009) and an inventory of executive function (Behavior Rating Inventory of Executive Function [Gioia, Isquith, Guy, & Kenworthy, 2000] or Behavior Rating Inventory of Executive Function-Preschool Version [Gioia, Espy, & Isquith, 2003]). The authors also evaluated children's receptive vocabulary (Peabody Picture Vocabulary Test-Fourth Edition; Dunn & Dunn, 2007) and global language skills (Preschool Language Scale-Fourth Edition [Zimmerman, Steiner, & Pond, 2002] and Clinical Evaluation of Language Fundamentals-Fourth Edition [Semel, Wiig, & Secord, 2003]). Results: The family environments of children with cochlear implants differed from those of normal-hearing children but not in clinically significant ways. Language development and executive function were found to be atypical but not uncharacteristic of this clinical population. Families with higher levels of self-reported control had children with smaller vocabularies. Families reporting a higher emphasis on achievement had children with fewer executive function and working memory problems. Finally, families reporting a higher emphasis on organization had children with fewer problems related to inhibition. Conclusion: Some of the variability in cochlear implantation outcomes that have protracted periods of development is related to family environment. Because family environment can be modified and enhanced by therapy or education, these preliminary findings hold promise for future work in helping families to create robust language-learning environments that can maximize their child's potential with a cochlear implant.	[Holt, Rachael Frush; Lalonde, Kaylah] Indiana Univ, Bloomington, IN 47405 USA; [Beer, Jessica; Kronenberger, William G.; Pisoni, David B.] Indiana Univ Sch Med, Indianapolis, IN USA	Holt, RF (corresponding author), Indiana Univ, Bloomington, IN 47405 USA.	raholt@indiana.edu			National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [T32 DC00011, DC009581]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [T32DC000011, R01DC009581, R55DC009581, T32DC000012] Funding Source: NIH RePORTER	This work was supported by National Institute on Deafness and Other Communication Disorders Grants T32 DC00011 and DC009581. Portions of this work were presented at the 13th Symposium of Cochlear Implants in Children, Chicago, IL (July 2011). We are grateful to Shirley Henning and Bethany Colson for their contributions to data collection.	AKHTAR N, 1991, J CHILD LANG, V18, P41, DOI 10.1017/S0305000900013283; Allhusen V, 2005, DEV PSYCHOL, V41, P99, DOI 10.1037/0012-1649.41.1.99; American National Standards Institute, 2004, S362004 ANSI; Bailey Jr. D., 1988, EXCEPT CHILDREN, V64, P313; Bates E., 1982, ADV CHILD DEV BEHAV, V16, P8; Beer Jessica, 2011, Cochlear Implants Int, V12 Suppl 1, pS89, DOI 10.1179/146701011X13001035752570; BELSKY J, 1981, DEV PSYCHOL, V17, P3, DOI 10.1037/0012-1649.17.1.3; Bernier A, 2010, CHILD DEV, V81, P326, DOI 10.1111/j.1467-8624.2009.01397.x; Bertram B, 1995, Ann Otol Rhinol Laryngol Suppl, V166, P97; Bibcok M. B., 2009, SOCIAL INTERACTION D, V123, P17; BIEDERMAN J, 1995, ARCH GEN PSYCHIAT, V52, P464; Blair C, 2007, CHILD DEV, V78, P647, DOI 10.1111/j.1467-8624.2007.01019.x; BRINICH PM, 1980, J COMMUN DISORD, V13, P75, DOI 10.1016/0021-9924(80)90024-6; BRUCE C, 1992, J COMMUNITY PSYCHOL, P10; Bull R, 2008, DEV NEUROPSYCHOL, V33, P205, DOI 10.1080/87565640801982312; Burger T, 2005, AM ANN DEAF, V150, P5, DOI 10.1353/aad.2005.0017; Carlson SM, 2002, INFANT CHILD DEV, V11, P73, DOI 10.1002/icd.298; Carlson SM, 2009, NEW DIR CHILD ADOLES, V123, P87, DOI 10.1002/cd.237; Ciccia AH, 2009, TOP LANG DISORD, V29, P249, DOI 10.1097/TLD.0b013e3181b53211; Clark CAC, 2010, DEV PSYCHOL, V46, P1176, DOI 10.1037/a0019672; Coldwell J, 2006, J CHILD PSYCHOL PSYC, V47, P1116, DOI 10.1111/j.1469-7610.2006.01655.x; Conway CM, 2011, DEV NEUROPSYCHOL, V36, P237, DOI 10.1080/87565641.2010.549869; Conway CM, 2011, DEVELOPMENTAL SCI, V14, P69, DOI 10.1111/j.1467-7687.2010.00960.x; Conway CM, 2009, CURR DIR PSYCHOL SCI, V18, P275, DOI 10.1111/j.1467-8721.2009.01651.x; Cross T. G., 1980, 1ST LANGUAGE, V1, P163; DesJardin JL, 2007, EAR HEARING, V28, P456, DOI 10.1097/AUD.0b013e31806dc1ab; DesJardin JL, 2009, J DEAF STUD DEAF EDU, V14, P22, DOI 10.1093/deafed/enn011; Desjardin JL, 2005, J EARLY INTERVENTION, V27, P193, DOI 10.1177/105381510502700306; Diamond A, 2007, SCIENCE, V318, P1387, DOI 10.1126/science.1151148; Dunn L., 2007, PEABODY PICTURE VOCA, V4th ed.; Edwards L, 2009, INT J AUDIOL, V48, P554, DOI 10.1080/14992020902894533; Espy KA, 2004, DEV NEUROPSYCHOL, V26, P379, DOI 10.1207/s15326942dn2601_1; Figueras B, 2008, J DEAF STUD DEAF EDU, V13, P362, DOI 10.1093/deafed/enm067; Geers A, 2003, EAR HEARING, V24, p24S, DOI 10.1097/01.AUD.0000051687.99218.0F; Geers Ann E, 2011, Ear Hear, V32, p84S, DOI 10.1097/AUD.0b013e3181ffd5b5; Gilotty L, 2002, CHILD NEUROPSYCHOL, V8, P241, DOI 10.1076/chin.8.4.241.13504; Gioia G.A., 2003, BEHAV RATING INVENTO; Gioia G.A., 2000, BEHAV RATING INVENTO; Hart B., 1995, MEANINGFUL DIFFERENC; HELLMAN SA, 1991, AM ANN DEAF, V136, P77, DOI 10.1353/aad.2012.1077; HENGGELER S W, 1983, Journal of Pediatric Psychology, V8, P83, DOI 10.1093/jpepsy/8.1.83; Hill D., 1987, PSYCHOSOC REHABIL, V10, P25; Hintermair M, 2006, J DEAF STUD DEAF EDU, V11, P493, DOI 10.1093/deafed/enl005; Hoff E, 2003, CHILD DEV, V74, P1368, DOI 10.1111/1467-8624.00612; Holt RF, 2008, EAR HEARING, V29, P492, DOI 10.1097/AUD.0b013e31816c409f; Hughes C, 2007, DEV PSYCHOL, V43, P1447, DOI 10.1037/0012-1649.43.6.1447; Hughes C, 2011, J EXP CHILD PSYCHOL, V108, P663, DOI 10.1016/j.jecp.2010.06.005; Hughes CH, 2009, NEW DIR CHILD ADOLES, V123, P35, DOI 10.1002/cd.234; Jarratt KP, 2005, APPL NEUROPSYCHOL, V12, P83, DOI 10.1207/s15324826an1202_4; Kaiser AP, 2003, INFANT YOUNG CHILD, V16, P9, DOI 10.1097/00001163-200301000-00003; Kaiser AP, 1996, TOP EARLY CHILD SPEC, V16, P375, DOI 10.1177/027112149601600307; Kirk KI, 2002, ANN OTO RHINOL LARYN, V111, P69; KRONENBERGER WG, 1990, J CLIN CHILD PSYCHOL, V19, P380, DOI 10.1207/s15374424jccp1904_10; Landry SH, 2002, DEV NEUROPSYCHOL, V21, P15, DOI 10.1207/S15326942DN2101_2; LEDERBERG AR, 1990, CHILD DEV, V61, P1596; Loomis JW, 1997, DEV MED CHILD NEUROL, V39, P620; MACTURK RH, 1993, AM ANN DEAF, V138, P19, DOI 10.1353/aad.2012.0575; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; McClelland MM, 2007, DEV PSYCHOL, V43, P947, DOI 10.1037/0012-1649.43.4.947; McWilliam RA, 2001, INFANT YOUNG CHILD, V13, P55, DOI 10.1097/00001163-200113040-00011; Meadow-Orlans K. P., 1993, J APPLIED DEV PSYCHO, V14, P407; MILLS PD, 1991, HOSP COMMUNITY PSYCH, V42, P1144; Mitchell R.E., 2004, SIGN LANG STUD, V4, P138, DOI DOI 10.1353/SLS.2004.0005; Moeller MP, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e43; Moos R.H., 2009, FAMILY ENV SCALE MAN; NIENHUYS TG, 1985, APPL PSYCHOLINGUIST, V6, P121, DOI 10.1017/S014271640000607X; Nikolopoulos TP, 2004, INT J PEDIATR OTORHI, V68, P137, DOI 10.1016/j.ijporl.2003.09.020; Noble KG, 2005, DEVELOPMENTAL SCI, V8, P74, DOI 10.1111/j.1467-7687.2005.00394.x; Pisoni David B, 2011, Ear Hear, V32, p60S, DOI 10.1097/AUD.0b013e3181ffd58e; Pisoni DB, 2010, OXFORD HDB DEAF STUD, V1, P439; PRATT SR, 1991, EAR HEARING, V12, P328, DOI 10.1097/00003446-199110000-00005; Pressman L., 1999, J DEAF STUDIES, V2, P27; Rice F, 2006, J AM ACAD CHILD PSY, V45, P841, DOI 10.1097/01.chi.0000219834.08602.44; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Rousey AM, 2002, RES DEV DISABIL, V23, P17, DOI 10.1016/S0891-4222(01)00089-0; Schroeder VM, 2010, EARLY CHILD DEV CARE, V180, P1285, DOI 10.1080/03004430902981512; Semel E., 2003, CLIN EVALUATION LANG; Spencer P. E., 1990, ED DEV ASPECTS DEAFN, P350; TOMASELLO M, 1986, CHILD DEV, V57, P1454, DOI 10.1111/j.1467-8624.1986.tb00470.x; Vaccari C, 1997, J CHILD PSYCHOL PSYC, V38, P793, DOI 10.1111/j.1469-7610.1997.tb01597.x; Varni JW, 1996, J CHILD PSYCHOL PSYC, V37, P321, DOI 10.1111/j.1469-7610.1996.tb01409.x; WEDELLMONNIG J, 1980, CHILD DEV, V51, P766, DOI 10.1111/j.1467-8624.1980.tb02612.x; Welsh JA, 2010, J EDUC PSYCHOL, V102, P43, DOI 10.1037/a0016738; Yoder P. J., 2001, COMMUN DISORD Q, V22, P135, DOI [10.1177/152574010102200303, DOI 10.1177/152574010102200303]; Zimmerman I. L., 2002, PRESCHOOL LANGUAGE S	85	50	53	0	47	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA	1092-4388			J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	JUN 1	2012	55	3					848	864		10.1044/1092-4388(2011/11-0143)			17	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	084FO	WOS:000314523500015	22232387	Green Accepted			2021-06-18	
J	Meyer, DL; Davies, DR; Barr, JL; Manzerra, P; Forster, GL				Meyer, Danielle L.; Davies, Daniel R.; Barr, Jeffrey L.; Manzerra, Pasquale; Forster, Gina L.			Mild traumatic brain injury in the rat alters neuronal number in the limbic system and increases conditioned fear and anxiety-like behaviors	EXPERIMENTAL NEUROLOGY			English	Article						Mild traumatic brain injury; Concussive injury; Apoptosis; Hippocampus; Amygdala; Anxiety; Posttraumatic stress disorder	POSTTRAUMATIC-STRESS-DISORDER; MEDIAL PREFRONTAL CORTEX; CEREBRAL-BLOOD-FLOW; EXPERIMENTAL-MODELS; AMYGDALA RESPONSE; CELL-DEATH; NEUROGENESIS; EXTINCTION; PTSD; CA1	Recent reports suggest that experiencing a mild closed head trauma or mild traumatic brain injury (mTBI) is associated with a greater incidence of anxiety disorders. Dysfunction of limbic structures, such as the medial prefrontal cortex, amygdala and hippocampus, is associated with the symptoms of anxiety disorders. Therefore, the goal of the current studies was to characterize the consequences of closed mTBI on these limbic structures and associated fear and anxiety-related behaviors. A weight-drop procedure was employed to induce mTBI in male rats. Rats were transcardically perfused 4 or 9 days following exposure to mTBI or control procedures, and neuronal number, brain region area, and the number of apoptotic cells in each region were determined. In separate groups of rats, the effects of mTBI on anxiety-like behaviors, motor function, nociception, and acquisition, retention and extinction of contextual fear were also assessed. Findings suggest that mTBI was associated with significant neuronal cell loss in the CA1 region of the dorsal hippocampus and increased cell number in subregions of the amygdala, both of which appear to be related to alterations to apoptosis in these regions following mTBI. Furthermore, mTBI increased expression of anxiety-like behaviors and conditioned fear, with no effect on motor performance or nociception. Overall, a single impact to the skull to mimic mTBI in rats produces discrete alterations to neuronal numbers within the limbic system and specific emotional deficits, providing a potential neurobiological link between mTBI and anxiety disorders. (c) 2012 Elsevier Inc. All rights reserved.	[Meyer, Danielle L.; Davies, Daniel R.; Barr, Jeffrey L.; Manzerra, Pasquale; Forster, Gina L.] Univ S Dakota, Div Basic Biomed Sci, Sanford Sch Med, Neurosci Grp, Vermillion, SD 57069 USA; [Barr, Jeffrey L.] Temple Univ, Dept Pharmacol, Sch Med, Philadelphia, PA 19140 USA	Forster, GL (corresponding author), Univ S Dakota, Div Basic Biomed Sci, Sanford Sch Med, Neurosci Grp, 414 E Clark St, Vermillion, SD 57069 USA.	gforster@usd.edu			South Dakota Board of Regents, Department of Defense [W81XWH-10-1-0578]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20 RR015567]; USD; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015567] Funding Source: NIH RePORTER	This work was supported by a South Dakota Board of Regents Competitive Research Grant, Department of Defense Grant W81XWH-10-1-0578, NIH P20 RR015567 which is a designated Center of Biomedical Research Excellence (COBRE), and a USD Undergraduate Research Grant to D.D. We thank Jamie Scholl, Emily Reinbold, Dr. Michael Watt, Michael Olson and Dr. Fran Day for their assistance with these experiments.	Akasu T, 2002, NEUROSCI LETT, V329, P305, DOI 10.1016/S0304-3940(02)00707-3; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Armony JL, 2005, AM J PSYCHIAT, V162, P1961, DOI 10.1176/appi.ajp.162.10.1961; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barr JL, 2010, NEUROPHARMACOLOGY, V59, P395, DOI 10.1016/j.neuropharm.2010.05.011; Bay Esther H, 2009, Res Theory Nurs Pract, V23, P42; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Biebl M, 2000, NEUROSCI LETT, V291, P17, DOI 10.1016/S0304-3940(00)01368-9; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Bremner JD, 2004, BIOL PSYCHIAT, V55, P612, DOI 10.1016/j.biopsych.2003.10.001; Bremner JD, 2003, BIOL PSYCHIAT, V53, P879, DOI 10.1016/S0006-3223(02)01891-7; Bryant RA, 2008, PSYCHOL MED, V38, P555, DOI 10.1017/S0033291707002231; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Clark RSB, 1997, J NEUROSCI, V17, P9172; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Ehninger D, 2008, CELL TISSUE RES, V331, P243, DOI 10.1007/s00441-007-0478-3; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Etkin A, 2009, ARCH GEN PSYCHIAT, V66, P1361, DOI 10.1001/archgenpsychiatry.2009.104; Fanselow MS, 1999, NEURON, V23, P229, DOI 10.1016/S0896-6273(00)80775-8; Feng N, 2009, HORM BEHAV, V56, P149, DOI 10.1016/j.yhbeh.2009.03.023; Forster GL, 2006, NEUROSCIENCE, V141, P1047, DOI 10.1016/j.neuroscience.2006.04.006; Fujiki M, 2008, J CLIN NEUROSCI, V15, P791, DOI 10.1016/j.jocn.2007.07.002; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Goosens KA, 2001, LEARN MEMORY, V8, P148, DOI 10.1101/lm.37601; Grillon C, 2002, BIOL PSYCHIAT, V52, P958, DOI 10.1016/S0006-3223(02)01665-7; Grillon C, 1999, J ABNORM PSYCHOL, V108, P134, DOI 10.1037/0021-843X.108.1.134; Helmstetter FJ, 2008, NEUROBIOL LEARN MEM, V89, P324, DOI 10.1016/j.nlm.2007.09.002; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Herman JP, 2005, PROG NEURO-PSYCHOPH, V29, P1201, DOI 10.1016/j.pnpbp.2005.08.006; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hopper JW, 2007, J TRAUMA STRESS, V20, P713, DOI 10.1002/jts.20284; Hunsaker MR, 2008, NEUROBIOL LEARN MEM, V89, P61, DOI 10.1016/j.nlm.2007.08.016; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kreisman NR, 2000, J NEUROPHYSIOL, V83, P1031; Kwon S. K. C., 2011, FRONT NEUROL, V2, P1; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Liberzon I, 1999, BIOL PSYCHIAT, V45, P817, DOI 10.1016/S0006-3223(98)00246-7; Lukkes JL, 2009, HORM BEHAV, V55, P248, DOI 10.1016/j.yhbeh.2008.10.014; Madathil SK, 2010, J NEUROTRAUM, V27, P95, DOI 10.1089/neu.2009.1002; Malherbe P, 2009, BRIT J PHARMACOL, V156, P1326, DOI 10.1111/j.1476-5381.2009.00127.x; McNaughton N, 2004, NEUROSCI BIOBEHAV R, V28, P285, DOI 10.1016/j.neubiorev.2004.03.005; Milad MR, 2008, J PSYCHIATR RES, V42, P515, DOI 10.1016/j.jpsychires.2008.01.017; Milad MR, 2006, BIOL PSYCHOL, V73, P61, DOI 10.1016/j.biopsycho.2006.01.008; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Okuda H, 2009, J NEUROSCI RES, V87, P3546, DOI 10.1002/jnr.22160; Ooba Satomi, 2009, Kurume Medical Journal, V56, P49; Paxinos CW G, 1998, RAT BRAIN STEREOTAXI; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Quirk GJ, 2003, J NEUROSCI, V23, P8800, DOI 10.1523/jneurosci.23-25-08800.2003; Quirk GJ, 2006, BIOL PSYCHIAT, V60, P337, DOI 10.1016/j.biopsych.2006.03.010; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Schienle A, 2011, EUR ARCH PSY CLIN N, V261, P303, DOI 10.1007/s00406-010-0147-5; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Shin LM, 2005, ARCH GEN PSYCHIAT, V62, P273, DOI 10.1001/archpsyc.62.3.273; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Slomianka L, 2005, NEUROSCIENCE, V136, P757, DOI 10.1016/j.neuroscience.2005.06.086; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Vuong SM, 2010, BEHAV BRAIN RES, V208, P278, DOI 10.1016/j.bbr.2009.11.036; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; Yoshino A, 1996, J CEREB BLOOD FLOW M, V12, P996; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238	78	50	50	0	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2012	235	2			SI		574	587		10.1016/j.expneurol.2012.03.012			14	Neurosciences	Neurosciences & Neurology	944DE	WOS:000304177800021	22498103				2021-06-18	
J	Rosenbloom, MH; Schmahmann, JD; Price, BH				Rosenbloom, Michael H.; Schmahmann, Jeremy D.; Price, Bruce H.			The Functional Neuroanatomy of Decision-Making	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							MEDIAL PREFRONTAL CORTEX; ORBITOFRONTAL CORTEX; MORAL JUDGMENT; ARCHITECTONIC SUBDIVISION; NEURONAL-ACTIVITY; NEURAL BASIS; EMOTION; DAMAGE; BEHAVIOR; REWARD	Decision-making is a complex executive function that draws on past experience, present goals, and anticipation of outcome, and which is influenced by prevailing and predicted emotional tone and cultural context. Functional imaging investigations and focal lesion studies identify the orbitofrontal, anterior cingulate, and dorsolateral prefrontal cortices as critical to decision-making. The authors review the connections of these prefrontal regions with the neocortex, limbic system, basal ganglia, and cerebellum, highlight current ideas regarding the cognitive processes of decision-making that these networks subserve, and present a novel integrated neuroanatomical model for decision-making. Finally, clinical relevance of this circuitry is illustrated through a discussion of frontotemporal dementia, traumatic brain injury, and sociopathy. (The Journal of Neuropsychiatry and Clinical Neurosciences 2012; 24:266-277)	[Rosenbloom, Michael H.] HealthPartners, Dept Neurol, Ctr Dementia & Alzheimers Care, St Paul, MN USA; [Schmahmann, Jeremy D.] Massachusetts Gen Hosp, Dept Neurol, Cognit Behav Neurol Unit, Ataxia Unit, Boston, MA 02114 USA; [Schmahmann, Jeremy D.; Price, Bruce H.] Harvard Univ, Sch Med, Boston, MA USA; [Price, Bruce H.] McLean Hosp, Dept Neurol, Belmont, MA 02178 USA; [Price, Bruce H.] Massachusetts Gen Hosp, Ctr Law Brain & Behav, Boston, MA 02114 USA	Rosenbloom, MH (corresponding author), HealthPartners, Dept Neurol, Ctr Dementia & Alzheimers Care, St Paul, MN USA.	Michael.H.Rosenbloom@HealthPartners.com			Birmingham Foundation; MINDlink Foundation; Sydney R. Baer Jr. Foundation	This work was supported in part by the Birmingham, MINDlink, and Sydney R. Baer Jr. Foundations. We also acknowledge the Massachusetts General Hospital Center for Law, Brain, and Behavior.	Adolphs R, 1998, NATURE, V393, P470, DOI 10.1038/30982; ALBERT ML, 1974, J NEUROL NEUROSUR PS, V37, P121, DOI 10.1136/jnnp.37.2.121; Alexander MP, 2007, NEUROLOGY, V68, P1515, DOI 10.1212/01.wnl.0000261482.99569.fb; Barbas H, 2000, ADV NEUROL, V84, P87; Barbas H, 2007, ANN NY ACAD SCI, V1121, P10, DOI 10.1196/annals.1401.015; Barbas H, 2007, J ANAT, V211, P237, DOI 10.1111/j.1469-7580.2007.00777.x; Baskin JH, 2007, AM J LAW MED, V33, P239, DOI 10.1177/009885880703300205; Bechara A, 2004, BRAIN COGNITION, V55, P30, DOI 10.1016/j.bandc.2003.04.001; Bechara A, 2004, INT REV NEUROBIOL, V62, P159, DOI 10.1016/S0074-7742(04)62006-X; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Beer JS, 2003, J PERS SOC PSYCHOL, V85, P594, DOI 10.1037/0022-3514.85.4.594; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; BOGOUSSLAVSKY J, 1988, NEUROLOGY, V38, P837, DOI 10.1212/WNL.38.6.837; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; Buckholtz JW, 2008, NEURON, V60, P930, DOI 10.1016/j.neuron.2008.10.016; Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005; Camille N, 2004, SCIENCE, V304, P1167, DOI 10.1126/science.1094550; Cardinal RN, 2004, ANN NY ACAD SCI, V1021, P33, DOI 10.1196/annals.1308.004; CARMICHAEL ST, 1994, J COMP NEUROL, V346, P366, DOI 10.1002/cne.903460305; Carmichael ST, 1995, J COMP NEUROL, V363, P642, DOI 10.1002/cne.903630409; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; Cella M, 2010, J AFFECT DISORDERS, V124, P207, DOI 10.1016/j.jad.2009.11.013; Chukwudelunzu FE, 2001, J NEUROL NEUROSUR PS, V71, P658, DOI 10.1136/jnnp.71.5.658; Clark L, 2008, BRAIN, V131, P1311, DOI 10.1093/brain/awn066; Clark L, 2004, NEUROCASE, V10, P398, DOI 10.1080/13554790490882799; Critchley HD, 2000, BIOL PSYCHIAT, V47, P928, DOI 10.1016/S0006-3223(00)00231-6; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; Delgado MR, 2007, ANN NY ACAD SCI, V1104, P70, DOI 10.1196/annals.1390.002; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fishbein DH, 2005, COGNITIVE BRAIN RES, V23, P119, DOI 10.1016/j.cogbrainres.2004.12.010; Floden D, 2008, NEUROPSYCHOLOGIA, V46, P213, DOI 10.1016/j.neuropsychologia.2007.07.020; Floresco SB, 2008, COGN AFFECT BEHAV NE, V8, P375, DOI 10.3758/CABN.8.4.375; Ghashghaei HT, 2002, NEUROSCIENCE, V115, P1261, DOI 10.1016/S0306-4522(02)00446-3; Ghika J, 1999, J NEUROSURG, V91, P313, DOI 10.3171/jns.1999.91.2.0313; Goel V, 2000, COGN NEUROPSYCHOL, V17, P415, DOI 10.1080/026432900410775; GOLDMANRAKIC PS, 1985, J COMP NEUROL, V242, P535, DOI 10.1002/cne.902420406; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Graybiel AM, 2008, ANNU REV NEUROSCI, V31, P359, DOI 10.1146/annurev.neuro.29.051605.112851; Greene JD, 2007, TRENDS COGN SCI, V11, P322, DOI 10.1016/j.tics.2007.06.004; Harenski CL, 2006, NEUROIMAGE, V30, P313, DOI 10.1016/j.neuroimage.2005.09.034; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hsu M, 2005, SCIENCE, V310, P1680, DOI 10.1126/science.1115327; Jones CL, J NEUROL NEUROSURG P, V81, P611; Kelly RM, 2003, J NEUROSCI, V23, P8432; Koenigs M, 2007, NATURE, V446, P908, DOI 10.1038/nature05631; Krawczyk DC, 2002, NEUROSCI BIOBEHAV R, V26, P631, DOI 10.1016/S0149-7634(02)00021-0; Kuhnen CM, 2005, NEURON, V47, P763, DOI 10.1016/j.neuron.2005.08.008; Kuruoglu AC, 1996, BRIT J PSYCHIAT, V169, P348, DOI 10.1192/bjp.169.3.348; Labudda K, 2010, NEUROCASE, V16, P59, DOI 10.1080/13554790903329125; Levenston GK, 2000, J ABNORM PSYCHOL, V109, P373, DOI 10.1037//0021-843X.109.3.373; Levisohn L, 2000, BRAIN, V123, P1041, DOI 10.1093/brain/123.5.1041; LEWIS DO, 1988, AM J PSYCHIAT, V145, P584; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Mendez MF, 2009, CNS SPECTRUMS, V14, P608, DOI 10.1017/S1092852900023853; Mendez MF, 2005, COGN BEHAV NEUROL, V18, P193, DOI 10.1097/01.wnn.0000191292.17964.bb; Mendez MF, 2005, DEMENT GERIATR COGN, V20, P99, DOI 10.1159/000086474; Middleton FA, 2001, J NEUROSCI, V21, P700, DOI 10.1523/JNEUROSCI.21-02-00700.2001; MILLER BL, 1993, DEMENTIA, V4, P204, DOI 10.1159/000107324; Miller BL, 2007, HUMAN FRONTAL LOBES; Moll J, 2007, TRENDS COGN SCI, V11, P319, DOI 10.1016/j.tics.2007.06.001; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; O'Doherty J, 2001, NAT NEUROSCI, V4, P95; O'Reilly JX, 2010, CEREB CORTEX, V20, P953, DOI 10.1093/cercor/bhp157; Ongur D, 2003, J COMP NEUROL, V460, P425, DOI 10.1002/cne.10609; Pandya DN, 1996, PHILOS T ROY SOC B, V351, P1423, DOI 10.1098/rstb.1996.0127; Petrides M, 2002, EUR J NEUROSCI, V16, P291, DOI 10.1046/j.1460-9568.2001.02090.x; Prehn K, 2008, SOC COGN AFFECT NEUR, V3, P33, DOI 10.1093/scan/nsm037; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; Raine A, 1998, NEUROPSY NEUROPSY BE, V11, P1; Raine A, 1997, BIOL PSYCHIAT, V42, P495, DOI 10.1016/S0006-3223(96)00362-9; Raine A, 1998, BEHAV SCI LAW, V16, P319, DOI 10.1002/(SICI)1099-0798(199822)16:3<319::AID-BSL311>3.0.CO;2-G; Roesch MR, 2005, J NEUROPHYSIOL, V94, P2457, DOI 10.1152/jn.00373.2005; Roesch MR, 2004, SCIENCE, V304, P307, DOI 10.1126/science.1093223; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Rolls ET, 2004, BRAIN COGNITION, V55, P11, DOI 10.1016/s0278-2626(03)00277-x; SCHMAHMANN JD, 1995, NEUROSCI LETT, V199, P175, DOI 10.1016/0304-3940(95)12056-A; Schmahmann JD, 1997, INT REV NEUROBIOL, V41, P31, DOI 10.1016/S0074-7742(08)60346-3; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; Schmahmann JD, 1997, J NEUROSCI, V17, P438; Schmahmann JD, 2006, FIBER PATHWAYS BRAIN; Schmahmann JD, 2008, ANN NY ACAD SCI, V1142, P266, DOI 10.1196/annals.1444.017; Schmahmann JD, 2008, CORTEX, V44, P1037, DOI 10.1016/j.cortex.2008.04.004; Schroeder SA, 2007, NEW ENGL J MED, V357, P1221, DOI 10.1056/NEJMsa073350; Seeley WW, 2009, NEURON, V62, P42, DOI 10.1016/j.neuron.2009.03.024; Shima K, 1998, SCIENCE, V282, P1335, DOI 10.1126/science.282.5392.1335; Soderstrom H, 2000, PSYCHIAT RES-NEUROIM, V98, P29, DOI 10.1016/S0925-4927(99)00049-9; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039; TATEMICHI TK, 1992, NEUROLOGY, V42, P1966, DOI 10.1212/WNL.42.10.1966; Ullsperger M, 2003, J NEUROSCI, V23, P4308, DOI 10.1523/jneurosci.23-10-04308.2003; Volkow ND, 2010, NEUROIMAGE, V49, P2536, DOI 10.1016/j.neuroimage.2009.10.088; Wallis JD, 2007, ANNU REV NEUROSCI, V30, P31, DOI 10.1146/annurev.neuro.30.051606.094334; Weller JA, 2009, SOC NEUROSCI-UK, V4, P347, DOI 10.1080/17470910902934400; Willis ML, 2010, NEUROPSYCHOLOGIA, V48, P2182, DOI 10.1016/j.neuropsychologia.2010.04.010; Yang YL, 2009, PSYCHIAT RES-NEUROIM, V174, P81, DOI 10.1016/j.pscychresns.2009.03.012; Yechiam E, 2008, PSYCHON B REV, V15, P44, DOI 10.3758/PBR.15.1.44; Yeterian EH, 1998, J COMP NEUROL, V399, P384; Zahn R, 2009, BRAIN, V132, P604, DOI 10.1093/brain/awn343	100	50	53	1	47	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2012	24	3					266	277		10.1176/appi.neuropsych.11060139			12	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	057VS	WOS:000312592800037	23037641				2021-06-18	
J	Zafar, SN; Khan, AA; Ghauri, AA; Shamim, MS				Zafar, Syed Nabeel; Khan, Abdul Ahad; Ghauri, Asfar Ayaz; Shamim, Muhammad Shahzad			Phenytoin versus Leviteracetam for Seizure Prophylaxis after brain injury - a meta analysis	BMC NEUROLOGY			English	Article						Levetiracetam; Phenytoin; Meta-analysis; Brain injury; Seizures; Prophylaxis; Anti-epileptic drugs	SUBARACHNOID HEMORRHAGE; LEVETIRACETAM; TUMORS; EPILEPSY; METAANALYSIS; THERAPY; SURGERY; GLIOMAS; SAFETY; TRIAL	Background: Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is emerging as an alternate treatment choice. We aimed to conduct a meta-analysis to compare these two drugs in patients with brain injury. Methods: An electronic search was performed in using Pubmed, Embase, and CENTRAL. We included studies that compared the use of LEV vs. PHY for seizure prophylaxis for brain injured patients (Traumatic brain injury, intracranial hemorrhage, intracranial neoplasms, and craniotomy). Data of all eligible studies was extracted on to a standardized abstraction sheet. Data about baseline population characteristics, type of intervention, study design and outcome was extracted. Our primary outcome was seizures. Results: The literature search identified 2489 unduplicated papers. Of these 2456 papers were excluded by reading the abstracts and titles. Another 25 papers were excluded after reading their complete text. We selected 8 papers which comprised of 2 RCTs and 6 observational studies. The pooled estimate's Odds Ratio 1.12 (95% CI = 0.34, 3.64) demonstrated no superiority of either drug at preventing the occurrence of early seizures. In a subset analysis of studies in which follow up for seizures lasted either 3 or 7 days, the effect estimate remained insignificant with an odds ratio of 0.96 (95% CI = 0.34, 2.76). Similarly, 2 trials reporting seizure incidence at 6 months also had insignificant pooled results while comparing drug efficacy. The pooled odds ratio was 0.96 (95% CI = 0.24, 3.79). Conclusions: Levetiracetam and Phenytoin demonstrate equal efficacy in seizure prevention after brain injury. However, very few randomized controlled trials (RCTs) on the subject were found. Further evidence through a high quality RCT is highly recommended.	[Zafar, Syed Nabeel; Shamim, Muhammad Shahzad] Aga Khan Univ, Dept Surg, Karachi, Pakistan; [Khan, Abdul Ahad; Ghauri, Asfar Ayaz] Aga Khan Univ, Coll Med, Karachi, Pakistan	Shamim, MS (corresponding author), Aga Khan Univ, Dept Surg, Karachi, Pakistan.	shahzad.shamim@aku.edu		Khan, Abdul Ahad/0000-0002-3915-9102; Zafar, Syed Nabeel/0000-0003-3843-9687			Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; ALLEN JP, 1979, CLIN PHARMACOL THER, V26, P445, DOI 10.1002/cpt1979264445; Brouwers MC, 2003, BMC HEALTH SERV RES, V3, DOI 10.1186/1472-6963-3-23; Butzkueven H, 2000, NEUROLOGY, V55, P1315, DOI 10.1212/WNL.55.9.1315; Byrne T N, 1983, J Neurooncol, V1, P313, DOI 10.1007/BF00165714; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Cotton BA, 2011, J TRAUMA, V71, P375, DOI 10.1097/TA.0b013e318224d307; De Santis A, 2002, EPILEPSIA, V43, P175, DOI 10.1046/j.1528-1157.2002.24801.x; DEUTSCHMAN CS, 1985, NEUROSURGERY, V17, P510, DOI 10.1227/00006123-198509000-00021; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Forsyth PA, 2003, CAN J NEUROL SCI, V30, P106, DOI 10.1017/S0317167100053361; FOY PM, 1981, ACTA NEUROCHIR, V57, P15, DOI 10.1007/BF01665108; Glantz MJ, 1996, NEUROLOGY, V46, P985, DOI 10.1212/WNL.46.4.985; HAGEN NA, 1990, NEUROLOGY, V40, P158, DOI 10.1212/WNL.40.1.158; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hildebrand J, 2005, NEUROLOGY, V65, P212, DOI 10.1212/01.wnl.0000168903.09277.8f; JONES GL, 1983, MED RES REV, V3, P383, DOI 10.1002/med.2610030403; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Ketz E., 1974, HDB CLIN NEUROLOGY, V16, P254; Klimek M, 2010, CURR OPIN ANESTHESIO, V23, P564, DOI 10.1097/ACO.0b013e32833e14f2; Lim DA, 2009, J NEURO-ONCOL, V93, P349, DOI 10.1007/s11060-008-9781-4; MAHALEY MS, 1981, SURG NEUROL, V16, P399, DOI 10.1016/0090-3019(81)90227-5; Milligan TA, 2008, NEUROLOGY, V71, P665, DOI 10.1212/01.wnl.0000324624.52935.46; MOOTS PL, 1995, ARCH NEUROL-CHICAGO, V52, P717, DOI 10.1001/archneur.1995.00540310091021; Murphy-Human T, 2011, WORLD NEUROSURG, V75, P269, DOI 10.1016/j.wneu.2010.09.002; Naidech AM, 2009, STROKE, V40, P3810, DOI 10.1161/STROKEAHA.109.559948; NORTH JB, 1983, J NEUROSURG, V58, P672, DOI 10.3171/jns.1983.58.5.0672; Ramael S, 2006, EPILEPSIA, V47, P1128, DOI 10.1111/j.1528-1167.2006.00586.x; Sahin S, 2008, CLIN NEUROPHARMACOL, V31, P93, DOI 10.1097/WNF.0b013e31806ad6cb; Schierhout G, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000173; Shah D, 2009, SEIZURE-EUR J EPILEP, V18, P676, DOI 10.1016/j.seizure.2009.09.003; Siomin V, 2005, J NEURO-ONCOL, V74, P211, DOI 10.1007/s11060-004-6912-4; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Szaflarski JP, 2007, NEUROCRIT CARE, V7, P140, DOI 10.1007/s12028-007-0042-8; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Taylor S, 2011, NEUROCRIT CARE, V15, P80, DOI 10.1007/s12028-010-9341-6; Temkin Nancy R., 2002, Epilepsy Curr, V2, P105, DOI 10.1046/j.1535-7597.2002.00038.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Tremont-Lukats IW, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004424.pub2	39	50	53	1	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	MAY 29	2012	12								30	10.1186/1471-2377-12-30			8	Clinical Neurology	Neurosciences & Neurology	980SN	WOS:000306913400001	22642837	DOAJ Gold, Green Published			2021-06-18	
J	Ferguson, PL; Pickelsimer, EE; Corrigan, JD; Bogner, JA; Wald, M				Ferguson, Pamela L.; Pickelsimer, Emily Elisabeth; Corrigan, John D.; Bogner, Jennifer A.; Wald, Marlena			Prevalence of Traumatic Brain Injury Among Prisoners in South Carolina	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; craniocerebral trauma; epidemiology; postconcussion syndrome; prevalence; prisoners	VIOLENT CRIMINAL BEHAVIOR; TBI IDENTIFICATION METHOD; HEAD-INJURY; SUBSTANCE-ABUSE; PSYCHIATRIC-DISORDERS; SEXUAL OFFENSES; BIRTH COHORT; FOLLOW-UP; POPULATION; VALIDITY	Objective: To determine lifetime prevalence of traumatic brain injury (TBI) in a statewide sample of prisoners. Design: Retrospective and cross-sectional cohort study. Participants: Stratified random sample of prisoners scheduled to be released by release type for each gender (275 men and 267 women with completed sentences and 19 men and 15 women granted parole) and a random sample of prisoners by gender with lifetime or death sentences (26 men and 34 women). Primary Measure: Weighted prevalence of TBI. In-person interviews ascertained history of TBI using a customized version of the Ohio State University TBI Identification Method. Results: Sixty-five percent of male releases and nonreleases, and 72% and 73% of female releases and nonreleases, reported at least 1 TBI with an alteration of consciousness. Forty-two percent of male releases and 50% of nonreleases, and 50% of female releases and 33% of nonreleases, reported at least 1 TBI with loss of consciousness. Thirty-five percent of male releases and 42% of nonreleases, and 55% of female releases and 58% of nonreleases, reported ongoing symptoms from TBI. Conclusions: A substantial proportion of prisoners reported having experienced a TBI during their lifetime. The ongoing TBI symptoms reported by prisoners may impact their success on release.	[Ferguson, Pamela L.; Pickelsimer, Emily Elisabeth] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Corrigan, John D.; Bogner, Jennifer A.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Wald, Marlena] Ctr Dis Control & Prevent, Natl Ctr Injury Control & Prevent, Atlanta, GA USA	Ferguson, PL (corresponding author), Med Univ S Carolina, Dept Med, 135 Cannon St,Ste 303,MSC 835, Charleston, SC 29425 USA.	ferguspl@musc.edu	Corrigan, John D./E-2921-2011; Bogner, Jennifer/E-2773-2011		NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U49CE001318] Funding Source: NIH RePORTER; NCIPC CDC HHS [U49CE001318] Funding Source: Medline		Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; [Anonymous], 2001, POL TRAIN SER MAR PO; [Anonymous], 2002, STAT 30 TRAIN CORR P; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Brain Injury Association of Wyoming, 2008, STUD UND BRAIN INJ W; Brewer-Smyth K, 2004, BIOL PSYCHIAT, V55, P21, DOI 10.1016/S0006-3223(03)00705-4; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; Browne A, 1999, INT J LAW PSYCHIAT, V22, P301, DOI 10.1016/S0160-2527(99)00011-4; CARLSSON GS, 1983, J NEUROL NEUROSUR PS, V46, P818, DOI 10.1136/jnnp.46.9.818; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; Center for Substance Abuse Treatment, 1998, TREATM IMPR PROT TIP; Cohen R A, 1999, Violence Vict, V14, P397; Coid J., 2005, TXB PERSONALITY DISO, P579; Colantonio A, 2007, BRAIN INJURY, V21, P1353, DOI 10.1080/02699050701785054; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, BRAIN INJURY, V21, P343, DOI 10.1080/02699050701253103; Corrigan John D., 2003, American Journal of Obstetrics and Gynecology, V188, pS71, DOI 10.1067/mob.2003.404; Souza Carlos Alberto Crespo de, 2003, Rev. Bras. Psiquiatr., V25, P206, DOI 10.1590/S1516-44462003000400005; DelBello MP, 1999, PSYCHIAT RES, V89, P281, DOI 10.1016/S0165-1781(99)00112-2; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Epilepsy Foundation of Texas, OFF REC TEX SIZ TRAI; Farrer TJ, 2011, PROG NEURO-PSYCHOPH, V35, P390, DOI 10.1016/j.pnpbp.2011.01.007; Felde AB, 2006, BRAIN INJURY, V20, P41, DOI 10.1080/02699050500309718; Freedman D, 2000, SOC SCI MED, V50, P1757, DOI 10.1016/S0277-9536(99)00417-7; Greve KW, 2001, BRAIN INJURY, V15, P255; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Halldorsson Jonas G, 2008, Neuropsychiatr Dis Treat, V4, P405; Harlow C. W., 1999, 172879 NCJ US DEP JU; Hawley CA, 2003, BRAIN INJURY, V17, P743, DOI 10.1080/0269905031000089341; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Jackson M, 2011, CORRECTIONS RES PAPE; Johnson H, 2004, RES PUBLIC POLICY SE; Kaufman CW, 2001, CARLOS ALBIZU U PUBL; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Kushel MB, 2005, AM J PUBLIC HEALTH, V95, P1747, DOI 10.2105/AJPH.2005.065094; Langevin R, 2006, BRAIN COGNITION, V60, P206; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; Luiselli JK, 2000, INT J OFFENDER THER, V44, P647, DOI 10.1177/0306624X00446002; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Merbitz C., 1995, J OFFENDER REHABILIT, V22, P11, DOI DOI 10.1300/J076V22N03_02; Miller E, 1999, PSYCHOL CRIME LAW, V5, P297, DOI 10.1080/10683169908401774; Minnesota Department of Corrections, 2008, ANN C BRAIN INJ ASS; Morrell RF, 1998, J OFFENDER REHABIL, V27, P1, DOI DOI 10.1300/J076V27N03_01; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; O'Shanick GJ, 2011, TXB TRAUMATIC BRAIN, P211; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Schofield P, 2011, BRAIN INJURY, V25, P74, DOI 10.3109/02699052.2010.531690; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Sherman RK, 2001, COLORADO MENTAL HLTH; Shiroma Eric J, 2010, J Correct Health Care, V16, P273, DOI 10.1177/1078345810378253; Shiroma Eric J, 2010, J Correct Health Care, V16, P147, DOI 10.1177/1078345809356538; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 1999, J HEAD TRAUMA REHAB, V14, P567, DOI 10.1097/00001199-199912000-00005; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Walker R, 2001, SUBST USE MISUSE, V36, P757, DOI 10.1081/JA-100104089; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697; Yeager CA, 2000, CHILD ADOL PSYCH CL, V9, P793; Young MH, 2004, J FORENSIC SCI, V49, P141	74	50	50	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2012	27	3					E11	E20		10.1097/HTR.0b013e31824e5f47			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	941CV	WOS:000303941500002	22573044				2021-06-18	
J	Abo-Zaid, G; Sauerbrei, W; Riley, RD				Abo-Zaid, Ghada; Sauerbrei, Willi; Riley, Richard D.			Individual participant data meta-analysis of prognostic factor studies: state of the art?	BMC MEDICAL RESEARCH METHODOLOGY			English	Article						Meta-analysis; Prognostic factor; Prognosis; Individual participant (patient) data; Systematic review; Reporting	TRAUMATIC BRAIN-INJURY; PATIENT DATA; MICROVESSEL DENSITY; IMPACT DATABASE; CANCER; MARKERS; QUALITY; DESIGN; TRIALS; PREDICTORS	Background: Prognostic factors are associated with the risk of a subsequent outcome in people with a given disease or health condition. Meta-analysis using individual participant data (IPD), where the raw data are synthesised from multiple studies, has been championed as the gold-standard for synthesising prognostic factor studies. We assessed the feasibility and conduct of this approach. Methods: A systematic review to identify published IPD meta-analyses of prognostic factors studies, followed by detailed assessment of a random sample of 20 articles published from 2006. Six of these 20 articles were from the IMPACT (International Mission for Prognosis and Analysis of Clinical Trials in traumatic brain injury) collaboration, for which additional information was also used from simultaneously published companion papers. Results: Forty-eight published IPD meta-analyses of prognostic factors were identified up to March 2009. Only three were published before 2000 but thereafter a median of four articles exist per year, with traumatic brain injury the most active research field. Availability of IPD offered many advantages, such as checking modelling assumptions; analysing variables on their continuous scale with the possibility of assessing for non-linear relationships; and obtaining results adjusted for other variables. However, researchers also faced many challenges, such as large cost and time required to obtain and clean IPD; unavailable IPD for some studies; different sets of prognostic factors in each study; and variability in study methods of measurement. The IMPACT initiative is a leading example, and had generally strong design, methodological and statistical standards. Elsewhere, standards are not always as high and improvements in the conduct of IPD meta-analyses of prognostic factor studies are often needed; in particular, continuous variables are often categorised without reason; publication bias and availability bias are rarely examined; and important methodological details and summary results are often inadequately reported. Conclusions: IPD meta-analyses of prognostic factors are achievable and offer many advantages, as displayed most expertly by the IMPACT initiative. However such projects face numerous logistical and methodological obstacles, and their conduct and reporting can often be substantially improved.	[Riley, Richard D.] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England; [Abo-Zaid, Ghada] Univ Exeter, European Ctr Environm & Human Hlth, Peninsula Coll Med & Dent, Knowledge Spa Royal Cornwall Hosp Truro, Truro TR1 3HD, Cornwall, England; [Sauerbrei, Willi] Univ Med Ctr Freiburg, Inst Med Biometry & Med Informat, Freiburg, Germany	Riley, RD (corresponding author), Univ Birmingham, Sch Hlth & Populat Sci, Publ Hlth Bldg, Birmingham B15 2TT, W Midlands, England.	r.d.riley@bham.ac.uk	Riley, Richard/G-2406-2011; Riley, Richard David/ABE-5877-2020; Abo-Zaid, Ghada/AAY-7516-2020	Riley, Richard David/0000-0001-8699-0735; 	MRC Midlands Hub for Trials Methodology Research, at The University of Birmingham (Medical Research Council Grant) [G0800808]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800808] Funding Source: researchfish	Whilst undertaking this work, GA-Z and RDR were supported by funding from the MRC Midlands Hub for Trials Methodology Research, at The University of Birmingham (Medical Research Council Grant ID G0800808). We thank the two reviewers for their constructive comments and suggestions, which have helped improve the manuscript considerably.	Ahmed I, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d7762; Altman DG, 2007, STAT IND TECHNOL, P3, DOI 10.1007/978-0-8176-4542-7_1; Blettner M, 1999, INT J EPIDEMIOL, V28, P1, DOI 10.1093/ije/28.1.1; Broeze KA, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-22; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; Cianfrocca M, 2004, ONCOLOGIST, V9, P606, DOI 10.1634/theoncologist.9-6-606; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Doughty RN, 2008, EUR J HEART FAIL, V10, P786, DOI 10.1016/j.ejheart.2008.06.005; Downing M, 2007, J PALLIAT CARE, V23, P245, DOI 10.1177/082585970702300402; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Goetz CG, 2008, MOVEMENT DISORD, V23, P690, DOI 10.1002/mds.21894; Hayden JA, 2006, ANN INTERN MED, V144, P427, DOI 10.7326/0003-4819-144-6-200603210-00010; Hemingway H, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4184; Higgins JP, 2008, COCHRANE HDB SYSTEMA; Higgins JPT, 2001, STAT MED, V20, P2219, DOI 10.1002/sim.918; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x; Hollander N, 2007, STAT IND TECHNOL, P19, DOI 10.1007/978-0-8176-4542-7_2; Illmer T, 2007, HAEMATOL-HEMATOL J, V92, P137, DOI 10.3324/haematol.10489; Ioannidis JPA, 2002, AM J EPIDEMIOL, V156, P204, DOI 10.1093/aje/kwf031; Koopman L, 2008, ARCH OTOLARYNGOL, V134, P128, DOI 10.1001/archoto.2007.3; Kyzas PA, 2005, JNCI-J NATL CANCER I, V97, P1043, DOI 10.1093/jnci/dji184; Kyzas PA, 2007, EUR J CANCER, V43, P2559, DOI 10.1016/j.ejca.2007.08.030; Lanterna LA, 2007, NEUROLOGY, V69, P766, DOI 10.1212/01.wnl.0000267640.03300.6b; Look MP, 2002, JNCI-J NATL CANCER I, V94, P116, DOI 10.1093/jnci/94.2.116; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; McKibbon KA, 1998, B MED LIBR ASSOC, V86, P396; McShane LM, 2005, JNCI-J NATL CANCER I, V97, P1023, DOI 10.1093/jnci/dji193; McShane LM, 2005, JNCI-J NATL CANCER I, V97, P1180, DOI 10.1093/jnci/dji237; Meert AP, 2002, BRIT J CANCER, V87, P694, DOI 10.1038/sj.bjc.6600551; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Moller JE, 2008, CIRCULATION, V117, P2591, DOI 10.1161/CIRCULATIONAHA.107.738625; Moons KGM, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b606; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Noordzij JP, 2007, J AM COLL SURGEONS, V205, P748, DOI 10.1016/j.jamcollsurg.2007.06.298; Riley RD, 2009, BRIT J CANCER, V100, P1219, DOI 10.1038/sj.bjc.6604999; Riley RD, 2003, BRIT J CANCER, V88, P1191, DOI 10.1038/sj.bjc.6600886; Riley RD, 2007, J CLIN EPIDEMIOL, V60, P431, DOI 10.1016/j.jclinepi.2006.09.009; Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549; Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221; Riley RD, 2010, RES SYNTH METHODS, V1, P2, DOI 10.1002/jrsm.4; Riley RD, 2010, INT J EPIDEMIOL, V39, P1359, DOI 10.1093/ije/dyq129; Rovers MM, 2007, PEDIATRICS, V119, P579, DOI 10.1542/peds.2006-2092; Royston P, 2006, STAT MED, V25, P127, DOI 10.1002/sim.2331; Royston P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b604; Sauerbrei W, 2005, ADV OTO-RHINO-LARYNG, V62, P184; Sauerbrei W, 2001, J CLIN EPIDEMIOL, V54, P537, DOI 10.1016/S0895-4356(00)00246-8; Sauerbrei W, 2007, WILEY ENCY CLIN TRIA, P1; Sauerbrei W, 2006, COMMUN STAT-THEOR M, V35, P1333, DOI 10.1080/03610920600629666; Smith CT, 2005, STAT MED, V24, P1307, DOI 10.1002/sim.2050; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; Steyerberg EW., 2009, CLIN PREDICTION MODE; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sutcliffe P, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13050; Sutton AJ., 2000, METHODS METAANALYSIS; Sylaja PN, 2007, NEUROCRIT CARE, V6, P181, DOI 10.1007/s12028-007-0018-8; Thakkinstian A, 2008, NEPHROL DIAL TRANSPL, V23, P3017, DOI 10.1093/ndt/gfn185; Thompson S, 2010, INT J EPIDEMIOL, V39, P1345, DOI 10.1093/ije/dyq063; Trivella M, 2007, LANCET ONCOL, V8, P488, DOI 10.1016/S1470-2045(07)70145-6; Turner RM, 2000, STAT MED, V19, P3417, DOI 10.1002/1097-0258(20001230)19:24<3417::AID-SIM614>3.3.CO;2-C; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Warkentin TE, 2006, BLOOD, V108, P2937, DOI 10.1182/blood-2005-11-012450; Yap YG, 2008, INT J CARDIOL, V126, P101, DOI 10.1016/j.ijcard.2007.03.122	73	50	50	0	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2288		BMC MED RES METHODOL	BMC Med. Res. Methodol.	APR 24	2012	12								56	10.1186/1471-2288-12-56			16	Health Care Sciences & Services	Health Care Sciences & Services	984YJ	WOS:000307229500001	22530717	DOAJ Gold, Green Published			2021-06-18	
J	Raja Beharelle, A; Kovcevic, N; McIntosh, AR; Levine, B				Raja Beharelle, Anjali; Kovcevic, Natasa; McIntosh, Anthony R.; Levine, Brian			Brain signal variability relates to stability of behavior after recovery from diffuse brain injury	NEUROIMAGE			English	Article						Variability; Noise; Multiscale entropy; Magnetoencephalography; Traumatic brain injury; Attention	PARTIAL LEAST-SQUARES; FUNCTIONAL CONNECTIVITY; APPROXIMATE ENTROPY; CEREBRAL-CORTEX; NERVOUS-SYSTEM; QUANTIFIED MRI; NOISE; FLUCTUATIONS; TIME; NEUROPATHOLOGY	Variability or noise is an unmistakable feature of neural signals; however such fluctuations have been regarded as not carrying meaningful information or as detrimental for neural processes. Recent empirical and computational work has shown that neural systems with a greater capacity for information processing are able to explore a more varied dynamic repertoire, and the hallmark of this is increased irregularity or variability in the neural signal. How this variability in neural dynamics affects behavior remains unclear. Here, we investigated the role of variability of magnetoencephalography signals in supporting healthy cognitive functioning, measured by performance on an attention task, in healthy adults and in patients with traumatic brain injury. As an index of variability, we calculated multiscale entropy, which quantifies the temporal predictability of a time series across progressively more coarse time scales. We found lower variability in traumatic brain injury patients compared to controls, arguing against the idea that greater variability reflects dysfunctional neural processing. Furthermore, higher brain signal variability indicated improved behavioral performance for all participants. This relationship was statistically stronger for people with brain injury, demonstrating that those with higher brain signal variability were also those who had recovered the most cognitive ability. Rather than impede neural processing, cortical signal variability within an optimal range enables the exploration of diverse functional configurations, and may therefore play a vital role in healthy brain function. Crown Copyright (c) 2012 Published by Elsevier Inc. All rights reserved.	[Raja Beharelle, Anjali; Kovcevic, Natasa; McIntosh, Anthony R.; Levine, Brian] Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON, Canada; [Raja Beharelle, Anjali; McIntosh, Anthony R.; Levine, Brian] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Levine, Brian] Univ Toronto, Dept Med Neurol, Toronto, ON, Canada	Raja Beharelle, A (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	anjali.raja@utoronto.ca	Levine, Brian/O-2725-2019; Raja Beharelle, Anjali/A-3756-2013; Levine, Brian/G-4328-2010	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; McIntosh, Anthony/0000-0002-1784-5662	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01 HD42385-01]; J.S. McDonnell Foundation; University of TorontoUniversity of Toronto; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042385] Funding Source: NIH RePORTER	This work was supported by NIH 1R01 HD42385-01 to Brian Levine, a grant from the J.S. McDonnell Foundation, and a University of Toronto fellowship. We wish to thank Aaron Beharelle, Wilkin Chau, Marina Mandic, Bratislav Misic, Irina Nica, Daniela Palombo, Jimmy Shen, and Danielle Tisserand.	Bellgrove MA, 2004, NEUROPSYCHOLOGIA, V42, P1910, DOI 10.1016/j.neuropsychologia.2004.05.007; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Costa M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.021906; Costa M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.068102; Deco G, 2011, NAT REV NEUROSCI, V12, P43, DOI 10.1038/nrn2961; Deco G, 2009, P NATL ACAD SCI USA, V106, P10302, DOI 10.1073/pnas.0901831106; Edgington E. S., 1980, RANDOMIZATION TESTS; Efron B, 1986, STAT SCI, V1; Faisal AA, 2008, NAT REV NEUROSCI, V9, P292, DOI 10.1038/nrn2258; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Garrett DD, 2011, J NEUROSCI, V31, P4496, DOI 10.1523/JNEUROSCI.5641-10.2011; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Ghosh A, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000196; Goldberger AL, 2000, CIRCULATION, V101, pE215, DOI 10.1161/01.CIR.101.23.e215; Zou GY, 2007, PSYCHOL METHODS, V12, P399, DOI 10.1037/1082-989X.12.4.399; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Honey CJ, 2007, P NATL ACAD SCI USA, V104, P10240, DOI 10.1073/pnas.0701519104; KATZ B, 1970, NATURE, V226, P962, DOI 10.1038/226962a0; Kleppe IC, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.041909; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lippe S, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.048.2009; MacDonald SWS, 2006, TRENDS NEUROSCI, V29, P474, DOI 10.1016/j.tins.2006.06.011; McIntosh AR, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000106; McIntosh AR, 1996, NEUROIMAGE, V3, P143, DOI 10.1006/nimg.1996.0016; McIntosh AR, 1998, J NEUROPHYSIOL, V80, P3148; McIntosh AR, 2004, NEUROIMAGE, V23, pS250, DOI 10.1016/j.neuroimage.2004.07.020; McIntosh AR, 2004, NEUROIMAGE, V23, P764, DOI 10.1016/j.neuroimage.2004.05.018; Misic B, 2010, J NEUROPHYSIOL, V104, P2667, DOI 10.1152/jn.00648.2010; Nenadovic V, 2008, J NEUROTRAUM, V25, P615, DOI 10.1089/neu.2007.0474; Neumann J, 2003, NEUROIMAGE, V19, P784, DOI 10.1016/S1053-8119(03)00177-0; Nunez PL, 2001, HUM BRAIN MAPP, V13, P125, DOI 10.1002/hbm.1030; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Raja Beharelle A., 2011, FRONT HUM NEUROSCI, V5; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; Robinson S., 1999, RECENT ADV BIOMAGNET; SAMPSON PD, 1989, NEUROTOXICOL TERATOL, V11, P477, DOI 10.1016/0892-0362(89)90025-1; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; SPORNS O, 1991, P NATL ACAD SCI USA, V88, P129, DOI 10.1073/pnas.88.1.129; Steinmetz PN, 2000, J COMPUT NEUROSCI, V9, P133, DOI 10.1023/A:1008967807741; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; TONONI G, 1994, P NATL ACAD SCI USA, V91, P5033, DOI 10.1073/pnas.91.11.5033; TONONI G, 1992, CEREB CORTEX, V2, P310, DOI 10.1093/cercor/2.4.310; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Vakorin VA, 2011, J NEUROSCI, V31, P6405, DOI 10.1523/JNEUROSCI.3153-10.2011; White JA, 2000, TRENDS NEUROSCI, V23, P131, DOI 10.1016/S0166-2236(99)01521-0; Winterer G, 2006, BIOL PSYCHIAT, V60, P578, DOI 10.1016/j.biopsych.2006.03.023; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Zachary R., 1986, SHIPLEY I LIVING SCA	57	50	51	1	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	APR 2	2012	60	2					1528	1537		10.1016/j.neuroimage.2012.01.037			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	932ED	WOS:000303272300063	22261371	Green Accepted			2021-06-18	
J	Bisschops, LLA; Hoedemaekers, CWE; Mollnes, TE; van der Hoeven, JG				Bisschops, Laurens L. A.; Hoedemaekers, Cornelia W. E.; Mollnes, Tom E.; van der Hoeven, Johannes G.			Rewarming after hypothermia after cardiac arrest shifts the inflammatory balance	CRITICAL CARE MEDICINE			English	Article						brain; cardiac arrest; complement activation; cytokine; hypoxia-ischemia; induced; inflammation; mild hypothermia	TRAUMATIC BRAIN-INJURY; SUCCESSFUL CARDIOPULMONARY-RESUSCITATION; ENDOTHELIAL ADHESION MOLECULES; MILD HYPOTHERMIA; BLOOD-BRAIN; INTERLEUKIN-8; COMPLEMENT; REPERFUSION; ACTIVATION; HEMORRHAGE	Objectives: The aim of this study was to simultaneously analyze the key components of the cerebral and systemic inflammatory response over time in cardiac arrest patients during mild therapeutic hypothermia and rewarming. Design and Setting: Clinical observational study in a tertiary care university hospital. Patients: Ten comatose patients after out-of-hospital cardiac arrest. Interventions: All patients were cooled to 32-34 degrees C for 24 hrs. After 24 hrs patients were passively rewarmed to normothermia. Measurements and Main Results: On admission and at 3, 6, 12, 24, and 48 hrs blood samples were taken from the arterial and jugular bulb catheter. Proinflammatory and anti-inflammatory cytokines and chemokines (interleukin-1ra, interleukin-1 beta, interleukin-6, interleukin-8, interleukin-10, interleukin-18, monocyte chemotactic protein-1, high-mobility group box-1 and tumor necrosis factor-alpha), complement activation products (C4d, Bb, C3a, and terminal complement complex), and the adhesion molecule soluble intercellular adhesion molecule were measured. Mean temperatures at the start of the study and at 12 and 24 hrs were 33.7 +/- 0.9 degrees C, 32.7 +/- 0.92 degrees C, and 34.5 +/- 1.5 degrees C, respectively. Passive rewarming resulted in a temperature of 37.8 +/- 0.5 degrees C at 48 hrs. The proinflammatory cytokine interleukin-6 increased from 12 to 24 hrs and returned to baseline levels after 48 hrs. In contrast, the chemokines interleukin-8 and monocyte chemotactic protein-1 stayed relatively high from the start and during the hypothermia period, decreasing to baseline levels after 48 hrs. The anti-inflammatory cytokines interleukin-10 and interleukin-1ra did not significantly change during mild therapeutic hypothermia and rewarming, although low values of interleukin-10 were observed after rewarming. A significant increase after rewarming was demonstrated on high-mobility group box-1 concentrations in the jugular bulb, whereas soluble intercellular adhesion molecule increased significantly during hypothermia and remained at this level after rewarming. Complement activation was increased on admission and decreased after induction of hypothermia, followed by a secondary increase during rewarming. No significant differences between any of the biomarkers were found between samples from the arterial and jugular bulb catheter. Conclusions: Complement activation occurs during rewarming from mild therapeutic hypothermia after cardiac arrest. Interleukin-6 increased already from 12 to 24 hrs, concomitantly with a significant increase in the temperature seen during this period of mild therapeutic hypothermia. The optimal rate of rewarming is unknown. Additional clinical studies are needed to determine the optimal rewarming rate and strategy. (Crit Care Med 2012; 40:1136-1142)	[Bisschops, Laurens L. A.; Hoedemaekers, Cornelia W. E.; van der Hoeven, Johannes G.] Radboud Univ Nijmegen, Dept Intens Care, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Mollnes, Tom E.] Oslo Univ Hosp, Inst Immunol, Oslo, Norway; Univ Oslo, N-0316 Oslo, Norway; [Mollnes, Tom E.] Nordlandssykehuset, Res Lab, Bodo, Norway; Univ Tromso, N-9001 Tromso, Norway	Bisschops, LLA (corresponding author), Radboud Univ Nijmegen, Dept Intens Care, Med Ctr, NL-6525 ED Nijmegen, Netherlands.	L.Bisschops@ic.umcn.nl	Mollnes, Tom/ABI-5183-2020; Hoedemaekers, C.W.E./L-4375-2015; van der Hoeven, J.G./H-8048-2014				Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Aibiki M, 1999, RESUSCITATION, V41, P263, DOI 10.1016/S0300-9572(99)00052-0; Andrassy M, 2008, CIRCULATION, V117, P3216, DOI 10.1161/CIRCULATIONAHA.108.769331; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bottiger BW, 2002, CRIT CARE MED, V30, P2473, DOI 10.1097/01.CCM.0000034689.78033.E2; Callaway CW, 2008, CRIT CARE MED, V36, P2607, DOI 10.1097/CCM.0b013e318184443b; Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009; Fries M, 2009, J CRIT CARE, V24, P453, DOI 10.1016/j.jcrc.2008.10.012; Gando S, 2000, INTENS CARE MED, V26, P38, DOI 10.1007/s001340050009; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Hildebrand F, 2005, CYTOKINE, V31, P382, DOI 10.1016/j.cyto.2005.06.008; Holzer M, 2002, NEW ENGL J MED, V346, P549; Inoue K, 2003, TRANSPLANTATION, V76, P409, DOI 10.1097/01.TP.0000076095.51697.5E; Izeboud CA, 1999, INFLAMM RES, V48, P497, DOI 10.1007/s000110050493; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Meybohm P, 2010, CRIT CARE, V14, DOI 10.1186/cc8879; Mizushima H, 1999, LIFE SCI, V65, P2127, DOI 10.1016/S0024-3205(99)00477-4; Mizushima Y, 2000, ARCH SURG-CHICAGO, V135, P175, DOI 10.1001/archsurg.135.2.175; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P197, DOI 10.1111/j.1365-3083.1985.tb01871.x; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Offner H, 2009, NEUROSCIENCE, V158, P1098, DOI 10.1016/j.neuroscience.2008.05.033; Sharma HS, 2011, J NEURAL TRANSM, V118, P87, DOI 10.1007/s00702-010-0486-4; Shireman PK, 2006, J SURG RES, V134, P145, DOI 10.1016/j.jss.2005.12.003; Shyu KG, 1997, AM HEART J, V134, P551, DOI 10.1016/S0002-8703(97)70094-2; Vaagenes P, 2003, RESUSCITATION, V58, P103, DOI 10.1016/S0300-9572(03)00102-3; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VIDEM V, 1992, ANN THORAC SURG, V54, P725, DOI 10.1016/0003-4975(92)91018-5; Youngquist ST, 2009, RESUSCITATION, V80, P249, DOI 10.1016/j.resuscitation.2008.08.018	33	50	50	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2012	40	4					1136	1142		10.1097/CCM.0b013e3182377050			7	Critical Care Medicine	General & Internal Medicine	912QC	WOS:000301813700012	22020246				2021-06-18	
J	McAllister, TW; Tyler, AL; Flashman, LA; Rhodes, CH; McDonald, BC; Saykin, AJ; Tosteson, TD; Tsongalis, GJ; Moore, JH				McAllister, Thomas W.; Tyler, Anna L.; Flashman, Laura A.; Rhodes, C. Harker; McDonald, Brenna C.; Saykin, Andrew J.; Tosteson, Tor D.; Tsongalis, Gregory J.; Moore, Jason H.			Polymorphisms in the Brain-Derived Neurotrophic Factor Gene Influence Memory and Processing Speed One Month after Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; genetic factors; head trauma; neuropsychology; traumatic brain injury	RAT HIPPOCAMPUS; UNITED-STATES; PROGESTERONE; POPULATION; EXPRESSION; HAPLOTYPES; PLASTICITY; TRAUMA; BDNF	Brain-derived neurotrophic factor (BDNF) plays a role in cognition, as well as neural survival and plasticity. There are several common polymorphisms in the BDNF gene, one of which (rs6265) is an extensively studied non-synonymous coding polymorphism (Val66Met) which has been linked to cognitive performance in healthy controls and some clinical populations. We hypothesized that the Met allele of rs6265 would be associated with poorer cognitive performance in individuals with mild-to-moderate traumatic brain injury, and that other polymorphisms in the BDNF gene would also affect cognition. Genotype at 9 single-nucleotide polymorphisms (SNPs) in the BDNF gene, and measures of speed of information processing, learning, and memory were assessed in 75 patients with mTBI and 38 healthy subjects. Consistent with previous reports, the Met allele of rs6265 was associated with cognition (slower processing speed) in the entire group. Two other SNPs were associated with processing speed in the mTBI group, but both are in linkage disequilibrium with rs6265, and neither remained significant after adjustment for rs6265 status. Within the mTBI group, but not the controls, 4 SNPs, but not rs6265, were associated with memory measures. These associations were not affected by adjustment for rs6265 status. Polymorphisms in BDNF influence cognitive performance shortly after mTBI. The results raise the possibility that a functional polymorphism other than rs6265 may contribute to memory function after mTBI.	[McAllister, Thomas W.; Flashman, Laura A.; McDonald, Brenna C.; Saykin, Andrew J.] Dartmouth Med Sch, Sect Neuropsychiat, Dept Psychiat, Lebanon, NH USA; [Tyler, Anna L.; Moore, Jason H.] Dartmouth Med Sch, Computat Genet Lab, Lebanon, NH USA; [Rhodes, C. Harker] Dartmouth Med Sch, Sect Mol Pathol, Lebanon, NH USA; [Tosteson, Tor D.] Dartmouth Med Sch, Sect Biostat & Epidemiol, Lebanon, NH USA; [Tosteson, Tor D.] Dartmouth Med Sch, Dept Community & Family Med, Lebanon, NH USA; [McDonald, Brenna C.; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN USA	McAllister, TW (corresponding author), Dartmouth Hitchcock Med Ctr, Sect Neuropsychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu	; Saykin, Andrew/A-1318-2007	Moore, Jason/0000-0002-5015-1099; Saykin, Andrew/0000-0002-1376-8532	Eunice Kennedy Shriver National Institute of Child Health & Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048176]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048176] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This work was supported by grants from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (R01HD048176), and the National Institute of Neurological Disorders and Stroke (R01NS055020). The authors would like to thank Reid Kehoe, Ph.D., and Ashlee Robbins, B.A., who assisted with some of the analyses in this work.	American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Deguise E, 2008, J HEAD TRAUMA REHAB, V23, P294, DOI 10.1097/01.HTR.0000336842.53338.f4; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; First MB., 1997, STRUCTURED CLIN INTE; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Gordon M., 1986, GORDON DIAGNOSTIC SY; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Lipsky RH, 2007, ANN NY ACAD SCI, V1122, P130, DOI 10.1196/annals.1403.009; Liu KJ, 2005, BIOINFORMATICS, V21, P2128, DOI 10.1093/bioinformatics/bti282; LONG JC, 1995, AM J HUM GENET, V56, P799; Lu B, 2000, PROG BRAIN RES, V128, P231; McAllister T., 2005, TXB TRAUMATIC BRAIN, P279; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2009, J HEAD TRAUMA REHAB, V24, P65, DOI 10.1097/HTR.0b013e3181996e6b; Petryshen TL, 2010, MOL PSYCHIATR, V15, P810, DOI 10.1038/mp.2009.24; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Pritchard JK, 2000, GENETICS, V155, P945; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SAVILLE DJ, 1990, AM STAT, V44, P174, DOI 10.2307/2684163; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; TUKEY JW, 1949, BIOMETRICS, V5, P99, DOI 10.2307/3001913; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986	37	50	51	0	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1111	1118		10.1089/neu.2011.1930			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100011	22188054	Green Published			2021-06-18	
J	Barwick, F; Arnett, P; Slobounov, S				Barwick, Fiona; Arnett, Peter; Slobounov, Semyon			EEG correlates of fatigue during administration of a neuropsychological test battery	CLINICAL NEUROPHYSIOLOGY			English	Article						Mental fatigue; EEG; Stroop Interference Test	EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; SLEEP-DEPRIVATION; MULTIPLE-SCLEROSIS; DRIVER FATIGUE; WAKING EEG; PERFORMANCE; CONCUSSION; ALERTNESS; INDEXES	Objective: Mental fatigue, a poorly understood symptom of sports-related concussion, ideally requires assessment across multiple modalities. Our study aimed to examine mental fatigue effects among 10 neurologically normal, athletically active students undergoing typical concussion testing. It is our intention to ultimately address the question whether fatigue effects due to mild traumatic brain injury (mTBI) may become confounded with fatigue effects due to testing effort. Methods: Fourteen athletically active and neurologically normal volunteers were initially recruited from Penn State University. Self-reported fatigue, neuropsychological performance, and electroencephalographic (EEG) activity were measured throughout the whole testing duration. EEG measures in frequency domain (e. g., relative power of theta, alpha, and beta bands) were examined over the course of neuropsychological (NP) test administration. Results: Predicted fatigue effects over the course of testing included: (a) increased self-reported fatigue; (b) increased errors on the Stroop Interference Test; (c) significantly increased relative power of theta activity during the Stroop Interference Test in frontal-central and parietal regions; and (d) migration of alpha activation from the occipital to anterior (left parietal and pre-central) regions during the Stroop Interference task administered at the beginning compared with the end of testing. Conclusions: Results supported predictions related to subjective fatigue and cognitive performance and offered partial support for predictions related to EEG activation patterns over the course of administering the NP testing. Significance: Neurologically intact and athletically active college students demonstrate effects related to fatigue after undergoing a typical sports concussion assessment battery, including an increase in subjectively experienced fatigue, a decrease in cognitive task performance accuracy and associated modulations in EEG activity. This finding should be considered by clinical practitioners while evaluating the symptoms of concussion and making a decision regarding the return-to-sport participation. (C) 2011 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Barwick, Fiona; Arnett, Peter] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA	Slobounov, S (corresponding author), 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu			NIH, NINDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS056227-02]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	We would like to thank Dr. Cao Cheng for EEG data analysis. This research was partly supported by NIH, NIND Grant R01 NS056227-02 "Identification of Athletes at Risk for Traumatic Brain Injury'', awarded to Dr. Slobounov.	Beebe DW, 2003, SLEEP, V26, P298, DOI 10.1093/sleep/26.3.298; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Buzsaki G., 2006, RHYTHMS BRAIN CYCLE, P341; Cajochen C, 1995, SLEEP, V18, P890, DOI 10.1093/sleep/18.10.890; CHAPMAN LJ, 1987, BRAIN COGNITION, V6, P175, DOI 10.1016/0278-2626(87)90118-7; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Corsi-Cabrera M, 2003, INT J PSYCHOPHYSIOL, V50, P213, DOI 10.1016/S0167-8760(03)00168-5; De Gennaro L, 2007, NEUROIMAGE, V36, P1277, DOI 10.1016/j.neuroimage.2007.04.013; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; DeLuca J, 2007, NAT AC NEUR 27 ANN C; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-2005-867080; FISK JD, 1994, CAN J NEUROL SCI, V21, P9, DOI 10.1017/S0317167100048691; Gevins A, 1997, CEREB CORTEX, V7, P374, DOI 10.1093/cercor/7.4.374; Gioia G, 2008, 3 INT C CONC SPORT Z; GRANDJEAN EP, 1970, AM IND HYG ASSOC J, V31, P401, DOI 10.1080/0002889708506267; HORVATH M, 1976, ACTIV NERV SUPER, V18, P207; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Jones K, 2001, SLEEP MED REV, V5, P463, DOI 10.1053/smrv.2001.0203; Karni A, 1998, P NATL ACAD SCI USA, V95, P861, DOI 10.1073/pnas.95.3.861; Kiroy VN, 1996, INT J NEUROSCI, V85, P31, DOI 10.3109/00207459608986349; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lal SKL, 2002, PSYCHOPHYSIOLOGY, V39, P313, DOI 10.1017/S0048577201393095; Lal SKL, 2001, BIOL PSYCHOL, V55, P173, DOI 10.1016/S0301-0511(00)00085-5; Lim JL, 2008, ANN NY ACAD SCI, V1129, P305, DOI 10.1196/annals.1417.002; Loomis AL, 1937, J EXP PSYCHOL, V21, P127, DOI 10.1037/h0057431; Makeig S, 1995, NEUROREPORT, V7, P213, DOI 10.1097/00001756-199512000-00051; MAKEIG S, 1993, ELECTROEN CLIN NEURO, V86, P23, DOI 10.1016/0013-4694(93)90064-3; MATOUSEK M, 1983, ELECTROEN CLIN NEURO, V55, P108, DOI 10.1016/0013-4694(83)90154-2; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OKEN BS, 1986, ANN NEUROL, V19, P493, DOI 10.1002/ana.410190511; Papadelis C, 2007, CLIN NEUROPHYSIOL, V118, P1906, DOI 10.1016/j.clinph.2007.04.031; Psychological Corporation, 2001, WECHSL TEST AD READ; Rosenbaum AM, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P137, DOI 10.1007/0-387-32565-4_7; SANTAMARIA J, 1987, J CLIN NEUROPHYSIOL, V4, P327, DOI 10.1097/00004691-198710000-00002; Shen KQ, 2008, CLIN NEUROPHYSIOL, V119, P1524, DOI 10.1016/j.clinph.2008.03.012; Slobounov SM, 2000, COGNITIVE BRAIN RES, V9, P287, DOI 10.1016/S0926-6410(00)00009-4; Smith ME, 1999, COGNITIVE BRAIN RES, V7, P389, DOI 10.1016/S0926-6410(98)00043-3; Stein KD, 2001, CANCER PRACT, V6, P143; Stern RM, 2000, PSYCHOPHYSIOLOGICAL; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Thompson J, 2007, THESIS PENN STATE U, V68, P3000; Tinguely G, 2006, NEUROIMAGE, V32, P283, DOI 10.1016/j.neuroimage.2006.03.017; TORSVALL L, 1987, ELECTROEN CLIN NEURO, V66, P502, DOI 10.1016/0013-4694(87)90096-4; TREJO LJ, 1995, BIOL PSYCHOL, V40, P33, DOI 10.1016/0301-0511(95)05103-1; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Whitehead L, 2009, J PAIN SYMPTOM MANAG, V37, P107, DOI 10.1016/j.jpainsymman.2007.08.019	52	50	52	1	58	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	FEB	2012	123	2					278	284		10.1016/j.clinph.2011.06.027			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	876PB	WOS:000299118600014	21798799	Green Accepted			2021-06-18	
J	Corrigan, JD; Bogner, J; Holloman, C				Corrigan, John D.; Bogner, Jennifer; Holloman, Christopher			Lifetime history of traumatic brain injury among persons with substance use disorders	BRAIN INJURY			English	Article						Craniocerebral trauma; substance-related disorder; speed of information processing	SICKNESS IMPACT PROFILE; YOUNG-ADULTS; SOCIALIZATION SCALE; ABUSE; RELIABILITY; CHILDREN; VALIDITY; TBI; IDENTIFICATION; PREVALENCE	Objective: Determine (a) if there are sub-groups of individuals with substance use disorders distinguished by their pattern of sustaining traumatic brain injury (TBI) over the lifetime and (b) whether sub-group membership affects current functioning. Design: Secondary analysis. Settings: Outpatient substance abuse treatment programme and state prison. Participants: Two hundred and fifty-seven participants with lifetime histories of both TBI and substance used disorder drawn from two previous studies of (a) persons in substance abuse treatment and (b) prison inmates. Main outcome measures: Ohio State University TBI Identification Method, speed of information processing, working memory, disinhibition, cognitive complaints, sociopathy and substance use disorder severity. Results: Seven clusters of lifetime history of TBI were characterized by the severity of injuries, age at occurrence and presence of a period of time when multiple mild injuries were incurred, often receiving no medical attention. Cluster membership contributed to the prediction of cognitive performance (i.e. processing speed), self-reported cognitive problems and alcohol and other drug severity. Conclusions: In addition to injury severity, age at injury and periods of repeated injury may be distinguishing aspects of a lifetime history of TBI for persons with substance use disorders. Results suggest that clinicians would benefit from knowledge of a person's full history of TBI.	[Corrigan, John D.; Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Holloman, Christopher] Ohio State Univ, Stat Consulting Serv, Columbus, OH 43210 USA	Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Corrigan, John D./E-2921-2011; Bogner, Jennifer/E-2773-2011		National Institute on Disability and Rehabilitation Research [H133A970032]; Ohio Department of Alcohol and Drug Addiction Services [99-08315-00-DISC-T-0263]; National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention [U49/CE000359-01]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U49CE000359] Funding Source: NIH RePORTER	Collection of data reported in this study was supported in part by grants from the National Institute on Disability and Rehabilitation Research to the Ohio Regional TBI Model System at the Ohio State University (H133A970032); the Ohio Department of Alcohol and Drug Addiction Services grant 99-08315-00-DISC-T-0263 and the National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention grant U49/CE000359-01. The contents do not necessarily represent the policy of the Department of Education, the Centers for Disease Control and Prevention nor the Ohio Department of Alcohol and Drug Addiction Services, and the reader should not assume endorsement	Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI 10.1089/neu.2008-0849; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Chapman S.B., 2006, BRAIN INJ PROF, V3, P10; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; Corrigan JD, 2005, PSYCHOL ADDICT BEHAV, V19, P131, DOI 10.1037/0893-164X.19.2.131; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2008, BRAIN INJURY, V22, P223, DOI 10.1080/02699050801938967; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Corrigan JD, 2007, BRAIN INJURY, V21, P343, DOI 10.1080/02699050701253103; DEFRANCESCO JJ, 1993, J PSYCHOPATHOL BEHAV, V15, P53, DOI 10.1007/BF00964323; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Felde AB, 2006, BRAIN INJURY, V20, P41, DOI 10.1080/02699050500309718; Gough Harrison G., 1957, MANUAL CALIFORNIA PS; GOUGH HG, 1992, J CLIN PSYCHOL, V48, P298, DOI 10.1002/1097-4679(199205)48:3<298::AID-JCLP2270480306>3.0.CO;2-X; GOUGH HG, 1994, PSYCHOL REP, V75, P651, DOI 10.2466/pr0.1994.75.1.651; Gough HG, 1987, MANUAL CALIFORNIA PS; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; Kadden RM, 1996, PSYCHOL ADDICT BEHAV, V10, P131, DOI 10.1037/0893-164X.10.3.131; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; Megargee EI, 1972, CALIFORNIA PSYCHOL I; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Psychological Corporation, 1997, WAIS 3 WMS 3 TECHN M; R Development Core Team, 2008, R LANGUAGE ENV STAT; Sacks AL, 2009, J DUAL DIAGN, V5, P404, DOI 10.1080/15504260903182755; Savola O, 2005, ALCOHOL ALCOHOLISM, V40, P269, DOI 10.1093/alcalc/agh159; Schofield P, 2011, BRAIN INJURY, V25, P74, DOI 10.3109/02699052.2010.531690; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50; Warner M, 2005, INJURY PREV, V11, P282, DOI 10.1136/ip.2004.006965; Warner M, 2000, VITAL HLTH STAT 10, V10, P1; Whiteneck G, 2001, COLORADO TRAUMATIC B; Winqvist S., 2006, J ADOLESC HLTH, V39, DOI [10.1016/j.jadohealth.2005.12.019, DOI 10.1016/J.JADOHEALTH.2005.12.019]; Winqvist S, 2008, BRAIN INJURY, V22, P780, DOI 10.1080/02699050802339397; Winqvist S, 2007, NEUROEPIDEMIOLOGY, V29, P136, DOI 10.1159/000110741; Winqvist S, 2007, BRAIN INJURY, V21, P1079, DOI 10.1080/02699050701553221	51	50	50	0	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2012	26	2					139	150		10.3109/02699052.2011.648705			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	897NP	WOS:000300658200003	22360520				2021-06-18	
J	Mihalik, JP; Guskiewicz, KM; Marshall, SW; Blackburn, JT; Cantu, RC; Greenwald, RM				Mihalik, Jason P.; Guskiewicz, Kevin M.; Marshall, Stephen W.; Blackburn, J. Troy; Cantu, Robert C.; Greenwald, Richard M.			Head Impact Biomechanics in Youth Hockey: Comparisons Across Playing Position, Event Types, and Impact Locations	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; Injury prevention; Kinematics; Mild traumatic brain injury; Pediatric; Sports biomechanics	COLLEGIATE FOOTBALL PLAYERS; INJURY SURVEILLANCE SYSTEM; ICE HOCKEY; DESCRIPTIVE EPIDEMIOLOGY; SEVERITY; RISK	The age at which young hockey players should safely body check is unknown. We sought to determine if playing position (defensemen vs. forwards), event type (practice vs. game), or head impact location (top vs. back vs. front vs. sides) had an effect on head impact biomechanics in youth hockey. A total of 52 Bantam (13-14 years old) and Midget (15-16 years old) ice hockey players wore accelerometer-instrumented helmets for two seasons. Biomechanical data were captured for 12,253 head impacts during 151 games and 137 practices. Random intercepts general mixed linear models were employed to analyze differences in linear acceleration, rotational acceleration, and HITsp by player position, event type, and head impact location. Head impacts sustained during games resulted in greater rotational acceleration and HITsp than those sustained during practices. No event type or playing position differences in linear acceleration were observed. Impacts to the top of the head resulted in greater linear acceleration, but lower rotational acceleration and HITsp, than impacts to back, front, or side of the head. Side head impacts yielded greater rotational acceleration and HITsp compared to the other head impact locations. Since linear and rotational accelerations were observed in all impacts, future hockey helmet design standards should include rotational acceleration limits in addition to the current linear acceleration standards.	[Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; [Blackburn, J. Troy] Univ N Carolina, Neuromuscular Res Lab, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Sport Med, Concord, MA USA; [Greenwald, Richard M.] Simbex, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA	Mihalik, JP (corresponding author), Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Dept Exercise & Sport Sci, 2207 Stallings Evans Sports Med Complex,Campus Bo, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu		Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130; Marshall, Stephen/0000-0002-2664-9233	Ontario Neurotrauma Foundation [2005-PREV-BANT-387]; USA Hockey Foundation; National Operating Committee on Standards for Athletic Equipment (NOCSAE); Simbex; HIT System technology	This study was supported in part by a grant from the Ontario Neurotrauma Foundation to The University of North Carolina at Chapel Hill Injury Prevention Research Center (Grant #2005-PREV-BANT-387). The USA Hockey Foundation and the National Operating Committee on Standards for Athletic Equipment (NOCSAE) also provided financial support. We would also like to thank the engineering team at Simbex for their continued support of this project. Dr. Greenwald has a financial interest in the HIT System technology used to collect data for this study.	Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Hodgson VR, 1983, P 27 STAPP CAR CRASH, P225; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Reed N, 2010, INT J SPORTS MED, V31, P826, DOI 10.1055/s-0030-1263103; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; STUART MJ, 1995, MAYO CLIN PROC, V70, P350, DOI 10.4065/70.4.350; USA Hockey, 2011, MEMB STAT	26	50	51	1	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		141	149		10.1007/s10439-011-0405-3			9	Engineering, Biomedical	Engineering	895HJ	WOS:000300486700013	22012083				2021-06-18	
J	Castel, AD; Humphreys, KL; Lee, SS; Galvan, A; Balota, DA; McCabe, DP				Castel, Alan D.; Humphreys, Kathryn L.; Lee, Steve S.; Galvan, Adriana; Balota, David A.; McCabe, David P.			The Development of Memory Efficiency and Value-Directed Remembering Across the Life Span: A Cross-Sectional Study of Memory and Selectivity	DEVELOPMENTAL PSYCHOLOGY			English	Article						memory; life span cognition; selective attention; metacognition; cognitive aging	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; INHIBITORY CONTROL; EXECUTIVE FUNCTION; AGE-DIFFERENCES; RISK-TAKING; ATTENTION; CHILDREN; DEMENTIA; CAPACITY	Although attentional control and memory change considerably across the life span, no research has examined how the ability to strategically remember important information (i.e., value-directed remembering) changes from childhood to old age. The present study examined this in different age groups across the life span (N = 320, 5-96 years old). A selectivity task was used in which participants were asked to study and recall items worth different point values in order to maximize their point score. This procedure allowed for measures of memory quantity/capacity (number of words recalled) and memory efficiency/selectivity (the recall of high-value items relative to low-value items). Age-related differences were found for memory capacity, as young adults recalled more words than the other groups. However, in terms of selectivity, younger and older adults were more selective than adolescents and children. The dissociation between these measures across the life span illustrates important age-related differences in terms of memory capacity and the ability to selectively remember high-value information.	[Castel, Alan D.; Humphreys, Kathryn L.; Lee, Steve S.; Galvan, Adriana] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [Balota, David A.] Washington Univ, Dept Psychol, St Louis, MO 63130 USA; [McCabe, David P.] Colorado State Univ, Dept Psychol, Ft Collins, CO 80523 USA	Castel, AD (corresponding author), Univ Calif Los Angeles, Dept Psychol, 1285 Franz Hall,Box 951563, Los Angeles, CA 90095 USA.	castel@ucla.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01 AG003991-16, P50 AG005681, AG10145, P50 AG005681-26, P01 AG003991, AG03991, AG05681] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG010145, P50AG005681, P01AG003991] Funding Source: NIH RePORTER		Adcock RA, 2006, NEURON, V50, P507, DOI 10.1016/j.neuron.2006.03.036; Ariel R, 2009, J EXP PSYCHOL GEN, V138, P432, DOI 10.1037/a0015928; Balota D. A., 2001, HDB NEUROPSYCHOLOGY, V6, P51, DOI DOI 10.1037/A0014888; Balota DA, 2007, BEHAV RES METHODS, V39, P445, DOI 10.3758/BF03193014; Baltes P. B., 1990, SUCCESSFUL AGING PER, P1, DOI [DOI 10.1017/CBO9780511665684, 10.1017/CBO9780511665684.003, DOI 10.1017/CBO9780511665684.003]; Bedard AC, 2002, DEV NEUROPSYCHOL, V21, P93, DOI 10.1207/S15326942DN2101_5; Bialystok E., 2006, LIFESPAN COGNITION M; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Castel AD, 2002, MEM COGNITION, V30, P1078, DOI 10.3758/BF03194325; Castel AD, 2007, PSYCHOL LEARN MOTIV, V48, P225, DOI 10.1016/S0079-7421(07)48006-9; Castel AD, 2007, MEM COGNITION, V35, P689, DOI 10.3758/BF03193307; Castel AD, 2011, NEUROPSYCHOLOGY, V25, P15, DOI 10.1037/a0020298; Castel AD, 2009, NEUROPSYCHOLOGY, V23, P297, DOI 10.1037/a0014888; Cepeda NJ, 2001, DEV PSYCHOL, V37, P715, DOI 10.1037/0012-1649.37.5.715; Cowan N, 2006, DEV PSYCHOL, V42, P1089, DOI 10.1037/0012-1649.42.6.1089; Coyle TR, 1997, DEV PSYCHOL, V33, P372, DOI 10.1037/0012-1649.33.2.372; DEMPSTER FN, 1992, DEV REV, V12, P45, DOI 10.1016/0273-2297(92)90003-K; Durston S, 2006, DEVELOPMENTAL SCI, V9, P1, DOI 10.1111/j.1467-7687.2005.00454.x; FLAVELL JH, 1979, AM PSYCHOL, V34, P906, DOI 10.1037/0003-066X.34.10.906; Galvan A, 2007, DEVELOPMENTAL SCI, V10, pF8, DOI 10.1111/j.1467-7687.2006.00579.x; Galvan A, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/neuro.09.006.2010; Galvan A, 2006, J NEUROSCI, V26, P6885, DOI 10.1523/JNEUROSCI.1062-06.2006; Games PA, 1976, J EDUCATIONAL STATIS, V1, P113, DOI DOI 10.2307/1164979; Geier CF, 2010, CEREB CORTEX, V20, P1613, DOI 10.1093/cercor/bhp225; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hanten G, 2007, DEV NEUROPSYCHOL, V32, P585, DOI 10.1080/87565640701361112; HASHER L, 1991, J EXP PSYCHOL LEARN, V17, P163, DOI 10.1037/0278-7393.17.1.163; Hertzog C, 2010, DEV PSYCHOL, V46, P939, DOI 10.1037/a0019812; Hess T. M., 2000, GENERATIVE MENTAL PR, P129, DOI DOI 10.1007/978-94-011-4373-8_5; JONES TC, 1995, EUR J COGN PSYCHOL, V7, P65, DOI 10.1080/09541449508520158; Koriat A, 1996, PSYCHOL REV, V103, P490, DOI 10.1037/0033-295X.103.3.490; Koriat A, 2007, CAMB HANDB PSYCHOL, P289; Lindenberger U., 2006, HDB PSYCHOL AGING, V2, P289, DOI DOI 10.1016/B978-012101264-9/50016-1; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; Luna B, 2001, NEUROIMAGE, V13, P786, DOI 10.1006/nimg.2000.0743; McCabe DP, 2010, NEUROPSYCHOLOGY, V24, P222, DOI 10.1037/a0017619; McGillivray S, 2011, PSYCHOL AGING, V26, P137, DOI 10.1037/a0022681; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1988, ANN NEUROL, V24, P17, DOI 10.1002/ana.410240105; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Moscovitch M., 2000, OXFORD HDB MEMORY, P609; Olkin, 1960, CONTRIBUTIONS PROBAB, P278; Park D.C., 2006, LIFESPAN COGNITION M, P128, DOI DOI 10.1093/ACPROF:OSO/9780195169539.003.0009; Park DC, 1996, PSYCHOL AGING, V11, P621, DOI 10.1037/0882-7974.11.4.621; PLUDE DJ, 1994, ACTA PSYCHOL, V86, P227, DOI 10.1016/0001-6918(94)90004-3; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Riediger M, 2006, PSYCHOL AGING, V21, P173, DOI 10.1037/0882-7974.21.1.173; Shin H, 2007, COGNITIVE DEV, V22, P197, DOI 10.1016/j.cogdev.2006.10.001; Stuss D. T., 2002, PRINCIPLES FRONTAL L, DOI [10.1093/acprof:oso/9780195134971.001.0001, DOI 10.1093/ACPROF:OSO/9780195134971.001.0001]; Thomas KM, 1999, NEUROIMAGE, V10, P327, DOI 10.1006/nimg.1999.0466; Tse CS, 2010, NEUROPSYCHOLOGY, V24, P300, DOI 10.1037/a0018274; Waszak F, 2010, DEV PSYCHOL, V46, P337, DOI 10.1037/a0018541; Watkins M. J., 1999, SELECTIVITY MEMORY E; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Winocur G, 1992, HDB AGING COGNITION, P315; Zelazo PD, 2004, ACTA PSYCHOL, V115, P167, DOI 10.1016/j.actpsy.2003.12.005	58	50	53	1	24	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0012-1649	1939-0599		DEV PSYCHOL	Dev. Psychol.	NOV	2011	47	6					1553	1564		10.1037/a0025623			12	Psychology, Developmental	Psychology	842QH	WOS:000296613600006	21942664	Green Accepted			2021-06-18	
J	Adelson, PD; Srinivas, R; Chang, Y; Bell, M; Kochanek, PM				Adelson, P. David; Srinivas, Ravi; Chang, Yuefang; Bell, Michael; Kochanek, Patrick M.			Cerebrovascular response in children following severe traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article						Pediatric; Head trauma; Cerebral blood flow; Autoregulation; Vasoreactivity; Xenon CT	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; METABOLISM; AUTOREGULATION; ADOLESCENTS; INFANTS; CIRCULATION; TOMOGRAPHY; SCORE; AGE	To describe the pathophysiologic response in cerebral blood flow (CBF) and autoregulation after severe traumatic brain injury (TBI), Glasgow Coma Score (GCS) a parts per thousand currency sign8 on admission, in children, defining a baseline for future studies. Retrospective chart review of 95 patients following TBI, ages 0.1-18.4 years (< 5 years (n = 44), < 2 years (n = 17)) for CBF using Xenon Computerized Tomography (XeCT) over a 10-year period and 6-month Glasgow Outcome Scores (GOS). A total of 140 CBF studies were performed variably from admission up to post injury day (PID) 9; 27 patients underwent repeat CBF study after PaCO2 was manipulated to determine CO2 vasoreactivity (CO2VR). Mean CBF on admission (PID 0, n = 26) was 32.05 +/- 21.45 ml/100 g/min (mean +/- SEM) and was a parts per thousand currency sign20 ml/100 g/min in eight patients. At PID 1-2, mean CBF increased to 55.36 +/- 23.11 ml/100 g/min. There was significant differences in mean CBF of "favorable" outcomes (GOS a parts per thousand yenaEuro parts per thousand 4) versus "unfavorable" outcome (GOS a parts per thousand currency signaEuro parts per thousand 3) (61.74 +/- 18.27 vs. 46.54 +/- 26.26, respectively (P = 0.01)). "Unfavorable" outcomes were seen in all patients with CBF a parts per thousand currency sign20 ml/100 mg/min during PID 0-2 and in 76.5% of children < 2 years. CO2VR < 2%/Torr PaCO2 within PID 0-2 was significantly associated with "unfavorable" outcome (P = 0.029). Younger age, early or later low CBF, and CO2VR < 2%/Torr PaCO2 were correlated with poorer outcomes in children. This represents the largest experience with XeCT CBF in children and confirms our preliminary report of low early CBF after TBI in children, disturbed CO2VR, and relationship of low CBF and unfavorable outcome.	[Adelson, P. David] Phoenix Childrens Neurosci Inst & Pediat Neurosur, Phoenix, AZ 85016 USA; [Srinivas, Ravi; Chang, Yuefang; Bell, Michael; Kochanek, Patrick M.] Childrens Hosp Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Srinivas, Ravi; Chang, Yuefang; Bell, Michael; Kochanek, Patrick M.] Univ Pittsburgh, Pittsburgh, PA USA	Adelson, PD (corresponding author), Phoenix Childrens Neurosci Inst & Pediat Neurosur, 4th Floor,Bldg B,1919 E Thomas Rd, Phoenix, AZ 85016 USA.	dadelson@phoenixchildrens.com	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS01809, NS052478]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001809, U01NS052478] Funding Source: NIH RePORTER	The authors would like to thank Ms. Christina Casanova for the preparation of this manuscript and S. Danielle Brown, MSN, who served as the honest broker. The author (PDA) was supported in part for this study by the National Institute of Health (NS01809, NS052478). The authors have no personal or institutional financial interest in drugs, materials, or devices described in this submission.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; BEYDA DH, 1996, CRIT CARE MED, V24, P134; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CHIRON C, 1992, J NUCL MED, V33, P696; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; GUR D, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P68; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; JENNETT B, 1975, LANCET, V1, P480; KASOFF SS, 1972, J NEUROSURG, V36, P463, DOI 10.3171/jns.1972.36.4.0463; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; KOCHANEK PK, 1995, CURRENT CONCEPTS PED; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARMAROU A, 1996, P 10 INT BRAIN ED S, P90; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1993, J CEREB BLOOD FLOW M, V13, P571; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; PIETRINI D, 2004, MINERVA ANESTESIOL, V70, P545; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2007, J NEUROTRAUM, V24, P87, DOI 10.1089/neu.2006.0058; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403	37	50	52	1	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	SEP	2011	27	9					1465	1476		10.1007/s00381-011-1476-z			12	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	807KY	WOS:000293897800017	21559825				2021-06-18	
J	Tsai, MC; Chen, WJ; Tsai, MS; Ching, CH; Chuang, JI				Tsai, Ming Che; Chen, Wei Ju; Tsai, Ming Shi; Ching, Cheng Hsin; Chuang, Jih Ing			Melatonin attenuates brain contusion-induced oxidative insult, inactivation of signal transducers and activators of transcription 1, and upregulation of suppressor of cytokine signaling-3 in rats	JOURNAL OF PINEAL RESEARCH			English	Article						brain contusion; glutathione; inducible nitric oxide synthetase; interleukine-6; melatonin; signal transducers and activators of transcription 1; suppressor of cytokine signaling 1	NF-KAPPA-B; INTRACRANIAL-PRESSURE; CEREBRAL-ISCHEMIA; GENE-EXPRESSION; NITRIC-OXIDE; CELL-DEATH; IN-VIVO; INJURY; STRESS; STAT1	The induction of oxidative stress and inflammation has been closely linked in traumatic brain injury (TBI). Transcriptional factors of signal transducers and activators of transcription (STAT) proteins are redox sensitive and participate in the regulation of cytokine signaling. Previous studies demonstrated that melatonin protects neurons through its antioxidative and anti-inflammatory effects in various neuropathological conditions. However, the effect of melatonin on STAT activity after TBI has not yet been explored. In this study, we used a controlled weight-drop TBI model and found that brain contusion induced oxidative stress (a decreased level of total glutathione and an increased ratio of oxidized glutathione to total glutathione), a reduction in STAT1 DNA-binding activity, and consequently neuronal loss in a contusion depth-dependent manner. A significant increased mRNA expression of suppressor of cytokine signaling (SOCS3), inducible nitric oxide synthetase (iNOS), and interleukine-6 (IL-6), but a decreased protein expression of protein inhibitor of activated STAT (PIAS1), was found 24 hr after brain contusion. SOCS3 and PIAS1 are endogenous negative regulators of STAT1. Moreover, the combination of intraperitoneal and local (presoaked in gelfoam and placed on the traumatic cortex) administration of melatonin had the most pronounced influence in inhibiting all effects except the PIAS1 downregulation induced by brain contusion. The results suggest that SOCS-3 upregulation and oxidative stress may contribute to the STAT1 inactivation after TBI. Melatonin protects neurons from TBI by reducing oxidative stress, STAT1 inactivation, and upregulation of SOCS-3 and pro-inflammatory cytokines.	[Chen, Wei Ju; Ching, Cheng Hsin; Chuang, Jih Ing] Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan; [Tsai, Ming Che] Chung Shan Med Univ Hosp, Dept Emergency Med, Taichung, Taiwan; [Tsai, Ming Che] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Tsai, Ming Shi] Sinying Hosp, Dept Hlth, Tainan, Taiwan	Chuang, JI (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan.	jichuang@mail.ncku.edu.tw			National Science Council in TaiwanMinistry of Science and Technology, Taiwan [NSC 95-2320-B006-053, NSC96-2320-B-006-043-MY3]	This work was supported by the National Science Council in Taiwan, grant no. NSC 95-2320-B006-053 and NSC96-2320-B-006-043-MY3.	ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Chen ST, 2002, J PINEAL RES, V32, P262, DOI 10.1034/j.1600-079X.2002.01871.x; Choi EY, 2011, J PINEAL RES, V50, P197, DOI 10.1111/j.1600-079X.2010.00829.x; Choi JS, 2008, NEUROSCI LETT, V441, P323, DOI 10.1016/j.neulet.2008.06.051; Chuang JI, 2004, J PINEAL RES, V36, P117, DOI 10.1046/j.1600-079X.2003.00107.x; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Das A, 2010, J PINEAL RES, V48, P157, DOI 10.1111/j.1600-079X.2009.00739.x; Dziennis S, 2008, REV NEUROSCIENCE, V19, P341; Emery B, 2006, P NATL ACAD SCI USA, V103, P7859, DOI 10.1073/pnas.0602574103; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Gorina R, 2007, GLIA, V55, P1313, DOI 10.1002/glia.20542; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Hong Y, 2010, J PINEAL RES, V49, P201, DOI 10.1111/j.1600-079X.2010.00786.x; Hoppe JB, 2010, J PINEAL RES, V48, P230, DOI 10.1111/j.1600-079X.2010.00747.x; Hung MW, 2008, J PINEAL RES, V44, P214, DOI 10.1111/j.1600-079X.2007.00514.x; Jung JE, 2009, J NEUROSCI, V29, P7003, DOI 10.1523/JNEUROSCI.1110-09.2009; Kabe Y, 2005, ANTIOXID REDOX SIGN, V7, P395, DOI 10.1089/ars.2005.7.395; Kerman M, 2005, EXP BRAIN RES, V163, P406, DOI 10.1007/s00221-005-2338-2; Kim HS, 2007, CELL SIGNAL, V19, P454, DOI 10.1016/j.cellsig.2006.09.003; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li L, 2010, CANCER RES, V70, P8222, DOI 10.1158/0008-5472.CAN-10-0894; Li LM, 2010, ANESTH ANALG, V111, P736, DOI 10.1213/ANE.0b013e3181e75cd1; Madan E, 2008, BIOCHEM BIOPH RES CO, V377, P1232, DOI 10.1016/j.bbrc.2008.10.158; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; McCormick J, 2006, FASEB J, V20, P2115, DOI 10.1096/fj.06-6188fje; Monroe RK, 2006, FREE RADICAL BIO MED, V41, P493, DOI 10.1016/j.freeradbiomed.2006.04.023; Monroe RK, 2009, NEUROTOXICOLOGY, V30, P589, DOI 10.1016/j.neuro.2009.03.007; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Negi G, 2011, J PINEAL RES, V50, P124, DOI 10.1111/j.1600-079X.2010.00821.x; Osuka K, 2010, BRAIN RES, V1332, P12, DOI 10.1016/j.brainres.2010.03.046; Park SJ, 2009, FREE RADICAL BIO MED, V46, P1694, DOI 10.1016/j.freeradbiomed.2009.03.026; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Reed TT, 2009, J NEUROSCI RES, V87, P408, DOI 10.1002/jnr.21872; Sarafian TA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009532; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shuai K, 2006, CELL RES, V16, P196, DOI 10.1038/sj.cr.7310027; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Smith PD, 2009, NEURON, V64, P617, DOI 10.1016/j.neuron.2009.11.021; Spangenburg EE, 2006, J PHYSIOL-LONDON, V572, P839, DOI 10.1113/jphysiol.2005.104315; Stephanou A, 2004, J CELL MOL MED, V8, P519, DOI 10.1111/j.1582-4934.2004.tb00476.x; Takagi Y, 2002, J CEREBR BLOOD F MET, V22, P1311, DOI 10.1097/01.WCB.0000034148.72481.F4; Terui K, 2004, BIOCHEM J, V380, P203, DOI 10.1042/BJ20031891; Timmons SD, 2010, CRIT CARE MED, V38, pS431, DOI 10.1097/CCM.0b013e3181ec57ab; Tocharus J, 2010, J PINEAL RES, V48, P347, DOI 10.1111/j.1600-079X.2010.00761.x; Toklu HZ, 2009, FREE RADICAL RES, V43, P658, DOI 10.1080/10715760902988843; Tsai MC, 2007, SHOCK, V27, P527, DOI 10.1097/01.shk.0000245032.31859.f2; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wang JP, 2002, P NATL ACAD SCI USA, V99, P16209, DOI 10.1073/pnas.252454799; Xie Y, 2009, ENDOCRINOLOGY, V150, P1122, DOI 10.1210/en.2008-1241; Yadav A, 2005, J BIOL CHEM, V280, P31830, DOI 10.1074/jbc.M501316200; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	57	50	52	1	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0742-3098			J PINEAL RES	J. Pineal Res.	SEP	2011	51	2					233	245		10.1111/j.1600-079X.2011.00885.x			13	Endocrinology & Metabolism; Neurosciences; Physiology	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	805SC	WOS:000293748300011	21545521				2021-06-18	
J	Spinella, PC; Wade, CE; Blackbourne, LH; Borgman, MA; Zarzabal, LA; Du, F; Perkins, JG; Maegele, M; Schreiber, M; Hess, JR; Jastrow, KM; Gonzalez, EA; Holcomb, JB; Kozar, R				Spinella, Philip C.; Wade, Charles E.; Blackbourne, Lorne H.; Borgman, Matthew A.; Zarzabal, Lee A.; Du, Fei; Perkins, Jeremy G.; Maegele, Marc; Schreiber, Martin; Hess, John R.; Jastrow, Kenneth M., III; Gonzalez, Ernest A.; Holcomb, John B.; Kozar, Rosemary		Trauma Outcomes Grp	The Association of Blood Component Use Ratios With the Survival of Massively Transfused Trauma Patients With and Without Severe Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Transfusion; Mortality; Red Blood Cell; Plasma; Platelets	DAMAGE CONTROL RESUSCITATION; FRESH-FROZEN PLASMA; EARLY COAGULOPATHY; MORTALITY; PLATELETS; IMPACT; CELLS; TIME; EPIDEMIOLOGY; COAGULATION	Background: The effect of blood component ratios on the survival of patients with traumatic brain injury (TBI) has not been studied. Methods: A database of patients transfused in the first 24 hours after admission for injury from 22 Level I trauma centers over an 18-month period was queried to find patients who (1) met different definitions of massive transfusion (5 units red blood cell [RBC] in 6 hours vs. 10 units RBC in 24 hours), (2) received high or low ratios of platelets or plasma to RBC units (<1:2 vs. >= 1:2), and (3) had severe TBI (head abbreviated injury score >= 3) (TBI+). Results: Of 2,312 total patients, 850 patients were transfused with >= 5 RBC units in 6 hours and 807 could be classified into TBI+ (n = 281) or TBI- (n = 526). Six hundred forty-three patients were transfused with >= 10 RBC units in 24 hours with 622 classified into TBI+ (n = 220) and TBI- (n = 402). For both high-risk populations, a high ratio of platelets:RBCs (not plasma) was independently associated with improved 30-day survival for patients with TBI+ and a high ratio of plasma:RBCs (not platelets) was independently associated with improved 30-day survival in TBI- patients. Conclusions: High platelet ratio was associated with improved survival in TBI+ patients while a high plasma ratio was associated with improved survival in TBI- patients. Prospective studies of blood product ratios should include TBI in the analysis for determination of optimal use of ratios on outcome in injured patients.	[Spinella, Philip C.] St Louis Childrens Hosp, Div Crit Care Med, Dept Pediat, St Louis, MO 63110 USA; [Spinella, Philip C.; Wade, Charles E.; Blackbourne, Lorne H.] USA, Inst Surg Res, San Antonio, TX USA; [Borgman, Matthew A.] Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; [Zarzabal, Lee A.; Du, Fei] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Perkins, Jeremy G.] Walter Reed Army Med Ctr, Dept Med, Washington, DC 20307 USA; [Maegele, Marc] Merheim Med Ctr, Dept Surg, Cologne, Germany; [Schreiber, Martin] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA; [Hess, John R.] R Adams Cowley Shock Trauma Ctr, Dept Pathol, Baltimore, MD USA; [Jastrow, Kenneth M., III; Gonzalez, Ernest A.; Holcomb, John B.; Kozar, Rosemary] Univ Texas Hlth Sci Ctr, Div Acute Care Surg, Ctr Translat Injury Res, Houston, TX USA	Spinella, PC (corresponding author), St Louis Childrens Hosp, Div Crit Care Med, Dept Pediat, 1 Childrens Pl,Campus Box 8116, St Louis, MO 63110 USA.	spinella_p@wustl.kids.edu	Borgman, Matthew A/L-9477-2015; Hess, John R./K-4001-2013	Borgman, Matthew A/0000-0002-2008-7380; Hess, John R./0000-0001-8596-4420; holcomb, john/0000-0001-8312-9157	US ArmyUnited States Department of Defense [W81XWH-07-1-0717]	We thank Joel Michalek, PhD, for his contributions to the statistical analysis and preparation of the manuscript. The authors wish to acknowledge the support of the numerous research coordinators at the various centers. This work was funded in part by a grant from the US Army to the University of Texas Health Science Center San Antonio, W81XWH-07-1-0717.	Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Beekley AC, 2008, CRIT CARE MED, V36, pS267, DOI 10.1097/CCM.0b013e31817da7dc; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Cotton BA, 2008, J TRAUMA, V64, P1177, DOI 10.1097/TA.0b013e31816c5c80; Demetriades D, 2004, J AM COLL SURGEONS, V198, P20, DOI 10.1016/j.jamcollsurg.2003.09.003; Duchesne JC, 2008, J TRAUMA, V65, P272, DOI 10.1097/TA.0b013e31817e5166; Duchesne JC, 2009, J TRAUMA, V67, P228; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hess JR, 2006, TRANSFUSION, V46, P685, DOI 10.1111/j.1537-2995.2006.00816.x; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; Kashuk JL, 2008, J TRAUMA, V65, P261, DOI 10.1097/TA.0b013e31817de3e1; KOZAR RA, 2009, SHOCK, V31, pS89; Maegele M, 2008, VOX SANG, V95, P112, DOI 10.1111/j.1423-0410.2008.01074.x; McMullin NR, 2006, INTENSIVE CARE MEDICINE: ANNUAL UPDATE 2006, P265, DOI 10.1007/0-387-35096-9_25; Moore FA, 2008, J TRAUMA, V64, P1010, DOI 10.1097/TA.0b013e31816a2417; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Pati S, 2010, J TRAUMA, V69, pS55, DOI 10.1097/TA.0b013e3181e453d4; Peng R, 1998, AM SURGEON, V64, P950; Perkins JG, 2009, J TRAUMA, V66, pS77, DOI 10.1097/TA.0b013e31819d8936; Rehm M, 2007, CIRCULATION, V116, P1896, DOI 10.1161/CIRCULATIONAHA.106.684852; Rhodes KE, 2006, NEUROSCIENCE, V140, P87, DOI 10.1016/j.neuroscience.2006.01.055; Sambasivan CN, 2009, AM J SURG, V197, P576, DOI 10.1016/j.amjsurg.2008.12.011; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Snyder CW, 2009, J TRAUMA, V66, P358, DOI 10.1097/TA.0b013e318196c3ac; Sperry JL, 2008, J TRAUMA, V65, P986, DOI 10.1097/TA.0b013e3181878028; Spinella PC, 2007, CRIT CARE MED, V35, pA152; Spinella PC, 2009, BLOOD REV, V23, P231, DOI 10.1016/j.blre.2009.07.003; Teixeira PGR, 2009, J TRAUMA, V66, P693, DOI 10.1097/TA.0b013e31817e5c77; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Watson GA, 2009, J TRAUMA, V67, P221, DOI 10.1097/TA.0b013e3181ad5957; Zink KA, 2009, AM J SURG, V197, P565, DOI 10.1016/j.amjsurg.2008.12.014	36	50	51	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2011	71			3			S343	S352		10.1097/TA.0b013e318227ef2d			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	806XE	WOS:000293849700005	21814102				2021-06-18	
J	Han, XD; Tong, J; Zhang, J; Farahvar, A; Wang, E; Yang, JK; Samadani, U; Smith, DH; Huang, JH				Han, Xiaodi; Tong, Jing; Zhang, Jun; Farahvar, Arash; Wang, Ernest; Yang, Jiankai; Samadani, Uzma; Smith, Douglas H.; Huang, Jason H.			Imipramine Treatment Improves Cognitive Outcome Associated with Enhanced Hippocampal Neurogenesis after Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessment; controlled cortical impact; medication; traumatic brain injury	CONTROLLED CORTICAL IMPACT; FIBROBLAST-GROWTH-FACTOR; ADULT-MOUSE HIPPOCAMPUS; CENTRAL-NERVOUS-SYSTEM; DENTATE GYRUS; NEUROTROPHIC FACTOR; CELL-PROLIFERATION; GRANULE CELLS; NEURONAL DIFFERENTIATION; ANTIDEPRESSANT TREATMENT	Previous animal and human studies have demonstrated that chronic treatment with several different antidepressants can stimulate neurogenesis, neural remodeling, and synaptic plasticity in the normal hippocampus. Imipramine is a commonly used tricyclic antidepressant (TCA). We employed a controlled cortical impact (CCI) mouse model of traumatic brain injury (TBI) to assess the effect of imipramine on neurogenesis and cognitive and motor function recovery after TBI. Mice were given daily imipramine injections for either 2 or 4 weeks after injury. Bromodeoxyuridine (BrdU) was administered 3-7 days post-brain injury to label the cells that proliferated as a result of the injury. We assessed the effects of imipramine on post-traumatic motor function using a beam-walk test and an assessment of cognitive function: the novel object recognition test (NOR). Histological analyses were performed at 2 and 4 weeks after CCI. Brain-injured mice treated with imipramine showed significantly improved cognitive function compared to a saline-treated group (p < 0.001). However, there was no significant difference in motor function recovery between imipramine-treated and saline-treated mice. Histological examination revealed increased preservation of proliferation of Ki-67- and BrdU-positive cells in the hippocampal dentate gyrus (DG) at 2 and 4 weeks after TBI. Immunofluorescence double-labeling with BrdU and neuron-specific markers at 4 weeks after injury showed that most progenitors became neurons in the DG and astrocytes in the hilus. Notably, treatment with imipramine increased preservation of the total number of newly-generated neurons. Our findings provide direct evidence that imipramine treatment contributes to cognitive improvement after TBI, perhaps by enhanced hippocampal neurogenesis.	[Han, Xiaodi; Tong, Jing; Farahvar, Arash; Wang, Ernest; Yang, Jiankai; Huang, Jason H.] Univ Rochester, Dept Neurosurg, Rochester, NY 14642 USA; [Han, Xiaodi; Tong, Jing; Yang, Jiankai; Huang, Jason H.] Univ Rochester, Ctr Neural Dev & Dis, Rochester, NY 14642 USA; [Han, Xiaodi] Beijing Tiantan Puhua Hosp, Dept Neurosurg, Beijing, Peoples R China; [Zhang, Jun] Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China; [Samadani, Uzma] NYU, Dept Neurosurg, New York, NY 10016 USA; [Smith, Douglas H.] Univ Penn, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA	Huang, JH (corresponding author), Univ Rochester, Dept Neurol Surg, 601 Elmwood Ave,Box 670, Rochester, NY 14642 USA.	Jason_huang@urmc.rochester.edu	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168	University of Rochester; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS-067435]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067435] Funding Source: NIH RePORTER	This work was supported in part by a University of Rochester SPAC grant (to J.H.H.), and by NIH grant R01-NS-067435 (to J.H.H.).	Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bachis A, 2008, NEUROPHARMACOLOGY, V55, P1114, DOI 10.1016/j.neuropharm.2008.07.014; Bessa JM, 2009, MOL PSYCHIATR, V14, P764, DOI 10.1038/mp.2008.119; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Bowen A, 1999, BRAIN INJURY, V13, P547; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bull ND, 2005, J NEUROSCI, V25, P10815, DOI 10.1523/JNEUROSCI.3249-05.2005; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Castren E, 2007, CURR OPIN PHARMACOL, V7, P18, DOI 10.1016/j.coph.2006.08.009; Chen CPLH, 1996, J NEUROCHEM, V66, P1592, DOI 10.1046/j.1471-4159.1996.66041592.x; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Czeh B, 2001, P NATL ACAD SCI USA, V98, P12796, DOI 10.1073/pnas.211427898; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deb S, 1999, AM J PSYCHIAT, V156, P374; Encinas JM, 2006, P NATL ACAD SCI USA, V103, P8233, DOI 10.1073/pnas.0601992103; Encinas JM, 2008, METHOD CELL BIOL, V85, P243, DOI 10.1016/S0091-679X(08)85011-X; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Gaskin S, 2003, HIPPOCAMPUS, V13, P962, DOI 10.1002/hipo.10154; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; KOCSIS JH, 1988, ARCH GEN PSYCHIAT, V45, P253; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Markakis EA, 1999, J COMP NEUROL, V406, P449; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Millan MJ, 2006, PHARMACOL THERAPEUT, V110, P135, DOI 10.1016/j.pharmthera.2005.11.006; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Nakagawa S, 2002, J NEUROSCI, V22, P3673; NIBUYA M, 1995, J NEUROSCI, V15, P7539; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Perera TD, 2007, J NEUROSCI, V27, P4894, DOI 10.1523/JNEUROSCI.0237-07.2007; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rantamaki T, 2007, NEUROPSYCHOPHARMACOL, V32, P2152, DOI 10.1038/sj.npp.1301345; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; ROBINSON RG, 1985, PSYCHOSOMATICS, V26, P769, DOI 10.1016/S0033-3182(85)72790-9; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Sairanen M, 2005, J NEUROSCI, V25, P1089, DOI 10.1523/JNEUROSCI.3741-04.2005; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Shapiro LA, 2005, BRAIN RES REV, V48, P43, DOI 10.1016/j.brainresrev.2004.08.003; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAKAHASHI T, 1992, J NEUROCYTOL, V21, P185, DOI 10.1007/BF01194977; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tsankova NM, 2006, NAT NEUROSCI, V9, P519, DOI 10.1038/nn1659; Wang JW, 2008, J NEUROSCI, V28, P1374, DOI 10.1523/JNEUROSCI.3632-07.2008; Wang SH, 2008, BEHAV BRAIN RES, V189, P9, DOI 10.1016/j.bbr.2007.11.028; Warner-Schmidt JL, 2007, P NATL ACAD SCI USA, V104, P4647, DOI 10.1073/pnas.0610282104; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	82	50	54	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					995	1007		10.1089/neu.2010.1563			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600013	21463148	Green Published			2021-06-18	
J	Hunt, RF; Scheff, SW; Smith, BN				Hunt, Robert F.; Scheff, Stephen W.; Smith, Bret N.			Synaptic Reorganization of Inhibitory Hilar Interneuron Circuitry after Traumatic Brain Injury in Mice	JOURNAL OF NEUROSCIENCE			English	Article							TEMPORAL-LOBE EPILEPSY; CONTROLLED CORTICAL IMPACT; DENTATE GRANULE CELLS; CA3 PYRAMIDAL CELLS; RAT HIPPOCAMPUS; POSTTRAUMATIC EPILEPSY; STATUS EPILEPTICUS; SOMATOSTATIN INTERNEURONS; IMMUNOREACTIVE NEURONS; GABAERGIC INTERNEURONS	Functional plasticity of synaptic networks in the dentate gyrus has been implicated in the development of posttraumatic epilepsy and in cognitive dysfunction after traumatic brain injury, but little is known about potentially pathogenic changes in inhibitory circuits. We examined synaptic inhibition of dentate granule cells and excitability of surviving GABAergic hilar interneurons 8-13 weeks after cortical contusion brain injury in transgenic mice that express enhanced green fluorescent protein in a subpopulation of inhibitory neurons. Whole-cell voltage-clamp recordings in granule cells revealed a reduction in spontaneous and miniature IPSC frequency after head injury; no concurrent change in paired-pulse ratio was found in granule cells after paired electrical stimulation of the hilus. Despite reduced inhibitory input to granule cells, action potential and EPSC frequencies were increased in hilar GABA neurons from slices ipsilateral to the injury versus those from control or contralateral slices. Furthermore, increased excitatory synaptic activity was detected in hilar GABA neurons ipsilateral to the injury after glutamate photostimulation of either the granule cell or CA3 pyramidal cell layers. Together, these findings suggest that excitatory drive to surviving hilar GABA neurons is enhanced by convergent input from both pyramidal and granule cells, but synaptic inhibition of granule cells is not fully restored after injury. This rewiring of circuitry regulating hilar inhibitory neurons may reflect an important compensatory mechanism, but it may also contribute to network destabilization by increasing the relative impact of surviving individual interneurons in controlling granule cell excitability in the posttraumatic dentate gyrus.	[Smith, Bret N.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Scheff, Stephen W.; Smith, Bret N.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Smith, BN (corresponding author), Univ Kentucky, Coll Med, Dept Physiol, MS508 Chandler Med Ctr,800 Rose St, Lexington, KY 40536 USA.	bret.smith@uky.edu	Ritter, Stefanie L/D-9312-2012	Hunt, Robert/0000-0003-4490-8718	Epilepsy Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG21981, NS052302]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS052302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER	This work was supported by an Epilepsy Foundation predoctoral fellowship (R. F. H.) and funding from National Institutes of Health Grants AG21981 (S. W. S.) and NS052302 (B.N.S.). Thanks to Dr. Peter Gyarmati for helpful discussion during the preparation of this manuscript.	Acsady L, 1998, J NEUROSCI, V18, P3386; BABB TL, 1989, J NEUROSCI, V9, P2562; BAKST I, 1986, J NEUROSCI, V6, P1452; Bhaskaran MD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010683; Bonifazi P, 2009, SCIENCE, V326, P1419, DOI 10.1126/science.1175509; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 2002, J COMP NEUROL, V445, P360, DOI 10.1002/cne.10183; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; Chang BS, 2003, NEW ENGL J MED, V349, P1257, DOI 10.1056/NEJMra022308; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; Cossart R, 2001, NAT NEUROSCI, V4, P52; Dantzker JL, 2000, NAT NEUROSCI, V3, P701, DOI 10.1038/76656; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Doherty J, 2001, J NEUROSCI, V21, P2048, DOI 10.1523/JNEUROSCI.21-06-02048.2001; Dudek FE, 1997, J CLIN NEUROPHYSIOL, V14, P90, DOI 10.1097/00004691-199703000-00002; ESCLAPEZ M, 1995, NEUROSCIENCE, V64, P339, DOI 10.1016/0306-4522(94)00406-U; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Halabisky B, 2006, J NEUROPHYSIOL, V96, P834, DOI 10.1152/jn.01079.2005; Halabisky B, 2010, J NEUROPHYSIOL, V104, P2214, DOI 10.1152/jn.00147.2010; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hirsch JC, 1999, NAT NEUROSCI, V2, P499; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; JOHANSEN FF, 1987, ACTA NEUROPATHOL, V73, P110, DOI 10.1007/BF00693775; Jones DL, 2007, J NEUROPHYSIOL, V98, P2737, DOI 10.1152/jn.00938.2007; Katona I, 1999, NEUROSCIENCE, V88, P37, DOI 10.1016/S0306-4522(98)00302-9; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; KNEISLER TB, 1995, J PHYSIOL-LONDON, V487, P125, DOI 10.1113/jphysiol.1995.sp020866; Kobayashi M, 2003, J NEUROSCI, V23, P2440; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; LERANTH C, 1990, J COMP NEUROL, V295, P111, DOI 10.1002/cne.902950110; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059; Mangin JM, 2008, J NEUROSCI, V28, P7610, DOI 10.1523/JNEUROSCI.1355-08.2008; MATHERN GW, 1995, J NEUROSCI, V15, P3990; Mathew SS, 2008, J NEUROSCI, V28, P725, DOI 10.1523/JNEUROSCI.3625-07.2008; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; Morgan RJ, 2008, P NATL ACAD SCI USA, V105, P6179, DOI 10.1073/pnas.0801372105; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Oliva AA, 2000, J NEUROSCI, V20, P3354, DOI 10.1523/JNEUROSCI.20-09-03354.2000; Patrylo PR, 1998, J NEUROPHYSIOL, V79, P418; PEARCE RA, 1993, NEURON, V10, P189, DOI 10.1016/0896-6273(93)90310-N; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; SCHARFMAN HE, 1990, NEUROSCIENCE, V37, P693, DOI 10.1016/0306-4522(90)90100-I; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shao LR, 2005, J NEUROPHYSIOL, V94, P952, DOI 10.1152/jn.01342.2004; Shibley H, 2002, EPILEPSY RES, V49, P109, DOI 10.1016/S0920-1211(02)00012-8; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272; Sun CS, 2007, J COMP NEUROL, V500, P876, DOI 10.1002/cne.21207; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Szabadics J, 2001, J NEUROSCI, V21, P5824; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Toth Z, 1997, J NEUROSCI, V17, P8106; TRAUB RD, 1982, SCIENCE, V216, P745, DOI 10.1126/science.7079735; vandenPol AN, 1996, J NEUROSCI, V16, P4283; Waldbaum S, 2009, EPILEPSIA, V50, P904, DOI 10.1111/j.1528-1167.2008.01939.x; Wendling F, 2002, EUR J NEUROSCI, V15, P1499, DOI 10.1046/j.1460-9568.2002.01985.x; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wittner L, 2006, EUR J NEUROSCI, V24, P1286, DOI 10.1111/j.1460-9568.2006.04992.x; WONG RKS, 1979, P NATL ACAD SCI USA, V76, P986, DOI 10.1073/pnas.76.2.986; WONG RKS, 1981, J NEUROPHYSIOL, V45, P86; Wuarin JP, 2001, J NEUROPHYSIOL, V85, P1067; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009; Zhang W, 2009, J NEUROSCI, V29, P7846, DOI 10.1523/JNEUROSCI.6199-08.2009	72	50	52	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAY 4	2011	31	18					6880	6890		10.1523/JNEUROSCI.0032-11.2011			11	Neurosciences	Neurosciences & Neurology	759AO	WOS:000290212100030	21543618	Green Published, Green Accepted, Bronze			2021-06-18	
J	Wilson, KR; Donders, J; Nguyen, L				Wilson, Kathryn R.; Donders, Jacobus; Nguyen, Loan			Self and Parent Ratings of Executive Functioning After Adolescent Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; executive functioning; deficit awareness	QUALITY-OF-LIFE; NEUROPSYCHOLOGICAL ASSESSMENT; CHILDREN; AWARENESS; INVENTORY; VALIDITY; DEFICITS; MODERATE; IMPACT	Objective: To examine the level of agreement between adolescents with traumatic brain injury (TB!) and their parents in standardized ratings of executive functioning, and to determine correlates of discrepancies between those ratings. Participants: Ninety-eight 11- to 16-year-old adolescents with TBI and their parents, and 97 neuropsychologically healthy controls. Method: Five-year consecutive series of rehabilitation referrals for TBI. Measures: Behavior Rating Inventory of Executive Function Self Report (BRIEF-SR) and Behavior Rating Inventory of Executive Function (BRIEF) parent report versions. Results: Self and parent ratings were moderately positively correlated in both the TBI group and the control group, but parents generally identified more executive dysfunction than did the adolescents. Parent-adolescent discrepancies were statistically significantly greater in the TBI group than in the control group on the Metacognitive index but not the Behavioral Regulation index. The degree of the former discrepancy was predicted by duration of coma in the TBI group. Conclusions: Adolescents with more severe TBI may underestimate their own degree of executive dysfunction in daily life, particularly aspects of metacognitive abilities, possibly, in part, because of an organic-based lack of deficit awareness.	[Wilson, Kathryn R.; Donders, Jacobus] Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; [Nguyen, Loan] Hope Coll, Dept Psychol, Holland, MI USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					Beardmore S, 1999, NEUROPSYCHOL REHABIL, V9, P45, DOI 10.1080/713755588; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Guy S. C., 2004, BRIEF SR BEHAV RATIN; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Heaton R. K, 1981, WISCONSIN CARD SORTI; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; HUGHES DM, 2008, INT J LANG COMM DIS, V1, P1; Kizilbash A, 1999, CHILD NEUROPSYCHOL, V5, P224, DOI 10.1076/0929-7049(199912)05:04;1-R;FT224; LeJeune B, 2010, CHILD NEUROPSYCHOL, V16, P182, DOI 10.1080/09297040903352556; MacAllister WS, 2009, MULT SCLER J, V15, P1502, DOI 10.1177/1352458509345902; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P258, DOI 10.1076/chin.8.4.258.13510; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; MCAULEY T, 2010, J INT NEUROPSYCH SOC, V16, P1; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; Morgan JE, 2008, TXB CLIN NEUROPSYCHO, P158; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; SESMA HW, 2010, PEDIATRICS, V121, P1686; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077	30	50	50	2	13	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2011	56	2					100	106		10.1037/a0023446			7	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	769KL	WOS:000291011800003	21574728				2021-06-18	
J	Chiodo, S; Tessitore, A; Cortis, C; Lupo, C; Ammendolia, A; Iona, T; Capranica, L				Chiodo, Salvatore; Tessitore, Antonio; Cortis, Cristina; Lupo, Corrado; Ammendolia, Antonio; Iona, Teresa; Capranica, Laura			EFFECTS OF OFFICIAL TAEKWONDO COMPETITIONS ON ALL-OUT PERFORMANCES OF ELITE ATHLETES	JOURNAL OF STRENGTH AND CONDITIONING RESEARCH			English	Article						countermovement jump; handgrip; heart rate; blood lactate	HEART-RATE; RESPONSES; LACTATE; INJURIES; PROFILE; POWER; PRACTITIONERS; RELIABILITY; RECOVERY; EXERCISE	Chiodo, S, Tessitore, A, Cortis, C, Lupo, C, Ammendolia, A, Iona, T, and Capranica, L. Effects of official Taekwondo competitions on all-out performances of elite athletes. J Strength Cond Res 25(2): 334-339, 2011-This study investigated physiological and performance aspects of 15 (4 women and 11 men) elite Taekwondo athletes (24.0 +/- 5.7 years) during their National Championship. The load of the competition was evaluated by means of heart rate (HR) and blood lactate (La). Pre and postmatch countermovement jump (CMJ), and handgrip performances were compared (p < 0.05). The match imposed a high load (HR > 85% of individual HRmax = 92 +/- 12%; La = 6.7 +/- 2.5 mmol.L-1) on athletes. After the match, better (p < 0.0001) CMJ (men: 43.9 +/- 5.2 cm; women: 30.8 +/- 2.3 cm) and worst (p = 0.006) handgrip performances (men: 459 +/- 87 N; women: 337 +/- 70 N) were found with respect to prematch ones (CMJ: men = 40.8 +/- 4.9 cm, women = 28.2 +/- 2.5 cm; handgrip: men = 486 +/- 88 N, women: 337 +/- 70 N). Results indicate that the intermittent activity of the Taekwondo competition elicits a high neuromuscular activation of the lower limbs. Instead, the decreases in grip strength could be because of the repeated concussions on the upper limbs used to protect from the opponent's kicks and punches directed toward the scoring area of the torso. Practically, these results urge coaches to structure training sessions that enable athletes to maintain their upper limb strength during their match.	[Tessitore, Antonio; Cortis, Cristina; Lupo, Corrado; Capranica, Laura] Univ Rome Foro Italico, Dept Human Movement & Sport Sci, Rome, Italy; [Chiodo, Salvatore; Ammendolia, Antonio; Iona, Teresa] Magna Graecia Univ Catanzaro, Expt & Clin Med Dept, Catanzaro, Italy; [Chiodo, Salvatore; Lupo, Corrado] Italian Taekwondo Federat, Rome, Italy	Capranica, L (corresponding author), Univ Rome Foro Italico, Dept Human Movement & Sport Sci, Rome, Italy.	laura.capranica@uniroma4.it	Iona, Teresa/O-6414-2019; Ammendolia, Antonio/K-2155-2016; Tessitore, Antonio/H-9922-2014; CORTIS, Cristina/AAB-9960-2020	Ammendolia, Antonio/0000-0002-2828-2455; Tessitore, Antonio/0000-0002-3542-0991; CORTIS, Cristina/0000-0001-9643-5532; Lupo, Corrado/0000-0003-1546-8573; LUPO, Corrado/0000-0002-5372-135X	FITA; University of Rome Foro Italico	The authors would like to express their gratitude to the Taekwondo athletes who participated in the study and to the General Secretary of the FITA Angelo Cito for his assistance in the organization of the experimental sessions. Furthermore, the technical support of Microgate Italy is greatly appreciated. The study was supported by FITA and the University of Rome Foro Italico.	Aggeloussis N, 2007, J SPORT SCI MED, V6, P6; Amtmann JA, 2008, J STRENGTH COND RES, V22, P645, DOI 10.1519/JSC.0b013e318166018e; Aziz Abdul Rashid, 2002, J Sports Sci Med, V1, P147; BANGSBO J, 1994, J APPL PHYSIOL, V77, P1890; BANGSBO J, 2002, SCI SOCCER, P51; Beis K, 2001, EUR J SPORT TRAUMA R, V23, P130; Beis K, 2007, J SPORT SCI MED, V6, P45; BILLOWS D, 2004, J SPORTS SCI, V22, P524; Bishop D, 2001, INT J SPORTS MED, V22, P525, DOI 10.1055/s-2001-17611; Bouhlel E, 2006, SCI SPORT, V21, P285, DOI 10.1016/j.scispo.2006.08.003; Bridge CA, 2007, J STRENGTH COND RES, V21, P718; BROOKS GA, 1991, MED SCI SPORT EXER, V23, P895; Butios S, 2007, J SPORT MED PHYS FIT, V47, P179; Cetin C, 2005, SAUDI MED J, V26, P848; CHUANG TY, 1992, J BIOMECH ENG-T ASME, V114, P346, DOI 10.1115/1.2891394; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, pXXI; Heller J, 1998, J SPORT SCI, V16, P243, DOI 10.1080/026404198366768; Iide K, 2008, J STRENGTH COND RES, V22, P839, DOI 10.1519/JSC.0b013e31816a5af6; Iwai K, 2008, J STRENGTH COND RES, V22, P350, DOI 10.1519/JSC.0b013e3181635d25; JACKSON AS, 1985, PHYSICIAN SPORTSMED, V13, P76, DOI 10.1080/00913847.1985.11708790; JUBIAK N, 2008, J STRENGTH COND RES, V22, P1194; Kazemi M, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-26; Kazemi M, 2006, J SPORT SCI MED, V5, P114; Koh JO, 2004, CLIN J SPORT MED, V14, P72, DOI 10.1097/00042752-200403000-00004; KOMI PV, 1978, MED SCI SPORT EXER, V10, P261; Koshida S, 2008, J STRENGTH COND RES, V22, P1584, DOI 10.1519/JSC.0b013e31817b03a1; Kravitz L, 2003, J STRENGTH COND RES, V17, P104; Kubo J, 2006, J STRENGTH COND RES, V20, P654; Lin WL, 2006, SCI SPORT, V21, P291, DOI 10.1016/j.scispo.2006.04.005; Markovic G, 2005, COLLEGIUM ANTROPOL, V29, P93; Melhim AF, 2001, BRIT J SPORT MED, V35, P231, DOI 10.1136/bjsm.35.4.231; Peolsson A, 2001, J REHABIL MED, V33, P36; Pieter W, 2000, SCI COACHING OLYMPIC; PIETER W, 1998, KINESIOLOGY, V30, P22, DOI DOI 10.1589/JPTS.28.231; Probst MM, 2007, J STRENGTH COND RES, V21, P451, DOI 10.1519/00124278-200705000-00028; Sbriccoli P, 2007, J STRENGTH COND RES, V21, P738; Slinde F, 2008, J STRENGTH COND RES, V22, P640, DOI 10.1519/JSC.0b013e3181660475; Tessitore A, 2007, J STRENGTH COND RES, V21, P1183; Tessitore A, 2007, J STRENGTH COND RES, V21, P745; Thompson WR, 1991, SPORTS MED TRAINING, V3, P49; Toskovic NN, 2004, J SPORT MED PHYS FIT, V44, P164; Toskovic NN, 2002, J STRENGTH COND RES, V16, P278; Vetter RE, 2007, J STRENGTH COND RES, V21, P819	43	50	51	1	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1064-8011	1533-4287		J STRENGTH COND RES	J. Strength Cond. Res.	FEB	2011	25	2					334	339		10.1519/JSC.0b013e3182027288			6	Sport Sciences	Sport Sciences	709SI	WOS:000286461300007	21233770				2021-06-18	
J	Toman, J; Fiskum, G				Toman, Julia; Fiskum, Gary			Influence of aging on membrane permeability transition in brain mitochondria	JOURNAL OF BIOENERGETICS AND BIOMEMBRANES			English	Article						Neurodegeneration; Neuron; Calcium; Oxidative stress; Apoptosis	ADENINE-NUCLEOTIDE TRANSLOCASE; CYTOCHROME-C RELEASE; OXIDATIVE STRESS; RAT-BRAIN; PORE; ACTIVATION; MECHANISMS; CALCIUM; INJURY; NEUROPROTECTION	The mitochondrial inner membrane permeability transition (MPT) plays an important role in the pathophysiology of acute disorders of the central nervous systems, including ischemic and traumatic brain injury, and possibly in neurodegenerative diseases. Opening of the permeability transition pore (PTP) by a combination of abnormally elevated intramitochondrial Ca2+ and oxidative stress induces the collapse of transmembrane ion gradients, resulting in membrane depolarization and uncoupling of oxidative phosphorylation. This loss of ATP synthesis eventually results in cellular metabolic failure and necrotic cell death. Drugs, e.g., cyclosporin A, can inhibit the permeability transition through their interaction with the mitochondria-specific protein, cyclophilin D, and demonstrate neuroprotection in several animal models. These characteristics of the MPT were developed almost exclusively from experiments performed with young, mature rodents whereas the neuropathologies associated with the MPT are most prevalent in the elderly population. Some evidence indicates that the sensitivity of mitochondria to Ca2+-induced PTP opening is greater in the aged compared to the young mature brain; however, the basis for this difference is unknown. Based on knowledge of factors that regulate the MPT and on other comparisons between cells and mitochondria from young and old animals, several features may be important. These aging-related features include impaired neuronal Ca2+ homeostasis, increased oxidative stress, increased cyclophilin D protein levels, oxidative modification of the adenine nucleotide translocase and of cardiolipin, and changes in the levels of anti-death mitochondrial proteins, e.g., Bcl-2. The influence of aging on both the contribution of the MPT to neuropathology and the neuroprotective efficacy of MPT inhibitors is a substantial knowledge gap that requires extensive research at the subcellular, cellular, and animal model levels.	[Toman, Julia; Fiskum, Gary] Univ Maryland, Dept Anesthesiol, Sch Med, Baltimore, MD 21201 USA; [Toman, Julia; Fiskum, Gary] Univ Maryland, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, Baltimore, MD 21201 USA	Fiskum, G (corresponding author), Univ Maryland, Dept Anesthesiol, Sch Med, 685 W Baltimore St, Baltimore, MD 21201 USA.	gfiskum@anes.umm.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T35AG036679] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T35 AG036679] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01 HD016596] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS034152] Funding Source: Medline		BAZIL JN, 2010, J THEORETIC IN PRESS; Brown MR, 2004, J BIOENERG BIOMEMBR, V36, P401, DOI 10.1023/B:JOBB.0000041775.10388.23; CHEN JJ, 1995, FREE RADICAL BIO MED, V19, P583, DOI 10.1016/0891-5849(95)00066-7; Crompton M, 2004, AGING CELL, V3, P3, DOI 10.1046/j.1474-9728.2003.00073.x; DI LF, 2005, CARDIOVASC RES, V66, P222; ELISEEV RA, 2006, NEUROBIOL AGING, P1532; Eliseev RA, 2009, J BIOL CHEM, V284, P9692, DOI 10.1074/jbc.M808750200; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; Fiskum G, 2008, ANN NY ACAD SCI, V1147, P129, DOI 10.1196/annals.1427.026; Garcia N, 2009, COMP BIOCHEM PHYS C, V149, P374, DOI 10.1016/j.cbpc.2008.09.006; GironCalle J, 1996, BIOCHEMISTRY-US, V35, P15440, DOI 10.1021/bi960840j; Gouspillou G, 2010, BBA-BIOENERGETICS, V1797, P143, DOI 10.1016/j.bbabio.2009.09.004; Greco T, 2010, J BIOENERG BIOMEMBR, V42, P491, DOI 10.1007/s10863-010-9312-9; Greco T, 2010, J ALZHEIMERS DIS, V20, pS427, DOI 10.3233/JAD-2010-100519; Groeger AL, 2010, MOL INTERV, V10, P39, DOI 10.1124/mi.10.1.7; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755; Halestrap AP, 2010, BIOCHEM SOC T, V38, P841, DOI 10.1042/BST0380841; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Hofer T, 2009, MECH AGEING DEV, V130, P297, DOI 10.1016/j.mad.2009.01.004; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Kowaltowski AJ, 2004, FREE RADICAL BIO MED, V37, P1845, DOI 10.1016/j.freeradbiomed.2004.09.005; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LaFrance R, 2005, AGING CELL, V4, P139, DOI 10.1111/j.1474-9726.2005.00156.x; Leite ACR, 2010, BBA-BIOENERGETICS, V1797, P1210, DOI 10.1016/j.bbabio.2010.01.034; Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009; Linard D, 2009, ARCH BIOCHEM BIOPHYS, V491, P39, DOI 10.1016/j.abb.2009.09.002; Macho A, 1997, J IMMUNOL, V158, P4612; Marzetti E, 2008, MECH AGEING DEV, V129, P542, DOI 10.1016/j.mad.2008.05.005; Mather M, 2000, BIOCHEM BIOPH RES CO, V273, P603, DOI 10.1006/bbrc.2000.2994; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Morrison CD, 2010, J NEUROCHEM, V114, P1581, DOI 10.1111/j.1471-4159.2010.06865.x; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicholls DG, 2009, BBA-BIOENERGETICS, V1787, P1416, DOI 10.1016/j.bbabio.2009.03.010; Pallardo FV, 1998, FREE RADICAL RES, V29, P617, DOI 10.1080/10715769800300671; Parihar MS, 2008, J NEUROSCI RES, V86, P2339, DOI 10.1002/jnr.21679; Petrosillo G, 2008, NEUROCHEM INT, V53, P126, DOI 10.1016/j.neuint.2008.07.001; Petrosillo G, 2010, J PINEAL RES, V48, P340, DOI 10.1111/j.1600-079X.2010.00758.x; Rasola A, 2010, FEBS LETT, V584, P1989, DOI 10.1016/j.febslet.2010.02.022; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; SAWADA M, 1987, MECH AGEING DEV, V41, P125, DOI 10.1016/0047-6374(87)90057-1; Sen T, 2007, NEUROCHEM INT, V50, P719, DOI 10.1016/j.neuint.2007.01.007; Soane L, 2007, J NEUROSCI RES, V85, P3407, DOI 10.1002/jnr.21498; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Toescu EC, 2004, TRENDS NEUROSCI, V27, P614, DOI 10.1016/j.tins.2004.07.010; Toescu EC, 2010, CELL CALCIUM, V47, P158, DOI 10.1016/j.ceca.2009.11.013; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; Jacob MHVM, 2010, EXP GERONTOL, V45, P957, DOI 10.1016/j.exger.2010.08.017; Wang XK, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00012; Xiong J, 2002, J NEUROSCI, V22, P10761; Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896; Zorov DB, 2009, CARDIOVASC RES, V83, P213, DOI 10.1093/cvr/cvp151	57	50	51	1	7	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0145-479X	1573-6881		J BIOENERG BIOMEMBR	J. Bioenerg. Biomembr.	FEB	2011	43	1					3	10		10.1007/s10863-011-9337-8			8	Biophysics; Cell Biology	Biophysics; Cell Biology	729SI	WOS:000287970700002	21311961	Green Accepted			2021-06-18	
J	Gill, CJ; Sander, AM; Robins, N; Mazzei, DK; Struchen, MA				Gill, Carol J.; Sander, Angelle M.; Robins, Nina; Mazzei, Diana K.; Struchen, Margaret A.			Exploring Experiences of Intimacy From the Viewpoint of Individuals With Traumatic Brain Injury and Their Partners	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; intimacy; relationships; sexuality; traumatic brain injury	BLUNT HEAD-INJURY; CAREGIVERS; DISTRESS; TBI; SATISFACTION; PREDICTORS; ADJUSTMENT; STABILITY; ABILITIES; SYMPTOMS	Objective: To explore qualitatively the experience of intimacy from the viewpoint of persons with traumatic brain injury (TBI) and their intimate partners. Design: Qualitative interview study. Setting: Outpatient community. Participants: Eighteen persons with TBI and their intimate partners at a mean length of 4.78 years postinjury. Main measures: Open-ended, semistructured, in-depth interviews regarding participants' experience of intimacy, factors impacting intimacy, and need for services. Results: Factors that were perceived as helping relationships remain strong included unconditional commitment, spending time together, open communication, a strong preinjury relationship, bonding through surviving the injury together, social support, family bonds, spirituality, experience with overcoming hardship, and coping skills. Factors that were perceived as barriers to intimacy included injury-related changes, emotional reactions to changes, sexual difficulties, role conflict and strain, family issues, social isolation, and communication issues. Conclusions and Implications: Education regarding the impact of TBI on intimacy should be integrated into rehabilitation. Health professionals should be sensitized as to the needs that persons with TBI and their partners have regarding intimacy and how to make appropriate referrals to assist them.	[Gill, Carol J.; Robins, Nina] Univ Illinois, Dept Disabil & Human Dev, Chicago, IL 60680 USA; [Sander, Angelle M.; Struchen, Margaret A.] Harris Cty Hosp Dist, Dept Phys Med & Rehabil, Baylor Coll Med, Houston, TX USA; [Mazzei, Diana K.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX USA	Gill, CJ (corresponding author), Univ Illinois, Dept Disabil & Human Dev, Chicago, IL 60680 USA.				National Institute on Disability and Rehabilitation Research, US Department of Education (Rehabilitation Research and Training Center on Community Integration of Persons With Traumatic Brain Injury)US Department of Education [H133B031117]; National Institute on Disability and Rehabilitation Research, US Department of Education (Rehabilitation Research and Training Center on Developing Strategies to Foster Community Integration and Participation for Individuals With Traumatic Brain Injury) [H133B090023]; National Institute on Disability and Rehabilitation Research, US Department of Education (Texas Traumatic Brain Injury Model System of TIRR)US Department of Education [H133A70015]	This work was supported by grants from the National Institute on Disability and Rehabilitation Research, US Department of Education (grants H133B031117, Rehabilitation Research and Training Center on Community Integration of Persons With Traumatic Brain Injury; H133B090023, Rehabilitation Research and Training Center on Developing Strategies to Foster Community Integration and Participation for Individuals With Traumatic Brain Injury; and H133A70015, Texas Traumatic Brain Injury Model System of TIRR). The authors thank the individuals with traumatic brain injury and their partners who trusted us enough to share intimate details of their relationships with us. We hope that the information published here will be a first step toward increasing the services available to couples to improve intimacy after traumatic brain injury.	ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; Aloni A, 1999, BRAIN INJURY, V13, P89, DOI 10.1080/026990599121755; Aloni R, 2003, SEXUAL DIFFICULTIES; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Anderson-Parente JK, 1990, COGNITIVE REHABILITA, P22; BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Gosling J, 1999, BRAIN INJURY, V13, P785; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jeon YH, 2004, SCAND J CARING SCI, V18, P249, DOI 10.1111/j.1471-6712.2004.00287.x; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; KRAVETZ S, 1995, BRAIN INJURY, V9, P131, DOI 10.3109/02699059509008186; Kravetz S, 2001, REHABIL PSYCHOL, V46, P436; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; Kreutzer JS, 2007, NEUROREHABILITATION, V22, P53; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Lippert T, 2001, PERS RELATIONSHIP, V8, P283, DOI 10.1111/j.1475-6811.2001.tb00041.x; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; McPherson KM, 2000, INT J REHABIL RES, V23, P295, DOI 10.1097/00004356-200023040-00005; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Panting A., 1972, REHABILITATION, V38, P33; Patton M., 2001, QUALITATIVE RES EVAL, V3; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; Porter D, 1994, DISS ABSTR INT A, P55; Resnick C, 1992, DISS ABSTR INT A, P53; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SANDEL ME, 2007, BRAIN INJURY MED PRI, P673; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Tate DG, 2003, AM PSYCHOL, V58, P289, DOI 10.1037/0003-066X.58.4.289; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; Webster G, 1999, BRAIN INJURY, V13, P593; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	47	50	50	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2011	26	1					56	68		10.1097/HTR.0b013e3182048ee9			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	703GA	WOS:000285965200006	21209563				2021-06-18	
J	Hayward, NMEA; Immonen, R; Tuunanen, PI; Ndode-Ekane, XE; Grohn, O; Pitkanen, A				Hayward, Nick M. E. A.; Immonen, Riikka; Tuunanen, Pasi I.; Ndode-Ekane, Xavier Ekolle; Grohn, Olli; Pitkanen, Asla			Association of Chronic Vascular Changes with Functional Outcome after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						cerebrovascular changes; functional outcome; MRI; seizure susceptibility; traumatic brain injury	CEREBRAL-BLOOD-FLOW; LATERAL FLUID-PERCUSSION; CLOSED-HEAD-INJURY; TECHNETIUM-99M-HMPAO SPECT; SEIZURE SUSCEPTIBILITY; IMMUNOHISTOCHEMICAL CHARACTERIZATION; POSTTRAUMATIC EPILEPSY; ELECTRICAL-STIMULATION; THALAMIC NUCLEI; VESSEL DENSITY	We tested the hypothesis that vascular remodeling in the cortex, hippocampus, and thalamus is associated with long-term functional recovery after traumatic brain injury (TBI). We induced TBI with lateral fluid-percussion (LFP) injury in adult rats. Animals were followed-up for 9 months, during which we tested motor performance using a neuroscore test, spatial learning and memory with a Morris water maze, and seizure susceptibility with a pentylenetetrazol (PTZ) test. At 8 months, they underwent structural MRI, and cerebral blood flow (CBF) was assessed by arterial spin labeling (ASL) MRI. Then, rats were perfused for histology to assess the density of blood vessels. In the perilesional cortex, the CBF decreased by 56% (p<0.01 compared to controls), and vessel density increased by 28% (p<0.01). There was a negative correlation between CBF in the perilesional cortex and vessel density (r = -0.75, p<0.01). However, in the hippocampus, we found a 13% decrease in CBF ipsilaterally (p<0.05) and 20% contralaterally (p<0.01), and no change in vessel number. In the ipsilateral thalamus, the increase in CBF (34%, p<0.01) was associated with a remarkable increase in vessel density (78%, p<0.01). Animals showed motor impairment that was not associated with vascular changes. Instead, poor performance in the Morris water maze correlated with enhanced thalamic vessel density (r = -0.81, p<0.01). Finally, enhanced seizure susceptibility was associated with reduced CBF in the ipsilateral hippocampus (r = 0.78, p<0.05) and increased vascular density in the thalamus (r = 0.69, p<0.05). There was little interaction between the behavioral measures. The present study demonstrates that each of the investigated brain areas has a unique pattern of vascular abnormalities. Chronic alterations in CBF could not be attributed to changes in vascular density. Association of thalamic hypervascularity to epileptogenesis warrants further studies. Finally, hippocampal hypoperfusion may predict later seizure susceptibility in the LFP injury model of TBI, which could be of value for pre-clinical antiepileptogenesis trials.	[Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Epilepsy Res Grp, Dept Neurobiol, FIN-70211 Kuopio, Finland; [Hayward, Nick M. E. A.; Immonen, Riikka; Tuunanen, Pasi I.; Grohn, Olli] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Biomed NMR Grp, Dept Neurobiol, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland	Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Epilepsy Res Grp, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	asla.pitkanen@uef.fi		Hayward, Nicholas/0000-0001-9496-7332; Ndode-Ekane, Xavier Ekolle/0000-0001-5682-5632	Marie Curie Early Stage Trainee Research Fellowship [MEST-CT-2005-019217]; Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius Fundation	We thank Mrs. Maarit Pulkkinen and Mr. Jarmo Hartikainen for providing technical assistance. This study was funded by a Marie Curie Early Stage Trainee Research Fellowship MEST-CT-2005-019217 (N.H., X.E., O.G.), by The Academy of Finland (A.P., O.G.), and by The Sigrid Juselius Fundation (A.P.).	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Berg Jenny, 2004, Eur J Health Econ, V5 Suppl 1, pS43, DOI 10.1007/s10198-005-0288-z; Best PJ, 2001, ANNU REV NEUROSCI, V24, P459, DOI 10.1146/annurev.neuro.24.1.459; Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x; Blumenfeld H, 2009, BRAIN, V132, P999, DOI 10.1093/brain/awp028; Bonilha L, 2004, ARCH NEUROL-CHICAGO, V61, P1379, DOI 10.1001/archneur.61.9.1379; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bratane BT, 2010, J CEREBR BLOOD F MET, V30, P336, DOI 10.1038/jcbfm.2009.218; Chen L, 2009, EXP MOL MED, V41, P849, DOI 10.3858/emm.2009.41.12.103; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Dombrowski SM, 2008, NEUROSCIENCE, V152, P346, DOI 10.1016/j.neuroscience.2007.11.049; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; DUIJVESTIJN AM, 1992, LAB INVEST, V66, P459; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; Ghabriel MN, 2010, ACTA NEUROCHIR SUPPL, V106, P239, DOI 10.1007/978-3-211-98811-4_45; Golarai G, 2001, J NEUROSCI, V21, P8523; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GOLDMAN H, 1992, EPILEPSY RES, V12, P227, DOI 10.1016/0920-1211(92)90077-7; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GRAY BG, 1992, J NUCL MED, V33, P52; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; HAYWARD NM, 2010, J CEREB BLO IN PRESS; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; Hiltunen M, 2009, NEUROBIOL DIS, V35, P103, DOI 10.1016/j.nbd.2009.04.009; Holley JE, 2010, NEUROSCI LETT, V470, P65, DOI 10.1016/j.neulet.2009.12.059; ICHISE M, 1994, J NUCL MED, V35, P217; Iltis I, 2005, J MAGN RESON IMAGING, V22, P242, DOI 10.1002/jmri.20352; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Inoue Y, 2005, J NEUROTRAUM, V22, P1411, DOI 10.1089/neu.2005.22.1411; Jacobs A, 1996, J NUCL MED, V37, P1605; Jejeli M, 2003, NEUROSCI RES, V47, P309, DOI 10.1016/S0168-0102(03)00224-4; Johnson V. E., 2010, NAT REV NEUROSCI; Karhunen H, 2003, EPILEPSY RES, V54, P1, DOI 10.1016/S0920-1211(03)00034-2; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; LEWIS DA, 1986, J COMP NEUROL, V248, P1, DOI 10.1002/cne.902480102; Lim YM, 2008, EPILEPSY RES, V82, P183, DOI 10.1016/j.eplepsyres.2008.08.001; Lin TN, 2002, STROKE, V33, P2985, DOI 10.1161/01.STR.0000037675.97888.9D; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Madri JA, 2009, J PHYSIOL PHARMACOL, V60, P95; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mora GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005759; Ndode-Ekane XE, 2010, NEUROSCIENCE, V166, P312, DOI 10.1016/j.neuroscience.2009.12.002; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; PRAYER L, 1993, ACTA RADIOL, V34, P593; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rougier A, 1999, J NEUROSURG, V90, P282, DOI 10.3171/jns.1999.90.2.0282; Schwartz TH, 2006, EPILEPSIA, V47, P567, DOI 10.1111/j.1528-1167.2006.00469.x; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; Stamatakis EA, 2002, J NUCL MED, V43, P476; Tetrault S, 2008, EUR J NEUROSCI, V28, P1330, DOI 10.1111/j.1460-9568.2008.06443.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; VEZZANI A, 1994, BRAIN RES, V660, P138, DOI 10.1016/0006-8993(94)90847-8; Vogel J, 2004, J CEREBR BLOOD F MET, V24, P849, DOI 10.1097/01.WCB.0000126564.89011.11; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zaharchuk G, 2000, J CEREBR BLOOD F MET, V20, P1341, DOI 10.1097/00004647-200009000-00009; Zhang C, 2005, J NEUROTRAUM, V22, P1456, DOI 10.1089/neu.2005.22.1456	84	50	50	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2203	2219		10.1089/neu.2010.1448			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400010	20839948				2021-06-18	
J	Kemp, K; Gray, E; Mallam, E; Scolding, N; Wilkins, A				Kemp, Kevin; Gray, Elizabeth; Mallam, Elizabeth; Scolding, Neil; Wilkins, Alastair			Inflammatory Cytokine Induced Regulation of Superoxide Dismutase 3 Expression by Human Mesenchymal Stem Cells	STEM CELL REVIEWS AND REPORTS			English	Article						Mesenchymal stem cell; Superoxide dismutase 3; Extracellular superoxide dismutase; Inflammation; Central nervous system	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MARROW STROMAL CELLS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; OXIDATIVE STRESS; MULTIPLE-SCLEROSIS; NITRIC-OXIDE; IFN-GAMMA; TNF-ALPHA	Increasing evidence suggests that bone marrow derived-mesenchymal stem cells (MSCs) have neuroprotective properties and a major mechanism of action is through their capacity to secrete a diverse range of potentially neurotrophic or anti-oxidant factors. The recent discovery that MSCs secrete superoxide dismutase 3 (SOD3) may help explain studies in which MSCs have a direct anti-oxidant activity that is conducive to neuroprotection in both in vivo and in vitro. SOD3 attenuates tissue damage and reduces inflammation and may confer neuroprotective effects against nitric oxide-mediated stress to cerebellar neurons; but, its role in relation to central nervous system inflammation and neurodegeneration has not been extensively investigated. Here we have performed a series of experiments showing that SOD3 secretion by human bone marrow-derived MSCs is regulated synergistically by the inflammatory cytokines TNF-alpha and IFN-gamma, rather than through direct exposure to reactive oxygen species. Furthermore, we have shown SOD3 secretion by MSCs is increased by activated microglial cells. We have also shown that MSCs and recombinant SOD are able to increase both neuronal and axonal survival in vitro against nitric oxide or microglial induced damage, with an increased MSC-induced neuroprotective effect evident in the presence of inflammatory cytokines TNF-alpha and IFN-gamma. We have shown MSCs are able to convey these neuroprotective effects through secretion of soluble factors alone and furthermore demonstrated that SOD3 secretion by MSCs is, at least, partially responsible for this phenomenon. SOD3 secretion by MSCs maybe of relevance to treatment strategies for inflammatory disease of the central nervous system.	[Kemp, Kevin] Frenchay Hosp, Burden Ctr, MS Labs, Bristol BS16 1JB, Avon, England; [Kemp, Kevin; Gray, Elizabeth; Mallam, Elizabeth; Scolding, Neil; Wilkins, Alastair] Univ Bristol, Multiple Sclerosis & Stem Cell Grp, Inst Clin Neurosci, Bristol, Avon, England	Kemp, K (corresponding author), Frenchay Hosp, Burden Ctr, MS Labs, 1st Floor, Bristol BS16 1JB, Avon, England.	kevin.kemp@bristol.ac.uk	; Kemp, Kevin/B-9755-2017	Scolding, Neil/0000-0001-9177-1043; Kemp, Kevin/0000-0003-1465-1309	Ataxia UK; Ataxia UK [7160] Funding Source: researchfish	This work was carried out using a project grant from Ataxia UK.	Abrams MB, 2009, RESTOR NEUROL NEUROS, V27, P307, DOI 10.3233/RNN-2009-0480; Arnhold S, 2006, EUR J CELL BIOL, V85, P551, DOI 10.1016/j.ejcb.2006.01.015; Baraczka Krisztina, 2003, Acta Microbiologica et Immunologica Hungarica, V50, P339, DOI 10.1556/AMicr.50.2003.4.3; Benveniste EN, 1995, FASEB J, V9, P1577; BERKOW RL, 1987, J IMMUNOL, V139, P3783; Bowler RP, 2004, AM J RESP CELL MOL, V31, P432, DOI 10.1165/rcmb.2004-0057OC; Broholm H, 2004, ACTA NEUROL SCAND, V109, P261, DOI 10.1111/j.1600-0404.2004.00207.x; Brown GC, 2006, BIOCHEM SOC T, V34, P953, DOI 10.1042/BST0340953; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Christofidou-Solomidou Melpo, 2006, Treat Respir Med, V5, P47, DOI 10.2165/00151829-200605010-00004; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004; Folz RJ, 1999, J CLIN INVEST, V103, P1055, DOI 10.1172/JCI3816; Gao F, 2008, J BIOL CHEM, V283, P6058, DOI 10.1074/jbc.M709273200; Ha HY, 2006, BIOCHEM BIOPH RES CO, V348, P450, DOI 10.1016/j.bbrc.2006.07.079; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; HARRIS CA, 1991, J IMMUNOL, V147, P149; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Jensen MB, 2000, J NEUROSCI, V20, P3612; Kemp K, 2010, J NEUROCHEM, V114, P1569, DOI 10.1111/j.1471-4159.2009.06553.x; Kim YJ, 2009, GLIA, V57, P13, DOI 10.1002/glia.20731; Lanza C, 2009, J NEUROCHEM, V110, P1674, DOI 10.1111/j.1471-4159.2009.06268.x; Laurila JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005786; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; LOB HE, HYPERTENSION, V55, P277; Lubrano V, 2006, CLIN EXP MED, V6, P84, DOI 10.1007/s10238-006-0100-0; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2003, NEUROSURGERY, V53, P702; MARKLUND SL, 1990, BIOCHEM J, V266, P213, DOI 10.1042/bj2660213; MARKLUND SL, 1992, J BIOL CHEM, V267, P6696; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; Mohamed A, 2003, BIOMED SCI INSTRUM, V39, P440; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; Nozik-Grayck E, 2005, INT J BIOCHEM CELL B, V37, P2466, DOI 10.1016/j.biocel.2005.06.012; Olofsson EM, 2007, MOL VIS, V13, P1285; Park HJ, 2007, EUR J NEUROSCI, V26, P79, DOI 10.1111/j.1460-9568.2007.05636.x; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Qi XP, 2007, INVEST OPHTH VIS SCI, V48, P5360, DOI 10.1167/iovs.07-0254; Rabbani ZN, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-59; Ratnam DV, 2006, J CONTROL RELEASE, V113, P189, DOI 10.1016/j.jconrel.2006.04.015; Renno T, 1998, MOL CELL NEUROSCI, V12, P376, DOI 10.1006/mcne.1998.0725; RENNO T, 1995, J IMMUNOL, V154, P944; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; Ruuls SR, 1996, CLIN EXP IMMUNOL, V103, P467; SHARIEF MK, 1993, J NEUROIMMUNOL, V43, P15, DOI 10.1016/0165-5728(93)90070-F; Shi N, 2009, MULT SCLER J, V15, P120, DOI 10.1177/1352458508096871; Smith KJ, 1999, BRAIN PATHOL, V9, P69; STRALIN P, 1994, BIOCHEM J, V298, P347, DOI 10.1042/bj2980347; Stralin P, 2001, AM J PHYSIOL-HEART C, V281, pH1621; Stralin P, 2000, ATHEROSCLEROSIS, V151, P433, DOI 10.1016/S0021-9150(99)00427-X; TIKU ML, 1990, J IMMUNOL, V145, P690; Ueda J, 2008, FREE RADICAL BIO MED, V45, P897, DOI 10.1016/j.freeradbiomed.2008.06.016; Vercelli A, 2008, NEUROBIOL DIS, V31, P395, DOI 10.1016/j.nbd.2008.05.016; Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006	57	50	52	0	8	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1550-8943			STEM CELL REV REP	Stem Cell Rev. Rep.	DEC	2010	6	4					548	559		10.1007/s12015-010-9178-6			12	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	657PG	WOS:000282424200007	20683679				2021-06-18	
J	Xiong, Y; Mahmood, A; Chopp, M				Xiong, Ye; Mahmood, Asim; Chopp, Michael			Neurorestorative Treatments for Traumatic Brain Injury	DISCOVERY MEDICINE			English	Article							MARROW STROMAL CELLS; ERYTHROPOIETIN ENHANCES NEUROGENESIS; HIPPOCAMPAL CA3 REGION; DENTATE GYRUS; THYMOSIN BETA-4; ANGIOGENESIS; RATS; SIMVASTATIN; INCREASE; STROKE	Traumatic brain injury (TBI) remains a major cause of death and permanent disability worldwide, especially in children and young adults. A total of 1.5 million people experience head trauma each year in the United States, with an annual economic cost exceeding $56 billion. Unfortunately, almost all Phase III TBI clinical trials have yet to yield a safe and effective neuroprotective treatment, raising questions regarding the use of neuroprotective strategies as the primary therapy for acute brain injuries. Recent preclinical data suggest that neurorestorative strategies that promote angiogenesis (formation of new blood vessels from pre-existing endothelial cells), axonal remodeling (axonal sprouting and pruning), neurogenesis (generation of new neurons) and synaptogenesis (formation of new synapses) provide promising opportunities for the treatment of TBI. This review discusses select cell-based and pharmacological therapies that activate and amplify these endogenous restorative brain plasticity processes to promote both repair and regeneration of injured brain tissue and functional recovery after TBI. [Discovery Medicine 10(54):434-442, November 2010]	[Xiong, Ye; Mahmood, Asim] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA	Chopp, M (corresponding author), Henry Ford Hlth Syst, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	michael.chopp@gmail.com		Xiong, Ye/0000-0001-9770-6031	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 NS62002, PO1 NS042259]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259, R01NS062002] Funding Source: NIH RePORTER	The authors' research was supported by NINDS grants RO1 NS62002 and PO1 NS042259.	Becher A, 1999, J NEUROSCI, V19, P1922; Besler Christian, 2008, Expert Rev Cardiovasc Ther, V6, P1071, DOI 10.1586/14779072.6.8.1071; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; Chopp M, 2006, ADV EXP MED BIOL, V585, P49; Chopp M, 2009, STROKE, V40, pS143, DOI 10.1161/STROKEAHA.108.533141; Crockford D, 2007, ANN NY ACAD SCI, V1112, P385, DOI 10.1196/annals.1415.051; Deng J, 2006, STEM CELLS, V24, P1054, DOI 10.1634/stemcells.2005-0370; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Harris N, 2010, J NEUROTRAU IN PRESS; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jia LF, 2010, STROKE, V41, P2071, DOI 10.1161/STROKEAHA.110.586198; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Lapchak PA, 2008, EXPERT OPIN INV DRUG, V17, P1175, DOI [10.1517/13543784.17.8.1175, 10.1517/13543784.17.8.1175 ]; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Lok J, 2007, NEUROCHEM RES, V32, P2032, DOI 10.1007/s11064-007-9342-9; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Morris DC, 2010, NEUROSCIENCE, V169, P674, DOI 10.1016/j.neuroscience.2010.05.017; Morris DC, 2010, ANN NY ACAD SCI, V1194, P112, DOI 10.1111/j.1749-6632.2010.05469.x; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Smart N, 2007, NATURE, V445, P177, DOI 10.1038/nature05383; Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun W, 2007, ANN NY ACAD SCI, V1112, P210, DOI 10.1196/annals.1415.013; Walker PA, 2010, STEM CELLS DEV, V19, P867, DOI 10.1089/scd.2009.0188; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 2008, J CEREBR BLOOD F MET, V28, P1361, DOI 10.1038/jcbfm.2008.32; Wible EF, 2010, NEUROTHERAPEUTICS, V7, P62, DOI 10.1016/j.nurt.2009.11.003; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xiong Y, 2010, J NEUROSURG IN PRESS; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Yamanaka S, 2007, CELL STEM CELL, V1, P39, DOI 10.1016/j.stem.2007.05.012; Yang XT, 2010, BRAIN RES B IN PRESS; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zhang J, 2009, NEUROSCIENCE, V164, P1887, DOI 10.1016/j.neuroscience.2009.09.054; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	74	50	54	0	0	DISCOVERY MEDICINE	TIMONIUM	10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA	1539-6509	1944-7930		DISCOV MED	Discov. Med.	NOV	2010	10	54					434	442					9	Medicine, Research & Experimental	Research & Experimental Medicine	V27UU	WOS:000208638900007	21122475				2021-06-18	
J	Coello, AF; Canals, AG; Gonzalez, JM; Martin, JJA				Fernandez Coello, Alejandro; Gabarros Canals, Andreu; Martino Gonzalez, Juan; Acebes Martin, Juan Jose			Cranial nerve injury after minor head trauma	JOURNAL OF NEUROSURGERY			English	Article						head injury; cranial nerve; minor head trauma	TEMPORAL BONE-FRACTURES; OCULOMOTOR NERVE; FACIAL PALSY; INITIAL SIGN; PARALYSIS; PROGNOSIS; TROCHLEAR; ANOSMIA	Object. There are no specific studies about cranial nerve (CM) injury following mild head trauma (Glasgow Coma Scale Score 14-15) in the literature. The aim of this analysis was to document the incidence of CN injury after mild head trauma and to correlate the initial CT findings with the final outcome 1 year after injury. Methods. The authors studied 49 consecutive patients affected by minor head trauma and CN lesions between January 2000 and January 2006. Detailed clinical and neurological examinations as well as CT studies using brain and bone windows were performed in all patients. Based on the CT findings the authors distinguished 3 types of traumatic injury: no lesion, skull base fracture, and other CT abnormalities. Patients were followed up for I year after head injury. The authors distinguished 3 grades of clinical recovery from CN palsy: no recovery, partial recovery, and complete recovery. Results. Posttraumatic single nerve palsy was observed in 38 patients (77.6%), and multiple nerve injuries were observed in II (22.4%). Cranial nerves were affected in 62 cases. The most affected CN was the olfactory nerve (CN I), followed by the facial nerve (CN VII) and the oculomotor nerves (CNs III, IV, and VI). When more than 1 CN was involved, the most frequent association was between CNs VII and VIII. One year after head trauma, a CN deficit was present in 26 (81.2%) of the 32 cases with a skull base fracture, 12 (60%) of 20 cases with other CT abnormalities, and 3 (30%) of 10 cases without CT abnormalities. Conclusions. Trivial head trauma that causes a minor head injury (Glasgow Coma Scale Score 14-15) can result in CN palsies with a similar distribution to moderate or severe head injuries. The CNs associated with the highest incidence of palsy in this study were the olfactory, facial, and oculomotor nerves. The trigeminal and lower CNs were rarely damaged. Oculomotor nerve injury can have a good prognosis, with a greater chance of recovery if no lesion is demonstrated on the initial CT scan. (DOI: 10.3171/2010.6.JNS091620)	[Fernandez Coello, Alejandro; Gabarros Canals, Andreu; Acebes Martin, Juan Jose] Bellvitge Univ Hosp, Dept Neurosurg, Barcelona, Spain; [Martino Gonzalez, Juan] Marques de Valdecilla Univ Hosp, Dept Neurosurg, Santander, Cantabria, Spain	Coello, AF (corresponding author), Comerc N10bis 2, Barcelona 08003, Spain.	jandrocoello@gmail.com	Fernandez-Coello, Alejandro/AAH-6457-2021; Fernandez-Coello, Alejandro/A-5772-2019	Fernandez-Coello, Alejandro/0000-0003-0418-0339			AGUILAR EA, 1987, HEAD NECK-J SCI SPEC, V9, P162, DOI 10.1002/hed.2890090306; Bhatoe CHS, 2007, INDIAN J NEUROTRAUM, V4, P89, DOI 10.1016/S0973-0508(07)80022-0; CHUNG SM, 1996, NEUROTRAUMA, P621; CROMPTON M R, 1970, Brain Behavior and Evolution, V93, P785, DOI 10.1093/brain/93.4.785; ELISEVICH KV, 1984, SURG NEUROL, V22, P565, DOI 10.1016/0090-3019(84)90433-6; EYSTER EF, 1972, J AMER MED ASSOC, V220, P1083, DOI 10.1001/jama.220.8.1083; FELIX H, 1991, ACTA OTO-LARYNGOL, V111, P332, DOI 10.3109/00016489109137396; FUKADO Y, 1981, CRANIAL NERVES, P125; HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202; Hughes B, 1964, ACUTE INJURIES HEAD, P408; JAFEK BW, 1989, ARCH NEUROL-CHICAGO, V46, P300, DOI 10.1001/archneur.1989.00520390066018; JENNETT B, 1976, LANCET, V1, P1031; Kaido T, 2006, J CLIN NEUROSCI, V13, P852, DOI 10.1016/j.jocn.2005.08.020; Katzen JT, 2003, J TRAUMA, V54, P1026, DOI 10.1097/01.TA.0000066180.14666.8B; Kaushik V, 2002, CLIN NEUROL NEUROSUR, V105, P42, DOI 10.1016/S0303-8467(02)00101-4; KEANE JR, 1992, NEUROL CLIN, V10, P849; Keane JR, 2005, ARCH NEUROL-CHICAGO, V62, P1714, DOI 10.1001/archneur.62.11.1714; KLINE LB, 1984, NEUROSURGERY, V14, P756, DOI 10.1227/00006123-198406000-00021; Leigh AD, 1943, LANCET, V1, P38; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; LEWIN W, 1954, BRIT J SURG, V42, P1, DOI 10.1002/bjs.18004217102; Li J, 2004, BRAIN INJURY, V18, P315, DOI 10.1080/0269905031000149489; MAHAPATRA AK, 1994, SKULL BASE SURGERY, P305; Mahapatra AK, 2004, IND J NEUROTRAUMA, V1, P33; MAHAPATRA AK, 1992, NEUROL INDIA, V40, P17; MEMON MY, 1971, J NEUROSURG, V35, P461, DOI 10.3171/jns.1971.35.4.0461; Muthu P, 2001, EMERG MED J, V18, P310, DOI 10.1136/emj.18.4.310; Patel P, 2005, INDIAN J NEUROTRAUM, V2, P27, DOI 10.1016/S0973-0508(05)80007-3; RICHARDS BW, 1992, AM J OPHTHALMOL, V113, P489, DOI 10.1016/S0002-9394(14)74718-X; RUSH JA, 1981, ARCH OPHTHALMOL-CHIC, V99, P76, DOI 10.1001/archopht.1981.03930010078006; SOLOMONS NB, 1980, S AFR MED J, V58, P109; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; SYDNOR CF, 1982, OPHTHALMOLOGY, V89, P134; Tiffin PAC, 1996, EYE, V10, P377, DOI 10.1038/eye.1996.77; Turner JWA, 1944, LANCET, V1, P756; WALSH F B, 1957, Br J Ophthalmol, V41, P577, DOI 10.1136/bjo.41.10.577; WALTER KA, 1994, NEUROLOGY, V44, P148, DOI 10.1212/WNL.44.1.148	37	50	52	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					547	555		10.3171/2010.6.JNS091620			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100018	20635856				2021-06-18	
J	Wagner, AK; Miller, MA; Scanlon, J; Ren, DX; Kochanek, PM; Conley, YP				Wagner, Amy K.; Miller, Megan A.; Scanlon, Joelle; Ren, Dianxu; Kochanek, Patrick M.; Conley, Yvette P.			Adenosine A1 receptor gene variants associated with post-traumatic seizures after severe TBI	EPILEPSY RESEARCH			English	Article						A1AR; Adenosine; ADORA1; Brain injury; Genetic susceptibility; Post-traumatic seizure	TRAUMATIC BRAIN-INJURY; STATUS EPILEPTICUS; RAT HIPPOCAMPUS; RISK-FACTORS; ADENOSINE; EPILEPSY; RECEPTORS; PHENYTOIN; MULTICENTER; INCREASE	Post-traumatic seizures (PTS) are a significant complication from traumatic brain injury (TBI). Adenosine, a major neuroprotective and neuroinhibitory molecule, is important in experimental epilepsy models. Thus, we investigated the adenosine A1 receptor (A1AR) gene and linked it with clinical data extracted for 206 subjects with severe TBI. Tagging SNPs rs3766553, rs903361, rs10920573, rs6701725, and rs17511192 were genotyped, and variant and haplotype associations with PTS were explored. We investigated further genotype, grouped genotype, and allelic associations with PTS for rs3766553 and rs10920573. Multivariate analysis of rs3766553 demonstrated an association between the AA genotype and increased early PTS incidence. In contrast, the GG genotype was associated with increased late and delayed-onset PTS rates. Multivariate analysis of rs10920573 revealed an association between the CT genotype and increased late PTS. Multiple risk genotype analysis showed subjects with both risk genotypes had a 46.7% chance of late PTS. To our knowledge, this is the first report implicating genetic variability in the A1AR with PTS, or any type of seizure disorder. These results provide a rationale for further studies investigating how adenosine neurotransmission impacts PTS, evaluating anticonvulsants in preventing and treating PTS, and developing and testing targeted adenosinergic therapies aimed at reducing PTS. (C) 2010 Elsevier B.V. All rights reserved.	[Wagner, Amy K.; Miller, Megan A.; Scanlon, Joelle] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, Amy K.; Kochanek, Patrick M.; Conley, Yvette P.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Ren, Dianxu; Conley, Yvette P.] Univ Pittsburgh, Dept Hlth Promot & Dev, Pittsburgh, PA 15213 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu; millerm8@upmc.edu; scanjm2@upmc.edu; dir8@pitt.edu; kochanekpm@ccm.upmc.edu; yconley@pitt.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD048162, R01NR008424, 5P01NS030318-16, NIHR01NS38087]; DODUnited States Department of Defense [W81XWH-07-1-0701]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038087, P01NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR008424] Funding Source: NIH RePORTER	The authors wish to thank Sandra Des touches for her genotyping efforts, Candace Kammerer, PhD for haplotype consultation, and the subjects and their families for their generous participation. This work was supported by NIH R01HD048162 and DOD W81XWH-07-1-0701 to AKW, NIH R01NR008424 and DOD W81XWH-07-1-0701 to YPC, and NIH 5P01NS030318-16 and NIHR01NS38087 to PMK.	ANDINE P, 1990, BRIT J PHARMACOL, V100, P814, DOI 10.1111/j.1476-5381.1990.tb14097.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; ARMSTRONG KK, 1990, ARCH PHYS MED REHAB, V71, P156; Avsar E, 2004, NEUROPHARMACOLOGY, V47, P427, DOI 10.1016/j.neuropharm.2004.04.015; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Cavalleri GL, 2007, EPILEPSIA, V48, P706, DOI 10.1111/j.1528-1167.2007.00977.x; Ciruela F, 2006, J NEUROSCI, V26, P2080, DOI 10.1523/JNEUROSCI.3574-05.2006; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DECKERT J, 1988, BRAIN RES, V446, P161, DOI 10.1016/0006-8993(88)91308-X; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Fedele DE, 2005, BRAIN, V128, P2383, DOI 10.1093/brain/awh555; Fedele DE, 2006, EXP NEUROL, V200, P184, DOI 10.1016/j.expneurol.2006.02.133; Franco R, 2000, NEUROPSYCHOPHARMACOL, V23, pS50, DOI 10.1016/S0893-133X(00)00144-5; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Hernandez-Saavedra D, 2009, CELL BIOCHEM FUNCT, V27, P223, DOI 10.1002/cbf.1560; Herzog AG, 2008, SEIZURE-EUR J EPILEP, V17, P151, DOI 10.1016/j.seizure.2007.11.014; Hung CC, 2005, PHARMACOGENOMICS, V6, P411, DOI 10.1517/14622416.6.4.411; JENNETT B, 1975, LANCET, V1, P480; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; MacKenzie A, 1999, P NATL ACAD SCI USA, V96, P15251, DOI 10.1073/pnas.96.26.15251; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Olah ME, 2000, PHARMACOL THERAPEUT, V85, P55, DOI 10.1016/S0163-7258(99)00051-0; Rhodes ME, 2005, EPILEPSY BEHAV, V6, P320, DOI 10.1016/j.yebeh.2005.02.006; Robertson CL, 2001, CRIT CARE MED, V29, P2287, DOI 10.1097/00003246-200112000-00009; Rosen N, 2003, BIOINFORMATICS, V19, pi222, DOI 10.1093/bioinformatics/btg1030; RUDOLPHI KA, 1992, CEREBROVAS BRAIN MET, V4, P346; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; SMITH KR, 1994, ARCH NEUROL-CHICAGO, V51, P653, DOI 10.1001/archneur.1994.00540190029012; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Temkin Nancy R., 2002, Epilepsy Curr, V2, P105, DOI 10.1046/j.1535-7597.2002.00038.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VAUGHAN KT, 1993, GENOMICS, V16, P34, DOI 10.1006/geno.1993.1136; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC	42	50	54	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	AUG	2010	90	3					259	272		10.1016/j.eplepsyres.2010.06.001			14	Clinical Neurology	Neurosciences & Neurology	638IB	WOS:000280885900012	20609566	Green Published, Green Accepted			2021-06-18	
J	Gottshall, KR; Hoffer, ME				Gottshall, Kim R.; Hoffer, Michael E.			Tracking Recovery of Vestibular Function in Individuals With Blast-Induced Head Trauma Using Vestibular-Visual-Cognitive Interaction Tests	JOURNAL OF NEUROLOGIC PHYSICAL THERAPY			English	Article						concussion; traumatic brain injury; balance	GAZE STABILIZATION; DYNAMIC POSTUROGRAPHY; DIZZINESS	Background and Purpose: Traumatic brain injury secondary to blast exposure is a significant international concern and a growing rehabilitation issue. Our objective was to determine whether a novel battery of vestibular-visual-cognitive interaction tests provides objective data to document functioning, and the changes in functioning associated with vestibular physical therapy (VPT) treatment, in individuals with blast-induced balance disorder. Methods: Eighty-two individuals with blast-induced mild traumatic brain injury were evaluated at baseline using a set of vestibular-visual-cognitive tests. Testing was repeated at 4-week intervals after beginning VPT. The tests included static visual acuity, perception time, target acquisition, target following (TF), dynamic visual acuity (DVA), and gaze stabilization tests. The VPT program consisted of exercise procedures that targeted the vestibulo-ocular reflex, cervico-ocular reflex, and depth perception. Somatosensory balance exercises, dynamic gait, and aerobic function exercises were also included. Participants attended VPT twice weekly for 1-hour appointments and were instructed to perform the exercises at home on other days. Mean test values were determined and compared with normative values previously collected in our laboratory from individuals without vestibular dysfunction. Results: Mean participant pre-VPT measures for perception time and target acquisition were similar to normative values, and there was no significant change in these measures. Initially, TF and DVA scores were below normative levels but returned to normative levels after 8 weeks of VPT. Gaze stabilization scores were below normative levels pre-VPT but improved by the time of the week 8 evaluation. Conclusions: This battery of vestibular-visual-cognitive tests seems to be reasonable to establish initial status and to evaluate participant progress associated with participation in VPT. Our data suggest meaningful improvement in TF and DVA after 8 weeks of treatment. A treatment period of 12 weeks or longer may be required for gaze stabilization scores to return to normative values.	[Gottshall, Kim R.; Hoffer, Michael E.] USN, Med Ctr, San Diego, CA 92152 USA	Gottshall, KR (corresponding author), USN, Med Ctr, San Diego, CA 92152 USA.	Kim.gottshall@med.navy.mil					Badaracco C, 2007, OTOL NEUROTOL, V28, P809, DOI 10.1097/MAO.0b013e3180cab73f; Drake AI, 2006, BRAIN INJURY, V20, P469, DOI 10.1080/02699050600676370; Goebel JA, 2007, OTOL NEUROTOL, V28, P68, DOI 10.1097/01.mao.0000244351.42201.a7; Gottshall Kim, 2005, Work, V24, P381; Gottshall KR, 2007, MIL MED, V172, P852, DOI 10.7205/MILMED.172.8.852; Gottshall KR, 2006, J VESTIBUL RES-EQUIL, V16, P29; Gottshall KR, 2003, LARYGNOSCOPE, V113, P1736; Herman T, 2009, GAIT POSTURE, V29, P237, DOI 10.1016/j.gaitpost.2008.08.013; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Mishra A, 2009, AM J AUDIOL, V18, P53, DOI 10.1044/1059-0889(2009/06-0024); NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; PAIGE GD, 1989, ACTA OTO-LARYNGOL, V108, P1, DOI 10.3109/00016488909107385; Pritcher MR, 2008, OTOL NEUROTOL, V29, P982, DOI 10.1097/MAO.0b013e31818457fb; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Shumway-Cook A., 1995, MOTOR CONTROL THEORY; Whitney SL, 2009, GAIT POSTURE, V29, P194, DOI 10.1016/j.gaitpost.2008.08.002	17	50	51	0	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1557-0576	1557-0584		J NEUROL PHYS THER	J. Neurol. Phys. Ther.	JUN	2010	34	2					94	97		10.1097/NPT.0b013e3181dead12			4	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	V21PD	WOS:000208218600008	20588095				2021-06-18	
J	Mtchedlishvili, Z; Lepsveridze, E; Xu, H; Kharlamov, EA; Lu, B; Kelly, KM				Mtchedlishvili, Zakaria; Lepsveridze, Eka; Xu, Hong; Kharlamov, Elena A.; Lu, Bo; Kelly, Kevin M.			Increase of GABA(A) receptor-mediated tonic inhibition in dentate granule cells after traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; Dentate granule cells; GABA(A) receptor; Diazepam; Furosemide; THIP; Bicuculline; mIPSCs; Synaptic currents; Tonic currents	NUCLEUS BASALIS MAGNOCELLULARIS; AMINOBUTYRIC ACID(A) RECEPTORS; ALPHA-5 SUBUNIT; SYNAPTIC-TRANSMISSION; INCREASED EXPRESSION; NEUROTROPHIC FACTOR; DELTA-SUBUNIT; POSTSYNAPTIC CURRENTS; PERSISTENT ACTIVATION; ALTERED EXPRESSION	Traumatic brain injury (TBI) can result in altered inhibitory neurotransmission, hippocampal dysfunction, and cognitive impairments. GABAergic spontaneous and miniature inhibitory postsynaptic currents (sIPSCs and mIPSCs) and tonic (extrasynaptic) whole cell currents were recorded in control rat hippocampal dentate granule cells (DGCs) and at 90 days after controlled cortical impact (CCI). At 34 degrees C, in CCI DGCs, sIPSC frequency and amplitude were unchanged, whereas mIPSC frequency was decreased (3.10 +/- 0.84 Hz, n = 16, and 2.44 +/- 0.67 Hz, n = 7, p<0.05). At 23 degrees C, 300 nM diazepam increased peak amplitude of mIPSCs in control and CCI DGCs, but the increase was 20% higher in control (26.81 +/- 2.2 pA and 42.60 +/- 1.22 pA, n = 9, p = 0.031) compared to CCI DGCs (33.46 +/- 2.98 pA and 46.13 +/- 1.09 pA, n = 10, p = 0.047). At 34 degrees C, diazepam did not prolong decay time constants (6.59 +/- 0.12 ms and 6.62 +/- 0.98 ms, n = 9, p = 0.12), the latter suggesting that CCI resulted in benzodiazepine-insensitive pharmacology in synaptic GABA(A) receptors (GABA(A)Rs). In CCI DGCs, peak amplitude of mIPSCs was inhibited by 100 mu M furosemide (51.30 +/- 0.80 pA at baseline and 43.50 +/- 5.30 pA after furosemide, n = 5. p<0.001), a noncompetitive antagonist of GABA(A)Rs with an enhanced affinity to alpha 4 subunit-containing receptors. Potentiation of tonic current by the GABA(A)R delta subunit-preferring competitive agonist THIP (1 and 3 mu M) was increased in CCI DGCs (47% and 198%) compared to control DGCs (13% and 162%), suggesting the presence of larger tonic current in CCI DGCs; THIP (1 mu M) had no effect on mIPSCs. Taken together, these results demonstrate alterations in synaptic and extrasynaptic GABAARs in DGCs following CCI. (C) 2010 Elsevier Inc. All rights reserved.	[Mtchedlishvili, Zakaria; Xu, Hong; Lu, Bo; Kelly, Kevin M.] Allegheny Gen Hosp, Allegheny Singer Res Inst, Ctr Res Neurosci, Pittsburgh, PA 15212 USA; [Mtchedlishvili, Zakaria; Kharlamov, Elena A.; Kelly, Kevin M.] Drexel Univ, Coll Med, Dept Neurol, Philadelphia, PA 19104 USA; [Kelly, Kevin M.] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA; [Lepsveridze, Eka] Ilia Chavchavadze State Univ, Fac Life Sci, Tbilisi, Georgia	Mtchedlishvili, Z (corresponding author), Allegheny Gen Hosp, Allegheny Singer Res Inst, Ctr Res Neurosci, 9J9 ST,320 East North Ave, Pittsburgh, PA 15212 USA.	zmtchedl@wpahs.org		Harris, Neil/0000-0002-1965-6750	Health Research Formula Fund [RFA 01-07-26]; Pennsylvania Department of Health; Epilepsy Foundation; Georgian National Science Scholars Program	The study was supported by Health Research Formula Fund RFA 01-07-26, Pennsylvania Department of Health (ZM), a Research Grant from the Epilepsy Foundation (ZM), and a grant from the Georgian National Science Scholars Program (EL). We thank Teresa M. Hentosz for assistance in the preparation of the manuscript.	Adkins CE, 2001, J BIOL CHEM, V276, P38934, DOI 10.1074/jbc.M104318200; Alldred MJ, 2005, J NEUROSCI, V25, P594, DOI 10.1523/JNEUROSCI.4011-04.2005; AROLFO MP, 1991, BEHAV NEURAL BIOL, V55, P131, DOI 10.1016/0163-1047(91)80133-Y; Atack JR, 2006, NEUROPHARMACOLOGY, V51, P1023, DOI 10.1016/j.neuropharm.2006.04.018; Bai DL, 2001, MOL PHARMACOL, V59, P814; Banks MI, 1998, J NEUROSCI, V18, P1305; Bianchi MT, 2002, J PHYSIOL-LONDON, V544, P3, DOI 10.1113/jphysiol.2002.020255; Binder DK, 1999, J NEUROSCI, V19, P4616; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Bowser DN, 2002, P NATL ACAD SCI USA, V99, P15170, DOI 10.1073/pnas.212320199; Brickley SG, 1996, J PHYSIOL-LONDON, V497, P753, DOI 10.1113/jphysiol.1996.sp021806; Bright DP, 2007, J NEUROSCI, V27, P2560, DOI 10.1523/JNEUROSCI.5100-06.2007; BRIONI JD, 1988, PSYCHOPHARMACOLOGY, V96, P505, DOI 10.1007/BF02180032; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brown N, 2002, BRIT J PHARMACOL, V136, P965, DOI 10.1038/sj.bjp.0704795; BUCKMASTER PS, 1995, EUR J NEUROSCI, V7, P1393, DOI 10.1111/j.1460-9568.1995.tb01131.x; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Caraiscos VB, 2004, P NATL ACAD SCI USA, V101, P3662, DOI 10.1073/pnas.0307231101; CASTELLANO C, 1993, PSYCHOPHARMACOLOGY, V111, P134, DOI 10.1007/BF02245514; Cohen AS, 2003, EUR J NEUROSCI, V17, P1607, DOI 10.1046/j.1460-9568.2003.02597.x; COLLINS RC, 1983, BRAIN RES, V280, P25, DOI 10.1016/0006-8993(83)91170-8; Collinson N, 2006, PSYCHOPHARMACOLOGY, V188, P619, DOI 10.1007/s00213-006-0361-z; Collinson N, 2002, J NEUROSCI, V22, P5572; DAHHAOUI M, 1994, PHYSIOL BEHAV, V56, P257, DOI 10.1016/0031-9384(94)90193-7; Das P, 2004, NEUROSCIENCE, V124, P195, DOI 10.1016/j.neuroscience.2003.12.005; Dawson GR, 2006, J PHARMACOL EXP THER, V316, P1335, DOI 10.1124/jpet.105.092320; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Dinocourt C, 2006, EUR J NEUROSCI, V24, P1857, DOI 10.1111/j.1460-9568.2006.05067.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; Elmer E, 1998, NEUROSCIENCE, V83, P351, DOI 10.1016/S0306-4522(97)00387-4; EMFORS P, 1991, NEURONS, V7, P165; Engel AK, 2001, TRENDS COGN SCI, V5, P16, DOI 10.1016/S1364-6613(00)01568-0; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Eugene E, 2007, J NEUROSCI, V27, P14108, DOI 10.1523/JNEUROSCI.2618-07.2007; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Feng HJ, 2008, J NEUROPHYSIOL, V99, P1285, DOI 10.1152/jn.01180.2007; Gao L, 2005, NEUROPHARMACOLOGY, V48, P333, DOI 10.1016/j.neuropharm.2004.10.010; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P2139; Glykys J, 2008, J NEUROSCI, V28, P1421, DOI 10.1523/JNEUROSCI.4751-07.2008; Golarai G, 2001, J NEUROSCI, V21, P8523; Goldschen-Ohm MP, 2010, MOL PHARMACOL, V77, P35, DOI 10.1124/mol.109.058289; Goodkin HP, 2008, J NEUROSCI, V28, P2527, DOI 10.1523/JNEUROSCI.3426-07.2008; Goodkin HP, 2005, J NEUROSCI, V25, P5511, DOI 10.1523/JNEUROSCI.0900-05.2005; Hajos N, 2000, EUR J NEUROSCI, V12, P810, DOI 10.1046/j.1460-9568.2000.00964.x; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; Hamann M, 2002, NEURON, V33, P625, DOI 10.1016/S0896-6273(02)00593-7; Hardingham NR, 1998, J PHYSIOL-LONDON, V507, P249, DOI 10.1111/j.1469-7793.1998.249bu.x; HEINEMANN U, 1992, EPILEPSY RES, P273; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Johansson IM, 2002, BRAIN RES, V934, P125, DOI 10.1016/S0006-8993(02)02414-9; Joshi S, 2009, NEUROSCIENCE, V164, P507, DOI 10.1016/j.neuroscience.2009.08.008; KANEDA M, 1995, J PHYSIOL-LONDON, V485, P419, DOI 10.1113/jphysiol.1995.sp020739; Kant GJ, 1996, PHARMACOL BIOCHEM BE, V53, P317, DOI 10.1016/0091-3057(95)02028-4; Kapur J, 1997, J NEUROSCI, V17, P7532, DOI 10.1523/jneurosci.17-19-07532.1997; Kharlamov EA, 2003, EPILEPSY RES, V56, P185, DOI 10.1016/j.eplepsyres.2003.09.005; Kittler JT, 2003, CURR OPIN NEUROBIOL, V13, P341, DOI 10.1016/S0959-4388(03)00064-3; Kneussel M, 2000, J PHYSIOL-LONDON, V525, P1, DOI 10.1111/j.1469-7793.2000.t01-4-00001.x; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Korpi ER, 1997, BRIT J PHARMACOL, V120, P741, DOI 10.1038/sj.bjp.0700922; Kozlov AS, 2006, P NATL ACAD SCI USA, V103, P10058, DOI 10.1073/pnas.0603741103; Krazem A, 2001, PHARMACOL BIOCHEM BE, V68, P235, DOI 10.1016/S0091-3057(00)00444-5; Kushmerick C, 2006, J NEUROSCI, V26, P1366, DOI 10.1523/JNEUROSCI.3889-05.2006; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Liu QY, 2000, J NEUROPHYSIOL, V84, P1392; Llinas R, 2001, ANN NY ACAD SCI, V929, P166; Mangan PS, 2005, MOL PHARMACOL, V67, P775, DOI 10.1124/mol.104.007385; Mann EO, 2010, NAT NEUROSCI, V13, P205, DOI 10.1038/nn.2464; Maubach K, 2003, CNS NEUROL DISORD-DR, V2, P233, DOI 10.2174/1568007033482779; MAYO W, 1993, BRAIN RES, V607, P324, DOI 10.1016/0006-8993(93)91524-V; MAYO W, 1992, BRAIN RES, V589, P109, DOI 10.1016/0006-8993(92)91168-E; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; Micheva KD, 2005, J NEUROSCI, V25, P7481, DOI 10.1523/JNEUROSCI.1801-05.2005; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; Mody I, 2004, TRENDS NEUROSCI, V27, P569, DOI 10.1016/j.tins.2004.07.002; Mtchedlishvili Z, 2006, MOL PHARMACOL, V69, P564, DOI 10.1124/mol.105.016683; Naylor DE, 2005, J NEUROSCI, V25, P7724, DOI 10.1523/JNEUROSCI.4944-04.2005; NUSSER Z, 1995, J NEUROSCI, V15, P2948; Nusser Z, 2002, J NEUROPHYSIOL, V87, P2624, DOI 10.1152/jn.2002.87.5.2624; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; Payne HL, 2006, J NEUROSCI, V26, P8600, DOI 10.1523/JNEUROSCI.1088-06.2006; Peng Z, 2002, J COMP NEUROL, V446, P179, DOI 10.1002/cne.10210; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Perrais D, 1999, J NEUROSCI, V19, P578; Pirker S, 2003, J NEUROPATH EXP NEUR, V62, P820, DOI 10.1093/jnen/62.8.820; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Qi ZH, 2007, J BIOL CHEM, V282, P33052, DOI 10.1074/jbc.M707233200; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RAFFALLISEBILLE MJ, 1990, PHARMACOL BIOCHEM BE, V35, P281, DOI 10.1016/0091-3057(90)90156-C; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Richerson GB, 2003, J NEUROPHYSIOL, V90, P1363, DOI 10.1152/jn.00317.2003; Rivera C, 2002, J CELL BIOL, V159, P747, DOI 10.1083/jcb.200209011; Rossi DJ, 1998, NEURON, V20, P783, DOI 10.1016/S0896-6273(00)81016-8; Rudolph U, 2006, CURR OPIN PHARMACOL, V6, P18, DOI 10.1016/j.coph.2005.10.003; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Sassoe-Pognetto M, 2000, J COMP NEUROL, V420, P481, DOI 10.1002/(SICI)1096-9861(20000515)420:4<481::AID-CNE6>3.0.CO;2-5; Shumate MD, 1998, EPILEPSY RES, V32, P114, DOI 10.1016/S0920-1211(98)00045-X; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; Silvers JM, 2003, BRAIN RES REV, V43, P275, DOI 10.1016/j.brainresrev.2003.09.002; SOLTESZ I, 1995, J NEUROPHYSIOL, V73, P1763; Somogyi P, 1996, NEUROPHARMACOLOGY, V35, P1425, DOI 10.1016/S0028-3908(96)00086-X; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Stell BM, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0003.2002; STRINGER JL, 1989, EPILEPSY RES, V4, P177, DOI 10.1016/0920-1211(89)90002-8; Sun CS, 2007, J NEUROSCI, V27, P12641, DOI 10.1523/JNEUROSCI.4141-07.2007; Sun CS, 2004, BRAIN RES, V1029, P207, DOI 10.1016/j.brainres.2004.09.056; Sundstrom-Poromaa I, 2002, NAT NEUROSCI, V5, P721, DOI 10.1038/nn888; Sur C, 1999, MOL PHARMACOL, V56, P110; Terunuma M, 2008, J NEUROSCI, V28, P376, DOI 10.1523/JNEUROSCI.4346-07.2008; Toth Z, 1997, J NEUROSCI, V17, P8106; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; TRAUB RD, 1991, ANN NY ACAD SCI, V627, P277; Turkmen S, 2006, NEUROSCIENCE, V139, P651, DOI 10.1016/j.neuroscience.2005.12.031; Volgushev M, 2004, J NEUROPHYSIOL, V92, P212, DOI 10.1152/jn.01166.2003; Wafford KA, 1996, MOL PHARMACOL, V50, P670; Wall MJ, 1997, EUR J NEUROSCI, V9, P533, DOI 10.1111/j.1460-9568.1997.tb01630.x; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/88259; Wei WZ, 2003, J NEUROSCI, V23, P10650; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zhan RZ, 2009, J NEUROPHYSIOL, V102, P670, DOI 10.1152/jn.00147.2009	130	50	53	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUN	2010	38	3			SI		464	475		10.1016/j.nbd.2010.03.012			12	Neurosciences	Neurosciences & Neurology	595XU	WOS:000277648200017	20304069				2021-06-18	
J	Rueda, MAF; Halley, WL; Gilchrist, MD				Rueda, Manuel A. Forero; Halley, Walter L.; Gilchrist, Michael D.			Fall and injury incidence rates of jockeys while racing in Ireland, France and Britain	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Jockey; Horse racing; Equestrian; Head injury; Concussion	TRAUMATIC BRAIN-INJURY; HORSE-RELATED INJURIES; GREAT-BRITAIN; HEAD; RECONSTRUCTION; SEVERITY; CHILDREN; HELMETS; IMPACTS; SPORT	This article presents and analyses injury incidence rates for amateur and professional racing jockeys in Ireland, France and Britain by means of a retrospective study and review of published data. Amateur jump racing was seen to have the highest fall risk in these three countries (between 115 and 140 falls/1000 rides). Jump racing also had the highest rates of injury/ride amongst both amateur and professional jockeys. Flat racing, however, had the highest rates of injuries/fall (34-44%). Of all the injuries in both jump and flat racing populations of amateur and professional jockeys, 15% were concussive head injuries, and more than half of these involved loss of consciousness. Professional jump jockeys in Ireland fell less frequently than those in France or Britain. Their injury/fall rate and injury/ride rate were highest in Britain. Professional flat racing jockeys in France had the lowest rates of injuries/fall and injuries/ride, while those in Ireland had the highest. (C) 2009 Elsevier Ltd. All rights reserved.	[Rueda, Manuel A. Forero; Gilchrist, Michael D.] Univ Coll Dublin, Sch Elect Elect & Mech Engn, Dublin 4, Ireland	Gilchrist, MD (corresponding author), Univ Coll Dublin, Sch Elect Elect & Mech Engn, Dublin 4, Ireland.	michael.gilchrist@ucd.ie	Gilchrist, Michael D/B-6100-2017	Gilchrist, Michael D/0000-0003-1765-429X	Turf Club	Financial support in the form of a PhD stipend was provided to MAFR by the Turf Club during the course of this research. Dr. Benoit LeMasson of France Galop kindly provided the authors with French jockey injury data. The assistance of Mr. Peter T. O'Neill of the UCD School of Electrical, Electronic & Mechanical Engineering with the R statistical analysis software is gratefully acknowledged.	Abu-Zidan FM, 2003, INJURY, V34, P897, DOI 10.1016/S0020-1383(03)00054-8; Balendra G, 2007, BRIT J SPORT MED, V41, P162, DOI 10.1136/bjsm.2006.033894; BROOKS WH, 1988, PHYSICIAN SPORTSMED, V16, P84, DOI 10.1080/00913847.1988.11709646; Chapman M A, 1991, Br J Sports Med, V25, P121; CONDIE C, 1993, PUBLIC HEALTH REP, V108, P121; CRIPPS RA, 2000, AUSTR INJURY PRE MAY, P24; DABREU F, 1976, LANCET, V7971, P1241; DEBENEDETTE V, 1989, Physician and Sportsmedicine, V17, P251; Dekker R, 2004, DISABIL REHABIL, V26, P91, DOI 10.1080/09638280310001629688; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; FINCH C, 1996, LOCKING STABLE DOOR, P1; Gabbe BJ, 2005, BRIT J SPORT MED, V39, P573, DOI 10.1136/bjsm.2004.015750; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; HARRISON TI, 1996, IRCOBI C DUBL, P49; Holland AJA, 2001, MED J AUSTRALIA, V175, P609, DOI 10.5694/j.1326-5377.2001.tb143746.x; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hunt H., 1989, IRCOBI C STOCKHOLM, P157; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; *IS EN, 1996, 1384 IS EN; LEVY AS, 2000, CNI REV MED J, P11; McCrory P, 2006, BRIT J SPORT MED, V40, P614, DOI 10.1136/bjsm.2006.028449; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; MILLS NJ, 1989, INJURY, V20, P189, DOI 10.1016/0020-1383(89)90108-3; NICHOLL JP, 1990, BRIT MED J, V301, P496, DOI 10.1136/bmj.301.6750.496-b; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; Paix BR, 1999, BRIT J SPORT MED, V33, P46, DOI 10.1136/bjsm.33.1.46; PRESS JM, 1995, CLIN J SPORT MED, V5, P236, DOI 10.1097/00042752-199510000-00005; Sahai H, 1996, STAT EPIDEMIOLOGY ME; The Turf Club, 2007, RUL RAC IR NAT HUNT; Turner M, 2002, BRIT J SPORT MED, V36, P403, DOI 10.1136/bjsm.36.6.403; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	32	50	52	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAY	2010	41	5					533	539		10.1016/j.injury.2009.05.009			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	596QJ	WOS:000277699800020	19524903				2021-06-18	
J	Hall, SD; Yamawaki, N; Fisher, AE; Clauss, RP; Woodhall, GL; Stanford, IM				Hall, Stephen D.; Yamawaki, Naoki; Fisher, Alison E.; Clauss, Ralf P.; Woodhall, Gavin L.; Stanford, Ian M.			GABA(A) alpha-1 subunit mediated desynchronization of elevated low frequency oscillations alleviates specific dysfunction in stroke - A case report	CLINICAL NEUROPHYSIOLOGY			English	Article						Magnetoencephalography (MEG); GABA; Theta; Beta; Stroke; Pathological oscillations	TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; VEGETATIVE STATE; ZOLPIDEM; MAGNETOENCEPHALOGRAPHY; IMPROVEMENT; INSOMNIA; SIGNAL	Objective: The paradoxical effects of the hypnotic imidazopyridine zolpidem, widely reported in persistent vegetative state, have been replicated recently in brain-injured and cognitively impaired patients. However, the neuronal mechanisms underlying these benefits are yet to be demonstrated. We implemented contemporary neuroimaging methods to investigate sensorimotor and cognitive improvements, observed in stroke patient JP following zolpidem administration. Methods: We used Magnetic-Resonance-Imaging (MRI) and Magnetic-Resonance-Spectroscopy (MRS) to anatomically and chemically characterize stroke damage. Single-photon-emission-computed-tomography (SPECT) and magnetoencephalography (MEG) were used to identify changes in cerebrovascular perfusion and neuronal network activity in response to sub-sedative doses of zolpidem, zopiclone and placebo. Cognitive improvements were measured using the WAIS-III and auditory-verbal tasks. Results: MRI and MRS revealed a lesion with complete loss of neuronal viability in the left temporal-parietal region; whilst SPECT indicated improved perfusion in the affected hemisphere following zolpidem. MEG demonstrated high-amplitude theta (4-10 Hz) and beta (15-30 Hz) oscillations within the peri-infarct region, which reduced in power coincident with zolpidem uptake and improvements in cognitive and motor function. Conclusions: In JP, functional deficits and pathological oscillations appear coincidentally reduced following administration of low-dose zolpidem. Significance: GABA(A) alpha-1 sensitive desynchronisation of pathological oscillations may represent a biomarker and potential therapeutic target in brain injury. (C) 2009 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Hall, Stephen D.; Yamawaki, Naoki; Woodhall, Gavin L.; Stanford, Ian M.] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England; [Fisher, Alison E.] Univ Bristol, Dept Expt Psychol, Bristol, Avon, England; [Clauss, Ralf P.] Royal Surrey Cty Hosp, Dept Nucl Med, Guildford, Surrey, England	Hall, SD (corresponding author), Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.	hallsd@aston.ac.uk		Hall, Stephen/0000-0002-9274-6867; Stanford, Ian M/0000-0002-5677-8538; woodhall, gavin/0000-0003-1281-9008	Regen Therapeutics Plc.; RCUKUK Research & Innovation (UKRI); Wellcome TrustWellcome TrustEuropean Commission; The Dr. Hadwen Trus; Lord Dowding Fund	This work was supported by Regen Therapeutics Plc. and an RCUK Fellowship (SDH). MEG work was supported by The Wellcome Trust and The Dr. Hadwen Trust and the MRI work was supported by The Lord Dowding Fund. We thank Dr. Peter Magill, for helpful comments on the manuscript.	Adjamian P, 2004, CLIN NEUROPHYSIOL, V115, P691, DOI 10.1016/j.clinph.2003.10.023; Basso MR, 2002, CLIN NEUROPSYCHOL, V16, P57, DOI 10.1076/clin.16.1.57.8329; Brown P, 2001, J NEUROSCI, V21, P1033; Canive JM, 1996, PSYCHOPHARMACOL BULL, V32, P741; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Clauss RP, 2004, ARZNEIMITTELFORSCH, V54, P641; Cohen L, 2004, NEW ENGL J MED, V350, P949, DOI 10.1056/NEJM200402263500922; Daniele A, 1997, LANCET, V349, P1222, DOI 10.1016/S0140-6736(05)62416-6; Dooley M, 2000, DRUGS, V60, P413, DOI 10.2165/00003495-200060020-00014; Farver DK, 2001, ANN PHARMACOTHER, V35, P435; HALL SD, HUM BRAIN M IN PRESS, DOI DOI 10.1002/HBM.20889; Hall-Stoodley L, 2005, TRENDS MICROBIOL, V13, P7, DOI 10.1016/j.tim.2004.11.004; Hillebrand A, 2005, HUM BRAIN MAPP, V25, P199, DOI 10.1002/hbm.20102; Holm KJ, 2000, DRUGS, V59, P865, DOI 10.2165/00003495-200059040-00014; Jarry C, 2002, ANN PHARMACOTHER, V36, P1808; Jensen O, 2005, NEUROIMAGE, V26, P347, DOI 10.1016/j.neuroimage.2005.02.008; Kuhn AA, 2006, EUR J NEUROSCI, V23, P1956, DOI 10.1111/j.1460-9568.2006.04717.x; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Pfurtscheller G, 2001, VISION RES, V41, P1257, DOI 10.1016/S0042-6989(00)00235-2; POZA J, 2007, C P IEEE ENG MED BIO, P6180; Shames JL, 2008, ARCH PHYS MED REHAB, V89, P386, DOI 10.1016/j.apmr.2007.08.137; Singh KD, 2002, NEUROIMAGE, V16, P103, DOI 10.1006/nimg.2001.1050; Taniguchi M, 2000, NEUROIMAGE, V12, P298, DOI 10.1006/nimg.2000.0611; Tecchio F, 2006, J NEUROSCI RES, V83, P1077, DOI 10.1002/jnr.20796; Thomson AM, 2000, EUR J NEUROSCI, V12, P425, DOI 10.1046/j.1460-9568.2000.00915.x; Vrba J, 2001, METHODS, V25, P249, DOI 10.1006/meth.2001.1238; Yamamoto T, 2002, ACT NEUR S, V79, P79	29	50	51	3	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	APR	2010	121	4					549	555		10.1016/j.clinph.2009.11.084			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	575TK	WOS:000276091100013	20097125				2021-06-18	
J	Hunt, RF; Scheff, SW; Smith, BN				Hunt, Robert F.; Scheff, Stephen W.; Smith, Bret N.			Regionally Localized Recurrent Excitation in the Dentate Gyrus of a Cortical Contusion Model of Posttraumatic Epilepsy	JOURNAL OF NEUROPHYSIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; KAINATE-TREATED RATS; GRANULE CELLS; SYNAPTIC REORGANIZATION; HIPPOCAMPAL SLICES; STATUS EPILEPTICUS; PYRAMIDAL CELLS; MOSSY FIBERS; SEIZURES	Hunt RF, Scheff SW, Smith BN. Regionally localized recurrent excitation in the dentate gyrus of a cortical contusion model of posttraumatic epilepsy. J Neurophysiol 103: 1490-1500, 2010. First published January 20, 2010; doi: 10.1152/jn.00957.2009. Posttraumatic epilepsy is a frequent consequence of brain trauma, but relatively little is known about how neuronal circuits are chronically altered after closed head injury. We examined whether local recurrent excitatory synaptic connections form between dentate granule cells in mice 8-12 wk after cortical contusion injury. Mice were monitored for behavioral seizures shortly after brain injury and <= 10 wk postinjury. Injury-induced seizures were observed in 15% of mice, and spontaneous seizures were observed weeks later in 40% of mice. Timm's staining revealed mossy fiber sprouting into the inner molecular layer of the dorsal dentate gyrus ipsilateral to the injury in 95% of mice but not contralateral to the injury or in uninjured controls. Whole cell patch-clamp recordings were made from granule cells in isolated hippocampal brain slices. Cells in slices with posttraumatic mossy fiber sprouting had an increased excitatory postsynaptic current (EPSC) frequency compared with cells in slices without sprouting from injured and control animals (P < 0.001). When perfused with Mg2+-free artificial cerebrospinal fluid containing 100 mu M picrotoxin, these cells had spontaneous bursts of EPSCs and action potentials. Focal glutamate photostimulation of the granule cell layer evoked a burst of EPSCs and action potentials indicative of recurrent excitatory connections in granule cells of slices with mossy fiber sprouting. In granule cells of slices without sprouting from injured animals and controls, spontaneous or photostimulation-evoked epileptiform activity was never observed. These results suggest that a new regionally localized excitatory network forms between dentate granule cells near the injury site within weeks after cortical contusion head injury.	[Hunt, Robert F.; Smith, Bret N.] Univ Kentucky, Dept Physiol, Chandler Med Ctr MS 508, Lexington, KY 40536 USA; [Scheff, Stephen W.; Smith, Bret N.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Smith, BN (corresponding author), Univ Kentucky, Dept Physiol, Chandler Med Ctr MS 508, 800 Rose St, Lexington, KY 40536 USA.	bret.smith@uky.edu		Hunt, Robert/0000-0003-4490-8718	Epilepsy Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG-21981, NS-052302]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS052302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER	This work was supported by an Epilepsy Foundation training fellowship to R. F. Hunt and National Institutes of Health Grants AG-21981 to S. W. Scheff and NS-052302 to B. N. Smith.	ALVAREZBUYLLA A, 1990, J NEUROSCI METH, V33, P129, DOI 10.1016/0165-0270(90)90016-9; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BUCKMASTER PS, 1992, HIPPOCAMPUS, V2, P349, DOI 10.1002/hipo.450020403; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 2002, J NEUROSCI, V22, P6650; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; CRONIN J, 1992, BRAIN RES, V573, P305, DOI 10.1016/0006-8993(92)90777-7; Dudek FE, 1997, J CLIN NEUROPHYSIOL, V14, P90, DOI 10.1097/00004691-199703000-00002; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; FRICKE RA, 1984, J NEUROPHYSIOL, V51, P195; Golarai G, 2001, J NEUROSCI, V21, P8523; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HOUSER CR, 1990, BRAIN RES, V535, P195, DOI 10.1016/0006-8993(90)91601-C; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; KELLER BU, 1991, J PHYSIOL-LONDON, V435, P275, DOI 10.1113/jphysiol.1991.sp018510; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kotti T, 1997, EXP NEUROL, V146, P323, DOI 10.1006/exnr.1997.6553; Lynch M, 2000, J NEUROPHYSIOL, V83, P693; Meldrum BS, 1999, EPILEPSY RES, V36, P189, DOI 10.1016/S0920-1211(99)00051-0; MILES R, 1984, NEUROSCIENCE, V12, P1179, DOI 10.1016/0306-4522(84)90012-5; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; Patrylo PR, 1998, J NEUROPHYSIOL, V79, P418; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Racine R. J., 1979, CLIN NEUROPHYSIOL, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Salin P, 1995, J NEUROSCI, V15, P8234; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; SCHARFMAN HE, 1995, J NEUROPHYSIOL, V74, P179; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schubert D, 2001, J NEUROSCI, V21, P3580, DOI 10.1523/JNEUROSCI.21-10-03580.2001; Shibley H, 2002, EPILEPSY RES, V49, P109, DOI 10.1016/S0920-1211(02)00012-8; Shumate Melissa, 1995, Epilepsia, V36, P118; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; Smith BN, 2002, J NEUROPHYSIOL, V87, P1655, DOI 10.1152/jn.00581.2001; Smith BN, 2001, J NEUROPHYSIOL, V85, P1, DOI 10.1152/jn.2001.85.1.1; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346; STALEY KJ, 1992, SYNAPSE, V9, P219; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Steinlein OK, 2004, NAT REV NEUROSCI, V5, P400, DOI 10.1038/nrn1388; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; TRAUB RD, 1982, SCIENCE, V216, P745, DOI 10.1126/science.7079735; TRAUB RD, 1981, NEUROSCIENCE, V6, P223, DOI 10.1016/0306-4522(81)90058-0; Winokur RS, 2004, EPILEPSY RES, V58, P93, DOI 10.1016/j.eplepsyres.2004.01.002; Wong RKS, 1983, NATURE, V306, P397; Wuarin JP, 1996, J NEUROSCI, V16, P4438; Wuarin JP, 2001, J NEUROPHYSIOL, V85, P1067	58	50	50	0	8	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	MAR	2010	103	3					1490	1500		10.1152/jn.00957.2009			11	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	570EY	WOS:000275656200033	20089815	Green Published			2021-06-18	
J	Carrera, E; Kim, DJ; Castellani, G; Zweifel, C; Czosnyka, Z; Kasparowicz, M; Smielewski, P; Pickard, JD; Czosnyka, M				Carrera, Emmanuel; Kim, Dong-Joo; Castellani, Gianluca; Zweifel, Christian; Czosnyka, Zofia; Kasparowicz, Magdalena; Smielewski, Peter; Pickard, John D.; Czosnyka, Marek			What Shapes Pulse Amplitude of Intracranial Pressure?	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow autoregulation; cerebral blood flow velocity; intracranial pressure; neurodegenerative disorders; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; VOLUME; WAVE; AUTOREGULATION; TRANSMISSION; THRESHOLD; SYSTEM; SPACE	The pulsatile component of intracranial pressure (ICP) has been shown to be a predictor of outcome in normal pressure hydrocephalus (NPH) and traumatic brain injury (TBI). Experimental studies have demonstrated that the pulse amplitude of ICP (AMP(ICP)) is dependent on the mean ICP (mICP), and on the pulse amplitude of the cerebral arterial blood volume (AMP(CaBV)), according to the exponential craniospinal compliance curve. In this study, we compared the influence of mICP and AMP(CaBV) on AMP(ICP) in patients with NPH (infusion study) and TBI (spontaneous recording). We retrospectively analyzed 25 NPH and 43 TBI patients with continuous monitoring of ICP and cerebral blood flow velocity (CBFV), as assessed with transcranial doppler. AMP(CaBV) was extracted from the CBFV waveform. The influence of mICP and AMP(CaBV) on AMP(ICP) were determined using partial coefficients a, b, and c of the multiple regression model: AMP(ICP)-a* mICP+b* AMP(CaBV)+c. AMP(ICP) was more dependent on mICP in NPH patients than in TBI patients (partial coefficient a-0.93 versus-0.03; p<0.001). On the contrary, AMP(ICP) was more dependent on AMP(CaBV) in patients with TBI than in those with NPH (b-0.86 versus 0.10; p<0.001). This study shows that AMP(ICP) depends mostly on changes in mean ICP during cerebrospinal fluid (CSF) infusion studies in patients with NPH, and on changes in cerebral arterial blood volume (AMP(CaBV)) in TBI patients. Further clinical studies will reveal whether AMP(ICP) is a better indicator of clinical severity and outcome than mICP in TBI and NPH patients.	[Carrera, Emmanuel; Kim, Dong-Joo; Castellani, Gianluca; Zweifel, Christian; Czosnyka, Zofia; Kasparowicz, Magdalena; Smielewski, Peter; Pickard, John D.; Czosnyka, Marek] Univ Cambridge, Acad Neurosurg Unit, Dept Clin Neurosci, Addenbrookes Hosp, Cambridge CB2 2QQ, England	Carrera, E (corresponding author), Univ Cambridge, Acad Neurosurg Unit, Dept Clin Neurosci, Addenbrookes Hosp, Level 4,A Block, Cambridge CB2 2QQ, England.	emmanuelcarrera@yahoo.com		Carrera, Emmanuel/0000-0003-0045-5382; Smielewski, Peter/0000-0001-5096-3938	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; SICPA Foundation; Foundation for Polish ScienceFoundation for Polish ScienceEuropean Commission; National Institute of Health ResearchNational Institute for Health Research (NIHR); Biomedical Research Centre; Cambridge University Hospital Foundation; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001237, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This work was supported by the Swiss National Science Foundation, the SICPA Foundation, The Foundation for Polish Science, and the National Institute of Health Research, Biomedical Research Centre, Cambridge University Hospital Foundation.	AASLID R, 1991, STROKE, V22, P1148, DOI 10.1161/01.STR.22.9.1148; AVEZAAT CJ, 1984, CEREBROSPINAL FLUID, P57; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; CARDOSO ER, 1983, J NEUROSURG, V59, P817, DOI 10.3171/jns.1983.59.5.0817; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; CHOPP M, 1980, J NEUROSURG, V53, P516, DOI 10.3171/jns.1980.53.4.0516; CZOSNYKA M, 1988, ACTA NEUROCHIR, V93, P140, DOI 10.1007/BF01402897; CZOSNYKA M, 1990, ACTA NEUROCHIR, V105, P112, DOI 10.1007/BF01669992; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka Marek, 2007, Neurosurg Focus, V22, pE2; DAVSON H, 1970, Brain Behavior and Evolution, V93, P665, DOI 10.1093/brain/93.4.665; Eide PK, 2007, ACTA ANAESTH SCAND, V51, P1273, DOI 10.1111/j.1399-6576.2007.01433.x; Eide PK, 2006, ACTA NEUROCHIR, V148, P1267, DOI 10.1007/s00701-006-0908-0; Eide PK, 2006, ACTA NEUROCHIR, V148, P1151, DOI 10.1007/s00701-006-0896-0; Hakim S, 1965, J Neurol Sci, V2, P307, DOI 10.1016/0022-510X(65)90016-X; HAMER J, 1977, J NEUROSURG, V46, P36, DOI 10.3171/jns.1977.46.1.0036; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Holm S, 2008, MED ENG PHYS, V30, P164, DOI 10.1016/j.medengphy.2007.03.003; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; LANGFITT TW, 1964, J NEUROSURG, V21, P998, DOI 10.3171/jns.1964.21.11.0998; LOFGREN J, 1973, ACTA NEUROL SCAND, V49, P557; PIPER IR, 1993, NEUROSURGERY, V32, P805, DOI 10.1227/00006123-199305000-00014; Ratanalert S, 2004, SURG NEUROL, V61, P429, DOI 10.1016/S0090-3019(03)00579-2; Schuhmann MU, 2008, PEDIATR NEUROSURG, V44, P269, DOI 10.1159/000131675; SZEWCZYKOWSKI J, 1977, J NEUROSURG, V47, P19, DOI 10.3171/jns.1977.47.1.0019; TAKIZAWA H, 1987, NEUROSURGERY, V20, P355, DOI 10.1227/00006123-198703000-00001; VANEIJNDHOVEN JHM, 1986, NEUROSURGERY, V19, P507, DOI 10.1227/00006123-198610000-00004	28	50	51	0	14	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					317	324		10.1089/neu.2009.0951			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800004	19852586				2021-06-18	
J	Gilmer, LK; Ansari, MA; Roberts, KN; Scheff, SW				Gilmer, Lesley K.; Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.			Age-related changes in mitochondrial respiration and oxidative damage in the cerebral cortex of the Fischer 344 rat	MECHANISMS OF AGEING AND DEVELOPMENT			English	Article						Aging; Clark-type electrode; Respiration; Cortex; Mitochondria; Oxidative damage	NON-SYNAPTIC MITOCHONDRIA; TRAUMATIC BRAIN-INJURY; NONSYNAPTIC MITOCHONDRIA; ANTIOXIDANT ENZYMES; DEPENDENT CHANGES; NEUROLOGICAL PERFORMANCE; LIPID-PEROXIDATION; TIME-COURSE; COMPLEX I; VITAMIN-E	This study probed possible age-related changes in mitochondrial bioenergetics in naive Fischer 344 rats. Synaptic and extrasynaptic mitochondria were isolated from the cortex of one hemisphere of young (3-5 months), middle (12-14 months), or aged (22-24 months) rats. Respiration parameters were obtained using a Clarke-type electrode. Aged rats displayed no significant alterations in respiration, indicating mitochondria must be more resilient to the aging process than previously thought. Synaptic mitochondria displayed lower respiration capacities than the extrasynaptic fraction. Aged F344 rats appear capable of normal electron transport chain function without declines in ability to produce ATP. Markers of cortical oxidative damage (3-nitrotyrosine [3-NT],4-hydroxynonenal [4-HNE], and protein carbonyls [PC]) were collected from the post-mitochondrial supernatant (PMS) from the contralateral hemisphere, and from mitochondrial samples following respiration analysis. Age-related increases in PC and 3-NT levels were found in synaptic mitochondria, whereas significant extrasynaptic elevations were only found in middle aged rats. These findings support an age-related increase in oxidative damage in the cortex, while proposing the two fractions of mitochondria are differentially affected by the aging process. Levels of oxidative damage that accumulates in the cortex with age does not appear to significantly impair cortical mitochondrial respiration of F344 rats. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Gilmer, Lesley K.; Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Scheff, Stephen W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 101 Sanders Brown Bldg,800 S Limestone, Lexington, KY 40536 USA.	lesleygilmer@uky.edu; mubeen.ansari@uky.edu; knrobe2@email.uky.edu; sscheff@email.uky.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG21981]; NIH-NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1T32 DA 022738-01]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	This work was supported by NIH grant AG21981 and training grant NIH-NIDA 1T32 DA 022738-01.	AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Armeni T, 2003, J BIOENERG BIOMEMBR, V35, P181, DOI 10.1023/A:1023754305218; Atamna H, 2007, MITOCHONDRION, V7, P297, DOI 10.1016/j.mito.2007.06.001; Baek BS, 1999, ARCH PHARM RES, V22, P361, DOI 10.1007/BF02979058; Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BENZI G, 1992, NEUROBIOL AGING, V13, P361, DOI 10.1016/0197-4580(92)90109-B; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHIU YJD, 1980, EXP GERONTOL, V15, P511, DOI 10.1016/0531-5565(80)90003-0; Cocco T, 2005, FREE RADICAL BIO MED, V38, P796, DOI 10.1016/j.freeradbiomed.2004.11.034; COLEMAN GL, 1977, J GERONTOL, V32, P258, DOI 10.1093/geronj/32.3.258; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Davey GP, 1997, J NEUROCHEM, V69, P2564; Davey GP, 1996, J NEUROCHEM, V66, P1617; Davies SMK, 2001, FREE RADICAL BIO MED, V31, P181, DOI 10.1016/S0891-5849(01)00576-7; Davis M, 1997, ACT NEUR S, V70, P56; DENNIS SC, 1977, BIOCHEM J, V164, P727, DOI 10.1042/bj1640727; DESHMUKH DR, 1982, MECH AGEING DEV, V20, P343, DOI 10.1016/0047-6374(82)90101-4; DESHMUKH DR, 1980, MECH AGEING DEV, V13, P75, DOI 10.1016/0047-6374(80)90131-1; DESHMUKH DR, 1980, J NEUROCHEM, V34, P1219, DOI 10.1111/j.1471-4159.1980.tb09962.x; DogruAbbasoglu S, 1997, MECH AGEING DEV, V98, P177, DOI 10.1016/S0047-6374(97)00082-1; Erecinska M, 1996, BBA-BIOENERGETICS, V1277, P13, DOI 10.1016/S0005-2728(96)00103-X; FERRANDIZ ML, 1994, BRAIN RES, V644, P335, DOI 10.1016/0006-8993(94)91699-3; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; Genova ML, 1997, FEBS LETT, V410, P467; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; GORINI A, 1989, BASIC APPL HISTOCHEM, V33, P139; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMON HJ, 1987, MECH AGEING DEV, V38, P167, DOI 10.1016/0047-6374(87)90076-5; Joseph JA, 2000, MECH AGEING DEV, V116, P141, DOI 10.1016/S0047-6374(00)00128-7; Kaufmann JA, 2001, J NEUROCHEM, V76, P1099, DOI 10.1046/j.1471-4159.2001.00118.x; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kwong LK, 2000, ARCH BIOCHEM BIOPHYS, V373, P16, DOI 10.1006/abbi.1999.1495; LaFrance R, 2005, AGING CELL, V4, P139, DOI 10.1111/j.1474-9726.2005.00156.x; LAI JCK, 1994, METAB BRAIN DIS, V9, P143, DOI 10.1007/BF01999767; LAI JCK, 1977, J NEUROCHEM, V28, P625, DOI 10.1111/j.1471-4159.1977.tb10434.x; LEONG SF, 1984, J NEUROCHEM, V42, P1306, DOI 10.1111/j.1471-4159.1984.tb02788.x; LESLIE SW, 1985, BRAIN RES, V329, P177, DOI 10.1016/0006-8993(85)90523-2; Lesnefsky EJ, 2006, AGEING RES REV, V5, P402, DOI 10.1016/j.arr.2006.04.001; Leuner K, 2007, ANTIOXID REDOX SIGN, V9, P1659, DOI 10.1089/ars.2007.1763; Long JG, 2009, NEUROCHEM RES, V34, P755, DOI 10.1007/s11064-008-9850-2; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Meng QY, 2007, MECH AGEING DEV, V128, P286, DOI 10.1016/j.mad.2006.12.008; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Navarro A, 2005, AM J PHYSIOL-REG I, V289, pR1392, DOI 10.1152/ajpregu.00834.2004; Navarro A, 2004, AM J PHYSIOL-REG I, V286, pR505, DOI 10.1152/ajpregu.00208.2003; Navarro A, 2002, AM J PHYSIOL-REG I, V282, pR985, DOI 10.1152/ajpregu.00537.2001; Navarro A, 2004, AM J PHYSIOL-REG I, V287, pR1244, DOI 10.1152/ajpregu.00226.2004; Navarro A, 2008, AM J PHYSIOL-REG I, V294, pR501, DOI 10.1152/ajpregu.00492.2007; Navarro A, 2007, FRONT BIOSCI-LANDMRK, V12, P1154, DOI 10.2741/2133; Nicholls DG, 2002, INT J BIOCHEM CELL B, V34, P1372, DOI 10.1016/S1357-2725(02)00077-8; O'Donnell E, 1998, NEUROBIOL AGING, V19, P461, DOI 10.1016/S0197-4580(98)00082-7; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Petrosillo G, 2008, NEUROCHEM INT, V53, P126, DOI 10.1016/j.neuint.2008.07.001; Petrosillo G, 2008, REJUV RES, V11, P935, DOI 10.1089/rej.2008.0772; Renes J, 2000, BIOCHEM J, V350, P555, DOI 10.1042/0264-6021:3500555; RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K; Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594; Sahoo A, 1997, INT J DEV NEUROSCI, V15, P939, DOI 10.1016/S0736-5748(97)00049-X; Sandhu SK, 2003, BIOGERONTOLOGY, V4, P19, DOI 10.1023/A:1022473219044; SCOTT ID, 1980, BIOCHEM J, V186, P21, DOI 10.1042/bj1860021; Sharman EH, 2001, NEUROBIOL AGING, V22, P629, DOI 10.1016/S0197-4580(01)00226-3; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Shin CM, 2002, BRAIN RES, V931, P194, DOI 10.1016/S0006-8993(01)03391-1; Shukitt-Hale B, 1998, EXP GERONTOL, V33, P615, DOI 10.1016/S0531-5565(98)00024-2; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; SPANGLER EL, 1994, NEUROBIOL AGING, V15, P319, DOI 10.1016/0197-4580(94)90027-2; Stuart JA, 2005, FREE RADICAL BIO MED, V38, P737, DOI 10.1016/j.freeradbiomed.2004.12.003; Tian LQ, 1998, FREE RADICAL BIO MED, V24, P1477, DOI 10.1016/S0891-5849(98)00025-2; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Van Remmen H, 2001, EXP GERONTOL, V36, P957; VILLA RF, 1989, MECH AGEING DEV, V49, P211, DOI 10.1016/0047-6374(89)90072-9; Walker LM, 2001, TOXICOL SCI, V63, P143, DOI 10.1093/toxsci/63.1.143; WEINDRUCH R, 1991, J GERONTOL, V46, pB87, DOI 10.1093/geronj/46.3.B87; WEINDRUCH RH, 1980, MECH AGEING DEV, V12, P375, DOI 10.1016/0047-6374(80)90070-6; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	83	50	52	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0047-6374	1872-6216		MECH AGEING DEV	Mech. Ageing Dev.	FEB	2010	131	2					133	143		10.1016/j.mad.2009.12.011			11	Cell Biology; Geriatrics & Gerontology	Cell Biology; Geriatrics & Gerontology	574LV	WOS:000275991600009	20080122	Green Accepted			2021-06-18	
J	Bloomfield, ILM; Espie, CA; Evans, JJ				Bloomfield, Imogen L. M.; Espie, Colin A.; Evans, Jonathan J.			Do sleep difficulties exacerbate deficits in sustained attention following traumatic brain injury?	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Arousal; Cognition; Neuropsychological tests; Frontal lobe; Closed head injury; Sleep initiation and maintenance disorders	INSOMNIA; PERFORMANCE; DEPRIVATION; DISTURBANCE; ACTIGRAPHY; DISORDERS; MEDICINE; FAILURES; CRITERIA; QUALITY	Sustained attention has been shown to be vulnerable following traumatic brain injury (TBI). Sleep restriction and disturbances have been shown to negatively affect Sustained attention. Sleep disorders are common but Under-diagnosed after TBI. Thus, it seems possible that Sleep disturbances may exacerbate neuropsychological deficits for a proportion of individuals who have Sustained a TBI. The aim of this prospective Study Was to examine whether poor sleepers post-TBI had poorer sustained and general attentional functioning than good sleepers post-TBI. Retrospective Subjective, prospective Subjective, and objective measures Were used to assess participants sleep. The results showed that the poor sleep group had significantly poorer Sustained attention ability than the good sleep group. The differences on other measures of attention were not significant. This study Supports the use of measures that capture specific components of attention rather than global measures of attention, and highlights the importance of assessing and treating sleep problems in brain injury rehabilitation. (JINS, 2010, 16, 17-25.)	[Bloomfield, Imogen L. M.; Espie, Colin A.; Evans, Jonathan J.] Univ Glasgow, Sect Psychol Med, Glasgow G12 0XH, Lanark, Scotland	Evans, JJ (corresponding author), Univ Glasgow, Fac Med, Sect Psychol Med, Gartnavel Royal Hosp, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	jonathan.evans@clinmed.gla.ac.uk	Sanguansri, Luz/B-6630-2011; Lang, Steven/AAE-8102-2021	Sanguansri, Luz/0000-0003-1908-7604; Lang, Steven/0000-0003-1669-9146; Espie, Colin/0000-0002-1294-8734	NHS Education for Scotland; Dr. Mortimer and Theresa Sackler Foundation	We thank all our participants, Headway. Momentum. and the Community Treatment Centre for Brain Injury, Glasgow for their time and contribution. In addition, we thank two anonymous reviewers and Professor Haaland for their constructive and encouraging comC merits. and NHS Education for Scotland and The Dr. Mortimer and Theresa Sackler Foundation for Supporting the project. The information in this manuscript has never been published either electronically or in print. The authors are not aware of any financial, or other. conflicts of interest.	Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Bastien CH, 2003, J PSYCHOSOM RES, V54, P39, DOI 10.1016/S0022-3999(02)00544-5; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Buysse DJ, 2006, SLEEP, V29, P1155, DOI 10.1093/sleep/29.9.1155; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Dinges D.F., 1991, SLEEP SLEEPINESS PER, P97; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-2005-867080; Edinger JD, 2004, SLEEP, V27, P1567, DOI 10.1093/sleep/27.8.1567; Erman MK, 2001, J CLIN PSYCHIAT, V62, P9; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; GRONWALL DMA, 1974, LANCET, V14, P605; Hauri PJ, 1997, ACTA NEUROL BELG, V97, P113; Hole G., 2003, DESIGN REPORT EXPT; Kamdar BB, 2004, SLEEP MED, V5, P441, DOI 10.1016/j.sleep.2004.05.003; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P1, DOI 10.1016/S0028-3932(01)00086-0; May CP, 1998, J EXP PSYCHOL HUMAN, V24, P363, DOI 10.1037/0096-1523.24.2.363; Morin CM., 1993, INSOMNIA PSYCHOL ASS; *NAT MED ADV PRESS, 1994, MAN ANX INS; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Roth T, 2001, SLEEP MED, V2, P379, DOI 10.1016/S1389-9457(01)00071-5; Sadeh A, 2002, SLEEP MED REV, V6, P113, DOI 10.1053/smrv.2001.0182; Schneider C, 2004, J SLEEP RES, V13, P373, DOI 10.1111/j.1365-2869.2004.00427.x; Spiegel R, 1999, BIOL PSYCHIAT, V45, P435, DOI 10.1016/S0006-3223(98)00042-0; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Versace F, 2006, BIOL PSYCHOL, V71, P248, DOI 10.1016/j.biopsycho.2005.04.003; Wechsler D., 2001, WTAR ADM SCORING MAN; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 1997, WAIS 3 ADM SCORING M; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Zafonte RD, 1996, NEUROREHABILITATION, V7, P189, DOI 10.3233/NRE-1996-7304; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	43	50	51	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2010	16	1					17	25		10.1017/S1355617709990798			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	543LR	WOS:000273579600003	19796442	Green Accepted			2021-06-18	
J	Signoretti, S; Di Pietro, V; Vagnozzi, R; Lazzarino, G; Amorini, AM; Belli, A; D'Urso, S; Tavazzi, B				Signoretti, Stefano; Di Pietro, Valentina; Vagnozzi, Roberto; Lazzarino, Giuseppe; Amorini, Angela M.; Belli, Antonio; D'Urso, Serafina; Tavazzi, Barbara			Transient alterations of creatine, creatine phosphate, N-acetylaspartate and high-energy phosphates after mild traumatic brain injury in the rat	MOLECULAR AND CELLULAR BIOCHEMISTRY			English	Article						Creatine; Energy metabolism; HPLC; Magnetic resonance spectroscopy; N-acetylaspartate; Traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; TRANSPORTER GENE SLC6A8; TEMPORAL WINDOW; MYOCARDIAL-INFARCTION; DEFICIENCY SYNDROME; OXIDATIVE STRESS; SKELETAL-MUSCLE; HEAD-INJURY; METABOLISM; CONCUSSION	In this study, the concentrations of creatine (Cr), creatine phosphate (CrP), N-acetylaspartate (NAA), ATP, ADP and phosphatidylcholine (PC) were measured at different time intervals after mild traumatic brain injury (mTBI) in whole brain homogenates of rats. Anaesthetized animals underwent to the closed-head impact acceleration "weight-drop" model (450 g delivered from 1 m height = mild traumatic brain injury) and were killed at 2, 6, 24, 48 and 120 h after the insult (n = 6 for each time point). Sham-operated rats (n = 6) were used as controls. Compounds of interest were synchronously measured by HPLC in organic solvent deproteinized whole brain homogenates. A reversible decrease of all metabolites but PC was observed, with minimal values recorded at 24 h post-injury (minimum of CrP = 48 h after impact). In particular, Cr and NAA showed a decrease of 44.5 and 29.5%, respectively, at this time point. When measuring NAA in relation to other metabolites, as it is commonly carried out in "in vivo" H-1-magnetic resonance spectroscopy (H-1-MRS), an increase in the NAA/Cr ratio and a decrease in the NAA/PC ratio was observed. Besides confirming a transient alteration of NAA homeostasis and ATP imbalance, our results clearly show significant changes in the cerebral concentration of Cr and CrP after mTBI. This suggests a careful use of the NAA/Cr ratio to measure NAA by H-1-MRS in conditions of altered cerebral energy metabolism. Viceversa, the NAA/PC ratio appears to be a better indicator of actual NAA levels during energy metabolism impairment. Furthermore, our data suggest that, under pathological conditions affecting the brain energetic, the Cr-CrP system is not a suitable tool to buffer possible ATP depletion in the brain, thus supporting the growing indications for alternative roles of cerebral Cr.	[Lazzarino, Giuseppe; D'Urso, Serafina] Univ Catania, Div Biochem & Mol Biol, Dept Chem Sci, I-95125 Catania, Italy; [Signoretti, Stefano] San Camillo Hosp, Div Neurosurg, Dept Neurosci Head & Neck Surg, Rome, Italy; [Di Pietro, Valentina; Amorini, Angela M.; Tavazzi, Barbara] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Vagnozzi, Roberto] Univ Roma Tor Vergata, Dept Neurosci, Chair Neurosurg, Rome, Italy; [Belli, Antonio] Univ Southampton, Div Clin Neurosci, Southampton, Hants, England	Lazzarino, G (corresponding author), Univ Catania, Div Biochem & Mol Biol, Dept Chem Sci, Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@mbox.unict.it	Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; Belli, Antonio/I-3799-2015; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; Belli, Antonio/0000-0002-3211-9933; Di Pietro, Valentina/0000-0001-9430-4723; lazzarino, giuseppe/0000-0002-5917-7279; AMORINI, Angela Maria/0000-0003-3525-9955	Italian Ministry of University and Research (MIUR)Ministry of Education, Universities and Research (MIUR) [PRIN [2007JBHZ5F]]; Catholic University of Rome "Sacro Cuore''; University of Catania	This study has been supported by the research grant PRIN [2007JBHZ5F] of the Italian Ministry of University and Research (MIUR) and in part by research funds of Catholic University of Rome "Sacro Cuore'' and University of Catania.	Almeida LS, 2006, SYNAPSE, V60, P118, DOI 10.1002/syn.20280; BAGORY M, 2007, C P IEEE ENG MED BIO, P3458; BARKER PB, 1993, NMR BIOMED, V6, P89, DOI 10.1002/nbm.1940060114; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bizzi A, 2002, ANN NEUROL, V52, P227, DOI 10.1002/ana.10246; Bogdanis GC, 1996, J APPL PHYSIOL, V80, P876; Bottomley PA, 2001, RADIOLOGY, V219, P411, DOI 10.1148/radiology.219.2.r01ma39411; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Carta M, 2006, NEUROSCIENCE, V139, P1163, DOI 10.1016/j.neuroscience.2006.01.027; Cave AC, 2000, CIRCULATION, V101, P2090, DOI 10.1161/01.CIR.101.17.2090; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; De Stefano N, 2007, NEUROLOGY, V69, P1942, DOI 10.1212/01.wnl.0000291557.62706.d3; Fayed N, 2008, EUR J RADIOL, V67, P427, DOI 10.1016/j.ejrad.2008.02.039; FOLCH J, 1957, J BIOL CHEM, V226, P497; Royes LF, 2008, NEUROCHEM INT, V53, P33, DOI 10.1016/j.neuint.2008.04.008; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Galbraith RA, 2006, BRAIN RES, V1101, P85, DOI 10.1016/j.brainres.2006.05.032; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Geeraerts T, 2006, J NEUROTRAUM, V23, P1059, DOI 10.1089/neu.2006.23.1059; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Headrick JP, 1998, J MOL CELL CARDIOL, V30, P1415, DOI 10.1006/jmcc.1998.0710; HOVDA DA, 1983, INTRACRANIAL PRESSUR, V8, P469; JIMING YE, 1996, J SURG RES, V61, P227; Kagan V E, 1998, Methods Mol Biol, V108, P71; Karatzaferi C, 1999, J CHROMATOGR B, V730, P183, DOI 10.1016/S0378-4347(99)00221-2; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Koga Y, 2005, NEUROSCIENCE, V132, P65, DOI 10.1016/j.neuroscience.2005.01.004; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LAZZARINO G, 1991, J MOL CELL CARDIOL, V23, P13, DOI 10.1016/0022-2828(91)90035-K; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; Lorentzon M, 2007, J CARD FAIL, V13, P230, DOI 10.1016/j.cardfail.2006.11.012; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; Mitsumoto H, 2007, NEUROLOGY, V68, P1402, DOI 10.1212/01.wnl.0000260065.57832.87; MONTASSER A, 1994, J NEUROSURG, V80, P301; NEUBAUER S, 1995, J CLIN INVEST, V95, P1092, DOI 10.1172/JCI117756; Salomons GS, 2001, AM J HUM GENET, V68, P1497, DOI 10.1086/320595; Schiaffino MC, 2005, NEUROGENETICS, V6, P165, DOI 10.1007/s10048-005-0002-4; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Seidl R, 2000, LIFE SCI, V67, P421, DOI 10.1016/S0024-3205(00)00630-5; Smith-Palmer T, 2002, J CHROMATOGR B, V781, P93, DOI 10.1016/S1570-0232(02)00617-7; SODERLUND K, 1991, AM J PHYSIOL, V261, pE737; STATHIS CG, 1994, J APPL PHYSIOL, V76, P1802; Stefanello FM, 2007, INT J DEV NEUROSCI, V25, P473, DOI 10.1016/j.ijdevneu.2007.08.004; Tavazzi B, 2005, CLIN BIOCHEM, V38, P997, DOI 10.1016/j.clinbiochem.2005.08.002; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8	54	50	51	0	7	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-8177	1573-4919		MOL CELL BIOCHEM	Mol. Cell. Biochem.	JAN	2010	333	1-2					269	277		10.1007/s11010-009-0228-9			9	Cell Biology	Cell Biology	534AZ	WOS:000272869200031	19688182				2021-06-18	
J	Gary, KW; Arango-Lasprilla, JC; Ketchum, JM; Kreutzer, JS; Copolillo, A; Novack, TA; Jha, A				Gary, Kelli W.; Arango-Lasprilla, Juan C.; Ketchum, Jessica M.; Kreutzer, Jeffrey S.; Copolillo, Al; Novack, Thomas A.; Jha, Amitabh			Racial Differences in Employment Outcome After Traumatic Brain Injury at 1, 2, and 5 Years Postinjury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Employment; Rehabilitation	DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; ACUTE PREDICTORS; MODEL SYSTEMS; FOLLOW-UP; RETURN; WORK; COMA; RELIABILITY; POPULATION	Objectives: To examine racial differences in competitive employment outcomes at 1, 2, and 5 years after traumatic brain injury (TBI) and to determine whether changes in not competitive employment rates over time differ between blacks and whites with TBI after adjusting for demographic and injury characteristics. Design: Retrospective cohort study. Setting: Sixteen TBI Model System Centers. Participants: Blacks (n=615) and whites (n=1407) with moderate to severe TBI. Interventions: Not applicable. Main Outcome Measure: Employment status dichotomized as competitively employed versus not competitively employed. Results: After adjusting for demographic and injury characteristics. repeated-measures logistic regression indicated that (1) the odds of not being competitively employed were significantly greater for blacks than whites regardless of the follow-up year (all P<.001); (2) the odds of not being competitively employed declined significantly over time for each race (P <=.004); and (3) changes over time in the odds of not being competitively employed versus being competitively employed were not different between blacks and whites (P=.070). In addition, age, discharge FIM and Disability Rating Scale, length of stay in acute and rehabilitation, preinjury employment, sex, education, marital status, and cause of injury were significant predictors of employment status postinjury. Conclusions: Short- and long-term employment is not favorable for people with TBI regardless of race; however, blacks fare worse in employment outcomes compared with whites. Rehabilitation professionals should work to improve return to work for all persons with TBI, with special emphasis on addressing specific needs of blacks.	[Gary, Kelli W.; Arango-Lasprilla, Juan C.; Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23219 USA; [Ketchum, Jessica M.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23219 USA; [Copolillo, Al] Virginia Commonwealth Univ, Dept Occupat Therapy, Richmond, VA 23219 USA; [Novack, Thomas A.] Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA; [Novack, Thomas A.] Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA; [Jha, Amitabh] Univ Colorado, Sch Med, Craig Hosp, Dept Phys Med & Rehabil, Englewood, CO USA	Gary, KW (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, 730 E Broad St,POB 843038, Richmond, VA 23219 USA.	williamsjonk@vcu.edu	Ketchum, Jessica/AAE-8200-2020	Ketchum, Jessica/0000-0002-5566-3691	National Institute on Disability and Rehabilitation Research; U.S. Department of EducationUS Department of Education [H133A070036, H133P040006, H133A070039, H133A060038]	Supported by the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant nos. H133A070036, H133P040006, H133A070039, H133A060038).	Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P467, DOI 10.1097/00001199-200611000-00002; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Molenberghs GVG, 2006, MODELS DISCRETE LONG; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P69; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; State University of New York at Buffalo, 1997, GUID UN DAT SET MED; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; SykesHorn W, 1997, ARCH PHYS MED REHAB, V78, P1327, DOI 10.1016/S0003-9993(97)90305-1; TEASDALE G, 1974, LANCET, V2, P81; *US BUR LAB STAT, 2009, EMPL SIT SUMM; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	41	50	50	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2009	90	10					1699	1707		10.1016/j.apmr.2009.04.014			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	507UA	WOS:000270879400009	19801059				2021-06-18	
J	Oshima, T; Lee, S; Sato, A; Oda, S; Hirasawa, H; Yamashita, T				Oshima, Taku; Lee, Sachiko; Sato, Akinobu; Oda, Shigeto; Hirasawa, Hiroyuki; Yamashita, Toshihide			TNF-alpha contributes to axonal sprouting and functional recovery following traumatic brain injury	BRAIN RESEARCH			English	Article						Axon; Brain injury; Motor function; Regeneration; TNF-alpha	TUMOR-NECROSIS-FACTOR; CLOSED-HEAD INJURY; RAT-BRAIN; MICE LACKING; EXPRESSION; RECEPTOR; PLASTICITY; ELEVATION; RESPONSES; PLASMA	In response to a central nervous system (CNS) injury, microglia and astrocytes release tumor necrosis factor-alpha (TNF-alpha). This proinflammatory cytokine has been implicated in both neuronal cell death and survival. Here, we show that TNF-alpha is involved in the recovery of neuromotor function following traumatic brain injury. Composite neuroscore and accel rotarod were employed to measure neuromotor function. TNF-alpha-deficient (TNF-alpha(-/-)) mice showed no improvement in their locomotor function up to 28 days following controlled cortical impact brain injury. Although collateral sprouting of the unlesioned corticospinal tract, as assessed by retrograde biotin dextran amine labeling, at the cervical spinal cord was observed following injury in the wild-type mice, such changes were not induced in the TNF-alpha(-/-) mice at 4 weeks after injury. These results provide evidence that TNF-alpha is involved in neuroanatomical plasticity and functional recovery following CNS injury. (C) 2009 Elsevier B.V. All rights reserved.	[Lee, Sachiko; Sato, Akinobu; Yamashita, Toshihide] Osaka Univ, Grad Sch Med, Dept Mol Neurosci, Suita, Osaka 5650871, Japan; [Oshima, Taku; Yamashita, Toshihide] Chiba Univ, Grad Sch Med, Dept Neurobiol, Chiba, Japan; [Oshima, Taku; Oda, Shigeto; Hirasawa, Hiroyuki] Chiba Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Chiba, Japan	Yamashita, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yamashita@molneu.med.osaka-u.ac.jp		Yamashita, Toshihide/0000-0003-4559-7018	National Institute of Biomedical InnovationNational Institute of Biomedical Innovation [05-12]	This work was supported by a Research Grant from the National Institute of Biomedical Innovation (05-12) and a Grant-in-Aid for Young Scientists (S) from JSPS to T.Y.	BERMPOHL D, 2007, J CEREB BLOOD FLOW M, V27, P1669; Blight AR, 2002, NAT NEUROSCI, V5, P1051, DOI 10.1038/nn939; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Maier B, 2006, SHOCK, V26, P122, DOI 10.1097/01.shk.0000223127.41641.f4; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17	23	50	59	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 22	2009	1290						102	110		10.1016/j.brainres.2009.07.022			9	Neurosciences	Neurosciences & Neurology	496GU	WOS:000269958600008	19616519				2021-06-18	
J	Atkins, CM; Falo, MC; Alonso, OF; Bramlett, HM; Dietrich, WD				Atkins, Coleen M.; Falo, M. Cristina; Alonso, Ofelia F.; Bramlett, Helen M.; Dietrich, W. Dalton			Deficits in ERK and CREB activation in the hippocampus after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						CREB; Hippocampus; ERK; Traumatic brain injury	FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; PROTEIN-KINASES; RAT; GLUTAMATE; MORPHOLOGY; POTASSIUM; INCREASES; MODERATE	Traumatic brain injury (TBI) activates several protein kinase signaling pathways in the hippocampus that are critical for hippocampal-dependent memory formation. In particular, extracellular signal-regulated kinase (ERK), a protein kinase activated during and necessary for hippocampal-dependent learning, is transiently activated after TBI. However, TBI patients experience hippocampal-dependent cognitive deficits that occur for several months to years after the initial injury. Although basal activation levels of ERK return to sham levels within hours after TBI, we hypothesized that activation of ERK may be impaired after TBI. Adult male Sprague-Dawley rats received either sham surgery or moderate parasagittal fluid-percussion brain injury. At 2, 8, or 12 weeks after surgery, the ipsilateral hippocampi of sham surgery and TBI animals were sectioned into transverse slices. After 2 h of recovery in oxygenated artificial cerebrospinal fluid, the hippocampal slices were stimulated with glutamate or KCl depolarization, then analyzed by western blotting for phosphorylated, activated ERK and one of its downstream effectors, the transcription factor cAMP response element-binding protein (CREB). We found that activation of ERK (p < 0.05) and CREB (p < 0.05) after 30 s of glutamate stimulation or KCl depolarization was decreased in hippocampal slices from animals at 2, 8, or 12 weeks after TBI as compared to sham animals. Basal levels of phosphorylated or total ERK were not significantly altered at 2, 8, or 12 weeks after TBI, although basal levels of phosphorylated CREB were decreased 12 weeks post-trauma. These results suggest that TBI results in chronic signaling deficits through the ERK-CREB pathway in the hippocampus. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Atkins, Coleen M.; Falo, M. Cristina; Alonso, Ofelia F.; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA	Atkins, CM (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, POB 016960 R-48, Miami, FL 33136 USA.	catkins@med.miami.edu		Atkins, Coleen/0000-0003-4718-7493	USAMRMCU.S. Army Medical Research & Materiel Command (USAMRMC) [PR054538]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS056072]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS056072] Funding Source: NIH RePORTER	This work was supported by USAMRMC PR054538 and NIH grant NS056072.	Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P139, DOI 10.1097/01.HTR.0000319930.69343.64; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Baron C, 1996, J NEUROCHEM, V66, P1005; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; COLE AE, 1989, SYNAPSE, V4, P11, DOI 10.1002/syn.890040103; COLLINS DR, 1994, NEUROPHARMACOLOGY, V33, P1055, DOI 10.1016/0028-3908(94)90143-0; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Deshpande LS, 2008, NEUROSCI LETT, V441, P115, DOI 10.1016/j.neulet.2008.05.113; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; SCHWARZBACH E, 2006, HIPPOCAMPUS; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Sindreu CB, 2007, NEURON, V53, P79, DOI 10.1016/j.neuron.2006.11.024; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Trifilieff P, 2006, LEARN MEMORY, V13, P349, DOI 10.1101/lm.80206; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	51	50	51	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 7	2009	459	2					52	56		10.1016/j.neulet.2009.04.064			5	Neurosciences	Neurosciences & Neurology	461GZ	WOS:000267254100002	19416748	Green Accepted			2021-06-18	
J	Puccio, AM; Fischer, MR; Jankowitz, BT; Yonas, H; Darby, JM; Okonkwo, DO				Puccio, Ava M.; Fischer, Michael R.; Jankowitz, Brian T.; Yonas, Howard; Darby, Joseph M.; Okonkwo, David O.			Induced Normothermia Attenuates Intracranial Hypertension and Reduces Fever Burden after Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Fever; Normothermia; Intracranial pressure; Critical care medicine	INTENSIVE-CARE-UNIT; MILD HYPOTHERMIA THERAPY; MODERATE HYPOTHERMIA; HEAD-INJURY; TEMPERATURE; PRESSURE; CHILDREN; ADULTS; RISK	Hyperthermia following a severe traumatic brain injury (TBI) is common, potentiates secondary injury, and worsens neurological outcome. Conventional fever treatment is often ineffective. An induced normothermia protocol, utilizing intravascular cooling, was used to assess the impact on fever incidence and intracranial pressure (ICP) in patients with severe TBI. A comparative cohort study of 21 adult patients with severe TBI (GCS a parts per thousand currency sign 8) treated with induced normothermia [36-36.5A degrees C rectal probe setting; intravascular cooling catheter (CoolLine(A (R)), Alsius Corporation, Irvine, CA)] were matched by age, gender, and severity of injury to 21 historical control severe TBI patients treated with conventional fever control methods. ICP was measured via an external ventricular catheter and time duration for ICP > 25 mmHg was calculated for the initial 72-h monitoring period. Non-parametric rank tests were performed. Mean (+/- SD) or median [range] demographics did not differ between groups [total N = 42 (6 female, 36 male, age 36.4 +/- A 14.8 years and initial GCS 7 [3-8], median and range]. Fever burden in the first 3 days (time > 38A degrees C) in the induced normothermia versus control group was significantly less at 1.6% versus 10.6%, respectively (P = 0.03). Mean ICP for patients with induced normothermia versus control was 12.74 +/- A 4.0 and 16.37 +/- A 6.9 mmHg, respectively. Furthermore, percentage of time with ICP > 25 mmHg was significantly less in the induced normothermia group (P = 0.03). Induced normothermia (fever prophylaxis via intravascular cooling catheter) is effective in reducing fever burden and may offer a means to attenuate secondary injury, as evidenced by a reduction in the intracranial hypertension burden.	[Puccio, Ava M.; Fischer, Michael R.; Jankowitz, Brian T.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Yonas, Howard] Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA; [Darby, Joseph M.] Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15213 USA	Puccio, AM (corresponding author), Univ Pittsburgh, Dept Neurol Surg, 200 Lothrop St,B-4 PUH, Pittsburgh, PA 15213 USA.	puccioam@upmc.edu; fischermr@upmc.edu; jankowitzbt@upmc.edu; HYonas@salud.unm.edu; darbyjm@upmc.edu; okonkwodo@upmc.edu			University of Pittsburgh Brain Trauma Research CenterUniversity of Pittsburgh; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ProNS30318]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P20NS030318, P50NS030318] Funding Source: NIH RePORTER	This research was supported by the University of Pittsburgh Brain Trauma Research Center (C. E. D.; NIH ProNS30318). We thank the nurses and residents for excellent patient care at the University of Pittsburgh Medical Center.	Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Geffroy A, 2004, INTENS CARE MED, V30, P785, DOI 10.1007/s00134-004-2280-y; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; Hoedemaekers CW, 2007, CRIT CARE, V11, DOI 10.1186/cc6104; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Nara I, 1998, ACT NEUR S, V71, P22; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Schwab S, 1997, NEUROLOGY, V48, P762, DOI 10.1212/WNL.48.3.762; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Suz P, 2006, J NEUROSURG ANESTH, V18, P5, DOI 10.1097/01.ana.0000189079.26212.37; Takahashi I, 2000, NEUROL SURG TOKYO, V28, P983; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	31	50	57	0	8	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2009	11	1					82	87		10.1007/s12028-009-9213-0			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	468AU	WOS:000267786400015	19337864	Green Accepted			2021-06-18	
J	Sharma, HS; Ali, S; Tian, ZR; Patnaik, R; Patnaik, S; Lek, P; Sharma, A; Lundstedt, T				Sharma, Hari S.; Ali, Syed; Tian, Z. Ryan; Patnaik, Ranjana; Patnaik, S.; Lek, Per; Sharma, Aruna; Lundstedt, Torbjorn			Nano-Drug Delivery and Neuroprotection in Spinal Cord Injury	JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY			English	Article; Proceedings Paper	1st International Symposium on Nanoneuroscience - Nanoeuroprotection and Nanoeurotoxicity	AUG 20-26, 2007	Killithea, GREECE			Nanowiring; Nano-Drug Delivery; Spinal Cord Injury; Neuroprotection; Blood-Spinal Cord Barrier; Functional Paralysis; Myelin Damage; Titanium Dioxide	TITANIUM-DIOXIDE NANOPARTICLES; SEROTONIN SYNTHESIS INHIBITOR; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; ELECTRON-MICROSCOPY; PARTICULATE MATTER; BARRIER DISRUPTION; TRAUMATIC INJURY; OXIDATIVE STRESS; EDEMA FORMATION	Recently nano-drug delivery to the central nervous system (CNS) has been shown to be more effective than the parent compound by itself. An increased availability of the drug for longer periods to the brain or spinal cord and/or a decrease in the drug metabolism altogether could lead to potentiation of the pharmacological activity of the nano-delivered compounds. However, it is still unclear whether the nanocarriers used to deliver the drugs may itself has any potential neurotoxic activity. Although, nanodrug-delivery appears to be a quite promising therapeutic tool for the future clinical therapy, its advantages and limitations for the routine use of patients still needs to be elucidated. Our laboratory is engaged to study a plethora of potential neuroprotective novel compounds delivered to the CNS using nanowiring techniques following brain or spinal cord trauma. Our investigations show that nanowired drugs, if delivered locally following spinal cord injury achieve better neuroprotection than the parent compounds. This effect of nano-drug delivery appears to be very selective in nature. Thus, a clear differentiation based on the compounds used for nano-drug delivery can be seen on various pathological parameters in spinal cord injury. These observations suggest that nanowiring may itself do not induce neuroprotection, but enhance the neuroprotective ability of compounds after trauma. This review describes some recent advances in nano-drug delivery to the CNS in relation to novel neuroprotective strategies with special emphasis on spinal cord trauma based on our own observations and recent findings from our laboratory investigations.	[Sharma, Hari S.; Sharma, Aruna] Uppsala Univ, Univ Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden; [Lek, Per; Lundstedt, Torbjorn] AcurePharma AB, SE-75643 Uppsala, Sweden; [Ali, Syed] US FDA, Neurochem Lab, Div Neurotoxicol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; [Tian, Z. Ryan] Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA; [Patnaik, Ranjana; Patnaik, S.] Banaras Hindu Univ, Inst Technol, Dept Pharm, Varanasi 221005, Uttar Pradesh, India; [Lundstedt, Torbjorn] Uppsala Univ, Div Organ Chem, Dept Med Chem, SE-75105 Uppsala, Sweden	Lundstedt, T (corresponding author), Uppsala Univ, Univ Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden.		Patnaik, Ranjana/D-1469-2017; Tian, Z. Ryan/R-6671-2016; Sharma, Aruna/D-4430-2011; Patnaik, Ranjana/AAZ-4440-2020	Patnaik, Ranjana/0000-0002-8131-177X; Tian, Z. Ryan/0000-0002-5644-8483; Patnaik, Ranjana/0000-0002-8131-177X			Assie MB, 2007, N-S ARCH PHARMACOL, V375, P241, DOI 10.1007/s00210-007-0162-x; BEGGS JL, 1975, EXP NEUROL, V49, P86, DOI 10.1016/0014-4886(75)90196-X; Betbeder D, 2000, PHARM RES-DORDR, V17, P743, DOI 10.1023/A:1007594602449; Boffetta P, 2004, CANCER CAUSE CONTROL, V15, P697, DOI 10.1023/B:CACO.0000036188.23970.22; Brigger I, 2002, J PHARMACOL EXP THER, V303, P928, DOI 10.1124/jpet.102.039669; Brokx RD, 2002, J CONTROL RELEASE, V78, P115, DOI 10.1016/S0168-3659(01)00491-6; Campbell A, 2005, NEUROTOXICOLOGY, V26, P133, DOI 10.1016/j.neuro.2004.08.003; Carty CL, 2003, J ENVIRON MONITOR, V5, P953, DOI 10.1039/b308488d; CHEN JL, 1988, J OCCUP ENVIRON MED, V30, P937, DOI 10.1097/00043764-198812000-00011; Chi B, 2007, J NANOSCI NANOTECHNO, V7, P668, DOI 10.1166/jnn.2007.147; COSTIGAN S, 2006, TOXICOLOGY NANOPARTI; CSERR HF, 1974, EXP NEUROL, V45, P50, DOI 10.1016/0014-4886(74)90099-5; De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596; Dong W, 2006, NANOMED-NANOTECHNOL, V2, P248, DOI 10.1016/j.nano.2006.10.005; Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Dyer AM, 2002, PHARM RES-DORDR, V19, P998, DOI 10.1023/A:1016418523014; ECETOC, 2006, WORKSH TEST STRAT ES; Elder A, 2006, ENVIRON HEALTH PERSP, V114, P1172, DOI 10.1289/ehp.9030; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; *EUR SCI FDN, 2005, 2005 POL BRIEF ESF E; Fabian E, 2008, ARCH TOXICOL, V82, P151, DOI 10.1007/s00204-007-0253-y; Fang C, 2006, EUR J PHARM SCI, V27, P27, DOI 10.1016/j.ejps.2005.08.002; Gao XL, 2006, BIOMATERIALS, V27, P3482, DOI 10.1016/j.biomaterials.2006.01.038; Gibaud S, 1996, J PHARM SCI, V85, P944, DOI 10.1021/js960032d; Gomes AJ, 2006, PHOTOMED LASER SURG, V24, P514, DOI 10.1089/pho.2006.24.514; Grassian VH, 2007, ENVIRON HEALTH PERSP, V115, P397, DOI 10.1289/ehp.9469; GRIFFITHS IR, 1980, VET CLIN N AM, V10, P131, DOI 10.1016/S0195-5616(80)50008-2; GRIFFITHS IR, 1983, J NEUROL SCI, V58, P335, DOI 10.1016/0022-510X(83)90093-X; GRIFFITHS IR, 1978, ACTA NEUROPATHOL, V43, P205; Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012; Kane RS, 2007, BIOTECHNOL PROGR, V23, P316, DOI 10.1021/bp060388n; Kipp JE, 2004, INT J PHARMACEUT, V284, P109, DOI 10.1016/j.ijpharm.2004.07.019; Kreuter J, 2004, J NANOSCI NANOTECHNO, V4, P484, DOI 10.1166/jnn.2003.077; Kreuter J, 2003, PHARM RES-DORDR, V20, P409, DOI 10.1023/A:1022604120952; Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8; Lockman PR, 2004, J DRUG TARGET, V12, P635, DOI 10.1080/10611860400015936; Lockman PR, 2003, PHARM RES-DORDR, V20, P705, DOI 10.1023/A:1023492015851; Michaelis K, 2006, J PHARMACOL EXP THER, V317, P1246, DOI 10.1124/jpet.105.097139; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Muller J, 2005, TOXICOL APPL PHARM, V207, P221, DOI 10.1016/j.taap.2005.01.008; Na K, 2006, EUR J PHARM SCI, V27, P115, DOI 10.1016/j.ejps.2005.08.012; Niidome T, 2006, J CONTROL RELEASE, V114, P343, DOI 10.1016/j.jconrel.2006.06.017; NOBLE LJ, 1987, BRAIN RES, V424, P177, DOI 10.1016/0006-8993(87)91208-X; NOBLE LJ, 1988, EXP NEUROL, V99, P567, DOI 10.1016/0014-4886(88)90173-2; Oberdorster E, 2004, ENVIRON HEALTH PERSP, V112, P1058, DOI 10.1289/ehp.7021; Olivier JC, 1999, PHARMACEUT RES, V16, P1836, DOI 10.1023/A:1018947208597; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Peracchia MT, 1999, J CONTROL RELEASE, V60, P121, DOI 10.1016/S0168-3659(99)00063-2; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Rapoport S. I., 1976, BLOOD BRAIN BARRIER; REULEN HJ, 1976, BRIT J ANAESTH, V48, P741, DOI 10.1093/bja/48.8.741; RHODIN JAG, 1968, J ULTRA MOL STRUCT R, V25, P452, DOI 10.1016/S0022-5320(68)80098-X; Ricci-Junior E, 2006, J MICROENCAPSUL, V23, P523, DOI 10.1080/02652040600775525; ROSS R, 2007, TOWN CTRY MAG, V68; Saez A, 2000, EUR J PHARM BIOPHARM, V50, P379, DOI 10.1016/S0939-6411(00)00125-9; Schins RPF, 2004, TOXICOL APPL PHARM, V195, P1, DOI 10.1016/j.taap.2003.10.002; Schins RPF, 2002, CHEM RES TOXICOL, V15, P1166, DOI 10.1021/tx025558u; Seki J, 2004, INT J PHARM, V273, P75, DOI 10.1016/j.ijpharm.2003.12.022; SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8; SENIOR J, 1982, FEBS LETT, V145, P109, DOI 10.1016/0014-5793(82)81216-7; SHAPIRO K, 1977, SURG NEUROL, V7, P275; Sharma, 2004, BLOOD SPINAL CORD BR, P437; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1929; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5055, DOI 10.1166/jnn.2009.GR09; Sharma HS, 2008, EXPERT OPIN PHARMACO, V9, P2773, DOI [10.1517/14656566.9.16.2773, 10.1517/14656566.9.16.2773 ]; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P197, DOI 10.1196/annals.1403.014; Sharma HS, 2007, NANOMEDICINE-UK, V2, P753, DOI 10.2217/17435889.2.6.753; Sharma HS, 2007, PROG BRAIN RES, V162, P245, DOI 10.1016/S0079-6123(06)62013-X; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1841; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5073, DOI 10.1166/jnn.2009.GR10; Sharma Hari Shanker, 2008, Central Nervous System Agents in Medicinal Chemistry, V8, P143; SHARMA HS, 1995, NEUROSCI RES, V21, P241, DOI 10.1016/0168-0102(94)00855-A; Sharma HS, 2005, ANN NY ACAD SCI, V1053, P407, DOI 10.1196/annals.1344.036; Sharma HS, 2006, J NEURAL TRANSM, V113, P497, DOI 10.1007/s00702-005-0406-1; Sharma HS, 2006, J NEURAL TRANSM, V113, P521, DOI 10.1007/s00702-005-0405-2; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; Sharma HS, 1995, PROG BRAIN RES, V104, P401; Sharma HS, 2000, ACTA NEUROCHIR SUPPL, V76, P297; SHARMA HS, 1995, RESTOR NEUROL NEUROS, V7, P207, DOI 10.3233/RNN-1994-7403; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; SHARMA HS, 1991, J NEUROL SCI, V102, P150, DOI 10.1016/0022-510X(91)90063-D; SHARMA HS, 1993, ACTA NEUROPATHOL, V85, P145; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Tomazic-Jezic VJ, 2001, J BIOMED MATER RES, V55, P523, DOI 10.1002/1097-4636(20010615)55:4<523::AID-JBM1045>3.0.CO;2-G; Umbreit T, 2007, TOXICOLOGIST, V96, P287; Wang JX, 2007, TOXICOL LETT, V168, P176, DOI 10.1016/j.toxlet.2006.12.001; Warheit DB, 2007, TOXICOLOGY, V230, P90, DOI 10.1016/j.tox.2006.11.002; Winkler T, 1998, SPINAL CORD MONITORING, P283; Xia T, 2006, NANO LETT, V6, P1794, DOI 10.1021/nl061025k; Yao CP, 2006, EPILEPSIA, V47, P1822, DOI 10.1111/j.1528-1167.2006.00814.x; YASHON D, 1973, J NEUROSURG, V38, P693, DOI 10.3171/jns.1973.38.6.0693; Zhao DB, 2006, SMALL, V2, P879, DOI 10.1002/smll.200500317	94	50	50	1	36	AMER SCIENTIFIC PUBLISHERS	VALENCIA	26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA	1533-4880	1533-4899		J NANOSCI NANOTECHNO	J. Nanosci. Nanotechnol.	AUG	2009	9	8					5014	5037		10.1166/jnn.2009.GR04			24	Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	470QO	WOS:000267994100068	19928182				2021-06-18	
J	Li, XF; Dai, LY				Li, Xin-Feng; Dai, Li-Yang			Three-Dimensional Finite Element Model of the Cervical Spinal Cord Preliminary Results of Injury Mechanism Analysis	SPINE			English	Article						spinal cord injuries; cervical spine; finite element model; injury mechanism	WHITE-MATTER; SPONDYLOTIC MYELOPATHY; GRAY-MATTER; TRAUMA; TISSUE; DAMAGE; INSUFFICIENCY; BIOMECHANICS; SENSITIVITY; ELASTICITY	Study Design. A three-dimensional finite element investigation. Objectives. To create a three-dimensional finite element model of the cervical spinal cord enlargement and to simulate a hyperextension injury of the cervical cord. Summary of Background Data. Experimental studies are difficult to simulate the complex mechanism of spinal cord injuries. The introduction of three-dimensional modeling technique into neurotrauma studies is essential to further understand mechanical behavior of the nerve tissue during traumatic injuries. Methods. Geometrical reconstruction of cervical spinal cord enlargement was developed based on the morphologic features of each segment of the fresh human cervical cord. After the validation of the model, the pinching condition in the hyperextension injuries was simulated with compressive and extension forces applied on the cervical enlargement model. The average von Mises stress of the 9 anatomic regions, such as anterior funiculus, lateral part of the lateral funiculus, medial part of the lateral funiculus, lateral part of the posterior funiculus, medial part of the posterior funiculus, anterior horn, the bottom of anterior horn, the apex of posterior horn, the cervix cornu posterioris, and caput cornu posterioris was recorded. Results. The force-displacement response of the spinal cord under compression and axial tension loading was close to the experimental results reported in the literature. The stress distribution of the spinal cord according to the numerical simulation and the morphologic features of the in vivo experiment were also in close agreement. Hyperextension injury simulation showed high localized stress at the anterior and posterior horn in the gray matter. Conclusion. The finite element method as a three-dimensional modeling technique can improve the understanding of the biomechanical behavior of the spinal cord. The results of hyperextension injury simulation of the cervical spinal cord probably account for the predominance of the hand weakness in patients with central cord injury.	[Li, Xin-Feng; Dai, Li-Yang] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Orthopaed Surg, Shanghai 200092, Peoples R China; [Li, Xin-Feng] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Orthopaed Surg, Shanghai 200092, Peoples R China	Dai, LY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Orthopaed Surg, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.	chinaspine@163.com	Dai, Li-Yang/C-7121-2009		National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [30672144, 39270663]; The Youth Science Funds of Shanghai Municipal Health Bureau [2008Y059]	National Natural Science Foundation funds were received in support of this work. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.; Supported by National Natural Science Foundation of China (30672144, 39270663) and The Youth Science Funds of Shanghai Municipal Health Bureau (2008Y059).	Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; BENOIST G, 1979, J NEUROSURG, V51, P834, DOI 10.3171/jns.1979.51.6.0834; BERQUIST TH, 1986, IMAGING ORTHOPEDIC T, P91; Bilston LE, 1996, ANN BIOMED ENG, V24, P67; Carlson GD, 2003, J BONE JOINT SURG AM, V85A, P86, DOI 10.2106/00004623-200301000-00014; CHANG GL, 1981, J TRAUMA, V21, P807, DOI 10.1097/00005373-198109000-00011; CHANG GL, 1988, J BIOMECH ENG-T ASME, V110, P115, DOI 10.1115/1.3108415; Dai L, 1997, INT ORTHOP, V21, P380; DOHRMANN GJ, 1971, J NEUROSURG, V35, P263, DOI 10.3171/jns.1971.35.3.0263; DOHRMANN GJ, 1978, J NEUROSURG, V48, P993, DOI 10.3171/jns.1978.48.6.0993; Fukushima M, 2006, SPINE, V31, P903, DOI 10.1097/01.brs.0000209257.47140.fc; Galle B, 2007, J BIOMECH, V40, P3029, DOI 10.1016/j.jbiomech.2007.03.014; Greaves CY, 2008, ANN BIOMED ENG, V36, P396, DOI 10.1007/s10439-008-9440-0; HUNG TK, 1982, SURG NEUROL, V17, P213, DOI 10.1016/0090-3019(82)90284-1; HUNG TK, 1981, J BIOMECH, V14, P269, DOI 10.1016/0021-9290(81)90072-5; Ichihara K, 2003, J NEUROSURG, V99, P278, DOI 10.3171/spi.2003.99.3.0278; Ichihara K, 2001, J NEUROTRAUM, V18, P361, DOI 10.1089/08977150151071053; Kameyama T, 1996, SPINE, V21, P1285, DOI 10.1097/00007632-199606010-00001; Kato Y, 2008, J NEUROSURG-SPINE, V8, P436, DOI 10.3171/SPI/2008/8/5/436; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Ko HY, 2004, SPINAL CORD, V42, P35, DOI 10.1038/sj.sc.3101538; Levine DN, 1997, J NEUROL NEUROSUR PS, V62, P334, DOI 10.1136/jnnp.62.4.334; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Maiman D J, 1989, J Spinal Disord, V2, P14; Maiman D J, 1989, J Spinal Disord, V2, P6; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; MIYASAKA K, 1992, Brain and Nerve (Tokyo), V44, P241; Ozawa H, 2001, J NEUROSURG, V95, P221, DOI 10.3171/spi.2001.95.2.0221; PANJABI M, 1988, SPINE, V13, P838, DOI 10.1097/00007632-198807000-00024; RAYNOR RB, 1985, SPINE, V10, P193, DOI 10.1097/00007632-198504000-00002; RAYNOR RB, 1968, J TRAUM, V8, P597, DOI 10.1097/00005373-196807000-00011; REBHUN WC, 1984, COMP CONT EDUC PRACT, V6, pS396; SCHNEIDER R, 1961, J NEUROSURG, V18, P348, DOI 10.3171/jns.1961.18.3.0348; SCHNEIDER RC, 1954, J NEUROSURG, V11, P546, DOI 10.3171/jns.1954.11.6.0546; SCHNEIDER RC, 1959, NEUROLOGY, V9, P643, DOI 10.1212/WNL.9.10.643; Scifert Jeffrey, 2002, Pain Physician, V5, P394; SEIBERT CE, 1981, AM J ROENTGENOL, V136, P777, DOI 10.2214/ajr.136.4.777; Seki T, 2002, NEUROSURGERY, V50, P1075, DOI 10.1097/00006123-200205000-00024; SHERMAN JL, 1990, AM J NEURORADIOL, V11, P369; SHIMOMURA Y, 1968, J NEUROSURG, V28, P565, DOI 10.3171/jns.1968.28.6.0565; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; SUZUKI F, 1985, Neurological Surgery, V13, P391; TAYLOR AR, 1951, J BONE JOINT SURG BR, V33, P543; TUNTURI AR, 1978, J NEUROSURG, V48, P975, DOI 10.3171/jns.1978.48.6.0975; Wilcox RK, 2004, EUR SPINE J, V13, P481, DOI 10.1007/s00586-003-0625-9; Wilcox RK, 2003, J BONE JOINT SURG AM, V85A, P2184, DOI 10.2106/00004623-200311000-00020	47	50	60	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	MAY 15	2009	34	11					1140	1147		10.1097/BRS.0b013e31819e2af1			8	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	447VO	WOS:000266220300004	19444060				2021-06-18	
J	Zazulia, AR; Videen, TO; Powers, WJ				Zazulia, Allyson R.; Videen, Tom O.; Powers, William J.			Transient Focal Increase in Perihematomal Glucose Metabolism After Acute Human Intracerebral Hemorrhage	STROKE			English	Article						intracerebral hemorrhage; glucose metabolism; fluorodeoxyglucose; positron emission tomography	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; FDG LUMPED CONSTANT; AUTOMATED ALGORITHM; DEOXYGLUCOSE METHOD; PET; GLUTAMATE; ISCHEMIA; RAT; MICRODIALYSIS	Background and Purpose-Progressive perihematomal cell death over 3 to 4 days has been described after experimental intracerebral hemorrhage (ICH). We investigated whether progressive perihematomal damage occurs in human subjects by measuring relative changes in regional cerebral glucose metabolism with (18)F-fluorordeoxyglucose (FDG) positron emission tomography at multiple time points during the first week after ICH. Methods-Thirteen subjects with a median hematoma volume of 22 cm(3) were studied 1.0 +/- 0.3, 2.9 +/- 0.8, and 6.7 +/- 1.6 days after ICH. Normalized mean counts in 5 concentric annular 2-mm-thick perihematomal volumes-of-interest (VOIs) were compared to the initial study. Next, automated searches with 0.5 to 5.0 mL spherical VOIs identified maximum focal changes in normalized counts compared to the initial study. Results-No annular or focal decrease in perihematomal FDG uptake developed. Instead, FDG uptake significantly increased at session #2 in the first 3 2-mm annular VOIs (9.2%+/- 14.2, 7.8%+/- 11.3, 5.9%+/- 9.0), returning to baseline at session #3. The VOI search identified focal regions of increased perihematomal FDG uptake relative to the contralateral control hemispheres in 6 subjects, which accounted for the annular increase. Conclusion-Perihematomal glucose metabolism increased transiently in a subset of patients 2 to 4 days after acute ICH. These transient focal increases in glucose metabolism occurring in the brain after acute ICH demonstrate that there are ongoing processes in response to injury that last for days. Although further studies are needed to elucidate their pathophysiology, these processes may be indicative of a prolonged window for intervention to improve neurological outcome. (Stroke. 2009; 40: 1638-1643.)	[Zazulia, Allyson R.; Videen, Tom O.; Powers, William J.] Washington Univ, Dept Neurol & Neurol Surg, St Louis, MO 63110 USA; [Zazulia, Allyson R.; Videen, Tom O.; Powers, William J.] Washington Univ, Dept Radiol, St Louis, MO 63110 USA; [Powers, William J.] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA	Zazulia, AR (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Campus Box 8111, St Louis, MO 63110 USA.	zazuliaa@neuro.wustl.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35966, NS044885] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS044885, P01NS035966, P50NS035966] Funding Source: NIH RePORTER		Ardizzone TD, 2004, STROKE, V35, P2587, DOI 10.1161/01.STR.0000143451.14228.ff; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bleeker-Rovers CP, 2008, Q J NUCL MED MOL IM, V52, P17; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Chapman AG, 1998, PROG BRAIN RES, V116, P371, DOI 10.1016/S0079-6123(08)60449-5; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Hasselbalch SG, 1998, J CEREBR BLOOD F MET, V18, P154, DOI 10.1097/00004647-199802000-00005; Hattori N, 2004, J NUCL MED, V45, P775; HUTCHINS GD, 1984, J CEREBR BLOOD F MET, V4, P35, DOI 10.1038/jcbfm.1984.5; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P73; Mackenzie J M, 1999, J Stroke Cerebrovasc Dis, V8, P1, DOI 10.1016/S1052-3057(99)80032-9; Meltzer CC, 2000, EPILEPSIA, V41, P193, DOI 10.1111/j.1528-1157.2000.tb00139.x; Miller CM, 2007, NEUROCRIT CARE, V6, P22, DOI 10.1385/NCC:6:1:22; NAKAI H, 1987, J CEREBR BLOOD F MET, V7, P640, DOI 10.1038/jcbfm.1987.117; Qureshi AI, 2003, CRIT CARE MED, V31, P1482, DOI 10.1097/01.CCM.0000063047.63862.99; REIVICH M, 1979, CIRC RES, V44, P127, DOI 10.1161/01.RES.44.1.127; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Spence AM, 1998, J NUCL MED, V39, P440; SUDA S, 1990, J CEREBR BLOOD F MET, V10, P499, DOI 10.1038/jcbfm.1990.92; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tsuchida T, 1999, J NUCL MED, V40, P1441; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Videen TO, 1999, J COMPUT ASSIST TOMO, V23, P248, DOI 10.1097/00004728-199903000-00014; WISNIEWSKI H, 1961, Acta Med Pol, V2, P379; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005	30	50	50	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	MAY	2009	40	5					1638	1643		10.1161/STROKEAHA.108.536037			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	438UB	WOS:000265579800018	19286594	Bronze			2021-06-18	
J	Baguley, IJ; Nott, MT; Slewa-Younan, S; Heriseanu, RE; Perkes, IE				Baguley, Ian J.; Nott, Melissa T.; Slewa-Younan, Shameran; Heriseanu, Roxana E.; Perkes, Iain E.			Diagnosing Dysautonomia After Acute Traumatic Brain Injury: Evidence for Overresponsiveness to Afferent Stimuli	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Autonomic nervous system; Brain injuries; Diagnosis; Heart rate; Rehabilitation	HEART-RATE-VARIABILITY; PAROXYSMAL AUTONOMIC INSTABILITY; MANAGEMENT; DYSREGULATION; DYSFUNCTION; PREDICTOR; DYSTONIA; DEATH	Baguley IJ, Nott MT, Slewa-Younan S, Heriseanu RE, Perkes IE. Diagnosing dysautonomia after acute traumatic brain injury: evidence for overresponsiveness to afferent stimuli. Arch Phys Med Reliabil 2009:90:580-6. Objective: To differentiate between traumatic brain injury (TBI) subjects with normal and elevated autonomic activity by quantifying cardiac responsivity to nociceptive stimuli and to determine the utility of heart rate variability (HRV) and event-related heart rate changes in diagnosing dysautonomia. Design: Prospective cohort study. Setting: Intensive care unit in a tertiary metropolitan trauma center. Participants: Adults (N=27) with TBI recruited from 79 consecutive TBI admissions comprising 16 autonomically aroused and 11 control subjects matched by age, sex, and injury severity. Interventions: None. Main Outcome Measures: Immediate: pattern of autonomic changes indexed by HRV and event-related heart rate after nociceptive stimuli. Six months: length of stay, Glasgow Coma Scale, and Disability Rating Scale. Results: Heart rate changes (for both HRV and event-related heart rate) were associated with the diagnostic group and 6-month outcome when evaluated pre- and poststimulus but not when evaluated at rest. When assessed on day 7 postinjury, the comparison of HRV and heart rate parameters suggested an overresponsivity to nociceptive stimuli in dysautonomic subjects. These subjects showed a 2-fold increase in mean heart rate relative to subjects with sympathetic arousal of short duration (16% vs 8%), and a 6-fold increase over nonaroused control subjects. Data suggest that post-TBI sympathetic arousal is a spectrum disorder comprising, at one end, a short-duration syndrome and, at the other end, a dramatic, severe sympathetic and motor overactivity syndrome that continued for many months postinjury and associated with a significantly worse 6-month outcome. These findings suggest that it is not the presence of reactivity per se but rather the failure of processes to control for overreactivity that contributes to dysautonomic storming. Conclusions: This study provides empirical evidence that dysautonomic subjects show overresponsiveness to afferent stimuli. Findings from this study suggest an evidence-driven revision of diagnostic criteria and a simple clinical algorithm for the improved identification of cases.	[Baguley, Ian J.; Nott, Melissa T.; Slewa-Younan, Shameran; Heriseanu, Roxana E.] Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia; [Baguley, Ian J.; Slewa-Younan, Shameran] Univ Sydney, Rehabil Studies Unit, Fac Med, Sydney, NSW 2006, Australia; [Perkes, Iain E.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Anaesthesia, Cambridge CB2 2QQ, England; [Perkes, Iain E.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia	Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Perkes, Iain/J-7001-2017; Baguley, Ian J/K-6878-2013; Nott, Melissa T/M-6778-2018	Perkes, Iain/0000-0001-8028-9032; Baguley, Ian J/0000-0001-5650-3705; Nott, Melissa T/0000-0001-7088-5826	Motor Accidents Authority of New South wales, Australia [02/836]	Supported by the Motor Accidents Authority of New South wales, Australia (grant no. 02/836).	ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 2008, SEMIN NEUROL, V28, P716, DOI 10.1055/s-0028-1105971; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Bakeman R, 2005, BEHAV RES METHODS, V37, P379, DOI 10.3758/BF03192707; BHIGJEE AI, 1985, J NEUROL SCI, V71, P77, DOI 10.1016/0022-510X(85)90038-3; Bilotta F, 2008, NEUROCRIT CARE, V8, P241, DOI 10.1007/s12028-007-9012-4; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Diesing TS, 2006, MOVEMENT DISORD, V21, P868, DOI 10.1002/mds.20831; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Jennett BT, 1981, MANAGEMENT HEAD INJU, P84; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Lemke DM, 2007, CRIT CARE NURSE, V27, P30; Lemke Denise M, 2004, J Neurosci Nurs, V36, P4; Leone M, 2004, ANESTH ANALG, V99, P1193, DOI 10.1213/01.ANE.0000132546.79769.91; Norris PR, 2006, ANN SURG, V243, P804, DOI 10.1097/01.sla.0000219642.92637.fd; Oh Su Jin, 2007, Korean Journal of Internal Medicine, V22, P51; PENFIELD W, 1954, AUTONOMIC SEIZURES E, P412; Rabinstein AA, 2004, ARCH NEUROL-CHICAGO, V61, P1625, DOI 10.1001/archneur.61.10.1625-a; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Rapenne T, 2000, ANESTH ANALG, V91, P329, DOI 10.1097/00000539-200008000-00018; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; Sacha J, 2005, J ELECTROCARDIOL, V38, P47, DOI 10.1016/j.jelectrocard.2004.09.015; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; Srinivasan S, 2007, CLIN AUTON RES, V17, P378, DOI 10.1007/s10286-007-0428-x; Tabachnick BG, 2007, USING MULTIVARIATE S; Tong CY, 2000, ANESTH ANALG, V91, P1450, DOI 10.1097/00000539-200012000-00028; Wang VY, 2008, J TRAUMA, V64, P500, DOI 10.1097/TA.0b013e31804a5738; Wijnen VJM, 2006, CLIN NEUROPHYSIOL, V117, P1794, DOI 10.1016/j.clinph.2006.03.006; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010	41	50	55	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2009	90	4					580	586		10.1016/j.apmr.2008.10.020			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	432TD	WOS:000265156200007	19345772				2021-06-18	
J	Jyoti, A; Sethi, P; Sharma, D				Jyoti, Amar; Sethi, Pallavi; Sharma, Deepak			Curcumin protects against electrobehavioral progression of seizures in the iron-induced experimental model of epileptogenesis	EPILEPSY & BEHAVIOR			English	Article						Iron-induced epilepsy; Curcumin; Video/EEG recording; Seizures; Epilepsy; Epileptogenesis; Post-traumatic epilepsy	TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; NEUROTROPHIC FACTOR; LIPID-PEROXIDATION; RAT HIPPOCAMPUS; KINASE-C; COGNITIVE FUNCTION; DIETARY CURCUMIN; EPILEPSY; ACID	The purpose of the study was to investigate whether dietary intake of curcumin can inhibit the onset and progression of seizures and their associated pathophysiology in experimental FeCl3-induced epileptogenesis. Curcumin was considered for this study because it can cross the blood-brain barrier and bind redox-active metal ions. It is also well known for its antioxidative, anticancer, and anti-inflammatory properties. In the present study, seizures were induced by intracortical injection of FeCl3 into young rats. Synchronized video/EEG recordings were obtained to diagnose the progression of seizures. Short-term treatment with a curcumin-supplemented diet (1500 ppm w/w) significantly inhibited the onset of grade III and IV seizures in rats with iron-induced epilepsy. The lower dose of curcumin (500 ppm) was not effective in inhibiting grade III seizures, but retarded the onset and progression of generalized seizures. The seizure-suppressing potential of curcumin is explained by the observed biochemical, behavioral, and ultrastructural results. Our results indicate that curcumin significantly prevents generalization of electroclinical seizure activity as well as the pathogenesis associated with iron-induced epileptogenesis. (C) 2009 Published by Elsevier Inc.	[Jyoti, Amar; Sethi, Pallavi; Sharma, Deepak] Jawaharlal Nehru Univ, Sch Life Sci, Neurobiol Lab, New Delhi 110067, India; [Sethi, Pallavi] Jamia Millia Islamia, Dept Biosci, New Delhi 110025, India	Sharma, D (corresponding author), Jawaharlal Nehru Univ, Sch Life Sci, Neurobiol Lab, New Delhi 110067, India.	dpak57@hotmail.com			Council for Scientific and Industrial Research (CSIR)Council of Scientific & Industrial Research (CSIR) - India	Author Amar Jyoti thankfully acknowledges the financial assistance extended by the Council for Scientific and Industrial Research (CSIR) through a junior Research Fellowship and Senior Research Fellowship. We are thankful to Professor Rameshwar Singh for his scientific guidance and constructive comments during this project. The authors are also thankful to staff at the SAIF facility of AIMS for help in electron microscopy.	AKAGAWA K, 1979, J NEUROCHEM, V32, P269, DOI 10.1111/j.1471-4159.1979.tb04544.x; AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; Bala K, 2006, BIOGERONTOLOGY, V7, P81, DOI 10.1007/s10522-006-6495-x; Baum L, 2004, J ALZHEIMERS DIS, V6, P367; Bolton MM, 2000, PROG BRAIN RES, V128, P203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunbech L, 2002, DRUGS, V62, P593, DOI 10.2165/00003495-200262040-00004; Deloncle R, 2001, EXP GERONTOL, V36, P231, DOI 10.1016/S0531-5565(00)00214-X; Fabene PF, 2006, NEUROBIOL DIS, V21, P80, DOI 10.1016/j.nbd.2005.06.013; Farooqui AA, 1998, CELL MOL NEUROBIOL, V18, P599, DOI 10.1023/A:1020261600498; Fiske CH, 1925, J BIOL CHEM, V66, P375; Frautschy SA, 2001, NEUROBIOL AGING, V22, P993, DOI 10.1016/S0197-4580(01)00300-1; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Kelloff GJ, 1996, J CELL BIOCHEM, P72; Kempaiah RK, 2006, J NUTR BIOCHEM, V17, P471, DOI 10.1016/j.jnutbio.2005.09.005; Kharlamov EA, 2003, EPILEPSY RES, V56, P185, DOI 10.1016/j.eplepsyres.2003.09.005; Khopde SM, 1998, FREE RADICAL BIO MED, V25, P66, DOI 10.1016/S0891-5849(98)00046-X; Komatsu M, 2000, EPILEPSIA, V41, P1091, DOI 10.1111/j.1528-1157.2000.tb00312.x; Kuhad A, 2007, EUR J PHARMACOL, V576, P34, DOI 10.1016/j.ejphar.2007.08.001; Kumar A, 2007, J MED FOOD, V10, P486, DOI 10.1089/jmf.2006.076; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; Lim GP, 2001, J NEUROSCI, V21, P8370; Lin JK, 2007, ADV EXP MED BIOL, V595, P227; LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; Mahmmoud YA, 2007, BRIT J PHARMACOL, V150, P200, DOI 10.1038/sj.bjp.0706970; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; Masuda T, 2001, J AGR FOOD CHEM, V49, P2539, DOI 10.1021/jf001442x; Mori A, 1998, EPILEPSY RES, V30, P153, DOI 10.1016/S0920-1211(97)00097-1; Mori A, 2004, ACTA MED OKAYAMA, V58, P111; MORIWAKI A, 1992, ELECTROEN CLIN NEURO, V83, P281, DOI 10.1016/0013-4694(92)90087-X; MORIWAKI A, 1990, NEUROSCI LETT, V110, P72, DOI 10.1016/0304-3940(90)90789-C; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; RACINE RJ, 1972, BRAIN RES, V47, P262, DOI 10.1016/0006-8993(72)90268-5; REDDY ACP, 1994, FOOD CHEM TOXICOL, V32, P279; RENKAWEK K, 1992, EPILEPSIA, V33, P58, DOI 10.1111/j.1528-1157.1992.tb02283.x; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; Sanchez DJ, 1998, PHYSIOL BEHAV, V63, P345, DOI 10.1016/S0031-9384(97)00433-2; Scheff SW, 2006, J ALZHEIMERS DIS, V9, P101; Sethi P, 2008, NEUROTOXICOLOGY, V29, P1069, DOI 10.1016/j.neuro.2008.08.005; SHARMA D, 1993, NEUROBIOL AGING, V14, P319, DOI 10.1016/0197-4580(93)90117-T; Sharma Varsha, 1999, Indian Journal of Experimental Biology, V37, P468; Shin HJ, 2007, NEUROSCI LETT, V416, P49, DOI 10.1016/j.neulet.2007.01.060; Shukla PK, 2008, NEUROCHEM RES, V33, P1036, DOI 10.1007/s11064-007-9547-y; SINGH R, 1990, EPILEPSIA, V31, P15, DOI 10.1111/j.1528-1157.1990.tb05354.x; Sng JCG, 2006, EUR J NEUROSCI, V23, P1269, DOI 10.1111/j.1460-9568.2006.04641.x; Sreejayan, 1997, J PHARM PHARMACOL, V49, P105, DOI 10.1111/j.2042-7158.1997.tb06761.x; Stadtman E R, 1992, EXS, V62, P64; Sumanont Y, 2007, BIOL PHARM BULL, V30, P1732, DOI 10.1248/bpb.30.1732; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu RM, 1996, ANN NY ACAD SCI, V786, P379, DOI 10.1111/j.1749-6632.1996.tb39078.x; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200	58	50	54	1	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	FEB	2009	14	2					300	308		10.1016/j.yebeh.2008.11.011			9	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	412ZB	WOS:000263761600005	19100339				2021-06-18	
J	Horneman, G; Emanuelson, I				Horneman, Goran; Emanuelson, Ingrid			Cognitive outcome in children and young adults who sustained severe and moderate traumatic brain injury 10 years earlier	BRAIN INJURY			English	Article						Children; traumatic brain injury; cognitive long-term outcome	NORMATIVE DATA; HEAD-INJURIES; SHORT-TERM; RECOVERY; CHILDHOOD; DEFICITS; PREDICTORS; SKILLS; COMA; AGE	Objective: This study is a population-based, retrospective follow-up study of neuropsychological functions after severe and moderate TBI. Methods: One hundred and sixty-five survivors of TBI injured in 1987-1991 in the 0-17-year age group were identified. Of the traceable individuals (149), 53 patients who sustained injury at a mean of 9.96 years participated in a neuropsychological investigation 10 years post-injury. A control group of 40 healthy subjects, matched for age and sex was chosen. An extensive neuropsychological test battery was used. Results: The TBI group showed significantly poorer performance in tests of intellectual function, with substantially lower results in verbal tests and in tests of verbal learning and memory, visuo-constructive ability and executive functions. The severely injured group showed substantial recovery. Poor results in visuo-constructive tests and tests of executive functions remained. Conclusions: Severity of injury is an important factor when assessing outcome, even 10 years after childhood TBI. The TBI group obtained poorer results on most of the measurements compared with healthy controls. Verbal function was strongly affected which needs to be taken into consideration when preparing for rehabilitation programmes. Evaluations of final outcome should not be made before the subjects reach adulthood.	[Horneman, Goran] Gothenburg Univ, Dept Psychol, Gothenburg, Sweden; [Emanuelson, Ingrid] Inst Clin Disciplines, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden	Horneman, G (corresponding author), Skeppspromenaden 5, SE-41763 Gothenburg, Sweden.	g.horneman@telia.com					Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; BARON IS, 1995, PEDIAT NEUROPSYCHOLO; BIRKENKAMP R, 1962, AUFMERKSAMKEITS BELA; Birkenkamp R., 1998, D2 TEST ATTENTION; BOLL T, 1993, CHILDRENS CATEGORY T; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; DROTAR D, 2001, HDB RES PEDIAT CLIN, V22; EKLUND G, 1965, STATISTISK TIDSKRIFT, V3, P355; EWINGCOBBS L, 1985, HEAD INJURY REHABILI, P71; FINLAYSON MAJ, 1976, PERCEPT MOTOR SKILL, V43, P475, DOI 10.2466/pms.1976.43.2.475; FLETCHER EJ, 1995, RECEPTOR CHANNEL, V3, P21; Forrester G., 1991, CLIN NEUROPSYCHOL, V5, P345, DOI DOI 10.1080/13854049108404102; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; Hill T., 2007, STAT METHODS APPL; Horneman G, 2005, INT J REHABIL RES, V28, P245, DOI 10.1097/00004356-200509000-00007; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; LESSER R, 1976, NEUROPSYCHOLOGIA, V14, P79, DOI 10.1016/0028-3932(76)90009-9; LURIA AR, 1964, NEUROPSYCHOLOGIA, V2, P95, DOI 10.1016/0028-3932(64)90015-6; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Meyers J., 1995, REY COMPLEX FIGURE T; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MUNGAS D, 1983, J CONSULT CLIN PSYCH, V51, P848, DOI 10.1037/0022-006X.51.6.848; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; PILLON B, 1981, NEUROPSYCHOLOGIA, V19, P375, DOI 10.1016/0028-3932(81)90067-1; Rey A, 1964, EXAMEN CLIN PSYCHOL; Romine CB, 2005, APPL NEUROPSYCHOL, V12, P190, DOI 10.1207/s15324826an1204_2; Spreen O., 1998, COMPENDIUM NEUROPSYC; TEASDALE G, 1974, LANCET, V2, P81; WECHSLER D, 1991, WECHSLER INTELLIGENC, V3; Wechsler D., 1991, MANUAL WECHSLER ADUL; WEISS J, SCIENCE, V282, P1652; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; Wolfson D., 1993, HALSTEAD REITAN NEUR; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; YEUDALL LT, 1986, J CLIN PSYCHOL, V42, P918, DOI 10.1002/1097-4679(198611)42:6<918::AID-JCLP2270420617>3.0.CO;2-Y	52	50	52	1	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	11					907	914	PII 915242694	10.1080/02699050903283239			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	498JY	WOS:000270137300007	20100127				2021-06-18	
J	Lima, FD; Souza, MA; Furian, AF; Rambo, LM; Ribeiro, LR; Martignoni, FV; Hoffmann, MS; Fighera, MR; Royes, LFF; Oliveira, MS; de Mello, CF				Lima, Frederico Diniz; Souza, Mauren Assis; Furian, Ana Flavia; Rambo, Leonardo Magno; Ribeiro, Leandro Rodrigo; Martignoni, Felipe Villa; Hoffmann, Mauricio Scopel; Fighera, Michele Rechia; Freire Royes, Luiz Fernando; Oliveira, Mauro Schneider; de Mello, Carlos Fernando			Na+,K+-ATPase activity impairment after experimental traumatic brain injury: Relationship to spatial learning deficits and oxidative stress	BEHAVIOURAL BRAIN RESEARCH			English	Article						Na+,K+-ATPase; protein carbonylation; TBARS; barnes maze; FPI	POSTTRAUMATIC EPILEPSY; CEREBROSPINAL-FLUID; RAT; ATPASE; TRANSPORT; CHILDREN; INFANTS	Traumatic brain injury (TBI) is a devastating disease that commonly causes persistent mental disturbances and cognitive deficits. Although studies indicate that oxidative stress and functional deficits occurring after TBI are interrelated events. the knowledge of the mechanisms underlying the development of such cognitive deficits has been limited. Thus, in the present study, we investigated the effect of fluid percussion brain injury (FPI) on a spatial learning task and levels of oxidative stress markers, namely, protein carbonylation and thiobarbituric acid-reactive substances (TBARS) and Na+,K+-ATPase activity 1 or 3 months after FPI in rats. Statistical analysis revealed that FPI increased the scape latency and mean number of error in Barnes maze test 1 and 3 months after FPI. We also found that protein carbonylation and TBARS content increased in the parietal cortex 1 and 3 months after FPI In addition, 3 months after FPI, protein carbonylation levels increased both in ipsilateral and contralateral cortices of FPI animals. Indeed, statistical analysis revealed a decrease in Na+,K+-ATPase activity in the cerebral cortex of 1 month FPI animals. Furthermore, the decrease in enzyme activity found 3 months was larger, when compared with 1 month after FPI. These results suggest that cognitive impairment following TBI may result, at least in part, from increase of two oxidative stress markers, protein carbonylation and TBARS that occurs concomitantly to a decrease in Na+,K+-ATPase activity. (C) 2008 Elsevier B.V. All rights reserved.	[Furian, Ana Flavia; Oliveira, Mauro Schneider] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Biol Bioquim, BR-90035003 Porto Alegre, RS, Brazil; [Lima, Frederico Diniz; Souza, Mauren Assis; Furian, Ana Flavia; Martignoni, Felipe Villa; Hoffmann, Mauricio Scopel; Oliveira, Mauro Schneider; de Mello, Carlos Fernando] Univ Fed Santa Maria, Dept Fisiol, Lab Psicofarmacol & Neurotoxicidade, Ctr Ciencias Saude, BR-97105900 Santa Maria, RS, Brazil; [Rambo, Leonardo Magno; Ribeiro, Leandro Rodrigo; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Dept Metodos & Tecnicas Desportivas, Ctr Educ Fis & Desportos, BR-97105900 Santa Maria, RS, Brazil; [Fighera, Michele Rechia] Univ Fed Santa Maria, Dept Pediat, Ctr Ciencias Saude, BR-97105900 Santa Maria, RS, Brazil	Oliveira, MS (corresponding author), Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Biol Bioquim, BR-90035003 Porto Alegre, RS, Brazil.	oliveira.ms@gmail.com	Oliveira, Mauro Schneider/G-3437-2012; Souza, Mauren/A-7990-2015; Rambo, Leonardo/F-8195-2012; Fighera, Michele R/J-9576-2014; Mello, Carlos/C-7188-2013; Hoffmann, Mauricio/AAM-9899-2020	Oliveira, Mauro Schneider/0000-0002-5381-1208; Mello, Carlos/0000-0002-1326-1045; Hoffmann, Mauricio/0000-0003-4232-3169; Ribeiro, Leandro/0000-0002-8442-4075; Rambo, Leonardo/0000-0002-4769-3663	CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [505527/2004-9, 301552/2007-0]; CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	Research supported by CNPq (grants 505527/2004-9 and 301552/2007-0) and CAPES. Mauro Schneider Oliveira is the recipient of CAPES fellowship. Carlos Fernando de Mello and Ana Flavia Furian are the recipients of CNPq fellowships.	BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dalle-Donne I, 2003, CLIN CHIM ACTA, V329, P23, DOI 10.1016/S0009-8981(03)00003-2; Dean RT, 1997, BIOCHEM J, V324, P1; Dobrota D, 1999, CELL MOL NEUROBIOL, V19, P141, DOI 10.1023/A:1006909927287; IKEDA Y, 1989, Neurological Research, V11, P213; Jamme I, 1995, NEUROREPORT, V7, P333; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morel P, 1998, NEUROCHEM INT, V33, P531, DOI 10.1016/S0197-0186(98)00062-X; Moseley AE, 2007, J NEUROSCI, V27, P616, DOI 10.1523/JNEUROSCI.4464-06.2007; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Oliveira MS, 2008, BEHAV BRAIN RES, V187, P200, DOI 10.1016/j.bbr.2007.09.004; Oliveira MS, 2004, NEUROSCIENCE, V128, P721, DOI 10.1016/j.neuroscience.2004.07.012; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Potts Mathew B, 2006, NeuroRx, V3, P143; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Siems WG, 1996, FREE RADICAL BIO MED, V20, P215, DOI 10.1016/0891-5849(95)02041-1; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052; YAN LJ, 1995, ANAL BIOCHEM, V228, P349, DOI 10.1006/abio.1995.1362; Zhan H, 2004, NEUROL RES, V26, P35, DOI 10.1179/016164104773026507	35	50	51	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	NOV 21	2008	193	2					306	310		10.1016/j.bbr.2008.05.013			5	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	350NP	WOS:000259359700020	18573545				2021-06-18	
J	Chen, JR; Cheng, GY; Sheu, CC; Tseng, GF; Wang, TJ; Huang, YS				Chen, Jeng-Rung; Cheng, Guang-Yan; Sheu, Ching-Chung; Tseng, Guo-Fang; Wang, Tsyr-Jiuan; Huang, Yong-San			Transplanted bone marrow stromal cells migrate, differentiate and improve motor function in rats with experimentally induced cerebral stroke	JOURNAL OF ANATOMY			English	Article						astrocyte; bone marrow stromal cells; cerebral stroke; differentiation; migration; oligodendrocyte	TRAUMATIC BRAIN-INJURY; MESENCHYMAL STEM-CELLS; SPINAL-CORD; INTRACEREBRAL TRANSPLANTATION; ISCHEMIC BRAIN; GROWTH-FACTOR; THERAPEUTIC BENEFIT; NEURAL PHENOTYPES; FOCAL ISCHEMIA; ADULT RATS	Bone marrow stromal cells are multipotential cells that can be induced to differentiate into osteoblasts, chondrocytes, myocytes and adipocytes in different microenvironments. Recent studies revealed that bone marrow stromal cells could improve neurological deficits of various damages or diseases of the central nervous system such as Parkinson's disease, brain trauma, spinal cord injury and multiple sclerosis, and promote glia-axonal remodeling in animal brain subjected to an experimentally induced stroke. In the present study, bone marrow stromal cells were intracerebrally transplanted into the cerebrum following a transient middle cerebral artery occlusion. Our aim was to find out whether the bone marrow stromal cells could survive and express neural phenotypic proteins and, in addition, whether they could restore the behavioral and functional deficits of the cerebral ischemic rats. Our results demonstrated that transplanted bone marrow stromal cells survived and migrated to areas around the lesion site. Some of them exhibited marker proteins of astrocytes and oligodendrocytes. Bone marrow stromal cell implantation significantly reduced the transient middle cerebral artery occlusion-induced cortical loss and thinning of the white matter and enhanced cortical beta-III-tubulin immunoreactivity. Rats implanted with bone marrow stromal cells showed significant improvement in their performance of elevated body swing test and forelimb footprint analysis and only transient recovery of the adhesive-removal test. Our data support bone marrow stromal cells as a valuable source of autologous or allogenic donor cells for transplantation to improve the outcome following cerebral ischemia.	[Chen, Jeng-Rung; Cheng, Guang-Yan; Sheu, Ching-Chung; Huang, Yong-San] Natl Chung Hsing Univ, Dept Vet Med, Coll Vet Med, Taichung 402, Taiwan; [Tseng, Guo-Fang] Tzu Chi Univ, Dept Anat, Coll Med, Hualien, Taiwan; [Wang, Tsyr-Jiuan] Natl Taichung Nursing Coll, Dept Nursing, Taichung, Taiwan	Huang, YS (corresponding author), Natl Chung Hsing Univ, Dept Vet Med, Coll Vet Med, 250 Kuo Kuang Rd, Taichung 402, Taiwan.	wtj@ntcnc.edu.tw; yshuang@mail.nchu.edu.tw		Wang, Tsyr-Jiuan/0000-0001-5693-2200; Chen, Jeng-Rung/0000-0002-4429-283X	National Science Council of TaiwanMinistry of Science and Technology, Taiwan [NSC-95-2313-B-005-046, NSC-95-2320-B-438-001]	This work was supported by research grants from the National Science Council of Taiwan (NSC-95-2313-B-005-046 and NSC-95-2320-B438-001) to J.-R.C. and T.-J.W.	Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BEDNAR MM, 1994, NEUROL RES, V16, P129; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Borlongan CV, 1998, NEUROREPORT, V9, P3615, DOI 10.1097/00001756-199811160-00012; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Cao Q, 2007, J NEUROSCI RES, V85, P116, DOI 10.1002/jnr.21092; Chen CH, 2007, J NEUROCHEM, V102, P1831, DOI 10.1111/j.1471-4159.2007.04652.x; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chen Y, 2007, J CELL BIOCHEM, V102, P52, DOI 10.1002/jcb.21275; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Dormady SP, 2001, J HEMATOTH STEM CELL, V10, P125, DOI 10.1089/152581601750098372; EAVES CJ, 1991, BLOOD, V78, P110; Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856; Garcia R, 2004, BIOCHEM BIOPH RES CO, V316, P753, DOI 10.1016/j.bbrc.2004.02.111; Grassel S, 2007, ORTHOPADE, V36, P227, DOI 10.1007/s00132-007-1058-7; Hermann A, 2006, J NEUROSCI RES, V83, P1502, DOI 10.1002/jnr.20840; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Iihoshi S, 2004, BRAIN RES, V1007, P1, DOI 10.1016/j.brainres.2003.09.084; ISAYAMA K, 1991, STROKE, V22, P1394, DOI 10.1161/01.STR.22.11.1394; Ishibashi S, 2003, ACT NEUR S, V86, P159; Ishibashi S, 2003, STROKE, V34, P1501, DOI 10.1161/01.STR.0000074034.32371.13; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kao TK, 2006, NEUROCHEM INT, V48, P166, DOI 10.1016/j.neuint.2005.10.008; Kronenwett R, 2006, MED KLIN, V101, P182; Li Y, 2006, EXP NEUROL, V198, P313, DOI 10.1016/j.expneurol.2005.11.029; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Liao SL, 2004, NEUROSCI LETT, V372, P40, DOI 10.1016/j.neulet.2004.09.013; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mimura T, 2005, J NEUROPATH EXP NEUR, V64, P1108, DOI 10.1097/01.jnen.0000190068.03009.b5; Munoz-Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060-03.2004; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; OWEN M, 1988, J CELL SCI, P63; OWEN M, 1988, CIBA F SYMP, V136, P42; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Sensebe L, 1997, STEM CELLS, V15, P133, DOI 10.1002/stem.150133; Seyfried D, 2006, J NEUROSURG, V104, P313, DOI 10.3171/jns.2006.104.2.313; Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092; Sughrue ME, 2006, J NEUROSCI METH, V151, P83, DOI 10.1016/j.jneumeth.2005.04.023; Suzuki H, 2004, BIOCHEM BIOPH RES CO, V322, P918, DOI 10.1016/j.bbrc.2004.07.201; TANAKA R, 1995, STROKE, V26, P2154, DOI 10.1161/01.STR.26.11.2154; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Wang ZH, 2002, NEUROSCIENCE, V113, P629, DOI 10.1016/S0306-4522(02)00204-X; Wlodarski Krzysztof H, 2006, Ortop Traumatol Rehabil, V8, P573; Yu S, 2006, BIOCHEM BIOPH RES CO, V344, P1071, DOI 10.1016/j.bbrc.2006.03.231; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	61	50	61	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-8782	1469-7580		J ANAT	J. Anat.	SEP	2008	213	3					249	258		10.1111/j.1469-7580.2008.00948.x			10	Anatomy & Morphology	Anatomy & Morphology	341QY	WOS:000258731000005	18647194	Green Published			2021-06-18	
J	Huh, JW; Widing, AG; Raghupathi, R				Huh, Jimmy W.; Widing, Ashley G.; Raghupathi, Ramesh			Midline brain injury in the immature rat induces sustained cognitive deficits, bihemispheric axonal injury and neurodegeneration	EXPERIMENTAL NEUROLOGY			English	Article						traumatic axonal injury; closed head injury; infants; children; mild traumatic brain injury; cognition; neurodegeneration; fluoro-jade	LATERAL FLUID PERCUSSION; MILD HEAD-INJURY; PRESCHOOL-CHILDREN; VULNERABILITY; MODEL; ADOLESCENTS; HIPPOCAMPUS; DYSFUNCTION; PLASTICITY; THALAMUS	infants and children less than 4 years old suffer chronic cognitive deficits following mild, moderate or severe diffuse traumatic brain injury (TBI). It has been suggested that the underlying neuropathologic basis for behavioral deficits following severe TBI is acute brain swelling, subarachnoid hemorrhage and axonal injury. To better understand mechanisms of cognitive dysfunction in mild-moderate TBI, a closed head injury model of midline TBI in the immature rat was developed. Following an impact over the midline suture of the intact skull, 17-day-old rats exhibited short apnea times (3-15 s), did not require ventilatory support and suffered no mortality, Suggestive of mild TBI. Compared to un-injured rats, brain-injured rats exhibited significant learning deficits over the first week post-injury (P < 0.0005), and, significant learning (p < 0.005) and memory deficits (p < 0.05) in the third post-injury week. Between 6 and 72 h, blood-brain barrier breakdown, extensive traumatic axonal injury in the subcortical white matter and thalamus, and focal areas of neurodegeneration in the cortex and hippocampus were observed in both hemispheres of the injured brain. At 8 to 18 days post-injury, reactive astrocytosis in the cortex, axonal degeneration in the subcortical white matter tracts, and degeneration of neuronal cell bodies and processes in the thalamus of both hemispheres were observed; however, cortical volumes were not different between un-injured and injured rat brains. These data Suggest that diffuse TBI in the immature rat can lead to ongoing degeneration of both cell soma and axonal compartments of neurons, which may contribute, in part, to the observed Sustained cognitive deficits. (C) 2008 Elsevier Inc. All rights reserved.	[Widing, Ashley G.; Raghupathi, Ramesh] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; [Huh, Jimmy W.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA	Raghupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.	rramesh@drexelmed.edu			The Endowed Chair of Critical Care Medicine; Children's Hospital of Philadelphia; University of Pennsylvania; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08-NS053651, R01-NS41561]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS053651, R01NS041561] Funding Source: NIH RePORTER	The authors acknowledge expert technical assistance from Michael Franklin. These studies were supported, in part, by The Endowed Chair of Critical Care Medicine, the Florence RC Murray grant from the Children's Hospital of Philadelphia (JWH, RR), a Research Foundation grant from the University of Pennsylvania (JWH, RR), and NINDS grants K08-NS053651 (JWH) and R01-NS41561 (RIZ).	Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2000, BRAIN INJURY, V14, P679; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Butler TL, 2002, BRAIN RES, V929, P252, DOI 10.1016/S0006-8993(01)03371-6; Chiaretti A, 1998, Pediatr Med Chir, V20, P393; Ciurea AV, 2005, ACT NEUR S, V93, P209; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Huh JW, 2007, J NEUROTRAUM, V24, P1460, DOI 10.1089/neu.2006.3787; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Rasband W, 1997, IMAGE J; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	39	50	52	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2008	213	1					84	92		10.1016/j.expneurol.2008.05.009			9	Neurosciences	Neurosciences & Neurology	344QX	WOS:000258943500010	18599043	Green Accepted			2021-06-18	
J	Yoganandan, N; Li, JR; Zhang, JY; Pintar, FA; Gennarelli, TA				Yoganandan, Narayan; Li, Jianrong; Zhang, Jiangyue; Pintar, Frank A.; Gennarelli, Thomas A.			Influence of angular acceleration-deceleration pulse shapes on regional brain strains	JOURNAL OF BIOMECHANICS			English	Article						rotational accelerations; brain trauma; finite element model; strain; pulse shape	DIFFUSE AXONAL INJURY; HEAD-INJURY; BIOMECHANICS; MODEL; VENTRICLES; CONCUSSION; MOTION; IMPACT	Recognizing the association of an-gular loading with brain injuries and inconsistency in previous studies in the application of the biphasic loads to animal, physical, and experimental models. the present Study examined the role of the acceleration-deceleration pulse shapes on region-specific strains. An experimentally validated two-dimensional finite element model representing the adult male human head was used. The model simulated the skull and falx Lis a linear clastic material, cerebrospinal fluid is a hydrodynamic material, and cerebrum as a linear viscoelastic material. The angular loading matrix consisted coronal plane rotation about a center of rotation that was acccleration-only (4.5 ms duration, 7.8 krad/s/s peak), deceleration-only (20 ms, 1.4 krad/s/s peak), acceleration-deceleration, and deceleration-acceleration pulses. Both biphasic pulses had peaks separated by intervals ranging from 0 to 25 ins. Principal strains were determined at the corpus callosum, base of the postcentral sulcus, and cerebral cortex of the parietal lobe. The cerebrum was divided into 17 regions and peak values of average maximum principal strains were determined. In all simulations. the corpus callosum responded with the highest strains. Strains were the least under all simulations in the lower parietal lobes. In all regions peak strains were the same for both monophase Pulses Suggesting that the angular velocity may be a better metric than peak acceleration or deceleration. In contrast, for the biphasic Pulse, peak strains were region- and pulse-shape specific. Peak values were lower in both biphasic pulses when there was no time separation between the Pulses than the corresponding monophase Pulse. Increasing separation time intervals increased strains, albeit non-uniformly. Acceleration followed by deceleration Pulse produced greater strains in all regions than the other form of biphasic pulse. Thus, pulse shape appears to have an effect on regional strains in the brain. Published by Elsevier Ltd.	[Yoganandan, Narayan] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; VA Med Ctr, Milwaukee, WI 53226 USA	Yoganandan, N (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	yoga@mcw.edu					ABEL J, 1978, P 22 STAPP CAR CRASH, P33; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; Gennarelli T.A., 1971, P 15 STAPP CAR CRASH, V39, P797; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1985, P 30 AM ASS ADV AUT, P447; GENNARELLI TA, 1979, P 23 STAPP CAR CRASH, P563; Gennarelli TA, 1972, P 16 STAPP CAR CRASH, P296; Gennarelli Thomas A, 1987, P 31 STAPP CAR CRASH, DOI [10.4271/872197, DOI 10.4271/872197]; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; HIGGINS LS, 1967, P 11 STAPP CAR CRASH, P35; Holbourn AHS, 1943, LANCET, V2, P438; Huang HM, 1999, J TRAUMA, V47, P538, DOI 10.1097/00005373-199909000-00019; Ivarsson J, 2002, J BIOMECH ENG-T ASME, V124, P422, DOI 10.1115/1.1485752; Ivarsson J, 2000, J BIOMECH, V33, P181, DOI 10.1016/S0021-9290(99)00144-X; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; LEE MC, 1987, P 31 STAPP CAR CRASH, P67; Li JR, 2007, BIOMED SCI INSTRUM, V43, P24; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MARGULIES SS, 1985, P INT RES COUNCIL BI, P223; Meaney D.F., 1990, P 1990 INT IRCOBI C, P215; MEANEY DF, 1994, P ANN C ASS, P345; MEYERS MA, 1984, MECH METALLURGY; Millan A, 1998, J IMAGING SCI TECHN, V42, P385; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1966, P 10 STAPP CAR CRASH, V10, P314; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; THIBAULT L, 1985, CENTRAL NERVOUS SYST, V1, P371; Thibault L.E., 1985, P 10 EXP SAF VEH C N, P79; THIBAULT LE, 1990, P ANN C ASS, P337; UNTERHARNSCHEID.F, 1969, ACTA NEUROPATHALOGIC, P200; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; YOGANANDAN N, 1998, FRONTIERS HEAD NECK; Zhang Jiangyue, 2006, Annu Proc Assoc Adv Automot Med, V50, P1; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhou C, 1995, P 39 STAPP CAR CRASH, V39, P121, DOI DOI 10.4271/952714; ZHOU C, 1996, P 1996 INT IRCOBI C, P35	42	50	51	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JUL 19	2008	41	10					2253	2262		10.1016/j.jbiomech.2008.04.019			10	Biophysics; Engineering, Biomedical	Biophysics; Engineering	336HF	WOS:000258354200023	18556004				2021-06-18	
J	Register-Mihalik, JK; Mihalik, JP; Guskiewicz, KM				Register-Mihalik, Johna K.; Mihalik, Jason P.; Guskiewicz, Kevin M.			Balance deficits after sports-related concussion in individuals reporting posttraumatic headache	NEUROSURGERY			English	Article						migraine; mild traumatic brain injury; postural stability	POSTURAL STABILITY; NEUROPSYCHOLOGICAL PERFORMANCE; MILD HEAD; MIGRAINE; INJURY; COLLEGIATE; DIZZINESS; SYMPTOMS; WHIPLASH; VERTIGO	OBJECTIVE: Posttraumatic headache (PTH) may affect neurocognition after sports-related concussion. To our knowledge, no studies have examined how PTH affects balance after concussion using dynamic posturography. The purpose of this study is to compare balance after concussion between athletes reporting PTH and athletes not reporting PTH. METHODS: We conducted a retrospective, repeated-measures design with participants grouped by presence of postinjury report of headache. Balance testing was conducted on 108 concussed collegiate athletes (age, 18.83 +/- 1.27 yr; height, 180.92 +/- 10.01 cm; mass, 83.29 +/- 19.62 kg). Presence of PTH during the first postinjury test session (group) and test time (baseline, postinjury) served as the independent variables. The composite equilibrium score and the somatosensory, vestibular, and visual ratio scores served as dependent variables. A 2 X 2 mixed model analysis of variance was used to analyze each outcome measure. RESULTS: Significant decreases in all four measures assessed were noted after concussion compared with preseason baseline measures (P < 0.05). Significant group by test-time interactions were observed, suggesting that composite equilibrium (F-1106 = 6.6089; P = 0.012) and vestibular ratio (F-1106 = 7.156; P = 0.009) scores are affected by the presence of PTH. Athletes reporting PTH also demonstrated worse visual ratio scores compared with individuals not experiencing PTH (F-1106 = 4.26; P = 0.041). No other significant findings were observed for the somatosensory ratio score. CONCLUSION: Current literature proposes that PTH is associated with cognitive deficits. Our study indicates that PTH may also contribute to increased balance deficits. We believe the deficits may be a result of increased sensory organization challenges after injury. Clinicians should be mindful of these findings when managing concussed athletes reporting headache.	[Register-Mihalik, Johna K.; Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Register-Mihalik, Johna K.; Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Curriculum Human Movement Sci, Chapel Hill, NC 27599 USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sport Sci, 209 Fetzer Gymnasium,Campus Box 8700,South Rd, Chapel Hill, NC 27599 USA.	gus@email.unc.edu	Mihalik, Jason P/E-7059-2010	Register-Mihalik, Johna/0000-0002-4229-4743; Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130			Broglio SP, 2005, MED SCI SPORT EXER, V37, P689, DOI 10.1249/01.MSS.0000159019.14919.09; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CUTRER FM, 1992, HEADACHE, V32, P300, DOI 10.1111/j.1526-4610.1992.hed3206300.x; FORDSMITH CD, 1995, ARCH PHYS MED REHAB, V76, P77, DOI 10.1016/S0003-9993(95)80047-6; Furman JM, 2003, CURR OPIN NEUROL, V16, P5, DOI 10.1097/00019052-200302000-00002; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Giacomini PG, 2004, EUR J PAIN, V8, P579, DOI 10.1016/j.ejpain.2004.02.004; GUIDETTI G, 1984, Acta Oto-Rhino-Laryngologica Belgica, V38, P140; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harno H, 2003, NEUROLOGY, V61, P1748, DOI 10.1212/01.WNL.0000098882.82690.65; HORSTMANN GA, 1988, NEUROSCI LETT, V95, P179, DOI 10.1016/0304-3940(88)90653-2; Hu Ming-Hsia, 1996, Proceedings of the National Science Council Republic of China Part B Life Sciences, V20, P78; KURITZKY A, 1981, HEADACHE, V21, P227, DOI 10.1111/j.1526-4610.1981.hed2105227.x; Lake AE, 1999, J HEAD TRAUMA REHAB, V14, P70, DOI 10.1097/00001199-199902000-00008; Mallinson AI, 1998, AM J OTOL, V19, P814; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; O'Bryant Sid E, 2005, Expert Rev Neurother, V5, P363, DOI 10.1586/14737175.5.3.363; Patel AV, 2007, J ATHL TRAINING, V42, P66; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rossi C, 2005, ACTA NEUROL SCAND, V111, P407, DOI 10.1111/j.1600-0404.2005.00422.x; RUBIN AM, 1995, AM J OTOL, V16, P216; Savundra PA, 1997, CEPHALALGIA, V17, P505, DOI 10.1046/j.1468-2982.1997.1704505.x; Soloman S, 1998, HEADACHE, V38, P772, DOI 10.1046/j.1526-4610.1998.3810772.x; Tang PF, 1998, J GERONTOL A-BIOL, V53, pM140, DOI 10.1093/gerona/53A.2.M140; TOGLIA JU, 1981, ANN OTO RHINOL LARYN, V90, P267, DOI 10.1177/000348948109000315; TSUSHIMA WT, 1993, HEADACHE, V33, P139, DOI 10.1111/j.1526-4610.1993.hed3303139.x	36	50	50	0	13	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2008	63	1					76	81		10.1227/01.NEU.0000335073.39728.CE			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	341LM	WOS:000258716000017	18728571				2021-06-18	
J	Jin, W; Zhu, L; Guan, Q; Chen, G; Wang, QF; Yin, HX; Hang, CH; Shi, JX; Wang, HD				Jin, Wei; Zhu, Lin; Guan, Qun; Chen, Gang; Wang, Qing Feng; Yin, Hong Xia; Hang, Chun Hua; Shi, Ji Xin; Wang, Han Dong			Influence of Nrf2 genotype on pulmonary NF-kappa B activity and inflammatory response after traumatic brain injury	ANNALS OF CLINICAL AND LABORATORY SCIENCE			English	Article						traumatic brain injury; lung; Nrf2; NF-kappa B; cytokines; pulmonary inflammatory response	TRANSCRIPTION FACTOR; LUNG INJURY; ENHANCES SUSCEPTIBILITY; NRF2-DEFICIENT MICE; HEAD-INJURY; RAT MODEL; ADHESION; PROTECTION; INDUCTION; MECHANISM	Inflammatory response plays an important role in the pathogenesis of acute lung injury (ALI) after traumatic brain injury (TBI). Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key transcription factor that plays a crucial role in cytoprotection against inflammation. The present study explored the influence of Nrf2 genotype on the production of cytokines and on activation of transcription factors in a murine TBI model. Wild-type Nrf2 (+/+) and Nrf2 (-/-) deficient mice were Subjected to a moderately severe weight-drop impact-acceleration head injury. Lung wet/dry weight ratio, Minor necrosis factor-CA (TNF-alpha), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), intercellular adhesion molecule-1 (ICAM-1), and nuclear factor kappaB (NF-kappa B) were investigated at 24 hr after TBI. Nrf2 (-/-) mice were shown to have a greater increase in the lung wet/dry weight ratio compared to their wild-type Nrf2 (+/+) counterparts after TBI. This exacerbation Of lung injury in Nrf2 (-/-) mice was associated with increased levels of TNF-alpha, IL-1 beta, IL-6, ICAM-1, and their mediator, NF-kappa B. The results suggest that Nrf2 plays ail important protective role in attenuating the Pulmonary inflammatory response and NF-kappa B activation after TBI.	[Jin, Wei; Zhu, Lin; Chen, Gang; Wang, Qing Feng; Yin, Hong Xia; Hang, Chun Hua; Shi, Ji Xin; Wang, Han Dong] Nanjing Univ, Dept Neurosurg, Sch Med, Jinling Hosp, Nanjing 210002, Jiangsu Prov, Peoples R China; [Guan, Qun] Nanjing Univ, Dept Obstet & Gynecol, Sch Med, Jinling Hosp, Nanjing 210002, Jiangsu Prov, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Dept Neurosurg, Sch Med, Jinling Hosp, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	hdwang_nj@yahoo.com.cn	Yin, Hong/AAC-5784-2020		Jinling Hospital of China	This work was supported by grants from Jinling Hospital of China. The authors thank Dr. Bo Wu 15 and Dr. Geng-bao Feng for technical assistance.	Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chen F, 1999, CLIN CHEM, V45, P7; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Cho HY, 2004, FASEB J, V18, P1258; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Church LD, 2008, NAT CLIN PRACT RHEUM, V4, P34, DOI 10.1038/ncprheum0681; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; DETTBARN CL, 1989, HEART LUNG, V18, P583; Fisher AJ, 1999, LANCET, V353, P1412, DOI 10.1016/S0140-6736(99)00494-8; Guo RF, 2007, ANTIOXID REDOX SIGN, V9, P1991, DOI 10.1089/ars.2007.1785; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Kawkitinarong K, 2004, AM J RESP CELL MOL, V31, P517, DOI 10.1165/rcmb.2003-0432OC; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Lukacs NW, 1996, ADV IMMUNOL, V62, P257, DOI 10.1016/S0065-2776(08)60432-0; Lv R, 2005, ANN CLIN LAB SCI, V35, P174; Miyao N, 2006, AM J PHYSIOL-LUNG C, V290, pL1059, DOI 10.1152/ajplung.00365.2005; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu S, 2006, EXP NEUROL, V200, P245, DOI 10.1016/j.expneurol.2006.01.027; Zhou ML, 2007, J SURG RES, V137, P103, DOI 10.1016/j.jss.2006.06.023	38	50	52	0	1	ASSOC CLINICAL SCIENTISTS	MIDDLEBURY	PO BOX 1287, MIDDLEBURY, VT 05753 USA	0091-7370	1550-8080		ANN CLIN LAB SCI	Ann. Clin. Lab. Sci.	SUM	2008	38	3					221	227					7	Medical Laboratory Technology	Medical Laboratory Technology	339MT	WOS:000258582400004	18715849				2021-06-18	
J	Gomez-Nicola, D; Valle-Argos, B; Pita-Thomas, DW; Nieto-Sampedro, M				Gomez-Nicola, Diego; Valle-Argos, Beatriz; Pita-Thomas, D. Wolfgang; Nieto-Sampedro, Manuel			Interleukin 15 expression in the CNS: Blockade of its activity prevents glial activation after an inflammatory injury	GLIA			English	Article						cytokines; IL-15; inflammation; lipopolysaccharide; microglia; astrocytes	NATURAL-KILLER-CELLS; RAT-BRAIN; INTRACELLULAR TRAFFICKING; REACTIVE ASTROGLIOSIS; MURINE MICROGLIA; IL-2 RECEPTOR; GROWTH-FACTOR; ALPHA-CHAIN; IN-VIVO; ISOFORMS	Although reactive glia formation after neuronal degeneration or traumatic damage is one of the hallmarks of central nervous system (CNS) injury, we have little information on the signals that direct activation of resting glia. IL-15, a pro-inflammatory cytokine involved in regulating the response of T and B cells, may be also key for the regulation of early inflammatory events in the nervous system. IL-15 was expressed in the CNS, most abundantly in cerebellum and hippocampus, mainly in astrocytes and in some projection neurons. Using a rodent model of acute inflammatory injury [lipopolysaccharide (LPS) injection], we found enhanced expression of IL-15 in both reactive astroglia and microglia, soon after CNS injury. Blockade of IL-15 activity with an antibody to the cytokine, reversed activation of both glial types, suggesting that IL-15 has a major role in the generation of gliotic tissue and in the regulation of neuroimmune responses. Because IL-15 appears to modulate the inflammatory environment acutely generated after CNS injury, regulating IL-15 expression seems a clear antiinflammatory therapy to improve the outcome of neurodegenerative diseases and CNS trauma. (C) 2008 Wiley-Liss, Inc.	[Gomez-Nicola, Diego; Valle-Argos, Beatriz; Pita-Thomas, D. Wolfgang; Nieto-Sampedro, Manuel] CSIC, Inst Cajal, Neural Plast Grp, Funct & Syst Neurobiol Dept, E-28002 Madrid, Spain; [Gomez-Nicola, Diego; Nieto-Sampedro, Manuel] Hosp Nacl Paraplej, Expt Neurol Unit, Toledo, Spain	Nieto-Sampedro, M (corresponding author), CSIC, Inst Cajal, Neural Plast Grp, Funct & Syst Neurobiol Dept, Avda Doctor Arce 37, E-28002 Madrid, Spain.	mns@cajal.csic.es	Gomez-Nicola, Diego/E-7728-2015	Gomez-Nicola, Diego/0000-0002-5316-2682			Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; ARAUJO DM, 1989, BRAIN RES, V498, P257, DOI 10.1016/0006-8993(89)91104-9; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; AWATSUJI H, 1993, J NEUROSCI RES, V35, P305, DOI 10.1002/jnr.490350310; Bauer J, 2001, GLIA, V36, P235, DOI 10.1002/glia.1112; Beck RD, 2005, BRAIN RES, V1041, P223, DOI 10.1016/j.brainres.2005.02.010; BENVENISTE EN, 1986, NATURE, V321, P610, DOI 10.1038/321610a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budagian V, 2006, CYTOKINE GROWTH F R, V17, P259, DOI 10.1016/j.cytogfr.2006.05.001; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; Depino AM, 2004, HIPPOCAMPUS, V14, P526, DOI 10.1002/hipo.10164; Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978; Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14; Gaggero A, 1999, EUR J IMMUNOL, V29, P1265, DOI 10.1002/(SICI)1521-4141(199904)29:04<1265::AID-IMMU1265>3.0.CO;2-V; Garcia-Moreno F, 2007, J COMP NEUROL, V500, P419, DOI 10.1002/cne.21128; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Gomez-Nicola D, 2006, J NEUROSCI RES, V83, P754, DOI 10.1002/jnr.20777; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Hanisch UK, 1997, J BIOL CHEM, V272, P28853, DOI 10.1074/jbc.272.46.28853; Hanisch UK, 1995, BRAIN RES REV, V21, P246, DOI 10.1016/0165-0173(95)00015-1; HANISCH UK, 1993, J NEUROSCI, V13, P3368; Hauss-Wegrzyniak B, 1998, BRAIN RES, V794, P211, DOI 10.1016/S0006-8993(98)00227-3; Herx LM, 2001, J NEUROPATH EXP NEUR, V60, P961, DOI 10.1093/jnen/60.10.961; Huang Z, 2007, NEUROSCI LETT, V417, P160, DOI 10.1016/j.neulet.2007.01.086; ISHIDA Y, 1989, J EXP MED, V170, P1103, DOI 10.1084/jem.170.4.1103; Jung YO, 2007, IMMUNOL LETT, V109, P21, DOI 10.1016/j.imlet.2006.12.006; Kennedy P, 2000, LAT TRADE, V8, P15; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kurowska M, 2002, ANN NY ACAD SCI, V966, P441, DOI 10.1111/j.1749-6632.2002.tb04245.x; Kurys G, 2000, J BIOL CHEM, V275, P30653, DOI 10.1074/jbc.M002373200; LAPCHAK PA, 1991, NEUROSCIENCE, V44, P173, DOI 10.1016/0306-4522(91)90259-Q; Lee YB, 1996, NEUROREPORT, V7, P1062, DOI 10.1097/00001756-199604100-00022; Lund S, 2006, J NEUROIMMUNOL, V180, P71, DOI 10.1016/j.jneuroim.2006.07.007; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; NIETOSAMPEDRO M, 1985, BRAIN RES, V343, P320, DOI 10.1016/0006-8993(85)90750-4; NIETOSAMPEDRO M, 1987, NEUROCHEM RES, V12, P723, DOI 10.1007/BF00970528; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Nishimura H, 2005, FASEB J, V19, P19, DOI 10.1096/fj.04-2633com; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Pereno R, 2000, ONCOGENE, V19, P5153, DOI 10.1038/sj.onc.1203873; Satoh J, 1998, J NEUROL SCI, V155, P170, DOI 10.1016/S0022-510X(97)00310-9; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; Schroeter M, 2005, NEUROMOL MED, V7, P183, DOI 10.1385/NMM:7:3:183; SMITH GM, 1990, DEV BIOL, V138, P377, DOI 10.1016/0012-1606(90)90204-V; SMITH KA, 1992, CURR OPIN IMMUNOL, V4, P271, DOI 10.1016/0952-7915(92)90076-Q; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; Watkins LR, 2002, PHYSIOL REV, V82, P981, DOI 10.1152/physrev.00011.2002; Yamashita T, 2005, J NEUROCHEM, V94, P459, DOI 10.1111/j.1471-4159.2005.03227.x	53	50	53	3	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	APR	2008	56	5					494	505		10.1002/glia.20628			12	Neurosciences	Neurosciences & Neurology	275KM	WOS:000254070300002	18240307				2021-06-18	
J	Harting, MT; Baumgartner, JE; Worth, LL; Ewing-Cobbs, L; Gee, AP; Day, MC; Cox, CS				Harting, Matthew T.; Baumgartner, James E.; Worth, Laura L.; Ewing-Cobbs, Linda; Gee, Adrian P.; Day, Mary-Clare; Cox, Charles S.			Cell therapies for traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						cell therapy; clinical trial; stem cells; traumatic brain injury	MARROW STROMAL CELLS; MESENCHYMAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; NEURAL PROGENITOR CELLS; CORD BLOOD-CELLS; BONE-MARROW; ADULT RATS; COGNITIVE FUNCTION; NEURONAL DIFFERENTIATION; STEM/PROGENITOR CELLS	Preliminary discoveries of the efficacy of cell therapy are currently being translated to clinical trials. Whereas a significant amount of work has been focused on cell therapy applications for a wide array of diseases, including cardiac disease, bone disease, hepatic disease, and cancer, there continues to be extraordinary anticipation that stem cells will advance the current therapeutic regimen for acute neurological disease. Traumatic brain injury is a devastating event for which current therapies are limited. In this report the authors discuss the current status of using adult stem cells to treat traumatic brain injury, including the basic cell types and potential mechanisms of action, preclinical data, and the initiation of clinical trials.	[Harting, Matthew T.; Day, Mary-Clare; Cox, Charles S.] Univ Texas Houston, Sch Med, Dept Pediat Surg, Houston, TX 77030 USA; [Harting, Matthew T.; Cox, Charles S.] Univ Texas Houston, Sch Med, Trauma Res Ctr, Houston, TX 77030 USA; [Baumgartner, James E.] Childrens Mem Hermann Hosp, Houston, TX USA; [Worth, Laura L.] Univ Texas MD Anderson Canc Ctr, Childrens Canc Hosp, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Houston, Sch Med, Dept Pediat, Childrens Learning Inst, Houston, TX USA; [Gee, Adrian P.] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA	Cox, CS (corresponding author), Univ Texas Houston, Sch Med, Dept Pediat Surg, 6431 Fannin St,MSB 5-254, Houston, TX 77030 USA.	charles.s.cox@uth.tmc.edu		Harting, Matthew/0000-0002-8929-8311	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR002558] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM008792-08, T32 GM008792] Funding Source: Medline		Al Nimer F, 2004, NEUROREPORT, V15, P1871, DOI 10.1097/00001756-200408260-00007; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; English D, 2006, EXP NEUROL, V199, P10, DOI 10.1016/j.expneurol.2006.03.005; Englund U, 2002, EXP NEUROL, V173, P1, DOI 10.1006/exnr.2001.7750; Englund U, 2002, DEV BRAIN RES, V134, P123, DOI 10.1016/S0165-3806(01)00330-3; Englund U, 2002, P NATL ACAD SCI USA, V99, P17089, DOI 10.1073/pnas.252589099; Freyman T, 2006, EUR HEART J, V27, P1114, DOI 10.1093/eurheartj/ehi818; FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365-2184.1970.tb00347.x; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Grinnemo KH, 2004, J THORAC CARDIOV SUR, V127, P1293, DOI 10.1016/j.jtcvs.2003.07.037; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; KRAUS JF, 1987, PEDIATRICS, V79, P501; Le Blanc K, 2005, CYTOTHERAPY, V7, P36, DOI 10.1080/14653240510018118; Long XX, 2005, STEM CELLS DEV, V14, P65, DOI 10.1089/scd.2005.14.65; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Makinen S, 2006, BRAIN RES, V1123, P207, DOI 10.1016/j.brainres.2006.09.056; MCKAY R, 1993, CR ACAD SCI III-VIE, V316, P1452; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mezey E, 2003, SCIENCE, V299; Miles DK, 2006, PROG BRAIN RES, V157, P187, DOI 10.1016/S0079-6123(06)57012-8; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Nan ZH, 2005, ANN NY ACAD SCI, V1049, P84, DOI 10.1196/annals.1334.009; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957; Schrepfer S, 2007, TRANSPL P, V39, P573, DOI 10.1016/j.transproceed.2006.12.019; Secco M, 2008, STEM CELLS, V26, P146, DOI 10.1634/stemcells.2007-0381; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Sinden JD, 1997, NEUROSCIENCE, V81, P599, DOI 10.1016/S0306-4522(97)00330-8; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Song L, 2004, FASEB J, V18, P980, DOI 10.1096/fj.03-1100fje; Tao H, 2005, DEV GROWTH DIFFER, V47, P423; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Theise ND, 2003, SCIENCE, V299, p1317A, DOI 10.1126/science.1078412; Tolar J, 2006, BLOOD, V107, P4182, DOI 10.1182/blood-2005-08-3289; Vescovi AL, 1999, J NEUROTRAUM, V16, P689, DOI 10.1089/neu.1999.16.689; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Wennersten A, 2006, EXP NEUROL, V199, P339, DOI 10.1016/j.expneurol.2005.12.035; Xiao J, 2005, STEM CELLS DEV, V14, P722, DOI 10.1089/scd.2005.14.722; Xu Y, 2003, J NEUROSCI RES, V74, P533, DOI 10.1002/jnr.10769; Zhang C, 2005, J NEUROTRAUM, V22, P1456, DOI 10.1089/neu.2005.22.1456	79	50	50	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	MAR	2008	24	3-4							E17	10.3171/FOC/2008/24/3-4/E17			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	308FQ	WOS:000256374100018	18341394	Green Accepted			2021-06-18	
J	Bragadeesh, T; Jayaweera, AR; Pascotto, M; Micari, A; Le, DE; Kramer, CM; Epstein, FH; Kaul, S				Bragadeesh, T.; Jayaweera, A. R.; Pascotto, M.; Micari, A.; Le, D. E.; Kramer, C. M.; Epstein, F. H.; Kaul, S.			Post-ischaemic myocardial dysfunction (stunning) results from myofibrillar oedema	HEART			English	Article							REPERFUSION INJURY; SARCOMERE-LENGTH; FORCE GENERATION; SKELETAL-MUSCLE; ISCHEMIA; CARDIOMYOCYTES; ULTRASTRUCTURE; LATTICE; BINDING; CELLS	Objective: To test the hypothesis that myocardial stunning is due to myofibrillar oedema. Methods: Experiments were performed in anaesthetised closed-chest pigs. In 15 pigs (group 1), myocardial stunning was produced by repetitive ischaemia and reperfusion; 5 pigs each were studied at 2 hours, 2 days, and 5 days later. Circumferential left ventricular (LV) midwall myocardial strain (E-cc) was estimated in vivo using tagged magnetic resonance imaging. Myocardial water content (MWC) was measured post mortem, from which interfilament lattice distance (d) was calculated. In 6 pigs (group 2), myocardial dysfunction was produced by intracoronary administration of a mast cell degranulator. Animals were euthanised immediately upon induction of regional LV dysfunction to avoid development of inflammation. In 4 pigs (group 3), transmission electron microscopy (EM) was performed to quantify d in stunned versus normal myocardium. Results: In group 1 pigs, MWC was raised in the stunned compared with normal myocardium (p < 0.02) and decreased over time. An inverse relation was found between Ecc and MWC in the stunned myocardium (r = -0.81) and between Ecc and d (r= -0.90). A similar relation was noted between wall thickening and increase in MWC in group 2 (r= -0.84) pigs. In group 3 pigs, d on EM was significantly lower (40 (3) nmol/ l) in normal myocardium than in stunned myocardium (46.4 (4) nmol/ l), p < 0.001. Conclusions: Ischaemia-reperfusion results in myocardial oedema, with consequent myocyte swelling and myofibrillar oedema. The latter leads to an increase in d, causing myosin heads to either fail to latch, or to latch improperly, onto the actin filament with poor force generation, leading to myocardial dysfunction. As the myocardial oedema abates, myocyte function improves.	[Bragadeesh, T.; Jayaweera, A. R.; Pascotto, M.; Micari, A.; Le, D. E.; Kaul, S.] OHSU, UHN62, Div Cardiovasc, Portland, OR 97239 USA; [Kramer, C. M.; Epstein, F. H.] Univ Virginia, Div Radiol, Charlottesville, VA USA	Kaul, S (corresponding author), OHSU, UHN62, Div Cardiovasc, 3181 SW Sam Jackson,Pk Rd, Portland, OR 97239 USA.	kauls@ohsu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL074289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB002069] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K08-HL74289] Funding Source: Medline; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R01-EB-002069] Funding Source: Medline		BERNE RM, PHYSIOLOGY, pCH1; Bolli R, 1998, BASIC RES CARDIOL, V93, P156, DOI 10.1007/s003950050079; Chandrashekhar Y, 1999, J AM COLL CARDIOL, V34, P594, DOI 10.1016/S0735-1097(99)00222-3; Decker RS, 2005, CIRCULATION, V111, P906, DOI 10.1161/01.CIR.0000155609.95618.75; DIBONA DR, 1980, CIRC RES, V47, P653, DOI 10.1161/01.RES.47.5.653; Dumont EAWJ, 2000, CIRCULATION, V102, P1564, DOI 10.1161/01.CIR.102.13.1564; Fuchs F, 1996, J MOL CELL CARDIOL, V28, P1375, DOI 10.1006/jmcc.1996.0129; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GUTTMAN MA, 1994, IEEE T MED IMAGING, V13, P74, DOI 10.1109/42.276146; JENNINGS RB, 1985, CIRC RES, V56, P262, DOI 10.1161/01.RES.56.2.262; Kennedy J. F., 1993, RECOVERY PROCESSES B; Kim D, 2003, MAGNET RESON MED, V50, P813, DOI 10.1002/mrm.10589; KLONER RA, 1974, AM J PATHOL, V74, P399; Kloner RA, 1998, CIRCULATION, V97, P1848, DOI 10.1161/01.CIR.97.18.1848; KLONER RA, 1983, CIRCULATION, V68, P8; KOIBUCHI Y, 1985, EUR J PHARMACOL, V115, P163; Lan GH, 2005, BIOPHYS J, V88, P4107, DOI 10.1529/biophysj.104.056846; Martyn DA, 2004, BIOPHYS J, V86, P1002, DOI 10.1016/S0006-3495(04)74175-2; Millman BM, 1998, PHYSIOL REV, V78, P359; Mizutani S, 2006, ANN THORAC SURG, V81, P154, DOI 10.1016/j.athoracsur.2005.06.057; PIAZZESI G, 1993, ADV EXP MED BIOL, V332, P691; PIAZZESI G, 1994, J PHYSIOL-LONDON, V476, P531, DOI 10.1113/jphysiol.1994.sp020152; Pomar F, 1995, EUR HEART J, V16, P1482, DOI 10.1093/oxfordjournals.eurheartj.a060768; SCHIERWAGEN C, 1990, J PHARMACOL METHOD, V23, P179, DOI 10.1016/0160-5402(90)90061-O; Sklenar J, 1992, J Am Soc Echocardiogr, V5, P33; STAHL LD, 1987, J AM COLL CARDIOL, V96, P1339; THALLER S, 2004, J THEOR BIOL, V31, P19; Turschner O, 2004, EUR HEART J, V25, P794, DOI 10.1016/j.ehj.2004.01.006; ZERHOUNI EA, 1998, RADIOLOGY, V69, P59; ZHAO MJ, 1992, J MOL CELL CARDIOL, V24, P269, DOI 10.1016/0022-2828(92)93164-F	30	50	52	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1355-6037			HEART	Heart	FEB	2008	94	2					166	171		10.1136/hrt.2006.102434			6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	256QX	WOS:000252745800011	17639092				2021-06-18	
J	Liao, ZB; Zhi, XG; Shi, QH; He, ZH				Liao, Z. B.; Zhi, X. G.; Shi, Q. H.; He, Z. H.			Recombinant human erythropoietin administration protects cortical neurons from traumatic brain injury in rats	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						apoptosis; Bcl-2; EPO receptor; rhEPO; traumatic brain injury	NEONATAL HYPOXIA-ISCHEMIA; CYTOCHROME-C RELEASE; CASPASE ACTIVATION; IN-VITRO; DEATH; APOPTOSIS; NEUROPROTECTION; MODULATION; PATHWAYS; RECOVERY	We explored the regulation of erythropoietin and erythropoietin receptor on traumatic brain injury (TBI), as well as the antiapoptotic effects of recombinant human erythropoietin (rhEPO) treatment. Female Wistar rats were randomly divided into three groups: rhEPO-treated TBI, vehicle-treated TBI, and sham-operated. TBI was induced by the Feeney free falling model. Rats were killed 5, 12, 24, 72, 120, or 168 h after TBI. Regulation of EPO, EPOR and Bcl-2 was detected by reverse transcription-polymerase chain reaction (RT-PCR), western blotting and immunofluorescence. Terminal deoxynucleotidyl transferase-mediated biotin-dUTP nick-end labeling (TUNEL) was used to assess DNA fragmentation after TBI. Induction of EPOR expression persisted for 168 h after TBI, whereas EPO was only slightly elevated for 72 h. In the rhEPO-treated TBI, Bcl-2 mRNA and protein levels were greater than in the vehicle-treated TBI. Bcl-2 mRNA peaked at 24 h and remained stable for 72-120 h. The number of TUNEL-positive cells in the rhEPO-treated TBI was far fewer than in the vehicle-treated TBI. EPOR regulation is enhanced for almost a week after TBI. Administration of rhEPO protects neurons by enhancing Bcl-2 expression, thereby inhibiting TBI-induced neuronal apoptosis.	[Liao, Z. B.; Zhi, X. G.; Shi, Q. H.; He, Z. H.] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China	Liao, ZB (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.	liaozhengbu@hotmail.com					Alafaci C, 2000, EUR J PHARMACOL, V406, P219, DOI 10.1016/S0014-2999(00)00691-9; Buki A, 2000, J NEUROSCI, V20, P2825; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chang YS, 2005, PEDIATR RES, V58, P106, DOI 10.1203/01.PDR.0000163616.89767.69; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Demers EJ, 2005, PEDIATR RES, V58, P297, DOI 10.1203/01.PDR.0000169971.64558.5A; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Ehrenreich H, 2005, P NATL ACAD SCI USA, V102, P862, DOI 10.1073/pnas.0406008102; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Golarai G, 2001, J NEUROSCI, V21, P8523; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Juul S, 2002, ACTA PAEDIATR, V91, P36, DOI 10.1080/080352502320764184; Kang JQ, 2003, MOL PHARMACOL, V64, P557, DOI 10.1124/mol.64.3.557; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Kumral A, 2003, BIOL NEONATE, V83, P224, DOI 10.1159/000068926; Liu CL, 2004, NEUROSCIENCE, V127, P113, DOI 10.1016/j.neuroscience.2004.03.062; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sola A, 2005, PEDIATR RES, V57, P481, DOI 10.1203/01.PDR.0000155760.88664.06; Spandou E, 2004, BRAIN RES, V1021, P167, DOI 10.1016/j.brainres.2004.06.057; Stefanis L, 2005, NEUROSCIENTIST, V11, P50, DOI 10.1177/1073858404271087; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sun Y, 2004, J CEREBR BLOOD F MET, V24, P259, DOI 10.1097/01.WCB.0000110049.43905.AC; Vairano M, 2002, EUR J NEUROSCI, V16, P584, DOI 10.1046/j.1460-9568.2002.02125.x; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wei L, 2004, BRAIN RES, V1022, P54, DOI 10.1016/j.brainres.2004.06.080; Wen TC, 2004, NEUROSCI LETT, V355, P165, DOI 10.1016/j.neulet.2003.10.078; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	30	50	56	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	FEB	2008	15	2					140	149		10.1111/j.1468-1331.2007.02013.x			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	253ZX	WOS:000252557200013	18093155				2021-06-18	
J	Williams, BR; Lazic, SE; Ogilvie, RD				Williams, Benjamin R.; Lazic, Stanley E.; Ogilvie, Robert D.			Polysomnographic and quantitative EEG analysis of subjects with long-term insomnia complaints associated with mild traumatic brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						FFT; head injury; insomnia; mild traumatic brain injury; post-concussion syndrome; sleep disorders	SLEEP-ONSET PERIOD; HEAD-INJURY; SPECTRAL-ANALYSIS; DISTURBANCES; ADOLESCENTS; PREVALENCE; DEPRESSION; SYMPTOMS; PATTERNS; RECOVERY	Objective: The aims of this study were (1) to characterise the extent and nature of disrupted sleep in individuals with long-term sleep complaints subsequent to mild traumatic brain injury (MTBI), and (2) to determine whether sleep disturbances in MTBI subjects were more characteristic of psychophysiological, psychiatric, or idiopathic insomnia. Methods: Nine MTBI patients (27.8 months post-injury; SD = 15.5 months) and nine control subjects underwent polysomnographic testing and completed self-report questionnaires on sleep quality. Power spectral (FFT) analysis of the sleep onset period was conducted, with both the power and variability in power being quantified. Results: Individuals with MTBI exhibited long-term sleep difficulties, along with various cognitive and affective abnormalities. The MTBI group had 4% less efficient sleep (p = 0.019), shorter REM onset latencies (p = 0.011), and longer sleep onset latencies, although the latter were highly variable in the MTBI group (F-test: p = 0.012). FFT analysis revealed greater intra-subject variability in the MTBI group in sigma, theta, and delta power during the sleep onset period. Conclusions: MTBI patients with persistent sleep complaints differ significantly from controls on a number of electrophysiological outcomes, but could not be easily classified into existing insomnia subtypes. Significance: Sleep disturbances can persist well after the injury in a subset of patients with MTBI. (c) 2007 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Williams, Benjamin R.; Lazic, Stanley E.; Ogilvie, Robert D.] Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada	Lazic, SE (corresponding author), Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3DY, England.	stan.lazic@cantab.net	Lazic, Stanley/F-1160-2011				Alloway CED, 1999, SLEEP, V22, P191, DOI 10.1093/sleep/22.2.191; American Sleep Disorders Association, 1990, INT CLASS SLEEP DIS; Argyropoulos SV, 2005, INT REV PSYCHIATR, V17, P237, DOI 10.1080/09540260500104458; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BIGLER E, 1990, NEUROPATHOLOGY TRAUM, P13; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; DOUGLASS AB, 1994, SLEEP, V17, P160, DOI 10.1093/sleep/17.2.160; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; EIDE PK, 1992, ACTA NEUROL SCAND, V86, P194, DOI 10.1111/j.1600-0404.1992.tb05065.x; GEORGE B, 1986, NEUROCHIRURGIA, V29, P45; GRONWALL D, 1989, CUMULATIVE PERSISTIN, P153; Hori T., 1994, TOPOGRAPHICAL EEG CH, P237; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI [DOI 10.1080/10618600.1996.10474713, 10.1080/10618600.1996.10474713]; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kristensen M, 2004, ADV PHYSIOL EDUC, V28, P2, DOI 10.1152/advan.00042.2003; Lamarche CH, 1997, SLEEP, V20, P724; LENARD HG, 1970, ACTA PAEDIATR SCAND, V59, P565, DOI 10.1111/j.1651-2227.1970.tb16809.x; LEVIN H, 1987, MINOR HEAD INJURY PO, P262; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MCCARTNEY T, 1998, SLEEP S, V21, P267; Mignot E, 2006, BRAIN, V129, P1609, DOI 10.1093/brain/awl079; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morey L. C., 1991, PERSONALITY ASSESSME; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Papadimitriou GN, 2005, INT REV PSYCHIATR, V17, P229, DOI 10.1080/09540260500104524; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PARSONS LC, 1982, NURS RES, V31, P260; Parsons LC, 1997, J NEUROTRAUM, V14, P549, DOI 10.1089/neu.1997.14.549; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; Pinheiro J., 2000, MIXED EFFECTS MODELS; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; R Development Core Team, 2006, R LANG ENV STAT COMP; Rechtschaffen A, 1968, MANUAL STANDARDIZED; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Singh M, 2006, SLEEP, V29, P890, DOI 10.1093/sleep/29.7.890; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006	44	50	52	1	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	FEB	2008	119	2					429	438		10.1016/j.clinph.2007.11.003			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	260SB	WOS:000253029600021	18083618				2021-06-18	
J	Longhi, L; Pagan, F; Valeriani, V; Magnoni, S; Zanier, E; Conte, V; Branca, V; Stocchetti, N				Longhi, Luca; Pagan, Francesca; Valeriani, Valerio; Magnoni, Sandra; Zanier, ElisaR.; Conte, Valeria; Branca, Vincenzo; Stocchetti, Nino			Monitoring brain tissue oxygen tension in brain-injured patients reveals hypoxic episodes in normal-appearing and in peri-focal tissue	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; brain oxygenation; brain hypoxia; PtiO(2); secondary insults; pathophysiology	CEREBRAL-BLOOD-FLOW; SUBSTRATE DELIVERY; NEUROCRITICAL CARE; HEAD-INJURY; METABOLISM; PERFUSION; MICROCIRCULATION; PRESSURE; ISCHEMIA	Objective: We compared brain tissue oxygen tension (PtiO(2)) measured in peri-focal and in normal-appearing brain parenchyma on computerized tomography (CT) in patients following traumatic brain injury (TBI). Design: Prospective observational study. Setting: Neuro-intensive care unit. Patients and participants: Thirty-two consecutive TBI patients were subjected to PtiO(2) monitoring. Interventions: Peri-focal tissue was identified by the presence of a hypodense area of the contusion and/or within 1 cm from the core of the contusion. The position of the tip of the PtiO(2) probe was assessed at follow-up CT scan. Measurements and results: Mean PtiO2 in the peri-contusional tissue was 19.7 +/- 2.1 mmHg and was lower than PtiO2 in normal-appearing tissue (25.5 +/- 1.5 mmHg, p < 0.05), despite a greater cerebral perfusion pressure (CPP) (73.7 +/- 2.3 mmHg vs. 67.4 +/- 1.4 mmHg, p < 0.05). We observed both in peri-focal tissue and in normal-appearing tissue episodes of brain hypoxia (PtiO(2) < 20 mmHg for at least 10 min), whose median duration was longer in peri-focal tissue than in normal-appearing tissue (51% vs. 34% of monitoring time, p < 0.01). In peri-focal tissue, we observed a progressive PtiO(2) increase from pathologic to normal values ( p < 0.01). Conclusions: Multiple episodes of brain hypoxia occurred over the first 5 days following severe TBI. PtiO(2) was lower in peri-contusional tissue than in normal-appearing tissue. In peri-contusional tissue, a progressive increase of PtiO(2) from pathologic to normal values was observed over time, suggestive of an improvement at microcirculatory level.	Univ Milan, Fdn IRCCS, Osped Maggiore Policlin, Neurosurg Intens Care Unit,Dept Anesthesia & Crit, I-20100 Milan, Italy; Osped Maggiore Policlin Mangiagalli Regina Elena, Fdn IRCCS, Dept Neuroradiol, Milan, Italy	Longhi, L (corresponding author), Univ Milan, Fdn IRCCS, Osped Maggiore Policlin, Neurosurg Intens Care Unit,Dept Anesthesia & Crit, Via Sforza N 35, I-20100 Milan, Italy.	lucalonghi@policlinico.mi.it	Stocchetti, Nino/O-7444-2017; Longhi, Luca/AAF-9903-2021; Zanier, Elisa/AAA-8095-2020	Stocchetti, Nino/0000-0003-3250-6834; Longhi, Luca/0000-0001-9894-8788; Zanier, Elisa/0000-0002-3011-8718			Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Longhi L, 2002, ACT NEUR S, V81, P315; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MARSHALL LF, 1991, J NEUROSURG S, V75; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Stocchetti N, 2004, CRIT CARE MED, V32, P1429, DOI 10.1097/01.CCM.0000128957.69536.A5; Stocchetti N, 1998, ACT NEUR S, V71, P162; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	33	50	50	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	DEC	2007	33	12					2136	2142		10.1007/s00134-007-0845-2			7	Critical Care Medicine	General & Internal Medicine	234JM	WOS:000251157400015	17846748				2021-06-18	
J	Soriano, FX; Hardingham, GE				Soriano, Francesc X.; Hardingham, Giles E.			Compartmentalized NMDA receptor signalling to survival and death	JOURNAL OF PHYSIOLOGY-LONDON			English	Article; Proceedings Paper	Symposium on Compartmentalized Signalling in Neurons	2007	Glasgow, SCOTLAND				RAT HIPPOCAMPAL-NEURONS; D-ASPARTATE ANTAGONISTS; TRAUMATIC BRAIN-INJURY; CELL-DEATH; GENE-EXPRESSION; CLINICAL-TRIALS; KINASE PATHWAY; DENTATE GYRUS; CREB SHUTOFF; MU-CALPAIN	The ability of Ca2+ influx through the N-methyl D-aspartate subclass of glutamate receptor (NMDA receptor) to both kill neurons and to promote survival under different circumstances is well established. Here we discuss the signal pathways that mediate this dichotomous signalling, and the factors that influence whether an NMDA receptor-dependent Ca2+ signal results in a net pro-survival or pro-death effect. The magnitude of NMDA receptor activation, be it intensity or duration, is of course very important in determining the nature of they response to an episode of NMDA receptor activity, with excitotoxic death pathways requiring higher levels than survival pathways. However, the NMDA receptor is not merely a conduit for Ca2+ influx: the consequences of NMDA receptor activity can be influenced by signalling molecules that physically associate with the NMDA receptor or indeed the location (synaptic versus extrasynaptic) of the receptor. Furthermore, we discuss the possibility that the Ca2+ effectors of survival and death are in different subcellular locations, and thus depend on the spatial characteristics of the Ca2+ transient. A greater understanding of these issues may point to ways of selectively blocking pro-death signalling in neurological disorders such as stroke, where global NMDA receptor antagonists have proved ineffective.	Univ Edinburgh, Ctr Res Neurosci, Edinburgh EH8 9XD, Midlothian, Scotland	Hardingham, GE (corresponding author), Univ Edinburgh, Ctr Res Neurosci, Edinburgh EH8 9XD, Midlothian, Scotland.	giles.hardingham@ed.ac.uk	Soriano, Francesc X/U-7552-2017	Soriano, Francesc X/0000-0003-1678-7162; Hardingham, Giles/0000-0002-7629-5314	Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/D011388/1] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Adams SM, 2004, J NEUROSCI, V24, P9441, DOI 10.1523/JNEUROSCI.3290-04.2004; Albers GV, 2001, JAMA-J AM MED ASSOC, V286, P2673, DOI 10.1001/jama.286.21.2673; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Camacho A, 2006, ARCH MED RES, V37, P11, DOI 10.1016/j.arcmed.2005.05.014; Chohan MO, 2006, J ALZHEIMERS DIS, V10, P81; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Frizelle PA, 2006, MOL PHARMACOL, V70, P1022, DOI 10.1124/mol.106.024042; GOULD E, 1994, J COMP NEUROL, V340, P551, DOI 10.1002/cne.903400408; Hansen HH, 2004, NEUROBIOL DIS, V16, P440, DOI 10.1016/j.nbd.2004.03.013; Harding JH, 2003, INTERFACE SCI, V11, P81, DOI 10.1023/A:1021539124206; Hardingham GE, 2006, BIOCHEM SOC T, V34, P936, DOI 10.1042/BST0340936; Hardingham GE, 2002, BBA-PROTEINS PROTEOM, V1600, P148, DOI 10.1016/S1570-9639(02)00455-7; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hardingham GE, 2001, NAT NEUROSCI, V4, P261, DOI 10.1038/85109; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hetman M, 2006, CURR TOP MED CHEM, V6, P787, DOI 10.2174/156802606777057553; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Ivanov A, 2006, J PHYSIOL-LONDON, V572, P789, DOI 10.1113/jphysiol.2006.105510; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Lafon-Cazal M, 2002, EUR J NEUROSCI, V16, P575, DOI 10.1046/j.1460-9568.2002.02124.x; Limback-Stokin K, 2004, J NEUROSCI, V24, P10858, DOI 10.1523/JNEUROSCI.1022-04.2004; Lipton SA, 1999, NAT MED, V5, P270, DOI 10.1038/6481; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Neyton J, 2006, J NEUROSCI, V26, P1331, DOI 10.1523/JNEUROSCI.5242-05.2006; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Papadia S, 2005, J NEUROSCI, V25, P4279, DOI 10.1523/JNEUROSCI.5019-04.2005; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Pottorf WJ, 2006, J NEUROCHEM, V98, P1646, DOI 10.1111/j.1471-4159.2006.04063.x; Rameau GA, 2007, J NEUROSCI, V27, P3445, DOI 10.1523/JNEUROSCI.4799-06.2007; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Sensi SL, 2004, CURR MOL MED, V4, P87, DOI 10.2174/1566524043479211; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Stout AK, 1998, NAT NEUROSCI, V1, P366; Tashiro A, 2006, NATURE, V442, P929, DOI 10.1038/nature05028; Thomas CG, 2006, J NEUROPHYSIOL, V95, P1727, DOI 10.1152/jn.00771.2005; Tompa P, 1996, J BIOL CHEM, V271, P33161, DOI 10.1074/jbc.271.52.33161; Torok K, 1998, CURR BIOL, V8, P692, DOI 10.1016/S0960-9822(98)70275-1; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Zhang SJ, 2007, NEURON, V53, P549, DOI 10.1016/j.neuron.2007.01.025	64	50	51	0	10	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0022-3751			J PHYSIOL-LONDON	J. Physiol.-London	OCT 15	2007	584	2					381	387		10.1113/jphysiol.2007.138875			7	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	227IV	WOS:000250651300007	17690142	Green Published			2021-06-18	
J	Schmidt, JH; Reyes, BJ; Fischer, R; Flaherty, SK				Schmidt, John H.; Reyes, Bernardo J.; Fischer, Roopan; Flaherty, Sarah K.			Use of hinge craniotomy for cerebral decompression - Technical note	JOURNAL OF NEUROSURGERY			English	Article						craniotomy; head trauma; hinge; intracranial pressure	TRAUMATIC BRAIN-INJURY; SUPRATENTORIAL MASS LESIONS; ACUTE SUBDURAL-HEMATOMA; COMA SCALE SCORE; INTRACRANIAL HYPERTENSION; CLINICAL RELEVANCE; CRANIECTOMY; MANAGEMENT; HEMICRANIECTOMY; INFARCTION	v,Decompressive craniectomy to relieve cerebral edema and intracranial hypertension due to traumatic brain injury is a generally accepted practice; however, the procedure remains controversial because of its uncertain effects on outcome, specific complications such as the syndrome of the sinking skin flap, and the need for subsequent cranioplasty. The authors developed a novel craniotomy technique using titanium bone plates in a hinged fashion, which maintains cerebral protection while reducing postoperative complications and eliminating subsequent cranioplasty procedures. The authors conducted a retrospective review of data obtained in all consecutive patients who had undergone post-traumatic cerebral decompression cramotomy using the hinge technique at a Level I trauma facility between 1990 and 2004. Twenty-five patients, most of whom were male (88%) and Caucasian (88%) with a mean age of 38.2 +/- 16.1 years, underwent the hinge craniotomy. The in-hospital mortality rate was 48%, and good cerebral decompression was achieved. None of the patients required surgery for flap replacement. Long-term follow-up data showed that one patient required subsequent cranioplasty due to infection and one patient presented with cranial deformities. None of the patients presented with bone resorption or sinking flap syndrome. The hinge technique effectively prevents procedure-related morbidity and the need for subsequent surgical bone replacement otherwise introduced by traditional decompressive craniectomy. A randomized controlled trial is required to substantiate these findings.	W Virginia Univ, Hlth Sci Ctr, Dept Surg, Sch Med,Charleston Div, Charleston, WV 25304 USA; W Virginia Univ, Dept Internal Med, Charleston, WV 25304 USA; Res Inst, Charleston, WV USA; Charleston Area Med Ctr Hlth Educ, Charleston, WV USA; W Virginia Univ, Sch Med, Morgantown, WV 26506 USA	Reyes, BJ (corresponding author), CCI, 3211 MacCorkle Ave SE, Charleston, WV 25304 USA.	bernardo.reyes@camc.org					BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; Bostrom S, 2005, ACTA NEUROCHIR, V147, P279, DOI 10.1007/s00701-004-0480-4; Buczko W, 2005, J TRAUMA, V58, P40, DOI 10.1097/01.TA.0000149332.17597.36; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; Curry WT, 2005, NEUROSURGERY, V56, P681, DOI 10.1227/01.NEU.0000156604.41886.62; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; Hutchinson P J, 2004, Curr Opin Crit Care, V10, P101, DOI 10.1097/00075198-200404000-00004; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; KRIEGER D, 1993, CRIT CARE MED, V21, P1944, DOI 10.1097/00003246-199312000-00024; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MCNEALY DE, 1962, ARCH NEUROL-CHICAGO, V7, P10, DOI 10.1001/archneur.1962.04210010016002; Munch E, 2000, NEUROSURGERY, V47, P315; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Poon WS, 2005, ACT NEUR S, V93, P207; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; Schneider GH, 2002, ACT NEUR S, V81, P77; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Stefini R, 1999, NEUROSURGERY, V45, P626, DOI 10.1097/00006123-199909000-00038; TABADDOR K, 1976, J NEUROSURG, V44, P506, DOI 10.3171/jns.1976.44.4.0506; Wada Y, 2002, NEUROL MED-CHIR, V42, P414, DOI 10.2176/nmc.42.414; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	34	50	50	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2007	107	3					678	682		10.3171/JNS-07/09/0678			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	206YZ	WOS:000249220100029	17886572				2021-06-18	
J	Vallat-Azouvi, C; Weber, T; Legrand, L; Azouvi, P				Vallat-Azouvi, Claire; Weber, Thomas; Legrand, Ludovic; Azouvi, Philippe			Working memory after severe traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						head injury; executive functions; attention; divided attention; central executive; short-term memory	DUAL-TASK PERFORMANCE; CLOSED-HEAD INJURY; CENTRAL EXECUTIVE COMPONENT; DIVIDED ATTENTION; NEUROPSYCHOLOGICAL DEFICITS; SELECTIVE IMPAIRMENT; LOAD	The aim of the present study was to assess the functioning of the different subsystems of working memory after severe traumatic brain injury (TBI). A total of 30 patients with severe chronic TBI and 28 controls received a comprehensive assessment of working memory addressing the phonological loop (forward and backward digit span; word length and phonological similarity effects), the visuospatial sketchpad (forward and backward visual spans), and the central executive (tasks requiring simultaneous storage and processing of information, dual-task processing, working memory updating). Results showed that there were only marginal group differences regarding the functioning of the two slave systems, whereas patients with severe TBI performed significantly poorer than controls on most central executive tasks, particularly on those requiring a high level of controlled processing. These results suggest that severe TBI is associated with an impairment of executive aspects of working memory. The anatomic substrate of this impairment remains to be elucidated. It might be related to a defective activation of a distributed network, including the dorsolateral prefrontal cortex.	Hop Raymond Poincare, Serv Med Phys & Readaptat, Garches 92380, France; Hop Raymond Poincare, UGECAM, Antenne UEROS, Garches, France; INSERM, U 731, Paris, France; Univ Versailles St Quentin, Serv Med Phys Readaptat, Garches, France; Hop Raymond Poincare, AP HP, Garches, France; Univ Paris 06, Fac Med, Lab Physiol & Physiopathol Motricite, Paris, France	Azouvi, P (corresponding author), Hop Raymond Poincare, Serv Med Phys & Readaptat, Garches 92380, France.	philippe.azouvi@rcp.aphp.fr					Allain P, 2001, BRAIN COGNITION, V45, P21, DOI 10.1006/brcg.2000.1249; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A, 1998, CURR OPIN NEUROBIOL, V8, P234, DOI 10.1016/S0959-4388(98)80145-1; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Baddeley A. D., 2002, PRINCIPLES FRONTAL L, P246, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0016; Baddeley A. D., 1986, WORKING MEMORY; Baddeley AD, 2001, BRAIN, V124, P1492, DOI 10.1093/brain/124.8.1492; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BROOKS D N, 1975, Cortex, V11, P329; Brouwer W, 2001, BRAIN COGNITION, V46, P54, DOI 10.1016/S0278-2626(01)80033-6; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Bublak P, 2000, J CLIN EXP NEUROPSYC, V22, P176, DOI 10.1076/1380-3395(200004)22:2;1-1;FT176; Cazalis F, 2006, BRAIN INJURY, V20, P1019, DOI 10.1080/02699050600664384; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Collette F, 2002, NEUROSCI BIOBEHAV R, V26, P105, DOI 10.1016/S0149-7634(01)00063-X; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Greene JDW, 1995, NEUROPSYCHOLOGIA, V33, P1647, DOI 10.1016/0028-3932(95)00046-1; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Logie RH, 1996, MEM COGNITION, V24, P305, DOI 10.3758/BF03213295; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; MORRIS N, 1990, BRIT J PSYCHOL, V81, P111, DOI 10.1111/j.2044-8295.1990.tb02349.x; NORMAN DA, 1980, N99 U CAL SAN DIEG; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TEASDALE G, 1974, LANCET, V2, P81; Vallat C, 2005, BRAIN INJURY, V19, P1157, DOI 10.1080/02699050500110595; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; WITHAAR FK, 2000, UNPUB DIVIDED ATTENT	56	50	54	1	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2007	13	5					770	780		10.1017/S1355617707070993			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	205UQ	WOS:000249140500004	17697408				2021-06-18	
J	Ellis, EF; Willoughby, KA; Sparks, SA; Chen, T				Ellis, Earl F.; Willoughby, Karen A.; Sparks, Sallie A.; Chen, Tao			S100B protein is released from rat neonatal neurons, astrocytes, and microglia by in vitro trauma and anti-S100 increases trauma-induced delayed neuronal injury and negates the protective effect of exogenous S100B on neurons	JOURNAL OF NEUROCHEMISTRY			English	Article						S100B; neuroprotection; traumatic brain injury	STRETCH-INDUCED INJURY; CULTURED ASTROCYTES; COGNITIVE RECOVERY; EXPRESSION; INFUSION; DAMAGE; CELLS; ATP	S100B protein is found in brain, has been used as a marker for brain injury and is neurotrophic. Using a well-characterized in vitro model of brain cell trauma, we have previously shown that strain injury causes S100B release from neonatal rat neuronal plus glial cultures and that exogenous S100B reduces delayed post-traumatic neuronal damage even when given at 6 or 24 h post-trauma. The purpose of the current studies was to measure post-traumatic S100B release by specific brain cell types and to examine the effect of an antibody to S100 on post-traumatic delayed (48 h) neuronal injury and the protective effect of exogenous S100B. Neonatal rat cortical cells grown on a deformable elastic membrane were subjected to a strain (stretch) injury produced by a 50 ms displacement of the membrane. S100B was measured with an ELISA kit. Trauma released S100B from pure cultures of astrocytes, microglia, and neurons. Anti-S100 reduced released S100B to below detectable levels, increased delayed neuronal injury in traumatized cells and negated the protective effect of exogenous S100B on injured cells. Heat denatured anti-S100 did not exacerbate injury. These studies provide further evidence for a protective role for S100B following neuronal trauma.	Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Ellis, EF (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA.	efellis@vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27214, NS07288] Funding Source: Medline		Adami C, 2001, GLIA, V33, P131, DOI 10.1002/1098-1136(200102)33:2<131::AID-GLIA1012>3.0.CO;2-D; Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Azmitia EC, 2002, PROG BRAIN RES, V136, P87; BOYES BE, 1986, NEUROSCIENCE, V17, P857, DOI 10.1016/0306-4522(86)90050-3; Brewton LS, 2001, BRAIN RES, V912, P9, DOI 10.1016/S0006-8993(01)02519-7; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hu JR, 1997, J NEUROCHEM, V69, P2294; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Lamb RG, 1997, J NEUROCHEM, V68, P1904; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neary JT, 2005, J NEUROTRAUM, V22, P491, DOI 10.1089/neu.2005.22.491; Reali C, 2005, J NEUROSCI RES, V81, P677, DOI 10.1002/jnr.20584; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Schreiber D., 1995, P 1995 INT RES C BIO, P233; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Tran MD, 2006, P NATL ACAD SCI USA, V103, P9321, DOI 10.1073/pnas.0603146103; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; WEBER JT, 2001, J NEUROTRAUM, V18, P1183; Willoughby KA, 2004, J NEUROCHEM, V91, P1284, DOI 10.1111/j.1471-4159.2004.02812.x; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	39	50	56	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2007	101	6					1463	1470		10.1111/j.1471-4159.2007.04515.x			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	177EB	WOS:000247135300003	17403138	Bronze			2021-06-18	
J	Friess, SH; Ichord, RN; Owens, K; Ralston, J; Rizol, R; Overall, KL; Smith, C; Helfaer, MA; Margulies, SS				Friess, Stuart H.; Ichord, Rebecca N.; Owens, Kristin; Ralston, Jill; Rizol, Rebecca; Overall, Karen L.; Smith, Colin; Helfaer, Mark A.; Margulies, Susan S.			Neurobehavioral functional deficits following closed head injury in the neonatal pig	EXPERIMENTAL NEUROLOGY			English	Article						head injury; neurobehavioral assessment; axonal injury	HYPOTHERMIC CIRCULATORY ARREST; TRAUMATIC BRAIN-INJURY; ASPHYXIC CARDIAC-ARREST; OPEN-FIELD ACTIVITY; HYPOXIA-ISCHEMIA; NEWBORN PIGS; CARDIOPULMONARY BYPASS; AXONAL INJURY; RAT; METABOLISM	Neurobehavioral deficits in higher cortical systems have not been described previously in a large animal model of diffuse brain injury. Anesthetized 3-5 day old piglets were subjected to either mild (142 rad/s) or moderate (188 rad/s) rapid non-impact axial rotations of the head. Multiple domains of cortical function were evaluated 5 times during the 12 day post-injury period using tests of neurobehavioral function devised for piglets. There were no observed differences in neurobehavioral outcomes between mild injury pigs (N=8) and instrumented shams (N=4). Moderately injured piglets (N=7) had significantly lower interest in exploring their environment and had higher failure rates in visual-based problem solving compared to instrumented shams (N=5) on days 1 and 4 after injury. Neurobehavioral functional deficits correlated with neuropathologic damage in the neonatal pigs after inertial head injury. Injured axons detected by immunohistochemistry (beta-APP) were absent in mild injury and sham piglets, but were observed in moderately injured piglet brains. In summary, we have developed a quantitative battery of neurobehavioral functional assessments for large animals that correlate with neuropathologic axonal damage and may have wide applications in the fields of cardiac resuscitation, stroke, and hypoxic-ischemic brain injury. (c) 2006 Elsevier Inc. All rights reserved.	Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Neurol, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Sch Engn & Appl Sci, Philadelphia, PA 19104 USA; Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Western Gen Hosp, Dept Neuropathol, Edinburgh, Midlothian, Scotland	Margulies, SS (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu		Smith, Colin/0000-0002-4507-5132	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS039679, R01-NS39679] Funding Source: Medline		Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Agnew DM, 2003, PEDIATR RES, V54, P253, DOI 10.1203/01.PDR.0000072783.22373.FF; Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; Armstead WM, 2002, DEV BRAIN RES, V139, P19, DOI 10.1016/S0165-3806(02)00511-4; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bolhuis JE, 2004, BEHAV BRAIN RES, V152, P351, DOI 10.1016/j.bbr.2003.10.024; Bona E, 1997, PEDIATR RES, V42, P678, DOI 10.1203/00006450-199711000-00021; Brambrink AM, 1999, J CEREBR BLOOD F MET, V19, P927, DOI 10.1097/00004647-199908000-00012; de Jong IC, 2000, PHYSIOL BEHAV, V68, P571, DOI 10.1016/S0031-9384(99)00212-7; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; Fisher M D, 1997, Crit Care Nurs Q, V20, P36; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hagberg H, 2002, DEV NEUROSCI-BASEL, V24, P364, DOI 10.1159/000069040; HAMMELL DL, 1975, J ANIM SCI, V40, P573; Head E, 1997, PHYSIOL BEHAV, V62, P963, DOI 10.1016/S0031-9384(97)00198-4; Jacob S, 2001, NEUROREPORT, V12, P2391, DOI 10.1097/00001756-200108080-00021; Kurth CD, 1999, J THORAC CARDIOV SUR, V118, P1068, DOI 10.1016/S0022-5223(99)70103-0; Martin LJ, 1997, J COMP NEUROL, V377, P262, DOI 10.1002/(SICI)1096-9861(19970113)377:2<262::AID-CNE8>3.0.CO;2-1; MIDULLA PS, 1994, J CARDIAC SURG, V9, P560; OMMAYA A, 1966, P 11 STAPP CAR CRASH, P73; Ozden S, 2004, J NEUROTRAUM, V21, P73, DOI 10.1089/089771504772695968; PIERCE K, 2001, PHYSIOL BEHAV, V68, P571; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Priestley MA, 2001, J THORAC CARDIOV SUR, V121, P336, DOI 10.1067/mtc.2001.112338; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Puppe B, 1999, LAB ANIM, V33, P215, DOI 10.1258/002367799780578110; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rossier J, 2003, BEHAV NEUROSCI, V117, P412, DOI 10.1037/0735-7044.117.3.412; Schultz S, 2004, ANN THORAC SURG, V77, P2138, DOI 10.1016/j.athoracsur.2003.12.047; Slotnick B, 2001, TRENDS COGN SCI, V5, P216, DOI 10.1016/S1364-6613(00)01625-9; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; YOUNG JK, 1986, PHYSIOL BEHAV, V36, P881, DOI 10.1016/0031-9384(86)90447-6	35	50	53	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	2007	204	1					234	243		10.1016/j.expneurol.2006.10.010			10	Neurosciences	Neurosciences & Neurology	148PC	WOS:000245086100023	17174304	Green Accepted			2021-06-18	
J	Hill-Briggs, F; Dial, JG; Morere, DA; Joyce, A				Hill-Briggs, Felicia; Dial, Jack G.; Morere, Donna A.; Joyce, Arthur			Neuropsychological assessment of persons with physical disability, visual impairment or blindness, and hearing impairment or deafness	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						accommodation; functional status; testing	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; SIGN-LANGUAGE; LATERALIZATION; REHABILITATION; PERFORMANCE; VALIDATION; ATTENTION; VALIDITY; DEFICITS	Conducting assessment with individuals with physical disability, visual impairment or blindness, and hearing impairment or deafness poses significant challenges for the neuropsychologist. Although standards for psychological testing have been devised to address assessment of persons with disabilities, little research has been conducted to validate neuropsychological test accommodation and modification practices that deviate from standard test administration or to develop test parameters and interpretive guidelines specifically for persons with different physical or sensory disabilities. This paper reviews issues pertaining to neuropsychological test selection and administration, common accommodation and modification practices, test development and validation, and disabilityrelated factors that influence interpretation of test results. Systematic research is needed to develop methodological parameters for testing and to ensure reliable and valid neuropsychological assessment practices for individuals with physical or sensory disabilities. (C) 2007 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Johns Hopkins Sch Med, Baltimore, MD USA; Clin & Consulting Neuropsychol, Irving, TX USA; Gallaudet Univ, Washington, DC 20002 USA; N Texas State Univ, Vernon, TX USA	Hill-Briggs, F (corresponding author), Dept Med, 2024 E Monument St, Baltimore, MD 21205 USA.	fbriggsh@jhmi.edu		Hill-Briggs, Felicia/0000-0002-2804-3278			ALLEN DV, 1971, PSYCHON SCI, V24, P295; ALTENBACH JF, 1992, THESIS LOYOLA U CHIC; American Educational Research Association American Psychological Association National Council of Measurement in Education Joint Committee on Standards for Educational Psychological Testing (US), 1999, STAND ED PSYCH TEST; BIGLER ED, 1981, J CLIN PSYCHOL, V37, P849, DOI 10.1002/1097-4679(198110)37:4<849::AID-JCLP2270370430>3.0.CO;2-3; Bosworth RG, 1999, PSYCHOL SCI, V10, P256, DOI 10.1111/1467-9280.00146; BRADEN JP, 1994, DEAFNESS DEPRIVATION; BRIGGS PF, 1963, J CLIN PSYCHOL, V19, P427, DOI 10.1002/1097-4679(196310)19:4<427::AID-JCLP2270190417>3.0.CO;2-0; BRIGGS PF, 1960, J CLIN PSYCHOL, V16, P318, DOI 10.1002/1097-4679(196007)16:3<318::AID-JCLP2270160327>3.0.CO;2-N; Cattani A, 2005, BRAIN COGNITION, V58, P226, DOI 10.1016/j.bandc.2004.12.001; CHAN F, 1993, VOCATIONAL EVALUATIO, V26, P57; Charlier BL, 2000, Q J EXP PSYCHOL-A, V53, P349, DOI 10.1080/027249800390529; CLARK MD, 1985, THESIS U N CAROLINA; Corina DP, 2003, J COGNITIVE NEUROSCI, V15, P718, DOI 10.1162/jocn.2003.15.5.718; CORINA DP, 1992, SCIENCE, V255, P1258, DOI 10.1126/science.1546327; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; DEE HL, 1969, CONFIN NEUROL, V31, P273; DEE HL, 1970, NEUROPSYCHOLOGIA, V8, P305, DOI 10.1016/0028-3932(70)90076-X; DEFILIPPO CL, 1981, THESIS WASHINGTON U; Dial J, 1990, MANUAL COMPREHENSIVE; DIAL JG, 1991, J VISUAL IMPAIR BLIN, V85, P153; DIAL JG, 1991, WORK WORTH DOING ADV, P47; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; EMMOREY K, 1993, COGNITION, V46, P139, DOI 10.1016/0010-0277(93)90017-P; GANNON JR, 1981, DEAF HERITAGE NARRAT; GARAHAN MB, 1992, J AM GERIATR SOC, V40, P130, DOI 10.1111/j.1532-5415.1992.tb01932.x; GUTTERMAN J, 1985, J VISUAL IMPAIRM FEB, P55; HAMMILL DD, 1997, EXAMINER MANUAL COMP; HANSON VL, 1982, J EXP PSYCHOL LEARN, V8, P572, DOI 10.1037/0278-7393.8.6.572; HAUSER PC, 2000, THESIS GALLAUDET U; HAYES SP, 1942, OUTLOOK BLIND, V36, P225; HAYES SP, 1943, OUTLOOK BLIND, V37, P37; HOLM MB, 1998, HUMAN BRAIN FUNCT, P9; Iezzoni LI, 2001, J GEN INTERN MED, V16, P235, DOI 10.1046/j.1525-1497.2001.016004235.x; JOYCE A, 2004, J APPL REHABILITATIO, V35, P3; KASKEL LM, 1991, ISSUES PAPERS 5 NATL, P167; KASKEL LM, 1994, DIRECTIONS REHABILIT, V5; KOO DS, 2003, THESIS U ROCHESTER; Kuo HK, 2005, J AM GERIATR SOC, V53, P1154, DOI 10.1111/j.1532-5415.2005.53368.x; LaSasso C., 2003, J DEAF STUDIES DEAF, V8, P250, DOI [DOI 10.1093/DEAFED/ENG014, 10.1093/deafed/eng014]; LEYBAERT J, 1983, CAHIERS PSYCHOL COGN, V3, P255; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; MacCluskie KC, 1998, J VISUAL IMPAIR BLIN, V92, P189, DOI 10.1177/0145482X9809200306; Maller S.J., 2003, OXFORD HDB DEAF STUD, P451; Mangiameli LJ, 1999, ARCH CLIN NEUROPSYCH, V14, P701; Mangiameli LJ, 1998, ARCH CLIN NEUROPSYCH, V13, P89; MARCOTTE AC, 1987, BRAIN LANG, V31, P276, DOI 10.1016/0093-934X(87)90075-7; Marschark M., 1997, RAISING ED DEAF CHIL; McCay V, 2005, J DEAF STUD DEAF EDU, V10, P225, DOI 10.1093/deafed/eni024; McCay V, 2001, AM ANN DEAF, V146, P429, DOI 10.1353/aad.2012.0200; MCGEE JM, 1994, THESIS U N TEXAS DEN; MCKEE DE, 1988, THESIS U PITTSBURGH; Meadow K, 1980, DEAFNESS CHILD DEV; Miller J. C., 2003, J VISUAL IMPAIR BLIN, V12, P769; MILLER KR, 2001, J DEAF STUD DEAF EDU, V6, P226; Mooradian AD, 1997, CLIN NEUROSCI, V4, P322; Nelson PA, 2002, REHABIL PSYCHOL, V47, P184, DOI 10.1037//0090-5550.47.2.184; Nelson PA, 2001, ARCH CLIN NEUROPSYCH, V16, P766; Nester M. A., 1994, IMPLICATIONS AM DISA, P25; NEVILLE HJ, 1987, BRAIN RES, V405, P284, DOI 10.1016/0006-8993(87)90297-6; O'Keeffe J., 1994, IMPLICATIONS AM DISA, P1; Park WL, 2005, ARCH PHYS MED REHAB, V86, P79, DOI 10.1016/j.apmr.2004.01.021; POIZNER H, 1981, J EXP PSYCHOL HUMAN, V7, P1146, DOI 10.1037/0096-1523.7.5.1146; Pollard RQ, 2005, REHABIL PSYCHOL, V50, P258, DOI 10.1037/0090-5550.50.3.258; Pratt S. I., 1998, TEST IMTERPRETATION, P349; PRICE JR, 1987, J VISUAL IMPAIR BLIN, V81, P28; Proksch J, 2002, J COGNITIVE NEUROSCI, V14, P687, DOI 10.1162/08989290260138591; RABECK DD, 1994, THESIS U N TEXAS DEN; Reid JMV, 1997, J VISUAL IMPAIR BLIN, V91, P546; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; Rettenbach R, 1999, J COGNITIVE NEUROSCI, V11, P560, DOI 10.1162/089892999563616; RICH CC, 1965, PERS GUID J, V43, P912, DOI 10.1002/j.2164-4918.1965.tb02848.x; RICHARDS JS, 1988, AM J PHYS MED REHAB, V67, P211, DOI 10.1097/00002060-198810000-00005; RODA M, 1987, LANGUAGE COGNITION D; ROTH E, 1989, PARAPLEGIA, V27, P480, DOI 10.1038/sc.1989.75; SANTISTEVAN EF, 1998, THESIS GALLAUDET U; SCHILDROTH A, 1994, AM J AUDIOLOGY   JUL, P27; Shapiro BK, 2004, J PEDIATR-US, V145, pS3, DOI 10.1016/j.jpeds.2004.05.014; Smith D. K., 2002, ASSESSING INDIVIDUAL, P147; Spreen O., 1995, DEV NEUROPSYCHOLOGY; Stivalet P, 1998, COGNITIVE BRAIN RES, V6, P227, DOI 10.1016/S0926-6410(97)00026-8; Tate DG, 2004, ARCH PHYS MED REHAB, V85, P1837, DOI 10.1016/j.apmr.2004.02.022; Tekin M, 2001, LANCET, V358, P1082, DOI 10.1016/S0140-6736(01)06186-4; *US CENS BUR, 2000, DIS STAT 2000; VERNON M, 1990, PSYCHOL DEAFNESS; WAINAPEL SF, 1989, ARCH PHYS MED REHAB, V70, P439, DOI 10.1016/0003-9993(89)90002-6; Wechsler D., 1997, WAIS 3 MANUAL; WESHSLER D, 1997, WECHSLER MEMORY SCAL; Wilson M, 1997, J Deaf Stud Deaf Educ, V2, P121; Wilson M, 1997, J Deaf Stud Deaf Educ, V2, P150; Wolfson D., 1993, HALSTEAD REITAN NEUR; Yaffe K, 2004, NEUROLOGY, V63, P658, DOI 10.1212/01.WNL.0000134666.64593.BA	92	50	50	2	20	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2007	22	3					389	404		10.1016/j.acn.2007.01.013			16	Psychology, Clinical; Psychology	Psychology	196IO	WOS:000248475100013	17303374	Bronze			2021-06-18	
J	Etemadrezaie, H; Baharvahdat, H; Shariati, Z; Lari, SM; Shakeri, MT; Ganjeifar, B				Etemadrezaie, Hamid; Baharvahdat, Humain; Shariati, Zhaleh; Lari, Shahrzad M.; Shakeri, Mohammad T.; Ganjeifar, Babak			The effect of fresh frozen plasma in severe closed head injury	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						coagulopathy; delayed traumatic intracerebral hematoma; fresh frozen plasma; traumatic brain injury; severe closed head injury	DISSEMINATED INTRAVASCULAR COAGULATION; TRAUMATIC INTRACEREBRAL HEMATOMA; BRAIN-INJURY; COAGULOPATHY; HEMORRHAGE; FIBRINOLYSIS	Objective: Traumatic brain injury (TBI) is one of the most common causes of morbidity and mortality. Coagulopathy, commonly occurring after severe TBI, is associated with poor outcome and secondary complications, especially delayed traumatic intracerebral hematoma (DTICH). In this study we evaluated the effect of fresh frozen plasma (FFP) on the reduction in the incidence of DTICH in severe closed head injury victims. Methods: This study was carried out as a double-blind randomized clinical trial. Ninety patients were entered in two parallel groups taking either FFP or normal saline (N/S). Patients' selection criteria for both groups were: severe closed head injury (Glasgow coma scale <= 8), no mass lesion required evacuation and no history of coagulopathy. The clinical findings, laboratory data, computed tomography (CT) scans and Glasgow outcome scale after I month were assessed and compared in two groups. Results: Out of 90 patients, 44 received FFP and 46 received N/S. The development of new intracerebral hematoma in follow-up CT scans were more common in the FFP group than the N/S group (p = 0.012). Both groups showed similar frequency of poor outcome (P = 0.343). The mortality was significantly more common in the FFP group than in the N/S group (63% versus 35%, p = 0.006). Conclusion: The result of this study revealed that early empirical infusion of FFP in patients with severe head injury may lead to adverse effects, such as an increase in the frequency of DTICH and an increase in the mortality. (c) 2006 Elsevier B.V. All rights reserved.	Mashhad Univ Med Sci, Shahid Kamyab Emdadi Hosp, Dept Neurosurg, Mashhad, Iran; MUMS, Hasheminejad Hosp, Dept Neurosurg, Mashhad, Iran; MUMS, Emam Reza Hosp, Dept Internal Med, Mashhad, Iran; MUMS, Emam Reza Hosp, Intens Care Unit, Mashhad, Iran; MUMS, Ghaem Hosp, Community Med & Publ Hlth Dept, Mashhad, Iran	Baharvahdat, H (corresponding author), 115,31 Abouzar Ghaffari Ave,Ahmadabad St, Mashhad 91768, Iran.	etemadrezaiens@yahoo.com; humainbv@yahoo.fr; jshariati@yahoo.com; s-lari@mums.ac.ir; m_t_shakeri@yahoo.com; b_ganjeifar@yahoo.com	Lari, Shahrzad/AAN-3015-2020; Baharvahdat, Humain/O-2086-2013; shakeri, Mohammad Taghi/Q-4293-2017	Baharvahdat, Humain/0000-0002-1154-8843; shakeri, Mohammad Taghi/0000-0002-8287-9594; Ganjeifar, Babak/0000-0002-5212-5791			AUER LM, 1979, ACTA NEUROCHIR, V49, P219, DOI 10.1007/BF01808961; BECKE RS, 1999, EU J PEDIAT, V158, pS197; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Cortiana M, 1986, J Neurosurg Sci, V30, P133; CRONE KR, 1987, NEUROSURGERY, V21, P532, DOI 10.1227/00006123-198710000-00015; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; GRAHAM DI, 1971, LANCET, V1, P265; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; Kaufmann CR, 1997, J TRAUMA, V42, P716, DOI 10.1097/00005373-199704000-00023; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Kushimoto S, 2003, J NEUROTRAUM, V20, P357, DOI 10.1089/089771503765172318; Lee KR, 1996, ACTA NEUROCHIR, V138, P396, DOI 10.1007/BF01420301; May AK, 1997, AM SURGEON, V63, P233; Moein H, 2006, CLIN NEUROL NEUROSUR, V108, P539, DOI 10.1016/j.clineuro.2005.09.003; Morenski JD, 2003, J NEUROSURG, V98, P611, DOI 10.3171/jns.2003.98.3.0611; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; PRETORIUS ME, 1992, ACTA NEUROCHIR, V65, P103; SAWADA Y, 1984, J NEUROL NEUROSUR PS, V47, P1125, DOI 10.1136/jnnp.47.10.1125; Sawauchi S, 2001, NEUROL SURG TOKYO, V29, P131; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; Winn HR, 2004, YOUMANS NEUROLOGICAL	27	50	52	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467			CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	FEB	2007	109	2					166	171		10.1016/j.clineuro.2006.09.001			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	135QP	WOS:000244168400008	17029771				2021-06-18	
J	Sakowitz, OW; Stover, JF; Sarrafzadeh, AS; Unterberg, AW; Kiening, KL				Sakowitz, Oliver W.; Stover, John F.; Sarrafzadeh, Asita S.; Unterberg, Andreas W.; Kiening, Karl L.			Effects of mannitol bolus administration on intracranial pressure, cerebral extracellular metabolites, and tissue oxygenation in severely head-injured patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						intracranial pressure; microdialysis; multimodal cerebral monitoring; osmotherapy; traumatic brain injury	BRAIN-INJURY; HYPERTONIC SALINE; MICRODIALYSIS; 7.5-PERCENT; ARTERIOLES; INSULTS; BURDEN; FLUID; COMA; DOGS	Background: Osmotic agents are widely used to lower elevated intracranial pressure (ICP). However, little data are available regarding cerebral oxygenation and metabolism in the traumatized brains studied under clinical conditions. The present prospective, open-labeled clinical study was designed to investigate whether administration of mannitol, with the aim of reducing moderate intracranial hypertension, improves cerebral metabolism and oxygenation in patients after severe traumatic brain injury (TBI). Methods: Multimodal cerebral monitoring (MCM), consisting of intraparenchymal ICP, tissue oxygenation (002), and micro dialysis measurements was initiated in six male TBI patients (mean age 45 years; Glasgow Coma Scale score < 9). A total of 14 mannitol boli (20%, 0.5g/kg, 20 minutes infusion time) were administered to treat ICP exceeding 20 mm Hg (2.7 kPa). Temporal alterations determined by MCM after mannitol infusions were recorded for 120 minutes. Microdialysates were assayed immediately for extracellular glucose, lactate, pyruvate, and glutamate concentrations. Results: Elevated ICP was successfully treated in all cases. This effect was maximal 40 minutes after start of infusion (25 +/- 6 mm Hg [3.3 +/- 0.8 kPa] to 17 +/- 3 mm Hg [2.3 +/- 0.4 kPa], p < 0.05) and lasted up to 100 minutes. Cerebral ptiO(2) remained unaffected (21 5 mm Hg [2.8 +/- 0.7 kPa] to 23 +/- 6 mm Hg [3.1 +/- 0.8 kPa], n.s.). Microdialysate concentrations of all analytes rose unspecifically by 10% to 40% from baseline, reaching maximum concentrations 40 to 60 minutes after start of the infusion. Conclusions: Mannitol efficiently reduces increased ICP. At an ICP of up to 30 mm Hg [4 kPa] it does not affect cerebral oxygenation. Unspecific increases of extracellular fluid metabolites can be explained by transient osmotic dehydration. Additional mechanisms, such as increased cerebral perfusion and blood volume, might explain an accelerated return to baseline.	Heidelberg Univ, Dept Neurosurg, D-69120 Heidelberg, Germany; Univ Zurich Hosp, Div Surg Intens Care Med, CH-8091 Zurich, Switzerland; Med Univ Berlin, Charite, Dept Neurosurg, Berlin, Germany	Sakowitz, OW (corresponding author), Heidelberg Univ, Dept Neurosurg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	oliver.sakowitz@med.uni-heidelberg.de					*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P451; Bateman H, 1910, P CAMB PHILOS SOC, V15, P423; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; Berger C, 2005, STROKE, V36, pE4, DOI 10.1161/01.STR.0000151328.70519.e9; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLOYD JC, 1986, J PHARMACOL EXP THER, V236, P301; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; Cruz J, 2001, NEUROSURGERY, V49, P864; CSERR HF, 1987, AM J PHYSIOL, V253, pF522; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; GORDON EL, 1995, J CEREBR BLOOD F MET, V15, P532, DOI 10.1038/jcbfm.1995.66; Hartl R, 1997, ACT NEUR S, V70, P40; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; INAO S, 1990, ACT NEUR S, V51, P401; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KIRKPATRICK PJ, 1994, J NEUROL NEUROSUR PS, V57, P1382, DOI 10.1136/jnnp.57.11.1382; Levenberg K., 1944, Quarterly of Applied Mathematics, V2, P164; Marquardt D, 1963, SIAM J APPL MATH, V11, P431, DOI 10.110111030; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; Nau R, 1997, EUR J CLIN PHARMACOL, V53, P271, DOI 10.1007/s002280050375; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Polderman KH, 2003, CRIT CARE MED, V31, P584, DOI 10.1097/01.CCM.0000050287.68977.84; RAVUSSIN P, 1986, J NEUROSURG, V64, P104, DOI 10.3171/jns.1986.64.1.0104; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSENBERG GA, 1988, METAB BRAIN DIS, V3, P217, DOI 10.1007/BF00999238; ROSENBLUM WI, 1983, AM J PHYSIOL, V245, pH139; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; TODD NV, 1990, ACT NEUR S, V51, P296; UNGERSTEDT U, 1998, PATHOPHYSIOLOGICAL P, P83; Unterberg AW, 1997, J TRAUMA, V42, pS32, DOI 10.1097/00005373-199705001-00006; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wakai A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub5; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	40	50	52	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2007	62	2					292	298		10.1097/01.ta.0000203560.03937.2d			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	137ZY	WOS:000244333300006	17297315				2021-06-18	
J	Sherer, M; Evans, CC; Leverenz, J; Stouter, J; Irby, JW; Lee, JE; Yablon, SA				Sherer, Mark; Evans, Clea C.; Leverenz, Joyce; Stouter, Josephine; Irby, James W., Jr.; Lee, Jae Eun; Yablon, Stuart A.			Therapeutic alliance in post-acute brain injury rehabilitation: Predictors of strength of alliance and impact of alliance on outcome	BRAIN INJURY			English	Article						traumatic brain injury; therapeutic alliance; post-acute brain injury rehabilitation; outcome	FAMILY ASSESSMENT DEVICE; WORKING ALLIANCE; AWARENESS QUESTIONNAIRE; IMPAIRED AWARENESS; PATIENT COMPLIANCE; RATING-SCALE; DEPRESSION; COMMUNITY	Primary objective: To determine factors that influence the strength of therapeutic alliance for patients with traumatic brain injury ( TBI) attending post- acute brain injury rehabilitation ( PABIR) and to examine the association of therapeutic alliance with outcome after PABIR. Research design: Prospective cohort study. Methods and procedures: The study sample consisted of 69 of 95 patients with TBI admitted to the PABIR programme during the study period. Demographic and injury severity data were abstracted from medical records or obtained through interview. Study questionnaires ( the modified California Psychotherapy Alliance Scales - patient, family and clinician forms; the Prigatano Alliance Scale; the Awareness Questionnaire; the Center for Epidemiologic Studies - Depression scale; and the Family Assessment Device - General Functioning Scale) were obtained within 2 weeks of patient admission to the PABIR programme. Main outcomes and results: Study outcomes were functional status ( Disability Rating Scale), programme completion and employment status at discharge from PABIR. Higher levels of family discord were associated with poorer therapeutic alliance. Greater discrepancies between family and clinician ratings of patient functioning were associated with poorer therapeutic alliance and poorer effort in therapies. Poor participation was predictive of programme dropout. Productivity status at discharge was predicted by functional status at admission and degree of therapeutic alliance. Conclusions: Findings indicate that family perceptions and family functioning are important determinants of therapeutic alliance for patients in PABIR. These results indicate that therapists in PABIR programmes should address family perceptions and functioning to facilitate patient bonding with the programme.	Methodist Rehabil Ctr, Jackson, MS USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA	Sherer, M (corresponding author), ABPP Cn Mem Hermann TIRR, 1333 Moursund, Houston, TX 77030 USA.	mark.sherer@memorialhermann.org		Leverenz, James/0000-0002-0896-0749			Bordin E. S., 1979, PSYCHOTHER-THEOR RES, V16, P252, DOI DOI 10.1037/H0085885; BUSH B, 2000, J INT NEUROPSYCH SOC, V6, P221; Conners GJ, 1997, J CONSULT CLIN PSYCH, V65, P588, DOI 10.1037/0022-006X.65.4.588; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Gaston L., 1994, WORKING ALLIANCE THE, P85; HORVATH AO, 1991, J COUNS PSYCHOL, V38, P139, DOI 10.1037/0022-0167.38.2.139; HORVATH AO, 1994, WORKING ALLIANCE THE; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; MARMAR CR, 1989, J NERV MENT DIS, V177, P464, DOI 10.1097/00005053-198908000-00003; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Patalano F, 1997, CONTEMP FAM THER, V19, P497, DOI 10.1023/A:1026178920750; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Raue PJ, 1997, J CONSULT CLIN PSYCH, V65, P582, DOI 10.1037/0022-006X.65.4.582; Safran J. D., 1991, PSYCHOL ASSESSMENT J, V3, P188, DOI DOI 10.1037/1040-3590.3.2.188; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P561, DOI 10.1080/09602010500263084; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P298, DOI 10.1080/09602010500176476; Schonberger M, 2006, BRAIN INJURY, V20, P445, DOI 10.1080/02699050600664772; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Weiss M, 1997, J CLIN PSYCHIAT, V58, P196, DOI 10.4088/JCP.v58n0504	26	50	51	1	18	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	7					663	672		10.1080/02699050701481589			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	192LX	WOS:000248204400002	17653940				2021-06-18	
J	Lescot, T; Degos, V; Zouaoui, A; Preteux, F; Coriat, P; Puybasset, L				Lescot, Thomas; Degos, Vincent; Zouaoui, Abderrezak; Preteux, Francoise; Coriat, Pierre; Puybasset, Louis			Opposed effects of hypertonic saline on contusions and noncontused brain tissue in patients with severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						head trauma; specific gravity; computed tomography; contusion; blood-brain barrier	CEREBRAL-BLOOD-FLOW; ELEVATED INTRACRANIAL-PRESSURE; IMMUNE FUNCTION; HEAD-INJURY; BARRIER; HYPERTENSION; RAT; MANNITOL; VOLUME; EDEMA	Objective. The aim of this study was to quantify the effect of hypertonic saline solution on contused and noncontused brain tissue in patients with traumatic brain injury. We hypothesize that hypertonic saline would increase the volume of brain contusion while decreasing the volume of noncontused hemispheric areas. Design: Prospective observational study. Setting. Neurosciences critical care unit of a university hospital. Patients: Fourteen traumatic brain injury patients with increased intracranial pressure. Interventions. A computed tomography scan was performed before and after a 20-min infusion of 40 mL of 20% saline. Measurements and Main Results. The volume, weight, and specific gravity of contused and noncontused hemispheric areas were assessed from computed tomography DICOM images by using a custom-designed software (BrainView). Physiologic variables and natremia were measured before and after infusion. Hypertonic saline significantly increased natremia from 143 +/- 5 to 146 +/- 5 mmol/L and decreased intracranial pressure from 23 +/- 3 to 17 +/- 5 mm Hg. The volume of the noncontused hemispheric areas decreased by 13 +/- 8 mL whereas the specific gravity increased by 0.029 +/- 0.027%. The volume of contused hemispheric tissue increased by 5 +/- 5 mL without any concomitant change in density. There was a wide interindividual variability in the response of the noncontused hemispheric tissue with changes in specific gravity varying between -0.0124% and 0.0998%. Conclusions. Three days after traumatic brain injury, the blood-brain barrier remains semipermeable in noncontused areas but not in contusions. Further studies are needed to tailor the use of hypertonic saline in patients with traumatic brain injury according to the volume of contusions assessed on computed tomography.	Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Anesthesiol & Crit Care, Paris, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Neuroradiol, Paris, France; Univ Paris 06, Paris, France; Inst Natl Telecommun, Artemis Project Unit, F-91011 Evry, France	Lescot, T (corresponding author), Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Anesthesiol & Crit Care, Paris, France.						Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Beaumont A, 2002, ACT NEUR S, V81, P217; Daneyemez M, 1999, NEUROSCIENCE, V92, P783, DOI 10.1016/S0306-4522(99)00035-4; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; Hartl R, 1997, ACT NEUR S, V70, P126; Hoelper BM, 2000, ACTA NEUROCHIR SUPPL, V76, P21; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Junger WG, 1997, SHOCK, V8, P235, DOI 10.1097/00024382-199710000-00001; JUNGER WG, 1994, CIRC SHOCK, V42, P190; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; KUSHI H, 1994, ACTA NEUROCHIR, P472; Lescot T, 2005, INTENS CARE MED, V31, P1042, DOI 10.1007/s00134-005-2709-y; Loomis WH, 2001, AM J PHYSIOL-CELL PH, V281, pC840; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2000, ACT NEUR S, V76, P349; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Mirski MA, 2000, J NEUROSURG ANESTH, V12, P334, DOI 10.1097/00008506-200010000-00006; MUIZELAAR JP, 1986, STROKE, V17, P44, DOI 10.1161/01.STR.17.1.44; Saltarini M, 2002, Eur J Emerg Med, V9, P262, DOI 10.1097/00063110-200209000-00011; Schatzmann C, 1998, ACT NEUR S, V71, P31; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; VANDENBRINK WA, 1994, ACT NEUR S, V60, P456; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wahl M, 1993, Acta Neurochir Suppl (Wien), V57, P64	26	50	53	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2006	34	12					3029	3033		10.1097/01.CCM.0000243797.42346.64			5	Critical Care Medicine	General & Internal Medicine	110QH	WOS:000242393100023	16971850				2021-06-18	
J	Shen, F; Tay, TE; Li, JZ; Nigen, S; Lee, PVS; Chan, HK				Shen, F.; Tay, T. E.; Li, J. Z.; Nigen, S.; Lee, P. V. S.; Chan, H. K.			Modified Bilston nonlinear viscoelastic model for finite element head injury studies	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						traumatic brain injury; rheological test; material properties; finite element simulation; impact biomechanics	HUMAN BRAIN-TISSUE; CONSTITUTIVE MODEL; SHEAR; DEFORMATION	This paper proposes a modified nonlinear viscoelastic Bilston model (Bilston et al., 2001, Biorheol., 38, pp. 335-345). for the modeling of brain tissue constitutive properties. The modified model can be readily implemented in a commercial explicit finite element (FE) code, PamCrash. Critical parameters of the model have been determined through a series of rheological tests on porcine brain tissue samples and the time-temperature superposition (TTS) principle has been used to extend the frequency to a high region. Simulations by using PamCrash are compared with the test results. Through the use of the TTS principle, the mechanical and rheological behavior at high frequencies up to 10(4) rad/s may be obtained. This is important because the properties of the brain tissue at high frequencies and impact rates are especially relevant to studies of traumatic head injury. The averaged dynamic modulus ranges from 130 Pa to 1500 Pa and loss modulus ranges from 35 Pa to 800 Pa in the frequency regime studied (0.01 rad/s to 3700 rad/s). The errors between theoretical predictions and averaged relaxation test results are within 20% for strains up to 20%. The FEM simulation results are in good agreement with experimental results. The proposed model will be especially useful for application to FE analysis of the head under impact loads. More realistic analysis of head injury can be carried out by incorporating the nonlinear viscoelastic constitutive law for brain tissue into a commercial FE code.	Natl Univ Singapore, Div Bioengn, Singapore 117576, Singapore; Def Med & Environm Res Inst, Singapore 117510, Singapore	Shen, F (corresponding author), Natl Univ Singapore, Div Bioengn, 9 Engn Dr 1, Singapore 117576, Singapore.	mpesf@nus.edu.sg	Lee, Peter/D-3506-2014	Lee, Peter/0000-0003-3666-4872; Tay, Tong-Earn/0000-0002-2846-1947			Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bilston LE, 2001, BIORHEOLOGY, V38, P335; BRANDS D. W. A., 2000, P STAPP CAR CRASH C, V44, P249; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; BYCROFT GN, 1973, J BIOMECH, V6, P487, DOI 10.1016/0021-9290(73)90007-9; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; European Transport Safety Council, 1999, RED SEV ROAD INJ POS; FRANKE EK, 1954, 5424 WRIGHT PATT AIR; KLEIVEN S, 2002, THESIS ROYAL I TECHN; Kyriacou SK, 2002, BIOMECH MODEL MECHAN, V1, P151, DOI 10.1007/s10237-002-0013-0; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MENDIS KK, 1995, ASME, V117, P279; Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; MISRA JC, 1984, J BIOMECH, V17, P459, DOI 10.1016/0021-9290(84)90014-9; Nasseri S, 2002, RHEOL ACTA, V41, P180, DOI 10.1007/s003970200017; PAMIDI MR, 1978, ASME, V100, P44; Peters GWM, 1997, BIORHEOLOGY, V34, P127, DOI 10.1016/S0006-355X(97)00009-7; Phan-Thien N, 2000, J NON-NEWTON FLUID, V95, P343, DOI 10.1016/S0377-0257(00)00175-0; PhanThien N, 1997, RHEOL ACTA, V36, P38, DOI 10.1007/BF00366722; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Trosseille X, 1992, 36 STAPP CAR CRASH C; Voo L, 1996, MED BIOL ENG COMPUT, V34, P375, DOI 10.1007/BF02520009; Zhang LM, 2001, CARBOHYD POLYM, V45, P1, DOI 10.1016/S0144-8617(00)00276-9	29	50	51	0	8	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	OCT	2006	128	5					797	801		10.1115/1.2264393			5	Biophysics; Engineering, Biomedical	Biophysics; Engineering	094YA	WOS:000241274000022	16995770				2021-06-18	
J	Stulemeijer, M; Van der Werf, SP; Jacobs, B; Biert, J; Van Vugt, AB; Brauer, JMP; Vos, PE				Stulemeijer, Maja; Van der Werf, Sieberen P.; Jacobs, Bram; Biert, Jan; Van Vugt, Arie B.; Brauer, Jolanda M. P.; Vos, Pieter E.			Impact of additional extracranial injuries on outcome after mild traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						head injury; mild traumatic brain injury; multiple trauma; outcome; post-concussion symptoms	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; GENERAL HEALTH; RELIABILITY; COMPLAINTS; SCALE	Many patients with mild traumatic brain injury (MTBI) concurrently sustain extracranial injuries; however, little is known about the impact of these additional injuries on outcome. We assessed the impact of additional injuries on the severity of postconcussional symptoms (PCS) and functional outcome 6 months post-injury. A questionnaire (including the Rivermead Post-Concussion Questionnaire and SF-36) was sent to consecutive MTBI patients (hospital admission Glasgow Coma Score 13-15; age range 18-60 years) admitted to the emergency department of a level-I trauma center, and, to serve as a baseline for PCS, a control group of minor-injury patients (ankle or wrist distortion). Of the 299 MTBI respondents (response rate 52%), 89 had suffered additional injuries (mean Injury Severity Score [ISS] of 14.5 +/- 7.4). After 6 months, 44% of the patients with additional injuries were still in some form of treatment, compared to 14% of patients with isolated MTBI and 5% of the controls. Compared to patients with isolated injury, MTBI patients with additional injuries had resumed work less frequently and reported more limitations in physical functioning. Overall, they did not report higher levels of PCS, despite somewhat more severe head injury. Regardless of the presence of additional injuries, patients that were still in treatment reported significantly more severe PCS, with highest rates in patients with isolated MTBI. In conclusion, many patients with additional extracranial injuries are still in the process of recovery at 6 months after injury. However, despite more severe impact to the head and inferior functional outcomes, these patients do not report more severe PCs.	Univ Nijmegen St Radboud Hosp, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen St Radboud Hosp, Med Ctr, Dept Surg, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen St Radboud Hosp, Med Ctr, Dept Psychol Med, NL-6500 HB Nijmegen, Netherlands	Vos, PE (corresponding author), Univ Nijmegen St Radboud Hosp, Med Ctr, Dept Neurol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	P.Vos@neuro.umcn.nl	Biert, J./L-4200-2015; Vos, Pieter/A-6043-2012				Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kibby M Y, 1997, Appl Neuropsychol, V4, P34, DOI 10.1207/s15324826an0401_4; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	33	50	50	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1561	1569		10.1089/neu.2006.23.1561			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500015	17020490				2021-06-18	
J	Goldman, SA; Windrem, MS				Goldman, Steven A.; Windrem, Martha S.			Cell replacement therapy in neurological disease	PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES			English	Article						leucodystrophy; oligodendrocyte; glial progenitor cell; transplantation; neural stem cell	EMBRYONIC STEM-CELLS; NEURAL PROGENITOR CELLS; FETAL NIGRAL TRANSPLANTATION; ADULT MAMMALIAN FOREBRAIN; SUBCORTICAL WHITE-MATTER; SPINAL-CORD; DOPAMINERGIC-NEURONS; IN-VITRO; PRECURSOR CELLS; DIRECTED DIFFERENTIATION	Diseases of the brain and spinal cord represent especially daunting challenges for cell-based strategies of repair, given the multiplicity of cell types within the adult central nervous system, and the precision with which they must interact in both space and time. Nonetheless, a number of diseases are especially appropriate for cell-based therapy, in particular those in which single phenotypes are lost, and in which the re-establishment of vectorially specific connections is not entirely requisite for therapeutic benefit. We review here a set of potential therapeutic indications that meet these criteria as potentially benefiting from the transplantation of neural stem and progenitor cells. These include: (i) transplantation of phenotypically restricted neuronal progenitor cells into diseases of a single neuronal phenotype, such as Parkinson's disease; (ii) implantation of mixed progenitor pools into diseases characterized by the loss of a limited number of discrete phenotypes, such as spinal cord injury and the motor neuronopathies; (iii) transplantation of glial and nominally oligodendrocytic progenitor cells as a means of treating disorders of myelin; and (iv) transplantation of neural stem cells as a means of treating lysosomal storage disorders and other diseases of enzymatic deficiency. Among the diseases potentially approachable by these strategies, the myelin disorders, including the paediatric leucodystrophies as well as adult traumatic and inflammatory demyelinations, may present the most compelling targets for cell-based neurological therapy.	Univ Rochester, Med Ctr, Div Cell & Gene Therapy, Dept Neurol, Rochester, NY 14642 USA; Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA	Goldman, SA (corresponding author), Univ Rochester, Med Ctr, Div Cell & Gene Therapy, Dept Neurol, 601 Elmwood Ave,POB 645, Rochester, NY 14642 USA.	steven_goldman@urmc.rochester.edu		Goldman, Steven/0000-0002-5498-4303			Arber S, 1999, NEURON, V23, P659, DOI 10.1016/S0896-6273(01)80026-X; Back SA, 2004, SEMIN PERINATOL, V28, P405, DOI 10.1053/j.semperi.2004.10.010; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHMIELNICKI E, 2005, NEURODEGENER DIS, P347; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Follett PL, 2004, J NEUROSCI, V24, P4412, DOI 10.1523/JNEUROSCI.0477-04.2004; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gao Y, 2004, NEURON, V44, P609, DOI 10.1016/j.neuron.2004.10.030; Gold PE, 2002, PSYCHOL SCI, P2, DOI 10.1111/1529-1006.00006; Goldman S, 2005, NAT BIOTECHNOL, V23, P862, DOI 10.1038/nbt1119; Goldman SA, 2005, NEUROLOGY, V64, P1675, DOI 10.1212/01.WNL.0000165312.12463.BE; Goldman SA, 2004, CURR OPIN MOL THER, V6, P466; Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871; Gritti A, 1996, J NEUROSCI, V16, P1091; Hagell P, 2002, NAT NEUROSCI, V5, P627, DOI 10.1038/nn863; Han SSW, 2004, GLIA, V45, P1, DOI 10.1002/glia.10282; Hauser RA, 1999, ARCH NEUROL-CHICAGO, V56, P179, DOI 10.1001/archneur.56.2.179; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hu FH, 2004, SEMIN PERINATOL, V28, P371, DOI 10.1053/j.semperi.2004.10.001; HUDSON LD, 2004, MYELIN BIOL DISORDER, P867; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Jeyakumar M., 2005, NAT REV NEUROSCI, V6, P1; Kawaguchi A, 2001, MOL CELL NEUROSCI, V17, P259, DOI 10.1006/mcne.2000.0925; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kaye EM, 2001, PEDIATR NEUROL, V24, P11, DOI 10.1016/S0887-8994(00)00232-0; Kerr DA, 2003, J NEUROSCI, V23, P5131; Keyoung HM, 2001, NAT BIOTECHNOL, V19, P843, DOI 10.1038/nbt0901-843; Kim DW, 2006, STEM CELLS, V24, P557, DOI 10.1634/stemcells.2005-0233; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; Kordower JH, 1998, MOVEMENT DISORD, V13, P383, DOI 10.1002/mds.870130303; Lacorazza HD, 1996, NAT MED, V2, P424, DOI 10.1038/nm0496-424; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Li XJ, 2005, NAT BIOTECHNOL, V23, P215, DOI 10.1038/nbt1063; Lindvall O, 1999, MOVEMENT DISORD, V14, P201, DOI 10.1002/1531-8257(199903)14:2<201::AID-MDS1001>3.0.CO;2-Q; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Nakano T, 2005, DEV BIOL, V283, P474, DOI 10.1016/j.ydbio.2005.04.017; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Nistor GI, 2005, GLIA, V49, P385, DOI 10.1002/glia.20127; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; PALMER T, 2006, NEURAL DEV STEM CELL, P343; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Park S, 2004, NEUROSCI LETT, V359, P99, DOI 10.1016/j.neulet.2004.01.073; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pellegatta S, 2006, NEUROBIOL DIS, V21, P314, DOI 10.1016/j.nbd.2005.07.016; Piccini P, 2005, BRAIN, V128, P2977, DOI 10.1093/brain/awh649; Pincus DW, 1998, ANN NEUROL, V43, P576, DOI 10.1002/ana.410430505; Pluchino S, 2004, CURR OPIN NEUROL, V17, P247, DOI 10.1097/00019052-200406000-00003; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Powers J., 2004, MYELIN BIOL DISORDER, V2, P663; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; Robinson S, 2005, NEUROBIOL DIS, V18, P568, DOI 10.1016/j.nbd.2004.10.024; Roy NS, 2004, NAT BIOTECHNOL, V22, P297, DOI 10.1038/nbt944; Roy NS, 2005, EXP NEUROL, V196, P224, DOI 10.1016/j.expneurol.2005.06.021; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Roy NS, 2000, NAT MED, V6, P271; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sawamoto K, 2001, J NEUROSCI, V21, P3895, DOI 10.1523/JNEUROSCI.21-11-03895.2001; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; Studer L, 1998, NAT NEUROSCI, V1, P290; Studer L, 2000, J NEUROSCI, V20, P7377; Svendsen CN, 1999, BRAIN PATHOL, V9, P499, DOI 10.1111/j.1750-3639.1999.tb00538.x; Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Urayama A, 2004, P NATL ACAD SCI USA, V101, P12658, DOI 10.1073/pnas.0405042101; vanderKnaap MS, 1997, NEUROLOGY, V48, P845, DOI 10.1212/WNL.48.4.845; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Wang S, 2000, DEV NEUROSCI-BASEL, V22, P167, DOI 10.1159/000017437; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Weiss S, 1996, J NEUROSCI, V16, P7599; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Windrem M, 2002, CONT NEUROS, P69; Windrem MS, 2004, NAT MED, V10, P93, DOI 10.1038/nm974; Windrem MS, 2002, J NEUROSCI RES, V69, P966, DOI 10.1002/jnr.10397; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3	100	50	57	0	7	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	0962-8436	1471-2970		PHILOS T R SOC B	Philos. Trans. R. Soc. B-Biol. Sci.	SEP 29	2006	361	1473					1463	1475		10.1098/rstb.2006.1886			13	Biology	Life Sciences & Biomedicine - Other Topics	090RJ	WOS:000240968400002	16939969	Green Published			2021-06-18	
J	Sakellaris, G; Kotsiou, M; Tamiolaki, M; Kalostos, G; Tsapaki, E; Spanaki, M; Spilioti, M; Charissis, G; Evangeliou, A				Sakellaris, G.; Kotsiou, M.; Tamiolaki, M.; Kalostos, G.; Tsapaki, E.; Spanaki, M.; Spilioti, M.; Charissis, G.; Evangeliou, A.			Prevention of complications related to traumatic brain injury in children and adolescents with creatine administration: An open label randomized pilot study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						creatine; traumatic; brain injury; pediatric; outcome	SEVERE HEAD-INJURY; MITOCHONDRIAL ENCEPHALOMYOPATHIES; RAT; SUPPLEMENTATION; MONOHYDRATE; DISABILITY; PROTECTS; DEFICIENCY; MUSCLE; DAMAGE	Background. There has been an enormous focus on the discovery and development of neuroprotective agents that might have clinical relevance after traumatic brain injury (TBI). Based on experimental facts, we studied administration of creatine to patients with TBI. Methods. A prospective, randomized, comparative, open-labeled pilot study of the possible neuroprotective effect of creatine was performed on 39 children and adolescents, aged between 1 to 18 years old, with TBI. The creatine was administered for 6 months, at a dose of 0.4 gr/kg in an oral suspension form every day. For categorical variables, we used the chi(2) test to identify differences between controls and cases. Statistical significance was defined as a p value < 0.05 and not statistically significant if p value > 0.1. Results. The administration of creatine to children with TBI improved results in several parameters, including duration of post-traumatic amnesia (PTA), duration of intubation, intensive care unit (ICU) stay, disability, good recovery, self care, communication, locomotion, sociability, personality/behavior and neurophysical, and cognitive function. Significant improvement was recorded in the categories of Cognitive (p < 0.001), personatity/behavior (p < 0.001), Self Care (p = 0.029), and communication (p = 0.018) aspects in all patients. No side effects were seen because of creatine administration. Conclusion. Preliminary data suggest that the administration of creatine may be beneficial to patients with traumatic brain injury.	Univ Hosp Heraklio, Dept Paediat Surg, Iraklion, Greece; Univ Hosp Heraklio, Dept Paediat, Iraklion, Greece; Univ Hosp Heraklio, Dept Neurosurg, Iraklion, Greece; Univ Hosp Heraklio, Paediat Intens Care Unit, Iraklion, Greece; Hippokratio Gen Hosp, Paediat Intens Care Unit, Thessaloniki, Greece	Sakellaris, G (corresponding author), Venizelou 105, GR-70014 Hersonissou P, Greece.	gsakell@mycosmos.gr					Bachmann C, 2004, MOL GENET METAB, V81, pS52, DOI 10.1016/j.ymgme.2003.10.014; Balestrino M, 1999, BRAIN RES, V816, P124, DOI 10.1016/S0006-8993(98)01131-7; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Berger R, 2004, J SOC GYNECOL INVEST, V11, P9, DOI 10.1016/j.jsgi.2003.07.002; Borchert A, 1999, MUSCLE NERVE, V22, P1299; Borges N, 2004, INT J NEUROSCI, V114, P217, DOI 10.1080/00207450490249419; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; EPPENBERGEREBERHARDT M, 1991, J CELL BIOL, V113, P289, DOI 10.1083/jcb.113.2.289; Felber S, 2000, NEUROL RES, V22, P145, DOI 10.1080/01616412.2000.11741051; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; GORDON A, 1995, CARDIOVASC RES, V30, P413, DOI 10.1016/0008-6363(95)00062-3; Holtzman D, 1998, PEDIATR RES, V44, P410, DOI 10.1203/00006450-199809000-00024; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Komura K, 2003, PEDIATR NEUROL, V28, P53, DOI 10.1016/S0887-8994(02)00469-1; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Scheff SW, 2004, NEUROCHEM RES, V29, P469, DOI 10.1023/B:NERE.0000013753.22615.59; Schulze A, 2003, ANN NEUROL, V53, P248, DOI 10.1002/ana.10455; SPLAINGARD ML, 1989, ARCH PHYS MED REHAB, V70, P318; Stockler S, 1997, METABOLISM, V46, P1189, DOI 10.1016/S0026-0495(97)90215-8; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C; TEGAS JJ, 1990, J PEDIATR SURG, V25, P92; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631	25	50	51	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2006	61	2					322	329		10.1097/01.ta.0000230269.46108.d5			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	075UW	WOS:000239911800017	16917445				2021-06-18	
J	Gillingwater, TH; Ingham, CA; Parry, KE; Wright, AK; Haley, JE; Wishart, TM; Arbuthnott, GW; Ribchester, RR				Gillingwater, Thomas H.; Ingham, Cali A.; Parry, Katherine E.; Wright, Ann K.; Haley, Jane E.; Wishart, Thomas M.; Arbuthnott, Gordon W.; Ribchester, Richard R.			Delayed synaptic degeneration in the CNS of Wld(s) mice after cortical lesion	BRAIN			English	Article						synapse; neurodegeneration; neuroprotection; brain; Alzheimer's disease; electron microscopy	TRAUMATIC BRAIN-INJURY; WALLERIAN DEGENERATION; NEUROMUSCULAR-JUNCTIONS; ALZHEIMERS-DISEASE; CORTICOSPINAL TRACT; AXON DEGENERATION; PROTEIN-SYNTHESIS; MUTANT; SYNAPSES; MODEL	Therapies that might delay degeneration of synapses offer an appealing strategy for treatment of neurodegenerative diseases, including Alzheimer's disease and related dementias, prion diseases, schizophrenia and amyotrophic lateral sclerosis. Analysis of mouse mutants provides one possible avenue towards identifying relevant mechanisms. Here, we used quantitative and serial section electron microscopy to find out whether the onset and time course of pre-synaptic nerve terminal degeneration is delayed in the striatum of Wallerian degeneration slow (Wld(s)) mutant mice. Synaptic degeneration was observed within 48 h of cortical ablation in wild-type mice but was delayed by approximately 1 week in Wld(s) mice. However, the morphological characteristics of degenerating nerve terminals in wild-type and Wld(s) mice were indistinguishable, in contrast to the differences reported previously in studies of the PNS. Surprisingly, the delayed onset of synaptic degeneration was accompanied by an increased incidence of complex synaptic morphologies on post-synaptic spines in the denervated Wld(S) striatum indicating an enhanced plastic response at both injured and uninjured synapses. The data suggest that targeting Wallerian-like mechanisms of synaptic degeneration could lead to the development of new therapies for the treatment of CNS disorders where synapse loss is a primary feature.	Univ Edinburgh, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland; Univ Edinburgh, Neurosci Res Ctr, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Div Vet Biomed Sci, Edinburgh, Midlothian, Scotland	Gillingwater, TH (corresponding author), Univ Edinburgh, Ctr Integrat Physiol, Hugh Robson Bldg, Edinburgh EH8 9XD, Midlothian, Scotland.	T.Gillingwater@ed.ac.uk	Arbuthnott, Gordon W/A-4606-2015; Gillingwater, Thomas/G-2880-2011	Arbuthnott, Gordon W/0000-0002-3386-8362; wishart, thomas/0000-0002-1973-6654; Haley, Jane/0000-0001-6178-2673; Ribchester, Richard/0000-0003-2670-6995; Gillingwater, Thomas/0000-0002-0306-5577	Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/D001722/1] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission [GR066272] Funding Source: Medline		Adalbert R, 2005, EUR J NEUROSCI, V21, P271, DOI 10.1111/j.1460-9568.2004.03833.x; Albensi BC, 2003, BRAIN INJURY, V17, P653, DOI 10.1080/0269905031000107142; Alvarez J, 2000, PROG NEUROBIOL, V62, P1, DOI 10.1016/S0301-0082(99)00062-3; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Bernard V, 1997, J NEUROSCI, V17, P819; BROWN MC, 1991, NEURON, V6, P359, DOI 10.1016/0896-6273(91)90245-U; Burbach GJ, 2004, GLIA, V48, P76, DOI 10.1002/glia.20057; Cadet JL, 2003, FASEB J, V17, P1775, DOI 10.1096/fj.03-0073rev; Carroll SL, 1998, J NEUROPATH EXP NEUR, V57, P915, DOI 10.1097/00005072-199810000-00004; Cesa R, 2005, EUR J NEUROSCI, V22, P579, DOI 10.1111/j.1460-9568.2005.04244.x; CHEN S, 1990, BRAIN RES, V520, P103, DOI 10.1016/0006-8993(90)91695-D; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Coleman MP, 2004, CNS NEUROL DISORD-DR, V3, P227, DOI 10.2174/1568007043337436; Coleman P, 2004, NEUROLOGY, V63, P1155, DOI 10.1212/01.WNL.0000140626.48118.0A; Cunningham C, 2003, EUR J NEUROSCI, V17, P2147, DOI 10.1046/j.1460-9568.2003.02662.x; DECKWERTH TL, 1994, DEV BIOL, V165, P63, DOI 10.1006/dbio.1994.1234; ERB DE, 1991, EXP BRAIN RES, V83, P253; Fang C, 2005, NEUROSCIENCE, V135, P1107, DOI 10.1016/j.neuroscience.2005.06.078; Ferri A, 2003, CURR BIOL, V13, P669, DOI 10.1016/S0960-9822(03)00206-9; Fischer LR, 2005, NEUROBIOL DIS, V19, P293, DOI 10.1016/j.nbd.2005.01.008; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Frankle W. Gordon, 2003, Neuron, V39, P205, DOI 10.1016/S0896-6273(03)00423-9; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Ganeshina O, 2004, NEUROSCIENCE, V125, P615, DOI 10.1016/j.neuroscience.2004.02.025; Gillingwater TH, 2004, J CEREBR BLOOD F MET, V24, P62, DOI 10.1097/01.WCB.0000095798.98378.34; Gillingwater TH, 2006, HUM MOL GENET, V15, P625, DOI 10.1093/hmg/ddi478; Gillingwater TH, 2003, J NEUROCYTOL, V32, P863, DOI 10.1023/B:NEUR.0000020629.51673.f5; Gillingwater TH, 2003, J ANAT, V203, P265, DOI 10.1046/j.1469-7580.2003.00214.x; Gillingwater TH, 2002, J PHYSIOL-LONDON, V543, P739, DOI 10.1113/jphysiol.2002.022343; Gillingwater TH, 2001, J PHYSIOL-LONDON, V534, P627, DOI 10.1111/j.1469-7793.2001.00627.x; Gilman CP, 2003, NEUROMOL MED, V3, P159, DOI 10.1385/NMM:3:3:159; GREENOUGH WT, 1978, SCIENCE, V202, P1096, DOI 10.1126/science.715459; Harrison PJ, 1999, BRAIN, V122, P593, DOI 10.1093/brain/122.4.593; Ingham CA, 1998, J NEUROSCI, V18, P4732; Ishimaru H, 2001, BRAIN RES, V903, P94, DOI 10.1016/S0006-8993(01)02439-8; Jourdain P, 2002, J NEUROSCI, V22, P3108, DOI 10.1523/JNEUROSCI.22-08-03108.2002; KEMP JM, 1971, PHILOS T R SOC B, V262, P413, DOI 10.1098/rstb.1971.0104; LaFontaine MA, 2002, NEUROCHEM RES, V27, P417, DOI 10.1023/A:1015560116208; Laser H, 2006, MOL BIOL CELL, V17, P1075, DOI 10.1091/mbc.E05-04-0375; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; LUDWIN SK, 1992, J NEUROL SCI, V109, P140, DOI 10.1016/0022-510X(92)90160-M; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Martin KC, 2004, CURR OPIN NEUROBIOL, V14, P305, DOI 10.1016/j.conb.2004.05.009; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; McNeill TH, 2003, J COMP NEUROL, V467, P32, DOI 10.1002/cne.10907; Meshul CK, 2000, EXP NEUROL, V165, P191, DOI 10.1006/exnr.2000.7467; Mi WQ, 2005, BRAIN, V128, P405, DOI 10.1093/brain/awh368; MILEDI R, 1970, J PHYSIOL-LONDON, V207, P507, DOI 10.1113/jphysiol.1970.sp009076; PARENT A, 1995, BRAIN RES REV, V20, P91, DOI 10.1016/0165-0173(94)00007-C; PERRY VH, 1991, EUR J NEUROSCI, V3, P102, DOI 10.1111/j.1460-9568.1991.tb00815.x; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; RIBCHESTER RR, 1995, EUR J NEUROSCI, V7, P1641, DOI 10.1111/j.1460-9568.1995.tb01159.x; Sajadi A, 2004, CURR BIOL, V14, P326, DOI 10.1016//j.cub.2004.01.053; Samsam M, 2003, J NEUROSCI, V23, P2833; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Sasaki S, 1996, NEUROSCI LETT, V204, P53, DOI 10.1016/0304-3940(96)12314-4; SCHEFF SW, 1993, ANN NEUROL, V33, P190, DOI 10.1002/ana.410330209; Scheff SW, 2003, NEUROBIOL AGING, V24, P1029, DOI 10.1016/j.neurobiolaging.2003.08.002; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SMALL JV, 1968, P 4 EUR REG C EL MIC; SOMOGYI P, 1981, J COMP NEUROL, V195, P567, DOI 10.1002/cne.901950403; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Steward O, 1997, J COMP NEUROL, V380, P70, DOI 10.1002/(SICI)1096-9861(19970331)380:1<70::AID-CNE5>3.0.CO;2-Q; Subang MC, 1997, J NEUROSCI RES, V49, P563, DOI 10.1002/(SICI)1097-4547(19970901)49:5<563::AID-JNR6>3.0.CO;2-9; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sutton MA, 2005, J NEUROBIOL, V64, P116, DOI 10.1002/neu.20152; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Tsai J, 2004, NAT NEUROSCI, V7, P1181, DOI 10.1038/nn1335; Upadhya SC, 2006, NEUROCHEM INT, V48, P296, DOI 10.1016/j.neuint.2005.11.003; Velde CV, 2004, NEUROMOL MED, V5, P193, DOI 10.1385/NMM:5:3:193; Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028; Wang MS, 2001, ANN NEUROL, V50, P773, DOI 10.1002/ana.10039; Wang MS, 2002, ANN NEUROL, V52, P442, DOI 10.1002/ana.10300; Zhou L, 1998, ANN NEUROL, V44, P99, DOI 10.1002/ana.410440116	76	50	50	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUN	2006	129		6				1546	1556		10.1093/brain/awl101			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	052HN	WOS:000238224900020	16738060				2021-06-18	
J	Itshayek, E; Rosenthal, G; Fraifeld, S; Perez-Sanchez, X; Cohen, JE; Spektor, S				Itshayek, E; Rosenthal, G; Fraifeld, S; Perez-Sanchez, X; Cohen, JE; Spektor, S			Delayed posttraumatic acute subdural hematoma in elderly patients on anticoagulation 10.1227/0	NEUROSURGERY			English	Article						anticoagulation; delayed subdural hematoma; elderly patients; intracranial injury; Glasgow coma scale; mild traumatic brain injury; subdural hematoma	MILD HEAD-INJURY; COMPUTED-TOMOGRAPHY; BRAIN INJURY; INTRACRANIAL HEMORRHAGE; EXTRADURAL HEMATOMA; EPIDURAL HEMATOMA; HIGH-RISK; TRAUMA; MANAGEMENT; METAANALYSIS	OBJECTIVE: To discuss delayed acute subdural hematoma (DASH), a relatively neglected entity, and to emphasize the potentially elevated risk for DASH among elderly, anticoagulated mild traumatic brain injury (TBI) patients. METHODS: The authors reviewed clinical and radiological data for four patients who had normal neurological examinations and normal computed tomographic scans after mild TBI, and who subsequently developed DASH and deteriorated rapidly. RESULTS: The patients included two men and two women, aged 65 to 86 years, who presented to the emergency department after mild TBI between January 2002 and June 2004. All were treated with chronic anticoagulation or anti-aggregation therapy. They deteriorated owing to DASH from 9 hours to 3 days after TBI. Three of the four patients underwent craniotomy for evacuation of their hematomas. One patient, who suffered only focal neurological deficit, was treated conservatively, and her hematoma gradually resolved. Two patients died and two reached Glasgow Outcome Scores of 3 and 4 after extended inpatient rehabilitation. CONCLUSION: A suspicion of DASH should be raised in elderly, anticoagulated, mild TBI patients, including those who present to the emergency department with Glasgow Coma Scores of 15 and normal computed tomographic scans after injury. Based on our experience, we recommend that elderly, anticoagulated mild TBI patients should be admitted for 24 to 48 hours of observation after injury.	Hebrew Univ Jerusalem, Med Ctr, Dept Neurosurg, IL-91120 Jerusalem, Israel	Itshayek, E (corresponding author), Hebrew Univ Jerusalem, Med Ctr, Dept Neurosurg, Kiryat Hadassah,POB 12000, IL-91120 Jerusalem, Israel.	eyalit@md.huji.ac.il					Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; ASHKENAZI E, 1990, J TRAUMA, V30, P613, DOI 10.1097/00005373-199005000-00015; Atzema C, 2004, ANN EMERG MED, V44, P47, DOI 10.1016/j.annemergmed.2004.02.032; Batchelor J, 2002, EMERG MED J, V19, P515, DOI 10.1136/emj.19.6.515; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Cohen T, 1995, TRAUMA, P689; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DEITCH D, 1989, NEUROLOGY, V39, P985, DOI 10.1212/WNL.39.7.985; DOHERTY DL, 1988, ARCH PHYS MED REHAB, V69, P542; DOMENICUCCI M, 1995, NEUROSURG REV, V18, P109, DOI 10.1007/BF00417668; DRAKE CG, 1961, J NEUROSURG, V18, P597, DOI 10.3171/jns.1961.18.5.0597; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P1787, DOI 10.1136/jnnp.2004.041384; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; FRANCEL P, 1996, NEUROLOGICAL SURG, P1595; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; He J, 1998, JAMA-J AM MED ASSOC, V280, P1930, DOI 10.1001/jama.280.22.1930; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; IUVARABOMMELI A, 1991, SCHWEIZ MED WSCHR, V121, P646; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1981, MANAGEMENT HEAD INQU, P155; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Linkins LA, 2003, ANN INTERN MED, V139, P893, DOI 10.7326/0003-4819-139-11-200312020-00007; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MATHIESEN T, 1995, ACTA NEUROL SCAND, V91, P208; MERTOL T, 1991, British Journal of Neurosurgery, V5, P491, DOI 10.3109/02688699108998478; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; POON WS, 1992, NEUROSURGERY, V30, P681; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; Riesgo P, 1997, SURG NEUROL, V48, P226, DOI 10.1016/S0090-3019(97)00194-8; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SHENKIN HA, 1982, J NEUROSURG, V57, P254, DOI 10.3171/jns.1982.57.2.0254; SNOEY ER, 1994, ANN EMERG MED, V23, P1127, DOI 10.1016/S0196-0644(94)70115-6; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wong KS, 2000, NEUROLOGY, V54, P2298, DOI 10.1212/WNL.54.12.2298; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006; Zwimpfer TJ, 1997, J NEUROSURG, V86, P433, DOI 10.3171/jns.1997.86.3.0433	51	50	52	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2006	58	5					851	856		10.1227/01.NEU.0000209653.B2936.96			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	039IC	WOS:000237298200011					2021-06-18	
J	Elie, MC				Elie, MC			Blunt cardiac injury	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						myocardial contusion; myocardial concussion; myocardial rupture; blunt cardiac injury; pericardial tamponade; blunt trauma; echocardiography; pericardiocentesis; cardiogenic failure	MYOCARDIAL CONTUSION; CLINICAL-SIGNIFICANCE; CARDIOGENIC-SHOCK; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; BALLOON COUNTERPULSATION; TRAUMATIC RUPTURE; THORACIC TRAUMA; LEFT-VENTRICLE; CHEST TRAUMA; TROPONIN-I	The diagnosis and management of blunt cardiac injury, formerly known as myocardial contusion, has challenged clinicians for decades. Caused primarily by motor vehicle collisions, significant blunt cardiac injury carries a high mortality rate. Yet no reliable diagnostic test exists to identify those patients at greatest risk for an adverse outcome. A literature search using the MEDLINE database was performed to compose a review of epidemiology, diagnostic intervention, and therapeutic approach. The results of the search indicate that, along with a high index of suspicion, utilizing a combination of electrocardiogram, troponin, and echocardiography for appropriate patients may improve the diagnosis, risk stratification and disposition of patients sustaining blunt cardiac injury.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Div Emergency Med, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Div Crit Care, Dept Med, Newark, NJ 07103 USA	Elie, MC (corresponding author), 150 Bergen St,M219, Newark, NJ 07103 USA.	eliema@umdnj.edu					Adams JE, 1996, AM HEART J, V131, P308, DOI 10.1016/S0002-8703(96)90359-2; BAUMGARTEL ED, 1992, ARCH SURG-CHICAGO, V127, P347; Bertinchant JP, 2000, J TRAUMA, V48, P924, DOI 10.1097/00005373-200005000-00018; BIFFL WL, 1994, AM J SURG, V168, P523, DOI 10.1016/S0002-9610(05)80115-1; BODAI BI, 1982, J TRAUMA, V22, P487, DOI 10.1097/00005373-198206000-00008; Bokelman TA, 1996, AM HEART J, V131, P411, DOI 10.1016/S0002-8703(96)90379-8; Bromberg BI, 1996, J PEDIATR-US, V128, P536, DOI 10.1016/S0022-3476(96)70366-9; BRUNEL W, 1988, J INTENSIVE CARE MED, V3, P253; CACHECHO R, 1992, J TRAUMA, V33, P68, DOI 10.1097/00005373-199207000-00014; Caparrelli DJ, 2002, J TRAUMA, V52, P377, DOI 10.1097/00005373-200202000-00028; Chirillo F, 1996, HEART, V75, P301, DOI 10.1136/hrt.75.3.301; Christensen M A, 1993, Am J Crit Care, V2, P28; DOTY DB, 1974, ANN SURG, V180, P452, DOI 10.1097/00000658-197410000-00010; Dowd MD, 1996, J TRAUMA, V40, P61, DOI 10.1097/00005373-199601000-00012; DUBROW TJ, 1989, SURGERY, V106, P267; FEGHALI NT, 1995, CHEST, V108, P1673, DOI 10.1378/chest.108.6.1673; FILDES JJ, 1995, AM SURGEON, V61, P832; FOIL MB, 1990, AM J SURG, V160, P638, DOI 10.1016/S0002-9610(05)80764-0; FRAZEE RC, 1986, J TRAUMA, V26, P510, DOI 10.1097/00005373-198606000-00004; FULDA G, 1991, J TRAUMA, V31, P167, DOI 10.1097/00005373-199131020-00003; GETZ BS, 1986, JAMA-J AM MED ASSOC, V255, P761, DOI 10.1001/jama.255.6.761; HEALEY MA, 1990, J TRAUMA, V30, P137, DOI 10.1097/00005373-199002000-00002; HIRSCH R, 1997, J PEDIATR-US, V6, P872; ILLIG KA, 1991, AM J SURG, V162, P537, DOI 10.1016/0002-9610(91)90105-M; KARALIS DG, 1994, J TRAUMA, V36, P53, DOI 10.1097/00005373-199401000-00008; KATO K, 1994, J TRAUMA, V36, P859, DOI 10.1097/00005373-199406000-00017; KEUNG ECH, 1981, JAMA-J AM MED ASSOC, V245, P144, DOI 10.1001/jama.245.2.144; Lindstaedt M, 2002, J TRAUMA, V52, P479, DOI 10.1097/00005373-200203000-00011; Link MS, 1998, NEW ENGL J MED, V338, P1805, DOI 10.1056/NEJM199806183382504; Maenza RL, 1996, AM J EMERG MED, V14, P237, DOI 10.1016/S0735-6757(96)90165-5; MALANGONI MA, 1994, SURGERY, V116, P628; Mandavia DP, 2001, ANN EMERG MED, V38, P377, DOI 10.1067/mem.2001.118224; MANYARI DE, 1978, CAN MED ASSOC J, V119, P445; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1142, DOI 10.1001/jama.287.9.1142; MATTOX KL, 1975, CIRCULATION, V52, P210; MATTOX KL, 1992, J TRAUMA, V33, P649; MAZZORANA V, 1994, AM SURGEON, V60, P516; Nagy KK, 2001, WORLD J SURG, V25, P108, DOI 10.1007/s002680020372; NEIMAN J, 1992, AM HEART J, V123, P1694, DOI 10.1016/0002-8703(92)90827-I; Nesbitt AD, 2001, LANCET, V357, P1195, DOI 10.1016/S0140-6736(00)04338-5; Orliaguet G, 2001, ANESTHESIOLOGY, V95, P544, DOI 10.1097/00000542-200108000-00041; PARMLEY LF, 1958, CIRCULATION, V18, P371, DOI 10.1161/01.CIR.18.3.371; PASQUALE MD, 1998, PRACTICE MANAGEMENT; Patel AN, 2003, ANN THORAC SURG, V76, P2043, DOI 10.1016/S0003-4975(03)01057-9; Patetsios P, 2000, J TRAUMA, V49, P771, DOI 10.1097/00005373-200010000-00032; Penney DJ, 2002, RESUSCITATION, V55, P337, DOI 10.1016/S0300-9572(02)00234-4; PEVEC WC, 1989, CRIT CARE MED, V17, P837, DOI 10.1097/00003246-198908000-00023; PEVEC WC, 1989, ANN THORAC SURG, V48, P139, DOI 10.1016/0003-4975(89)90203-8; PRETRE R, 1993, ANN THORAC SURG, V56, P1426, DOI 10.1016/0003-4975(93)90708-P; Pretre R, 1997, NEW ENGL J MED, V336, P626, DOI 10.1056/NEJM199702273360906; Relos RP, 2003, CRIT CARE MED, V31, P2598, DOI 10.1097/01.CCM.0000089931.09635.D2; ROBERTS JR, 2004, ROBERTS CLIN PROCEDU; Rozycki GS, 1999, J TRAUMA, V46, P543, DOI 10.1097/00005373-199904000-00002; Rozycki GS, 1996, ANN SURG, V223, P737, DOI 10.1097/00000658-199606000-00012; Salim A, 2001, J TRAUMA, V50, P237, DOI 10.1097/00005373-200102000-00008; Schultz JM, 2004, CRIT CARE CLIN, V20, P57, DOI 10.1016/S0749-0704(03)00092-7; SHORR RM, 1987, ANN SURG, V206, P200, DOI 10.1097/00000658-198708000-00013; Sisley AC, 1998, J TRAUMA, V44, P291, DOI 10.1097/00005373-199802000-00009; SNOW N, 1982, J TRAUMA, V22, P426, DOI 10.1097/00005373-198205000-00015; Spodick DH, 2003, NEW ENGL J MED, V349, P684, DOI 10.1056/NEJMra022643; STURAITIS M, 1986, ARCH INTERN MED, V146, P1765, DOI 10.1001/archinte.146.9.1765; SYMBAS PN, 1991, CURR PROB CARDIOLOGY, V16, P537; TENZER ML, 1985, J TRAUMA, V25, P620, DOI 10.1097/00005373-198507000-00008; TSUNG SH, 1976, CLIN CHEM, V22, P173; *US DEP HHS, 2004, VIT HLTH STAT; US Department of Health and Human Services; Centers for Disease Control and Prevention; National Center for Health Statistics National Hospital Discharge Survey (NHDS), 2004, NAT HOSP DISCH SURV; Velmahos GC, 2003, J TRAUMA, V54, P45, DOI 10.1097/00005373-200301000-00006; VLAY SC, 1980, AM HEART J, V100, P907, DOI 10.1016/0002-8703(80)90073-3; Weiss RL, 1996, CHEST, V109, P73, DOI 10.1378/chest.109.1.73; Zangwill SD, 2004, PEDIATR CLIN N AM, V51, P1347, DOI 10.1016/j.pcl.2004.04.001	70	50	56	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	MAR	2006	73	2					542	552					11	Medicine, General & Internal	General & Internal Medicine	020NB	WOS:000235915100005	16568196				2021-06-18	
J	Javouhey, E; Guerin, AC; Chiron, M				Javouhey, E; Guerin, AC; Chiron, M			Incidence and risk factors of severe traumatic brain injury resulting from road accidents: A population-based study	ACCIDENT ANALYSIS AND PREVENTION			English	Article						traumatic brain injury; road traffic accident; risk factors; epidemiology; logistic regression	MORTALITY; FRANCE; AGE; EPIDEMIOLOGY; MANAGEMENT; HEMATOMA; DEATHS	A population-based study was carried out in 1996-2001 to provide the incidence and to identify the risk factors of severe traumatic brain injury (TBI) resulting from a road accident. The severe TBI was defined as an injury to the brain or the skull, excluding scalp injuries, with an abbreviated injury scale (AIS) severity score greater than 2. The severe TBI of 1238 patients were described. The annual incidence and mortality of severe TBI were, respectively, 13.7 per 100,000 and 5.3 per 100,000. The fatality rate increased from 20% in childhood to 71% over 75-year-old. Compared to restrained car occupants, the odds ratio for having a severe TBI was 18.1 (95% confidence interval, CI = 12.8-25.5) for un-helmeted motorcyclists, 9.2 (95% CI = 7.5-11.3) for pedestrians, 6.4 (95% CI = 4.7-8.8) for un-helmeted cyclists, 3.9 (95% CI = 3.1-4.8) for unrestrained car occupants and 2.8 (95% CI = 2.2-3.5) for helmeted motorcyclists. Even after adjustment for several severity factors, male gender and age above 55 were both risk factors. Prevention programs aiming at improving the head protection should be promoted. The circumstances of the accident should be taken into account to predict a severe TBI. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Lyon 1, UMRESTTE Epidemiol Res & Surveillance Unit Transp, Joint Unit Inrets, French Natl Inst Transport & Safety Res, F-69675 Bron, France; InVS Natl Inst Publ Hlth Surveillance, F-69675 Bron, France	Javouhey, E (corresponding author), Univ Lyon 1, UMRESTTE Epidemiol Res & Surveillance Unit Transp, Joint Unit Inrets, French Natl Inst Transport & Safety Res, 25 Ave Francois Mitterrand,Case 24, F-69675 Bron, France.	etienne.javouhey@inrets.fr; anne-celine.guerin@inrets.fr; mireille.chiron@inrets.fr	Javouhey, Etienne/G-3651-2013				Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Caroli M, 2001, SURG NEUROL, V56, P82, DOI 10.1016/S0090-3019(01)00540-7; Demetriades D, 2004, J AM COLL SURGEONS, V199, P382, DOI 10.1016/j.jamcollsurg.2004.03.027; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Farin A, 2004, ACT NEUR S, V89, P101; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; HUSSAIN LM, 1994, BRIT MED J, V308, P1077, DOI 10.1136/bmj.308.6936.1077; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Laumon B, 2002, REV EPIDEMIOL SANTE, V50, P277; Martin JL, 2004, REV EPIDEMIOL SANTE, V52, P357, DOI 10.1016/S0398-7620(04)99065-7; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; *ONISR, 2004, SEC ROUT FRANC BIL A; ROZZELLE CJ, 1995, J AM GERIATR SOC, V43, P240, DOI 10.1111/j.1532-5415.1995.tb07329.x; Servadei F, 2002, J Neurosurg Sci, V46, P111; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Turner C, 2004, ACCIDENT ANAL PREV, V36, P93, DOI 10.1016/S0001-4575(02)00131-8	24	50	52	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	MAR	2006	38	2					225	233		10.1016/j.aap.2005.08.001			9	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	011JZ	WOS:000235265700002	16242108				2021-06-18	
J	Coles, JP; Fryer, TD; Bradley, PG; Nortje, J; Smielewski, P; Rice, K; Clark, JC; Pickard, JD; Menon, DK				Coles, JP; Fryer, TD; Bradley, PG; Nortje, J; Smielewski, P; Rice, K; Clark, JC; Pickard, JD; Menon, DK			Intersubject variability and reproducibility of O-15 PET studies	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral blood flow; cerebral metabolism; head injury; positron emission tomography	CEREBRAL BLOOD-FLOW; POSITRON EMISSION TOMOGRAPHY; TRAUMATIC BRAIN-INJURY; STEADY-STATE TECHNIQUE; OXYGEN UTILIZATION; HEAD-INJURY; INVIVO MEASUREMENT; NORMAL VALUES; HYPERVENTILATION; METABOLISM	Oxygen-15 positron emission tomography (O-15 PET) can provide important data regarding patients with head injury. We provide reference data on intersubject variability and reproducibility of cerebral blood flow (CBF), cerebral blood volume (CBV), cerebral metabolism (CMRO2) and oxygen extraction fraction (OEF) in patients and healthy controls, and explored alternative ways of assessing reproducibility within the context of a single PET study. In addition, we used independent measurements of CBF and CMRO2 to investigate the effect of mathematical correlation on the relationship between flow and metabolism. In patients, intersubject coefficients of variation (CoV) for CBF, CMRO2 and OEF were larger than in controls (32.9% +/- 2.2%, 23.2% +/- 2.0% and 22.5% +/- 3.4% versus 13.5% +/- 1.4%, 12.8% +/- 1.1% and 7.3% +/- 1.2%), while CoV for CBV were lower (15.2% +/- 2.1% versus 22.5% +/- 2.8%) (P < 0.001). The CoV for the test-retest reproducibility of CBF, CBV, CMRO2 and OEF in patients were 2.1% +/- 1.5%, 3.8% +/- 3.0%, 3.7% +/- 3.0% and 4.6% +/- 3.5%, respectively. These were much lower than the intersubject CoV figures, and were similar to alternative measures of reproducibility obtained by fractionating data from a single study. The physiological relationship between flow and metabolism was preserved even when mathematically independent measures were used for analysis. These data provide a context for the design and interpretation of interventional PET studies. While ideally each centre should develop its own bank of such data, the figures provided will allow initial generic approximations of sample size for such studies.	Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; Addenbrookes Hosp, MRC, Biostat Unit, Inst Publ Hlth, Cambridge, England	Coles, JP (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	jpc44@wbic.cam.ac.uk	Rice, Kenneth M/A-4150-2013	Rice, Kenneth M/0000-0001-5779-4495; Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237, G0600986] Funding Source: Medline		Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; BERGSTROM M, 1983, J COMPUT ASSIST TOMO, V7, P42, DOI 10.1097/00004728-198302000-00008; Carriere Isabelle, 2002, BMC Med Res Methodol, V2, P15, DOI 10.1186/1471-2288-2-15; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; LAMMERTSMA AA, 1988, J CEREBR BLOOD F MET, V8, P411, DOI 10.1038/jcbfm.1988.77; LAMMERTSMA AA, 1981, J COMPUT ASSIST TOMO, V5, P544, DOI 10.1097/00004728-198108000-00016; LAMMERTSMA AA, 1992, J CEREBR BLOOD F MET, V12, P291, DOI 10.1038/jcbfm.1992.39; LAMMERTSMA AA, 1983, J CEREBR BLOOD F MET, V3, P425, DOI 10.1038/jcbfm.1983.68; LAMMERTSMA AA, 1984, J CEREBR BLOOD F MET, V4, P317, DOI 10.1038/jcbfm.1984.47; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P372, DOI 10.1038/jcbfm.1987.75; LEBRUNGRANDIE P, 1983, ARCH NEUROL-CHICAGO, V40, P230, DOI 10.1001/archneur.1983.04050040060010; LEENDERS KL, 1990, BRAIN, V113, P27, DOI 10.1093/brain/113.1.27; MATTHEW E, 1993, J CEREBR BLOOD F MET, V13, P748, DOI 10.1038/jcbfm.1993.95; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PHELPS ME, 1979, J NUCL MED, V20, P328; Smielewski Peter, 2002, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; Stearns C, 1995, J NUCL MED, V36, P105; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; Talairach J., 1998, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81	30	50	51	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2006	26	1					48	57		10.1038/sj.jcbfm.9600179			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	021HY	WOS:000235975500005	15988475	Bronze			2021-06-18	
J	Coelho, CA; Grela, B; Corso, M; Gamble, A; Feinn, R				Coelho, CA; Grela, B; Corso, M; Gamble, A; Feinn, R			Microlinguistic deficits in the narrative discourse of adults with traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; discovery; linguistic	CLOSED-HEAD-INJURY; ELICITATION TASK; MILD; ADOLESCENTS; COHESION	Background: Recent studies of microlinguistic impairments in the narrative discourse of adults with traumatic brain injury (TBI) have applied syntactic analyses, with some noting no deficits and others specific problems with sentence formulation. An alternative approach to examining the microlinguistic dysfunction in the discourse of individuals with TBI is through the use of propositional analysis. The advantage of propositional analysis is that it enables one to assess semantic complexity of utterances apart from sentence structure and grammaticality. Aims: The present study applied propositional analysis to the story narratives of participants with TBI and participants with no brain injury (NBI). Specifically, the mean number of propositions within a sentence was tallied, in other words the participants' ability to insert multiple ideas into single surface sentences. It was hypothesized that the participants with TBI would produce fewer propositions per sentence because of organizational problems than the participants with NBI, regardless of level of education. Methods and procedures: Two story narratives ( retelling and generation) previously elicited from the two participant groups ( TBI ( n = 53) and NBI ( n = 42)) were analysed. For each language sample, the number of propositions was tallied and divided by the number of T-units. The resulting number, the propositional complexity index (PCI), was the average number of predicates per sentence. Outcomes and results: Results indicated that the group with TBI produced significantly fewer propositions per T-unit. Conclusions: The present findings are in harmony with the notion that the participants with TBI studied presented with impairments of both micro- and macrolinguistic processes involved with the organization of semantic information in discourse. Clinical implications are discussed.	Univ Connecticut, Dept Commun Sci, Storrs, CT 06269 USA; Univ Connecticut, Ctr Hlth, Farmington, CT USA	Coelho, CA (corresponding author), Univ Connecticut, Dept Commun Sci, Unit 1085, Storrs, CT 06269 USA.	coelho@uconn.edu					CANNIZZARO MS, 2000, BRAIN INJURY, V14, P397; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Cohen J., 1977, STAT POWER ANAL BEHA, P1; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Frederiksen C.H., 1990, DISCOURSE ABILITY BR, P69, DOI 10.1007/978-1-4612-3262-9_4; GLOSSER G, 1993, NARRATIVE DISCOURSE IN NEUROLOGICALLY IMPAIRED AND NORMAL AGING ADULTS, P191; Glosser G., 1990, BRAIN LANG, V40, P67; HAGAN C, 1980, REHABILITATION HEAD; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HOLLINGSHEAD A, 1972, UNPUB 4 FACTOR INDEX; Hughes D., 1997, GUIDE NARRATIVE LANG; HUNT CEL, 1970, J NUCL MATER, V35, P134, DOI 10.1016/0022-3115(70)90040-1; Kamhi AG, 1992, BEST PRACTICES SCH S, P99; Kertesz A., 1982, W APHASIA BATTERY; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; Kintsch W., 1994, HDB PSYCHOLINGUISTIC, P721; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; Mattis S, 1976, GERIATRIC PSYCHIAT; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P583; Parente R., 1996, RETRAINING COGNITION; Peach R. K., 1986, ANN CONV AM SPEECH L; Penn C, 1997, APHASIOLOGY, V11, P601, DOI 10.1080/02687039708248492; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow PC, 2000, BRAIN INJURY, V14, P397; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Ulatowska H.K., 1990, DISCOURSE ABILITY BR, P180, DOI [10.1007/978-1-4612-3262-9_8, DOI 10.1007/978-1-4612-3262-9_8]; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Winter P., 1976, BEAR FLY; WOLFOLK WB, 1992, B PSYCHONOMIC SOC, V30, P226; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745	36	50	51	1	10	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2005	19	13					1139	1145		10.1080/02699050500110678			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZD	WOS:000233270000008	16286327				2021-06-18	
J	Poca, MA; Sahuquillo, J; Mataro, M; Benejam, B; Arikan, F; Baguena, M				Poca, MA; Sahuquillo, J; Mataro, M; Benejam, B; Arikan, F; Baguena, M			Ventricular enlargement after moderate or severe head injury: A frequent and neglected problem	JOURNAL OF NEUROTRAUMA			English	Article						head injury; incidence; outcome; post-traumatic hydrocephalus; ventricular dilation; ventriculomegaly	PROLONGED POSTTRAUMATIC UNAWARENESS; INTRACRANIAL-PRESSURE; COMPUTERIZED-TOMOGRAPHY; TRAUMATIC COMA; CSF DYNAMICS; BRAIN-INJURY; HYDROCEPHALUS; DIAGNOSIS; CLASSIFICATION; MANAGEMENT	The primary goal of this study was to determine the incidence of post-traumatic ventriculomegaly (Evans' index >= 0.30) in 95 head-injured patients with a Glasgow Coma Scale (GCS) score of <= 13 at admission. Additional objectives were to determine the relationship between an increase in ventricular size and several clinical and radiological features and outcome. A planimetric study was carried out in the sequential control computed tomography (CT) scans of 34 moderately head-injured (GCS 9-13) and 61 severely head-injured (GCS 3-8) patients with a minimum follow-up of 2 months. Between two and six CT scans were evaluated in each patient. The presence of subarachnoid hemorrhage (SAH) was registered. Evans' index was determined in all CT scans. In the final CT scan of each patient, ventricular size was related to the admission GCS score, age, the presence of SAH in the initial CT scans, type of brain lesion (classified according to the final diagnosis in the Traumatic Coma Data Bank classification), and outcome. Ventriculomegaly was found in 39.3% of patients with severe head injury and in 27.3 % of those with a moderate head injury. Increased ventricular size was evident 4 weeks after injury in 57.6% and 2 months after injury in 69.7%. No relationship was found between post-traumatic ventriculomegaly and age, initial GCS score, the presence of SAH, or type of lesion (focal or diffuse). Post-traumatic ventriculomegaly was significantly correlated with outcome. Post-traumatic ventriculomegaly is a frequent and early finding in patients with moderate or severe traumatic brain injury.	Autonomous Univ Barcelona, Hosp Gen Valle Hebron, Dept Neurosurg, Barcelona, Spain; Autonomous Univ Barcelona, Hosp Gen Valle Hebron, Neurotraumatol Res Unit, Barcelona, Spain; Autonomous Univ Barcelona, Hosp Gen Valle Hebron, Neurotraumatol Intens Care Unit, Barcelona, Spain; Univ Barcelona, Fac Psychol, Dept Psychiat & Clin Psychobiol, Barcelona, Spain	Poca, MA (corresponding author), Univ Barcelona, Hosp Gen Valle Hebron, Dept Neurosurg, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	pocama@neurotrauma.net	Poca, Maria A./B-8475-2008; Mataro, Maria/B-4524-2011; Martinez, Marcelino Baguena/AAG-7379-2019; Arikan, Fuat/F-8900-2016; Sahuquillo, Juan/B-3577-2008	Poca, Maria A./0000-0002-3831-0536; Mataro, Maria/0000-0002-9946-2656; Martinez, Marcelino Baguena/0000-0001-9598-4791; Arikan, Fuat/0000-0002-9459-0915; Sahuquillo, Juan/0000-0003-0713-5875			Albeck MJ, 1998, J NEUROSURG, V89, P275, DOI 10.3171/jns.1998.89.2.0275; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; BEYERL B, 1984, NEUROSURGERY, V15, P257, DOI 10.1227/00006123-198408000-00020; BORISENKO VV, 1997, LIK SPRAVA, V4, P91; BORISENKO VV, 1998, LIK SPRAVA, V5, P77; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; DOBROKHOTOVA TA, 1997, ZH VOPR NEIROKHIR N, V4, P12; Evans WA, 1942, ARCH NEURO PSYCHIATR, V47, P931, DOI 10.1001/archneurpsyc.1942.02290060069004; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; JENNETT B, 1975, LANCET, V1, P480; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; KATZ RT, 1989, AM J PHYS MED REHAB, V68, P91, DOI 10.1097/00002060-198904000-00009; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Licata C, 2001, J Neurosurg Sci, V45, P141; LOSHAKOV VA, 1993, ZH VOPR NEIROKHIR N, V3, P18; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; Matsushita H, 2000, NEUROL SURG TOKYO, V28, P773; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Meier U, 1987, Psychiatr Neurol Med Psychol (Leipz), V39, P754; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Paoletti P, 1983, J Neurosurg Sci, V27, P171; Poca MA, 2004, J NEUROSURG, V100, P855, DOI 10.3171/jns.2004.100.5.0855; Poca MA, 2004, J NEUROSURG, V100, P260, DOI 10.3171/jns.2004.100.2.0260; Poca MA, 2001, NEUROLOGIA, V16, P303; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Sahuquillo J, 2002, NEUROCIRUGIA, V13, P78; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SAZBON L, 1991, J NEUROL NEUROSUR PS, V54, P149, DOI 10.1136/jnnp.54.2.149; VANDONGEN KJ, 1980, NEUROSURGERY, V7, P14, DOI 10.1227/00006123-198007000-00003; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37	40	50	61	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2005	22	11					1303	1310		10.1089/neu.2005.22.1303			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	989OI	WOS:000233683000004	16305318				2021-06-18	
J	Feinstein, AJ; Patel, MB; Sanui, M; Cohn, SM; Majetschak, M; Proctor, KG				Feinstein, AJ; Patel, MB; Sanui, M; Cohn, SM; Majetschak, M; Proctor, KG			Resuscitation with pressors after traumatic brain injury	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article; Proceedings Paper	Annual Meeting of the American-College-of-Surgeons-Florida-Committee-on-Trauma	NOV, 2004	Miami Beach, FL	Amer Coll Surg FL Comm Trauma			UNCONTROLLED HEMORRHAGIC-SHOCK; CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; ARGININE-VASOPRESSIN; FLUID RESUSCITATION; VASODILATORY SHOCK; LIVER TRAUMA; EPINEPHRINE; PHASE; NOREPINEPHRINE	BACKGROUND: The purpose of the study was to compare initial resuscitation with arginine vasopressin (AVP), phenylephrine (PE), or isotonic crystalloid fluid alone after traumatic brain injury and vasodilatory shock. STUDY DESIGN: Anesthetized, ventilated swine (n = 39, 30 +/- 2 kg) underwent fluid percussion traumatic brain injury followed by hemorrhage (30 +/- 2 mL/kg) to a mean arterial pressure < 30 mmHg, then were randomized to 1 of 5 groups to maintain mean arterial pressure > 60 mmHg for 30 to 60 minutes, then cerebral perfusion pressure > 60 mmHg for 60 to 300 minutes, either unlimited crystalloid fluid only (n = 9), arginine vasopressin + fluid (n = 9), phenylephrine + fluid (n = 9), arginine vasopressin only (n = 5), or phenylephrine only (n = 5). Heterologous transfusions were administered if hematocrit was < 13, and mannitol was administered if intracranial pressure was > 20 mmHg. Cerebrovascular reactivity was evaluated with serial CO2 challenges. RESULTS: In all groups, physiologic variables were similar at baseline and at the end of shock. On resuscitation, all achieved mean arterial pressure and cerebral perfusion pressure goals. Brain tissue PO(2)s were similar. With fluid only, more blood and mannitol were required, intracranial pressure and peak inspiratory pressure were higher, and cerebrovascular reactivity was decreased (all p < 0.05 versus pressor + fluid). With either pressor + fluid, cardiac output, heart rate, lactate, and mixed venous O-2 saturation were similar to fluid only, but total fluid requirements and urine output were both reduced (p < 0.05). With either pressor only, intracranial. pressure remained low, but mixed venous O-2 saturation, cardiac output, and urine output were decreased (all p < 0.05 versus other groups). CONCLUSIONS: To correct vasodilatory shock after traumatic brain injury, a resuscitation strategy that combined either phenylephrine or arginine vasopressin plus crystalloid was superior to either fluid alone or pressor alone.	Univ Miami, Miller Sch Med, Ryder Trauma Ctr, Dewitt Daughtry Family Dept Surg,Div Trauma, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dewitt Daughtry Family Dept Surg, Div Surg Crit Care, Miami, FL 33136 USA	Proctor, KG (corresponding author), Univ Miami, Miller Sch Med, Ryder Trauma Ctr, Dewitt Daughtry Family Dept Surg,Div Trauma, 1800 NW 10th Ave, Miami, FL 33136 USA.		Patel, Mayur/K-2363-2013	Feinstein, Ara/0000-0001-6214-5334	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM08749-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008749] Funding Source: NIH RePORTER		Alspaugh DM, 2000, J TRAUMA, V48, P851, DOI 10.1097/00005373-200005000-00008; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P493; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Crookes BA, 2005, J TRAUMA, V58, P806, DOI 10.1097/01.TA.0000158269.68409.1C; Crookes BA, 2004, SURGERY, V135, P662, DOI 10.1016/j.surg.2003.11.017; DeWitt DS, 2000, CRIT CARE MED, V28, P3933, DOI 10.1097/00003246-200012000-00036; Dunser MW, 2003, CRIT CARE MED, V31, P1394, DOI 10.1097/01.CCM.0000059722.94182.79; Dunser MW, 2004, ANESTH ANALG, V99, P201, DOI 10.1213/01.ANE.0000118105.85933.8A; FEINSTEIN AJ, 2004, J TRAUMA, V57, P1377; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Hilwig RW, 2000, RESUSCITATION, V47, P203, DOI 10.1016/S0300-9572(00)00261-6; Huang Wei-dong, 2003, Chin J Traumatol, V6, P139; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; Landry DW, 1997, CIRCULATION, V95, P1122; Liu LM, 2003, J TRAUMA, V54, pS159, DOI 10.1097/01.TA.0000054649.46525.A5; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; MATTOX KL, 1996, TRAUMA; Morales D, 1999, CIRCULATION, V100, P226, DOI 10.1161/01.CIR.100.3.226; Pope A, 1999, FLUID RESUSCITATION; Potas JR, 2004, AUTON NEUROSCI-BASIC, V111, P1, DOI 10.1016/j.autneu.2003.12.003; RABINOVICI R, 1992, SURG GYNECOL OBSTET, V175, P341; Raedler C, 2004, ANESTH ANALG, V98, P1759, DOI 10.1213/01.ANE.0000117150.29361.5A; REMINGTON JW, 1950, AM J PHYSIOL, V161, P116; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; SANUI M, 2004, ANESTHESIOLOGY, V101, pA414; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; Wenzel V, 2004, NEW ENGL J MED, V350, P105, DOI 10.1056/NEJMoa025431; WIGGERS HC, 1950, CIRCULATION, V2, P179, DOI 10.1161/01.CIR.2.2.179	32	50	50	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	OCT	2005	201	4					536	545		10.1016/j.jamcollsurg.2005.05.031			10	Surgery	Surgery	972DF	WOS:000232433500008	16183491				2021-06-18	
J	Clausen, H; McCrory, P; Anderson, V				Clausen, H; McCrory, P; Anderson, V			The risk of chronic traumatic brain injury in professional boxing: change in exposure variables over the past century	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							BOXERS; SPORTS; DAMAGE	Objectives: To determine if boxing exposure has changed over time and hence if current professional boxers are at the same risk of developing chronic traumatic brain injury (CTBI) as historical controls. Design: Literature review of published studies and analysis of data of active professional boxers. Subjects: Professional boxers in the United Kingdom and Australia. Main outcome measures: Boxing history and participation in sparring and professional bouts. Results: Since the 1930s, the average duration of a professional boxer's career has dropped from 19 years to five years, and the mean number of career bouts has reduced from 336 to 13. This is despite no significant decline in participation rates from 1931 until 2002. Conclusions: The incidence of boxing related CTBI will diminish in the current era of professional boxing because of the reduction in exposure to repetitive head trauma and increasing medical monitoring of boxers, with preparticipation medical and neuroimaging assessments resulting in the detection of early and potentially pre-symptomatic cases of CTBI.	Univ Melbourne, Parkville, Vic 3052, Australia	McCrory, P (corresponding author), POB 93, Melbourne, Vic 3916, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019				*A L BLACK, 2003, WHIT ALM; *ABS, 2002, 31010 ABS; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY E, 1937, MED ANN, P318; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HOGG JM, 2003, AUSTR BOXING RECORDS; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; Kemp P L, 1995, J R Nav Med Serv, V81, P182; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAWDSLEY C, 1963, LANCET          1019, P796; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Ravdin LD, 2003, CLIN J SPORT MED, V13, P21, DOI 10.1097/00042752-200301000-00005; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; SPILLANE JD, 1962, BRIT MED J, P1205	21	50	52	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2005	39	9					661	664		10.1136/bjsm.2004.017046			4	Sport Sciences	Sport Sciences	957UF	WOS:000231398100021	16118306	Green Published, Bronze			2021-06-18	
J	Yu, CG; Yezierski, RP				Yu, CG; Yezierski, RP			Activation of the ERK1/2 signaling cascade by excitotoxic spinal cord injury	MOLECULAR BRAIN RESEARCH			English	Article						spinal cord injury; glutamate receptor; ERK; gene expression; pain; excitotoxicity	NF-KAPPA-B; METABOTROPIC GLUTAMATE RECEPTORS; INFLAMMATORY PAIN HYPERSENSITIVITY; TRAUMATIC BRAIN-INJURY; MAP KINASE ACTIVATION; RAT STRIATAL NEURONS; PROTEIN-KINASE; TRANSCRIPTION FACTOR; REGULATED KINASE; GENE-EXPRESSION	The role of the ERK1/2 signal transduction pathway and related transcription factors in the regulation of gene expression and pain behavior following excitotoxic spinal cord injury (SCI) was examined. Specifically, phosphorylation of ERK1/2, activation of transcription factors NF-kappa B, ELK-1, and CREB, and gene expression of the neurokinin-1 receptor and NMDA receptor subunits NR1 and NR-2A were investigated. Excitotoxic injury was produced by intraspinal injection of quisqualic acid (QUIS) in male Sprague-Dawley rats. Western blots were used to evaluate phosphorylation and activation of ERK1/2 and transcription factors using phospho-specific or total antibodies. Real-time PCR was used to evaluate gene expression of NK-1R, NR-1, and NR-2A. Assessment of excessive grooming behavior was used to evaluate the presence of spontaneous pain behavior. Excitotoxic spinal injury resulted in: (1) increased phosphorylation of ERK1/2; (2) increased activation of NF-kappa B and phosphorylation of ELK-1; and (3) increased gene expression for the NK-1 receptor and NR1 and NR-2A subunits of the NMDA receptor. Blockade of the ERK cascade with the MEK inhibitor PD98059 inhibited phosphorylation of ELK-1, activation of NF-kappa B and gene expression of NR1, NR-2A and NK-1R, and prevented the development of excessive grooming behavior. The results have shown that excitotoxic spinal injury leads to the injury-induced activation of the ERK -> ELK-1 and NF-kappa B signaling cascades and transcriptional regulation of receptors important in the development of chronic pain. Blockade of this intracellular kinase cascade prevented the onset of injury-induced pain behavior. (c) 2005 Elsevier B.V. All rights reserved.	Univ Florida, Dept Orthodont & Neurosci, Coll Dent, Gainesville, FL 32610 USA; Univ Florida, Mcknight Brain Inst, Comprehens Ctr Pain Res, Gainesville, FL 32610 USA	Yezierski, RP (corresponding author), Univ Florida, Dept Orthodont & Neurosci, Coll Dent, 1600 SW Archer Rd,POB 100444, Gainesville, FL 32610 USA.	RYEZIERSKI@dental.ufl.edu	Yu, Chen Guang/C-6176-2011		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40096] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040096] Funding Source: NIH RePORTER		Abraham KE, 2001, NEUROSCIENCE, V104, P863, DOI 10.1016/S0306-4522(01)00134-8; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; BACUERLE PA, 1996, CELL, V87, P13; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Begon S, 2001, BRIT J PHARMACOL, V134, P1227, DOI 10.1038/sj.bjp.0704354; Bethea JR, 1998, J NEUROSCI, V18, P3251; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Caudle RM, 2003, NEUROSCI LETT, V349, P37, DOI 10.1016/S0304-3940(03)00700-6; Choe ES, 2002, NEUROSCIENCE, V114, P557, DOI 10.1016/S0306-4522(02)00318-4; Choe ES, 2002, INT J MOL MED, V9, P3; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; Curtis J, 1999, J NEUROSCI RES, V58, P88, DOI 10.1002/(SICI)1097-4547(19991001)58:1<88::AID-JNR9>3.3.CO;2-I; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Eide PK, 1998, SPINAL CORD, V36, P601, DOI 10.1038/sj.sc.3100737; Fairbanks CA, 2000, P NATL ACAD SCI USA, V97, P10584, DOI 10.1073/pnas.97.19.10584; Ferrer I, 2001, MOL BRAIN RES, V94, P48, DOI 10.1016/S0169-328X(01)00198-X; Fiebich BL, 2000, J NEUROCHEM, V75, P2020, DOI 10.1046/j.1471-4159.2000.0752020.x; Fundytus ME, 2001, CNS DRUGS, V15, P29, DOI 10.2165/00023210-200115010-00004; Galan A, 2003, MOL BRAIN RES, V116, P126, DOI 10.1016/S0169-328X(03)00284-5; Gallo A, 2002, ONCOGENE, V21, P6434, DOI 10.1038/sj.onc.1205822; Grossman SD, 2000, J NEUROCHEM, V75, P174, DOI 10.1046/j.1471-4159.2000.0750174.x; Hao JX, 2003, J REHABIL MED, V35, P81, DOI 10.1080/16501960310010197; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040; Ji RR, 2002, J NEUROSCI, V22, P478, DOI 10.1523/JNEUROSCI.22-02-00478.2002; Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017; Ji RR, 2001, NEUROBIOL DIS, V8, P1, DOI 10.1006/nbdi.2000.0360; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; Karim F, 2001, J NEUROSCI, V21, P3771, DOI 10.1523/JNEUROSCI.21-11-03771.2001; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kawasaki Y, 2004, J NEUROSCI, V24, P8310, DOI 10.1523/JNEUROSCI.2396-04.2004; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Lee KM, 2004, EUR J NEUROSCI, V19, P3375, DOI 10.1111/j.0953-816X.2004.03441.x; Liu AG, 2004, J BIOL CHEM, V279, P17449, DOI 10.1074/jbc.M311267200; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; Loop T, 2002, ANESTHESIOLOGY, V96, P1202, DOI 10.1097/00000542-200205000-00025; Ma VY, 1998, BRAIN RES, V797, P243, DOI 10.1016/S0006-8993(98)00380-1; Ma WY, 2002, PAIN, V99, P175, DOI 10.1016/S0304-3959(02)00097-0; Mao LM, 2004, EUR J NEUROSCI, V19, P1207, DOI 10.1111/j.1460-9568.2004.03223.x; Mills CD, 2002, J NEUROTRAUM, V19, P23, DOI 10.1089/089771502753460213; Mills CD, 2002, EXP NEUROL, V173, P153, DOI 10.1006/exnr.2001.7828; Mills CD, 2001, EXP NEUROL, V170, P244, DOI 10.1006/exnr.2001.7721; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171; Obata K, 2004, LIFE SCI, V74, P2643, DOI 10.1016/j.lfs.2004.01.007; Obata K, 2003, J NEUROSCI, V23, P4117, DOI 10.1523/jneurosci.23-10-04117.2003; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Plunkett JA, 2001, EXP NEUROL, V168, P144, DOI 10.1006/exnr.2000.7604; Quartara L, 1998, NEUROPEPTIDES, V32, P1, DOI 10.1016/S0143-4179(98)90015-4; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Richter M, 2002, GENE, V295, P135, DOI 10.1016/S0378-1119(02)00833-8; Riedel W, 2001, Z RHEUMATOL, V60, P404, DOI 10.1007/s003930170003; Roberts JR, 2002, CRYOBIOLOGY, V44, P161, DOI 10.1016/S0011-2240(02)00018-4; Siddall PJ, 2001, SPINAL CORD, V39, P63, DOI 10.1038/sj.sc.3101116; Simeonidis S, 2003, P NATL ACAD SCI USA, V100, P2957, DOI 10.1073/pnas.0530112100; Subramaniam S, 2004, J CELL BIOL, V165, P357, DOI 10.1083/jcb.200403028; THOMPSON SWN, 1994, J NEUROSCI, V14, P3672; Varney MA, 2002, CNS NEUROL DISORD-DR, V1, P283, DOI 10.2174/1568007023339300; Wang X, 1998, BIOCHEM J, V333, P230; Wu X, 2004, J NEUROCHEM, V90, P807, DOI 10.1111/j.1471-4159.2004.02526.x; Yezierski R P, 2000, Prog Brain Res, V129, P429; Yezierski RP, 2004, NEUROSCI LETT, V361, P232, DOI 10.1016/j.neulet.2003.12.035; Yezierski RP, 1998, PAIN, V75, P141, DOI 10.1016/S0304-3959(97)00216-9; YEZIERSKI RP, 1993, J NEUROTRAUM, V10, P445, DOI 10.1089/neu.1993.10.445; Yu CG, 2003, J PAIN, V4, P129, DOI 10.1054/jpai.2003.11; YU CG, 2003, 33 NEUR M NEW ORL; ZIMMER M, 1995, GENE, V159, P219, DOI 10.1016/0378-1119(95)00044-7	70	50	54	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	AUG 18	2005	138	2					244	255		10.1016/j.molbrainres.2005.04.013			12	Neurosciences	Neurosciences & Neurology	958VH	WOS:000231475800016	15922485				2021-06-18	
J	Shewchenko, N; Withnall, C; Keown, M; Gittens, R; Dvorak, J				Shewchenko, N; Withnall, C; Keown, M; Gittens, R; Dvorak, J			Heading in football. Part 1: Development of biomechanical methods to investigate head response	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL SOCCER PLAYERS; BRAIN-INJURY; INTRACRANIAL PRESSURE; BALL PROPERTIES; CONCUSSION; IMPACT; ACCELERATION; IMPAIRMENT; SKILL	Objectives: There has been growing controversy regarding long term effects of repeated low severity head impacts such as when heading a football. However, there are few scientific data substantiating these concerns in terms of the biomechanical head response to impact. The present study aimed to develop a research me thodology to investigate the biomechanical response of human subjects during intentional heading and identify strategies for reducing head impact severity. Methods: A controlled laboratory study was carried. but with seven active football players, aged. 20-23 and of average stature and weight. The subjects were fitted with photographic targets for kinematic analysis and instrumented to measure head linear/angular accelerations and neck muscle activity. Balls were delivered at two speeds (6 m/s 8 m/s) as the subjects executed several specific forward heading manoeuvres in the standing position." Heading "speeds up to 11 m/s were seen when the head closing. speed was considered. One subject demonstrating averaged flexion extension muscle activity phased with head acceleration data and upper torso kinematics was used to validate a biofidelic 50th percentile human model with a detailed head and neck. The model was exercised under ball incoming speeds of 6-7 m/s with parameter variations including torso/head alignment, neck muscle tensing, and follow through. The model output was subsequently compared with additional laboratory tests with football players (n = 3). Additional heading scenarios were investigated including follow through, non-active ball impact, and non-contact events. Subject and model head responses were evaluated with peak linear and rotational accelerations and maximum incremental head impact power. Results: Modelling of neck muscle tensing predicted lower head accelerations and higher neck loads whereas volunteer head acceleration reductions were not consistent. Modelling of head-torso alignment predicted a modest reduction in volunteer head accelerations. Exaggerated follow through while heading reduced volunteer head accelerations modestly. Conclusion: Biomechanical methods were developed to measure head impact response. Changing the h biomechanics of currently accepted heading techniques will have inconsistent benefits towards the reduction of head loading. Furthermore, mathematical modelling suggested an increased risk of neck loads with one alternative technique. No consistent recommendations can be made on the basis of the current study for altering heading techniques to reduce impact severity.	FIFA Med Assessment & Res Ctr, Zurich, Switzerland		shewchenko@biokinetics.com					Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Anderson SJ, 2000, PEDIATRICS, V105, P659, DOI 10.1542/peds.105.3.640; BABBS CF, 2001, BIOMECHANICS HEADING; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Bayly PV, 2002, P ANN INT IEEE EMBS, P2577, DOI 10.1109/IEMBS.2002.1053434; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Burslem I, 1988, SCI FOOTBALL, P243; Dvorak J, 2000, AM J SPORT MED, V28, pS3; GLAISTER D, 1997, ACCLERATION INJURY S, P314; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; GURDJIAN ES, 1961, SURG GYNECOL OBSTET, V113, P185; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HARDY W, 2002, ACCIDENTAL INJURY BI, P27; Hirsch AE, 1970, 14 STAPP CAR CRASH C; Holbourn A. H. S., 1943, LANCET, V245, P438; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Klein GN, 2001, EUR SPINE J, V10, P141, DOI 10.1007/s005860100248; KRAMER F, 1990, IRCOBI C BIOM IMP; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; LUDWIG KM, 1998, BIOMECHANICAL ANAL S; Lynch JM, 1996, US SOCCER SPORTS MED, P81; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; MAWDSLEY HY, 1978, MOMENTUM, V3, P30; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; Moss S., 2000, ANTHROPOMETRY WORLDS; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; NEWMAN J, 2005, IN PRESS J BIOMECH; Newman J, 2000, 44 STAPP CAR CRASH C; Newman JA., 1986, GEN ACCELERATION MOD; OMMAYA AK, 1984, HEAD INJURY BIOMECHA; Ono I., 1980, 24 STAPP CAR CRASH C; Peterson L, 2000, AM J SPORT MED, V28, pS51; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P258; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI33, DOI 10.1136/bjsm.2005.019059; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI26, DOI 10.1136/bjsm.2005.019042; Sortland O, 1982, Br J Sports Med, V16, P80; SZABO TJ, 1996, 40 STAPP CAR CRASH C; THIBAULT LE, 1990, 34 ANN C ASS ADV AUT; TORTORA GJ, 1984, PRINCIPLES ANATOMY P; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; ZIEJEWSKI M, 2003, BRAIN INJ ASS 20 ANN	55	50	51	0	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	AUG	2005	39			1			I10	I25		10.1136/bjsm.2005.019034			16	Sport Sciences	Sport Sciences	954KI	WOS:000231153600003	16046351	Bronze, Green Published			2021-06-18	
J	Chesler, M				Chesler, M			Failure and function of intracellular pH regulation in acute hypoxic-ischemic injury of astrocytes	GLIA			English	Article						lactate; acidosis; Na+-H+ exchange; Na+-Ca2+ exchange; KB-R7943; HOE-694	EXTRACELLULAR CALCIUM ACTIVITY; DIFFUSE CEREBRAL-ISCHEMIA; BRAIN LACTIC-ACIDOSIS; HIPPOCAMPAL-NEURONS; GLUTAMATE NEUROTOXICITY; GLUCOSE PRETREATMENT; NA+-CA2+ EXCHANGER; REPERFUSION INJURY; TRANSIENT HYPOXIA; RAT HIPPOCAMPUS	Astrocytes can die rapidly following ischemic and traumatic injury to the CNS. Brain acid-base status has featured prominently in theories of acute astrocyte injury. Failure of astrocyte pH regulation can lead to cell loss under conditions of severe acidosis. By contrast, the function of astrocyte pH regulatory mechanisms appears to be necessary for acute cell death following the simulation of transient ischemia and reperfusion. Severe lactic acidosis, and the failure of astrocytes to regulate intracellular pH (pH(i)) have been emphasized in brain ischemia under hyperglycemic conditions. Direct measurements of astrocyte pHi after cardiac arrest demonstrated a mean pH(i) of 5.3 in hyperglycemic rats. In addition, both in vivo and in vitro studies of astrocytes have shown similar pH levels to be cytotoxic. Whereas astrocytes exposed to hypoxia alone may require 12-24 h to die, acidosis has been found to exacerbate and speed hypoxic loss of these cells. Recently, astrocyte cultures were exposed to hypoxic, acidic media in which the large ionic perturbations characteristic of brain ischemia were simulated. Upon return to normal saline ("reperfusion"), the majority of cells died. This injury was dependent on external Ca2+ and was prevented by inhibition of reversed Na+-Ca+ exchange, blockade of Na+-H+ exchange, or by low pH of the reperfusion saline. These data suggested that cytotoxic elevation of [Ca2+](i) occurred during reperfusion due to a sequence of activated Na+-H+ exchange, cytosolic Na+ loading, and resultant reversal of Na+-Ca2+ exchange. The significance of this reperfusion model to ischemic astrocyte injury in vivo is discussed. (c) 2005 Wiley-Liss, Inc.	NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU, Sch Med, Dept Neurosurg, New York, NY 10016 USA	Chesler, M (corresponding author), NYU, Sch Med, Dept Physiol & Neurosci, 550 1St Ave, New York, NY 10016 USA.	mitch.chesler@med.nyu.edu		Chesler, Mitchell/0000-0002-3189-8234			Agrawal SK, 1996, J NEUROSCI, V16, P545; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BALENTINE JD, 1978, LAB INVEST, V39, P236; BALLANYI K, 1994, NEUROREPORT, V6, P33, DOI 10.1097/00001756-199412300-00010; Baxter KA, 1996, J PHYSIOL-LONDON, V493, P457, DOI 10.1113/jphysiol.1996.sp021396; Bevensee MO, 1997, J GEN PHYSIOL, V110, P453, DOI 10.1085/jgp.110.4.453; BLAUSTEIN MP, 1988, TRENDS NEUROSCI, V11, P438, DOI 10.1016/0166-2236(88)90195-6; Bondarenko A, 2005, GLIA, V49, P143, DOI 10.1002/glia.20107; Bondarenko A, 2001, GLIA, V34, P134, DOI 10.1002/glia.1048; Bondarenko A, 2001, GLIA, V34, P143, DOI 10.1002/glia.1049; BURTON RF, 1978, RESP PHYSIOL, V33, P51, DOI 10.1016/0034-5687(78)90083-X; BUSA WB, 1984, AM J PHYSIOL, V246, pR409; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; CHESLER M, 1991, BRAIN RES, V556, P71, DOI 10.1016/0006-8993(91)90548-A; CHESLER M, 1994, EXP NEUROL, V125, P93, DOI 10.1006/exnr.1994.1011; CHESLER M, 1987, AM J PHYSIOL, V253, pR666; CHESLER M, 1989, J NEUROSCI, V9, P2011; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; FRIEDE RL, 1961, EXP NEUROL, V4, P197, DOI 10.1016/0014-4886(61)90041-3; GARCIA JH, 1993, AM J PATHOL, V142, P623; Gido G, 1997, STROKE, V28, P206, DOI 10.1161/01.STR.28.1.206; GIFFARD RG, 1990, BRAIN RES, V530, P138, DOI 10.1016/0006-8993(90)90670-7; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; Giffard RG, 2000, J NEUROSCI, V20, P1001, DOI 10.1523/JNEUROSCI.20-03-01001.2000; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GOLDMAN SA, 1989, J CEREBR BLOOD F MET, V9, P471, DOI 10.1038/jcbfm.1989.70; HANSEN AJ, 1988, NEUROCHEM PATHOL, V9, P195; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; Hertz L, 1975, Int Rev Neurobiol, V18, P141, DOI 10.1016/S0074-7742(08)60035-5; HILLERED L, 1984, J CEREBR BLOOD F MET, V4, P430, DOI 10.1038/jcbfm.1984.62; HOCHACHKA PW, 1983, SCIENCE, V219, P1391, DOI 10.1126/science.6298937; Hulse RE, 2001, GLIA, V33, P169, DOI 10.1002/1098-1136(200102)33:2<169::AID-GLIA1016>3.0.CO;2-B; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; Karmazyn M, 1999, ANN NY ACAD SCI, V874, P326, DOI 10.1111/j.1749-6632.1999.tb09248.x; KELLEHER JA, 1993, STROKE, V24, P855, DOI 10.1161/01.STR.24.6.855; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMLEE MH, 1992, GLIA, V5, P56, DOI 10.1002/glia.440050109; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KRAIG RP, 1990, J CEREBR BLOOD F MET, V10, P104, DOI 10.1038/jcbfm.1990.13; KRAIG RP, 1985, BRAIN RES, V342, P281, DOI 10.1016/0006-8993(85)91127-8; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; KRAIG RP, 1986, AM J PHYSIOL, V250, pR348; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831; Lascola C, 1997, NEUROSCI BIOBEHAV R, V21, P143, DOI 10.1016/S0149-7634(96)00004-8; Levitsky J, 1998, J CLIN PHARMACOL, V38, P887, DOI 10.1002/j.1552-4604.1998.tb04383.x; LEYBAERT L, 1994, EXP BRAIN RES, V100, P369, DOI 10.1007/BF02738397; LIJIMA T, 1992, J CEREB BLOOD FLOW M, V12, P727; Lukaszevicz AC, 2002, J CEREBR BLOOD F MET, V22, P289, DOI 10.1097/00004647-200203000-00006; Matsuda T, 2001, J PHARMACOL EXP THER, V298, P249; Matsuda T, 1996, EUR J NEUROSCI, V8, P951, DOI 10.1111/j.1460-9568.1996.tb01582.x; McDonald JW, 1998, J NEUROSCI, V18, P6290; Meller A., 1967, ORGANOMET CHEM REV, V2, P1; MELLERGARD PE, 1991, NEUROREPORT, V2, P695, DOI 10.1097/00001756-199111000-00016; MILLER RJ, 1991, PROG NEUROBIOL, V37, P255, DOI 10.1016/0301-0082(91)90028-Y; MORIYA T, 1994, J NEUROTRAUM, V11, P255, DOI 10.1089/neu.1994.11.255; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; MYERS RE, 1977, ARCH NEUROL-CHICAGO, V34, P65, DOI 10.1001/archneur.1977.00500140019003; NEDERGAARD M, 1991, J NEUROSCI, V11, P2489; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; NORENBERG MD, 1987, J NEUROPATH EXP NEUR, V46, P154, DOI 10.1097/00005072-198703000-00004; Payne RS, 2003, BRAIN RES, V971, P9, DOI 10.1016/S0006-8993(03)02276-5; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; PETITO CK, 1982, ANN NEUROL, V11, P510, DOI 10.1002/ana.410110511; Phillis JW, 1999, BRAIN RES, V839, P199, DOI 10.1016/S0006-8993(99)01705-9; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; PLUTA R, 1987, RESUSCITATION, V15, P267, DOI 10.1016/0300-9572(87)90005-0; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; ROOS A, 1981, PHYSIOL REV, V61, P296; Rose CR, 1998, J NEUROSCI, V18, P3554; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Schurr A, 2002, NEUROCHEM INT, V41, P1, DOI 10.1016/S0197-0186(01)00142-5; SCHWIENING CJ, 1994, J PHYSIOL-LONDON, V475, P59, DOI 10.1113/jphysiol.1994.sp020049; Sheldon C, 2002, J NEUROPHYSIOL, V87, P2209, DOI 10.1152/jn.2002.87.5.2209; SHEN H, 1995, NEUROSCI LETT, V185, P115, DOI 10.1016/0304-3940(94)11238-E; SIESJO BK, 1985, J CEREBR BLOOD F MET, V5, P253, DOI 10.1038/jcbfm.1985.32; SMITH ML, 1986, J CEREBR BLOOD F MET, V6, P574, DOI 10.1038/jcbfm.1986.104; SOCHOCKA E, 1994, BRAIN RES, V638, P21, DOI 10.1016/0006-8993(94)90628-9; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; STYS PK, 1992, J NEUROSCI, V12, P430; Swanson RA, 1997, GLIA, V21, P142, DOI 10.1002/(SICI)1098-1136(199709)21:1<142::AID-GLIA16>3.0.CO;2-S; SWANSON RA, 1995, J CEREBR BLOOD F MET, V15, P417, DOI 10.1038/jcbfm.1995.52; THOMAS RC, 1984, J PHYSIOL-LONDON, V354, pP3; TOMBAUGH GC, 1990, BRAIN RES, V506, P343, DOI 10.1016/0006-8993(90)91277-N; Trafton J, 1996, BRAIN RES, V731, P122, DOI 10.1016/0006-8993(96)00488-X; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355; Yao H, 2001, AM J PHYSIOL-CELL PH, V281, pC1205; Ying WH, 1999, J NEUROCHEM, V73, P1549, DOI 10.1046/j.1471-4159.1999.0731549.x; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1982, BRAIN RES, V253, P115, DOI 10.1016/0006-8993(82)90678-3; YU ACH, 1989, J CEREBR BLOOD F MET, V9, P20, DOI 10.1038/jcbfm.1989.3; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	99	50	52	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUN	2005	50	4			SI		398	406		10.1002/glia.20141			9	Neurosciences	Neurosciences & Neurology	922WW	WOS:000228871600011	15846798				2021-06-18	
J	Broglio, SP; Tomporowski, PD; Ferrara, MS				Broglio, SP; Tomporowski, PD; Ferrara, MS			Balance performance with a cognitive task: A dual-task testing paradigm	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						concussion; postural control; cognitive function; task-switch; neurocom	COLLEGIATE FOOTBALL PLAYERS; POSTURAL CONTROL; ATTENTIONAL DEMANDS; EXECUTIVE CONTROL; CONCUSSION; STABILITY; RECOVERY	Purpose: Athletic performance demands simultaneous use of cognitive and postural control capabilities. Decrements to both systems have been observed following concussion. This study evaluated a dual-task methodology to establish the tenability of using this testing model in concussed athletes. Methods: Nonconcussed subjects were assessed over 2 d. Subjects were introduced to the task-switching cognitive assessment test and a NeuroCom Smart Balance Master postural control assessment protocol on day 1. In the following session, subjects were evaluated on postural control and cognitive function tests independently (single task), and then concurrently (dual task). Results: Significant improvements were seen in three of the four balance conditions and in three of the four reaction times when the cognitive and balance task were performed simultaneously (P < 0.05). No significant balance by cognitive task interaction was revealed (P > 0.05): however. significant differences existed in reaction time based on stimulus position and increasing balance demands (P < 0.05). Conclusion: Combining the cognitive and balance assessments resulted in healthy subjects showing improved performance when compared with individual task performance. The dual-task methodology brought about systematic changes to reaction time in relation to increasing balance demands. The ability of this protocol to detect changes in postural control or cognitive function following concussive injury requires further study.	Univ Georgia, Dept Exercise Sci, St Marys Athlet Training Res & Educ Lab, Athens, GA 30602 USA; Univ Georgia, Dept Exercise Sci, Cognit & Skill Acquist Lab, Athens, GA 30602 USA	Broglio, SP (corresponding author), Univ Georgia, Dept Exercise Sci, St Marys Athlet Training Res & Educ Lab, 300 River Rd, Athens, GA 30602 USA.	sbroglio@coe.uga.edu					Andersson G, 2002, BRAIN RES BULL, V58, P135, DOI 10.1016/S0361-9230(02)00770-0; Arbuthnott K, 2000, CAN J EXP PSYCHOL, V54, P33, DOI 10.1037/h0087328; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Dault MC, 2001, GAIT POSTURE, V14, P248, DOI 10.1016/S0966-6362(01)00130-8; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; GUYTON A, 2000, TXB MED PHYSL, P622; Hunter MC, 2001, GAIT POSTURE, V13, P41, DOI 10.1016/S0966-6362(00)00089-8; Kramer AF, 2001, HUMAN FACTORS INTERVENTIONS FOR THE HEALTH CARE OF OLDER ADULTS, P91; LAJOIE Y, 1993, EXP BRAIN RES, V97, P139; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maki BE, 1996, J VESTIBUL RES-EQUIL, V6, P53; MARTIN JH, 1996, NEUROANATOMY TEXT AT, P328; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Melzer I, 2001, GERONTOLOGY, V47, P189, DOI 10.1159/000052797; *NEUR INT, 2001, NEUR SYST OP MAN, pPO1; PETERSON C, 2002, THESIS U GEORGIA ATH; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Riemann BL, 2000, PROPRIOCEPTION AND NEUROMUSCULAR CONTROL IN JOINT STABILITY, P37; Royall DR, 2002, J NEUROPSYCH CLIN N, V14, P377, DOI 10.1176/appi.neuropsych.14.4.377; Shumway-Cook A, 2000, J GERONTOL A-BIOL, V55, pM10; ShumwayCook A, 1997, J GERONTOL A-BIOL, V52, pM232, DOI 10.1093/gerona/52A.4.M232; Tomporowski PD, 2003, EDUC GERONTOL, V29, P447, DOI 10.1080/713844359; Vuillerme N, 2000, NEUROSCI LETT, V291, P77, DOI 10.1016/S0304-3940(00)01374-4; WOLFSON L, 1994, J GERONTOL, V49, pM160, DOI 10.1093/geronj/49.4.M160	31	50	50	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	APR	2005	37	4					689	695		10.1249/01.MSS.0000159019.14919.09			7	Sport Sciences	Sport Sciences	913QC	WOS:000228166900024	15809571				2021-06-18	
J	Shinozaki, Y; Koizumi, S; Ishida, S; Sawada, JI; Ohno, Y; Inoue, K				Shinozaki, Y; Koizumi, S; Ishida, S; Sawada, JI; Ohno, Y; Inoue, K			Cytoprotection against oxidative stress-induced damage of astrocytes by extracellular ATP via P2Y(1) receptors	GLIA			English	Article						ATP; P2Y(1) receptors; astrocytes; oxidative stress	DORSAL SPINAL-CORD; ALZHEIMERS-DISEASE; THIOREDOXIN REDUCTASE; INTRACELLULAR CALCIUM; IMMUNOHISTOCHEMICAL LOCALIZATION; CULTURED ASTROCYTES; CARBONYL REDUCTASE; ADENOSINE-TRIPHOSPHATE; SYNAPTIC-TRANSMISSION; GLUCOSE DEPRIVATION	Oxidative stress is the main cause of neuronal damage in traumatic brain injury, hypoxia/reperfusion injury, and neurodegenerative disorders. Although extracellular nucleosides, especially adenosine, are well known to protect against neuronal damage in such pathological conditions, the effects of these nucleosides or nucleotides on glial cell damage remain largely unknown. We report that ATP but not adenosine protects against the cell death of cultured astrocytes induced by hydrogen peroxide (H2O2). ATP ameliorated the H2O2-induced decrease in cell viability of astrocytes in an incubation time- and concentration-dependent fashion. Protection by ATP was inhibited by P2 receptor antagonists and was mimicked by P2Y(1) receptor agonists but not by adenosine. The expressions of P2Y(1) mRNAs and functional P2Y(1) receptors in astrocytes were confirmed. Thus, ATP, acting on P2Y(1) receptors in astrocytes, showed a protective action against H2O2. The astrocytic protection by the P2Y(1) receptor agonist 2-methylthio-ADP was inhibited by an intracellular Ca2+ chelator and a blocker of phospholipase C, indicating the involvement of intracellular signals mediated by Gq/11-coupled P2Y(1) receptors. The ATP-induced protection was inhibited by cycloheximide, a protein synthesis inhibitor, and it took more than 12 h for the onset of the protective action. In the DNA microarray analysis, ATP induced a dramatic upregulation of various oxidoreductase genes. Taken together, ATP acts on P2Y(1) receptors coupled to Gq/11, resulting in the upregulation of oxidoreductase genes, leading to the protection of astrocytes against H2O2. (C) 2004 Wiley-Liss. Inc.	Natl Inst Hlth Sci, Div Biosignaling, Setagaya Ku, Tokyo 1588501, Japan; Natl Inst Hlth Sci, Div Pharmacol, Setagaya Ku, Tokyo 1588501, Japan; Natl Inst Hlth Sci, Div Biochem & Immunochem, Setagaya Ku, Tokyo 1588501, Japan; Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol & Syst Pharmacol, Fukuoka 812, Japan	Inoue, K (corresponding author), Natl Inst Hlth Sci, Div Biosignaling, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.	inoue@nihs.go.jp	Koizumi, Schuichi/E-8568-2010; Shinozaki, Youichi/AAC-9431-2019; Shinozaki, Youichi/E-8594-2010	Koizumi, Schuichi/0000-0001-6184-3106; Shinozaki, Youichi/0000-0002-6448-1304; Shinozaki, Youichi/0000-0002-6448-1304	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15500274, 17023057] Funding Source: KAKEN		ABBRACCHIO MP, 1995, BIOCHEM BIOPH RES CO, V213, P908, DOI 10.1006/bbrc.1995.2215; ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; AGARDH CD, 1991, INT J DEV NEUROSCI, V9, P127, DOI 10.1016/0736-5748(91)90003-5; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Aihara H, 2002, BRAIN RES, V952, P31, DOI 10.1016/S0006-8993(02)03185-2; Akbar GKM, 1996, J BIOL CHEM, V271, P18363, DOI 10.1074/jbc.271.31.18363; ALTMAN FP, 1976, HISTOCHEM J, V8, P471, DOI 10.1007/BF01003837; Appel E, 2001, J MOL NEUROSCI, V17, P285, DOI 10.1385/JMN:17:3:285; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Araque A, 2001, ANNU REV PHYSIOL, V63, P795, DOI 10.1146/annurev.physiol.63.1.795; Araque A, 1999, CAN J PHYSIOL PHARM, V77, P699, DOI 10.1139/cjpp-77-9-699; Ayyanathan K, 1996, BIOCHEM BIOPH RES CO, V218, P783, DOI 10.1006/bbrc.1996.0139; Balcz B, 2001, J NEURAL TRANSM-SUPP, P193; Behan WMH, 2002, BRIT J PHARMACOL, V135, P1435, DOI 10.1038/sj.bjp.0704613; Brambilla R, 1999, BRIT J PHARMACOL, V126, P563, DOI 10.1038/sj.bjp.0702333; Braun N, 1998, J NEUROSCI, V18, P4891; Braun N, 1997, BRAIN RES, V766, P213, DOI 10.1016/S0006-8993(97)00559-3; Butterfield DA, 2003, J NEUROCHEM, V86, P1313, DOI 10.1046/j.1471-4159.2003.01948.x; Ceruti S, 2000, J NEUROSCI RES, V60, P388, DOI 10.1002/(SICI)1097-4547(20000501)60:3<388::AID-JNR14>3.0.CO;2-V; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; Chen JG, 1997, J NEUROSCI, V17, P7278; Ciccarelli R, 2001, INT J DEV NEUROSCI, V19, P395, DOI 10.1016/S0736-5748(00)00084-8; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; Desagher S, 1996, J NEUROSCI, V16, P2553; Di Iorio P, 2002, GLIA, V38, P179, DOI 10.1002/glia.10055; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577; Eftekharpour E, 2000, GLIA, V31, P241, DOI 10.1002/1098-1136(200009)31:3<241::AID-GLIA50>3.0.CO;2-9; Fam SR, 2000, J NEUROSCI, V20, P2800; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; Forrest GL, 2000, CHEM-BIOL INTERACT, V129, P21, DOI 10.1016/S0009-2797(00)00196-4; Franke H, 2001, NEUROSCIENCE, V108, P421, DOI 10.1016/S0306-4522(01)00416-X; Franke H, 2001, BRIT J PHARMACOL, V134, P1180, DOI 10.1038/sj.bjp.0704353; FREDHOLM BB, 1988, TRENDS PHARMACOL SCI, V9, P130, DOI 10.1016/0165-6147(88)90194-0; Fumagalli M, 2003, GLIA, V43, P218, DOI 10.1002/glia.10248; FURUTA A, 1995, AM J PATHOL, V146, P357; Gallagher CJ, 2003, J NEUROSCI, V23, P6728; GLAUM SR, 1990, P NATL ACAD SCI USA, V87, P3454, DOI 10.1073/pnas.87.9.3454; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; HANSSON HA, 1989, EXP EYE RES, V48, P411, DOI 10.1016/S0014-4835(89)80009-0; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Hentschel S, 2003, RESTOR NEUROL NEUROS, V21, P55; HO C, 1995, BRIT J PHARMACOL, V116, P2909, DOI 10.1111/j.1476-5381.1995.tb15944.x; Huang XD, 2000, J NUTR, V130, p1488S, DOI 10.1093/jn/130.5.1488S; Idestrup CP, 1998, NEUROSCIENCE, V86, P913, DOI 10.1016/S0306-4522(98)00128-6; INAZU N, 1992, BIOCHIM BIOPHYS ACTA, V1116, P50, DOI 10.1016/0304-4165(92)90127-G; Innocenti B, 2000, J NEUROSCI, V20, P1800; INOUE K, 1995, NEUROREPORT, V6, P437; James G, 2002, EUR J PHARMACOL, V447, P247, DOI 10.1016/S0014-2999(02)01756-9; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Jurkowitz MS, 1998, J NEUROCHEM, V71, P535; Kim HS, 2003, DNA REPAIR, V2, P1321, DOI 10.1016/j.dnarep.2003.07.004; Kim SG, 2003, BIOCHEM PHARMACOL, V65, P923, DOI 10.1016/S0006-2952(02)01614-3; Kim SH, 2001, LIFE SCI, V68, P2741, DOI 10.1016/S0024-3205(01)01074-8; Koizumi S, 1997, BRIT J PHARMACOL, V122, P51, DOI 10.1038/sj.bjp.0701344; Koizumi S, 2002, LIFE SCI, V72, P431, DOI 10.1016/S0024-3205(02)02273-7; Koizumi S, 2003, P NATL ACAD SCI USA, V100, P11023, DOI 10.1073/pnas.1834448100; Lei BP, 1997, NEUROSCI LETT, V222, P91, DOI 10.1016/S0304-3940(97)13349-3; Lenz G, 2000, BRIT J PHARMACOL, V129, P927, DOI 10.1038/sj.bjp.0703138; Lovell MA, 2000, FREE RADICAL BIO MED, V28, P418, DOI 10.1016/S0891-5849(99)00258-0; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Lutz PL, 1997, BRAIN RES, V769, P281, DOI 10.1016/S0006-8993(97)00719-1; Moore D, 2000, NEUROREPORT, V11, P3799, DOI 10.1097/00001756-200011270-00041; Neary JT, 1999, J NEUROSCI, V19, P4211, DOI 10.1523/jneurosci.19-11-04211.1999; Newman EA, 2003, J NEUROSCI, V23, P1659, DOI 10.1523/jneurosci.23-05-01659.2003; Panenka W, 2001, J NEUROSCI, V21, P7135, DOI 10.1523/JNEUROSCI.21-18-07135.2001; Parkinson FE, 2002, NEUROPHARMACOLOGY, V43, P836, DOI 10.1016/S0028-3908(02)00083-7; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pasti L, 1997, J NEUROSCI, V17, P7817; PEAKMAN MC, 1994, BRIT J PHARMACOL, V111, P191, DOI 10.1111/j.1476-5381.1994.tb14043.x; PORTER JT, 1995, J NEUROCHEM, V65, P1515, DOI 10.1046/j.1471-4159.1995.65041515.x; Porter JT, 1996, J NEUROSCI, V16, P5073; Queiroz G, 1999, NEUROSCIENCE, V91, P1171, DOI 10.1016/S0306-4522(98)00644-7; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; Schipke CG, 2001, FASEB J, V15, P255, DOI 10.1096/fj.01-0514fje; Schubert P, 1997, ANN NY ACAD SCI, V825, P1, DOI 10.1111/j.1749-6632.1997.tb48409.x; SCHWARZCHILD MA, 2003, NEUROLOGY S, V61, pS56; Servitja JM, 2000, J NEUROCHEM, V75, P788, DOI 10.1046/j.1471-4159.2000.0750788.x; Shahidullah M, 1997, CURR EYE RES, V16, P1006, DOI 10.1076/ceyr.16.10.1006.9018; Shin CY, 2002, GLIA, V37, P268, DOI 10.1002/glia.10032; Tabner Brian J., 2001, Current Topics in Medicinal Chemistry, V1, P507, DOI 10.2174/1568026013394822; Tamagno E, 2003, EXP NEUROL, V180, P144, DOI 10.1016/S0014-4886(02)00059-6; TOKUYAMA Y, 1995, BIOCHEM BIOPH RES CO, V211, P211, DOI 10.1006/bbrc.1995.1798; TWENTYMAN PR, 1987, BRIT J CANCER, V56, P279, DOI 10.1038/bjc.1987.190; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; Viana F, 1998, CELL CALCIUM, V24, P117, DOI 10.1016/S0143-4160(98)90079-3; Webb TE, 1998, NEUROSCIENCE, V84, P825, DOI 10.1016/S0306-4522(97)00478-8; WIERASZKO A, 1989, BRAIN RES, V485, P244, DOI 10.1016/0006-8993(89)90567-2; WIRTH H, 1992, J HISTOCHEM CYTOCHEM, V40, P1857, DOI 10.1177/40.12.1453004; Yamakuni H, 2002, J NEUROIMMUNOL, V129, P43, DOI 10.1016/S0165-5728(02)00179-0; Zhang JM, 2003, NEURON, V40, P971, DOI 10.1016/S0896-6273(03)00717-7; Zhang M, 2000, J PHYSIOL-LONDON, V525, P143, DOI 10.1111/j.1469-7793.2000.t01-1-00143.x; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	93	50	54	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JAN 15	2005	49	2					288	300		10.1002/glia.20118			13	Neurosciences	Neurosciences & Neurology	885RN	WOS:000226174700011	15494980				2021-06-18	
J	Khateb, A; Ammann, J; Annoni, JM; Diserens, K				Khateb, A; Ammann, J; Annoni, JM; Diserens, K			Cognition-enhancing effects of donepezil in traumatic brain injury	EUROPEAN NEUROLOGY			English	Article						brain injury; cognition; donepezil; attention; neuropsychology	ALZHEIMERS-DISEASE; NEUROBEHAVIORAL DEFICITS; ATTENTION; MEMORY; DEPRESSION; CHOLINESTERASE; REHABILITATION; PERFORMANCE; IMPAIRMENT; INHIBITORS	The purpose of this study was to investigate the effects of donepezil, a cholinergic agent, on chronic cognitive impairment due to traumatic brain injury (TBI). Chronic patients underwent two standardized neuropsychological evaluations - one before and the other 3 months following treatment with donepezil. Together with global inventories that appraised behaviour, fatigue, anxiety and depression, these evaluations also assessed executive functioning, memory and attention. Of the 10 patients who followed the therapy, 8 reported subjective improvement in at least one cognitive domain following therapy and most of them reported better functioning in everyday activities. This effect was supported by a slight global improvement when considering the global score of the different affectivo-behavioural scales. At the neuropsychological level, although we could observe a slight improvement in the majority of the considered tests, significant positive changes were mainly found in tests assessing speed of processing, learning and divided attention. These findings suggest that donepezil may lead to better general functioning and improve attentional skills in patients with chronic TBI. Copyright (C) 2005 S. Karger AG, Basel.	Univ Hosp Geneva, Dept Neurol, Lab Expt Neuropsychol, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Dept Neurol, Neuropsychol Unit, CH-1211 Geneva, Switzerland; Univ Lausanne Hosp, Dept Neurol, Lausanne, Switzerland	Khateb, A (corresponding author), Univ Hosp Geneva, Dept Neurol, Lab Expt Neuropsychol, 24 Rue Micheli Crest, CH-1211 Geneva, Switzerland.	Asaid.Khateb@hcuge.ch	Khateb, Asaid/AAF-1609-2020	Khateb, Asaid/0000-0003-4639-1564			Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Beglinger LJ, 2004, J PSYCHOPHARMACOL, V18, P102, DOI 10.1177/0269881104040248; Bourgeois JA, 2002, J NEUROPSYCH CLIN N, V14, P463, DOI 10.1176/appi.neuropsych.14.4.463; CARDEBAT D, 1990, ACTA NEUROL BELG, V90, P207; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; Cummings JL, 2000, AM J PSYCHIAT, V157, P4, DOI 10.1176/ajp.157.1.4; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Giacobini E, 2002, J NEURAL TRANSM, V109, P1053, DOI 10.1007/s007020200089; Griffin SL, 2003, J NEUROPSYCH CLIN N, V15, P17, DOI 10.1176/appi.neuropsych.15.1.17; Jackson G, 2004, INT J CLIN PRACT, V58, P1, DOI 10.1111/j.1368-5031.2004.0101.x; Lawrence AD, 1998, NEUROCHEM RES, V23, P787, DOI 10.1023/A:1022419712453; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; LEZAK MD, 1989, FRONT CLIN NEUROSCI, V7, P1; Lopez-Pousa S, 2001, NEUROLOGIA, V16, P342; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; Muir JL, 1996, COGNITIVE BRAIN RES, V3, P215, DOI 10.1016/0926-6410(96)00008-0; Olazaran-Rodriguez J, 2004, REV NEUROLOGIA, V38, P938, DOI 10.33588/rn.3810.2003573; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Pepeu G, 2004, LEARN MEMORY, V11, P21, DOI 10.1101/lm.68104; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; SCHWARTZ JE, 1993, J PSYCHOSOM RES, V37, P753, DOI 10.1016/0022-3999(93)90104-N; Spreen O., 1998, COMPENDIUM NEUROPSYC; Staub F, 2001, CEREBROVASC DIS, V12, P75, DOI 10.1159/000047685; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Taverni JP, 1998, BRAIN INJURY, V12, P77; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; Whitlock JA, 1999, J HEAD TRAUMA REHAB, V14, P424, DOI 10.1097/00001199-199908000-00010; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZIMMERMANN P, 1994, TEST ATTENTIONAL PER	36	50	51	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0014-3022	1421-9913		EUR NEUROL	Eur. Neurol.		2005	54	1					39	45		10.1159/000087718			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	963RV	WOS:000231824500007	16118495				2021-06-18	
J	Van Geel, WJA; Rosengren, LE; Verbeek, MM				Van Geel, WJA; Rosengren, LE; Verbeek, MM			An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid	JOURNAL OF IMMUNOLOGICAL METHODS			English	Article						cerebrospinal fluid; neurofilament light chain; immunoassay; brain damage	PROTEIN	Neurofilament light chain is a component of the axonal cytoskeleton. The concentration of the neurofilament light chain in cerebrospinal fluid may reflect axonal damage or the extent of white matter damage. In this study we describe a sensitive immunoassay for the detection of neurofilament light chain in cerebrospinal fluid using commercially available materials. The detection limit of the assay was 5 ng/l and the assay was linear up to 390 ng/l. Mean recovery was 91.5% and inter-assay and intra-assay coefficients of variation were below 18%. Strongly increased levels of neurofilament light chain were observed in patients with cerebrovascular accidents, subarachnoid hemorrhage and severe traumatic brain injury, suggesting the occurrence of axonal damage in these conditions. (C) 2004 Elsevier B.V. All rights reserved.	Univ Nijmegen, Med Ctr, Dept Neurol, Lab Pediat & Neurol, NL-6500 HB Nijmegen, Netherlands; Univ Gothenburg, Sahlgrens Univ Hosp, Inst Clin Neurosci, S-41345 Gothenburg, Sweden; Univ Nijmegen, Med Ctr, Dept Neurol, Nijmegen, Netherlands	Verbeek, MM (corresponding author), Univ Nijmegen, Med Ctr, Dept Neurol, Lab Pediat & Neurol, 319 LKN,POB 9101, NL-6500 HB Nijmegen, Netherlands.	m.verbeek@cukz.umcn.nl	Verbeek, Marcel M/D-1971-2010	Verbeek, Marcel M/0000-0003-4635-7876; Rosengren, Lars/0000-0003-0505-8896			Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Carpenter DA, 1996, J CELL SCI, V109, P2493; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; HOLMBERG B, 1998, MOL DISORD, V13, P170; Kay A, 2003, STROKE, V34, pE240, DOI 10.1161/01.STR.0000100157.88508.2F; LAMERS KJB, 1995, ACTA NEUROL SCAND, V92, P247; Lycke JN, 1998, J NEUROL NEUROSUR PS, V64, P402, DOI 10.1136/jnnp.64.3.402; Norgren N, 2003, BRAIN RES, V987, P25, DOI 10.1016/S0006-8993(03)03219-0; Nylen K, 2002, J NEUROSCI RES, V67, P844, DOI 10.1002/jnr.10180; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Rosengren LE, 1996, J NEUROCHEM, V67, P2013, DOI 10.1046/j.1471-4159.1996.67052013.x; Sjogren M, 2000, NEUROLOGY, V54, P1960, DOI 10.1212/WNL.54.10.1960; Sjogren M, 2001, J NEUROSCI RES, V66, P510, DOI 10.1002/jnr.1242; Sjogren M, 2001, CLIN CHEM, V47, P1776; Tullberg M, 1998, NEUROLOGY, V50, P1122, DOI 10.1212/WNL.50.4.1122; Tullberg M, 2002, ACTA NEUROL SCAND, V105, P417, DOI 10.1034/j.1600-0404.2002.01189.x; VANENGELEN BGM, 1992, CLIN CHEM, V38, P813; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC	19	50	50	1	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-1759	1872-7905		J IMMUNOL METHODS	J. Immunol. Methods	JAN	2005	296	1-2					179	185		10.1016/j.jim.2004.11.015			7	Biochemical Research Methods; Immunology	Biochemistry & Molecular Biology; Immunology	898ZW	WOS:000227115700018	15680162				2021-06-18	
J	Gall, B; Parkhouse, WS; Goodman, D				Gall, B; Parkhouse, WS; Goodman, D			Exercise following a sport induced concussion	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SYMPTOMS	Objective: To determine if an athlete's capacity to perform exercise is impaired following concussion and whether this would be reflected by an altered heart rate response. Methods: Of the 14 concussed athletes, nine missed playing time as a direct result of their concussion and five did not. The concussed athletes performed an exercise protocol on a cycle ergometer within 72 hours of being asymptomatic at rest and a second test at 5 days following the previous assessment. Matched controls (n = 14) were tested using the same time line. The exercise protocol consisted of a 2 minute warm up, 10 minute, low-moderate intensity, steady state exercise session, and a high intensity interval protocol. The interval protocol consisted of a 40 second high intensity bout, followed by a 40 second rest period. This protocol continued until the participant had reached volitional fatigue. Results: The number of exercise bouts completed was not significantly different from their matched controls. However, concussed athletes who missed playing time had a significantly higher heart rate during the steady state exercise session. During this same period, they also exhibited a greater rise in heart rate over time. Conclusion: These findings indicate that exercise capacity is unaffected in concussed athletes who are asymptomatic at rest. However, their heart rate response to submaximal exercise is increased.	Simon Fraser Univ, Sch Kinesiol, Burnaby, BC V5A 1S6, Canada	Parkhouse, WS (corresponding author), Simon Fraser Univ, Sch Kinesiol, 8888 Univ Blvd, Burnaby, BC V5A 1S6, Canada.	parkhouse@sfu.ca					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Baker Robert J., 2000, Indian Journal of Pediatrics, V67, P317, DOI 10.1007/BF02820676; *CAN HOCK ASS, 1999, GAT CAN HOCK SAF PRO; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FARDY PS, 1969, RES QUART, V40, P502, DOI 10.1080/10671188.1969.10614869; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; GRONWALL D, 1975, LANCET, V2, P995; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrory PR, 2002, PHYSICIAN SPORTSMED, V30, P43, DOI 10.3810/psm.2002.08.403; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Mujika I, 2001, MED SCI SPORT EXER, V33, P413, DOI 10.1097/00005768-200103000-00013; Penny G D, 1975, J Sports Med Phys Fitness, V15, P223; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011	22	50	50	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC 1	2004	38	6					773	777		10.1136/bjsm.2003.009530			5	Sport Sciences	Sport Sciences	873SH	WOS:000225300700022	15562179	Green Published, Bronze			2021-06-18	
J	Ahn, MJ; Sherwood, ER; Prough, DS; Lin, CY; DeWitt, DS				Ahn, MJ; Sherwood, ER; Prough, DS; Lin, CY; DeWitt, DS			The effects of traumatic brain injury on cerebral blood flow and brain tissue nitric oxide levels and cytokine expression	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; cytokine; nitric oxide; rats; traumatic brain injury	TUMOR-NECROSIS-FACTOR; CORTICAL IMPACT INJURY; FLUID-PERCUSSION INJURY; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; L-ARGININE; RAT-BRAIN; SYNTHASE EXPRESSION; FACTOR-ALPHA; TNF-ALPHA	Adult, finale, Sprague-Dawley rats were anesthetized, intubated, and mechanically ventilated with 1.5-2.0% isoflurane in oxygen (30%) and air. Rats were prepared for fluid percussion traumatic brain injury (TBI), laser Doppler flowmetry, and measurement of brain tissue nitric oxide (NO) levels using an ISO-NO electrode system. After preparation, isoflurane was reduced to 1.5%, and the rats were randomly assigned to receive sham (n = 6), moderate (1.9 atm, n = 6), or severe (2.8 atm, n = 6) parasagittal fluid percussion TBI. CBF and brain tissue NO levels were measured for 4 h, and then isoflurane levels were increased to 4.0% and the rats were decapitated and the brains were removed. Total RNA was isolated from rat brains and cytokine expression was determined. Laser Doppler flow velocity remained constant in the sham-injured rats but decreased significantly in rats subjected to moderate (p < 0.05) or severe (p < 0.05) TBI. Brain tissue NO levels remained constant in the sham-injured rats but decreased significantly (p < 0.01) after moderate TBI. Severe TBI produced slight, insignificant reductions in NO levels. Cytokine expression was very low in the sham-injured rats. TBI-induced expression of mRNAs for interleukin-1 alpha (IL-1alpha), IL-1beta, IL-6, and tumor necrosis factor-alpha (TNFalpha). IL-lalpha and 1L-1beta mRNA expression increased significantly (p < 0.05 vs. sham-injury) after severe TBI and IL-6 and TNFa mRNA expression increased significant (p < 0.05 vs. sham-injury) after both moderate and severe TBI. Other cytokine mRNA expression was unchanged after TBI.	Univ Texas, Med Branch, Dept Anesthesiol, Charles R Allen Res Labs, Galveston, TX 77555 USA	DeWitt, DS (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, Charles R Allen Res Labs, 301 Univ Blvd, Galveston, TX 77555 USA.	ddewitt@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019355] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19355] Funding Source: Medline		Al-Turki A, 1998, CRIT CARE MED, V26, P917, DOI 10.1097/00003246-199805000-00029; Alagarsamy S, 1998, J NEUROTRAUM, V15, P627, DOI 10.1089/neu.1998.15.627; Armstead WM, 2000, AM J PHYSIOL-HEART C, V279, pH2188; Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; Armstead WM, 1998, J NEUROTRAUM, V15, P721, DOI 10.1089/neu.1998.15.721; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BONVENTO G, 1994, J CEREBR BLOOD F MET, V14, P699, DOI 10.1038/jcbfm.1994.90; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brian JE, 1996, CLIN EXP PHARMACOL P, V23, P449, DOI 10.1111/j.1440-1681.1996.tb02760.x; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; DeWitt D. S., 2000, Journal of Neurotrauma, V17, P993; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DING AH, 1988, J IMMUNOL, V141, P2407; FABIAN RH, 1995, J CEREBR BLOOD F MET, V15, P242, DOI 10.1038/jcbfm.1995.30; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Faraci FM, 1998, J CEREBR BLOOD F MET, V18, P1047, DOI 10.1097/00004647-199810000-00001; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Golding EM, 2002, STROKE, V33, P661; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gulbenkian S, 2001, PEPTIDES, V22, P995, DOI 10.1016/S0196-9781(01)00408-9; HABERL RL, 1989, AM J PHYSIOL, V256, pH1247; Hlatky R, 2003, J CEREBR BLOOD F MET, V23, P582, DOI 10.1097/01.WCB.0000059586.71206.F3; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; LEON A, 1990, STROKE, V21, P95; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Monroy M, 2001, AM J PHYSIOL-HEART C, V280, pH1448; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MORIKAWA E, 1992, BRIT J PHARMACOL, V107, P905, DOI 10.1111/j.1476-5381.1992.tb13382.x; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; PELLIGRINO DA, 1993, J CEREBR BLOOD F MET, V13, P80, DOI 10.1038/jcbfm.1993.10; Prat R, 1997, NEUROL RES, V19, P393, DOI 10.1080/01616412.1997.11740832; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Sherwood ER, 2001, CLIN SCI, V101, P541, DOI 10.1042/CS20010074; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; STERN MD, 1977, AM J PHYSIOL, V232, pH441; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Varma TK, 2002, CLIN DIAGN LAB IMMUN, V9, P530, DOI 10.1128/CDLI.9.3.530-543.2002; Varma TK, 2001, INFECT IMMUN, V69, P5249, DOI 10.1128/IAI.69.9.5249-5263.2001; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WANG Q, 1992, J CEREBR BLOOD F MET, V12, P947, DOI 10.1038/jcbfm.1992.131; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; WHITE PF, 1974, ANESTHESIOLOGY, V40, P52, DOI 10.1097/00000542-197401000-00012; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	82	50	59	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2004	21	10					1431	1442		10.1089/neu.2004.21.1431			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	867BT	WOS:000224817800007	15672633				2021-06-18	
J	Bauer, R; Fritz, H				Bauer, R; Fritz, H			Pathophysiology of traumatic injury in the developing brain: an introduction and short update	EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	4th International Congress of Pathophysiology	JUN 29-JUL 05, 2002	BUDAPEST, HUNGARY			pediatric TBI; pathogenetic models; review	PEDIATRIC HEAD-INJURY; DEFICIT HYPERACTIVITY DISORDER; CONTROLLED CORTICAL IMPACT; AQUAPORIN-4 WATER CHANNEL; CEREBRAL-BLOOD-FLOW; COMA DATA-BANK; RAT-BRAIN; DOPAMINE TRANSPORTER; HYDROGEN-PEROXIDE; STRIATAL DOPAMINE	Current understanding about the main peculiarities in pathophysiology of immature brain traumatic injury involves marked developmental discrepancy of biomechanical properties, aspects of altered features in water and electrolyte homeostasis as well as maturation dependent differences in structural and functional responses of major transmitter systems. Based on the fact that traumatic brain injury (TBI) is one of the major causes of morbidity and mortality in infants and children, the currently available epidemiological data are reviewed in order to. gain insights about scope and dimension of health care engagement and derive the requirements for reinforced pathogenetic research. To this end, the main aspects of peculiarities in primary and secondary TBI mechanisms in the immature/developing brain are discussed, including structural and functional conditions resulting in a markedly diminished shear resistance of the immature brain tissue. As such, the immature brain tissue appears to be more susceptible to mechanical alterations, because similar mechanical load induces a more intense brain tissue displacement. Furthermore, available indications for increased incidence of brain swelling in the immature brain after TBI are reviewed, focusing on the inter relationship between the age-dependent differences in extracellular space and aquaporin-4 expression during brain maturation. The developmental differences of TBI induced cerebrovascular response as well as some relevant aspects of altered neurotransmission following TBI of the immature brain in regard to the glutamatergic and dopaminergic transmitter system are assessed. Thus, this mini-review highlights some progress but also an increased necessity for expanded pathogenetic research on a clinical scale in order to develop a solid foundation for adequate therapeutic strategies for the different life-threatening consequences of TBI in infancy and childhood, which mainly have failed up to now. (C) 2004 Elsevier GmbH. All rights reserved.	Univ Jena, Univ Klinikum Jena, Inst Pathophysiol & Pathobiochem, D-07740 Jena, Germany; Univ Jena, Univ Klinikum Jena, Dept Anesthesiol & Intens Care Med, D-07740 Jena, Germany	Bauer, R (corresponding author), Univ Jena, Univ Klinikum Jena, Inst Pathophysiol & Pathobiochem, D-07740 Jena, Germany.	Reinhard.Bauer@mti.uni-jena.de					Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Adelson PD, 2002, CRIT CARE MED, V30, pS383, DOI 10.1097/00003246-200211001-00001; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1999, AM J PHYSIOL-HEART C, V277, pH1884; Armstead WM, 2000, MICROCIRCULATION, V7, P225, DOI 10.1038/sj.mn.7300110; Bauer R, 1999, DEV BRAIN RES, V112, P89, DOI 10.1016/S0165-3806(98)00167-9; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BEHRING EA, 1952, J NEUROSURG, V9, P275; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; BUTT AM, 1990, J PHYSIOL-LONDON, V429, P47, DOI 10.1113/jphysiol.1990.sp018243; Dobbing J, 1981, SCI F PAEDIATRICS, P744; DODSON RF, 1977, J NEUROL SCI, V33, P161, DOI 10.1016/0022-510X(77)90190-3; Dougherty DD, 1999, LANCET, V354, P2132, DOI 10.1016/S0140-6736(99)04030-1; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Dziegielewska KM, 2000, CELL MOL NEUROBIOL, V20, P41, DOI 10.1023/A:1006943926765; EICHELBERGER MR, 1988, J TRAUMA, V28, P430, DOI 10.1097/00005373-198804000-00002; Emanuelson I, 1997, ACTA PAEDIATR, V86, P730, DOI 10.1111/j.1651-2227.1997.tb08576.x; Ernst M, 1999, AM J PSYCHIAT, V156, P1209; Feher G, 1996, DEV BRAIN RES, V91, P209, DOI 10.1016/0165-3806(95)00178-6; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Ferriero DM, 2001, DEV NEUROSCI-BASEL, V23, P198, DOI 10.1159/000046143; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Fullerton HJ, 1998, ANN NEUROL, V44, P357, DOI 10.1002/ana.410440311; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; Graham DI, 2001, BRAIN, V124, P1261, DOI 10.1093/brain/124.7.1261; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HALLER JA, 1983, JAMA-J AM MED ASSOC, V249, P47, DOI 10.1001/jama.249.1.47; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Jackson PS, 1997, PEDIATR NEUROSURG, V27, P286, DOI 10.1159/000121272; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P114; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Knott GW, 1997, J PHYSIOL-LONDON, V499, P179, DOI 10.1113/jphysiol.1997.sp021919; Kochanek PM, 2001, PEDIATR CLIN N AM, V48, P661, DOI 10.1016/S0031-3955(05)70333-3; Konrad KN, 2000, BRAIN INJURY, V14, P859; KRAUS JF, 1987, PEDIATRICS, V79, P501; Krause KH, 2000, NEUROSCI LETT, V285, P107, DOI 10.1016/S0304-3940(00)01040-5; LEHMENKUHLER A, 1993, NEUROSCIENCE, V55, P339, DOI 10.1016/0306-4522(93)90503-8; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MAKER HS, 1981, J NEUROCHEM, V36, P589, DOI 10.1111/j.1471-4159.1981.tb01631.x; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Nico B, 2001, J CELL SCI, V114, P1297; Nielsen S, 1997, J NEUROSCI, V17, P171; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; Saunders NR, 2000, CELL MOL NEUROBIOL, V20, P29, DOI 10.1023/A:1006991809927; SCHULZE C, 1992, DEV BRAIN RES, V69, P85, DOI 10.1016/0165-3806(92)90125-G; SLIVKA A, 1985, J BIOL CHEM, V260, P5466; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Tang YP, 1997, EUR J NEUROSCI, V9, P1720, DOI 10.1111/j.1460-9568.1997.tb01529.x; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vles JSH, 2003, NEUROPEDIATRICS, V34, P77; Walter B., 2001, Pfluegers Archiv European Journal of Physiology, V441, pR111; Walter B, 2004, J NEUROTRAUM, V21, P1076, DOI 10.1089/0897715041651024; WARD JD, 1994, PEDIATR NEUROSURG, V20, P183, DOI 10.1159/000120784; Ward JD, 1996, NEUROTRAUMA, P859; WEGMAN ME, 1982, PEDIATRICS, V70, P835; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003	86	50	53	0	5	URBAN & FISCHER VERLAG	JENA	BRANCH OFFICE JENA, P O BOX 100537, D-07705 JENA, GERMANY	0940-2993			EXP TOXICOL PATHOL	Exp. Toxicol. Pathol.	OCT	2004	56	1-2					65	73		10.1016/j.etp.2004.04.002			9	Pathology; Toxicology	Pathology; Toxicology	872QF	WOS:000225221900009	15581277				2021-06-18	
J	Fromm, L; Heath, DL; Vink, R; Nimmo, AJ				Fromm, L; Heath, DL; Vink, R; Nimmo, AJ			Magnesium attenuates post-traumatic depression/anxiety following diffuse traumatic brain injury in rats	JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION			English	Article						depression; brain magnesium; neurotrauma; antidepressants; post-traumatic stress	SYMPTOMS; SEQUELAE; ANXIETY	Objective: Magnesium (Mg) declines after traumatic brain injury (TBI), a decline believed associated with ensuing neuronal cell death and subsequent functional impairment. While Mg's effects on motor and cognitive deficits following TBI have been well studied, few studies have addressed post-traumatic depression as an outcome parameter, despite its being a major clinical problem with an incidence of between 6 and 77%. We investigated the incidence of post-traumatic depression/anxiety in an animal model of diffuse TBI, and explored the use of magnesium sulfate (MgSO4) as an interventional treatment. Methods: Diffuse TBI was induced in 32 anesthetized, adult, male Sprague-Dawley rats, using the 2 in impact-acceleration model of injury. At 30 min after injury, half of the rats received 250 mumol/kg i.v.. MgSO4; the other half served as non-treated controls. Before and for 6 weeks after injury, the open-field, spontaneous activity test was used to determine post-traumatic depression/anxiety relative to pre-injury. In this test, animals are placed in a I-meter square box with 100 squares marked on the base. The number of squares entered in a 5-min period is recorded. Incidence of post-traumatic depression/anxiety was defined as the number of animals demonstrating a reduction in spontaneous activity to less than 100 squares in 5 min. Prior to injury, rats typically entered a mean of 201 +/- 12 (SEM) squares over a 5 min observation period. Results: At I week after injury, non-treated animals had a mean core of 62 +/- 13. The incidence of post-traumatic depression/anxiety in these animals was 61%, which is similar to that observed clinically. In contrast, animals treated with MgSO4 had a mean activity score of 144 +/- 23 at I week after TBI and an incidence of depression/anxiety of less than 30%. The significant difference between groups persisted for the entire 6-week observation period. Conclusions: The improvement in post-traumatic depression/anxiety conferred by Mg adds further weight to available evidence of Mg's benefit as a neuroprotective agent after TBI.	Univ Adelaide, Dept Pathol, Adelaide, SA, Australia; James Cook Univ N Queensland, Sch Pharm & Mol Sci, Townsville, Qld 4811, Australia	Vink, R (corresponding author), Univ Adelaide, Dept Pathol, GPO Box 498, Adelaide, SA, Australia.	robert.vink@adelaide.edu.au	Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667; Nimmo, Alan/0000-0002-0718-7934			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X; BACHMAN DL, 1992, J HEAD TRAUMA REHAB, V7, P50; Ducrocq F, 2001, ENCEPHALE, V27, P159; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Izumi J, 1997, PHARMACOL BIOCHEM BE, V57, P883, DOI 10.1016/S0091-3057(96)00455-8; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JOSEPH AB, 1995, J HEAD TRAUMA REHAB, V10, P90, DOI 10.1097/00001199-199504000-00010; Kontinen VK, 1999, PAIN, V80, P341, DOI 10.1016/S0304-3959(98)00230-9; Kulkarni S, 1977, INDIAN J PHARM, V9, P241; Levine J, 2000, BIOL PSYCHIAT, V47, P586, DOI 10.1016/S0006-3223(99)00284-X; Mar A, 2002, PHARMACOL BIOCHEM BE, V73, P703, DOI 10.1016/S0091-3057(02)00881-X; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SCHWARTZ RD, 1994, J NEUROCHEM, V62, P916; Suarez M, 2002, LIFE SCI, V71, P1125, DOI 10.1016/S0024-3205(02)01830-1; Szewczyk B, 2001, POL J PHARMACOL, V53, P641; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Von Horsten S, 1998, PHARMACOL BIOCHEM BE, V60, P71, DOI 10.1016/S0091-3057(97)00467-X; WIDMER J, 1995, J AFFECT DISORDERS, V34, P201, DOI 10.1016/0165-0327(95)00018-I; BRAIN INJ, V15, P563	27	50	51	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0731-5724	1541-1087		J AM COLL NUTR	J. Am. Coll. Nutr.	OCT	2004	23	5					529S	533S		10.1080/07315724.2004.10719396			5	Nutrition & Dietetics	Nutrition & Dietetics	863AF	WOS:000224531900017	15466958				2021-06-18	
J	Li, HH; Lee, SM; Cai, Y; Sutton, RL; Hovda, DA				Li, HH; Lee, SM; Cai, Y; Sutton, RL; Hovda, DA			Differential gene expression in hippocampus following experimental brain trauma reveals distinct features of moderate and severe injuries	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; gene expression; hippocampus; lateral fluid percussion injury; microarray; real-time RT-PCR	CORTICAL IMPACT INJURY; MESSENGER-RNA EXPRESSION; NITRIC-OXIDE SYNTHASE; RAT-BRAIN; CEREBRAL-CORTEX; HEAD-INJURY; SIGNAL-TRANSDUCTION; CYTOKINE EXPRESSION; GROWTH-FACTOR; IN-VITRO	Microarray technology was employed to determine the differential pattern of gene expression within the hippocampus as a result of traumatic brain injury (TBI). The validity of the microarray data was confirmed using real-time RT-PCR. Following either moderate or severe lateral fluid percussion injury, rats were studied 0.5, 4, and 24 h after injury. In general, animals exhibited mRNA up or down regulation of approximately 10% of the genes studied. However, it was clear that the pattern of gene expression was influenced by both the severity of injury and the time after injury at which animals were studied. For example, genes encoding molecules for cellular signaling, synaptic plasticity, metabolism, ion channels and transporters were up regulated following severe injury, but down regulated following moderate injury. Furthermore, moderate injury was associated with an increasing number of responsive genes as a function of time post-injury. However, animals sustaining a severe level of injury exhibited decreasing number of responsive genes during the same post-injury period. The different patterns of gene expression between injury severity and across time after the insult suggests that the pathophysiological cascade induced by TBI is accompanied by a molecular response which, like the other aspects of the cellular response for survival, may indicate a "molecular window" that may offer an opportunity for therapeutic interventions involving gene therapy. Our results also suggest that fundamentally different pathophysiological processes or cascades may be induced by different severities of injury.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA	Hovda, DA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	dhovda@mednet.ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS037365, R01NS027544] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27544, NS 30308, NS 37365] Funding Source: Medline		Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Allan SM, 2001, MOL BRAIN RES, V93, P180, DOI 10.1016/S0169-328X(01)00211-X; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Blanchard RK, 2001, P NATL ACAD SCI USA, V98, P13507, DOI 10.1073/pnas.251532498; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; CONFERENCE NC, 1999, JAMA-J AM MED ASSOC, V282, P974; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Gong QZ, 1999, J NEUROTRAUM, V16, P893, DOI 10.1089/neu.1999.16.893; GRIESBACH GS, 2002, J NEUROTRAUM, V97, P1045; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hoehn B, 2001, J CEREBR BLOOD F MET, V21, P1303, DOI 10.1097/00004647-200111000-00006; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Koistinaho J, 2000, NEUROCHEM RES, V25, P645, DOI 10.1023/A:1007559003261; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LOGAN A, 1992, J NEUROSCI, V12, P3828; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Qiu JH, 2002, J NEUROSCI, V22, P3504; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Rao VLR, 1998, J NEUROCHEM, V70, P2020; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Samii A, 2001, HEAD TRAUMA, P203; SLOVITER RS, 1992, J NEUROSCI, V12, P3004; Song GQ, 2001, J NEUROCHEM, V79, P804, DOI 10.1046/j.1471-4159.2001.00626.x; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; SZELE FG, 1995, J NEUROSCI, V15, P4429; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; WANG XK, 1995, J NEUROTRAUM, V12, P825, DOI 10.1089/neu.1995.12.825; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Whitfield PC, 2000, NEUROL RES, V22, P138, DOI 10.1080/01616412.2000.11741050; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; Yunoki M, 1998, ACT NEUR S, V71, P142; Zhang L, 2000, MOL BRAIN RES, V79, P174, DOI 10.1016/S0169-328X(00)00124-8	57	50	55	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2004	21	9					1141	1153		10.1089/0897715041953777			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	855HC	WOS:000223962900004	15453985				2021-06-18	
J	Hattori, N; Huang, SC; Wu, HM; Liao, WH; Glenn, TC; Vespa, PM; Phelps, ME; Hovda, DA; Bergsneider, M				Hattori, N; Huang, SC; Wu, HM; Liao, WH; Glenn, TC; Vespa, PM; Phelps, ME; Hovda, DA; Bergsneider, M			Acute changes in regional cerebral F-18-FDG kinetics in patients with traumatic brain injury	JOURNAL OF NUCLEAR MEDICINE			English	Article						neurology; PET; traumatic brain injury; glucose transporter; hexokinase F-18-FDG	POSITRON-EMISSION-TOMOGRAPHY; HEAD-INJURY; GLUCOSE-UTILIZATION; BLOOD-FLOW; METABOLIC-CHANGES; BARRIER CHANGES; RAT-BRAIN; MICRODIALYSIS; PHOSPHORYLATION; PET	During the acute phase after traumatic brain injury (TBI), the metabolic state is regionally heterogeneous. The purpose of this study was to characterize contusional, pericontusional, and remote regions of TBI by estimating glucose transporter and hexokinase activities on the basis of F-18-FDG kinetic modeling. Methods: A standard 2-compartment model was used to measure 18F-FDG kinetic parameters in 21 TBI patients with cerebral contusions studied during the acute phase (3.1 +/- 2.1 [mean +/- SD] d after injury). Nineteen patients also underwent O-15-water PET to measure regional cerebral blood flow (CBF). A control study (F-18-FDG and O-15-water) was done with 18 healthy volunteers. The rate constants K-i, K-1, and k(3) were assumed to represent the uptake, transport, and hexokinase activity of F-18-FDG, respectively; K-i was calculated as K-1 x [k(3)/(k(2) + k(3))]. Results: The areas of contusional and pericontusional tissues located 4.5, 13.5, and 22.5 mm away from the contusion (PC4.5, PC13.5, and PC22.5, respectively) demonstrated significantly reduced K-i values, whereas the K-1 values for remote areas remained normal. The k(3) values were significantly reduced regardless of the distance from the contusion. Pericontusional areas with CT- or MRI-evidenced tissue damage showed significantly lower K-i (P < 0.001), CBF (P < 0.01), and K-1 (P < 0.0001) values than did areas without such damage, whereas the k(3) values did not differ significantly. Seven patients showed regionally increased F-18-FDG uptake (hot spots) in pericontusional areas. The k(3) value for the hot spots (0.086 +/- 0.024/min) was significantly higher than that for the remote cortex (P < 0.01), whereas the K-i, CBF, and K-1 values did not show significant differences. Patients with hot spots showed significantly higher K-i and values in PC4.5 (P < 0.05) and higher k(3) values in PC22.5 (P < 0.05) than did patients without hot spots, whereas the K-1 and CBF values did not differ significantly. Conclusion: Brain tissue F-18-FDG kinetics in TBI patients were consistent with reduced hexokinase activity in the whole brain (including apparently uninjured cortex), whereas glucose transport was impaired only in the area immediately around the contusion. Pericontusional high levels of F-18-FDG uptake observed in a subgroup of patients could have been the result of regionally increased hexokinase activity.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Hattori, N (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Box 956948, Los Angeles, CA 90095 USA.	nhattori@mednet.ucla.edu	Hattori, Naoya/G-2298-2012; Hattori, Naoya/AAR-6405-2020	Glenn, Thomas/0000-0003-4273-3408	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [30308] Funding Source: Medline		Alessandri B, 1999, ACT NEUR S, V75, P25; ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, ACT NEUR S, V70, P243; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHAMPE PC, 1984, BIOCHEMISTRY-US, P89; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; CRANE PD, 1983, J NEUROCHEM, V40, P160, DOI 10.1111/j.1471-4159.1983.tb12666.x; CUNNINGHAM VJ, 1981, BRAIN RES, V221, P319, DOI 10.1016/0006-8993(81)90781-2; DRAPER NR, 1981, APPL REGRESSION ANAL, P157; EICHLING JO, 1974, CIRC RES, V35, P358, DOI 10.1161/01.RES.35.3.358; FOSTER NL, 1987, J CEREBR BLOOD F MET, V7, P415, DOI 10.1038/jcbfm.1987.84; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hattori N, 2003, J NUCL MED, V44, P1709; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HUANG SC, 1983, J CEREBR BLOOD F MET, V3, P141, DOI 10.1038/jcbfm.1983.21; Huang SC, 2004, MOL IMAGING BIOL, V6, P34, DOI 10.1016/j.mibio.2003.12.002; HUANG SC, 1982, J CEREBR BLOOD F MET, V2, P99, DOI 10.1038/jcbfm.1982.11; HUANG SC, 1980, AM J PHYSIOL, V238, pE69; HUANG SC, 1987, FEBS LETT, V216, P128, DOI 10.1016/0014-5793(87)80770-6; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KUWABARA H, 1990, J CEREBR BLOOD F MET, V10, P180, DOI 10.1038/jcbfm.1990.33; LANG DA, 1991, ACTA NEUROCHIR, V109, P5, DOI 10.1007/BF01405689; LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P73; Maes F, 1997, IEEE T MED IMAGING, V16, P187, DOI 10.1109/42.563664; Magistretti PJ, 1996, MOL PSYCHIATR, V1, P445; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; POWELL MJD, 1964, COMPUT J, V7, P155, DOI 10.1093/comjnl/7.2.155; Press WH, 1992, NUMERICAL RECIPES C, P394; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; ROSENSTEIN JM, 1994, J COMP NEUROL, V350, P229, DOI 10.1002/cne.903500207; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; WORLEY G, 1995, DEV MED CHILD NEUROL, V37, P213; Yamaki T, 1996, J NUCL MED, V37, P1166; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhou Y, 2001, IEEE T NUCL SCI, V48, P125, DOI 10.1109/23.910842	43	50	51	0	3	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	MAY	2004	45	5					775	783					9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	819WZ	WOS:000221348300017	15136626				2021-06-18	
J	Tate, RL				Tate, RL			Assessing support needs for people with traumatic brain injury: the care and needs scale (CANS)	BRAIN INJURY			English	Article							RATING-SCALE; HEAD-INJURY; DISABILITY	Background: After traumatic brain injury (TBI), many individuals have support needs, but the variety, frequency and intensity of such needs vary widely. Currently available scales do not assess all facets of required supports and the eight-category Care and Needs Scale (CANS) was developed in order to capture the range of support needs. The aim of the present study was to examine the sensitivity and validity of the CANS. Method: Using a sample of 67 people who sustained severe TBI 20-26 years previously, the CANS was compared with the Supervision Rating Scale (SRS), five scales from the Craig Handicap Assessment and Reporting Technique (CHART) and the Sydney Psychosocial Reintegration Scale (SPRS). Results: The data showed a spread across all CANS categories: 28.4% of participants were fully independent, 46.3% had support needs on less than a daily basis (25.4% intermittently, 13.4% at least weekly and 7.5% every few days) and the remaining 25.4% had needs on a daily basis (ranging from 11.9% for up to 11 hours per day to 4.5% for 24 hours per day). By contrast, the 13-category SRS classified 61.2% in the best category and five categories did not contain any individuals. The CANS showed strong correlation with the SRS ( r s = 0.75), as well as CHART and SPRS scores (range r s = -0.46 to -0.85) and statistically significant differences were found among participant sub-groups. Logistic regression analyses, using variables collected at the time of discharge from rehabilitation, were able to predict independence on the CANS with classification accuracy of 77% and presence of neuropsychological disability was an individual predictor. Conclusion: These results suggest that the CANS shows promise as a sensitive and valid instrument to measure care and support needs after TBI, particularly in the longer term, and further examination of its psychometric properties is warranted.	Royal Rehabil Ctr Sydney, Rehabil Studies Unit, Ryde, NSW 1680, Australia; Univ Sydney, Dept Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia	Tate, RL (corresponding author), Royal Rehabil Ctr Sydney, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	rtate@med.usyd.edu.au					Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Bowling A., 1997, MEASURING HLTH REV Q, V2nd; BROE GA, 1982, BRAIN IMPAIR, P59; CAVALLO MM, 1995, J HEAD TRAUMA REHAB, V10, P66, DOI 10.1097/00001199-199504000-00008; Cieza A, 2002, J REHABIL MED, V34, P205, DOI 10.1080/165019702760279189; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Feeney TJ, 2001, J HEAD TRAUMA REHAB, V16, P61, DOI 10.1097/00001199-200102000-00008; Hagen C., 1972, LEVELS COGNITIVE FUN; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kolakowsky-Hayner SA, 2000, NEUROREHABILITATION, V14, P151; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McDowell I, 1996, MEASURING HLTH GUIDE; OKEEFE J, 1994, J HEAD TRAUMA REHAB, V9, P49; PONSFORD J, 2003, 26 ANN BRAIN IMP C S; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tate RL, 2003, STUD NEUROPSYCHOL DE, P137; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; TATE RL, 2003, 26 ANN BRAIN IMP C S; TATE RL, IN PRESS ARCH PHYS M; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Wade DT, 1992, MEASUREMENT NEUROLOG; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 2001, INT CLASS FUNCT DIS	35	50	50	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2004	18	5					445	460		10.1080/02699050310001641183			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	800SS	WOS:000220048600004	15195793				2021-06-18	
J	Carroll, LJ; Cassidy, JD; Peloso, PM; Garritty, C; Giles-Smith, L				Carroll, LJ; Cassidy, JD; Peloso, PM; Garritty, C; Giles-Smith, L			Systematic search and review procedures: Results of the who collaborating centre task force on mild traumatic brain injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; systematic review; best-evidence synthesis	HEALTH-CARE	The WHO Collaborating Centre for Neurotrauma Task Force on Mild Traumatic Brain Injury performed a comprehensive search and critical review of the literature published between 1980 and 2002 to assemble the best evidence on the epidemiology, diagnosis, prognosis and treatment of mild traumatic brain injury. Our primary sources of literature were Medline, Cinahl, PsycINFO and Embase. Citations were screened for relevance to mild traumatic brain injury, using a priori criteria, and relevant studies were critically reviewed for scientific merit. We identified 38,806 citations, of which 671 studies were judged relevant to the mandate of the task force. These, plus 70 studies found by hand-searching reference lists and 2 original research reports performed as part of the task force mandate were subjected to critical reviews. After review, 313 (42%) were accepted on scientific merit and comprise our best-evidence synthesis. Ninety percent of the literature on mild traumatic brain injury was found in Medline and another 5% in PsycINFO.	Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB T6G 2E1, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada; Karolinska Inst, Dept Clin Neurosci, Sect Personal Injury Prevent, Stockholm, Sweden; Univ Iowa, Ctr Hlth, Dept Internal Med, Iowa City, IA USA; Inst Work & Hlth, Toronto, ON, Canada	Carroll, LJ (corresponding author), Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, 3080 RTF,8308-114 St, Edmonton, AB T6G 2E1, Canada.	lcarroll@ualberta.ca	Garritty, Chantelle/ABG-7790-2020	Giles-Smith, Lori/0000-0002-2248-9164; Carroll, Linda/0000-0003-0876-2336			BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cook DJ, 1997, ANN INTERN MED, V127, P210, DOI 10.7326/0003-4819-127-3-199708010-00006; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; Juni P, 2002, INT J EPIDEMIOL, V31, P115, DOI 10.1093/ije/31.1.115; LOWE HJ, 1994, JAMA-J AM MED ASSOC, V271, P1103, DOI 10.1001/jama.271.14.1103; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Rothman K.J., 1998, MODERN EPIDEMIOLOGY, V2nd ed.; Slavin R. E., 1986, EDUC RES, V15, P5, DOI [10.3102/0013189X015009005, DOI 10.3102/0013189X015009005]; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; SPITZER WO, 1995, SPINE, V20, P2372; SPITZER WO, 1995, SPINE, V20, pS1; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633; Wagner E.H., 1996, CLIN EPIDEMIOLOGY ES	16	50	50	0	3	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2004	36			43			11	14		10.1080/16501960410023660			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	800QR	WOS:000220043300004	15083867	DOAJ Gold			2021-06-18	
J	Peloso, PM; Carroll, LJ; Cassidy, JD; Borg, J; von Holst, H; Holm, L; Yates, D				Peloso, PM; Carroll, LJ; Cassidy, JD; Borg, J; von Holst, H; Holm, L; Yates, D			Critical evaluation of the existing guidelines on mild traumatic brain injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						guidelines; mild traumatic brain injury; critical appraisal; evidence-based medicine	CLINICAL-PRACTICE GUIDELINES; MEDICAL LITERATURE; HEAD-INJURIES; USERS GUIDES; MANAGEMENT GUIDELINES; SYSTEMATIC REVIEWS; SAFE RETURN; CONCUSSION; SPORT; CARE	The purpose of guidelines is to reduce practice variability, but they need to be evidence-based. We examine current mild traumatic brain injury guidelines, critique their basis in evidence and examine their variability in recommendations. A systematic search of the literature found 38,806 abstracts, with 41 guidelines. There were 18 sports-related guidelines, 13 related to admission policies, 12 related to imaging and 5 related to neuropsychological assessment. Some guidelines addressed several areas. Only 5 guidelines reported a methodology for the assembly of evidence used to develop the guideline. After appraising the guidelines against a validated index, we found that 3 of the 41 guidelines could be categorized as evidence-based. Two of these focused on paediatric patients and 1 on adult patients. Limited methodological quality in the current guidelines results in conflicting recommendations amongst them.	Univ Iowa, Ctr Hlth, Dept Internal Med, Iowa City, IA USA; Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada; Karolinska Inst, Dept Clin Neurosci, Sect Personal Injury Prevent, Stockholm, Sweden; Uppsala Univ, Dept Neurosci, Uppsala, Sweden; Karolinska Inst, Dept Neurosurg, Stockholm, Sweden; Univ Manchester, Hope Hosp, Emergency Dept, Manchester, Lancs, England	Peloso, PM (corresponding author), Univ Iowa Hlth Care, Room E 330 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	paul-peloso@uiowa.edu		Borg, Jorgen/0000-0002-2372-7478; Carroll, Linda/0000-0003-0876-2336			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bergman DA, 1999, PEDIATRICS, V104, P1407; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; BRIGGS M, 1984, BRIT MED J, V288, P983; BRITTON M, 2000, 153 SBU SWED COUNC T; BROCKLEHURST G, 1987, BRIT MED J, V294, P345, DOI 10.1136/bmj.294.6568.345; Brown C, 1999, Nasnewsletter, V14, P6; BROWN C, 1999, NAS NEWSLETTER, V14, P6; BRUNO LA, 1987, CLIN SPORT MED, V6, P17; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CANTU RC, 1991, SPORTS ADOLESCENT, P17; CANTU RV, 1994, J NEUROSURG, V80, P592; Carroll LJ, 2004, J REHABIL MED, V36, P11, DOI 10.1080/16501960410023660; *CO MED SOC SPORTS, 1991, GUID MAN CONC SPORTS; Cote P, 2001, Spine (Phila Pa 1976), V26, pE445, DOI 10.1097/00007632-200110010-00020; Cripe LI, 1987, COGNITIVE REHABILITA, V5, P18; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Davis P C, 2000, Radiology, V215 Suppl, P507; de Andrade AF, 2001, WORLD J SURG, V25, P1186; DELACEY G, 1990, BRIT J RADIOL, V63, P14, DOI 10.1259/0007-1285-63-745-14; Dicker G, 1993, Aust Fam Physician, V22, P750; Fernandez R, 1997, ZBL NEUROCHIR, V58, P72; FOWKES FGR, 1986, BRIT J SURG, V73, P891, DOI 10.1002/bjs.1800731112; Gennarelli T A, 1984, Emerg Med Clin North Am, V2, P749; Guyatt GH, 1999, JAMA-J AM MED ASSOC, V281, P1836, DOI 10.1001/jama.281.19.1836; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; Hutchinson PJA, 1998, J ACCID EMERG MED, V15, P84; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 2001, J ATHL TRAINING, V36, P249; Lawler KA, 1996, J HEAD TRAUMA REHAB, V11, P18, DOI 10.1097/00001199-199612000-00005; LeBlanc K E, 1998, J La State Med Soc, V150, P312; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; MACLAREN RE, 1993, ARCH EMERG MED, V10, P138; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; *NAT ATHL TRAIN AS, 1994, P MILD BRAIN INJ SPO; OXMAN AD, 1993, ANN NY ACAD SCI, V703, P125, DOI 10.1111/j.1749-6632.1993.tb26342.x; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648, DOI 10.1136/bmj.309.6955.648; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; Sackett DL., 1991, CLIN EPIDEMIOLOGY BA; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Shaneyfelt TM, 1999, JAMA-J AM MED ASSOC, V281, P1900, DOI 10.1001/jama.281.20.1900; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; Spence R A, 1980, Ulster Med J, V49, P65; SPITZER WO, 1990, CLIN INVEST MED, V13, P17; SPITZER WO, 1995, SPINE, V20, P2372; SPITZER WO, 1995, SPINE, V20, pS1; SPITZER WO, 1987, SPINE, V12, pS1; Study Group on Head Injury of the Italian Society for Neurosurgery, 1996, J NEUROSURG SCI, V40, P11; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; Young CC, 1997, CLIN J SPORT MED, V7, P196, DOI 10.1097/00042752-199707000-00008	63	50	50	0	5	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2004	36			43			106	112		10.1080/16501960410023868			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	800QR	WOS:000220043300011	15083874	DOAJ Gold			2021-06-18	
J	Vasa, RA; Grados, M; Slomine, B; Herskovits, EH; Thompson, RE; Salorio, C; Christensen, J; Wursta, C; Riddle, MA; Gerring, JP				Vasa, RA; Grados, M; Slomine, B; Herskovits, EH; Thompson, RE; Salorio, C; Christensen, J; Wursta, C; Riddle, MA; Gerring, JP			Neuroimaging correlates of anxiety after pediatric traumatic brain injury	BIOLOGICAL PSYCHIATRY			English	Article						traumatic brain injury; orbitofrontal cortex; temporal lobe; anxiety; children	CLOSED-HEAD INJURY; UNILATERAL TEMPORAL LOBECTOMY; OBSESSIVE-COMPULSIVE DISORDER; HUMAN AMYGDALA; ORBITOFRONTAL CORTEX; CONDITIONED FEAR; FRONTAL LESIONS; CHILDREN; EMOTION; PSYCHOPATHOLOGY	Background: Anxiety disorders are common after traumatic brain injury (TBI). Data on the neural correlates of these conditions are lacking. This study examines the relationship between brain damage, particularly to the orbitofrontal cortex (OFC) and temporal lobe, and anxiety symptoms and disorders. Methods: Ninety-five children and adolescents were followed for one year postinjury. Preinjury and one-year postinjury anxiety status were obtained from the parent. Magnetic resonance imaging was performed to evaluate brain lesions. The primary analysis used regression models to determine relationships between brain lesions and anxiety outcomes. As a secondary analysis, previously reported posttraumatic stress disorder (PTSD) data were reanalyzed using similar methods for purposes of comparison. Results: The primary analysis showed that greater volume and number of OFC lesions correlated with decreased risk for anxiety, whereas lesions in other brain areas did not correlate with anxiety. Consistent with prior data, the secondary analysis showed an inverse correlation between OFC damage and PTSD; temporal lobe damage was positively correlated with PTSD. Conclusions: After pediatric TBI greater damage to the OFC is associated with decreased risk for anxiety outcomes. Similar to adult data, these findings implicate OFC dysfunction in childhood anxiety. Temporal lobe damage did not correlate with anxiety, in contrast to the findings for PTSD.	Kennedy Krieger Res Inst, Baltimore, MD 21211 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Univ Penn, Sch Med, Dept Radiol, Philadelphia, PA 19104 USA	Vasa, RA (corresponding author), Kennedy Krieger Res Inst, 3901 Greenspring Ave, Baltimore, MD 21211 USA.			Grados, Marco/0000-0002-6189-6264	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR 00052] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH 00997] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER		Adolphs R, 1999, NEUROPSYCHOLOGIA, V37, P1111, DOI 10.1016/S0028-3932(99)00039-1; Anderson AK, 2001, NATURE, V411, P305, DOI 10.1038/35077083; Armony JL, 1997, ANN NY ACAD SCI, V821, P259, DOI 10.1111/j.1749-6632.1997.tb48285.x; Astrom M, 1996, STROKE, V27, P270, DOI 10.1161/01.STR.27.2.270; Baird AA, 1999, J AM ACAD CHILD PSY, V38, P195, DOI 10.1097/00004583-199902000-00019; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; Breiter HC, 1996, NEURON, V17, P875, DOI 10.1016/S0896-6273(00)80219-6; BREMNER JD, 2000, CURR PSYCHIAT REP, V4, P254; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BUTTER CM, 1970, J COMP PHYSIOL PSYCH, V72, P132, DOI 10.1037/h0029303; Cassidy John W., 1994, P43; CASTILLO CS, 1993, J NERV MENT DIS, V181, P100, DOI 10.1097/00005053-199302000-00005; Chua P, 1999, NEUROIMAGE, V9, P563, DOI 10.1006/nimg.1999.0407; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Damasio H., 1989, LESION ANAL NEUROPSY; Davatzikos C, 1998, HUM BRAIN MAPP, V6, P334; DAVIDSON RJ, 1989, J ABNORM PSYCHOL, V98, P127, DOI 10.1037/0021-843X.98.2.127; De Bellis MD, 2000, BIOL PSYCHIAT, V48, P51, DOI 10.1016/S0006-3223(00)00835-0; De Bellis MD, 2001, BIOL PSYCHIAT, V50, P305, DOI 10.1016/S0006-3223(01)01105-2; Funayama ES, 2001, J COGNITIVE NEUROSCI, V13, P721, DOI 10.1162/08989290152541395; Gallagher M, 1999, J NEUROSCI, V19, P6610; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; Hackett TA, 2001, J COMP NEUROL, V441, P197, DOI 10.1002/cne.1407; Hatfield T, 1996, J NEUROSCI, V16, P5256; Heilman KM, 1997, J NEUROPSYCH CLIN N, V9, P439, DOI 10.1176/jnp.9.3.439; Herskovits EH, 2002, RADIOLOGY, V224, P345, DOI 10.1148/radiol.2242011439; HERSKOVITZ EH, 2002, RADIOLOGY, V21, P389; *INT SOL GROUP, 1995, ALL SOFTW; KAGAN J, 1987, CHILD DEV, V58, P1459, DOI 10.1111/j.1467-8624.1987.tb03858.x; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LABAR KS, 1995, J NEUROSCI, V15, P6846; LaBar KS, 1998, NEURON, V20, P937, DOI 10.1016/S0896-6273(00)80475-4; LaBar KS, 1996, BEHAV NEUROSCI, V110, P991, DOI 10.1037/0735-7044.110.5.991; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Liotti M, 2000, BIOL PSYCHIAT, V48, P30, DOI 10.1016/S0006-3223(00)00874-X; Machado CJ, 2003, J CHILD PSYCHOL PSYC, V44, P64, DOI 10.1111/1469-7610.00103; Malizia AL, 1999, J PSYCHOPHARMACOL, V13, P372, DOI 10.1177/026988119901300418; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; MORGAN MA, 1995, BEHAV NEUROSCI, V109, P681, DOI 10.1037/0735-7044.109.4.681; Morris JS, 1998, BRAIN, V121, P47, DOI 10.1093/brain/121.1.47; Pine DS, 1999, J CHILD ADOL PSYCHOP, V9, P1, DOI 10.1089/cap.1999.9.1; RABEHESKETH S, 2000, HDB STAT ANAL USING; RAUCH SL, 1995, ARCH GEN PSYCHIAT, V52, P20; RAUCH SL, 1994, ARCH GEN PSYCHIAT, V51, P62; Rauch SL, 1997, BIOL PSYCHIAT, V42, P446, DOI 10.1016/S0006-3223(97)00145-5; Rauch SL, 2003, ANN NY ACAD SCI, V985, P389; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; Salloway S, 1997, J NEUROPSYCH CLIN N, V9, P403; Schoenbaum G, 1998, NAT NEUROSCI, V1, P155, DOI 10.1038/407; SCHWARTZ ML, 1991, J COMP NEUROL, V307, P144, DOI 10.1002/cne.903070113; SLIFER KJ, 1993, J APPL BEHAV ANAL, V26, P469, DOI 10.1901/jaba.1993.26-469; SWEDO SE, 1992, ARCH GEN PSYCHIAT, V49, P690; SZATMARI P, 1994, INT J METHOD PSYCH, V4, P231; Szeszko PR, 1999, ARCH GEN PSYCHIAT, V56, P913, DOI 10.1001/archpsyc.56.10.913; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Thomas KM, 2001, ARCH GEN PSYCHIAT, V58, P1057, DOI 10.1001/archpsyc.58.11.1057; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; WEINGARTEN SM, 1999, SCI PRACT NEUROPSYCH, P446; WILSON J T L, 1990, Brain Injury, V4, P349; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zald DH, 1996, J NEUROPSYCH CLIN N, V8, P249	66	50	51	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	FEB 1	2004	55	3					208	216		10.1016/S0006-3223(03)00708-X			9	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	767HK	WOS:000188434000002	14744460				2021-06-18	
J	McCauley, SR; Levin, HS				McCauley, SR; Levin, HS			Prospective memory in pediatric traumatic brain injury: A preliminary study	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; TASK COMPLEXITY; CHILDREN; ADOLESCENTS; CUES; AGE; POPULATION; RETRIEVAL; SEQUELAE; MRI	Prospective memory (PM) performance was investigated in a preliminary study of children and adolescents ages 10-19 in 3 groups: individuals with orthopedic injuries (not involving the head) requiring hospitalization (Ortho, N = 15), mild traumatic brain injury (TBI, N = 17), and severe TBI (N= 15). All participants with TBI were at least 5 years postinjury and participants in the Ortho group were at least 3 years postinjury. The PM task involved reporting words presented in blue during a category decision task in which words were presented in several different colors and participants were to determine which of two categories the word belonged. Participants were asked to make their choices as quickly as possible. After a 10- to 15-min intervening computer task in which all words were presented in black letters, a large proportion of participants with mild or severe TBI failed to indicate any blue words when they appeared. After a reminder to perform the PM task was given to all at the same point in the task, PM performance increased in the Ortho and Mild TBI groups, but remained comparably impaired in the Severe TBI group. Reaction time (RT) data indicated that mean RT was slower with increasing TBI severity. Further, there was a significant cost in RT for performing the PM task during the ongoing category decision task for all groups. The cost in terms of slowed RT increased with greater TBI severity.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Cognit Neurosci Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Cognit Neurosci Lab, Houston, TX 77030 USA	McCauley, SR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin St,Ste 1144, Houston, TX 77030 USA.	mccauley@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		BEAL CR, 1985, CHILD DEV, V56, P631; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CECI SJ, 1985, CHILD DEV, V56, P152, DOI 10.2307/1130182; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; EINSTEIN GO, 1992, PSYCHOL AGING, V7, P471, DOI 10.1037/0882-7974.7.3.471; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Flannery M A, 1997, Pediatr Rehabil, V1, P239; Guajardo NR, 2000, COGNITIVE DEV, V15, P75, DOI 10.1016/S0885-2014(00)00016-2; HANNAY HJ, 1989, J CLIN EXP NEUROPSYC, V11, P444, DOI 10.1080/01688638908400905; HANNAY HJ, 1979, CONTINUOUS RECOGNITI; Hanten G, 2000, J MEM LANG, V43, P335, DOI 10.1006/jmla.2000.2731; Harris J. E., 1984, EVERYDAY MEMORY ACTI, P71; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; Kerns KA, 2000, J INT NEUROPSYCH SOC, V6, P62, DOI 10.1017/S1355617700611074; KRAUS JF, 1987, PEDIATRICS, V79, P501; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kreutzer M. A., 1975, MEMORY OBSERVED REME, P343; Kvavilashvili L, 2001, DEV PSYCHOL, V37, P418, DOI 10.1037//0012-1649.37.3.418; KVAVILASHVILI L, 1990, REMEMBERING FORGETTI; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; McCauley S. R., 2000, ANN M COGN NEUR SOC; McCauley S. R., 2001, 3 INT C MEM ICOM 3 V; McDaniel M A, 1993, Memory, V1, P23, DOI 10.1080/09658219308258223; MEACHAM JA, 1980, J EDUC RES, V73, P299; MEACHAM JA, 1976, CATALOG SELECTED DOC, V6, P66; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; NOVACK TA, 1995, CLIN NEUROPSYCHOL, V9, P38; PASSOLUNGHI MC, 1995, INT J BEHAV DEV, V18, P1995; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; SCHWANENFLUGEL PJ, 1994, CHILD DEV, V65, P1546; SCHWEINBERGER SR, 1993, CORTEX, V29, P333, DOI 10.1016/S0010-9452(13)80186-4; SOMMERVILLE SC, 1983, J GENET PSYCHOL, V143, P87; TEASDALE G, 1974, LANCET, V2, P81; WELLMAN HM, 1975, DEV PSYCHOL, V11, P780, DOI 10.1037/0012-1649.11.6.780; WICHMAN H, 1983, HUM FACTORS, V25, P583; Winograd E., 1988, PRACTICAL ASPECTS ME, V1, P348	43	50	51	0	5	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	25	1-2					5	20		10.1207/s15326942dn2501&2_2			16	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	774CG	WOS:000188961700002	14984326				2021-06-18	
J	Zanier, ER; Lee, SM; Vespa, PM; Giza, CC; Hovda, DA				Zanier, ER; Lee, SM; Vespa, PM; Giza, CC; Hovda, DA			Increased hippocampal CA3 vulnerability to low-level kainic acid following lateral fluid percussion injury	JOURNAL OF NEUROTRAUMA			English	Article						kainic acid; secondary injury; seizures; traumatic brain injury	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; EXCITATORY AMINO-ACIDS; HUMAN HEAD-INJURY; GLUCOSE-UTILIZATION; INTRACRANIAL HYPERTENSION; GLUTAMATE RELEASE; RAT; SEIZURES; HYPOXIA	This study was designed to determine whether a secondary increase in neuronal activity induced by a low dose of kainic acid (KA), a glutamate analogue, exacerbates the anatomical damage in hippocampal regions following a mild lateral fluid percussion (LFP) brain injury. KA (9 mg/kg) was injected intraperitoneally in LFP-injured rats (n = 16) 1 h post-trauma. The neuronal loss in the CA3, CA4, and hilar regions at 7 days was quantified by two-dimensional cell counts. Hippocampal activation 15 min following KA injection was assessed by measuring local glucose metabolic rates (ICMRglc). Following LFP+KA, the ipsilateral side exhibited a 62.7%, 75.7%, and 52.1% decrease in the number of CA3, CA4 and hilar neurons, respectively, compared to naive rats (n = 3). These CA3 and CA4 neuronal counts were also significantly decreased compared to LFP+saline (n = 5) and sham+KA (n = 9) groups. The median Racine Score, used to rate the severity of behavioral seizures, was 4 in LFP+KA and 2 in sham+KA groups (p < 0.015), suggesting a reduction in seizure threshold following injury. lCMR(glc) in CA3 following LFP+KA was 121.8 +/- 2.0 (mean +/- SE) ipsilaterally and 71.5 +/- 5.4 contralaterally (p < 0.0012). No changes were found in the BBB permeability as measured by [C-14]aminoisobutyric acid in CA3, CA4, and hilar regions. We conclude that the presence of low-level KA I h after LFP dramatically increases the extent of hippocampal. activation and induces a striking; loss of ipsilateral CA3 and CA4 pyramidal neurons. Neuronal excitation during a time of cellular vulnerability may trigger or amplify the cycle of secondary damage in functionally impaired, but potentially viable, tissue.	Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg Neurosurg, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat Neurol, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA	Lee, SM (corresponding author), Univ Calif Los Angeles, Med Ctr, 18-228 NPI,Box 957039, Los Angeles, CA 90095 USA.		Zanier, Elisa/AAA-8095-2020	Zanier, Elisa/0000-0002-3011-8718	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS02089-02, NS30308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER		ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Becker DP, 1989, TXB HEAD INJURY, P1; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; BERGSNEIDER M, 1997, J NEUROSURG, V86, P5241; BLASBERG RONALD, 1966, BRAIN RES, V1, P86, DOI 10.1016/0006-8993(66)90107-7; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cotman C W, 1986, Adv Exp Med Biol, V203, P237; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERKANY JW, 1982, NATURE, V298, P757, DOI 10.1038/298757a0; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Friedberg MH, 1999, J NEUROPHYSIOL, V81, P2243; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Golarai G, 2001, J NEUROSCI, V21, P8523; Goodman JC, 1996, ACT NEUR S, V67, P37; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Kudo M, 2001, ANESTHESIOLOGY, V94, P303, DOI 10.1097/00000542-200102000-00021; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miller JD, 1996, NEUROTRAUMA, P61; Moore A. H., 2000, Journal of Neurotrauma, V17, P994; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Prough DS, 2001, CRIT CARE MED, V29, P1278, DOI 10.1097/00003246-200106000-00042; RACINE R, 1972, ELECTROEN CLIN NEURO, V32, P295, DOI 10.1016/0013-4694(72)90178-2; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; SATER RA, 1988, NEUROSCI LETT, V84, P73, DOI 10.1016/0304-3940(88)90340-0; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Sommer C, 2001, ACTA NEUROPATHOL, V101, P460; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Suzuki M, 2002, J NEUROTRAUM, V19, P285, DOI 10.1089/08977150252807027; Toth Z, 1997, J NEUROSCI, V17, P8106; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Xiong LZ, 2003, ANESTH ANALG, V96, P233, DOI 10.1097/00000539-200301000-00047; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	67	50	50	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2003	20	5					409	420		10.1089/089771503765355496			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682MY	WOS:000183096900002	12803974				2021-06-18	
J	Greve, KW; Bianchini, KJ; Mathias, CW; Houston, RJ; Crouch, JA				Greve, KW; Bianchini, KJ; Mathias, CW; Houston, RJ; Crouch, JA			Detecting malingered performance on the Wechsler Adult Intelligence Scale Validation of Mittenberg's approach in traumatic brain injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; response bias; WAIS; TBI	INCOMPLETE EFFORT; HEAD-INJURY; IDENTIFICATION	This study assesses the effectiveness of the Wechsler Adult Intelligence Scale (WAIS) performance validity markers devised by Mittenberg et al. [Prof. Psychol.: Res. Pract. 26 (1995) 491] in the detection of malingered neurocognitive dysfunction (MND). Subjects were 65 traumatic brain injury (TBI) patients referred for neuropsychological evaluation. Twenty-eight met the Slick et al. [Clin. Neuropsychol. 13 (1999) 545] criteria for at least probable MND. The control group was comprised of 37 patients without external incentive and who thus did not meet the Slick et al. criteria. All subjects completed the Wechsler Adult Intelligence Scale-Revised (WAIS-R or WAIS-III). The discriminant function score (DFS) and the vocabulary-digit span (VDS) difference score were calculated and sensitivity, specificity, and predictive power were examined for several cut-offs for each marker individually and the two combined. Classification accuracy for the DFS was acceptable and better than for VDS. The use of the two markers in combination resulted in no incremental increase in classification accuracy. Issues related to the clinical application of these techniques are discussed. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA; Inst Living, Hartford, CT USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu		Mathias, Charles/0000-0003-1902-673X			American Psychiatric Association, 1994, DIAGN STAT MAN, V4th; Axelrod B. N., 1999, J FORENSIC NEUROPSYC, V1, P15; BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; BIANCHINI KB, IN PRESS CLIN NEUROP; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Guilmette T J, 1990, Arch Clin Neuropsychol, V5, P373, DOI 10.1016/0887-6177(90)90016-I; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Hartlage LC, 1998, CRIT ISS NE, P239; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Hennekens CH, 1987, EPIDEMIOLOGY MED; Heubrock D, 1998, EUR J PSYCHOL ASSESS, V14, P211, DOI 10.1027/1015-5759.14.3.211; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; MITTENBERG W, IN PRESS CLIN NEUROP; Pankratz L., 1988, CLIN ASSESSMENT MALI, P169; Reynolds CR, 1998, CRIT ISS NE, P261; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILLIAMS RW, 1999, AM J FORENSIC PSYCH, V17, P35; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; Youngjohn J.R., 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]	35	50	50	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	APR	2003	18	3					245	260	PII S0887-6177(02)00137-3	10.1016/S0887-6177(02)00137-3			16	Psychology, Clinical; Psychology	Psychology	666FJ	WOS:000182166200002	14591458	Bronze			2021-06-18	
J	Bushnik, T; Hanks, RA; Kreutzer, J; Rosenthal, M				Bushnik, T; Hanks, RA; Kreutzer, J; Rosenthal, M			Etiology of traumatic brain injury: Characterization of differential outcomes up to 1 year postinjury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; outcome assessment (health care); rehabilitation; violence	PENETRATING HEAD-INJURY; UNITED-STATES; COMMUNITY INTEGRATION; SUBSTANCE-ABUSE; PREDICTORS; VIOLENCE; EMPLOYMENT; SEVERITY; SCALE; COMA	Objective: To characterize outcomes after traumatic brain injury (TBI) resulting from vehicular crashes, violence, falls, or other causes. Design: Prospective, multicenter, longitudinal. Setting: Seventeen Traumatic Brain Injury Model Systems. Participants: A total of 1170 individuals with moderate to severe TBI with data from initial medical and rehabilitation stays and 1-year follow-up. Interventions: Not applicable. Main Outcome Measures: At rehabilitation discharge, FIMTM instrument, Disability Rating Scale (DRS), and Rancho Los Amigo Levels of Cognitive Functioning Scale. At 1 year postinjury, FIM, DRS, Community Integration Questionnaire (CIQ), employment, residence, marital status, and seizure occurrence. Results: The 4 etiology groups could be distinguished based on premorbid characteristics. Severity of injury indices indicated that individuals in vehicular crashes showed a trend toward incurring more severe injuries than the other 3 groups. At rehabilitation discharge, there were no functional differences between groups. At 1 year postinjury, the groups could be differentiated: individuals in violence-related TBI had higher unemployment rates and lower CIQ scores; persons in vehicular crashes reported the best functional and psychosocial outcomes; and individuals in the falls and other groups had outcomes lying between the vehicular and violence groups. Conclusion: This study elucidated important differences between persons with violence-related TBI and those with non-violence-related TBI. Further research is needed to find effective interventions to address these differences.	Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Dept PM&R, San Jose, CA 95128 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; Rehabilitat Inst Michigan, Detroit, MI USA; Virginia Commonwealth Univ, Richmond, CA USA; Virginia Commonwealth Univ Med Coll Virginia, Richmond, VA USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA	Bushnik, T (corresponding author), Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA.			Bushnik, Tamara/0000-0003-3328-257X			Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; *DIV AC CAR REH RE, 1999, TRAUM BRAIN INJ US R; ENGLANDER J, 1999, REHABILITATION ADULT, P453; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hagen C., 1972, LEVELS COGNITIVE FUN; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; JENNETT B, 1981, MANAGEMENT HEAD INJU, P77; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kraus JF, 1993, HEAD INJURY, P1; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vollmer DG, 1991, J NEUROSURG S, V75, P37; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; Wehman P, 1999, REHABILITATION ADULT, P326; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, BRAIN INJURY REHABIL, P355; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; Zafonte RD, 1997, BRAIN INJURY, V11, P403; Zafonte RD, 2001, NEUROL RES, V23, P219, DOI 10.1179/016164101101198370; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226; 2000, TRAUMATIC BRAIN INJ, V6, P8	43	50	50	0	11	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					255	262		10.1053/apmr.2003.50092			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700016	12601658				2021-06-18	
J	Chan, RCK				Chan, RCK			Attentional deficits in patients with persisting postconcussive complaints: A general deficit or specific component deficit?	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; EXECUTIVE FUNCTION; REACTION-TIME; LOBE LESIONS; CONCUSSION; SYMPTOMS; RECOVERY; BRAIN; QUESTIONNAIRE	This study aimed to examine attentional performance in patients with persisting postconcussive complaints. using a multi-componential perspective. Comparisons of attentional performances of 92 patients with postconcussive complaints and 86 normal controls were conducted using tests of sustained attention (Sustained Attention to Response Task Digit Backward Span). selective attention (Stroop Word-Color Test; Color Trails Test), divided attention (Paced Auditory Serial Addition Test Symbol Digit Modalities Test), and attentional control processing (Six Elements Test: Tower of Hanoi). Questionnaires on daily life inattentive behaviour were also administered to all participants and their significant others. A MANOVA indicated that patients with persisting postconcussive complaints demonstrated a general deficit in attentional performance as compared with their normal controls, F(18, 145)=7.939. p=.005. These patterns still persisted when measures of emotional disturbance were controlled, F(18,143)=5.159, p=.005. Moreover, for sustained attention and selective attention, we were able to statistically control for speed and the differences remained. Future research should be conducted to better control the potential confound of speed for all the attentional components in order to differentiate any specific component deficits in these patients.	Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China	Chan, RCK (corresponding author), Univ Hong Kong, Dept Psychiat, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	rckchan@hkucc.hku.hk	Chan, Raymond CK/B-6717-2009	Chan, Raymond CK/0000-0002-3414-450X			Baker SC, 1996, NEUROPSYCHOLOGIA, V34, P515, DOI 10.1016/0028-3932(95)00133-6; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BINDER LM, 1997, J CLIN EXPT NEUROPSY, V19, P529; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BRUDER G, 1980, PSYCHOL MED, V10, P549, DOI 10.1017/S0033291700047449; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cabeza R, 1997, J COGNITIVE NEUROSCI, V9, P1, DOI 10.1162/jocn.1997.9.1.1; CHAN CM, 1984, COGNITIVE THER RES, V8, P501, DOI 10.1007/BF01173287; Chan RCK, 1999, ARCH CLIN NEUROPSYCH, V14, P735, DOI 10.1016/S0887-6177(99)80228-5; Chan RCK, 2001, BRAIN INJURY, V15, P71, DOI 10.1080/02699050118215; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; DELIA LF, 1996, COLOUR TRAILS TEST P; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1989, FRONTAL LOBE FUNCTIO, P229; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GEOL V, 1995, NEUROPSYCHOLOGIA, V33, P623; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hair J.F., 1995, MULTIVARIATE DATA AN, V4th ed.; Humes GE, 1997, ASSESSMENT, V4, P249, DOI 10.1177/107319119700400305; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; Lee TMC, 2000, J CLIN EXP NEUROPSYC, V22, P465, DOI 10.1076/1380-3395(200008)22:4;1-0;FT465; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEONCARRION J, 1997, NEUROPSYCHOL REHABIL, P47; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MANDEL S, 1989, POSTGRAD MED, V85, P213; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mirsky A.F., 1996, ATTENTION MEMORY EXE, P71; Morris RG, 1997, COGN NEUROPSYCHOL, V14, P1007, DOI 10.1080/026432997381330; Naugle RI, 1990, TRAUMATIC BRAIN INJU, P69; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Reitan RM, 1997, NEUROPSYCHOL REV, V7, P3, DOI 10.1007/BF02876970; REZAI K, 1993, ARCH NEUROL-CHICAGO, V50, P636, DOI 10.1001/archneur.1993.00540060066020; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spreen O., 1998, COMPENDIUM NEUROPSYC; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Wechsler D., 1981, WAIS R MANUAL WECHSL; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P940	56	50	54	2	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2002	24	8					1081	1093		10.1076/jcen.24.8.1081.8371			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	642HA	WOS:000180797100009	12650233				2021-06-18	
J	Zhang, L; Abreu, BC; Gonzales, V; Seale, G; Masel, B; Ottenbacher, KJ				Zhang, L; Abreu, BC; Gonzales, V; Seale, G; Masel, B; Ottenbacher, KJ			Comparison of the Community Integration Questionnaire, the Craig Handicap Assessment and Reporting Technique, and the disability rating scale in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						correlation; outcome measurement; participation; rehabilitation; traumatic brain injury	SEVERE HEAD-INJURY; FOLLOW-UP; EPIDEMIOLOGY; RELIABILITY; OUTCOMES; VALIDITY; COMA	To examine the concurrent validity of the Community Integration Questionnaire (CIQ) in assessing outcomes in traumatic brain injury (TBI) by comparing it with two widely used and well-validated measurements of rehabilitation outcome. Design: A retrospective relational study of the concurrent validity of the CIQ, Craig Handicap Assessment and Reporting Technique (CHART), and Disability Rating Scale (DRS). Setting: A postacute rehabilitation facility. Participants: Seventy patients with a medical diagnosis of TBI admitted between April 1996 and October 1998 participated in the study. Results: CIQ and CHART provide ratings that are similar in several areas to those provided by the DRS. Correlation (r) among total scores and subscales for all three instruments ranged from 0.021 to 0.671 (P < .01). Correlation between CIQ and CHART is stronger than that between CIQ and DRS or between CHART and DRS, and the correlation between CHART and DRS is stronger than that between CIQ and DRS. Conclusion: The CIQ appears to be the most appropriate instrument in quantifying rehabilitation outcome in patients with TBI at the participatory (handicap) level. The findings of this study can help clinicians gain a greater understanding of the nature, redundancy, and gaps among functional outcome measures. Monitoring outcomes can also help clinicians better understand the effectiveness of interventions.	Transit Learning Ctr, Galveston, TX USA; Univ Texas, Med Branch, Sch Allied Hlth Sci, Galveston, TX 77550 USA; Univ Texas, Med Branch, Sealy Ctr Aging, Galveston, TX 77550 USA				Ottenbacher, Kenneth/0000-0001-5990-3982	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG17638] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG017638] Funding Source: NIH RePORTER		BEUKELMAN DR, 1991, COMMUNICATION DISORD; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; BROWN ME, 1984, FUNCTIONAL ASSESSMEN, P187; CAREY RG, 1978, ARCH PHYS MED REHAB, V59, P330; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cope D., 1993, J HEAD TRAUMA REHAB, V8, P1; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRANGER V, 1984, FUNCTIONAL ASSESSMEN, P14; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA; Hall K M, 1994, NeuroRehabilitation, V4, P76, DOI 10.3233/NRE-1994-4204; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HEINEMANN A, 1995, J HEAD TRAUMA REHAB, V10, P64; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; Ottenbacher KJ, 1998, AM J EPIDEMIOL, V147, P615; RAPPAPORT M, 1977, ARCH PHYS MED REHAB, V58, P333; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SARNO JE, 1973, ARCH PHYS MED REHAB, V54, P214; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Switzer S F, 1991, J Insur Med, V23, P239; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WHITENECK G, 1988, GUIDE USE CHART CRAI; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Willer B., 1993, BRAIN INJURY REHABIL, P355; World Health Organization, 1980, INT CLASS IMP DIS HA	39	50	50	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2002	17	6					497	509		10.1097/00001199-200212000-00002			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	617NN	WOS:000179367900002	12802241				2021-06-18	
J	O'Brien, CF				O'Brien, CF			Treatment of spasticity with botulinum toxin	CLINICAL JOURNAL OF PAIN			English	Article						spasticity; neural pathways; demyelination; botulinum toxin	PLACEBO-CONTROLLED TRIAL; TRAUMATIC BRAIN INJURY; UPPER-LIMB SPASTICITY; UPPER EXTREMITY SPASTICITY; DOUBLE-BLIND; CEREBRAL-PALSY; MULTIPLE-SCLEROSIS; MUSCLE SPASTICITY; CERVICAL DYSTONIA; STROKE PATIENTS	Spasticity is an abnormal increase in muscle contraction often caused by damage to central motor pathways that control voluntary movement. During clinical examination, spasticity manifests as an increase in stretch reflexes, producing tendon jerks and resistance appearing as muscle tone. There are many causes of spasticity, including demyelination from multiple sclerosis, congenital damage from diseases such as cerebral palsy, trauma to the brain or spinal cord, hemorrhage or infarction, and other pathologic conditions that interrupt neural pathways. Effects of spasticity range from mild muscle stiffness to severe, painful muscle contractures and repetitive spasms that reduce mobility and substantially impede normal activitics of daily living. Botulinum toxin therapy reduces spasticity and pain associated with several disorders. Local treatment with botulinum toxins can be used as adjunctive therapy, along with oral antispasticity medications, or alone to provide localized decrease in symptoms of spasticity and pain. Botulinum toxin therapy may be particularly useful for patients with spasticity due to stroke, whose treatment can be tailored based on recovery of function over time. In addition, botulinum toxin therapy is safe for pediatric patients, including children with cerebral palsy, who may not be able to tolerate the cognitive side effects of oral medications. Results of studies evaluating botulinum toxin for the treatment of spasticity due to various causes are presented here.	Elan Pharmaceut, San Diego, CA 92121 USA	O'Brien, CF (corresponding author), Elan Pharmaceut, 7475 Lusk Blvd, San Diego, CA 92121 USA.	Christopher.Obrien@elan.com					Bakheit AMO, 2000, STROKE, V31, P2402, DOI 10.1161/01.STR.31.10.2402; Bakheit AMO, 2001, EUR J NEUROL, V8, P559, DOI 10.1046/j.1468-1331.2001.00277.x; Bakheit AMO, 2001, DEV MED CHILD NEUROL, V43, P234, DOI 10.1017/S0012162201000445; Barnes MP, 1999, BRIT MED BULL, V55, P927, DOI 10.1258/0007142991902727; Bentivoglio AR, 1999, CURR OPIN NEUROL, V12, P447, DOI 10.1097/00019052-199908000-00012; Bhakta BB, 2000, J NEUROL NEUROSUR PS, V69, P217, DOI 10.1136/jnnp.69.2.217; Bhakta BB, 1996, J NEUROL NEUROSUR PS, V61, P30, DOI 10.1136/jnnp.61.1.30; Blitzer A, 2001, LARYNGOSCOPE, V111, P218, DOI 10.1097/00005537-200102000-00006; BORGSTEIN J, 1993, AM J PHYS MED REHAB, V72, P364; Brin M F, 1997, Muscle Nerve Suppl, V6, pS208; Brin MF, 1999, NEUROLOGY, V53, P1431, DOI 10.1212/WNL.53.7.1431; Corry IS, 1999, GAIT POSTURE, V10, P206, DOI 10.1016/S0966-6362(99)00037-5; Dauer WT, 1998, BRAIN, V121, P547, DOI 10.1093/brain/121.4.547; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; Goldstein EM, 2001, J CHILD NEUROL, V16, P16, DOI 10.1177/088307380101600104; Gordon N, 1999, BRAIN DEV-JPN, V21, P147, DOI 10.1016/S0387-7604(98)00099-0; Gormley ME, 2001, J CHILD NEUROL, V16, P113, DOI 10.2310/7010.2001.6901; Gormley ME, 1997, MUSCLE NERVE, pS14; Gracies JM, 1997, MUSCLE NERVE, pS92; GRACIES JM, 1997, MUSCLE NERVE       S, V6, pS61; Graham HK, 2000, GAIT POSTURE, V11, P67, DOI 10.1016/S0966-6362(99)00054-5; Hesse S, 2001, DRUG AGING, V18, P255, DOI 10.2165/00002512-200118040-00003; Hyman N, 2000, J NEUROL NEUROSUR PS, V68, P707, DOI 10.1136/jnnp.68.6.707; Kesselring J, 1997, BAILLIERE CLIN NEUR, V6, P429; Kirazli Y, 1998, AM J PHYS MED REHAB, V77, P510, DOI 10.1097/00002060-199811000-00012; KIRSCHNER J, 2001, J NEUROL S1, V248; Kita M, 2000, DRUGS, V59, P487, DOI 10.2165/00003495-200059030-00006; Koman LA, 2000, J PEDIATR ORTHOPED, V20, P108, DOI 10.1097/00004694-200001000-00022; Lagalla G, 2000, AM J PHYS MED REHAB, V79, P377, DOI 10.1097/00002060-200007000-00010; Lew MF, 2000, NEUROLOGY, V55, pS29; Mahant N, 2000, J CLIN NEUROSCI, V7, P389, DOI 10.1054/jocn.2000.0684; Mayer NH, 1997, MUSCLE NERVE, pS1; METAXIOTIS D, 2002, CLIN ORTHOP RELAT R, V394, P177; OBRIEN C, 2002, INT C 2002 BAS THER; OBrien CF, 1996, DRUG AGING, V9, P332, DOI 10.2165/00002512-199609050-00004; Pavesi G, 1998, J NEUROL NEUROSUR PS, V64, P419, DOI 10.1136/jnnp.64.3.419; Ruiz PJG, 2000, EUR J NEUROL, V7, P191, DOI 10.1046/j.1468-1331.2000.00043.x; Sampaio C, 1997, CLIN REHABIL, V11, P3, DOI 10.1177/026921559701100102; Schapiro R T, 2001, Curr Neurol Neurosci Rep, V1, P299, DOI 10.1007/s11910-001-0034-6; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; Simpson DM, 2000, MUSCLE NERVE, V23, P447, DOI 10.1002/(SICI)1097-4598(200004)23:4<447::AID-MUS1>3.0.CO;2-J; Wang HC, 2002, AM J PHYS MED REHAB, V81, P272, DOI 10.1097/00002060-200204000-00005; Watanabe Y, 1998, DISABIL REHABIL, V20, P62, DOI 10.3109/09638289809166055; Wissel J, 2000, J PAIN SYMPTOM MANAG, V20, P44, DOI 10.1016/S0885-3924(00)00146-9; Wong V, 2002, J CHILD NEUROL, V17, P138, DOI 10.1177/088307380201700210; Wong V, 1998, PEDIATR NEUROL, V18, P124, DOI 10.1016/S0887-8994(97)00164-1; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939; 2002, SUGGESTED ADULT MYOB	48	50	51	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-8047	1536-5409		CLIN J PAIN	Clin. J. Pain	NOV-DEC	2002	18	6		S			S182	S190		10.1097/00002508-200211001-00011			9	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	614AV	WOS:000179165400011	12569967				2021-06-18	
J	Constantinidou, F; Baker, S				Constantinidou, F; Baker, S			Stimulus modality and verbal learning performance in normal aging	BRAIN AND LANGUAGE			English	Article						stimulus modality; working memory; delay; interference; recall retrieval; recognition; learning styles	CLOSED-HEAD INJURY; WORKING-MEMORY; MODERATE; ADULTS; YOUNG	The present study investigated the effects of modality presentation on the verbal learning performance of 26 older adults and 26 younger cohorts. A multitrial free-recall paradigm was implemented incorporating three modalities: Auditory, Visual, and simultaneous Auditory plus Visual. Older subjects learned fewer words than younger subjects but their rate of learning was similar to that of the younger group. The visual presentation of objects (with or without the simultaneous auditory presentation of names) resulted in better learning, recall, and retrieval of information than the auditory presentation alone. (C) 2002 Elsevier Science (USA). All rights reserved.	Miami Univ, Dept Speech Pathol & Audiol, Oxford, OH 45056 USA; Univ Florida, Dept Commun Sci & Disorders, Gainesville, FL USA	Constantinidou, F (corresponding author), Miami Univ, Dept Speech Pathol & Audiol, 2 Bachelor Hall, Oxford, OH 45056 USA.			Constantinidou, Fofi/0000-0002-7928-8363			ALESANDRINI KL, 1981, J EDUC PSYCHOL, V73, P358, DOI 10.1037/0022-0663.73.3.358; Baddeley A, 1999, BRAIN COGNITION, V41, P87, DOI 10.1006/brcg.1999.1097; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Constantinidou F, 1999, J MED SPEECH-LANG PA, V7, P283; Constantinidou F, 1996, J GEN PSYCHOL, V123, P173, DOI 10.1080/00221309.1996.9921270; CONSTANTINIDOU F, 1995, J HEAD TRAUMA REHAB, V10, P90, DOI 10.1097/00001199-199508000-00009; Craik F.I.M., 1991, MEMORY DISORDERS RES; Craik F.I.M., 1986, HUMAN MEMORY COGNITI; CRAIK FIM, 1992, HDB AGING COGNITION; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; DELIS DC, 1987, CALIF VERBAL LEARNIN; Diller L., 1974, STUDIES COGNITION RE; ELBERT M, 1980, CONTRASTS PICTURE FI; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; JONES SJ, 1994, Q J EXP PSYCHOL-A, V47, P1001, DOI 10.1080/14640749408401104; Kasniak A.W., 1986, HDB CLIN MEMORY ASSE; King DA, 1998, J INT NEUROPSYCH SOC, V4, P115, DOI 10.1017/S1355617798001155; KIRBY JR, 1988, CONTEMP EDUC PSYCHOL, V13, P169, DOI 10.1016/0361-476X(88)90017-3; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; ODONNELL JP, 1988, J GEN PSYCHOL, V115, P355, DOI 10.1080/00221309.1988.9710572; Paivio A., 1976, MENTAL REPRESENTATIO; Paivio A., 1971, IMAGERY VERBAL PROCE; Richardson A., 1977, J MENTAL IMAGERY, V1, P109; Riding R., 1991, ED PSYCHOL, V11, P193; Riding R.J., 1996, EDUC PSYCHOL-UK, V16, P81; SCHOFIELD NJ, 1994, COGNITION INSTRUCT, V12, P35, DOI 10.1207/s1532690xci1201_2; SHARPS MJ, 1988, J GERONTOL, V43, pP8, DOI 10.1093/geronj/43.1.P8; SHARPS MJ, 1991, PSYCHOL AGING, V6, P309, DOI 10.1037/0882-7974.6.2.309; Swanson HL, 1999, DEV PSYCHOL, V35, P986, DOI 10.1037/0012-1649.35.4.986; Thorndike EL, 1944, TEACHERS BOOK 30000; Wechsler D., 1987, WECHSLER MEMORY SCAL	32	50	50	1	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	SEP	2002	82	3					296	311	PII S0093-934X(02)00018-4	10.1016/S0093-934X(02)00018-4			16	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	587WV	WOS:000177667800002	12160526				2021-06-18	
J	Kinoshita, K; Kraydieh, S; Alonso, O; Hayashi, N; Dietrich, WD				Kinoshita, K; Kraydieh, S; Alonso, O; Hayashi, N; Dietrich, WD			Effect of posttraumatic hyperglycemia on contusion volume and neutrophil accumulation after moderate fluid-percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						fluid-percussion; hyperglycemia; inflammation; neutrophil accumulation; secondary injury; traumatic brain injury	CEREBRAL-ARTERY OCCLUSION; ISCHEMIC CELL-DAMAGE; CULTURED ENDOTHELIAL-CELLS; CONTROLLED CORTICAL IMPACT; ADHESION MOLECULES; OXIDATIVE STRESS; POLYMORPHONUCLEAR LEUKOCYTES; GLUCOSE-CONCENTRATION; FOREBRAIN ISCHEMIA; REPERFUSION INJURY	The purpose of this study was to evaluate the effects of posttraumatic hyperglycemia on contusion volume and neutrophil accumulation following moderate traumatic brain injury (TBI) in rats. A parasagittal fluid-percussion (F-P) brain injury (1.8-2.1 atm) was induced in male Sprague-Dawley rats. Rats were then randomized into four trauma groups (n = 7/group) by the timing of dextrose injection (2.0 gm/kg/ip), which included (1) early (E) group: 5 min after TBI; (2) delayed (D) group: 4 h after TBI; (3) 24-h group: 24 h after TBI; or (4) control (C) group: no dextrose injection. A sham operated control group also received dextrose to document physiological parameters (n = 4). Rats were perfusion fixed 3 days following TBI, and the brains were processed for routine histopathological and immunocytochemical analysis. Contusion areas and volumes, as well as the frequency of myeloperoxidase immunoreactive polymorphonuclear leukocytes (PMNLs) were determined. Dextrose injections significantly increased blood glucose levels (p < 0.005) in all treated groups. Although acute hyperglycemia following TBI did not significantly affect total contusion volume, contusion area was significantly elevated in the early treatment group. In addition, early posttraumatic hyperglycemia enhanced neutrophil accumulation in the area of the cortical contusion (p < 0.005). In contrast, delayed induced hyperglycemia (i.e., 4 h, 24 h) did not significantly affect histopathological outcome or neutrophil accumulation. Taken together, these findings indicate that acute but not delayed hyperglycemia aggravates histopathological outcome and increased accumulation of PMNLs. Posttraumatic hyperglycemia in the acute phase may worsen traumatic outcome by enhancing secondary injury processes, including inflammation.	Univ Miami, Sch Med, Miami Project Cure Paralysis R 48, Miami, FL 33101 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis R 48, POB 016960, Miami, FL 33101 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30261] Funding Source: Medline		Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BAUMGARTNERPARZER SM, 1995, DIABETOLOGIA, V38, P1367; BEYNON HLC, 1993, CLIN EXP IMMUNOL, V91, P314; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Ceriello A, 1996, METABOLISM, V45, P498, DOI 10.1016/S0026-0495(96)90226-7; Ceriello A, 1997, DIABETIC MED, V14, pS45, DOI 10.1002/(SICI)1096-9136(199708)14:3+<S45::AID-DIA444>3.3.CO;2-I; Ceriello A, 1998, HORM METAB RES, V30, P146, DOI 10.1055/s-2007-978854; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; Cherian L, 1998, J NEUROTRAUM, V15, P1059, DOI 10.1089/neu.1998.15.1059; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DECOURTENMYERS G, 1988, STROKE, V19, P623, DOI 10.1161/01.STR.19.5.623; DECOURTENMYERS GM, 1989, STROKE, V20, P1707, DOI 10.1161/01.STR.20.12.1707; DECOURTENMYERS GM, 1994, J CEREBR BLOOD F MET, V14, P227, DOI 10.1038/jcbfm.1994.29; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1993, STROKE, V24, P111, DOI 10.1161/01.STR.24.1.111; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; FOLBERGROVA J, 1992, J CEREBR BLOOD F MET, V12, P25, DOI 10.1038/jcbfm.1992.4; Giardino I, 1996, J CLIN INVEST, V97, P1422, DOI 10.1172/JCI118563; GINSBERG MD, 1987, STROKE, V18, P570, DOI 10.1161/01.STR.18.3.570; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; Gisselsson L, 1999, J CEREBR BLOOD F MET, V19, P288, DOI 10.1097/00004647-199903000-00007; GLABINSKI AR, 1995, INT J DEV NEUROSCI, V13, P153, DOI 10.1016/0736-5748(95)00017-B; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; HARIK SI, 1988, J NEUROCHEM, V51, P1924, DOI 10.1111/j.1471-4159.1988.tb01179.x; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; Hartleb M, 1997, LIVER, V17, P1; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hudome S, 1997, PEDIATR RES, V41, P607, DOI 10.1203/00006450-199705000-00002; HURN PD, 1991, AM J PHYSIOL, V261, pH853; Jean WC, 1998, NEUROSURGERY, V43, P1382, DOI 10.1097/00006123-199812000-00076; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; Kawai N, 1997, STROKE, V28, P149, DOI 10.1161/01.STR.28.1.149; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kent TA, 2001, STROKE, V32, P2318, DOI 10.1161/hs1001.096588; Kim JS, 1996, J NEUROL SCI, V137, P69, DOI 10.1016/0022-510X(95)00338-3; Kishimoto T K, 1994, Adv Pharmacol, V25, P117, DOI 10.1016/S1054-3589(08)60431-7; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KRAFT SA, 1990, STROKE, V21, P447, DOI 10.1161/01.STR.21.3.447; KRAIG RP, 1986, AM J PHYSIOL, V250, P348; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Li PA, 1997, ACTA PHYSIOL SCAND, V161, P567, DOI 10.1046/j.1365-201X.1997.00264.x; Lin BW, 1998, ACTA NEUROPATHOL, V96, P610, DOI 10.1007/s004010050942; Lin BW, 2000, NEUROSCI LETT, V278, P1, DOI 10.1016/S0304-3940(99)00889-7; Marfella R, 2000, CIRCULATION, V101, P2247, DOI 10.1161/01.CIR.101.19.2247; MARMAROU A, 1992, J NEUROTRAUM, V9, P551; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; McIntosh TK, 1996, LAB INVEST, V74, P315; MCLEOD DS, 1995, AM J PATHOL, V147, P642; MERGUERIAN P, 1981, CRIT CARE MED, V9, P939; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; MYERS RE, 1977, ARCH NEUROL-CHICAGO, V34, P65, DOI 10.1001/archneur.1977.00500140019003; Myers RE, 1979, ADV PERINATAL NEUROL, V1, P85; NEDERGAARD M, 1987, BRAIN RES, V408, P79, DOI 10.1016/0006-8993(87)90360-X; Nishikawa T, 2000, NATURE, V404, P787; NORDSTROM C, 1976, ACTA PHYSL SCAND, V98, P248; PALJARVI L, 1983, ACTA NEUROPATHOL, V60, P232, DOI 10.1007/BF00691871; Panes J, 1996, CIRCULATION, V93, P161, DOI 10.1161/01.CIR.93.1.161; Pieper GM, 1997, J CARDIOVASC PHARM, V30, P528, DOI 10.1097/00005344-199710000-00019; PIEPER GM, 1995, AM J PHYSIOL-HEART C, V269, pH845; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; RICHARDSON M, 1994, ARTERIOSCLER THROMB, V14, P760, DOI 10.1161/01.ATV.14.5.760; ROBERTSON C, 1992, STROKE, V23, P564, DOI 10.1161/01.STR.23.4.564; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Siesjo BK, 1996, ACT NEUR S, V66, P8; SIESJO BK, 1985, J CEREBR BLOOD F MET, V5, P253, DOI 10.1038/jcbfm.1985.32; SMITH ML, 1988, ACTA NEUROPATHOL, V76, P253, DOI 10.1007/BF00687772; Soares HD, 1995, J NEUROSCI, V15, P8223; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; TONNESEN MG, 1988, MOL CELLULAR BIOL WO, P149; Vink R, 1997, J CEREBR BLOOD F MET, V17, P50, DOI 10.1097/00004647-199701000-00007; WAGNER KR, 1992, J CEREBR BLOOD F MET, V12, P213, DOI 10.1038/jcbfm.1992.31; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; WARNER DS, 1995, STROKE, V26, P655, DOI 10.1161/01.STR.26.4.655; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; ZASSLOW MA, 1989, STROKE, V20, P519, DOI 10.1161/01.STR.20.4.519; ZILLES KJL, 1985, CORTEX BRAIN STEREOT	93	50	54	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2002	19	6					681	692		10.1089/08977150260139075			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	569EZ	WOS:000176588900001	12165130				2021-06-18	
J	Cvek, M; Mejare, I; Andreasen, JO				Cvek, M; Mejare, I; Andreasen, JO			Healing and prognosis of teeth with intraalveolar fractures involving the cervical part of the root	DENTAL TRAUMATOLOGY			English	Article						dental trauma; permanent teeth; root fractures	PERMANENT	Healing and long-term prognosis of 94 cervical root fractures were evaluated. The teeth were divided into two groups according to type of fracture: transverse fractures limited to the cervical third of the root (51 incisors) and oblique fractures involving both the cervical and middle parts of the root (43 incisors). Neither the frequency nor the type of fracture healing differed significantly between the two groups. In the material as a whole, healing of the fracture with hard tissue formation was observed in 17 teeth (18%), and healing with interposition of periodontal ligament (PDL) and, in some cases, hard tissue between the fragments in 62 teeth (66%). Fifteen teeth (16%) showed no healing and a radiolucency adjacent to the fracture. Statistical analyses revealed that incomplete root formation and a positive sensibility test at the time of injury were significantly related to both healing and hard tissue repair. The same applied to concussion or subluxation compared with dislocation of coronal fragment, as well as optimal compared with suboptimal reposition of displaced coronal fragments. The type and duration of splinting (or no splinting) appeared to be of no significance for frequency or type of healing of cervical root fractures. During the observation time (mean = 75 months), 19 (44%) of the teeth with transverse fractures and 3 (8%) of those with oblique fractures were lost after healing. In conclusion, fractures in the cervical part of the root had a healing potential and the predictive parameters identified for fractures in other parts of the root seemed to be valid for the healing of cervical root fractures. Transverse fractures appeared to have a significantly poorer long-term prognosis compared to oblique fractures, apparently due to a marked post-treatment mobility, which often led to new luxation caused by even minor impacts.	Eastman Dent Inst, Dept Pedodont, S-11324 Stockholm, Sweden; Rigshosp, Dept Oral & Maxillofacial Surg, DK-2100 Copenhagen, Denmark	Mejare, I (corresponding author), Eastman Dent Inst, Dept Pedodont, Dalagatan 11, S-11324 Stockholm, Sweden.						ANDREASEN FM, 1989, ENDOD DENT TRAUMATOL, V5, P11; ANDREASEN FM, 1994, TXB COLOR ATLAS TRAU, P301; ANDREASEN J O, 1971, Journal of Dentistry for Children, V38, P29; ANDREASEN JO, 1967, J ORAL SURG, V25, P414; Austin LT., 1930, JADA, V17, P1930; BENATI FW, 1994, OKLA DENT ASS J, V85, P30; Cvek M, 2001, DENT TRAUMATOL, V17, P53, DOI 10.1034/j.1600-9657.2001.017002053.x; Feiglin B, 1995, Dent Clin North Am, V39, P53; Lindahl B., 1958, ODONTOL REVY, V9, P10; Ravn J J, 1976, Tandlaegebladet, V80, P391; VERGARAEDWARDS I, 1960, REV STOMAT, V61, P794; YATES JA, 1992, INT ENDOD J, V25, P150, DOI 10.1111/j.1365-2591.1992.tb00778.x; ZACHRISSON BU, 1975, SCAND J DENT RES, V83, P345; Zerman N, 1990, Minerva Stomatol, V39, P307	14	50	50	0	8	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	1600-4469			DENT TRAUMATOL	Dent. Traumatol.	APR	2002	18	2					57	65		10.1034/j.1600-9657.2002.180202.x			9	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	540LU	WOS:000174931100002	12184212				2021-06-18	
J	Kumar, A; Zou, LL; Yuan, XQ; Long, Y; Yang, K				Kumar, A; Zou, LL; Yuan, XQ; Long, Y; Yang, K			N-methyl-D-aspartate receptors: Transient loss of NR1/NR2A/NR2B subunits after traumatic brain injury in a rodent model	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						N-methyl-D-aspartate receptor; hippocampus; brain injury; memory; rodent model	CORTICAL IMPACT INJURY; NMDA RECEPTORS; RAT-BRAIN; MEDIATED REGULATION; CALPAIN ACTIVATION; MESSENGER-RNA; EXPRESSION; MEMORY; CELLS; NR1	Hippocampal N-methyl-D-aspartate (NMDA) receptor subunits, by virtue of their involvement in excitotoxic injury as well as memory association, may play an important role in the pathophysiologic mechanisms of traumatic brain injury (TBI). In this study, temporal changes in NMDA receptor subunit (NR1, NR2A, and NR2B) levels in rat hippocampus after TBI were investigated by Western blot and mRNA expression levels by RT-PCR methods. Sprague-Dawley rats (250-350 g) were employed, and a controlled cortical impact injury device was used to produce the TBI in rodents. At different postinjury time points (2, 6, 12, 24, and 48 hr), the rat hippocampi were dissected out for protein and RNA preparation. Western blot analysis revealed significant decreases of NR1, NR2A, and NR2B subunit proteins at 6 and 12 hr postinjury in rat hippocampus. Complete recovery of NR1, NR2A, and NR2B subunit protein to the levels of sham controls was observed at 24 hr postinjury. However, RT-PCR analysis did not show any significant change in the mRNA levels at 2, 6, and 12 hr postinjury in comparison with sham controls, suggesting nontranscriptional change in the levels of these subunits. Thus, TBI can produce transient degradation of NMDA receptor subunits in the hippocampus, which might contribute to temporary memory impairment after injury. (C) 2002 Wiley-Liss, Inc.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Dept Vet Affairs Med Ctr, Neurol Care Line, Houston, TX USA	Yang, K (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS35502-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035502] Funding Source: NIH RePORTER		Bi XN, 1996, BRAIN RES, V726, P98, DOI 10.1016/0006-8993(95)01360-1; Bi XN, 1998, BRAIN RES, V790, P245, DOI 10.1016/S0006-8993(98)00067-5; Bi XN, 2000, METH MOL B, V144, P203; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gellerman DM, 1997, J NEUROCHEM, V69, P131; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kim WT, 1998, BRAIN RES, V799, P49, DOI 10.1016/S0006-8993(98)00464-8; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Lu XY, 2001, J NEUROCHEM, V77, P1553, DOI 10.1046/j.1471-4159.2001.00359.x; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nakao Y, 2001, J THORAC CARDIOV SUR, V122, P136, DOI 10.1067/mtc.2001.114101; Takagi N, 1997, J NEUROCHEM, V69, P1060; Tang YP, 1999, NATURE, V401, P63; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; Zhang L, 1997, J NEUROCHEM, V69, P1983; Zou LL, 1999, GENE THER, V6, P994, DOI 10.1038/sj.gt.3300936	25	50	78	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAR 15	2002	67	6					781	786		10.1002/jnr.10181			6	Neurosciences	Neurosciences & Neurology	526ZC	WOS:000174158700010	11891792				2021-06-18	
J	Chapman, J; Korczyn, AD; Karussis, DM; Michaelson, DM				Chapman, J; Korczyn, AD; Karussis, DM; Michaelson, DM			The effects of APOE genotype on age at onset and progression of neurodegenerative diseases	NEUROLOGY			English	Article							APOLIPOPROTEIN-E EPSILON-4; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN INJURY; MOTOR-NEURON DISEASE; AMYLOID BETA-PROTEIN; E TYPE-4 ALLELE; ALZHEIMERS-DISEASE; MULTIPLE-SCLEROSIS; COGNITIVE DECLINE; E POLYMORPHISM	APOE genotype influences the age at onset of some neurodegenerative diseases such as AD and the rate of progression in others such as MS. The authors hypothesize that APOE genotype ubiquitously determines the efficacy of neuronal maintenance and repair in these diseases and that the seemingly divergent clinical effects are due to the stage of disease at which the diagnosis is made. Early diagnosis facilitates the measurement of effects on disease progression rate, whereas late diagnosis results in a marked effect of APOE genotype on disease onset.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69789 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Dept Neurol, IL-69978 Tel Aviv, Israel; Hadassah Med Ctr, Dept Neurol, IL-91120 Jerusalem, Israel	Michaelson, DM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69789 Tel Aviv, Israel.		Korczyn, Amos D/C-3461-2017; Chapman, Joab/E-4598-2010	Korczyn, Amos D/0000-0003-0125-2579; 			AlChalabi A, 1996, LANCET, V347, P159, DOI 10.1016/S0140-6736(96)90343-8; Arai H, 1997, GERONTOLOGY, V43, P2; BASUN H, 1995, NEUROSCI LETT, V183, P32, DOI 10.1016/0304-3940(94)11107-T; Basun H, 1996, STROKE, V27, P1310, DOI 10.1161/01.STR.27.8.1310; Birnbaum M, 2000, NEUROLOGY, V54, pA341; Breitner JCS, 1999, NEUROLOGY, V53, P321, DOI 10.1212/WNL.53.2.321; Buttini M, 1999, J NEUROSCI, V19, P4867; Camicioli R, 1999, DEMENT GERIATR COGN, V10, P437, DOI 10.1159/000017186; Chapman J, 1999, ARCH NEUROL-CHICAGO, V56, P1484, DOI 10.1001/archneur.56.12.1484; Chapman J, 2000, NEUROLOGY, V54, pA348; Chapman J, 1998, NEUROLOGY, V51, P548, DOI 10.1212/WNL.51.2.548; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Craft S, 1998, NEUROLOGY, V51, P149, DOI 10.1212/WNL.51.1.149; DalForno G, 1996, ARCH NEUROL-CHICAGO, V53, P345; Evangelou N, 1999, J NEUROL NEUROSUR PS, V67, P203, DOI 10.1136/jnnp.67.2.203; Fazekas F, 2000, J NEUROL NEUROSUR PS, V69, P25, DOI 10.1136/jnnp.69.1.25; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GEARING M, 1995, NEUROLOGY, V45, P1985, DOI 10.1212/WNL.45.11.1985; GomezIsla T, 1996, ANN NEUROL, V39, P62, DOI 10.1002/ana.410390110; Growdon JH, 1996, NEUROLOGY, V47, P444, DOI 10.1212/WNL.47.2.444; Harhangi BS, 2000, NEUROLOGY, V54, P1272, DOI 10.1212/WNL.54.6.1272; Helisalmi S, 1996, NEUROSCI LETT, V205, P61, DOI 10.1016/0304-3940(96)12373-9; Hogh P, 2000, MULT SCLER J, V6, P226, DOI 10.1191/135245800678827851; Holmes C, 1996, J NEUROL NEUROSUR PS, V61, P580, DOI 10.1136/jnnp.61.6.580; Hyman BT, 1996, ANN NY ACAD SCI, V802, P1, DOI 10.1111/j.1749-6632.1996.tb32592.x; Inzelberg R, 1998, ALZ DIS ASSOC DIS, V12, P45, DOI 10.1097/00002093-199803000-00007; Jonker C, 1998, ARCH NEUROL-CHICAGO, V55, P1065, DOI 10.1001/archneur.55.8.1065; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kanai M, 1999, NEUROSCI LETT, V267, P65, DOI 10.1016/S0304-3940(99)00323-7; Kehoe P, 1999, J MED GENET, V36, P108; Kurz A, 1996, NEUROLOGY, V47, P440, DOI 10.1212/WNL.47.2.440; Kurz A, 1996, J NEUROL, V243, P452, DOI 10.1007/BF00900498; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; MARTINOLI MG, 1995, ACTA NEUROPATHOL, V90, P239; Moulard B, 1996, J NEUROL SCI, V139, P34, DOI 10.1016/0022-510X(96)00085-8; MUI S, 1995, ANN NEUROL, V38, P460, DOI 10.1002/ana.410380318; Murman DL, 1996, DEMENTIA, V7, P251, DOI 10.1159/000106888; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Oliveri RL, 1999, NEUROSCI LETT, V277, P83, DOI 10.1016/S0304-3940(99)00853-8; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Roses AD, 1997, ANN NY ACAD SCI, V826, P200, DOI 10.1111/j.1749-6632.1997.tb48471.x; ROSES AD, 1996, A REV MED, V47, P378; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schiefermeier M, 2000, BRAIN, V123, P585, DOI 10.1093/brain/123.3.585; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Slooter AJC, 1999, J NEUROL, V246, P304, DOI 10.1007/s004150050351; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Smith RG, 1996, LANCET, V348, P334, DOI 10.1016/S0140-6736(05)64502-3; Stern Y, 1997, ANN NEUROL, V41, P615, DOI 10.1002/ana.410410510; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Sylantiev C, 1998, NEUROLOGY, V50, pA150; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TERRY RD, 1994, PROG BRAIN RES, V101, P383; Whitehead AS, 1996, J NEUROL NEUROSUR PS, V61, P347, DOI 10.1136/jnnp.61.4.347	58	50	52	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	OCT 23	2001	57	8					1482	1485		10.1212/WNL.57.8.1482			4	Clinical Neurology	Neurosciences & Neurology	484GH	WOS:000171681500023	11673593				2021-06-18	
J	Clark, RSB; Chen, MZ; Kochanek, PM; Watkins, SC; Jin, KL; Draviam, R; Nathaniel, PD; Pinto, R; Marion, DW; Graham, SH				Clark, RSB; Chen, MZ; Kochanek, PM; Watkins, SC; Jin, KL; Draviam, R; Nathaniel, PD; Pinto, R; Marion, DW; Graham, SH			Detection of single- and double-strand DNA breaks after traumatic brain injury in rats: Comparison of in situ labeling techniques using DNA polymerase 1, the Klenow fragment of DNA polymerase 1, and terminal deoxynucleotidyl transferase	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; controlled cortical impact; Klenow; PANT; TUNEL	CORTICAL IMPACT INJURY; APOPTOTIC CELL-DEATH; CLOSED-HEAD INJURY; NEURONAL APOPTOSIS; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASE; MITOCHONDRIAL DYSFUNCTION; ENDONUCLEASE ACTIVITY; CEREBRAL-ISCHEMIA; DAMAGING AGENTS	DNA damage is a common sequela of traumatic brain injury (TBI). Available techniques for the in situ identification of DNA damage include DNA polymerase I-mediated biotin-dATP nick-translation (PANT), the Klenow fragment of DNA polymerase I-mediated biotin-dATP nick-end labeling (Klenow), and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL). While TUNEL has been widely utilized to detect primarily double-strand DNA breaks, the use of PANT to detect primarily single-strand DNA breaks and Klenow to detect both single- and double-strand DNA breaks has not been reported after TBI. Accordingly, coronal brain sections from naive rats and rats at 0, 0.5, 1, 2, 6, 24, and 72 h (n = 3-5/group) after controlled cortical impact with imposed secondary insult were processed using the PANT, Klenow, and TUNEL methods. Cells with DNA breaks were detected by PANT in the ipsilateral hemisphere as early as 0.5 h after injury and were maximal at 6 h (cortex = 66.3 +/- 15.8, dentate gyrus 58.6 +/- 12.8, CAI = 15.8 +/- 5.9, CA3 = 12.8 +/- 4.2 cells/ x 400 field, mean +/- SEM, all p < 0.05 versus naive). Cells with DNA breaks were detected by Klenow as early as 30 min and were maximal at 24 h (cortex = 56.3 +/- 14.3, dentate gyrus 78.0 +/- 16.7, CA1 = 25.8 +/- 4.7, CA3 = 29.3 +/- 15.1 cells/ x 400 field, all p < 0.05 versus naive). Cells with DNA breaks were not detected by TUNEL until 2 h and were maximal at 24 h (cortex = 47.7 +/- 21.4, dentate gyrus 63.0 +/- 11.9, CA1 = 5.6 +/- 5.4, CA3 = 6.9 +/- 3.7 cells/x400 field, cortex and dentate gyrus p < 0.05 versus naive). Dual-label immunofluorescence revealed that PANT-positive cells were predominately neurons. These data demonstrate that TBI results in extensive DNA damage, which includes both single- and double-strand breaks in injured cortex and hippocampus. The presence of multiple types of DNA breaks implicate several pathways in the evolution of DNA damage after TBI.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA	Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@anes.upmc.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; watkins, simon/0000-0003-4092-1552	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD028836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001946, R01NS038620, P50NS030318] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD28836] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [KO8 NS01946, P50 NS30318, R01 NS 38620] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BRYANT PE, 1985, INT J RADIAT BIOL, V48, P55, DOI 10.1080/09553008514551061; CHARRIAUTMARLANGUE C, 1995, J CEREBR BLOOD F MET, V15, P385, DOI 10.1038/jcbfm.1995.48; Chavez JC, 2000, J APPL PHYSIOL, V89, P1937; Chen J, 1997, J NEUROCHEM, V69, P232; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; COULTON GR, 1992, J CELL SCI, V102, P653; Didier M, 1996, J NEUROSCI, V16, P2238; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Edwards M, 1998, J NEUROSCI RES, V54, P635, DOI 10.1002/(SICI)1097-4547(19981201)54:5<635::AID-JNR8>3.3.CO;2-8; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gobbel GT, 1998, J NEUROSCI, V18, P147; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P475, DOI 10.1016/0006-291X(73)90736-5; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; Jin KL, 1999, J NEUROCHEM, V72, P1204, DOI 10.1046/j.1471-4159.1999.0721204.x; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Lan J, 2000, J NEUROCHEM, V74, P302, DOI 10.1046/j.1471-4159.2000.0740302.x; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; MacManus JP, 1999, J CEREBR BLOOD F MET, V19, P502, DOI 10.1097/00004647-199905000-00004; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; Nagayama T, 2000, J NEUROCHEM, V75, P1716, DOI 10.1046/j.1471-4159.2000.0751716.x; Park DS, 1998, J NEUROSCI, V18, P830; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; Pearigen P, 1996, BRAIN RES, V725, P184; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; RADFORD IR, 1985, INT J RADIAT BIOL, V48, P45, DOI 10.1080/09553008514551051; RINK A, 1995, AM J PATHOL, V147, P1575; Rossiter JP, 1996, EXP NEUROL, V138, P33, DOI 10.1006/exnr.1996.0044; Shackelford DA, 1999, J NEUROSCI, V19, P4727; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Tagaya M, 1997, STROKE, V28, P1245, DOI 10.1161/01.STR.28.6.1245; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; WARD JF, 1985, RADIAT RES, V103, P383, DOI 10.2307/3576760; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yuan JL, 2000, CANCER RES, V60, P4372; Zhang C, 1999, J NEUROCHEM, V73, P1650, DOI 10.1046/j.1471-4159.1999.0731650.x; ZHANG J, 1995, J NEUROCHEM, V65, P1411; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	56	50	51	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2001	18	7					675	689		10.1089/089771501750357627			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	457CK	WOS:000170119400004	11497094				2021-06-18	
J	McCullagh, S; Ouchterlony, D; Protzner, A; Blair, N; Feinstein, A				McCullagh, S; Ouchterlony, D; Protzner, A; Blair, N; Feinstein, A			Prediction of neuropsychiatric outcome following mild trauma brain injury: an examination of the Glasgow Coma Scale	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; POSTTRAUMATIC AMNESIA; RATING-SCALE; PRACTICAL SCALE; GENERAL HEALTH; SEQUELAE; QUESTIONNAIRE; SYMPTOMS; RECOVERY; RISK	The relationship between the Glasgow Coma Scale (GCS) and neuropsychiatric outcome was examined in 57 consecutive subjects with mild traumatic brain injury (TBI) attending a follow-up clinic. Subjects were grouped according to initial GCS score (15 versus 13-14) and contrasted at an average of 5-6 months post-injury. As expected, those with GCS 13-14 had longer PTA (p = 0.001) and a higher rate of abnormal brain CT scans (p = 0.005). However, no significant differences emerged for indices of neuropsychiatric status, including measures of neurobehavioural symptoms/signs, overall psychological distress, psychiatric 'caseness', functional and psychosocial outcome, frequency of common somatic complaints, and rate of return to work. Subsidiary analyses based upon the presence/absence of CT abnormalities and the duration of PTA (<1 hour versus 1-24 hours) also failed to predict outcome, although a trend associating longer PTA with lower functional outcome was observed. Thus, despite early neurosurgical differences, the results suggest that initial GCS scores do not clearly translate into neuropsychiatric sequelae at follow-up within the rubric of GCS 13-15.	Univ Toronto, Sunnybrook & Womens Coll Hosp, Neuropsychiat Program, Toronto, ON M4N 3M5, Canada	McCullagh, S (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hosp, Neuropsychiat Program, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.			Protzner, Andrea/0000-0001-8062-2923			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIKMEN SS, 1989, MILD HEAD INJURY, P229; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; EVANS RW, 1992, NEUROL CLIN, V10, P815; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KRAUS JF, 1989, MILD HEAD INJURY, P8; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Ocana M, 2000, BRAIN COGNITION, V44, P83, DOI 10.1006/brcg.1999.1211; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Rutherford W. H., 1989, MILD HEAD INJURY, P217; *SPSS INC, 1999, SPSS WIND REL 10 0; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Symonds CP, 1943, LANCET, V1, P7; TEASDALE G, 1974, LANCET, V2, P81; Tellier A, 1999, BRAIN INJURY, V13, P463; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	48	50	51	0	0	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2001	15	6					489	497		10.1080/02699050010007353			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	439VE	WOS:000169137600002	11394968				2021-06-18	
J	Meythaler, JM; Depalma, L; Devivo, MJ; Guin-Renfroe, S; Novack, TA				Meythaler, JM; Depalma, L; Devivo, MJ; Guin-Renfroe, S; Novack, TA			Sertraline to improve arousal and alertness in severe traumatic brain injury secondary to motor vehicle crashes	BRAIN INJURY			English	Article							SEROTONIN UPTAKE INHIBITORS; HEAD-INJURY; RECEPTORS; SYSTEM; SCALE; PHARMACOKINETICS; PHARMACOLOGY; FLUVOXAMINE; ORIENTATION; RECOVERY	Objective: To establish whether or not the serotonin reuptake inhibitor (SSRI) sertraline can improve arousal and alertness of patients with traumatic brain injury (TBI) and associated diffuse axonal injury (DAI). Serotonin is a major inhibitory as well an excitatory neurotransmitter, and serotonergic neurons modulate the activity of brain regions responsible for motor control, arousal, attention, and emotional regulation. Setting: Tertiary care inpatient rehabilitation centre directly attached to a university hospital level-one trauma centre. Design: Prospective placebo-controlled randomized trial utilizing sertraline on admission to acute rehabilitation. Data set: Eleven subjects, post-high speed motor vehicle crash and post-severe TBI (GCS less than or equal to 8) with presumed DAI randomized to receive either sertraline 100 mg per day or placebo for 2 weeks. All subjects were within 2 weeks of acute injury. Outcome measures recorded were the Orientation Log (daily), Agitated Behaviour Scale (daily), and the Galveston Orientation and Amnesia Test (weekly). Results: Both placebo and active medication groups demonstrated similar rates of improvement on all three scales. There was no difference in the rates of recovery for either study group (p > 0.05, ANOVA with repeated measures). The groups did not demonstrate a statistically significant negative effect on recovery either, although the size is too small for a statistically reliable beta-effect. Conclusion: This pilot study fails to establish whether the early use of sertraline may improve alertness, decrease agitation or improve cognitive recall of material. This may be due to the small size of the study group, the brief duration of treatment or by a skewed placebo group. Larger studies will be required to prove any efficacy. There were no complications with its use and sertraline did not demonstrate a detrimental effect on recovery. This indicates that sertraline may be safe to use in the treatment of psychiatric or behavioural complications attributable to TBI.	Univ Alabama Birmingham, Sch Med, Dept Phys Med & Rehabil, Spain Rehabil Ctr, Birmingham, AL 35233 USA	Meythaler, JM (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Phys Med & Rehabil, Spain Rehabil Ctr, 1717 6th Ave S, Birmingham, AL 35233 USA.	jmeythal@uab.com					ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V5, P459; AZMITIA EC, 1990, ANN NY ACAD SCI, V600, P343, DOI 10.1111/j.1749-6632.1990.tb16894.x; Azmitia EC, 1978, HDB PSYCHOPHARMACOLO, P233; CARDENAS DD, 1992, PHYS MED REH CLIN N, V3, P273; Chandler M C, 1988, Brain Inj, V2, P309; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; FULLER RW, 1987, J CLIN PSYCHOPHARM, V7, pS36; GOLDSTEIN LB, 1990, STROKE, V21, P139; GOLDSTEIN LB, 1991, J NEUROL REHABIL, V5, P129; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HRDINA PD, 1991, J PSYCHIATR NEUROSCI, V16, P10; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JACOBS BL, 1990, ANN NY ACAD SCI, V600, P260, DOI 10.1111/j.1749-6632.1990.tb16888.x; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, MANAGEMENT HEAD INJU, P90; LAUDER JM, 1990, ANN NY ACAD SCI, V600, P297, DOI 10.1111/j.1749-6632.1990.tb16891.x; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; Minderhoud JM., 1990, PHYS MED REHABILITAT, V4, P447; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; Novack T A, 1993, NeuroRehabilitation, V3, P79, DOI 10.3233/NRE-1993-3309; OVERMARS H, 1983, EUR J DRUG METAB PH, V8, P269, DOI 10.1007/BF03188757; PALACIOS JM, 1990, ANN NY ACAD SCI, V600, P36, DOI 10.1111/j.1749-6632.1990.tb16871.x; PEROUTKA SJ, 1990, ANN NY ACAD SCI, V600, P104, DOI 10.1111/j.1749-6632.1990.tb16876.x; PRESKORN SH, 1993, J CLIN PSYCHIAT, V54, P14; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1992, J NEUROSURG, V76, pA399; SANDEL ME, 1993, AM J PHYS MED REHAB, V72, P325, DOI 10.1097/00002060-199310000-00013; SCOTT DE, 1995, EXP NEUROL, V131, P23, DOI 10.1016/0014-4886(95)90004-7; SELIGER G M, 1992, Brain Injury, V6, P267, DOI 10.3109/02699059209029668; SLOAN R L, 1992, Brain Injury, V6, P315, DOI 10.3109/02699059209034945; VANHARTEN J, 1993, CLIN PHARMACOKINET, V24, P203, DOI 10.2165/00003088-199324030-00003; WAGNER JC, 1986, ACCOMPLISHMENT ONCOL, V1, P1; Wagner W, 1992, Drugs, V43 Suppl 2, P48; WESTER P, 1990, J NEUROCHEM, V54, P1148, DOI 10.1111/j.1471-4159.1990.tb01942.x; WHITAKERAZMITIA PM, 1990, ANN NY ACAD SCI, V600, P315, DOI 10.1111/j.1749-6632.1990.tb16892.x; WHITAKERAZMITIA PM, 1992, NEUROPHARMACOLOGY SE; Whyte J, 1993, REHABILITATION MED P, P825; WHYTE J, 1988, REHABILITATION MED P, P585; WONG DT, 1983, BIOCHEM PHARMACOL, V32, P1287, DOI 10.1016/0006-2952(83)90284-8	49	50	51	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2001	15	4					321	331		10.1080/026990501750111274			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	420ZK	WOS:000168035000004	11299133				2021-06-18	
J	Bidmon, HJ; Emde, B; Oermann, E; Kubitz, R; Witte, OW; Zilles, K				Bidmon, HJ; Emde, B; Oermann, E; Kubitz, R; Witte, OW; Zilles, K			Heme oxygenase-1 (HSP-32) and heme oxygenase-2 induction in neurons and glial cells of cerebral regions and its relation to iron accumulation after focal cortical photothrombosis	EXPERIMENTAL NEUROLOGY			English	Article						brain; ischemia; glia; oligodendrocytes; thiyl radicals; carbon monoxide; nitrotyrosine; transferrin receptor	NITRIC-OXIDE SYNTHASE; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN INJURY; RAT-BRAIN; PARKINSONS-DISEASE; OXIDATIVE STRESS; CARBON-MONOXIDE; MESSENGER-RNA; IN-VITRO; MEDIATED EXCITOTOXICITY	Cerebral ischemic injury results in the liberation of heme from degenerating heme-containing proteins. The neurotoxic heme is usually detoxified by the constitutive heme oxygenase-a (HO-2) and its inducible isoform HO-l(heat shock protein 32) resulting in the formation of biliverdin which becomes reduced to bilirubin, carbon monoxide (CO), and iron. Biliverdin and bilirubin have antioxidative properties whereas CO is discussed as a signaling molecule, Iron if it remains free could catalyze Haber-Weiss and Fenton reactions causing the formation of highly toxic radicals, We have studied the alterations of cerebral HO-2 and HO-1 in relation to iron accumulations after defined cortical photothrombosis within the hindlimb area of the rat. HO-2 immunohistochemistry showed that the number of HO-2-positive neurons in most perilesional regions remained constant. However, much stronger systemic immunoreactivity for HO-2 was observed between days 1 and 7 postlesion, For HO-1 a systemic increase of immunoreactivity occurred also between days 1 and 7, In addition HO-1-positive astrocytes and microglia appeared as early as 4 h postlesion and increased up to day 3 followed by a sharp decline toward day 14 within the injured hemisphere. HO-1-positive astrocytes and microglia occurred in ipsilateral cortex, corpus callosum, hippocampus, striatum, and thalamic nuclei, Additionally an increase of HO-1 in myelin-associated globulin-positive oligodendrocytes was found in ipsilateral and contralateral cortex, Next to the lesion iron accumulation occurred after day 3 and increased strongly toward day 14 at times when HO-1 and -2 had decreased, suggesting that HO activity does not directly contribute to postlesional iron deposition. (C) 2000 Academic Press.	Univ Dusseldorf, Inst Neuroanat, D-40225 Dusseldorf, Germany; Med Res Ctr, D-52425 Julich, Germany; Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Gastroenterol, D-40225 Dusseldorf, Germany	Bidmon, HJ (corresponding author), Univ Dusseldorf, Inst Neuroanat, Moorenstr 5, D-40225 Dusseldorf, Germany.		Zilles, Karl/Y-3784-2019; Zilles, Karl/J-9704-2013; Witte, Otto/P-4127-2018	Zilles, Karl/0000-0002-4705-4175; Zilles, Karl/0000-0001-9296-9959; Witte, Otto/0000-0003-2101-4105			Adcock LM, 1996, METAB BRAIN DIS, V11, P359, DOI 10.1007/BF02029496; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Bergeron M, 1998, DEV BRAIN RES, V105, P181, DOI 10.1016/S0165-3806(97)00169-7; Bergeron M, 1997, J CEREBR BLOOD F MET, V17, P647; Bidmon HJ, 1998, NEUROSCIENCE, V82, P397; Bidmon HJ, 1998, NEUROSCIENCE, V82, P377; Bidmon HJ, 1997, NEUROSCI LETT, V228, P163, DOI 10.1016/S0304-3940(97)00389-3; BIDMON HJ, 1998, ANN ANAT, V180, P47; BOJE KMK, 1998, NEUROINFLAMMATION ME, P331; Buchkremer-Ratzmann I, 1998, J NEUROL SCI, V156, P133, DOI 10.1016/S0022-510X(98)00034-3; BURCK HC, 1973, HISTOLOGISCHE TECHNI, P145; Coeroli L, 1998, J NEUROCHEM, V70, P2516; Connor JR, 1996, GLIA, V17, P83, DOI 10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7; Deramaudt TB, 1999, P SOC EXP BIOL MED, V222, P185, DOI 10.1046/j.1525-1373.1999.d01-130.x; Dietrich WD, 1998, INT REV NEUROBIOL, V42, P55, DOI 10.1016/S0074-7742(08)60608-X; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Double KL, 1998, J NEUROCHEM, V70, P2492; Eliasson MJL, 1999, J NEUROSCI, V19, P5910, DOI 10.1523/JNEUROSCI.19-14-05910.1999; EWING JF, 1995, BRAIN RES, V672, P29, DOI 10.1016/0006-8993(94)01290-X; Ewing JF, 1997, BRAIN RES PROTOC, V1, P165, DOI 10.1016/S1385-299X(96)00027-X; Foresti R, 1999, FREE RADICAL RES, V31, P459, DOI 10.1080/10715769900301031; FORSTING M, 1994, NEURORADIOLOGY, V36, P264, DOI 10.1007/BF00593255; Gassen M, 1997, PHARMACOL TOXICOL, V80, P159, DOI 10.1111/j.1600-0773.1997.tb00390.x; Gilissen EP, 1998, AM J PRIMATOL, V45, P291, DOI 10.1002/(SICI)1098-2345(1998)45:3<291::AID-AJP5>3.0.CO;2-R; Hempel SL, 1996, ARCH BIOCHEM BIOPHYS, V330, P401, DOI 10.1006/abbi.1996.0268; Ingi T, 1995, J NEUROSCI, V15, P8214; Jellinger KA, 1999, DRUG AGING, V14, P115, DOI 10.2165/00002512-199914020-00004; Johnson RA, 1997, HYPERTENSION, V30, P962, DOI 10.1161/01.HYP.30.4.962; KASARSKIS EJ, 1995, J NEUROL SCI, V130, P203, DOI 10.1016/0022-510X(95)00037-3; Kaur C, 1999, NEUROSCI LETT, V262, P183, DOI 10.1016/S0304-3940(99)00075-0; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; Kitamura Y, 1998, GLIA, V22, P138; Kitamura Y, 1998, LIFE SCI, V62, P1717, DOI 10.1016/S0024-3205(98)00134-9; KOEPPEN AH, 1995, J NEUROPATH EXP NEUR, V54, P395, DOI 10.1097/00005072-199505000-00012; Koistinaho J, 1996, EUR J NEUROSCI, V8, P2265, DOI 10.1111/j.1460-9568.1996.tb01190.x; KONDO Y, 1995, J CEREBR BLOOD F MET, V15, P216, DOI 10.1038/jcbfm.1995.27; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; Kuroki M, 1998, STROKE, V29, P683, DOI 10.1161/01.STR.29.3.683; Liochev SI, 1997, FREE RADICAL BIO MED, V23, P668, DOI 10.1016/S0891-5849(97)00060-9; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Luo YZ, 1996, J BIOL CHEM, V271, P21167, DOI 10.1074/jbc.271.35.21167; Lyons SA, 1998, J CEREBR BLOOD F MET, V18, P521, DOI 10.1097/00004647-199805000-00007; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Mayer AMS, 1998, MEDICINA-BUENOS AIRE, V58, P377; McCord JM, 1998, SEMIN HEMATOL, V35, P5; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Meng W, 1996, AM J PHYSIOL-HEART C, V271, pH1145; Morell Pierre, 1994, P117; MORO V, 1995, NEUROSCIENCE, V69, P797, DOI 10.1016/0306-4522(95)00285-Q; Motterlini R, 1996, AM J PHYSIOL-HEART C, V270, pH107; Nakaso K, 1999, BIOCHEM BIOPH RES CO, V259, P91, DOI 10.1006/bbrc.1999.0724; OBA H, 1993, RADIOLOGY, V189, P843, DOI 10.1148/radiology.189.3.8234713; Palmer C, 1999, J NEUROSCI RES, V56, P60, DOI 10.1002/(SICI)1097-4547(19990401)56:1<60::AID-JNR8>3.0.CO;2-A; Panahian N, 1999, J NEUROCHEM, V72, P1187; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Pappius HM, 1995, NEUROCHEM RES, V20, P1311, DOI 10.1007/BF00992506; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; Qu M, 1998, NEUROSCIENCE, V85, P29, DOI 10.1016/S0306-4522(97)00656-8; Qu MS, 1998, BRAIN RES, V813, P374, DOI 10.1016/S0006-8993(98)01063-4; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Richmon JD, 1998, BRAIN RES, V780, P108, DOI 10.1016/S0006-8993(97)01314-0; ROOS RAC, 1994, HDB CLIN NEUROLOGY 1, V20, P31; Rosenberg PA, 1999, J NEUROCHEM, V73, P476, DOI 10.1046/j.1471-4159.1999.0730476.x; Roseth S, 1998, PEDIATR RES, V44, P312, DOI 10.1203/00006450-199809000-00008; Schipper HM, 1998, EXP NEUROL, V150, P60, DOI 10.1006/exnr.1997.6752; Schipper HM, 1998, EXP NEUROL, V152, P188, DOI 10.1006/exnr.1998.6854; Schmidt J, 1999, MOL BRAIN RES, V73, P50, DOI 10.1016/S0169-328X(99)00231-4; SCHROETER M, 1995, EXP BRAIN RES, V106, P1; Siesjo BK, 1996, ACT NEUR S, V66, P8; Silva CCS, 1999, BRAIN RES, V824, P147, DOI 10.1016/S0006-8993(99)01157-9; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; St'astny F, 1999, NEUROSCI LETT, V262, P105, DOI 10.1016/S0304-3940(99)00061-0; Takahashi A, 1997, ACTA NEUROPATHOL, V93, P354, DOI 10.1007/s004010050627; TRAKSHEL GM, 1986, J BIOL CHEM, V261, P1131; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; Venters HD, 1997, BRAIN RES, V764, P93, DOI 10.1016/S0006-8993(97)00425-3; VIGNE P, 1995, BIOCHEM BIOPH RES CO, V214, P1, DOI 10.1006/bbrc.1995.2248; Witte OW, 1997, ADV NEUROL, V73, P207; YANG L, 1999, LUNG CELL MOL PHYSL, V21, pL127; YASUI M, 1993, NEUROTOXICOLOGY, V14, P445; ZHANG ZG, 1993, STROKE, V24, P2016, DOI 10.1161/01.STR.24.12.2016; Zilles Karl, 1995, P649	85	50	51	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2001	168	1					1	22		10.1006/exnr.2000.7456			22	Neurosciences	Neurosciences & Neurology	406ER	WOS:000167202400001	11170717				2021-06-18	
J	Perino, C; Rago, R; Cicolin, A; Torta, R; Monaco, F				Perino, C; Rago, R; Cicolin, A; Torta, R; Monaco, F			Mood and behavioural disorders following traumatic brain injury: clinical evaluation and pharmacological management	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; DEPRESSION; CARBAMAZEPINE; CITALOPRAM; DYSCONTROL; DIAGNOSIS; PATIENT; MANIA	In order to investigate pharmacotherapeutic responsiveness of major depression and other behavioural disturbances associated with traumatic brain injury (TBI), 20 post-TBI patients were diagnosed as being depressed by two independent neuropsychiatrist observers, out of 37 consecutive TBI subjects sent to psychiatric counselling for poor compliance during rehabilitation programmes or psychiatric/behavioural disturbances after return to society. They were subsequently divided into two subgroups, depending on time elapsed from trauma (A: within 6 months; B: at 24-36 months post-trauma) and were enrolled in an open informed pharmacological study. Rating at baseline included Glasgow Coma Score on hospital admission, length of coma, length of hospitalization, Functional Independence Measure (FIM), Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression scale (CGI). BPRS and CGI were repeated after 12 weeks of oral administration of citalopram (20 mg a day) and carbamazepine (600 mg a day). At baseline, psychiatric symptoms in group B were worse than in group A (particularly somatic overconcern, anxiety, depressed mood, psychomotor slowness, inappropriate and labile affect). At T-1, the global (group A and B combined) CGI and BPRS scores showed a statistically significant improvement when compared with T-0, even if group B scores remained higher than group A. The results of this study suggest that: (a) citalopram combined with carbamazepine is effective in reducing depression and behavioural disorders following TBI, and (b) these disturbances should be addressed as soon as possible during the acute rehabilitation period.	Presidio Sanitario Ausiliatrice, I-10143 Turin, Italy; Univ Turin, Dept Neurosci, Turin, Italy; Univ Amedeo Avogadro, Dept Neurol, Novara, Italy	Perino, C (corresponding author), Presidio Sanitario Ausiliatrice, Via Peyron 42, I-10143 Turin, Italy.			CICOLIN, Alessandro/0000-0001-6196-3925			Azouvi P, 1999, BRAIN INJURY, V13, P797, DOI 10.1080/026990599121188; BakerPrice LA, 1996, PERCEPT MOTOR SKILL, V83, P491, DOI 10.2466/pms.1996.83.2.491; BOBON DP, 1977, FEUILL PSYCHIATR LIE, V10, P339; BUROTN LA, 1992, J NEUROLOGICAL REHAB, V8, P63; CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; CHRISTENSEN BK, 1995, J INT NEUROPSYCH SOC, V1, P122; Cicerone K. D., 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GARDNER DL, 1986, AM J PSYCHIAT, V143, P519; Glenn J K, 1988, J Rural Health, V4, P85, DOI 10.1111/j.1748-0361.1988.tb00315.x; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; GUALTIERI CT, 1995, NEUROPSYCHIATRY PHAR, P110; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; LEWIN J, 1992, BRIT J PSYCHIAT, V161, P261, DOI 10.1192/bjp.161.2.261; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LIPSEY JR, 1983, BRIT J PSYCHIAT, V143, P266, DOI 10.1192/bjp.143.3.266; MARKIANOS M, 1992, ACTA NEUROL SCAND, V86, P190, DOI 10.1111/j.1600-0404.1992.tb05064.x; MILNE RJ, 1991, DRUGS, V41, P450, DOI 10.2165/00003495-199141030-00008; MONACO F, 1984, J INT MED RES, V12, P108, DOI 10.1177/030006058401200208; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Muller U, 1999, BRAIN INJURY, V13, P805, DOI 10.1080/026990599121197; Newburn G, 1999, BRAIN INJURY, V13, P637; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; ROSS ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; SANDER A, 1999, REHABILITATION ADULT, P199; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; STARKSTEIN SE, 1987, ARCH NEUROL-CHICAGO, V44, P1069, DOI 10.1001/archneur.1987.00520220065019; Tan JY, 1999, PHARMACOTHERAPY, V19, P675, DOI 10.1592/phco.19.9.675.31538; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; WROBLEWSKI BA, 1992, AM J PSYCHIAT, V149, P273	41	50	51	0	3	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2001	15	2					139	148		10.1080/026990501458371			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	398BG	WOS:000166733800006	11260764				2021-06-18	
J	Killgore, WDS; DellaPietra, L				Killgore, WDS; DellaPietra, L			Using the WMS-III to detect malingering: Empirical validation of the Rarely Missed Index (RMI)	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							SIMULATED MEMORY IMPAIRMENT; TRAUMATIC BRAIN-INJURY; FORCED-CHOICE METHOD; REY 15-ITEM TEST; NEUROPSYCHOLOGICAL TESTS; HEAD-INJURY; DEFICITS; PERFORMANCE; HISCOCK	To detect malingering during memory assessment, we evaluated item response biases to the Logical Memory Delayed Recognition (LMDR) subtest of the WMS-III. In a sample of 50 healthy volunteers who were completely naive to the content of the Logical Memory stories, 6 LMDR items were correctly endorsed above chance probabilities. These 6 rarely missed items significantly discriminated 51 patients with neurological impairment from 36 volunteers who attempted to feign head injury and poor cognitive performance. A weighted combination of the 6 items was summed to form a single Rarely Missed Index (RMI). The RMI accurately classified over 98% of participants acid demonstrated high sensitivity (97%) and specificity (100%) in discriminating between analog malingerers and patients. Because the RMI is calculated directly from the LMDR items, it has the advantage of requiring no additional administration time or materials, and thus may serve as a quick screen for dissimulation that can be obtained without additional testing.	Harvard Univ, McLean Hosp, Sch Med, Brain Imaging Ctr,Cognit Neuroimaging Lab, Belmont, MA 02478 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Killgore, WDS (corresponding author), Harvard Univ, McLean Hosp, Sch Med, Brain Imaging Ctr,Cognit Neuroimaging Lab, 115 Mill St, Belmont, MA 02478 USA.			Killgore, William/0000-0002-5328-0208			ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; ELLWANGER J, 1993, J CLIN EXPT NEUROPSY, V21, P866; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; KILLGORE WDS, 1998, 18 ANN M NAT ACAD NE; Lee G.P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI [10.1037/1040-3590.4.1.43, DOI 10.1037/1040-3590.4.1.43]; Martin RC, 1998, CLIN NEUROPSYCHOL, V12, P84, DOI 10.1076/clin.12.1.84.1722; MILLIS SR, 1995, CLIN NEUROPSYCHOL, V9, P241, DOI 10.1080/13854049508400486; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; MOSTELLER F, 1968, HDB SOCIAL PSYCHOLOG, V2, P133; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; PANKRATZ L, 1979, J CONSULT CLIN PSYCH, V47, P409, DOI 10.1037/0022-006X.47.2.409; *PSYCH CORP, 1997, WECHSL MEM SCAL; Rey A, 1964, EXAMEN CLIN PSYCHOL; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P245; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; ZISKIN J, 1988, COPING PSYCHIAT PRAC	32	50	50	1	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2000	22	6					761	771					11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	403QT	WOS:000167054500005	11320434				2021-06-18	
J	Stahel, PF; Kariya, K; Shohami, E; Barnum, SR; Eugster, HP; Trentz, O; Kossmann, T; Morganti-Kossmann, MC				Stahel, PF; Kariya, K; Shohami, E; Barnum, SR; Eugster, HP; Trentz, O; Kossmann, T; Morganti-Kossmann, MC			Intracerebral complement C5a receptor (CD88) expression is regulated by TNF and lymphotoxin-alpha following closed head injury in mice	JOURNAL OF NEUROIMMUNOLOGY			English	Article						traumatic brain injury; complement; C5a; serpentine receptors; knockout mice	CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TGW NEUROBLASTOMA-CELLS; TRAUMATIC BRAIN INJURY; SIGNAL-TRANSDUCTION; HUMAN ASTROCYTES; ANAPHYLATOXIN; MICROGLIA; DISEASE	The anaphylatoxin C5a is a potent mediator of inflammation in the CNS. We analyzed the intracerebral expression of the C5a receptor (C5aR) in a model of closed head injury (CHI) in mice. Up-regulation of C5aR mRNA and protein expression was observed mainly on neurons in sham-operated and head-injured wild-type mice at 24 h. In contrast, in TNF/lymphotoxin-alpha knockout mice, the intracerebral C5aR expression remained at low constitutive levels after sham operation, whereas it strongly increased in response to trauma between 24 and 72 h. Interestingly, by 7 days after CHI, the intrathecal C5aR expression was clearly attenuated in the knockout animals. These data show that the posttraumatic neuronal expression of the C5aR is, at least in part, regulated by TNF and lymphotoxin-alpha at 7 days after trauma. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, Jerusalem, Israel; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Zurich, Dept Med, Clin Immunol Sect, Zurich, Switzerland	Stahel, PF (corresponding author), Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			ARMSTRONG RC, 1990, J NEUROSCI RES, V27, P400, DOI 10.1002/jnr.490270319; Barnum SR, 1999, MOL MED, V5, P569, DOI 10.1007/BF03402070; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Davoust N, 1999, J IMMUNOL, V163, P6551; Ember J., 1998, HUMAN COMPLEMENT SYS, P241; Eugster HP, 1996, INT IMMUNOL, V8, P23, DOI 10.1093/intimm/8.1.23; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Farkas I, 1999, NEUROREPORT, V10, P3021, DOI 10.1097/00001756-199909290-00027; GASQUE P, 1995, J IMMUNOL, V155, P4882; Gasque P, 1997, AM J PATHOL, V150, P31; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.immunol.12.1.775; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; LACY M, 1995, J NEUROIMMUNOL, V61, P71, DOI 10.1016/0165-5728(95)00075-D; McGeer EG, 1998, DRUGS, V55, P739, DOI 10.2165/00003495-199855060-00001; Morgan BP, 1996, IMMUNOL TODAY, V17, P461, DOI 10.1016/0167-5699(96)20028-F; Mukherjee P, 2000, J NEUROIMMUNOL, V105, P124, DOI 10.1016/S0165-5728(99)00261-1; MullerLadner U, 1996, J NEUROL SCI, V144, P135, DOI 10.1016/S0022-510X(96)00217-1; Nataf S, 1998, J NEUROIMMUNOL, V91, P147, DOI 10.1016/S0165-5728(98)00169-6; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; Osaka H, 1999, NEUROSCIENCE, V88, P1073, DOI 10.1016/S0306-4522(98)00372-8; Osaka H, 1999, J CELL BIOCHEM, V73, P303, DOI 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.0.CO;2-2; Pasinetti GM, 1996, NEUROBIOL AGING, V17, P707, DOI 10.1016/0197-4580(96)00113-3; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SPIEGEL K, 1997, NEUROINFLAMMATION ME, P129; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1997, J IMMUNOL, V159, P861; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X; WILLIAMS CA, 1985, J NEUROIMMUNOL, V9, P29, DOI 10.1016/S0165-5728(85)80004-7; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106	33	50	50	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	SEP 22	2000	109	2					164	172		10.1016/S0165-5728(00)00304-0			9	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	358VC	WOS:000089577000014	10996218				2021-06-18	
J	Gerring, J; Brady, K; Chen, A; Quinn, C; Herskovits, E; Bandeen-Roche, K; Denckla, MB; Bryan, RN				Gerring, J; Brady, K; Chen, A; Quinn, C; Herskovits, E; Bandeen-Roche, K; Denckla, MB; Bryan, RN			Neuroimaging variables related to development of Secondary Attention Deficit Hyperactivity Disorder after closed head injury in children and adolescents	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; INFARCTION; ADHD; RISK	Objective: To characterize children who develop Secondary Attention Deficit Hyperactivity Disorder (S-ADHD) after severe and moderate closed head injury (CHI) according to neuroimaging variables. Method: Ninety-nine children fi-om 4-19 years who suffered severe and moderate CHI were prospectively followed for a year after injury. Premorbid psychiatric status was determined by administration to the parent of a structured psychiatric interview. This interview was readministered 1 year after injury to determine the presence of post-dosed head injury S-ADHD. An MRI was performed 3 months after injury to define lesion locations and volumes. Results: A set of multiple logistic regression models determined that the odds of developing S-ADHD were 3.64 times higher among children with thalamus injury, and 3.15 times higher among children with basal ganglia injury. There was no significant difference in lesion volumes in any of the locations of interest between the group who developed S-ADHD and the group who did not develop S-ADHD. Conclusion: The data support an association between S-ADHD and injury in either or both the thalamus and basal ganglia, but they do not definitively demonstrate whether injury in either structure has an effect on S-ADHD in the absence of injury in the other.	Kennedy Krieger Res Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Johns Hopkins Sch Publ Hlth, Baltimore, MD USA; NIH, Bethesda, MD 20892 USA	Gerring, J (corresponding author), Kennedy Krieger Res Inst, 707 N Broadway, Baltimore, MD 21205 USA.		Bryan, R. Nick/P-1661-2014		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO-RR00052] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; ASIXAINEN I, 1996, BRAIN INJURY, V10, P883; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; BIEDERMAN J, 1995, ARCH GEN PSYCHIAT, V52, P464; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Castellanos FX, 1997, CHILD ADOL PSYCH CL, V6, P383, DOI 10.1016/S1056-4993(18)30310-9; Damasio H., 1989, LESION ANAL NEUROPSY; ESLINGER PJ, 1991, NEUROLOGY, V41, P450, DOI 10.1212/WNL.41.3.450; GENTILINI M, 1987, J NEUROL NEUROSUR PS, V50, P900, DOI 10.1136/jnnp.50.7.900; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; *ISG TECHN, 1995, ALL SOFTW; Kaplan DM, 1997, PSYCHIAT RES-NEUROIM, V76, P15, DOI 10.1016/S0925-4927(97)00055-3; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; Moore BD, 1996, NEUROLOGY, V46, P1660, DOI 10.1212/WNL.46.6.1660; PAGANO M, 1993, PRINCIPLES BIOSTATIS; SANDSON TA, 1991, ARCH NEUROL-CHICAGO, V48, P1300, DOI 10.1001/archneur.1991.00530240106031; SLIFER KJ, 1993, J APPL BEHAV ANAL, V26, P469, DOI 10.1901/jaba.1993.26-469; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; SZATMARI P, 1994, INT J METHOD PSYCH, V4, P231; Talairach J., 1988, COPLANAR STEREOTAXIC; WELNER Z, 1987, J AM ACAD CHILD PSY, V26, P649, DOI 10.1097/00004583-198709000-00007; WILSON DS, 1992, EVOL ECOL, V6, P331, DOI 10.1007/BF02270969; WILSON J T L, 1990, Brain Injury, V4, P349; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	30	50	50	0	4	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2000	14	3					205	218					14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	294EE	WOS:000085897700001	10759038				2021-06-18	
J	Wardlaw, JM; Statham, PFX				Wardlaw, JM; Statham, PFX			How often is haemosiderin not visible on routine MRI following traumatic intracerebral haemorrhage?	NEURORADIOLOGY			English	Article						haemorrhage, intracerebral; haemosiderin; magnetic resonance imaging	HEMORRHAGE; BRAIN	Intracerebral haemorrhage may be visible indefinitely on MRI, due to persistence of haemosiderin in macrophages around the lesion, but it is not clear whether all haemorrhages produce haemosiderin or, if not, what proportion cannot be identified as former haemorrhages on routine MRI. We performed routine MRI (spin-echo T2- and proton-density weighted images) in 116 survivors of moderate to severe head injury, 1-5 years after injury. We reviewed the images blindly and correlated them with CT in the acute stage, to determine how many haemorrhages from the acute stage were identifiable by virtue of haemosiderin deposition on late MRI. Of 106 haemorrhages in 78 patients on CT at the time of injury, 96 (90 %) were visible as haemosiderin on late MRI. Of the old haemorrhages without haemosiderin, seven of ten were in patients where another haemorrhage with haemosiderin was still visible elsewhere in the brain. No patient or haemorrhage features explained the formation or absence of haemosiderin. Thus about 10 % of definite haematomas show no trace of haemosiderin on routine spin-echo MRI. Radiologists should be alerted to supplement routine spin-echo with gradient-echo sequences if there is a reason to suspect, or specifically exclude, prior haemorrhage.	Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	Wardlaw, JM (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.						BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; DARROW VC, 1988, AM J PATHOL, V130, P44; FAZEKAS F, 1996, CEREBROVASC DIS S2, V6, P105; GARCIA JH, 1994, INTRACEREBRAL HEMORR, P48; JIANG H, 1998, JAMA-J AM MED ASSOC, V280, P1930; Offenbacher H, 1996, AM J NEURORADIOL, V17, P573; Patel MR, 1996, STROKE, V27, P2321, DOI 10.1161/01.STR.27.12.2321; SCHARF J, 1994, NEURORADIOLOGY, V36, P504, DOI 10.1007/BF00593508; WEHRLI FW, 1996, MAGNETIC RESONANCE I, P1413	9	50	50	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0028-3940			NEURORADIOLOGY	Neuroradiology	FEB	2000	42	2					81	84		10.1007/s002340050019			4	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	285YK	WOS:000085415800001	10663479				2021-06-18	
J	Taylor, HG; Klein, N; Minich, NM; Hack, M				Taylor, HG; Klein, N; Minich, NM; Hack, M			Verbal memory deficits in children with less than 750 g birth weight	CHILD NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; SCHOOL-AGE OUTCOMES; INTRAVENTRICULAR HEMORRHAGE; PRETERM INFANTS; LEARNING TEST; INTRACRANIAL HEMORRHAGE; STANDARDIZATION SAMPLE; COGNITIVE-ABILITIES; PERFORMANCE; ACHIEVEMENT	Numerous studies have documented memory deficits in very low birthweight (VLBW, < 1500 g) children, yet we know little about the nature of these memory problems. To clarify memory sequelae and examine memory deficits in relation to the degree of low birth weight, we administered the California Verbal Learning Test-Children's Version (CVLT-C) to a regional sample of 57 < 750 g birthweight children and to groups of 53 750-1499 g birthweight children and 49 term-born controls. Group comparisons revealed significant differences between the < 750 g birthweight group and term-born children on measures of list learning, delayed recall, and inaccurate recall. In addition, the percentage improvement in correct recognitions relative to long-term delayed recall was greater in the < 750 g group than in the term-born controls. Similar differences were observed between VLBW children with and without abnormal neonatal cerebral ultrasounds (high-and low-risk groups). Differences in learning rate between the VLBW and term-born groups, and between high-and low-risk VLBW children, were evident even when vocabulary skill was covaried or when children with neurosensory deficits or IQ < 80 were excluded from analysis. The findings document deficits in verbal memory in the subset of VLBW children at greatest biological risk, and suggest that acquisition processes are selectively impaired.	Case Western Reserve Univ, Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; Cleveland State Univ, Dept Educ, Cleveland, OH 44115 USA	Taylor, HG (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Dept Pediat, 11100 Euclid Ave, Cleveland, OH 44106 USA.	dsg5@po.cwru.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD26554] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD026554] Funding Source: NIH RePORTER		BAKER LL, 1988, RADIOLOGY, V168, P809, DOI 10.1148/radiology.168.3.3406411; Breslau N, 1996, BIOL PSYCHIAT, V40, P389, DOI 10.1016/0006-3223(95)00399-1; CHAPMAN LJ, 1978, J PSYCHIAT RES, V14, P303, DOI 10.1016/0022-3956(78)90034-1; CIONI G, 1992, BEHAV BRAIN RES, V49, P7, DOI 10.1016/S0166-4328(05)80190-1; Dammann O, 1996, DEV MED CHILD NEUROL, V38, P97; Delis D, 1994, CALIFORNIA VERBAL LE; Donders J, 1999, DEV NEUROPSYCHOL, V15, P395, DOI 10.1080/87565649909540757; Donders J, 1999, J INT NEUROPSYCH SOC, V5, P26, DOI 10.1017/S1355617799511041; EVARD P, 1992, BIOL NEONATE, V61, P1; Fletcher JM, 1997, DEV MED CHILD NEUROL, V39, P596; FORD LM, 1989, CLIN PEDIATR, V28, P302, DOI 10.1177/000992288902800702; FRISK V, 1994, DEV NEUROPSYCHOL, V10, P313, DOI 10.1080/87565649409540586; GADIAN DG, IN PRESS BRAIN; HACK M, 1992, J DEV BEHAV PEDIATR, V13, P412; HACK M, 1995, FUTURE CHILD, V5, P176, DOI 10.2307/1602514; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; Hall A, 1995, DEV MED CHILD NEUROL, V37, P1037; HERRGARD E, 1993, DEV MED CHILD NEUROL, V35, P1083; HOFFMAN N, IN PRESS ARCH CLIN N; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; KAUFMAN AS, 1988, J CLIN CHILD PSYCHOL, V17, P359, DOI 10.1207/s15374424jccp1704_10; KLEBANOV PK, 1994, J DEV BEHAV PEDIATR, V15, P248, DOI 10.1097/00004703-199408000-00005; KLEIN N, 1985, PEDIATRICS, V75, P531; KLEIN NK, 1989, J DEV BEHAV PEDIATR, V10, P32; LANDRY SH, 1993, J CLIN EXP NEUROPSYC, V15, P205, DOI 10.1080/01688639308402558; Lou HC, 1996, ACTA PAEDIATR, V85, P1266, DOI 10.1111/j.1651-2227.1996.tb13909.x; Maalouf EF, 1999, J PEDIATR-US, V135, P351, DOI 10.1016/S0022-3476(99)70133-2; MASSMAN PJ, 1990, J CLIN EXP NEUROPSYC, V12, P729, DOI 10.1080/01688639008401015; Mattson SN, 1996, ALCOHOL CLIN EXP RES, V20, P810, DOI 10.1111/j.1530-0277.1996.tb05256.x; Mattson SN, 1999, J INT NEUROPSYCH SOC, V5, P462, DOI 10.1017/S1355617799555082; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PENNINGTON BF, 1994, MAC FDN MEN, P243; RAZ S, 1995, NEUROPSYCHOLOGY, V9, P91, DOI 10.1037/0894-4105.9.1.91; RICKARDS AL, 1993, J DEV BEHAV PEDIATR, V14, P363; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; ROSS G, 1991, PEDIATRICS, V88, P1125; Ross G, 1996, BRAIN COGNITION, V32, P1, DOI 10.1006/brcg.1996.0054; SAIGAL S, 1990, J PEDIATR-US, V116, P409, DOI 10.1016/S0022-3476(05)82835-5; Sattler J. M., 1992, ASSESSMENT CHILDREN; SELZER SC, 1992, J PEDIATR PSYCHOL, V17, P407, DOI 10.1093/jpepsy/17.4.407; Squire Larry R., 1995, P825; Stewart AL, 1999, LANCET, V353, P1653, DOI 10.1016/S0140-6736(98)07130-X; Taylor HG, 1998, J DEV BEHAV PEDIATR, V19, P235; TAYLOR HG, IN PRESS DEV NEUROPS; TAYLOR HG, IN PRESS CHILD DEV; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; WECHSLER D, 1991, WISC, V3; Whitaker AH, 1996, PEDIATRICS, V98, P719; Whitfield MF, 1997, ARCH DIS CHILD-FETAL, V77, pF85, DOI 10.1136/fn.77.2.F85; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; WOLKE D, 1994, EUR J PEDIATR, V153, P906, DOI 10.1007/BF01954744; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; YEATES KO, 1995, J PEDIATR PSYCHOL, V20, P801, DOI 10.1093/jpepsy/20.6.801; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	54	50	51	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.		2000	6	1					49	63		10.1076/0929-7049(200003)6:1;1-B;FT049			15	Clinical Neurology	Neurosciences & Neurology	353BN	WOS:000089254000005	10980668				2021-06-18	
J	Baren, JM; Anicetti, JP; Ledesma, S; Biros, MH; Mahabee-Gittens, M; Lewis, RJ				Baren, JM; Anicetti, JP; Ledesma, S; Biros, MH; Mahabee-Gittens, M; Lewis, RJ			An approach to community consultation prior to initiating an emergency research study incorporating a waiver of informed consent	ACADEMIC EMERGENCY MEDICINE			English	Article						waiver of informed consent; community consultation; research		Objectives: In November 1996, the Food and Drug Administration (FDA) and the Department of Health and Human Services (DHHS) enacted rules allowing a narrow exception to the requirement for prospective informed consent when enrolling critically ill patients in clinical research studies of emergency treatments. These rules require that, prior to initiation of the study, the applicable institutional review board (IRB) assess the acceptability of the proposed research study to members of the community in which the research will be conducted. Specifically, the IRE must perform community consultation-a process during which community members learn about the proposed research and communicate their opinions regarding its acceptability to investigators or IRE representatives. The FDA and DHHS rules do not define specific acceptable methods for performing this community consultation. The objective of this study is to demonstrate the feasibility and utility of one proposed method for performing such community consultation. Methods: Parents of children being seen for minor traumatic injuries in three pediatric EDs were asked to participate in a study regarding informed consent. After consent, an instructor described to the parent a prospective, randomized, placebo-controlled trial of phenytoin for the prophylaxis of posttraumatic seizures in children with severe closed head trauma. All parents were then asked whether they would have consented for their own child's participation, if their child had suffered such head injury. The parents were further asked to explain the reason(s) for their responses. Results: Parents of 227 children (children's mean +/- SD age 8.0 +/- 4.8 years, 57% male) were interviewed. Sixty-six percent of parents (149/227) stated they would give consent for their child's participation. Of the 149 consenting parents, 85% (126/149) cited potential benefit to their child, 72% (107/149) cited potential benefit to other children, and 60% (90/149) cited furthering medical knowledge. Of the 78 nonconsenting parents (34% of total), 54% (42/78) cited fear of adverse effects, 39% (30/78) did not want their child to be a research subject in general, 27% (21/78) believed they needed to discuss participation with family members who were unavailable, and 26% (20/78) stated they were unable to decide unless they were in the actual situation. Parental ethnicity and household income were found to influence the consent decision, while the parent's gender, religion, language, and educational level were not associated with the consent decision. Conclusions: Community consultation regarding the acceptability of an emergency research protocol can be obtained via interview techniques in the ED. This methodology may allow investigators to obtain data on opinion from a targeted community for IRE consideration during the review of emergency research studies proposing a waiver of informed consent.	Hosp Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; Kaiser Permanente Med Ctr, Dept Emergency Med, Vallejo, CA 94589 USA; Univ Colorado, Hlth Sci Ctr, Dept Internal Med, Denver, CO 80202 USA; Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA; Childrens Hosp, Med Ctr, Dept Emergency Med, Cincinnati, OH 45229 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Univ Calif Los Angeles, Harbor Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA	Lewis, RJ (corresponding author), Univ Calif Los Angeles, Harbor Med Ctr, Dept Emergency Med, 1000 W Carson St, Torrance, CA 90509 USA.						Adams JG, 1999, ANN EMERG MED, V33, P218, DOI 10.1016/S0196-0644(99)70398-7; ANICETTI JP, 1996, ACAD EMERG MED, V3, P490; [Anonymous], 1996, Fed Regist, V61, P51498; BIROS MH, 1995, JAMA-J AM MED ASSOC, V273, P1283, DOI 10.1001/jama.273.16.1283; Kremers MS, 1999, ANN EMERG MED, V33, P224, DOI 10.1016/S0196-0644(99)70399-9; Lewis R.J., 1996, BAYESIAN BIOSTATISTI; Marwick C, 1997, JAMA-J AM MED ASSOC, V278, P1392, DOI 10.1001/jama.1997.03550170020008; *OFF SCI TECHN POL, 1991, FED REGISTER, V56, P28002; OKADA PJ, 1994, ARCH PEDIAT ADOLESC, V148, pP104; YOUNG K, 1996, ACAD EMERG MED, V3, P400	10	50	50	0	1	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	DEC	1999	6	12					1210	1215		10.1111/j.1553-2712.1999.tb00135.x			6	Emergency Medicine	Emergency Medicine	268EZ	WOS:000084402500007	10609922	Bronze			2021-06-18	
J	Beaumont, A; Marmarou, A; Czigner, A; Yamamoto, M; Demetriadou, K; Shirotani, T; Marmarou, C; Dunbar, J				Beaumont, A; Marmarou, A; Czigner, A; Yamamoto, M; Demetriadou, K; Shirotani, T; Marmarou, C; Dunbar, J			The impact-acceleration model of head injury: Injury severity predicts motor and cognitive performance after trauma	NEUROLOGICAL RESEARCH			English	Article						Impact Acceleration Model; traumatic brain injury; diffuse axonal injury; secondary insult; neuropsychological tests; motor deficits; cognitive deficits	CONTROLLED CORTICAL IMPACT; CONCUSSIVE BRAIN INJURY; RATING-SCALE; RATS; RECOVERY; DEFICITS; IMPAIRMENT; SEQUELAE; MODERATE; MEMORY	This study examines neuropsychological dysfunction after varying severities of the Impact Acceleration Model of diffuse traumatic brain injury. Adult rats (340 g-400 g) were divided into five groups, and exposed to varying degrees of Impact Acceleration Injury (1 m, 2 m, 2.1 m/500 g and second insult). After injury, animals were allowed to recover; acute neurological reflexes, beam walk score, beam balance score, inclined plane store, and Morris Water Maze score were then assessed at multiple time points. Injury of all severities caused significant motor and cognitive deficits. With milder injuries these effects were transient; however, with more severe injuries no recovery in function was seen. The addition of hypoxia and hypotension made a moderate injury worse than a severe injury. The acute neurological reflexes, the beam balance test and the inclined plane test distinguished between the more severely injured groups, but were affected less by mild injury. The beam walk test was sensitive to mild injury, but appeared unable to distinguish between the severe groups. The Morris Water Maze was sensitive for all injury groups, bur appeared to adopt a different response profile with secondary insult. This study has for the first time characterized the degree of motor and cognitive deficits in rodents exposed to differing severities of impact Acceleration Injury. These data confirm that the tests considered, and the Injury Model used provide a useful system for the consideration of potential therapies which might ameliorate neuropsychological deficits in diffuse brain injury.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Marmarou, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980508,Sanger Hall,Room 8004,1101 E Marshall, Richmond, VA 23298 USA.		Beaumont, Andrew/AAJ-7457-2020				Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GOLDEN CJ, 1985, LURIA NEBRASKA NEURO; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1988, BRAIN INJURY, V2, P51; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1985, STATUS REPORT CENTRA, P281; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARION DW, 1993, J NEUROSURG, V78, pA347; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Miller JR, 1989, MILD MODERATE HEAD I, P125; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHIROTANI T, 1994, INTRACRANIAL PRESSUR, V9, P409; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487	38	50	53	0	11	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	DEC	1999	21	8					742	754		10.1080/01616412.1999.11741008			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	260KA	WOS:000083947500006	10596383				2021-06-18	
J	Pratico, D; Rokach, J; Tangirala, RK				Pratico, D; Rokach, J; Tangirala, RK			Brains of aged apolipoprotein E-deficient mice have increased levels of F-2-isoprostanes, in vivo markers of lipid peroxidation	JOURNAL OF NEUROCHEMISTRY			English	Article						apolipoprotein E-deficient mice; lipid peroxidation; isoprostanes	SPORADIC ALZHEIMERS-DISEASE; CLOSED-HEAD INJURY; INCREASED SUSCEPTIBILITY; OXIDATIVE STRESS; E POLYMORPHISM; IN-VIVO; ALLELE; APOE; PROTEIN; ATHEROSCLEROSIS	Apolipoprotein E (apoE) is the major apolipoprotein of the CNS, Differential expression of apoE isoforms has been linked to longevity and to the pathogenesis of Alzheimer's disease. Several studies have demonstrated that this glycoprotein is important in mature as well as in aging CNS, where it may serve neurotrophic and/or neuroprotective functions. Some reports have shown that apoE-deficient mice have age-dependent neurodegeneration and cognitive impairment; others have not confirmed these observations, ApoE-deficient mice also develop hypercholesterolemia on a chow diet and have in vivo increased plasma lipid peroxidation products. F-2-isoprostanes are prostaglandin F-2 alpha isomers and chemically stable peroxidation products of arachidonic acid. Both isoprostane F-2 alpha-III and isoprostane F-2 alpha-VI were markedly elevated in the brains of aged apoE-deficient mice compared with either wild-type C57 Bl/6 mice or a distinct mouse model of hypercholesterolemia, the low-density lipoprotein receptor-deficient mouse. By contrast, no difference in isoprostane levels was observed in young apoE-deficient mice compared with age-matched wild-type control mice. Our findings indicate that disorder of lipid metabolism in the absence of apoE can induce an age-dependent increase in brain lipid peroxidation products.	Univ Penn, Sch Med, Stellar Chance Labs, Ctr Expt Therapeut,Dept Pharmacol, Philadelphia, PA 19104 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	Pratico, D (corresponding author), Univ Penn, Sch Med, Stellar Chance Labs, Ctr Expt Therapeut,Dept Pharmacol, Room 901A, Philadelphia, PA 19104 USA.		Pratico, Domenico/ABA-9590-2020	Rokach, Joshu/0000-0003-1814-7505			Anderson R, 1998, NEUROSCIENCE, V85, P93, DOI 10.1016/S0306-4522(97)00598-8; Arendt T, 1997, J NEUROSCI, V17, P516; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; BRESLOW JL, 1993, P NATL ACAD SCI USA, V90, P8314, DOI 10.1073/pnas.90.18.8314; CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P106, DOI 10.1006/abbi.1995.1347; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Fagan AM, 1998, EXP NEUROL, V151, P314, DOI 10.1006/exnr.1998.6818; Gandy S., 1995, Society for Neuroscience Abstracts, V21, P5; GORDON I, 1995, NEUROSCI LETT, V199, P1, DOI 10.1016/0304-3940(95)12006-P; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; LOUHIJA J, 1994, ARTERIOSCLER THROMB, V14, P1084, DOI 10.1161/01.ATV.14.7.1084; Lyras L, 1996, FREE RADICAL RES, V24, P397, DOI 10.3109/10715769609088038; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Masliah E, 1997, BRAIN RES, V751, P307, DOI 10.1016/S0006-8993(96)01420-5; MASLIAH E, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P405; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; Matthews RT, 1996, BRAIN RES, V718, P181, DOI 10.1016/0006-8993(95)01576-0; Mercken L, 1995, NEUROREPORT, V6, P2381, DOI 10.1097/00001756-199511270-00025; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Montine TJ, 1998, ANN NEUROL, V44, P410, DOI 10.1002/ana.410440322; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; Morrow JD, 1996, BIOCHEM PHARMACOL, V51, P1, DOI 10.1016/0006-2952(95)02072-1; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; Patrono C, 1997, ARTERIOSCL THROM VAS, V17, P2309, DOI 10.1161/01.ATV.17.11.2309; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; Pratico D, 1998, FASEB J, V12, P1777; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; PRATICO D, 1997, AGENTS ACTIONS, V48, P26; PRATICO D, 1997, J CLIN INVEST, V100, P2027; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; REBECK GW, 1993, NEURON, V11, P575; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P853, DOI 10.1016/S0090-6980(97)00184-6; ROSES AD, 1995, EXP NEUROL, V132, P149, DOI 10.1016/0014-4886(95)90019-5; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SING CF, 1985, AM J HUM GENET, V37, P268; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Walker LC, 1997, AM J PATHOL, V151, P1371; Weisgraber KH, 1996, FASEB J, V10, P1485; WEST HL, 1994, NEUROSCI LETT, V175, P46, DOI 10.1016/0304-3940(94)91074-X	51	50	50	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3042			J NEUROCHEM	J. Neurochem.	AUG	1999	73	2					736	741		10.1046/j.1471-4159.1999.0730736.x			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	218CG	WOS:000081535200034	10428071	Bronze			2021-06-18	
J	Meythaler, JM; Guin-Renfroe, S; Hadley, MN				Meythaler, JM; Guin-Renfroe, S; Hadley, MN			Continuously infused intrathecal baclofen for spastic dystonic hemiplegia - A preliminary report	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						intrathecal; baclofen; brain injury; spasticity; hypertonia; rehabilitation; hemiparesis; stroke	ACQUIRED BRAIN INJURY; SPINAL SPASTICITY; DRUG-THERAPY; HYPERTONIA; ORIGIN; REFLEX	The objective of this study was to determine whether the continuous intrathecal delivery of baclofen will control spastic hypertonia associated with long-standing hemiplegia from acquired brain injury. Six hemiparetic patients (average age, 50 (range, 42-66) yr) with more than 6 mo of disabling lower limb spastic hypertonia on one side caused by either a unilateral traumatic brain injury or a stroke were recruited in a consecutive manner. The setting was a tertiary care outpatient and inpatient rehabilitation center directly attached to a university hospital. Patients were screened via a randomized, double-blind, placebo-controlled, crossover design to receive either an intrathecally administered bolus injection of normal saline or 50 mu g of baclofen. Data for Ashworth rigidity scores, spasm scores, and deep tendon reflex scores were collected on the affected upper limb and lower limb side. Those who dropped an average of two points on their affected lower limb side Ashworth scores were then offered computer-controlled pump implantation for continuous intrathecal administration of baclofen. Differences over time were assessed via descriptive statistics and Wilcoxon's signed-rank test. After 3 mo of treatment, the average lower limb Ashworth score on the affected side decreased from 3.7 +/- 1.0 to 1.9 +/- 0.6 standard deviation (SD) (P < 0.0001), the reflex score from 1.8 +/- 1.3 to 0.5 +/- 0.8 SD (P = 0.0208), and the spasm score from 1.3 +/- 1.2 to 0.8 +/- 1.3 SD (P > 0.05). The average upper limb Ashworth score on the affected side decreased from 3.4 +/- 0.9 to 2.1 +/- 0.9 SD (P = 0.0002), the reflex score from 2.3 +/- 0.5 to 1.7 +/- 0.5 SD (P > 0.050, and the spasm score from 0.8 +/- 1.3 to 0 +/- 0 SD (P > 0.05). The average intrathecally administered dose of baclofen that was required to attain these effects was 205.3 mu g, which was continuously infused for 24 h. Continuous intrathecal infusion of baclofen is capable of maintaining a reduction in the dystonia on the hemiparetic side without significantly affecting motor strength on the normal side.	Univ Alabama, Sch Med, Dept Phys Med & Rehabil, Birmingham, AL 35233 USA; Univ Alabama, Sch Med, Div Neurol Surg, Birmingham, AL USA	Meythaler, JM (corresponding author), Univ Alabama, Sch Med, Dept Phys Med & Rehabil, Birmingham, AL 35233 USA.						ADAMS RD, 1993, PRINCIPLES NEUROLOGY, P68; Albright AL, 1996, NEUROSURGERY, V38, P934, DOI 10.1097/00006123-199605000-00015; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; ALBRIGHT LA, 1997, INTRATHECAL BACLOFEN; ASHBY P, 1974, J NEUROL NEUROSUR PS, V37, P1352, DOI 10.1136/jnnp.37.12.1352; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Ford B, 1996, ARCH NEUROL-CHICAGO, V53, P1241, DOI 10.1001/archneur.1996.00550120049016; Hattab J.R., 1980, SPASTICITY DISORDERE, P71; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; Lee K.-C., 1989, J NEUROL REHABIL, V3, P205, DOI DOI 10.1177/136140968900300406; MACDONELL RAL, 1989, J NEUROL NEUROSUR PS, V52, P1110, DOI 10.1136/jnnp.52.9.1110; Mann NH, 1991, J NEUROL REHABIL, V5, P51; MEYTHALER JM, 1992, AM J PHYS MED REHAB, V71, P321, DOI 10.1097/00002060-199212000-00003; MEYTHALER JM, 1992, ARCH PHYS MED REHAB, V73, P794; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Meythaler JM, 1997, J HEAD TRAUMA REHAB, V12, P87, DOI 10.1097/00001199-199702000-00012; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P461, DOI 10.1016/S0003-9993(96)90034-9; Meythaler JM, 1996, PERSPECT NEUROSURG, V7, P99; Muller H., 1988, LOCAL SPINAL THERAPY, P223; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; TERRENCE CF, 1981, ARCH NEUROL-CHICAGO, V38, P588, DOI 10.1001/archneur.1981.00510090082011; WILSON PR, 1978, EUR J PHARMACOL, V51, P323, DOI 10.1016/0014-2999(78)90423-5; YAKSH TL, 1981, ANESTHESIOLOGY, V54, P451, DOI 10.1097/00000542-198106000-00004; Yarkony GM, 1987, CLIN ORTHOP RELAT R, V219, P93; YOUNG RR, 1981, NEW ENGL J MED, V304, P28; YOUNG RR, 1981, NEW ENGL J MED, V304, P96	26	50	52	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAY-JUN	1999	78	3					247	254		10.1097/00002060-199905000-00012			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	196DP	WOS:000080294000010	10340423				2021-06-18	
J	Zhao, X; Pike, BR; Newcomb, JK; Wang, KKW; Posmantur, RM; Hayes, RL				Zhao, X; Pike, BR; Newcomb, JK; Wang, KKW; Posmantur, RM; Hayes, RL			Maitotoxin induces calpain but not caspase-3 activation and necrotic cell death in primary septo-hippocampal cultures	NEUROCHEMICAL RESEARCH			English	Article						calpain; caspases; maitotoxin; necrosis; apoptosis	TRAUMATIC BRAIN INJURY; CORTICAL IMPACT INJURY; RAT-BRAIN; NEURONAL APOPTOSIS; PHOSPHOINOSITIDE BREAKDOWN; GLOBAL-ISCHEMIA; DNA FRAGMENTATION; CALCIUM CHANNELS; GRANULE CELLS; PC12 CELLS	Maitotoxin is a potent toxin that activates voltage and receptor-mediated Ca2+ channels, resulting in Ca2+ overload and rapid cell death. We report that maitotoxin-induced cell death is associated with activation of calpain but not caspase-3 proteases in septo-hippocampal cell cultures. Calpain and caspase-3 activation were examined by accumulation of protease-specific breakdown products to a-spectrin. Cell death manifested exclusively necrotic-like characteristics including round, shrunken nuclei, even distribution of chromatin, absence of DNA fragmentation and failure of protein synthesis inhibition to reduce cell death. Necrotic cell death was observed in neurons and astroglia. Calpain inhibitor II inhibited calpain-specific processing of alpha-spectrin and significantly reduced cell death. The pan-caspase inhibitor, Z-D-DCB, nominally attenuated cell death. Results suggest that: (1) calpain, but not caspase-3, is activated as a result of maitotoxin-induced Ca2+ influx; (2) necrotic cell death caused by maitotoxin exposure is partially mediated by calpain activation; (3) maitotoxin is a useful tool to investigate pathological mechanisms of necrosis.	Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77030 USA; Warner Lambert Co, Parke Davis Pharmaceut Res, Dept Immunopathol, Dept Neurosci Therapeut, Ann Arbor, MI 48105 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA	Hayes, RL (corresponding author), Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, 6431 Fannin,Suite 7-154, Houston, TX 77030 USA.			Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS21458] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458] Funding Source: NIH RePORTER		Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; BEHRENS MM, 1995, CELL GROWTH DIFFER, V6, P1375; BERTA P, 1986, FEBS LETT, V197, P349, DOI 10.1016/0014-5793(86)80355-6; CHOI OH, 1990, MOL PHARMACOL, V37, P222; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; CONTI AC, 1996, J NEUROTRAUM, V13, P595; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Eldadah BA, 1997, J NEUROSCI, V17, P6105; FALCIERI E, 1993, BIOCHEM BIOPH RES CO, V193, P19, DOI 10.1006/bbrc.1993.1584; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; GUSOVSKY F, 1987, CELL MOL NEUROBIOL, V7, P317, DOI 10.1007/BF00711308; GUSOVSKY F, 1990, BIOCHEM PHARMACOL, V39, P1633, DOI 10.1016/0006-2952(90)90105-T; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; Haseldonckx M, 1997, STROKE, V28, P428, DOI 10.1161/01.STR.28.2.428; Higuchi T, 1997, MAGNET RESON MED, V37, P851, DOI 10.1002/mrm.1910370608; Honkaniemi J, 1996, MOL BRAIN RES, V42, P79, DOI 10.1016/S0169-328X(96)00121-0; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Jordan J, 1997, J NEUROCHEM, V68, P1612; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kawaguchi K, 1997, J NEUROCHEM, V69, P412; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KUTTY RK, 1989, TOXICOL APPL PHARM, V101, P1, DOI 10.1016/0041-008X(89)90206-8; Li ZH, 1996, NEUROCHEM RES, V21, P441, DOI 10.1007/BF02527708; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; MELLGREN RL, 1986, ARCH BIOCHEM BIOPHYS, V246, P233, DOI 10.1016/0003-9861(86)90468-6; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; MEUCCI O, 1992, J NEUROCHEM, V59, P679, DOI 10.1111/j.1471-4159.1992.tb09422.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUSGRAVE IF, 1994, BIOCHEM J, V301, P437, DOI 10.1042/bj3010437; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; NATH R, 1995, J NEUROSCI, V15, P1001; NATH R, 1998, IN PRESS J NEUROCHEM; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NITATORI T, 1995, J NEUROSCI, V15, P1001; OBERHAMMER F, 1993, J CELL SCI, V104, P317; PERLMUTTER LS, 1990, J COMP NEUROL, V296, P269, DOI 10.1002/cne.902960207; PIKE BR, 1998, IN PRESS J NEUROSCI; Qian Liang, 1996, Bulletin of Tokyo Medical and Dental University, V43, P53; Regan RF, 1995, BRAIN RES, V705, P188, DOI 10.1016/0006-8993(95)01170-6; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROSSER BG, 1993, J BIOL CHEM, V268, P23593; SAIDO TC, 1994, FASEB J, V8, P814; SANTOSTASI G, 1990, TOXICOL APPL PHARM, V102, P164, DOI 10.1016/0041-008X(90)90093-A; SOERGEL DG, 1992, MOL PHARMACOL, V41, P487; Sorimachi Y, 1997, J BIOCHEM-TOKYO, V122, P743; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; TAKAHASHI M, 1982, J BIOL CHEM, V257, P7287; TERAO K, 1988, TOXICON, V26, P395, DOI 10.1016/0041-0101(88)90008-6; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1998, IN PRESS J BIOL CHEM; WANG KKW, 1998, IN PRESS BIOREGULADO; Widdowson PS, 1997, TOXICOL APPL PHARM, V142, P248, DOI 10.1006/taap.1996.7940; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YUEN P, 1996, BIOCHEM J, V319, P683; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	72	50	52	2	4	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	MAR	1999	24	3					371	382		10.1023/A:1020933616351			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	161EB	WOS:000078274800005	10215511				2021-06-18	
J	Maeda, T; Hashizume, K; Tanaka, T				Maeda, T; Hashizume, K; Tanaka, T			Effect of hypothermia on kainic acid induced limbic seizures: an electroencephalographic and C-14-deoxyglucose autoradiographic study	BRAIN RESEARCH			English	Article						hypothermia; kainic acid; limbic seizure; autoradiography	TRAUMATIC BRAIN INJURY; MODERATE HYPOTHERMIA; ENTORHINAL CORTEX; AMYGDALOID COMPLEX; CEREBRAL-ISCHEMIA; MILD HYPOTHERMIA; FEBRILE SEIZURES; RAT; TEMPERATURE; GLUTAMATE	The effect of body temperature on kainic acid (KA)-induced limbic seizures was examined in Wistar rats. In rats undergoing limbic seizure induced by 1 mu g intra-amygdaloid injection of KA, the post-injection latency of initial ictal discharges in the left amygdala was significantly longer in rats whose body temperature was lowered to 30 degrees C (2.55 +/- 0.94 min at 37 degrees C, 13.19 +/- 5.70 min at 30 degrees C; p = 0.0017). The post-injection latency of initial ictal discharges in the left hippocampus was also significantly longer under the same conditions (23.68 +/- 9.96 min at 37 degrees C, 43.85 +/- 17.98 min at 30 degrees C; p = 0.0253). The number of limbic seizures occurring in the first 2 h post-injection was significantly lower in hypothermic rats (30.0 +/- 10.7 at 37 degrees C, 8.71 +/- 2.69 at 30 degrees C; p = 0.0017), as was the total duration of limbic seizures over the same period (23.61 +/- 8.45 min at 37 degrees C, 10.30 +/- 4.48 min at 30 degrees C; p = 0.0060). Local cerebral glucose utilization (LCGU), measured 2 h post-injection, was significantly lower in hypothermic rats, mainly in the limbic structures. C-deoxyglucose autoradiograms showed decreased radiation density not only in the left amygdala and bilateral hippocampus, but also in the cerebral cortex of hypothermic rats. The results of the present experiment demonstrate that the use of hypothermia, which has been shown to be effective in the treatment of acute cerebral ischemia and brain injury, may also be effective in the treatment of status epileptics. (C) 1999 Elsevier Science B.V. All rights reserved.	Asahikawa Med Coll, Dept Neurosurg, Asahikawa, Hokkaido 0788510, Japan	Maeda, T (corresponding author), Asahikawa Med Coll, Dept Neurosurg, 4-5 Nishikagura, Asahikawa, Hokkaido 0788510, Japan.						Babb T.L., 1987, SURGICAL TREATMENT E, P511; BECKSTEAD RM, 1978, BRAIN RES, V152, P249, DOI 10.1016/0006-8993(78)90254-8; BENARI Y, 1980, NEUROSCIENCE, V5, P515, DOI 10.1016/0306-4522(80)90049-4; Bernard SA, 1997, ANN EMERG MED, V30, P146, DOI 10.1016/S0196-0644(97)70133-1; Bertram EH, 1997, EPILEPSIA, V38, P95, DOI 10.1111/j.1528-1157.1997.tb01083.x; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1988, NEUROSCI LETT, V91, P36, DOI 10.1016/0304-3940(88)90245-5; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; HJORTHSIMONSEN A, 1972, J COMP NEUROL, V146, P219, DOI 10.1002/cne.901460206; JOHNSON DD, 1985, EPILEPSIA, V26, P466, DOI 10.1111/j.1528-1157.1985.tb05682.x; KADER A, 1994, NEUROSURGERY, V35, P272, DOI 10.1227/00006123-199408000-00013; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; KRETTEK JE, 1977, J COMP NEUROL, V172, P723, DOI 10.1002/cne.901720409; LENNOXBUCHTAL MA, 1974, EPILEPSIES, P246; LIU Z, 1993, BRAIN RES, V631, P51, DOI 10.1016/0006-8993(93)91185-U; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCCAUGHRAN JA, 1982, EPILEPSIA, V23, P173, DOI 10.1111/j.1528-1157.1982.tb05065.x; MORIMOTO T, 1993, EPILEPSIA, V34, P447, DOI 10.1111/j.1528-1157.1993.tb02585.x; NELSON KB, 1990, ANN NEUROL, V27, P127, DOI 10.1002/ana.410270206; OKAZAKI MM, 1988, NEUROSCIENCE, V26, P763, DOI 10.1016/0306-4522(88)90097-8; Olney J W, 1986, Adv Neurol, V44, P857; OLNEY JW, 1974, BRAIN RES, V77, P507, DOI 10.1016/0006-8993(74)90640-4; PELLEGRINO LJ, 1979, STEROTAXIC ATLAS RAT; ROSENE DL, 1977, SCIENCE, V198, P315, DOI 10.1126/science.410102; ROSOMOFF HL, 1956, J NEUROSURG, V13, P332; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SUTULA T, 1986, BRAIN RES, V385, P291, DOI 10.1016/0006-8993(86)91075-9; TANAKA T, 1992, PROG NEUROBIOL, V38, P317, DOI 10.1016/0301-0082(92)90023-8; TANCREDI V, 1992, EPILEPSIA, V33, P228, DOI 10.1111/j.1528-1157.1992.tb02311.x; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259; VANGROEN T, 1990, J COMP NEUROL, V302, P515, DOI 10.1002/cne.903020308; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9; WYSS JM, 1981, J COMP NEUROL, V199, P495	39	50	54	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 13	1999	818	2					228	235		10.1016/S0006-8993(98)01269-4			8	Neurosciences	Neurosciences & Neurology	166DD	WOS:000078560200006	10082808				2021-06-18	
S	Bullock, MR; Merchant, RE; Carmack, CA; Doppenberg, E; Shah, AK; Wilner, KD; Ko, G; Williams, SA		Trembly, B; Slikker, W		Bullock, MR; Merchant, RE; Carmack, CA; Doppenberg, E; Shah, AK; Wilner, KD; Ko, G; Williams, SA			An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage	NEUROPROTECTIVE AGENTS: FOURTH INTERNATIONAL CONFERENCE	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	4th International Conference on Neuroprotective Agents - Clinical and Experimental Aspects	NOV 15-19, 1998	ANNAPOLIS, MARYLAND	US FDA, Natl Ctr Toxicol Res, Dept Vet Affairs Med Ctr			EXPERIMENTAL BRAIN INJURY; REGIONAL CEREBRAL EDEMA; ANTAGONIST; RAT; CP101,606; CP-98,113; DAMAGE	CP-101,606 is a postsynaptic antagonist of N-methyl-D-aspartate (NMDA) receptors bearing the NR2B subunit, When administered intravenously (i.v.), it decreases the effects of traumatic brain injury (TBI) and focal ischemia in animal models. Therapeutic plasma concentrations (200 ng/ml) in animals, have been well tolerated in healthy human volunteers. The purpose of the present dose escalation study was to assess the safety, tolerability, and pharmacokinetics of CP-101,606 in subjects who had suffered either an acute severe TBI (Glasgow Coma Scale 3-8) or spontaneous intracerebral hemorrhage, Thirty patients, 20 with a TBI and 10 with a stroke, were enrolled in the trial and began receiving an i.v. infusion of CP-101,606 for 2 hours, 24 hours, or 72 hours within 12 hours of brain injury. For the first two hours,the drug was given a rate of 0.75 mg/kg/hr and then stopped (n = 17) dr continued for 22 (n = 2) or 70 hours (n = 11) at 0.37 mg/kg/hr, Plasma and cerebrospinal fluid (CSF) were collected at serial times during and after treatment. There were no consistent changes in blood pressure or pulse nor any clinically significant hematological or electrocardiogram (ECG) abnormalities attributable to CP-101,606, No adverse events or behavioral changes were considered to be related to the drug. Plasma concentrations of CP-101,606 over 200 ng/ml were rapidly achieved in the blood and CSF within two hours and were sustained there as long as the drug was infused. CSF concentrations were slightly higher than that in plasma by the end of infusion suggesting good penetration of CP-101,606 into the CSF, Outcome in the severe TBI patients, as measured by the Glasgow Outcome Score at six months, suggested that a two-hour infusion yielded a range of scores similar to contemporary patients with a severe TBI treated at our hospital while the outcomes of the patients treated with either a 24- or 72-hour infusion were better on average. Thus, these results indicate that CP-101,606 infused for up to 72 hours is well tolerated, penetrates the CSF and brain, and may improve outcome in the brain-injured patient.	Virginia Commonwealth Univ, Div Neurosurg, MCV Stn, Med Coll Virginia, Richmond, VA 23298 USA; Pfizer Inc, Div Cent Res, Groton, CT 06340 USA	Merchant, RE (corresponding author), Virginia Commonwealth Univ, Div Neurosurg, MCV Stn, Med Coll Virginia, Box 980631, Richmond, VA 23298 USA.						Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Di X, 1997, STROKE, V28, P2244, DOI 10.1161/01.STR.28.11.2244; Menniti F, 1997, EUR J PHARMACOL, V331, P117, DOI 10.1016/S0014-2999(97)10092-9; MENNITI FS, 1998, UNPUB EUR J PHARM; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; PAGNOZZI MJ, 1995, SOC NEUR ABSTR 1 S, V21; Tsuchida E, 1997, J NEUROTRAUM, V14, P409, DOI 10.1089/neu.1997.14.409	8	50	50	0	1	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-222-3	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1999	890						51	58		10.1111/j.1749-6632.1999.tb07980.x			8	Biochemistry & Molecular Biology; Multidisciplinary Sciences; Clinical Neurology; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BP50F	WOS:000085330700005	10668413				2021-06-18	
J	Rueckert, L; Grafman, J				Rueckert, L; Grafman, J			Sustained attention deficits in patients with lesions of posterior cortex	NEUROPSYCHOLOGIA			English	Article						parietal cortex; vigilance	CLOSED-HEAD-INJURY; UNILATERAL NEGLECT; FRONTAL LESIONS; VIGILANCE; PARIETAL; NETWORK; SYSTEM; TASK	Patients with lesions to posterior cortex were compared to controls, matched for age and education, on tests on sustained attention. One test was a simple reaction time task requiring subjects to respond whenever they saw an 'X'. The other was a Continuous Performance Test that required subjects to respond to an 'X' but refrain from responding to other letters. The patients missed more targets than control subjects on both tests. On the Continuous Performance Test the difference between patients and controls increased with time on task, suggesting a sustained attention deficit similar to that previously observed in patients with right frontal lesions. However, whereas frontal patients showed a tendency toward greater impairment when the rate of stimulus presentation was relatively slow, the posterior patients performed significantly worse when the stimuli were presented at a faster rate. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.	NINDS, Cognit Neurosci Sect, NIH, Chicago, IL USA	Rueckert, L (corresponding author), NE Illinois Univ, Dept Psychol, 5500 N St Louis Ave, Chicago, IL 60625 USA.			Grafman, Jordan H./0000-0001-8645-4457			BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; BUCK L, 1966, PSYCHOL BULL, V65, P291, DOI 10.1037/h0023207; COHEN RM, 1988, NEUROPSY NEUROPSY BE, V1, P3; Coull JT, 1996, NEUROPSYCHOLOGIA, V34, P1085, DOI 10.1016/0028-3932(96)00029-2; CRAIG A, 1987, HUM FACTORS, V29, P675; Damasio H., 1989, LESION ANAL NEUROPSY; DAVIES DR, 1969, HUMAN VIGILANCE PERF; DERENZI DE, 1982, DISORDERS SPACE EXPL; DEUTSCH G, 1987, INT J NEUROSCI, V36, P23, DOI 10.3109/00207458709002136; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; GOLDBERG ME, 1987, NEUROPSYCHOLOGIA, V25, P107, DOI 10.1016/0028-3932(87)90047-9; HEILMAN KM, 1977, HEMIINATTENTION HEMI; Hjaltason H, 1996, NEUROPSYCHOLOGIA, V34, P1229, DOI 10.1016/0028-3932(96)00044-9; JENKINS HM, 1958, AM J PSYCHOL, V71, P647, DOI 10.2307/1420323; JERISON HJ, 1963, HUM FACTORS, V5, P211, DOI 10.1177/001872086300500305; JOHNSTON WA, 1966, J EXP PSYCHOL, V22, P736; LOEB M, 1970, ACTA PSYCHOL, V33, P343, DOI 10.1016/0001-6918(70)90146-0; LYNCH JC, 1977, J NEUROPHYSIOL, V40, P362; MACKWORTH JF, 1970, VIGILANCE HABITUATIO; MENNEMEIER MS, 1994, NEUROPSYCHOLOGIA, V32, P703, DOI 10.1016/0028-3932(94)90030-2; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; NICKERSON RA, 1969, J EXP PSYCHOL, V79, P452, DOI 10.1037/h0026889; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PARASURAMAN R, 1984, VARIETIES ATTENTION, P243; PARASURAMAN R, 1979, SCIENCE, V205, P925; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PETERSEN SE, 1988, ASS RES VISION OPHTH, P22; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RICHER F, 1993, BRAIN COGNITION, V21, P203, DOI 10.1006/brcg.1993.1016; ROBERTSON IH, 1995, J CLIN EXP NEUROPSYC, V17, P416, DOI 10.1080/01688639508405133; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Rueckert L, 1996, NEUROPSYCHOLOGIA, V34, P953, DOI 10.1016/0028-3932(96)00016-4; SALMASO D, 1982, PERCEPT MOTOR SKILL, V54, P1147, DOI 10.2466/pms.1982.54.3c.1147; SEE JE, 1995, PSYCHOL BULL, V117, P230, DOI 10.1037/0033-2909.117.2.230; SIDDLE DAT, 1972, BRIT J PSYCHOL, V63, P191, DOI 10.1111/j.2044-8295.1972.tb02099.x; WEINSTEIN E, 1977, HEMIINATTENTION HEMI; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; WOODS DL, 1986, NEUROLOGY, V36, P212, DOI 10.1212/WNL.36.2.212; WURTZ RH, 1980, PROGR PSYCHOBIOLOGY, V9, P32	40	50	50	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	JUL	1998	36	7					653	660		10.1016/S0028-3932(97)00150-4			8	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	106JN	WOS:000075126300007	9723936				2021-06-18	
J	Satz, P; Zaucha, K; Forney, DL; McCleary, C; Asarnow, RF; Light, R; Levin, H; Kelly, D; Bergsneider, M; Hovda, D; Martin, N; Caron, MJ; Namerow, N; Becker, D				Satz, P; Zaucha, K; Forney, DL; McCleary, C; Asarnow, RF; Light, R; Levin, H; Kelly, D; Bergsneider, M; Hovda, D; Martin, N; Caron, MJ; Namerow, N; Becker, D			Neuropsychological, psychosocial and vocational correlates of the Glasgow Outcome Scale at 6 months post-injury: a study of moderate to severe traumatic brain injury patients	BRAIN INJURY			English	Article							HEAD-INJURY; SELF-REPORT; DEPRESSION; DIAGNOSIS	Traumatic brain injury (TBI) subjects at Glasgow Outcome Scale levels 3 (severe disability), 4 (moderate disability), 5 (good recovery), and an other-injury control group (OIC) were compared in terms of neuropsychological, psychosocial, and vocational functioning 6 months after injury. Subjects were a sample of 100 patients with a moderate to severe traumatic brain injury (TBI) and a matched sample of 30 other-injury control subjects (OIC) enrolled in the UCLA Brain Injury Research Center study of TBI outcome. Overall, the results showed a systematic decrease in mean neuropsychological test performance as a function of increasing GOS severity, as well as an increased prevalence of symptoms of depression and lower ratings on measures assessing employability and capacity for self care. TBI patients in the 'severe' and 'moderate disability' groups were distinctly inferior to the 'good recovery' and 'OIC' groups, who were quite similar to each other in terms of cognitive, psychosocial, and vocational outcomes. The results demonstrate overall support for the predictive and concurrent validity of the GOS 6 months post injury. Despite these results, which strengthen the utility and appeal of the GOS for multicentre studies, concerns still remain regarding GOS category 4 (moderate disability), which was shown to lack sufficient discriminability in this study.	Univ Calif Los Angeles, Los Angeles, CA 90024 USA; USC, Sch Med, Dept Neurol, Los Angeles, CA USA; Daniel Freeman Mem Hosp, Los Angeles, CA USA; Univ Texas, Med Ctr, Houston, TX USA; Chicago Inst Neurosurg & Neurores, Chicago, IL 60614 USA	Satz, P (corresponding author), Univ Calif Los Angeles, NPI Room C80747,760 Westwood Plaza, Los Angeles, CA 90024 USA.			Martin, Neil/0000-0002-6565-4131			Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BROOKS N, 1987, NEUROBEHAVIORAL RECO, P57; BROOKS N, 1979, INT REHABIL MED, V1, P166; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; DEROGATIS LR, 1983, SYMPTOM CHECKLIST 90; EISENBERG HM, 1983, CENTRAL NERVOUS SYST, P271; GRANT I, 1987, NEUROBEHAVIORAL RECO, P57; HUTTER O, 1993, NEUROSURGERY, V33, P99; JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Marshall LF, 1987, NEUROBEHAVIORAL RECO, P206; NELSON LD, 1989, J CONSULT CLIN PSYCH, V1, P266; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; SATZ P, 1996, PSYCHOL ASSESSMENT, V8, P1; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; UZZELL BP, 1987, SURG NEUROL, V27, P419, DOI 10.1016/0090-3019(87)90247-3; UZZELL BP, 1988, SURG NEUROL, V29, P246, DOI 10.1016/0090-3019(88)90016-X; WETZLER S, 1993, J PERS ASSESS, V60, P1, DOI 10.1207/s15327752jpa6001_1; WETZLER S, 1989, J PERS ASSESS, V53, P22, DOI 10.1207/s15327752jpa5301_3	23	50	52	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1998	12	7					555	567		10.1080/026990598122322			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZX249	WOS:000074495200002	9653519				2021-06-18	
J	Mautes, AEM; Kim, DH; Sharp, FR; Panter, S; Sato, M; Maida, N; Bergeron, M; Guenther, K; Noble, LJ				Mautes, AEM; Kim, DH; Sharp, FR; Panter, S; Sato, M; Maida, N; Bergeron, M; Guenther, K; Noble, LJ			Induction of heme oxygenase-1 (HO-1) in the contused spinal cord of the rat	BRAIN RESEARCH			English	Article						heat shock protein; heme oxygenase; contusion injury; microglia; macrophage	TRANSIENT FOREBRAIN ISCHEMIA; TRAUMATIC BRAIN INJURY; HSP32 MESSENGER-RNA; HEAT-SHOCK; CEREBRAL-ISCHEMIA; PROTEIN; EXPRESSION; STRESS; GENE; FIBROBLASTS	The induction of heme oxygenase-1 (HO-1) was studied in intact spinal cords and injured spinal cords after a moderate, thoracic contusion injury. HO-1 was immunolocalized in the normal cord and along the axis of the cord at 1, 2, 3 and 4 days after contusion. Induction of this enzyme in astrocytes and microglia/macrophages was evaluated using immunofluorescent double labeling with monoclonal antibodies to HO-1 and either glial fibrillary acidic protein or the complement C3bi receptor. HO-1 was expressed in neurons in the normal spinal cord. After contusion, HO-1 was induced in both gray and white matter at the impact site. In segments of cord that were 1 cm proximal or distal to the injury, HO-1 was primarily induced in the dorsal columns and occasionally in the lateral white matter. This pattern of induction was noted at all time points. The HO-1 was induced primarily in microglia/macrophages. The distribution of the HO-1 positive cells closely correlated with the pattern of intraparenchymal hemorrhage. These findings demonstrate acute induction of HO-1 in non-neuronal cells in the injured spinal cord. Induction of HO-1 in glia may be a consequence of multiple factors including exposure to heme proteins, hypoxia and oxidative stress. (C) 1998 Elsevier Science B.V. All rights reserved.	Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco State Univ, Grad Program Phys Therapy, San Francisco, CA USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA; Vet Adm Med Ctr, San Francisco, CA 94121 USA	Noble, LJ (corresponding author), Univ Calif San Francisco, Dept Neurosurg, 521 Parnassus Ave,Room C224, San Francisco, CA 94143 USA.			Rui, Yanning/0000-0002-4482-5579; Kim, Dong/0000-0002-1523-6396	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS23324] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023324] Funding Source: NIH RePORTER		ALAM J, 1992, J BIOL CHEM, V267, P21894; ANATHAN J, 1986, SCIENCE, V232, P522; APPLEGATE LA, 1991, CANCER RES, V51, P974; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Dwyer BE, 1996, MOL BRAIN RES, V38, P251, DOI 10.1016/0169-328X(95)00341-O; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; DWYER BE, 1995, NEUROREPORT, V6, P973, DOI 10.1097/00001756-199505090-00006; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; EWING JF, 1992, J NEUROCHEM, V58, P1140, DOI 10.1111/j.1471-4159.1992.tb09373.x; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Geddes JW, 1996, NEUROSCI LETT, V210, P205, DOI 10.1016/0304-3940(96)12703-8; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; KEYSE SM, 1990, CARCINOGENESIS, V11, P787, DOI 10.1093/carcin/11.5.787; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kim DH, 1996, NEUROREPORT, V7, P2221, DOI 10.1097/00001756-199609020-00033; MAINES MD, 1984, CRC CR REV TOXICOL, V12, P241, DOI 10.3109/10408448409021604; MAINES MD, 1993, J PHARMACOL EXP THER, V264, P457; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Matz PG, 1996, J NEUROSURG, V85, P892, DOI 10.3171/jns.1996.85.5.0892; MAUTES A, 1996, 14 ANN M NEUR SOC WA; MULLER RM, 1987, J BIOL CHEM, V262, P6795; Nimura T, 1996, MOL BRAIN RES, V37, P201, DOI 10.1016/0169-328X(95)00315-J; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; OKINAGA S, 1993, EUR J BIOCHEM, V212, P167, DOI 10.1111/j.1432-1033.1993.tb17647.x; PANNIZON KL, 1996, NEUROREPORT, V7, P662; PASCHEN W, 1994, NEUROSCI LETT, V180, P5, DOI 10.1016/0304-3940(94)90900-8; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; Takeda A, 1996, NEUROSCI LETT, V205, P169, DOI 10.1016/0304-3940(96)12405-8; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; TRAKSHEL GM, 1986, J BIOL CHEM, V261, P1131	34	50	50	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 8	1998	795	1-2					17	24		10.1016/S0006-8993(98)00230-3			8	Neurosciences	Neurosciences & Neurology	100FY	WOS:000074806500003	9622586				2021-06-18	
J	Chesnut, RM; Gautille, T; Blunt, BA; Klauber, MR; Marshall, LF				Chesnut, RM; Gautille, T; Blunt, BA; Klauber, MR; Marshall, LF			Neurogenic hypotension in patients with severe head injuries	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							SCORE; BRAIN	Objective: To examine the occurrence of hypotensive episodes in patients with severe traumatic brain injuries that are not of hypovolemic origin and to investigate possible neurogenic or iatrogenic causes of such episodes. Methods: We reviewed Traumatic Coma Data Bank (TCDB) records of the 248 patients with early hypotension. We attempted to eliminate episodes related to hemorrhagic hypovolemia by excluding patients with (1) extracranial injuries of Abbreviated Injury Scale scores > 3 (n = 99, 40%); (2) postresuscitation hematocrit levels < 35% (n = 76, 30.6%); (3) hematocrit levels decreasing to <35% during the first 24 hours after injury (n = 47, 19%); and (4) patients with conflicting data (n = 5, 2%), This left 21 patients (8.5%) without discernible extracranial causes for their hypotension. Results: Of these 21 patients, 4 had no extracranial injuries and 4 had only a single injury with Abbreviated Injury Scale score = 1, Hypotensive episodes were not associated with terminal or unsalvageable status. Mortality was 43%, Of the multiple factors investigated, the only two that were strongly associated with these "unexplained" hypotensive episodes were the presence of a diffuse injury pattern on computed tomography (n = 15, 71%) and the early use of mannitol or furosemide (n = 16, 76%) (It was policy at TCDB centers that hypotensive patients not receive diuretics until they were resuscitated,) Conclusions: (1) Some episodes of severe traumatic brain injury-related hypotension may be of neurogenic origin. (2) The risk/benefit ratio of early diuretic use in patients with severe traumatic brain injuries may be too high to support liberal use. These data strongly support the need for a study involving prospective collection of data describing the early blood pressure courses in such patients.	Oregon Hlth & Sci Univ, Dept Neurosurg L472, Portland, OR 97201 USA; Univ Calif San Diego, Med Ctr, Dept Surg, Div Neurosurg, San Diego, CA 92103 USA; Univ Calif San Diego, Med Ctr, Dept Family & Community Med, San Diego, CA 92103 USA; Univ Calif San Francisco, Med Ctr, Dept Radiol, San Francisco, CA 94143 USA	Chesnut, RM (corresponding author), Oregon Hlth & Sci Univ, Dept Neurosurg L472, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	chesnutr@ohsu.edu		Chesnut, Randall/0000-0001-6377-3666	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS032341, N01NS032339, N01NS032340] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01-NS-3-2339, N01-NS-3-2340, N01-NS-3-2341] Funding Source: Medline		BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brown F. D., 1982, HEAD INJURY BASIC CL, P151; BULLOCK R, 1996, GUIDELINES MANAGEMEN; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; *COMM INJ SEV, 1985, ABBR INJ SCAL 1985 R; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; CROCKARD A, 1982, J NEUROSURG, V57, P203, DOI 10.3171/jns.1982.57.2.0203; DUNPHY JE, 1977, CURRENT SURG DIAGNOS; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fulton R L, 1993, J Invest Surg, V6, P117, DOI 10.3109/08941939309141603; ILLINGWORTH G, 1965, LANCET, V2, P511; ISRAEL RS, 1988, ANN EMERG MED, V17, P560; JENNETT B, 1975, LANCET, V1, P480; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; ROSNER MJ, 1982, HEAD INJURY BASIC CL, P103; TEASDALE G, 1974, LANCET, V2, P81; TRUNKEY D, 1982, HDB SURG, P1	25	50	53	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1998	44	6					958	963		10.1097/00005373-199806000-00003			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	ZU123	WOS:000074164600003	9637149				2021-06-18	
J	Copeland, CE; Mitchell, KA; Brumback, RJ; Gens, DR; Burgess, AR				Copeland, CE; Mitchell, KA; Brumback, RJ; Gens, DR; Burgess, AR			Mortality in patients with bilateral femoral fractures	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						bilateral femoral fractures; blunt trauma; mortality; adult respiratory distress syndrome	PROPHYLACTIC MECHANICAL VENTILATION; RESPIRATORY-DISTRESS SYNDROME; EARLY INTERNAL-FIXATION; INJURY SEVERITY SCORE; MULTIPLE INJURIES; FAT-EMBOLISM; TRAUMA	Objectives: To determine and compare the mortality rates of patients with bilateral versus unilateral femoral fractures and to determine the contribution of the femoral fracture to, and identify risk factors for, such mortality. Study Design: Retrospective analysis using trauma registry data on consecutive blunt trauma patients with unilateral (800 patients, group I) or bilateral (eighty-five patients, group II) femoral fractures. Methods: Univariate data analysis was performed to compare the groups' ages, Injury Severity Scores, Glasgow Coma Scale values, mortality, and the presence of adult respiratory distress syndrome (ARDS). Logistic regression analysis was performed to determine variables statistically associated with mortality. Results: Group II patients had a significantly higher Injury Severity Score (30.2 versus 24.5, p < 0.001), lower Glasgow Coma Scale value (12.3 versus 13.1, p = 0.05), higher mortality rate (25.9 vs 11.7%, p < 0.001), and higher incidence of ARDS (15.7 versus 7.27%, p = 0.014) than group I patients. Group II patients also had significantly more closed head injuries, open skull fractures, intraabdominal injuries requiring surgical intervention, and pelvic fractures; the rates of thoracic injury were similar. Regression analysis of variables evident on admission revealed a significant correlation between bilateral femoral fractures and death; however, other factors (shock, closed head injury, and thoracic injury) had much stronger correlations with mortality. Conclusions: Patients with bilateral femoral fractures have a significantly higher risk of death, ARDS, and associated injuries than patients with unilateral femoral fractures. This increase in mortality is more closely related to associated injuries and physiologic parameters than to the presence of bilateral femoral fractures. The presence of bilateral femoral fractures should alert the clinician to the likelihood of associated injuries, a higher Injury Severity Score, and the potential for a more serious prognosis.	Univ Maryland, Med Syst, R Adams Cowley Shock Trauma Ctr, Sect Orthopaed, Baltimore, MD 21201 USA	Copeland, CE (corresponding author), Care of Bulson EP, Univ Maryland, Med Syst, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA.						ALLARDYCE DB, 1974, J TRAUMA, V14, P955, DOI 10.1097/00005373-197411000-00008; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BALK R, 1983, MED CLIN N AM, V67, P685, DOI 10.1016/S0025-7125(16)31197-X; BEAM HP, 1980, J TRAUMA, V20, P399, DOI 10.1097/00005373-198020050-00006; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; CARLSON DA, 1995, CLIN ORTHOP RELAT R, P115; DENDRINOS G, 1993, J TRAUMA, V34, P157, DOI 10.1097/00005373-199301000-00032; Dunham C M, 1989, Md Med J, V38, P227; GORIS RJA, 1982, J TRAUMA, V22, P895, DOI 10.1097/00005373-198211000-00002; GORIS RJA, 1982, INJURY, V14, P39, DOI 10.1016/S0020-1383(82)80010-7; GORIS RJA, 1982, J TRAUMA, V22, P141, DOI 10.1097/00005373-198202000-00011; Hosmer D, 1989, APPL LOGISTIC REGRES; Johnson K D, 1990, Instr Course Lect, V39, P565; JOHNSON KD, 1985, J TRAUMA, V25, P375, DOI 10.1097/00005373-198505000-00001; MEEK RN, 1986, INJURY, V17, P2, DOI 10.1016/0020-1383(86)90003-3; RISKA EB, 1982, J TRAUMA, V22, P891, DOI 10.1097/00005373-198211000-00001; RISKA EB, 1977, J TRAUMA, V17, P111, DOI 10.1097/00005373-197702000-00005; RISKA EB, 1976, INJURY, V8, P110, DOI 10.1016/0020-1383(76)90043-7; WU CC, 1992, J TRAUMA, V32, P289, DOI 10.1097/00005373-199203000-00004	20	50	51	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	JUN-JUL	1998	12	5					315	319		10.1097/00005131-199806000-00003			5	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	ZW514	WOS:000074418600003	9671181				2021-06-18	
J	Miller, W; Riehl, E; Napier, M; Barber, K; Dabideen, H				Miller, W; Riehl, E; Napier, M; Barber, K; Dabideen, H			Use of physician assistants as surgery/trauma house staff at an American College of Surgeons-verified Level II trauma center	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							NURSE PRACTITIONERS; CARE; RESIDENTS; QUALITY	Background: Historically, surgical physicians staff trauma centers, which provide trauma patients with improved outcomes, Such benefits fuel the expansion of designated trauma centers, Cutbacks in residency programs of surgical specialties, however, necessitate substitutions for traditional trauma providers. Methods: A literature and record review was conducted to examine the use of physician assistants in a large community hospital's verified trauma center, Current and historical outcomes were analyzed regarding the trauma surgeon/physician assistant model. Results: Injury Severity Scores increased 19%, transfer time to the operating room decreased 43%, transfer time to the intensive care unit decreased 51%, and transfer time to the floor decreased 20%, The length of stay for admissions decreased 13%, and the length of stay for neurotrauma intensive care unit patients decreased 33%. Conclusion: The Hurley Medical Center trauma surgeon/ physician assistant model is a viable alternative for verified trauma centers unable to maintain a surgical residency program. Consistency and quality of care indicated by shortened length of stay is a hallmark of such a model providing the highest quality of care.	Hurley Med Ctr, Trauma Serv, Dept Physician Assistants, PA C, Flint, MI 48503 USA; Hurley Med Ctr, Dept Trauma, Flint, MI USA; Hurley Med Ctr, Res Dept, Flint, MI USA	Miller, W (corresponding author), Hurley Med Ctr, Trauma Serv, Dept Physician Assistants, PA C, Flint, MI 48503 USA.						*AM AC PHYS ASS, 1997, INF UPD PROJ NUMB PH; *AM AC PHYS ASS, 1997, PHYS ASS STAT TRENDS; CARZOLI RP, 1994, ARCH PEDIAT ADOL MED, V148, P1271, DOI 10.1001/archpedi.1994.02170120033005; DUBAYBO BA, 1991, CHEST, V99, P89, DOI 10.1378/chest.99.1.89; GOLDFRANK L, 1980, ANN EMERG MED, V9, P96, DOI 10.1016/S0196-0644(80)80338-6; Hooker RS, 1996, AM J EMERG MED, V14, P245, DOI 10.1016/S0735-6757(96)90167-9; JONES PE, 1994, JAMA-J AM MED ASSOC, V271, P1266, DOI 10.1001/jama.271.16.1266; MAXFIELD RG, 1975, TRAUMA, V15, P795; RECORD JC, 1980, J HEALTH POLIT POLIC, V5, P470; RIPORTELLAMULLER R, 1995, HEALTH AFFAIR, V14, P181, DOI 10.1377/hlthaff.14.2.181; SCHULMAN M, 1995, AM J PERINAT, V12, P442, DOI 10.1055/s-2007-994517; SOX HC, 1994, ANN INTERN MED, V121, P714, DOI 10.7326/0003-4819-121-9-199411010-00014; SPISSO J, 1990, J TRAUMA, V30, P660, DOI 10.1097/00005373-199006000-00001	13	50	50	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	1998	44	2					372	376		10.1097/00005373-199802000-00025			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	YZ995	WOS:000072317300026	9498514				2021-06-18	
J	Zhang, RL; Shohami, E; BeitYannai, E; Bass, R; Trembovler, V; Samuni, A				Zhang, RL; Shohami, E; BeitYannai, E; Bass, R; Trembovler, V; Samuni, A			Mechanism of brain protection by nitroxide radicals in experimental model of closed-head injury	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						spin label; oxidative damage; superoxide; transition metals; traumatic brain injury	BUTYL-ALPHA-PHENYLNITRONE; MEMBRANE-ASSOCIATED PROTEINS; INDUCED LIPID-PEROXIDATION; CENTRAL-NERVOUS-SYSTEM; OXYGEN FREE-RADICALS; POSTTRAUMATIC HYPOTHERMIA; SUPEROXIDE-DISMUTASE; OXIDATIVE DAMAGE; RAT-BRAIN; EDEMA	Reactive oxygen-derived species wen previously implicated in mediation of post-traumatic brain damage: however, the efficacy of traditional antioxidants in preventing/reversing the damage is sometimes limited. The present work focused on the mechanisms underlying the neuroprotective activity of cell permeable, nontoxic, antioxidants, namely stable nitroxide radicals in an experimental model of rat closed-head injury. Brain damage was induced by the weight-drop method and the clinical status was evaluated according to a neurological severity score at 1 h and 24 h, where the difference between these scores reflects the extent of recovery. The metal chelator deferoxamine as well as three nitroxide derivatives, differing in hydrophilicity and charge, and one hydroxylamine (a reduced nitroxide) facilitated the clinical recovery and decreased the brain edema. The nitroxides. but neither the hydroxylamine nor deferoxamine, protected the integrity of the blood-brain barrier. Superoxide dismutase also improved the clinical recovery but did not affect brain edema or the blood-brain barrier. The results suggest that by switching back and forth between themselves, the nitroxide and hydroxylamine act catalytically as self-replenishing antioxidants, and protect brain tissue by terminating radical-chain reactions, oxidizing deleterious metal ions, and by removal of intracellular superoxide. (C) 1998 Elsevier Science Inc.	HEBREW UNIV JERUSALEM, SCH MED, FAC MED, DEPT BIOL MOL, IL-91120 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, FAC MED, DEPT PHARMACOL, IL-91120 JERUSALEM, ISRAEL			Beit-Yannai, Elie/F-2141-2012	Beit-Yannai, Elie/0000-0001-9347-822X			BAGCHI M, 1995, FREE RADICAL BIO MED, V19, P867, DOI 10.1016/0891-5849(95)00088-F; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; Butterfield DA, 1997, P NATL ACAD SCI USA, V94, P674, DOI 10.1073/pnas.94.2.674; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HAHN SM, 1992, RADIAT RES, V132, P87, DOI 10.2307/3578338; HALL NC, 1995, NEUROSCIENCE, V69, P591, DOI 10.1016/0306-4522(95)00289-U; HALLIWELL B, 1989, ACTA NEUROL SCAND, V80, P23, DOI 10.1111/j.1600-0404.1989.tb01779.x; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Howard BJ, 1996, J NEUROCHEM, V67, P2045; IKEDA Y, 1990, NEUROSURGERY, V27, P1; IKEDA Y, 1989, NEUROSURGERY, V24, P820, DOI 10.1227/00006123-198906000-00006; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KRISHNA MC, 1994, METHOD ENZYMOL, V234, P580; Krishna MC, 1996, J BIOL CHEM, V271, P26026, DOI 10.1074/jbc.271.42.26026; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; Krishna MC, 1996, J BIOL CHEM, V271, P26018, DOI 10.1074/jbc.271.42.26018; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MORI A, 1990, PAVLOVIAN J BIOL SCI, V25, P54; RACHMILEWITZ D, 1994, GUT, V35, P1181, DOI 10.1136/gut.35.9.1181; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SAMUNI A, 1991, BIOCHEMISTRY-US, V30, P555, DOI 10.1021/bi00216a033; SAMUNI A, 1991, J CLIN INVEST, V87, P1526, DOI 10.1172/JCI115163; Samuni AM, 1997, FREE RADICAL BIO MED, V22, P1165, DOI 10.1016/S0891-5849(96)00509-6; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SWARTZ HM, 1990, FREE RADICAL RES COM, V9, P399, DOI 10.3109/10715769009145700; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; WHITE BC, 1993, ANN EMERG MED, V22, P970, DOI 10.1016/S0196-0644(05)82737-4; WILLMORE LJ, 1991, INT J DEV NEUROSCI, V9, P175, DOI 10.1016/0736-5748(91)90009-B; WILSON JT, 1995, J TRAUMA, V39, P473; YUE TL, 1992, BRAIN RES, V574, P193, DOI 10.1016/0006-8993(92)90816-R	43	50	52	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	JAN 15	1998	24	2					332	340		10.1016/S0891-5849(97)00267-0			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	YL368	WOS:A1998YL36800016	9433909				2021-06-18	
J	Rosenbower, TJ; Morris, JA; Eddy, VA; Ries, WR				Rosenbower, TJ; Morris, JA; Eddy, VA; Ries, WR			The long-term complications of percutaneous dilatational tracheostomy	AMERICAN SURGEON			English	Article; Proceedings Paper	65th Annual Scientific Meeting and Postgraduate Course Program of the Southeastern-Surgical-Congress	FEB 01-05, 1997	NASHVILLE, TENNESSEE	SE Surg Congress			CRITICALLY ILL PATIENTS; INTENSIVE-CARE UNIT; DILATIONAL TRACHEOSTOMY; BEDSIDE PROCEDURE; TRACHEOTOMY; TRIAL	Percutaneous dilatational tracheostomy was adopted at our institution, because it was demonstrated to be more cost effective than standard open tracheostomy in critically ill patients. The objective of this study was to evaluate the long-term outcome and complication rate of percutaneous dilatational tracheostomy in critically ill patients. We performed a consecutive case study of all Level I trauma patients from August 1991 to May 1994 who underwent percutaneous dilatational tracheostomy. All patients were prospectively evaluated by a standard questionnaire a minimum of 1 year after the procedure. All symptomatic patients were offered fiberoptic laryngoscopy. Descriptive statistical methods and the Student's T test were used to analyze the data. Of 7054 consecutive trauma admissions, 237 tracheostomies were performed. A total of 143 tracheostomies (60%) were open, and 95 (40%) were percutaneous. Of the 95 patients, 20 were lost to follow-up, 12 died from causes unrelated to the procedure, 6 had severe traumatic brain injuries and were unable to participate, and 2 patients required conversion to an open procedure. This left a study group of 55 patients. At a minimum of 1 year follow-up, 40 patients (73%) were asymptomatic. Of the 15 (27%) symptomatic patients, two patients had acute airway compromise after decannulation secondary to subglottic stenosis. Both were recannulated and subsequently decannulated uneventfully. Six patients declined fiberoptic laryngoscopy, because their symptoms were minimal (minor voice changes in three and intermittent hoarseness in three). Nine patients underwent fiberoptic laryngoscopy, and all examinations were normal. The mean cost of standard open tracheostomy at our institution is $1134 (58%) more than the mean cost of percutaneous dilatational tracheostomy. Of the study group patients undergoing percutaneous dilatational tracheostomy, 27 per cent complained of symptoms a minimum of 1 year posttracheostomy, Of these patients, 60 per cent underwent fiberoptic laryngoscopy, and no subglottic lesions were identified. Our findings suggest that percutaneous dilatational tracheostomy is a safe, cost-effective alternative to standard tracheostomy in critically ill patients.	Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Otolaryngol, Nashville, TN 37212 USA	Rosenbower, TJ (corresponding author), 1103 N Elm St, Greensboro, NC 27401 USA.						BODENHAM A, 1991, ANAESTHESIA, V46, P570, DOI 10.1111/j.1365-2044.1991.tb09659.x; CIAGLIA P, 1992, CHEST, V101, P464, DOI 10.1378/chest.101.2.464; CIAGLIA P, 1985, CHEST, V87, P715, DOI 10.1378/chest.87.6.715; DEVITA MA, 1990, CRIT CARE MED, V18, P1328, DOI 10.1097/00003246-199012000-00004; FRIEDMAN Y, 1993, CHEST, V104, P532, DOI 10.1378/chest.104.2.532; GRIGGS WM, 1990, SURG GYNECOL OBSTET, V170, P543; HAZARD P, 1991, CRIT CARE MED, V19, P1018, DOI 10.1097/00003246-199108000-00008; HAZARD PB, 1988, ANN THORAC SURG, V46, P63, DOI 10.1016/S0003-4975(10)65854-7; HEFFNER JE, 1986, CHEST, V90, P430, DOI 10.1378/chest.90.3.430; IVATURY R, 1992, J TRAUMA, V32, P133, DOI 10.1097/00005373-199202000-00004; MARELLI D, 1990, J TRAUMA, V30, P433, DOI 10.1097/00005373-199030040-00012; MOORE FA, 1992, J TRAUMA, V33, P435, DOI 10.1097/00005373-199209000-00017; MYERS EN, 1991, CLIN CHEST MED, V12, P589; PAUL A, 1989, ANN THORAC SURG, V47, P314, DOI 10.1016/0003-4975(89)90301-9; RILEY H, 1993, COMPLICATIONS HEAD N, P257; SCHACHNER A, 1989, CRIT CARE MED, V17, P1052, DOI 10.1097/00003246-198910000-00017; STOCK MC, 1986, CRIT CARE MED, V14, P861, DOI 10.1097/00003246-198610000-00005; TOURSARKISSIAN B, 1994, ANN THORAC SURG, V57, P862, DOI 10.1016/0003-4975(94)90191-0; WOOD DE, 1991, CLIN CHEST MED, V12, P597	19	50	50	0	0	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	JAN	1998	64	1					82	86					5	Surgery	Surgery	YT981	WOS:000071667500028	9457043				2021-06-18	
J	Petras, JM; Bauman, RA; Elsayed, NM				Petras, JM; Bauman, RA; Elsayed, NM			Visual system degeneration induced by blast overpressure	TOXICOLOGY			English	Article; Proceedings Paper	Symposium on the Molecular Mechanism(s) of Blast Overpressure-Induced Injury	OCT   26, 1995	WALTER REED ARMY INST RES, WASHINGTON, DC		WALTER REED ARMY INST RES	brain injury; visual; axonopathy; blast overpressure; rats	SUPERIOR COLLICULUS; INJURIES; NUCLEUS; MAMMALS; EAR	The effect of blast overpressure on visual system pathology was studied in 14 male Sprague-Dawley rats weighing 360-432 g. Blast overpressure was simulated using a compressed-air driven shock tube, with the aim of studying a range of overpressures causing sublethal injury. Neither control (unexposed) rats nor rats exposed to 83 kiloPascals (kPa) overpressure showed evidence of visual system pathology. Neurological injury to brain visual pathways was observed in male rats surviving blast overpressure exposures of 104-110 kPa and 129-173 kPa. Optic nerve fiber degeneration was ipsilateral to the blast pressure wave. The optic chiasm contained small numbers of degenerated fibers. Optic tract fiber degeneration was present bilaterally, but was predominantly ipsilateral. Optic tract fiber degeneration was followed to nuclear groups at the level of the midbrain, midbrain-diencephalic junction, and the thalamus where degenerated fibers arborized among the neurons of: (i) the superior colliculus, (ii) pretectal region, and (iii) the lateral geniculate body. The superior colliculus contained fiber degeneration localized principally to two superficial layers (i) the stratum opticum (layer III) and (ii) stratum cinereum (layer II). The pretectal area contained degenerated fibers which were widespread in (i) the nucleus of the optic tract, (ii) olivary pretectal nucleus, (iii) anterior pretectal nucleus, and (iv) the posterior pretectal nucleus. Degenerated fibers in the lateral geniculate body were not universally distributed. They appeared to arborize among neurons of the dorsal and ventral nuclei: the ventral lateral geniculate nucleus (parvocellular and magnocellular parts); and the dorsal lateral geniculate nucleus. The axonopathy observed in the central visual pathways and nuclei of the rat brain are consistent with the presence of blast overpressure induced injury to the retina. The orbital cavities of the human skull contain frontally-directed eyeballs for binocular vision. Humans looking directly into an oncoming blast wave place both eyes at risk. With bilateral visual system injury, neurological deficits may include loss or impairments of ocular movements, and of the pupillary and accommodation reflexes, retinal hemorrhages, scotomas, and general blindness. These findings suggest that the retina should be investigated for the presence of traumatic or ischemic cellular injury, hemorrhages, scotomas, and retinal detachment. (C) 1997 Elsevier Science Ireland Ltd.	WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,DIV MED,DEPT RESP RES,WASHINGTON,DC 20307; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT ENVIRONM & OCCUPAT HLTH SCI,LOS ANGELES,CA 90024	Petras, JM (corresponding author), WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,DIV NEUROSCI,DEPT NEUROBEHAV ASSESSMENT,WASHINGTON,DC 20307, USA.						Abbott WD, 1943, J AMER MED ASSOC, V121, P664, DOI 10.1001/jama.1943.02840090034010; ALBANO JE, 1982, J NEUROPHYSIOL, V48, P318; ASCROFT PB, 1943, LANCET, V244, P234; Barrow DW, 1944, J AMER MED ASSOC, V125, P900, DOI 10.1001/jama.1944.02850310020006; BIZZI E, 1981, HDB PHYSL 1, V2, P1321; BRISMAR B, 1982, J TRAUMA, V22, P216, DOI 10.1097/00005373-198203000-00007; Buttner-Ennever J A, 1979, Prog Brain Res, V50, P619; BUTTNERENNEVER JA, 1982, BRAIN, V105, P125, DOI 10.1093/brain/105.1.125; CAMMERMEYER J, 1962, Ergeb Anat Entwicklungsgesch, V36, P1; CAMMERMEYER J, 1978, HISTOCHEMISTRY, V56, P97, DOI 10.1007/BF00508437; CAMMERMEYER J, 1960, EXP NEUROL, V2, P379, DOI 10.1016/0014-4886(60)90022-4; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; CAMPBELL CB, 1969, ANN NY ACAD SCI, V167, P388, DOI 10.1111/j.1749-6632.1969.tb20458.x; CELANDER H, 1955, ACTA PHYSL SCAND, V33, P5; CHAIT RH, 1989, ANN OTO RHINOL LARYN, V98, P9; CLEMEDSON C.-J., 1957, ACTA PATHOL ET MICROBIOL SCAND, V40, P89; COHEN B, 1968, ARCH NEUROL-CHICAGO, V18, P78, DOI 10.1001/archneur.1968.00470310092008; COOPER GJ, 1983, J TRAUMA, V23, P955, DOI 10.1097/00005373-198311000-00001; CUMMINGS JF, 1977, J COMP NEUROL, V173, P655, DOI 10.1002/cne.901730404; CUMMINGS JF, 1969, ANN NY ACAD SCI, V167, P293, DOI 10.1111/j.1749-6632.1969.tb20452.x; Drury RAB, 1980, CARLETONS HISTOLOGIC; Ebbesson S.O.E., 1970, CONT RES METHODS NEU, P132; FINK ROBERT P., 1967, BRAIN RES, V4, P369, DOI 10.1016/0006-8993(67)90166-7; FRYBERG ER, 1988, ANN SURG, V208, P569; HAYHOW WR, 1959, J COMP NEUROL, V113, P281, DOI 10.1002/cne.901130205; HENN V, 1984, BRAIN, V107, P619, DOI 10.1093/brain/107.2.619; Henn V, 1982, Hum Neurobiol, V1, P77; Henn V, 1982, Hum Neurobiol, V1, P87; HIRSCH FG, 1968, ANN NY ACAD SCI, V152, P147, DOI 10.1111/j.1749-6632.1968.tb11972.x; KEREN A, 1981, BRIT HEART J, V46, P455; KERR AG, 1975, J LARYNGOL OTOL, V89, P131, DOI 10.1017/S002221510008018X; KERR AG, 1975, BRIT MED J, V1, P559, DOI 10.1136/bmj.1.5957.559; LEIGH RJ, 1983, NEUROLOGY EYE MOVEME; MASON WV, 1971, P SOC EXP BIOL MED, V136, P1253; MILLER JD, 1993, AM J PHYSIOL, V264, pR821; MOE JB, 1986, NATO ASI SERIES A, V111, P473; MORIN LP, 1994, BRAIN RES REV, V67, P102; Nauta W. J. H., 1970, CONT RES METHODS NEU; NAUTA WJH, 1951, STAIN TECHNOL, V26, P5, DOI 10.3109/10520295109113170; NAUTA WJH, 1954, STAIN TECHNOL, V29, P91, DOI 10.3109/10520295409115448; PHILLIPS YY, 1986, ANN EMERG MED, V15, P1446, DOI 10.1016/S0196-0644(86)80940-4; PHILLIPS YY, 1989, ANN OTOL RHINOL S140, V98, P17; PHILLIPS YY, 1991, TXB MILITARY MED 1, V5, P221; Phillips YY, 1991, CONVENTIONAL WARFARE, P295; Richmond D R, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P35; RICHMOND DR, 1968, NEW YORK ACAD SCI, V152, P103; ROBERTO M, 1989, ANN OTO RHINOL LARYN, V98, P23; ROBINSON DA, 1981, HDB PHYSL NERVOUS SY, V2, P1275; SCALIA F, 1972, J COMP NEUROL, V145, P223, DOI 10.1002/cne.901450208; Sharpnack D.D., 1991, TXB MILITARY MED, V1, P271; WHITE CS, 1970, SPACE LIFE SCI, V2, P158, DOI 10.1007/BF01101282; WHITE CS, 1967, DASA2064, pR1; WHITE CS, 1960, CLINICAL CARDIOPULMO, P974; WURTZ RH, 1980, ANNU REV NEUROSCI, V3, P189, DOI 10.1146/annurev.ne.03.030180.001201; ZEE DS, 1986, DIS NERVOUS SYSTEM C, V1, P507; Zuckerman S, 1940, LANCET, V2, P219	56	50	52	0	4	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0300-483X			TOXICOLOGY	Toxicology	JUL 25	1997	121	1					41	49		10.1016/S0300-483X(97)03654-8			9	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	XG756	WOS:A1997XG75600004	9217314				2021-06-18	
J	Feldman, Z; Robertson, CS				Feldman, Z; Robertson, CS			Monitoring of cerebral hemodynamics with jugular bulb catheters	CRITICAL CARE CLINICS			English	Article							VENOUS OXYGEN-SATURATION; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; FLUID-PERCUSSION INJURY; BLOOD-FLOW VELOCITY; CARDIOPULMONARY BYPASS; INTRACRANIAL HYPERTENSION; COMATOSE PATIENTS; METABOLISM; HYPOXIA	Jugular venous oxygen saturation (SjvO(2)) monitoring is useful for detecting episodes of cerebral hypoxia/ischemia in patients with head injury, patients undergoing neurosurgical procedures, and patients undergoing cardiopulmonary bypass. The use of SjvO(2) monitoring can direct the treatment of ischemic episodes and identify the optimal level of cerebral perfusion pressure and PCO2 for the individual patient.		Feldman, Z (corresponding author), BAYLOR COLL MED,DEPT NEUROSURG,6560 FANNIN,SUITE 900,HOUSTON,TX 77030, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; BANKIER AA, 1995, AM J ROENTGENOL, V164, P437, DOI 10.2214/ajr.164.2.7839985; BUSIJA DW, 1988, AM J PHYSIOL, V255, pH343; CALON B, 1995, J NEUROSURG, V83, P910, DOI 10.3171/jns.1995.83.5.0910; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1992, SURG NEUROL, V38, P433, DOI 10.1016/0090-3019(92)90111-Y; CHAN KH, 1993, NEUROSURGERY, V32, P547; CHAN KH, 1992, NEUROSURGERY, V30, P697; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183; CROUGHWELL N, 1992, J THORAC CARDIOV SUR, V103, P549; CROUGHWELL ND, 1995, J CARDIAC SURG, V10, P503, DOI 10.1111/j.1540-8191.1995.tb00685.x; CROUGHWELL ND, 1994, ANN THORAC SURG, V58, P1702, DOI 10.1016/0003-4975(94)91666-7; CROUGHWELL ND, 1992, ANN THORAC SURG, V53, P827, DOI 10.1016/0003-4975(92)91445-F; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; DENYS BG, 1991, CRIT CARE MED, V19, P1516, DOI 10.1097/00003246-199112000-00013; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; FINNERTY FA, 1954, J CLIN INVEST, V33, P1227, DOI 10.1172/JCI102997; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GARLICK R, 1987, SCAND J CLIN LAB INV, V47, P47; Gibbs EL, 1942, J BIOL CHEM, V144, P325; GIBBS EL, 1945, AM J PSYCHIAT, V102, P184, DOI 10.1176/ajp.102.2.184; GIBBS EL, 1934, ANAT REC, V54, P419; GOETTING MG, 1991, INTENS CARE MED, V17, P195, DOI 10.1007/BF01709876; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GOPINATH SP, UNPUB ANESTH ANALG; HATIBOGLU MT, 1992, J ANAT, V180, P191; HAYMAN AL, IN PRESS EMERGENCY R; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JAKOBSEN M, 1989, J CEREBR BLOOD F MET, V9, P717, DOI 10.1038/jcbfm.1989.101; JOHANNSSON H, 1975, ACTA PHYSIOL SCAND, V93, P269, DOI 10.1111/j.1748-1716.1975.tb05815.x; KATAYAMA Y, 1994, J NEUROSURG, V80, P826, DOI 10.3171/jns.1994.80.5.0826; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Lennox WG, 1935, ARCH NEURO PSYCHIATR, V34, P1001, DOI 10.1001/archneurpsyc.1935.02250230073006; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; LYONS C, 1964, ANN SURG, V160, P561, DOI 10.1097/00000658-196410000-00001; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MATTA BF, 1994, ANESTH ANALG, V79, P745; MCCORMICK PW, 1991, CRIT CARE MED, V19, P89, DOI 10.1097/00003246-199101000-00020; MELDRUM BS, 1976, BRAIN, V99, P523, DOI 10.1093/brain/99.3.523; MEYER JS, 1965, NEUROLOGY, V15, P892, DOI 10.1212/WNL.15.10.892; MICHENFELDER JD, 1991, ANESTHESIOLOGY, V75, P130, DOI 10.1097/00000542-199107000-00021; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P435; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NAKAJIMA T, 1992, ANESTH ANALG, V74, P630; NAKAJIMA T, 1993, ANESTH ANALG, V77, P1111; NILSSON B, 1978, CIBA F S, V56, P199; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OKADA M, 1993, JAPANESE J THORACIC, V46, P668; PAULSON OB, 1973, J APPL PHYSIOL, V35, P111; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PIERCE EC, 1962, J CLIN INVEST, V41, P1664, DOI 10.1172/JCI104623; RAICHLE ME, 1976, ARCH NEUROL-CHICAGO, V33, P523, DOI 10.1001/archneur.1976.00500080001001; RITTER AM, IN PRESS J CLIN MONI; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Rosner M., 1987, CEREBRAL BLOOD FLOW, P425; SAPPIRE KJ, UNPUB J THORAC CARDI; SENDFF MG, 1985, INTENS CARE MED, P16; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SHENKIN HA, 1948, ARCH NEURO PSYCHIATR, V60, P240, DOI 10.1001/archneurpsyc.1948.02310030021002; Souter M. J., 1995, Journal of Neurotrauma, V12, P471; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; Stocchetti N, 1991, Minerva Anestesiol, V57, P319; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927	76	50	60	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0749-0704			CRIT CARE CLIN	Crit. Care Clin.	JAN	1997	13	1					51	&		10.1016/S0749-0704(05)70296-7			28	Critical Care Medicine	General & Internal Medicine	WE065	WOS:A1997WE06500005	9012576				2021-06-18	
J	Rzigalinski, BA; Liang, S; McKinney, JS; Willoughby, KA; Ellis, EF				Rzigalinski, BA; Liang, S; McKinney, JS; Willoughby, KA; Ellis, EF			Effect of Ca2+ on in vitro astrocyte injury	JOURNAL OF NEUROCHEMISTRY			English	Article						extracellular Ca2+; intracellular free Ca2+; astrocyte injury; traumatic brain injury	BRAIN INJURY; PLASMA-MEMBRANE; CALCIUM ENTRY; CELLS; NEURONS; STORES; ACID; NEUROTOXICITY; METABOLISM; ANNEXINS	Current literature suggests that a massive influx of Ca2+ into the cells of the CNS induces cell damage associated with traumatic brain injury (TBI). Using an in vitro model for stretch-induced cell injury developed by our laboratory, we have investigated the role of extracellular Ca2+ in astrocyte injury. The degree of injury was assessed by measurement of propidium iodide uptake and release of lactate dehydrogenase. Based on results of in vivo models of TBI developed by others, our initial hypothesis was that decreasing extracellular Ca2+ would result in a reduction in astrocyte injury. Quite unexpectedly, our results indicate that decreasing extracellular Ca2+ to levels observed after in vivo TBI increased astrocyte injury. Elevating the extracellular Ca2+ content to twofold above physiological levels (2 mM) produced a reduction in cell injury. The reduction in injury afforded by Ca2+ could not be mimicked with Ba2+, Mn2+, Zn2+, or Mg2+, suggesting that a Ca2+-specific mechanism is involved. Using Ca-45(2+), we demonstrate that injury induces a rapid influx of extracellular Ca2+ into the astrocyte, achieving an elevation in total cell-associated Ca2+ content two- to threefold above basal levels. Pharmacological elevation of intracellular Ca2+ levels with the Ca2+ ionophore A231 87 or thapsigargin before injury dramatically reduced astrocyte injury. Our data suggest that, contrary to popular assumptions, an elevation of total cell-associated Ca2+ reduces astrocyte injury produced by a traumatic insult.		Rzigalinski, BA (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,BOX 980613,RICHMOND,VA 23298, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27214] Funding Source: Medline		ALLAN D, 1993, PROG LIPID RES, V32, P195, DOI 10.1016/0163-7827(93)90015-O; AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; BARRETT JN, 1994, T AM SOC NEUROCHEM, V25, P207; BERLIN RD, 1993, CELL CALCIUM, V14, P379, DOI 10.1016/0143-4160(93)90042-5; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; CHARLES AC, 1994, DEV NEUROSCI-BASEL, V16, P196, DOI 10.1159/000112107; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DAWIDOWICZ EA, 1987, ANNU REV BIOCHEM, V56, P43, DOI 10.1146/annurev.biochem.56.1.43; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; ERNST JD, 1994, BIOCHEM BIOPH RES CO, V200, P867, DOI 10.1006/bbrc.1994.1531; FINEMAN I, 1990, Society for Neuroscience Abstracts, V16, P778; FLOTT B, 1991, GLIA, V4, P293, DOI 10.1002/glia.440040307; FRANKLIN JL, 1995, J NEUROSCI, V15, P643; GIULIAN D, 1994, NEUROBIOLOGY CNS TRA, P155; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HANSSON E, 1995, FASEB J, V9, P343; HOLZWARTH JA, 1994, J NEUROSCI, V14, P1879; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; INOUE M, 1992, J LIPID RES, V33, P985; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; KLINGMAN JG, 1990, J NEUROSCI METH, V31, P47, DOI 10.1016/0165-0270(90)90008-4; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; LAMB RG, 1995, J NEUROTRAUM, V12, P969; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MICHEL PP, 1994, EUR J NEUROSCI, V6, P577, DOI 10.1111/j.1460-9568.1994.tb00302.x; NAKANISHI K, 1994, BRAIN RES, V659, P169, DOI 10.1016/0006-8993(94)90876-1; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RZIGALINSKI BA, 1996, FASEB J, V10, pA280; SCHOOTEMEIJER A, 1994, EUR J BIOCHEM, V224, P423, DOI 10.1111/j.1432-1033.1994.00423.x; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SHINITZKY M, 1994, PHYSL MEMBRANE FLUID, P1; SJOLIN C, 1994, BIOCHEM J, V300, P325; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; TAVALIN SJ, 1995, J NEUROTRAUM, V12, P144; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSUDA K, 1987, HYPERTENSION, V9, P19; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; XIE XY, 1991, J NEUROSCI, V11, P3257; YOUNG W, 1992, J NEUROTRAUM, V9, pS9	51	50	52	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	JAN	1997	68	1					289	296					8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	VY893	WOS:A1997VY89300035	8978737				2021-06-18	
J	Schob, OM; Allen, DC; Benzel, E; Curet, MJ; Adams, MS; Baldwin, NG; Largiader, F; Zucker, KA				Schob, OM; Allen, DC; Benzel, E; Curet, MJ; Adams, MS; Baldwin, NG; Largiader, F; Zucker, KA			A comparison of the pathophysiologic effects of carbon dioxide, nitrous oxide, and helium pneumoperitoneum on intracranial pressure	AMERICAN JOURNAL OF SURGERY			English	Article								BACKGROUND: Previous studies have suggested that diagnostic laparoscopy may be contraindicated in multiple trauma patients with closed head injuries because of the detrimental effects of carbon dioxide (CO2) pneumoperitoneum on intracranial pressure (ICP). In this study we compared the effects of two alternative inflation gases, helium (He) and nitrous oxide (N2O), against the standard agent used in most hospitals, CO2. ICP was monitored in experimental animals both with and without a space occupying intracranial lesion designed to simulate a closed head injury. METHODS: Twenty-four domestic pigs (mean, 30 kg) were divided into four groups (6 CO2, 6 He, 6 N2O, and 6 control animals without insufflation). All animals were monitored for ICP, intraabdominal pressure, mean arterial pressure, end-tidal CO2 (ETCO(2)), and arterial blood gases. These parameters were measured for 30 minutes prior to introducing a pneumoperitoneum and then for 80 minutes thereafter. The measurements were repeated after artificially elevating the ICP with a balloon placed in the epidural space. RESULTS: The mean ICP increased significantly in all groups during peritoneal insufflation compared with the control group (P <0.005). The CO2-insufflated animals also showed a significant increase in PaCO2 (P <0.05) and ETCO(2) (P <0.05), as well as a decrease in pH (P <0.05). After inflating the epidural balloon the ICP remained significantly higher in animals inflated with CO2 as compared with the He and N2O groups (P <0.05). CONCLUSIONS: Peritoneal insufflation with He and N2O resulted in a significantly less increase in ICP as compared with CO2. That difference was most likely due to a metabolically mediated increase in cerebral perfusion (PaCO2) in the CO2 group. Further studies need to be conducted to determine the safety and efficacy of using He and N2O as inflation agents prior to attempting diagnostic or therapeutic laparoscopy in patients with potential closed head injuries.	UNIV NEW MEXICO,SCH MED,DEPT SURG,ALBUQUERQUE,NM 87131; UNIV ZURICH HOSP,DEPT SURG,CH-8091 ZURICH,SWITZERLAND								0	50	51	0	4	CAHNERS PUBL CO	NEW YORK	249 WEST 17 STREET, NEW YORK, NY 10011	0002-9610			AM J SURG	Am. J. Surg.	SEP	1996	172	3					248	252		10.1016/S0002-9610(96)00101-8			5	Surgery	Surgery	VK095	WOS:A1996VK09500008	8862077				2021-06-18	
J	Tegner, Y; Lorentzon, R				Tegner, Y; Lorentzon, R			Concussion among Swedish elite ice hockey players	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						ice hockey; concussion; management; incidence	HEAD-INJURIES; CEREBRAL CONCUSSION; CONTACT-SPORTS; TRAUMA; GUIDELINES; PREVENTION; MANAGEMENT; IMPACT; MILD	Objective-To evaluate the frequency of concussion in Swedish ice hockey and to establish a uniform grading and treatment model for concussions of different severity. Methods-Frequency of concussion was investigated in two studies, one retrospective and one prospective. In the retrospective study, all Swedish elite ice hockey players (n=265) were asked to answer a questionnaire on the number and treatment of previous concussions. Only concussions diagnosed by a doctor were recorded. The questionnaire was completed by 227 players (86%). In the prospective study, all injuries including concussions occurring during game and practice in the Swedish Elite League (n=12 teams) were recorded during four years. The causes of injury, referees judgements, diagnosis, treatment, and time absent from ice hockey were registered on special cards. Results-In the retrospective study, 51 out of 227 players (22%) in the Swedish Elite League reported at least one concussion. In the prospective study, 52 concussions were reported. The incidence of a concussion is at least one concussion every year/team or a yearly risk of about 5% for a player to sustain a concussion. Most concussions occurred during league play (81%). Body contact (checking or boarding) was the most common cause of concussions. The players were absent from full training and play on a mean of 6 d. Conclusions-As this injury is potentially dangerous it must be treated seriously according to a simple treatment model presented. In cases of repeated concussions during the same season, a longer period of time away from play is suggested. In players who have sustained several concussions over the years a thorough medical examination including EEG, CT/MRI, MRI, and neuropsychological tests should be performed. If any of these is pathological the player should be advised to give up ice hockey.	UNIV UMEA HOSP,DEPT ORTHOPAED SURG,SPORTS MED UNIT,S-90185 UMEA,SWEDEN				Tegner, Yelverton/0000-0003-3628-0705			BRUNO LA, 1987, CLIN SPORT MED, V6, P17; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; CASTALDI CR, 1989, ASTM STP, V1050, P14; FERIENCIK K, 1979, PHYSICIAN SPORTSMED, V7, P81; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; HASTINGS DE, 1974, ONTARIO MED REV  NOV, P686; HENDERSON JM, 1994, MED CLIN N AM, V78, P289, DOI 10.1016/S0025-7125(16)30160-2; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; INGERSOLL CD, 1993, SPORTS MED, V16, P342, DOI 10.2165/00007256-199316050-00005; JENKINS A, 1986, LANCET, V2, P445; Jorgensen U, 1986, Br J Sports Med, V20, P7; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LORENTZON R, 1988, AM J SPORT MED, V16, P392, DOI 10.1177/036354658801600415; MCLATCHIE G, 1994, BRIT MED J, V308, P1620, DOI 10.1136/bmj.308.6944.1620; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; MCSHERRY JA, 1989, AM FAM PHYSICIAN, V40, P186; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; REILLY PL, 1975, LANCET, V2, P375; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Ryan A J, 1991, Br J Sports Med, V25, P81; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; *SWED MED ASS, 1985, TREATM CONC SPORTS; Tegner Y, 1991, Br J Sports Med, V25, P87; THORNDIKE A, 1952, NEW ENGL J MED, V247, P554, DOI 10.1056/NEJM195210092471504; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; YARNELL PR, 1970, LANCET, V2, P863; 1990, COLO MED, V87, P4	34	50	50	0	3	BUTTERWORTH-HEINEMANN LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	SEP	1996	30	3					251	255		10.1136/bjsm.30.3.251			5	Sport Sciences	Sport Sciences	VJ620	WOS:A1996VJ62000021	8889123	Green Published, Bronze			2021-06-18	
J	Gehrmann, J				Gehrmann, J			Microglia: A sensor to threats in the nervous system?	RESEARCH IN VIROLOGY			English	Article; Proceedings Paper	5th Rhine-Main Symposium on Macrophages and HIV	MAY, 1995	FRANKFURT, GERMANY	Natl Agcy AIDS Res, INSERM, BMBFT, DLR		CNS; AIDS; microglia; astrocytes; HIV encephalitis; neurotoxicity; cell death; apoptosis	COLONY-STIMULATING FACTOR; MARROW-DERIVED ELEMENTS; MULTINUCLEATED GIANT-CELLS; IMMUNE-DEFICIENCY-SYNDROME; RAT FACIAL NUCLEUS; ADULT-MOUSE BRAIN; MONOCLONAL-ANTIBODIES; PERIVASCULAR CELLS; RESIDENT MICROGLIA; AMEBOID MICROGLIA	The parenchymal microglia are now believed to settle the CNS antenatally, being derived from a bone marrow precursor cell. Based on developmental and pathophysiological studies, at least four different types of parenchymal microglia can be distinguished: (i) the amoeboid microglia which are mainly found perinatally in white matter areas such as the corpus callosum, i.e. the so-called ''fountains of microglia'', (ii) the ramified, resting microglia in the adult CNS, (iii) the activated, non-phagocytic microglia found in areas of secondary reaction due to nerve transection and (iv) the phagocytic microglia, found in areas of trauma, infection or neuronal necrosis. In addition, there are perivascular cells enclosed in the basal lamina which have a high turnover with a bone marrow precursor pool. While the function of resting microglia is still largely unknown, it is clear from observations in neuropathology that microglia are among the first cell types in the brain to respond to injuries. Their reaction pattern to injury has been termed a graded response, since the transformation of resting cells into phagocytes is under strict control in vivo. Microglial activation is a key cellular response in many infectious, inflammatory, traumatic, neoplastic, ischaemic and degenerative conditions in the CNS. In HIV encephalitis, the microglial involvement is striking, and approximately 25% of microglia contain viral DNA or RNA. Based on natural homing mechanisms with bone marrow precursor cells, HIV-infected monocytes/macrophages may home at an early stage to the CNS perivascular space and eventually spread the infection to resident microglia in the CNS which may be difficult to reach by pharmacological intervention. Further understanding of the mechanisms regulating microglial proliferation and activation in vivo may help to develop therapies targeting the potentially harmful microglial response in the injured CNS.		Gehrmann, J (corresponding author), UNIV ZURICH HOSP,DEPT PATHOL,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND.						BANATI RB, 1991, J NEUROSCI RES, V30, P593, DOI 10.1002/jnr.490300402; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; BUDKA H, 1986, ACTA NEUROPATHOL, V69, P253, DOI 10.1007/BF00688301; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; Del Rio-Hortega P., 1932, CYTOLOGY CELLULAR PA, P481; DICKSON DW, 1991, LAB INVEST, V64, P135; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; FERRER I, 1990, NEUROSCIENCE, V39, P451, DOI 10.1016/0306-4522(90)90281-8; FLARIS NA, 1993, GLIA, V7, P34, DOI 10.1002/glia.440070108; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEHRMANN J, 1993, GLIA, V7, P50, DOI 10.1002/glia.440070110; GEHRMANN J, 1992, J CEREBR BLOOD F MET, V12, P257, DOI 10.1038/jcbfm.1992.36; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; GEHRMANN J, 1991, RESTOR NEUROL NEUROS, V2, P181, DOI 10.3233/RNN-1991-245605; GEHRMANN J, 1991, J COMP NEUROL, V313, P409, DOI 10.1002/cne.903130302; GEHRMANN J, 1995, J NEUROPATH EXP NEUR, V54, P680, DOI 10.1097/00005072-199509000-00010; GEHRMANN J, 1995, NEUROPATH APPL NEURO, V21, P277, DOI 10.1111/j.1365-2990.1995.tb01062.x; GEHRMANN J, 1993, BRAIN PATHOL, V3, P11, DOI 10.1111/j.1750-3639.1993.tb00720.x; GEHRMANN J, 1992, LAB INVEST, V67, P100; GEHRMANN J, 1994, CURR DIAG PATHOL, V1, P121; Gehrmann Jochen, 1995, P883; GIULIAN D, 1988, J NEUROSCI, V8, P4707; GOSZTONYI G, 1994, J NEUROPATH EXP NEUR, V53, P521, DOI 10.1097/00005072-199409000-00012; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; GRAEBER MB, 1992, J NEUROPATH EXP NEUR, V51, P303, DOI 10.1097/00005072-199205000-00009; GRAEBER MB, 1989, J NEUROSCI RES, V22, P103, DOI 10.1002/jnr.490220114; HAO C, 1990, J NEUROSCI RES, V27, P314, DOI 10.1002/jnr.490270310; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; JORDAN CA, 1991, J VIROL, V65, P736, DOI 10.1128/JVI.65.2.736-742.1991; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KETTENMANN H, 1990, J NEUROSCI RES, V26, P278, DOI 10.1002/jnr.490260303; KIEFER R, 1994, NEUROSCI LETT, V166, P161, DOI 10.1016/0304-3940(94)90475-8; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; KRALL WJ, 1994, BLOOD, V83, P2737; KREUTZBERG GW, 1966, ACTA NEUROPATHOL, V7, P149, DOI 10.1007/BF00686781; KURE K, 1990, AM J PATHOL, V136, P1085; LASSMANN H, 1991, J NEUROSCI RES, V28, P236, DOI 10.1002/jnr.490280211; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; LIPTON SA, 1992, TRENDS NEUROSCI, V15, P75, DOI 10.1016/0166-2236(92)90013-X; MAJNO G, 1995, AM J PATHOL, V146, P3; MALIPIERO UV, 1990, J IMMUNOL, V144, P3816; MATSUMOTO Y, 1986, J IMMUNOL, V136, P3668; MATSUMOTO Y, 1987, J NEUROIMMUNOL, V17, P71, DOI 10.1016/0165-5728(87)90032-4; MORIOKA T, 1992, GLIA, V6, P75, DOI 10.1002/glia.440060110; NGUYEN KB, 1994, J AUTOIMMUN, V7, P145, DOI 10.1006/jaut.1994.1011; Nissl F., 1899, ARCH, V32, P1; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PETITO CK, 1995, AM J PATHOL, V146, P1121; RAIVICH G, 1991, J NEUROSCI RES, V30, P682, DOI 10.1002/jnr.490300412; RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x; RAIVICH G, 1994, GLIA, V11, P129, DOI 10.1002/glia.440110208; REID DM, 1993, NEUROSCIENCE, V56, P529, DOI 10.1016/0306-4522(93)90353-H; RINAMAN L, 1993, J NEUROSCI, V13, P685; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; SAWADA M, 1995, INT J DEV NEUROSCI, V13, P253, DOI 10.1016/0736-5748(94)00076-F; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; SHARER LR, 1985, HUM PATHOL, V16, P760, DOI 10.1016/S0046-8177(85)80245-8; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; STREIT WJ, 1989, J NEUROIMMUNOL, V21, P117, DOI 10.1016/0165-5728(89)90167-7; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; SUZUMURA A, 1990, J NEUROIMMUNOL, V30, P111, DOI 10.1016/0165-5728(90)90094-4; THERY C, 1990, J NEUROSCI RES, V26, P129, DOI 10.1002/jnr.490260117; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; UNGER ER, 1993, J NEUROPATH EXP NEUR, V52, P460, DOI 10.1097/00005072-199309000-00004; VASS K, 1993, LAB INVEST, V69, P275; VASS K, 1990, AM J PATHOL, V137, P789; WILLIAMS AE, 1990, NEUROPATH APPL NEURO, V16, P377, DOI 10.1111/j.1365-2990.1990.tb01274.x	76	50	52	0	4	EDITIONS SCIENTIFIQUES ELSEVIER	PARIS CEDEX 15	141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE	0923-2516			RES VIROLOGY	Res. Virol.	MAR-JUN	1996	147	2-3					79	88		10.1016/0923-2516(96)80220-2			10	Virology	Virology	UC606	WOS:A1996UC60600002	8901425				2021-06-18	
J	LEVIN, HS				LEVIN, HS			PREDICTION OF RECOVERY FROM TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article						NEUROPSYCHOLOGICAL RECOVERY; OUTCOME; PREDICTION; TRAUMATIC BRAIN INJURY	SEVERE HEAD-INJURY; IMPAIRED CONSCIOUSNESS; INTELLECTUAL FUNCTION; PRACTICAL SCALE; AMNESIA TEST; COGNITION; COMA; ORIENTATION; CONCUSSION; MEMORY	This paper encompasses the prediction of early and late recovery from traumatic brain injury (TBI). Predictors of the duration of coma and the utilization of posttraumatic amnesia duration to predict residual memory function are discussed. The issues surrounding prediction of long-term neurobehavioral recovery from TBI are considered, particularly the patient and clinical variables that are related to intellectual recovery. Findings from the NIH Traumatic Coma Data are reviewed pertaining to testability as a criterion for outcome. In addition to discussing the relationship of specific neurologic indices of TBI as predictors, the results obtained using a regression model are summarized. Finally, the relationship of neuroimaging findings to neurobehavioral outcome is discussed including directions for future research.	UNIV MARYLAND,MED SYST,DIV NEUROL SURG,BALTIMORE,MD 21201					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ALEXANDRE A, 1983, J NEUROSURG, V5, P751; [Anonymous], 1944, MANUAL DIRECTIONS SC; Benton A., 1976, MULTILINGUAL APHASIA; Benton AL., 1974, REVISED VISUAL RETEN; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1984, J CLIN NEUROPSYCHOL, V6, P71, DOI 10.1080/01688638408401198; BUSCHKE H, 1974, NEUROLOGY, V24, P1919; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; GOLDSTEIN FC, 1986, J CLIN EXP NEUROPSYC, V8, P405, DOI 10.1080/01688638608401330; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; JENNETT B, 1975, LANCET, V1, P480; LADOUX JE, 1977, ANN NEUROL, V2, P417; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1989, LANCET, V1, P1001; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, ARCH NEUROL-CHICAGO, V38, P623; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MATHEWS CG, 1964, INSTRUCTIONAL MANUAL; MAZZUCCHI A, 1992, J NEUROL, V239, P256; Nelson H., 1982, NATIONAL ADULT READI; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SALAZAR AM, 1986, NEUROLOGY, V36, P459, DOI 10.1212/WNL.36.4.459; SCHWARTZ B, 1967, ACTA NEUROL SCAND, V43, P513, DOI 10.1111/j.1600-0404.1967.tb05757.x; SERAFETINIDES EA, 1965, BRAIN, V88, P107, DOI 10.1093/brain/88.1.107; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; UZZELL BP, 1979, CORTEX, V15, P391, DOI 10.1016/S0010-9452(79)80066-0; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	44	50	51	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					913	922		10.1089/neu.1995.12.913			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600017	8594220				2021-06-18	
J	GALE, SD; JOHNSON, SC; BIGLER, ED; BLATTER, DD				GALE, SD; JOHNSON, SC; BIGLER, ED; BLATTER, DD			TRAUMA-INDUCED DEGENERATIVE CHANGES IN BRAIN INJURY - A MORPHOMETRIC ANALYSIS OF 3 PATIENTS WITH PREINJURY AND POSTINJURY MR SCANS	JOURNAL OF NEUROTRAUMA			English	Article						TRAUMATIC BRAIN INJURY; QUANTITATIVE NEUROIMAGING	CLOSED HEAD-INJURY; HERNIATION; ATROPHY	Three patients with pretraumatic and posttraumatic brain injury (TBI) MR imaging of the brain are presented, Two patients had moderate to severe injury, whereas the third patient sustained a mild injury. Using imaging software to conduct morphometric analyses, quantitative neuropathologic change was ascertained in each TBI patient, Each case was compared quantitatively to preinjury scans as well as to an age-matched control group, For the moderately to severely injured patients, extensive degenerative changes were found throughout the various cortical structures and the cerebellum, whereas most midbrain and brainstem measures did not demonstrate significant change, For these two patients, the most significant changes occurred within the ventricular system, where generalized ventricular dilation was observed post-TBI, In the mild case, no significant anatomic changes were evident, These case studies demonstrate the use of quantitative methods for examining the structural basis of TBI sequelae.	LDS HOSP, PROVO, UT USA	GALE, SD (corresponding author), BRIGHAM YOUNG UNIV, DEPT PSYCHOL, POB 25543, PROVO, UT 84602 USA.						ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; ENDO M, 1991, NEURORADIOLOGY, V33, P296, DOI 10.1007/BF00587809; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GALE SD, 1994, BEHAV NEUROL, V7, P160; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HASHIMOTO T, 1992, J CHILD NEUROL, V7, P188, DOI 10.1177/088307389200700209; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; JOHNSON SC, 1994, BRAIN RES BULL, V35, P373, DOI 10.1016/0361-9230(94)90116-3; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; LAISSY JP, 1993, AM J NEURORADIOL, V14, P145; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; RAZ N, 1992, ARCH NEUROL-CHICAGO, V49, P412, DOI 10.1001/archneur.1992.00530280106030; REICH JB, 1993, ANN NEUROL, V33, P159, DOI 10.1002/ana.410330205; Roberts M, 1970, ATLAS HUMAN BRAIN SE; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135	30	50	50	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1995	12	2					151	158		10.1089/neu.1995.12.151			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	QZ508	WOS:A1995QZ50800001	7629861				2021-06-18	
J	ZIETLOW, SP; CAPIZZI, PJ; BANNON, MP; FARNELL, MB				ZIETLOW, SP; CAPIZZI, PJ; BANNON, MP; FARNELL, MB			MULTISYSTEM GERIATRIC TRAUMA	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							MAJOR TRAUMA; CARE; SURVIVAL; INJURY	Purpose: To analyze the demographics, hospital course, functional outcome, and reimbursement for elderly patients sustaining multisystem trauma. Methods: The Trauma Registry was searched for patients greater than or equal to 65 years old with an Injury Severity Score (ISS) greater than or equal to 10 admitted with multisystem trauma from January 1991 through December 1991. Hospital data were obtained from the Trauma Registry; reimbursement data from the business office; and complete follow-up (mean, 12 months) data by telephone survey for all patients. Results: Of the 1931 trauma patients admitted during the study period, 601 (31%) were greater than or equal to 65 years old and 94 (5%) met the study criteria. Of these 94 patients, 52 were women and 42 were men; their mean age was 79 years (range, 65-100). Falls (59%) and motor vehicle crashes (36%) were the predominant causes of injury; closed head injury (CHI) and fractures were the most frequent injuries. The mean ISS was 18 (range, 10-57), and hospital stay averaged 10 days. Intensive care unit admission was necessary for 37%, and 38% required surgical intervention. Factors associated with mortality included previous myocardial infarction, chronic renal insufficiency, ventilatory or inotropic support (or both), shock (systolic BP less than or equal to 90 mm Hg) at admission, bradycardia (HR less than or equal to 60 bpm) at admission, and severe CHI (Glasgow Coma Scale score less than or equal to 8). Mortality was 23% (22 of the 94 patients); three quarters of the deaths occurred in the first 24 hours-most from severe CHI. At discharge, 53% of patients (38 of 72) went home and 36% (26 of 72) went to nursing homes. At a mean follow-up of 12 months, an additional seven patients had died, and three quarters of the patients were at home with an independent functional status. The percentage of reimbursement for care was two thirds of cost. Conclusions: Mortality rates are high for elderly patients who sustain multisystem trauma. Most deaths occur within the first 24 hours, and most injuries are severe CHIs. More than half of survivors are discharged home, and most are independent at longterm follow-up. Reimbursement is not commensurate with the functional outcome achieved and the care provided.		ZIETLOW, SP (corresponding author), MAYO CLIN & MAYO FDN,DEPT SURG,200 1ST ST SW,ROCHESTER,MN 55905, USA.						BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; CHAMPION HR, 1991, TRAUMA, P47; DEMARIA EJ, 1987, J TRAUMA, V27, P1200; DEMARIA EJ, 1987, ANN SURG, V206, P738, DOI 10.1097/00000658-198712000-00009; DEMARIA EJ, 1988, J TRAUMA, V28, P1244, DOI 10.1097/00005373-198808000-00018; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; JACOBS BB, 1991, TRUMA, P15; KAUDER DR, 1990, ADV TRAUMA, V5, P215; MCCOY GF, 1989, J TRAUMA, V29, P494, DOI 10.1097/00005373-198904000-00013; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; ORESKOVICH MR, 1984, J TRAUMA, V24, P565, DOI 10.1097/00005373-198407000-00003; OSLER T, 1988, AM J SURG, V156, P537, DOI 10.1016/S0002-9610(88)80548-8; ROSS N, 1989, SOUTHERN MED J, V82, P857, DOI 10.1097/00007611-198907000-00016; SCALEA TM, 1990, J TRAUMA, V30, P129, DOI 10.1097/00005373-199002000-00001; SCHWAB CW, 1992, ARCH SURG-CHICAGO, V127, P701; SMITH DP, 1990, SOUTHERN MED J, V83, P171, DOI 10.1097/00007611-199002000-00010; VANAALST JA, 1991, J TRAUMA, V31, P1096; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; ZIETLOW SP, 1993, CURRENT SURGERY, V50, P18	20	50	51	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Inf. Crit. Care	DEC	1994	37	6					985	988		10.1097/00005373-199412000-00020			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	PY536	WOS:A1994PY53600020	7996616				2021-06-18	
J	GOLDSTEIN, FC; LEVIN, HS; PRESLEY, RM; SEARCY, J; COLOHAN, ART; EISENBERG, HM; JANN, B; BERTOLINOKUSNERIK, L				GOLDSTEIN, FC; LEVIN, HS; PRESLEY, RM; SEARCY, J; COLOHAN, ART; EISENBERG, HM; JANN, B; BERTOLINOKUSNERIK, L			NEUROBEHAVIORAL CONSEQUENCES OF CLOSED-HEAD INJURY IN OLDER ADULTS	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							ALZHEIMERS-DISEASE; BEHAVIORAL SEQUELAE; PRACTICAL SCALE; BRAIN INJURY; TRAUMA; POPULATION; CLINICIAN; MILD	This study examined the neurobehavioural effects of closed head injury (CHI) in adults aged 50 years and older. Twenty two mild to moderate CHI patients who were within seven months of the injury were administered measures of language, memory, attention, and executive functioning, Compared with demographically similar normal controls, the patients exhibited significantly poorer functioning on the cognitive domains. Naming and word fluency under timed conditions, verbal and visual memory, and the ability to infer similarities were especially vulnerable. These initial findings indicate that CHI in older adults produces considerable cognitive deficits in the early stages of recovery. Future research should characterise long term outcome and the potential links between head injury and the development of progressive dementia.	EMORY UNIV,SCH MED,DEPT NEUROL,NEUROBEHAV PROGRAM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT NEUROSURG,ATLANTA,GA; EMORY UNIV,SCH MED,DEPT REHABIL MED,ATLANTA,GA; UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550; UNIV MARYLAND,SCH MED,DEPT NEUROL SURG,BALTIMORE,MD 21201	GOLDSTEIN, FC (corresponding author), EMORY UNIV,WESLEY WOODS HLTH CTR,SCH MED,1841 CLIFTON RD NE,ATLANTA,GA 30329, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Benton A., 1976, MULTILINGUAL APHASIA; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; DAVIS CS, 1988, J AM GERIATR SOC, V36, P225, DOI 10.1111/j.1532-5415.1988.tb01805.x; DELIS DC, 1988, CALIFORNIA VERBAL LE; DELIS DC, 1986, CALIFORNIA VERBAL LE; DEMARIA EJ, 1987, ANN SURG, V206, P738, DOI 10.1097/00000658-198712000-00009; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GALBRAITH S, 1987, BRIT MED J, V294, P325, DOI 10.1136/bmj.294.6568.325; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Gronwall D, 1989, MILD HEAD INJURY, P153; Gustafson L, 1990, Adv Neurol, V51, P65; HANNAY HJ, 1988, CONTINUOUS RECOGNITI; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1987, HEAD INJURY, P1; LEUERSSEN TG, 1988, J NEUROSURG, V68, P409; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MAZZUCCHI A, 1992, J NEUROL, V239, P256; MILLER BL, 1991, NEUROLOGY, V41, P1374, DOI 10.1212/WNL.41.9.1374; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OLNEY JW, 1990, PROG BRAIN RES, V86, P37; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROY CW, 1986, INJURY, V17, P220, DOI 10.1016/0020-1383(86)90222-6; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; Sarno M, 1985, SPEECH LANGUAGE EVAL, P323; Stuss D.T., 1986, FRONTAL LOBES; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456	44	50	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	1994	57	8					961	966		10.1136/jnnp.57.8.961			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	PB921	WOS:A1994PB92100016	8057121	Green Published, Bronze			2021-06-18	
J	SMALHEISER, NR; SWANSON, DR				SMALHEISER, NR; SWANSON, DR			ASSESSING A GAP IN THE BIOMEDICAL LITERATURE - MAGNESIUM-DEFICIENCY AND NEUROLOGIC DISEASE	NEUROSCIENCE RESEARCH COMMUNICATIONS			English	Article						MAGNESIUM; NMDA RECEPTOR; EXCITOTOXICITY; DIET; INFORMATION RETRIEVAL	AMYOTROPHIC-LATERAL-SCLEROSIS; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; LOW CALCIUM-MAGNESIUM; DEPRIVATION ENCEPHALOPATHY; MULTIPLE-SCLEROSIS; KII PENINSULA; YOUNG-RATS; MIGRAINE; NEURONS	Recent studies have focused great attention upon the role of NMDA receptor-mediated excitotoxicity in the pathogenesis of a variety of acute and chronic neurologic diseases, and upon the role of endogenous Mg ions in regulating this process. Yet, very few studies have sought to ascertain whether exogenous, e.g., dietary, manipulations of Mg levels can modulate brain function or the expression of neurologic diseases (apart from hyperexcitability and seizures that are elicited directly when Mg levels are extremely low). We argue that this issue is important, and should be addressed in existing animal models of acute and chronic CNS insults.	UNIV CHICAGO, INFORMAT SCI, CHICAGO, IL 60637 USA	SMALHEISER, NR (corresponding author), UNIV CHICAGO, DEPT PEDIAT, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA.						ABELE AE, 1990, NEURON, V4, P413, DOI 10.1016/0896-6273(90)90053-I; ADAM WR, 1989, CLIN EXP PHARMACOL P, V16, P33, DOI 10.1111/j.1440-1681.1989.tb01906.x; Altura B M, 1991, Magnes Trace Elem, V10, P182; ALTURA BM, 1978, BLOOD VESSELS, V15, P5; ARSENIAN MA, 1993, PROG CARDIOVASC DIS, V35, P271, DOI 10.1016/0033-0620(93)90008-2; BARBEAU A, 1972, EXPERIENTIA, V28, P289, DOI 10.1007/BF01928694; Castelli S, 1993, Pediatr Med Chir, V15, P481; CEVETTE MJ, 1989, OTOLARYNG HEAD NECK, V101, P537, DOI 10.1177/019459988910100504; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHUTKOW JG, 1979, J NEURAL TRANSM, V44, P297, DOI 10.1007/BF01250324; CHUTKOW JG, 1972, AM J PHYSIOL, V223, P1407; CHUTKOW JG, 1974, NEUROLOGY, V24, P780, DOI 10.1212/WNL.24.8.780; Costello R B, 1992, Magnes Res, V5, P61; COX JA, 1989, BRAIN RES, V499, P267, DOI 10.1016/0006-8993(89)90774-9; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DEPOORTERE H, 1993, NEUROPSYCHOBIOLOGY, V27, P237, DOI 10.1159/000118988; Durlach J, 1989, Magnes Res, V2, P195; Durlach J, 1990, Magnes Res, V3, P217; ELIN RJ, 1988, YEARBOOK CHICAGO, V34, P161; FACCHINETTI F, 1991, HEADACHE, V31, P298, DOI 10.1111/j.1526-4610.1991.hed3105298.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FURSHPAN EJ, 1989, NEURON, V3, P199, DOI 10.1016/0896-6273(89)90033-0; GALLAI V, 1992, HEADACHE, V32, P132, DOI 10.1111/j.1526-4610.1992.hed3203132.x; GALLAI V, 1993, CEPHALALGIA, V13, P94, DOI 10.1046/j.1468-2982.1993.1302094.x; Galland L, 1991, Magnes Trace Elem, V10, P287; GARRUTO RM, 1985, NEUROLOGY, V35, P193, DOI 10.1212/WNL.35.2.193; GLICK JL, 1990, MED HYPOTHESES, V31, P211, DOI 10.1016/0306-9877(90)90095-V; GOLDBERG P, 1986, MED HYPOTHESES, V21, P193, DOI 10.1016/0306-9877(86)90010-1; GOTO I, 1986, BRAIN RES, V372, P31, DOI 10.1016/0006-8993(86)91455-1; GUIDERI G, 1985, J AM COLL NUTR, V4, P139; GUNTHER T, 1988, BIOL TRACE ELEM RES, V16, P43, DOI 10.1007/BF02795332; GUNTHER T, 1981, TERATOLOGY, V24, P225, DOI 10.1002/tera.1420240213; ISHIGAMI M, 1991, ALCOHOL CLIN EXP RES, V15, P757, DOI 10.1111/j.1530-0277.1991.tb00594.x; Joachims Z, 1993, Schriftenr Ver Wasser Boden Lufthyg, V88, P503; KANOFSKY JD, 1991, INT J NEUROSCI, V61, P87, DOI 10.3109/00207459108986275; KASSOUNY ME, 1985, INT J VITAM NUTR RES, V55, P295; KIMURA M, 1977, J NEUROCHEM, V28, P389, DOI 10.1111/j.1471-4159.1977.tb07759.x; Kubena K S, 1990, Magnes Res, V3, P219; KUMAMOTO T, 1979, EXPERIENTIA, V35, P1604, DOI 10.1007/BF01953218; LANDFIELD PW, 1984, BRAIN RES, V322, P167, DOI 10.1016/0006-8993(84)91199-5; LERMA A, 1993, ANN NUTR METAB, V37, P210, DOI 10.1159/000177770; Luthringer C, 1988, Magnes Res, V1, P163; MANSMANN HC, 1993, PEDIATR ASTHMA ALLER, V7, P211, DOI 10.1089/pai.1993.7.211; MARIER JR, 1982, MAGNESIUM, V1, P3; MAUSKOP A, 1993, HEADACHE, V33, P135, DOI 10.1111/j.1526-4610.1993.hed3303135.x; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCCREARY PA, 1966, P SOC EXP BIOL MED, V121, P1130; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Mitani K, 1992, Magnes Res, V5, P203; Morris M E, 1992, Magnes Res, V5, P303; MURAKAMI M, 1975, ENDOKRINOLOGIE, V66, P268; NAKAGAWA S, 1980, WAKAYAMA MED REP, V22, P1; NAKANISHI H, 1991, EUR J PHARMACOL, V204, P29, DOI 10.1016/0014-2999(91)90831-A; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OPAVSKY J, 1991, Acta Universitatis Palackianae Olomucensis Facultatis Medicae, V131, P157; POENARU S, 1984, MAGNESIUM-B, V6, P142; RAMADAN NM, 1989, HEADACHE, V29, P416, DOI 10.1111/j.1526-4610.1989.hed2907416.x; Rayssiguier Y, 1984, Magnesium, V3, P226; ROOT EJ, 1988, NUTR REP INT, V37, P959; SARCHIELLI P, 1992, CEPHALALGIA, V12, P21, DOI 10.1046/j.1468-2982.1992.1201021.x; SAUL RF, 1991, ARCH NEUROL-CHICAGO, V38, P650; SCHOENEN J, 1991, CEPHALALGIA, V11, P97, DOI 10.1046/j.1468-2982.1991.1102097.x; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SEELIG MS, 1964, AM J CLIN NUTR, V14, P342, DOI 10.1093/ajcn/14.6.342; SEELIG MS, 1993, J AM COLL NUTR, V12, P442, DOI 10.1080/07315724.1993.10718335; SHILS ME, 1969, MEDICINE, V48, P61, DOI 10.1097/00005792-196901000-00003; SHILS ME, 1988, ANNU REV NUTR, V8, P429, DOI 10.1146/annurev.nu.08.070188.002241; SINGH NP, 1979, ARCH ENVIRON HEALTH, V34, P168, DOI 10.1080/00039896.1979.10667391; SMITT PAES, 1989, J NEUROL SCI, V91, P231, DOI 10.1016/0022-510X(89)90056-7; SREBRO Z, 1972, ACTA NEUROPATHOL, V21, P258, DOI 10.1007/BF00688505; STAFFORD RE, 1993, BIOCHEM BIOPH RES CO, V196, P596, DOI 10.1006/bbrc.1993.2291; SWANSON DR, 1986, PERSPECT BIOL MED, V30, P7; SWANSON DR, 1993, LIBR TRENDS, V41, P606; SWANSON DR, 1990, PERSPECT BIOL MED, V33, P157; SWANSON DR, 1990, B MED LIBR ASSOC, V78, P29; SWANSON DR, 1988, PERSPECT BIOL MED, V31, P526; Taubert K, 1991, Z Arztl Fortbild (Jena), V85, P67; Thomas J, 1992, Magnes Res, V5, P127; TOUITOU Y, 1987, CLIN CHEM, V33, P518; TRAVIESA DC, 1974, J NEUROL NEUROSUR PS, V37, P959, DOI 10.1136/jnnp.37.8.959; WEGLICKI WB, 1992, AM J PHYSIOL, V263, pR734; WHETSELL WO, 1993, LAB INVEST, V68, P372; WONG ET, 1983, AM J CLIN PATHOL, V79, P348, DOI 10.1093/ajcp/79.3.348; YASUI M, 1990, ACTA NEUROL SCAND, V81, P197; YASUI M, 1990, J NEUROL SCI, V99, P177, DOI 10.1016/0022-510X(90)90154-F; YASUI M, 1992, EUR NEUROL, V32, P95, DOI 10.1159/000116800; Yasui M, 1992, Magnes Res, V5, P295; YASUI M, 1991, BIOL TRACE ELEM RES, V31, P293, DOI 10.1007/BF02990198; YASUI M, 1991, NEUROTOXICOLOGY, V12, P615; YOSHIDA S, 1990, BIOMED RES-TOKYO, V11, P11, DOI 10.2220/biomedres.11.11	92	50	51	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0893-6609			NEUROSCI RES COMMUN	Neurosci. Res. Commun.	JUL-AUG	1994	15	1					1	9					9	Neurosciences	Neurosciences & Neurology	PA792	WOS:A1994PA79200001					2021-06-18	
J	KISHI, Y; ROBINSON, RG; FORRESTER, AW				KISHI, Y; ROBINSON, RG; FORRESTER, AW			PROSPECTIVE LONGITUDINAL-STUDY OF DEPRESSION FOLLOWING SPINAL-CORD INJURY	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							TRAUMATIC BRAIN INJURY; STROKE PATIENTS	A group of 60 patients with spinal cord injury was examined to assess mood disorders during the rehabilitation hospital admission and 6 months of follow-up. During the initial evaluations, 13 patients (22%) had major depression and 5 patients (8%) had minor depression. The development of mood disorders during the hospital admission appeared to be related to heterogeneous etiological factors, including previous psychiatric history and severity of impairment in activities of daily living. During the first 3 months after SCI, about half of the depressions resolved. Nonrecovery from depression may be related to lack of adequate social support.	UNIV IOWA,COLL MED,DEPT PSYCHIAT,IOWA CITY,IA 52242; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; NIPPON MED COLL,DEPT MED PHYS,TOKYO 113,JAPAN			Kishi, Yasuhiro/T-4047-2019		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH00163, MH40355] Funding Source: Medline		BRACKEN MB, 1981, PARAPLEGIA, V19, P271, DOI 10.1038/sc.1981.53; Claus-Walker J, 1972, Paraplegia, V10, P142; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; CULPEPPERMORGAN JA, 1992, METABOLISM, V41, P578, DOI 10.1016/0026-0495(92)90048-F; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORRESTER AW, 1992, INT J PSYCHIAT MED, V22, P33, DOI 10.2190/CJ9D-32C2-8CM7-FT3D; FRANK RG, 1985, AM J PSYCHIAT, V142, P252; FULLERTON DT, 1981, ARCH GEN PSYCHIAT, V38, P1361; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HANCOCK KM, 1993, PARAPLEGIA, V31, P349, DOI 10.1038/sc.1993.59; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JUDD FK, 1989, BRIT J PSYCHIAT, V154, P668, DOI 10.1192/bjp.154.5.668; KATHOL RG, 1981, J AFFECT DISORDERS, V3, P111, DOI 10.1016/0165-0327(81)90036-7; LAWSON NC, 1978, ARCH PHYS MED REHAB, V59, P573; MALEC J, 1983, ARCH PHYS REHABIL, V64, P271; MORRIS PLP, 1990, INT J PSYCHIAT MED, V20, P349, DOI 10.2190/N8VU-6LWU-FLJN-XQKV; NESTOROS JN, 1982, PSYCHOSOMATICS, V23, P823; PARIKH RM, 1990, ARCH NEUROL-CHICAGO, V47, P785, DOI 10.1001/archneur.1990.00530070083014; RABINS PV, 1982, BRIT J PSYCHIAT, V140, P149, DOI 10.1192/bjp.140.2.149; ROBINSON RG, 1981, BRAIN LANG, V14, P282, DOI 10.1016/0093-934X(81)90080-8; ROBINSON RG, 1983, COMPR PSYCHIAT, V24, P555, DOI 10.1016/0010-440X(83)90024-X; Starr L B, 1982, Soc Work Res Abstr, V18, P28; TWIST DJ, 1992, AM J PHYS MED REHAB, V71, P156, DOI 10.1097/00002060-199206000-00006; Wing J. K., 1974, INSTRUCTION MANUAL P; WOODRICH F, 1983, J REHABIL, V49, P26	26	50	50	0	2	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	1994	6	3					237	244					8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	NY895	WOS:A1994NY89500003	7950345				2021-06-18	
J	ELSON, LM; WARD, CC				ELSON, LM; WARD, CC			MECHANISMS AND PATHOPHYSIOLOGY OF MILD HEAD-INJURY	SEMINARS IN NEUROLOGY			English	Article							BRAIN INJURY; STIMULUS RATE; IMPAIRMENT; CONCUSSION; SEQUELAE; TRAUMA	Mild head (brain) injury (MBI) accounts for the great majority of all head injuries (trauma) treated in emergency departments, outpatient departments, and physicians' offices in the United States.1-5 The biomechanics and pathophysiology of nonmissile (closed), severe, traumatic brain injury have been extensively investigated6-12 and increased understanding of mild head injury has resulted from biomechanical research and analysis. In any collection of retrospective severe traumatic brain injury studies, there is a consistent array of clinical, radiologic, surgical and pathoanatomic findings on which to focus. The same is not true for MBI.	BIODYNAM ENGN INC,15304 SUNSET BLVD,PACIFIC PALISADES,CA 90272							ABEL J, 1978, 22ND P STAPP CAR CRA, P33; Adams J. H., 1982, HEAD INJURY BASIC CL, P141; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ADAMS RD, 1989, PRINCIPLES NEUROLOGY, P693; ADAMS RD, 1989, PRINCIPLES NEUROLOGY, P870; AGUAYO AJ, 1986, DIS NERV SYST, P98; AUERBACH SH, 1987, HOSP PRACT      1030, P9; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BARRON KD, 1982, HEAD INJURY BASIC CL, P42; BECKER DP, 1988, WESTERN J MED, V148, P670; BIJUR PE, 1990, PEDIATRICS, V86, P337; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; CHAN M, 1981, P ASME BIOMECHANICS, P157; COLLINS JG, 1986, US VITAL HLTH ST 159, V10; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIETRICH WD, 1984, J NEUROPATH EXP NEUR, V43, P72, DOI 10.1097/00005072-198401000-00006; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIMAIO DJ, 1989, FORENSIC PATHOLOGY, P167; EIBAND AM, NASA51959E LEW RES C; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; FOLTZ EL, 1956, J NEUROSURG, V13, P145, DOI 10.3171/jns.1956.13.2.0145; GADD C, 1985, DEV HEAD INJURY CRIT, P17; GADD CW, 1966, 10 STAPP CAR CRASH C, P164; GARCIA JH, 1983, J NEUROPATHOL EXP NE, V42, P41; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1979, 23RD P STAPP CAR CRA, P235; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GLICK SD, 1974, PLASTICITY RECOVERY, P339; GURDJAN ES, 1975, IMPACT HEAD INJURY, P145; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; Holbourn AHS, 1943, LANCET, V2, P438; JACOBSON DM, 1988, J CLIN NEURO-OPHTHAL, V8, P263; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JANE JA, 1986, T NEUROSURG, V62, P96; JANE JA, 1982, HEAD INJURY BASIC CL, P229; JENNETT B, 1977, LANCET, V1, P878; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; KOWAL L, 1992, AUST NZ J OPHTHALMOL, V20, P35, DOI 10.1111/j.1442-9071.1992.tb00701.x; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LISSNER HR, SURG GYNECOL OBSTET, V111, P329; Lowenhielm P, 1986, Acta Neurochir Suppl (Wien), V36, P31; Marshall L. F., 1985, CENTRAL NERVOUS SYST, P45; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MILLER JD, 1985, LANCET, V1, P1141; Nahum A., 1980, 24TH STAPP CAR CRASH, P43; NAHUM A, 1981, 25TH STAPP CAR CRASH, P241; Nahum AM, 1977, 21ST P STAPP CAR CRA, P303; NAHUM AM, 1981, HEAD NECK INJURY CRI, P31; NAHUM AM, 1982, AGARD P, V322, P1; NAHUM AM, 1979, 23RD P STAPP CAR CRA, P613; NEWMAN J, 1985, P WINTERLUDE HEAD IN, P1; NUSHOLTZ G, 1985, CRITICAL FACTORS HEA, P157; NUSHOLTZ GS, 1979, UNHSRI7990 HIGHW SAF; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1988, 32ND ANN P ASS ADV A; Ono K, 1980, 24TH P STAPP CAR CRA, P101; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARKINSON D, 1988, SURG NEUROL, V30, P102, DOI 10.1016/0090-3019(88)90094-8; PARKINSON D, 1988, AM ASS ANATOMISTS, pA73; Patrick L. M., 1963, P 7 STAPP CAR CRASH, P483; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; PLUCHE R, 1985, FINITE ELEMENT MODEL, P235; PODOSHIN L, 1990, J LARYNGOL OTOL, V104, P191, DOI 10.1017/S0022215100112241; POVLISHOCK JT, 1982, HEAD INJURY BASIC CL; PRATT H, 1981, ELECTROEN CLIN NEURO, V51, P80, DOI 10.1016/0013-4694(81)91511-X; Rand CW, 1934, ARCH NEURO PSYCHIATR, V31, P527, DOI 10.1001/archneurpsyc.1934.02250030067004; Rimel R. W., 1981, NEUROSURGERY, V9, P35; RUAN J, 1991, 1ST P S INJ PREV BIO, P97; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TARRIERE C, 1981, HEAD INJURY CRITERIA, P198; Ueno K, 1989, AM SOC MECHANICA AMD, V106, P123; VERSACE J, 1971, 15TH P STAPP CAR CRA, P771; WARD CC, 1981, HEAD NECK INJURY CRI, P159; WARD CC, 1981, 24TH P STAPP CAR CRA, P161; WARD CC, 1982, IMPACT INJURY HEAD S, P421; WARD CC, 1979, 4 P INT C BIOM TRAUM, P133; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	82	50	50	0	1	THIEME MEDICAL PUBL INC	NEW YORK	381 PARK AVE SOUTH, NEW YORK, NY 10016	0271-8235			SEMIN NEUROL	Semin. Neurol.	MAR	1994	14	1					8	18		10.1055/s-2008-1041053			11	Clinical Neurology	Neurosciences & Neurology	NE151	WOS:A1994NE15100004	8029564				2021-06-18	
J	NEDD, K; SFAKIANAKIS, G; GANZ, W; URICCHIO, B; VERNBERG, D; VILLANUEVA, P; JABIR, AM; BARTLETT, J; KEENA, J				NEDD, K; SFAKIANAKIS, G; GANZ, W; URICCHIO, B; VERNBERG, D; VILLANUEVA, P; JABIR, AM; BARTLETT, J; KEENA, J			TC-99M-HMPAO SPECT OF THE BRAIN IN MILD-TO-MODERATE TRAUMATIC BRAIN INJURY PATIENTS - COMPARED WITH CT - A PROSPECTIVE-STUDY	BRAIN INJURY			English	Article							CEREBRAL BLOOD-FLOW; HM-PAO-SPECT; HEAD-INJURY; COMPUTED-TOMOGRAPHY; INITIAL EXPERIENCE; PERFUSION; STROKE; RETENTION; RECOVERY; I-123	Single photon emission computed tomography (SPECT) with Technetium-99m hexamethyl propylenamine oxime (Tc-99m-HMPAO) was used in 20 patients with mild to moderate traumatic brain injury (TBI) to evaluate the effects of brain trauma on regional cerebral blood flow (rCBF). SPECT scan was compared with CT scan in 16 patients. SPECT showed intraparenchymal differences in rCBF more often than lesions diagnosed with CT scans (87.5% vs. 37.5%). In five of six patients with lesions in both modalities, the area of involvement was relatively larger on SPECT scans than on CT scans. Contrecoup changes were seen in five patients on SPECT alone, two patients with CT alone and one patient had contrecoup lesions on CT and SPECT. Of the eight patients (50%) with skull fractures, seven (43.7%) had rCBF findings on SPECT scan and five (31.3%) demonstrated decrease in rCBF in brain underlying the fracture. All these patients with fractures had normal brain on CT scans. Conversely, extra-axial lesions and fractures evident on CT did not visualize on SPECT, but SPECT demonstrated associated changes in rCBF. Although there is still lack of clinical and pathological correlation, SPECT appears to be a promising method for a more sensitive evaluation of axial lesions in patients with mild to moderate TBI.	UNIV MIAMI,SCH MED,DEPT RADIOL,DIV NUCL MED,D-57,POB 016960,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT NEUROL,DIV NEUROL REHAB,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT NEUROSURG,MIAMI,FL 33101; JACKSON MEM HOSP,MIAMI,FL 33136							ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ACKERMAN RH, 1984, STROKE, V15, P1; ANDERSON A, 1985, EUR J NUCL MED, V11, pA5; [Anonymous], 1990, ABBREVIATED INJURY S; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BIERSACK H J, 1987, Nuclear Medicine Communications, V8, P513; CHOKSEY MS, 1989, NUCL MED COMMUN, V10, P609, DOI 10.1097/00006231-198908010-00011; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; COSTA DC, 1989, LANCET, V1, P213; COSTA DC, 1986, NUCL MED COMMUN, V7, P647; COTA DC, 1988, NUCLEARMEDIZIN S, V24, P762; DUCOURS JL, 1990, NUCL MED COMMUN, V11, P361, DOI 10.1097/00006231-199005000-00003; ELL PJ, 1985, EUR J NUCL MED, V11, pA5; FELDMANN M, 1990, J NEUROL, V237, P475, DOI 10.1007/BF00314765; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FUMEYA H, 1990, ACT NEUR S, V51, P283; GRAY BG, 1992, J NUCL MED, V33, P52; HILL TC, 1984, STROKE, V15, P40, DOI 10.1161/01.STR.15.1.40; HILL TC, 1985, DIAG IMAG, V7, P64; HOFFMAN TJ, 1986, J NUCL MED, V27, P1050; HOLMAN BL, 1984, J NUCL MED, V25, P25; HOLMAN BL, 1984, APPL RADIOL, V13, P21; HOLMES RA, 1985, NUCL MED COMMUN, V6, P443, DOI 10.1097/00006231-198508000-00003; KUNG HF, 1984, J NUCL MED, V25, P326; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MILLER JD, 1990, REHABILITATION ADULT, P236; MOUNTZ JM, 1989, CLIN NUCL MED, V14, P192, DOI 10.1097/00003072-198903000-00011; MOUNTZ JM, 1990, J NUCL MED, V31, P61; NEIRINCKX RD, 1987, J NUCL MED, V28, P191; NOWOTNIK DP, 1985, NUCL MED COMMUN, V6, P499, DOI 10.1097/00006231-198509000-00002; ODER W, 1991, INTENS CARE MED, V17, P149, DOI 10.1007/BF01704718; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PODREKA I, 1987, J NUCL MED, V28, P1657; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; ROPER SN, 1991, J NUCL MED, V32, P2070; SHARP PF, 1986, J NUCL MED, V27, P171; SHIELDS RA, 1986, NUCL MED COMMUN, V7, P284; SULLIVAN T, 1991, CLIN NUCL MED, V16, P170, DOI 10.1097/00003072-199103000-00008	40	50	50	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	NOV-DEC	1993	7	6					469	479		10.3109/02699059309008174			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	MA173	WOS:A1993MA17300001	8260951				2021-06-18	
J	HAYES, RL; LYETH, BG; JENKINS, LW; ZIMMERMAN, R; MCINTOSH, TK; CLIFTON, GL; YOUNG, HF				HAYES, RL; LYETH, BG; JENKINS, LW; ZIMMERMAN, R; MCINTOSH, TK; CLIFTON, GL; YOUNG, HF			POSSIBLE PROTECTIVE EFFECT OF ENDOGENOUS OPIOIDS IN TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article										HAYES, RL (corresponding author), VIRGINIA COMMONWEALTH UNIV,DEPT SURG,DIV NEUROSURG,RICHARD ROLAND REYNOLDS NEUROSURG RES LABS,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21458, NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS012587, P50NS012587] Funding Source: NIH RePORTER		ADLER MW, 1976, J PHARMACOL EXP THER, V198, P655; ARAUJO DM, 1987, J NEUROSCI, V7, P1698; BAKER HJ, 1979, LABORATORY RAT, V1; BASKIN DS, 1982, LIFE SCI, V31, P2201, DOI 10.1016/0024-3205(82)90118-7; BELENKY GL, 1979, BRAIN RES, V177, P414, DOI 10.1016/0006-8993(79)90797-2; BERRY SC, 1984, BRIT J PHARMACOL, V83, P179, DOI 10.1111/j.1476-5381.1984.tb10133.x; CHOI D W, 1987, Society for Neuroscience Abstracts, V13, P1029; CHOI DW, 1987, BRAIN RES, V403, P333, DOI 10.1016/0006-8993(87)90070-9; CHOI DW, 1987, J NEUROSCI, V7, P369; CHURCH J, 1985, EUR J PHARMACOL, V111, P185, DOI 10.1016/0014-2999(85)90755-1; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; COWAN A, 1979, SCIENCE, V206, P465, DOI 10.1126/science.504986; DEWITT D S, 1988, Society for Neuroscience Abstracts, V14, P621; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DRAGUNOW M, 1986, TRENDS PHARMACOL SCI, V7, P128, DOI 10.1016/0165-6147(86)90285-3; FADEN A I, 1983, Current Concepts of Cerebrovascular Disease and Stroke, V18, P27; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1983, STROKE, V14, P169, DOI 10.1161/01.STR.14.2.169; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEESER H R, 1987, Society for Neuroscience Abstracts, V13, P1157; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; GEORGE C P, 1987, Society for Neuroscience Abstracts, V13, P1446; HARDY C, 1980, BRAIN RES, V194, P293, DOI 10.1016/0006-8993(80)91347-5; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; Hayes R L, 1988, Brain Inj, V2, P31, DOI 10.3109/02699058809150930; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1988, J NEUROTRAUM, V5, P287; Hayes RL, 1989, MILD HEAD INJURY, P54; Holaday JW, 1984, CENTRAL PERIPHERAL E, P237; HOSOBUCHI Y, 1982, SCIENCE, V215, P69, DOI 10.1126/science.6274019; ITZHAK Y, 1988, OPIATE RECEPTORS, P95; JEFTINIJA S, 1987, Society for Neuroscience Abstracts, V13, P1305; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; JENKINS LW, 1989, MICHIGAN S SERIES TR, V1, P47; KELSEY JE, 1982, BRAIN RES, V253, P337, DOI 10.1016/0006-8993(82)90705-3; LAPCHAK P A, 1987, Society for Neuroscience Abstracts, V13, P1192; LASON W, 1987, Society for Neuroscience Abstracts, V13, P1306; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; Lindgren S O, 1966, Acta Chir Scand Suppl, V360, P1; Long J B, 1986, Cent Nerv Syst Trauma, V3, P295; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, IN PRESS NEUROTRAUMA; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MELDRUM BS, 1985, INT REV NEUROBIOL, V17, P1; MORLEY JE, 1983, NEUROSCI BIOBEHAV R, V7, P281, DOI 10.1016/0149-7634(83)90020-9; Newcombe F, 1980, Int Rehabil Med, V2, P133; NORTH RA, 1979, LIFE SCI, V24, P1527, DOI 10.1016/0024-3205(79)90014-6; OLNEY JW, 1983, NATURE, V301, P520, DOI 10.1038/301520a0; PATERSON SJ, 1983, BRIT MED BULL, V39, P31, DOI 10.1093/oxfordjournals.bmb.a071787; PRINCE D A, 1987, Society for Neuroscience Abstracts, V13, P1446; ROSNER MJ, 1982, 5TH P INT S INTR PRE, P154; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; RUTHERFORD WH, 1977, LANCET, V1, P1; SAPOLSKY RM, 1989, NEUROSCI LETT, V97, P157, DOI 10.1016/0304-3940(89)90156-0; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; STERNAU L, 1987, J CEREB BLOOD FLO S1, V7, P147; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SWAN JH, 1987, J CEREB BLOOD FLO S1, V7, P145; TEASDALE G, 1976, BRIT J ANAESTH, V48, P761, DOI 10.1093/bja/48.8.761; TORTELLA F C, 1987, Society for Neuroscience Abstracts, V13, P208; TORTELLA FC, 1982, LIFE SCI, V31, P881, DOI 10.1016/0024-3205(82)90544-6; TORTELLA FC, 1986, J PHARMACOL EXP THER, V237, P49; TORTELLA FC, 1985, BRAIN RES, V332, P174, DOI 10.1016/0006-8993(85)90403-2; TORTELLA FC, 1985, SCIENCE, V228, P1106, DOI 10.1126/science.2986292; TORTELLA FC, 1986, BRAIN RES, V383, P314, DOI 10.1016/0006-8993(86)90031-4; TORTELLA FC, 1987, INACTIVATION HYPERSE, P33; TURSKI WA, 1983, EXPERIENTIA, V39, P1408, DOI 10.1007/BF01990130; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WHITE JD, 1985, PHYSIOL REV, V65, P553; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZIMMERMAN R S, 1989, Society for Neuroscience Abstracts, V15, P131	80	50	52	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	1990	72	2					252	261		10.3171/jns.1990.72.2.0252			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CK260	WOS:A1990CK26000013	2295922				2021-06-18	
J	DAVIDOFF, G; MORRIS, J; ROTH, E; BLEIBERG, J				DAVIDOFF, G; MORRIS, J; ROTH, E; BLEIBERG, J			COGNITIVE DYSFUNCTION AND MILD CLOSED HEAD-INJURY IN TRAUMATIC SPINAL-CORD INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT REHABIL MED,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT PSYCHIAT,CHICAGO,IL 60611							BLEIBERG J, 1983, ARCH PHYS MED REHAB, V64, P448; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DUBO H, 1984, P AM SPINAL INJURY A, P35; FITZHUGH KB, 1961, J CONSULT PSYCHOL, V25, P61, DOI 10.1037/h0043344; GUTTMANN L, 1963, P S SPINAL INJURIES, P81; Harris P, 1968, Paraplegia, V5, P215; LYNCH W, 1983, REHABILITATION HEAD, P292; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; Meinecke F W, 1968, Paraplegia, V5, P196; REITAN R M, 1955, AMA Arch Neurol Psychiatry, V73, P28; REMINGTON RD, 1970, STATISTICS APPLICATI; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SCHUENEMAN A, 1982, SCI DIG, V4, P35; Schueneman AL, 1982, SCI DIG, V4, P64; SHAW DJ, 1966, J CLIN PSYCHOL, V22, P176, DOI 10.1002/1097-4679(196604)22:2<176::AID-JCLP2270220215>3.0.CO;2-O; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; WAGNER KA, 1984, P AM SPINAL INJURY A, P96; WILMOT CB, 1984, P AM SPINAL INJURY A, P105; YOUNG JS, 1982, SPINAL CORD INJURY S, P34	27	50	53	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.		1985	66	8					489	491					3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	APA30	WOS:A1985APA3000293	4026547				2021-06-18	
J	Ricker, G				Ricker, G			The origin of pathlogical anatomical findings from cerebral concussion in addition to the vascular system of the brain.	VIRCHOWS ARCHIV FUR PATHOLOGISCHE ANATOMIE UND PHYSIOLOGIE UND FUR KLINISCHE MEDIZIN			German	Article																Berger H., 1901, LEHRE BLUTZIRKULATIO; BICKEL H, 1916, BERUCKSICHTIGUNG PSY; BOLLINGER, 1891, INT BEITRAGE WISSENS; BRODMANN K, 1902, J PHYSL NEUROLOGIE, V1; DAHLMANN, 1910, Z GES NEUROLOGIE PSY, V3; FRIEDMANN M, 1892, ARCH PSYCHIATRIE, V23; KANINCHENS, 1910, VIRCHOWS ARCH, V199; KULBS, 1910, ARCH EXPTL PATHOLOGI, V62; LUXENBURGER A, 1903, EXPTL STUDIEN RUCKEN; REINEBOTH, 1898, MUNCH MED WOCHENSCHR; RICKER G, 1915, THEORIE MESOTHORIUM; SCHMAUS H, 1890, VIRCHOWS ARCH, V122; SCHMAUS H, 1891, ARCH KLIN CHIRURG, V42; WILHELM K, 1874, ARCH KLIN CHIRURGIE, V17; 1910, DTSCH MED WOCHENSCHR, V36	15	50	50	0	0	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0376-0081			VIRCHOWS ARCH A	Virchows Arch. Pathol. Anat. Physiol. Klin. Med.	JUN	1919	226	2					180	212		10.1007/BF02039959			33	Pathology	Pathology	V15DO	WOS:000201023200003					2021-06-18	
J	Stern, RA; Adler, CH; Chen, KW; Navitsky, M; Luo, J; Dodick, DW; Alosco, ML; Tripodis, Y; Goradia, DD; Martin, B; Mastroeni, D; Fritts, NG; Jarnagin, J; Devous, MD; Mintun, MA; Pontecorvo, MJ; Shenton, ME; Reiman, EM				Stern, Robert A.; Adler, Charles H.; Chen, Kewei; Navitsky, Michael; Luo, Ji; Dodick, David W.; Alosco, Michael L.; Tripodis, Yorghos; Goradia, Dhruman D.; Martin, Brett; Mastroeni, Diego; Fritts, Nathan G.; Jarnagin, Johnny; Devous, Michael D., Sr.; Mintun, Mark A.; Pontecorvo, Michael J.; Shenton, Martha E.; Reiman, Eric M.			Tau Positron-Emission Tomography in Former National Football League Players	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; ALZHEIMER-DISEASE; BETA	BACKGROUND Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that has been associated with a history of repetitive head impacts. The neuropathological diagnosis is based on a specific pattern of tau deposition with minimal amyloid-beta deposition that differs from other disorders, including Alzheimer's disease. The feasibility of detecting tau and amyloid deposition in the brains of living persons at risk for CTE has not been well studied. METHODS We used flortaucipir positron-emission tomography (PET) and florbetapir PET to measure deposition of tau and amyloid-beta, respectively, in the brains of former National Football League (NFL) players with cognitive and neuropsychiatric symptoms and in asymptomatic men with no history of traumatic brain injury. Automated image-analysis algorithms were used to compare the regional tau standardized uptake value ratio (SUVR, the ratio of radioactivity in a cerebral region to that in the cerebellum as a reference) between the two groups and to explore the associations of SUVR with symptom severity and with years of football play in the former-player group. RESULTS A total of 26 former players and 31 controls were included in the analysis. The mean flortaucipir SUVR was higher among former players than among controls in three regions of the brain: bilateral superior frontal (1.09 vs. 0.98; adjusted mean difference, 0.13; 95% confidence interval [CI], 0.06 to 0.20; P<0.001), bilateral medial temporal (1.23 vs. 1.12; adjusted mean difference, 0.13; 95% CI, 0.05 to 0.21; P<0.001), and left parietal (1.12 vs. 1.01; adjusted mean difference, 0.12; 95% CI, 0.05 to 0.20; P = 0.002). In exploratory analyses, the correlation coefficients in these three regions between the SUVRs and years of play were 0.58 (95% CI, 0.25 to 0.79), 0.45 (95% CI, 0.07 to 0.71), and 0.50 (95% CI, 0.14 to 0.74), respectively. There was no association between tau deposition and scores on cognitive and neuropsychiatric tests. Only one former player had levels of amyloid-beta deposition similar to those in persons with Alzheimer's disease. CONCLUSIONS A group of living former NFL players with cognitive and neuropsychiatric symptoms had higher tau levels measured by PET than controls in brain regions that are affected by CTE and did not have elevated amyloid-beta levels. Further studies are needed to determine whether elevated CTE-associated tau can be detected in individual persons.	[Stern, Robert A.; Alosco, Michael L.; Fritts, Nathan G.; Jarnagin, Johnny] Boston Univ, Sch Med, Boston, MA 02118 USA; [Tripodis, Yorghos; Martin, Brett] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Shenton, Martha E.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Shenton, Martha E.] Harvard Med Sch, Boston, MA 02115 USA; [Shenton, Martha E.] Vet Affairs Boston Healthcare Syst, Boston, MA USA; [Adler, Charles H.; Dodick, David W.] Mayo Clin Arizona, Scottsdale, AZ USA; [Chen, Kewei; Luo, Ji; Goradia, Dhruman D.; Reiman, Eric M.] Banner Alzheimers Inst, Phoenix, AZ USA; [Mastroeni, Diego] Arizona State Univ, Tempe, AZ USA; [Navitsky, Michael; Devous, Michael D., Sr.; Mintun, Mark A.; Pontecorvo, Michael J.] Avid Radio Pharmaceut, Philadelphia, PA USA	Stern, RA (corresponding author), Boston Univ, Sch Med, Alzheimers Dis Ctr, 72 E Concord St,B-7800, Boston, MA 02118 USA.	bobstern@bu.edu	Shenton, Martha/V-8780-2019; , Bob/ABA-8507-2020	Tripodis, Yorghos/0000-0003-2190-7608	Avid Radiopharmaceuticals; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS102399, U01NS093334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG019610, U19AG024904, P30AG013846] Funding Source: NIH RePORTER	Funded by Avid Radiopharmaceuticals and others.	Alosco ML, 2018, ALZHEIMERS DEMENT, V14, P1159, DOI 10.1016/j.jalz.2018.05.004; Alosco ML, 2018, ANN NEUROL, V83, P886, DOI 10.1002/ana.25245; Alosco ML, 2017, J NEUROTRAUM, V34, P772, DOI 10.1089/neu.2016.4536; Alosco ML, 2016, ALZHEIMERS DEMENT, V7, P33; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Congdon EE, 2018, NAT REV NEUROL, V14, P399, DOI 10.1038/s41582-018-0013-z; Dickstein DL, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.175; Falcon B, 2019, NATURE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Laforce R, 2018, ALZHEIMERS DEMENT, V14, P1522, DOI 10.1016/j.jalz.2018.06.2855; Lee CM, 2018, J ALZHEIMERS DIS, V62, P1691, DOI 10.3233/JAD-170840; Lyoo CH, 2018, J MOV DISORD, V11, P1, DOI 10.14802/jmd.17071; Marquie M, 2017, ANN NEUROL, V81, P117, DOI 10.1002/ana.24844; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Ossenkoppele R, 2018, JAMA-J AM MED ASSOC, V320, P1151, DOI 10.1001/jama.2018.12917; Phillips JS, 2018, HUM BRAIN MAPP, V39, P691, DOI 10.1002/hbm.23874; Pontecorvo MJ, 2017, BRAIN, V140, P748, DOI 10.1093/brain/aww334; Schonhaut DR, 2017, ANN NEUROL, V82, P622, DOI 10.1002/ana.25060; Smith R, 2018, JAMA NEUROL; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Villemagne VL, 2018, NAT REV NEUROL, V14, P225, DOI 10.1038/nrneurol.2018.9; 2012, LANCET NEUROL, V11, P669, DOI DOI 10.1016/S1474-4422(12)70142-4; 2017, ACTA NEUROPATHOL, V133, P337, DOI DOI 10.1007/S00401-017-1680-3	28	49	50	2	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	2019	380	18					1716	1725		10.1056/NEJMoa1900757			10	Medicine, General & Internal	General & Internal Medicine	HX9ZK	WOS:000467767800007	30969506	Green Accepted, Bronze	Y	N	2021-06-18	
J	Zou, P; Liu, XX; Li, G; Wang, YG				Zou, Peng; Liu, Xiaoxiao; Li, Gang; Wang, Yangang			Resveratrol pretreatment attenuates traumatic brain injury in rats by suppressing NLRP3 inflammasome activation via SIRT1	MOLECULAR MEDICINE REPORTS			English	Article						traumatic brain injury; resveratrol; NLR family pyrin domain containing 3; inflammasome; reactive oxygen species; sirtuin 1	ACUTE LUNG INJURY; ENDOTHELIAL-CELLS; STEM-CELLS; NEUROPROTECTION; PATHWAY; STROKE; EXPRESSION; SIRTUINS; DISEASE; MODEL	The inflammatory response in the cerebral cortex serves an important role in the progression of secondary injury following traumatic brain injury (TBI). The NLR family pyrin domain containing 3 (NLRP3) inflammasome is necessary for initiating inflammation and is involved in various central nervous system disorders. The aim of the present study was to investigate the neuroprotective effect of resveratrol and elucidate the underlying mechanisms of resveratrol associated regulation of the NLRP3 inflammasome in TBI. The results demonstrated that the activation of NLRP3, caspase-1 and sirtuin 1 (SIRT1), enhanced the production of inflammatory cytokines and reactive oxygen species (ROS) following TBI. Administration of resveratrol alleviated the degree of TBI, as evidenced by the reduced neuron-specific enolase (NSE) and brain water content (WBC). Resveratrol pretreatment also inhibited the activation of NLRP3 and caspase-1, and reduced the production of inflammatory cytokines and ROS. In addition, resveratrol further promoted SIRT1 activation. Furthermore, the suppressing effect of resveratrol on the NLRP3 inflammasome and ROS was blocked by the SIRT1 inhibitor, sirtinol. The results revealed that the activation of the NLRP3 inflammasome and the subsequent inflammatory responses in the cerebral cortex were involved in the process of TBI. Resveratrol may attenuate the inflammatory response and relieve TBI by reducing ROS production and inhibiting NLRP3 activation. The effect of resveratrol on NLRP3 inflammasome and ROS may also be SIRT1 dependent.	[Zou, Peng; Wang, Yangang] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Liu, Xiaoxiao] Xian Med Univ, Affiliated Northern Hosp, Dept Cardiol, Xian 710032, Shaanxi, Peoples R China; [Li, Gang] Jiangxian Peoples Hosp, Dept Neurosurg, Yuncheng 043600, Shanxi, Peoples R China	Wang, YG (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.	yg-wang@163.com					Abdel-Aleem GA, 2016, ARCH PHYSIOL BIOCHEM, V122, P200, DOI 10.1080/13813455.2016.1182190; Butterfield DA, 2016, PROTEOM CLIN APPL, V10, P1191, DOI 10.1002/prca.201600003; Czerska M, 2015, MED PR, V66, P393, DOI 10.13075/mp.5893.00137; Dong HJ, 2017, J CRANIOFAC SURG, V28, P1615, DOI 10.1097/SCS.0000000000003563; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Gardner AJ, 2017, PHYS MED REH CLIN N, V28, P413, DOI 10.1016/j.pmr.2016.12.014; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Jardim FR, 2017, MOL NEUROBIOL, DOI [10.1007/s12035-017-0448-z, DOI 10.1007/S12035-017-0448-Z28283884]; Jiang L, 2016, BIOMED PHARMACOTHER, V84, P130, DOI 10.1016/j.biopha.2016.09.020; Jin RL, 2017, MOL CELLS, V40, P222, DOI 10.14348/molcells.2017.2314; Kleszcz R, 2015, PHARMACOL REP, V67, P1068, DOI 10.1016/j.pharep.2015.03.021; Kumar A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0819-4; Li L., 2014, AM J CANCER RES, V5, P442; Li YX, 2017, IMMUNOBIOLOGY, V222, P552, DOI 10.1016/j.imbio.2016.11.002; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu Y, 2014, BASIC RES CARDIOL, V109, DOI 10.1007/s00395-014-0415-z; Lopez MS, 2015, NEUROCHEM INT, V89, P75, DOI 10.1016/j.neuint.2015.08.009; Martin A, 2015, IMMUNOL RES, V61, P187, DOI 10.1007/s12026-014-8557-5; Matsushima S, 2015, AM J PHYSIOL-HEART C, V309, pH1375, DOI 10.1152/ajpheart.00053.2015; Minutoli Letteria, 2016, Oxid Med Cell Longev, V2016, P2183026, DOI 10.1155/2016/2183026; Naghibi T, 2017, J CLIN DIAGN RES, V11, pPC6, DOI 10.7860/JCDR/2017/19132.9198; Pennisi M, 2017, J NEUROSCI RES, V95, P1360, DOI 10.1002/jnr.23986; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Shah FA, 2014, J VET MED SCI, V76, P1367, DOI 10.1292/jvms.14-0169; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Su Q, 2016, NEUROL RES, V38, P60, DOI 10.1080/01616412.2015.1133027; Tan MS, 2013, MOL NEUROBIOL, V48, P875, DOI 10.1007/s12035-013-8475-x; Tang BL, 2016, MOL CELLS, V39, P87, DOI 10.14348/molcells.2016.2318; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Wan D, 2016, BRAIN RES BULL, V121, P255, DOI 10.1016/j.brainresbull.2016.02.011; Wang K, 2015, NEUROSCI LETT, V591, P53, DOI 10.1016/j.neulet.2015.02.016; Yang H, 2017, ACTA PHARMACOL SIN, V38, P168, DOI 10.1038/aps.2016.130; Yin N, 2016, AM J TRANSL RES, V8, P2033; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004	37	49	59	0	25	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	FEB	2018	17	2					3212	3217		10.3892/mmr.2017.8241			6	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	FT5WP	WOS:000423224300146	29257276	Bronze			2021-06-18	
J	Albalawi, F; Lu, WN; Beckel, JM; Lim, JC; McCaughey, SA; Mitchell, CH				Albalawi, Farraj; Lu, Wennan; Beckel, Jonathan M.; Lim, Jason C.; McCaughey, Stuart A.; Mitchell, Claire H.			The P2X7 Receptor Primes IL-1 beta and the NLRP3 Inflammasome in Astrocytes Exposed to Mechanical Strain	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						IL-1 beta; astrocytes; glaucoma; pannexin; ATP release; NF kappa B; caspase 1; NLRP3	OPTIC-NERVE HEAD; NF-KAPPA-B; RETINAL GANGLION-CELLS; TRAUMATIC BRAIN-INJURY; EXTRACELLULAR ATP; P2X(7) RECEPTOR; PANNEXIN HEMICHANNELS; SUSTAINED ELEVATION; ACUTE GLAUCOMA; UP-REGULATION	Inflammatory responses play a key role in many neural pathologies, with localized signaling from the non-immune cells making critical contributions. The NLRP3 inflammasome is an important component of innate immune signaling and can link neural insult to chronic inflammation. The NLRP3 inflammasome requires two stages to contribute: priming and activation. The priming stage involves upregulation of inflammasome components while the activation stage results in the assembly and activation of the inflammasome complex. The priming step can be rate limiting and can connect insult to chronic inflammation, but our knowledge of the signals that regulate NLRP3 inflammasome priming in sterile inflammation is limited. This study examined the link between mechanical strain and inflammasome priming in neural systems. Transient non-ischemic elevation of intraocular pressure increased mRNA for inflammasome components IL-1 beta, NLRP3, ASC, and CASP1 in rat and mouse retinas. The elevation was greater 1 day after the insult, with the rise in IL-1 beta most pronounced. The P2X7 receptor was implicated in the mechanosensitive priming of IL-1 beta mRNA in vivo, as the antagonist Brilliant Blue G (BBG) blocked the increased expression, the agonist BzATP mimicked the pressure-dependent rise in IL-1 beta, and the rise was absent in P2X7 knockout mice. In vitro measurements from optic nerve head astrocytes demonstrated an increased expression of IL-1 beta following stretch or swelling. This increase in IL-1 beta was eliminated by degradation of extracellular ATP with apyrase, or by the block of pannexin hemichannels with carbenoxolone, probenecid, or 10panx1 peptide. The rise in IL-1 beta expression was also blocked by P2X7 receptor antagonists BBG, A839977 or A740003. The rise in IL-1 beta was prevented by blocking transcription factor NF kappa B with Bay 11-7082, while the swelling-dependent fall in NF kappa B inhibitor I kappa B-alpha was reduced by A839977 and in P2X7 knockout mice. In summary, mechanical trauma to the retina primed NLRP3 inflammasome components, but only if there was ATP release through pannexin hemichannels, and autostimulation of the P2X7 receptor. As the P2X7 receptor can also trigger stage two of inflammasome assembly and activation, the P2X7 receptor may have a central role in linking mechanical strain to neuroinflammation.	[Albalawi, Farraj; Lu, Wennan; Beckel, Jonathan M.; Lim, Jason C.; McCaughey, Stuart A.; Mitchell, Claire H.] Univ Penn, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA; [Albalawi, Farraj] Univ Penn, Dept Orthodont, Philadelphia, PA 19104 USA; [Beckel, Jonathan M.] Pittsburgh Univ, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Mitchell, Claire H.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA; [Mitchell, Claire H.] Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	Mitchell, CH (corresponding author), Univ Penn, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA.; Mitchell, CH (corresponding author), Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.; Mitchell, CH (corresponding author), Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA.	chm@upenn.edu	Beckel, Jonathan M./A-6758-2008	Beckel, Jonathan M./0000-0003-1390-2292	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EY015537, EY013434, EY001583, DK106115]; Jody Sack Fund; King Saud bin Abdulaziz University for Health Sciences; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY013434, P30EY001583, R01EY015537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K01DK106115, R03DK114492] Funding Source: NIH RePORTER	This work is supported by grants from the NIH EY015537 and EY013434 and core grant EY001583 (CM), NIH DK106115 (JB), Jody Sack Fund (WL) and King Saud bin Abdulaziz University for Health Sciences (FA). These funding bodies had no direct role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript.	Albalawi F, 2016, FASEB J, V30; Beckel JM, 2014, GLIA, V62, P1486, DOI 10.1002/glia.22695; Bernier LP, 2012, J GEN PHYSIOL, V140, P571, DOI 10.1085/jgp.201210875; Boaru SG, 2015, BIOCHEM BIOPH RES CO, V458, P700, DOI 10.1016/j.bbrc.2015.02.029; Bruzzone R, 2005, J NEUROCHEM, V92, P1033, DOI 10.1111/j.1471-4159.2004.02947.x; Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001; Chi W, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0360-2; Chi W, 2014, P NATL ACAD SCI USA, V111, P11181, DOI 10.1073/pnas.1402819111; Choi HJ, 2015, MOL VIS, V21; Coffey EE, 2014, NEUROSCIENCE, V263, P111, DOI 10.1016/j.neuroscience.2014.01.001; COGSWELL JP, 1994, J IMMUNOL, V153, P712; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Crowston JG, 2015, EXP EYE RES, V141, P3, DOI 10.1016/j.exer.2015.03.006; Dinarello CA, 2007, EUR J IMMUNOL, V37, pS34, DOI 10.1002/eji.200737772; Donnelly-Roberts DL, 2009, BRIT J PHARMACOL, V157, P1203, DOI 10.1111/j.1476-5381.2009.00233.x; Downs JC, 2008, OPTOMETRY VISION SCI, V85, P425, DOI 10.1097/OPX.0b013e31817841cb; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Guha S, 2012, J NEUROCHEM, V122, P823, DOI 10.1111/j.1471-4159.2012.07804.x; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8; Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559; Honore P, 2009, BEHAV BRAIN RES, V204, P77, DOI 10.1016/j.bbr.2009.05.018; Hu HL, 2010, EXP EYE RES, V91, P425, DOI 10.1016/j.exer.2010.06.017; Johnson EC, 2009, J GLAUCOMA, V18, P341, DOI 10.1097/IJG.0b013e31818c6ef6; Karmakar M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10555; Katsnelson MA, 2015, J IMMUNOL, V194, P3937, DOI 10.4049/jimmunol.1402658; Kaushik DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032270; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Li A, 2011, EXP EYE RES, V93, P528, DOI 10.1016/j.exer.2011.06.020; Lim JC, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00270; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu YH, 2011, CYTOKINE, V55, P229, DOI 10.1016/j.cyto.2011.05.003; Lu WN, 2017, J NEUROCHEM, V141, P436, DOI 10.1111/jnc.13998; Lu W, 2013, INVEST OPHTH VIS SCI, V54; Lu WN, 2015, INVEST OPHTH VIS SCI, V56, P3075, DOI 10.1167/iovs.14-15891; Lye-Barthel M, 2013, INVEST OPHTH VIS SCI, V54, P909, DOI 10.1167/iovs.12-10109; Mandal A, 2009, AM J PHYSIOL-CELL PH, V297, pC111, DOI 10.1152/ajpcell.00539.2008; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Masin M, 2012, BRIT J PHARMACOL, V165, P978, DOI 10.1111/j.1476-5381.2011.01624.x; Mitchell CH, 2017, INVEST OPHTH VIS SCI, V58; Mitchell CH, 2016, INVEST OPHTH VIS SCI, V57; Mitchell CH, 2009, PURINERG SIGNAL, V5, P241, DOI 10.1007/s11302-009-9142-6; Morgan JE, 2000, EYE, V14, P437, DOI 10.1038/eye.2000.128; Morrison JC, 2010, INVEST OPHTH VIS SCI, V51; Morrison JC, 2014, INVEST OPHTH VIS SCI, V55; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Nadal-Nicolas FM, 2016, SCI REP-UK, V6, DOI 10.1038/srep38499; Patel MN, 2017, TRENDS MOL MED, V23, P165, DOI 10.1016/j.molmed.2016.12.007; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195; Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237; Reigada D, 2005, AM J PHYSIOL-CELL PH, V289, pC617, DOI 10.1152/ajpcell.00542.2004; Reigada D, 2008, NEUROSCIENCE, V157, P396, DOI 10.1016/j.neuroscience.2008.08.036; Sanderson J, 2014, EXP EYE RES, V127, P270, DOI 10.1016/j.exer.2014.08.009; Sappington RM, 2006, INVEST OPHTH VIS SCI, V47, P3860, DOI 10.1167/iovs.05-1408; Schindelin J, 2015, MOL REPROD DEV, V82, P518, DOI 10.1002/mrd.22489; Sperlagh B, 2014, TRENDS PHARMACOL SCI, V35, P537, DOI 10.1016/j.tips.2014.08.002; Stutz A, 2009, J CLIN INVEST, V119, P3502, DOI 10.1172/JCI40599; Tehrani S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167364; Miras-Portugal MT, 2015, COMPUT STRUCT BIOTEC, V13, P176, DOI 10.1016/j.csbj.2015.02.005; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Xia JS, 2012, J PHYSIOL-LONDON, V590, P2285, DOI 10.1113/jphysiol.2012.227983; Yilmaz O, 2015, PERIODONTOL 2000, V69, P83, DOI 10.1111/prd.12084; Zhang X, 2007, EXP EYE RES, V85, P637, DOI 10.1016/j.exer.2007.07.016; Zhang XL, 2005, INVEST OPHTH VIS SCI, V46, P2183, DOI 10.1167/iovs.05-0052; Zode GS, 2011, J CLIN INVEST, V121, P3542, DOI 10.1172/JCI58183	70	49	51	2	21	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	AUG 8	2017	11								227	10.3389/fncel.2017.00227			14	Neurosciences	Neurosciences & Neurology	FD1JN	WOS:000407293700001	28848393	DOAJ Gold, Green Published			2021-06-18	
J	Cheng, PC; Yin, P; Ning, PD; Wang, LJ; Cheng, XJ; Liu, YN; Schwebel, DC; Liu, JM; Qi, JL; Hu, GQ; Zhou, MG				Cheng, Peixia; Yin, Peng; Ning, Peishan; Wang, Lijun; Cheng, Xunjie; Liu, Yunning; Schwebel, David C.; Liu, Jiangmei; Qi, Jinlei; Hu, Guoqing; Zhou, Maigeng			Trends in traumatic brain injury mortality in China, 2006-2013: A population-based longitudinal study	PLOS MEDICINE			English	Article							ROAD TRAFFIC MORTALITY; OLDER WOMEN; NEW-ZEALAND; DEATH; EPIDEMIOLOGY; RISK; PREVENTION; BEHAVIORS; INCREASES; BALANCE	Background Traumatic brain injury (TBI) is a significant global public health problem, but has received minimal attention from researchers and policy-makers in low-and middle-income countries (LMICs). Epidemiological evidence of TBI morbidity and mortality is absent at the national level for most LMICs, including China. Using data from China's Disease Surveillance Points (DSPs) system, we conducted a population-based longitudinal analysis to examine TBI mortality, and mortality differences by sex, age group, location (urban/rural), and external cause of injury, from 1 January 2006 to 31 December 2013 in China. Method and findings Mortality data came from the national DSPs system of China, which has coded deaths using the International Classification of Diseases-10th Revision (ICD-10) since 2004. Crude and age-standardized mortality with 95% CIs were estimated using the census population in 2010 as a reference population. The Cochran-Armitage trend test was used to examine the significance of trends in mortality from 2006 to 2013. Negative binomial models were used to examine the associations of TBI mortality with location, sex, and age group. Subgroup analysis was performed by external cause of TBI. We found the following: (1) Age-adjusted TBI mortality increased from 13.23 per 100,000 population in 2006 to 17.06 per 100,000 population in 2008 and then began to fall slightly. In 2013, age-adjusted TBI mortality was 12.99 per 100,000 population (SE = 0.13). (2) Compared to females and urban residents, males and rural residents had higher TBI mortality risk, with adjusted mortality rate ratios of 2.57 and 1.71, respectively. TBI mortality increased substantially with older age. (3) Motor vehicle crashes and falls were the 2 leading causes of TBI mortality between 2006 and 2013. TBI deaths from motor vehicle crashes in children aged 0-14 years and adults aged 65 years and older were most often in pedestrians, and motorcyclists were the first or second leading category of road user for the other age groups. (4) TBI mortality attributed to motor vehicle crashes increased for pedestrians and motorcyclists in all 7 age groups from 2006 to 2013. Our analysis was limited by the availability and quality of data in the DSPs dataset, including lack of injury-related socio-economic factors, policy factors, and individual and behavioral factors. The dataset also may be incomplete in TBI death recording or contain misclassification of mortality data. Conclusions TBI constitutes a serious public health threat in China. Further studies should explore the reasons for the particularly high risk of TBI mortality among particular populations, as well as the reasons for recent increases in certain subgroups, and should develop solutions to address these challenges. Interventions proven to work in other cultures should be introduced and implemented nationwide. Examples of these in the domain of motor vehicle crashes include policy change and enforcement of laws concerning helmet use for motorcyclists and bicyclists, car seat and booster seat use for child motor vehicle passengers, speed limit and drunk driving laws, and alcohol ignition interlock use. Examples to prevent falls, especially among elderly individuals, include exercise programs, home modification to reduce fall risk, and multifaceted interventions to prevent falls in all age groups.	[Cheng, Peixia; Ning, Peishan; Cheng, Xunjie; Hu, Guoqing] Cent S Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R China; [Yin, Peng; Wang, Lijun; Liu, Yunning; Liu, Jiangmei; Qi, Jinlei; Zhou, Maigeng] Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R China; [Schwebel, David C.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA	Hu, GQ (corresponding author), Cent S Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R China.; Zhou, MG (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R China.	huguoqing009@gmail.com; maigengzhou@126.com	Liu, You-Nian/G-2697-2013	Liu, You-Nian/0000-0002-7078-5937; Hu, Guoqing/0000-0002-5002-8015			Adams RS, 2013, SUBST USE MISUSE, V48, P821, DOI 10.3109/10826084.2013.797995; Alcorn T, 2011, LANCET, V378, P305, DOI 10.1016/S0140-6736(11)61153-7; [Anonymous], 2010, LANCET NEUROL, V9, P331, DOI 10.1016/S1474-4422(10)70069-7; Asbridge M, 2010, ACCIDENT ANAL PREV, V42, P1408, DOI 10.1016/j.aap.2010.03.005; Barr GC, 2015, J EMERG MED, V48, P366, DOI 10.1016/j.jemermed.2014.09.055; Campbell AJ, 1999, AGE AGEING, V28, P513, DOI 10.1093/ageing/28.6.513; Chinese Center for Disease Control and Prevention National Center for Chronic and Noncommunicable Disease Control and Prevention, 2008, DAT SETS DEATH CAUS; Chinese Center for Disease Control and Prevention National Center for Chronic and Noncommunicable Disease Control and Prevention, 2013, DAT SETS DEATH CAUS; Coronado VG, 2011, MMWR SURVEILL SUMM, V60, P1; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; D'Souza AJ, 2008, J EPIDEMIOL COMMUN H, V62, P899, DOI 10.1136/jech.2007.068072; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Firsching R, 2001, WORLD J SURG, V25, P1221; Hu G, 2008, INJURY PREV, V14, P129, DOI 10.1136/ip.2007.017822; Hu GQ, 2011, B WORLD HEALTH ORGAN, V89, P41, DOI 10.2471/BLT.10.080317; Hu GQ, 2010, J RURAL HEALTH, V26, P73, DOI 10.1111/j.1748-0361.2009.00255.x; Hu GQ, 2009, LANCET, V373, P214, DOI 10.1016/S0140-6736(09)60068-4; Huang HL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153251; Huang YX, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1111; Hui Z, 2012, BIOMED ENVIRON SCI, V25, P483, DOI 10.3967/0895-3988.2012.04.015; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JUDGE JO, 1993, PHYS THER, V73, P254, DOI 10.1093/ptj/73.4.254; Kessaram T, 2016, DRUG ALCOHOL REV, V35, P412, DOI 10.1111/dar.12328; Li L, 2015, B WORLD HEALTH ORGAN, V93, P169, DOI 10.2471/BLT.14.139998; Liu Ming-bo, 2013, Zhonghua Liu Xing Bing Xue Za Zhi, V34, P985; LORD SR, 1993, ARCH PHYS MED REHAB, V74, P837, DOI 10.1016/0003-9993(93)90010-8; Mack M G, 2000, Inj Prev, V6, P141, DOI 10.1136/ip.6.2.141; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Michael YL, 2010, ANN INTERN MED, V153, P815, DOI 10.7326/0003-4819-153-12-201012210-00008; Mooney P, 2006, B WORLD HEALTH ORGAN, V84, P168; National Health and Family Planning Commission of the People's Republic of China, 2007, CHIN HLTH STAT YB 20; National Health and Family Planning Commission of the PRC, 2014, CHIN HLTH STAT YB 20; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; Nicodemus KK, 2008, MOL PSYCHIATR, V13, P873, DOI 10.1038/sj.mp.4002153; Ning P, 2017, INJ PREV; Ning PS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164560; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Reidy DE, 2016, INJURY PREV, V22, P370, DOI 10.1136/injuryprev-2015-041599; Riesch SK, 2013, INT J NURS STUD, V50, P1067, DOI 10.1016/j.ijnurstu.2012.10.012; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sasser S., 2005, PREHOSPITAL TRAUMA C; Sasser SM, 2006, B WORLD HEALTH ORGAN, V84, P507, DOI 10.2471/BLT.06.033605; Scholten AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110905; Song SL, 2016, COMPUT J, V59, P91, DOI 10.1093/comjnl/bxv066; Statistical Consulting Group, NEG BIN REGR STAT AN; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Thurman DJ., 1995, GUIDELINES SURVEILLA; Tian DP, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0330-z; US Centers for Disease Control and Prevention, EXT CAUS INJ MORT MA; Vaaramo K, 2015, J NEUROTRAUM, V32, P1579, DOI 10.1089/neu.2014.3757; Vos T, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Wang Li-jun, 2007, Zhonghua Liu Xing Bing Xue Za Zhi, V28, P571; Wang Lin, 2011, Zhonghua Yu Fang Yi Xue Za Zhi, V45, P1061; World Health Organization, 2013, MAK WALK SAF BRIEF O; World Health Organization, 2007, WHO GLOB REP FALLP; World Health Organization (WHO), 2013, PED SAF ROAD SAF MAN; [杨冬立 Yang Dongli], 2013, [中国急救医学, Chinese Journal of Critical Care Medicine], V33, P1130; Yang G, 1992, Zhonghua Liu Xing Bing Xue Za Zhi, V13, P197; Yang Gonghuan, 2005, Popul Health Metr, V3, P3, DOI 10.1186/1478-7954-3-3; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang HaoSu, 2016, Chinese Journal of Emergency Medicine, V25, P779; Zhang Y, 2016, J TRAUMA SURG, V18, P328; [张溢华 Zhang Yihua], 2014, [中华创伤杂志, Chinese Journal of Trauma], V30, P1215; Zhou M, 2010, JI BING JIAN CE, V25, P239; Zhou Mai-geng, 2006, Zhonghua Liu Xing Bing Xue Za Zhi, V27, P328	71	49	59	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1277	1549-1676		PLOS MED	PLos Med.	JUL	2017	14	7							e1002332	10.1371/journal.pmed.1002332			22	Medicine, General & Internal	General & Internal Medicine	FC1QA	WOS:000406611200034	28700591	DOAJ Gold, Green Published			2021-06-18	
J	Erdodi, LA; Abeare, CA; Lichtenstein, JD; Tyson, BT; Kucharski, B; Zuccato, BG; Roth, RM				Erdodi, Laszlo A.; Abeare, Christopher A.; Lichtenstein, Jonathan D.; Tyson, Bradley T.; Kucharski, Brittany; Zuccato, Brandon G.; Roth, Robert M.			Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Processing Speed Scores as Measures of Noncredible Responding: The Third Generation of Embedded Performance Validity Indicators	PSYCHOLOGICAL ASSESSMENT			English	Article						performance validity testing; embedded validity indicators; processing speed; WAIS-IV; coding	TRAUMATIC BRAIN-INJURY; RECOGNITION MEMORY TEST; LEARNING TEST-II; CLASSIFICATION ACCURACY; SYMPTOM VALIDITY; DIGIT SPAN; NEUROPSYCHOLOGICAL TESTS; INCOMPLETE EFFORT; CROSS-VALIDATION; CLINICAL UTILITY	Research suggests that select processing speed measures can also serve as embedded validity indicators (EVIs). The present study examined the diagnostic utility of Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) subtests as EVIs in a mixed clinical sample of 205 patients medically referred for neuropsychological assessment (53.3% female, mean age = 45.1). Classification accuracy was calculated against 3 composite measures of performance validity as criterion variables. A PSI <= 79 produced a good combination of sensitivity (.23-.56) and specificity (.92-.98). A Coding scaled score <= 5 resulted in good specificity (.94-1.00), but low and variable sensitivity (.04-.28). A Symbol Search scaled score <= 6 achieved a good balance between sensitivity (.38-.64) and specificity (.88-.93). A Coding-Symbol Search scaled score difference >= 5 produced adequate specificity (.89-.91) but consistently low sensitivity (.08-.12). A 2-tailed cutoff on the Coding/Symbol Search raw score ratio (<= 1.41 or >= 3.57) produced acceptable specificity (.87-.93), but low sensitivity (.15-.24). Failing >= 2 of these EVIs produced variable specificity (.81-.93) and sensitivity (.31-.59). Failing >= 3 of these EVIs stabilized specificity (.89-.94) at a small cost to sensitivity (.23-.53). Results suggest that processing speed based EVIs have the potential to provide a cost-effective and expedient method for evaluating the validity of cognitive data. Given their generally low and variable sensitivity, however, they should not be used in isolation to determine the credibility of a given response set. They also produced unacceptably high rates of false positive errors in patients with moderate-to-severe head injury. Combining evidence from multiple EVIs has the potential to improve overall classification accuracy.	[Erdodi, Laszlo A.; Abeare, Christopher A.; Kucharski, Brittany; Zuccato, Brandon G.] Univ Windsor, Dept Psychol, Dartmouth, NS, Canada; [Erdodi, Laszlo A.; Lichtenstein, Jonathan D.; Tyson, Bradley T.; Roth, Robert M.] Geisel Sch Med, Dept Psychiat, Neuropsychol Serv, Dartmouth, NS, Canada; [Tyson, Bradley T.] Western Washington Med Grp, Everett, WA USA	Erdodi, LA (corresponding author), 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com		Abeare, Christopher/0000-0002-7163-7434			Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Boone K. B., 2013, CLIN PRACTICE FORENS; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Cottingham ME, 2014, CLIN NEUROPSYCHOL, V28, P1030, DOI 10.1080/13854046.2014.951397; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Curtis KL, 2009, ASSESSMENT, V16, P401, DOI 10.1177/1073191109338161; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Green P., 2013, CLIN PRACTICE FORENS; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; HAYWARD L, 1987, AUST NZ J PSYCHIAT, V21, P87, DOI 10.3109/00048678709160904; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Kolb B., 2009, FUNDAMENTALS HUMAN N; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Loring DW, 2010, NEUROLOGY, V74, P685, DOI 10.1212/WNL.0b013e3181d0cd12; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Pearson, 2009, ADV CLIN SOLUTIONS W; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	47	49	49	1	26	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	FEB	2017	29	2					148	157		10.1037/pas0000319			10	Psychology, Clinical	Psychology	EN5MZ	WOS:000396051100003	27124099				2021-06-18	
J	Di Virgilio, TG; Hunter, A; Wilson, L; Stewart, W; Goodall, S; Howatson, G; Donaldson, DI; Ietswaart, M				Di Virgilio, Thomas G.; Hunter, Angus; Wilson, Lindsay; Stewart, William; Goodall, Stuart; Howatson, Glyn; Donaldson, David I.; Ietswaart, Magdalena			Evidence for Acute Electrophysiological and Cognitive Changes Following Routine Soccer Heading	EBIOMEDICINE			English	Article						Sports concussion; Transcranial magnetic stimulation; Sub-concussion; Traumatic brain injury	TRANSCRANIAL MAGNETIC STIMULATION; TRAUMATIC BRAIN-INJURY; MOTOR CORTEX; SPORTS CONCUSSION; POSTURAL CONTROL; LONG-TERM; INHIBITION; ABNORMALITIES	Introduction: There is growing concern around the effects of concussion and sub-concussive impacts in sport. Routine game-play in soccer involves intentional and repeated head impacts through ball heading. Although heading is frequently cited as a risk to brain health, little data exist regarding the consequences of this activity. This study aims to assess the immediate outcomes of routine football heading using direct and sensitive measures of brain function. Methods: Nineteen amateur football players (5 females; age 22 +/- 3 y) headed machine-projected soccer balls at standardized speeds, modelling routine soccer practice. The primary outcome measure of corticomotor inhibition measured using transcranial magnetic stimulation, was assessed prior to heading and repeated immediately, 24 h, 48 h and 2 weeks post-heading. Secondary outcome measures were cortical excitability, postural control, and cognitive function. Results: Immediately following heading an increase in corticomotor inhibition was detected; further to these electrophysiological alterations, measurable reduction memory function were also found. These acute changes appear transient, with values normalizing 24 h post-heading. Discussion: Sub-concussive head impacts routine in soccer heading are associated with immediate, measurable electrophysiological and cognitive impairments. Although these changes in brain function were transient, these effects may signal direct consequences of routine soccer heading on (long-term) brain health which requires further study. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Di Virgilio, Thomas G.; Hunter, Angus] Univ Stirling, Physiol Exercise & Nutr Res Grp, Stirling FK9 4LA, Scotland; [Wilson, Lindsay; Donaldson, David I.; Ietswaart, Magdalena] Univ Stirling, Psychol, Stirling FK9 4LA, Scotland; [Stewart, William] Univ Glasgow, Queen Elizabeth Univ Hosp, Glasgow & Inst Neurosci & Psychol, Dept Neuropathol, Glasgow G12 8QQ, Lanark, Scotland; [Goodall, Stuart; Howatson, Glyn] Northumbria Univ, Fac Hlth & Life Sci, Newcastle Upon Tyne, Tyne & Wear, England; [Howatson, Glyn] North West Univ, Water Res Grp, Unit Environm Sci & Management, Potchefstroom, South Africa	Ietswaart, M (corresponding author), Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland.	magdalena.ietswaart@stir.ac.uk	Wilson, Lindsay/A-3659-2009; Howatson, Glyn/AAE-9508-2021; Wilson, Lindsay/O-8883-2019; Goodall, Stuart/AAE-7871-2020; Donaldson, David I/A-5249-2009	Wilson, Lindsay/0000-0003-4113-2328; Howatson, Glyn/0000-0001-8494-2043; Wilson, Lindsay/0000-0003-4113-2328; Goodall, Stuart/0000-0001-9029-2171; Donaldson, David I/0000-0002-8036-3455; Hunter, Angus/0000-0001-7562-6145; Stewart, William/0000-0003-2199-2582; Ietswaart, Magdalena/0000-0003-4576-9393			Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Cantu R., 2012, CONCUSSIONS OUR KIDS; Chen R, 1999, EXP BRAIN RES, V128, P539, DOI 10.1007/s002210050878; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Classen J, 1997, BRAIN, V120, P605, DOI 10.1093/brain/120.4.605; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Goodall S, 2009, EXP PHYSIOL, V94, P995, DOI 10.1113/expphysiol.2009.047902; Goodall S, 2014, EUR J SPORT SCI, V14, pS332, DOI 10.1080/17461391.2012.704079; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; Major BP, 2015, CLIN EXP PHARMACOL P, V42, P394, DOI 10.1111/1440-1681.12363; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Miller NR, 2014, BRAIN INJURY, V28, P1270, DOI 10.3109/02699052.2014.915987; Patlak M., 2002, SUMM IOM WORKSH NEUR; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Peugh JL, 2005, EDUC PSYCHOL MEAS, V65, P811, DOI 10.1177/0013164405278558; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Singer J.D., 2003, APPL LONGITUDINAL DA; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; WILSON SA, 1995, ELECTROMYOGR MOTOR C, V97, P246, DOI 10.1016/0013-4694(95)00052-Z	32	49	49	2	21	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	2352-3964			EBIOMEDICINE	EBioMedicine	NOV	2016	13						66	71		10.1016/j.ebiom.2016.10.029			6	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	EG0EU	WOS:000390704800022	27789273	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Lancaster, MA; Olson, DV; McCrea, MA; Nelson, LD; LaRoche, AA; Muftuler, LT				Lancaster, Melissa A.; Olson, Daniel V.; McCrea, Michael A.; Nelson, Lindsay D.; LaRoche, Ashley A.; Muftuler, L. Tugan			Acute white matter changes following sport-related concussion: A serial diffusion tensor and diffusion kurtosis tensor imaging study	HUMAN BRAIN MAPPING			English	Article						sport-related concussion; diffusion tensor imaging; diffusion kurtosis imaging; concussion management; concussion symptoms; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; GAUSSIAN WATER DIFFUSION; MILD HEAD-INJURY; NCAA CONCUSSION; AXONAL DAMAGE; MRI; METAANALYSIS; ADOLESCENTS; ANISOTROPY	Recent neuroimaging studies have suggested that following sport-related concussion (SRC) physiological brain alterations may persist after an athlete has shown full symptom recovery. Diffusion MRI is a versatile technique to study white matter injury following SRC, yet serial follow-up studies in the very acute stages following SRC utilizing a comprehensive set of diffusion metrics are lacking. The aim of the current study was to characterize white matter changes within 24 hours of concussion in a group of high school and collegiate athletes, using Diffusion Tensor and Diffusion Kurtosis Tensor metrics. Participants were reassessed a week later. At 24 hours post-injury, the concussed group reported significantly more concussion symptoms than a well-matched control group and demonstrated poorer performance on a cognitive screening measure, yet these differences were nonsignificant at the 8-day follow-up. Similarly, within 24-hours after injury, the concussed group exhibited a widespread decrease in mean diffusivity, increased axial kurtosis and, to a lesser extent, decreased axial and radial diffusivities compared with control subjects. At 8 days post injury, the differences in these diffusion metrics were even more widespread in the injured athletes, despite improvement of symptoms and cognitive performance. These MRI findings suggest that the athletes might not have reached full physiological recovery a week after the injury. These findings have significant implications for the management of SRC because allowing an athlete to return to play before the brain has fully recovered from injury may have negative consequences. Hum Brain Mapp 37:3821-3834, 2016. (c) 2016 Wiley Periodicals, Inc.	[Lancaster, Melissa A.; McCrea, Michael A.; Nelson, Lindsay D.; Muftuler, L. Tugan] Med Coll Wisconsin, Dept Neurol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Lancaster, Melissa A.; McCrea, Michael A.; Nelson, Lindsay D.; LaRoche, Ashley A.; Muftuler, L. Tugan] Med Coll Wisconsin, Dept Neurosurg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Olson, Daniel V.] Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA	Muftuler, LT (corresponding author), Med Coll Wisconsin, Froedtert Hosp, Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	lmuftuler@mcw.edu	Muftuler, L. Tugan/AAG-7539-2021	Muftuler, L. Tugan/0000-0002-6635-5678	GE-NFL Head Health Challenge I; U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0004]; Clinical and Translational Science Institute [1UL1-RR031973 (-01)]; National Center for Advancing Translational Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8UL1TR000055]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031973] Funding Source: NIH RePORTER	Contract grant sponsor: GE-NFL Head Health Challenge I and the U.S. Army Medical Research and Materiel Command; Contract grant sponsor: W81XWH-12-1-0004; Contract grant sponsor: Clinical and Translational Science Institute; Contract grant sponsor: 1UL1-RR031973 (-01); Contract grant sponsor: National Center for Advancing Translational Sciences, National Institutes of Health; Contract grant sponsor: 8UL1TR000055	Andersson JLR, 2003, NEUROIMAGE, V20, P870, DOI 10.1016/S1053-8119(03)00336-7; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Borich M, 2013, J NEUROTRAUM, V30, P1243, DOI 10.1089/neu.2012.2818; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Coutu JP, 2014, NEUROBIOL AGING, V35, P1412, DOI 10.1016/j.neurobiolaging.2013.12.001; Croall ID, 2014, NEUROLOGY, V83, P494, DOI 10.1212/WNL.0000000000000666; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dimou S, 2014, J NEUROTRAUM, V31, P413, DOI 10.1089/neu.2013.3050; Echemendia RJ, 2015, BRAIN INJURY, V29, P185, DOI 10.3109/02699052.2014.965212; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gosselin N, 2010, PHYSICIAN SPORTSMED, V38, P27, DOI 10.3810/psm.2010.10.1805; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Helmick K, 2006, DEFENSE VETERANS BRA; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Paydar A, 2014, AM J NEURORADIOL, V35, P808, DOI 10.3174/ajnr.A3764; Pfefferbaum A, 2000, MAGNET RESON MED, V44, P259, DOI 10.1002/1522-2594(200008)44:2<259::AID-MRM13>3.0.CO;2-6; Pfefferbaum A, 2003, MAGNET RESON MED, V49, P953, DOI 10.1002/mrm.10452; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Steven AJ, 2014, AM J ROENTGENOL, V202, pW26, DOI 10.2214/AJR.13.11365; Stokum JA, 2015, BRAIN INJURY, V29, P47, DOI 10.3109/02699052.2014.947628; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Veeramuthu V, 2015, J NEUROTRAUM, V32, P1497, DOI 10.1089/neu.2014.3750; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhu Y., 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/548392; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	66	49	50	1	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	NOV	2016	37	11					3821	3834		10.1002/hbm.23278			14	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DZ7VM	WOS:000386075900010	27237455	Green Published			2021-06-18	
J	Kawata, K; Rubin, LH; Lee, JH; Sim, T; Takahagi, M; Szwanki, V; Bellamy, A; Darvish, K; Assari, S; Henderer, JD; Tierney, R; Langford, D				Kawata, Keisuke; Rubin, Leah H.; Lee, Jong Hyun; Sim, Thomas; Takahagi, Masahiro; Szwanki, Victor; Bellamy, Al; Darvish, Kurosh; Assari, Soroush; Henderer, Jeffrey D.; Tierney, Ryan; Langford, Dianne			Association of Football Subconcussive Head Impacts With Ocular Near Point of Convergence	JAMA OPHTHALMOLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; SPORT-RELATED CONCUSSION; HIGH-SCHOOL; INSTRUMENTED MOUTHGUARD; IN-VIVO; PLAYERS; SYMPTOMS; VERGENCE; EXPOSURE; SYSTEM	IMPORTANCE An increased understanding of the relationship between subconcussive head impacts and near point of convergence (NPC) ocular-motor function may be useful in delineating traumatic brain injury. OBJECTIVE To investigate whether repetitive subconcussive head impacts during preseason football practice cause changes in NPC. DESIGN, SETTING, AND PARTICIPANTS This prospective, observational study of 29 National Collegiate Athletic Association Division I football players included baseline and preseason practices (1 noncontact and 4 contact), and postseason follow-up and outcome measures were obtained for each time. An accelerometer-embedded mouthguard measured head impact kinematics. Based on the sum of head impacts from all 5 practices, players were categorized into lower (n = 7) or higher (n = 22) impact groups. EXPOSURES Players participated in regular practices, and all head impacts greater than 10g from the 5 practices were recorded using the i1Biometerics Vector mouthguard (i1 Biometrics Inc). MAIN OUTCOMES AND MEASURES Near point of convergence measures and symptom scores. RESULTS A total of 1193 head impacts were recorded from 5 training camp practices in the 29 collegiate football players; 22 were categorized into the higher-impact group and 7 into the lower-impact group. There were significant differences in head impact kinematics between lower-and higher-impact groups (number of impacts, 6 vs 41 [lower impact minus higher impact = 35; 95% CI, 21-51; P < .001]; linear acceleration, 99g vs 1112g [lower impact minus higher impact = 1013; 95% CI, 621-1578; P < .001]; angular acceleration, 7589 radian/s(2) vs 65016 radian/s(2) [lower impact minus higher impact = 57 427; 95% CI, 31 123-80 498; P < .001], respectively). The trajectory and cumulative burden of subconcussive impacts on NPC differed by group (F for group x linear trend(1, 238) = 12.14, P < .001 and F for group x quadratic trend(1,) (238) = 12.97, P < .001). In the higher-impact group, there was a linear increase in NPC over time (B for linear trend, unstandardized coefficient [SE]: 0.76[0.12], P < .001) that plateaued and resolved by postseason follow-up (B for quadratic trend [SE]: -0.06[0.008], P < .001). In the lower-impact group, there was no change in NPC over time. Group differences were first observed after the first contact practice and remained until the final full-gear practice. No group differences were observed postseason follow-up. There were no differences in symptom scores between groups over time. CONCLUSIONS AND RELEVANCE Although asymptomatic, these data suggest that repetitive subconcussive head impacts were associated with changes in NPC. The increase in NPC highlights the vulnerability and slow recovery of the ocular-motor system following subconcussive head impacts. Changes in NPC may become a useful clinical tool in deciphering brain injury severity.	[Kawata, Keisuke; Lee, Jong Hyun; Langford, Dianne] Temple Univ, Lewis Katz Sch Med, Dept Neurosci, 3500 N Broad St,Med Educ & Res Bldg, Philadelphia, PA 19140 USA; [Kawata, Keisuke; Sim, Thomas; Tierney, Ryan] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Rubin, Leah H.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA; [Takahagi, Masahiro; Szwanki, Victor; Bellamy, Al] Temple Univ, Dept Athlet, Philadelphia, PA 19122 USA; [Darvish, Kurosh; Assari, Soroush] Temple Univ, Dept Mech Engn, Philadelphia, PA 19122 USA; [Henderer, Jeffrey D.] Temple Univ, Dept Ophthalmol, Lewis Katz Sch Med, Philadelphia, PA 19122 USA	Langford, D (corresponding author), Temple Univ, Lewis Katz Sch Med, Dept Neurosci, 3500 N Broad St,Med Educ & Res Bldg, Philadelphia, PA 19140 USA.	tdl@temple.edu		Darvish, Kurosh/0000-0002-6674-266X	Pennsylvania Athletic Trainers' Society; seed grant from Temple University Office of the Vice Provost for Research	Dr Kawata received support from a research grant from the Pennsylvania Athletic Trainers' Society. Dr Langford received support from Athole G. Jacobi, MD, the Marianne Garman Burton Foundation for Caregivers, and a seed grant from Temple University Office of the Vice Provost for Research.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bartsch Adam, 2014, Stapp Car Crash J, V58, P1; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Hamed MM, 2013, INDIAN J OPHTHALMOL, V61, P325, DOI 10.4103/0301-4738.97553; Hedeker D., 2006, LONGITUDINAL DATA AN; Higgins M, 2007, J ATHL TRAINING, V42, P5; HUNG GK, 1980, IEEE T BIO-MED ENG, V27, P439, DOI 10.1109/TBME.1980.326752; HUNG GK, 1986, DOC OPHTHALMOL, V62, P165, DOI 10.1007/BF00229128; HUNG GK, 1994, INVEST OPHTH VIS SCI, V35, P3486; Hung GK, 1997, VISION RES, V37, P1197, DOI 10.1016/S0042-6989(97)00271-X; Hwang S, 2016, J NEUROTRAUMA; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson B, 2015, NEUROLOGY, V85, P1163, DOI 10.1212/WNL.0000000000001968; Johnson B, 2015, BRAIN IMAGING BEHAV, V9, P564, DOI 10.1007/s11682-014-9316-x; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Kawata K, 2016, INT J SPORTS MED; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Phillips J, 2015, J EYE MOVEMENT RES, V8; Reynolds BB, 2016, J NEUROSURG, V124, P501, DOI 10.3171/2015.5.JNS15573; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Von Noorden G. K., 2002, BINOCULAR VISION OCU; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3	41	49	49	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6165	2168-6173		JAMA OPHTHALMOL	JAMA Ophthalmol.	JUL	2016	134	7					763	769		10.1001/jamaophthalmol.2016.1085			7	Ophthalmology	Ophthalmology	DR0KA	WOS:000379595200012	27257799	Bronze			2021-06-18	
J	Sahoo, D; Deck, C; Willinger, R				Sahoo, Debasis; Deck, Caroline; Willinger, Remy			Brain injury tolerance limit based on computation of axonal strain	ACCIDENT ANALYSIS AND PREVENTION			English	Article						DTI; Brain modeling; Head trauma simulation; Axonal strain; Brain injury tolerance limit	ELEMENT HEAD MODELS; DYNAMIC-RESPONSE; SKULL FRACTURE; DIFFUSION; IMPACT; VALIDATION; GENERATION; CRITERION; BEHAVIOR; SIMON	Traumatic brain injury (TBI) is the leading cause of death and permanent impairment over the last decades. In both the severe and mild TBIs, diffuse axonal injury (DAI) is the most common pathology and leads to axonal degeneration. Computation of axonal strain by using finite element head model in numerical simulation can enlighten the DAI mechanism and help to establish advanced head injury criteria. The main objective of this study is to develop a brain injury criterion based on computation of axonal strain. To achieve the objective a state-of-the-art finite element head model with enhanced brain and skull material laws, was used for numerical computation of real world head trauma. The implementation of new medical imaging data such as, fractional anisotropy and axonal fiber orientation from Diffusion Tensor Imaging (DTI) of 12 healthy patients into the finite element brain model was performed to improve the brain constitutive material law with more efficient heterogeneous anisotropic visco hyper-elastic material law. The brain behavior has been validated in terms of brain deformation against Hardy et al. (2001), Hardy et al. (2007), and in terms of brain pressure against Nahum et al. (1977) and Trosseille et al. (1992) experiments. Verification of model stability has been conducted as well. Further, 109 well-documented TBI cases were simulated and axonal strain computed to derive brain injury tolerance curve. Based on an in-depth statistical analysis of different intra-cerebral parameters (brain axonal strain rate, axonal strain, first principal strain, Von Mises strain, first principal stress, Von Mises stress, CSDM (0.10), CSDM (0.15) and CSDM (0.25)), it was shown that axonal strain was the most appropriate candidate parameter to predict DAI. The proposed brain injury tolerance limit for a 50% risk of DAI has been established at 14.65% of axonal strain. This study provides a key step for a realistic novel injury metric for DAI. (C) 2016 Elsevier Ltd. All rights reserved.	[Sahoo, Debasis; Deck, Caroline; Willinger, Remy] Univ Strasbourg ICube, UNISTRA CNRS, 2 Rue Boussingault, F-67000 Strasbourg, France	Sahoo, D; Deck, C (corresponding author), Univ Strasbourg ICube, UNISTRA CNRS, 2 Rue Boussingault, F-67000 Strasbourg, France.	deb4uinl@gmail.com; deck.caroline@gmail.com; remy.willinger@unistra.fr	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; DECK, Caroline/0000-0003-2289-1222			Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bandak F. A., 1995, P 38 STAPP CAR CRASH; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bourdet N, 2012, INT J CRASHWORTHINES, V17, P51, DOI 10.1080/13588265.2011.625676; Bourdet N., 2013, INT J CRASHWORTHINES; Carlsen RW, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00028; Chatelin Simon, 2013, Journal of Biorheology, V27, P26, DOI 10.1007/s12573-012-0055-6; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; COST, 2001, MOT SAF HELM EUR COO; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Deck C., 2008, P 7 EUR LS DYNA C SA; EVANS FG, 1957, J APPL PHYSIOL, V10, P493; Faul M.D., 2010, TRAUMATIC BRAIN INJU; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gennarelli T.A., 1990, 34 ANN P ASS ADV AUT; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; HAFTEK J, 1970, Journal of Bone and Joint Surgery British Volume, V52, P354; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Ho J, 2009, INT J CRASHWORTHINES, V14, P555, DOI 10.1080/13588260902895708; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Hynd D., 2004, AP SP; Kang HS, 1997, P STAPP CAR CRASH J, V41, P329; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; King A., 2003, P IRCOBI C LISB PORT; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kleiven S., 2007, P 51 STAPP CAR CRASH, P81; Kraft R.H., 2012, PLOS COMPUT BIOL, V30, P102; LANGLOIS JA, 2004, TRAUMATIC BRAIN INJU, P1; Longhitano D., 2005, P 19 INT C ENH SAF V; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; MCELHANEY JH, 1966, J APPL PHYSIOL, V21, P1231; Mellor A., 2000, SOC AUTOMOT ENG; Melvin JW., 1969, DEV, V5, P811; METZ CE, 1986, INVEST RADIOL, V21, P720, DOI 10.1097/00004424-198609000-00009; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Munsch M., 2009, P IRCOBI C YORK UK; Nahum A. M., 1977, P 21 STAPP CAR CRASH; Nakadate H., 2014, J BIOMECH SCI ENG; Newman J., 1999, P IRCOBI C SITG SPAI; Newman J. A., 2000, P IRCOBI C MONTP FRA; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Peng Y, 2013, TRAFFIC INJ PREV, V14, P639, DOI 10.1080/15389588.2012.733841; Peng Y, 2013, INT J IMPACT ENG, V57, P27, DOI 10.1016/j.ijimpeng.2013.01.010; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RYDEVIK BL, 1990, J ORTHOPAED RES, V8, P694, DOI 10.1002/jor.1100080511; Sahoo D., 2014, P INT RES C BIOM INJ; Sahoo D, 2016, J MECH BEHAV BIOMED, V57, P24, DOI 10.1016/j.jmbbm.2015.11.014; Sahoo D, 2015, MED BIOL ENG COMPUT, V53, P869, DOI 10.1007/s11517-015-1295-6; Sahoo D, 2014, J MECH BEHAV BIOMED, V33, P24, DOI 10.1016/j.jmbbm.2013.08.022; Sahoo D, 2013, J MECH BEHAV BIOMED, V28, P340, DOI 10.1016/j.jmbbm.2013.08.010; Shaoo D, 2015, ACCIDENT ANAL PREV, V80, P97, DOI 10.1016/j.aap.2015.04.004; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Singh Anita, 2006, Stapp Car Crash J, V50, P601; Stranding S., 2008, ANATOMICAL BASIS CLI; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts EG, 2008, STAPP CAR C, V52, P1; Trosseille X., 1992, P 36 STAPP CAR CRASH; WOOD JL, 1971, J BIOMECH, V4, P1, DOI 10.1016/0021-9290(71)90010-8; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Zhang L, 2001, Stapp Car Crash J, V45, P369	74	49	53	0	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	JUL	2016	92						53	70		10.1016/j.aap.2016.03.013			18	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	DM9NW	WOS:000376694000007	27038501				2021-06-18	
J	Artigas, A; Wernerman, J; Arroyo, V; Vincent, JL; Levy, M				Artigas, Antonio; Wernerman, Jan; Arroyo, Vicente; Vincent, Jean-Louis; Levy, Mitchell			Role of albumin in diseases associated with severe systemic inflammation: Pathophysiologic and clinical evidence in sepsis and in decompensated cirrhosis	JOURNAL OF CRITICAL CARE			English	Article						Albumin; Cirrhosis; Hepatorenal syndrome; Inflammation; Sepsis	HUMAN-SERUM-ALBUMIN; SPONTANEOUS BACTERIAL PERITONITIS; CHRONIC LIVER-FAILURE; TYPE-1 HEPATORENAL-SYNDROME; TUMOR-NECROSIS-FACTOR; LIPOPOLYSACCHARIDE-BINDING PROTEIN; TERLIPRESSIN PLUS ALBUMIN; TRAUMATIC BRAIN-INJURY; INTRAVENOUS ALBUMIN; SYNTHESIS RATES	The metabolism of albumin in inflammatory states such as sepsis or major surgery is complex and still not well characterized. Nevertheless, in inflammatory states, albumin synthesis has been observed to increase. By contrast, in decompensated cirrhosis, a disease characterized by systemic inflammation, albumin synthesis by the liver may decrease to 30% to 50% of normal values. Furthermore, in these conditions, there are high capillary leakage and altered albumin kinetics. The discussion regarding the effect of exogenous albumin administration on intravascular volume in inflammatory states should therefore address albumin turnover. To add complexity to our understanding of the effects of albumin, there are many data indicating that the therapeutic action of albumin is mediated not only through the impact on plasma volume expansion but also through a modulatory effect on inflammation and oxidative stress. All these characteristics are relevant to diseases associated with systemic inflammation including sepsis and decompensated cirrhosis. (C) 2016 Elsevier Inc. All rights reserved.	[Artigas, Antonio] Autonomous Univ Barcelona, Sabadell Hosp, CIBER Enfermedades Resp, Crit Care Ctr,Corp Sanitaria Univ Parc Tauli, Barcelona, Spain; [Wernerman, Jan] Karolinska Univ, Huddinge Hosp, Dept Anesthesiol & Intens Care Med, Stockholm, Sweden; [Arroyo, Vicente] Univ Barcelona, Liver Unit, Hosp Clin, Barcelona, Spain; [Arroyo, Vicente] Ctr Esther Koplowitz, Chron Liver Failure Consortium, Barcelona, Spain; [Vincent, Jean-Louis] Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [Levy, Mitchell] Rhode Isl Hosp, Pulm & Crit Care Med, Providence, RI USA	Artigas, A (corresponding author), Hosp Sabadell, Serv Med Intens, Parc Tauli 1, Barcelona 08208, Spain.	aartigas@tauli.cat; jan.wernerman@karolinska.se; varroyo@clinic.ub.es; jlvincen@ulb.ac.be; mitchell_levy@brown.edu	; Arroyo, Vicente/F-9189-2015	Vincent, Jean-Louis/0000-0001-6011-6951; antonio, artigas/0000-0002-8029-1017; Arroyo, Vicente/0000-0002-2728-1848	Grifols; Braum; Astute; Phillips; HillRom	This review is based on the contents of a satellite symposium organized by Grifols, manufacturer of albumin, held in the context of the 27th Annual Congress of the European Society of Intensive Care Medicine, Barcelona (Spain), September 27-October 1, 2014. A.A. declares having received a research grant from Grifols, speaker's fees from Grifols, Braum, Astute, Phillips and HillRom, and scientific advisor honorariums from Rubio, Astute, and Ferrer Farma. V.A. declares having received grants and research support from Grifols. J.W. declares being a member of the Medical Advisory Boards and also invited speaker for Baxter, Danone, Fresenius-Kabi, Grifols, and Nestle. J.L.V. declares no conflict of interest regarding this manuscript. M.L. declares being a member of advisory board for Merck and ImmuneExpress.	Albillos A, 2003, HEPATOLOGY, V37, P208, DOI 10.1053/jhep.2003.50038; Alessandria C, 2007, J HEPATOL, V47, P499, DOI 10.1016/j.jhep.2007.04.010; Alphonsus CS, 2014, ANAESTHESIA, V69, P777, DOI 10.1111/anae.12661; Angeli P, 2009, J HEPATOL, V50, pS73, DOI 10.1016/S0168-8278(09)60177-X; Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1053/jhep.1996.v23.ajhep0230164; BALLMER PE, 1990, AM J PHYSIOL, V259, pE797; Ballmer PE, 1996, HEPATOLOGY, V24, P53, DOI 10.1002/hep.510240111; Barle H, 2006, CLIN SCI, V110, P93, DOI 10.1042/CS20050222; Barle H, 1997, HEPATOLOGY, V25, P154, DOI 10.1053/jhep.1997.v25.pm0008985282; Barle H, 2002, CLIN SCI, V103, P525; Barle H, 2001, INTENS CARE MED, V27, P836, DOI 10.1007/s001340100914; Barle H, 1999, AM J PHYSIOL-ENDOC M, V277, pE591; BEEKEN WL, 1962, J CLIN INVEST, V41, P1312, DOI 10.1172/JCI104594; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bernardi M, 2012, HEPATOLOGY, V55, P1172, DOI 10.1002/hep.24786; Blunt MC, 1998, ANAESTHESIA, V53, P755, DOI 10.1046/j.1365-2044.1998.00488.x; Bortoluzzi A, 2013, HEPATOLOGY, V57, P266, DOI 10.1002/hep.26021; Bourdon E, 2005, FREE RADICAL RES, V39, P15, DOI 10.1080/10715760400024935; Boyer TD, 2011, J HEPATOL, V55, P315, DOI 10.1016/j.jhep.2010.11.020; Bruschi M, 2013, BBA-GEN SUBJECTS, V1830, P5473, DOI 10.1016/j.bbagen.2013.04.017; BYL B, 1993, GASTROENTEROLOGY, V104, P1492, DOI 10.1016/0016-5085(93)90361-F; Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; CARTER DC, 1989, SCIENCE, V244, P1195, DOI 10.1126/science.2727704; Chan JK, 2012, J CLIN INVEST, V122, P2711, DOI 10.1172/JCI62423; Charpentier J, 2011, INTENS CARE MED, V37, pS115; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Cooper DJ, 2013, J NEUROTRAUM, V30, P512, DOI 10.1089/neu.2012.2573; DAMICO G, 1986, DIGEST DIS SCI, V31, P468, DOI 10.1007/BF01320309; DAVID SA, 1995, J ENDOTOXIN RES, V2, P325; de Carvalho GC, 2012, ANN HEPATOL, V11, P90; de Sain-van der Velden MGM, 1998, KIDNEY INT, V53, P181, DOI 10.1046/j.1523-1755.1998.00729.x; Dubois MJ, 2006, CRIT CARE MED, V34, P2536, DOI 10.1097/01.CCM.0000239119.57544.0C; DZIARSKI R, 1994, J BIOL CHEM, V269, P20431; Esparza GA, 2012, INNATE IMMUN-LONDON, V18, P478, DOI 10.1177/1753425911422723; Essen P, 1998, CRIT CARE MED, V26, P92, DOI 10.1097/00003246-199801000-00022; Fasolato S, 2007, HEPATOLOGY, V45, P223, DOI 10.1002/hep.21443; Fernandez J, 2005, HEPATOLOGY, V42, P627, DOI 10.1002/hep.20829; Fernandez J, 2004, J HEPATOL, V41, P384, DOI 10.1016/j.jhep.2004.05.009; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2006, BRIT MED J, V333, P1044, DOI 10.1136/bmj.38985.398704.7C; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Finkenstedt A, 2013, LIVER TRANSPLANT, V19, P879, DOI 10.1002/lt.23678; FITZPATRICK FA, 1984, J BIOL CHEM, V259, P2722; FLECK A, 1985, LANCET, V1, P781; FOLCO G, 1977, FEBS LETT, V82, P321, DOI 10.1016/0014-5793(77)80611-X; FOLLO A, 1994, HEPATOLOGY, V20, P1495, DOI 10.1002/hep.1840200619; Fujiwara S, 2013, BBA-GEN SUBJECTS, V1830, P5427, DOI 10.1016/j.bbagen.2013.03.032; Galley HF, 2011, BRIT J ANAESTH, V107, P57, DOI 10.1093/bja/aer093; Galley HF, 2010, CRIT CARE, V14, DOI 10.1186/cc9098; Garcia-Tsao G, 2010, HEPATOLOGY, V51, P1445, DOI 10.1002/hep.23478; Gines A, 1996, GASTROENTEROLOGY, V111, P1002, DOI 10.1016/S0016-5085(96)70068-9; GINES P, 1988, GASTROENTEROLOGY, V94, P1493, DOI 10.1016/0016-5085(88)90691-9; GINES P, 1987, GASTROENTEROLOGY, V93, P234, DOI 10.1016/0016-5085(87)91007-9; Gines P, 2004, NEW ENGL J MED, V350, P1646, DOI 10.1056/NEJMra035021; Gines P, 2010, J HEPATOL, V53, P397, DOI 10.1016/j.jhep.2010.05.004; Gioannini TL, 2002, J BIOL CHEM, V277, P47818, DOI 10.1074/jbc.M206404200; Guevara M, 1998, HEPATOLOGY, V27, P35, DOI 10.1002/hep.510270107; Ha CE, 2013, BBA-GEN SUBJECTS, V1830, P5486, DOI 10.1016/j.bbagen.2013.04.012; Hoque R, 2013, J GASTROEN HEPATOL, V28, P61, DOI 10.1111/jgh.12018; Jalan R, 2002, BLOOD PURIFICAT, V20, P252, DOI 10.1159/000047017; Jalan R, 2014, J HEPATOL, V61, P1038, DOI 10.1016/j.jhep.2014.06.012; Jalan R, 2013, J HEPATOL, V59, P918, DOI 10.1016/j.jhep.2013.08.001; Jiang LB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114666; Jurgens G, 2002, J ENDOTOXIN RES, V8, P115, DOI 10.1179/096805102125000263; Khuroo MS, 2004, LIVER TRANSPLANT, V10, P1099, DOI 10.1002/lt.20139; Kjaergard LL, 2003, JAMA-J AM MED ASSOC, V289, P217, DOI 10.1001/jama.289.2.217; Kragh-Hansen U, 2013, BBA-GEN SUBJECTS, V1830, P5535, DOI 10.1016/j.bbagen.2013.03.015; LEMOINE O, 1995, J HEPATOL, V23, P391, DOI 10.1016/0168-8278(95)80196-0; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Li CP, 1996, J GASTROEN HEPATOL, V11, P635, DOI 10.1111/j.1440-1746.1996.tb00306.x; Martin-Llahi M, 2008, GASTROENTEROLOGY, V134, P1352, DOI 10.1053/j.gastro.2008.02.024; Montoliu C, 2009, J CLIN GASTROENTEROL, V43, P272, DOI 10.1097/MCG.0b013e31815e7f58; Moreau R, 2002, GASTROENTEROLOGY, V122, P923, DOI 10.1053/gast.2002.32364; Moreau R, 2013, GASTROENTEROLOGY, V144, P1426, DOI 10.1053/j.gastro.2013.02.042; MOSHAGE HJ, 1987, J CLIN INVEST, V79, P1635, DOI 10.1172/JCI113000; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Navasa M, 1998, HEPATOLOGY, V27, P1227, DOI 10.1002/hep.510270507; Nazar A, 2010, HEPATOLOGY, V51, P219, DOI 10.1002/hep.23283; Norberg A, 2012, INTENS CARE MED, V38, pS19; Norberg A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136371; O'Brien AJ, 2014, NAT MED, V20, P522, DOI 10.1038/nm.3516; Oettl K, 2013, J HEPATOL, V59, P978, DOI 10.1016/j.jhep.2013.06.013; Oettl K, 2010, METHOD ENZYMOL, V474, P181, DOI 10.1016/S0076-6879(10)74011-8; Ortega R, 2002, HEPATOLOGY, V36, P941, DOI 10.1053/jhep.2002.35819; Patel A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4561; Pereira G, 2012, J HEPATOL, V56, P1040, DOI 10.1016/j.jhep.2011.11.023; Peters TJ., 1996, ALL ALBUMIN BIOCH GE; Petersen CE, 2000, J BIOL CHEM, V275, P20985, DOI 10.1074/jbc.M001038200; Rafikova O, 2002, P NATL ACAD SCI USA, V99, P5913, DOI 10.1073/pnas.092048999; REINHARDT GF, 1980, JPEN-PARENTER ENTER, V4, P357, DOI 10.1177/0148607180004004357; Rittler P, 2007, SURGERY, V141, P660, DOI 10.1016/j.surg.2006.09.018; Rittler P, 2011, JPEN-PARENTER ENTER, V35, P405, DOI 10.1177/0148607110382782; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rochwerg B, 2014, ANN INTERN MED, V161, P347, DOI 10.7326/M14-0178; Ruiz-del-Arbol W, 2003, HEPATOLOGY, V38, P1210, DOI 10.1053/jhep.2003.50447; RuizdelArbol L, 1997, GASTROENTEROLOGY, V113, P579, DOI 10.1053/gast.1997.v113.pm9247479; Salerno F, 2013, CLIN GASTROENTEROL H, V11, P123, DOI 10.1016/j.cgh.2012.11.007; Salo J, 1997, J HEPATOL, V27, P645, DOI 10.1016/S0168-8278(97)80081-5; Sanyal AJ, 2008, GASTROENTEROLOGY, V134, P1360, DOI 10.1053/j.gastro.2008.02.014; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; SHAPIRO MD, 1985, KIDNEY INT, V28, P206, DOI 10.1038/ki.1985.142; Sharma P, 2008, AM J GASTROENTEROL, V103, P1689, DOI 10.1111/j.1572-0241.2008.01828.x; Singer M, 2014, VIRULENCE, V5, P66, DOI 10.4161/viru.26907; Singh V, 2012, J HEPATOL, V56, P1293, DOI 10.1016/j.jhep.2012.01.012; Sort P, 1999, NEW ENGL J MED, V341, P403, DOI 10.1056/NEJM199908053410603; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Taverna M, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-4; Terra C, 2005, GASTROENTEROLOGY, V129, P1944, DOI 10.1053/j.gastro.2005.09.024; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; TITO L, 1990, GASTROENTEROLOGY, V98, P146, DOI 10.1016/0016-5085(90)91303-N; TOLEDO C, 1993, HEPATOLOGY, V17, P251, DOI 10.1016/0270-9139(93)90085-2; Uriz J, 2000, J HEPATOL, V33, P43, DOI 10.1016/S0168-8278(00)80158-0; van der Vusse GJ, 2009, DRUG METAB PHARMACOK, V24, P300, DOI 10.2133/dmpk.24.300; Viasus D, 2013, J INFECTION, V66, P415, DOI 10.1016/j.jinf.2012.12.007; Vila MC, 1998, J HEPATOL, V28, P639, DOI 10.1016/S0168-8278(98)80288-2; Vincent JL, 2009, BEST PRACT RES-CLIN, V23, P183, DOI 10.1016/j.bpa.2008.11.004; Vincent JL, 2014, CRIT CARE, V18, DOI 10.1186/cc13991; Vincent JL, 2003, ANN SURG, V237, P319, DOI 10.1097/00000658-200303000-00005; Wang ZM, 2013, BBA-GEN SUBJECTS, V1830, P5356, DOI 10.1016/j.bbagen.2013.06.032; Wiest R, 2014, J HEPATOL, V60, P197, DOI 10.1016/j.jhep.2013.07.044; WYNALDA MA, 1980, PROSTAGLANDINS, V20, P853, DOI 10.1016/0090-6980(80)90138-0; Yang JS, 2002, PROTEIN SCI, V11, P538, DOI 10.1110/ps.28702	122	49	55	0	22	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	JUN	2016	33						62	70		10.1016/j.jcrc.2015.12.019			9	Critical Care Medicine	General & Internal Medicine	DK8EP	WOS:000375160300015	26831575				2021-06-18	
J	Schumacher, M; Denier, C; Oudinet, JP; Adams, D; Guennoun, R				Schumacher, Michael; Denier, Christian; Oudinet, Jean-Paul; Adams, David; Guennoun, Rachida			Progesterone neuroprotection: The background of clinical trial failure	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article; Proceedings Paper	8th International Meeting on Steroids and Nervous System	2015	Torino, ITALY			Progesterone; Traumatic brain injury; Stroke; Translational research; Biomarkers; Animal models; Clinical trials	TRAUMATIC BRAIN-INJURY; GLASGOW COMA SCALE; SEX STEROID-HORMONES; SEVERE HEAD-INJURY; INTRAVENOUS T-PA; VITAMIN-D; ISCHEMIC-STROKE; NERVOUS-SYSTEM; ENDOVASCULAR TREATMENT; GENE-EXPRESSION	Since the first pioneering studies in the 1990s, a large number of experimental animal studies have demonstrated the neuroprotective efficacy of progesterone for brain disorders, including traumatic brain injury (TBI). In addition, this steroid has major assets: it easily crosses the blood-brain-barrier, rapidly diffuses throughout the brain and exerts multiple beneficial effects by acting on many molecular and cellular targets. Moreover, progesterone therapies are well tolerated. Notably, increased brain levels of progesterone are part of endogenous neuroprotective responses to injury. The hormone thus emerged as a particularly promising protective candidate for TBI and stroke patients. The positive outcomes of small Phase 2 trials aimed at testing the safety and potential protective efficacy of progesterone in TBI patients then provided support and guidance for two large, multicenter, randomized and placebo-controlled Phase 3 trials, with more than 2000 TBI patients enrolled. The negative outcomes of both trials, named ProTECT III and SyNAPSE, came as a big disappointment. If these trials were successful, progesterone would have become the first efficient neuroprotective drug for brain-injured patients. Thus, progesterone has joined the numerous neuroprotective candidates that have failed in clinical trials. The aim of this review is a reappraisal of the preclinical animal studies, which provided the proof of concept for the clinical trials, and we critically examine the design of the clinical studies. We made efforts to present a balanced view of the strengths and limitations of the translational studies and of some serious issues with the clinical trials. We place particular emphasis on the translational value of animal studies and the relevance of TBI biomarkers. The probability of failure of ProTECT III and SyNAPSE was very high, and we present them within the broader context of other unsuccessful trials. (C) 2015 Elsevier Ltd. All rights reserved.	[Schumacher, Michael; Denier, Christian; Oudinet, Jean-Paul; Adams, David; Guennoun, Rachida] INSERM, U1195, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France; [Schumacher, Michael; Denier, Christian; Oudinet, Jean-Paul; Adams, David; Guennoun, Rachida] Univ Paris 11, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France; [Schumacher, Michael; Denier, Christian; Oudinet, Jean-Paul; Adams, David; Guennoun, Rachida] Univ Paris Saclay, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France; [Denier, Christian; Adams, David] CHU Bicetre, Dept Neurol, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France	Schumacher, M (corresponding author), INSERM, U1195, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.; Schumacher, M (corresponding author), Univ Paris 11, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.; Schumacher, M (corresponding author), Univ Paris Saclay, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	michael.schumacher@inserm.fr	Guennoun, Rachida/F-2420-2011; Schumacher, Michael/G-3581-2013	Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371			Almad A, 2011, NEUROTHERAPEUTICS, V8, P262, DOI 10.1007/s13311-011-0033-5; Aminmansour Bahram, 2012, Adv Biomed Res, V1, P58, DOI 10.4103/2277-9175.100176; Armstrong RC, 2015, NEUROPHARMACOLOGY; Atif F, 2013, NEUROPHARMACOLOGY, V67, P78, DOI 10.1016/j.neuropharm.2012.10.004; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Banks WA, 2012, ENDOCRINOLOGY, V153, P4111, DOI 10.1210/en.2012-1435; Bansal Y, 2014, EUR J MED CHEM, V76, P31, DOI 10.1016/j.ejmech.2014.01.060; Barakat-Walter I, 2007, J NEUROTRAUM, V24, P567, DOI 10.1089/neu.2006.0104; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; Lopez-Rodriguez AB, 2015, PSYCHONEUROENDOCRINO, V56, P1, DOI 10.1016/j.psyneuen.2015.02.018; Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Betz J, 2012, J NEUROTRAUM, V29, P1292, DOI 10.1089/neu.2011.2215; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bosse F, 2006, J NEUROCHEM, V96, P1441, DOI 10.1111/j.1471-4159.2005.03635.x; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brinton RD, 2013, NAT REV ENDOCRINOL, V9, P241, DOI 10.1038/nrendo.2013.31; Broderick JP, 2013, NEW ENGL J MED, V368, P893, DOI 10.1056/NEJMoa1214300; Brody David L, 2015, Handb Clin Neurol, V127, P267, DOI 10.1016/B978-0-444-52892-6.00017-9; Bruce ED, 2015, MOL CELL NEUROSCI, V66, P103, DOI 10.1016/j.mcn.2015.03.017; Buccafusco JJ, 2009, NEUROTHERAPEUTICS, V6, P4, DOI 10.1016/j.nurt.2008.10.031; Butler J, 2015, AM HEART J, V169, P305, DOI 10.1016/j.ahj.2014.12.001; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792; Campbell BCV, 2015, INT J STROKE, V10, P153, DOI 10.1111/ijs.12186; Caterino JM, 2011, ACAD EMERG MED, V18, P1014, DOI 10.1111/j.1553-2712.2011.01164.x; Cekic M, 2012, RESTOR NEUROL NEUROS, V30, P115, DOI 10.3233/RNN-2011-0628; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Cermenati G, 2010, J NEUROSCI, V30, P11896, DOI 10.1523/JNEUROSCI.1898-10.2010; Chase Alex, 2015, Nat Rev Neurol, V11, P65, DOI 10.1038/nrneurol.2014.258; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Ciccone A, 2013, NEW ENGL J MED, V368, P904, DOI 10.1056/NEJMoa1213701; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; Cook D, 2014, NAT REV DRUG DISCOV, V13, P419, DOI 10.1038/nrd4309; Cudnik MT, 2009, J TRAUMA, V66, P1321, DOI 10.1097/TA.0b013e3181929e2b; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Dechartres A, 2009, J CLIN EPIDEMIOL, V62, P695, DOI 10.1016/j.jclinepi.2008.09.011; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Edlow BL, 2013, NEUROCRIT CARE, V19, P364, DOI 10.1007/s12028-013-9870-x; El-Etr M, 2015, GLIA, V63, P104, DOI 10.1002/glia.22736; English SW, 2013, NEUROCRIT CARE, V18, P131, DOI 10.1007/s12028-012-9748-3; Eyles DW, 2013, FRONT NEUROENDOCRIN, V34, P47, DOI 10.1016/j.yfrne.2012.07.001; Eyles DW, 2005, J CHEM NEUROANAT, V29, P21, DOI 10.1016/j.jchemneu.2004.08.006; Fancy SPJ, 2011, ANNU REV NEUROSCI, V34, P21, DOI 10.1146/annurev-neuro-061010-113629; Farooqi N, 2010, J NEUROCHEM, V115, P829, DOI 10.1111/j.1471-4159.2010.06982.x; Feala JD, 2013, J NEUROTRAUM, V30, P1101, DOI 10.1089/neu.2012.2631; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Finlay CJ, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00095; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Furlan AJ, 2015, NEW ENGL J MED, V372, P2347, DOI 10.1056/NEJMe1503217; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Garay L, 2008, NEUROIMMUNOMODULAT, V15, P76, DOI 10.1159/000135627; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Genazzani AR, 1998, J CLIN ENDOCR METAB, V83, P2099, DOI 10.1210/jc.83.6.2099; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Gilmer LK, 2008, J NEUROTRAUM, V25, P593, DOI 10.1089/neu.2007.0477; GLOTH FM, 1995, J AM GERIATR SOC, V43, P822, DOI 10.1111/j.1532-5415.1995.tb07059.x; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Grossman KJ, 2011, BEHAV BRAIN RES, V217, P202, DOI 10.1016/j.bbr.2010.09.029; Groves NJ, 2014, ANNU REV NUTR, V34, P117, DOI 10.1146/annurev-nutr-071813-105557; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; GUTAI JP, 1977, J CLIN ENDOCR METAB, V44, P116, DOI 10.1210/jcem-44-1-116; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Hapgood JP, 2004, TRENDS PHARMACOL SCI, V25, P554, DOI 10.1016/j.tips.2004.09.005; Harsan LA, 2008, J NEUROSCI, V28, P14189, DOI 10.1523/JNEUROSCI.4453-08.2008; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hoyer C, 2014, NEUROPSYCHOBIOLOGY, V69, P187, DOI 10.1159/000360859; Hua F, 2012, HORM BEHAV, V61, P642, DOI 10.1016/j.yhbeh.2012.02.017; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Hueston CM, 2014, ENDOCRINOLOGY, V155, P3527, DOI 10.1210/en.2014-1060; Hussain R, 2011, ENDOCRINOLOGY, V152, P3820, DOI 10.1210/en.2011-1219; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; Irwin RW, 2011, ENDOCRINOLOGY, V152, P556, DOI 10.1210/en.2010-1061; Jalali R, 2014, CRIT CARE RES PRACT, V2014, DOI 10.1155/2014/289803; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jickling GC, 2015, METAB BRAIN DIS, V30, P461, DOI 10.1007/s11011-014-9499-2; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780; Kahle MP, 2012, STROKE RES TREAT, V2012, DOI 10.1155/2012/374098; Kasturi BS, 2009, RESTOR NEUROL NEUROS, V27, P265, DOI [10.3233/RNN-2009-0475, 10.3233/RNN-2009-0476]; Kehoe A, 2015, EMERG MED J, V32, P613, DOI 10.1136/emermed-2013-203488; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; Kidwell CS, 2013, NEW ENGL J MED, V368, P914, DOI 10.1056/NEJMoa1212793; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470; Kumasaka K, 2014, AM J SURG, V208, P961, DOI 10.1016/j.amjsurg.2014.08.004; Kurki T, 2014, NEURORADIOLOGY, V56, P833, DOI 10.1007/s00234-014-1410-7; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Laouchedi M, 2015, J NEURORADIOLOGY, V42, P202, DOI 10.1016/j.neurad.2014.03.001; LeGrand SA, 2007, J NEUROTRAUM, V24, P1437, DOI 10.1089/neu.2007.0293; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Liere P, 2009, J LIPID RES, V50, P2430, DOI 10.1194/jlr.M900162-JLR200; Lips P, 2010, J STEROID BIOCHEM, V121, P297, DOI 10.1016/j.jsbmb.2010.02.021; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lofgren M, 2006, HORM BEHAV, V50, P208, DOI 10.1016/j.yhbeh.2006.03.002; Lu J, 2008, J NEUROTRAUM, V25, P641, DOI 10.1089/neu.2007.0510; Lu J, 2010, J NEUROTRAUM, V27, P843, DOI 10.1089/neu.2010.1293; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MacDougall NJJ, 2011, J CEREBR BLOOD F MET, V31, P807, DOI 10.1038/jcbfm.2010.210; Makoukji J, 2012, P NATL ACAD SCI USA, V109, P3973, DOI 10.1073/pnas.1121367109; Marcucci M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003143; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; McGonigle P, 2014, BIOCHEM PHARMACOL, V87, P162, DOI 10.1016/j.bcp.2013.08.006; McGrath J, 2001, TRENDS NEUROSCI, V24, P570, DOI 10.1016/S0166-2236(00)01949-4; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Meffre D, 2015, P NATL ACAD SCI USA, V112, P7587, DOI 10.1073/pnas.1424951112; Melcangi RC, 2014, PROG NEUROBIOL, V113, P1, DOI 10.1016/j.pneurobio.2013.09.005; Mitro N, 2012, NEUROCHEM INT, V60, P616, DOI 10.1016/j.neuint.2012.02.025; Morgan P, 2012, DRUG DISCOV TODAY, V17, P419, DOI 10.1016/j.drudis.2011.12.020; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Mumford SL, 2010, J CLIN ENDOCR METAB, V95, pE80, DOI 10.1210/jc.2010-0109; Namiki J, 2011, CLIN NEUROL NEUROSUR, V113, P393, DOI 10.1016/j.clineuro.2011.01.001; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Palacios C, 2014, J STEROID BIOCHEM, V144, P138, DOI 10.1016/j.jsbmb.2013.11.003; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Pankevich DE, 2014, NEURON, V84, P546, DOI 10.1016/j.neuron.2014.10.007; Pardridge WM, 2012, J CEREBR BLOOD F MET, V32, P1959, DOI 10.1038/jcbfm.2012.126; Pascual JL, 2013, AM J SURG, V206, P840, DOI 10.1016/j.amjsurg.2013.07.016; Peng WJ, 2014, J NEUROSURG, V121, P653, DOI 10.3171/2014.6.JNS132577; Peper JS, 2011, PSYCHONEUROENDOCRINO, V36, P1101, DOI 10.1016/j.psyneuen.2011.05.004; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Ringel M, 2013, NAT REV DRUG DISCOV, V12, P901, DOI 10.1038/nrd4164; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sakoglu U, 2011, BIOCHEM PHARMACOL, V81, P1374, DOI 10.1016/j.bcp.2010.12.029; Salottolo K, 2014, JAMA SURG, V149, P727, DOI 10.1001/jamasurg.2014.13; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schoepp DD, 2011, NAT REV DRUG DISCOV, V10, P715, DOI 10.1038/nrd3559; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332; Schumacher M, 2014, PROG NEUROBIOL, V113, P6, DOI 10.1016/j.pneurobio.2013.09.004; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; Schumacher M, 2015, STEROIDS, V103, P42, DOI 10.1016/j.steroids.2015.08.013; Schumacher M, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00010; Schumacher M, 2008, CURR OPIN PHARMACOL, V8, P740, DOI 10.1016/j.coph.2008.10.002; Schwamm LH, 2014, NEW ENGL J MED, V371, P2522, DOI 10.1056/NEJMe1412951; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shakeri M, 2013, CLIN NEUROL NEUROSUR, V115, P2019, DOI 10.1016/j.clineuro.2013.06.013; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shin SS, 2014, PROG NEUROL SURG, V28, P86, DOI 10.1159/000358767; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Si DW, 2014, EXP THER MED, V8, P1010, DOI 10.3892/etm.2014.1840; Si DW, 2014, BEHAV BRAIN RES, V264, P135, DOI 10.1016/j.bbr.2014.01.049; Si DW, 2013, NEUROSCI LETT, V553, P18, DOI 10.1016/j.neulet.2013.07.052; Sieber BA, 2014, ANN NEUROL, V76, P469, DOI 10.1002/ana.24261; Siffrin V, 2010, TRENDS NEUROSCI, V33, P202, DOI 10.1016/j.tins.2010.01.002; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith SS, 2007, PHARMACOL THERAPEUT, V116, P58, DOI 10.1016/j.pharmthera.2007.03.008; Smith SS, 1998, NATURE, V392, P926, DOI 10.1038/31948; Stanczyk FZ, 2013, ENDOCR REV, V34, P171, DOI 10.1210/er.2012-1008; Stein DG, 2011, NEUROSCIENCE, V191, P101, DOI 10.1016/j.neuroscience.2011.04.013; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2015, Handb Clin Neurol, V127, P433, DOI 10.1016/B978-0-444-52892-6.00028-3; Strom JO, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-41; Suskauer SJ, 2009, J PEDIATR REHAB MED, V2, P249, DOI 10.3233/PRM-2009-0099; Tang H., 2015, BRAIN INJURY, V29, P1259; Tang HL, 2013, HORM BEHAV, V64, P527, DOI 10.1016/j.yhbeh.2013.06.009; Tawk M, 2011, J NEUROSCI, V31, P3729, DOI 10.1523/JNEUROSCI.4270-10.2011; TEASDALE G, 1974, LANCET, V2, P81; Tsilidis KK, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001609; VanLandingham JW, 2008, J CEREBR BLOOD F MET, V28, P1786, DOI 10.1038/jcbfm.2008.73; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Vukusic S, 2009, J NEUROL SCI, V286, P114, DOI 10.1016/j.jns.2009.08.056; Vukusic S, 2015, NAT REV NEUROL, V11, P280, DOI 10.1038/nrneurol.2015.53; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wali B, 2011, RESTOR NEUROL NEUROS, V29, P61, DOI 10.3233/RNN-2011-0579; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Washington P. M., 2015, EXP NEUROL; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Witte OW, 2000, J CEREBR BLOOD F MET, V20, P1149, DOI 10.1097/00004647-200008000-00001; Wong R, 2013, J CEREBR BLOOD F MET, V33, P1362, DOI 10.1038/jcbfm.2013.120; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wright DW, 2005, J CLIN PHARMACOL, V45, P640, DOI 10.1177/0091270005276201; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu FF, 2014, BRAIN INJURY, V28, P1594, DOI 10.3109/02699052.2014.943289; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yates MA, 2010, J NEUROIMMUNOL, V220, P136, DOI 10.1016/j.jneuroim.2010.01.013; Yawno T, 2009, NEUROSCIENCE, V163, P838, DOI 10.1016/j.neuroscience.2009.07.009; Yousuf S, 2014, J CEREBR BLOOD F MET, V34, P297, DOI 10.1038/jcbfm.2013.198; Yu CG, 2015, J NEUROSCI RES, V93, P199, DOI 10.1002/jnr.23503; Yu HJ, 2010, NEUROSCI LETT, V476, P42, DOI 10.1016/j.neulet.2010.03.079; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171	218	49	51	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	JUN	2016	160				SI		53	66		10.1016/j.jsbmb.2015.11.010			14	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	DN1QM	WOS:000376840500008	26598278				2021-06-18	
S	Cullen, DK; Harris, JP; Browne, KD; Wolf, JA; Duda, JE; Meaney, DF; Margulies, SS; Smith, DH		Kobeissy, F; Dixon, CE; Hayes, RL; Mondello, S		Cullen, D. Kacy; Harris, James P.; Browne, Kevin D.; Wolf, John A.; Duda, John E.; Meaney, David F.; Margulies, Susan S.; Smith, Douglas H.			A Porcine Model of Traumatic Brain Injury via Head Rotational Acceleration	INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS	Methods in Molecular Biology		English	Article; Book Chapter						Traumatic brain injury (TBI); Biomechanics; Neuropathology; Diffuse brain injury (DBI); Axonal injury; Modeling; Degeneration; Concussion	DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; SWINE MODEL; CEREBRAL CONCUSSION; ANIMAL-MODELS; AMYLOID-BETA; INTRACRANIAL HEMORRHAGE; WHITE-MATTER; NEONATAL PIG; CORTICAL-NEURONS	Unique from other brain disorders, traumatic brain injury (TBI) generally results from a discrete biomechanical event that induces rapid head movement. The large size and high organization of the human brain makes it particularly vulnerable to traumatic injury from rotational accelerations that can cause dynamic deformation of the brain tissue. Therefore, replicating the injury biomechanics of human TBI in animal models presents a substantial challenge, particularly with regard to addressing brain size and injury parameters. Here we present the historical development and use of a porcine model of head rotational acceleration. By scaling up the rotational forces to account for difference in brain mass between swine and humans, this model has been shown to produce the same tissue deformations and identical neuropathologies found in human TBI. The parameters of scaled rapid angular accelerations applied for the model reproduce inertial forces generated when the human head suddenly accelerates or decelerates in falls, collisions, or blunt impacts. The model uses custom-built linkage assemblies and a powerful linear actuator designed to produce purely impulsive nonimpact head rotation in different angular planes at controlled rotational acceleration levels. Through a range of head rotational kinematics, this model can produce functional and neuropathological changes across the spectrum from concussion to severe TBI. Notably, however, the model is very difficult to employ, requiring a highly skilled team for medical management, biomechanics, neurological recovery, and specialized outcome measures including neuromonitoring, neurophysiology, neuroimaging, and neuropathology. Nonetheless, while challenging, this clinically relevant model has proven valuable for identifying mechanisms of acute and progressive neuropathologies as well as for the evaluation of noninvasive diagnostic techniques and potential neuroprotective treatments following TBI.	[Cullen, D. Kacy; Harris, James P.; Browne, Kevin D.; Wolf, John A.; Meaney, David F.; Margulies, Susan S.; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA; [Harris, James P.; Browne, Kevin D.; Wolf, John A.; Duda, John E.] Philadelphia Vet Affairs Med Ctr, Perelman Sch Med, Dept Neurol, Philadelphia, PA USA; [Margulies, Susan S.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA	Cullen, DK (corresponding author), Univ Penn, Perelman Sch Med, Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA.		Wolf, John A/A-1034-2007	Wolf, John A/0000-0002-6950-2303; Meaney, David/0000-0002-0954-4122; Harris, James/0000-0002-8458-5434	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104, T32NS043126, R01NS088176, R01NS050598] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [IK2RX001479, I01RX001097] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01 EB021293] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS038104, R01 NS050598, T32 NS043126, R01 NS088176, R01 NS101108] Funding Source: Medline; RRD VA [I01 RX001097, IK2 RX001479] Funding Source: Medline		Aare M, 2004, INT J CRASHWORTHINES, V9, P15, DOI 10.1533/ijcr.2004.0268; Adams J H, 1981, Acta Neuropathol Suppl, V7, P26; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Bailey EL, 2009, STROKE, V40, pE451, DOI 10.1161/STROKEAHA.108.528430; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; Clevenger AC, 2015, J NEUROTRAUM, V32, P120, DOI 10.1089/neu.2014.3570; Coats B, 2012, INT J DEV NEUROSCI, V30, P191, DOI 10.1016/j.ijdevneu.2011.12.009; Coats B, 2010, INVEST OPHTH VIS SCI, V51, P4792, DOI 10.1167/iovs.10-5211; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cullen DK, 2007, BRAIN RES, V1158, P103, DOI 10.1016/j.brainres.2007.04.070; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Denny-Brown D E, 1941, Proc R Soc Med, V34, P691; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Friess SH, 2012, LAB ANIM-UK, V46, P164, DOI 10.1258/la.2011.011084; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Friess SH, 2015, J NEUROTRAUM, V32, P237, DOI 10.1089/neu.2014.3468; Friess SH, 2012, CRIT CARE MED, V40, P2400, DOI 10.1097/CCM.0b013e31825333e6; Friess SH, 2011, NEUROSURGERY, V69, P1139, DOI 10.1227/NEU.0b013e3182284aa1; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; Gennarelli T.A., 1971, P 15 STAPP CAR CRASH, V39, P797; Gennarelli T.A., 1972, STAPP CAR CRASH J, P296; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Gennarelli TA, 2003, ANN P ASS ADV AUTOMO, P624; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Graham D I, 1988, Prog Clin Biol Res, V264, P159; Graham R., 2014, SPORTS RELATED CONCU; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Howells DW, 2010, J CEREBR BLOOD F MET, V30, P1412, DOI 10.1038/jcbfm.2010.66; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ibrahim NG, 2010, J NEUROTRAUM, V27, P1021, DOI 10.1089/neu.2009.1212; Ibrahim NG, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000956; Jaber SM, 2015, DEV NEUROPSYCHOL, V40, P34, DOI 10.1080/87565641.2014.969733; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kleiven Svein, 2013, Front Bioeng Biotechnol, V1, P15; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LETCHER FS, 1973, J NEUROSURG, V39, P167, DOI 10.3171/jns.1973.39.2.0167; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Margulies SS, 2015, BRAIN PATHOL, V25, P289, DOI 10.1111/bpa.12247; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mcintosh TK, 1999, TRAUMATIC BRAIN INJU, P39; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meng X, 2012, ELECTRON LETT, V48, P363, DOI 10.1049/el.2012.0281; Meng X, 2013, NAT NEUR SOC ANN M; MILLER RT, 1998, 42 STAPP CAR CRASH C; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Naim MY, 2010, DEV NEUROSCI-BASEL, V32, P466, DOI 10.1159/000322448; Newman J A, 2000, Stapp Car Crash J, V44, P215; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1967, P 11 STAPP CAR CRASH, P73; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prado GR, 2005, J NEURAL ENG, V2, P148, DOI 10.1088/1741-2560/2/4/011; Prevention C. f. D. C. a. and Control N. C. f. I. P. a., 2003, REP C MILD TRAUM BRA; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SAHAY KB, 1992, J BIOMECH, V25, P319, DOI 10.1016/0021-9290(92)90029-Z; Santiago LA, 2012, BRAIN INJURY, V26, P107, DOI 10.3109/02699052.2011.635363; Sattler R, 2000, J MOL MED, V78, P3, DOI 10.1007/s001090000077; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 2015, J NEUROTRAUM, V32, P1725, DOI 10.1089/neu.2014.3861; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Sullivan S, 2013, J NEUROTRAUM, V30, P1770, DOI 10.1089/neu.2013.2913; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tekriwal A, 2015, NAT NEUR SOC ANN M; Thibault LE, 1989, P 10 INT TECHN C EXP; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Weeks D, 2014, J NEUROTRAUM, V31, P206, DOI 10.1089/neu.2013.3113; Wolf JA, 2014, WINT C BRAIN RES; Wolf JA, CONCUSSION IN PRESS; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; YARNELL P, 1969, B NEW YORK ACAD MED, V45, P39; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang K, 2000, P NATL ACAD SCI USA, V97, P5621, DOI 10.1073/pnas.090504197; Zhou C, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3146814; Zhu Q, 2006, DEV NEUROSCI-BASEL, V28, P388, DOI 10.1159/000094165	157	49	50	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA	1064-3745	1940-6029	978-1-4939-3816-2; 978-1-4939-3814-8	METHODS MOL BIOL	Methods Mol. Biol.		2016	1462						289	324		10.1007/978-1-4939-3816-2_17	10.1007/978-1-4939-3816-2		36	Biochemical Research Methods; Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	BH1UG	WOS:000398551500019	27604725	Green Accepted			2021-06-18	
J	Young, JC; Roper, BL; Arentsen, TJ				Young, J. Christopher; Roper, Brad L.; Arentsen, Timothy J.			Validity testing and neuropsychology practice in the VA healthcare system: results from recent practitioner survey	CLINICAL NEUROPSYCHOLOGIST			English	Article						Symptom validity test; performance validity test; response bias; malingering; neuropsychology	TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; RESPONSE BIAS SCALE; TEST-PERFORMANCE; REPEATABLE BATTERY; DIGIT SPAN; BASE RATES; VETERANS; SOLDIERS; INDEXES	Objective: A survey of neuropsychologists in the Veterans Health Administration examined symptom/performance validity test (SPVT) practices and estimated base rates for patient response bias. Method: Invitations were emailed to 387 psychologists employed within the Veterans Affairs (VA), identified as likely practicing neuropsychologists, resulting in 172 respondents (44.4% response rate). Practice areas varied, with 72% at least partially practicing in general neuropsychology clinics and 43% conducting VA disability exams. Results: Mean estimated failure rates were 23.0% for clinical outpatient, 12.9% for inpatient, and 39.4% for disability exams. Failure rates were the highest for mTBI and PTSD referrals. Failure rates were positively correlated with the number of cases seen and frequency and number of SPVT use. Respondents disagreed regarding whether one (45%) or two (47%) failures are required to establish patient response bias, with those administering more measures employing the more stringent criterion. Frequency of the use of specific SPVTs is reported. Conclusions: Base rate estimates for SPVT failure in VA disability exams are comparable to those in other medicolegal settings. However, failure in routine clinical exams is much higher in the VA than in other settings, possibly reflecting the hybrid nature of the VA's role in both healthcare and disability determination. Generally speaking, VA neuropsychologists use SPVTs frequently and eschew pejorative terms to describe their failure. Practitioners who require only one SPVT failure to establish response bias may overclassify patients. Those who use few or no SPVTs may fail to identify response bias. Additional clinical and theoretical implications are discussed.	[Young, J. Christopher] Siskin Hosp Phys Rehabil, Chattanooga, TN USA; [Roper, Brad L.; Arentsen, Timothy J.] Memphis Vet Affairs Med Ctr, Memphis, TN USA	Young, JC (corresponding author), Siskin Hosp Phys Rehabil, Chattanooga, TN USA.	jcyoung@siskinrehab.org					Arbisi P.A, 2004, PSYCHOL SERV, V1, P56, DOI DOI 10.1037/1541-1559.1.1.56; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Barker MD, 2010, CLIN NEUROPSYCHOL, V24, P1064, DOI 10.1080/13854046.2010.486009; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Boone K. B., 2007, ASSESSMENT FEIGNED C, P29; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Brewin B., 2012, NATL J; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA, 2010, CLIN NEUROPSYCHOL, V24, P759, DOI 10.1080/13854041003712951; Chafetz MD, 2008, CLIN NEUROPSYCHOL, V22, P529, DOI 10.1080/13854040701346104; Clark AL, 2014, CLIN NEUROPSYCHOL, V28, P802, DOI 10.1080/13854046.2014.904928; Congressional Budget Office, 2014, VET DIS COMP TRENDS; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Goldstein G, 2010, CLIN NEUROPSYCHOL, V24, P401, DOI 10.1080/13854040903313597; Green, 2004, GREENS MED SYMPTOM V; Green P., 2005, WORD MEMORY TEST WIN; Guilmette T. J., 2013, MILD TRAUMATIC BRAIN, P31; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jackson JC, 2011, J TRAUMA STRESS, V24, P609, DOI 10.1002/jts.20688; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Novitski J, 2012, ARCH CLIN NEUROPSYCH, V27, P190, DOI 10.1093/arclin/acr119; Roebuck-Spencer TM, 2012, CLIN NEUROPSYCHOL, V26, P473, DOI 10.1080/13854046.2011.650214; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith G. E., 2008, TXB CLIN NEUROPSYCHO, P38; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sullivan K., 2006, J FORENSIC NEUROPSYC, V4, DOI [https://doi.org/10.1300/J151v04n04_04, DOI 10.1300/J151V04N04_04]; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 1996, TEST MEMORY MALINGER; United States Department of Veterans Affairs, 2014, VET COMP BEN RAT TAB; United States Government Accountability Office, 2010, VET DIS BEN FURTH EV; Van Dyke SA, 2013, CLIN NEUROPSYCHOL, V27, P1234, DOI 10.1080/13854046.2013.835447; Vasterling JJ, 2012, J INT NEUROPSYCH SOC, V18, P390, DOI 10.1017/S1355617712000367; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001; Wisdom NM, 2014, CLIN NEUROPSYCHOL, V28, P128, DOI 10.1080/13854046.2013.863977; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083; Young JC, 2011, ARCH CLIN NEUROPSYCH, V26, P194, DOI 10.1093/arclin/acr015	50	49	49	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2016	30	4					497	514		10.1080/13854046.2016.1159730			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	DO6YO	WOS:000377929600002	27032437				2021-06-18	
J	Hoffmire, CA; Kemp, JE; Bossarte, RM				Hoffmire, Claire A.; Kemp, Janet E.; Bossarte, Robert M.			Changes in Suicide Mortality for Veterans and Nonveterans by Gender and History of VHA Service Use, 2000-2010	PSYCHIATRIC SERVICES			English	Article							ADVERSE CHILDHOOD EXPERIENCES; DEATH REPORTING SYSTEM; TRAUMATIC BRAIN-INJURY; 16 STATES; RISK; AFGHANISTAN; INDIVIDUALS; INCREASE; RATES	Objective: Veterans are believed to be at high risk of suicide. However, research comparing suicide rates between veterans and nonveterans is limited, and even less is known regarding differences by history of Veterans Health Administration (VHA) service use. This study directly compared veteran and nonveteran suicide risk while for the first time differentiating veterans by VHA service use. Methods: The cross-sectional study analyzed data from 173,969 adult suicide decedents from 23 states (2000-2010) included in the U.S. Department of Veterans Affairs suicide data archive. Annual standardized mortality ratios (SMRs) were computed for veterans compared with nonveterans and for veterans who used VHA services compared with veterans who did not, overall and separately for males and females. Results: After the analysis controlled for age and gender differences, the number of observed veteran suicides was approximately 20% higher than expected in 2000 (SMR=1.19, 95% confidence interval [CI]=1.10-1.28), and this increased to 60% higher by 2010 (SMR=1.63, CI=1.58-1.68). The elevated risk for female veterans (2010 SMR=5.89) was higher than that observed for male veterans (2010 SMR=1.54). Trends for non-VHA-utilizing veterans mirrored those of the veteran population as a whole, and the SMR for VHA-utilizing veterans declined. Since 2003, the number of suicides among VHA-utilizing veterans was less than expected when compared directly with the suicide rate among non-VHA-utilizing veterans. Conclusions: Veterans are members of the community and, as such, are an important part of observed increases in U.S. suicide rates. Not all veterans are at equal or increasing risk of suicide, however. VHA-utilizing veterans appear to have declining absolute and relative suicide rates.	[Hoffmire, Claire A.; Kemp, Janet E.] US Dept Vet Affairs, Ctr Excellence Suicide Prevent VISN2, Canandaigua, NY USA; [Bossarte, Robert M.] US Dept Vet Affairs, Off Publ Hlth, Washington, DC USA; [Hoffmire, Claire A.; Bossarte, Robert M.] Univ Rochester, Dept Psychiat, Rochester, NY USA	Hoffmire, CA (corresponding author), US Dept Vet Affairs, Ctr Excellence Suicide Prevent VISN2, Canandaigua, NY USA.	claire.hoffmire@va.gov	Bossarte, Robert/AAF-8571-2019				[Anonymous], 2013, DAT STAT; [Anonymous], 2008, 116001 VAH; Armed Forces Health Surveillance Center (AFHSC), 2012, MSMR, V19, P7; Baker SP, 2013, AM J PREV MED, V44, P146, DOI 10.1016/j.amepre.2012.10.010; Black SA, 2011, MIL PSYCHOL, V23, P433, DOI 10.1080/08995605.2011.590409; Blosnich JR, 2014, JAMA PSYCHIAT, V71, P1041, DOI 10.1001/jamapsychiatry.2014.724; Blow FC, 2012, AM J PUBLIC HEALTH, V102, pS98, DOI 10.2105/AJPH.2011.300441; Bossarte RM, 2013, PSYCHIAT SERV, V64, P713, DOI 10.1176/appi.ps.201300128; Bossarte RM, 2010, MIL MED, V175, P703, DOI 10.7205/MILMED-D-10-00247; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Centers for Disease Control and Prevention (CDC), 2013, MMWR Morb Mortal Wkly Rep, V62, P321; Erlangsen A, 2014, LANCET PSYCHIAT; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Goldman DA, 2000, STAT MED, V19, P1081, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1081::AID-SIM406>3.3.CO;2-1; Hoffmire CA, 2013, ANN EPIDEMIOL, V23, P298, DOI 10.1016/j.annepidem.2013.03.007; Hoyert Donna L, 2012, Natl Vital Stat Rep, V61, P1; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kaplan MS, 2012, AM J PUBLIC HEALTH, V102, pS21, DOI 10.2105/AJPH.2011.300611; Karch Debra L., 2012, Morbidity and Mortality Weekly Report, V61, P1; Katz IR, 2012, AM J PUBLIC HEALTH, V102, pS105, DOI 10.2105/AJPH.2011.300503; Kimerling R, 2010, AM J PUBLIC HEALTH, V100, P1409, DOI 10.2105/AJPH.2009.171793; Klein RJ., 2001, HLTH PEOPLE STAT NOT, V20; McCarthy JF, 2009, AM J EPIDEMIOL, V169, P1033, DOI 10.1093/aje/kwp010; McIntosh JL, 2012, US SUIC 2010 OFF FIN; Miller M, 2012, AM J PUBLIC HEALTH, V102, pS20, DOI 10.2105/AJPH.2011.300572; National Strategy for Suicide Prevention, 2012, GOALS OBJ ACT REP US; Reeves A, 2012, LANCET, V380, P1813, DOI 10.1016/S0140-6736(12)61910-2; Rockett Ian R H, 2012, Am J Public Health, V102, pe84, DOI 10.2105/AJPH.2012.300960; Rockett IRH, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-705; US Department of Defense, 2013, DEP DEF ANN REP SEX, V1; VENZON DJ, 1988, J R STAT SOC C-APPL, V37, P87, DOI 10.2307/2347496; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Yip PSF, 2011, J EPIDEMIOL COMMUN H, V65, P733, DOI 10.1136/jech.2010.110726	33	49	49	0	4	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	1075-2730	1557-9700		PSYCHIAT SERV	Psychiatr. Serv.	SEP	2015	66	9					959	965		10.1176/appi.ps.201400031			7	Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry	Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry	DE6EB	WOS:000370725400016	25930036	Bronze			2021-06-18	
J	Finfer, S				Finfer, Simon		Australian New Zealand Intensive C; Canadian Critical Care Trials Grp	Intensive versus conventional glucose control in critically ill patients with traumatic brain injury: long-term follow-up of a subgroup of patients from the NICE-SUGAR study	INTENSIVE CARE MEDICINE			English	Article						Brain injury; Blood glucose; Hypoglycemia; Treatment outcome; Randomized trial	TIGHT GLYCEMIC CONTROL; INSULIN THERAPY; HEAD-INJURY; HOSPITALIZED-PATIENTS; HYPERGLYCEMIA; MULTICENTER; METABOLISM; MORTALITY; IMPACT; SCORE	To compare the effect of intensive versus conventional blood glucose control in patients with traumatic brain injury. In a large international randomized trial patients were randomly assigned to a target blood glucose (BG) range of either 4.5-6.0 mmol/L (intensive control) or < 10 mmol/L (conventional control). Patients with traumatic brain injury (TBI) were identified at randomization and data were collected to examine the extended Glasgow outcome score (includes mortality) at 24 months. Of the 6104 randomized patients, 391 satisfied diagnostic criteria for TBI; 203 (51.9 %) were assigned to intensive and 188 (48.1 %) to conventional control; the primary outcome was available for 166 (81.8 %) and 149 (79.3 %) patients, respectively. The two groups had similar baseline characteristics. At 2 years 98 (58.7 %) patients in the intensive group and 79 (53.0 %) in the conventional group had a favorable neurological outcome (odds ratio [OR] 1.26, 95 % CI 0.81-1.97; P = 0.3); 35 patients (20.9 %) in the intensive group and 34 (22.8 %) in the conventional group had died (OR 0.90, 95 % CI 0.53-1.53; P = 0.7); moderate hypoglycemia (BG 2.3-3.9 mmol/L; 41-70 mg/dL) occurred in 160/202 (79.2 %) and 17/188 (9.0 %), respectively (OR 38.3, 95 % CI 21.0-70.1; P < 0.0001); severe hypoglycemia (BG a parts per thousand currency sign 2.2 mmol/L; a parts per thousand currency sign40 mg/dL) in 10 (4.9 %) and 0 (0.0 %), respectively (OR 20.5 95 % CI 1.2-351.6, P = 0.003). Although patients with traumatic brain injury randomly assigned to intensive compared to conventional glucose control experienced moderate and severe hypoglycemia more frequently, we found no significant difference in clinically important outcomes.	George Inst Global Hlth, Sydney, NSW 2001, Australia	Finfer, S (corresponding author), George Inst Global Hlth, GPO Box 5389, Sydney, NSW 2001, Australia.	sfinfer@georgeinstitute.org	Mehta, Sangeeta/C-4623-2015; Higgins, Alisa/AAM-8088-2020; Billot, Laurent/Y-1241-2019; Ranse, Jamie/AAU-1649-2020; Ferguson, Niall/D-7619-2019; Young, John D/M-9756-2016	Higgins, Alisa/0000-0001-8295-7559; Billot, Laurent/0000-0002-4975-9793; Ranse, Jamie/0000-0002-5265-6365; Ferguson, Niall/0000-0002-6213-5264; Parr, Michael/0000-0003-3507-474X; /0000-0002-4157-5148; Lipman, Jeffrey/0000-0002-5965-9876; Young, John Duncan/0000-0002-6838-4835; Finfer, Simon/0000-0002-2785-5864; SHEHABI, Yahya/0000-0003-4707-7462; Mitchell, Imogen/0000-0001-6013-4922; MacMahon, Stephen/0000-0003-2064-7699; McEvoy, Suzanne/0000-0002-9804-4276; French, Craig/0000-0003-1363-9711; Bellomo, Rinaldo/0000-0002-1650-8939; Hammond, Naomi/0000-0002-6559-7747			Annane D, 2010, JAMA-J AM MED ASSOC, V303, P341, DOI 10.1001/jama.2010.2; [Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc12-s011, 10.2337/dc35-S011]; Arabi YM, 2008, CRIT CARE MED, V36, P3190, DOI 10.1097/CCM.0b013e31818f21aa; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Cinotti R, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0498-9; Coester A, 2010, J TRAUMA, V68, P904, DOI 10.1097/TA.0b013e3181c9afc2; De la Rosa GD, 2008, CRIT CARE, V12, DOI 10.1186/cc7017; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Egi M, 2010, MAYO CLIN PROC, V85, P217, DOI 10.4065/mcp.2009.0394; Finfer S., 2009, NEW ENGL J MED, V360, P1346; Finfer S, 2012, NEW ENGL J MED, V367, P1108, DOI 10.1056/NEJMoa1204942; Gale SC, 2007, AM SURGEON, V73, P454; Griesdale DE, 2009, CMAJ, V180, P831; Griesdale DEG, 2009, NEUROCRIT CARE, V11, P311, DOI 10.1007/s12028-009-9249-1; Hermanides J, 2010, CRIT CARE MED, V38, P1430, DOI 10.1097/CCM.0b013e3181de562c; Kalfon P, 2014, INTENS CARE MED, V40, P171, DOI 10.1007/s00134-013-3189-0; Kansagara D, 2011, ANN INTERN MED, V154, P268, DOI 10.7326/0003-4819-154-4-201102150-00008; Kaukonen KM, 2009, ACTA ANAESTH SCAND, V53, P61, DOI 10.1111/j.1399-6576.2008.01795.x; Kramer AH, 2012, CRIT CARE, V16, DOI 10.1186/cc11812; Krinsley JS, 2003, MAYO CLIN PROC, V78, P1471, DOI 10.4065/78.12.1471; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Meierhans R, 2010, CRIT CARE, V14, DOI 10.1186/cc8869; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Preiser JC, 2009, INTENS CARE MED, V35, P1738, DOI 10.1007/s00134-009-1585-2; Qaseem A, 2011, ANN INTERN MED, V154, P260, DOI 10.7326/0003-4819-154-4-201102150-00007; Salim A, 2009, AM SURGEON, V75, P25; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Yang M, 2009, INT J NURS STUD, V46, P753, DOI 10.1016/j.ijnurstu.2009.01.004; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6	40	49	52	1	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUN	2015	41	6					1037	1047		10.1007/s00134-015-3757-6			11	Critical Care Medicine	General & Internal Medicine	CL2UO	WOS:000356801200008	26088909				2021-06-18	
J	Ni, HB; Jin, W; Zhu, TS; Wang, J; Yuan, BY; Jiang, J; Liang, WB; Ma, ZL				Ni, Hongbin; Jin, Wei; Zhu, Tiansheng; Wang, Jing; Yuan, Baoyu; Jiang, Jian; Liang, Weibang; Ma, Zhengliang			Curcumin modulates TLR4/NF-kappa B inflammatory signaling pathway following traumatic spinal cord injury in rats	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Curcumin; Toll-like receptor 4; Nuclear factor-kappa B; Inflammation; Spinal cord injury	TOLL-LIKE RECEPTORS; KAPPA-B ACTIVATION; BRAIN-INJURY; MICE; NEUROPROTECTION; EXPRESSION; CYTOKINES; PROTECTS	Background: Curcumin, a polyphenolic compound extracted from the plant turmeric, has protective effects on spinal cord injury (SCI) through attenuation of inflammatory response. This study was designed to detect whether curcumin modulates toll-like receptor 4 (TLR4) and the nuclear factor-kappa B (NF-kappa B) inflammatory signaling pathway in the injured rat spinal cord following SCI. Methods: Adult male Sprague-Dawley rats were subjected to laminectomy at T8-T9 and compression with a vascular clip. There were three groups: (a) sham group; (b) SCI group; and (g) SCI + curcumin group. We measured TLR4 gene and protein expression by real-time polymerase chain reaction and western blot analysis; NF-kappa B activity by electrophoretic mobility shift assay, inflammatory cytokines tumor necrosis factor-a, interleukin-1 beta, and interleukin-6 levels by enzyme-linked immunosorbent assay, hindlimb locomotion function by Basso, Beattie, and Bresnahan rating, spinal cord edema by wet/dry weight method, and apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) analysis. Results: The results showed that SCI induced the up-regulation of TLR4, NF-kappa B, and inflammatory cytokines in the injured rat spinal cord. Treatment with curcumin following SCI markedly down-regulated the levels of these agents related to the TLR4/NF-kappa B inflammatory signaling pathway. Administration of curcumin also significantly ameliorated SCI induced hind limb locomotion deficits, spinal cord edema, and apoptosis. Conclusions: Post-SCI curcumin administration attenuates the TLR4/NF-kappa B inflammatory signaling pathway in the injured spinal cord, and this may be a mechanism whereby curcumin improves the outcome following SCI.	[Ni, Hongbin; Ma, Zhengliang] Nanjing Univ Chinese Med, Nanjing Drum Tower Hosp, Clin Coll Tradit Chinese & Western Med, Dept Anesthesiol, Nanjing 210008, Jiangsu, Peoples R China; [Jin, Wei; Zhu, Tiansheng; Wang, Jing; Yuan, Baoyu; Jiang, Jian; Liang, Weibang] Nanjing Univ Chinese Med, Nanjing Drum Tower Hosp, Clin Coll Tradit Chinese & Western Med, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China	Ma, ZL (corresponding author), Drum Tower Hosp, Dept Anesthesiol, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.	njglyy110@163.com			Drum Tower Hospital of China	This work was supported by grants from Drum Tower Hospital of China. We thank Dr Lizhi Xu and Dr Gengbao Feng for technical assistance.	ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; Arslan F, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/704202; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Cadotte DW, 2011, CLIN ORTHOP RELAT R, V469, P732, DOI 10.1007/s11999-010-1674-0; Casula M, 2011, NEUROSCIENCE, V179, P233, DOI 10.1016/j.neuroscience.2011.02.001; Cemil B, 2010, ACTA NEUROCHIR, V152, P1583, DOI 10.1007/s00701-010-0702-x; Chen F, 1999, CLIN CHEM, V45, P7; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Jeong CW, 2012, J CARDIOVASC PHARM T, V17, P387, DOI 10.1177/1074248412438102; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Jin W, 2011, ANN CLIN LAB SCI, V41, P25; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jobin C, 1999, J IMMUNOL, V163, P3474; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Liang WB, 2010, BIOMATERIALS, V31, P8634, DOI 10.1016/j.biomaterials.2010.07.084; Lin MS, 2011, J SURG RES, V166, P280, DOI 10.1016/j.jss.2009.07.001; Loannou S, 2010, MEDIAT INFLAMM, V2010; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Ormond DR, 2012, J NEUROSURG-SPINE, V16, P497, DOI 10.3171/2012.1.SPINE11769; Shukla PK, 2008, NEUROCHEM RES, V33, P1036, DOI 10.1007/s11064-007-9547-y; Soetikno V, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-35; Strimpakos AS, 2008, ANTIOXID REDOX SIGN, V10, P511, DOI 10.1089/ars.2007.1769; Sun YH, 2011, J NEUROTRAUM, V28, P2513, DOI 10.1089/neu.2011.1958; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tanga FY, 2004, NEUROCHEM INT, V45, P397, DOI 10.1016/j.neuint.2003.06.002; Wu AG, 2011, NEUROREHAB NEURAL RE, V25, P332, DOI 10.1177/1545968310397706; Xiao XF, 2012, J SURG RES, V176, pE31, DOI 10.1016/j.jss.2011.11.1032; Yang CH, 2009, BRAIN RES, V1282, P133, DOI 10.1016/j.brainres.2009.05.009; Yao AH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/591298; Yu Wen-Guang, 2011, Indian J Med Res, V134, P717, DOI 10.4103/0971-5916.91009	36	49	58	0	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	MAR	2015	38	2					199	206		10.1179/2045772313Y.0000000179			8	Clinical Neurology	Neurosciences & Neurology	CD4RX	WOS:000351072300011	24621048	Green Published			2021-06-18	
J	Sisniega, A; Zbijewski, W; Xu, J; Dang, H; Stayman, JW; Yorkston, J; Aygun, N; Koliatsos, V; Siewerdsen, JH				Sisniega, A.; Zbijewski, W.; Xu, J.; Dang, H.; Stayman, J. W.; Yorkston, J.; Aygun, N.; Koliatsos, V.; Siewerdsen, J. H.			High-fidelity artifact correction for cone-beam CT imaging of the brain	PHYSICS IN MEDICINE AND BIOLOGY			English	Article						cone beam CT; Monte Carlo; scatter correction; traumatic brain injury; variance reduction; artifact correction; soft-tissue brain imaging	X-RAY SCATTER; FLAT-PANEL DETECTOR; MONTE-CARLO SIMULATIONS; EMPIRICAL CUPPING CORRECTION; DIFFUSE AXONAL INJURY; DEDICATED BREAST CT; COMPUTED-TOMOGRAPHY; LAG CORRECTION; CORRECTION ALGORITHM; HARDENING CORRECTION	CT is the frontline imaging modality for diagnosis of acute traumatic brain injury (TBI), involving the detection of fresh blood in the brain (contrast of 30-50 HU, detail size down to 1 mm) in a non-contrast-enhanced exam. A dedicated point-of-care imaging system based on cone-beam CT (CBCT) could benefit early detection of TBI and improve direction to appropriate therapy. However, flat-panel detector (FPD) CBCT is challenged by artifacts that degrade contrast resolution and limit application in soft-tissue imaging. We present and evaluate a fairly comprehensive framework for artifact correction to enable soft-tissue brain imaging with FPD CBCT. The framework includes a fast Monte Carlo (MC)-based scatter estimation method complemented by corrections for detector lag, veiling glare, and beam hardening. The fast MC scatter estimation combines GPU acceleration, variance reduction, and simulation with a low number of photon histories and reduced number of projection angles (sparse MC) augmented by kernel de-noising to yield a runtime of similar to 4 min per scan. Scatter correction is combined with two-pass beam hardening correction. Detector lag correction is based on temporal deconvolution of the measured lag response function. The effects of detector veiling glare are reduced by deconvolution of the glare response function representing the long range tails of the detector point-spread function. The performance of the correction framework is quantified in experiments using a realistic head phantom on a testbench for FPD CBCT. Uncorrected reconstructions were non-diagnostic for soft-tissue imaging tasks in the brain. After processing with the artifact correction framework, image uniformity was substantially improved, and artifacts were reduced to a level that enabled visualization of similar to 3 mm simulated bleeds throughout the brain. Non-uniformity (cupping) was reduced by a factor of 5, and contrast of simulated bleeds was improved from similar to 7 to 49.7 HU, in good agreement with the nominal blood contrast of 50 HU. Although noise was amplified by the corrections, the contrast-to-noise ratio (CNR) of simulated bleeds was improved by nearly a factor of 3.5 (CNR = 0.54 without corrections and 1.91 after correction). The resulting image quality motivates further development and translation of the FPD-CBCT system for imaging of acute TBI.	[Sisniega, A.; Zbijewski, W.; Xu, J.; Dang, H.; Stayman, J. W.; Siewerdsen, J. H.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA; [Yorkston, J.] Carestream Hlth, Rochester, NY 14615 USA; [Aygun, N.; Siewerdsen, J. H.] Johns Hopkins Univ, Russel H Morgan Dept Radiol, Baltimore, MD 21205 USA; [Koliatsos, V.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA	Sisniega, A (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA.	jeff.siewerdsen@jhu.edu	Dang, Hao/U-4865-2018	Dang, Hao/0000-0001-5861-6535; Stayman, Joseph/0000-0003-4358-378X; Sisniega, Alejandro/0000-0003-2030-2711	Carestream Health (Rochester NY)	This work was supported by academic-industry research collaboration with Carestream Health (Rochester NY). Collaboration and useful discussions regarding the MC-GPU package with Dr Andreu Badal and Dr Iacovos Kyprianou (US FDA CDRH, Bethesda MD) are gratefully acknowledged. The authors thank Joshua Levy and colleagues at The Phantom Laboratory (Greenwich NY) for development of the anthropomorphic head phantom and Dr Adam S Wang and Nicholas Uebele (Johns Hopkins University, Baltimore MD) for assistance with the low-contrast simulated brain and bleed formulations.	ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; Badal A, 2009, MED PHYS, V36, P4878, DOI 10.1118/1.3231824; Baer M, 2012, PHYS MED BIOL, V57, P6849, DOI 10.1088/0031-9155/57/21/6849; Bertram M, 2005, P SOC PHOTO-OPT INS, V5745, P259, DOI 10.1117/12.595032; Boone JM, 2001, RADIOLOGY, V221, P657, DOI 10.1148/radiol.2213010334; Bootsma GJ, 2013, MED PHYS, V40, DOI 10.1118/1.4822484; Carrino JA, 2014, RADIOLOGY, V270, P816, DOI 10.1148/radiol.13130225; Carton AK, 2009, MED PHYS, V36, P920, DOI 10.1118/1.3077922; Cho YB, 2005, MED PHYS, V32, P968, DOI 10.1118/1.1869652; COURVILLE C B, 1950, Bull Los Angel Neuro Soc, V15, P72; Dang H, 2014, P SPIE MED IN PRESS; De Man B, 2001, IEEE T MED IMAGING, V20, P999, DOI 10.1109/42.959297; Dong X, 2012, MED PHYS, V39, P5901, DOI 10.1118/1.4750054; Elbakri IA, 2003, PHYS MED BIOL, V48, P2453, DOI 10.1088/0031-9155/48/15/314; Fahrig R, 2006, MED PHYS, V33, P4541, DOI 10.1118/1.2370508; Gang GJ, 2010, MED PHYS, V37, P1948, DOI 10.1118/1.3352586; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GLOVER GH, 1982, MED PHYS, V9, P860, DOI 10.1118/1.595197; Greenberg MS, 2006, HDB NEUROSURGERY; Grills IS, 2008, INT J RADIAT ONCOL, V70, P1045, DOI 10.1016/j.ijrobp.2007.07.2352; Grimmer R, 2012, MED PHYS, V39, P825, DOI 10.1118/1.3676180; Hernandez AM, 2014, MED PHYS, V41, DOI 10.1118/1.4866216; Hsieh J, 2000, PROC SPIE, V3977, P298, DOI 10.1117/12.384505; Hsieh J, 2000, MED PHYS, V27, P23, DOI 10.1118/1.598853; Hsieh J., 2009, COMPUTED TOMOGRAPHY; Hubbell J.H., 1996, TABLES XRAY MASS ATT; Jaffray DA, 2002, INT J RADIAT ONCOL, V53, P1337, DOI 10.1016/S0360-3016(02)02884-5; Jarry G, 2006, MED PHYS, V33, P4320, DOI 10.1118/1.2358324; Jia X, 2012, MED PHYS, V39, P7368, DOI 10.1118/1.4766436; Joseph PM, 1997, MED PHYS, V24, P1629, DOI 10.1118/1.597970; JOSEPH PM, 1978, J COMPUT ASSIST TOMO, V2, P100, DOI 10.1097/00004728-197801000-00017; Kachelriess M, 2006, MED PHYS, V33, P1269, DOI 10.1118/1.2188076; KIJEWSKI P K, 1978, Medical Physics (Woodbury), V5, P209, DOI 10.1118/1.594429; Koskinen SK, 2013, SKELETAL RADIOL, V42, P649, DOI 10.1007/s00256-012-1516-0; Kyriakou Y, 2006, PHYS MED BIOL, V51, P4567, DOI 10.1088/0031-9155/51/18/008; Kyriakou Y, 2010, MED PHYS, V37, P5179, DOI 10.1118/1.3477088; La Riviere PJ, 2006, IEEE T MED IMAGING, V25, P1022, DOI 10.1109/TMI.2006.875429; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lazos D, 2012, MED PHYS, V39, P5639, DOI 10.1118/1.4747260; Liu X, 2005, MED PHYS, V32, P2093, DOI 10.1118/1.1998386; LOVE LA, 1987, MED PHYS, V14, P178, DOI 10.1118/1.596126; Luhta R P, 2003, US Patent Number, Patent No. [10/256,059, 10256059]; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mail N, 2008, MED PHYS, V35, P5187, DOI 10.1118/1.2977759; Mainegra-Hing E, 2010, PHYS MED BIOL, V55, P4495, DOI 10.1088/0031-9155/55/16/S05; Mainegra-Hing E, 2008, J PHYS CONF SER, V102, DOI 10.1088/1742-6596/102/1/012017; Maltz JS, 2008, IEEE T MED IMAGING, V27, P1791, DOI 10.1109/TMI.2008.928922; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Miracle AC, 2009, AM J NEURORADIOL, V30, P1285, DOI 10.3174/ajnr.A1654; Mori S, 2006, PHYS MED BIOL, V51, P3953, DOI 10.1088/0031-9155/51/16/005; NALCIOGLU O, 1979, PHYS MED BIOL, V24, P330, DOI 10.1088/0031-9155/24/2/009; NEITZEL U, 1992, MED PHYS, V19, P475, DOI 10.1118/1.596836; Ning R, 2004, MED PHYS, V31, P1195, DOI 10.1118/1.1711475; Nuyts J, 2013, PHYS MED BIOL, V58, pR63, DOI 10.1088/0031-9155/58/12/R63; Parizel PM, 2001, EUR RADIOL, V11, P1770, DOI 10.1007/s003300000800; Poludniowski G, 2011, PHYS MED BIOL, V56, P1837, DOI 10.1088/0031-9155/56/6/019; Poludniowski G, 2009, PHYS MED BIOL, V54, P3847, DOI 10.1088/0031-9155/54/12/016; Prakash P, 2011, MED PHYS, V38, P5612, DOI 10.1118/1.3633937; Ruhrnschopf EP, 2011, MED PHYS, V38, P5186, DOI 10.1118/1.3589140; Ruhrnschopf EP, 2011, MED PHYS, V38, P4296, DOI 10.1118/1.3599033; Samei E, 1998, MED PHYS, V25, P102, DOI 10.1118/1.598165; Schneider W, 2000, PHYS MED BIOL, V45, P459, DOI 10.1088/0031-9155/45/2/314; SEIBERT JA, 1988, MED PHYS, V15, P567, DOI 10.1118/1.596208; Siewerdsen JH, 2011, NUCL INSTRUM METH A, V648, pS241, DOI 10.1016/j.nima.2010.11.088; Siewerdsen JH, 1999, MED PHYS, V26, P1624, DOI 10.1118/1.598657; Siewerdsen JH, 2006, MED PHYS, V33, P187, DOI 10.1118/1.2148916; Siewerdsen JH, 2005, MED PHYS, V32, P241, DOI 10.1118/1.1836331; Siewerdsen JH, 1999, MED PHYS, V26, P2635, DOI 10.1118/1.598803; Siewerdsen JH, 2000, MED PHYS, V27, P1903, DOI 10.1118/1.1286590; Siewerdsen JH, 2001, MED PHYS, V28, P220, DOI 10.1118/1.1339879; Sisniega A, 2013, MED PHYS, V40, DOI 10.1118/1.4801895; Starman J, 2012, MED PHYS, V39, P6035, DOI 10.1118/1.4752087; Starman J, 2012, MED PHYS, V39, P18, DOI 10.1118/1.3664004; Starman J, 2011, MED PHYS, V38, P2398, DOI 10.1118/1.3574873; Sun M, 2010, PHYS MED BIOL, V55, P6695, DOI 10.1088/0031-9155/55/22/007; Tang XY, 2005, PHYS MED BIOL, V50, P3889, DOI 10.1088/0031-9155/50/16/016; Thibault JB, 2007, MED PHYS, V34, P4526, DOI 10.1118/1.2789499; TUY HK, 1983, SIAM J APPL MATH, V43, P546, DOI 10.1137/0143035; Tward DJ, 2007, MED PHYS, V34, P4459, DOI 10.1118/1.2790586; Van Gompel G, 2011, MED PHYS, V38, pS36, DOI 10.1118/1.3577758; Wang AS, 2014, PHYS MED BIOL, V59, P1005, DOI 10.1088/0031-9155/59/4/1005; Weisfield RL, 1999, PROC SPIE, V3659, P307, DOI 10.1117/12.349505; Xu J, 2012, MED PHYS, V39, P4932, DOI 10.1118/1.4736805; Yang K, 2007, MED PHYS, V34, P2059, DOI 10.1118/1.2737263; Yang K, 2012, PROC SPIE, V8313, DOI 10.1117/12.911093; Yang WT, 2007, AM J ROENTGENOL, V189, P1312, DOI 10.2214/AJR.07.2403; Yu LF, 2010, AM J ROENTGENOL, V194, pW193, DOI 10.2214/AJR.09.2951; Zbijewski W, 2011, MED PHYS, V38, P4700, DOI 10.1118/1.3611039; Zbijewski W, 2009, P SPIE MED IMAGING, V7258; Zeng K, 2004, MED PHYS, V31, P3206, DOI 10.1118/1.1809792; Zhao W, 2005, MED PHYS, V32, P488, DOI 10.1118/1.1843353; Zhu L, 2005, P SOC PHOTO-OPT INS, V5745, P251, DOI 10.1117/12.594699; Zhu L, 2006, IEEE T MED IMAGING, V25, P1573, DOI 10.1109/TMI.2006.884636; Zhu L, 2009, MED PHYS, V36, P2258, DOI 10.1118/1.3130047; Zoumalan RA, 2009, OTOLARYNG HEAD NECK, V140, P841, DOI 10.1016/j.otohns.2009.01.010	95	49	51	0	15	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0031-9155	1361-6560		PHYS MED BIOL	Phys. Med. Biol.	FEB 21	2015	60	4					1415	1439		10.1088/0031-9155/60/4/1415			25	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Engineering; Radiology, Nuclear Medicine & Medical Imaging	CB3LK	WOS:000349529100003	25611041				2021-06-18	
J	Carlozzi, NE; Kratz, AL; Sander, AM; Chiaravalloti, ND; Brickell, TA; Lange, RT; Hahn, EA; Austin, A; Miner, JA; Tulsky, DS				Carlozzi, Noelle E.; Kratz, Anna L.; Sander, Angelle M.; Chiaravalloti, Nancy D.; Brickell, Tracey A.; Lange, Rael T.; Hahn, Elizabeth A.; Austin, Amy; Miner, Jennifer A.; Tulsky, David S.			Health-Related Quality of Life in Caregivers of Individuals With Traumatic Brain Injury; Development of a Conceptual Model	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Caregivers; Outcome assessment (health care); Quality of life; Rehabilitation	PATIENT-REPORTED OUTCOMES; SOCIAL SUPPORT; ISSUES RELEVANT; HEAD-INJURY; FAMILY; BURDEN; REHABILITATION; IDENTIFICATION; INSTRUMENT; PREDICTORS	Objectives: To identify aspects of health-related quality of life (HRQOL) that are relevant to caregivers of individuals with traumatic brain injury (TBI) and to propose an integrated conceptual framework based on this information. Design: Nine focus groups with caregivers of individuals with moderate-to-severe TBI were qualitatively analyzed to ascertain the effect that caring for an individual with a TBI has on caregiver HRQOL. Setting: University hospitals and rehabilitation treatment centers. Participants: Caregivers (N=55) of individuals with moderate-to-severe TBI. Interventions: Not applicable. Main Outcome Measures: Not applicable. Results: Qualitative analysis indicated that caregivers were most concerned about their social health (42% of comments). Other important issues were emotional health (34%), physical health (11%), cognitive health (3%), and feelings of loss (9%; feelings of loss related to changes in the future/potential of the care recipient or related to the caregiver). Areas of concern that were discussed that were specific to the caregiver and not fully evaluated by existing patient-reported outcomes (PROs) included feelings of loss, anxiety related to the caregiver role (reinjury concerns, worry about leaving the person alone, etc), and caregiver strain (burden, stress, feeling overwhelmed, etc). Conclusions: Although existing PROs capture relevant aspects of HRQOL for caregivers, there are HRQOL domains that are not addressed. A validated and sensitive HRQOL tool for caregivers of individuals with TBI will facilitate initiatives to improve outcomes in this underserved group. (C) 2015 by the American Congress of Rehabilitation Medicine	[Carlozzi, Noelle E.; Kratz, Anna L.; Austin, Amy; Miner, Jennifer A.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Sander, Angelle M.] Mem Hermann Res Ctr, Inst Rehabil Res, Houston, TX USA; [Sander, Angelle M.] Baylor Coll Med, Houston, TX 77030 USA; [Chiaravalloti, Nancy D.] Kessler Fdn Res Ctr, Traumat Brain Injury Lab, Neuropsychol & Neurosci Lab, W Orange, NJ USA; [Brickell, Tracey A.; Lange, Rael T.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Brickell, Tracey A.; Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Hahn, Elizabeth A.] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA; [Tulsky, David S.] Univ Delaware, Dept Phys Therapy, Newark, DE USA; [Tulsky, David S.] Kessler Fdn, Neuropsychol & Neurosci Lab, Spinal Cord Injury Lab, W Orange, NJ USA	Carlozzi, NE (corresponding author), Univ Michigan, Med Ctr, Dept Phys Med & Rehabil, North Campus Res Complex,Bldg 14,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu		Tulsky, David/0000-0002-4335-4509; Chiaravalloti, Nancy/0000-0003-2943-7567	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [05R01NR013658]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [K01AR064275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013658] Funding Source: NIH RePORTER	Supported by the National Institutes of Health (grant no. 05R01NR013658).	Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; BASCH CE, 1987, HEALTH EDUC QUART, V14, P411, DOI 10.1177/109019818701400404; Brouwer WBF, 2006, QUAL LIFE RES, V15, P1005, DOI 10.1007/s11136-005-5994-6; Carlozzi NE, 2013, ARCH PHYS MED REHAB, V94, P1721, DOI 10.1016/j.apmr.2013.02.024; Carlozzi NE, 2013, J HEALTH PSYCHOL, V18, P212, DOI 10.1177/1359105312438109; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Cella D, 2007, QUAL LIFE RES, V16, P133, DOI 10.1007/s11136-007-9204-6; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; CELLA DF, 1995, SEMIN ONCOL, V22, P73; Derogatis LR, 2001, BRIEF SYMPTOM INVENT; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Glaser B. G., 1967, DISCOVERY GROUNDED T; Goldberg D., 1978, MANUAL GEN HLTH QUES; Grad FP, 2002, B WORLD HEALTH ORGAN, V80, P981; Hahn EA, 2014, HEALTH PSYCHOL, V33, P490, DOI 10.1037/hea0000055; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Harris JKJ, 2001, BRAIN INJURY, V15, P223; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Katz S, 2005, BRAIN INJURY, V19, P59, DOI 10.1080/02699050410001719970; Kisala Pamela A, 2010, J Appl Meas, V11, P315; Knight RG, 1997, J CLIN EXP NEUROPSYC, V19, P7, DOI 10.1080/01688639708403832; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McLaughlin Anne Marie, 1993, Brain Injury, V7, P45, DOI 10.3109/02699059309008155; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; MONTGOMERY RJV, 1985, FAM RELAT, V34, P19, DOI 10.2307/583753; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Pelletier PM, 2000, BRAIN COGNITION, V44, P45; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; Rapport LJ, 2006, J HEAD TRAUMA REHAB, V21, P432, DOI 10.1097/00001199-200609000-00055; Rothman ML, 2007, VALUE HEALTH, V10, pS66, DOI 10.1111/j.1524-4733.2007.00269.x; Sady MD, 2010, ARCH PHYS MED REHAB, V91, P1542, DOI 10.1016/j.apmr.2010.07.012; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sander AM, 2012, ARCH PHYS MED REHAB, V93, P842, DOI 10.1016/j.apmr.2011.11.031; Smith A M, 1998, Rehabil Nurs, V23, P252; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Strauss A., 1998, BASICS QUALITATIVE R; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Thurman D, 2007, BRAIN INJURY MED PRI, P373; Traumatic Brain Injury Model Systems, TRAUM BRAIN INJ MOD; Turner RR, 2007, VALUE HEALTH, V10, pS86, DOI 10.1111/j.1524-4733.2007.00271.x; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Zarit S., 1985, HIDDEN VICTIMS ALZHE; Zemke R., 1985, FIGURING THINGS OUT	58	49	50	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2015	96	1					105	113		10.1016/j.apmr.2014.08.021			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AY6EW	WOS:000347661100015	25239281	Green Accepted			2021-06-18	
J	Shin, JC; Kim, KN; Yoo, J; Kim, IS; Yun, S; Lee, H; Jung, K; Hwang, K; Kim, M; Lee, IS; Shin, JE; Park, KI				Shin, Ji Cheol; Kim, Keung Nyun; Yoo, Jeehyun; Kim, Il-Sun; Yun, Seokhwan; Lee, Hyejin; Jung, Kwangsoo; Hwang, Kyujin; Kim, Miri; Lee, Il-Shin; Shin, Jeong Eun; Park, Kook In			Clinical Trial of Human Fetal Brain-Derived Neural Stem/Progenitor Cell Transplantation in Patients with Traumatic Cervical Spinal Cord Injury	NEURAL PLASTICITY			English	Article							QUALITY-OF-LIFE; STEM-CELLS; FUNCTIONAL RECOVERY; MOTOR RECOVERY; IMMUNE CELLS; ICCP PANEL; REPAIR; MODEL; DIFFERENTIATION; COMPLICATIONS	In a phase I/IIa open-label and nonrandomized controlled clinical trial, we sought to assess the safety and neurological effects of human neural stem/progenitor cells (hNSPCs) transplanted into the injured cord after traumatic cervical spinal cord injury (SCI). Of 19 treated subjects, 17 were sensorimotor complete and 2 were motor complete and sensory incomplete. hNSPCs derived from the fetal telencephalon were grown as neurospheres and transplanted into the cord. In the control group, who did not receive cell implantation but were otherwise closely matched with the transplantation group, 15 patients with traumatic cervical SCI were included. At 1 year after cell transplantation, there was no evidence of cord damage, syrinx or tumor formation, neurological deterioration, and exacerbating neuropathic pain or spasticity. The American Spinal Injury Association Impairment Scale (AIS) grade improved in 5 of 19 transplanted patients, 2 (A -> C), 1 (A -> B), and 2 (B -> D), whereas only one patient in the control group showed improvement (A -> B). Improvements included increased motor scores, recovery of motor levels, and responses to electrophysiological studies in the transplantation group. Therefore, the transplantation of hNSPCs into cervical SCI is safe and well-tolerated and is of modest neurological benefit up to 1 year after transplants. This trial is registered with Clinical Research Information Service (CRIS), Registration Number: KCT0000879.	[Shin, Ji Cheol; Yoo, Jeehyun] Yonsei Univ, Coll Med, Dept Rehabil Med, Seoul 120752, South Korea; [Shin, Ji Cheol; Yoo, Jeehyun] Yonsei Univ, Coll Med, Res Inst Rehabil Med, Seoul 120752, South Korea; [Kim, Keung Nyun] Yonsei Univ, Coll Med, Dept Neurosurg, Seoul 120752, South Korea; [Kim, Il-Sun; Lee, Il-Shin; Shin, Jeong Eun; Park, Kook In] Yonsei Univ, Coll Med, Severance Childrens Hosp, Dept Pediat, Seoul 120752, South Korea; [Yun, Seokhwan; Lee, Hyejin; Jung, Kwangsoo; Hwang, Kyujin; Kim, Miri; Park, Kook In] Yonsei Univ, Coll Med, Plus Project Med Sci BK21, Seoul 120752, South Korea	Park, KI (corresponding author), Yonsei Univ, Coll Med, Severance Childrens Hosp, Dept Pediat, Seoul 120752, South Korea.	kipark@yuhs.ac		Kim, Il-Sun/0000-0003-4033-4323; Shin, Ji Cheol/0000-0002-1133-1361; Hwang, kyujin/0000-0001-5193-5154; Shin, Jeong Eun/0000-0002-4376-8541; Yun, Seokhwan/0000-0002-9504-5230; Yoo, Jeehyun/0000-0002-1555-8029; Jung, Kwangsoo/0000-0001-7365-7247	National Research Foundation [2013M3A9B4076545]; Korean Health Technology RD Project [A121943, HI14C1564]; Faculty Grant of Yonsei University College of Medicine [6-2006-0017]; Severance Hospital in Seoul, Korea	This work was supported by Grants from National Research Foundation (2013M3A9B4076545) and Korean Health Technology R&D Project (A121943, HI14C1564), Faculty Grant of Yonsei University College of Medicine (6-2006-0017), and the Severance Hospital in Seoul, Korea. The authors thank Professor Chang-il Park, Department of Rehabilitation Medicine, and Professor Chul Lee, Department of Pediatrics, Yonsei University College of Medicine, for supporting the clinical trial in the Severance Hospital.	Abematsu M, 2010, J CLIN INVEST, V120, P3255, DOI 10.1172/JCI42957; Akesson E, 2007, PHYSIOL BEHAV, V92, P60, DOI 10.1016/j.physbeh.2007.05.056; Bacigaluppi M, 2009, BRAIN, V132, P2239, DOI 10.1093/brain/awp174; Baptiste DC, 2007, PROG BRAIN RES, V161, P217, DOI 10.1016/S0079-6123(06)61015-7; Barnabe-Heider F, 2008, CELL STEM CELL, V3, P16, DOI 10.1016/j.stem.2008.06.011; Barrett H, 2003, ARCH PHYS MED REHAB, V84, P789, DOI 10.1016/S0003-9993(02)04944-4; Burns AS, 2003, J NEUROTRAUM, V20, P477, DOI 10.1089/089771503765355540; Cheriyan T, 2014, SPINAL CORD, V52, P588, DOI 10.1038/sc.2014.91; Consortium for Spinal Cord Medicine, 2003, J SPINAL CORD MED, V23, P289; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; Curt A, 1999, SPINAL CORD, V37, P157, DOI 10.1038/sj.sc.3100809; Curt A, 2008, J NEUROTRAUM, V25, P677, DOI 10.1089/neu.2007.0468; Dietz V, 2006, LANCET NEUROL, V5, P688, DOI 10.1016/S1474-4422(06)70522-1; Ditunno JF, 2000, ARCH PHYS MED REHAB, V81, P389, DOI 10.1053/mr.2000.3779; Ditunno Jr J. F., 2002, SPINAL CORD MED; Dumitru D, 2002, ELECTRODIAGNOSTIC ME; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Feron F, 2005, BRAIN, V128, P2951, DOI 10.1093/brain/awh657; Fisher CG, 2005, SPINE, V30, P2200, DOI 10.1097/01.brs.0000181058.06412.a9; Flanders AE, 1996, RADIOLOGY, V201, P649, DOI 10.1148/radiology.201.3.8939210; Globe Newswire Stem Cells Inc, STEM CELLS; Hernandez J, 2011, CURR STEM CELL RES T, V6, P273, DOI 10.2174/157488811796575323; Hitzig SL, 2008, AM J PHYS MED REHAB, V87, P545, DOI 10.1097/PHM.0b013e31817c16d6; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hooshmand MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005871; Jensen MP, 1992, HDB PAIN ASSESSMENT; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Kim YT, 2006, EXP NEUROL, V199, P222, DOI 10.1016/j.expneurol.2006.03.015; Knoller N, 2005, J NEUROSURG-SPINE, V3, P173, DOI 10.3171/spi.2005.3.3.0173; Kokaia Z, 2012, NAT NEUROSCI, V15, P1078, DOI 10.1038/nn.3163; Lechner HE, 2006, ARCH PHYS MED REHAB, V87, P15, DOI 10.1016/j.apmr.2005.07.312; Lee H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104092; Lima C, 2010, NEUROREHAB NEURAL RE, V24, P10, DOI 10.1177/1545968309347685; Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Macias MY, 2006, EXP NEUROL, V201, P335, DOI 10.1016/j.expneurol.2006.04.035; Mackay-Sim A, 2008, BRAIN, V131, P2376, DOI 10.1093/brain/awn173; MARINO RJ, 1994, MUSCLE NERVE, V17, P1466, DOI 10.1002/mus.880171218; Marino RJ, 1999, ARCH PHYS MED REHAB, V80, P1391, DOI 10.1016/S0003-9993(99)90249-6; Marino RJ., 2003, J SPINAL CORD MED, V26, pS50, DOI [10.1080/10790268.2003.11754575, DOI 10.1080/10790268.2003.11754575]; Moviglia GA, 2006, CYTOTHERAPY, V8, P202, DOI 10.1080/14653240600736048; Noonan VK, 2008, ARCH PHYS MED REHAB, V89, P1074, DOI 10.1016/j.apmr.2007.10.041; Pandyan AD, 1999, CLIN REHABIL, V13, P373, DOI 10.1191/026921599677595404; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Potter K, 2003, BRIT J RADIOL, V76, P347, DOI 10.1259/bjr/11881183; Ramon S, 1997, SPINAL CORD, V35, P664, DOI 10.1038/sj.sc.3100490; Saberi H, 2008, NEUROSCI LETT, V443, P46, DOI 10.1016/j.neulet.2008.07.041; Sahni V, 2010, NAT REV NEUROL, V6, P363, DOI 10.1038/nrneurol.2010.73; Salazar DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012272; Shinawi M, 2008, DRUG DISCOV TODAY, V13, P760, DOI 10.1016/j.drudis.2008.06.007; Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005; Steeves JD, 2007, SPINAL CORD, V45, P206, DOI 10.1038/sj.sc.3102008; Steeves JD, 2011, SPINAL CORD, V49, P257, DOI 10.1038/sc.2010.99; Svendsen CN, 1999, BRAIN PATHOL, V9, P499, DOI 10.1111/j.1750-3639.1999.tb00538.x; Sykova E, 2006, CELL TRANSPLANT, V15, P675, DOI 10.3727/000000006783464381; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Titomanlio L, 2011, ANN NEUROL, V70, P698, DOI 10.1002/ana.22518; WATERS RL, 1993, ARCH PHYS MED REHAB, V74, P242; WATERS RL, 1992, ARCH PHYS MED REHAB, V73, P784; Xie J, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E11; Yan J, 2007, PLOS MED, V4, P318, DOI 10.1371/journal.pmed.0040039; Yoon SH, 2007, STEM CELLS, V25, P2066, DOI 10.1634/stemcells.2006-0807; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Ziv Y, 2006, P NATL ACAD SCI USA, V103, P13174, DOI 10.1073/pnas.0603747103	65	49	53	1	9	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-5904	1687-5443		NEURAL PLAST	Neural. Plast.		2015	2015								630932	10.1155/2015/630932			22	Neurosciences	Neurosciences & Neurology	CU5KD	WOS:000363569900001	26568892	DOAJ Gold, Green Published			2021-06-18	
J	Zehtabchi, S; Baki, SGA; Falzon, L; Nishijima, DK				Zehtabchi, Shahriar; Baki, Samah G. Abdel; Falzon, Louise; Nishijima, Daniel K.			Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							COAGULOPATHY; COAGULATION	Objective: The antifibrinolytic agent tranexamic acid (TXA) has demonstrated clinical benefit in trauma patients with severe bleeding, but its effectiveness in patients with traumatic brain injury (TBI) is unclear. We conducted a systematic review to evaluate the following research question: In ED patients with or at risk of intracranial hemorrhage (ICH) secondary to TBI, does TXA compared to placebo improve patients' outcomes? Methods: MEDLINE, EMBASE, CINAHL, and other databases were searched for randomized controlled trial (RCT) or quasi-RCT studies that compared the effect of TXA to placebo on outcomes of TBI patients. The main outcomes of interest included mortality, neurologic function, hematoma expansion, and adverse effects. We used "Grading quality of evidence and strength of recommendations" to assess the quality of trials. Two authors independently abstracted data using a data collection form. Results from studies were pooled when appropriate. Results: Of 1030 references identified through the search, 2 high-quality RCTs met inclusion criteria. The effect of TXA on mortality had a pooled relative risk of 0.64 (95% confidence interval [CI], 0.41-1.02); on unfavorable functional status, a relative risk of 0.77 (95% CI, 0.59-1.02); and on ICH progression, a relative risk of 0.76 (95% CI, 0.58-0.98). No serious adverse effects (such as thromboembolic events) associated with TXA group were reported in the included trials. Conclusion: Pooled results from the 2 RCTs demonstrated statistically significant reduction in ICH progression with TXA and a nonstatistically significant improvement of clinical outcomes in ED patients with TBI. Further evidence is required to support its routine use in patients with TBI. (C) 2014 Elsevier Inc. All rights reserved.	[Zehtabchi, Shahriar; Baki, Samah G. Abdel] Suny Downstate Med Ctr, Dept Emergency Med, Brooklyn, NY 11203 USA; [Falzon, Louise] Columbia Univ, Dept Med, Med Ctr, Ctr Behav Cardiovasc Hlth, New York, NY USA; [Nishijima, Daniel K.] Univ Calif Davis, Dept Emergency Med, Davis, CA 95616 USA	Zehtabchi, S (corresponding author), Suny Downstate Med Ctr, Dept Emergency Med, 450 Clarkson Ave,Box 1228, Brooklyn, NY 11203 USA.	Shahriar.zehtabchi@downstate.edu; samahabdulbaki@gmail.com; af2215@cumc.columbia.edu; daniel.nishijima@ucdmc.ucdavis.edu	Falzon, Louise/AAG-2404-2019	Falzon, Louise/0000-0002-9449-6056; zehtabchi, shahriar/0000-0002-6427-986X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R41HD072881-02]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R41HD072881] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000002] Funding Source: NIH RePORTER	SZ, LF, and DKN have no conflict of interest to report. SGA owns stock options in Bio-Signal Group Corporation and is a coinventor on US patents pending 61/554, 743 and 13/284, and 886. He is also the principal investigator of a National Institutes of Health-funded trial 5R41HD072881-02.	Bayir A, 2006, NEUROL INDIA, V54, P363, DOI 10.4103/0028-3886.28106; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; CRASH-2 CollaboratorsIntracranial Bleeding Study, 2011, BMJ-BRIT MED J, V343, P354; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Dowlatshahi D, 2011, NEUROLOGY, V76, P1238, DOI 10.1212/WNL.0b013e3182143317; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Figueroa BE, 1998, STROKE, V29, P1202, DOI 10.1161/01.STR.29.6.1202; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Guerriero C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018987; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P407, DOI 10.1016/j.jclinepi.2010.07.017; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Olin GL, 2006, 5 MOST COSTLY MED CO; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Roberts I, 2012, COCHRANE DB SYST REV, V12; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Yutthakasemsunt S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-20	25	49	52	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	DEC	2014	32	12					1503	1509		10.1016/j.ajem.2014.09.023			7	Emergency Medicine	Emergency Medicine	AW6AX	WOS:000346353000013	25447601	Green Accepted			2021-06-18	
J	Balakathiresan, NS; Chandran, R; Bhomia, M; Jia, M; Li, H; Maheshwari, RK				Balakathiresan, Nagaraja S.; Chandran, Raghavendar; Bhomia, Manish; Jia, Min; Li, He; Maheshwari, Radha K.			Serum and amygdala microRNA signatures of posttraumatic stress: Fear correlation and biomarker potential	JOURNAL OF PSYCHIATRIC RESEARCH			English	Article						Traumatic stress; Biomarker; microRNA; Serum; Amygdala; PTSD	TARGET GENES; BRAIN; EXPRESSION; MEMORY; PLASTICITY	Exposure to acute traumatic stress can cause permanent changes in neurological circuitry and may lead to the development of an anxiety disorder known as posttraumatic stress disorder (PTSD). Current diagnosis of PTSD is based on clinical or behavioral symptom assessment, however, these are not definitive due to overlapping symptoms with other psychiatric disorders or mild traumatic brain injury (mTBI). No FDA approved diagnostic tests or biomarkers are currently available for diagnosis of PTSD. Recently, circulating miRNAs have emerged as novel biomarkers of many diseases. In this study, we have examined the altered expression of serum and amygdala miRNAs in an animal model of PTSD. Differentially expressed and statistically significant miRNAs in serum were validated for their presence in amygdala of corresponding animals. A panel of nine stress-responsive miRNAs viz., miR-142-5p, miR-19b, miR-1928, miR-223-3p, miR-322*, miR-324, miR-421-3p and miR-463* and miR-674* were identified, and may have potential as biomarker(s) for PTSD. Further validations by bioinformatics and system biology approaches indicate that five miRNAs such as miR-142-5p, miR-19b, miR-1928, miR-223 and miR-421-3p may play a potential role in the regulation of genes associated with delayed and exaggerated fear. To the best of our knowledge, this is the first report demonstrating the plausibility of using circulating miRNAs as biomarkers of PTSD. Published by Elsevier Ltd.	[Balakathiresan, Nagaraja S.; Chandran, Raghavendar; Bhomia, Manish; Maheshwari, Radha K.] Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA; [Chandran, Raghavendar] Birla Inst Technol & Sci, Biol Sci Grp, Pilani 333031, Rajasthan, India; [Jia, Min; Li, He] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA	Maheshwari, RK (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	radha.maheshwari@usuhs.edu	Chandran, Raghavendar/AAB-9402-2019; Balakathiresan, Nagaraja Sethuraman/O-3213-2019; Bhomia, Manish/C-7683-2015	Chandran, Raghavendar/0000-0002-7915-2810; Bhomia, Manish/0000-0003-2808-9927; Balakathiresan, Nagaraja Sethuraman/0000-0001-5756-6070	Defense Medical Research and Development Program [D10_I_AR_J6_855]	This work was financially supported by a grant (# D10_I_AR_J6_855) from the Defense Medical Research and Development Program to Dr. Radha K Maheshwari.	Abu Fanne R, 2010, NEUROPHARMACOLOGY, V58, P972, DOI 10.1016/j.neuropharm.2009.12.017; Andero R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005656; Andrews JA, 2012, J NEUROCHEM, V120, P26, DOI 10.1111/j.1471-4159.2011.07545.x; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Berna G, 2012, J ANXIETY DISORD, V26, P239, DOI 10.1016/j.janxdis.2011.11.011; Beveridge NJ, 2010, MOL PSYCHIATR, V15, P1176, DOI 10.1038/mp.2009.84; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Fanselow MS, 1999, NEURON, V23, P229, DOI 10.1016/S0896-6273(00)80775-8; Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271; Griggs EM, 2013, J NEUROSCI, V33, P1734, DOI 10.1523/JNEUROSCI.2873-12.2013; Harraz MM, 2012, P NATL ACAD SCI USA, V109, P18962, DOI 10.1073/pnas.1121288109; Jia M, 2012, J VISUALIZED EXPT, P68; Jiang XL, 2011, J PSYCHOPHARMACOL, V25, P287, DOI 10.1177/0269881109106911; Jovicic A, 2013, J NEUROSCI, V33, P5127, DOI 10.1523/JNEUROSCI.0600-12.2013; Konopka W, 2010, J NEUROSCI, V30, P14835, DOI 10.1523/JNEUROSCI.3030-10.2010; Lai CY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021635; Lau P, 2013, EMBO MOL MED, V5, P1613, DOI 10.1002/emmm.201201974; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li L, 2013, NEUROMOL MED, V15, P593, DOI 10.1007/s12017-013-8244-z; Lin Q, 2011, NAT NEUROSCI, V14, P1115, DOI 10.1038/nn.2891; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Malan-Muller S, 2013, MOL NEUROBIOL, V47, P726, DOI 10.1007/s12035-012-8374-6; Mannironi C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073385; Marchand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044532; Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68; Morey RA, 2012, ARCH GEN PSYCHIAT, V69, P1169, DOI 10.1001/archgenpsychiatry.2012.50; Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052; Oliveros J. C. Venny, INTERACTIVE TOOL COM; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Rong H, 2011, J PSYCHIATR RES, V45, P92, DOI 10.1016/j.jpsychires.2010.04.028; Sayed ASM, 2013, DIS MARKERS, V2013, P561, DOI 10.1155/2013/217948; Schmidt U, 2013, DIS MARKERS, V2013, P43, DOI 10.1155/2013/835876; Scholer N, 2010, EXP HEMATOL, V38, P1126, DOI 10.1016/j.exphem.2010.10.004; SERVATIUS RJ, 1995, BIOL PSYCHIAT, V38, P539, DOI 10.1016/0006-3223(94)00369-E; Sheinerman KS, 2012, AGING-US, V4, P590, DOI 10.18632/aging.100486; Shumyatsky GP, 2005, CELL, V123, P697, DOI 10.1016/j.cell.2005.08.038; Smalheiser NR, 2011, INT J NEUROPSYCHOPH, V14, P1315, DOI 10.1017/S1461145710001628; Sones HM, 2011, PSYCHIAT CLIN N AM, V34, P79, DOI 10.1016/j.psc.2010.11.001; Taguchi YH, 2013, BIODATA MIN, V6, DOI 10.1186/1756-0381-6-11; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wu D, 2011, NEUROSCIENCE, V190, P386, DOI 10.1016/j.neuroscience.2011.06.017; Zhang L, 2011, ANXIETY DISORDERS, P69	44	49	49	2	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3956	1879-1379		J PSYCHIATR RES	J. Psychiatr. Res.	OCT	2014	57						65	73		10.1016/j.jpsychires.2014.05.020			9	Psychiatry	Psychiatry	AO7RK	WOS:000341550100008	24998397				2021-06-18	
J	Coulter, IC; Pesic-Smith, JD; Cato-Addison, WB; Khan, SA; Thompson, D; Jenkins, AJ; Strachan, RD; Mukerji, N				Coulter, Ian C.; Pesic-Smith, Jonathan D.; Cato-Addison, William B.; Khan, Shahid A.; Thompson, Daniel; Jenkins, Alistair J.; Strachan, Roger D.; Mukerji, Nitin			Routine but risky: A multi-centre analysis of the outcomes of cranioplasty in the Northeast of England	ACTA NEUROCHIRURGICA			English	Article						Decompressive craniectomy; Cranioplasty; Complications; Functional outcome	MIDDLE CEREBRAL-ARTERY; TRAUMATIC BRAIN-INJURY; EARLY DECOMPRESSIVE CRANIECTOMY; DEATH FOLLOWING CRANIOPLASTY; AFFECTING GRAFT INFECTION; CLINICAL ARTICLE; TITANIUM CRANIOPLASTY; MALIGNANT INFARCTION; RANDOMIZED-TRIAL; HEAD-INJURY	Cranioplasty is undertaken as a routine secondary operation following craniectomy. At a time when decompressive craniectomy is being evaluated by several large trials, we aimed to evaluate the morbidity associated with cranioplasty and investigate its potential effect on outcome. The outcomes of 166 patients undergoing cranioplasty at two centres in the United Kingdom between June 2006 and September 2011 were retrospectively analysed. Outcome measures included mortality, morbidity and functional outcome determined by the modified Rankin score (mRS) at last follow-up. A logistic regression analysis was performed to model and predict determinants related to neurological outcome following cranioplasty. Sixty-seven out of 166 patients (40.4 %) experienced at least one complication during a median follow-up time of 15 months (inter-quartile range 5-38 months). Thirty six patients (21.7 %) developed infection requiring antibiotics, with 27 (16.3 %) requiring removal of the cranioplasty. Nine of 25 patients (36 %) with bi-frontal defects developed an infection whereas 21 of the 153 patients (16.4 %) with a defect other than bi-frontal developed an infection (Chi square p = 0.009). Further surgery in the two groups was required in 16.4 % and 11.7, % respectively. Pseudomeningocoele (9 %), seizures (8.4 %) and poor cosmesis (7.2 %) were also commonly observed. Logistic regression analysis identified initial operation (p < 0.03), mRS at the time of cranioplasty (p < 0.0001) and complications (p < 0.04) as being predictive of neurological outcome at last follow-up. Age at the time of cranioplasty and the timing of cranioplasty were not predictive of last mRS score at follow-up. Cranioplasty harbours significant morbidity, a risk that appears to be higher with a bifrontal defect. The complications experienced influence subsequent functional outcome. The timing of cranioplasty, early or late, after the initial operation does not impact on the ultimate outcome. These findings should be considered when making decisions relating to craniectomy and cranioplasty.	[Coulter, Ian C.; Cato-Addison, William B.; Khan, Shahid A.; Strachan, Roger D.; Mukerji, Nitin] James Cook Univ Hosp, Dept Neurosurg, Middlesbrough TS4 3BW, Cleveland, England; [Pesic-Smith, Jonathan D.; Jenkins, Alistair J.] Royal Victoria Infirm, Dept Neurosurg, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Thompson, Daniel] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Coulter, IC (corresponding author), James Cook Univ Hosp, Dept Neurosurg, Middlesbrough TS4 3BW, Cleveland, England.	ian.coulter@doctors.org.uk	Mukerji, Nitin/AAF-8507-2020; Strachan, Roger/AAT-8295-2020; Thompson, Daniel/R-5821-2018	Thompson, Daniel/0000-0002-0698-4018; Coulter, Ian/0000-0001-7500-5592			Agner C, 2002, ACTA NEUROCHIR, V144, P1033, DOI 10.1007/s00701-002-0996-4; Archavlis E, 2012, ACTA NEUROCHIR, V154, P1055, DOI 10.1007/s00701-012-1333-1; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bender A, 2013, BRAIN INJURY, V27, P1073, DOI 10.3109/02699052.2013.794972; Bobinski L, 2013, CLIN NEUROL NEUROSUR, V115, P1788, DOI 10.1016/j.clineuro.2013.04.013; Broughton E, 2014, BRIT J NEUROSURG, V28, P34, DOI 10.3109/02688697.2013.815319; Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Goldstein JA, 2013, CURR OPIN OTOLARYNGO, V21, P400, DOI 10.1097/MOO.0b013e328363003e; Gooch MR, 2013, NEUROSURG FOCUS, V26, pE9; Hill CS, 2012, BRIT J NEUROSURG, V26, P832, DOI 10.3109/02688697.2012.692839; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kim H, 2013, ACTA NEUROCHIR, V155, P2171, DOI 10.1007/s00701-013-1877-8; Klinger DR, 2014, WORLD NEUROSURG, V82, pE525, DOI 10.1016/j.wneu.2013.08.005; Kolias AG, 2013, BRIT J NEUROSURG, DOI [10.3109/0288697, DOI 10.3109/0288697]; Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106; Kolias AG, 2013, ACTA NEUROCHIR, V155, P183, DOI 10.1007/s00701-012-1503-1; Lee CH, 2012, J TRAUMA ACUTE CARE, V73, P255, DOI 10.1097/TA.0b013e318256a150; Lee L, 2013, BRIT J NEUROSURG, V27, P629, DOI 10.3109/02688697.2013.815313; LUNDJOHANSEN M, 1994, NEUROSURGERY, V35, P839, DOI 10.1227/00006123-199411000-00006; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Nagayama K, 2002, NEUROL SURG TOKYO, V30, P165; Piedra MP, 2013, J NEUROSURG, V118, P109, DOI 10.3171/2012.10.JNS121037; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Rocque BG, 2013, J NEUROSURG-PEDIATR, V12, P120, DOI 10.3171/2013.4.PEDS12605; Roth J, 2011, NEUROSURGERY, V68, pE271, DOI 10.1227/NEU.0b013e3181fe6165; Stelling H, 2011, BRIT J NEUROSURG, V25, P407, DOI 10.3109/02688697.2011.566385; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Sundseth J, 2014, ACTA NEUROCHIR WIEN; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Tokoro K, 1989, Neurol Med Chir (Tokyo), V29, P196, DOI 10.2176/nmc.29.196; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wachter D, 2013, CLIN NEUROL NEUROSUR, V115, P1293, DOI 10.1016/j.clineuro.2012.12.002; Walcott BP, 2013, J NEUROSURG, V118, P757, DOI 10.3171/2013.1.JNS121626; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Wiggins A, 2013, NEUROSURGERY, V72, P248, DOI 10.1227/NEU.0b013e31827b98f3; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; Zebian B, 2011, BRIT J NEUROSURG, V25, P785, DOI 10.3109/02688697.2011.623801	50	49	51	1	12	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JUL	2014	156	7					1361	1368		10.1007/s00701-014-2081-1			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AK1SD	WOS:000338195300017	24752723				2021-06-18	
J	Wade, SL; Stancin, T; Kirkwood, M; Brown, TM; McMullen, KM; Taylor, HG				Wade, Shari L.; Stancin, Terry; Kirkwood, Michael; Brown, Tanya Maines; McMullen, Kendra M.; Taylor, H. Gerry			Counselor-Assisted Problem Solving (CAPS) Improves Behavioral Outcomes in Older Adolescents With Complicated Mild to Severe TBI	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adolescent; behavior; telehealth; traumatic brain injury; problem solving	TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; FAMILY INTERVENTION; SOCIAL COMPETENCE; CHILDREN; PREVALENCE; PREDICTORS; CAREGIVERS; EFFICACY; SKILLS	Objective: To test the efficacy of Counselor-Assisted Problem Solving (CAPS) versus an Internet resource comparison (IRC) condition in reducing behavior problems in adolescents following traumatic brain injury (TBI). Design: Randomized clinical trial with interviewers naive to treatment condition. Setting: Three large tertiary children's hospitals and 2 general hospitals with pediatric commitment. Participants: A total of 132 children and adolescents aged 12 to 17 years hospitalized during the previous 6 months for moderate to severe TBI. Interventions: Participants in CAPS (n = 65) completed 8 to 12 online modules providing training in problem solving, communication skills, and self-regulation and subsequent synchronous videoconferencing with a therapist. Participants in the IRC group (n = 67) received links to Internet resources about pediatric TBI. Main Outcome Measures: Child Behavior Checklist administered before and after completion of treatment (ie, approximately 6 months after treatment initiation). Results: Post hoc analysis of covariance, controlling for pretreatment scores, was used to examine group differences in behavior problems in the entire sample and among older (n = 59) and younger adolescents (n = 53). Among older but not younger adolescents, CAPS resulted in greater improvements on multiple dimensions of externalizing behavior problems than IRC. Conclusion: Online problem-solving therapy may be effective in reducing behavior problems in older adolescent survivors of moderate-severe TBI.	[Wade, Shari L.; McMullen, Kendra M.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Wade, Shari L.; McMullen, Kendra M.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Stancin, Terry] Case Western Reserve Univ, Metrohlth Med Ctr, Cleveland, OH USA; [Taylor, H. Gerry] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Kirkwood, Michael] Childrens Hosp Colorado, Aurora, CO USA; [Kirkwood, Michael] Univ Colorado, Sch Med, Aurora, CO USA; [Brown, Tanya Maines] Mayo Clin, Rochester, MN USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Stancin, Terry/L-7993-2019		NIH grant from the National Institute of Mental Health [R01-MH073764]; Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER	This work was supported in part by (1) NIH grant R01-MH073764 from the National Institute of Mental Health and (2) a grant from the Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program. The authors acknowledge the contributions of Robert Blaha, Elizabeth Hagesfeld, Michelle Jacobs, Daniel Maier, and Nina Fox in data collection and entry, Amy Cassedy in data management, and John Stullenberger in Website support. The authors also acknowledge the contributions of the therapists JoAnne Carey, PsyD, Britt Nielsen, PsyD, and Brad Jackson, PhD.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Department of Veterans Affairs, 2010, STR PLAN FY 2010 201; DZurilla TJ, 2006, PROBLEM SOLVING THER; Elliott TR, 2009, BEHAV RES THER, V47, P548, DOI 10.1016/j.brat.2009.03.006; Elliott TR, 2009, J CLIN PSYCHOL, V65, P406, DOI 10.1002/jclp.20527; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; Foster SL., 1989, NEGOTIATING PARENT A; Gan C, 2010, BRAIN INJURY, V24, P651, DOI 10.3109/02699051003692142; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McLaughlin KA, 2013, J HEAD TRAUMA REHAB, V28, P341, DOI 10.1097/HTR.0b013e31824e1d43; NEZU AM, 1989, J CONSULT CLIN PSYCH, V57, P408, DOI 10.1037/0022-006X.57.3.408; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	25	49	49	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2014	29	3					198	207		10.1097/HTR.0b013e31828f9fe8			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AG9SE	WOS:000335759100007	23640543	Green Accepted			2021-06-18	
J	Di Pietro, V; Lazzarino, G; Amorini, AM; Tavazzi, B; D'Urso, S; Longo, S; Vagnozzi, R; Signoretti, S; Clementi, E; Giardina, B; Lazzarino, G; Belli, A				Di Pietro, Valentina; Lazzarino, Giacomo; Amorini, Angela Maria; Tavazzi, Barbara; D'Urso, Serafina; Longo, Salvatore; Vagnozzi, Roberto; Signoretti, Stefano; Clementi, Elisabetta; Giardina, Bruno; Lazzarino, Giuseppe; Belli, Antonio			Neuroglobin expression and oxidant/antioxidant balance after graded traumatic brain injury in the rat	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Brain antioxidants; Neuroglobin; Neuroprotection; Nitrosative stress; Oxidative stress; Traumatic brain injury; Free radicals	OXYGEN-GLUCOSE DEPRIVATION; MOUSE CORTICAL-NEURONS; OXIDATIVE STRESS; GENE-EXPRESSION; IN-VITRO; MODEL; APOPTOSIS; SAMPLES; PATHOPHYSIOLOGY; NEUROPROTECTION	Neuroglobin is a neuron-specific hexacoordinated globin capable of binding various ligands, including 02, NO, and CO, the biological function of which is still uncertain. Various studies seem to indicate that neuroglobin is a neuroprotective agent when overexpressed, acting as a potent inhibitor of oxidative and nitrosative stress. In this study, we evaluated the pathophysiological response of the neuroglobin gene and protein expression in the cerebral tissue of rats sustaining traumatic brain injury of differing severity, while simultaneously measuring the oxidant/antioxidant balance. Two levels of trauma (mild and severe) were induced in anesthetized animals using the weight-drop model of diffuse axonal injury. Rats were then sacrificed at 6, 12, 24, 48, and 120 h after traumatic brain injury, and the gene and protein expression of neuroglobin and the concentrations of malondialdehyde (as a parameter representative of reactive oxygen species-mediated damage), nitrite nitrate (indicative of NO metabolism), ascorbate, and glutathione (GSH) were determined in the brain tissue. Results indicated that mild traumatic brain injury, although causing a reversible increase in oxidative/nitrosative stress (increase in malondialdehyde and nitrite nitrate) and an imbalance in antioxidants (decrease in ascorbate and GSH), did not induce any change in neuroglobin. Conversely, severe traumatic brain injury caused an over nine- and a fivefold increase in neuroglobin gene and protein expression, respectively, as well as a remarkable increase in oxidative/nitrosative stress and depletion of antioxidants. The results of this study, showing a lack of effect in mild traumatic brain injury as well as asynchronous time course changes in neuroglobin expression, oxidative/nitrosative stress, and antioxidants in severe traumatic brain injury, do not seem to support the role of neuroglobin as an endogenous neuroprotective antioxidant agent, at least under pathophysiological conditions.(c) 2014 The Authors. Published by Elsevier Inc	[Di Pietro, Valentina; Belli, Antonio] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Neurotrauma & Neurodegenerat Sect, Birmingham, W Midlands, England; [Lazzarino, Giacomo; Amorini, Angela Maria; Tavazzi, Barbara; Longo, Salvatore; Giardina, Bruno] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [D'Urso, Serafina; Lazzarino, Giuseppe] Univ Catania, Div Biochem & Mol Biol, Dept Biol Geol & Environm Sci, I-95125 Catania, Italy; [Vagnozzi, Roberto] Univ Roma Tor Vergata, Neurosurg Sect, Dept Biomed & Prevent, Rome, Italy; [Signoretti, Stefano] San Camillo Hosp, Div Neurosurg, Dept Neurosci Head & Neck Surg, Rome, Italy; [Clementi, Elisabetta] Univ Cattolica Sacro Cuore, CNR Inst Chim Riconoscimento Mol, Rome, Italy	Lazzarino, G (corresponding author), Univ Catania, Div Biochem & Mol Biol, Dept Biol Geol & Environm Sci, I-95125 Catania, Italy.	lazzarig@unict.it	Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; Clementi, Maria Elisabetta/E-5936-2017; Belli, Antonio/I-3799-2015; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; Clementi, Maria Elisabetta/0000-0002-4615-7826; Belli, Antonio/0000-0002-3211-9933; Lazzarino, Giacomo/0000-0003-1639-0966; lazzarino, giuseppe/0000-0002-5917-7279; AMORINI, Angela Maria/0000-0003-3525-9955; Di Pietro, Valentina/0000-0001-9430-4723	Catholic University of Rome; University of Birmingham; University of Catania	This work has been supported, in part, by funds from the Catholic University of Rome, the University of Catania, and the University of Birmingham.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Balan IS, 2013, J NEUROTRAUM, V30, P367, DOI 10.1089/neu.2012.2339; Bonding SH, 2008, INT J BIOL MACROMOL, V43, P295, DOI 10.1016/j.ijbiomac.2008.07.003; Brittain T, 2010, IUBMB LIFE, V62, P878, DOI 10.1002/iub.405; Chuang PY, 2010, J NEUROTRAUM, V27, P999, DOI 10.1089/neu.2009.1129; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Di Pietro V, 2013, MOL CELL BIOCHEM, V375, P185, DOI 10.1007/s11010-012-1541-2; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Eakin K, 2012, J NEUROTRAUM, V29, P1180, DOI 10.1089/neu.2011.2192; Giza CC, 2001, J ATHL TRAINING, V36, P228; Haines B, 2013, NEUROSCI LETT, V549, P3, DOI 10.1016/j.neulet.2013.04.039; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hua S, 2010, CURR MED CHEM, V17, P160; Hundahl CA, 2012, BIOCHEM BIOPH RES CO, V425, P100, DOI 10.1016/j.bbrc.2012.07.061; Hundahl CA, 2008, NEUROENDOCRINOLOGY, V88, P183, DOI 10.1159/000135617; Jin KL, 2011, PHARMACOLOGY, V87, P81, DOI 10.1159/000322998; Jin KL, 2010, STROKE, V41, P557, DOI 10.1161/STROKEAHA.109.567149; Kakar S, 2010, BIOPHYS CHEM, V152, P1, DOI 10.1016/j.bpc.2010.08.008; Khan AA, 2006, P NATL ACAD SCI USA, V103, P17944, DOI 10.1073/pnas.0607497103; Kiger L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020478; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; LAZZARINO G, 1989, ANAL BIOCHEM, V181, P239, DOI 10.1016/0003-2697(89)90236-4; Lechauve C, 2012, BBA-MOL CELL RES, V1823, P2261, DOI 10.1016/j.bbamcr.2012.09.009; Li RC, 2008, BRAIN RES, V1190, P159, DOI 10.1016/j.brainres.2007.11.022; Li SQ, 2013, MOL NEUROBIOL, V47, P197, DOI 10.1007/s12035-012-8373-7; Li WG, 2011, PROTEINS, V79, P115, DOI 10.1002/prot.22863; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lusardi TA, 2012, EXP NEUROL, V234, P161, DOI 10.1016/j.expneurol.2011.12.026; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; Raida Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076565; Raida Zindy, 2012, Exp Transl Stroke Med, V4, P15, DOI 10.1186/2040-7378-4-15; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Romitelli F, 2007, J CHROMATOGR B, V851, P257, DOI 10.1016/j.jchromb.2007.02.003; Shang AJ, 2012, NEUROL RES, V34, P588, DOI 10.1179/1743132812Y.0000000052; Shang AJ, 2012, NEUROL SCI, V33, P551, DOI 10.1007/s10072-011-0772-4; Shang AJ, 2006, BRAIN RES, V1078, P219, DOI 10.1016/j.brainres.2006.01.064; Sharma R, 2012, CURR NEUROL NEUROSCI, V12, P560, DOI 10.1007/s11910-012-0301-8; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Singh S, 2013, NITRIC OXIDE-BIOL CH, V32, P21, DOI 10.1016/j.niox.2013.03.008; Tavazzi B, 2005, CLIN BIOCHEM, V38, P997, DOI 10.1016/j.clinbiochem.2005.08.002; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Tiso M, 2011, J BIOL CHEM, V286, P18277, DOI 10.1074/jbc.M110.159541; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Van Leuven W, 2013, BBA-PROTEINS PROTEOM, V1834, P1764, DOI 10.1016/j.bbapap.2013.04.015; Yamada KH, 2012, J BIOL CHEM, V287, P13182, DOI 10.1074/jbc.M111.302612; Yu Z, 2012, NEUROSCIENCE, V218, P235, DOI 10.1016/j.neuroscience.2012.05.054; Yu Z, 2009, NEUROSCIENCE, V162, P396, DOI 10.1016/j.neuroscience.2009.04.055; Yu ZY, 2013, NEUROBIOL DIS, V56, P95, DOI 10.1016/j.nbd.2013.04.015; Yu ZY, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/756989; Yu ZY, 2012, INT J MOL SCI, V13, P6995, DOI 10.3390/ijms13066995	56	49	49	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	APR	2014	69						258	264		10.1016/j.freeradbiomed.2014.01.032			7	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	AD8BC	WOS:000333490500027	24491879	Green Published, Other Gold			2021-06-18	
J	Pugh, KR; Frost, SJ; Rothman, DL; Hoeft, F; Del Tufo, SN; Mason, GF; Molfese, PJ; Mencl, WE; Grigorenko, EL; Landi, N; Preston, JL; Jacobsen, L; Seidenberg, MS; Fulbright, RK				Pugh, Kenneth R.; Frost, Stephen J.; Rothman, Douglas L.; Hoeft, Fumiko; Del Tufo, Stephanie N.; Mason, Graeme F.; Molfese, Peter J.; Mencl, W. Einar; Grigorenko, Elena L.; Landi, Nicole; Preston, Jonathan L.; Jacobsen, Leslie; Seidenberg, Mark S.; Fulbright, Robert K.			Glutamate and Choline Levels Predict Individual Differences in Reading Ability in Emergent Readers	JOURNAL OF NEUROSCIENCE			English	Article						decoding; individual differences; MRS; phonological processing; reading; reading disability	MAGNETIC-RESONANCE-SPECTROSCOPY; GAMMA-AMINOBUTYRIC-ACID; TRAUMATIC BRAIN-INJURY; WHITE-MATTER; GABA CONCENTRATION; FUNCTIONAL CONNECTIVITY; DEVELOPMENTAL DYSLEXIA; AUDITORY-CORTEX; ANGULAR GYRUS; ATTENTION	Reading disability is a brain-based difficulty in acquiring fluent reading skills that affects significant numbers of children. Although neuroanatomical and neurofunctional networks involved in typical and atypical reading are increasingly well characterized, the underlying neurochemical bases of individual differences in reading development are virtually unknown. The current study is the first to examine neurochemistry in children during the critical period in which the neurocircuits that support skilled reading are still developing. In a longitudinal pediatric sample of emergent readers whose reading indicators range on a continuum from impaired to superior, we examined the relationship between individual differences in reading and reading-related skills and concentrations of neurometabolites measured using magnetic resonance spectroscopy. Both continuous and group analyses revealed that choline and glutamate concentrations were negatively correlated with reading and related linguistic measures in phonology and vocabulary (such that higher concentrations were associated with poorer performance). Correlations with behavioral scores obtained 24 months later reveal stability for the relationship between glutamate and reading performance. Implications for neurodevelopmental models of reading and reading disability are discussed, including possible links of choline and glutamate to white matter anomalies and hyperexcitability. These findings point to new directions for research on gene-brain-behavior pathways in human studies of reading disability.	[Pugh, Kenneth R.; Frost, Stephen J.; Hoeft, Fumiko; Del Tufo, Stephanie N.; Molfese, Peter J.; Mencl, W. Einar; Grigorenko, Elena L.; Landi, Nicole; Preston, Jonathan L.; Jacobsen, Leslie; Seidenberg, Mark S.; Fulbright, Robert K.] Haskins Labs Inc, New Haven, CT 06511 USA; [Pugh, Kenneth R.; Rothman, Douglas L.; Mason, Graeme F.; Fulbright, Robert K.] Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06520 USA; [Pugh, Kenneth R.; Del Tufo, Stephanie N.; Landi, Nicole] Univ Connecticut, Dept Psychol, Storrs, CT 06269 USA; [Hoeft, Fumiko] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; [Grigorenko, Elena L.; Landi, Nicole] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA; [Preston, Jonathan L.] So Connecticut State Univ, Dept Commun Disorders, New Haven, CT 06515 USA; [Seidenberg, Mark S.] Univ Wisconsin, Dept Psychol, Madison, WI 53706 USA	Pugh, KR (corresponding author), Haskins Labs Inc, 300 George St,Suite 900, New Haven, CT 06511 USA.	pugh@haskins.yale.edu	landi, nicole/ABG-5374-2020; Grigorenko, Elena/V-2418-2019; Landi, Nicole/P-2954-2014; Preston, Jonathan/E-9310-2010	Landi, Nicole/0000-0003-2890-2519; Del Tufo, Stephanie/0000-0002-2463-1785; Preston, Jonathan/0000-0001-9971-6321	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01 HD001994, R01 HD048830]; NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); NIHM; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01-HD02-3343, N01-MH9-0002, N01-NS-9-2314, N01-NS-9-2315, N01-NS-9-2316, N01-NS-9-2317, N01-NS-9-2319, N01-NS-9-2320]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD065794, P01HD001994] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [N01HD023343, R01HD048830] Funding Source: NIH RePORTER	This study is supported by NICHD P01 HD001994 to Haskins Laboratories (Carol Fowler) and NICHD R01 HD048830 to Yale University (K.R.P.). The 4T MR system was partially purchased by a generous gift from the W.M. Keck Foundation. Data used in the preparation of this article were obtained from the NIH Pediatric MRI Data Repository created by the NIH MRI Study of Normal Brain Development. This is a multisite, longitudinal study of typically developing children from ages newborn through young adulthood conducted by the Brain Development Cooperative Group and supported by NICHD, NIDA, NIHM, and NINDS (Contract nos. N01-HD02-3343, N01-MH9-0002, and N01-NS-9-2314, -2315, -2316, -2317, -2319, -2320). This paper reflects the views of the authors and may not reflect the opinions or views of the NIH.	Baruth JM, 2013, AUTISM RES, V6, P119, DOI 10.1002/aur.1273; Beaulieu C, 2005, NEUROIMAGE, V25, P1266, DOI 10.1016/j.neuroimage.2004.12.053; BEHAR KL, 1994, MAGNET RESON MED, V32, P294, DOI 10.1002/mrm.1910320304; BRADLEY L, 1978, NATURE, V271, P746, DOI 10.1038/271746a0; Braze D, 2007, J LEARN DISABIL-US, V40, P226, DOI 10.1177/00222194070400030401; Brennan BP, 2013, BIOL PSYCHIAT, V73, P24, DOI 10.1016/j.biopsych.2012.06.023; Brown MS, 2013, AUTISM RES, V6, P1, DOI 10.1002/aur.1260; Bruno JL, 2013, NEUROIMAGE, V67, P175, DOI 10.1016/j.neuroimage.2012.10.092; Buzsaki G, 2012, ANNU REV NEUROSCI, V35, P203, DOI 10.1146/annurev-neuro-062111-150444; Carrey N, 2002, J CHILD ADOL PSYCHOP, V12, P331, DOI 10.1089/104454602762599871; Carrey NJ, 2007, J CHILD ADOL PSYCHOP, V17, P11, DOI 10.1089/cap.2006.0008; Centanni T, 2013, CEREB CORTE IN PRESS; Che A, 2014, BIOL PSYCHI IN PRESS; Courvoisie H, 2004, J NEUROPSYCH CLIN N, V16, P63, DOI 10.1176/appi.neuropsych.16.1.63; de Diego-Adelino J, 2013, J PSYCHIATR NEUROSCI, V38, P107, DOI 10.1503/jpn.110185; Dougherty RF, 2007, P NATL ACAD SCI USA, V104, P8556, DOI 10.1073/pnas.0608961104; Dunn L. M., 1997, PPVT 3 PEABODY PICTU; Edden RAE, 2012, ARCH GEN PSYCHIAT, V69, P750, DOI 10.1001/archgenpsychiatry.2011.2280; Essa MM, 2012, NEUROCHEM RES, V37, P1829, DOI 10.1007/s11064-012-0799-9; Fletcher JM, 2012, LEARNING LEARNING DI; Frye RE, 2010, CEREB CORTEX, V20, P2625, DOI 10.1093/cercor/bhq010; Gallinat J, 2006, PSYCHOPHARMACOLOGY, V187, P103, DOI 10.1007/s00213-006-0397-0; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Gass A, 2013, NEUROLOGY, V80, P17, DOI 10.1212/WNL.0b013e31827b1b4c; Giraud AL, 2007, NEURON, V56, P1127, DOI 10.1016/j.neuron.2007.09.038; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Henry PG, 2001, MAGNET RESON MED, V45, P517, DOI 10.1002/1522-2594(200103)45:3<517::AID-MRM1068>3.0.CO;2-6; Hoeft F, 2007, P NATL ACAD SCI USA, V104, P4234, DOI 10.1073/pnas.0609399104; Hornickel J, 2013, J NEUROSCI, V33, P3500, DOI 10.1523/JNEUROSCI.4205-12.2013; Horwitz B, 1998, P NATL ACAD SCI USA, V95, P8939, DOI 10.1073/pnas.95.15.8939; Kalia M, 2008, METABOLISM, V57, pS2, DOI 10.1016/j.metabol.2008.07.009; Klingberg T, 2000, NEURON, V25, P493, DOI 10.1016/S0896-6273(00)80911-3; Landi N, 2013, DEVELOPMENTAL SCI, V16, P13, DOI 10.1111/j.1467-7687.2012.01180.x; Laycock R, 2008, NEUROSCI BIOBEHAV R, V32, P1409, DOI 10.1016/j.neubiorev.2008.04.008; Lehongre K, 2011, NEURON, V72, P1080, DOI 10.1016/j.neuron.2011.11.002; LoTurco JJ, 1995, NEURON, V15, P1287, DOI 10.1016/0896-6273(95)90008-X; LOTURCO JJ, 1991, J NEUROSCI, V11, P792; Lyon GR, 2003, ANN DYSLEXIA, V53, P1, DOI 10.1007/s11881-003-0001-9; Maisog JM, 2008, ANN NY ACAD SCI, V1145, P237, DOI 10.1196/annals.1416.024; Mason GF, 1997, J MAGN RESON, V126, P18, DOI 10.1006/jmre.1997.1143; Mason GF, 2002, MAGN RESON IMAGING, V20, P431, DOI 10.1016/S0730-725X(02)00510-6; Michael N, 2009, PSYCHIAT RES-NEUROIM, V172, P78, DOI 10.1016/j.pscychresns.2009.01.002; Morillon B, 2010, P NATL ACAD SCI USA, V107, P18688, DOI 10.1073/pnas.1007189107; Muthukumaraswamy SD, 2009, P NATL ACAD SCI USA, V106, P8356, DOI 10.1073/pnas.0900728106; Niogi SN, 2006, NEUROPSYCHOLOGIA, V44, P2178, DOI 10.1016/j.neuropsychologia.2006.01.011; Perlov E, 2009, WORLD J BIOL PSYCHIA, V10, P355, DOI 10.1080/15622970802176032; Peterson RL, 2012, LANCET, V379, P1997, DOI 10.1016/S0140-6736(12)60198-6; Pfefferbaum A, 1999, MAGNET RESON MED, V41, P276, DOI 10.1002/(SICI)1522-2594(199902)41:2<276::AID-MRM10>3.0.CO;2-8; Pignatelli M, 2012, J PHYSIOL-PARIS, V106, P81, DOI 10.1016/j.jphysparis.2011.09.007; Poelmans G, 2011, AM J PSYCHIAT, V168, P365, DOI 10.1176/appi.ajp.2010.10070948; Pugh KR, 2013, BRAIN LANG, V125, P173, DOI 10.1016/j.bandl.2012.04.004; Pugh KR, 2000, PSYCHOL SCI, V11, P51, DOI 10.1111/1467-9280.00214; Pugh KR, 2010, NEURAL BASIS READING, P281, DOI DOI 10.1093/ACPROF:OSO/9780195300369.003.0011; Rae C, 1998, LANCET, V351, P1849, DOI 10.1016/S0140-6736(97)99001-2; Richardson AJ, 1997, NMR BIOMED, V10, P309, DOI 10.1002/(SICI)1099-1492(199710)10:7<309::AID-NBM484>3.0.CO;2-0; Richlan F, 2013, HUM BRAIN MAPP, V34, P3055, DOI 10.1002/hbm.22127; Richlan F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012073; Richlan F, 2009, HUM BRAIN MAPP, V30, P3299, DOI 10.1002/hbm.20752; Rojas DC, 2014, NEUROIMAGE, V86, P28, DOI 10.1016/j.neuroimage.2013.01.045; Ross AJ, 2004, BRAIN RES REV, V44, P83, DOI 10.1016/j.brainresrev.2003.11.001; ROTHMAN DL, 1993, P NATL ACAD SCI USA, V90, P5662, DOI 10.1073/pnas.90.12.5662; Rothman DL, 1994, NMR PHYSL BIOMEDICIN, P353; Sagvolden T, 2005, BEHAV BRAIN SCI, V28, P397, DOI 10.1017/S0140525X05000075; Sagvolden T, 2009, NEUROPHARMACOLOGY, V57, P619, DOI 10.1016/j.neuropharm.2009.08.004; Sanacora G, 2003, ANN NY ACAD SCI, V1003, P292, DOI 10.1196/annals.1300.018; Sanacora G, 1999, ARCH GEN PSYCHIAT, V56, P1043, DOI 10.1001/archpsyc.56.11.1043; Schlaggar BL, 2007, ANNU REV NEUROSCI, V30, P475, DOI 10.1146/annurev.neuro.28.061604.135645; SHAYWITZ BA, 1992, J LEARN DISABIL, V25, P639, DOI 10.1177/002221949202501003; Shen J, 2004, J MAGN RESON, V170, P290, DOI 10.1016/j.jmr.2004.05.022; Shen J, 1997, MAGNET RESON MED, V38, P834, DOI 10.1002/mrm.1910380521; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Singh KD, 2012, NEUROIMAGE, V62, P1121, DOI 10.1016/j.neuroimage.2012.01.028; SNOWLING MJ, 1981, PSYCHOL RES-PSYCH FO, V43, P219, DOI 10.1007/BF00309831; Sperling AJ, 2006, PSYCHOL SCI, V17, P1047, DOI 10.1111/j.1467-9280.2006.01825.x; Torgesen JK, 2009, TEST WORD READING EF; Valentine GW, 2011, PSYCHIAT RES-NEUROIM, V191, P122, DOI 10.1016/j.pscychresns.2010.10.009; Wagner RK., 1999, COMPREHENSIVE TEST P; Wechsler D., 2011, WECHLSER ABBREVIATED; Woodcock R, 2003, WOODCOCK JOHNSON 3 S; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427	80	49	50	0	20	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 12	2014	34	11					4082	4089		10.1523/JNEUROSCI.3907-13.2014			8	Neurosciences	Neurosciences & Neurology	AC9UG	WOS:000332879500028	24623786	Green Published, Bronze			2021-06-18	
J	O'Kane, JW; Spieker, A; Levy, MR; Neradilek, M; Polissar, NL; Schiff, MA				O'Kane, John W.; Spieker, Amy; Levy, Marni R.; Neradilek, Moni; Polissar, Nayak L.; Schiff, Melissa A.			Concussion Among Female Middle-School Soccer Players	JAMA PEDIATRICS			English	Article							STATES HIGH-SCHOOL; SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; FOOTBALL PLAYERS; POSTURAL CONTROL; EPIDEMIOLOGY; SYMPTOMS; RECOVERY	IMPORTANCE Despite recent increased awareness about sports concussions, little research has evaluated concussions among middle-school athletes. OBJECTIVES To evaluate the frequency and duration of concussions in female youth soccer players and to determine if concussions result in stopping play and seeking medical care. DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study from March 2008 through May 2012 among 4 soccer clubs from the Puget Sound region of Washington State, involving 351 elite female soccer players, aged 11 to 14 years, from 33 randomly selected youth soccer teams. Of the players contacted, 83.1% participated and 92.4% completed the study. MAIN OUTCOMES AND MEASURES Concussion cumulative incidence, incidence rate, and description of the number, type, and duration of symptoms. We inquired weekly about concussion symptoms and, if present, the symptom type and duration, the event resulting in symptom onset, and whether the player sought medical attention or played while symptomatic. RESULTS Among the 351 soccer players, there were 59 concussions with 43 742 athletic exposure hours. Cumulative concussion incidence was 13.0% per season, and the incidence rate was 1.2 per 1000 athletic exposure hours (95% CI, 0.9-1.6). Symptoms lasted a median of 4.0 days (mean, 9.4 days). Heading the ball accounted for 30.5% of concussions. Players with the following symptoms had a longer recover time than players without these symptoms: light sensitivity (16.0 vs 3.0 days, P = .001), emotional lability (15.0 vs 3.5 days, P = .002), noise sensitivity (12.0 vs 3.0 days, P = .004), memory loss (9.0 vs 4.0 days, P = .04), nausea (9.0 vs 3.0 days, P = .02), and concentration problems (7.0 vs 2.0 days, P = .02). Most players (58.6%) continued to play with symptoms, with almost half (44.1%) seeking medical attention. CONCLUSIONS AND RELEVANCE Concussion rates in young female soccer players are greater than those reported in older age groups, and most of those concussed report playing with symptoms. Heading the ball is a frequent precipitating event. Awareness of recommendations to not play and seek medical attention is lacking for this age group.	[O'Kane, John W.] Univ Washington, Sports Med Clin, Seattle, WA 98195 USA; [Spieker, Amy; Levy, Marni R.; Schiff, Melissa A.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Spieker, Amy; Levy, Marni R.; Schiff, Melissa A.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA; [Neradilek, Moni; Polissar, Nayak L.] Mt Whisper Light Stat, Seattle, WA USA	O'Kane, JW (corresponding author), Univ Washington, Sports Med Clin, 3950 Montlake Blvd,Bank Amer Arena Room 148, Seattle, WA 98195 USA.	jokane@u.washington.edu	Meijer, Anna/K-5118-2016		National Institute of ArthritisUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR051059]; Musculoskeletal and Skin Diseases of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR051059] Funding Source: NIH RePORTER	This study was supported by grant R01AR051059 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (Dr Schiff).	Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Schiff MA, 2010, J ATHL TRAINING, V45, P238, DOI 10.4085/1062-6050-45.3.238; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; US Youth Soccer, 2013, GLANC; Yard EE, 2008, AM J SPORT MED, V36, P1930, DOI 10.1177/0363546508318047; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	36	49	49	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	MAR	2014	168	3					258	264		10.1001/jamapediatrics.2013.4518			7	Pediatrics	Pediatrics	AC8GR	WOS:000332772000013	24446018	Bronze			2021-06-18	
J	Greig, NH; Tweedie, D; Rachmany, L; Li, YZ; Rubovitch, V; Schreiber, S; Chiang, YH; Hoffer, BJ; Miller, J; Lahiri, DK; Sambamurti, K; Becker, RE; Pick, CG				Greig, Nigel H.; Tweedie, David; Rachmany, Lital; Li, Yazhou; Rubovitch, Vardit; Schreiber, Shaul; Chiang, Yung-Hsiao; Hoffer, Barry J.; Miller, Jonathan; Lahiri, Debomoy K.; Sambamurti, Kumar; Becker, Robert E.; Pick, Chaim G.			Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury	ALZHEIMERS & DEMENTIA			English	Article							GLUCAGON-LIKE PEPTIDE-1; TYPE-2 DIABETES-MELLITUS; FOCAL CEREBRAL-ISCHEMIA; MESENCHYMAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; GLP-1 RECEPTOR; AMYLOID-BETA; PARKINSONS-DISEASE; DENTATE GYRUS	Traumatic brain injury (TBI), either as an isolated injury or in conjunction with other injuries, is an increasingly common event. An estimated 1.7 million injuries occur within the USA each year and 10 million people are affected annually worldwide. Indeed, nearly one third (30.5%) of all injury-related deaths in the USA are associated with TBI, which will soon outpace many common diseases as the major cause of death and disability. Associated with a high morbidity and mortality and no specific therapeutic treatment, TBI has become a pressing public health and medical problem. The highest incidence of TBI occurs in young adults (15-24 years age) and in the elderly (>= 75 years of age). Older individuals are particularly vulnerable to these types of injury, often associated with falls, and have shown increased mortality and worse functional outcome after lower initial injury severity. In addition, a new and growing form of TBI, blast injury, associated with the detonation of improvised explosive devices in the war theaters of Iraq and Afghanistan, are inflicting a wave of unique casualties of immediate impact to both military personnel and civilians, for which long-term consequences remain unknown and may potentially be catastrophic. The neuropathology underpinning head injury is becoming increasingly better understood. Depending on severity, TBI induces immediate neuropathologic effects that, for the mildest form, may be transient; however, with increasing severity, these injuries cause cumulative neural damage and degeneration. Even with mild TBI, which represents the majority of cases, a broad spectrum of neurologic deficits, including cognitive impairments, can manifest that may significantly influence quality of life. Further, TBI can act as a conduit to longer term neurodegenerative disorders. Prior studies of glucagon-like peptide-1 (GLP-1) and long-acting GLP-1 receptor agonists have demonstrated neurotrophic/neuroprotective activities across a broad spectrum of cellular and animal models of chronic neurodegenerative (Alzheimer's and Parkinson's diseases) and acute cerebrovascular (stroke) disorders. In view of the mechanisms underpinning these disorders as well as TBI, we review the literature and recent studies assessing GLP-1 receptor agonists as a potential treatment strategy for mild to moderate TBI. (C) 2014 The Alzheimer's Association. All rights reserved.	[Greig, Nigel H.; Tweedie, David; Li, Yazhou; Becker, Robert E.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Schreiber, Shaul] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-69978 Tel Aviv, Israel; [Schreiber, Shaul] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Chiang, Yung-Hsiao] Taipei Med Univ Hosp, Dept Neurosurg, Taipei, Taiwan; [Chiang, Yung-Hsiao] Taipei Med Univ, Grad Inst Neural Regenerat Med, Taipei, Taiwan; [Hoffer, Barry J.; Miller, Jonathan] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA; [Lahiri, Debomoy K.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Sambamurti, Kumar] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA; [Becker, Robert E.] Aristea Translat Med, Park City, UT USA	Greig, NH (corresponding author), NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA.	greign@grc.nia.nih.gov	Sambamurti, Kumar/A-1620-2012; Schreiber, Shaul/E-5821-2010	Sambamurti, Kumar/0000-0001-9507-9214; Schreiber, Shaul/0000-0002-2189-0693	National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Michael J. Fox Foundation; Sackler School of Medicine, Tel-Aviv University; Israeli Science FoundationIsrael Science Foundation [108/09]; Alzheimer's AssociationAlzheimer's Association [IIRG 10-173-180 IIRG 10-173180, IIRG-11-206418]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG022103 R21AG046200, AG18379, AG18884, AG42804]; Lincoln Scholar Award; Taiwan NSCMinistry of Science and Technology, Taiwan [98-2321-B-038-002-MY3]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG042804, R01AG018379, R21AG046200, R01AG018884, R01AG022103, ZIAAG000333] Funding Source: NIH RePORTER	N.H.G., D.T., and Y.L. were supported by the Intramural Research Program, National Institute on Aging, National Institutes of Health, and in part by the Michael J. Fox Foundation. C.G.P., L.R., and V.R. were supported by the Sackler School of Medicine, Tel-Aviv University, and in part by a grant from the Israeli Science Foundation (108/09). K.S. received grant support from the Alzheimer's Association (IIRG 10-173-180 IIRG 10-173180) and the National Institute on Aging (AG022103 R21AG046200). D.K.L. received grant support from the National Institute on Aging (AG18379, AG18884 and AG42804) and Alzheimer's Association (IIRG-11-206418). J.M. was supported by the Lincoln Scholar Award and Y.-H.C. was supported by Taiwan NSC (98-2321-B-038-002-MY3). R.E.B. is President of Aristea Translational Medicine Corp., but has received no support in relation to this article.	Abu-Hamdah R, 2009, J CLIN ENDOCR METAB, V94, P1843, DOI 10.1210/jc.2008-1296; Alvarez E, 2005, J NEUROCHEM, V92, P798, DOI 10.1111/j.1471-4159.2004.02914.x; Alvarez E, 1996, J NEUROCHEM, V66, P920; [Anonymous], 2008, MULTINATIONAL CORPS; Aviles-Olmos I, 2013, J CLIN INVEST, V123, P2730, DOI 10.1172/JCI68295; Bak AM, 2011, EXPERT OPIN THER TAR, V15, P1153, DOI 10.1517/14728222.2011.600691; Banks WA, 2004, J PHARMACOL EXP THER, V309, P469, DOI 10.1124/jpet.103.063222; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Becker RE., 2013, NAT REV DRUG DISCOV; Becker RE, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000446; Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483; Bomfim TR, 2012, J CLIN INVEST, V122, P1339, DOI 10.1172/JCI57256; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Briyal S, 2012, BRAIN RES, V1427, P23, DOI 10.1016/j.brainres.2011.10.026; Brubaker PL, 2004, ENDOCRINOLOGY, V145, P2653, DOI 10.1210/en.2004-0015; CALVO JC, 1995, BRAIN RES BULL, V38, P435, DOI 10.1016/0361-9230(95)02010-O; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008; CAMPOS RV, 1994, ENDOCRINOLOGY, V134, P2156, DOI 10.1210/en.134.5.2156; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; CHOI DW, 1987, J NEUROSCI, V7, P357; Chong ZZ, 2005, HISTOL HISTOPATHOL, V20, P299, DOI 10.14670/HH-20.299; Chowen JA, 1999, NEUROPEPTIDES, V33, P212, DOI 10.1054/npep.1999.0757; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Cui Qi, 2004, Anatomical Science International, V79, P209, DOI 10.1111/j.1447-073x.2004.00089.x; Dailey MJ, 2013, TRENDS ENDOCRIN MET, V24, P85, DOI 10.1016/j.tem.2012.11.008; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Darsalia V, 2012, CLIN SCI, V122, P473, DOI 10.1042/CS20110374; DeOre K, 1997, J GERONTOL A-BIOL, V52, pB245, DOI 10.1093/gerona/52A.5.B245; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Doyle ME, 2005, ENDOCRINE, V27, P1, DOI 10.1385/ENDO:27:1:001; Doyle ME, 2003, REGUL PEPTIDES, V114, P153, DOI 10.1016/S0167-0115(03)00120-4; Doyle ME, 2001, ENDOCRINOLOGY, V142, P4462, DOI 10.1210/en.142.10.4462; Drucker DJ, 2013, DIABETES, V62, P3316, DOI 10.2337/db13-0822; Drucker DJ, 2011, J CLIN ENDOCR METAB, V96, P2027, DOI 10.1210/jc.2011-0599; Duarte AI, 2013, BBA-MOL BASIS DIS, V1832, P527, DOI 10.1016/j.bbadis.2013.01.008; Duckworth Josh L, 2013, Pathophysiology, V20, P23, DOI 10.1016/j.pathophys.2012.03.001; During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919; Eakin K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082016; Eakin K, 2012, J NEUROTRAUM, V29, P1180, DOI 10.1089/neu.2011.2192; ENG J, 1992, J BIOL CHEM, V267, P7402; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Gallwitz B, 2011, DRUGS, V71, P1675, DOI 10.2165/11592810-000000000-00000; Gault VA, 2008, EUR J PHARMACOL, V587, P112, DOI 10.1016/j.ejphar.2008.03.025; Gilman CP, 2003, J NEUROCHEM, V87, P1137, DOI 10.1046/j.1471-4159.2003.02073.x; GOKE R, 1993, J BIOL CHEM, V268, P19650; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greig NH, 1999, DIABETOLOGIA, V42, P45, DOI 10.1007/s001250051111; Greig NH, 2004, ANN NY ACAD SCI, V1035, P290, DOI 10.1196/annals.1332.018; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Habib AM, 2012, ENDOCRINOLOGY, V153, P3054, DOI 10.1210/en.2011-2170; Hadjiyanni I, 2010, DIABETOLOGIA, V53, P730, DOI 10.1007/s00125-009-1643-x; Hamilton A, 2009, NEUROREPORT, V20, P1161, DOI 10.1097/WNR.0b013e32832fbf14; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Han WN, 2013, NEUROBIOL AGING, V34, P576, DOI 10.1016/j.neurobiolaging.2012.04.009; Harkavyi A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-19; Harkavyi A, 2010, BRIT J PHARMACOL, V159, P495, DOI 10.1111/j.1476-5381.2009.00486.x; Heile Anna, 2011, Dialogues Clin Neurosci, V13, P279; Heile AMB, 2009, NEUROSCI LETT, V463, P176, DOI 10.1016/j.neulet.2009.07.071; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Himeno T, 2011, DIABETES, V60, P2397, DOI 10.2337/db10-1462; Holscher C, 2012, CNS DRUGS, V26, P871, DOI 10.2165/11635890-000000000-00000; Holscher C, 2010, VITAM HORM, V84, P331, DOI [10.1016/S0083-6729(10)84005-1, 10.1016/B978-0-12-381517-0.00013-8]; Holscher C, 2010, NEUROBIOL AGING, V31, P1495, DOI 10.1016/j.neurobiolaging.2008.08.023; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Hogan AE, 2011, DIABETOLOGIA, V54, P2745, DOI 10.1007/s00125-011-2232-3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holst JJ, 2011, CURR MED RES OPIN, V27, P547, DOI 10.1185/03007995.2010.549466; Hong LZ, 2010, NEUROSCI BULL, V26, P232, DOI 10.1007/s12264-010-1111-0; Hosek B, 2011, IS DEPLOYMENT IRAQ A; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Hunter K, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-33; Jolivalt CG, 2011, DIABETES OBES METAB, V13, P990, DOI 10.1111/j.1463-1326.2011.01431.x; Kastin AJ, 2003, INT J OBESITY, V27, P313, DOI 10.1038/sj.ijo.0802206; Kastin AJ, 2002, J MOL NEUROSCI, V18, P7, DOI 10.1385/JMN:18:1-2:07; Kim S, 2009, J ENDOCRINOL, V202, P431, DOI 10.1677/JOE-09-0132; Klinge PM, 2011, NEUROSCI LETT, V497, P6, DOI 10.1016/j.neulet.2011.03.092; Knippenberg S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036857; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kwon YK, 2002, J BIOCHEM MOL BIOL, V35, P87; Larsen PJ, 1997, NEUROSCIENCE, V77, P257, DOI 10.1016/S0306-4522(96)00434-4; Lazarov O, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00043; Lazarov O, 2010, TRENDS NEUROSCI, V33, P569, DOI 10.1016/j.tins.2010.09.003; Lee CH, 2011, J NEUROSCI RES, V89, P1103, DOI 10.1002/jnr.22596; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Li Y., 2000, P NATL ACAD SCI USA, V106, P1285; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Li YZ, 2003, J BIOL CHEM, V278, P471, DOI 10.1074/jbc.M209423200; Lim JG, 2010, NEUROSCI LETT, V479, P13, DOI 10.1016/j.neulet.2010.05.017; Liu WJ, 2011, BRIT J PHARMACOL, V164, P1410, DOI 10.1111/j.1476-5381.2011.01272.x; Long-Smith CM, 2013, NEUROMOL MED, V15, P102, DOI 10.1007/s12017-012-8199-5; Lovshin JA, 2009, NAT REV ENDOCRINOL, V5, P262, DOI 10.1038/nrendo.2009.48; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Markakis EA, 1999, J COMP NEUROL, V406, P449; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Martin B, 2009, DIABETES, V58, P318, DOI 10.2337/db08-0799; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; McClean PL, 2014, NEUROPHARMACOLOGY, V76, P57, DOI 10.1016/j.neuropharm.2013.08.005; McClean PL, 2011, J NEUROSCI, V31, P6587, DOI 10.1523/JNEUROSCI.0529-11.2011; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntyre RS, 2013, BEHAV BRAIN RES, V237, P164, DOI 10.1016/j.bbr.2012.09.021; Meneilly GS, 2003, DIABETES CARE, V26, P2835, DOI 10.2337/diacare.26.10.2835; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Mossello E, 2011, EXP DIABETES RES, DOI 10.1155/2011/281674; Muehlschlegel S, 2013, NEUROCRIT CARE, V18, P318, DOI 10.1007/s12028-013-9817-2; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Panjwani N, 2013, ENDOCRINOLOGY, V154, P127, DOI 10.1210/en.2012-1937; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Parthsarathy V., 2013, PLOS ONE, V8; Perry T, 2003, TRENDS PHARMACOL SCI, V24, P377, DOI 10.1016/S0165-6147(03)00160-3; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; Perry TA, 2004, CURR DRUG TARGETS, V5, P565, DOI 10.2174/1389450043345245; Perry Tracy Ann, 2005, Current Alzheimer Research, V2, P377, DOI 10.2174/1567205054367892; Perry T, 2007, EXP NEUROL, V203, P293, DOI 10.1016/j.expneurol.2006.09.028; Perry T, 2002, J ALZHEIMERS DIS, V4, P487; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Prakash A, 2008, CURR OPIN ANESTHESIO, V21, P565, DOI 10.1097/ACO.0b013e32830f44e4; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; RITZEL R, 1995, DIABETOLOGIA, V38, P720, DOI 10.1007/BF00401846; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Saykally JN, 2012, NEUROSCIENCE, V223, P305, DOI 10.1016/j.neuroscience.2012.07.070; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Smith RL, 2012, PEDIATR CRIT CARE ME, V13, P85, DOI 10.1097/PCC.0b013e3182192c30; Sun H, 2013, CELL MOL NEUROBIOL, V33, P347, DOI 10.1007/s10571-012-9900-9; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Szayna M, 2000, ENDOCRINOLOGY, V141, P1936, DOI 10.1210/en.141.6.1936; Talbot K, 2012, J CLIN INVEST, V122, P1316, DOI 10.1172/JCI59903; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Teramoto S, 2011, J CEREBR BLOOD F MET, V31, P1696, DOI 10.1038/jcbfm.2011.51; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tourrel C, 2001, DIABETES, V50, P1562, DOI 10.2337/diabetes.50.7.1562; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Urusova IA, 2004, TRENDS ENDOCRIN MET, V15, P27, DOI 10.1016/j.tem.2003.11.006; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Vivar C, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2101; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; Wang MD, 2012, NEUROSCIENCE, V226, P388, DOI 10.1016/j.neuroscience.2012.09.025; Wang XH, 2010, NEUROSCIENCE, V170, P1239, DOI 10.1016/j.neuroscience.2010.08.028; Wang X, 2013, J LABELLED COMPD RAD, V56, pS77; Wang YH, 1997, J CLIN INVEST, V99, P2883, DOI 10.1172/JCI119482; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xiong H, 2013, J ALZHEIMERS DIS, V37, P623, DOI 10.3233/JAD-130584; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yang Y, 2013, J ALZHEIMERS DIS, V37, P637, DOI 10.3233/JAD-130491; Yu JH, 2012, DIABETES METAB J, V36, P391, DOI 10.4093/dmj.2012.36.6.391; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006; Zhou J, 2002, J CELL PHYSIOL, V192, P304, DOI 10.1002/jcp.10143; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	184	49	52	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	FEB	2014	10			1			S62	S75		10.1016/j.jalz.2013.12.011			14	Clinical Neurology	Neurosciences & Neurology	CN6OW	WOS:000358555100009	24529527	Green Accepted			2021-06-18	
J	Allison, MA; Kang, YS; Bolte, JH; Maltese, MR; Arbogast, KB				Allison, Mari A.; Kang, Yun Seok; Bolte, John H.; Maltese, Matthew R.; Arbogast, Kristy B.			Validation of a Helmet-Based System to Measure Head Impact Biomechanics in Ice Hockey	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						HEAD ACCELERATION; HEAD INJURY; CONCUSSION; mTBI; SENSORS; KINEMATICS	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; ANGULAR ACCELERATION; MILD; SEVERITY; LOCATION; SOCCER	Purpose This study aimed to quantify differences between head acceleration measured by a helmet-based accelerometer system for ice hockey and an anthropometric test device (ATD) to validate the system's use in measuring on-ice head impacts. Methods A Hybrid III 50th percentile male ATD head and neck was fit with a helmet instrumented with the Head Impact Telemetry (HIT) System for hockey and impacted at various speeds and directions with different interfaces between the head and helmet. Error between the helmet-based and reference peak accelerations was quantified, and the influence of impact direction and helmet-head interface was evaluated. Regression equations were used to reduce error. System-reported impact direction was validated. Results Nineteen percent of impacts were removed from the data set by the HIT System processing algorithm and were not eligible for analysis. Errors in peak acceleration between the system and ATD varied from 18% to 31% and from 35% to 64% for linear and rotational acceleration, respectively, but were reduced via regression equations. The relationship between HIT System and reference acceleration varied by direction (P < 0.001) and head-helmet interface (P = 0.005). Errors in impact azimuth were approximately 4%, 10%, and 31% for side, back, and oblique back impacts, respectively. Conclusions This is the first comprehensive evaluation of peak head acceleration measured by the HIT System for hockey. The HIT System processing algorithm removed 19% of the impacts from the data set, the correlation between HIT System and reference peak resultant acceleration was strong and varied by head surface and impact direction, and the system error was larger than reported for the 6-degree-of-freedom HIT System for football but could be reduced via calibration factors. These findings must be considered when interpreting on-ice data.	[Allison, Mari A.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Allison, Mari A.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Kang, Yun Seok; Bolte, John H.] Ohio State Univ, Injury Biomech Res Lab, Columbus, OH 43210 USA; [Maltese, Matthew R.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Arbogast, Kristy B.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	Arbogast, KB (corresponding author), 3535 Market St,Suite 1150, Philadelphia, PA 19104 USA.	arbogast@email.chop.edu	Bolte, John/AAK-9695-2021	Arbogast, Kristy/0000-0002-1694-4562; Bolte, John/0000-0001-9894-4998			[Anonymous], 2003, C MILD TRAUM BRAIN I, P26; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Faul M., 2010, TRAUMATIC BRAIN INJU, P7; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gwin J., 2006, J BIOMECH, V39, pS153; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Mihalik JP, 2011, CLIN J SPORT MED, V21, P416, DOI 10.1097/JSM.0B013E31822C8A5C; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Reed N, 2010, INT J SPORTS MED, V31, P826, DOI 10.1055/s-0030-1263103; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stojsih S, 2010, BRIT J SPORT MED, V44, P725, DOI 10.1136/bjsm.2008.052845; USA Hockey, EQ SIZ GUID; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019	35	49	49	0	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JAN	2014	46	1					115	123		10.1249/MSS.0b013e3182a32d0d			9	Sport Sciences	Sport Sciences	AH0VT	WOS:000335839500017	23846161				2021-06-18	
J	McLean, AM; Jarus, T; Hubley, AM; Jongbloed, L				McLean, Alison M.; Jarus, Tal; Hubley, Anita M.; Jongbloed, Lyn			Associations between social participation and subjective quality of life for adults with moderate to severe traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						Community integration; leisure; participation; quality of life; social reintegration; traumatic brain injury	COMMUNITY INTEGRATION QUESTIONNAIRE; PORTLAND ADAPTABILITY INVENTORY; OCCUPATIONAL GAPS; EVERYDAY LIFE; OUTCOMES; SATISFACTION; INDIVIDUALS; HEALTH; DISABILITY; LONELINESS	Purpose: To examine the association between social participation and subjective quality of life (SQOL) for non-employed, community-dwelling adults with moderate to severe traumatic brain injury (TBI) at 1 year or greater post-injury. Method: A correlational study was conducted involving 46 participants. Social participation was measured using the Community Integration Questionnaire, Social Provisions Scale and the Adult Subjective Assessment of Participation. SQOL was measured using the Quality of Life and Health Questionnaire, Abdel-Khalek Happiness Scale and UCLA Loneliness Scale. Results: Higher levels of happiness and global quality of life were each associated with higher levels of enjoyment, satisfaction with performance and higher proportion of activities performed with others. Lower levels of loneliness were associated with higher levels of general social integration and higher levels of perceived social supports. There were no associations found between SQOL and the objective social participation measures of diversity, frequency (intensity) or proportion of activities performed outside of home. Conclusions: Findings contribute to the TBI literature in showing that it is: (a) the more subjective and not objectively measured nature of participation that is associated with SQOL and (b) positive and negative aspects of quality of life show different relationships with social participation variables.	[McLean, Alison M.] GF Strong Rehabil Ctr, Vancouver, BC, Canada; [McLean, Alison M.; Jarus, Tal; Jongbloed, Lyn] Univ British Columbia, Dept Occupat Sci & Occupat Therapy, Vancouver, BC V6T 2B5, Canada; [Hubley, Anita M.] Univ British Columbia, Dept Educ & Counselling Psychol & Special Educ, Vancouver, BC V6T 2B5, Canada	McLean, AM (corresponding author), Univ British Columbia, Dept Occupat Sci & Occupat Therapy, T-325,2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada.	almclean@mail.ubc.ca		Jarus, Tal/0000-0003-4124-7782	University of British Columbia's College of Health Disciplines Cedar Lodge Endowment Award; Frederick Banting and Charles Best Canada Graduate Scholarship Master's Award from the Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Thelma Cardwell Scholarship from the Canadian Occupational Therapy Foundation	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This study was supported by an operational grant from The University of British Columbia's College of Health Disciplines Cedar Lodge Endowment Award (awarded to the first and second authors) and the Frederick Banting and Charles Best Canada Graduate Scholarship Master's Award from the Canadian Institutes of Health Research and a Thelma Cardwell Scholarship from the Canadian Occupational Therapy Foundation (both awarded to the first author).	Abdel-Khalek AM, 2006, SOC BEHAV PERSONAL, V34, P139, DOI 10.2224/sbp.2006.34.2.139; Aggarwal A., 2010, NEUROSCI MED, V1, P39, DOI DOI 10.4236/NM.2010.12006; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 2001, ICF INTRO; Bekhet AK, 2008, NURS FORUM, V43, P207, DOI 10.1111/j.1744-6198.2008.00114.x; Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; Blake H, 2009, CLIN REHABIL, V23, P589, DOI 10.1177/0269215508101736; Braden CA, 2012, BRAIN INJURY, V26, P1315, DOI 10.3109/02699052.2012.706351; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Camfield L, 2008, J HEALTH PSYCHOL, V13, P764, DOI 10.1177/1359105308093860; Cicerone KD, 2004, J HEAD TRAUMA REHAB, V19, P494, DOI 10.1097/00001199-200411000-00006; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Cutrona CE., 1987, ADV PERSONAL RELATIO, V1, P37; Dawson DR, 2000, BRAIN COGNITION, V44, P35; DePalma J A, 2001, Crit Care Nurs Q, V23, P42; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Diener E, 1999, PSYCHOL BULL, V125, P276, DOI 10.1037//0033-2909.125.2.276; Diener E, 2002, PSYCHOL SCI, V13, P81, DOI 10.1111/1467-9280.00415; Diener E., 2006, APPL RES QUAL LIFE, V7, P397, DOI DOI 10.1007/S11482-006-9007-X; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Dolan P, 2008, J ECON PSYCHOL, V29, P94, DOI 10.1016/j.joep.2007.09.001; Dolbier CL, 2000, BEHAV MED, V25, P169, DOI 10.1080/08964280009595746; Douglas JM, 2006, BRAIN IMPAIR, V7, P107, DOI DOI 10.1375/BRIM.7.2.107; Dunn DS, 2008, REHABIL PSYCHOL, V53, P413, DOI 10.1037/a0013749; Eriksson G, 2006, J REHABIL MED, V38, P159, DOI 10.1080/16501970500415322; Eriksson G, 2009, J REHABIL MED, V41, P187, DOI 10.2340/16501977-0307; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Fischer J., 2007, MEASURES CLIN PRACTI; Fraas M, 2007, BRAIN INJURY, V21, P1267, DOI 10.1080/02699050701721794; Fraas MR, 2009, AM J SPEECH-LANG PAT, V18, P315, DOI 10.1044/1058-0360(2009/08-0008); Geurtsen GJ, 2010, J REHABIL MED, V42, P97, DOI 10.2340/16501977-0508; Grace M, 2001, FRONTAL SYSTEMS BEHA; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; HADORN DC, 1995, J CLIN EPIDEMIOL, V48, P619, DOI 10.1016/0895-4356(94)00186-T; Haggstrom A, 2008, J REHABIL MED, V40, P89, DOI 10.2340/16501977-0138; Hanks RA, 2012, ARCH PHYS MED REHAB, V93, P1297, DOI 10.1016/j.apmr.2012.04.027; Harker WF, 2002, INT J REHABIL RES, V25, P93, DOI 10.1097/00004356-200206000-00003; Heinrich LA, 2006, CLIN PSYCHOL REV, V26, P695, DOI 10.1016/j.cpr.2006.04.002; Hemmingsson H, 2005, AM J OCCUP THER, V59, P569, DOI 10.5014/ajot.59.5.569; Hoofien D, 2001, BRAIN INJURY, V15, P189; Huebner RA, 2003, AM J OCCUP THER, V57, P177, DOI 10.5014/ajot.57.2.177; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Jarus T, 2006, ISRAELI J OCCUP THER, V15, pH93; Johnson K, 1998, BEHAV MODIF, V22, P502, DOI 10.1177/01454455980224004; Johnston MV, 2006, BRAIN INJURY, V20, P391, DOI 10.1080/02699050500487795; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Jumisko Eija, 2005, J Neurosci Nurs, V37, P42; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; KUIPERS P, 1999, J COGNITIVE REHABILI, V17, P6; KUYKEN W, 1995, SOC SCI MED, V41, P1403, DOI 10.1016/0277-9536(95)00112-k; Law M, 2002, AM J OCCUP THER, V56, P640, DOI 10.5014/ajot.56.6.640; Leith KH, 2004, BRAIN INJURY, V18, P1191, DOI 10.1080/02699050410001719943; Levasseur M, 2004, DISABIL REHABIL, V26, P1206, DOI 10.1080/09638280412331270371; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malloy P, 2005, COGN BEHAV NEUROL, V18, P18, DOI 10.1097/01.wnn.0000152232.47901.88; Martelli MF, 2012, NEUROREHABILITATION, V31, P3, DOI 10.3233/NRE-2012-0770; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; McColl MA, 2007, BRAIN IMPAIR, V8, P238, DOI DOI 10.1375/BRIM.8.3.238; McLean AM, 2012, BRAIN INJURY, V26, P83, DOI 10.3109/02699052.2011.635353; Mellor D, 2008, PERS INDIV DIFFER, V45, P213, DOI 10.1016/j.paid.2008.03.020; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; Minnes P, 2001, NEUROREHABILITATION, V16, P3; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ownsworth T, 2004, NEUROPSYCHOL REHABIL, V14, P535, DOI 10.1080/09602010343000538; Pallant J., 2013, SPSS SURVIVAL MANUAL; PAVOT W, 1993, SOC INDIC RES, V28, P1, DOI 10.1007/BF01086714; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Reyes-Garcia V, 2009, HUM NATURE-INT BIOS, V20, P431, DOI 10.1007/s12110-009-9073-5; Ring L, 2007, SOC INDIC RES, V82, P443, DOI 10.1007/s11205-006-9041-y; Rochette A, 2006, DISABIL REHABIL, V28, P1231, DOI 10.1080/09638280600554827; RUSSELL D, 1978, J PERS ASSESS, V42, P290, DOI 10.1207/s15327752jpa4203_11; Russell DW, 1996, J PERS ASSESS, V66, P20, DOI 10.1207/s15327752jpa6601_2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Shrive Fiona M, 2006, BMC Med Res Methodol, V6, P57, DOI 10.1186/1471-2288-6-57; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Statistics Canada, 2008, LOW INC CUT OFFS 200; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Teasell R, 2012, INTRO METHODOLOGY EV; Thomas MD, 2009, BRAIN INJURY, V23, P516, DOI 10.1080/02699050902926333; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Vella-Brodrick DA, 2009, SOC INDIC RES, V90, P165, DOI 10.1007/s11205-008-9251-6; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Watanabe TK, 2003, ARCH PHYS MED REHAB, V84, pS23, DOI 10.1053/apmr.2003.50054; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Ylvisaker M., 1998, COLLABORATIVE BRAIN; Ylvsaker M, 2001, BRAIN INJ SOURCE, V5; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002; ZUNG WWK, 1967, ARCH GEN PSYCHIAT, V16, P543	108	49	49	1	37	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2014	36	17					1409	1418		10.3109/09638288.2013.834986			10	Rehabilitation	Rehabilitation	AN8XG	WOS:000340888500004	24059448				2021-06-18	
J	Sosa, MAG; De Gasperi, R; Janssen, PL; Yuk, FJ; Anazodo, PC; Pricop, PE; Paulino, AJ; Wicinski, B; Shaughness, MC; Maudlin-Jeronimo, E; Hall, AA; Dickstein, DL; McCarron, RM; Chavko, M; Hof, PR; Ahlers, ST; Elder, GA				Sosa, Miguel A. Gama; De Gasperi, Rita; Janssen, Pierce L.; Yuk, Frank J.; Anazodo, Pamela C.; Pricop, Paul E.; Paulino, Alejandro J.; Wicinski, Bridget; Shaughness, Michael C.; Maudlin-Jeronimo, Eric; Hall, Aaron A.; Dickstein, Dara L.; McCarron, Richard M.; Chavko, Mikulas; Hof, Patrick R.; Ahlers, Stephen T.; Elder, Gregory A.			Selective vulnerability of the cerebral vasculature to blast injury in a rat model of mild traumatic brain injury	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article						Blast; Rat; Traumatic brain injury; Vascular pathology	POSTTRAUMATIC-STRESS-DISORDER; BLOOD-VESSELS; ANEURYSMS; EXPOSURE; PARAMETERS; PRESSURE; MATRIX	Background: Blast-related traumatic brain injury (TBI) is a common cause of injury in the military operations in Iraq and Afghanistan. How the primary blast wave affects the brain is not well understood. The aim of the present study was to examine whether blast exposure affects the cerebral vasculature in a rodent model. We analyzed the brains of rats exposed to single or multiple (three) 74.5 kPa blast exposures, conditions that mimic a mild TBI. Rats were sacrificed 24 hours or between 6 and 10 months after exposure. Blast-induced cerebral vascular pathology was examined by a combination of light microscopy, immunohistochemistry, and electron microscopy. Results: We describe a selective vascular pathology that is present acutely at 24 hours after injury. The vascular pathology is found at the margins of focal shear-related injuries that, as we previously showed, typically follow the patterns of penetrating cortical vessels. However, changes in the microvasculature extend beyond the margins of such lesions. Electron microscopy revealed that microvascular pathology is found in regions of the brain with an otherwise normal neuropil. This initial injury leads to chronic changes in the microvasculature that are still evident many months after the initial blast exposure. Conclusions: These studies suggest that vascular pathology may be a central mechanism in the induction of chronic blast-related injury.	[Sosa, Miguel A. Gama] Affairs Med Ctr, James J Peters Dept Vet, Gen Med Res Serv, 130 West Kingsbridge Rd, Bronx, NY 10451 USA; [De Gasperi, Rita; Anazodo, Pamela C.; Pricop, Paul E.; Paulino, Alejandro J.] Affairs Med Ctr, James J Peters Dept Vet, Res & Dev Serv, Bronx, NY USA; [Elder, Gregory A.] Affairs Med Ctr, James J Peters Dept Vet, Neurol Serv, Bronx, NY USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Anazodo, Pamela C.; Pricop, Paul E.; Paulino, Alejandro J.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Janssen, Pierce L.; Yuk, Frank J.; Wicinski, Bridget; Dickstein, Dara L.; Hof, Patrick R.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA; [Dickstein, Dara L.; Hof, Patrick R.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Care, New York, NY 10029 USA; [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Dickstein, Dara L.; Hof, Patrick R.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [Shaughness, Michael C.; Maudlin-Jeronimo, Eric; Hall, Aaron A.; McCarron, Richard M.; Chavko, Mikulas; Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Silver Spring, MD USA	Sosa, MAG (corresponding author), Affairs Med Ctr, James J Peters Dept Vet, Gen Med Res Serv, 130 West Kingsbridge Rd, Bronx, NY 10451 USA.	miguel.gama-sosa@mssm.edu	Dickstein, Dara/AAH-6603-2020	Wicinski, Bridget/0000-0002-2972-7081	Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health AdministrationUS Department of Veterans Affairs; Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [1I01RX000179-01, 1I01RX000996-01]; General Medical Research Service; VA Medical Center; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P50 AG005138]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005138] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000996, I01RX000179] Funding Source: NIH RePORTER	We thank Dr. Virginia Lee for the gift of the rat anti-GFAP monoclonal antibody. The research described here was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1I01RX000179-01 and 1I01RX000996-01. MAGS is supported by the General Medical Research Service, James J. Peters VA Medical Center. PRH and DLD are supported in part by NIH grant P50 AG005138. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense nor the U.S. Government.	Abdul-Hussien H, 2007, AM J PATHOL, V170, P809, DOI 10.2353/ajpath.2007.060522; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Ahmed FA, 2013, ELECTROPHORESIS, V34, P2229, DOI 10.1002/elps.201300077; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Aoki T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/535921; Bauman RA, 2009, INTRO CHAR COMB CAS; Bir C, 2012, MAGN RESON IMAGING, V30, P527, DOI [10.1016/j.mri.2011.12003, DOI 10.1016/J.MRI.2011.12003]; Bochicchio GV, 2008, AM SURGEON, V74, P267; CALEY DW, 1970, J COMP NEUROL, V138, P31, DOI 10.1002/cne.901380104; CAMPAGNE MV, 1991, J HISTOCHEM CYTOCHEM, V39, P1267, DOI 10.1177/39.9.1833448; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chalouhi N, 2012, J CEREBR BLOOD F MET, V32, P1659, DOI 10.1038/jcbfm.2012.84; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; COHEN H, 1946, ARCH PATHOL, V42, P12; Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Franciosi S, 2007, J NEUROSCI METH, V163, P76, DOI 10.1016/j.jneumeth.2007.02.020; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; HASHIMOTO N, 1978, SURG NEUROL, V10, P3; HASHIMOTO N, 1980, SURG NEUROL, V13, P41; HJELLE OP, 1994, EUR J NEUROSCI, V6, P793, DOI 10.1111/j.1460-9568.1994.tb00990.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Janssen WGM, 2005, EXP NEUROL, V191, pS28, DOI 10.1016/j.expneurol.2004.08.020; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; JUCKER M, 1992, BRAIN RES, V586, P166, DOI 10.1016/0006-8993(92)91390-Z; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Lucca JJD, 2012, J NEUROL SCI, V318, P146, DOI 10.1016/j.jns.2012.02.002; Matti ED, 1986, SCAN ELECT MICROSC, V4, P1501; MORI S, 1992, HISTOCHEMISTRY, V97, P237, DOI 10.1007/BF00267633; Mott FW, 1916, LANCET, V1, P441; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Prima V, 2013, J NEUROTRAUM, V30, P1881, DOI 10.1089/neu.2012.2758; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Redzic ZB, 2004, ADV DRUG DELIV REV, V56, P1695, DOI [10.10164.addr.2004.07.005, DOI 10.1016/J.ADDR.2004.07.005]; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Skotak M, 2013, NEUROTRAUMA, V30, P1147, DOI [10.1089/neu.2012.2652, DOI 10.1089/NEU.2012.2652]; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Sosa MAG, 2010, AM J PATHOL, V176, P353, DOI 10.2353/ajpath.2010.090482; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Szabo A, 2004, NEUROPATH APPL NEURO, V30, P169, DOI 10.1046/j.0305-1846.2003.00524.x; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Valiyaveettil M, 2013, NEUROSCI LETT, V539, P1, DOI 10.1016/j.neulet.2013.01.028	57	49	49	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.		2014	2								67	10.1186/2051-5960-2-67			18	Neurosciences	Neurosciences & Neurology	V9K3A	WOS:000422389300067	24938728	DOAJ Gold, Green Published			2021-06-18	
J	Zhu, J; Qu, C; Lu, X; Zhang, S				Zhu, Jin; Qu, Chen; Lu, Xiang; Zhang, Shu			Activation of Microglia by Histamine and Substance P	CELLULAR PHYSIOLOGY AND BIOCHEMISTRY			English	Article						Microglial activation; Histamine; Substance P; CNS immune inflammation	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; MAST-CELL; INFLAMMATORY RESPONSE; DOPAMINERGIC-NEURONS; OXIDATIVE STRESS; RECEPTORS; EXPRESSION; DISEASE	Background: Activated microglia perform many of the immune effector functions typically associated with macrophages. However, the regulators involved in microglial activation are not well defined. Because microglia play a pivotal role in immune surveillance of the CNS, we studied the effect of the neuromediators histamine and substance P on microglia. Methods: The induction of microglial activation by histamine and substance P was examined using primary cultured microglia. Fluorescent images were acquired with a confocal microscope. The levels of TNF-alpha and IL-6 were measured with a commercial ELISA kit. Intracellular reactive oxygen species (ROS) levels were determined by dichlorodihydrofluorescein oxidation. The mitochondrial membrane potential was assessed with the MitoProbe (TM) JC-1 assay kit. Results: We found that the neuromediators histamine and substance P were able to stimulate microglial activation and the subsequent production of ROS and proinflammatory factors TNF-alpha and IL-6, These effects were partially abolished by antagonists of the histamine receptors H1 and H4 and of the substance P receptors NK-1, NK-2 and NK-3. Histamine induced mitochondrial membrane depolarization in microglia. Conclusions: These results indicate that the neuromediators histamine and SP can trigger microglial activation and release of pro inflammatory factors from microglia, thus contributing to the development of microglia-mediated inflammation in the brain. Copyright (C) 2014 S. Karger AG, Basel	[Zhu, Jin; Zhang, Shu] Nanjing Med Univ, Affiliated Hosp 1, Clin Res Ctr, Nanjing 210029, Jiangsu, Peoples R China; [Zhu, Jin] Nanjing Med Univ, Nanjing Affiliated Hosp 1, Dept Emergency, Nanjing 210029, Jiangsu, Peoples R China; [Qu, Chen; Lu, Xiang] Nanjing Med Univ, Affiliated Hosp 2, Dept Geriatr, Nanjing 210029, Jiangsu, Peoples R China	Zhang, S (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Clin Res Ctr, Nanjing 210029, Jiangsu, Peoples R China.	luxiang66@njmu.edu.cn; zszqs@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81102422, 81373398]; Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK2010020]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This project was sponsored the National Natural Science Foundation of China (No. 81102422, 81373398); the Natural Science Foundation of Jiangsu Province (BK2010020); and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Akdis CA, 2006, EUR J PHARMACOL, V533, P69, DOI 10.1016/j.ejphar.2005.12.044; Akundi RS, 2005, GLIA, V51, P199, DOI 10.1002/glia.20198; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; Ciallella JR, 2005, EUR J PHARMACOL, V515, P179, DOI 10.1016/j.ejphar.2005.04.016; Crivellato E, 2004, HISTOL HISTOPATHOL, V19, P259, DOI 10.14670/HH-19.259; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Donkin JJ, 2007, PROG BRAIN RES, V161, P97, DOI 10.1016/S0079-6123(06)61007-8; Ebner K, 2006, AMINO ACIDS, V31, P251, DOI 10.1007/s00726-006-0335-9; Ferreira R, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-90; Friberg H, 2002, NEUROSCI LETT, V334, P111, DOI 10.1016/S0304-3940(02)01116-3; Galient RA, 1997, PROG NEUROBIOL, V52, P379; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gao HM, 2003, TRENDS PHARMACOL SCI, V24, P395, DOI 10.1016/S0165-6147(03)00176-7; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; HARTUNG HP, 1986, J IMMUNOL, V136, P3856; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Herrera AJ, 2005, J NEURAL TRANSM, V112, P111, DOI 10.1007/s00702-004-0121-3; HOLZER P, 1995, J PHARMACOL EXP THER, V274, P322; Holzer P, 1997, PHARMACOL THERAPEUT, V73, P219, DOI 10.1016/S0163-7258(96)00196-9; Huang JF, 2008, CURR ALLERGY ASTHM R, V8, P21, DOI 10.1007/s11882-008-0005-y; Ikarashi Y, 2002, PHARMACOL BIOCHEM BE, V72, P437, DOI 10.1016/S0091-3057(02)00708-6; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; KincyCain T, 1996, J IMMUNOL, V157, P255; Lai JP, 2000, NEUROSCIENCE, V101, P1137, DOI 10.1016/S0306-4522(00)00398-5; LAURENZI MA, 1990, SCAND J IMMUNOL, V31, P529, DOI 10.1111/j.1365-3083.1990.tb02801.x; Linker RA, 2008, J NEUROIMMUNOL, V205, P64, DOI 10.1016/j.jneuroim.2008.09.007; Lotz M, 1988, SCIENC, V241, P1218; LUBERNAROD J, 1994, J IMMUNOL, V152, P819; Lund S, 2005, J NEUROCHEM, V92, P1439, DOI 10.1111/j.1471-4159.2005.03014.x; Maggi CA, 2000, REGUL PEPTIDES, V93, P53, DOI 10.1016/S0167-0115(00)00177-4; Marriott I, 2000, J IMMUNOL, V165, P182, DOI 10.4049/jimmunol.165.1.182; Marriott I, 2001, ADV EXP MED BIOL, V493, P247; Marriott I, 2001, J NEUROIMMUNOL, V114, P131, DOI 10.1016/S0165-5728(00)00466-5; Mecia L, 1999, J NEUROIMMUNOL, V93, P45; Medina MA, 1999, BIOCHEM PHARMACOL, V57, P1341, DOI 10.1016/S0006-2952(99)00005-2; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; O'Connor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Quintana A, 2009, J IMMUNOL, V183, P2079, DOI 10.4049/jimmunol.0900242; Raley A, 2004, J IMMUNOL, V172, P5707; Rasley A, 2002, GLIA, V37, P258, DOI 10.1002/glia.10034; Repka-Ramirez M Susana, 2002, Clin Allergy Immunol, V17, P1; Saligrama N, 2012, EUR J IMMUNOL, V42, P1536, DOI 10.1002/eji.201141859; Streit WJ, 2005, NEUROL RES, V27, P685, DOI 10.1179/016164105X49463; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Tiligada E, 2009, EXPERT OPIN INV DRUG, V18, P1519, DOI 10.1517/14728220903188438; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Waetzig V, 2005, GLIA, V50, P235, DOI 10.1002/glia.20173; Wei HG, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-52; Wei J, 2013, PARASITOL RES, V112, P207, DOI 10.1007/s00436-012-3127-z; Wilkinson BL, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-30; Zhang S, 2012, CELL PHYSIOL BIOCHEM, V29, P931, DOI 10.1159/000171029	54	49	51	0	13	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1015-8987	1421-9778		CELL PHYSIOL BIOCHEM	Cell. Physiol. Biochem.		2014	34	3					768	780		10.1159/000363041			13	Cell Biology; Physiology	Cell Biology; Physiology	AR7NA	WOS:000343765200015	25170632	DOAJ Gold			2021-06-18	
J	Asemota, AO; George, BP; Cumpsty-Fowler, CJ; Haider, AH; Schneider, EB				Asemota, Anthony O.; George, Benjamin P.; Cumpsty-Fowler, Carolyn J.; Haider, Adil H.; Schneider, Eric B.			Race and Insurance Disparities in Discharge to Rehabilitation for Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						disparities; epidemiology; rehabilitation; traumatic brain injury	HEALTH-CARE; RACIAL DISPARITIES; ETHNIC DISPARITIES; COGNITIVE REHABILITATION; CULTURAL COMPETENCE; LANGUAGE BARRIERS; UNITED-STATES; OUTCOMES; MODERATE; SEVERITY	Post-acute inpatient rehabilitation services are associated with improved functional outcomes among persons with traumatic brain injury (TBI). We sought to investigate racial and insurance-based disparities in access to rehabilitation. Data from the Nationwide Inpatient Sample from 2005-2010 were analyzed using standard descriptive methods and multivariable logistic regression to assess race- and insurance-based differences in access to inpatient rehabilitation after TBI, controlling for patient- and hospital-level variables. Patients with moderate to severe TBI aged 18-64 years with complete data on race and insurance status discharged alive from inpatient care were eligible for study. Among 307,675 TBI survivors meeting study criteria and potentially eligible for discharge to rehabilitation, 66% were white, 12% black, 15% Hispanic, 2% Asian, and 5% other ethnic minorities. Most whites (70%), Asians (70%), blacks (59%), and many Hispanics (49%) had insurance. Compared with insured whites, insured blacks had reduced odds of discharge to rehabilitation (odds ratio [OR] 0.84; 95% confidence interval [CI] 0.75-0.95). Also, insured Hispanics (OR 0.52; 95% CI 0.44-0.60) and insured Asians (OR 0.54; 95% CI 0.39-0.73) were less likely to be discharged to rehabilitation than insured whites. Compared with insured whites, uninsured whites (OR 0.57; 95% CI 0.51-0.63), uninsured blacks (OR 0.33; 95% CI 0.26-0.42), uninsured Hispanics (OR 0.27; 95% CI 0.22-0.33), and uninsured Asians (OR 0.40; 95% CI 0.22-0.73) were less likely to be discharged to rehabilitation. Race and insurance are strong predictors of discharge to rehabilitation among adult TBI survivors in the United States. Efforts are needed to understand and eliminate disparities in access to rehabilitation after TBI.	[Asemota, Anthony O.] Johns Hopkins Sch Med, Dept Neurol Neurosurg, Baltimore, MD USA; [Asemota, Anthony O.; George, Benjamin P.; Haider, Adil H.; Schneider, Eric B.] Johns Hopkins Univ, CSTOR, Baltimore, MD 21287 USA; [George, Benjamin P.] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Cumpsty-Fowler, Carolyn J.] Johns Hopkins Univ, Sch Nursing, Dept Community Publ Hlth, Baltimore, MD 21287 USA; [Cumpsty-Fowler, Carolyn J.] Johns Hopkins Univ, Ctr Injury Res & Policy, Baltimore, MD 21287 USA; [Cumpsty-Fowler, Carolyn J.; Haider, Adil H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Haider, Adil H.; Schneider, Eric B.] Johns Hopkins Sch Med, Dept Surg, Div Acute Care Surg & Adult Trauma, Baltimore, MD USA	Asemota, AO (corresponding author), Johns Hopkins Univ, Dept Surg, CSTOR, 600 N Wolfe St,Blalock 618, Baltimore, MD 21287 USA.	aasemota@jhsph.edu		George, Benjamin/0000-0001-9966-5632			Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; [Anonymous], 1999, JAMA, V282, P974; [Anonymous], 1997, ICDMAP 90 INJ SEV CO; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Baicker K, 2005, PERSPECT BIOL MED, V48, pS42; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Betancourt JR, 2005, HEALTH AFFAIR, V24, P499, DOI 10.1377/hlthaff.24.2.499; Blackwell M, 2009, STATA J, V9, P524, DOI 10.1177/1536867X0900900402; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Brach C, 2000, MED CARE RES REV, V57, P181, DOI 10.1177/107755800773743655; Casas-Zamora JA, 2004, AM J PUBLIC HEALTH, V94, P2055, DOI 10.2105/AJPH.94.12.2055; Chin MH, 2007, MED CARE RES REV, V64, p7S, DOI 10.1177/1077558707305413; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cryer C, 2006, INJURY PREV, V12, P67, DOI 10.1136/ip.2006.011668; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Englum BR, 2011, J AM COLL SURGEONS, V213, P699, DOI 10.1016/j.jamcollsurg.2011.08.017; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Holmes GM, 2012, HEALTH SERV RES, V47, P1158, DOI 10.1111/j.1475-6773.2011.01363.x; Ibrahim SA, 2003, AM J PUBLIC HEALTH, V93, P1619, DOI 10.2105/AJPH.93.10.1619; Jacobs E, 2006, MILBANK Q, V84, P111, DOI 10.1111/j.1468-0009.2006.00440.x; Jacobs EA, 2004, AM J PUBLIC HEALTH, V94, P866, DOI 10.2105/AJPH.94.5.866; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Mayes S D, 1989, Brain Inj, V3, P301, DOI 10.3109/02699058909029643; Millham F, 2009, WORLD J SURG, V33, P23, DOI 10.1007/s00268-008-9745-z; Nationwide Inpatient Sample, 2011, NAT INP SAMPL HEALTH; Roberts AL, 2011, PSYCHOL MED, V41, P71, DOI 10.1017/S0033291710000401; Sacks GD, 2011, J TRAUMA, V71, P1011, DOI 10.1097/TA.0b013e3182092c27; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sandhaug M, 2012, DISABIL REHABIL, V34, P904, DOI 10.3109/09638288.2011.626484; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Shen YC, 2010, AM J PUBLIC HEALTH, V100, P1462, DOI 10.2105/AJPH.2009.175828; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Timmons SD, 2011, J TRAUMA, V71, P1172, DOI 10.1097/TA.0b013e31822b0f4b; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; Wehman P, 2007, J HEAD TRAUMA REHAB, V22, P95, DOI 10.1097/01.HTR.0000265097.44683.22	49	49	49	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 15	2013	30	24					2057	2065		10.1089/neu.2013.3091			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	271QK	WOS:000328406500007	23972035	Green Published			2021-06-18	
J	Ferreira, APO; Rodrigues, FS; Della-Pace, ID; Mota, BC; Oliveira, SM; Gewehr, CDV; Bobinski, F; de Oliveira, CV; Brum, JS; Oliveira, MS; Furian, AF; de Barros, CSL; Ferreira, J; dos Santos, ARS; Fighera, MR; Royes, LFF				Oliveira Ferreira, Ana Paula; Rodrigues, Fernanda Silva; Della-Pace, Iuri Domingues; Mota, Bibiana Castagna; Oliveira, Sara Marchesan; Velho Gewehr, Camila de Campos; Bobinski, Franciane; de Oliveira, Clarissa Vasconcelos; Brum, Juliana Sperotto; Oliveira, Mauro Schneider; Furian, Ana Flavia; Lombardo de Barros, Claudio Severo; Ferreira, Juliano; Soares dos Santos, Adair Roberto; Fighera, Michele Rechia; Royes, Luiz Fernando Freire			The effect of NADPH-oxidase inhibitor apocynin on cognitive impairment induced by moderate lateral fluid percussion injury: Role of inflammatory and oxidative brain damage	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; NADPH oxidase; Apocynin; Object recognition task; Oxidative stress	OXYGEN SPECIES PRODUCTION; SPECTROPHOTOMETRIC METHOD; NA+,K+-ATPASE ACTIVITY; CELL-DEATH; ACTIVATION; ATPASE; ADAPTATION; EXPRESSION; VOLUME; STRESS	Traumatic brain injury (TBI) is a devastating disease that commonly causes persistent mental disturbances and cognitive deficits. Although studies have indicated that overproduction of free radicals, especially superoxide (O-2(-)) derived from nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is a common underlying mechanism of pathophysiology of TBI, little information is available regarding the role of apocynin, an NADPH oxidase inhibitor, in neurological consequences of TBI. Therefore, the present study evaluated the therapeutic potential of apocynin for treatment of inflammatory and oxidative damage, in addition to determining its action on neuromotor and memory impairments caused by moderate fluid percussion injury in mice (mLFPI). Statistical analysis revealed that apocynin (5 mg/kg), when injected subcutaneously (s.c.) 30 min and 24 h after injury, had no effect on neuromotor deficit and brain edema, however it provided protection against mLFPI-induced object recognition memory impairment 7 days after neuronal injury. The same treatment protected against mLFPI-induced IL-1 beta, TNF-alpha, nitric oxide metabolite content (NOx) 3 and 24 h after neuronal injury. Moreover, apocynin treatment reduced oxidative damage (protein carbonyl, lipoperoxidation) and was effective against mLFPI-induced Na+,K+-ATPase activity inhibition. The present results were accompanied by effective reduction in lesion volume when analyzed 7 days after neuronal injury. These data suggest that superoxide (O-2(-)) derived from NADPH oxidase can contribute significantly to cognitive impairment, and that the post injury treatment with specific NADPH oxidase inhibitors, such as apocynin, may provide a new therapeutic approach to the control of neurological disabilities induced by TBI. (C) 2013 Published by Elsevier Ltd.	[Oliveira Ferreira, Ana Paula; Rodrigues, Fernanda Silva; Della-Pace, Iuri Domingues; Mota, Bibiana Castagna; Fighera, Michele Rechia; Royes, Luiz Fernando Freire] Univ Fed Santa Maria, Ctr Educ Fis & Desportos, Dept Metodos & Tecn Desport, Lab Bioquim Exercicio, BR-97105900 Santa Maria, RS, Brazil; [Oliveira Ferreira, Ana Paula; Rodrigues, Fernanda Silva; Della-Pace, Iuri Domingues; Mota, Bibiana Castagna; Oliveira, Sara Marchesan; Velho Gewehr, Camila de Campos; Ferreira, Juliano; Fighera, Michele Rechia; Royes, Luiz Fernando Freire] Univ Fed Santa Maria, Programa Posgrad Ciencias Biol Bioquim Toxicol, BR-97105900 Santa Maria, RS, Brazil; [Bobinski, Franciane; Soares dos Santos, Adair Roberto] Univ Fed Santa Maria, Ctr Ciencias Biol, Dept Ciencias Fisiol, BR-97105900 Santa Maria, RS, Brazil; [de Oliveira, Clarissa Vasconcelos; Oliveira, Mauro Schneider] Univ Fed Santa Maria, Ctr Ciencias Saude, Dept Fisiol & Farmacol, BR-97105900 Santa Maria, RS, Brazil; [Brum, Juliana Sperotto; Lombardo de Barros, Claudio Severo] Univ Fed Santa Maria, Ctr Ciencias Rurais, Dept Patol, BR-97105900 Santa Maria, RS, Brazil; [Furian, Ana Flavia] Univ Fed Santa Maria, Ctr Ciencias Saude, Dept Ciencia & Tecnol Alimentos, BR-97105900 Santa Maria, RS, Brazil; [Fighera, Michele Rechia] Univ Fed Santa Maria, Ctr Ciencias Saude, Dept Neuropsiquiatria, BR-97105900 Santa Maria, RS, Brazil	Royes, LFF (corresponding author), Univ Fed Santa Maria, Ctr Educ Fis & Desportos, Dept Metodos & Tecn Desport, BR-97105900 Santa Maria, RS, Brazil.	nandoroyes@yahoo.com.br	Ferreira, Juliano/A-9803-2013; Bobinski, Franciane/AAV-8234-2020; Fighera, Michele R/J-9576-2014; royes, luiz/T-3581-2019; Oliveira, Mauro Schneider/G-3437-2012; Santos, Adair/C-5565-2013	Ferreira, Juliano/0000-0002-9562-0602; Bobinski, Franciane/0000-0002-3537-1712; Oliveira, Mauro Schneider/0000-0002-5381-1208; Santos, Adair/0000-0002-6435-4698; royes, luiz/0000-0003-4045-4827; oliveira, sara/0000-0003-2960-5284	Conselho Nacional de Desenvolvimento Cientifico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior (CAPES) (Brazil)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [301552/2007-0]; CNPq/FAPERGSConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS) [11/2082-4]	The present study was supported by Conselho Nacional de Desenvolvimento Cientifico (CNPq) and by Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior (CAPES) (Brazil). Ferreira J. is the recipient of CNPq fellowships, Grant numbers 301552/2007-0. Royes L.F.F. is recipient of CNPq/FAPERGS fellowships, Grant numbers 11/2082-4. The funding sources were not involved in the study design, data collection, and analysis, interpretation of data and in the writing of the report.	Arun P., 2013, J NEUROTRAUMA; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Chen H, 2011, NEUROBIOL DIS, V42, P341, DOI 10.1016/j.nbd.2011.01.027; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Dalle-Donne I, 2006, J CELL MOL MED, V10, P389, DOI 10.1111/j.1582-4934.2006.tb00407.x; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Dean RT, 1997, BIOCHEM J, V324, P1; Dobrota D, 1999, CELL MOL NEUROBIOL, V19, P141, DOI 10.1023/A:1006909927287; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hayashi T, 2005, DIABETES OBES METAB, V7, P334, DOI 10.1111/j.1463-1326.2004.00393.x; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Infanger DW, 2006, ANTIOXID REDOX SIGN, V8, P1583, DOI 10.1089/ars.2006.8.1583; Jackman KA, 2009, BRIT J PHARMACOL, V156, P680, DOI 10.1111/j.1476-5381.2008.00073.x; Jamme I, 1995, NEUROREPORT, V7, P333; Jinnouchi Y, 2007, BRAIN RES, V1167, P92, DOI 10.1016/j.brainres.2007.04.088; Kahles T, 2012, CELL MOL LIFE SCI, V69, P2345, DOI 10.1007/s00018-012-1011-8; Komada M, 2008, J VIS EXP; Lambert AJ, 2009, METHODS MOL BIOL, V554, P165, DOI 10.1007/978-1-59745-521-3_11; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; Lima FD, 2009, BRAIN RES, V1279, P147, DOI 10.1016/j.brainres.2009.04.052; Liu SM, 2007, CAN J NEUROL SCI, V34, P356, DOI 10.1017/S031716710000682X; Lo W, 2007, NEUROSCI LETT, V414, P228, DOI 10.1016/j.neulet.2006.12.055; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Mander PK, 2006, J IMMUNOL, V176, P1046, DOI 10.4049/jimmunol.176.2.1046; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Morel P, 1998, NEUROCHEM INT, V33, P531, DOI 10.1016/S0197-0186(98)00062-X; Mota BC, 2012, NEUROTOX RES, V21, P175, DOI 10.1007/s12640-011-9257-8; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Oliveira MS, 2004, NEUROSCIENCE, V128, P721, DOI 10.1016/j.neuroscience.2004.07.012; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Romano CC, 2004, INT IMMUNOPHARMACOL, V4, P1067, DOI 10.1016/j.intimp.2004.04.013; Silva L.F., 2013, J NEUROTRAUMA; Singh P, 2003, NEUROL INDIA, V51, P215; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Song S.X., 2012, MOL MED REP; Souza MA, 2009, EPILEPSIA, V50, P811, DOI 10.1111/j.1528-1167.2008.01908.x; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Tang JP, 2005, J NEUROCHEM, V94, P1342, DOI 10.1111/j.1471-4159.2005.03292.x; Tang XN, 2008, NEUROSCIENCE, V154, P556, DOI 10.1016/j.neuroscience.2008.03.090; Toklu HZ, 2009, FREE RADICAL RES, V43, P658, DOI 10.1080/10715760902988843; Van den Worm E, 2001, EUR J PHARMACOL, V433, P225, DOI 10.1016/S0014-2999(01)01516-3; Wu F, 2008, J CELL PHYSIOL, V217, P207, DOI 10.1002/jcp.21495; YAN LJ, 1995, ANAL BIOCHEM, V228, P349, DOI 10.1006/abio.1995.1362; Yang CS, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-27; Zhan H, 2004, NEUROL RES, V26, P35, DOI 10.1179/016164104773026507; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	59	49	50	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	NOV	2013	63	6					583	593		10.1016/j.neuint.2013.09.012			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	255IJ	WOS:000327232300007	24076474				2021-06-18	
J	Klemenhagen, KC; O'Brien, SP; Brody, DL				Klemenhagen, Kristen C.; O'Brien, Scott P.; Brody, David L.			Repetitive Concussive Traumatic Brain Injury Interacts with Post-Injury Foot Shock Stress to Worsen Social and Depression-Like Behavior in Mice	PLOS ONE			English	Article							TAIL-SUSPENSION TEST; ANTIDEPRESSANT ACTIVITY; RECURRENT CONCUSSION; DISORDER; MODEL; OXYTOCIN; MOUSE; RISK; RECOGNITION; EXPRESSION	The debilitating effects of repetitive concussive traumatic brain injury (rcTBI) have been increasingly recognized in both military and civilian populations. rcTBI may result in significant neurological, cognitive, and affective sequelae, and is often followed by physical and/or psychological post-injury stressors that may exacerbate the effects of the injury and prolong the recovery period for injured patients. However, the consequences of post-injury stressors and their subsequent effects on social and emotional behavior in the context of rcTBI have been relatively little studied in animal models. Here, we use a mouse model of rcTBI with two closed-skull blunt impacts 24 hours apart and social and emotional behavior testing to examine the consequences of a stressor (foot shock fear conditioning) following brain injury (rcTBI). rcTBI alone did not affect cued or contextual fear conditioning or extinction compared to uninjured sham animals. In the sucrose preference test, rcTBI animals had decreased preference for sucrose, an anhedonia-like behavior, regardless of whether they experienced foot shock stress or were non-shocked controls. However, rcTBI and post-injury foot shock stress had synergistic effects in tests of social recognition and depression-like behavior. In the social recognition test, animals with both injury and shock were more impaired than either nonshocked injured mice or shocked but uninjured mice. In the tail suspension test, injured mice had increased depression-like behavior compared with uninjured mice, and shock stress worsened the depression-like behavior only in the injured mice with no effect in the uninjured mice. These results provide a model of subtle emotional behavioral deficits after combined concussive brain injury and stress, and may provide a platform for testing treatment and prevention strategies for social behavior deficits and mood disorders that are tailored to patients with traumatic brain injury.	[Klemenhagen, Kristen C.; O'Brien, Scott P.; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Brody, David L.] Hope Ctr Neurol Disorders, St Louis, MO USA	Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS065069]; Department of DefenseUnited States Department of Defense; Health South Research; Alafi Neuroimaging Laboratory; Hope Center for Neurological Disorders; NIH Neuroscience Blueprint Center CoreUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 NS057105]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065069, P30NS057105] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) R01-NS065069, The Department of Defense, and a Health South Research Grant to DLB. This work was also supported by the Alafi Neuroimaging Laboratory, the Hope Center for Neurological Disorders, and NIH Neuroscience Blueprint Center Core Grant P30 NS057105 to Washington University. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Apfelbach R, 2005, NEUROSCI BIOBEHAV R, V29, P1123, DOI 10.1016/j.neubiorev.2005.05.005; Bielsky IF, 2004, NEUROPSYCHOPHARMACOL, V29, P483, DOI 10.1038/sj.npp.1300360; Boscarino JA, 2012, J NERV MENT DIS, V200, P740, DOI 10.1097/NMD.0b013e318266b5ea; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2011, DEPRESS ANXIETY, V28, P802, DOI 10.1002/da.20737; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Buynitsky T, 2009, NEUROSCI BIOBEHAV R, V33, P1089, DOI 10.1016/j.neubiorev.2009.05.004; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cholfin JA, 2007, P NATL ACAD SCI USA, V104, P7652, DOI 10.1073/pnas.0702225104; Compton RJ, 2008, EMOTION, V8, P684, DOI 10.1037/a0012910; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Couch Y, 2013, BRAIN BEHAV IMMUN, V29, P136, DOI 10.1016/j.bbi.2012.12.017; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; Davies RC, 2012, J HEAD TRAUMA REHAB, V27, pE21, DOI 10.1097/HTR.0b013e31825360da; de Sousa A, 2011, CORTEX, V47, P526, DOI 10.1016/j.cortex.2010.02.004; DENNIS M, 2012, J INT NEUROPSYCH SOC, V19, P1; Ducottet C, 2004, BEHAV BRAIN RES, V155, P291, DOI 10.1016/j.bbr.2004.04.020; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040; Fourtassi M, 2011, CLIN NEUROL NEUROSUR, V113, P716, DOI 10.1016/j.clineuro.2011.07.010; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Karelina K, 2011, PSYCHOSOM MED, V73, P67, DOI 10.1097/PSY.0b013e3182002116; Kavaliers M, 2004, GENES BRAIN BEHAV, V3, P189, DOI 10.1111/j.1601-183x.2004.00068.x; Kennedy CH, 2012, ARCH CLIN NEUROPSYCH, V27, P817, DOI 10.1093/arclin/acs092; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kercmar J, 2011, BEHAV BRAIN RES, V216, P647, DOI 10.1016/j.bbr.2010.09.007; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; KLEMENHAGEN KC, 2013, DRYAD DIGITAL REPOSI, DOI DOI 10.5061/DRYADV1T54; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lad HV, 2007, MAMM GENOME, V18, P482, DOI 10.1007/s00335-007-9029-1; Litvin Y, 2011, PHYSIOL BEHAV, V103, P393, DOI 10.1016/j.physbeh.2011.03.007; Liu XQ, 2003, BRAIN RES BULL, V60, P223, DOI 10.1016/S0361-9230(03)00033-9; MacPherson P, 2008, BRAIN RES, V1210, P179, DOI 10.1016/j.brainres.2008.03.008; Martin AL, 2010, BEHAV BRAIN RES, V207, P196, DOI 10.1016/j.bbr.2009.10.006; Mayorga AJ, 2001, PSYCHOPHARMACOLOGY, V155, P110, DOI 10.1007/s002130100687; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; National Research Council (NRC), 2011, GUIDE CARE USE LAB A; O'Leary OF, 2009, NEUROMETHODS, V42, P119, DOI 10.1007/978-1-60761-303-9_7; Pietropaolo S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019965; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; Reboussin DM, 2000, CONTROL CLIN TRIALS, V21, P190, DOI 10.1016/S0197-2456(00)00057-X; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Savignac HM, 2011, NEUROSCIENCE, V192, P524, DOI 10.1016/j.neuroscience.2011.04.054; Scearce-Levie K, 2008, GENES BRAIN BEHAV, V7, P344, DOI 10.1111/j.1601-183X.2007.00357.x; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Skopp Nancy A, 2012, MSMR, V19, P7; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; Strekalova T, 2010, PROG NEURO-PSYCHOPH, V34, P348, DOI 10.1016/j.pnpbp.2009.12.014; Symington SH, 2010, SOC NEUROSCI-UK, V5, P296, DOI 10.1080/17470910903462419; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Walker AK, 2013, NEUROPSYCHOPHARMACOL, V38, P1609, DOI 10.1038/npp.2013.71; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	64	49	49	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2013	8	9							e74510	10.1371/journal.pone.0074510			15	Multidisciplinary Sciences	Science & Technology - Other Topics	221YD	WOS:000324695900052	24058581	DOAJ Gold, Green Published			2021-06-18	
J	Monaco, CM; Mattiola, VV; Folweiler, KA; Tay, JK; Yelleswarapu, NK; Curatolo, LM; Matter, AM; Cheng, JP; Kline, AE				Monaco, Christina M.; Mattiola, Vincent V.; Folweiler, Kaitlin A.; Tay, Justin K.; Yelleswarapu, Narayana K.; Curatolo, Lauren M.; Matter, Ashley M.; Cheng, Jeffrey P.; Kline, Anthony E.			Environmental enrichment promotes robust functional and histological benefits in female rats after controlled cortical impact injury	EXPERIMENTAL NEUROLOGY			English	Article						Behavior; Controlled cortical impact; Environmental enrichment; Functional recovery; Learning and memory; Morris water maze; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; RECEPTOR AGONIST 8-OH-DPAT; COGNITIVE DEFICITS; SPATIAL MEMORY; NEUROBEHAVIORAL BENEFIT; SYNAPTOPHYSIN LEVELS; NEUROTROPHIC FACTOR; HYPOXIA-ISCHEMIA; CONTUSION INJURY; CLINICAL-TRIALS	Environmental enrichment (EE) consistently induces marked benefits in male rats after traumatic brain injury (TBI), but whether similar efficacy extends to females is not well established. Hence, the aim of this study was to reassess the effect of EE on functional and histological outcome in female rats after brain trauma. Twenty-four normal cycling adult female rats underwent verification of estrous stage prior to controlled cortical impact (CCI) or sham injury and then were assigned to EE or standard (STD) housing. Motor function was assessed with beam-balance/beam-walk and rotarod tasks on post-operative days 1-5 and every other day from 1-19, respectively. Spatial learning/memory was evaluated in a Morris water maze on days 14-19. Morphologically intact hippocampal CA(1/3) cells and cortical lesion volume were quantified 3 weeks after injury. No differences were observed between the EE and STD sham groups in any endpoint measure and thus the data were pooled. In the TBI groups, EE improved beam-balance, beam-walk, rotarod, and spatial learning performance vs. STD (p's<0.05). EE also provided significant histological protection as confirmed by increased CA(1/3) cell survival and decreased cortical lesion size vs. STD. These data demonstrate that EE confers robust benefits in female rats after CCI injury, which parallels numerous studies in males and lends further credence for EE as a preclinical model of neurorehabilitation. (C) 2013 Elsevier Inc. All rights reserved.	[Monaco, Christina M.; Mattiola, Vincent V.; Folweiler, Kaitlin A.; Tay, Justin K.; Yelleswarapu, Narayana K.; Curatolo, Lauren M.; Matter, Ashley M.; Cheng, Jeffrey P.; Kline, Anthony E.] Univ Pittsburgh, Pittsburgh, PA 15213 USA; [Mattiola, Vincent V.; Folweiler, Kaitlin A.; Tay, Justin K.; Yelleswarapu, Narayana K.; Curatolo, Lauren M.; Matter, Ashley M.; Cheng, Jeffrey P.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Pittsburgh, PA 15213 USA	Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS060005, HD069620]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	Supported, in part, by NIH grants NS060005 and HD069620 (AEK)	BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; Frick KM, 2003, LEARN MEMORY, V10, P187, DOI 10.1101/lm.50703; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Garcia AN, 2011, PM&R, V3, pS18, DOI 10.1016/j.pmrj.2011.03.017; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gomez-Pinilla F, 2011, EUR J NEUROSCI, V33, P383, DOI 10.1111/j.1460-9568.2010.07508.x; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2012, J NEUROTRAUM, V29, P1960, DOI 10.1089/neu.2012.2385; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; Lambert TJ, 2005, NEUROBIOL LEARN MEM, V83, P206, DOI 10.1016/j.nlm.2004.12.001; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Martinez-Cue C, 2002, BEHAV BRAIN RES, V134, P185, DOI 10.1016/S0166-4328(02)00026-8; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Olsen AS, 2012, J NEUROTRAUM, V29, P1898, DOI 10.1089/neu.2012.2358; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Pereira LO, 2008, BRAIN RES, V1218, P257, DOI 10.1016/j.brainres.2008.04.010; Pereira LO, 2009, BRAIN RES, V1247, P188, DOI 10.1016/j.brainres.2008.10.017; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROSE FD, 1987, BEHAV BRAIN RES, V24, P195, DOI 10.1016/0166-4328(87)90057-X; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Yelleswarapu NK, 2012, NEUROSCI LETT, V515, P153, DOI 10.1016/j.neulet.2012.03.033	58	49	50	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	2013	247						410	418		10.1016/j.expneurol.2013.01.007			9	Neurosciences	Neurosciences & Neurology	204VO	WOS:000323399600050	23333563	Green Accepted			2021-06-18	
J	Anderson, V; Beauchamp, MH; Yeates, KO; Crossley, L; Hearps, SJC; Catroppa, C				Anderson, Vicki; Beauchamp, Miriam H.; Yeates, Keith Owen; Crossley, Louise; Hearps, Stephen J. C.; Catroppa, Cathy			Social Competence at 6 Months Following Childhood Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Brain injury; Children; Recovery; Social skills; Behavior; Environment	PROBLEM-SOLVING SKILLS; CLOSED-HEAD-INJURY; SELF-REGULATION; CHILDREN; ADJUSTMENT; OUTCOMES; RECOVERY; ADOLESCENTS; FRIENDSHIP; TERM	Children with traumatic brain injury (TBI) are at risk for social impairment. This study aimed to examine social function at 6 months post-TBI and to explore the contribution of injury, cognitive, and environmental influences. The sample included 136 children, 93 survivors of TBI, and 43 healthy controls. TBI participants were recruited on admission and underwent magnetic resonance imaging scan within 8 weeks of injury and behavioral assessment at 6 months post-injury. Healthy controls underwent magnetic resonance imaging scans and behavioral assessment on recruitment. Assessment included parent and child questionnaires tapping social outcome and child-direct testing of cognitive abilities important for social competence (communication, attention/executive function, social cognition). Injury characteristics and environmental measures were collected. At 6-months post-injury, social problems were evident, but not global. Social participation appeared most vulnerable, with more severe injuries leading to greater problems. Greater injury severity and poorer communication skills were associated with poorer social adjustment and social participation, with the impact of family function also significant. Processing speed, younger age, and male gender also contributed to social outcomes. Further follow-up is required to track the recovery of social skills and the changing influences of cognition, brain, and environment over time.	[Anderson, Vicki; Beauchamp, Miriam H.; Crossley, Louise; Hearps, Stephen J. C.; Catroppa, Cathy] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy] Royal Childrens Hosp, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy] Univ Melbourne, Melbourne, Vic 3010, Australia; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.] St Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwides Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA	Anderson, V (corresponding author), Murdoch Childrens Res Inst, 4 West,Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Hearps, Stephen/L-6853-2016; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	Victorian Government Operational Infrastructure Scheme; Victorian Neurotrauma Initiative	The Victorian Neurotrauma Initiative funded this research, and it was also supported by the Victorian Government Operational Infrastructure Scheme. The authors declare no conflicts of interest.	Ackerman BP, 2006, ADV CHILD DEV BEHAV, V34, P91, DOI 10.1016/S0065-2407(06)80005-4; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Anaby D, 2012, DEV MED CHILD NEUROL, V54, P339, DOI 10.1111/j.1469-8749.2011.04204.x; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bedell G, 2008, J HEAD TRAUMA REHAB, V23, P341, DOI 10.1097/01.HTR.0000336850.29574.7a; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; Belsky J, 2011, J CHILD PSYCHOL PSYC, V52, P409, DOI 10.1111/j.1469-7610.2010.02281.x; Blakemore SJ, 2010, NEURON, V65, P744, DOI 10.1016/j.neuron.2010.03.004; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Bos KJ, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.016.2009; Bowker JC, 2010, J APPL DEV PSYCHOL, V31, P231, DOI 10.1016/j.appdev.2010.01.001; Bowker JC, 2007, EUR J DEV PSYCHOL, V4, P1, DOI 10.1080/17405620701632069; Bowlby J., 1962, DEPRIVATION MATERNAL; Bulotsky-Shearer RJ, 2008, DEV PSYCHOL, V44, P139, DOI 10.1037/0012-1649.44.1.139; Burgess KB, 2006, CHILD DEV, V77, P371, DOI 10.1111/j.1467-8624.2006.00876.x; Burnett S., 2012, DEV SOCIAL NEUROSCIE, P45; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; CAVELL TA, 1990, J CLIN CHILD PSYCHOL, V19, P111, DOI 10.1207/s15374424jccp1902_2; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; COFFEY CE, 1991, PSYCHOPATHOLOGY BRAI; CRICK NR, 1994, PSYCHOL BULL, V115, P74, DOI 10.1037/0033-2909.115.1.74; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M, 2000, AUTISM, V4, P370, DOI DOI 10.1177/1362361300004004003; DENNIS M, 2012, J INT NEUROPSYCH SOC, V19, P1; Dennis M., 2012, J INT NEUROPSYCH SOC, V18, P1; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; Dwyer KM, 2010, J SOC PERS RELAT, V27, P91, DOI 10.1177/0265407509346420; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Frith CD, 2012, ANNU REV PSYCHOL, V63, P287, DOI 10.1146/annurev-psych-120710-100449; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; Ganesalingam K, 2007, J NEUROPSYCHOL, V1, P149, DOI 10.1348/174866407X185300; Greenham M, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00022; Hanten G., 2008, NEUROIMAGE, V31, P429; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Jackson C, 2007, OCCUP MED-OXFORD, V57, P79, DOI 10.1093/occmed/kql169; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Manly T., 1999, TEA CH TEST EVERYDAY; Masten AS, 1999, DEV PSYCHOPATHOL, V11, P143, DOI 10.1017/S0954579499001996; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Parker J. G., 1989, FRIENDSHIP QUALITY Q; Poggi G, 2005, BRAIN INJURY, V19, P777, DOI 10.1080/0269905500110132; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Sullivan MC, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/657923; Tabachnick B.G., 2000, USING MULTIVARIATE S, V4th; TEASDALE G, 1974, LANCET, V2, P81; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turkstra LS, 2008, NEUROREHABILITATION, V23, P501; UCLA: Academic Technology Services, 2012, STAT DAT AN EX TOB A; Van Overwalle F, 2009, HUM BRAIN MAPP, V30, P829, DOI 10.1002/hbm.20547; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Warschausky S, 1997, Pediatr Rehabil, V1, P77; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D, 1999, WASI WECHSLER ABBREV; Wigg E. H., 1989, TEST LANGUAGE COMPET; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	74	49	50	0	28	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2013	19	5					539	550		10.1017/S1355617712001543			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	136OB	WOS:000318370100006	23552444				2021-06-18	
J	Mehta, SP; Bhananker, SM; Posner, KL; Domino, KB				Mehta, Sonya P.; Bhananker, Sanjay M.; Posner, Karen L.; Domino, Karen B.			Operating Room Fires A Closed Claims Analysis	ANESTHESIOLOGY			English	Article							OPTIMIZING SAFETY; FACIAL SURGERY; AIRWAY FIRE; ANESTHESIA; ELECTROCAUTERY; OXYGEN; TRACHEOSTOMY; PREVENTION; LIABILITY; IGNITION	Background: To assess patterns of injury and liability associated with operating room (OR) fires, closed malpractice claims in the American Society of Anesthesiologists Closed Claims Database since 1985 were reviewed. Methods: All claims related to fires in the OR were compared with nonfire-related surgical anesthesia claims. An analysis of fire-related claims was performed to identify causative factors. Results: There were 103 OR fire claims (1.9% of 5,297 surgical claims). Electrocautery was the ignition source in 90% of fire claims. OR fire claims more frequently involved older outpatients compared with other surgical anesthesia claims (P < 0.01). Payments to patients were more often made in fire claims (P < 0.01), but payment amounts were lower (median $120,166) compared to nonfire surgical claims (median $250,000, P < 0.01). Electrocautery-induced fires (n = 93) increased over time (P < 0.01) to 4.4% claims between 2000 and 2009. Most (85%) electrocautery fires occurred during head, neck, or upper chest procedures (high-fire-risk procedures). Oxygen served as the oxidizer in 95% of electrocautery-induced OR fires (84% with open delivery system). Most electrocautery-induced fires (n = 75, 81%) occurred during monitored anesthesia care. Oxygen was administered via an open delivery system in all high-risk procedures during monitored anesthesia care. In contrast, alcohol-containing prep solutions and volatile compounds were present in only 15% of OR fires during monitored anesthesia care. Conclusions: Electrocautery-induced fires during monitored anesthesia care were the most common cause of OR fires claims. Recognition of the fire triad (oxidizer, fuel, and ignition source), particularly the critical role of supplemental oxygen by an open delivery system during use of the electrocautery, is crucial to prevent OR fires. Continuing education and communication among OR personnel along with fire prevention protocols in high-fire-risk procedures may reduce the occurrence of OR fires.	[Mehta, Sonya P.; Bhananker, Sanjay M.; Posner, Karen L.; Domino, Karen B.] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA USA	Domino, KB (corresponding author), Dept Anesthesiol & Pain Med, Box 356540,1959 NE Pacific St, Seattle, WA 98195 USA.	kdomino@uw.edu			American Society of Anesthesiologists (ASA), Park Ridge, Illinois	Supported by the American Society of Anesthesiologists (ASA), Park Ridge, Illinois. All opinions expressed are those of the authors and do not reflect the policy of the ASA.	ALY A, 1991, ANN OTO RHINOL LARYN, V100, P31, DOI 10.1177/000348949110000105; BAILEY MK, 1990, ANESTH ANALG, V71, P702; Barker SJ, 2001, ANESTH ANALG, V93, P960, DOI 10.1097/00000539-200110000-00031; Barnes A M, 2000, AANA J, V68, P153; Bhananker SM, 2006, ANESTHESIOLOGY, V104, P228, DOI 10.1097/00000542-200602000-00005; BOYD CH, 1969, ANAESTHESIA, V24, P441, DOI 10.1111/j.1365-2044.1969.tb02883.x; Caplan RA, 2008, ANESTHESIOLOGY, V108, P786; Chee WK, 1998, ANESTHESIOLOGY, V89, P1576, DOI 10.1097/00000542-199812000-00040; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; Dini GM, 2006, PLAST RECONSTR SURG, V117, P325, DOI 10.1097/01.prs.0000196235.01758.f6; ECRI Institute, 2009, HLTH DEVICES, V328, P314; Engel SJ, 2012, PLAST RECONSTR SURG, V130, P681, DOI 10.1097/PRS.0b013e31825dc14a; Goldberg Jessica, 2006, AANA J, V74, P352; GRECO RJ, 1995, PLAST RECONSTR SURG, V95, P978, DOI 10.1097/00006534-199505000-00004; Greene BA, 1941, ANESTHESIOLOGY, V2, P141; Greene BA., 1942, SURG GYNECOL OBSTET, V74, P895; Howard BK, 1997, ANN OTO RHINOL LARYN, V106, P248, DOI 10.1177/000348949710600313; Kaddoum RN, 2006, J CLIN ANESTH, V18, P129, DOI 10.1016/j.jclinane.2005.09.032; Lampotang S, 2005, ANESTH ANALG, V101, P1407, DOI 10.1213/01.ANE.0000180215.50589.02; Le Clair J, 1990, AANA J, V58, P259; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; Meneghetti SC, 2007, PLAST RECONSTR SURG, V120, P1701, DOI 10.1097/01.prs.0000282729.23202.da; Orhan-Sungur M, 2009, ANAESTHESIA, V64, P521, DOI 10.1111/j.1365-2044.2008.05820.x; POSNER KL, 1990, STAT MED, V9, P1103, DOI 10.1002/sim.4780090917; Roy S, 2011, INT J PEDIATR OTORHI, V75, P227, DOI 10.1016/j.ijporl.2010.11.005; SIMPSON JI, 1986, ANESTHESIOLOGY, V65, P76, DOI 10.1097/00000542-198607000-00012; Smith LP, 2011, AM J OTOLARYNG, V32, P109, DOI 10.1016/j.amjoto.2009.11.004; Stoelting RK., 2012, APSF NEWSLETTER, V26, P41; Wolf GL, 2004, ANESTHESIOLOGY, V100, P1167, DOI 10.1097/00000542-200405000-00019	29	49	51	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAY	2013	118	5					1133	1139		10.1097/ALN.0b013e31828afa7b			7	Anesthesiology	Anesthesiology	131BA	WOS:000317964300019	23422795				2021-06-18	
J	Nakase-Richardson, R; Sherer, M; Barnett, SD; Yablon, SA; Evans, CC; Kretzmer, T; Schwartz, DJ; Modarres, M				Nakase-Richardson, Risa; Sherer, Mark; Barnett, Scott D.; Yablon, Stuart A.; Evans, Clea C.; Kretzmer, Tracy; Schwartz, Daniel J.; Modarres, Mo			Prospective Evaluation of the Nature, Course, and Impact of Acute Sleep Abnormality After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Delirium; Length of stay; Outcome assessment (health care); Rehabilitation; Sleep	CLOSED-HEAD INJURY; POSTTRAUMATIC AMNESIA; ISCHEMIC-STROKE; ACUTE CONFUSION; WAKE DISTURBANCES; DEPRIVATION; MEMORY; REHABILITATION; INSOMNIA; COGNITION	Objective: To prospectively characterize the prevalence, course, and impact of acute sleep abnormality among traumatic brain injury (TBI) neurorehabilitation admissions. Design: Prospective observational study. Setting: Freestanding rehabilitation hospital. Participants: Primarily severe TBI (median emergency department Glasgow Coma Scale [GCS] score =7; N=205) patients who were mostly men (71%) and white (68%) were evaluated during acute neurorehabilitation. Interventions: None. Main Outcome Measure: Delirium Rating Scale-Revised-98 (DelRS-R98) was administered weekly throughout rehabilitation hospitalization. De1RS-R98 item 1 was used to classify severity of sleep-wake cycle disturbance (SWCD) as none, mild, moderate, or severe. SWCD ratings were analyzed both serially and at 1 month postinjury. Results: For the entire sample, 66% (mild to severe) had SWCD at 1 month postinjury. The course of the SWCD using a subset (n=152) revealed that 84% had SWCD on rehabilitation admission, with 63% having moderate to severe ratings (median, 24d postinjury). By the third serial exam (median, 35d postinjury), 59% remained with SWCD, and 28% had moderate to severe ratings. Using general linear modeling and adjusting for age, emergency department GCS score, and days postinjury, presence of moderate to severe SWCD at 1 month postinjury made significant contributions in predicting duration of posttraumatic amnesia (P<.01) and rehabilitation hospital length of stay (P<.01). Conclusions: Results suggest that sleep abnormalities after TBI are prevalent and decrease over time. However, a high percent remained with SWCD throughout the course of rehabilitation intervention. Given the brevity of inpatient neurorehabilitation, future studies may explore targeting SWCD to improve early outcomes, such as cognitive functioning and economic impact, after TBI. Archives of Physical Medicine and Rehabilitation 2013;94:875-82 (C) 2013 by the American Congress of Rehabilitation Medicine	[Nakase-Richardson, Risa; Kretzmer, Tracy] James A Haley Vet Hosp, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA; [Nakase-Richardson, Risa; Barnett, Scott D.] Res Ctr Excellence Maximizing Rehabil Outcomes, Tampa, FL USA; [Nakase-Richardson, Risa; Barnett, Scott D.; Kretzmer, Tracy; Schwartz, Daniel J.] Univ S Florida, Tampa, FL USA; [Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Sherer, Mark] Baylor Coll Med, Houston, TX 77030 USA; [Yablon, Stuart A.] Glenrose Rehabil Hosp, Edmonton, AB, Canada; [Yablon, Stuart A.] Univ Alberta, Div Phys Med & Rehabil, Edmonton, AB, Canada; [Evans, Clea C.] Methodist Rehabil Ctr, Jackson, MS USA; [Evans, Clea C.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Schwartz, Daniel J.] James A Haley Vet Hosp, Dept Med, Tampa, FL 33612 USA; [Modarres, Mo] Charles Stark Draper Lab Inc, Tampa, FL USA	Nakase-Richardson, R (corresponding author), James A Haley Vet Hosp, 13000 Bruce B Downs Blvd 116-B, Tampa, FL 33612 USA.	Risa.Richardson@va.gov			National Institute on Disability and Rehabilitation Research, Department of Education [H133A060038, H133B090023, H133A070043]; Health Services Research and Development (HSR&D)/Rehabilitation Research and Development (RR&D) Center of Excellence for Maximizing Rehabilitation Outcomes [COE - HFP 09-156]	Supported by the National Institute on Disability and Rehabilitation Research, Department of Education (grant nos. H133A060038 [TEE Model System National Data and Statistical Center], H133B090023 [Rehabilitation Research and Training Center on Developing Strategies to Foster Community Integration and Participation for Individuals With Traumatic Brain Injury], and H133A070043 [Texas TBI Model System of TIRR]) and the Health Services Research and Development (HSR&D)/Rehabilitation Research and Development (RR&D) Center of Excellence for Maximizing Rehabilitation Outcomes (grant no. COE - HFP 09-156).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Antic NA, 2011, SLEEP, V34, P111, DOI 10.1093/sleep/34.1.111; Basetti CL, 2011, HDB CLIN NEUROL, V99, P1051; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Bloomfield IL, 2009, J INTERN NEUROPSYCH, V2, P1; Burke DT, 2004, J APPL RES, V4, P239; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chee MWL, 2007, P NATL ACAD SCI USA, V104, P9487, DOI 10.1073/pnas.0610712104; Chee MWL, 2004, J NEUROSCI, V24, P4560, DOI 10.1523/JNEUROSCI.0007-04.2004; Chuah YML, 2006, J NEUROSCI, V26, P7156, DOI 10.1523/JNEUROSCI.0906-06.2006; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Dash MB, 2009, J NEUROSCI, V29, P580, DOI 10.1523/JNEUROSCI.5486-08.2009; Dinges DF, 1997, SLEEP, V20, P267; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Guan ZW, 2004, BRAIN RES, V1018, P38, DOI 10.1016/j.brainres.2004.05.032; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hermann DM, 2009, NEUROLOGY, V73, P1313, DOI 10.1212/WNL.0b013e3181bd137c; HORNE JA, 1985, ANN CLIN RES, V17, P199; Johnson EO, 1998, SLEEP, V21, P178, DOI 10.1093/sleep/21.2.178; Kalmar K, 2008, ARCH PHYS MED REHAB, V89, P942, DOI 10.1016/j.apmr.2008.01.008; Leppavuori A, 2002, CEREBROVASC DIS, V14, P90, DOI 10.1159/000064737; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Longordo F, 2009, EUR J NEUROSCI, V29, P1810, DOI 10.1111/j.1460-9568.2009.06719.x; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; Massicotte-Marquez J, 2008, NEUROLOGY, V70, P1250, DOI 10.1212/01.wnl.0000286943.79593.a6; McDermott CM, 2003, J NEUROSCI, V23, P9687; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Nakase-Richardson R, 2009, ARCH PHYS MED REHAB, V90, P17, DOI 10.1016/j.apmr.2008.06.030; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Nowell Peter D., 1997, JAMA (Journal of the American Medical Association), V278, P2170, DOI 10.1001/jama.278.24.2170; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Sherer M, 2009, ARCH PHYS MED REHAB, V90, P1749, DOI 10.1016/j.apmr.2009.05.011; Siccoli MM, 2008, EUR J NEUROL, V15, P565, DOI 10.1111/j.1468-1331.2008.02119.x; Silva MA, 2012, AM J PHYS MED REHAB, V91, P890, DOI 10.1097/PHM.0b013e31825a1648; Tomfohr LM, 2011, SLEEP, V34, P121, DOI 10.1093/sleep/34.1.121; Traumatic Brain Injury Model Systems National Data and Statistical Center, SYLL; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229; Van Someren EJW, 2007, SLEEP MED REV, V11, P465, DOI 10.1016/j.smrv.2007.07.003; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Walker MP, 2009, ANN NY ACAD SCI, V1156, P168, DOI 10.1111/j.1749-6632.2009.04416.x; Zohar D, 2005, SLEEP, V28, P47, DOI 10.1093/sleep/28.1.47; Zunzunegui C, 2011, SLEEP, V34, P1261, DOI 10.5665/SLEEP.1252	49	49	50	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2013	94	5					875	882		10.1016/j.apmr.2013.01.001			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	134HX	WOS:000318202100012	23296143				2021-06-18	
J	Martini, D; Eckner, J; Kutcher, J; Broglio, SP				Martini, Douglas; Eckner, James; Kutcher, Jeffery; Broglio, Steven P.			Subconcussive Head Impact Biomechanics: Comparing Differing Offensive Schemes	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						ACCELERATION; HELMET; MAGNITUDE; HEAD IMPACT TELEMETRY SYSTEM; FOOTBALL	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL FOOTBALL; CHRONIC TRAUMATIC ENCEPHALOPATHY; PROFESSIONAL FOOTBALL; BRAIN-INJURY; CONCUSSION; ASSOCIATION; IMPAIRMENT; SEVERITY	MARTINI, D., J. ECKNER, J. KUTCHER, and S. P. BROGLIO. Subconcussive Head Impact Biomechanics: Comparing Differing Offensive Schemes. Med. Sci. Sports Exerc., Vol. 45, No. 4, pp. 755-761, 2013. Purpose: Recent literature suggests that subconcussive impacts may influence cognitive functioning across the life span. These effects are suggested to manifest as functional and possibly structural changes. Head impact biomechanics during American football have been characterized from the high school to professional level, but style of play has not been considered. The aim of this investigation was to quantify and compare head impact frequencies and magnitudes between two different offensive schemes. Methods: We investigated the frequencies and magnitudes (linear acceleration [g], rotational acceleration [rad.s(-2)], and HITsp) of head impacts sustained by 83 high school football athletes, playing for schools using two different offensive schemes. The two schemes comprised a run-first offense (42 athletes) and a pass-first offense (41 athletes). The Head Impact Telemetry System was used to record head impact measures. Results: A total of 35,620 impacts were recorded across two seasons. Athletes in the run-first offense sustained an average of 456 head impacts per season (41 practices and 9 games), whereas the pass-first offense athletes sustained an average of 304 head impacts per season (44 practices and 9 games). The pass-first offense, however, sustained significantly higher impact magnitudes (P values < 0.05; 28.56g, 1777.58 rad.s(-2), and 16.24) than the run-first offense (25.67g, 1675.36 rad.s(-2), and 15.48) across a season. Conclusions: These data provide a first look at how different offensive strategies may influence head impact exposure in football athletes. In the study population, a run-first offense was associated with more frequent head impacts, of smaller magnitude, than a pass-first offense.	[Martini, Douglas; Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Neurotrauma Res Lab, Ann Arbor, MI 48109 USA; [Eckner, James] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Eckner, James; Kutcher, Jeffery; Broglio, Steven P.] Michigan NeuroSport, Ann Arbor, MI USA; [Kutcher, Jeffery] Univ Michigan, Dept Neurol, Ann Arbor, MI USA	Broglio, SP (corresponding author), Univ Michigan, Sch Kinesiol, 1402 Washington Hts, Ann Arbor, MI 48109 USA.	broglio@umich.edu	Meijer, Anna/K-5118-2016		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12 HD001097] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER		Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Greenwald RM, 2012, CLIN J SPORT MED, V22, P83, DOI 10.1097/JSM.0b013e31824cc5d3; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2011, CLIN J SPORT MED, V21, P416, DOI 10.1097/JSM.0B013E31822C8A5C; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Talavage T. M., 2010, J NEUROTRAUMA; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0	27	49	49	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	APR	2013	45	4					755	761		10.1249/MSS.0b013e3182798758			7	Sport Sciences	Sport Sciences	109ZK	WOS:000316410600019	23135370	Green Accepted			2021-06-18	
J	Xu, JG; Wang, HD; Ding, K; Lu, XY; Li, T; Wang, JW; Wang, CX; Wang, J				Xu, Jianguo; Wang, Handong; Ding, Ke; Lu, Xinyu; Li, Tao; Wang, Jiawei; Wang, Chunxi; Wang, Jian			Inhibition of Cathepsin S Produces Neuroprotective Effects after Traumatic Brain Injury in Mice	MEDIATORS OF INFLAMMATION			English	Article							MHC CLASS-II; CYSTEINE PROTEASE; POSTTRAUMATIC EPILEPSY; INCREASED EXPRESSION; MESSENGER-RNA; MECHANISM; MODEL	Cathepsin S (CatS) is a cysteine protease normally present in lysosomes. It has long been regarded as an enzyme that is primarily involved in general protein degradation. More recently, mounting evidence has shown that it is involved in Alzheimer disease, seizures, age-related inflammatory processes, and neuropathic pain. In this study, we investigated the time course of CatS protein and mRNA expression and the cellular distribution of CatS in a mouse model of traumatic brain injury (TBI). To clarify the roles of CatS in TBI, we injected the mice intraventricularly with LHVS, a nonbrain penetrant, irreversible CatS inhibitor, and examined the effect on inflammation and neurobehavioral function. We found that expression of CatS was increased as early as 1 h after TBI at both protein and mRNA levels. The increased expression was detected in microglia and neurons. Inhibition of CatS significantly reduced the level of TBI-induced inflammatory factors in brain tissue and alleviated brain edema. Additionally, administration of LHVS led to a decrease in neuronal degeneration and improved neurobehavioral function. These results imply that CatS is involved in the secondary injury after TBI and provide a new perspective for preventing secondary injury after TBI.	[Xu, Jianguo; Wang, Handong; Ding, Ke; Lu, Xinyu; Li, Tao; Wang, Jiawei; Wang, Chunxi] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21218 USA	Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com	Wang, Jian/I-4874-2019	Wang, Jian/0000-0003-2291-640X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070974]; Key Subject of Jiangsu Province [X4200722]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K01AG031926]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG031926] Funding Source: NIH RePORTER	This work was supported by Grants from the National Natural Science Foundation of China (no. 81070974), the Key Subject of Jiangsu Province (no. X4200722), and NIH (K01AG031926). The authors thank Claire Levine, MS, ELS, for assistance with this paper.	Akahoshi N, 2007, NEUROSCI LETT, V429, P136, DOI 10.1016/j.neulet.2007.10.007; Arnlov J, 2012, BIOMARK MED, V6, P9, DOI [10.2217/BMM.11.102, 10.2217/bmm.11.102]; Barclay J, 2007, PAIN, V130, P225, DOI 10.1016/j.pain.2006.11.017; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Cattaruzza F, 2011, GASTROENTEROLOGY, V141, P1864, DOI 10.1053/j.gastro.2011.07.035; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen H., 2013, CARDIOVASCULAR RES; Chen JWY, 2009, J REHABIL RES DEV, V46, P685, DOI 10.1682/JRRD.2008.09.0130; Chen KL, 2012, CANCER LETT, V317, P89, DOI 10.1016/j.canlet.2011.11.015; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Clark AK, 2012, ARTHRITIS RHEUM-US, V64, P2038, DOI 10.1002/art.34351; Clark AK, 2012, EXP NEUROL, V234, P283, DOI 10.1016/j.expneurol.2011.09.012; Clark AK, 2009, J NEUROSCI, V29, P6945, DOI 10.1523/JNEUROSCI.0828-09.2009; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; de Nooijer R, 2009, ARTERIOSCL THROM VAS, V29, P188, DOI 10.1161/ATVBAHA.108.181578; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Honey K, 2003, NAT REV IMMUNOL, V3, P472, DOI 10.1038/nri1110; Hsieh CS, 2002, J IMMUNOL, V168, P2618, DOI 10.4049/jimmunol.168.6.2618; Huang C. C., 2013, FREE RADICAL BIOL ME; Lecaille F, 2002, CHEM REV, V102, P4459, DOI 10.1021/cr0101656; LEMERE CA, 1995, AM J PATHOL, V146, P848; Liu J, 2006, ATHEROSCLEROSIS, V186, P411, DOI 10.1016/j.atherosclerosis.2005.08.001; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; Pan LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035315; Phipps-Yonas H, 2013, EUR J IMMUNOL, V43, P65, DOI 10.1002/eji.201242379; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Pozgan U, 2010, BIOL CHEM, V391, P571, DOI 10.1515/BC.2010.035; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; Riese RJ, 1998, J CLIN INVEST, V101, P2351, DOI 10.1172/JCI1158; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Small DM, 2011, CLIN REV BONE MINER, V9, P122, DOI 10.1007/s12018-011-9095-5; Spielmann N, 2008, CLIN GENET, V74, P155, DOI 10.1111/j.1399-0004.2008.01043.x; Taleb S, 2006, J CLIN ENDOCR METAB, V91, P1042, DOI 10.1210/jc.2005-1601; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Wang B, 2006, J BIOL CHEM, V281, P6020, DOI 10.1074/jbc.M509134200; Wang J, 2005, STROKE, V36, P613, DOI 10.1161/01.STR.0000155729.12931.8f; Wang JW, 2012, BRAIN RES, V1464, P73, DOI 10.1016/j.brainres.2012.05.014; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wendt W, 2008, BRAIN RES, V1232, P7, DOI 10.1016/j.brainres.2008.07.067; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Williams AS, 2009, PULM PHARMACOL THER, V22, P27, DOI 10.1016/j.pupt.2008.11.002; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yamashima T, 2009, PROG NEUROBIOL, V89, P343, DOI 10.1016/j.pneurobio.2009.09.003; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X	52	49	49	0	5	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2013	2013								187873	10.1155/2013/187873			11	Cell Biology; Immunology	Cell Biology; Immunology	246HI	WOS:000326528300001	24282339	DOAJ Gold, Green Published			2021-06-18	
J	de Joode, EA; van Boxtel, MPJ; Verhey, FR; van Heugten, CM				de Joode, Elisabeth A.; van Boxtel, Martin P. J.; Verhey, Frans R.; van Heugten, Caroline M.			Use of assistive technology in cognitive rehabilitation: Exploratory studies of the opinions and expectations of healthcare professionals and potential users	BRAIN INJURY			English	Article						Brain injury; patients; caregivers; attitude; implementation; diffusion of innovation	TRAUMATIC BRAIN-INJURY; PORTABLE ELECTRONIC DEVICES; ALTERNATIVE COMMUNICATION; STROKE; INDIVIDUALS; IMPAIRMENTS; MEMORY; INTERVENTION; RECOVERY; ADULTS	Objective: To provide recommendations for the successful implementation of Assistive Technology (AT) in cognitive rehabilitation by investigating the attitudes towards AT of professionals, individuals with acquired brain injury (ABI) and their caregivers in two exploratory studies. Method: A total of 147 professionals in cognitive rehabilitation filled out a web-based survey. Fifteen patients with ABI and 14 caregivers were interviewed. Results: Most professionals were willing to use AT in the future, although only 27% used AT currently in a treatment setting. Professionals with AT experience were more positive than those without about the potential of AT and their own ability to use it in their treatment programmes. Most patients and caregivers were positive about using AT in the future, still, only a minority currently used AT. Refusal to reimburse AT devices by health insurance companies appeared an important barrier for a more widespread use. Conclusions: Although enthusiasm about AT was evident in both studies, a lack of progress in the implementation of AT was noted. This could be improved by promoting knowledge and hands-on experience of professionals who work in rehabilitation centres. More evidence on the efficacy of AT is required to improve coverage of AT devices by insurance companies.	[de Joode, Elisabeth A.; van Boxtel, Martin P. J.; Verhey, Frans R.; van Heugten, Caroline M.] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, NL-6200 MD Maastricht, Netherlands	van Heugten, CM (corresponding author), Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, POB 616, NL-6200 MD Maastricht, Netherlands.	c.vanheugten@maastrichtuniversity.nl	de Joode, Elsbeth/AAT-3805-2020		Netherlands Organization for Health Research and Development (ZonMW)Netherlands Organization for Health Research and Development [14350052]	This work was funded by The Netherlands Organization for Health Research and Development (ZonMW, project number 14350052).	Beukelman DR, 2007, AUGMENT ALTERN COMM, V23, P230, DOI 10.1080/07434610701553668; Chang YJ, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-45; De Bie SE, 1987, VOORSTELLEN UNIFORME, V87; de Joode E, 2010, CLIN REHABIL, V24, P701, DOI 10.1177/0269215510367551; DePompei R, 2008, NEUROREHABILITATION, V23, P487; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; Hart T, 2004, J HEAD TRAUMA REHAB, V19, P351, DOI 10.1097/00001199-200409000-00001; Hart T, 2003, BRAIN INJURY, V17, P401, DOI 10.1080/0269905021000038438; Hochstenbach JB, 2003, ARCH PHYS MED REHAB, V84, P1499, DOI 10.1016/S0003-9993(03)00370-8; Jacobs B, 2004, DISABIL REHABIL, V26, P1231, DOI 10.1080/09638280412331280244; Khaw KT, 1996, J NEUROL NEUROSUR PS, V61, P333, DOI 10.1136/jnnp.61.4.333; Kirsch NL, 2004, J HEAD TRAUMA REHAB, V19, P366, DOI 10.1097/00001199-200409000-00002; Kirsch NL, 2004, REHABIL PSYCHOL, V49, P200, DOI 10.1037/0090-5550.49.3.200; Lund SK, 2007, AUGMENT ALTERN COMM, V23, P323, DOI 10.1080/02656730701189123; O'Neil-Pirozzi TM, 2004, BRAIN INJURY, V18, P179, DOI 10.1080/0269905031000149560; Patel M, 2003, CLIN REHABIL, V17, P158, DOI 10.1191/0269215503cr596oa; Rasquin SMC, 2002, J NEUROL SCI, V203, P115, DOI 10.1016/S0022-510X(02)00264-2; Rogers EM., 2003, DIFFUSION INNOVATION, V5th ed; Scholte op Reimer W, 1998, STROKE, V29; Scholte Op Reimer W., 1999, THESIS U AMSTERDAM; Smith MM, 2008, DISABIL REHABIL-ASSI, V3, P260, DOI 10.1080/17483100802338499; Sohlberg MM, 2007, BRAIN INJURY, V21, P531, DOI 10.1080/02699050701311000; SUNDET K, 1988, J CLIN EXP NEUROPSYC, V10, P363, DOI 10.1080/01688638808408245; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van Heugten C, 2004, HDB HANDICAP CHRONIS, V87, P37; Visser-Meily A, 2005, PATIENT EDUC COUNS, V56, P257, DOI 10.1016/j.pec.2004.02.013; Wilson BA, 2005, BRAIN INJURY, V19, P891, DOI 10.1080/02699050400002363	28	49	49	0	12	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2012	26	10					1257	1266		10.3109/02699052.2012.667590			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	984GR	WOS:000307178600011	22571738				2021-06-18	
J	Mabry, RL; Apodaca, A; Penrod, J; Orman, JA; Gerhardt, RT; Dorlac, WC				Mabry, Robert L.; Apodaca, Amy; Penrod, Jason; Orman, Jean A.; Gerhardt, Robert T.; Dorlac, Warren C.			Impact of critical care-trained flight paramedics on casualty survival during helicopter evacuation in the current war in Afghanistan	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	Advanced Technology Applications for Combat Casualty Care Conference (ATACCC)	AUG 15-18, 2011	Fort Lauderdale, FL			Helicopter; military; trauma; flight medic; Afghanistan; emergency medical services	TRAUMATIC BRAIN-INJURY; EMERGENCY CARE; SERVICES; TRANSPORT; MORTALITY; INTUBATION; OUTCOMES; VICTIMS; PATIENT; ILL	BACKGROUND: The US Army pioneered medical evacuation (MEDEVAC) by helicopter, yet its system remains essentially unchanged since the Vietnam era. Care is provided by a single combat medic credentialed at the Emergency Medical Technician - Basic level. Treatment protocols, documentation, medical direction, and quality improvement processes are not standardized and vary significantly across US Army helicopter evacuation units. This is in contrast to helicopter emergency medical services that operate within the United States. Current civilian helicopter evacuation platforms are routinely staffed by critical care-trained flight paramedics (CCFP) or comparably trained flight nurses who operate under trained EMS physician medical direction using formalized protocols, standardized patient care documentation, and rigorous quality improvement processes. This study compares mortality of patients with injury from trauma between the US Army's standard helicopter evacuation system staffed with medics at the Emergency Medical Technician - Basic level (standard MEDEVAC) and one staffed with experienced CCFP using adopted civilian helicopter emergency medical services practices. METHODS: This is a retrospective study of a natural experiment. Using data from the Joint Theater Trauma Registry, 48-hour mortality for severely injured patients (injury severity score >= 16) was compared between patients transported by standard MEDEVAC units and CCFP air ambulance units. RESULTS: The 48-hour mortality for the CCFP-treated patients was 8% compared to 15% for the standard MEDEVAC patients. After adjustment for covariates, the CCFP system was associated with a 66% lower estimated risk of 48-hour mortality compared to the standard MEDEVAC system. CONCLUSIONS: These findings demonstrate that using an air ambulance system based on modern civilian helicopter EMS practice was associated with a lower estimated risk of 48-hour mortality among severely injured patients in a combat setting. (J Trauma Acute Care Surg. 2012;73: S32-S37. Copyright (c) 2012 by Lippincott Williams & Wilkins) LEVEL OF EVIDENCE: Therapeutic study, level II.	[Mabry, Robert L.] USA, Inst Surg Res, MCMR SRJ, San Antonio, TX 78234 USA	Mabry, RL (corresponding author), USA, Inst Surg Res, MCMR SRJ, 3400 Rawley E Chambers Ave, San Antonio, TX 78234 USA.	robert.mabry@us.army.mil	Gerhardt, Robert/ABI-5668-2020	Gerhardt, Robert/0000-0002-7714-119X			Air Medical Physician Association, 2003, Air Med J, V22, P14; BAXT WG, 1985, ANN EMERG MED, V14, P859, DOI 10.1016/S0196-0644(85)80634-X; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; Berry J, 2010, NEWSWEEK        0313; Bledsoe Bryan E, 2003, Emerg Med Serv, V32, P88; BURNEY RE, 1986, ANN EMERG MED, V15, P1491, DOI 10.1016/S0196-0644(86)80950-7; Burney RE, 1987, ANN EMERG MED, V16, P54; COWLEY RA, 1973, J TRAUMA, V13, P1029, DOI 10.1097/00005373-197312000-00001; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2005, NEUROCRIT CARE, V2, P165, DOI 10.1385/NCC:2:2:165; DeLorenzo RA, 1997, AVIAT SPACE ENVIR MD, V68, P56; Driscoll RS, 2001, MIL MED, V166, P290; Eastridge Brian J, 2009, Am J Surg, V198, P852, DOI 10.1016/j.amjsurg.2009.04.029; FALLON MJ, 1990, ANN EMERG MED, V19, P914, DOI 10.1016/S0196-0644(05)81570-7; Frankema SPG, 2004, BRIT J SURG, V91, P1520, DOI 10.1002/bjs.4756; FREILICH DA, 1990, NEW YORK STATE J MED, V90, P358; Gearhart PA, 1997, ANN EMERG MED, V30, P500, DOI 10.1016/S0196-0644(97)70010-6; Gerhardt R T, 2000, Prehosp Emerg Care, V4, P136, DOI 10.1080/10903120090941407; Higgins RA, 2010, AACN ADV CRIT CARE, V21, P288, DOI 10.1097/NCI.0b013e3181e6741f; Iirola TT, 2006, EUR J EMERG MED, V13, P335, DOI 10.1097/01.mej.0000224429.51623.fb; JACOBS LM, 1989, J NATL MED ASSOC, V81, P1157; Lehmann R, 2009, J TRAUMA, V66, pS31, DOI 10.1097/TA.0b013e31819d9575; McCowan CL, 2007, PREHOSP EMERG CARE, V11, P383, DOI 10.1080/10903120701536867; McCowan Christy L, 2008, Air Med J, V27, P78, DOI 10.1016/j.amj.2007.10.001; MEIER DR, 1989, SOUTHERN MED J, V82, P885, DOI 10.1097/00007611-198907000-00022; MOYLAN JA, 1988, ANN SURG, V208, P673, DOI 10.1097/00000658-198812000-00001; NICHOLL JP, 1995, BRIT MED J, V311, P217, DOI 10.1136/bmj.311.6999.217; Parker Paul J, 2006, J R Army Med Corps, V152, P202; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; Ringburg Akkie N, 2009, Air Med J, V28, P298, DOI 10.1016/j.amj.2009.03.007; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Warren J, 2004, CRIT CARE MED, V32, P256, DOI 10.1097/01.CCM.0000104917.39204.0A; WHITE MS, 1971, AEROSPACE MED, V42, P780; Zoroya G, 2009, US TODAY        0120	35	49	49	3	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2012	73			1			S32	S37		10.1097/TA.0b013e3182606001			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	992VP	WOS:000307808500006	22847091				2021-06-18	
J	Wu, JF; Pajoohesh-Ganji, A; Stoica, BA; Dinizo, M; Guanciale, K; Faden, AI				Wu, Junfang; Pajoohesh-Ganji, Ahdeah; Stoica, Bogdan A.; Dinizo, Michael; Guanciale, Kelsey; Faden, Alan I.			Delayed expression of cell cycle proteins contributes to astroglial scar formation and chronic inflammation after rat spinal cord contusion	JOURNAL OF NEUROINFLAMMATION			English	Article						Contusive spinal cord injury; Cell cycle pathway; Cyclin-dependent kinases; Chronic; CR8; Astrogliosis; Inflammation; Rat	FOCAL CEREBRAL-ISCHEMIA; ADHESION MOLECULE L1; CDK INHIBITOR; IN-VITRO; PROVIDES NEUROPROTECTION; NADPH OXIDASE; CLOSE HOMOLOG; BRAIN; MICROGLIA; INJURY	Background: Traumatic spinal cord injury (SCI) induces secondary tissue damage that is associated with astrogliosis and inflammation. We previously reported that acute upregulation of a cluster of cell-cycle-related genes contributes to post-mitotic cell death and secondary damage after SCI. However, it remains unclear whether cell cycle activation continues more chronically and contributes to more delayed glial change. Here we examined expression of cell cycle-related proteins up to 4 months following SCI, as well as the effects of the selective cyclin-dependent kinase (CDKs) inhibitor CR8, on astrogliosis and microglial activation in a rat SCI contusion model. Methods: Adult male rats were subjected to moderate spinal cord contusion injury at T8 using a well-characterized weight-drop model. Tissue from the lesion epicenter was obtained 4 weeks or 4 months post-injury, and processed for protein expression and lesion volume. Functional recovery was assessed over the 4 months after injury. Results: Immunoblot analysis demonstrated a marked continued upregulation of cell cycle-related proteins - including cyclin D1 and E, CDK4, E2F5 and PCNA - for 4 months post-injury that were highly expressed by GFAP(+) astrocytes and microglia, and co-localized with inflammatory-related proteins. CR8 administrated systemically 3 h post-injury and continued for 7 days limited the sustained elevation of cell cycle proteins and immunoreactivity of GFAP, Iba-1 and p22(PHOX) - a key component of NADPH oxidase - up to 4 months after SCI. CR8 treatment significantly reduced lesion volume, which typically progressed in untreated animals between 1 and 4 months after trauma. Functional recovery was also significantly improved by CR8 treatment after SCI from week 2 through week 16. Conclusions: These data demonstrate that cell cycle-related proteins are chronically upregulated after SCI and may contribute to astroglial scar formation, chronic inflammation and further tissue loss.	[Wu, Junfang; Stoica, Bogdan A.; Dinizo, Michael; Guanciale, Kelsey; Faden, Alan I.] Univ Maryland, Dept Anesthesiol, Sch Med, Baltimore, MD 21201 USA; [Wu, Junfang; Stoica, Bogdan A.; Dinizo, Michael; Guanciale, Kelsey; Faden, Alan I.] Univ Maryland, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, Baltimore, MD 21201 USA; [Pajoohesh-Ganji, Ahdeah] George Washington Univ, Dept Neurosci, Sch Med, Washington, DC 20037 USA	Wu, JF (corresponding author), Univ Maryland, Dept Anesthesiol, Sch Med, Baltimore, MD 21201 USA.	jwu@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Pajoohesh-Ganji, Ahdeah/0000-0002-1542-029X	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS054221-06]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054221] Funding Source: NIH RePORTER	This project was supported by the National Institutes of Health (NIH) grant no. R01NS054221-06.	Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; Atanasoski S, 2008, MOL CELL NEUROSCI, V37, P519, DOI 10.1016/j.mcn.2007.11.005; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Bettayeb K, 2008, ONCOGENE, V27, P5797, DOI 10.1038/onc.2008.191; Bettayeb Karima, 2010, Genes Cancer, V1, P369, DOI 10.1177/1947601910369817; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Byrnes KR, 2006, GLIA, V53, P420, DOI 10.1002/glia.20295; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Fitch MT, 1999, J NEUROSCI, V19, P8182; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Jakovcevski I, 2007, J NEUROSCI, V27, P7222, DOI 10.1523/JNEUROSCI.0739-07.2007; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kato H, 2003, BRAIN RES BULL, V60, P215, DOI 10.1016/S0361-9230(03)00036-4; Laabs TL, 2007, J NEUROSCI, V27, P14494, DOI 10.1523/JNEUROSCI.2807-07.2007; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Nagamoto-Combs K, 2010, J NEUROTRAUM, V27, P565, DOI 10.1089/neu.2009.0966; Naphade SB, 2010, ACTA NEUROPATHOL, V119, P123, DOI 10.1007/s00401-009-0616-y; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith ME, 1998, J NEUROSCI RES, V54, P68, DOI 10.1002/(SICI)1097-4547(19981001)54:1<68::AID-JNR8>3.0.CO;2-F; Spranger M, 1996, NEUROSCIENTIST, V2, P293, DOI 10.1177/107385849600200515; Tator C H, 1996, J Spinal Cord Med, V19, P206; Tator CH, 2002, INJURY PREV, V8, pIV33, DOI 10.1136/ip.8.suppl_4.iv33; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; Tian DS, 2006, J NEUROSCI RES, V84, P1053, DOI 10.1002/jnr.20999; Tokumoto YM, 2002, DEV BIOL, V245, P224, DOI 10.1006/dbio.2002.0626; Totoiu MO, 2005, J COMP NEUROL, V486, P373, DOI 10.1002/cne.20517; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang W, 2008, J CLIN NEUROSCI, V15, P278, DOI 10.1016/j.jocn.2007.02.004; Wu JF, 2012, CELL CYCLE, V11, P1782, DOI 10.4161/cc.20153; Wu JF, 2011, J NEUROSCI RES, V89, P628, DOI 10.1002/jnr.22598; Wu JF, 2011, NEUROTHERAPEUTICS, V8, P221, DOI 10.1007/s13311-011-0028-2; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zhang Q, 2009, GLIA, V57, P908, DOI 10.1002/glia.20816; Zhu Z, 2007, GLIA, V55, P546, DOI 10.1002/glia.20476	58	49	50	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUL 11	2012	9								169	10.1186/1742-2094-9-169			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	983LF	WOS:000307120100001	22784881	DOAJ Gold, Green Published			2021-06-18	
J	Register-Mihalik, JK; Kontos, DL; Guskiewicz, KM; Mihalik, JP; Conder, R; Shields, EW				Register-Mihalik, Johna K.; Kontos, Daniel L.; Guskiewicz, Kevin M.; Mihalik, Jason P.; Conder, Robert; Shields, Edgar W.			Age-Related Differences and Reliability on Computerized and Paper-and-Pencil Neurocognitive Assessment Batteries	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; traumatic brain injuries; serial testing	TEST-RETEST RELIABILITY; RELIABLE CHANGE INDEXES; VERBAL-LEARNING TEST; HIGH-SCHOOL; NEUROPSYCHOLOGICAL DEFICITS; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; SPORT HELD; CONCUSSION; RECOVERY	Context: Neurocognitive testing is a recommended component in a concussion assessment. Clinicians should be aware of age and practice effects on these measures to ensure appropriate understanding of results. Objective: To assess age and practice effects on computerized and paper-and-pencil neurocognitive testing batteries in collegiate and high school athletes. Design: Cohort study. Setting: Classroom and laboratory. Patients or Other Participants: Participants consisted of 20 collegiate student-athletes (age 20.00 +/- 0.79 years) and 20 high school student-athletes (age = 16.00 +/- 0.86 years). Main Outcome Measure(s): Hopkins Verbal Learning Test scores, Brief Visual-Spatial Memory Test scores, Trail Making Test B total time, Symbol Digit Modalities Test score, Stroop Test total score, and 5 composite scores from the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) served as outcome measures. Mixed-model analyses of variance were used to examine each measure. Results: Collegiate student-athletes performed better than high school student-athletes on ImPACT processing speed composite score (F-1,F-38 = 5.03, P = .031) at all time points. No other age effects were observed. The Trail Making Test B total time (F-2,F-66 = 73.432, P < .001), Stroop Test total score (F-2,F-76 = 96.85, P = < .001) and ImPACT processing speed composite score (F-2,F-76 = 5.81, P = .005) improved in test sessions 2 and 3 compared with test session 1. Intraclass correlation coefficient calculations demonstrated values ranging from 0.12 to 0.72. Conclusions: An athlete's neurocognitive performance may vary across sessions. It is important for clinicians to know the reliability and precision of these tests in order to properly interpret test scores.	[Register-Mihalik, Johna K.] WakeMed Hlth & Hosp, Emergency Serv Inst, Clin Res Unit, Raleigh, NC 27610 USA; [Register-Mihalik, Johna K.; Guskiewicz, Kevin M.; Mihalik, Jason P.] Matthew Gfeller Sport Related Traumat Brain Inju, Raleigh, NC USA; [Kontos, Daniel L.; Shields, Edgar W.] Univ N Carolina, Dept Exercise Sci, Chapel Hill, NC 27515 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Allied Hlth Sci, Curriculum Human Movement Sci, Chapel Hill, NC 27515 USA; [Conder, Robert] Carolina Neuropsychol Serv, Raleigh, NC USA	Register-Mihalik, JK (corresponding author), WakeMed Hlth & Hosp, Emergency Serv Inst, Clin Res Unit, 3024 New Bern Ave, Raleigh, NC 27610 USA.	jmihalik@wakemed.org		Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130			Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedict RHB, 2008, MULT SCLER J, V14, P940, DOI 10.1177/1352458508090923; Benedict RHB, 2005, J INT NEUROPSYCH SOC, V11, P727, DOI 10.1017/S1355617705050782; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Brandt J., 2001, HOPKINS VERBAL LEARN; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Duff K, 2001, ARCH CLIN NEUROPSYCH, V16, P461; Duff K, 2007, ARCH CLIN NEUROPSYCH, V22, P15, DOI 10.1016/j.acn.2006.08.013; Elwell MD, 1989, RELIABILITY VALIDITY; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Franzen M D, 1987, Arch Clin Neuropsychol, V2, P265, DOI 10.1016/0887-6177(87)90014-X; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Iverson G.L., 2003, IMMEDIATE POSTCONCUS; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kortte Kathleen Bechtold, 2002, Appl Neuropsychol, V9, P106, DOI 10.1207/S15324826AN0902_5; Lemay S, 2004, CLIN NEUROPSYCHOL, V18, P284, DOI 10.1080/13854040490501718; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MCCAFFREY RJ, 1992, CLIN NEUROPSYCHOL, V6, P32, DOI DOI 10.1080/13854049208404115; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Mitrushina M., 1999, HDB NORMATIVE DATA N; Parsons TD, 2009, INT J NEUROSCI, V119, P492, DOI 10.1080/00207450802330876; Reitan R. M., 1992, TRAIL MAKING TEST MA; Rosenbaum AM, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P137, DOI 10.1007/0-387-32565-4_7; Salthouse TA, 2009, J INT NEUROPSYCH SOC, V15, P650, DOI 10.1017/S1355617709990385; Salthouse TA, 2009, NEUROBIOL AGING, V30, P507, DOI 10.1016/j.neurobiolaging.2008.09.023; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Smith A, 1972, SYMBOL DIGIT MODALIT; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Woods SP, 2005, ASSESSMENT, V12, P96, DOI 10.1177/1073191104270342	47	49	49	0	23	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAY-JUN	2012	47	3					297	305		10.4085/1062-6050-47.3.13			9	Sport Sciences	Sport Sciences	953AJ	WOS:000304839000007	22892411	Green Published			2021-06-18	
J	Kashif, FM; Verghese, GC; Novak, V; Czosnyka, M; Heldt, T				Kashif, Faisal M.; Verghese, George C.; Novak, Vera; Czosnyka, Marek; Heldt, Thomas			Model-Based Noninvasive Estimation of Intracranial Pressure from Cerebral Blood Flow Velocity and Arterial Pressure	SCIENCE TRANSLATIONAL MEDICINE			English	Article							CLINICAL-EXPERIENCE; BRAIN-INJURY; ICP; HYPERTENSION; DYNAMICS	Intracranial pressure (ICP) is affected in many neurological conditions. Clinical measurement of pressure on the brain currently requires placing a probe in the cerebrospinal fluid compartment, the brain tissue, or other intracranial space. This invasiveness limits the measurement to critically ill patients. Because ICP is also clinically important in conditions ranging from brain tumors and hydrocephalus to concussions, noninvasive determination of ICP would be desirable. Our model-based approach to continuous estimation and tracking of ICP uses routinely obtainable time-synchronized, noninvasive (or minimally invasive) measurements of peripheral arterial blood pressure and blood flow velocity in the middle cerebral artery (MCA), both at intra-heartbeat resolution. A physiological model of cerebrovascular dynamics provides mathematical constraints that relate the measured waveforms to ICP. Our algorithm produces patient-specific ICP estimates with no calibration or training. Using 35 hours of data from 37 patients with traumatic brain injury, we generated ICP estimates on 2665 nonoverlapping 60-beat data windows. Referenced against concurrently recorded invasive parenchymal ICP that varied over 100 millimeters of mercury (mmHg) across all records, our estimates achieved a mean error (bias) of 1.6 mmHg and SD of error (SDE) of 7.6 mmHg. For the 1673 data windows over 22 hours in which blood flow velocity recordings were available from both the left and the right MCA, averaging the resulting bilateral ICP estimates reduced the bias to 1.5 mmHg and SDE to 5.9 mmHg. This accuracy is already comparable to that of some invasive ICP measurement methods in current clinical use.	[Kashif, Faisal M.; Verghese, George C.; Heldt, Thomas] MIT, Elect Res Lab, Cambridge, MA 02139 USA; [Novak, Vera] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA; [Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 0SP, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, PL-00665 Warsaw, Poland	Heldt, T (corresponding author), MIT, Elect Res Lab, Cambridge, MA 02139 USA.	thomas@mit.edu		/0000-0002-5930-7694	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 EB001659, 4R37 AG2537-05, 4P30 AG02871702]; Center for Integration of Medicine and Innovative Technology, Boston; National Institute of Health Research Biomedical Research Centre, Cambridge University Hospital Foundation Trust-Neurosciences ThemeNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390, G0600986] Funding Source: researchfish; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028717, R37AG025037] Funding Source: NIH RePORTER	F.M.K., G.C.V., and T.H. were supported in part by NIH R01 EB001659 and by the Center for Integration of Medicine and Innovative Technology, Boston. M. C. was supported by the National Institute of Health Research Biomedical Research Centre, Cambridge University Hospital Foundation Trust-Neurosciences Theme. V.N. was supported in part by NIH grants 4R37 AG2537-05 and 4P30 AG02871702.	Alperin NJ, 2000, RADIOLOGY, V217, P877, DOI 10.1148/radiology.217.3.r00dc42877; Banister K, 2000, PHYSIOL MEAS, V21, P473, DOI 10.1088/0967-3334/21/4/304; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Borchert M., 1998, U.S. Patent, Patent No. [09/021 966, 09021966]; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Eide PK, 2010, J NEUROSURG, V113, P1317, DOI 10.3171/2010.7.JNS10483; Frank AM, 2000, ZBL NEUROCHIR, V61, P177, DOI 10.1055/s-2000-15597; HANLO PW, 1995, ULTRASOUND MED BIOL, V21, P613, DOI 10.1016/0301-5629(94)00147-6; HAYASHI M, 1991, BRAIN, V114, P2681, DOI 10.1093/brain/114.6.2681; Hlatky Roman, 2003, Neurosurg Focus, V14, pe2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Kashif FM, 2008, COMPUTERS IN CARDIOLOGY 2008, VOLS 1 AND 2, P369, DOI 10.1109/CIC.2008.4749055; Kashif F.M., 2011, THESIS MIT; Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Marmarou A, 2007, NEUROSURG FOCUS, V22, pE1, DOI DOI 10.3171/F0C.2007.22.5.2; MENDELOW AD, 1983, J NEUROSURG, V58, P45, DOI 10.3171/jns.1983.58.1.0045; Michaeli D, 2002, J NEUROSURG, V96, P1132, DOI 10.3171/jns.2002.96.6.1132; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Morgalla MH, 2001, J NEUROSURG, V95, P529, DOI 10.3171/jns.2001.95.3.0529; Mourad PD, 2004, US Patent, Patent No. [7,547,283, 7547283]; Novak V, 2004, BIOMED ENG ONLINE, V3, DOI 10.1186/1475-925X-3-39; Olufsen MS, 2002, AM J PHYSIOL-REG I, V282, pR611, DOI 10.1152/ajpregu.00285.2001; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; Piper I, 2001, NEUROSURGERY, V49, P1158, DOI 10.1097/00006123-200111000-00026; Popovic Djordje, 2009, Recent Patents on Biomedical Engineering, V2, P165, DOI 10.2174/1874764710902030165; Querfurth HW, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-106; Ragauskas A, 2005, ACT NEUR S, V95, P357; Ragauskas A, 2003, MED ENG PHYS, V25, P667, DOI 10.1016/S1350-4533(03)00082-1; REID A, 1989, J NEUROL NEUROSUR PS, V52, P610, DOI 10.1136/jnnp.52.5.610; Schmidt B, 2003, STROKE, V34, P84, DOI 10.1161/01.STR.0000047849.01376.AE; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Ueno T, 1998, ACT NEUR S, V71, P66; Ursino M, 1997, J APPL PHYSIOL, V82, P1256; Wakeland W, 2008, COMPUT BIOL MED, V38, P1024, DOI 10.1016/j.compbiomed.2008.07.004; Westerhof N, 2009, MED BIOL ENG COMPUT, V47, P131, DOI 10.1007/s11517-008-0359-2; Xu P, 2010, IEEE T INF TECHNOL B, V14, P971, DOI 10.1109/TITB.2009.2027317; Zhao YL, 2005, ACTA NEUROCHIR SUPPL, V95, P351; Zhu YS, 2011, J APPL PHYSIOL, V111, P376, DOI 10.1152/japplphysiol.01418.2010; Zong W, 2003, COMPUT CARDIOL, V30, P259, DOI 10.1109/CIC.2003.1291140	46	49	49	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	1946-6234	1946-6242		SCI TRANSL MED	Sci. Transl. Med.	APR 11	2012	4	129							129ra44	10.1126/scitranslmed.3003249			9	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	925QY	WOS:000302777300004	22496546	Green Accepted			2021-06-18	
J	Kirkwood, MW; Yeates, KO; Randolph, C; Kirk, JW				Kirkwood, Michael W.; Yeates, Keith Owen; Randolph, Christopher; Kirk, John W.			The Implications of Symptom Validity Test Failure for Ability-Based Test Performance in a Pediatric Sample	PSYCHOLOGICAL ASSESSMENT			English	Article						symptom validity testing; response bias; mild traumatic brain injury; postconcussion syndrome; children	TRAUMATIC BRAIN-INJURY; WORD MEMORY TEST; CLINICAL NEUROPSYCHOLOGY; RESPONSE BIAS; CHILDREN; TOMM; ADOLESCENTS; CAPACITY; RECOVERY; ADULTS	If an examinee exerts inadequate effort to perform well during a psychological or neuropsychological exam, the resulting data will represent an inaccurate representation of the individual's true abilities and difficulties. In adult populations, methodologies to identify noncredible effort have grown exponentially in the last 2 decades. Though a comparatively modest amount of work has focused on tools to identify noncredible effort in pediatric populations, recent research has demonstrated that children can consistently pass several stand-alone symptom validity tests (SVTs) using cutoffs established with adults. However, no identified studies have examined the implications of pediatric SVT failure for ability-based test performance. The current sample consisted of 276 children aged 8-16 years referred consecutively for outpatient clinical neuropsychological consultation following mild traumatic brain injury (TB!). An earlier subgroup of this same case series that also included 17-year-olds was presented in Kirkwood and Kirk (2010). Nineteen percent of the current sample performed below the actuarial cutoff on the Medical Symptom Validity Test (MSVT). No background or injury-related variable differentiated those who passed from those who failed the MSVT. Performance on the MSVT was correlated significantly with performance on all ability-based tests and explained 38% of the total ability-based test variance. Participants failing the MSVT performed significantly worse on nearly all neuropsychological tests, with large effect sizes apparent across most tests. The results provide compelling evidence that practitioners should add objective SVTs to the evaluation of school-aged youth, even when secondary gain issues might not be readily apparent and particularly following mild TBI.	[Kirkwood, Michael W.; Kirk, John W.] Childrens Hosp Colorado, Concuss Program, Aurora, CO 80045 USA; [Kirkwood, Michael W.; Kirk, John W.] Univ Colorado Denver Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Randolph, Christopher] Loyola Univ, Med Ctr, Dept Neurol, Maywood, IL 60153 USA	Kirkwood, MW (corresponding author), Childrens Hosp Colorado, Concuss Program, B285,13123 E 16th Ave, Aurora, CO 80045 USA.	michael.kirkwood@childrenscolorado.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892			Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Baron I., 2004, NEUROPSYCHOLOGICAL E; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Boone, 2007, ASSESSMENT FEIGNED C; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Courtney JC, 2003, CHILD NEUROPSYCHOL, V9, P109, DOI 10.1076/chin.9.2.109.14507; Delis D, 1994, CALIFORNIA VERBAL LE; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Flaro L., 2009, NEUROPSYCHOLOGY MALI, P369; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2004, MANUAL MED SYMPTOM V; Green P., DETECTION M IN PRESS; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P1250, DOI 10.1080/13854040902828272; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry G. K., 2005, FORENSIC NEUROPSYCHO, P205; Kirk JW, 2011, CHILD NEUROPSYCHOL, V17, P242, DOI 10.1080/09297049.2010.533166; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2010, CHILD NEUROPSYCHOL, V16, P604, DOI 10.1080/09297049.2010.495059; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; KLOVE H, 1963, MED CLIN N AM, V47, P1647, DOI 10.1016/S0025-7125(16)33515-5; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; MacAllister WS, 2009, CHILD NEUROPSYCHOL, V15, P521, DOI 10.1080/09297040902748226; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; McCaffrey R. J., 2009, NEUROPSYCHOLOGY MALI, P377; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Newton P, 2000, BRIT J DEV PSYCHOL, V18, P297, DOI 10.1348/026151000165706; Reitan RM., 1969, MANUAL ADM NEUROPSYC; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; STOUTHAMERLOEBER M, 1986, J ABNORM CHILD PSYCH, V14, P551, DOI 10.1007/BF01260523; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P481, DOI 10.1076/clin.16.4.481.13914; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHLSER ABBREVIATED; Wilson AE, 2003, SOC DEV, V12, P21, DOI 10.1111/1467-9507.00220; Woodcock R.W., 2001, WOODCOCKJOHNSON 3 TE	50	49	49	0	10	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	MAR	2012	24	1					36	45		10.1037/a0024628			10	Psychology, Clinical	Psychology	905XT	WOS:000301310200004	21767023				2021-06-18	
J	Zhu, XX; Tao, LY; Tejima-Mandeville, E; Qiu, JH; Park, J; Garber, K; Ericsson, M; Lo, EH; Whalen, MJ				Zhu, Xiaoxia; Tao, Luyang; Tejima-Mandeville, Emiri; Qiu, Jianhua; Park, Juyeon; Garber, Kent; Ericsson, Maria; Lo, Eng H.; Whalen, Michael J.			Plasmalemma Permeability and Necrotic Cell Death Phenotypes After Intracerebral Hemorrhage in Mice	STROKE			English	Article						apoptosis; inflammation; intracerebral hemorrhage; mice; necrosis; plasmalemma	CONTROLLED CORTICAL IMPACT; HYPOXIA-ISCHEMIA; APOPTOSIS; BRAIN; INHIBITION; NEURONS; MODEL; RAT; NEUROPROTECTION; IDENTIFICATION	Background and Purpose-Traumatic and ischemic brain injury induce plasmalemma permeability and necrosis; however, no studies have examined these aspects of cellular injury in intracerebral hemorrhage models. Methods-In vivo propidium iodide (PI) and YOYO-1 were used to assess plasmalemma damage after collagenase-induced intracerebral hemorrhage in mice. Ex vivo aspartylglutamylvalylaspartic acid, terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling, and electron microscopy were used to assess the relationship between plasmalemma permeability and mode of cell death. Cell types vulnerable to plasmalemma damage were determined by immunohistochemistry. Results-Plasma lemma permeability was first detected in the lesion at 1 to 3 hours and peaked at 48 to 72 hours. Neurons and IBA-1-positive cells with morphological features of monocytes were sensitive, whereas resident microglia and astocytes were resistant to plasmalemma permeability. PI+ cells colocalized with fluorescent-labeled caspase substrates and terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling beginning at 3 to 6 hours. At 48 hours, greater than half of injured cells were PI+/aspartylglutamylvalylaspartic acid- or PI+/terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling -suggesting necrosis, and <5% were PI-/terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling+ or PI-/aspartylglutamylvalylaspartic acid+. Electron microscopy confirmed ultrastructural features of necrosis at 24 hours after intracerebral hemorrhage, high mobility group box protein-1 was released from permeable cells, and mice deficient in receptor interacting protein kinase (RIPK) 3, a known necrosis trigger, had 50% less PI+ cells at 24 hours. Permeable cells remained in the brain for at least 24 hours with <10% spontaneous resealing. Conclusions-Necrosis contributes to cell demise after intracerebral hemorrhage. Programmed necrosis and plasmalemma damage may represent novel therapeutic targets to prevent cell death or rescue injured cells after intracerebral hemorrhage. (Stroke. 2012;43:524-531.)	[Whalen, Michael J.] Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Ctr Neurosci, Charlestown, MA 02129 USA; [Zhu, Xiaoxia; Tao, Luyang; Qiu, Jianhua; Park, Juyeon; Garber, Kent; Whalen, Michael J.] Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA; [Tejima-Mandeville, Emiri; Lo, Eng H.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; [Tejima-Mandeville, Emiri; Lo, Eng H.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; [Zhu, Xiaoxia] Fudan Univ, Huashan Hosp, Dept Rheumatol, Shanghai 200433, Peoples R China; [Tao, Luyang] Soochow Univ, Dept Forens Med, Suzhou, Peoples R China; [Ericsson, Maria] Harvard Univ, Sch Med, Electron Microscopy Facil, Boston, MA USA	Whalen, MJ (corresponding author), Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Ctr Neurosci, 149 13th St, Charlestown, MA 02129 USA.	MWhalen@Partners.org			China Natural Science FoundationNational Natural Science Foundation of China (NSFC) [30571909, 30872666, R37-NS37074, P01-NS55104, RO1NS061255, RO1NS064545]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS055104, R37NS037074, R01NS064545, R01NS061255] Funding Source: NIH RePORTER	Supported by the China Natural Science Foundation (30571909 and 30872666, L.T.), R37-NS37074, P01-NS55104 (E.H.L.), and RO1NS061255, RO1NS064545 (M.J.W.).	BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Cadichon SB, 2007, J NEUROSURG, V106, P36, DOI 10.3171/ped.2007.106.1.36; Carloni S, 2007, NEUROBIOL DIS, V27, P354, DOI 10.1016/j.nbd.2007.06.009; Cevik IU, 2003, CELL DEATH DIFFER, V10, P928, DOI 10.1038/sj.cdd.4401250; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Felberg RA, 2002, ANN NEUROL, V51, P517, DOI 10.1002/ana.10160; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Grossetete M, 2008, J CEREBR BLOOD F MET, V28, P752, DOI 10.1038/sj.jcbfm.9600572; Gurer G, 2009, BRAIN PATHOL, V19, P630, DOI 10.1111/j.1750-3639.2008.00226.x; Hayakawa K, 2010, ANN NY ACAD SCI, V1207, P50, DOI 10.1111/j.1749-6632.2010.05728.x; Hong JR, 1999, J VIROL, V73, P5056, DOI 10.1128/JVI.73.6.5056-5063.1999; Kelly KJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1309, DOI 10.1152/ajpcell.00353.2002; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215; Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003; Li H, 2010, INT J NEUROSCI, V120, P683, DOI 10.3109/00207454.2010.513460; London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202; Ma QY, 2011, J CEREBR BLOOD F MET, V31, P881, DOI 10.1038/jcbfm.2010.167; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Matsushita K, 2000, J CEREBR BLOOD F MET, V20, P396, DOI 10.1097/00004647-200002000-00022; Nguyen AP, 2008, CURR NEUROVASC RES, V5, P171, DOI 10.2174/156720208785425710; Northington FJ, 2001, NEUROBIOL DIS, V8, P207, DOI 10.1006/nbdi.2000.0371; Pisetsky DS, 2011, ANTIOXID REDOX SIGN, V15, P2209, DOI 10.1089/ars.2010.3865; Qiu JH, 2010, STROKE, V41, P2077, DOI 10.1161/STROKEAHA.110.590463; Qureshi AI, 2003, NEUROSURGERY, V52, P1041, DOI 10.1227/01.NEU.0000057694.96978.BC; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Unal-Cevik I, 2004, STROKE, V35, P2189, DOI 10.1161/01.STR.0000136149.81831.c5; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang XY, 2002, STROKE, V33, P1882, DOI 10.1161/01.STR.0000020121.41527.5D; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhao XR, 2009, STROKE, V40, pS92, DOI 10.1161/STROKEAHA.108.533158	35	49	53	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	FEB	2012	43	2					524	531		10.1161/STROKEAHA.111.635672			8	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	885RK	WOS:000299798300041	22076006	Bronze, Green Accepted			2021-06-18	
J	Li, J; Jiang, JY				Li, Jin; Jiang, Ji-yao			Chinese Head Trauma Data Bank: Effect of Hyperthermia on the Outcome of Acute Head Trauma Patients	JOURNAL OF NEUROTRAUMA			English	Article						acute head trauma patients; hyperthermia; outcome	PERCUSSION BRAIN-INJURY; PREDICTION; HYPOTHERMIA	Hyperthermia may accentuate the detrimental consequences of brain injury and worsen the outcome of patients with acute head trauma, especially severe traumatic brain injury (TBI). We explored the effect of different magnitudes and durations of hyperthermia in the first 3 days after injury on the outcome of 7145 patients with acute head trauma, including 1626 with severe TBI. The differences in mortality and unfavorable outcome between the normothermia group, mild fever group, moderate fever group, and high fever group were statistically significant (p < 0.001). The mortality and unfavorable outcome of severe TBI patients in the groups also differed significantly (p < 0.001). The mortality and unfavorable outcome of patients with 1 day, 2 days, and 3 days of high fever were significantly increased (p < 0.01). Our data strongly indicate that both degree and duration of early post-trauma hyperthermia are closely correlated with the outcome of acute TBI patients, especially severely injured ones, which indicates that hyperthermia may play a detrimental role in the delayed mechanisms of damage after acute TBI. Prevention of early hyperthermia after acute head trauma is therefore essential to the management of TBI patients.	[Li, Jin; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Dept Neurosurg, Sch Med, Renji Hosp, Shanghai 200127, Peoples R China	Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Dept Neurosurg, Sch Med, Renji Hosp, Shanghai 200127, Peoples R China.	Jiangjyb@online.sh.cn			National Health Science [200802093]; National Key Basic Research ProjectNational Basic Research Program of China [2012CB518100]; Science and Technology Committee of ShanghaiShanghai Science & Technology Committee [10JC1409800, 08411951900]; Program for Shanghai Outstanding Medical Academic Leaders	This work was supported by funding from a National Health Science Grant (no. 200802093), the National Key Basic Research Project (no. 2012CB518100), the Science and Technology Committee of Shanghai (no. 10JC1409800 and 08411951900), and the Program for Shanghai Outstanding Medical Academic Leaders.	Alyagari V, 2007, J NEUROL SCI, V261, P39, DOI 10.1016/j.jns.2007.04.030; Badjatia N, 2009, CRIT CARE MED, V37, pS250, DOI 10.1097/CCM.0b013e3181aa5e8d; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cairns Chris J S, 2002, Curr Opin Crit Care, V8, P106, DOI 10.1097/00075198-200204000-00003; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Childs C, 2006, NEUROCRIT CARE, V5, P10, DOI 10.1385/NCC:5:1:10; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Low D, 2009, J NEUROTRAUM, V26, P1177, DOI [10.1089/neu.2008.0841, 10.1089/neu.2008-0841]; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; TEASDALE G, 1974, LANCET, V2, P81; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	21	49	66	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					96	100		10.1089/neu.2011.1753			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300011	22026424	Green Published			2021-06-18	
J	Lifshitz, J; Lisembee, AM				Lifshitz, Jonathan; Lisembee, Amanda M.			Neurodegeneration in the somatosensory cortex after experimental diffuse brain injury	BRAIN STRUCTURE & FUNCTION			English	Article						Disector; Fractionator; Nucleator	TRAUMATIC AXONAL INJURY; NERVE GROWTH-FACTOR; HEAD-INJURY; OPTICAL FRACTIONATOR; CEREBRAL-CORTEX; TOTAL NUMBER; NEURONS; PLASTICITY; ATROPHY; ADULT	Disruption and consequent reorganization of central nervous system circuits following traumatic brain injury may manifest as functional deficits and behavioral morbidities. We previously reported axotomy and neuronal atrophy in the ventral basal (VB) complex of the thalamus, without gross degeneration after experimental diffuse brain injury in adult rats. Pathology in VB coincided with the development of late-onset aberrant behavioral responses to whisker stimulation, which lead to the current hypothesis that neurodegeneration after experimental diffuse brain injury includes the primary somatosensory barrel cortex (S1BF), which receives projection of VB neurons and mediates whisker somatosensation. Over 28 days after midline fluid percussion brain injury, argyrophilic reaction product within superficial layers and layer IV barrels at 1 day progresses into the cortex to subcortical white matter by 7 days, and selective inter-barrel septa and subcortical white matter labeling at 28 days. Cellular consequences were determined by stereological estimates of neuronal nuclear volumes and number. In all cortical layers, neuronal nuclear volumes significantly atrophied by 42-49% at 7 days compared to sham, which marginally attenuated by 28 days. Concomitantly, the number of healthy neurons was reduced by 34-45% at 7 days compared to sham, returning to control levels by 28 days. Progressive neurodegeneration, including argyrophilic reaction product and neuronal nuclear atrophy, indicates injury-induced damage and reorganization of the reciprocal thalamocortical projections that mediate whisker somatosensation. The rodent whisker barrel circuit may serve as a discrete model to evaluate the causes and consequences of circuit reorganization after diffuse brain injury.	[Lifshitz, Jonathan; Lisembee, Amanda M.] Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Coll Med, Dept Phys Med & Rehabil, Lexington, KY 40536 USA	Lifshitz, J (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Off B463,Biomed & Biol Sci Res Bldg,741 S Limesto, Lexington, KY 40536 USA.	JLifshitz@uky.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS065052, P30 NS051220]; Kentucky Spinal Cord and Head Injury Research Trust [7-11]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052, P30NS051220] Funding Source: NIH RePORTER	We are grateful to Dr. John T. Povlishock, Ms. C. Lynn Davis and Ms. Sue Walker for support and assistance in generating the tissue for stereological analysis. We thank the reviewers for constructive criticisms that improved the manuscript. This work was supported, in part, by the National Institutes of Health research grant (R01 NS065052) and core facility grant (P30 NS051220) and the Kentucky Spinal Cord and Head Injury Research Trust (7-11).	Beltramino C A, 1993, NIDA Res Monogr, V136, P101; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; Bothwell S, 2001, J NEUROSCI, V21, P4789, DOI 10.1523/JNEUROSCI.21-13-04789.2001; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; de Olmos S, 2009, NEUROSCIENCE, V164, P1347, DOI 10.1016/j.neuroscience.2009.09.022; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Feldman DE, 2005, SCIENCE, V310, P810, DOI 10.1126/science.1115807; FINCH CE, 1993, TRENDS NEUROSCI, V16, P104, DOI 10.1016/0166-2236(93)90134-8; Giaume C, 2009, NEUROSCIENTIST, V15, P351, DOI 10.1177/1073858409336092; GLASSMAN RB, 1994, EXP NEUROL, V125, P125, DOI 10.1006/exnr.1994.1016; Gogolla N, 2007, CURR OPIN NEUROBIOL, V17, P516, DOI 10.1016/j.conb.2007.09.002; GOLD BG, 1991, J NEUROSCI, V11, P943; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; GUNDERSEN HJG, 1988, J MICROSC-OXFORD, V151, P3, DOI 10.1111/j.1365-2818.1988.tb04609.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mikics E, 2008, PHYSIOL BEHAV, V94, P341, DOI 10.1016/j.physbeh.2008.01.023; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; O'Leary D D, 1994, Curr Opin Neurobiol, V4, P535, DOI 10.1016/0959-4388(94)90054-X; PAXINOS G, 1998, RAT BRAIN STEREOTAXI, V4; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; RICH KM, 1989, J NEUROCYTOL, V18, P569, DOI 10.1007/BF01187077; RICH KM, 1984, J COMP NEUROL, V230, P110, DOI 10.1002/cne.902300110; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; Sa MJ, 2000, ACTA NEUROPATHOL, V99, P643, DOI 10.1007/s004010051175; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SOFRONIEW MV, 1993, J NEUROSCI, V13, P5263; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Turrigiano GG, 2008, CELL, V135, P422, DOI 10.1016/j.cell.2008.10.008; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; Waite P, 1995, RAT NERVOUS SYSTEM; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	64	49	49	0	6	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653			BRAIN STRUCT FUNCT	Brain Struct. Funct.	JAN	2012	217	1					49	61		10.1007/s00429-011-0323-z			13	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	922UC	WOS:000302572800005	21597967	Green Accepted			2021-06-18	
J	Rasulo, FA; Girardini, A; Lavinio, A; De Peri, E; Stefini, R; Cenzato, M; Nodari, I; Latronico, N				Rasulo, Frank Anthony; Girardini, Alan; Lavinio, Andrea; De Peri, Elena; Stefini, Roberto; Cenzato, Marco; Nodari, Ilaria; Latronico, Nicola			Are Optimal Cerebral Perfusion Pressure and Cerebrovascular Autoregulation Related to Long-term Outcome in Patients With Aneurysmal Subarachnoid Hemorrhage?	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						subarachnoid hemorrhage; cerebrovascular autoregulation; cerebral perfusion pressure	BRAIN-INJURY; BLOOD-FLOW; REACTIVITY; VALIDATION; MANAGEMENT	Background and Objectives: Continuous assessment of the cerebrovascular autoregulation (CVA) through use of the pressure reactivity index (PRx), a moving linear correlation coefficient between mean arterial blood pressure and intracranial pressure, has been effective in optimizing cerebral perfusion pressure (CPPopt) in traumatic brain injured (TBI) patients. This study investigates the feasibility of measuring CPPopt in patients with aneurysmal subarachnoid hemorrhage (aSAH) by continuously assessing the CVA. Methods: Twenty-nine aSAH patients were enrolled, and data from CVA status, CPPopt, and periods when CPP was below, within, or above CPPopt were computed daily. Outcome was assessed at 6 months with the Glasgow Outcome Scale. Mann-Whitney U test was used to analyze differences in the duration of impaired CVA and duration of CPP below CPPopt in patients with good and poor outcomes. Multivariable logistic regression analysis was used to identify independent predictors of outcome. Results: CVA monitoring data were available for all 29 patients with a total monitoring time of 2757 h. The duration of impaired CVA was 36.5% (interquartile range: 24.6 to 49.8) of the total monitoring time in 15 patients with good outcome and 71.6% of the total monitoring time (51.2 to 80.0) in 14 patients with poor outcome (Mann-Whitney U test 3.295, P= 0.0010). PRx-based CPPopt could be identified in 26 patients (89.6%) with a total monitoring time of 2691 h. The duration of CPP below the CPPopt range was 28.0% (interquartile range: 18.0 to 47.0) of the total monitoring time in patients with good outcome and 76.0% (48.5 to 82.5) in patients with poor outcome (Mann-Whitney U test 2.779, P - 0.0054). Glasgow Coma Scale score and duration of impaired CVA were independently associated with 6-month outcome (Glasgow Coma Scale score odds ratio: 1.95, 95% confidence interval: 1.01-3.75; duration of impaired CVA odds ratio: 0.88, 95% confidence interval: 0.78-0.99). Conclusions: The assessment of CVA and CPPopt is feasible in aSAH patients and may provide important information regarding long-term outcome. A PRx above the 0.2 threshold and a CPP below the CPPopt range are associated with worse outcome.	[Rasulo, Frank Anthony; Girardini, Alan; Lavinio, Andrea; De Peri, Elena; Nodari, Ilaria; Latronico, Nicola] Univ Brescia, Spedali Civili, Dept Neuroanesthesia Neurointens Care, Brescia, Italy; [Stefini, Roberto; Cenzato, Marco] Univ Brescia, Spedali Civili, Dept Neurosurg, Brescia, Italy; [Lavinio, Andrea; Nodari, Ilaria] Cambridge Univ Hosp Fdn Trust, Dept Anaesthesia, Cambridge, England	Rasulo, FA (corresponding author), Spedali Civili Brescia, Policlin Satellite, Dept Anesthesiol Intens Care & Perioperat Med, Piazzale Osped Civili 1, I-25123 Brescia, Italy.	rasulo@med.unibs.it	Lavinio, Andrea/M-1778-2016; Cenzato, Marco/Q-7546-2016; LATRONICO, Nicola/F-1557-2010	Cenzato, Marco/0000-0003-0283-7421; LATRONICO, Nicola/0000-0002-2521-5871; RASULO, Francesco Antonio/0000-0002-7187-5168	University of Brescia	This study used internal funds of the University of Brescia.	Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Bijlenga P, 2010, NEUROCRIT CARE, V13, P17, DOI 10.1007/s12028-010-9362-1; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1998, ACT NEUR S, V71, P74; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; Diehl Rolf R, 2002, Eur J Ultrasound, V16, P31, DOI 10.1016/S0929-8266(02)00048-4; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Fujii Y, 1996, J NEUROSURG, V84, P35, DOI 10.3171/jns.1996.84.1.0035; Hartman JM, 2002, LARYNGOSCOPE, V112, P23, DOI 10.1097/00005537-200201000-00005; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lam JMK, 2000, NEUROSURGERY, V47, P819, DOI 10.1097/00006123-200010000-00004; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; Mascia L, 2000, INTENS CARE MED, V26, P202, DOI 10.1007/s001340050046; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; Myburgh J A, 2005, Crit Care Resusc, V7, P206; Naval NS, 2006, CRIT CARE MED, V34, P511, DOI 10.1097/01.CCM.0000198331.45998.85; Ogawa Y, 2007, ANESTH ANALG, V105, P1389, DOI 10.1213/01.ane.0000281910.95740.e4; Ohkuma H, 2001, STROKE, V32, P1176, DOI 10.1161/01.STR.32.5.1176; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Sackett D. L., 2000, EVIDENCE BASED MED P, V2nd; Schmidt B, 2003, STROKE, V34, P84, DOI 10.1161/01.STR.0000047849.01376.AE; SOLOMON RA, 1988, NEUROSURGERY, V23, P699, DOI 10.1227/00006123-198812000-00002; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; WIJDICKS EFM, 1990, CLIN NEUROL NEUROSUR, V92, P111, DOI 10.1016/0303-8467(90)90085-J	29	49	49	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2012	24	1					3	8		10.1097/ANA.0b013e318224030a			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	863EB	WOS:000298144500002	21709587				2021-06-18	
J	Shields, CG; Finley, MA; Chawla, N; Meadors, P				Shields, Cleveland G.; Finley, Michelle A.; Chawla, Neelu; Meadors, Patrick			Couple and Family Interventions in Health Problems	JOURNAL OF MARITAL AND FAMILY THERAPY			English	Article							TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; SPINAL-CORD-INJURY; QUALITY-OF-LIFE; IMPROVE REGIMEN ADHERENCE; POOR METABOLIC-CONTROL; EARLY-STAGE BREAST; CHRONIC CARE MODEL; MULTISYSTEMIC THERAPY; EDUCATION-PROGRAM	Intervention research for couples and families managing chronic health problems is in an early developmental stage. We reviewed randomized clinical trials of family interventions for common neurological diseases, cardiovascular diseases, cancer, and diabetes, which is similar to the content of previous reviews discussed later. One overriding theme of these studies is that patients with chronic illnesses and their families face a variety of challenges to which researchers have responded with an array of treatment modalities. Very few of the interventions reviewed, with the exception of treatment for adolescents with diabetes, tested family psychotherapy models. Most interventions were time-limited therapeutic interventions that trained families to improve their communication and problem-solving skills, individual and family coping skills, and medical management. Researchers more clearly described mechanisms of change in intervention studies with cancer and diabetes than with other diseases, and not surprisingly, they found greater empirical support for their interventions. Family interventions show promise to help patients and family members manage chronic illnesses. To develop an empirical base for family approaches to managing chronic illnesses, interventions must be based on theories that delineate mechanisms of change in family processes and skills in medical management necessary to maintain patients and family members health.	[Shields, Cleveland G.] Purdue Univ, Human Dev & Family Studies Dept, Marriage & Family Therapy Program, W Lafayette, IN 47907 USA	Shields, CG (corresponding author), Fowler Mem House,1200 W State St, W Lafayette, IN 47907 USA.	cgshields@purdue.edu		Shields, Cleveland/0000-0003-3709-6969			Aggarwal B, 2010, J CARDIOVASC NURS, V25, P444, DOI 10.1097/JCN.0b013e3181defd3e; ANDERSON BJ, 1990, J PEDIATR PSYCHOL, V15, P477, DOI 10.1093/jpepsy/15.4.477; [Anonymous], 2008, SPINAL CORD INJURY F; Askins MA, 2009, J PEDIATR PSYCHOL, V34, P551, DOI 10.1093/jpepsy/jsn124; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Berg CA, 2007, PSYCHOL BULL, V133, P920, DOI 10.1037/0033-2909.133.6.920; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Bowman KF, 2006, PSYCHO-ONCOL, V15, P834, DOI 10.1002/pon.1039; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Broadbent E, 2009, J PSYCHOSOM RES, V67, P17, DOI 10.1016/j.jpsychores.2008.12.001; Budin WC, 2008, NURS RES, V57, P199, DOI 10.1097/01.NNR.0000319496.67369.37; Burton J, 2010, AIDS BEHAV, V14, P1, DOI 10.1007/s10461-008-9471-4; Campbell TL, 2003, J MARITAL FAM THER, V29, P263, DOI 10.1111/j.1752-0606.2003.tb01204.x; Carnevale GJ, 2006, ARCH PHYS MED REHAB, V87, P1289, DOI 10.1016/j.apmr.2006.06.010; Chaney J. M., 2005, FAMILIES SYSTEMS HLT, V23, P329, DOI DOI 10.1037/1091-7527.23.3.329; Clayton JM, 2007, J CLIN ONCOL, V25, P715, DOI 10.1200/JCO.2006.06.7827; Cohen D., 2009, DIABETIC MED, V8, P928; Coleman K, 2009, HEALTH AFFAIR, V28, P75, DOI 10.1377/hlthaff.28.1.75; Cox MJ, 2003, CURR DIR PSYCHOL SCI, V12, P193, DOI 10.1111/1467-8721.01259; Dabelea D, 2007, JAMA-J AM MED ASSOC, V297, P2716; Donenberg GR, 2006, J PEDIATR PSYCHOL, V31, P869, DOI 10.1093/jpepsy/jsj102; Driscoll WD, 2004, PRIMARY CARE PSYCHOLOGY, P133, DOI 10.1037/10651-007; Dzewaltowski DA, 2004, ANN BEHAV MED, V28, P75, DOI 10.1207/s15324796abm2802_1; Elliott TR, 2008, BEHAV RES THER, V46, P1220, DOI 10.1016/j.brat.2008.08.004; Elliott TR, 2009, J CLIN PSYCHOL, V65, P406, DOI 10.1002/jclp.20527; Ellis DA, 2005, PEDIATRICS, V116, pE826, DOI 10.1542/peds.2005-0638; Ellis DA, 2005, J PEDIATR PSYCHOL, V30, P656, DOI 10.1093/jpepsy/jsi052; Ellis DA, 2005, DIABETES CARE, V28, P1604, DOI 10.2337/diacare.28.7.1604; Ellis DA, 2004, J CLIN PSYCHOL MED S, V11, P315, DOI 10.1023/B:JOCS.0000045351.98563.4d; Ellis D, 2008, DIABETES CARE, V31, P1746, DOI 10.2337/dc07-2094; Ellis DA, 2007, J PEDIATR PSYCHOL, V32, P194, DOI 10.1093/jpepsy/jsj116; Frank R. G., 2004, PRIMARY CARE PSYCHOL; Franks MM, 2006, J FAM PSYCHOL, V20, P311, DOI 10.1037/0893-3200.20.2.311; Franzen-Dahlin A, 2008, CLIN REHABIL, V22, P722, DOI 10.1177/0269215508090161; Geffken GR, 2008, REHABIL PSYCHOL, V53, P231, DOI 10.1037/0090-5550.53.2.231; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Glasgow RE, 2001, MILBANK Q, V79, P579, DOI 10.1111/1468-0009.00222; Glass TA, 2004, PSYCHOSOM MED, V66, P889, DOI 10.1097/01.psy.0000146326.01642.ca; Goudas LC, 2005, CANCER INVEST, V23, P182, DOI 10.1081/CNV-200050482; Grey M, 2009, RES NURS HEALTH, V32, P405, DOI 10.1002/nur.20336; Haley W E, 2001, Hosp J, V15, P1, DOI 10.1300/J011v15n04_01; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harrington R, 2010, CLIN REHABIL, V24, P3, DOI 10.1177/0269215509347437; Henggeler SW, 1999, CHILD PSYCHOL PSYCHI, V4, P2, DOI DOI 10.1017/S1360641798001786; Howe Carol J, 2005, J Pediatr Nurs, V20, P83, DOI 10.1016/j.pedn.2004.12.010; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kalaitzi C, 2007, J SURG ONCOL, V96, P235, DOI 10.1002/jso.20811; Kazak AE, 2005, J PEDIATR PSYCHOL, V30, P644, DOI 10.1093/jpepsy/jsi051; Kazak AE, 2004, J FAM PSYCHOL, V18, P493, DOI 10.1037/0893-3200.18.3.493; Keefe FJ, 2005, J PAIN SYMPTOM MANAG, V29, P263, DOI 10.1016/j.jpainsymman.2004.06.014; Kissane DW, 2006, AM J PSYCHIAT, V163, P1208, DOI 10.1176/appi.ajp.163.7.1208; Kuijer RG, 2004, PSYCHO-ONCOLOGY, V13, P321, DOI 10.1002/pon.749; Kurtz ME, 2005, J PAIN SYMPTOM MANAG, V30, P112, DOI 10.1016/j.jpainsymman.2005.02.008; Laffel LMB, 2003, J PEDIATR-US, V142, P409, DOI 10.1067/mpd.2003.138; Larson J, 2005, J CLIN NURS, V14, P995, DOI 10.1111/j.1365-2702.2005.01206.x; Lazarus R. S., 1984, STRESS COPING APPRAI; Lazarus RS, 2000, AM PSYCHOL, V55, P665, DOI 10.1037//0003-066X.55.6.665; Lett H, 2008, PSYCHOSOM MED, V70, P444, DOI 10.1097/PSY.0b013e31816c3c5c; Levine C, 2010, HEALTH AFFAIR, V29, P116, DOI 10.1377/hlthaff.2009.0520; Lewis MA, 2006, SOC SCI MED, V62, P1369, DOI 10.1016/j.socscimed.2005.08.006; Lincoln NB, 2003, STROKE, V34, P116, DOI 10.1161/01.STR.0000047850.33686.32; Lind M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004412; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; Lucke KT, 2004, QUAL LIFE RES, V13, P97, DOI 10.1023/B:QURE.0000015284.95515.17; Manne S, 2004, J CONSULT CLIN PSYCH, V72, P660, DOI 10.1037/0022-006X.72.4.660; Manne S, 2004, PSYCHO-ONCOL, V13, P37, DOI 10.1002/pon.724; Martire LM, 2004, HEALTH PSYCHOL, V23, P599, DOI 10.1037/0278-6133.23.6.599; McDaniel S., 1992, MED FAMILY THERAPY B; MCDANIEL SH, 1992, AM J FAM THER, V20, P101, DOI 10.1080/01926189208250882; McMillan SC, 2006, CANCER, V106, P214, DOI 10.1002/cncr.21567; MILLER L, 1993, AM J FAM THER, V21, P111, DOI 10.1080/01926189308250910; MILLERJOHNSON S, 1994, J CONSULT CLIN PSYCH, V62, P603, DOI 10.1037/0022-006X.62.3.603; Modi AC, 2009, EPILEPSY BEHAV, V14, P237, DOI 10.1016/j.yebeh.2008.10.009; Molton IR, 2009, J REHABIL RES DEV, V46, P31, DOI 10.1682/JRRD.2008.03.0044; Moos R. H., 1981, MANUAL FAMILY ENV SC, V50, P33; Morris AD, 1997, LANCET, V350, P1505, DOI 10.1016/S0140-6736(97)06234-X; Mosca L, 2008, CIRC-CARDIOVASC QUAL, V1, P98, DOI 10.1161/CIRCOUTCOMES.108.825786; Murphy HR, 2007, DIABETIC MED, V24, P1261, DOI 10.1111/j.1464-5491.2007.02229.x; Naar-King S., 2007, FAMILIES SYSTEMS HLT, V25, p[178, 112], DOI [10.1037/1091-7527.25.2.178, DOI 10.1037/1091-7527.25.2.178]; Nezu A., 2007, PROBLEM SOLVING THER, V3rd ed; Nezu AM, 2003, J CONSULT CLIN PSYCH, V71, P1036, DOI 10.1037/0022-006X.71.6.1036; Nijboer C, 1998, PSYCHO-ONCOL, V7, P3, DOI 10.1002/(SICI)1099-1611(199801/02)7:1<3::AID-PON320>3.3.CO;2-X; NINDS, 2009, NAT I NEUR DIS STRAT; Northouse L, 2005, PSYCHO-ONCOLOGY, V14, P478, DOI 10.1002/pon.871; Northouse LL, 2007, CANCER-AM CANCER SOC, V110, P2809, DOI 10.1002/cncr.23114; Pattison HM, 2006, ARCH DIS CHILD, V91, P487, DOI 10.1136/adc.2004.061416; Reisner Sari L, 2009, Top HIV Med, V17, P14; Rewers M, 2007, PEDIATR DIABETES, V8, P408, DOI 10.1111/j.1399-5448.2007.00352.x; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rodgers ML, 2007, AM J PHYS MED REHAB, V86, P482, DOI 10.1097/PHM.0b013e31805c00a1; Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918; Sahler OJZ, 2005, J CONSULT CLIN PSYCH, V73, P272, DOI 10.1037/0022-006X.73.2.272; Schulz R, 2009, REHABIL PSYCHOL, V54, P1, DOI 10.1037/a0014932; Schure LM, 2006, PATIENT EDUC COUNS, V62, P46, DOI 10.1016/j.pec.2005.05.015; Scott JL, 2004, J CONSULT CLIN PSYCH, V72, P1122, DOI 10.1037/0022-006X.72.6.1122; Seaburn D., 2007, J MARITAL FAMILY THE, V19, P177; SHIELDS CG, 1994, J MARITAL FAM THER, V20, P117, DOI 10.1111/j.1752-0606.1994.tb01021.x; Smith J, 2004, CLIN REHABIL, V18, P726, DOI 10.1191/0269215504cr790oa; Song MK, 2005, MED CARE, V43, P1049, DOI 10.1097/01.mlr.0000178192.10283.b4; Stehl ML, 2009, J PEDIATR PSYCHOL, V34, P803, DOI 10.1093/jpepsy/jsn130; Swift EE, 2006, ANN BEHAV MED, V32, P39, DOI 10.1207/s15324796abm3201_5; Tsouna-Hadjis E, 2000, ARCH PHYS MED REHAB, V81, P881, DOI 10.1053/apmr.2000.4435; Uchino B.N., 2004, SOCIAL SUPPORT PHYS; van Zyl LT, 2009, J THROMB THROMBOLYS, V27, P48, DOI 10.1007/s11239-007-0189-3; Visser-Meily A, 2008, PATIENT EDUC COUNS, V73, P153, DOI 10.1016/j.pec.2008.03.011; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Ward SE, 2009, HEALTH PSYCHOL, V28, P588, DOI 10.1037/a0015216; Wysocki T, 2008, J PEDIATR PSYCHOL, V33, P875, DOI 10.1093/jpepsy/jsn024; Wysocki T, 2007, DIABETES CARE, V30, P555, DOI 10.2337/dc06-1613; Wysocki T, 2006, J PEDIATR PSYCHOL, V31, P928, DOI 10.1093/jpepsy/jsj098	116	49	49	0	42	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0194-472X	1752-0606		J MARITAL FAM THER	J. Marital Fam. Ther.	JAN	2012	38	1					265	280		10.1111/j.1752-0606.2011.00269.x			16	Psychology, Clinical; Family Studies	Psychology; Family Studies	883KO	WOS:000299633100013	22283390				2021-06-18	
J	Meng, YL; Xiong, Y; Mahmood, A; Zhang, YL; Qu, CS; Chopp, M				Meng, Yuling; Xiong, Ye; Mahmood, Asim; Zhang, Yanlu; Qu, Changsheng; Chopp, Michael			Dose-dependent neurorestorative effects of delayed treatment of traumatic brain injury with recombinant human erythropoietin in rats Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						angiogenesis; cell proliferation; erythropoietin; neurogenesis; rat; sensorimotor; spatial learning; traumatic brain injury	ANEURYSMAL SUBARACHNOID HEMORRHAGE; ENDOTHELIAL GROWTH-FACTOR; ENHANCES NEUROGENESIS; FUNCTIONAL RECOVERY; SPATIAL MEMORY; DOUBLE-BLIND; STROKE; ANGIOGENESIS; CELLS; THERAPY	Object. Delayed (24 hours postinjury) treatment with erythropoietin (EPO) improves functional recovery following experimental traumatic brain injury (TBI). In this study, the authors tested whether therapeutic effects of delayed EPO treatment for TBI are dose dependent in an attempt to establish an optimal dose paradigm for the delayed EPO treatment. Methods. Experimental TBI was performed in anesthetized young adult male Wistar rats using a controlled cortical impact device. Sham animals underwent the same surgical procedure without injury. The animals (8 rats/group) received 3 intraperitoneal injections of EPO (0,1000,3000,5000, or 7000 U/kg body weight, at 24,48, and 72 hours) after TBI. Sensorimotor and cognitive functions were assessed using a modified neurological severity score and foot fault test, and Morris water maze tests, respectively. Animals were killed 35 days after injury, and the brain sections were stained for immunohistochemical analyses. Results. Compared with the saline treatment, EPO treatment at doses from 1000 to 7000 U/kg did not alter lesion volume but significantly reduced hippocampal neuron loss, enhanced angiogenesis and neurogenesis in the injured cortex and hippocampus, and significantly improved sensorimotor function and spatial learning. The animals receiving the medium dose of 5000 U/kg exhibited a significant improvement in histological and functional outcomes compared with the lower or higher EPO dose groups. Conclusions. These data demonstrate that delayed (24 hours postinjury) treatment with EPO provides dose-dependent neurorestoration, which may contribute to improved functional recovery after TBI, implying that application of an optimal dose of EPO is likely to increase successful preclinical and clinical trials for treatment of TBI. (DOI: 10.3171/2011.3.JNS101721)	[Meng, Yuling; Xiong, Ye; Mahmood, Asim; Zhang, Yanlu; Qu, Changsheng] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsxye@neuro.hfh.edu	Zhang, Yanlu/H-1275-2011	Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS62002, P01 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062002, P01NS042345] Funding Source: NIH RePORTER	This work was supported by NIH Grant Nos. R01 NS62002 (to Dr. Xiong) and P01 NS42345 (to Drs. Mahmood and Chopp).	BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cariou A, 2008, RESUSCITATION, V76, P397, DOI 10.1016/j.resuscitation.2007.10.003; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Chen Jieli, 2006, NeuroRx, V3, P466, DOI 10.1016/j.nurx.2006.07.007; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; Cotena S, 2008, PANMINERVA MED, V50, P185; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2005, NEUROSURGERY, V56, P821, DOI 10.1227/01.NEU.0000156493.00904.7E; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Grasso G, 2007, DRUG NEWS PERSPECT, V20, P315, DOI 10.1358/dnp.2007.20.5.1120219; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Iwai M, 2007, STROKE, V38, P2795, DOI 10.1161/STROKEAHA.107.483008; Jia LF, 2010, STROKE, V41, P2071, DOI 10.1161/STROKEAHA.110.586198; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lieutaud T, 2008, J NEUROTRAUM, V25, P1179, DOI 10.1089/neu.2008.0591; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Minnerup J, 2009, STROKE, V40, P3113, DOI 10.1161/STROKEAHA.109.555789; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nirula R, 2010, CRIT CARE RES PRACT, V2010, DOI 10.1155/2010/209848; Noguchi Constance Tom, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000860; Popoli P, 2007, ANN NY ACAD SCI, V1112, P219, DOI 10.1196/annals.1415.033; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Springborg JB, 2007, ACTA NEUROCHIR, V149, P1089, DOI 10.1007/s00701-007-1284-z; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tseng MY, 2009, J NEUROSURG, V111, P171, DOI 10.3171/2009.3.JNS081332; VELLY L, 2010, PHARMACOL THERAPEUT, V28, P445; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 2008, J CEREBR BLOOD F MET, V28, P1361, DOI 10.1038/jcbfm.2008.32; Wang L, 2011, J CEREBR BLOOD F MET, V31, P640, DOI 10.1038/jcbfm.2010.138; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077	68	49	53	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2011	115	3					550	560		10.3171/2011.3.JNS101721			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	816FG	WOS:000294583500017	21495821	Green Accepted			2021-06-18	
J	Kirkwood, MW; Hargrave, DD; Kirk, JW				Kirkwood, Michael W.; Hargrave, David D.; Kirk, John W.			The Value of the WISC-IV Digit Span Subtest in Detecting Noncredible Performance during Pediatric Neuropsychological Examinations	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Digit span; Reliable digit span; Wechsler intelligence scale for children; Symptom validity testing; Response bias; Postconcussion; Mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; WORD MEMORY TEST; CHILDREN; TOMM; POPULATION; CAPACITY; SAMPLE; TESTS; SCALE	In adult populations, research on methodologies to identify negative response bias has grown exponentially in the last two decades. Far less work has focused on methods appropriate for children. Although several recent studies have demonstrated the appropriateness of using stand-alone symptom validity tests with younger populations, a near absence of pediatric work has investigated embedded validity indicators. The present study examined the classification value of several scores derived from the WISC-IV Digit Span subtest. The sample consisted of 274 clinically referred mild traumatic brain injury patients aged 8 through 16 years. Fourteen percent of the participants failed both the Medical Symptom Validity Test and Test of Memory Malingering, which was used as the criterion for noncredible effort. For age-corrected scaled scores, a score of <= 5 resulted in the optimal cut-score, yielding sensitivity of 51% and specificity of 96%. For Reliable Digit Span, the optimal cut-score was <= 6, with sensitivity of 51% and specificity of 92%. Although only moderately sensitive, Digit Span scores are likely to have good utility in identifying noncredible performance in relatively high-functioning older children and adolescents. Indeed, classification statistics produced in this pediatric sample compare favorably with those produced in many real-world adult patients.	[Kirkwood, Michael W.] Childrens Hosp, Concuss Program, Dept Phys Med & Rehabil, Aurora, CO 80045 USA; Univ Colorado, Sch Med, Aurora, CO USA	Kirkwood, MW (corresponding author), Childrens Hosp, Concuss Program, Dept Phys Med & Rehabil, B285,13123 E 16th Ave, Aurora, CO 80045 USA.	kirkwood.michael@tchden.org					Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Babikian T., 2007, ASSESSMENT FEIGNED C, P103; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Boone, 2007, ASSESSMENT FEIGNED C; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Courtney JC, 2003, CHILD NEUROPSYCHOL, V9, P109, DOI 10.1076/chin.9.2.109.14507; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; Duncan SA, 2002, ASSESSMENT, V9, P56, DOI 10.1177/1073191102009001007; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Flaro L., 2009, NEUROPSYCHOLOGY MALI, P369; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P., 2004, MANUAL MED SYMPTOM V; Green P., 2007, ASSESSMENT FEIGNED C; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Harrison AG, 2010, ASSESSMENT, V17, P283, DOI 10.1177/1073191109348590; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Henry G. K., 2005, FORENSIC NEUROPSYCHO, P205; KIRK JW, 2011, CHILD NEUROPSYCHOL, DOI DOI 10.1080/09297049.2010.533166; Kirkwood M. W., PEDIAT FORE IN PRESS; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2010, CHILD NEUROPSYCHOL, V16, P604, DOI 10.1080/09297049.2010.495059; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; MacAllister WS, 2009, CHILD NEUROPSYCHOL, V15, P521, DOI 10.1080/09297040902748226; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; McCaffrey R. J., 2009, NEUROPSYCHOLOGY MALI, P377; Suhr J. A., 2007, ASSESSMENT MALINGERE; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D., 2003, WECHSLER INTELLIGENC; Ylioja SG, 2009, ARCH CLIN NEUROPSYCH, V24, P729, DOI 10.1093/arclin/acp078	42	49	49	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2011	26	5					377	384		10.1093/arclin/acr040			8	Psychology, Clinical; Psychology	Psychology	799QC	WOS:000293300200001	21602179	Bronze			2021-06-18	
J	Bouzat, P; Francony, G; Declety, P; Genty, C; Kaddour, A; Bessou, P; Brun, J; Jacquot, C; Chabardes, S; Bosson, JL; Payen, JF				Bouzat, Pierre; Francony, Gilles; Declety, Philippe; Genty, Celine; Kaddour, Affif; Bessou, Pierre; Brun, Julien; Jacquot, Claude; Chabardes, Stephan; Bosson, Jean-Luc; Payen, Jean-Francois			Transcranial Doppler to Screen on Admission Patients With Mild to Moderate Traumatic Brain Injury	NEUROSURGERY			English	Article						Computed tomographic scan; Mild traumatic brain injury; Minor head injury; Moderate head injury; Neuroworsening; Outcome; Transcranial Doppler	CRANIAL COMPUTED-TOMOGRAPHY; MINIMAL HEAD-INJURY; EMERGENCY-DEPARTMENT; NEUROLOGICAL DETERIORATION; INTRACRANIAL-PRESSURE; DECISION-MAKING; FLOW-VELOCITY; MANAGEMENT; TALK; RISK	BACKGROUND: Detecting patients at risk for secondary neurological deterioration (SND) after mild to moderate traumatic brain injury is challenging. OBJECTIVE: To assess the diagnostic accuracy of transcranial Doppler (TCD) on admission in screening these patients. METHODS: This prospective, observational cohort study enrolled 98 traumatic brain injury patients with an initial Glasgow Coma Scale score of 9 to 15 whose initial computed tomography (CT) scan showed either absent or mild lesions according to the Trauma Coma Data Bank (TCDB) classification, ie, TCDB I and TCDB II, respectively. TCD measurements of the 2 middle cerebral arteries were obtained on admission under stable conditions in all patients. Neurological outcome was reassessed on day 7. RESULTS: Of the 98 patients, 21 showed SND, ie, a decrease of >= 2 points from the initial Glasgow Coma Scale or requiring any treatment for neurological deterioration. Diastolic cerebral blood flow velocities and pulsatility index measurements were different between patients with SND and patients with no SND. Using receiver-operating characteristic analysis, we found the best threshold limits to be 25 cm/s (sensitivity, 92%; specificity, 76%; area under curve, 0.93) for diastolic cerebral blood flow velocity and 1.25 (sensitivity, 90%; specificity, 91%; area under curve, 0.95) for pulsatility index. According to a recursive-partitioning analysis, TCDB classification and TCD measurements were the most discriminative among variables to detect patients at risk for SND. CONCLUSION: In patients with no severe brain lesions on CT after mild to moderate traumatic brain injury, TCD on admission, in complement with brain CT scan, could accurately screen patients at risk for SND.	[Bouzat, Pierre; Francony, Gilles; Declety, Philippe; Brun, Julien; Jacquot, Claude; Payen, Jean-Francois] Hop Albert Michallon, Dept Anesthesia & Crit Care, F-38043 Grenoble, France; [Genty, Celine; Bosson, Jean-Luc] Hop Albert Michallon, Div Biostat, F-38043 Grenoble, France; [Kaddour, Affif] Hop Albert Michallon, Dept Emergency Med, F-38043 Grenoble, France; [Bessou, Pierre] Hop Albert Michallon, Dept Radiol, F-38043 Grenoble, France; [Chabardes, Stephan] Hop Albert Michallon, Dept Neurosurg, F-38043 Grenoble, France	Payen, JF (corresponding author), Hop Albert Michallon, Dept Anesthesia & Crit Care, BP 217, F-38043 Grenoble, France.	jfpayen@ujf-grenoble.fr	Bouzat, Pierre/AAC-4105-2019; bosson, jean-luc/AAP-5163-2020; Bouzat, Pierre/L-6881-2014; Payen, Jean-Francois/L-6667-2014	Bouzat, Pierre/0000-0003-4667-6738; bosson, jean-luc/0000-0003-0967-6026; 			af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Bouzat P, 2010, INTENS CARE MED, V36, P1514, DOI 10.1007/s00134-010-1919-0; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Compagnone C, 2009, NEUROSURGERY, V64, P690, DOI 10.1227/01.NEU.0000340796.18738.F7; Davis DP, 2007, J TRAUMA, V62, P277, DOI 10.1097/TA.0b013e31802ef4a3; de Andrade AF, 2006, SURG NEUROL, V65, pS10, DOI 10.1016/j.surneu.2005.11.034; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Gennarelli TA, 2005, ABBREVIATED INJURY S; Jaffres P, 2005, INTENS CARE MED, V31, P785, DOI 10.1007/s00134-005-2630-4; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; KLINGELHOFER J, 1988, J NEUROL, V235, P159, DOI 10.1007/BF00314307; LEE ST, 1995, ACTA NEUROCHIR, V135, P136, DOI 10.1007/BF02187757; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL RJ, 1986, STAT MED, V5, P517, DOI 10.1002/sim.4780050516; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Shafe M, 2004, ACAD EMERG MED, V11, P774, DOI 10.1197/j.aem.2004.02.518; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Thiruppathy SP, 2004, ACTA NEUROCHIR, V146, P1075, DOI 10.1007/s00701-004-0335-z; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; White H, 2006, INTENS CARE MED, V32, P981, DOI 10.1007/s00134-006-0173-y	39	49	51	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2011	68	6					1603	1609		10.1227/NEU.0b013e31820cd43e			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	760CK	WOS:000290299700059	21311381				2021-06-18	
J	Bryant, RA; Felmingham, KL; Silove, D; Creamer, M; O'Donnell, M; McFarlane, AC				Bryant, Richard A.; Felmingham, Kim L.; Silove, Derrick; Creamer, Mark; O'Donnell, Meaghan; McFarlane, Alexander C.			The association between menstrual cycle and traumatic memories	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Posttraumatic stress disorder; Flashback; Trauma memory; Menstrual; Glucocorticoid	POSTTRAUMATIC-STRESS-DISORDER; PITUITARY-ADRENAL AXIS; SEX-DIFFERENCES; CORTISOL; WOMEN	Background: Women in the mid-luteal phase of the menstrual cycle have been shown to have stronger emotional memories than other women. We investigated the extent to which experiencing a traumatic event during the luteal phase of the menstrual cycle is associated with stronger traumatic flashback memories. Methods: Consecutive female patients admitted to hospital after traumatic injury (n = 138) were assessed for days since last menstruation, as well as assessment of flashbacks. Twenty three (17%) women were in the mid-luteal phase (18-24) days at the time of trauma exposure and 29 (21%) were in the mid-luteal phase at the time of assessment. Results: Women were more likely to experience flashback memories if they were in the luteal phase during the trauma (22% vs. 9%), adjusted OR: 3.64 [95%CI: 0.99-13.29] after controlling for injury severity, age, trauma type, and mild traumatic brain injury. Women in the luteal phase at assessment were 4.89 times more likely to have flashbacks. Adjusted OR: 4.89 [95%CI: 1.39-17.86]. Conclusions: Increased glucocorticoid release associated with the luteal phase of the menstrual cycle may facilitate consolidation of trauma memories. (C) 2010 Elsevier B.V. All rights reserved.	[Bryant, Richard A.; Felmingham, Kim L.; Silove, Derrick] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Creamer, Mark; O'Donnell, Meaghan] Univ Melbourne, Melbourne, Vic 3010, Australia; [McFarlane, Alexander C.] Univ Adelaide, Adelaide, SA 5005, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; O'Donnell, Meaghan/0000-0003-4349-0022	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Australian Research CouncilAustralian Research Council	This research was supported by a National Health and Medical Research Council Program Grant and an Australian Research Council Discovery Grant.	Abercrombie HC, 2003, BEHAV NEUROSCI, V117, P505, DOI 10.1037/0735-7044.117.3.505; Andreano JM, 2008, PSYCHONEUROENDOCRINO, V33, P874, DOI 10.1016/j.psyneuen.2008.03.009; Andreano JM, 2009, LEARN MEMORY, V16, P248, DOI 10.1101/lm.918309; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Breslau N, 1999, PSYCHOL MED, V29, P813, DOI 10.1017/S0033291799008612; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Cahill L, 2006, NAT REV NEUROSCI, V7, P477, DOI 10.1038/nrn1909; Ferree NK, 2009, CONSCIOUS COGN, V18, P126, DOI 10.1016/j.concog.2008.11.008; HANDA RJ, 1994, HORM BEHAV, V28, P464, DOI 10.1006/hbeh.1994.1044; Koubovec D, 2005, MOL CELL ENDOCRINOL, V242, P23, DOI 10.1016/j.mce.2005.07.001; Kuhlmann S, 2005, PSYCHOPHARMACOLOGY, V183, P65, DOI 10.1007/s00213-005-0143-z; Olff M, 2007, PSYCHOL BULL, V133, P183, DOI 10.1037/0033-2909.133.2.183; PITMAN RK, 1989, BIOL PSYCHIAT, V26, P221, DOI 10.1016/0006-3223(89)90033-4; Roca CA, 2003, J CLIN ENDOCR METAB, V88, P3057, DOI 10.1210/jc.2002-021570; Roozendaal B, 1997, ANN NY ACAD SCI, V821, P247, DOI 10.1111/j.1749-6632.1997.tb48284.x	17	49	49	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0327			J AFFECT DISORDERS	J. Affect. Disord.	JUN	2011	131	1-3					398	401		10.1016/j.jad.2010.10.049			4	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	775KI	WOS:000291457800052	21093927				2021-06-18	
J	Scherer, MR; Burrows, H; Pinto, R; Littlefield, P; French, LM; Tarbett, AK; Schubert, MC				Scherer, Matthew R.; Burrows, Holly; Pinto, Robin; Littlefield, Philip; French, Louis M.; Tarbett, Aaron K.; Schubert, Michael C.			Evidence of Central and Peripheral Vestibular Pathology in Blast-Related Traumatic Brain Injury	OTOLOGY & NEUROTOLOGY			English	Article						Blast; Traumatic brain injury; Vestibular function testing; Videonystagmography	NICOTINE-INDUCED NYSTAGMUS; PSYCHIATRIC-DISORDERS; POSITIONAL VERTIGO; DIZZINESS; COMPLAINTS; RESPONSES; HANDICAP; ATAXIA; TESTS	Objective: To prospectively assay the vestibular and oculomotor systems of blast-exposed service members with traumatic brain injury (TBI). Study Design: Prospective, nonblinded, nonrandomized descriptive study. Setting: Tertiary care facility (Department of Defense Medical Center). Patients: Twenty-four service members recovering from blast-related TBI sustained in Iraq or Afghanistan. Interventions: Focused history and physical, videonystagmography (VNG), rotational chair, cervical vestibular-evoked myogenic potentials, computerized dynamic posturography, and self-report measures. Results: Vestibular testing confirms a greater incidence of vestibular and oculomotor dysfunction in symptomatic (vestibularlike dizziness) personnel with blast-related TBI relative to asymptomatic group members. VNG in the symptomatic group revealed abnormal nystagmus or oculomotor findings in 6 of 12 subjects tested. Similarly, rotational chair testing in this group revealed evidence of both peripheral (4/12) and central (2/12) vestibular pathology. By contrast, the asymptomatic group revealed less vestibular impairment with 1 of 10 rotational chair abnormalities. The asymptomatic group was further characterized by fewer aberrant nystagmus findings (4/12 abnormal VNGs). Computerized dynamic posturography testing revealed no significant differences between groups. Self-report measures demonstrated differences between groups. Conclusion: Vestibular function testing confirms a greater incidence of peripheral vestibular hypofunction in dizzy service members with blast-related TBI relative to those who are asymptomatic. Additionally, oculomotor abnormalities and/or nystagmus consistent with central involvement were present in 10 of the 24 study participants tested. The precise cause of these findings remains unknown.	[Scherer, Matthew R.] Univ Maryland, Dept Phys Therapy & Rehabil Sci, Baltimore, MD 21201 USA; [Burrows, Holly; Pinto, Robin] Army Audiol & Speech Ctr, No Washington, DC USA; [Tarbett, Aaron K.] Walter Reed Army Med Ctr, Optometry Serv, No Washington, DC USA; [French, Louis M.] Walter Reed Army Med Ctr, Traumat Brain Injury Serv, No Washington, DC USA; [Scherer, Matthew R.; Schubert, Michael C.] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA	Scherer, MR (corresponding author), Univ Maryland, Dept Phys Therapy & Rehabil Sci, Baltimore, MD 21201 USA.	Matthew.scherer@us.army.mil	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604; Littlefield, Philip/0000-0002-1890-2278			BARBER HO, 1984, OTOLARYNG HEAD NECK, V92, P55, DOI 10.1177/019459988409200112; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bertholon P, 2002, J NEUROL NEUROSUR PS, V72, P366, DOI 10.1136/jnnp.72.3.366; Bertholon P, 2006, ANN OTO RHINOL LARYN, V115, P587, DOI 10.1177/000348940611500804; Brey R, 2008, BALANCE FUNCTION ASS, P254; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Clarke AH, 2001, ACTA OTO-LARYNGOL, P84; COHEN H, 1992, OTOLARYNG HEAD NECK, V107, P638, DOI 10.1177/019459989210700505; Deutschlander A, 2008, NEUROIMAGE, V41, P479, DOI 10.1016/j.neuroimage.2008.03.001; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FERNANDEZ C, 1960, ANN OTOL RHINOL AND LARYNGOL, V69, P94; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; Gottshall K, 2009, ASS RES OT MIDW M BA; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; GROSSMAN GE, 1988, EXP BRAIN RES, V70, P470; Hoffer M, 2008, VESTIBULAR DIFFERENC; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer Michael E, 2009, Int Tinnitus J, V15, P115; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; Honrubia V, 1996, AM J OTOL, V17, P595; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Kattah JC, 2005, ANN NY ACAD SCI, V1039, P540, DOI 10.1196/annals.1325.063; KATTAH JC, 1984, NEUROLOGY, V34, P527, DOI 10.1212/WNL.34.4.527; Kim Ji Soo, 2006, J Clin Neurol, V2, P58, DOI 10.3988/jcn.2006.2.1.58; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Mott F. W., 1917, J ROY ARMY MED CORPS, V29, P662; NASHNER LM, 1977, EXP BRAIN RES, V30, P13; NASHNER LM, 1976, EXP BRAIN RES, V26, P59; O'Donnell J, 2000, J TOXICOL-CLIN TOXIC, V38, P659, DOI 10.1081/CLT-100102017; Oh Sun-Young, 2006, J Clin Neurol, V2, P283, DOI 10.3988/jcn.2006.2.4.283; PAIGE GD, 1989, ACTA OTO-LARYNGOL, V108, P1, DOI 10.3109/00016488909107385; Park HJ, 2005, ACTA OTO-LARYNGOL, V125, P852, DOI 10.1080/00016480510033667; Pereira CB, 2000, NEUROLOGY, V55, P1563, DOI 10.1212/WNL.55.10.1563; Polensek SH, 2010, AUDIOL NEURO-OTOL, V15, P241, DOI 10.1159/000255440; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; SAKATA E, 1991, ACTA OTO-LARYNGOL, P254; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Shepard NT, 1996, PRACTICAL MANAGEMENT; Shoman N, 2007, J LARYNGOL OTOL, V121, P166, DOI 10.1017/S0022215106004063; Strupp M, 1998, NEUROLOGY, V51, P838, DOI 10.1212/WNL.51.3.838; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; WAESPE W, 1985, SCIENCE, V228, P199, DOI 10.1126/science.3871968; Walker MF, 1999, ANN NY ACAD SCI, V871, P205, DOI 10.1111/j.1749-6632.1999.tb09186.x; Weathers F., 1991, PTSD CHECKLIST MILIT; Yabe I, 2003, J NEUROL, V250, P440, DOI 10.1007/s00415-003-1020-5; YARDLEY L, 1994, SOC SCI MED, V39, P573, DOI 10.1016/0277-9536(94)90100-7; Zapala DA, 2008, J AM ACAD AUDIOL, V19, P257, DOI 10.3766/jaaa.19.3.10	51	49	49	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1531-7129	1537-4505		OTOL NEUROTOL	Otol. Neurotol.	JUN	2011	32	4					571	580		10.1097/MAO.0b013e318210b8fa			10	Clinical Neurology; Otorhinolaryngology	Neurosciences & Neurology; Otorhinolaryngology	763ME	WOS:000290560600009	21358450				2021-06-18	
J	Fraser, DD; Close, TE; Rose, KL; Ward, R; Mehl, M; Farrell, C; Lacroix, J; Creery, D; Kesselman, M; Stanimirovic, D; Hutchison, JS				Fraser, Douglas D.; Close, Taylor E.; Rose, Keeley L.; Ward, Roxanne; Mehl, Martin; Farrell, Catherine; Lacroix, Jacques; Creery, David; Kesselman, Murray; Stanimirovic, Danica; Hutchison, James S.		Canadian Critical Care Translati	Severe traumatic brain injury in children elevates glial fibrillary acidic protein in cerebrospinal fluid and serum	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; glial fibrillary acidic protein; biomarker; cerebrospinal fluid; serum; therapeutic hypothermia	MODERATE HYPOTHERMIA; SENSITIVE ELISA; HEAD-INJURY; S100B; CSF; GFAP; BIOMARKER; DISEASE; MARKERS; DAMAGE	Objectives: 1) To determine the levels of glial fibrillary acidic protein (GFAP) in both cerebrospinal fluid and serum; 2) to determine whether serum GFAP levels correlate with functional outcome; and 3) to determine whether therapeutic hypothermia, as compared with normothermia, alters serum GFAP levels in children with severe traumatic brain injury (TBI). Design: Laboratory-based analyses; postrandomized, controlled trial. Setting: Four Canadian pediatric intensive care units and a university-affiliated laboratory. Patients: Twenty-seven children, aged 2-17 yrs, with severe TBI (Glasgow Coma Scale score of <= 8). Interventions: Hypothermia therapy (32.5 degrees C) for 24 hrs with cooling started within 8 hrs of injury and rewarming at a rate of 0.5 degrees C every 2 hrs or normothermia (37.0 degrees C). Measurements and Main Results: GFAP was measured in cerebrospinal fluid and serum, using enzyme-linked immunosorbent assay. Levels of GFAP were maximal on day 1 post-TBI, with cerebrospinal fluid GFAP (15.5 +/- 6.1 ng/mL) 25-fold higher than serum GFAP (0.6 +/- 0.2 ng/mL). Cerebro-spinal fluid GFAP normalized by day 7, whereas serum GFAP decreased gradually to reach a steady state by day 10. Serum GFAP measured on day 1 correlated with Pediatric Cerebral Performance Category scores determined at 6 months post-TBI rho = 0.527; p = .008) but failed to correlate with the injury scoring on admission, physiologic variables, or indices of injury measured on computerized tomography imaging. The areas under the receiver operating characteristic curves for pediatric intensive care unit day 1 serum GFAP in determining good outcome were 0.80 (pediatric cerebral performance category, 1-2; normal-mild disability) and 0.91 (pediatric cerebral performance category, 1-3; normal-moderate disability). For a serum GFAP cutoff level of 0.6 ng/mL, sensitivity and specificity were 88% to 90% and 43% to 71%, respectively. Serum GFAP levels were similar among children randomized to either therapeutic hypothermia or normothermia. Conclusions: GFAP was markedly elevated in cerebrospinal fluid and serum in children after severe TBI and serum GFAP measured on pediatric intensive care unit day 1 correlated with functional outcome at 6 months. Hypothermia therapy did not alter serum GFAP levels compared with normothermia after severe TBI in children. Serum GFAP concentration, together with other biomarkers, may have prognostic value after TBI in children. (Pediatr Crit Care Med 2011; 12:319-324)	[Fraser, Douglas D.] Univ Western Ontario, Dept Pediat, Div Crit Care Med, London, ON N6A 3K7, Canada; [Fraser, Douglas D.; Close, Taylor E.; Rose, Keeley L.] Univ Western Ontario, Dept Physiol, London, ON, Canada; [Fraser, Douglas D.; Close, Taylor E.; Rose, Keeley L.] Univ Western Ontario, Dept Pharmacol, London, ON, Canada; [Fraser, Douglas D.] Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada; [Fraser, Douglas D.; Close, Taylor E.; Rose, Keeley L.] Childrens Hlth Res Inst, London, ON, Canada; [Fraser, Douglas D.] Ctr Crit Illness Res, London, ON, Canada; [Ward, Roxanne] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8L1, Canada; [Mehl, Martin] R Biopharm AG, Darmstadt, Germany; [Farrell, Catherine; Lacroix, Jacques] St Justine Hosp, Div Intens Care, Dept Pediat, Montreal, PQ, Canada; [Creery, David] Childrens Hosp Eastern Ontario, Dept Pediat, Div Intens Care, Ottawa, ON K1H 8L1, Canada; [Kesselman, Murray] Childrens Hosp, Div Intens Care, Dept Pediat, Winnipeg, MB R3A 1S1, Canada; [Stanimirovic, Danica] CNR, Inst Biol Sci, Ottawa, ON, Canada; [Hutchison, James S.] Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.] Hosp Sick Children, Res Inst, Neurosci & Mental Hlth Res Program, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	Fraser, DD (corresponding author), Univ Western Ontario, Dept Pediat, Div Crit Care Med, London, ON N6A 3K7, Canada.	douglas.fraser@lhsc.on.ca			Children's Health Research Institute; Centre for Critical Illness Research; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MCT50398]; Canadian Diabetic Association; National Research Council of Canada Genomics and Health Initiative; Ontario Neurotrauma Foundation [ONBO-00009, ONRO-41]; Rick Hansen Institute [XG 99-057]; Hospital for Sick Children Foundation; Physicians Services Incorporated [98-62]; Fonds de la Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec [004095-104]; Children's Hospital of Eastern Ontario Research Institute [98/16S[E]]	Douglas D. Fraser was supported, in part, by the Children's Health Research Institute and the Centre for Critical Illness Research. He is a Canadian Institutes of Health Research Strategic Training Fellow in the Canadian Child Health Clinician Scientist Program. Taylor E. Close was supported, in part, by a Canadian Institutes of Health Research Doctoral Scholarship. Keeley L. Rose was supported, in part, by a Canadian Diabetic Association Doctoral Scholarship. The remaining authors have not disclosed any potential conflicts of interest. The biomarker research program within HyP-HIT was supported, in part, by a National Research Council of Canada Genomics and Health Initiative funding (D.S.).; The Hypothermia Pediatric Head Injury Trial (HyP-HIT) was supported by grant MCT50398 from the Canadian Institutes of Health Research (Canadian Neurotrauma Research Program), grants ONBO-00009 and ONRO-41 from the Ontario Neurotrauma Foundation, grant XG 99-057 from the Rick Hansen Institute, the Hospital for Sick Children Foundation, grant 98-62 from Physicians Services Incorporated, grant 004095-104 from Fonds de la Recherche en Sante du Quebec, and grant 98/16S[E] from Children's Hospital of Eastern Ontario Research Institute.	Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326; Bishop Naomi B, 2006, Curr Probl Pediatr Adolesc Health Care, V36, P318, DOI 10.1016/j.cppeds.2006.05.004; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CROLS R, 1986, J NEUROL, V233, P157, DOI 10.1007/BF00314423; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Geyer C, 2009, J NEUROS-PEDIATR, V4, P339, DOI 10.3171/2009.5.PEDS08481; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Hsu AA, 2008, PEDIATR CRIT CARE ME, V9, P245, DOI 10.1097/PCC.0b013e3181727b22; Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Kaneko T, 2009, RESUSCITATION, V80, P790, DOI 10.1016/j.resuscitation.2009.04.003; Lo TYM, 2009, J NEUROTRAUM, V26, P1479, DOI [10.1089/neu.2008.0753, 10.1089/neu.2008-0753]; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Martin C, 2008, CURR OPIN PEDIATR, V20, P294, DOI 10.1097/MOP.0b013e3282ff0dfa; MARTIN PM, 1995, J NEUROSCI METH, V58, P181, DOI 10.1016/0165-0270(94)00175-G; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Missler U, 1999, CLIN CHEM, V45, P138; Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd; NOPPE M, 1986, CLIN CHIM ACTA, V155, P143, DOI 10.1016/0009-8981(86)90275-5; Notturno F, 2009, MUSCLE NERVE, V40, P50, DOI 10.1002/mus.21323; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; ROSENGREN LE, 1992, J NEUROSCI METH, V44, P113, DOI 10.1016/0165-0270(92)90004-W; Shafi NI, 2006, PEDIATR CRIT CARE ME, V7, P468, DOI 10.1097/01.PCC.0000235258.79253.8C; SIMPSON D, 1982, LANCET, V2, P450; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4	39	49	50	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAY	2011	12	3					319	324		10.1097/PCC.0b013e3181e8b32d			6	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	759MB	WOS:000290248500022	20625342				2021-06-18	
J	Mustafa, AG; Wang, JA; Carrico, KM; Hall, ED				Mustafa, Ayman G.; Wang, Juan A.; Carrico, Kimberly M.; Hall, Edward D.			Pharmacological inhibition of lipid peroxidation attenuates calpain-mediated cytoskeletal degradation after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						alpha-spectrin; calpain; lipid peroxidation; traumatic brain injury; U-83836E	ALPHA-II-SPECTRIN; ACUTE MITOCHONDRIAL DYSFUNCTION; CONTROLLED CORTICAL IMPACT; EXPERIMENTAL HEAD-INJURY; CYCLOSPORINE-A ANALOG; NA+/K+-PUMP ATPASE; BREAKDOWN PRODUCTS; CEREBROSPINAL-FLUID; OXIDATIVE DAMAGE; MOUSE MODEL	P>Free radical-induced lipid peroxidation (LP) is critical in the evolution of secondary injury following traumatic brain injury (TBI). Previous studies in our laboratory demonstrated that U-83836E, a potent LP inhibitor, can reduce post-TBI LP along with an improved maintenance of mouse cortical mitochondrial bioenergetics and calcium (Ca2+) buffering following severe (1.0 mm; 3.5 m/s) controlled cortical impact TBI (CCI-TBI). Based upon this preservation of a major Ca2+ homeostatic mechanism, we have now performed dose-response and therapeutic window analyses of the ability of U-83836E to reduce post-traumatic calpain-mediated cytoskeletal (alpha-spectrin) proteolysis in ipsilateral cortical homogenates at its 24 h post-TBI peak. In the dose-response analysis, mice were treated with a single i.v. dose of vehicle or U-83836E (0.1, 0.3, 1.3, 3.0, 10.0 or 30.0 mg/kg) at 15 min after injury. U-83836E produced a dose-related attenuation of alpha-spectrin degradation with the maximal decrease being achieved at 3.0 mg/kg. Next, the therapeutic window was tested by delaying the single 3 mg/kg i.v. dose from 15 min post-injury out to 1, 3, 6 or 12 h. No reduction in alpha-spectrin degradation was observed when the treatment delay was 1 h or longer. However, in a third experiment, we re-examined the window with repeated U-83836E dosing (3.0 mg/kg i.v. followed by 10 mg/kg i.p. maintenance doses at 1 and 3 h after the initial i.v. dose) which significantly reduced 24 h alpha-alpha-spectrin degradation even when treatment initiation was withheld until 12 h post-TBI. These results demonstrate the relationship between post-TBI LP, disruptions in neuronal Ca2+ homeostasis and calpain-mediated cytoskeletal damage.	[Mustafa, Ayman G.; Wang, Juan A.; Carrico, Kimberly M.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Mustafa, Ayman G.] Jordan Univ Sci & Technol, Dept Anat, Irbid, Jordan	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone Str,BBSRB Room 483, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1P30 NS051220, 1P01 NS058484]; Kentucky Spinal Cord & Head Injury Research Trust; Jordan University of Science and Technology; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS046566, P01NS058484] Funding Source: NIH RePORTER	These studies were supported by NIH grants 1P30 NS051220 and 1P01 NS058484 and funding from the Kentucky Spinal Cord & Head Injury Research Trust and from the Jordan University of Science and Technology.	Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Aikman J, 2006, DEV NEUROSCI-BASEL, V28, P457, DOI 10.1159/000094171; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Cardali S, 2006, J Neurosurg Sci, V50, P25; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Durmaz R, 2003, CAN J NEUROL SCI, V30, P143, DOI 10.1017/S0317167100053415; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gadelha FR, 1997, ARCH BIOCHEM BIOPHYS, V345, P243, DOI 10.1006/abbi.1997.0259; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Hall ED, 1998, J NEUROSCI RES, V53, P66, DOI 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.3.CO;2-K; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Jacquard C, 2006, FASEB J, V20, P1021, DOI 10.1096/fj.05-5085fje; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; KIMURA M, 1992, BRIT J PHARMACOL, V107, P488, DOI 10.1111/j.1476-5381.1992.tb12772.x; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LIU TH, 1989, AM J PHYSIOL, V256, pH589; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; MUNNS PL, 1995, FREE RADICAL BIO MED, V18, P467, DOI 10.1016/0891-5849(94)00163-E; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Ozsuer H, 2005, NEUROSURG REV, V28, P143, DOI 10.1007/s10143-004-0374-1; Pedersen WA, 1999, EXP NEUROL, V155, P1, DOI 10.1006/exnr.1998.6890; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Racay P, 1997, BIOCHEM MOL BIOL INT, V41, P647; RANDALL RD, 1992, J NEUROSCI, V12, P1882; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; ROHN TT, 1993, BIOCHEM PHARMACOL, V46, P525, DOI 10.1016/0006-2952(93)90530-A; Rohn TT, 1996, BIOCHEM PHARMACOL, V51, P471, DOI 10.1016/0006-2952(95)02222-8; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Spiteller G, 2006, FREE RADICAL BIO MED, V41, P362, DOI 10.1016/j.freeradbiomed.2006.03.013; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Violi F, 1999, DIABETES-METAB RES, V15, P283, DOI 10.1002/(SICI)1520-7560(199907/08)15:4<283::AID-DMRR42>3.0.CO;2-U; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6	72	49	49	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2011	117	3					579	588		10.1111/j.1471-4159.2011.07228.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	749KJ	WOS:000289464500020	21361959	Bronze, Green Accepted			2021-06-18	
J	Whiteneck, G; Gassaway, J; Dijkers, M; Backus, D; Charlifue, S; Chen, D; Hammond, F; Hsieh, CH; Smout, RJ				Whiteneck, Gale; Gassaway, Julie; Dijkers, Marcel; Backus, Deborah; Charlifue, Susan; Chen, David; Hammond, Flora; Hsieh, Ching-Hui; Smout, Randall J.			Inpatient treatment time across disciplines in spinal cord injury rehabilitation	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Spinal cord injuries; Rehabilitation; Health services research; Occupational therapy; Physical therapy; Rehabilitation nursing; Psychology; Speech-language pathology; Social work; Case management; Recreation therapy; Practice-based evidence; Paraplegia; Tetraplegia	LENGTH-OF-STAY; SCIREHAB PROJECT SERIES; MEDICAL REHABILITATION; STROKE REHABILITATION; FUNCTIONAL STATUS; TRAUMATIC BRAIN; OUTCOMES; IMPROVEMENT; SEVERITY; INTENSITY	Background/objective: Length of stay (LOS) for rehabilitation treatment after spinal cord injury (SCI) has been documented extensively. However, there is almost no published research on the nature, extent, or intensity of the various treatments patients receive during their stay. This study aims at providing such information on a large sample of patients treated by specialty rehabilitation inpatient programs. Methods: Six hundred patients with traumatic SCI admitted to six rehabilitation centers were enrolled. Time spent on various therapeutic activities was documented by each rehabilitation clinician after each patient encounter. Patients were grouped by neurologic level and completeness of injury. Total time spent by each rehabilitation discipline over a patient's stay and total minutes of treatment per week were calculated. Ordinary least squares stepwise regression models were used to identify patient and injury characteristics associated with time spent in rehabilitation treatment overall and within each discipline. Results: Average LOS was 55 days (standard deviation 37), during which 180 (106) hours of treatment were received, or 24 (5) hours per week. Extensive variation was found in the amount of treatment received, between and within neurologic groups. Total hours of treatment provided throughout a patient's stay were primarily determined by LOS, which in turn was primarily predicted by medical acuity. Variation in minutes per week of treatment delivered by individual disciplines was predicted poorly by patient and injury characteristics. Conclusions: Variations between and within SCI rehabilitation patient groups in LOS, minutes of treatment per week overall, and for each rehabilitation discipline are large. Variation in treatment intensity was not well explained by patient and injury characteristics. In accordance with practice-based evidence methodology, the next step in the SCIRehab study will be to determine which treatment interventions are related with positive outcomes (at 1 year post injury), after controlling for patient and injury differences.	[Gassaway, Julie; Smout, Randall J.] Inst Clin Outcomes Res, Salt Lake City, UT 84102 USA; [Whiteneck, Gale; Charlifue, Susan] Craig Hosp, Englewood, CO USA; [Dijkers, Marcel] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Backus, Deborah] Shepherd Ctr, Atlanta, GA USA; [Backus, Deborah] Emory Univ, Sch Med, Atlanta, GA USA; [Chen, David] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Hammond, Flora] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora] Indiana Univ, Indianapolis, IN 46204 USA; [Hsieh, Ching-Hui] Natl Rehabil Hosp, Ctr Postacute Studies, Washington, DC USA	Gassaway, J (corresponding author), Inst Clin Outcomes Res, 699 E South Temple, Salt Lake City, UT 84102 USA.	jgassaway@isiscor.com	Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research, Office of Rehabilitative Services, US Department of EducationUS Department of Education [H133A060103, H133N060005]; Carolinas Rehabilitation, Mount Sinai School of Medicine [H133N060027]; National Rehabilitation Hospital [H133N060028]; Rehabilitation Institute of Chicago [H133N060014]; Shepherd Center [H133N060009]	The contents of this paper were developed under grants from the National Institute on Disability and Rehabilitation Research, Office of Rehabilitative Services, US Department of Education, to Craig Hospital (grant # H133A060103 and # H133N060005), Carolinas Rehabilitation, Mount Sinai School of Medicine (grant # H133N060027), National Rehabilitation Hospital (grant # H133N060028), Rehabilitation Institute of Chicago (grant # H133N060014), and Shepherd Center (grant # H133N060009). The opinions contained in this publication are those of the grantees and do not necessarily reflect those of the US Department of Education.	Abeyta N, 2009, J SPINAL CORD MED, V32, P336, DOI 10.1080/10790268.2009.11760787; AVERILL RF, 1992, HEALTH SERV RES, V27, P587; Berns S, 1957, REHABILITATION MONOG; Brougham R, 2011, J SPINAL CORD MED, V34, P186, DOI 10.1179/107902611X12971826988174; Cahow C, 2009, J SPINAL CORD MED, V32, P298, DOI 10.1080/10790268.2009.11760783; Clemmer TP, 1999, CRIT CARE MED, V27, P1768, DOI 10.1097/00003246-199909000-00011; DEJONG G, 2007, ANN C AM C REH MED W; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1284, DOI 10.1016/j.apmr.2009.02.009; Eastwood EA, 1999, ARCH PHYS MED REHAB, V80, P1457, DOI 10.1016/S0003-9993(99)90258-7; Fiedler R.C., 1996, FUNCTIONAL EVALUATIO, P75; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P184, DOI 10.1097/00002060-200003000-00012; Foy T, 2011, J SPINAL CORD MED, V34, P162, DOI 10.1179/107902611X12971826988093; Fromovich-Amit Y, 2009, SPINAL CORD, V47, P597, DOI 10.1038/sc.2008.178; Garcia RA, 2002, AM J PHYS MED REHAB, V81, P458, DOI 10.1097/00002060-200206000-00011; Gassaway J, 2005, ARCH PHYS MED REHAB, V86, pS16, DOI 10.1016/j.apmr.2005.08.114; Gassaway J, 2011, J SPINAL CORD MED, V34, P176, DOI 10.1179/107902611X12971826988138; Gassaway J, 2009, J SPINAL CORD MED, V32, P260, DOI 10.1080/10790268.2009.11760780; Gordan W, 2009, J SPINAL CORD MED, V32, P307, DOI 10.1080/10790268.2009.11760784; HAMMOND F, 2010, J SPINAL CORD MED, V33; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS8, DOI 10.1016/j.apmr.2005.08.116; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Horn SD, 2002, J PEDIATR-US, V141, P496, DOI 10.1067/mpd.2002.126925; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; HORN SD, 1997, CLIN PRACTICE IMPROV; Horn SD, 2007, MED CARE, V45, pS50, DOI 10.1097/MLR.0b013e318070c07b; Huston T, 2011, J SPINAL CORD MED, V34, P196, DOI 10.1179/107902611X12971826988219; Jakob W, 2009, J NEUROTRAUM, V26, P2037, DOI 10.1089/neu.2008.0824; Johnson K, 2009, J SPINAL CORD MED, V32, P329, DOI 10.1080/10790268.2009.11760786; Johnston MV, 2004, J SPINAL CORD MED, V27, P241, DOI 10.1080/10790268.2004.11753755; Marino R, 2003, REFERENCE MANUAL INT; McKinley W, 2007, J SPINAL CORD MED, V30, P215, DOI 10.1080/10790268.2007.11753929; MEINERS T, 2004, E REHABILITATION STU, V43, P129; Natale A, 2009, J SPINAL CORD MED, V32, P270, DOI 10.1080/10790268.2009.11760781; National Spinal Cord Injury Statistical Center, 2009, ANN REP SPIN CORD IN; Osterthun R, 2009, SPINAL CORD, V47, P339, DOI 10.1038/sc.2008.127; Ozelie R, 2009, J SPINAL CORD MED, V32, P283, DOI 10.1080/10790268.2009.11760782; Pagliacci MC, 2003, ARCH PHYS MED REHAB, V84, P1266, DOI 10.1016/S0003-9993(03)00234-X; Pagliacci MC, 2003, SPINAL CORD, V41, P620, DOI 10.1038/sj.sc.3101521; Post MWM, 2005, J REHABIL RES DEV, V42, P75, DOI 10.1682/JRRD.2004.10.0133; Rundquist J, 2011, J SPINAL CORD MED, V34, P205, DOI 10.1179/107902611X12971826988255; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Seel R T, 2001, J Spinal Cord Med, V24, P241; Stevens J., 1999, INTERMEDIATE STAT MO, V2nd ed.; Stevens J., 2003, PARTIAL SEMIPARTIAL; Taylor S, 2011, J SPINAL CORD MED, V34, P151, DOI 10.1179/10 7902611X12971826988057; Tooth L, 2003, SPINAL CORD, V41, P220, DOI 10.1038/sj.sc.3101433; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Whiteneck G, 2009, J SPINAL CORD MED, V32, P251, DOI 10.1080/10790268.2009.11760779; Willson D F, 2000, Pediatr Crit Care Med, V1, P127, DOI 10.1097/00130478-200010000-00007; Wilson C, 2009, J SPINAL CORD MED, V32, P319, DOI 10.1080/10790268.2009.11760785; Yokoyama O, 2006, ARCH PHYS MED REHAB, V87, P1189, DOI 10.1016/j.apmr.2006.05.017	53	49	50	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	MAR	2011	34	2					133	148		10.1179/107902611X12971826988011			16	Clinical Neurology	Neurosciences & Neurology	744FR	WOS:000289080800003	21675353	Green Published			2021-06-18	
J	Danckwardt, S; Gantzert, AS; Macher-Goeppinger, S; Probst, HC; Gentzel, M; Wilm, M; Grone, HJ; Schirmacher, P; Hentze, MW; Kulozik, AE				Danckwardt, Sven; Gantzert, Anne-Susan; Macher-Goeppinger, Stephan; Probst, Hans Christian; Gentzel, Marc; Wilm, Matthias; Groene, Hermann-Josef; Schirmacher, Peter; Hentze, Matthias W.; Kulozik, Andreas E.			p38 MAPK Controls Prothrombin Expression by Regulated RNA 3 ' End Processing	MOLECULAR CELL			English	Article							TRAUMATIC BRAIN-INJURY; POLY(A) SITE SELECTION; PRE-MESSENGER-RNA; GENE-EXPRESSION; MOLECULAR-MECHANISMS; CANCER DEVELOPMENT; VENOUS THROMBOSIS; PROTEASE NEXIN-1; 3'-END FORMATION; FACTOR CSTF-64	Thrombin is a key protease involved in blood coagulation, complement activation, inflammation, angiogenesis, and tumor invasion. Although induced in many (patho-)physiological conditions, the underlying mechanisms controlling prothrombin expression remained enigmatic. We have now discovered that prothrombin expression is regulated by a post-transcriptional regulatory mechanism responding to stress and inflammation. This mechanism is triggered by external stimuli that activate p38 MAPK. In turn, p38 MAPK upmodulates canonical 3' end processing components and phosphorylates the RNA-binding proteins FBP2 and FBP3, which inhibit 3' end processing of mRNAs, such as prothrombin mRNA, that bear a defined upstream sequence element (USE) in their 3'UTRs. Upon phosphorylation, FBP2 and FBP3 dissociate from the USE, making it accessible to proteins that stimulate 3' end processing. We provide in vivo evidence suggesting the importance of this mechanism in inflammatory hypercoagulation and tumor invasion. Regulated 3' end processing thus emerges as a key mechanism of gene regulation with broad biological and medical implications.	[Danckwardt, Sven; Gantzert, Anne-Susan; Hentze, Matthias W.; Kulozik, Andreas E.] European Mol Biol Lab, Mol Med Partnership Unit, Heidelberg, Germany; [Danckwardt, Sven; Gantzert, Anne-Susan; Kulozik, Andreas E.] Univ Heidelberg, Dept Pediat Oncol Hematol & Immunol, Heidelberg, Germany; [Macher-Goeppinger, Stephan; Schirmacher, Peter] Univ Heidelberg, Inst Pathol, D-6900 Heidelberg, Germany; [Probst, Hans Christian] Johannes Gutenberg Univ Mainz, Inst Immunol, D-6500 Mainz, Germany; [Gentzel, Marc] Max Planck Inst Mol Cell Biol & Genet MPI CBG, Dresden, Germany; [Wilm, Matthias] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 2, Ireland; [Groene, Hermann-Josef] German Canc Res Ctr, Dept Cellular & Mol Pathol, D-6900 Heidelberg, Germany	Hentze, MW (corresponding author), European Mol Biol Lab, Mol Med Partnership Unit, Heidelberg, Germany.	hentze@embl.de; andreas.kulozik@med.uni-heidelberg.de	Kulozik, Andreas/AAO-2432-2020; Hentze, Matthias W/V-3980-2017	Hentze, Matthias W/0000-0002-4023-7876; PROBST, Hans Christian/0000-0002-7926-0651; Gentzel, Marc/0000-0002-4482-6010; Wilm, Matthias/0000-0002-5461-6834	University of Heidelberg; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG); Fritz-Thyssen Stiftung; DFG ForschergruppeGerman Research Foundation (DFG) [FOR 426]; Lautenschlager Research Prize	We are grateful to T. Heise, J. Patton, A. Krainer, B. Blencowe, C. and J. Lutz, H.-J. Chung, D. Levens, A.-B. Shyu, J. Izaquierdo, J. Valcarcel, M. Sattler, A. Lamond, V. Lohmann, B. Jockusch for providing plasmids, cell lines, and antibodies. We thank the Tissue Bank of the National Center for Tumor Diseases (NCT), Heidelberg, Germany, for providing patient samples. We thank P. Ivanov, N. Gehring, S. Breit, G. Neu-Yilik, O. Reddy Bandapalli, and the team of the Molecular Medicine Partnership Unit for advice and discussions. This work was funded by the Young Investigator Award fellowship from the University of Heidelberg (to S.D. and to S.M.G.), by grants from the Deutsche Forschungsgemeinschaft (to S.D. and to A.E.K.), the Fritz-Thyssen Stiftung (to A.E.K.), the DFG Forschergruppe (FOR 426: "Complex RNA-protein interactions in the maturation and function of eukaryotic mRNA"), and funds from the Lautenschlager Research Prize (to A.E.K. and M.W.H.).	Barabino SML, 1999, CELL, V99, P9, DOI 10.1016/S0092-8674(00)80057-4; Blom JW, 2005, JAMA-J AM MED ASSOC, V293, P715, DOI 10.1001/jama.293.6.715; Boccaccio C, 2005, CANCER RES, V65, P8579, DOI 10.1158/0008-5472.CAN-05-2277; Boven LA, 2003, J IMMUNOL, V170, P2638, DOI 10.4049/jimmunol.170.5.2638; Briata P, 2005, MOL CELL, V20, P891, DOI 10.1016/j.molcel.2005.10.021; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Chapman J, 2006, AUTOIMMUN REV, V5, P528, DOI 10.1016/j.autrev.2006.02.011; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Citron BA, 2000, J NEUROTRAUM, V17, P1191, DOI 10.1089/neu.2000.17.1191; Danckwardt S, 2004, BLOOD, V104, P428, DOI 10.1182/blood-2003-08-2894; Danckwardt S, 2008, EMBO J, V27, P482, DOI 10.1038/sj.emboj.7601932; Danckwardt S, 2007, EMBO J, V26, P2658, DOI 10.1038/sj.emboj.7601699; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Gehring NH, 2001, NAT GENET, V28, P389, DOI 10.1038/ng578; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Hall-Pogar T, 2007, RNA, V13, P1103, DOI 10.1261/rna.577707; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; Hu L, 2008, CANCER RES, V68, P4666, DOI 10.1158/0008-5472.CAN-07-6276; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Ji Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008419; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kazerouninia A, 2010, RNA, V16, P197, DOI 10.1261/rna.1622010; Kim S, 1998, J NEUROSCI RES, V53, P304, DOI 10.1002/(SICI)1097-4547(19980801)53:3<304::AID-JNR4>3.0.CO;2-E; Kuderer NM, 2009, J CLIN ONCOL, V27, P4902, DOI 10.1200/JCO.2009.22.4584; Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Licatalosi DD, 2008, NATURE, V456, P464, DOI 10.1038/nature07488; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lutz CS, 2008, ACS CHEM BIOL, V3, P609, DOI 10.1021/cb800138w; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Miller GJ, 2004, J THROMB HAEMOST, V2, P2107, DOI 10.1111/j.1538-7836.2004.01011.x; Millevoi S, 2009, NUCLEIC ACIDS RES, V37, P4672, DOI 10.1093/nar/gkp470; Moreira A, 1998, GENE DEV, V12, P2522, DOI 10.1101/gad.12.16.2522; Murakami H, 2003, THROMB RES, V111, P81, DOI 10.1016/S0049-3848(03)00404-3; Nierodzik ML, 2006, CANCER CELL, V10, P355, DOI 10.1016/j.ccr.2006.10.002; Palumbo JS, 2007, BLOOD, V110, P133, DOI 10.1182/blood-2007-01-065995; Pawlicki JM, 2010, TRENDS CELL BIOL, V20, P52, DOI 10.1016/j.tcb.2009.10.004; Petralia GA, 2005, NAT CLIN PRACT ONCOL, V2, P356, DOI 10.1038/ncponc0225; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Riek-Burchardt M, 2002, NEUROSCI LETT, V329, P181, DOI 10.1016/S0304-3940(02)00645-6; Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Schulman S, 2000, NEW ENGL J MED, V342, P1953, DOI 10.1056/NEJM200006293422604; Shell SA, 2005, J BIOL CHEM, V280, P39950, DOI 10.1074/jbc.M508848200; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Sullivan KD, 2009, MOL CELL, V34, P322, DOI 10.1016/j.molcel.2009.04.024; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158; VanLandingham JW, 2008, J CEREBR BLOOD F MET, V28, P1786, DOI 10.1038/jcbfm.2008.73; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wilhelm BT, 2008, NATURE, V453, P1239, DOI 10.1038/nature07002; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Xiang KH, 2010, NATURE, V467, P729, DOI 10.1038/nature09391; Yin XL, 2010, AM J PATHOL, V176, P1600, DOI 10.2353/ajpath.2010.090406; Zoubine MN, 1996, DEV BIOL, V179, P447, DOI 10.1006/dbio.1996.0274	66	49	52	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1097-2765	1097-4164		MOL CELL	Mol. Cell	FEB 4	2011	41	3					298	310		10.1016/j.molcel.2010.12.032			13	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	722UM	WOS:000287460500008	21292162				2021-06-18	
J	Mellergard, P; Aneman, O; Sjogren, F; Saberg, C; Hillman, J				Mellergard, Pekka; Aneman, Oscar; Sjogren, Florence; Saberg, Carina; Hillman, Jan			Differences in Cerebral Extracellular Response of Interleukin-1 beta, Interleukin-6, and Interleukin-10 After Subarachnoid Hemorrhage or Severe Head Trauma in Humans	NEUROSURGERY			English	Article						Interleukins; Interleukin-1; Interleukin-6; Interleukin-10; Microdialysis; Subarachnoid hemorrhage; Traumatic brain injury	NEUROSURGICAL INTENSIVE-CARE; BRAIN-INJURY; INTRACEREBRAL MICRODIALYSIS; CEREBROSPINAL-FLUID; CYTOKINE EXPRESSION; NERVOUS-SYSTEM; INFLAMMATION; PRINCIPLES; CORRELATE; RECOVERY	BACKGROUND: Microdialysis has become a routine method for biochemical surveillance of patients in neurosurgical intensive care units. OBJECTIVE: To analyze the intracerebral extracellular levels of 3 interleukins (ILs) during the 7 days after major subarachnoid hemorrhage or traumatic brain injury). METHODS: Microdialysate from 145 severely injured neurosurgical intensive care unit patients (88 with subarachnoid hemorrhage, 57 with traumatic brain injury) was collected every 6 hours for 7 days. The concentrations of IL-1 beta and IL-6 were determined by fluorescence multiplex bead technology, and IL-10 was determined by enzyme-linked immunosorbent assay. RESULTS: Presented are the response patterns of 3 ILs during the first week after 2 different types of major brain injury. These patterns are different for each IL and also differ with respect to the kind of pathological impact. For both IL-1 beta and IL-6, the initial peaks (mean values for all patients at day 2 being 26.9 +/- 4.5 and 4399 +/- 848 pg/mL, respectively) were followed by a gradual decline, with IL-6 values remaining 100-fold higher compared with IL-1 beta. Female patients showed a stronger and more sustained response. The response of IL-10 was different, with mean values less than 23 pg/mL and with no significant variation between any of the postimpact days. For all 3 ILs, the responses were stronger in subarachnoid hemorrhage patients. The study also indicates that under normal conditions, IL-1 beta, IL-6, and IL-10 are present only at very low concentrations or not at all in the extracellular space of the human brain. CONCLUSION: This is the first report presenting in some detail the human cerebral response of IL-1 beta, IL-6, and IL-10 after subarachnoid hemorrhage and traumatic brain injury. The 3 ILs have different reaction patterns, with the response of IL-1 beta and IL-6 being related to the type of cerebral damage sustained, whereas the IL-10 response was less varied.	[Mellergard, Pekka; Aneman, Oscar; Saberg, Carina; Hillman, Jan] Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden	Mellergard, P (corresponding author), Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden.						Ao XP, 2006, METHODS, V38, P331, DOI 10.1016/j.ymeth.2005.11.012; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BENEVISTE H, 1990, PROG NEUROBIOL, V35, P195; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Fulwyler M J, 1990, Methods Cell Biol, V33, P613; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; KEMENY DM, 1992, J IMMUNOL METHODS, V150, P57, DOI 10.1016/0022-1759(92)90065-2; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Kriz Jasna, 2006, Critical Reviews in Neurobiology, V18, P145; Liu S, 2008, BRAIN RES, V1231, P63, DOI 10.1016/j.brainres.2008.07.035; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Sturnegk P, 2007, BRIT J NEUROSURG, V21, P332, DOI 10.1080/02688690701411574; TARKOWSKI E, 1995, STROKE, V26, P1393, DOI 10.1161/01.STR.26.8.1393; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Waelgaard L, 2006, SCAND J IMMUNOL, V64, P345, DOI 10.1111/j.1365-3083.2006.01826.x; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021	32	49	51	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2011	68	1					12	19		10.1227/NEU.0b013e3181ef2a40			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	694IE	WOS:000285288200018	21150751				2021-06-18	
J	Roquilly, A; Mahe, PJ; Latte, DDD; Loutrel, O; Champin, P; Di Falco, C; Courbe, A; Buffenoir, K; Hamel, O; Lejus, C; Sebille, V; Asehnoune, K				Roquilly, Antoine; Mahe, Pierre Joachim; Latte, Dominique Demeure Dit; Loutrel, Olivier; Champin, Philippe; Di Falco, Christelle; Courbe, Athanase; Buffenoir, Kevin; Hamel, Olivier; Lejus, Corinne; Sebille, Veronique; Asehnoune, Karim			Continuous controlled-infusion of hypertonic saline solution in traumatic brain-injured patients: a 9-year retrospective study	CRITICAL CARE			English	Article							ELEVATED INTRACRANIAL-PRESSURE; DECOMPRESSIVE CRANIECTOMY; CEREBRAL EDEMA; RENAL-FAILURE; PRIMARY-CARE; CELL-VOLUME; HEAD-INJURY; HYPONATREMIA; MANNITOL; RESUSCITATION	Introduction: Description of a continuous hypertonic saline solution (HSS) infusion using a dose-adaptation of natremia in traumatic brain injured (TBI) patients with refractory intracranial hypertension (ICH). Methods: We performed a single-center retrospective study in a surgical intensive care unit of a tertiary hospital. Fifty consecutive TBI patients with refractory ICH treated with continuous HSS infusion adapted to a target of natremia. In brief, a physician set a target of natremia adapted to the evolution of intracranial pressure (ICP). Flow of NaCl 20% was a priori calculated according to natriuresis, and the current and target natremia that were assessed every 4 hours. Results: The HSS infusion was initiated for a duration of 7 (5 to 10) (8 +/- 4) days. ICP decreased from 29 (26 to 34) (31 +/- 9) mm Hg at H0 to 20 (15 to 26) (21 +/- 8) mm Hg at H1 (P < 0.05). Cerebral perfusion pressure increased from 61 (50 to 70) (61 +/- 13) mm Hg at H0 up to 67 (60 to 79) (69 +/- 12) mm Hg at H1 (P < 0.05). No rebound of ICH was reported after stopping continuous HSS infusion. Natremia increased from 140 (138 to 143) (140 +/- 4) at H0 up to 144 (141 to 148) (144 +/- 4) mmol/L at H4 (P < 0.05). Plasma osmolarity increased from 275 (268 to 281) (279 +/- 17) mmol/L at H0 up to 290 (284 to 307) (297 +/- 17) mmol/L at H24 (P < 0.05). The main side effect observed was an increase in chloremia from 111 (107 to 119) (113 +/- 8) mmol/L at H0 up to 121 (117 to 124) (121 +/- 6) mmol/L at H24 (P < 0.05). Neither acute kidney injury nor pontine myelinolysis was recorded. Conclusions: Continuous HSS infusion adapted to close biologic monitoring enables long-lasting control of natremia in TBI patients along with a decreased ICP without any rebound on infusion discontinuation.	[Roquilly, Antoine; Mahe, Pierre Joachim; Latte, Dominique Demeure Dit; Loutrel, Olivier; Champin, Philippe; Di Falco, Christelle; Courbe, Athanase; Lejus, Corinne; Asehnoune, Karim] Nantes Univ Hosp, Hotel Dieu, Anesthesiol & Intens Care Unit, F-44093 Nantes, France; [Buffenoir, Kevin; Hamel, Olivier] Nantes Univ Hosp, Hotel Dieu, Neurosurg Unit, F-44093 Nantes, France; [Sebille, Veronique] Univ Nantes, UFR Pharm, EA 4275, F-44000 Nantes, France	Asehnoune, K (corresponding author), Nantes Univ Hosp, Hotel Dieu, Anesthesiol & Intens Care Unit, 1 Pl Alexis Ricordeau, F-44093 Nantes, France.	karim.asehnoune@chu-nantes.fr	Roquilly, Antoine/P-9826-2017; Sebille, Veronique/L-8761-2015; Sebille, Veronique/I-3309-2015; Buffenoir, Kevin/ABD-9003-2020	Sebille, Veronique/0000-0002-0780-7742			Adrogue HJ, 1997, INTENS CARE MED, V23, P309, DOI 10.1007/s001340050333; Adrogue HJ, 2000, NEW ENGL J MED, V342, P1493, DOI 10.1056/NEJM200005183422006; Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Barsoum NR, 2002, NEPHROL DIAL TRANSPL, V17, P1176, DOI 10.1093/ndt/17.7.1176; BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; CSERR HF, 1991, J PHYSIOL-LONDON, V442, P277, DOI 10.1113/jphysiol.1991.sp018793; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Handy JM, 2008, BRIT J ANAESTH, V101, P141, DOI 10.1093/bja/aen148; Hauer EM, 2011, CRIT CARE MED, V39, P1766, DOI 10.1097/CCM.0b013e318218a390; HOCHWALD GM, 1974, LIFE SCI, V15, P1309, DOI 10.1016/0024-3205(74)90312-9; HUANG PP, 1995, ANN SURG, V221, P543, DOI 10.1097/00000658-199505000-00012; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Ke CS, 2002, EXP NEUROL, V178, P194, DOI 10.1006/exnr.2002.8037; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; LIEN YHH, 1991, J CLIN INVEST, V88, P303, DOI 10.1172/JCI115292; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; RUDEHILL A, 1993, J NEUROSURG ANESTH, V5, P4; Schatzmann C, 1998, ACT NEUR S, V71, P31; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Tyagi R, 2007, NEUROSURG REV, V30, P277, DOI 10.1007/s10143-007-0091-7; Uchino S, 2006, CRIT CARE MED, V34, P1913, DOI 10.1097/01.CCM.0000224227.70642.4F; Upadhyay A, 2006, AM J MED, V119, pS30, DOI 10.1016/j.amjmed.2006.05.005; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4	35	49	50	1	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2011	15	5							R260	10.1186/cc10522			9	Critical Care Medicine	General & Internal Medicine	929GB	WOS:000303048200056	22035596	DOAJ Gold, Green Published			2021-06-18	
J	Schofield, P; Butler, T; Hollis, S; D'Este, C				Schofield, Peter; Butler, Tony; Hollis, Stephanie; D'Este, Catherine			Are prisoners reliable survey respondents? A validation of self-reported traumatic brain injury (TBI) against hospital medical records	BRAIN INJURY			English	Article						Traumatic brain injury; prisoners; validation; medical records	DRUG-USE; HAIR ANALYSIS; HEAD-INJURY; ALCOHOL-USE; VALIDITY; RELIABILITY; AGREEMENT; SAMPLE; USERS; MEN	Aims: To compare prisoners' self-reported history of TBI associated with hospital attendance with details extracted from relevant hospital medical records and to identify factors associated with the level of agreement between the two sources. Methods: From a sample of prison entrants, this study obtained a history of TBIs for which medical attention was sought at a hospital. Audit tools were developed for data extraction relevant to any possible TBI from records at a total of 23 hospitals located within New South Wales, Australia. The level of agreement between self-report and hospital records was compared in relation to demographic, psychological and criminographic characteristics. Results: Of the 200 participants in the study, 164 (82%) reported having sustained a past TBI giving a total of 420 separate TBI incidents. Of these, 156 (37%) were alleged to have resulted in attendance at a hospital emergency department including 112 (72%) at a hospital accessible for the validation exercise. For 93/112 (83%) of reported TBIs, a corresponding hospital medical record was located of which 78/112 (70%) supported the occurrence of a TBI. Lower education and a lifetime history of more than seven TBIs were associated with less agreement between self-report and medical record data with regard to specific details of the TBI. Conclusions: Overall, these findings suggest that prisoners' self-report of TBI is generally accurate when compared with the 'gold standard' of hospital medical record. This finding is contrary to the perception of this group as 'dishonest' and 'unreliable'.	[Schofield, Peter] Hunter New England Hlth, Neuropsychiat Serv, Newcastle, NSW 2300, Australia; [Schofield, Peter] Univ Newcastle, Ctr Brain & Mental Hlth Res, Callaghan, NSW 2308, Australia; [Butler, Tony] Curtin Univ Technol, Natl Drug Res Inst, Perth, WA, Australia; [Hollis, Stephanie; D'Este, Catherine] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2308, Australia	Schofield, P (corresponding author), Hunter New England Hlth, Neuropsychiat Serv, POB 833, Newcastle, NSW 2300, Australia.	peter.schofield@hnehealth.nsw.gov.au	Hollis, Stephanie J/B-5977-2011; Butler, Tony/F-4614-2012; D'ESTE, CATHERINE ANNE/G-7392-2013; Schofield, Peter/J-7133-2013	Butler, Tony/0000-0002-2679-2769; Schofield, Peter/0000-0001-8298-8590			Aitken JF, 2004, AM J EPIDEMIOL, V159, P1098, DOI 10.1093/aje/kwh143; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Bergmann MM, 1998, AM J EPIDEMIOL, V147, P969; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Butler T, 1999, AUST NZ J PUBL HEAL, V23, P377, DOI 10.1111/j.1467-842X.1999.tb01278.x; Butler T, 2000, INT J STD AIDS, V11, P743, DOI 10.1258/0956462001915174; Butler T, 2003, 2001 INMATE HLTH SUR; Cantor JB, 2004, ARCH PHYS MED REHAB, V85, pS54, DOI 10.1016/j.apmr.2003.08.113; Caplan LS, 2003, CANCER EPIDEM BIOMAR, V12, P1182; CARLSSON GS, 1983, J NEUROL NEUROSUR PS, V46, P818, DOI 10.1136/jnnp.46.9.818; Darke S, 1998, DRUG ALCOHOL DEPEN, V51, P253, DOI 10.1016/S0376-8716(98)00028-3; de Boer EJ, 2005, AM J EPIDEMIOL, V161, P978, DOI 10.1093/aje/kwi120; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Fishbain DA, 1999, CLIN J PAIN, V15, P184, DOI 10.1097/00002508-199909000-00005; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; GRONWALL D, 1975, LANCET, V2, P995; Harrison L, 1997, NIDA Res Monogr, V167, P17; HORWITZ RI, 1984, J CHRON DIS, V37, P825, DOI 10.1016/0021-9681(84)90015-8; Ismail AA, 2000, OSTEOPOROSIS INT, V11, P248, DOI 10.1007/s001980050288; Ivers RQ, 2002, J CLIN EPIDEMIOL, V55, P452, DOI 10.1016/S0895-4356(01)00518-2; KESSLER RC, 1991, PSYCHOL MED, V21, P723, DOI 10.1017/S0033291700022364; Klabunde CN, 2005, MED CARE, V43, P391, DOI 10.1097/01.mlr.0000156851.80900.d1; Langenbucher J, 2001, EVALUATION REV, V25, P184, DOI 10.1177/0193841X0102500204; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Louie AD, 2000, BONE MARROW TRANSPL, V25, P1191, DOI 10.1038/sj.bmt.1702419; Lu NT, 2001, AM J DRUG ALCOHOL AB, V27, P399, DOI 10.1081/ADA-100104509; Magura S, 1996, SUBST USE MISUSE, V31, P1131, DOI 10.3109/10826089609063969; MCKENNA MT, 1992, AM J PREV MED, V8, P287; Mieczkowski T, 1998, SUBST USE MISUSE, V33, P1547, DOI 10.3109/10826089809069812; Okura Y, 2004, J CLIN EPIDEMIOL, V57, P1096, DOI 10.1016/j.jclinepi.2004.04.005; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Savola O, 2005, ALCOHOL ALCOHOLISM, V40, P269, DOI 10.1093/alcalc/agh159; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Shearer J, 2006, DRUG ALCOHOL REV, V25, P425, DOI 10.1080/09595230600868512; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; SPSS Inc, 2006, SPSS VERS 15; Walker R, 2001, SUBST USE MISUSE, V36, P757, DOI 10.1081/JA-100104089; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50	41	49	49	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2011	25	1					74	82		10.3109/02699052.2010.531690			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731JI	WOS:000288101700009	21117913				2021-06-18	
J	Theriault, M; De Beaumont, L; Tremblay, S; Lassonde, M; Jolicoeur, P				Theriault, Martin; De Beaumont, Louis; Tremblay, Sebastien; Lassonde, Maryse; Jolicoeur, Pierre			Cumulative effects of concussions in athletes revealed by electrophysiological abnormalities on visual working memory	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Event-related potentials; Sustained posterior contralateral negativity; Concussion; Athletes	SHORT-TERM-MEMORY; TRAUMATIC BRAIN-INJURY; RECURRENT CONCUSSION; LONG-TERM; SPORTS CONCUSSION; NEURAL ACTIVITY; EPIDEMIOLOGY; PERFORMANCE; COLLEGIATE; ATTENTION	Event-related potentials (ERPs) have been useful to detect subtle, pervasive alterations of cognition-related waveforms in athletes with multiple concussions. This study used the sustained posterior contralateral negativity (SPCN) waveform component recorded while participants performed a visual short-term memory task to investigate how working memory (WM) storage capacity was affected among athletes who differed according to their history of sports concussions. Fifty-five university-level football players were assigned to three groups: 1-2 concussion athletes; 3+ concussion athletes; non-concussed athletes. The main finding of the present study was that athletes with a history of three concussions or more exhibited significantly attenuated SPCN amplitude relative to both concussed athletes with only one or two prior concussions and athletes without concussions. The latter finding adds to previous evidence of disproportionately worse outcome in athletes presenting with a history of three or more concussions relative to those with fewer concussions. In addition, SPCN amplitude was found to correlate significantly with a visual memory capacity estimate (K), but this K value did not significantly differ across groups. This suggests that attenuated SPCN amplitude after three or more concussions did not interfere with apparent WM function. Taken together, these findings suggest that the altered neurophysiological index of WM storage might be a more sensitive measure of a latent WM function abnormality which may well worsen with aging, or perhaps additional brain insults.	[Jolicoeur, Pierre] Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H3C 3J7, Canada	Jolicoeur, P (corresponding author), Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	pierre.jolicoeur@umontreal.ca		Tremblay, Sebastien/0000-0001-6251-9797			American Clinical Neurophysiology Society, 2006, J Clin Neurophysiol, V23, P107; [Anonymous], 1994, J Clin Neurophysiol, V11, P111; [Anonymous], 1991, J CLIN NEUROPHYSIOL, V8, P200, DOI 10.1097/00004691-199104000-00007; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Awh E, 2007, PSYCHOL SCI, V18, P622, DOI 10.1111/j.1467-9280.2007.01949.x; BARTH J, 1989, J COGNITIVE NEUROREH, V26, P451; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chuah YML, 2004, BRAIN COGNITION, V56, P304, DOI 10.1016/j.bandc.2004.08.002; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cowan N, 2001, BEHAV BRAIN SCI, V24, P87, DOI 10.1017/S0140525X01003922; Craik FIM, 2006, TRENDS COGN SCI, V10, P131, DOI 10.1016/j.tics.2006.01.007; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Drew TW, 2006, CLIN EEG NEUROSCI, V37, P286, DOI 10.1177/155005940603700405; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Fales CL, 2008, COGN AFFECT BEHAV NE, V8, P239, DOI 10.3758/CABN.8.3.239; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hecht S, 2005, CLIN J SPORT MED, V15, P281, DOI DOI 10.1097/01.jsm.0000172669.85640.05; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jolicoeur P, 2008, BRAIN RES, V1215, P160, DOI 10.1016/j.brainres.2008.03.059; Jolicoeur P, 2006, PSYCHOL RES-PSYCH FO, V70, P414, DOI 10.1007/s00426-005-0008-4; Klaver P, 1999, NEUROREPORT, V10, P2001, DOI 10.1097/00001756-199907130-00002; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Luck S.J., 2005, **DROPPED REF**; Mazza V, 2007, EXP BRAIN RES, V181, P531, DOI 10.1007/s00221-007-1002-4; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCollough AW, 2007, CORTEX, V43, P77, DOI 10.1016/S0010-9452(08)70447-7; McCrory P, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.014860; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; PASHLER H, 1988, PERCEPT PSYCHOPHYS, V44, P369, DOI 10.3758/BF03210419; Perron R, 2009, PSYCHOL RES-PSYCH FO, V73, P222, DOI 10.1007/s00426-008-0214-y; Polich J, 1998, J CLIN NEUROPHYSIOL, V15, P14, DOI 10.1097/00004691-199801000-00004; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Tabachnick BG, 2007, USING MULTIVARIATE S; Todd JJ, 2004, NATURE, V428, P751, DOI 10.1038/nature02466; Vogel EK, 2004, NATURE, V428, P748, DOI 10.1038/nature02447; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	54	49	51	1	29	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2011	33	1					30	41	PII 922289540	10.1080/13803391003772873			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	714QK	WOS:000286823900004	20480425				2021-06-18	
J	de Sousa, A; McDonald, S; Rushby, J; Li, S; Dimoska, A; James, C				de Sousa, Arielle; McDonald, Skye; Rushby, Jacqueline; Li, Sophie; Dimoska, Aneta; James, Charlotte			Why don't you feel how I feel? Insight into the absence of empathy after severe Traumatic Brain Injury	NEUROPSYCHOLOGIA			English	Article						Emotional empathy; Cognitive empathy; Emotional responsivity; Facial electromyography (EMG); Skin conductance	ANXIETY STRESS SCALES; EMOTIONAL CONTAGION; FACIAL EXPRESSIONS; BEHAVIORAL-CHANGES; MIMICRY; RECOGNITION; DEPRESSION; STATES; MIND	Although the existence of empathy deficits in people with traumatic brain injury (TBI) is generally well accepted it has been a topic of limited investigation The current study examined the relationship between self-reported emotional and cognitive empathy and psychophysiological responding to emotionally evocative pictures in 20 patients with severe TBI and 22 control participants Eighteen pictures with alternating pleasant unpleasant and neutral content selected from the International Affective Picture System (IAPS) were presented whilst facial muscle responses skin conductance and valence and arousal ratings were measured Self-reported emotional and cognitive empathy questionnaires were also administered In comparison to control participants those in the TBI group displayed a reduction in the ability to empathize both emotionally and cognitively and evidence that these two aspects of empathy may be interconnected was established Further TBI participants showed reduced facial responding to unpleasant pictures while also rating them as less unpleasant and arousing than controls In addition they exhibited lowered autonomic arousal to all pictures regardless of affective valence Interestingly hypoarousal to pleasant pictures in particular was found to be related to the absence of empathy observed after TBI and is consistent with the view that impaired emotional responsivity is associated with impairment to the empathy network The results represent a further step towards understanding what processes shape empathy (C) 2010 Elsevier Ltd All rights reserved	[de Sousa, Arielle; McDonald, Skye; Rushby, Jacqueline; Li, Sophie; Dimoska, Aneta; James, Charlotte] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	de Sousa, A (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		McDonald, Skye/G-4118-2014; Rushby, Jacqueline/D-1820-2010	McDonald, Skye/0000-0003-0723-6094; Rushby, Jacqueline/0000-0002-5018-638X			Adolphs Ralph, 2002, Behav Cogn Neurosci Rev, V1, P21, DOI 10.1177/1534582302001001003; [Anonymous], 1996, BRIT MED J, V313, P1448; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; BARON CS, 2004, J AUTISM DEV DISORD, V34, P163; Bernat E, 2006, PSYCHOPHYSIOLOGY, V43, P93, DOI 10.1111/j.1469-8986.2006.00380.x; Blair RJR, 2005, CONSCIOUS COGN, V14, P698, DOI 10.1016/j.concog.2005.06.004; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Bradley M.M., 2000, SER AFFECTIVE SCI, P242; Bradley MM, 2001, EMOTION, V1, P276, DOI 10.1037//1528-3542.1.3.276; Britton JC, 2006, NEUROIMAGE, V31, P906, DOI 10.1016/j.neuroimage.2005.12.050; Center for the Study of Emotion and Attention [CSEA-NIMH], 1999, INT AFF PICT SYST DI; Critchley HD, 2000, J NEUROSCI, V20, P3033; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Darwin C., 1998, EXPRESSION EMOTIONS; Davis M.H, 1980, J PERS SOC PSYCHOL, V10, P85; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; DESOUSA A, CORTEX IN PRESS, DOI DOI 10.1016/J.CORTEX.2010.02.004; DIMBERG U, 1982, PSYCHOPHYSIOLOGY, V19, P643, DOI 10.1111/j.1469-8986.1982.tb02516.x; Forster KI, 2003, BEHAV RES METH INS C, V35, P116, DOI 10.3758/BF03195503; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; Hariri AR, 2003, BIOL PSYCHIAT, V53, P494, DOI 10.1016/S0006-3223(02)01786-9; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hess U, 2001, INT J PSYCHOPHYSIOL, V40, P129, DOI 10.1016/S0167-8760(00)00161-6; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Lang P.J., 1980, TECHNOLOGY MENTAL HL, P119; Lang P.J., 1999, A4 U FLOR CTR RES PS; Lawrence EJ, 2004, PSYCHOL MED, V34, P911, DOI 10.1017/S0033291703001624; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; MCDONALD S, J CLIN EXPT IN PRESS; Mehrabian A., 2000, MANUAL BALANCED EMOT; Moody EJ, 2007, EMOTION, V7, P447, DOI 10.1037/1528-3542.7.2.447; Muncer SJ, 2006, PERS INDIV DIFFER, V40, P1111, DOI 10.1016/j.paid.2005.09.020; Nummenmaa L, 2008, NEUROIMAGE, V43, P571, DOI 10.1016/j.neuroimage.2008.08.014; ODDY M, 2003, HDB NEUROLOGICAL REH; Preston SD, 2002, BEHAV BRAIN SCI, V25, P1, DOI 10.1017/S0140525X02000018; SANCHEZ NJP, 2005, BEHAV NEUROSCI, V119, P87; Saunders JC, 2006, NEUROPSYCHOLOGY, V20, P224, DOI 10.1037/0894-4105.20.2.224; SCHULTE R, 2007, J COGNITIVE NEUROSCI, V19, P1354; SHAMAY TSG, 2008, BRAIN, V132, P617; SHAMAY TSG, 2003, J COGNITIVE NEUROSCI, V15, P1; SHAMAY TSG, 2007, NEUROPSYCHOLOGIA, V45, P3054; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Siegel S., 1956, NONPARAMETRIC STAT B; SONNBY BM, 2003, J NONVERBAL BEHAV, V27, P3; Sonnby-Borgstrom M, 2002, SCAND J PSYCHOL, V43, P433, DOI 10.1111/1467-9450.00312; Stone VE, 2003, NEUROPSYCHOLOGIA, V41, P209, DOI 10.1016/S0028-3932(02)00151-3; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326	56	49	50	0	28	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	OCT	2010	48	12					3585	3595		10.1016/j.neuropsychologia.2010.08.008			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	677UM	WOS:000284017300024	20713073				2021-06-18	
J	Leon-Carrion, J; Martin-Rodriguez, JF; Madrazo-Atutxa, A; Soto-Moreno, A; Venegas-Moreno, E; Torres-Vela, E; Benito-Lopez, P; Galvez, MA; Tinahones, FJ; Leal-Cerro, A				Leon-Carrion, Jose; Francisco Martin-Rodriguez, Juan; Madrazo-Atutxa, Ainara; Soto-Moreno, Alfonso; Venegas-Moreno, Eva; Torres-Vela, Elena; Benito-Lopez, Pedro; Angeles Galvez, Maria; Tinahones, Francisco J.; Leal-Cerro, Alfonso			Evidence of Cognitive and Neurophysiological Impairment in Patients with Untreated Naive Acromegaly	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; HORMONE GH DEFICIENCY; PREFRONTAL CORTEX; LONG-TERM; ALZHEIMERS-DISEASE; CORTICAL RHYTHMS; EPISODIC MEMORY; EEG; QUESTIONNAIRE	Context: Recent studies have suggested that long-term exposure to high levels of GH and IGF-I affect brain and cognitive functions. However, very few human studies have challenged this hypothesis. Objective: The aim of this study is to explore whether GH/IGF-I excess in naive patients with acromegaly alters cognitive functions, particularly memory, and whether these alterations are accompanied by neurophysiological correlates. Design: We conducted a comprehensive neuropsychological and neurophysiological exam on 16 naive acromegaly patients and 16 strictly matched healthy controls. Comparative analyses were carried out on major neurocognitive domains (executive functions, visual/verbal memory, attention, visuoconstructive abilities, and verbal fluency) and on quantitative electroencephalogram and low-resolution brain electromagnetic tomography sources. Results were correlated with GH and IGF-I hormone concentrations. Results: Short-and long-term memory were the most severely impaired cognitive functions. Moreover, memory performance correlated negatively with GH and IGF-I concentrations. No association was detected between depression and memory impairment, and only a marginal association was found with quality of life. Finally, acromegaly patients showed power attenuation in fast frequency electroencephalogram bands, as well as decreased activity in prefrontal and middle temporal cortices, that was associated to cognitive performance. Conclusions: Results provide evidence of cognitive and neurophysiological impairment, characterized by moderate-to-severe memory impairment and decreased neural activity in specific brain areas. High levels of GH and IGF-I in acromegaly patients could be the basis for these findings. (J Clin Endocrinol Metab 95: 4367-4379, 2010)	[Leon-Carrion, Jose] Univ Seville, Human Neuropsychol Lab, Fac Psicol, Dept Expt Psychol, Seville 41018, Spain; [Madrazo-Atutxa, Ainara; Soto-Moreno, Alfonso; Venegas-Moreno, Eva; Leal-Cerro, Alfonso] Univ Seville, Biomed Inst Seville, Univ Hosp Virgen Rocio, Consejo Super Invest Cient, Seville 41018, Spain; Virgen Rocio Univ Hosp, Div Endocrinol, Seville 41013, Spain; [Torres-Vela, Elena] San Cecilio Hosp, Granada 18071, Spain; [Benito-Lopez, Pedro; Angeles Galvez, Maria] Reina Sofia Hosp, Cordoba 14004, Spain; [Tinahones, Francisco J.] Virgen Victoria Hosp, Malaga 29720, Spain	Leon-Carrion, J (corresponding author), Univ Seville, Human Neuropsychol Lab, Fac Psicol, Dept Expt Psychol, C Camilo Jose Cela S-N, Seville 41018, Spain.	leoncarrion@us.es; aleal@ibis-sevilla.es	Tinahones, Francisco Jose/AAB-2882-2020	Martin Rodriguez, Juan Francisco/0000-0003-1392-8775	Novartis Oncology	This work was supported by a grant from Novartis Oncology.	Babiloni C, 2004, NEUROIMAGE, V22, P57, DOI 10.1016/j.neuroimage.2003.09.028; Badia Xavier, 2004, Health Qual Life Outcomes, V2, P13, DOI 10.1186/1477-7525-2-13; Bartke A, 2003, NEUROENDOCRINOLOGY, V78, P210, DOI 10.1159/000073704; Beck AT., 1996, BECK DEPRESSION INVE, V2; Benton A., 1976, MULTILINGUAL APHASIA; Biermasz NR, 2004, J CLIN ENDOCR METAB, V89, P5369, DOI 10.1210/jc.2004-0669; BIGLER ED, 2003, HDB REY OSTERRIETH C, P323; Blumenfeld RS, 2006, J NEUROSCI, V26, P916, DOI 10.1523/JNEUROSCI.2353-05.2006; CANAVAN AGM, 1989, NEUROPSYCHOLOGIA, V27, P787, DOI 10.1016/0028-3932(89)90003-1; Chung YH, 2002, BRAIN RES, V946, P307, DOI 10.1016/S0006-8993(02)03041-X; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Colao A, 2004, ENDOCR REV, V25, P102, DOI 10.1210/er.2002-0022; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Dudai Y, 2004, ANNU REV PSYCHOL, V55, P51, DOI 10.1146/annurev.psych.55.090902.142050; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Fletcher PC, 1998, BRAIN, V121, P1249, DOI 10.1093/brain/121.7.1249; Gilboa A., 2002, HDB MEMORY DISORDERS, P315; Granada ML, 2008, CLIN ENDOCRINOL, V68, P942, DOI 10.1111/j.1365-2265.2007.03120.x; Henson RNA, 1999, BRAIN, V122, P1367, DOI 10.1093/brain/122.7.1367; Hornberger M, 2008, NEUROLOGY, V71, P1481, DOI 10.1212/01.wnl.0000334299.72023.c8; Jelic V, 2000, NEUROBIOL AGING, V21, P533, DOI 10.1016/S0197-4580(00)00153-6; LAI ZN, 1991, BRAIN RES, V546, P222, DOI 10.1016/0006-8993(91)91485-J; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Leon-Carrion J, 2008, CLIN NEUROPHYSIOL, V119, P1506, DOI 10.1016/j.clinph.2008.03.030; Leon-Carrion J, 2009, CLIN ENDOCRINOL, V70, P192, DOI 10.1111/j.1365-2265.2008.03355.x; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Maeshima S, 1997, BRAIN INJURY, V11, P211; Moore MJ, 1998, J NEUROL SCI, V160, pS53, DOI 10.1016/S0022-510X(98)00203-2; O'Kusky JR, 2000, J NEUROSCI, V20, P8435, DOI 10.1523/JNEUROSCI.20-22-08435.2000; Owen AM, 2000, EXP BRAIN RES, V133, P33, DOI 10.1007/s002210000398; Pantanetti Paola, 2002, Pituitary, V5, P17, DOI 10.1023/A:1022145116901; Pascual-Marqui RD, 1994, ISBET NEWSLETTER ISN, V5, P4; Richert S, 1987, Schweiz Arch Neurol Psychiatr (1985), V138, P61; Rowles SV, 2005, J CLIN ENDOCR METAB, V90, P3337, DOI 10.1210/jc.2004-1565; Sanz J, 1998, PSICOTHEMA, V10, P303; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sievers C, 2009, PITUITARY, V12, P177, DOI 10.1007/s11102-008-0143-1; Sievers C, 2009, CLIN ENDOCRINOL, V71, P691, DOI 10.1111/j.1365-2265.2009.03555.x; Spalletta G, 2005, AM J GERIAT PSYCHIAT, V13, P108; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; Talairach J., 1988, COPLANAR STEREOTAXIC; Tanriverdi F, 2009, GROWTH HORM IGF RES, V19, P24, DOI 10.1016/j.ghir.2008.05.002; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Tolis G, 2006, NEUROENDOCRINOLOGY, V83, P249, DOI 10.1159/000095535; Turner MS, 2008, CORTEX, V44, P637, DOI 10.1016/j.cortex.2007.01.002; van Dam PS, 2000, GROWTH HORM IGF RES, V10, P69, DOI 10.1016/S1096-6374(00)80013-1; Webb SM, 2006, EUR J ENDOCRINOL, V155, P269, DOI 10.1530/eje.1.02214; Wechsler, 1997, WAIS 3 WMS 3 TECHNIC; WERNER S, 2006, SOMATOTROPHIC AXIS B, P267; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	50	49	49	0	10	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	SEP	2010	95	9					4367	4379		10.1210/jc.2010-0394			13	Endocrinology & Metabolism	Endocrinology & Metabolism	647SU	WOS:000281640300054	20554710	Bronze			2021-06-18	
J	Sigurdardottir, S; Jerstad, T; Andelic, N; Roe, C; Schanke, AK				Sigurdardottir, Solrun; Jerstad, Tone; Andelic, Nada; Roe, Cecilie; Schanke, Anne-Kristine			Olfactory Dysfunction, Gambling Task Performance and Intracranial Lesions After Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						neuropsychology; frontal lesions; anosmia; Iowa Gambling Task; MRI	VENTROMEDIAL PREFRONTAL CORTEX; DECISION-MAKING; WORKING-MEMORY; DAMAGE; INDIVIDUALS; PREDICTORS; AMBIGUITY; ANOSMIA	Objective: To estimate the incidence of olfactory dysfunction across traumatic brain injury (TBI) severity and decision-making deficits with regard to intracranial lesions' location and laterality. Method: A 1-year prospective study including 115 participants (16-55 years) with mild, moderate, and severe TBI. The Brief Smell Identification Test was used 3 months postinjury with a follow-up testing of olfactory dysfunction at I year. The Iowa Gambling Task (IGT) and 3 tasks of the Delis-Kaplan Executive Function System were administered 3-months postinjury. MRI was performed 1-year postinjury and TBI severity groups were then divided with respect to frontal, fronto-temporal, diffuse, and no lesions. Results: The incidence of olfactory dysfunction was estimated to be 22.3% at 3 months and 13.5% at I year. No significant differences were found on olfactory dysfunction across TBI severity at either check. Anosmia was identified in 10% with severe TBI and 3% with mild TBI. Olfactory dysfunction was associated with verbal fluency tasks. Repeated-measures analysis of variance revealed no significant effect over blocks on IGT, and no main group or interaction effects regarding TBI severity, lesions' location, or laterality. IGT performance at 3-months postinjury was deficient in 83% of persons with intracranial lesions and 71% of those without lesions. Conclusions: Olfactory dysfunction is independent of TBI severity, showing improvements in one third of cases from 3- to 12-months postinjury. However. anosmia was related to TBI severity. There is evidence for marked decision-making deficits after TBI, all subgroups performed similarly and failed to develop an advantageous strategy over time.	[Sigurdardottir, Solrun; Schanke, Anne-Kristine] Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway; [Sigurdardottir, Solrun; Andelic, Nada; Roe, Cecilie; Schanke, Anne-Kristine] Univ Oslo, N-0316 Oslo, Norway; [Jerstad, Tone] Oslo Univ Hosp, Dept Neuroradiol, Ulleval, Norway; [Andelic, Nada; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway	Sigurdardottir, S (corresponding author), Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway.	solrun.sigurdardottir@sunnaas.no		Andelic, Nada/0000-0002-3719-4406	South-Eastern Norway Regional Health Authority	This study was supported by grants from the South-Eastern Norway Regional Health Authority. Special thanks to all participants, to Antoine Bechara for providing the University of Oslo with a copy of the Iowa Gambling Task, and to Susan Schanche for the proofreading the English text. There were no competing interests.	Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1675, DOI 10.1016/S0028-3932(02)00015-5; Bechara A, 2004, NEUROPSYCHOLOGY, V18, P152, DOI 10.1037/0894-4105.18.1.152; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Bechara A, 2005, TRENDS COGN SCI, V9, P159, DOI 10.1016/j.tics.2005.02.002; Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1999, J NEUROSCI, V19, P5473; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bonatti E, 2008, COGN BEHAV NEUROL, V21, P164, DOI 10.1097/WNN.0b013e318184e688; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Brand M, 2007, J CLIN EXP NEUROPSYC, V29, P86, DOI 10.1080/13803390500507196; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Costanzo RM, 1992, J HEAD TRAUMA REHAB, V7, P15, DOI DOI 10.1097/00001199-199203000-00005; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; Delis DC, 2001, DELISKAPLAN EXECUTIV; Doty R.L., 2001, BRIEF SMELL IDENTIFI; Doty RL, 2007, AM J RHINOL, V21, P460, DOI 10.2500/ajr.2007.21.3043; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Grant S, 2000, NEUROPSYCHOLOGIA, V38, P1180, DOI 10.1016/S0028-3932(99)00158-X; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Haxel BR, 2008, J HEAD TRAUMA REHAB, V23, P407, DOI 10.1097/01.HTR.0000341437.59627.ec; Jollant F, 2007, EUR PSYCHIAT, V22, P455, DOI 10.1016/j.eurpsy.2007.06.001; Krantz EM, 2009, CHEM SENSES, V34, P435, DOI 10.1093/chemse/bjp018; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; Malloy-Diniz L, 2007, J INT NEUROPSYCH SOC, V13, P693, DOI 10.1017/S1355617707070889; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; Haaland VO, 2007, J INT NEUROPSYCH SOC, V13, P699, DOI 10.1017/S1355617707070890; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Santos DV, 2004, ARCH OTOLARYNGOL, V130, P317, DOI 10.1001/archotol.130.3.317; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Smeding HMM, 2007, J NEUROL NEUROSUR PS, V78, P517, DOI 10.1136/jnnp.2006.102061; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; TEASDALE G, 1974, LANCET, V2, P81; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yousem DM, 1999, ACAD RADIOL, V6, P264, DOI 10.1016/S1076-6332(99)80449-8; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; Zamarian L, 2008, NEUROPSYCHOLOGY, V22, P645, DOI 10.1037/0894-4105.22.5.645	46	49	51	0	11	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2010	24	4					504	513		10.1037/a0018934			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	619HN	WOS:000279420500009	20604624				2021-06-18	
J	Rubovitch, V; Edut, S; Sarfstein, R; Werner, H; Pick, CG				Rubovitch, Vardit; Edut, Shahaf; Sarfstein, Rive; Werner, Haim; Pick, Chaim G.			The intricate involvement of the Insulin-like growth factor receptor signaling in mild traumatic brain injury in mice	NEUROBIOLOGY OF DISEASE			English	Article						mTBI; IGF-1R; Akt; ERK1/2; Spatial memory; Y-maze test	MINOR HEAD-INJURY; CELL-SURVIVAL; AKT PHOSPHORYLATION; COGNITIVE DEFICITS; FACTOR-I; RATS; DEATH; IGF-1; APOPTOSIS; ACTIVATION	Insulin-like growth factor-1 (IGF-1) was suggested as a potential neuroprotective treatment for traumatic brain injury (TBI) induced damage (cognitive as well as cellular). The main goal of the present study was to evaluate the role of the IGF-1R activation in spatial memory outcome following mild traumatic brain injury. mTBI-induced phosphorylation of IGF-1R, AKT and ERK1/2, in mice hippocampus, which was inhibited when mice were pretreated with the selective IGF-1R inhibitor AG1024. IGF-1 administration prevented spatial memory deficits following mTBI. Surprisingly, blocking the IGF-1R signaling in mTBI mice did not augment the spatial memory deficit. In addition, this data imply an intriguing and complex role of the IGF-1 signaling axis in the cellular and behavioral events following mTBI. (C) 2010 Elsevier Inc. All rights reserved.	[Rubovitch, Vardit; Edut, Shahaf; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Sarfstein, Rive; Werner, Haim] Tel Aviv Univ, Sackler Fac Med, Dep Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel	Pick, CG (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il			Adams Super Center for Brain Studies, Sackler Faculty of Medicine, Tel Aviv University	This work was supported by the Adams Super Center for Brain Studies, Sackler Faculty of Medicine, Tel Aviv University.	Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; ALEMAN A, 2009, PROG NEUROBIOL; BARATZ RR, J NEUROTRAU IN PRESS; Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911; Carter CS, 2002, TRENDS GENET, V18, P295, DOI 10.1016/S0168-9525(02)02696-3; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; EDUT SRV, 2008, ISR SOC NEUR 17 ANN; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; FRANK TF, 2008, J NEUROPATHOL EXP NE, V59, P641; Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lin SY, 2009, EXP NEUROL, V217, P361, DOI 10.1016/j.expneurol.2009.03.021; MADATHIL KS, 2009, J NEUROTRAUMA; Margulies S, 2000, J CLIN NEUROSCI, V7, P495, DOI 10.1054/jocn.1999.0773; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sawatzky DA, 2006, AM J PATHOL, V168, P33, DOI 10.2353/ajpath.2006.050058; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Tang BL, 2006, NEUROBIOL AGING, V27, P501, DOI 10.1016/j.neurobiolaging.2005.02.001; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	37	49	51	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	MAY	2010	38	2			SI		299	303		10.1016/j.nbd.2010.01.021			5	Neurosciences	Neurosciences & Neurology	590UN	WOS:000277253900019	20138993				2021-06-18	
J	Sandhaug, M; Andelic, N; Vatne, A; Seiler, S; Mygland, A				Sandhaug, Maria; Andelic, Nada; Vatne, Anita; Seiler, Stephen; Mygland, Aase			Functional level during sub-acute rehabilitation after traumatic brain injury: Course and predictors of outcome	BRAIN INJURY			English	Article						Level of function; functional independence measure; rehabilitation; traumatic brain injury	CLOSED-HEAD INJURY; GLASGOW COMA SCALE; INDEPENDENCE MEASURE; POSTTRAUMATIC AMNESIA; LENGTH; STAY; POPULATION; IMPAIRMENT; IMPACT	Objectives: To describe the functional level during sub-acute rehabilitation after moderate and severe traumatic brain injury (TBI) and to evaluate the impact of pre-injury and injury-related factors as predictors of early recovery. Material and methods: A prospective study of 55 patients with moderate (n = 21) and severe (n = 34) TBI who received specialized, inpatient rehabilitation. Functional level was assessed by the FIM. Possible predictors were analysed in a regression model using FIM total score at discharge as outcome. Results: At discharge from sub-acute rehabilitation, on average 53 (+/-24) days post-injury, 57% of moderate TBI patients and 91% of severe TBI patients were still disabled with a FIM score < 126. The disability was mild (FIM 109-126) in 95% with moderate TBI and in 62% with severe TBI. The disability was severe (FIM < 72) in 24% with severe TBI. Only one patient did not improve. Predictors of functional level at discharge from rehabilitation were Glasgow Coma Scale (GCS) score at rehabilitation admission (B = 5.991), FIM total score at rehabilitation admission (B = 0.393), length of stay (LOS) in the rehabilitation unit (B = 0.264) and length of Post-Traumatic Amnesia (PTA) (B = -0.120). Together, these predictors explained 86% of variance of FIM total scores at discharge. Conclusion: Less than half of moderate TBI patients reached a normal functional level at discharge from sub-acute rehabilitation. A short PTA period, a high GCS score and FIM score at admission to rehabilitation and a longer stay in the rehabilitation unit were positive predictors of functional level at discharge.	[Sandhaug, Maria; Seiler, Stephen] Agder Univ, Fac Hlth & Sports, N-4604 Kristiansand, Norway; [Sandhaug, Maria; Mygland, Aase] Sorlandet Hosp, Clin Rehabil, Kristiansand, Norway; [Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway; [Vatne, Anita; Mygland, Aase] Sorlandet Hosp, Dept Neurol, Kristiansand, Norway; [Mygland, Aase] Univ Bergen, Inst Clin Med, Bergen, Norway	Sandhaug, M (corresponding author), Agder Univ, Fac Hlth & Sports, Serv Box 422, N-4604 Kristiansand, Norway.	maria.sandhaug@uia.no		Andelic, Nada/0000-0002-3719-4406			Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bode RK, 2002, ARCH PHYS MED REHAB, V83, P100, DOI 10.1053/apmr.2002.26073; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; De Guise E, 2005, BRAIN INJURY, V19, P1087, DOI 10.1080/02699050500149882; Deutsch A, 2006, STROKE, V37, P1477, DOI 10.1161/01.STR.0000221172.99375.5a; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; FINSET A, 2002, HEAD INJURY, P14; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Grimby G, 1996, SCAND J REHABIL MED, V28, P51; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Kunik CL, 2006, ARCH PHYS MED REHAB, V87, P1590, DOI 10.1016/j.apmr.2006.09.001; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MCMILLAN T, 1993, NEUROLOGICAL REHABIL, P437; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Stineman MG, 1996, AM J PHYS MED REHAB, V75, P68, DOI 10.1097/00002060-199601000-00018; Tooth L, 2001, BRAIN INJURY, V15, P613, DOI 10.1080/02699050010013923; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	29	49	50	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2010	24	5					740	747		10.3109/02699051003652849			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	592PJ	WOS:000277391300006	20334472				2021-06-18	
J	Hall, KD; Lifshitz, J				Hall, Kelley D.; Lifshitz, Jonathan			Diffuse traumatic brain injury initially attenuates and later expands activation of the rat somatosensory whisker circuit concomitant with neuroplastic responses	BRAIN RESEARCH			English	Article						Regeneration; Ventral posterior medial; Barrel field; GAP-43; APP; Sport-related concussion	FUNCTIONAL REORGANIZATION; STRUCTURAL PLASTICITY; GENE-EXPRESSION; AXONAL INJURY; ADULT CAT; CORTEX; GAP-43; EXPERIENCE; SEQUELAE; AXOTOMY	Traumatic brain injury can initiate an array of chronic neurological deficits, effecting executive function, language and sensorimotor integration. Mechanical forces produce the diffuse pathology that disrupts neural circuit activation across vulnerable brain regions. The present manuscript explores the hypothesis that the extent of functional activation of brain-injured circuits is a consequence of initial disruption and consequent reorganization. In the rat, enduring sensory sensitivity to whisker stimulation directs regional analysis to the whisker barrel circuit. Adult, male rats were subjected to midline fluid percussion brain or sham injury and evaluated between 1 day and 42 days post-injury. Whisker somatosensory regions of the cortex and thalamus maintained cellular composition as visualized by Nissl stain. Within the first week post-injury, quantitatively less cFos activation was elicited by whisker stimulation, potentially due to axotomy within and surrounding the whisker circuit as visualized by amyloid precursor protein immunohistochemistry. Over six weeks post-injury, cFos activation after whisker stimulation showed a significant linear correlation with time in the cortex (r(2)=0.545; p=0.015), non-significant correlation in the thalamus (r(2)=0.326) and U-shaped correlation in the dentate gyrus (r(2)=0.831), all eventually exceeding sham levels. Ongoing neuroplastic responses in the cortex are evidenced by accumulating growth associated protein and synaptophysin gene expression. In the thalamus, the delayed restoration of plasticity markers may explain the broad distribution of neuronal activation extending into the striatum and hippocampus with whisker stimulation. The sprouting of diffuse-injured circuits into diffuse-injured tissue likely establishes maladaptive circuits responsible for behavioral morbidity. Therapeutic interventions to promote adaptive circuit restructuring may mitigate post-traumatic morbidity. (C) 2010 Elsevier B.V. All rights reserved.	[Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, BBSRB, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Dept Phys Med & Rehabil, Lexington, KY 40536 USA	Lifshitz, J (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, BBSRB, B463,741 S Limestone St, Lexington, KY 40536 USA.	jlifshitz@uky.com			University of Kentucky Chandler Medical Center [F32 HD-049343];  [R01 NINDS-NS065052];  [P30 NINDS-NS051220]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD049343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS065052] Funding Source: NIH RePORTER	Supported, in part, by R01 NINDS-NS065052, the University of Kentucky Chandler Medical Center, F32 HD-049343 and P30 NINDS-NS051220. Special thanks to Ms. C. Lynn Davis and Amanda M. Lisembee for technical support.	Bergmann M, 1997, EXP BRAIN RES, V117, P80, DOI 10.1007/s002210050201; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bisler S, 2002, J CHEM NEUROANAT, V23, P187, DOI 10.1016/S0891-0618(01)00155-7; Carmichael ST, 2005, EXP NEUROL, V193, P291, DOI 10.1016/j.expneurol.2005.01.004; Carmichael ST, 2003, NEUROSCIENTIST, V9, P64, DOI 10.1177/1073858402239592; Chklovskii DB, 2004, NATURE, V431, P782, DOI 10.1038/nature03012; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Chuckowree JA, 2004, NEUROSCIENTIST, V10, P280, DOI 10.1177/1073858404263511; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; DeBello WM, 2008, TRENDS NEUROSCI, V31, P577, DOI 10.1016/j.tins.2008.08.006; DI GS, 2005, FASEB J, V19, P153; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; DUNNMEYNELL AA, 1992, J COMP NEUROL, V315, P160, DOI 10.1002/cne.903150204; Emery DL, 2000, J COMP NEUROL, V424, P521; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Feldman DE, 2005, SCIENCE, V310, P810, DOI 10.1126/science.1115807; Franklin JL, 1998, J CELL BIOL, V142, P1313, DOI 10.1083/jcb.142.5.1313; Haidarliu S, 2001, J COMP NEUROL, V429, P372, DOI 10.1002/1096-9861(20010115)429:3<372::AID-CNE2>3.0.CO;2-3; Holtmaat A, 2008, BEHAV BRAIN RES, V192, P20, DOI 10.1016/j.bbr.2008.04.005; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Iarocci G, 2006, J AUTISM DEV DISORD, V36, P77, DOI 10.1007/s10803-005-0044-3; Jain N, 2008, J NEUROSCI, V28, P11042, DOI 10.1523/JNEUROSCI.2334-08.2008; Johansen-Berg H, 2007, CURR BIOL, V17, pR141, DOI 10.1016/j.cub.2006.12.022; Jones EG, 2000, ANNU REV NEUROSCI, V23, P1, DOI 10.1146/annurev.neuro.23.1.1; Jones EG, 1998, SCIENCE, V282, P1121, DOI 10.1126/science.282.5391.1121; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Povlishock JT, 2001, HEAD TRAUMA, P281; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; VAUDANO E, 1995, J NEUROSCI, V15, P3594; Waite Phil M. E., 1995, P705; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011	57	49	49	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 6	2010	1323						161	173		10.1016/j.brainres.2010.01.067			13	Neurosciences	Neurosciences & Neurology	583MJ	WOS:000276680300018	20122903	Green Accepted			2021-06-18	
J	Reinhard, M; Neunhoeffer, F; Gerds, TA; Niesen, WD; Buttler, KJ; Timmer, J; Schmidt, B; Czosnyka, M; Weiller, C; Hetzel, A				Reinhard, Matthias; Neunhoeffer, Florian; Gerds, Thomas A.; Niesen, Wolf-Dirk; Buttler, Klaus-Juergen; Timmer, Jens; Schmidt, Bernhard; Czosnyka, Marek; Weiller, Cornelius; Hetzel, Andreas			Secondary decline of cerebral autoregulation is associated with worse outcome after intracerebral hemorrhage	INTENSIVE CARE MEDICINE			English	Article						Cerebral autoregulation; Spontaneous intracerebral hemorrhage; Transcranial Doppler sonography	ACUTE ISCHEMIC-STROKE; TRAUMATIC BRAIN-INJURY; CEREBROVASCULAR AUTOREGULATION; BLOOD-FLOW; PERFUSION-PRESSURE; TRIAL; FLUCTUATIONS; VALIDATION	Blood pressure management in acute intracerebral hemorrhage (ICH) relies on functioning cerebral autoregulation. The time course of autoregulation in acute ICH and its relation with clinical outcome are not known. Twenty-six patients with spontaneous ICH were studied on days 1, 3 and 5 after ictus. Autoregulation was noninvasively measured from spontaneous fluctuations of blood pressure and middle cerebral artery flow velocity (assessed by transcranial Doppler) using the correlation coefficient index Mx. From the same signals, non-invasive cerebral perfusion pressure was calculated. Results were compared with 55 healthy controls and related with clinical and radiological factors and 90-day outcome (modified Rankin scale). Average Mx values of all patients did not differ across days or from controls. Higher Mx (i.e., poorer autoregulation) on day 5 was significantly related with lower Glasgow coma score, ventricular hemorrhage (both sides) and lower noninvasive cerebral perfusion pressure (ipsilateral). Increasing ipsilateral Mx between days 3 and 5 was related with lower Glasgow coma score and ventricular hemorrhage. In a multivariate analysis controlling for other hemodynamic factors, higher ipsilateral Mx on day 5 (p = 0.013) was a significant predictor for poor 90-day outcome. Cerebral autoregulation is primarily preserved in acute ICH, but a secondary decline mainly ipsilateral to the ICH can occur. This is associated with poor clinical status, ventricular hemorrhage, lower cerebral perfusion pressure and worse clinical outcome.	[Reinhard, Matthias; Neunhoeffer, Florian; Niesen, Wolf-Dirk; Weiller, Cornelius; Hetzel, Andreas] Univ Freiburg, Dept Neurol, Neuroctr, D-79106 Freiburg, Germany; [Buttler, Klaus-Juergen] Univ Freiburg, Dept Neurosurg, Neuroctr, D-79106 Freiburg, Germany; [Gerds, Thomas A.] Univ Copenhagen, Dept Biostat, Copenhagen, Denmark; [Timmer, Jens] Univ Freiburg, Ctr Data Anal & Modeling, Freiburg, Germany; [Timmer, Jens] Univ Freiburg, Freiburg Inst Adv Studies FRIAS, Freiburg, Germany; [Schmidt, Bernhard] Med Ctr Chemnitz, Dept Neurol, Chemnitz, Germany; [Czosnyka, Marek] Univ Cambridge, Dept Neurosci, Acad Neurosurg Unit, Cambridge, England	Reinhard, M (corresponding author), Univ Freiburg, Dept Neurol, Neuroctr, Breisacherstr 64, D-79106 Freiburg, Germany.	matthias.reinhard@uniklinik-freiburg.de		Gerds, Thomas Alexander/0000-0002-5955-816X	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [He 1949/4-1, Ti 315/4-2]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0600986, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	M. R. acknowledges support from the Deutsche Forschungsgemeinschaft (He 1949/4-1 and Ti 315/4-2).	Anderson CS, 2008, LANCET NEUROL, V7, P391, DOI 10.1016/S1474-4422(08)70069-3; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Bruder N, 1998, ANESTH ANALG, V86, P320, DOI 10.1097/00000539-199802000-00020; Christ M, 2007, INTENS CARE MED, V33, P246, DOI 10.1007/s00134-006-0451-8; Cipolla MJ, 2002, STROKE, V33, P2094, DOI 10.1161/01.STR.0000020712.84444.8D; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Dawson SL, 2000, CEREBROVASC DIS, V10, P126, DOI 10.1159/000016041; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; Dohmen C, 2007, STROKE, V38, P56, DOI 10.1161/01.STR.0000251642.18522.b6; FitzMaurice E, 2008, STROKE, V39, P2151, DOI 10.1161/STROKEAHA.107.508861; Huttner HB, 2006, STROKE, V37, P404, DOI 10.1161/01.STR.0000198806.67472.5c; KANEKO T, 1983, J CEREB BLOOD FLO S1, V5, pS51; KLINGELHOFER J, 1992, STROKE, V23, P962, DOI 10.1161/01.STR.23.7.962; Kuwata N, 1995, NEUROSURG REV, V18, P237, DOI 10.1007/BF00383874; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; Mendelow AD, 2005, LANCET, V365, P387; Merino JG, 2005, STROKE, V36, P232, DOI 10.1161/01.STR.0000153055.43138.2f; Powers WJ, 2001, NEUROLOGY, V57, P18, DOI 10.1212/WNL.57.1.18; Reinhard M, 2005, STROKE, V36, P1684, DOI 10.1161/01.STR.0000173183.36331.ee; Reinhard M, 2008, CEREBROVASC DIS, V26, P147, DOI 10.1159/000139662; Schmidt B, 2003, STROKE, V34, P84, DOI 10.1161/01.STR.0000047849.01376.AE; Soehle M, 2004, ANESTH ANALG, V98, P1133, DOI 10.1213/01.ANE.0000111101.41190.99; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner T, 2006, CEREBROVASC DIS, V22, P294, DOI 10.1159/000094831; STRANDGAARD S, 1976, CIRCULATION, V53, P720, DOI 10.1161/01.CIR.53.4.720; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; von Helden A, 1993, Acta Neurochir Suppl (Wien), V59, P102; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403	31	49	52	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	FEB	2010	36	2					264	271		10.1007/s00134-009-1698-7			8	Critical Care Medicine	General & Internal Medicine	546KU	WOS:000273810500012	19838669				2021-06-18	
J	Green, W; Ciuffreda, KJ; Thiagarajan, P; Szymano-wicz, D; Ludlam, DP; Kapoor, N				Green, Wesley; Ciuffreda, Kenneth J.; Thiagarajan, Preethi; Szymano-wicz, Dora; Ludlam, Diana P.; Kapoor, Neera			Accommodation in mild traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						accommodation; accommodative dysfunction; brain injury; head injury; rehabilitation; TBI; traumatic brain injury; vision; vision rehabilitation; visual dysfunction	HEAD TRAUMA; CONVERGENCE INSUFFICIENCY; SYSTEM; REHABILITATION; SPASM; VERGENCE; FACILITY; WHIPLASH; MODEL	Accommodative dysfunction in individuals with mild traumatic brain injury (mTBI) can have a negative impact on quality of life, functional abilities, and rehabilitative progress. In this study, we used a range of dynamic and static objective laboratory and clinical measurements of accommodation to assess 12 adult patients (ages 18-40 years) with mTBI. The results were compared with either 10 control subjects with no visual impairment or normative literature values where available. Regarding the dynamic parameters, responses in those with mTBI were slowed and exhibited fatigue effects. With respect to static parameters, reduced accommodative amplitude and abnormal accommodative interactions were found in those with mTBI. These results provide further evidence for the substantial impact of mTBI on accommodative function. These findings suggest that a range of accommodative tests should be included in the comprehensive vision examination of individuals with mTBI.	[Green, Wesley; Ciuffreda, Kenneth J.; Thiagarajan, Preethi; Szymano-wicz, Dora; Ludlam, Diana P.] SUNY, Dept Vis Sci, State Coll Optometry, New York, NY 10036 USA; [Kapoor, Neera] SUNY Coll Optometry, Dept Clin Sci, New York, NY 10036 USA	Ciuffreda, KJ (corresponding author), SUNY, Dept Vis Sci, State Coll Optometry, 33 W 42nd St, New York, NY 10036 USA.	kciuffreda@sunyopt.edu			SUNY/State College of Optometry	This material is the result of work supported with resources of the Graduate Studies Program at SUNY/State College of Optometry.	ALQURAINY IA, 1995, BRIT J ORAL MAX SURG, V33, P71, DOI 10.1016/0266-4356(95)90203-1; Benjamin WJ, 2006, BORISHS CLIN REFRACT; BOHLMANN BJ, 1987, J CLIN NEURO-OPHTHAL, V7, P129; Brown S, 2003, CLIN EXP OPHTHALMOL, V31, P424, DOI 10.1046/j.1442-9071.2003.00690.x; BURKE JP, 1992, GRAEF ARCH CLIN EXP, V230, P335, DOI 10.1007/BF00165941; Chan RVP, 2002, J NEURO-OPHTHALMOL, V22, P15, DOI 10.1097/00041327-200203000-00005; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda KJ, 2006, NEUROREHABILITATION, V21, P9; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Ciuffreda Kenneth J, 2002, Optometry, V73, P735; Ciuffreda KJ, 2009, OPTOM VIS DEV, V40, P16; Ciuffreda KJ, 2001, VISUAL VESTIBULAR CO, P77; Ciuffreda KJ., 2006, ACCOMMODATION PUPIL, V6th ed, P93, DOI DOI 10.1016/B978-0-7506-7524-6.50009-0; Duane A, 1922, Trans Am Ophthalmol Soc, V20, P132; GIANUTSOS R, 1988, ARCH PHYS MED REHAB, V69, P573; GILMARTIN B, 1986, OPHTHAL PHYSL OPT, V6, P23, DOI 10.1111/j.1475-1313.1986.tb00697.x; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Griffin JR, 2002, BINOCULAR ANOMALIES; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Han Y, 2004, BRAIN RES PROTOC, V14, P1, DOI 10.1016/j.brainresprot.2004.06.002; Harrison RJ, 1987, BINOC VIS, V2, P93; HEATH G G, 1956, Am J Optom Arch Am Acad Optom, V33, P569; Hung GK, 1996, OPHTHAL PHYSL OPT, V16, P31, DOI 10.1016/0275-5408(95)00110-7; HUNG GK, 1986, IEEE T BIO-MED ENG, V33, P1021, DOI 10.1109/TBME.1986.325868; HUNG GK, 1988, OPHTHAL PHYSL OPT, V8, P327, DOI 10.1111/j.1475-1313.1988.tb01062.x; KAWASAKI T, 1993, BRIT J OPHTHALMOL, V77, P678, DOI 10.1136/bjo.77.10.678; KOWAL L, 1992, AUST NZ J OPHTHALMOL, V20, P35, DOI 10.1111/j.1442-9071.1992.tb00701.x; Leslie S., 2001, VISUAL VESTIBULAR CO, P56; Levine S, 1985, J Am Optom Assoc, V56, P286; Monteiro MLR, 2003, BRIT J OPHTHALMOL, V87, P243, DOI 10.1136/bjo.87.2.243; Morgan M. W., 1944, OPTOMETRY VISION SCI, V21, P183; Ohtsuka K, 2002, AM J OPHTHALMOL, V133, P425, DOI 10.1016/S0002-9394(01)01356-3; Ohtsuka K, 1997, BRIT J OPHTHALMOL, V81, P476, DOI 10.1136/bjo.81.6.476; OHTSUKA K, 1988, AM J OPHTHALMOL, V106, P60, DOI 10.1016/S0002-9394(14)76389-5; Rabbetts R.B., 2007, BENNETT RABBETTS CLI, V4th ed.; REDING MJ, 1988, STROKE, V19, P1354, DOI 10.1161/01.STR.19.11.1354; Roca P D, 1972, Ann Ophthalmol, V4, P63; Rouse MW, 2004, OPHTHAL PHYSL OPT, V24, P384, DOI 10.1111/j.1475-1313.2004.00202.x; Scheiman M, 2001, VISUAL VESTIBULAR CO, P89; Scheiman M, 2002, CLIN MANAGEMENT BINO; SIDEROV J, 1990, OPTOMETRY VISION SCI, V67, P551, DOI 10.1097/00006324-199007000-00014; SIDEROV J, 1991, OPTOMETRY VISION SCI, V68, P49, DOI 10.1097/00006324-199101000-00008; STEPHENS KG, 1985, AM J OPTOM PHYS OPT, V62, P402; Suchoff I B, 1999, J Am Optom Assoc, V70, P301	44	49	49	0	17	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2010	47	3					183	199		10.1682/JRRD.2009.04.0041			17	Rehabilitation	Rehabilitation	609JL	WOS:000278652400004	20665345	Bronze			2021-06-18	
J	Molenberghs, P; Gillebert, CR; Schoofs, H; Dupont, P; Peeters, R; Vandenberghe, R				Molenberghs, Pascal; Gillebert, Celine R.; Schoofs, Hanne; Dupont, Patrick; Peeters, Ronald; Vandenberghe, Rik			Lesion neuroanatomy of the Sustained Attention to Response task	NEUROPSYCHOLOGIA			English	Article						Inferior frontal; Stroke; Cognitive control; Go no-go	ANTERIOR CINGULATE CORTEX; FRONTAL-LOBE; PREFRONTAL CORTEX; COGNITIVE CONTROL; CONFLICT; GO; DISSOCIATION; PERFORMANCE; INHIBITION; PARIETAL	The Sustained Attention to Response task is a classical neuro psychological test that has been used by many centres to characterize the attentional deficits in traumatic brain injury, ADHD, autism and other disorders. During the SART a random series of digits 1-9 is presented repeatedly and subjects have to respond to each digit (go trial) except the digit '3' (no-go trial). Using voxel-based lesion symptom mapping (VLSM) in a consecutive series of 44 ischemic unifocal non-lacunar hemispheric stroke patients we determined the neuroanatomy of 4 SART parameters: commission and omission error rate, reaction time variability and post-error slowing. Lesions of the right inferior frontal gyrus significantly increased commission error rate. Lesions of the middle third of the right inferior frontal sulcus (IFS) reduced post-error slowing, a measure of how well subjects can utilize errors to adjust cognitive resource allocation. Omissions and reaction time variability had less localising value in our sample. To conclude, commission errors and post-error slowing in the SART mainly probe right inferior frontal integrity. (C) 2009 Elsevier Ltd. All rights reserved.	[Schoofs, Hanne; Vandenberghe, Rik] Univ Hosp Leuven, Dept Neurol, B-3000 Louvain, Belgium; [Molenberghs, Pascal; Gillebert, Celine R.; Dupont, Patrick; Vandenberghe, Rik] Katholieke Univ Leuven, Expt Neurol Sect, Cognit Neurol Lab, Louvain, Belgium; [Peeters, Ronald] Univ Hosp Leuven, Dept Radiol, B-3000 Louvain, Belgium	Vandenberghe, R (corresponding author), Univ Hosp Leuven, Dept Neurol, Herestr 49, B-3000 Louvain, Belgium.	rik.vandenberghe@uz.kuleuven.ac.be	Molenberghs, Pascal/C-8176-2009; Gillebert, Celine/J-4177-2012; Vandenberghe, Rik/K-2145-2014; Vandenberghe, Rik/AAR-7485-2020; Dupont, Patrick/B-8044-2009	Molenberghs, Pascal/0000-0003-0350-6659; Vandenberghe, Rik/0000-0001-6237-2502; Vandenberghe, Rik/0000-0001-6237-2502; Dupont, Patrick/0000-0003-1980-2540; Gillebert, Celine/0000-0001-6686-7262	FWOFWO [G.0076.02, G0668.07]; KU Leuven ResearchKU Leuven [OT/04/41, EF/05/014]; Inter-University Attraction PoleBelgian Federal Science Policy Office [P6/29]; Flanders (Belgium)	Supported by FWO grants G.0076.02 and G0668.07 (EuroCores) (R.V.), KU Leuven Research grants OT/04/41 and EF/05/014 (R.V.), and Inter-University Attraction Pole P6/29. R.V. is a Clinical Investigator of the Fund for Scientific Research (FWO), Flanders (Belgium), and CRG an FWO research fellow.	Alexander MP, 2007, NEUROLOGY, V68, P1515, DOI 10.1212/01.wnl.0000261482.99569.fb; Alexander MP, 2005, NEUROLOGY, V65, P572, DOI 10.1212/01.wnl.0000172912.07640.92; Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Bates E, 2003, NAT NEUROSCI, V6, P448, DOI 10.1038/nn1050; Bellgrove MA, 2006, CORTEX, V42, P838, DOI 10.1016/S0010-9452(08)70426-X; BENDER MB, 1952, DISORDERS PERCEPTION; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Braver TS, 2003, NEURON, V39, P713, DOI 10.1016/S0896-6273(03)00466-5; Brunner E, 2000, BIOMETRICAL J, V42, P17, DOI 10.1002/(SICI)1521-4036(200001)42:1<17::AID-BIMJ17>3.0.CO;2-U; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Chambers CD, 2006, J COGNITIVE NEUROSCI, V18, P444, DOI 10.1162/jocn.2006.18.3.444; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050119721; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Crawford JR, 1998, CLIN NEUROPSYCHOL, V12, P482, DOI 10.1076/clin.12.4.482.7241; Derrfuss J, 2005, HUM BRAIN MAPP, V25, P22, DOI 10.1002/hbm.20127; DREWE EA, 1975, NEUROPSYCHOLOGIA, V13, P421, DOI 10.1016/0028-3932(75)90065-2; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Fellows LK, 2005, BRAIN, V128, P788, DOI 10.1093/brain/awh405; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Garavan H, 2003, NEUROIMAGE, V20, P1132, DOI 10.1016/S1053-8119(03)00334-3; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; Greene CM, 2009, NEUROPSYCHOLOGIA, V47, P591, DOI 10.1016/j.neuropsychologia.2008.10.003; Hjaltason H, 1996, NEUROPSYCHOLOGIA, V34, P1229, DOI 10.1016/0028-3932(96)00044-9; Hon N, 2006, J NEUROSCI, V26, P9805, DOI 10.1523/JNEUROSCI.3165-06.2006; Husain M, 1997, NATURE, V385, P154, DOI 10.1038/385154a0; Husain M, 2003, NAT REV NEUROSCI, V4, P26, DOI 10.1038/nrn1005; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P2234, DOI 10.1016/j.neuropsychologia.2007.02.019; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Konishi S, 1999, BRAIN, V122, P981, DOI 10.1093/brain/122.5.981; Konishi S, 1998, EUR J NEUROSCI, V10, P1209, DOI 10.1046/j.1460-9568.1998.00167.x; KONOW A, 1970, NEUROPSYCHOLOGIA, V8, P489, DOI 10.1016/0028-3932(70)90044-8; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Lutcke H, 2008, CEREB CORTEX, V18, P508, DOI 10.1093/cercor/bhm090; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Malhotra P, 2009, BRAIN, V132, P645, DOI 10.1093/brain/awn350; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; MENNEMEIER MS, 1994, NEUROPSYCHOLOGIA, V32, P703, DOI 10.1016/0028-3932(94)90030-2; Molenberghs P, 2008, J NEUROSCI, V28, P3359, DOI 10.1523/JNEUROSCI.5247-07.2008; Mort DJ, 2003, BRAIN, V126, P1986, DOI 10.1093/brain/awg200; Nakahara K, 2002, SCIENCE, V295, P1532, DOI 10.1126/science.1067653; O'Connell RG, 2008, NEUROPSYCHOLOGIA, V46, P1379, DOI 10.1016/j.neuropsychologia.2007.12.018; Picton TW, 2007, CEREB CORTEX, V17, P826, DOI 10.1093/cercor/bhk031; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Raven JC., 1995, COLOURED PROGR MATRI; Richer F, 1996, NEUROPSYCHOLOGIA, V34, P509, DOI 10.1016/0028-3932(95)00132-8; Riddoch M. J., 1993, BIRMINGHAM OBJECT RE; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P1527, DOI 10.1016/S0028-3932(97)00084-5; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rorden C, 2007, J COGNITIVE NEUROSCI, V19, P1081, DOI 10.1162/jocn.2007.19.7.1081; Rubia K, 2001, NEUROIMAGE, V13, P250, DOI 10.1006/nimg.2000.0685; Samuelsson H, 1998, J CLIN EXP NEUROPSYC, V20, P73, DOI 10.1076/jcen.20.1.73.1481; Schall JD, 2002, NEURON, V36, P309, DOI 10.1016/S0896-6273(02)00964-9; Scheffers MK, 1996, PSYCHOPHYSIOLOGY, V33, P42, DOI 10.1111/j.1469-8986.1996.tb02107.x; SCHENKENBERG T, 1980, NEUROLOGY, V30, P509, DOI 10.1212/WNL.30.5.509; Shallice T, 2002, DEV NEUROPSYCHOL, V21, P43, DOI 10.1207/S15326942DN2101_3; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Sohn MH, 2000, P NATL ACAD SCI USA, V97, P13448, DOI 10.1073/pnas.240460497; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Swick D, 2002, P NATL ACAD SCI USA, V99, P16354, DOI 10.1073/pnas.252521499; Talairach J., 1988, COPLANAR STEREOTAXIC; Tyler LK, 2005, NEUROPSYCHOLOGIA, V43, P771, DOI 10.1016/j.neuropsychologia.2004.07.020; Van Essen DC, 2005, NEUROIMAGE, V28, P635, DOI 10.1016/j.neuroimage.2005.06.058; Van Essen DC, 2001, J AM MED INFORM ASSN, V8, P443, DOI 10.1136/jamia.2001.0080443; Vandenberghe R, 2001, NEUROIMAGE, V14, P37, DOI 10.1006/nimg.2001.0790; Warrington E., 1991, VISUAL OBJECT SPACE; Wechsler D, 1998, WECHSLER MEMORY SCAL; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; Zordan L, 2008, BRAIN COGNITION, V66, P57, DOI 10.1016/j.bandc.2007.05.005	77	49	50	1	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	NOV	2009	47	13					2866	2875		10.1016/j.neuropsychologia.2009.06.012			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	510DB	WOS:000271067100021	19545580				2021-06-18	
J	Park, JH; Park, SW; Kang, SH; Nam, TK; Min, BK; Hwang, SN				Park, Jong-Hwa; Park, Seung-Won; Kang, Suk-Hyung; Nam, Taek-Kyun; Min, Byung-Kook; Hwang, Sung-Nam			Detection of Traumatic Cerebral Microbleeds by Susceptibility-Weighted Image of MRI	JOURNAL OF KOREAN NEUROSURGICAL SOCIETY			English	Article						Traumatic brain injury; Susceptibility-weighted image; Microbleeds	DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; CHILDREN; LESIONS; ADOLESCENTS; VENOGRAPHY; MODERATE	Objective : Susceptibility-weighted image (SWI) is a sensitive magnetic resonance image (MRI) technique to detect cerebral microbleeds (MBLs), which would not be detected by conventional MRI. We performed SWI to detect MBLs and investigated its usefulness in the evaluation of mild traumatic brain injury (MTBI) patients. Methods : From December 2006 to June 2007, twenty-one MTBI patients without any parenchymal hemorrhage on conventional MRI were selected. Forty-two patients without trauma were selected for control group. According to the presence of MBLs, we divided the MTBI group into MBLs positive [SWI (+)] and negative [SWI (-)] group. Regional distribution of MBLs and clinical factors were compared between groups. Results : Fifty-one MBLs appeared in 16 patients of SWI (+) group and 16 MBLs in 10 patients of control group [control (+)], respectively. In SWI (+) group, MBLs were located more frequently in white matters than in deep nucleus different from the control (+) group (p < 0.05). Nine patients (56.3%) of SWI (+) group had various neurological deficits (disorientation in 4, visual field defect in 2, hearing difficulty in 2 and Parkinson syndrome in 1). Initial Glasgow Coma Scale (GCS)/mean Glasgow Outcome Scale (GOS) were 13.9 +/- 1.5/4.7 +/- 0.8 and 15.0 +/- 0.0/5.0 +/- 0.0 in SWI (+) and SWI (-) groups, respectively (p < 0.05). Conclusion : Traumatic cerebral MBLs showed characteristic regional distribution, and seemed to have an importance on the initial neurological status and the prognosis. SWI is useful for detection of traumatic cerebral MBLs, and can provide etiologic evidences for some post-traumatic neurologic deficits which were unexplainable with conventional MRI.	[Park, Jong-Hwa; Park, Seung-Won; Kang, Suk-Hyung; Nam, Taek-Kyun; Min, Byung-Kook; Hwang, Sung-Nam] Chung Ang Univ, Coll Med, Dept Neurosurg, Yongsan Hosp, Seoul 140757, South Korea	Park, SW (corresponding author), Chung Ang Univ, Coll Med, Dept Neurosurg, Yongsan Hosp, 65-207 Hangangro 3 Ga, Seoul 140757, South Korea.	nspsw@hanmail.net	Kang, Sukhyung/R-6333-2019; Won, Park Seung/F-2877-2014	Won, Park Seung/0000-0001-8305-7501; Park, Jong-Hwa/0000-0002-8008-6785; Kang, Sukhyung/0000-0002-1130-9754			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; GENTRY LR, 1994, RADIOLOGY, V191, P1; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; HAACKE EM, 2002, SUSCEPTIBILITY WEIGH; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Lee BCP, 1999, AM J NEURORADIOL, V20, P1239; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Matsushita T, 2008, ACTA MED OKAYAMA, V62, P159; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176	18	49	62	0	2	KOREAN NEUROSURGICAL SOC	SEOUL	#402 POSCO # OFFICE BUILDING 151 SUNHWA-DONG, JUNG-GU, SEOUL, 100-130, SOUTH KOREA	2005-3711	1598-7876		J KOREAN NEUROSURG S	J. Korean. Neurosurg. Soc.	OCT	2009	46	4					365	369		10.3340/jkns.2009.46.4.365			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	513FT	WOS:000271308600015	19893728	DOAJ Gold, Green Published			2021-06-18	
J	Croft, AP; Przyborski, SA				Croft, Adam P.; Przyborski, Stefan A.			Mesenchymal stem cells expressing neural antigens instruct a neurogenic cell fate on neural stem cells	EXPERIMENTAL NEUROLOGY			English	Article						Bone marrow stromal cells; Co-culture; Mesenchymal stem cells; Neural stem cells; Neurogenesis; Neuritogenesis	MARROW STROMAL CELLS; TRAUMATIC BRAIN-INJURY; ADULT BONE-MARROW; SPINAL-CORD-INJURY; GROWTH-FACTOR; CEREBRAL-ISCHEMIA; FUNCTIONAL RECOVERY; PROGENITOR CELLS; INTRACEREBRAL TRANSPLANTATION; ENHANCES ANGIOGENESIS	The neurogenic response to injury in the postnatal brain is limited and insufficient for restoration of function. Recent evidence suggests that transplantation of mesenchymal stem cells (MSCs) into the injured brain is associated with improved functional recovery, mediated in part through amplification in the endogenous neurogenic response to injury. In the Current study we investigate the interactions between bone marrow-derived MSCs and embryonic neural stem cells (NSCs) plus their differentiated progeny using an in vitro co-culture system. Two populations of MSCs were used, MSCs induced to express neural antigens (nestin+, Tuj-1+, GFAP+) and neural antigen negative MSCs. Following co-culture of induced MSCs with differentiating NSC/progenitor cells a significant increase in Tuj-1+ neurons was detected compared to co-culture of non-induced MSCs in which an increase in astrocyte (GFAP+) differentiation was observed. The effect was mediated by soluble interactions between the two cell populations and was independent of any effect on cell death and proliferation. induced and non-induced MSCs also promoted the survival of Tuj-1+ cell progeny in long-term cultures and both promoted axonal growth, an effect also seen in differentiating neuroblastoma cells. Therefore, MSCs provide instructive signals that are able to direct the differentiation of NSCs and promote axonal development in neuronal progeny. The data indicates that the nature of MSC derived signals is dependent not only on their microenvironment but on the developmental status of the MSCs. Pre-manipulation of MSCs prior to transplantation in vivo may be an effective means of enhancing the endogenous neurogenic response to injury. (c) 2008 Elsevier Inc. All rights reserved.	[Croft, Adam P.; Przyborski, Stefan A.] Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England; [Przyborski, Stefan A.] Univ Durham, Reinnervate Ltd, Durham DH1 3LE, England	Przyborski, SA (corresponding author), Univ Durham, Sch Biol & Biomed Sci, South Rd, Durham DH1 3LE, England.	stefan.przyborski@durham.ac.uk	Croft, Adam/AAN-1900-2021	Croft, Adam/0000-0002-9487-0511	Wellcome TrustWellcome TrustEuropean Commission	We would like to thank A. Richie for the technical assistance. This work was supported in part by awards to SAP by The Wellcome Trust (Registered Charity: 210183) and Biotechnology and Biological Sciences Research Council.	Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Ay H, 1999, CEREBROVASC DIS, V9, P131, DOI 10.1159/000015941; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bae JS, 2007, STEM CELLS, V25, P1307, DOI 10.1634/stemcells.2006-0561; Bai LH, 2007, NEUROCHEM RES, V32, P353, DOI 10.1007/s11064-006-9212-x; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bushong EA, 2004, INT J DEV NEUROSCI, V22, P73, DOI 10.1016/j.ijdevneu.2003.12.008; Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Croft AP, 2006, STEM CELLS, V24, P1841, DOI 10.1634/stemcells.2005-0609; Deng J, 2006, STEM CELLS, V24, P1054, DOI 10.1634/stemcells.2005-0370; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Hamano K, 2000, CELL TRANSPLANT, V9, P439, DOI 10.1177/096368970000900315; HEFTI F, 1986, J NEUROSCI, V6, P2155; Hermann A, 2004, J CELL SCI, V117, P4411, DOI 10.1242/jcs.01307; Hermann A, 2006, J NEUROSCI RES, V83, P1502, DOI 10.1002/jnr.20840; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; HOKARI M, 2007, J NEUROSCI RES; Honma T, 2006, EXP NEUROL, V199, P56, DOI 10.1016/j.expneurol.2005.05.004; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Kabos P, 2002, EXP NEUROL, V178, P288, DOI 10.1006/exnr.2002.8039; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; Li Y, 2006, EXP NEUROL, V198, P313, DOI 10.1016/j.expneurol.2005.11.029; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2001, CELL TRANSPLANT, V10, P31; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lou SJ, 2003, BRAIN RES, V968, P114, DOI 10.1016/S0006-8993(03)02224-8; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Munoz JR, 2005, P NATL ACAD SCI USA, V102, P18171, DOI 10.1073/pnas.0508945102; Nakano K, 2001, TRANSPLANTATION, V71, P1735, DOI 10.1097/00007890-200106270-00006; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Palmer TD, 1999, J NEUROSCI, V19, P8487; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Rivera FT, 2006, STEM CELLS, V24, P2209, DOI 10.1634/stemcells.2005-0614; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; SHEN LH, 2007, CEREB BLOOD FLOW MET, V27, P6; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Tohill M, 2004, NEUROSCI LETT, V362, P200, DOI 10.1016/j.neulet.2004.03.077; Tondreau T, 2004, DIFFERENTIATION, V72, P319, DOI 10.1111/j.1432-0436.2004.07207003.x; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wislet-Gendebien S, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-33; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369	60	49	55	0	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2009	216	2					329	341		10.1016/j.expneurol.2008.12.010			13	Neurosciences	Neurosciences & Neurology	424ZK	WOS:000264606600013	19159625				2021-06-18	
J	Porcu, P; O'Buckley, TK; Alward, SE; Marx, CE; Shampine, LJ; Girdler, SS; Morrow, AL				Porcu, Patrizia; O'Buckley, Todd K.; Alward, Sarah E.; Marx, Christine E.; Shampine, Lawrence J.; Girdler, Susan S.; Morrow, A. Leslie			Simultaneous quantification of GABAergic 3 alpha,5 alpha/3 alpha,5 beta neuroactive steroids in human and rat serum	STEROIDS			English	Article						GABAergic neuroactive neurosteroid; Pregnenolone; Gas chromatography-mass spectrometry	TRAUMATIC BRAIN-INJURY; CHROMATOGRAPHY-MASS-SPECTROMETRY; MAJOR DEPRESSION; A RECEPTOR; GABA(A) RECEPTORS; CEREBRAL-CORTEX; 3-ALPHA-HYDROXY-5-ALPHA-PREGNAN-20-ONE LEVELS; NEUROSTEROID ALLOPREGNANOLONE; DEHYDROEPIANDROSTERONE LEVELS; PREMENSTRUAL-SYNDROME	The 3 alpha,5 alpha- and 3 alpha,5 beta-reduced derivatives of progesterone, deoxycorticosterone, dehydroepiandrosterone and testosterone enhance GABAergic neurotransmission and produce inhibitory neurobehavioral and anti-inflammatory effects. Despite Substantial information oil the progesterone derivative (3 alpha,5 alpha)-3-hydroxypregnan-20-one (3 alpha,5 alpha-THP, allopregnanolone), the physiological significance of the other endogenous GABAergic neuroactive steroids has remained elusive. Here, we describe the validation of a method using gas chromatography-mass spectrometry to simultaneously identify serum levels of the eight 3 alpha,5 alpha- and 3 alpha,5 beta-reduced derivatives of progesterone, deoxycorticosterone, dehydroepiandrosterone and testosterone. The method shows specificity. sensitivity and enhanced throughput compared to other methods already available for neuroactive steroid quantification. Administration of pregnenolone to rats and progesterone to women produced selective effects on the 3 alpha,5 alpha- and 3 alpha,5 beta-reduced neuroactive steroids, indicating differential regulation of their biosynthetic pathways. Pregnenolone administration increased serum levels of 3 alpha,5 alpha-THP (+1488%, p<0.001), (3 alpha,5 alpha)-3,21-dihydroxypregnan-20-one (3 alpha,5 alpha-THDOC, +205%, p<0.01), (3 alpha,5 alpha)-3-hydroxyandrostan-17-one (3 alpha,5 alpha-A, +216%, p<0.001), (3 alpha,5 alpha,17 beta)-androstane-3,17-diol (3 alpha,5 alpha-A-diol, +190%, p<0.01). (3 alpha,5 beta)-3-hydroxypregnan-20-one (3 alpha,5 beta-THP) and (3 alpha,5 beta)-3-hydroxyandrostan-17-one (3 alpha,5 beta-A) were not altered, while (3 alpha,5 beta)-3,21-dihydroxypregnan-20-one (3 alpha,5 beta-THDOC) and (3 alpha,5 beta,17 beta)-androstane-3,17-diol (3 alpha,5 beta-A-diol) were increased from undetectable levels to 271 +/- 100 and 2.4 +/- 0.9 pg +/- SEM, respectively (5/8 rats). Progesterone administration increased serum levels of 3 alpha,5 beta-THP (+1806%, p<0.0001), 3 alpha,5 beta-THP (+575%, p<0.001), 3 alpha,5 beta-THDOC (+309%, p<0.001). 3 alpha,5 beta-THDOC levels were increased by 307%, although this increase was not significant because this steroid was detected only in 3/16 control Subjects. Levels of 3 alpha,5 alpha-A, 3 alpha,5 beta-A and pregnenolone were not altered. This method can be used to investigate the physiological and pathological role of neuroactive steroids and to develop bioinarkers and new therapeutics for neurological and psychiatric disorders. (C) 2009 Elsevier Inc. All rights reserved.	[Porcu, Patrizia; O'Buckley, Todd K.; Alward, Sarah E.; Girdler, Susan S.; Morrow, A. Leslie] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC 27599 USA; [Porcu, Patrizia; O'Buckley, Todd K.; Alward, Sarah E.; Morrow, A. Leslie] Univ N Carolina, Sch Med, Bowles Ctr Alcahol Studies, Chapel Hill, NC 27599 USA; [Marx, Christine E.; Shampine, Lawrence J.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27705 USA; [Marx, Christine E.; Shampine, Lawrence J.] Dept Vet Affairs Med Ctr, Durham, NC 27705 USA; [Girdler, Susan S.] Univ N Carolina, Sch Med, Dept Psychol, Chapel Hill, NC 27599 USA; [Morrow, A. Leslie] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	Morrow, AL (corresponding author), Univ N Carolina, Sch Med, Dept Psychiat, 3027 Thurston Bowles Bldg,CB7178, Chapel Hill, NC 27599 USA.	morrow@med.unc.edu	Porcu, Patrizia/B-8400-2015	Porcu, Patrizia/0000-0003-0848-7258; O'Buckley, Todd/0000-0001-8723-734X	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AA010564, U01 AA013515, U01 AA016677]; ALM [R01 MH051246]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH051246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA010564, U01AA013515, R37AA010564, U01AA016672, R21AA016677] Funding Source: NIH RePORTER	The authors wish to express their appreciation to Drs. Synthia H. Mellon (University of California, San Francisco), Robert H. Purdy (The Scripps Research Institute, La Jolla, and Veterans Medical Research Foundation, San Diego, California) and Elena Romeo (Tor Vergata University, Rome, Italy) for many helpful discussions and Suggestions during the course of development and validation of this assay. We also wish to thank Dr. Steven M. Paul (Eli Lilly and Company, Indianapolis, Indiana) for helpful comments on the manuscript.; Source of Funding: This study was supported by the National Institute of Health grants R01 AA010564, U01 AA013515 and U01 AA016677 to ALM and R01 MH051246 to SSG.	Barbaccia ML, 2001, NEUROPSYCHOPHARMACOL, V25, P489, DOI 10.1016/S0893-133X(01)00254-8; BIGGIO G, 2001, INT REV NEUROBIOLOGY, V46; Brambilla F, 2003, PSYCHIAT RES, V118, P107, DOI 10.1016/S0165-1781(03)00077-5; Budzinski H, 2006, ANAL BIOANAL CHEM, V386, P1429, DOI 10.1007/s00216-006-0686-9; Buffet NC, 1998, FRONT NEUROENDOCRIN, V19, P151, DOI 10.1006/frne.1998.0167; CHENEY DL, 1995, J NEUROSCI, V15, P4641; Concas A, 2000, PHARMACOL BIOCHEM BE, V66, P39, DOI 10.1016/S0091-3057(00)00237-9; Concas A, 1998, P NATL ACAD SCI USA, V95, P13284, DOI 10.1073/pnas.95.22.13284; Concas A, 2006, PSYCHOPHARMACOLOGY, V186, P281, DOI 10.1007/s00213-005-0111-7; de Michele F, 2003, NEUROL SCI, V24, P172, DOI 10.1007/s10072-003-0115-1; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; El-Etr M, 2005, J NEUROL SCI, V233, P49, DOI 10.1016/j.jns.2005.03.004; Evans SEG, 2005, GYNECOL ENDOCRINOL, V21, P268, DOI 10.1080/09513590500361747; Follesa P, 2002, NEUROPHARMACOLOGY, V42, P325, DOI 10.1016/S0028-3908(01)00187-3; Frye CA, 1996, BEHAV BRAIN RES, V79, P109, DOI 10.1016/0166-4328(96)00004-6; Genazzani AR, 1998, J CLIN ENDOCR METAB, V83, P2099, DOI 10.1210/jc.83.6.2099; GEORGE MS, 1994, BIOL PSYCHIAT, V35, P775, DOI 10.1016/0006-3223(94)91139-8; Girdler SS, 2001, BIOL PSYCHIAT, V49, P788, DOI 10.1016/S0006-3223(00)01044-1; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Grobin AC, 2005, PSYCHOPHARMACOLOGY, V179, P544, DOI 10.1007/s00213-004-2084-3; Grobin AC, 2001, DEV BRAIN RES, V131, P31; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hill M, 2000, J STEROID BIOCHEM, V75, P237, DOI 10.1016/S0960-0760(00)00192-8; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Kaminski RM, 2005, EPILEPSIA, V46, P819, DOI 10.1111/j.1528-1167.2005.00705.x; Kancheva L, 2007, STEROIDS, V72, P792, DOI 10.1016/j.steroids.2007.06.006; Kim YS, 2000, ANAL BIOCHEM, V277, P187, DOI 10.1006/abio.1999.4384; Klak J, 2003, PHYSIOL RES, V52, P211; Klatzkin RR, 2006, PSYCHONEUROENDOCRINO, V31, P1208, DOI 10.1016/j.psyneuen.2006.09.002; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Liere P, 2000, J CHROMATOGR B, V739, P301, DOI 10.1016/S0378-4347(99)00563-0; Lombardi I, 2004, GYNECOL ENDOCRINOL, V18, P79, DOI 10.1080/09513590310001652955; Maguire JL, 2005, NAT NEUROSCI, V8, P797, DOI 10.1038/nn1469; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Marx CE, 2000, BIOL PSYCHIAT, V47, P1000, DOI 10.1016/S0006-3223(99)00305-4; Marx CE, 2003, NEUROPSYCHOPHARMACOL, V28, P1, DOI 10.1038/sj.npp.1300015; MARX CE, 2008, INT J NEUROPSYCHOPH, P1; Marx CE, 2007, BIOL PSYCHIAT, V61, p13S; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P598, DOI 10.1016/j.pbb.2006.07.026; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P609, DOI 10.1016/j.pbb.2006.07.032; Marx CE, 2006, NEUROPSYCHOPHARMACOL, V31, P1249, DOI 10.1038/sj.npp.1300952; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Morrow A Leslie, 2006, Dialogues Clin Neurosci, V8, P463; Morrow AL, 2007, PHARMACOL THERAPEUT, V116, P1, DOI 10.1016/j.pharmthera.2007.04.003; Morrow AL, 1998, NATURE, V395, P652, DOI 10.1038/27106; Naylor JC, 2008, J CLIN ENDOCR METAB, V93, P3173, DOI 10.1210/jc.2007-1229; PAUL SM, 1992, FASEB J, V6, P2311; Pieribone VA, 2007, EPILEPSIA, V48, P1870, DOI 10.1111/j.1528-1167.2007.01182.x; Pisu MG, 2004, LIFE SCI, V74, P3181, DOI 10.1016/j.lfs.2003.12.002; Porcu P, 2003, PHARMACOL BIOCHEM BE, V74, P683, DOI 10.1016/S0091-3057(02)01065-1; PURDY RH, 1991, P NATL ACAD SCI USA, V88, P4553, DOI 10.1073/pnas.88.10.4553; PURDY RH, 2007, HDB NEUROCHEMISTRY M, P1; Rasmusson AM, 2006, BIOL PSYCHIAT, V60, P704, DOI 10.1016/j.biopsych.2006.03.026; Ritsner M, 2007, EUR NEUROPSYCHOPHARM, V17, P358, DOI 10.1016/j.euroneuro.2006.10.001; Romeo E, 1998, AM J PSYCHIAT, V155, P910, DOI 10.1176/ajp.155.7.910; Savitz AJ, 2007, SCHIZOPHRENIA BULL, V33, P458; Schule C, 2006, MOL PSYCHIATR, V11, P261, DOI 10.1038/sj.mp.4001782; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shen H, 2007, NAT NEUROSCI, V10, P469, DOI 10.1038/nn1868; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; STENBERG A, 1976, J ENDOCRINOL, V68, P265, DOI 10.1677/joe.0.0680265; Strohle A, 1999, BIOL PSYCHIAT, V45, P274, DOI 10.1016/S0006-3223(98)00328-X; Strohle A, 2003, ARCH GEN PSYCHIAT, V60, P161, DOI 10.1001/archpsyc.60.2.161; Uzunov DP, 1996, P NATL ACAD SCI USA, V93, P12599, DOI 10.1073/pnas.93.22.12599; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; Vallee M, 2000, ANAL BIOCHEM, V287, P153, DOI 10.1006/abio.2000.4841; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang JM, 2008, BRAIN RES REV, V57, P398, DOI 10.1016/j.brainresrev.2007.08.010; Wang MD, 1996, J CLIN ENDOCR METAB, V81, P1076, DOI 10.1210/jc.81.3.1076; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932	72	49	49	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0039-128X	1878-5867		STEROIDS	Steroids	APR-MAY	2009	74	4-5					463	473		10.1016/j.steroids.2008.12.015			11	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	429ST	WOS:000264941100010	19171160	Green Accepted			2021-06-18	
J	Ivins, BJ; Kane, R; Schwab, KA				Ivins, Brian J.; Kane, Robert; Schwab, Karen A.			Performance on the Automated Neuropsychological Assessment Metrics in a Nonclinical Sample of Soldiers Screened for Mild TBI After Returning From Iraq and Afghanistan: A Descriptive Analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Afghanistan; cognitive testing; Iraq; traumatic brain injury; US Army	TRAUMATIC BRAIN-INJURY; SPORTS CONCUSSION; DEPLOYMENT; OUTCOMES	Purpose: To characterize cognitive test performance in a sample of US Army soldiers who had served in Iraq and Afghanistan and were tested after returning to their home base. To determine whether if a self-reported history of deployment-related traumatic brain injury (TBI), lifetime history of TBI, and the current postconcussive symptom status affected cognitive test performance. Methods: A convenience sample of 956 soldiers was administered the Automated Neuropsychological Assessment Metrics (ANAM) test battery as well as questionnaires asking about deployment-related TBI, lifetime TBI history, and current TBI-related symptoms. Results: Consistent with past mild TBI (MTBI) research, having a history of deployment-related MTBI up to 2 years prior to cognitive testing was not associated with poor ANAM performance after deployment. There also were no associations between poor ANAM performance and the number of lifetime TBIs, and injury severity and the number of problematic postconcussive symptoms. Conclusions: A history of self-reported MTBI or current postconcussive symptoms does not increase the risk of cognitive impairment in service members returning from Iraq and Afghanistan.	[Ivins, Brian J.; Kane, Robert; Schwab, Karen A.] Def & Vet Brain Injury Ctr, Washington, DC 20012 USA	Ivins, BJ (corresponding author), Def & Vet Brain Injury Ctr, POB 59181, Washington, DC 20012 USA.	brian.ivins@amedd.army.mil					Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Gabbe BJ, 2003, BRIT J SPORT MED, V37, P545, DOI 10.1136/bjsm.37.6.545; HANNAY HJ, 2004, NEUROPSYCHOLOGICAL A, pCH6; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Randolph C, 2005, J ATHL TRAINING, V40, P139; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; SCHELL TL, 2008, 1NVISIBLE WOUNDS MEN, pCH4; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; TANIELIAN T, 2008, INVISIBLE WOUNDS MEN, pCH1; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; *USA, 2007, REP SURG GEN; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	29	49	49	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2009	24	1					24	31		10.1097/HTR.0b013e3181957042			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	427GT	WOS:000264768500005	19158593				2021-06-18	
J	Percy, A; Widman, S; Rizzo, JA; Tranquilli, M; Elefteriades, JA				Percy, Andrew; Widman, Shannon; Rizzo, John A.; Tranquilli, Maryann; Elefteriades, John A.			Deep Hypothermic Circulatory Arrest in Patients With High Cognitive Needs: Full Preservation of Cognitive Abilities	ANNALS OF THORACIC SURGERY			English	Article							DYSFUNCTION; PROTECTION; INJURY	Background. Owing to controversy regarding the efficacy and safety of deep hypothermic circulatory arrest (DHCA) during thoracic aortic surgery, we conducted a psychometric study in which high-cognitive patients and their informants were interviewed to determine whether DHCA had any adverse effect on their daily activities or work performance. Methods. A total of 29 patients (18 males, 11 females; age, 26 to 75 years; mean 52.6 years) whose jobs require high cognitive capability and who had undergone aortic surgery using DHCA (range, 17 to 54 minutes; mean arrest time, 27.4 minutes) at Yale-New Haven Hospital were retrospectively studied. These 29 patients represented the responders among 45 such patients to whom questionnaires were mailed. A control group of 21 high-cognitive patients (20 males, 1 female; ages, 36 to 77 years; mean, 54.7 years) who underwent aortic surgery without DHCA were surveyed as well. During surgery, DHCA was used as the sole means of cerebral protection. The head was packed in ice, and carbon dioxide flooding of the field was used in all cases. The ascending aorta was resected with an open distal anastomosis and a hemiarch or total arch replacement. A 21-part questionnaire (adapted from A. F. Jorm's Short Form IQCODE and supplemented by our own questions) was distributed postoperatively to subjects and to their informants (generally a spouse). A value of 3 on the questionnaire indicated "not much change" from preoperative status (1 indicated much worse and 5 indicated much improved). Results. There were no statistically significant differences in any functional outcomes by study group (by patient: DHCA 3.01, control 3.09; by informant: DHCA 3.00, control 3.03; p > 0.05). Mean values of the outcomes for study groups and control subjects were essentially identical and quite close to 3 (the value assigned to " not much change") for overall score, for occupational score, and for memory-related score. Conclusions. These data indicate that high-cognitive patients experienced very little cognitive change as a result of undergoing DHCA. Our assessment strongly supports the adequacy of straight DHCA as a cerebral protectant strategy during short- to moderate-duration circulatory arrest. We found excellent preservation of functional state and no difference from patients undergoing aortic surgery without DHCA.	[Elefteriades, John A.] Yale Univ, Sch Med, Sect Cardiothorac Surg, New Haven, CT 06437 USA; SUNY Stony Brook, Sch Med, Dept Prevent Med, Stony Brook, NY 11794 USA	Elefteriades, JA (corresponding author), Yale Univ, Sch Med, Sect Cardiothorac Surg, 121 FMB,333 Cedar St, New Haven, CT 06437 USA.	john.elefteriades@yale.edu		Widman, Shannon/0000-0002-0594-1884			Ahonen J, 2004, ACTA ANAESTH SCAND, V48, P4, DOI 10.1111/j.1399-6576.2004.00275.x; Amir G, 2005, ANN THORAC SURG, V80, P1955, DOI 10.1016/j.athoracsur.2004.12.040; CHRISTENSEN H, 1992, INT J GERIATR PSYCH, V7, P159, DOI 10.1002/gps.930070304; Cooper WA, 2000, ANN THORAC SURG, V69, P696, DOI 10.1016/S0003-4975(99)01524-6; Ergin MA, 1999, ANN THORAC SURG, V67, P1887, DOI 10.1016/S0003-4975(99)00432-4; Gega A, 2007, ANN THORAC SURG, V84, P759, DOI 10.1016/j.athoracsur.2007.04.107; Haverich A, 2003, J THORAC CARDIOV SUR, V125, P460, DOI 10.1067/mtc.2003.291; Immer FF, 2004, CIRCULATION, V110, pII250, DOI 10.1161/01.CIR.0000138387.61103.a0; Jorm AF, 1996, CLIN PSYCHOL REV, V16, P51, DOI 10.1016/0272-7358(95)00056-9; Jorm AF, 1996, INT J GERIATR PSYCH, V11, P131; Jorm AF, 2002, PRINCIPLES PRACTICE, P141; Kumral E, 2001, TEX HEART I J, V28, P83; Mendelowitsch A, 1998, J NEUROL NEUROSUR PS, V64, P611, DOI 10.1136/jnnp.64.5.611; MORAMANGANO CT, 2001, CIRCULATION S1, V104, P276; Reich DL, 1999, J THORAC CARDIOV SUR, V117, P156, DOI 10.1016/S0022-5223(99)70481-2; SVENSSON L, 1997, CARDIOVASCULAR VASCU; Welz A, 1997, EUR J CARDIO-THORAC, V11, P650, DOI 10.1016/S1010-7940(96)01129-3	17	49	50	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0003-4975	1552-6259		ANN THORAC SURG	Ann. Thorac. Surg.	JAN	2009	87	1					117	123		10.1016/j.athoracsur.2008.10.025			7	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	385SN	WOS:000261834000026	19101283				2021-06-18	
J	Sorond, FA; Serrador, JM; Jones, RN; Shaffer, ML; Lipsitz, LA				Sorond, Farzaneh A.; Serrador, Jorge M.; Jones, Richard N.; Shaffer, Michele L.; Lipsitz, Lewis A.			THE SIT-TO-STAND TECHNIQUE FOR THE MEASUREMENT OF DYNAMIC CEREBRAL AUTOREGULATION	ULTRASOUND IN MEDICINE AND BIOLOGY			English	Article						Dynamic cerebral autoregulation; Sit-to-stand procedure; Transcranial Doppler ultrasound	BLOOD-FLOW-VELOCITY; TRANSCRANIAL DOPPLER ULTRASOUND; CRITICAL CLOSING PRESSURE; VALSALVA MANEUVER; HEAD-INJURY; HUMANS; HEMODYNAMICS; CIRCULATION; SONOGRAPHY; STRESS	Measurement of cerebral autoregulation is important for the evaluation and management of a number of clinical disorders that affect cerebral blood flow. We currently lack simple bedside measures that mimic common physiologic stresses. Therefore, we evaluated a new sit-to-stand technique as an alternative method to the frequently-used thigh-cuff technique in health, volunteers. Continuous middle cerebral artery (MCA) blood flow velocities (BFV) and arterial blood pressure (ABP) were measured in response to standing from a sitting position, or rapid thigh-cuff deflation in 24 healthy subjects (50 +/- 22). Autoregulatory index (ARI) was calculated as the BFNI response for step changes in 6P using a second-order differential equation with a set of parameters that can be used to grade the performance of autoregulation. Of these 24 subjects, 30% could tolerate only two thigh-cuffs and refused to proceed with the third cuff, whereas none of our subjects had any difficulty with performing the three sit-to-stand trials. The two techniques produced similar changes in mean ABP, but the times to nadir of the blood pressure and BFV were significantly faster for the thigh-cuff. The mean group ARIs were similar between the two techniques. Although between-subjects variability was higher for sit-to-stand ARIs, the within-subject sit-to-stand ART variability was small. Thus, for the assessment of cerebral autoregulation, the sit-to-stand procedure is well tolerated and produces ART values that have low, within-subject variability. The sit-to-stand technique appears to be a suitable measure of individual ART values for inferring dynamic cerebral autoregulation.	[Sorond, Farzaneh A.] Brigham & Womens Hosp, Dept Neurol, Stroke Div, Boston, MA 02115 USA; [Sorond, Farzaneh A.; Jones, Richard N.; Shaffer, Michele L.; Lipsitz, Lewis A.] Hebrew SeniorLife, Inst Aging Res, Boston, MA USA; [Sorond, Farzaneh A.; Serrador, Jorge M.; Jones, Richard N.; Lipsitz, Lewis A.] Harvard Univ, Sch Med, Boston, MA USA; [Lipsitz, Lewis A.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gerontol, Boston, MA 02215 USA; [Serrador, Jorge M.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Shaffer, Michele L.] Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA USA	Sorond, FA (corresponding author), Brigham & Womens Hosp, Dept Neurol, Stroke Div, 45 Francis St, Boston, MA 02115 USA.	fsorond@partners.org	Serrador, Jorge/A-9172-2009; Jones, Richard Norman/J-3488-2013	Jones, Richard Norman/0000-0002-1049-218X; Serrador, Jorge Manuel/0000-0003-1830-4398	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG030967, Z01AG000294, K12AG000294, P60AG008812, P50AG005134, P01AG004390] Funding Source: NIH RePORTER; Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z01 AG000294] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K12 AG000294, P01 AG004390, P01 AG004390-20, P50 AG005134, P50 AG005134-259004, P60 AG008812, K23 AG030967-01A1, K23 AG030967, P60 AG008812-15, K12 AG000294-18] Funding Source: Medline		Aaslid R, 1999, ACT NEUR S, V72, P47; AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Bakker SLM, 2004, NEUROEPIDEMIOLOGY, V23, P178, DOI 10.1159/000078503; BIRCH AA, 1995, STROKE, V26, P834, DOI 10.1161/01.STR.26.5.834; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; Clark JM, 1996, J CEREBR BLOOD F MET, V16, P1255, DOI 10.1097/00004647-199611000-00021; DAHL A, 1992, J CEREBR BLOOD F MET, V12, P1049, DOI 10.1038/jcbfm.1992.142; Dawson SL, 1999, J APPL PHYSIOL, V86, P675; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Eames PJ, 2002, J NEUROL NEUROSUR PS, V72, P467; Folino AF, 2006, HEART, V92, P724, DOI 10.1136/hrt.2005.069179; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; GREENFIELD JC, 1984, STROKE, V15, P76, DOI 10.1161/01.STR.15.1.76; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; LARSEN FS, 1995, HEPATOLOGY, V22, P730, DOI 10.1002/hep.1840220307; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; Lipsitz LA, 2000, STROKE, V31, P1897, DOI 10.1161/01.STR.31.8.1897; Mahony PJ, 2000, STROKE, V31, P476, DOI 10.1161/01.STR.31.2.476; Matz P G, 1997, Clin Neurosurg, V44, P267; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; Novak V, 2006, DIABETES CARE, V29, P1529, DOI 10.2337/dc06-0261; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Oehm E, 2003, ULTRASOUND OBST GYN, V22, P395, DOI 10.1002/uog.183; Panerai RB, 2003, MED ENG PHYS, V25, P621, DOI 10.1016/S1350-4533(03)00027-4; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Panerai RB, 1999, AM J PHYSIOL-HEART C, V277, pH1089; Panerai RB, 2001, AM J PHYSIOL-HEART C, V280, pH2162; Ratsep T, 2001, J NEUROSURG, V95, P393, DOI 10.3171/jns.2001.95.3.0393; Schroeter ML, 2005, J CEREBR BLOOD F MET, V25, P1675, DOI 10.1038/sj.jcbfm.9600159; Serrador JM, 2000, STROKE, V31, P1672, DOI 10.1161/01.STR.31.7.1672; Serrador JM, 2005, J APPL PHYSIOL, V98, P151, DOI 10.1152/japplphysiol.00471.2004; Shrout Patrick E., 1995, P213; Sorond FA, 2005, J GERONTOL A-BIOL, V60, P1484, DOI 10.1093/gerona/60.11.1484; SORTEBERG W, 1989, ACTA NEUROCHIR, V97, P47, DOI 10.1007/BF01577739; SUGIMORI H, 1995, STROKE, V26, P2053, DOI 10.1161/01.STR.26.11.2053; TIECKS FP, 1995, STROKE, V26, P1386, DOI 10.1161/01.STR.26.8.1386; Tiecks FP, 1996, STROKE, V27, P1177, DOI 10.1161/01.STR.27.7.1177; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; ULRICH PT, 1995, J NEUROL SCI, V129, P120, DOI 10.1016/0022-510X(94)00252-J; VORSTRUP S, 1992, Neurological Research, V14, P31; White RP, 1997, STROKE, V28, P1340, DOI 10.1161/01.STR.28.7.1340; Wieling W, 2007, CLIN SCI, V112, P157, DOI 10.1042/CS20060091	44	49	50	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0301-5629			ULTRASOUND MED BIOL	Ultrasound Med. Biol.	JAN	2009	35	1					21	29		10.1016/j.ultrasmedbio.2008.08.001			9	Acoustics; Radiology, Nuclear Medicine & Medical Imaging	Acoustics; Radiology, Nuclear Medicine & Medical Imaging	390DN	WOS:000262144600004	18834658	Green Accepted			2021-06-18	
J	Batchelor, PE; Tan, S; Wills, TE; Porritt, MJ; Howells, DW				Batchelor, Peter E.; Tan, Simon; Wills, Taryn E.; Porritt, Michelle J.; Howells, David W.			Comparison of Inflammation in the Brain and Spinal Cord following Mechanical Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	International Symposium on Traumatic Brain Injury Research Priorities	OCT 13-16, 2005	Johnstown, PA	John P Murtha Neursci & Pain Inst, Natl Brain Injury Res, Treatments & Training Fdn, Brain Injury Assoc Amer		brain; inflammation; injury; macrophage; spinal cord	CENTRAL-NERVOUS-SYSTEM; ACTIVATED MACROPHAGES; NEUROTROPHIC FACTOR; AXON REGENERATION; CELLULAR REACTION; MICROGLIAL CELLS; MOTOR FUNCTION; OPTIC-NERVE; RAT; METHYLPREDNISOLONE	Inflammation in the CNS predominantly involves microglia and macrophages, and is believed to be a significant cause of secondary injury following trauma. This study compares the microglial and macrophage response in the rat brain and spinal cord following discrete mechanical injury to better appreciate the degree to which these cells could contribute to secondary damage in these areas. We find that, 1 week after injury, the microglial and macrophage response is significantly greater in the spinal cord compared to the brain. This is the case for injuries to both gray and white matter. In addition, we observed a greater inflammatory response in white matter compared to gray matter within both the brain and spinal cord. Because activated microglia and macrophages appear to be effectors of secondary damage, a greater degree of inflammation in the spinal cord is likely to result in more extensive secondary damage. Tissue saving strategies utilizing anti-inflammatory treatments may therefore be more useful in traumatic spinal cord than brain injury.	[Howells, David W.] Austin Hlth, Dept Med, Heidelberg, Vic 3084, Australia; Austin Hlth, Dept Neurol, Heidelberg, Vic 3084, Australia	Howells, DW (corresponding author), Austin Hlth, Dept Med, Heidelberg, Vic 3084, Australia.	david.howells@unimelb.edu.au		Howells, David/0000-0002-2512-7724			Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Batchelor PE, 2000, EUR J NEUROSCI, V12, P3462, DOI 10.1046/j.1460-9568.2000.00239.x; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Batchelor PE, 2002, EUR J NEUROSCI, V15, P826, DOI 10.1046/j.1460-9568.2002.01914.x; Batchelor PE, 1999, J NEUROSCI, V19, P1708; BIGNAMI A, 1969, BRAIN RES, V13, P444, DOI 10.1016/0006-8993(69)90259-5; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; BLIGHT AR, 1992, J NEUROTRAUMA S, V1, pS83; Bomstein Y, 2003, J NEUROIMMUNOL, V142, P10, DOI 10.1016/S0165-5728(03)00260-1; Campbell SJ, 2002, J NEUROCHEM, V83, P432, DOI 10.1046/j.1471-4159.2002.01166.x; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; EIDELBERG E, 1977, EXP NEUROL, V56, P312, DOI 10.1016/0014-4886(77)90350-8; FAWCETT JW, 2001, BRAIN DAMAGE BRAIN R, P15; Franzen R, 1998, J NEUROSCI RES, V51, P316, DOI 10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.0.CO;2-J; Fujita T, 1998, ACTA NEUROCHIR, V140, P275, DOI 10.1007/s007010050095; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Gomes-Leal W, 2005, BRAIN RES, V1066, P57, DOI 10.1016/j.brainres.2005.10.069; GREEN BA, 1980, SURG NEUROL, V13, P91; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; HOLTZ A, 1990, ACTA NEUROL SCAND, V82, P68; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LazarovSpiegler O, 1996, FASEB J, V10, P1296; Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000; Lorber B, 2005, EUR J NEUROSCI, V21, P2029, DOI 10.1111/j.1460-9568.2005.04034.x; Mayhan WG, 2001, MICROCIRCULATION, V8, P89, DOI 10.1038/sj.mn.7300154; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Paxinos G, 1986, RAT BRAIN STEREOTAXI; POPOVICH PG, 1993, J NEUROTRAUM, V10, P37, DOI 10.1089/neu.1993.10.37; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Reijerkerk A, 2006, FASEB J, V20, P2550, DOI 10.1096/fj.06-6099fje; RIVADEPATY I, 1994, EXP NEUROL, V128, P77, DOI 10.1006/exnr.1994.1114; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Szczepanik AM, 1996, NEUROSCIENCE, V70, P57, DOI 10.1016/0306-4522(95)00296-U; Takami T, 2002, J NEUROTRAUM, V19, P653, DOI 10.1089/089771502753754118; Vela JM, 2002, J NEUROTRAUM, V19, P1503, DOI 10.1089/089771502320914723; WAKEFIELD CL, 1975, EXP NEUROL, V48, P637, DOI 10.1016/0014-4886(75)90020-5; Watanabe T, 1999, J NEUROTRAUM, V16, P255, DOI 10.1089/neu.1999.16.255; Weaver LC, 2005, J NEUROTRAUM, V22, P1375, DOI 10.1089/neu.2005.22.1375; WINDLE WF, 1958, NEUROLOGY, V8, P518, DOI 10.1212/WNL.8.7.518; Wu JM, 2006, BRAIN RES, V1098, P79, DOI 10.1016/j.brainres.2006.04.074; Yin YQ, 2003, J NEUROSCI, V23, P2284; Young W, 1991, J Neurotrauma, V8 Suppl 1, pS43	58	49	52	1	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2008	25	10					1217	1225		10.1089/neu.2007.0308			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	370XK	WOS:000260796200010	18986223				2021-06-18	
J	Guzel, A; Er, U; Tatli, M; Aluclu, U; Ozkan, U; Duzenli, Y; Satici, O; Guzel, E; Kemaloglu, S; Ceviz, A; Kaplan, A				Guzel, Aslan; Er, Uygur; Tatli, Mehmet; Aluclu, Ufuk; Ozkan, Umit; Duzenli, Yucel; Satici, Omer; Guzel, Ebru; Kemaloglu, Serdar; Ceviz, Adnan; Kaplan, Abdurrahman			Serum neuron-specific enolase as a predictor of short-term outcome and its correlation with Glasgow Coma Scale in traumatic brain injury	NEUROSURGICAL REVIEW			English	Article						neuron-specific enolase; Glasgow Coma Scale; outcome; prognosis; traumatic brain injury	SEVERE HEAD-INJURY; ACUTE ISCHEMIC-STROKE; CEREBROSPINAL-FLUID; S-100 PROTEIN; MARKERS; CHILDREN; DAMAGE; BIOMARKERS; BLOOD	Elevated serum neuron-specific enolase levels are correlated with brain cell damage. Low scores according to Glasgow Coma Scale are also considered as serious poor prognostic factor. The aims of the study were to investigate whether there is a correlation between the two measurements in patients with traumatic brain injury and whether serum neuron-specific enolase levels have potential as a screening test to predict outcome. A total of 169 consecutive patients with traumatic brain injury admitted to our clinic between 2002 and 2005 are included in this study. Those patients, who had any major health problem before trauma, were excluded from the study. However, patients with isolated head injury were included in the study. Serial serum neuron-specific enolase concentrations taken at the first 2, 24, and 48 h after traumatic brain injury were analyzed. A computed tomography was performed on each patient on admission. Their Glasgow Coma Scale scores were recorded serially. The relationship between Glasgow Coma Scale scores and the serum neuron-specific enolase levels were assessed by statistical methods. There was a significant negative correlation between the serum neuron-specific enolase levels and Glasgow Coma Scale scores. The levels of neuron-specific enolase were significantly higher in the patients who died in 30 days after trauma and whose scores were lower than or equal to 8 points in Glasgow Coma Scale. Although there are several serious limitations of the use of neuron-specific enolase as a biomarker in traumatic brain injury (i.e., hypoperfusion, extracranial trauma, bleeding, liver, or kidney damage also increase the level of neuron-specific enolase), its concentrations may be useful as a practical and helpful screening test to identify neurotrauma patients who are at increased risk and may provide supplementary estimation with radiological and clinical findings.	[Guzel, Aslan; Tatli, Mehmet; Ozkan, Umit; Duzenli, Yucel; Kemaloglu, Serdar; Ceviz, Adnan] Dicle Univ, Fac Med, Dept Neurosurg, Diyarbakir, Turkey; [Er, Uygur] Diskapi Yildirim Bayezit Training & Res Hosp, Neusurg Clin 2, Ankara, Turkey; [Aluclu, Ufuk] Dicle Univ, Fac Med, Dept Neurol, Diyarbakir, Turkey; [Satici, Omer] Dicle Univ, Fac Med, Dept Biostat, Diyarbakir, Turkey; [Guzel, Ebru] Veni Vidi Hosp, Radiol Clin, Diyarbakir, Turkey; [Kaplan, Abdurrahman] Dicle Univ, Fac Med, Dept Biochem, Diyarbakir, Turkey	Er, U (corresponding author), Sogutozu C,4th Sk 22-7, TR-06510 Ankara, Turkey.	uygurer@gmail.com	ALUCLU, MEHMET/A-6726-2016				Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Beems T, 2003, ACTA NEUROCHIR, V145, P37, DOI 10.1007/s00701-002-1019-1; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Casmiro M, 2005, EUR J NEUROL, V12, P369, DOI 10.1111/j.1468-1331.2004.01021.x; Cho T, 2006, CRIT CARE MED, V34, pA2, DOI 10.1097/00003246-200612002-00007; Guan Wei, 2003, Chin J Traumatol, V6, P218; Hermann DM, 1999, RESTOR NEUROL NEUROS, V14, P103; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Kruijk J.R., 2001, ACTA NEUROL SCAND, V103, P175; Li Ning, 2004, Chin J Traumatol, V7, P156; Loy DN, 2005, NEUROSURGERY, V56, P391, DOI 10.1227/01.NEU.0000148906.83616.D2; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; SCHAARSCHMIDT H, 1994, STROKE, V25, P558, DOI 10.1161/01.STR.25.3.558; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 2000, J TRAUMA, V49, P570, DOI 10.1097/00005373-200009000-00033; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Wunderlich MT, 2004, J NEUROL SCI, V227, P49, DOI 10.1016/j.jns.2004.08.005; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	28	49	53	2	18	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	OCT	2008	31	4					439	444		10.1007/s10143-008-0148-2			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	344YF	WOS:000258962500017	18560914				2021-06-18	
J	Rhinn, H; Marchand-Leroux, C; Croci, N; Plotkine, M; Scherman, D; Escriou, V				Rhinn, Herve; Marchand-Leroux, Catherine; Croci, Nicole; Plotkine, Michel; Scherman, Daniel; Escriou, Virginie			Housekeeping while brain's storming validation of normalizing factors for gene expression studies in a murine model of traumatic brain injury	BMC MOLECULAR BIOLOGY			English	Article							REAL-TIME PCR; POLYMERASE-CHAIN-REACTION; UP-REGULATION; NEURONAL SURVIVAL; PROTEIN-LEVELS; RNA; SEVERITY; RATS; INTERLEUKIN-1; PROGESTERONE	Background: Traumatic brain injury models are widely studied, especially through gene expression, either to further understand implied biological mechanisms or to assess the efficiency of potential therapies. A large number of biological pathways are affected in brain trauma models, whose elucidation might greatly benefit from transcriptomic studies. However the suitability of reference genes needed for quantitative RT-PCR experiments is missing for these models. Results: We have compared five potential reference genes as well as total cDNA level monitored using Oligreen reagent in order to determine the best normalizing factors for quantitative RT-PCR expression studies in the early phase (0-48 h post-trauma (PT)) of a murine model of diffuse brain injury. The levels of 18S rRNA, and of transcripts of beta-actin, glyceraldehyde-3P-dehydrogenase (GAPDH), beta-microtubulin and S100 beta were determined in the injured brain region of traumatized mice sacrificed at 30 min, 3 h, 6 h, 12 h, 24 h and 48 h post-trauma. The stability of the reference genes candidates and of total cDNA was evaluated by three different methods, leading to the following rankings as normalization factors, from the most suitable to the less: by using geNorm VBA applet, we obtained the following sequence: cDNA (Oligreen); GAPDH > 18S rRNA > S100 beta > beta-microtubulin > beta-actin; by using NormFinder Excel Spreadsheet, we obtained the following sequence: GAPDH > cDNA(Oligreen) > S100 beta > 18S rRNA > beta-actin > beta-microtubulin; by using a Confidence-Interval calculation, we obtained the following sequence: cDNA(Oligreen) > 18S rRNA; GAPDH > S100 beta > beta-microtubulin > beta-actin. Conclusion: This work suggests that Oligreen cDNA measurements, 18S rRNA and GAPDH or a combination of them may be used to efficiently normalize qRT-PCR gene expression in mouse brain trauma injury, and that beta-actin and beta-microtubulin should be avoided. The potential of total cDNA as measured by Oligreen as a first-intention normalizing factor with a broad field of applications is highlighted. Pros and cons of the three methods of normalization factors selection are discussed. A generic time- and cost-effective procedure for normalization factor validation is proposed.	[Rhinn, Herve; Scherman, Daniel; Escriou, Virginie] INSERM, U640, F-75006 Paris, France; [Rhinn, Herve; Scherman, Daniel; Escriou, Virginie] CNRS, UMR8151, F-75006 Paris, France; Univ Paris 05, Fac Pharmaceut & Biol, Chem & Genet Pharmacol Lab, F-75006 Paris, France; Ecole Natl Super Chim Paris, F-75005 Paris, France; [Marchand-Leroux, Catherine; Croci, Nicole; Plotkine, Michel] Univ Paris 05, Fac Sci Pharmaceut & Biol, Unite Pharmacol Circulat Cerebrale, F-75006 Paris, France	Rhinn, H (corresponding author), INSERM, U640, F-75006 Paris, France.	herve.rhinn@gmail.com; catherine.marchand@univ-paris5.fr; nicole.croci@univ-paris5.fr; michel.plotkine@univ-paris5.fr; daniel.scherman@univ-paris5.fr; virginie.escriou@univ-paris5.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Scherman, Daniel/0000-0003-1207-1298; Escriou, Virginie/0000-0001-5686-9301			Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Argyropoulos D, 2006, FEBS J, V273, P770, DOI 10.1111/j.1742-4658.2006.05109.x; Burbach GJ, 2004, GLIA, V48, P76, DOI 10.1002/glia.20057; Dheda K, 2005, ANAL BIOCHEM, V344, P141, DOI 10.1016/j.ab.2005.05.022; Friedrich DH, 2000, ACTA NEUROCHIR SUPPL, V76, P257; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Haller F, 2004, ANAL BIOCHEM, V335, P1, DOI 10.1016/j.ab.2004.08.024; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190; Iino M, 2003, INT J LEGAL MED, V117, P153, DOI 10.1007/s00414-003-0370-y; Johnson EA, 2004, J NEUROTRAUM, V21, P1183, DOI 10.1089/neu.2004.21.1183; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Ke CS, 2002, EXP NEUROL, V178, P194, DOI 10.1006/exnr.2002.8037; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lundby C, 2005, EUR J APPL PHYSIOL, V95, P351, DOI 10.1007/s00421-005-0022-7; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rhinn H, 2008, ANAL BIOCHEM, V372, P116, DOI 10.1016/j.ab.2007.08.023; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; Rutledge RG, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh177; Sang Q, 2006, J NEUROSCI, V26, P7234, DOI 10.1523/JNEUROSCI.1398-06.2006; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; Smith RD, 2003, BIOTECHNIQUES, V34, P88, DOI 10.2144/03341st05; Stahlberg A, 2004, CLIN CHEM, V50, P1678, DOI 10.1373/clinchem.2004.035469; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yoshiya K, 2003, J NEUROTRAUM, V20, P1147, DOI 10.1089/089771503770802844	43	49	50	1	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2199			BMC MOL BIOL	BMC Mol. Biol.	JUL 8	2008	9								62	10.1186/1471-2199-9-62			12	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	336EH	WOS:000258346600001	18611280	Green Published, Other Gold			2021-06-18	
J	Buss, A; Pech, K; Kakulas, BA; Martin, D; Schoenen, J; Noth, J; Brook, GA				Buss, A.; Pech, K.; Kakulas, B. A.; Martin, D.; Schoenen, J.; Noth, J.; Brook, G. A.			TGF-beta 1 and TGF-beta 2 expression after traumatic human spinal cord injury	SPINAL CORD			English	Article						spinal cord injury; Wallerian degeneration; scar; inflammation	GROWTH-FACTOR-BETA; TGF-BETA; ALZHEIMERS-DISEASE; NERVOUS-SYSTEM; MESSENGER-RNA; RAT-BRAIN; LOCALIZATION; SCAR; DEGENERATION; REGENERATION	Study design: Immunohistochemical investigation in control and lesioned human spinal cords. Objectives: To assess the spatial and temporal expression patterns of transforming growth factor-beta 1 and -beta 2 (TGF-beta 1 and TGF-beta 2) in the human spinal cord after traumatic injury. Setting: Germany, Aachen, Aachen University Hospital. Methods: Sections from human spinal cords from 4 control patients and from 14 patients who died at different time points after traumatic spinal cord injury (SCI) were investigated immunohistochemically. Results: In control cases, TGF-beta 1 was confined to occasional blood vessels, intravascular monocytes and some motoneurons, whereas TGF-beta 2 was only found in intravascular monocytes. After traumatic SCI, TGF-beta 1 immunoreactivity was dramatically upregulated by 2 days after injury (the earliest survival time investigated) and was detected within neurons, astrocytes and invading macrophages. The staining was most intense over the first weeks after injury but gradually declined by 1 year. TGF-beta 2 immunoreactivity was first detected 24 days after injury. It was located in macrophages and astrocytes and remained elevated for up to 1 year. In white matter tracts undergoing Wallerian degeneration, there was no induction of either isoform. Conclusion: The early induction of TGF-beta 1 at the point of SCI suggests a role in the acute inflammatory response and formation of the glial scar, while the later induction of TGF-beta 2 may indicate a role in the maintenance of the scar. Neither of these TGF-beta isoforms appears to contribute to the astrocytic scar formation in nerve fibre tracts undergoing Wallerian degeneration.	[Buss, A.; Pech, K.; Noth, J.; Brook, G. A.] Rhein Westfal TH Aachen, Dept Neurol, Aachen Univ Hosp, D-52074 Aachen, Germany; [Kakulas, B. A.] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Perth, WA 6009, Australia; [Martin, D.] Univ Liege, Dept Neurosurg, Sart Tilman Hosp, Liege, Belgium; [Schoenen, J.] Univ Liege, Dept Neurol, Liege, Belgium; [Schoenen, J.] Univ Liege, Dept Neuroanat, Liege, Belgium; [Brook, G. A.] Rhein Westfal TH Aachen, Dept Neuropathol, Aachen Univ Hosp, D-52074 Aachen, Germany	Buss, A (corresponding author), Rhein Westfal TH Aachen, Dept Neurol, Aachen Univ Hosp, Pauwelsstr 30, D-52074 Aachen, Germany.	abuss@ukaachen.de		MARTIN, Didier/0000-0001-7325-4958			Ashcroft GS, 1999, MICROBES INFECT, V1, P1275, DOI 10.1016/S1286-4579(99)00257-9; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Bunge R P, 1997, Adv Neurol, V72, P305; Buss A, 2004, BRAIN, V127, P34, DOI 10.1093/brain/awh001; De Groot CJA, 1999, J NEUROPATH EXP NEUR, V58, P174, DOI 10.1097/00005072-199902000-00007; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; FLANDERS KC, 1995, NEUROLOGY, V45, P1561, DOI 10.1212/WNL.45.8.1561; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Lagord C, 2002, MOL CELL NEUROSCI, V20, P69, DOI 10.1006/mcne.2002.1121; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; Mangasser-Stephan K, 1999, CELL TISSUE RES, V297, P363, DOI 10.1007/s004410051364; McTigue DM, 2000, EXP NEUROL, V163, P220, DOI 10.1006/exnr.2000.7372; Moon LDF, 2001, EUR J NEUROSCI, V14, P1667, DOI 10.1046/j.0953-816x.2001.01795.x; OBRIEN MF, 1994, SPINE, V19, P2321, DOI 10.1097/00007632-199410150-00012; PERESS NS, 1995, J NEUROPATH EXP NEUR, V54, P802, DOI 10.1097/00005072-199511000-00007; ROBERTS AB, 1992, KIDNEY INT, V41, P557, DOI 10.1038/ki.1992.81; ROGISTER B, 1993, J NEUROSCI RES, V34, P32, DOI 10.1002/jnr.490340105; Schwab ME, 1996, PHYSIOL REV, V76, P319; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Unsicker K, 2002, ADV EXP MED BIOL, V513, P353; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004	23	49	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	MAY	2008	46	5					364	371		10.1038/sj.sc.3102148			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	295VS	WOS:000255502600009	18040277	Bronze			2021-06-18	
J	Dottori, M; Leung, J; Turnley, AM; Pebay, A				Dottori, Mirella; Leung, Jessie; Turnley, Ann M.; Pebay, Alice			Lysophosphatidic acid inhibits neuronal differentiation of neural stem/progenitor cells derived from human embryonic stem cells	STEM CELLS			English	Article						embryonic stem cells; embryonic stem cell biology; in vitro differentiation; neural stem cell; neural differentiation; signal transduction	PROTEIN-COUPLED RECEPTORS; MORPHOLOGICAL-CHANGES; PROLIFERATION; LPA; SPHINGOSINE-1-PHOSPHATE; IDENTIFICATION; NEUROBLASTS; MAINTENANCE; PROGENITORS; EXPRESSION	Lysophospholipids are signaling molecules that play broad and major roles within the nervous system during both early development and neural injury. We used neural differentiation of human embryonic stem cells (hESC) as an in vitro model to examine the specific effects of lysophosphatidic acid (LPA) at various stages of neural development, from neural induction to mature neurons and glia. We report that LPA inhibits neurosphere formation and the differentiation of neural stem cells (NSC) toward neurons, without modifying NSC proliferation, apoptosis, or astrocytic differentiation. LPA acts through the activation of the Rho/ROCK and the phosphatidylinositol 3-kinase/Akt pathways to inhibit neuronal differentiation. This study is the first demonstration of a role for LPA signaling in neuronal differentiation of hESC. As LPA concentrations increase during inflammation, the inhibition of neuronal differentiation by LPA might contribute to the low level of neurogenesis observed following neurotrauma.	[Dottori, Mirella; Leung, Jessie; Turnley, Ann M.; Pebay, Alice] Univ Melbourne, Ctr Neurosci, Parkville, Vic 3010, Australia; [Dottori, Mirella; Pebay, Alice] Univ Melbourne, Dept Pharmacol, Parkville, Vic 3010, Australia	Pebay, A (corresponding author), Univ Melbourne, Ctr Neurosci, Parkville, Vic 3010, Australia.	apebay@unimelb.edu.au	Turnley, Ann/A-8125-2010	Dottori, Mirella/0000-0003-0598-4195; Pebay, Alice/0000-0002-7408-9453; Turnley, Ann/0000-0002-8442-127X			Brault S, 2007, AM J PHYSIOL-REG I, V292, pR1174, DOI 10.1152/ajpregu.00619.2006; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; CONTOS JJ, 1920, P NATL ACAD SCI USA, V97, P13384; Davidson KC, 2007, MOL CELL NEUROSCI, V36, P408, DOI 10.1016/j.mcn.2007.07.013; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Fukushima N, 2004, J CELL BIOCHEM, V92, P993, DOI 10.1002/jcb.20093; Fukushima N, 2000, DEV BIOL, V228, P6, DOI 10.1006/dbio.2000.9930; Fukushima N, 2007, NEUROCHEM INT, V50, P302, DOI 10.1016/j.neuint.2006.09.008; Goetzl EJ, 2000, J IMMUNOL, V164, P4996, DOI 10.4049/jimmunol.164.10.4996; Goetzl EJ, 1999, CANCER RES, V59, P4732; Harada J, 2004, J NEUROCHEM, V88, P1026, DOI 10.1046/j.1471-4159.2003.02219.x; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Holtsberg FW, 1998, J NEUROCHEM, V70, P66; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; Keller JN, 1997, J NEUROCHEM, V69, P1073; Keller JN, 1996, J NEUROCHEM, V67, P2300; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; Kotarsky K, 2006, J PHARMACOL EXP THER, V318, P619, DOI 10.1124/jpet.105.098848; Lee CW, 2007, J BIOL CHEM, V282, P4310, DOI 10.1074/jbc.M610826200; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Moller T, 2001, J BIOL CHEM, V276, P25946, DOI 10.1074/jbc.M102691200; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Pebay A, 2005, STEM CELLS, V23, P1541, DOI 10.1634/stemcells.2004-0338; Pebay A, 1999, GLIA, V28, P25, DOI 10.1002/(SICI)1098-1136(199910)28:1<25::AID-GLIA3>3.0.CO;2-D; Pebay A, 2007, PROSTAG OTH LIPID M, V84, P83, DOI 10.1016/j.prostaglandins.2007.08.004; Pera MF, 2004, J CELL SCI, V117, P1269, DOI 10.1242/jcs.00970; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399; Rhee HJ, 2006, NEUROREPORT, V17, P523; Steiner MR, 2002, BBA-MOL CELL BIOL L, V1582, P154, DOI 10.1016/S1388-1981(02)00150-6; Svetlov SI, 2004, STEM CELLS DEV, V13, P685, DOI 10.1089/scd.2004.13.685; Takuwa Y, 2002, J BIOCHEM, V131, P767, DOI 10.1093/oxfordjournals.jbchem.a003163; Wada K, 2006, J BIOL CHEM, V281, P12673, DOI 10.1074/jbc.M513786200; Ward JE, 2004, BRIT J PHARMACOL, V141, P517, DOI 10.1038/sj.bjp.0705630; Weiner JA, 1998, J COMP NEUROL, V398, P587; Yanagida K, 2007, J BIOL CHEM, V282, P5814, DOI 10.1074/jbc.M610767200; zu Heringdorf DM, 2007, BBA-BIOMEMBRANES, V1768, P923, DOI 10.1016/j.bbamem.2006.09.026	39	49	49	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	MAY	2008	26	5					1146	1154		10.1634/stemcells.2007-1118			9	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	305SB	WOS:000256197000007	18308941				2021-06-18	
J	Londos, E; Boschian, K; Linden, A; Persson, C; Minthon, L; Lexell, J				Londos, E.; Boschian, K.; Linden, A.; Persson, C.; Minthon, L.; Lexell, J.			Effects of a goal-oriented rehabilitation program in mild cognitive impairment: A pilot study	AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS			English	Article						mild cognitive impairment; traumatic brain injury; cognitive rehabilitation; memory training; occupational therapy; quality of life	QUALITY-OF-LIFE; ALZHEIMERS-DISEASE; OLDER-ADULTS; DEMENTIA; MEMORY; MCI	Background: Memory disturbance, deficient concentration, and fatigue are symptoms seen in amnestic mild cognitive impairment (MCI) as well as in mild traumatic brain injury (TBI). The aim of this study was to assess if an established rehabilitation program commonly used in TBI can aid MCI patients to develop compensatory memory strategies that can improve their cognition, occupational performance, and quality of life (QoL). Methods: Fifteen patients with MCI participated in the program 2 days per week for 8 weeks. Cognitive function, occupational performance, and self-perceived QoL were assessed at baseline, at the end of the intervention, and at follow-up after 6 months. Results: Significant improvements were seen in cognitive processing speed, occupational performance, and in some of the QoL domains. Conclusion: As this goal-oriented rehabilitation program in MCI resulted in some improvements in cognition, occupational performance, and QoL, further randomized controlled studies are warranted.	[Lexell, J.] Lulea Univ Technol, Dept Hlth Sci, S-95187 Lulea, Sweden; [Lexell, J.] Lund Univ, Clin Sci Lund, Div Rehabil Med, Lund, Sweden; [Boschian, K.; Linden, A.; Lexell, J.] Univ Lund Hosp, Dept Rehabil, S-22185 Lund, Sweden; [Londos, E.; Persson, C.; Minthon, L.] Lund Univ, Clin Sci Malmo, Clin Memory Res Unit, Lund, Sweden	Londos, E (corresponding author), Malmo Univ Hosp, Clin Memory Res Unit, Neuropsychiat Clin, Simrisbanv 14, S-20502 Malmo, Sweden.	elisabet.londos@skane.se		Lexell, Jan/0000-0001-5294-3332	Swedish Alzheimer Foundation, Lund, Sweden	This study was supported by grants from the Swedish Alzheimer Foundation, Lund, Sweden.	Akhtar S, 2006, NEUROPSYCHOL REHABIL, V16, P329, DOI 10.1080/09602010500176674; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Clare L., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003260; FLICKER C, 1991, NEUROLOGY, V41, P1006, DOI 10.1212/WNL.41.7.1006; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hanninen T, 2002, ACTA NEUROL SCAND, V106, P148, DOI 10.1034/j.1600-0404.2002.01225.x; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; Larrieu S, 2002, NEUROLOGY, V59, P1594, DOI 10.1212/01.WNL.0000034176.07159.F8; Law M, 1998, CANADIAN OCCUPATIONA; Logsdon RG, 2002, PSYCHOSOM MED, V64, P510, DOI 10.1097/00006842-200205000-00016; Meyers, 1995, REY COMPLEX FIGURES; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; Palmer K, 2003, ACTA NEUROL SCAND, V107, P14, DOI 10.1034/j.1600-0404.107.s179.2.x; Perneczky R, 2006, INT J GERIATR PSYCH, V21, P158, DOI 10.1002/gps.1444; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; PETERSEN RC, 1995, JAMA-J AM MED ASSOC, V273, P1274, DOI 10.1001/jama.273.16.1274; Rapp S, 2002, AGING MENT HEALTH, V6, P5, DOI 10.1080/13607860120101077; Ready RE, 2004, INT J GERIATR PSYCH, V19, P256, DOI 10.1002/gps.1075; Ready Rebecca E, 2006, Am J Alzheimers Dis Other Demen, V21, P242, DOI 10.1177/1533317506290589; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Shin IS, 2005, AM J GERIAT PSYCHIAT, V13, P469, DOI 10.1176/appi.ajgp.13.6.469; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.1997.03550160083043; Talassi E, 2007, ARCH GERONTOL GERIAT, V44, P391, DOI 10.1016/j.archger.2007.01.055; Thorgrimsen L, 2003, ALZ DIS ASSOC DIS, V17, P201, DOI 10.1097/00002093-200310000-00002; Tuokko H, 2005, NEUROCASE, V11, P40, DOI 10.1080/13554790490896802; WECHSLCR D, 1997, MANUAL WECHSLER ADUL; Wechsler D., 1981, WAIS R MANUAL WECHSL; WIIG EH, 2002, ALZHEIMERS QUICK TES; WIIG EH, 2004, AQT SCREENING TEST A; Wold Health Organisation, 1997, INT STAT CLASS DIS R; Wressle E., 1999, SCAND J OCCUP THER, V6, P84, DOI DOI 10.1080/110381299443771	31	49	53	0	20	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1533-3175	1938-2731		AM J ALZHEIMERS DIS	Am. J. Alzheimers Dis. Other Dement.	APR-MAY	2008	23	2					177	183		10.1177/1533317507312622			7	Geriatrics & Gerontology; Clinical Neurology	Geriatrics & Gerontology; Neurosciences & Neurology	344WC	WOS:000258957000008	18182471				2021-06-18	
J	Hu, K; Peng, CK; Czosnyka, M; Zhao, P; Novak, V				Hu, Kun; Peng, C. K.; Czosnyka, Marek; Zhao, Peng; Novak, Vera			Nonlinear assessment of cerebral autoregulation from spontaneous blood pressure and cerebral blood flow fluctuations	CARDIOVASCULAR ENGINEERING			English	Article; Proceedings Paper	Workshop on Short-Term Cardiovascular-Respiratory Control Mechanisms	OCT 09-13, 2006	Amer Inst Math, Palo Alto, CA		Amer Inst Math	spontaneous oscillations; instantaneous phase shift; Valsalva maneuver; baseline resting condition; stroke; hypertension; traumatic brain injury	ARTERIAL-PRESSURE; VELOCITY; VARIABILITY; COHERENCE; FINAPRES; DYNAMICS	Cerebral autoregulation ( CA) is an most important mechanism responsible for the relatively constant blood flow supply to brain when cerebral perfusion pressure varies. Its assessment in nonacute cases has been relied on the quantification of the relationship between noninvasive beat-to-beat blood pressure ( BP) and blood flow velocity (BFV). To overcome the nonstationary nature of physiological signals such as BP and BFV, a computational method called multimodal pressure-flow (MMPF) analysis was recently developed to study the nonlinear BP-BFV relationship during the Valsalva maneuver (VM). The present study aimed to determine (i) whether this method can estimate autoregulation from spontaneous BP and BFV fluctuations during baseline rest conditions; (ii) whether there is any difference between the MMPF measures of autoregulation based on intra-arterial BP (ABP) and based on cerebral perfusion pressure (CPP); and (iii) whether the MMPF method provides reproducible and reliable measure for noninvasive assessment of autoregulation. To achieve these aims, we analyzed data from existing databases including: ( i) ABP and BFV of 12 healthy control, 10 hypertensive, and 10 stroke subjects during baseline resting conditions and during the Valsalva maneuver, and ( ii) ABP, CPP, and BFV of 30 patients with traumatic brain injury (TBI) who were being paralyzed, sedated, and ventilated. We showed that autoregulation in healthy control subjects can be characterized by specific phase shifts between BP and BFV oscillations during the Valsalva maneuver, and the BP-BFV phase shifts were reduced in hypertensive and stroke subjects (P < 0.01), indicating impaired autoregulation. Similar results were found during baseline condition from spontaneous BP and BFV oscillations. The BP-BFV phase shifts obtained during baseline and during VM were highly correlated (R > 0.8, P < 0.0001), showing no statistical difference (paired-t test P > 0.47). In TBI patients there were strong correlations between phases of ABP and CPP oscillations (R = 0.99, P < 0.0001) and, thus, between ABP-BFV and CPP-BFV phase shifts (P < 0.0001, R = 0.76). By repeating the MMPF 4 times on data of TBI subjects, each time on a selected cycle of spontaneous BP and BFV oscillations, we showed that MMPF had better reproducibility than traditional autoregulation index. These results indicate that the MMPF method, based on instantaneous phase relationships between cerebral blood flow velocity and peripheral blood pressure, has better performance than the traditional standard method, and can reliably assess cerebral autoregulation dynamics from ambulatory blood pressure and cerebral blood flow during supine rest conditions.	[Hu, Kun; Zhao, Peng; Novak, Vera] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02115 USA; [Peng, C. K.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Margret & HA Rey Inst Nonlinear Dynam Med, Boston, MA 02115 USA; [Peng, C. K.] Harvard Univ, Sch Med, Div Interdisciplinary Med & Biotechnol, Boston, MA 02115 USA; [Czosnyka, Marek] Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge, England	Hu, K (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gerontol, 812 Stoneman Bldg,330 Brookline Ave, Boston, MA 02115 USA.	khu@bidmc.harvard.edu; vnovak@bidmc.harvard.edu	Hu, Kun/AAJ-1897-2020; Peng, Chung-Kang/N-1308-2019; Peng, Chung-Kang/E-1489-2011	Peng, Chung-Kang/0000-0003-3666-9833; Peng, Chung-Kang/0000-0003-3666-9833; , Kun/0000-0003-0350-3132	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0600986, G9439390] Funding Source: Medline; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41 RR013622, P41 RR013622-076028] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P60 AG008812, P01 AG004390-250015, P60 AG008812-15S2, P01 AG004390] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS045745, R01 NS045745-04, R41 NS053128-01A2, R41 NS053128] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR013622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045745, R41NS053128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG004390, P60AG008812] Funding Source: NIH RePORTER		Aaslid R, 1992, TRANSCRANIAL DOPPLER, P49; Altman D, 1991, PRACTICAL STAT MED R; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Carey BJ, 2003, STROKE, V34, P1871, DOI 10.1161/01.STR.0000081981.99908.F3; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Dawson SL, 1999, J APPL PHYSIOL, V86, P675; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Diehl RR, 1998, CLIN AUTON RES, V8, P7, DOI 10.1007/BF02267598; Eames PJ, 2002, J NEUROL NEUROSUR PS, V72, P467; Giller CA, 1997, NEUROL RES, V19, P634; GILLER CA, 1990, NEUROSURGERY, V27, P362, DOI 10.1227/00006123-199009000-00004; Hamner JW, 2004, J PHYSIOL-LONDON, V559, P965, DOI 10.1113/jphysiol.2004.066969; HU K, 2007, PHYSICA A IN PRESS; Hu K, 2007, DIABETES, V56, pA585; Huang NE, 1998, P ROY SOC A-MATH PHY, V454, P903, DOI 10.1098/rspa.1998.0193; Huang W, 1998, P NATL ACAD SCI USA, V95, P4816, DOI 10.1073/pnas.95.9.4816; Immink RV, 2005, STROKE, V36, P2595, DOI 10.1161/01.STR.0000189624.06836.03; Lipsitz LA, 2000, STROKE, V31, P1897, DOI 10.1161/01.STR.31.8.1897; Mitsis GD, 2004, IEEE T BIO-MED ENG, V51, P1932, DOI 10.1109/TBME.2004.834272; NOVAK V, 1994, J CLIN MONITOR, V10, P118, DOI 10.1007/BF02886824; Novak V, 1998, STROKE, V29, P1876, DOI 10.1161/01.STR.29.9.1876; Novak V, 2003, NEUROLOGY, V60, P1657, DOI 10.1212/01.WNL.0000068023.14587.06; Novak V, 2004, BIOMED ENG ONLINE, V3, DOI 10.1186/1475-925X-3-39; Olufsen MS, 2002, AM J PHYSIOL-REG I, V282, pR611, DOI 10.1152/ajpregu.00285.2001; OMBONI S, 1993, HYPERTENSION, V22, P26, DOI 10.1161/01.HYP.22.1.26; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Panerai RB, 2001, AM J PHYSIOL-HEART C, V280, pH2162; Panerai RB, 2006, AM J PHYSIOL-HEART C, V291, pH251, DOI 10.1152/ajpheart.01348.2005; Pinna GD, 1996, PHYSIOL MEAS, V17, P147, DOI 10.1088/0967-3334/17/3/002; Schmidt EA, 2003, J NEUROSURG, V99, P991, DOI 10.3171/jns.2003.99.6.0991; TIECKS FP, 1995, STROKE, V26, P1386, DOI 10.1161/01.STR.26.8.1386; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; WU Z, 2005, 193 CTR OC LAND ATM; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233	35	49	49	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1567-8822	1573-6806		CARDIOVASC ENG	Cardiovasc. Eng.	MAR	2008	8	1					60	71		10.1007/s10558-007-9045-5			12	Cardiac & Cardiovascular Systems; Engineering, Biomedical	Cardiovascular System & Cardiology; Engineering	343SU	WOS:000258876200007	18080758	Green Accepted			2021-06-18	
